,insulin lispro protamine (rDNA origin)/insulin lispro (rDNA origin),"***For the treatment of type 1 diabetes mellitus or for type 2 diabetes mellitus inadequately managed by diet, exercise, and oral hypoglycemics. <br />        NOTE: A consensus algorithm issued by the ADA and the European Association for the Study of Diabetes lists basal or intermediate-acting insulin as a second line or third line agent in patients with type 2 diabetes not controlled on oral drugs; metformin is the initial recommended therapy in all type 2 diabetics without contraindications. Once insulin is added, therapy can be intensified (e.g., addition of prandial insulin) to achieve optimal glycemic control. In patients that are receiving a sulfonylurea, the sulfonylurea should be discontinued when insulin therapy is initiated.<br />     ***Formoterol; Mometasone","***General Information***Diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Hepatic disease, renal failure, renal impairment***Coma, continuous subcutaneous insulin infusion (CSII) administration, diabetic ketoacidosis, hyperosmolar hyperglycemic state (HHS), intravenous administration***Hypoglycemia***Hypokalemia***Cresol hypersensitivity***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants***Tobacco smoking***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['306266', '1546027']",entecavir,"***For the treatment of chronic hepatitis B infection in patients with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (AST or ALT) or histologically active disease.***For the treatment of chronic hepatitis B in nucleoside-treatment-naive patients with compensated liver disease.***For treatment of chronic hepatitis B in patients with compensated liver disease and a history of hepatitis B viremia while receiving lamivudine or with known lamivudine or telbivudine resistance mutations (rtM204I/V with or without rtL180M, rtL80I/V, or rtV173L).***For the treatment of chronic hepatitis B in patients coinfected with HIV�. <br />          NOTE: Per HIV treatment guidelines, patients who are coinfected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV), and who are unable to receive tenofovir, may use entecavir as an alternative; however, entecavir must be use in combination with a fully suppressive antiretroviral treatment regimen that includes either lamivudine or emtricitabine. HIV and HBV resistance may develop in a coinfected patient who is not receiving HAART and is taking entecavir. <br />       ***For the treatment of chronic hepatitis B in patients with decompensated liver disease.","***Hepatitis B exacerbation***Hepatitis B and HIV coinfection, human immunodeficiency virus (HIV) infection***Organ transplant***Females, hepatic disease, hepatotoxicity or lactic acidosis, obesity***Dialysis, geriatric, renal failure, renal impairment***Children, infants, neonates***Breast-feeding***Pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['60212'],atovaquone,"***For the treatment of acute, mild to moderately-severe Pneumocystis pneumonia (PCP) infections in patients who do not tolerate trimethoprim-sulfamethoxazole.***For primary or secondary Pneumocystis pneumonia (PCP) prophylaxis.***For the acute treatment of toxoplasmic encephalitis� (toxoplasmosis�) due to <em>Toxoplasma gondii</em> in HIV-infected patients. <br />        NOTE: The FDA has designated atovaquone as an orphan drug for this indication.<br />     ***For toxoplasmosis prophylaxis�, specifically toxoplasmic encephalitis (TE), in HIV-infected patients. <br />        NOTE: The FDA has designated atovaquone as an orphan drug for this indication.<br />     ***For primary toxoplasmosis prophylaxis� in HIV-infected patients.***For secondary toxoplasmosis prophylaxis� (i.e., prevention of recurrent disease) in HIV-infected patients.***For the treatment of babesiosis� in combination with azithromycin.","***General Information***GI disease***Infection, respiratory insufficiency***Pregnancy***Breast-feeding***Benzyl alcohol hypersensitivity, neonates***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['358274'],ambrisentan,***For improvement in exercise ability and delay in clinical worsening in patients with WHO Group I pulmonary hypertension (PAH).,"***Hepatic disease, hepatitis***Anemia***Geriatric, peripheral edema***Pulmonary edema, veno-occlusive disease (VOD)***Pulmonary fibrosis***Pregnancy***Breast-feeding***Contraception requirements, infertility, pregnancy testing, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['60548'],exenatide,***For the treatment of type 2 diabetes mellitus in combination with diet and exercise.,"***General Information***Diabetic ketoacidosis, type 1 diabetes mellitus***Burns, diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Crohn's disease, gastroparesis, GI disease, inflammatory bowel disease, ulcerative colitis***Hypoglycemia***Dehydration, dialysis, kidney transplant, renal disease, renal failure, renal impairment***Tobacco smoking***Pregnancy***Breast-feeding***Children, infants***Pancreatitis***Medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), thyroid cancer, thyroid C-cell tumors***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['9639'],selegiline,***For the treatment of Parkinson's disease or parkinsonism in combination with levodopa or levodopa/carbidopa.***For the treatment of major depression.,"***General Information***MAOI therapy***Alcoholism, ethanol ingestion, hypertension, hypertensive crisis***Pheochromocytoma***Children, suicidal ideation***Bipolar disorder, mania***Behavioral changes, psychosis, schizophrenia***Impulse control symptoms***Hypotension, orthostatic hypotension***Hepatic disease***Renal failure, renal impairment***Melanoma***Driving or operating machinery***Abrupt discontinuation***Pregnancy***Breast-feeding***Geriatric***Phenylketonuria***Ambient temperature increase, heating pad, sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3407'],digoxin,"***For ventricular rate control in patients with chronic atrial fibrillation and/or atrial flutter�; or for the treatment of narrow-complex paroxysmal supraventricular tachycardia (PSVT)� or for paroxysmal supraventricular tachycardia (PSVT) prophylaxis� in patients without a delta wave on ECG during sinus rhythm; or for the treatment of congestive heart failure. <br />        NOTE: In patients with undetectable serum digoxin concentrations, the total loading dose should be based on lean body weight and clinical response, and divided into several doses administered at 4- to 8-hour intervals. Higher doses (i.e., concentrations) may be required for treating arrhythmias than for treating heart failure. Patients with moderate-severe renal insufficiency should receive smaller loading doses than patients with normal renal function due to a reduced volume of distribution.<br />NOTE: Maintenance doses should be based on lean body weight, clinical response, and renal function. Higher doses (i.e., concentrations) may be required for treating arrhythmias than for treating heart failure. Lower doses should be considered for geriatric patients, patients with impaired renal function, and in patients whose lean weight is an abnormally small fraction of their total body mass because of obesity or edema. In 1 small study of men with NYHA class II or III heart failure who were in normal sinus rhythm, left ventricular function improved significantly on a dose of 0.125 mg/day that produced mean serum concentrations of 0.8 ng/mL but doses of 0.25 mg/day and corresponding higher concentrations of 1.5 ng/mL did not produce further improvement over the lower dosage. In another small study of men with NYHA class II or III heart failure who were in normal sinus rhythm, left ventricular ejection fraction improved significantly when digoxin was increased from a mean dose of 0.2 mg/day (mean trough 0.67 ng/mL) to a mean dose of 0.39 mg/day (mean trough 1.22 ng/mL); however, no significant changes were observed in heart failure score or exercise tolerance***For the transplacental treatment of fetal supraventricular tachyarrhythmias�.","***Acute myocardial infarction, Adams-Stokes syndrome, AV block, bradycardia, cardiomyopathy, cor pulmonale, hyperthyroidism, hypothyroidism, hypoxemia, myocarditis, myxedema, pulmonary disease, sick sinus syndrome***Carotid sinus hypersensitivity, ventricular arrhythmias, ventricular fibrillation, ventricular tachycardia, Wolff-Parkinson-White syndrome***Renal disease, renal failure, renal impairment***Geriatric***Hepatic disease***Constrictive pericarditis, idiopathic hypertrophic subaortic stenosis***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypocalcemia, hypokalemia, hypomagnesemia***Hypertension***Infants, neonates, premature neonates***Pregnancy***Breast-feeding***Diarrhea, malabsorption syndrome***Intramuscular administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,valacyclovir hydrochloride,"***For the treatment of herpes simplex virus infection, including herpes labialis and herpes genitalis, and including HIV-infected patients�.***For the treatment of herpes labialis (i.e., cold sores).***For the treatment of initial episode of herpes genitalis.***For the treatment of recurrent herpes genitalis, including HIV-infected patients�.***For the treatment of herpes zoster (shingles) infection. <br />  NOTE: Valacyclovir is not approved for the treatment of disseminated herpes zoster infections.<br /***For the treatment of varicella (chickenpox) infection.***For the treatment of acute retinal necrosis (ARN)� due to varicella-zoster virus in HIV-infected patients.***For herpes genitalis prophylaxis or for secondary herpes simplex infection prophylaxis�.***For suppressive therapy of recurrent herpes genitalis in all patients or for secondary herpes simplex infection prophylaxis� in HIV-patients for frequent or severe recurrences.***For the reduction of transmission of genital herpes to an immunocompetent uninfected sex partner, in immunocompetent patients with a history of 9 or fewer recurrences per year.***For primary cytomegalovirus (CMV) disease prophylaxis�.***For primary cytomegalovirus (CMV) disease prophylaxis� in patients after kidney transplantation.***For primary cytomegalovirus (CMV) disease prophylaxis� in patients after bone marrow transplantation.***For primary cytomegalovirus (CMV) disease prophylaxis� in patients after heart transplantation.***For the treatment and prophylaxis of encephalitis� due to B virus (cercopithecine herpesvirus) infection�.***For the adjunctive treatment of Bell's palsy� in combination with steroids.***For post-exposure varicella (chickenpox) infection prophylaxis� to prevent primary infection in HIV-infected patients.","***Acyclovir hypersensitivity, famciclovir hypersensitivity, ganciclovir hypersensitivity, penciclovir hypersensitivity, valacyclovir hypersensitivity, valganciclovir hypersensitivity***Renal failure, renal impairment***Geriatric***Dehydration***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],drospirenone/ethinyl estradiol,"***For routine contraception.***For the treatment of acne vulgaris in women who also desire oral contraception.***For the treatment of premenstrual dysphoric disorder (PMDD) in women who also desire oral contraception.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception.***For the treatment or adjuvant treatment of conditions such as amenorrhea�, hirsutism�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who desire oral contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Adrenal insufficiency, electrolyte imbalance, hyperkalemia, renal disease, renal failure, renal impairment***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia, pancreatitis***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, hypertension, myocardial infarction, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,U-500) (insulin human,"***For the treatment of type 1 diabetes mellitus or for type 2 diabetes mellitus inadequately managed by diet, exercise, and oral hypoglycemics.***For the treatment of gestational diabetes or for the treatment of patients with pre-existing diabetes mellitus (Type 1 or type 2) who are now pregnant.***For pregnant patients with gestational-onset diabetes not controlled by diet-therapy alone.***For pregnant patients with preexisting diabetes prior to pregnancy.***For the treatment of diabetic ketoacidosis (DKA).***For the treatment of hyperosmolar hyperglycemic state (HHS) in patients with type 2 diabetes mellitus.***For the treatment of neonatal diabetes mellitus�.***For nutritional supplementation� to maintain normoglycemia in very low birthweight infants with persistent glucose intolerance, including those neonates on parenteral nutrition with persistent glucose intolerance.***For the treatment of hyperkalemia�.***Formoterol; Mometasone","***Diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Hepatic disease, renal failure, renal impairment***Intramuscular administration, intravenous administration***Continuous subcutaneous insulin infusion (CSII) administration***Hypoglycemia***Hypokalemia***Cresol hypersensitivity***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Children, infants***Tobacco smoking***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,salmeterol xinafoate,"***For the maintenance prevention of bronchospasm (e.g., bronchospasm prophylaxis) in patients with asthma.***For the treatment of asthma, including nocturnal asthma symptoms, in patients receiving optimum treatment with antiinflammatory asthma agents and who still require a inhaled beta-adrenergic bronchodilator on a regular schedule.***For exercise-induced bronchospasm prophylaxis.***For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) including emphysema and chronic bronchitis.***For altitude sickness prophylaxis<strong>***Formoterol***Formoterol; Mometasone","***General Information***Monotherapy treatment of asthma***Milk protein hypersensitivity***Acute bronchospasm, asthma-related death, status asthmaticus***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, tachycardia***Diabetes mellitus, hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***Labor, pregnancy***Breast-feeding***Children, infants***Hepatic disease***Paradoxical bronchospasm***MAOI therapy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,triamcinolone acetonide,"***For bronchospasm prophylaxis or maintenance therapy in patients who require chronic treatment with corticosteroids for control of bronchial asthma.***For the treatment of severe or incapacitating allergic conditions such as asthma that are intractable to adequate trials of conventional treatment.***For the treatment of symptoms of seasonal and perennial allergic rhinitis.***For the treatment of severe or incapacitating allergic conditions that are intractable to adequate trials of conventional treatment.***For the treatment of ocular inflammation (i.e., sympathetic ophthalmia and ocular inflammatory conditions unresponsive to topical corticosteroids), temporal arteritis, and uveitis.***For visualization during ocular surgery (i.e., vitrectomy).***For the treatment of acute rheumatic carditis, berylliosis, temporal arteritis�, or systemic lupus erythematosus (SLE). <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses (e.g., alopecia areata, atopic dermatitis, contact dermatitis including <em>Rhus dermatitis</em> due to poison ivy, poison oak, poison sumac, subacute cutaneous or discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex chronicus, mycosis fungoides, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, psoriasis, sarcoidosis, seborrheic dermatitis, sunburn, or xerosis). <br />        NOTE: Occlusive dressings may be necessary for chronic or severe cases of psoriasis or other recalcitrant conditions.<br />     ***For the treatment of ulcerative or inflammatory oral lesions including aphthous ulcer, desquamative gingivitis�, and oral lichen planus�.***For the treatment of severe or incapacitating allergic conditions such as atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions, bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome) that are intractable to adequate trials of conventional treatment and for the treatment of idiopathic eosinophilic pneumonias.***For the treatment of symptomatic sarcoidosis.***For the treatment of primary (Addison's disease) or secondary adrenocortical insufficiency. <br />        NOTE: Hydrocortisone and cortisone are the preferred agents for these conditions.<br />     ***For the treatment of congenital adrenal hyperplasia.***For the treatment of hypercalcemia associated with cancer.***For the treatment of nonsuppurative thyroiditis.***For the treatment of a critical period of regional enteritis and ulcerative colitis.***For the treatment of autoimmune hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, or selected cases of secondary thrombocytopenia.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of acute exacerbations of multiple sclerosis. <br />        NOTE: Corticosteroids are effective in speeding the resolution of acute exacerbations, but they do not affect the ultimate outcome or natural history of the disease.<br />     ***For the treatment of cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.***For the treatment of proteinuria or to induce diuresis in idiopathic nephrotic syndrome or lupus erythematosus.***For the treatment of an acute episode or exacerbation of ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA) as adjunctive therapy for short-term administration.***For the treatment of dermatomyositis or polymyositis.***For the relief of inflammation and for immunosuppression associated with a variety of disorders, like Hodgkin lymphoma. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the palliative treatment of leukemias and lymphomas.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of diabetic macular edema�.***For the relief of inflammation associated with synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; gout with acute gouty arthritis; epicondylitis; acute non-specific tenosynovitis; polychondritis�; posttraumatic osteoarthritis. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of osteoarthritis pain of the knee. <br />  NOTE: Zilretta is not interchangeable with other formulations of triamcinolone acetonide.<br /","***Epidural administration, intramuscular administration, intrathecal administration, intravenous administration, subcutaneous administration***Acute bronchospasm, status asthmaticus***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hyperthyroidism, hypothalamic-pituitary-adrenal (HPA) suppression, hypothyroidism, increased intracranial pressure, occlusive dressing, skin abrasion***Head trauma***Growth inhibition, osteoporosis***Surgery***Fungal infection, infection, viral infection***Tuberculosis***Immunosuppression***Herpes infection, measles, varicella***Glaucoma***Acne rosacea, acne vulgaris***Peripheral vascular disease***Nasal septal perforation, nasal surgery, nasal trauma***Myocardial infarction***Heart failure, hypertension***Diabetes mellitus***Skin atrophy***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Myasthenia gravis***Psychosis, seizure disorder***Coagulopathy, hemophilia, thromboembolic disease***Cataracts, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Vaccination***Breast-feeding***Tartrazine dye hypersensitivity***Neonates, premature neonates***Idiopathic thrombocytopenic purpura (ITP)***Corticosteroid hypersensitivity***Geriatric***Renal disease, renal impairment***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3108'],dapsone,"***For the treatment of dermatitis herpetiformis.***For the treatment leprosy (Hansen's disease).***For multibacillary leprosy.***For paucibacillary leprosy.***For the treatment of acne vulgaris.***For the treatment of actinomycotic mycetoma�.***For actinomycotic mycetoma� caused by <em>Actinomadura madurae</em>� or <em>Streptomyces somaliensis</em>�.***For actinomycotic mycetoma� caused by <em>Nocardia</em> sp.�.***For the treatment of granuloma annulare�.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP)�.***For the treatment of polychondritis�.***For the treatment of mild to moderate Pneumocystis pneumonia (PCP)�.***For Pneumocystis pneumonia (PCP) prophylaxis�.***For primary PCP prophylaxis� in HIV-infected patients.***For secondary PCP prophylaxis� in HIV-infected patients after PCP treatment.***For primary toxoplasmosis prophylaxis� in HIV-infected patients, specifically prevention of toxoplasmic encephalitis (TE)� due to <em>Toxoplasmosis gondii</em>.***For the treatment of pyoderma gangrenosum�.***For the treatment of subcorneal pustular dermatosis�.","***Anemia, G6PD deficiency, methemoglobin reductase deficiency***Hepatic disease***Pregnancy***Breast-feeding***Children, infants, neonates***Sulfonamide hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluticasone propionate,"***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses, including the treatment of alopecia areata, discoid lupus erythematosus, generalized exfoliative dermatitis, cutaneous lichen planus, lichen simplex chronicus, lichen striatus, nodular prurigo, pompholyx (dyshidrosis), pemphigus, polymorphous light eruption, psoriasis, seborrheic dermatitis, severe contact dermatitis, severe Rhus dermatitis (due to plants like poison ivy), and xerosis.***For the treatment of eczema, including atopic dermatitis.***For the management of symptoms associated with seasonal or perennial allergic rhinitis, including allergic conjunctivitis.***For the management of nasal symptoms associated with vasomotor rhinitis (perennial nonallergic rhinitis).***For the maintenance treatment of asthma.***For the treatment of nasal polyps.***For exercise-induced bronchospasm prophylaxis�.***Formaldehyde hypersensitivit","***General Information***Corticosteroid hypersensitivity, milk protein hypersensitivity***Acute bronchospasm, status asthmaticus***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion, surgery***Diabetes mellitus***Nasal septal perforation, nasal surgery, nasal trauma***Fungal infection, herpes infection, infection, measles, tuberculosis, varicella, viral infection***Malnutrition, osteoporosis, tobacco smoking***Geriatric***Hepatic disease***Acne rosacea, acne vulgaris, perioral dermatitis, peripheral vascular disease, skin atrophy***Cataracts, glaucoma, increased intraocular pressure, ocular exposure***Formaldehyde hypersensitivity***Children, growth inhibition, increased intracranial pressure, infants***Pregnancy***Breast-feeding***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pramlintide acetate,***For the treatment of type 1 diabetes mellitus and type 2 diabetes mellitus.***For the adjunct treatment of type 1 diabetes mellitus in patients who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy.***For the adjunct treatment of type 2 diabetes mellitus in patients who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy.,"***General Information***Gastroparesis***Dialysis, renal failure***Driving or operating machinery, hypoglycemia***Cresol hypersensitivity***Diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Osteoporosis***Pregnancy***Breast-feeding***Children***Tobacco smoking***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine","***For simultaneous diphtheria prophylaxis, tetanus prophylaxis, pertussis prophylaxis, hepatitis B prophylaxis, and poliovirus prophylaxis for primary immunization.","***General Information***Hepatitis***Anticoagulant therapy, coagulopathy, hemophilia, intraarterial administration, intravenous administration, subcutaneous administration, thrombocytopenia, vitamin K deficiency***Children, geriatric, infants, neonates, premature neonates***Neomycin hypersensitivity, polymyxin hypersensitivity, yeast hypersensitivity***Latex hypersensitivity***Fever, shock***Coma, encephalopathy, neurological disease, seizure disorder, seizures***Guillain-Barre syndrome***Chemotherapy, immunosuppression, radiation therapy***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['28439'],lamotrigine,"***For the treatment of partial seizures with or without secondary generalization. <br />        NOTE: Lamotrigine should be initiated at a low dose, with gradual increases according to the dose escalation guidelines provided by the manufacturer. This may minimize the occurrence of a severe, and potentially life-threatening skin rash, which has been associated with lamotrigine administration.<br />NOTE: Therapeutic plasma concentrations have not been established. In general, dosage should be based upon clinical response.<br />NOTE: Discontinuation of lamotrigine should be done in a step-wise fashion over at least 2 weeks (approximately 50% dosage reduction per week), unless safety concerns warrant a more rapid withdrawal***For monotherapy of partial seizures in patients currently receiving treatment with a single enzyme-inducing anti-epileptic drug (AED) (e.g., carbamazepine, phenobarbital, phenytoin, primidone) NOT to include valproate.***For monotherapy of partial seizures in patients  currently receiving treatment with valproate.***For adjunctive therapy to other anticonvulsants in the treatment of partial seizures.***For monotherapy of partial seizures in patients currently receiving treatment with a single anti-epileptic drug (AED)  OTHER than carbamazepine, phenytoin, phenobarbital, primidone, or valproate. <br />  NOTE: Safety and effectiveness of extended-release tablets have not been established as initial monotherapy or for simultaneous conversion to monotherapy from 2 or more concomitant AEDs.<br /***For adjunctive therapy to other anticonvulsants in the treatment of primary generalized tonic-clonic seizures. <br />        NOTE: Lamotrigine should be initiated at a low dose, with gradual increases according to the dose escalation guidelines provided by the manufacturer. This may minimize the occurrence of a severe, and potentially life-threatening skin rash, which has been associated with lamotrigine administration.<br />NOTE: Therapeutic plasma concentrations have not been established. In general, dosage should be based upon clinical response.<br />NOTE: Discontinuation of lamotrigine should be done in a step-wise fashion over at least 2 weeks (approximately 50% dosage reduction per week), unless safety concerns warrant a more rapid withdrawal***For adjunctive therapy to other anticonvulsants in the treatment of generalized seizures of Lennox-Gastaut syndrome. <br />        NOTE: Lamotrigine should be initiated at a low dose, with gradual increases according to the dose escalation guidelines provided by the manufacturer. This may minimize the occurrence of a severe, and potentially life-threatening skin rash, which has been associated with lamotrigine administration.<br />NOTE: Therapeutic plasma concentrations have not been established. In general, dosage should be based upon clinical response.<br />NOTE: Discontinuation of lamotrigine should be done in a step-wise fashion over at least 2 weeks (approximately 50% dosage reduction per week), unless safety concerns warrant a more rapid withdrawal***For the long-term maintenance treatment of bipolar disorder (bipolar I disorder) to delay the occurrence of mood episodes (i.e., depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy. <br />        NOTE: Do not exceed initial and subsequent dose escalations of lamotrigine due to increased risk of rash. Periodically re-assess the need for continued treatment. Lamotrigine should not be abruptly discontinued; taper downward roughly 50% per week for 2 weeks unless safety issues require a more rapid dose reduction.<br />     ***For the treatment of absence seizures�.***For long-term prophylaxis of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT)�.","***General Information***Serious rash***Depression, suicidal ideation***Abrupt discontinuation***Driving or operating machinery***Hepatic disease***Dialysis, renal disease, renal failure, renal impairment***Cardiac disease, heart failure***Black patients***Geriatric***Children, infants, neonates***Folate deficiency, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['318341'],cetuximab,"***For the treatment of KRAS wild-type metastatic colorectal cancer. <br />        NOTE: Cetuximab is not indicated for the treatment of RAS mutant colorectal cancer or when the results of RAS mutation tests are unknown. The absence of a RAS mutation should be confirmed by an FDA approved test prior to starting therapy.<br />NOTE: The serine-threonine kinase BRAF is the principal effector of KRAS. The introduction of the mutant BRAF V600E allele may impair therapeutic response to EGFR inhibitors. Mutant BRAF may be present in wild-type KRAS***For the treatment of KRAS wild-type, EGFR-expressing, metastatic colorectal cancer (mCRC) as a single agent after failure of both irinotecan- and oxaliplatin-based regimens or in patients who are intolerant to irinotecan-based chemotherapy. <br />          NOTE: In the clinical trials, patients were required to have immunohistochemical evidence of positive EGFR expression from primary tumor or metastatic tumor site using the DakCytomation EGFR pharmDx test kit. Response rate did not correlate with either the percentage of positive cells or the intensity of EGFR expression. EGFR expression status should be determined by an FDA approved test prior to starting therapy.<br />       ***For the treatment of KRAS wild-type, EGFR-expressing, metastatic colorectal cancer (mCRC) in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy. <br />          NOTE: In the clinical trials, patients were required to have immunohistochemical evidence of positive EGFR expression from primary tumor or metastatic tumor site using the DakCytomation EGFR pharmDx test kit. Response rate did not correlate with either the percentage of positive cells or the intensity of EGFR expression. EGFR expression status should be determined by an FDA approved test prior to starting therapy.<br />       ***For the first-line treatment of KRAS wild-type, EGFR-expressing, metastatic colorectal cancer (mCRC) in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin). <br />          NOTE: In the clinical trials, patients were required to have immunohistochemical evidence of positive EGFR expression from primary tumor or metastatic tumor site using the DakCytomation EGFR pharmDx test kit. Response rate did not correlate with either the percentage of positive cells or the intensity of EGFR expression. EGFR expression status should be determined by an FDA approved test prior to starting therapy.<br />       ***For the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC), in combination with mFOLFOX6 (leucovorin, oxaliplatin, 5-fluorouracil)�. <br />          NOTE: Response rates do not correlate with either the percentage of EGFR-positive cells or the intensity of EGFR expression.<br />       ***For the treatment of BRAF mutation-positive, RAS wild-type, metastatic colorectal cancer, in combination with irinotecan and vemurafenib�.***For the treatment of head and neck cancer. <br />        NOTE: Pretreatment assessment for evidence of EGFR expression is not required for patients with squamous cell cancer of the head and neck.<br />NOTE: Progression-free survival was not improved when cetuximab was added to radiation therapy and cisplatin for the treatment of locally advanced squamous cell carcinoma of the head and neck in a controlled study (n = 940); grade 3 and 4 toxicity and adverse reactions with fatal outcomes occurred more often in cetuximab-treated patients in this study***For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in combination with cisplatin�.***For the first-line treatment of recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy and fluorouracil.***For the first-line treatment of advanced non-small cell lung cancer (NSCLC)� in combination with cisplatin and vinorelbine.","***Acute bronchospasm, hypotension, infusion-related reactions, murine protein hypersensitivity, urticaria***Pulmonary disease, pulmonary edema, pulmonary fibrosis***Infection, sunlight (UV) exposure***Cardiac arrest, cardiac arrhythmias, cardiac disease, coronary artery disease, electrolyte imbalance, heart failure, hypocalcemia, hypokalemia, hypomagnesemia, radiation therapy, respiratory arrest***Male-mediated teratogenicity, pregnancy***Breast-feeding***Children***KRAS mutations",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluticasone furoate,"***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses, including the treatment of alopecia areata, discoid lupus erythematosus, generalized exfoliative dermatitis, cutaneous lichen planus, lichen simplex chronicus, lichen striatus, nodular prurigo, pompholyx (dyshidrosis), pemphigus, polymorphous light eruption, psoriasis, seborrheic dermatitis, severe contact dermatitis, severe Rhus dermatitis (due to plants like poison ivy), and xerosis.***For the treatment of eczema, including atopic dermatitis.***For the management of symptoms associated with seasonal or perennial allergic rhinitis, including allergic conjunctivitis.***For the management of nasal symptoms associated with vasomotor rhinitis (perennial nonallergic rhinitis).***For the maintenance treatment of asthma.***For the treatment of nasal polyps.***For exercise-induced bronchospasm prophylaxis�.***Formaldehyde hypersensitivit","***General Information***Corticosteroid hypersensitivity, milk protein hypersensitivity***Acute bronchospasm, status asthmaticus***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion, surgery***Diabetes mellitus***Nasal septal perforation, nasal surgery, nasal trauma***Fungal infection, herpes infection, infection, measles, tuberculosis, varicella, viral infection***Malnutrition, osteoporosis, tobacco smoking***Geriatric***Hepatic disease***Acne rosacea, acne vulgaris, perioral dermatitis, peripheral vascular disease, skin atrophy***Cataracts, glaucoma, increased intraocular pressure, ocular exposure***Formaldehyde hypersensitivity***Children, growth inhibition, increased intracranial pressure, infants***Pregnancy***Breast-feeding***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,tenofovir disoproxil fumarate,"***For the treatment of human immunodeficiency virus (HIV) infection in combination with other anti-retroviral agents.***For treatment of chronic hepatitis B infection.***For human immunodeficiency virus (HIV) prophylaxis�.***For human immunodeficiency virus (HIV) prophylaxis� after occupational exposure.***For human immunodeficiency virus (HIV) prophylaxis� after nonoccupational exposure, including sexual assault. <br />          NOTE: Higher risk exposures for which prophylaxis is recommended include exposure of vagina, rectum, eye, mouth, or other mucous membrane, nonintact skin, or percutaneous contact with blood, semen, vaginal secretions, rectal secretions, breast milk, or any body fluid that is visibly contaminated with blood when the source is known to be HIV-positive. Exposures to a source patient with unknown HIV status should be assessed on a case-by-case basis.<br />       ***For pre-exposure HIV prophylaxis� of uninfected individuals to reduce the risk of sexually acquired HIV in heterosexual adults at high risk and to reduce the acquisition risk of HIV in adult injection drug users.","***General Information***Bone fractures, hypophosphatemia, renal failure, renal impairment***Osteomalacia, osteoporosis***Geriatric***Children, infants, neonates***Alcoholism, females, hepatic disease, hepatotoxicity or lactic acidosis, obesity***Pregnancy***Breast-feeding***Hepatitis B and HIV coinfection, hepatitis B exacerbation***Human immunodeficiency virus (HIV) infection resistance***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***HIV serum status***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sodium chloride,"***For the treatment of dehydration or hypovolemia, including during diabetic ketoacidosis, cardiopulmonary resuscitation, and shock (e.g., septic shock, anaphylactic shock, cardiogenic shock).***For the treatment of hyponatremia. <br />        NOTE: In general, initial correction of acute or symptomatic hyponatremia should be undertaken with hypertonic 3% Sodium Chloride Injection. Asymptomatic, chronic hyponatremia should be corrected with isotonic 0.9% Sodium Chloride Injection. <br />     ***For mucolysis and sputum induction in patients with cystic fibrosis.***For the treatment of nasal congestion and dryness.***For nutritional supplementation.***For temporary relief of corneal edema (i.e., ocular inflammation).***For the treatment of increased intracranial pressure�.***For the inpatient management of viral bronchiolitis�.***Formoterol; Mometasone","***Cardiac disease, diabetic ketoacidosis, edema, heart failure, hyperaldosteronism, hyperchloremia, hypernatremia, hypertension, hypervolemia, metabolic acidosis, renal artery stenosis, renal disease, renal failure, renal impairment***Alcoholism, females, hyponatremia, hypoxemia, malnutrition***Hepatic disease***Hemolysis***Pregnancy***Breast-feeding***Neonates, premature neonates***Requires an experienced clinician***Visual impairment***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,warfarin sodium,"***For general dosing information in patients requiring warfarin anticoagulation. <br />        NOTE: Clinical practice guidelines recommend against the routine use of pharmacogenetic testing for guiding dosing in patients initiating warfarin therapy.<br />     ***For treatment of deep venous thrombosis (DVT) or pulmonary embolism and deep vein thrombosis (DVT) prophylaxis or pulmonary embolism prophylaxis.***For the treatment and further prevention of DVT or pulmonary embolism (PE) after the initial, acute phase of treatment.***For DVT prophylaxis in patients undergoing total hip or knee replacement surgery or hip fracture surgery�.***For DVT prophylaxis in patients with long-term indwelling central venous catheters to prevent axillary-subclavian venous thrombosis�.***For thrombosis prophylaxis (i.e., arterial thromboembolism prophylaxis, stroke prophylaxis, or coronary artery thrombosis prophylaxis). <br />        NOTE: For information regarding prophylaxis in orthopedic surgery or with central venous catheters, see 'deep venous thrombosis (DVT) prophylaxis'.<br />     ***For coronary artery thrombosis prophylaxis in high or very high-risk patients with stable angina� or chronic coronary artery disease�.***For thrombosis prophylaxis in patients with atrial fibrillation.***For thrombosis prophylaxis in patients with atrial fibrillation or atrial flutter who are undergoing cardioversion.***For thrombosis prophylaxis in patients with prosthetic heart valves.***For thrombosis prophylaxis in patients with mechanical prosthetic heart valves and a history of bleeding while receiving warfarin therapy.***For stroke prophylaxis in patients with cerebral venous sinus thrombosis (CVST) after primary treatment with heparin or LMWH.***For thrombosis prophylaxis in patients with valvular heart disease.***For stroke prophylaxis in patients with dilated cardiomyopathy (DCM), particularly in the subgroup of patients with concomitant atrial fibrillation or with a prior history of systemic embolization.***For secondary myocardial infarction prophylaxis (i.e., prevention of a subsequent myocardial infarction or coronary artery thrombosis prophylaxis) or for stroke prophylaxis in high-risk postmyocardial infarction patients (e.g., patients with acute MI complicated by severe LV dysfunction, CHF, atrial fibrillation, previous emboli, or 2D echocardiograph evidence of mural thrombosis).***For the coronary artery thrombosis prophylaxis in patients with unstable angina�.***For prophylaxis of arterial and/or venous thromboembolism in patients with antiphospholipid antibody syndrome.***For thromboprophylaxis� in patients with heart failure� who are in sinus rhythm.","***Coumarin anticoagulants hypersensitivity***Anemia, aneurysm, aortic dissection, atrial fibrillation, bleeding, cardiac disease, cerebrovascular disease, eclampsia, endocarditis, epidural anesthesia, GI bleeding, head trauma, hematological disease, hemophilia, hypertension, intracranial bleeding, leukemia, lumbar puncture, neoplastic disease, peptic ulcer disease, pericardial effusion, pericarditis, polycythemia vera, preeclampsia, renal disease, renal failure, renal impairment, retinal bleeding, spinal anesthesia, stroke, surgery, vasculitis***Asian patients***Dental work***Diabetes mellitus***Heparin-induced thrombocytopenia (HIT), idiopathic thrombocytopenic purpura (ITP)***Heart failure***Cholestasis, hepatic disease, hepatitis, jaundice***Intramuscular injections***Protein C deficiency, protein S deficiency***Vitamin C deficiency***Anorexia nervosa, bulimia nervosa, vitamin K deficiency***Alcoholism, dementia, psychosis***Fever, hyperthyroidism, infection***Diarrhea, hyperlipidemia, hypothyroidism, peripheral edema***Tobacco smoking***Geriatric***Labor, obstetric delivery, pregnancy***Children, infants, neonates***Breast-feeding***Contraception requirements, pregnancy testing, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bupropion hydrochloride,"***For the treatment of major depression.***For the prevention of seasonal major depressive disorder episodes associated with seasonal affective disorder (SAD).***For use as an adjunct to psychosocial interventions in the management of tobacco cessation (smoking cessation).***For use alone to aide in tobacco cessation.***For aide with tobacco cessation using bupropion in combination with a nicotine transdermal system (NTS).***For the treatment of attention-deficit hyperactivity disorder (ADHD)�.***For use as monotherapy of attention-deficit hyperactivity disorder (ADHD)� in adults.***For the symptomatic treatment of neuropathic pain� due to various causes, including pain associated with peripheral diabetic neuropathy� or postherpetic neuralgia�.***Formoterol; Mometasone","***General Information***Alcoholism, anorexia nervosa, benzodiazepine withdrawal, brain tumor, bulimia nervosa, diabetes mellitus, head trauma, hypoglycemia, hyponatremia, hypoxemia, intracranial mass, obesity treatment, seizure disorder, seizures, stroke, substance abuse***Children, suicidal ideation***Tics, Tourette's syndrome***Behavioral changes, bipolar disorder, depression, mania, psychiatric event, schizophrenia***MAOI therapy***Neonates, pregnancy***Breast-feeding***Hepatic disease***Renal disease, renal failure, renal impairment***Acute myocardial infarction, cardiac disease, heart failure, hypertension, tobacco smoking***Geriatric***Driving or operating machinery, ethanol intoxication***Closed-angle glaucoma, increased intraocular pressure***Abrupt discontinuation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['613391'],prasugrel,"***For arterial thromboembolism prophylaxis (thrombotic cardiovascular events including stent thrombosis) in patients with acute coronary syndrome (i.e., unstable angina, non-ST-elevation myocardial infarction [NSTEMI], or ST-elevation acute myocardial infarction [STEMI]) who are to be managed with percutaneous coronary intervention (PCI).","***Anticoagulant therapy, bleeding, body weight less than 60 kg, coronary artery bypass graft surgery (CABG), GI bleeding, intracranial bleeding, peptic ulcer disease, surgery, trauma***Stroke***Hepatic disease***Thrombotic thrombocytopenic purpura (TTP)***Abrupt discontinuation***Asian patients***Children***Pregnancy***Breast-feeding***Renal impairment***Thienopyridine hypersensitivity***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],drospirenone/ethinyl estradiol,"***For routine contraception.***For the treatment of acne vulgaris in women who also desire oral contraception.***For the treatment of premenstrual dysphoric disorder (PMDD) in women who also desire oral contraception.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception.***For the treatment or adjuvant treatment of conditions such as amenorrhea�, hirsutism�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who desire oral contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Adrenal insufficiency, electrolyte imbalance, hyperkalemia, renal disease, renal failure, renal impairment***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia, pancreatitis***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, hypertension, myocardial infarction, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['197'],acetylcysteine,"***For the prevention of hepatotoxicity after an acute acetaminophen overdose or repeated ingestion of supratherapeutic doses. <br />  NOTE: The Rumack-Matthew nomogram should be used to estimate the hepatotoxicity potential from an acute acetaminophen (APAP) overdose in patients with a known APAP concentration, a known APAP ingestion time, and who present within 8 hours of the overdose. For patients whose serum APAP concentrations fall above the possible"" toxicity line on the nomogram",initiate treatment within 8 hours of suspected APAP ingestion for maximal protection against hepatic injury. Give activated charcoal as soon as possible after ingestion to prevent APAP absorption. For regular-release APAP overdoses,obtain serum drug concentration at least 4 hours post-ingestion; concentrations obtained earlier than 4 hours may not represent maximum APAP concentrations. For extended-release APAP overdoses,if the initial APAP serum concentration was below the possible toxicity line,obtain a second concentration 8 to 10 hours post-ingestion. The efficacy of acetylcysteine diminishes progressively after 8 hours post-ingestion. Beginning treatment 15 to 24 hours post-ingestion results in limited efficacy; however,it does not appear to worsen the condition and should not be withheld since the reported time of ingestion may not be correct. If the time of ingestion is unknown,or the serum APAP concentration is not available,cannot be interpreted,or is not available within 8 hours of APAP ingestion,acetylcysteine should be administered immediately regardless of the quantity reported to have been ingested. If greater than 24 hours has elapsed since the APAP ingestion,the clinician should determine the appropriateness of acetylcysteine administration based on the patients liver status and clinical presentation.<br />NOTE: The Rumack-Matthew nomogram is ineffective at predicting hepatotoxicity in patients who have ingested repeated supratherapeutic doses of acetaminophen over an extended period of time. In these patients,treatment should be guided by information obtained from laboratory tests,including: acetaminophen serum concentrations,liver function tests (LFTs),serum creatinine,BUN,electrolytes,bilirubin,blood glucose,and INR. Assistance may be obtained by contacting your regional poison control center at 1�800�222�1222 or the acetaminophen overdose center at 1�800�525�6115.***For adjunctive treatment of chronic bronchopulmonary disorders such as chronic obstructive pulmonary disease (COPD),including chronic bronchitis,emphysema,tuberculosis,bronchiectasis,and primary amyloidosis of the lung.***For mucolysis of viscous or inspissated mucous secretions in patients with pulmonary conditions (e.g.,pneumonia,bronchitis,cystic fibrosis,atelectasis due to mucous obstruction,and post-traumatic chest conditions) and for use during tracheostomy care,anaesthesia,"and diagnostic bronchograms.***For diagnostic bronchial studies.***For nephrotoxicity prophylaxis� against radiographic-contrast-induced reductions in renal function in those patients with preexisting renal insufficiency (SCr > 1.2mg/dl or CrCl < 60 ml/min) or who are otherwise at risk for radiocontrast-induced nephropathy.***For the treatment of giant papillary conjunctivitis (GPC)�.***For the treatment of distal intestinal obstruction syndrome (DIOS)� (previously called meconium ileus equivalent).""","***General Information***Acute bronchospasm, asthma, gag reflex depression, respiratory insufficiency***Esophageal varices, GI bleeding, peptic ulcer disease, vomiting***Children, infants, neonates***Pregnancy***Breast-feeding***Heart failure, hypertension, renal disease"
"['2105', '343027']",carmustine,"***For the treatment of brain tumors including malignant glioma and glioblastoma multiforme.***For the treatment of brain tumors including malignant glioma, glioblastoma, medulloblastoma, astrocytoma, ependymoma, and brain metastases. <br />  NOTE: Carmustine injection has been designated an orphan drug by the FDA for the treatment of intracranial malignancies.<br /***For the treatment of newly-diagnosed high grade malignant glioma as an adjunct to surgery and radiation and as an adjunct to surgery in patients with recurrent glioblastoma multiforme. <br />  NOTE: Carmustine implantable wafer has been designated an orphan drug by the FDA for the treatment of malignant glioma.<br /***For the treatment of multiple myeloma in combination with prednisone.***For the treatment of relapsed or refractory Hodgkin lymphoma or non-Hodgkin's lymphoma (NHL), in combination with other approved drugs.***For the first-line treatment of metastatic malignant melanoma in combination with dacarbazine, cisplatin, and tamoxifen�. <br />        NOTE: Since the major toxicity associated with carmustine administration is delayed bone marrow suppression, blood counts should be monitored weekly for at least 6 weeks after a dose and courses of carmustine should not be given more frequently than every 6 weeks.<br />     ***For the treatment of cutaneous T-cell lymphoma (CTCL)� (aka mycosis fungoides�).***For stem cell transplant preparation, in combination with other chemotherapy agents�.***Formoterol; Mometasone","***General Information***Anemia, aseptic meningitis, bleeding, bone marrow suppression, infection, leukopenia, neutropenia, thrombocytopenia***Pulmonary fibrosis, pulmonary toxicity***New primary malignancy***Extravasation***Intraarterial administration***Seizures***Wound dehiscence***Increased intracranial pressure***Renal disease, renal failure, renal impairment***Hepatic disease, hepatotoxicity***Children***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,influenza vaccine,***For annual seasonal influenza prophylaxis.,"***General Information***Intravenous administration, subcutaneous administration***Fever, respiratory infection***Egg hypersensitivity, kanamycin hypersensitivity, latex hypersensitivity, neomycin hypersensitivity***Guillain-Barre syndrome***Geriatric***Children, infants***Pregnancy***Breast-feeding***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Acquired immunodeficiency syndrome (AIDS), agammaglobulinemia, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Syncope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['475342', '1546019']",dasatinib,"***For the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). <br />        NOTE: The FDA has designated dasatinib as an orphan drug for the treatment of CML.<br />     ***For the treatment of myeloid or lymphoid blast-phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib.***For the treatment of chronic-phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib.***For the treatment of newly diagnosed chronic-phase Ph+ CML. <br />          NOTE: Dasatinib was not active against the T315I mutation based on in vitro data.<br />       ***For the treatment of accelerated-phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib.***For the treatment of chronic-phase Ph+ CML.***For the treatment of Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL). <br />  NOTE: Dasatinib has been designated as an orphan drug by the FDA for the treatment of Ph+ ALL.<br /***For the treatment of For the treatment of Ph+ ALL with resistance or intolerance to prior therapy.***Formoterol***Formoterol; Mometasone","***Anemia, bone marrow suppression, neutropenia, thrombocytopenia***Anticoagulant therapy, bleeding, GI bleeding, intracranial bleeding***Edema, pericardial effusion, pleural effusion***Alcoholism, cardiac arrhythmias, cardiac disease, diabetes mellitus, females, heart failure, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, thyroid disease***Lactase deficiency***Tumor lysis syndrome (TLS)***Pulmonary hypertension***Geriatric***Children, growth inhibition, infants, neonates***Pregnancy***Contraception requirements, infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['35636'],risperidone,"***For the treatment of schizophrenia.***For the treatment of bipolar disorder (Bipolar I Disorder), including acute mania or mixed episodes and maintenance therapy.***For the treatment of acute mania or mixed episodes associated with Bipolar I Disorder.***For the maintenance treatment of Bipolar I Disorder as monotherapy or adjunct therapy to lithium or valproate.***For the treatment of irritability associated with autistic disorder.***For the treatment of moderate to severe tics associated with Tourette's syndrome�.***For the treatment of moderate to severe disruptive behaviors� (e.g., aggression) associated with oppositional defiant disorder� or other disruptive behavioral disorders�.***For the treatment of delirium� in the pediatric intensive care unit (PICU).***For the treatment of severe behavioral or psychological symptoms of dementia�.***Formoterol***Formoterol; Mometasone","***General Information***CNS depression, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Agranulocytosis, hematological disease, leukopenia, neutropenia, thrombotic thrombocytopenic purpura (TTP)***Phenylketonuria***Suicidal ideation***Abrupt discontinuation***Tardive dyskinesia***Cardiac disease, cerebrovascular disease, heart failure, hypovolemia, myocardial infarction, orthostatic hypotension, syncope***Alcoholism, bradycardia, cardiac arrhythmias, coronary artery disease, females, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, thyroid disease, torsade de pointes***Hyponatremia, seizure disorder, seizures***Renal failure, renal impairment***Hepatic disease***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Dysphagia***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Diabetes mellitus, diabetic ketoacidosis, hypercholesterolemia, hyperglycemia, hyperlipidemia, hyperosmolar hyperglycemic state (HHS), hypertriglyceridemia, obesity***Breast cancer, hyperprolactinemia, infertility***Intravenous administration, subcutaneous administration***Priapism***Neonates, pregnancy, pregnancy testing***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3407'],digoxin,"***For ventricular rate control in patients with chronic atrial fibrillation and/or atrial flutter�; or for the treatment of narrow-complex paroxysmal supraventricular tachycardia (PSVT)� or for paroxysmal supraventricular tachycardia (PSVT) prophylaxis� in patients without a delta wave on ECG during sinus rhythm; or for the treatment of congestive heart failure. <br />        NOTE: In patients with undetectable serum digoxin concentrations, the total loading dose should be based on lean body weight and clinical response, and divided into several doses administered at 4- to 8-hour intervals. Higher doses (i.e., concentrations) may be required for treating arrhythmias than for treating heart failure. Patients with moderate-severe renal insufficiency should receive smaller loading doses than patients with normal renal function due to a reduced volume of distribution.<br />NOTE: Maintenance doses should be based on lean body weight, clinical response, and renal function. Higher doses (i.e., concentrations) may be required for treating arrhythmias than for treating heart failure. Lower doses should be considered for geriatric patients, patients with impaired renal function, and in patients whose lean weight is an abnormally small fraction of their total body mass because of obesity or edema. In 1 small study of men with NYHA class II or III heart failure who were in normal sinus rhythm, left ventricular function improved significantly on a dose of 0.125 mg/day that produced mean serum concentrations of 0.8 ng/mL but doses of 0.25 mg/day and corresponding higher concentrations of 1.5 ng/mL did not produce further improvement over the lower dosage. In another small study of men with NYHA class II or III heart failure who were in normal sinus rhythm, left ventricular ejection fraction improved significantly when digoxin was increased from a mean dose of 0.2 mg/day (mean trough 0.67 ng/mL) to a mean dose of 0.39 mg/day (mean trough 1.22 ng/mL); however, no significant changes were observed in heart failure score or exercise tolerance***For the transplacental treatment of fetal supraventricular tachyarrhythmias�.","***Acute myocardial infarction, Adams-Stokes syndrome, AV block, bradycardia, cardiomyopathy, cor pulmonale, hyperthyroidism, hypothyroidism, hypoxemia, myocarditis, myxedema, pulmonary disease, sick sinus syndrome***Carotid sinus hypersensitivity, ventricular arrhythmias, ventricular fibrillation, ventricular tachycardia, Wolff-Parkinson-White syndrome***Renal disease, renal failure, renal impairment***Geriatric***Hepatic disease***Constrictive pericarditis, idiopathic hypertrophic subaortic stenosis***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypocalcemia, hypokalemia, hypomagnesemia***Hypertension***Infants, neonates, premature neonates***Pregnancy***Breast-feeding***Diarrhea, malabsorption syndrome***Intramuscular administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sumatriptan succinate,***For the acute treatment of migraine attacks with or without aura. <br />        NOTE: Sumatriptan is not indicated for hemiplegic or basilar migraine.<br />     ***For the acute treatment of cluster headache.,"***General Information***Sumatriptan hypersensitivity***Acute myocardial infarction, angina, arteriosclerosis, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, hypercholesterolemia, obesity, tobacco smoking, vasospastic angina, Wolff-Parkinson-White syndrome***Hypertension***Cerebrovascular disease, intracranial bleeding, stroke***Basilar/hemiplegic migraine***Intravenous administration***Pregnancy***Breast-feeding***Hepatic disease***Renal disease, renal failure, renal impairment***Children***Geriatric***Driving or operating machinery***Colitis, peripheral vascular disease, Raynaud's phenomenon***Seizure disorder, seizures***Visual disturbance***MAOI therapy***Magnetic resonance imaging (MRI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083']['6373'],estradiol/levonorgestrel,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae) in women with an intact uterus.***For osteoporosis prophylaxis due to menopause (either natural or surgical) in women with an intact uterus.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1895'],drospirenone/ethinyl estradiol/levomefolate calcium,"***For routine contraception and to increase folate levels in women who desire to use oral contraception.***For the treatment of premenstrual dysphoric disorder (PMDD) in women who desire to use an oral contraceptive.***For the treatment of moderate acne vulgaris in women who also desire to use an oral contraceptive.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception.***Formoterol; Mometasone","***Adrenal insufficiency, electrolyte imbalance, hyperkalemia, renal failure, renal impairment***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, hypertension, myocardial infarction, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Breast cancer***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Surgery***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Headache, migraine***Depression***Hypothyroidism, thyroid disease***Pernicious anemia, vitamin B12 deficiency***Contact lenses, glaucoma, visual disturbance***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Obesity***Systemic lupus erythematosus (SLE)***Children, infants, neonates***Angioedema, hereditary angioedema***Chloasma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,aminosalicylic acid,"***For the treatment of tuberculosis infection in combination with other agents as second line therapy. <br />        NOTE: Aminosalicylic acid is most commonly used in the treatment of multi-drug resistant tuberculosis or when isoniazid and rifampin therapy is not possible due to resistance and/or intolerance.<br />NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., at least 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. The initial regimen for the treatment of tuberculosis should include four drugs unless the likelihood of INH or rifampin resistance is low (i.e., &lt; 4%), in which case an initial regimen of INH, rifampin, and pyrazinamide may be considered. HIV positive patients should always receive induction therapy with four drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate.   For multi-drug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, the CDC recommends treatment for 18�24 months after culture conversion in patients with bacteriologic confirmation and for at least 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months in MDR-TB***For aminosalicylic acid desensitization.","***Renal disease, renal failure***Hepatitis, jaundice***Hepatic disease***Vitamin B12 deficiency***Malabsorption syndrome***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,collagenase,"***For the treatment of severe partial- or full-thickness burns. <br />  NOTE: Removal of necrotic tissue by mechanical debridement should be considered during the initial and subsequent assessments.<br />NOTE: Collagenase should only be used on wounds that have necrotic material. Antibiotic administration is paramount for infected wounds.<br />NOTE: Collagenase should be discontinued as soon as the wound bed is devoid of necrotic tissue and has more than 90% granulation tissue***For the treatment of decubitus ulcer, diabetic foot ulcer, or varicose ulcer that requires debridement. <br />  NOTE: Removal of necrotic tissue by mechanical debridement should be considered during the initial and subsequent assessments.<br />NOTE: Collagenase should only be used on wounds that have necrotic material. Stage 1 ulcers are not appropriate candidates. Antibiotic administration is paramount for infected wounds.<br />NOTE: Collagenase should be discontinued as soon as the wound bed is devoid of necrotic tissue and has more than 90% granulation tissue***For the treatment of Dupuytren's contracture with a palpable cord.***For the treatment of Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.","***General Information***Bone marrow suppression, hyperglycemia, immunosuppression, infection, malnutrition***Arteriosclerosis, diabetes mellitus, peripheral vascular disease***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Children***Pregnancy***Breast-feeding***Corporal rupture***Requires an experienced clinician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8703'],fenofibrate,"***For use as an adjunct to diet for the treatment of adult patients with severe hypertriglyceridemia. <br />  NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.     <br />NOTE: Markedly elevated levels of serum triglycerides (e.g., &gt; 2000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.  ***For use as an adjunct to diet to reduce elevated LDL-cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase HDL-cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. <br />        NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.   ","***General Information***Cardiac disease***Biliary cirrhosis, cholelithiasis, gallbladder disease, hepatic disease***Dialysis, renal disease, renal failure, renal impairment***Anticoagulant therapy***Thromboembolic disease***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding***Diabetes mellitus***Hypothyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sodium oxybate,***For the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.,"***General Information***Succinic semialdehyde dehydrogenase deficiency***Alcoholism, behavioral changes, CNS depression, coadministration with other CNS depressants, coma, depression, driving or operating machinery, ethanol ingestion, respiratory depression, substance abuse, suicidal ideation, surgery***Hypoxemia, respiratory insufficiency, sleep apnea***Seizure disorder, seizures***Hepatic disease***Cardiac arrhythmias, cardiac disease, heart failure, hypertension, renal disease***Urinary incontinence***Electrolyte imbalance, hypernatremia, hyperprolactinemia, hypokalemia***Abrupt discontinuation***Geriatric***Eclampsia, labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['276237'],emtricitabine/tenofovir disoproxil fumarate,"***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents. <br />  NOTE: Emtricitabine; tenofovir disoproxil fumarate (DF) is not indicated for the treatment of chronic hepatitis B virus (HBV) infection, and safety and efficacy of treatment have not been established in patients co-infected with HBV and HIV.<br />NOTE: Children must be able to swallow whole tablets in order to use emtricitabine; tenofovir DF fixed-dose combination tablets***For human immunodeficiency virus (HIV) prophylaxis.***For HIV prophylaxis� after occupational exposure to HIV.***For pre-exposure HIV prophylaxis of uninfected individuals to reduce the risk of sexually acquired HIV-1 in adults at high risk.***For HIV prophylaxis� after nonoccupational exposure to HIV, including sexual assault. <br />  NOTE: Higher risk exposures for which prophylaxis is recommended include exposure of vagina, rectum, eye, mouth, or other mucous membrane, nonintact skin, or percutaneous contact with blood, semen, vaginal secretions, rectal secretions, breast milk, or any body fluid that is visibly contaminated with blood when the source is known to be HIV-positive. Exposures to a source patient with unknown HIV status should be assessed on a case-by-case basis.<br /***For pre-exposure HIV prophylaxis of uninfected individuals at high risk of acquiring HIV infection through injection drug use�.","***General Information***Human immunodeficiency virus (HIV) infection resistance***Hepatitis B and HIV coinfection, hepatitis B exacerbation***Alcoholism, females, hepatic disease, hepatotoxicity or lactic acidosis, obesity***Bone fractures, hypophosphatemia, renal failure, renal impairment***Osteomalacia, osteoporosis***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Children***Pregnancy***Breast-feeding***HIV serum status***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,naratriptan hydrochloride,***For the acute treatment of migraine with or without aura. <br />        NOTE: Naratriptan is not indicated for hemiplegic or basilar migraine.<br />     ***For menstrual migraine prophylaxis�.,"***General Information***Acute myocardial infarction, angina, arteriosclerosis, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, hypercholesterolemia, myocardial infarction, obesity, tobacco smoking, vasospastic angina, Wolff-Parkinson-White syndrome***Hypertension***Colitis, peripheral vascular disease***Cerebrovascular disease, intracranial bleeding, stroke***Basilar/hemiplegic migraine***Renal failure, renal impairment***Hepatic disease***Pregnancy***Breast-feeding***Geriatric***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1272'],aztreonam,"***For the management of pulmonary infections in patients with cystic fibrosis.***For the improvement of respiratory symptoms in cystic fibrosis patients with <em>Pseudomonas aeruginosa</em> and an FEV1 between 25% to 75% predicted.***For the treatment of pulmonary exacerbation in patients with cystic fibrosis.***For the treatment of gram-negative infections including intraabdominal infections (peritonitis), gynecologic infections (endometritis, pelvic cellulitis), skin and skin structure infections (diabetic foot ulcer, postoperative wounds, burn wound infection), and bacteremia.***For the treatment of peritonitis in patients receiving peritoneal dialysis.***For the treatment of complicated and uncomplicated urinary tract infection (UTI) including cystitis and pyelonephritis.***For the treatment of lower respiratory tract infections, including bronchitis and pneumonia (community-acquired pneumonia and nosocomial pneumonia).***For the treatment of community-acquired pneumonia (CAP).***For the treatment of nosocomial pneumonia, including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).***For the treatment of bronchitis.***For surgical infection prophylaxis�.***For the empiric treatment of febrile neutropenia�.***For the treatment of febrile neutropenia in adults.***For the treatment of febrile neutropenia in pediatric patients.","***General Information***Viral infection***Carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Renal disease, renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Acute bronchospasm***Children, infants, neonates***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['283810'],bimatoprost,***For the reduction of elevated or increased intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.***For treatment of hypotrichosis of the eyelashes.,"***General Information***Closed-angle glaucoma***Aphakia, corneal abrasion, iritis, keratitis, ocular infection, ocular surgery, ocular trauma, uveitis***Contact lenses***Sunlight (UV) exposure***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['73710'],paricalcitol,"***For the prevention and treatment of secondary hyperparathyroidism and resultant metabolic bone disease (renal osteodystrophy�). <br />        NOTE: Dosage adjustments should be determined based on serum calcium, serum phosphorous, and serum or plasma iPTH concentrations. Initially and following a dosage adjustment, serum calcium, serum phosphorous, and serum or plasma iPTH concentrations should be monitored at least every 2 weeks for 3 months, monthly for 3 months, and then every 3 months thereafter.<br />     ***For initial dosing and dosage titration in pre-dialysis patients with Stage 3 or 4 chronic kidney disease. <br />  NOTE: In general, the dose should be adjusted no more frequently than every 2 to 4 weeks in adults and every 4 weeks in pediatric patients. In clinical trials of paricalcitol in adults, the average weekly dose was 9.6 mcg in patients taking once daily and 9.5 mcg in patients taking 3 times per week.<br /***For initial dosing and dosage titration in patients with Stage 5 chronic kidney disease on dialysis.***For initial dosing and dosage titration in patients with stage 5 chronic kidney disease on dialysis (National Kidney Foundation Guidelines). <br />  NOTE: Serum calcium concentration should be less than 9.5 mg/dL in patients with a serum iPTH less than 1000 pg/mL. In patients with a serum iPTH greater 1000 pg/mL, the serum calcium concentration should be less than 10 mg/dL. Serum phosphorous concentration should be less than 5.5 mg/dL and the calcium-phosphorous product should be less than 55.<br />Dosage adjustments should be determined based on serum calcium, serum phosphorous, and plasma iPTH concentrations. Initially and during dosage titration, monitor serum calcium and phosphorous concentrations every 2 weeks for 1 month and then monthly. Plasma iPTH concentration should be monitored monthly for 3 months then every 3 months once target iPTH concentrations are achieved (150 to 300 pg/mL)","***Hypercalcemia***Hypervitaminosis D***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hepatitis B vaccine (recombinant),***For hepatitis B prophylaxis.***For prophylaxis of hepatitis B using Recombivax HB.***For prophylaxis of hepatitis B using Engerix-B.***For booster vaccination using Engerix-B.***For prophylaxis of hepatitis B using Heplisav-B.,"***General Information***Yeast hypersensitivity***Neonates, premature neonates***Anticoagulant therapy, coagulopathy, hemophilia, intravenous administration, subcutaneous administration, thrombocytopenia, vitamin K deficiency***Cardiac disease, fever, infection***Chemotherapy, human immunodeficiency virus (HIV) infection, immunosuppression***Dialysis, renal disease, renal failure***Pregnancy***Breast-feeding***Latex hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,leuprolide acetate,"***For the palliative treatment of advanced prostate cancer, particularly when orchiectomy or estrogen therapy are not indicated or are unacceptable.***For the management of endometriosis including pain relief and reduction of endometriotic lesions.***For the treatment of central precocious puberty (idiopathic or neurogenic) in children. <br />        NOTE: Leuprolide has been designated an orphan drug by the FDA for this indication.<br />NOTE: Downregulation is determined by GnRH agonist stimulation test, sex steroid concentrations, and Tanner staging. Give consideration to discontinuing treatment before 11 years of age in girls and 12 years of age in boys***For the preoperative treatment of anemia due to uterine leiomyomata (fibroids) in combination with iron supplementation when iron therapy alone fails to correct the anemia.***For the treatment of benign prostatic hyperplasia (BPH)�.***For the adjuvant treatment of premenopausal women with hormone receptor-positive breast cancer�.***For the treatment of nonspecific symptoms associated with premenstrual syndrome (PMS)�.***For inhibiting premature leuteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation and subsequent in vitro fertilization (IVF) or other assisted reproductive technology (ART) for the treatment of infertility�. <br />        NOTE: Drugs such as ganirelix and cetrorelix are now more commonly used and are FDA-approved for this purpose. Leuprolide should only be used by a qualified infertility specialist. Withhold HCG administration in cases where the ovaries are abnormally enlarged to reduce the chance of inducing ovarian hyperstimulation syndrome (OHSS).<br />     ***For prevention of stuttering priapism� (i.e., recurrent priapism).***Formoterol***Formoterol; Mometasone","***Benzyl alcohol hypersensitivity***Gonadotropin-Releasing Hormone (GnRH) analogs hypersensitivity***Renal impairment, spinal cord compression, urinary tract obstruction***Pituitary insufficiency***Dysfunctional uterine bleeding, menstruation, vaginal bleeding***Children, geriatric, osteoporosis***Females, pregnancy***Breast-feeding***Cardiac disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, stroke, tobacco smoking***Diabetes mellitus, hyperglycemia***Alcoholism, cardiac arrhythmias, coronary artery disease, heart failure, hepatic disease, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, thyroid disease***Brain tumor, cerebrovascular disease, seizure disorder***Depression, suicidal ideation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['228790']['77492'],dutasteride/tamsulosin hydrochloride,***For the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate. <br />        NOTE: Instruct patient to swallow capsules whole; do not chew or open since contact with the capsule contents may cause irritation of the oropharyngeal mucosa.<br />     ,"***General Information***Females, pregnancy***Breast-feeding***Children, infants, neonates***Geriatric, orthostatic hypotension, renal disease, renal failure, renal impairment, syncope***Prostate cancer, urinary tract obstruction***Blood donation***Ocular surgery***Sulfonamide hypersensitivity***Hepatic disease***Priapism***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,loteprednol etabonate/tobramycin,"***For the treatment of corticosteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where a superficial bacterial ophthalmic infection or a risk of bacterial infection exists, including bacterial conjunctivitis, allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster ocular infection (keratitis), iritis, cyclitis, and chronic anterior uveitis or corneal injury resulting from chemical, radiation, or thermal ocular burns or from the penetration of foreign bodies. <br />  NOTE: Care should be taken not to discontinue therapy prematurely. Not more than 20 mL should be prescribed initially and the prescription should not be refilled without further evaluation.<br /","***Aminoglycoside hypersensitivity, corticosteroid hypersensitivity, glycerin hypersensitivity***Fungal infection, herpes infection, herpes simplex keratitis (dendritic keratitis), mycobacterial infection, ocular infection, varicella, viral infection***Glaucoma, increased intraocular pressure, open-angle glaucoma***Cataracts***Diabetes mellitus***Corneal abrasion***Contact lenses***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['38454']['11170'],trandolapril/verapamil hydrochloride,"***For the treatment of hypertension in patients who do not respond to monotherapy. <br />        NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br />NOTE: The possibility of exacerbation of hypotensive effects with trandolapril; verapamil in patients taking diuretics may be minimized by either discontinuing the diuretic or cautiously increasing the salt intake prior to initiating this combination. If it is not possible to discontinue the diuretic, the starting dose should be reduced","***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, Black patients, hereditary angioedema***Acute myocardial infarction, bradycardia, cardiogenic shock, heart failure, ventricular dysfunction***AV block, sick sinus syndrome***Atrial fibrillation, atrial flutter, Lown-Ganong-Levine syndrome, ventricular tachycardia, Wolff-Parkinson-White syndrome***Myasthenia gravis, neuromuscular disease***Constipation, fecal impaction, GI obstruction, ileus***Diabetes mellitus, hyperkalemia***Autoimmune disease, bone marrow suppression, collagen-vascular disease, immunosuppression, renal artery stenosis, renal disease, renal failure, renal impairment, scleroderma, systemic lupus erythematosus (SLE)***Aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease, dialysis, hyponatremia, hypotension, hypovolemia***Hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Geriatric***Hepatic disease***Surgery***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['614391'],abatacept,"***For the treatment of moderate to severe rheumatoid arthritis to reduce signs and symptoms of the disease, to induce a major clinical response, to inhibit the progression of structural damage, and to improve physical function.***For the treatment of moderate to severe polyarticular juvenile idiopathic arthritis as monotherapy or with methotrexate to reduce signs and symptoms of the disease.***For the treatment active psoriatic arthritis in adult patients.","***Maltose hypersensitivity***Agranulocytosis, asthma, bone marrow suppression, chronic obstructive pulmonary disease (COPD), corticosteroid therapy, cystic fibrosis, diabetes mellitus, emphysema, hepatitis, immunosuppression, infection, respiratory infection, sepsis, tobacco smoking, tuberculosis***Neoplastic disease***Geriatric***Children, infants***Pregnancy***Breast-feeding***Hyperglycemia***Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['31555'],nebivolol,***For the treatment of hypertension either alone or in combination with other agents.***For the treatment of heart failure�.***For migraine prophylaxis�.,"***General Information***Abrupt discontinuation, coronary artery disease***Acute heart failure, AV block, bradycardia, cardiogenic shock, sick sinus syndrome***Hepatic disease***Acute bronchospasm***Hyperthyroidism, thyrotoxicosis***Diabetes mellitus***Surgery***Peripheral vascular disease***Pheochromocytoma***Renal impairment***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,acetylcholine chloride,"***For miosis induction in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment ocular surgery where rapid miosis may be required.","***General Information***Iritis***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,eprosartan mesylate/hydrochlorothiazide,"***For the treatment of hypertension in patients who do not respond to monotherapy. <br />        NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, heart failure, renal artery stenosis, renal disease, renal failure, renal impairment***Hepatic disease***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***ACE-inhibitor induced angioedema, angioedema***Surgery***Pregnancy***Breast-feeding***Children***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia, hyponatremia***Diabetes mellitus, hyperglycemia***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,olopatadine hydrochloride,"***For the treatment of the signs and symptoms of allergic conjunctivitis, including ocular pruritus.***For the treatment of symptoms associated with seasonal allergic rhinitis such as rhinorrhea, sneezing, and nasal pruritus.","***Contact lenses***Geriatric***Driving or operating machinery***Children, infants, neonates***Nasal septal perforation, nasal trauma***Depression***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1092437'],belimumab,"***For the treatment of active, autoantibody-positive, systemic lupus erythematosus (SLE) in combination with standard therapy.","***Infusion-related reactions, requires an experienced clinician, risk of serious hypersensitivity reactions or anaphylaxis***Immunosuppression, infection, progressive multifocal leukoencephalopathy***Depression, psychiatric event, suicidal ideation***Vaccination***New primary malignancy***Black patients***Infants, neonates, pregnancy***Contraception requirements, reproductive risk***Breast-feeding***Geriatric***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6373'],levonorgestrel,"***For routine contraception.***For use as postcoital contraception within 72 hours of unprotected intercourse or known or suspected contraceptive failure - for use in females who have no known contraindications to use, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of menorrhagia (heavy menstrual bleeding).***For the treatment of endometriosis� in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception.","***General Information***Ectopic pregnancy, intrauterine fetal death, pregnancy, pregnancy testing***Breast-feeding***Cervical cancer, incomplete abortion, uterine cancer, vaginal bleeding***Breast cancer***Menstrual irregularity, ovarian cyst***Diabetes mellitus***Children***Hepatic disease, hepatocellular cancer, jaundice***Asian patients***Obstetric delivery***Requires an experienced clinician, uterine leiomyomata***Acquired immunodeficiency syndrome (AIDS), cervicitis, endometritis, infection, leukemia, vaginal discharge, vaginitis***Human immunodeficiency virus (HIV) infection, sexually transmitted disease***Bradycardia, seizure disorder, syncope***Obesity***Anticoagulant therapy, coagulopathy***Cerebrovascular disease, hypertension, myocardial infarction, stroke, thromboembolic disease, thrombophlebitis, tobacco smoking, valvular heart disease***Headache, migraine, visual disturbance***Renal disease***Magnetic resonance imaging (MRI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,rabeprazole sodium,"***For the symptomatic treatment of non-erosive gastroesophageal reflux disease (GERD).***For the healing of duodenal ulcer. <br />        NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br />     ***For the treatment of erosive esophagitis (erosive GERD).***For the treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.***For the short-term treatment of frequent dyspepsia� or pyrosis (heartburn)� that occurs >= 2 times per week.***For the healing of gastric ulcer�. <br />        NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br />     ***For the treatment of proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) in the differential diagnosis of eosinophilic esophagitis (EoE)�.","***Proton pump inhibitors (PPIs) hypersensitivity***Hepatic disease***Diarrhea, pseudomembranous colitis***Gastric cancer***Vitamin B12 deficiency***Bone fractures, geriatric, osteoporosis***Hypomagnesemia, long QT syndrome***Rebound acid hypersecretion***Pregnancy***Breast-feeding***Infants, neonates***Systemic lupus erythematosus (SLE)***Laboratory test interference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,onabotulinumtoxinA,"***For the treatment of blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders.***For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.***For the treatment of strabismus. <br />  NOTE: Injection should be carried out only with electromyographic guidance. The toxin must be suitably diluted, and the volume injected should be between 0.05�0.15 mL per muscle, dependent on the extent of strabismus. Use the lower doses for small deviations and the larger doses only for large deviations. Initial doses typically create paralysis of injected muscles beginning 1�2 days after injection and increasing in intensity during the first week. The paralysis lasts for 2�6 weeks and gradually resolves over a similar time period. Overcorrections lasting longer than 6 months rarely occur. About 50% of patients will require subsequent doses because of inadequate paralytic response to the initial dose, because of mechanical factors such as large deviations or restrictions, or because of the lack of binocular motor fusion to stabilize the alignment.<br /***For vertical muscles, and for horizontal strabismus of less than 20 prism diopters.***For horizontal strabismus of 20 prism diopters to 50 prism diopters.***For persistent VI nerve palsy of 1 month or longer duration.***For subsequent dosing for residual or recurrent strabismus.***For temporary improvement in the appearance of facial wrinkles.***For temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugators and/or procerus muscle activity.***For temporary improvement in the appearance of other wrinkles such as melolabial folds� and other hyperkinetic facial lines�.***For temporary improvement in the appearance of moderate to severe lateral canthal lines associated with orbicularis oculi activity (crow's feet).***For the treatment of moderate to severe forehead lines associated with frontalis muscle activity.***For the treatment of spasticity.***For the chronic management of focal spasticity� in pediatric patients with cerebral palsy with concurrent equinus gait (tiptoeing).***For the treatment of severe primary axillary hyperhidrosis (excessive underarm sweating). <br />        NOTE: Safety and efficacy for the treatment of hyperhidrosis in other body areas have not ben established. Use for palmar hyperhidrosis may lead to weakness of hand muscles and use for facial hyperhidrosis may lead to blepharoptosis.<br />NOTE: Evaluate patients for potential causes of secondary hyperhidrosis (e.g. hyperthyroidism) prior to initiating therapy***For migraine prophylaxis in adult patients with chronic migraine.***For the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (e.g., as occurs with neurogenic bladder in spinal cord injury, multiple sclerosis) in patients with an inadequate response or intolerance to an anticholinergic medication.***For second line treatment of neurogenic bladder� in children.***For the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency in adults intolerant to or with inadequate response from anticholinergic medications.***For the treatment of achalasia�.***For the treatment of sialorrhea� (excessive drooling).***For sialorrhea� associated with Parkinson's disease�.***For sialorrhea� associated with amyotrophic lateral sclerosis (ALS)�.***For sialorrhea� associated with cerebral palsy� .","***General Information***Intravenous administration, requires an experienced clinician***Cerebral palsy, children, distant spread of toxin effects, infants, neonates***Infection, urinary tract infection (UTI)***Hyperthyroidism, thyroid disease***Albumin hypersensitivity, viral infection***Dysphagia***Pregnancy***Breast-feeding***Geriatric***Ocular disease, visual disturbance***Amyotrophic lateral sclerosis (ALS), autonomic neuropathy, myasthenia gravis, myopathy, neuromuscular disease***Cardiac disease***Respiratory insufficiency***Driving or operating machinery***Surgery***Anticoagulant therapy***Urinary retention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,methylphenidate hydrochloride,***For the treatment of attention-deficit hyperactivity disorder (ADHD).***For once-daily product dosing.***For the treatment of narcolepsy.***For the treatment of major depression� or post-stroke depression refractory to other therapies. <br />        NOTE: The use of stimulants for the treatment of depressive disorders is usually limited to treatment-refractory cases or when standard medical therapies are not tolerated. Stimulants may aggravate coexisting anxiety or agitation in depressed patients.<br />     ,"***General Information***Hereditary fructose intolerance***Anxiety, bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Tics, Tourette's syndrome***Glaucoma, visual disturbance***Abrupt discontinuation, alcoholism, substance abuse***Hypertension***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular arrhythmias, ventricular dysfunction***Cerebrovascular disease, stroke***Children, growth inhibition***Hyperthyroidism***Seizure disorder, seizures***Neonates, pregnancy***Breast-feeding***Driving or operating machinery***Surgery***Radiographic contrast administration***Dysphagia, esophageal stricture, GI obstruction, ileus***Hepatic disease***Geriatric***MAOI therapy***Peripheral vascular disease, Raynaud's phenomenon***Chemical leukoderma, skin hypopigmentation, vitiligo***Phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['228790'],dutasteride,"***For the treatment of benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve urinary symptoms, reduce risk of acute urinary retention, and reduce the risk of the need for BPH-related surgery. <br />        NOTE: Instruct patient to swallow capsules whole; do not chew or open since contact with the capsule contents may cause irritation of the oropharyngeal mucosa.<br />     ***For use in combination with tamsulosin.***For the treatment of male pattern hair loss� (i.e., androgenetic alopecia�), in patients with mild to moderate hair loss of the vertex and anterior mid-scalp area.","***General Information***Females, pregnancy***Breast-feeding***Hepatic disease***Children, infants, neonates***Prostate cancer, urinary tract obstruction***Blood donation***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['57308'],topotecan,"***For the treatment of patients with metastatic ovarian cancer with disease progression on or after initial or subsequent chemotherapy. <br />  NOTE: Patients must have a neutrophil count &gt; 1500 cells/mm3 and a platelet count &gt; 100,000 cells/mm3 before topotecan initiation. Do NOT give subsequent courses of topotecan until the neutrophil count is &gt; 1000 cells/mm3, the platelet count is &gt; 100,000 cells/mm3, and the hemoglobin concentration is &gt; 9 g/dL (transfusion may be necessary).<br /***For the treatment of small cell lung cancer (SCLC). <br />        NOTE: Patients must have a neutrophil count &gt; 1500 cells/mm3 and a platelet count &gt; 100,000 cells/mm3 before topotecan initiation. Do NOT give subsequent courses of topotecan until the neutrophil count is &gt; 1000 cells/mm3, the platelet count is &gt; 100,000 cells/mm3, and the hemoglobin concentration is &gt; 9 g/dL (transfusion may be necessary).<br />     ***For platinum-sensitive small cell lung cancer (SCLC) who progressed at least 60 days after initiation of first-line chemotherapy.***For relapsed small cell lung cancer (SCLC) in patients with a prior complete or partial response and who are at least 45 days from the end of first-line chemotherapy.***For chemotherapy-naive, extensive-stage SCLC in combination with paclitaxel�.***For chemotherapy-naive, extensive-stage SCLC sequentially after treatment with cisplatin and etoposide�.***For the treatment of stage IV-B recurrent or persistent cervical cancer that is not amendable to curative treatment with surgery and/or radiation therapy. <br />        NOTE: Patients must have a neutrophil count &gt; 1500 cells/mm3 and a platelet count &gt; 100,000 cells/mm3 before topotecan initiation. Do NOT give subsequent courses of topotecan until the neutrophil count is &gt; 1000 cells/mm3, the platelet count is &gt; 100,000 cells/mm3, and the hemoglobin concentration is &gt; 9 g/dL (transfusion may be necessary).<br />     ***For the treatment of metastatic rhabdomyosarcoma� in combination with cyclophosphamide and vincristine alternating with VAC.***For the treatment of non-small cell lung cancer (NSCLC)�.***For the treatment of previously untreated advanced non-small cell lung cancer (NSCLC) in combination with gemcitabine�.***For the second-line treatment of advanced non-small cell lung cancer in combination with gemcitabine�.","***Gelatin hypersensitivity, mannitol hypersensitivity***Anemia, bone marrow suppression, herpes infection, infection, neutropenia, radiation therapy, thrombocytopenia, varicella, viral infection***Dehydration, diarrhea***Lung cancer, pulmonary fibrosis***Extravasation***Children, infants, neonates***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4678'],ganciclovir,"***For induction treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including HIV-infected patients.***For cytomegalovirus (CMV) disease prophylaxis in patients at risk for CMV disease.***For prophylaxis in allogeneic hematopoietic cell transplant (HCT) recipients.***For solid organ transplant recipients who are CMV-seropositive or CMV-seronegative receiving an organ from a CMV-seropositive donor. <br />          NOTE: Treatment regimens are organ, transplant center, and recipient specific; CMV hyperimmune globulin may be added to the ganciclovir regimen and/or the duration of IV therapy may vary from 14 days to 6 months, with total ganciclovir treatment duration of 3 to 6 months.<br />       ***For solid organ transplant recipients who are CMV-seropositive and receiving immunosuppressive induction therapy (i.e., transplant rejection treatment) with antithymocyte globulin (ATG)�.***For preemptive therapy in hematopoietic cell transplant (HCT) recipients who are less than 100 days post HCT�.***For preemptive therapy in hematopoietic cell transplant (HCT) recipients who are more than 100 days post HCT�.***For the treatment of acute herpes simplex keratitis (dendritic keratitis). <br />        NOTE: Ganciclovir ophthalmic gel is an FDA-designated orphan drug for this indication.<br />     ***For chronic suppressive therapy of cytomegalovirus (CMV) disease, including CMV retinitis (i.e., secondary cytomegalovirus (CMV) retinitis prophylaxis) in HIV-infected patients. <br />        NOTE: Ganciclovir intravenous injection has been designated an orphan drug by the FDA for CMV retinitis.<br />NOTE: The HIV guidelines generally do not recommend ganciclovir for chronic suppressive therapy following acute CMV disease other than retinitis in adults and adolescents. In infants and children, chronic suppressive therapy is recommended after disseminated disease, neurologic disease, retinitis, or gastrointestinal disease with relapse.<br />NOTE: For patients who experience progression of CMV retinitis while receiving maintenance therapy, re-induction treatment with the same drug used for maintenance followed by reinstitution of maintenance therapy is recommended.***For the treatment of viral encephalitis�.***For varicella-zoster (herpes zoster) encephalitis� as an alternative to acyclovir.***For the treatment of cytomegalovirus (CMV) encephalitis� and for the treatment of cytomegalovirus (CMV) neurological disease� (including encephalitis�) in HIV-infected patients.***For encephalitis� due to B virus (cercopithecine herpesvirus) infection� as an alternative to valacyclovir.***For the treatment of cytomegalovirus (CMV)-associated gastrointestinal disease� (e.g., esophagitis�, gastroenteritis�, or colitis�).***For the treatment of cytomegalovirus (CMV) pneumonitis�.***For the treatment of symptomatic congenital cytomegalovirus (CMV) disease�.***For the treatment of acute retinal necrosis (ARN)� due to varicella-zoster virus  in HIV-infected patients.***For the treatment of progressive outer retinal necrosis (PORN)� due to varicella zoster virus (VZV)� in HIV-infected patients.***For the treatment of severe human herpesvirus 8 (HHV-8) infection� and associated diseases in HIV-infected patients, including multicentric Castleman disease� (MCD) and primary effusion lymphoma� (PEL).***For multicentric Castleman disease (MCD)�.***For the treatment of herpes simplex virus infection� or varicella (chickenpox) infection� due to varicella-zoster virus in hospitalized immunocompromised patients unable to take oral therapy. <br />        NOTE: For CNS disease, see encephalitis.<br />     ***For the treatment of neonatal herpes simplex virus infection�.***For the treatment of encephalitis caused by human herpesvirus 6 (HHV-6) infection� in immunocompromised patients.","***Acyclovir hypersensitivity, famciclovir hypersensitivity, ganciclovir hypersensitivity, penciclovir hypersensitivity, valacyclovir hypersensitivity, valganciclovir hypersensitivity***Anemia, bone marrow suppression, chemotherapy, leukopenia, neutropenia, radiation therapy, thrombocytopenia***Intramuscular administration, subcutaneous administration***Dehydration, geriatric, renal failure, renal impairment***Accidental exposure, neoplastic disease, ocular exposure***Children, infants, neonates***Infertility, reproductive risk***Antimicrobial resistance***Contraception requirements, male-mediated teratogenicity, pregnancy, pregnancy testing***Breast-feeding***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,glucagon (rDNA origin),"***For the treatment of severe hypoglycemia.***For the treatment of severe hypoglycemia in neonates.***For use in radiographic examination of the GI tract.***For the treatment of congenital hyperinsulinemia� (e.g., hyperinsulinemic hypoglycemia).***For the treatment of beta-blocker toxicity�, or for adjunctive treatment of calcium channel blocker toxicity (e.g., verapamil toxicity�).***For the emergency treatment of choking due to esophageal foreign body impaction�.","***General Information***Insulinoma, pheochromocytoma***Adrenal insufficiency, malnutrition***Cardiac disease, coronary artery disease***Children***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,acyclovir,"***For the treatment of neonatal herpes simplex virus infection.***For the treatment of viral encephalitis.***For herpes simplex encephalitis.***For varicella-zoster encephalitis�.***For encephalitis due to B virus (cercopithecine herpesvirus) infection� as an alternative to valacyclovir.***For the treatment of herpes labialis (i.e., cold sores) or herpes fibrilis caused by herpes simplex virus.***For the treatment of recurrent herpes labialis in immunocompetent adults.***For the treatment of varicella (chickenpox) infection.***For the treatment of varicella (chickenpox) infection in immunocompetent patients.***For the treatment of for varicella (chickenpox) infection in immunocompromised patients.***For the treatment of herpes zoster (shingles) infection. <br />        NOTE: For CNS infections, see encephalitis.<br />     ***For the treatment of herpes zoster (shingles) infection in bone marrow and organ transplant patients, patients receiving chemotherapy, and other immunocompromised patients.***For the treatment of herpes zoster (shingles) infection in immunocompetent patients.***For the treatment of herpes genitalis caused by herpes simplex virus.***For the treatment of initial herpes genitalis infection.***For the treatment of recurrent herpes genitalis.***For chronic suppression therapy of recurrent herpes genitalis (i.e., herpes genitalis prophylaxis).***For the treatment of complicated herpes simplex virus infection (e.g., disseminated disease�, pneumonitis�, infection in immunocompromised hosts, and infections requiring hospitalization). <br />        NOTE: For congenital herpes, see neonatal herpes simplex virus infection; for CNS disease, see encephalitis.<br />     ***For neonatal herpes simplex virus infection prophylaxis� (i.e., suppressive therapy) in neonates with any neonatal herpes simplex disease classification.***For chronic suppression of recurrent herpes labialis� (i.e., herpes labialis prophylaxis�).***For herpes simplex infection prophylaxis� in immunocompromised hosts.***For primary herpes simplex infection prophylaxis in HSV-seropositive recipients of a bone marrow transplant�.***For primary herpes simplex infection prophylaxis in immunocompromised hosts who are HSV-seropositive patients�.***For primary varicella (chickenpox) infection prophylaxis� in HIV-infected patients with significant exposure to chickenpox or shingles for patients who have no history of either condition or, if available, negative antibody to varicella-zoster virus (VZV).***For cytomegalovirus (CMV) disease prophylaxis�.***For prevention of CMV disease� in immunocompromised patients.***For prevention of CMV disease� in CMV-seropositive patients receiving bone marrow transplantation.***For CMV disease prophylaxis� in adults receiving renal transplantation.***For the treatment of hairy leukoplakia� in HIV-positive adults.***For the adjunctive treatment of Bell's palsy�in combination with steroids.***For secondary herpes simplex ocular infection prophylaxis�.***For the treatment of acute herpes zoster ocular infection� (herpes zoster ophthalmicus�) in immunocompetent patients.***For the treatment of acute retinal necrosis (ARN)� due to varicella-zoster virus in HIV-infected patients.","***Acyclovir hypersensitivity, famciclovir hypersensitivity, ganciclovir hypersensitivity, milk protein hypersensitivity, penciclovir hypersensitivity, valacyclovir hypersensitivity, valganciclovir hypersensitivity***Dehydration, renal failure, renal impairment***Neurological disease, seizure disorder***Geriatric***Pregnancy***Breast-feeding***Children, infants, neonates***Ophthalmic administration***Extravasation, intramuscular administration, subcutaneous administration***Obesity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5487']['10763'],hydrochlorothiazide/triamterene,"***For the treatment of peripheral edema or hypertension. <br />        NOTE: Determine dosage by individual titration of the separate components. When triamterene is administered with other diuretics, it is recommended that the initial dosage of each drug be lowered and then adjusted to attain clinical goals.<br />NOTE: Diuretics do not prevent the development of edema associated with toxemia of pregnancy, and should be avoided to minimize unnecessary risk to the mother and fetus***Formoterol***Formoterol; Mometasone","***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, diabetes mellitus, electrolyte imbalance, geriatric, hyperglycemia, hyperkalemia, hypovolemia, renal disease, renal failure, renal impairment***Hypotension, orthostatic hypotension, sympathectomy, syncope***Hypercalcemia, hyponatremia***Acid/base imbalance, metabolic acidosis, respiratory acidosis***Pancreatitis***Preeclampsia, pregnancy***Breast-feeding***Children, infants, neonates***Hepatic disease, jaundice***Gout, hyperuricemia, nephrolithiasis***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['195088']['85762'],lopinavir/ritonavir,"***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents. <br />NOTE: The following abbreviations are used: nucleoside reverse transcriptase inhibitors (NRTIs); nonnucleoside reverse transcriptase inhibitors (NNRTIs); protease inhibitors (PIs).<br />NOTE: Lopinavir; ritonavir should not be administered once daily in pediatric patients due to inferior efficacy observed with once daily dosing compared with twice daily dosing.<br /***For human immunodeficiency virus (HIV) prophylaxis�.***For human immunodeficiency virus (HIV) prophylaxis� after occupational exposure.***For human immunodeficiency virus (HIV) prophylaxis� after nonoccupational exposure, including sexual assault.***Formoterol***Formoterol; Mometasone","***General Information***Hepatitis, hepatitis B and HIV coinfection***Alcoholism, hepatic disease, jaundice***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, pancreatitis***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia***Hemophilia***Human immunodeficiency virus (HIV) infection resistance***Children, infants, neonates***Breast-feeding***Pregnancy***AV block, cardiac disease, cardiomyopathy***Bradycardia, cardiac arrhythmias, coronary artery disease, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,penicillin G benzathine,"***For the treatment of yaws (<em>Treponema pallidum</em> subsp. pertenue), pinta (<em>Treponema carateum</em>), and bejel (<em>Treponema pallidum</em> subsp. endemicum).***For the treatment of upper respiratory tract infections such as pharyngitis, including group A beta-hemolytic streptococcal (GAS) pharyngitis (rheumatic fever prophylaxis), and for bacterial colonization eradication� in chronic carriers of group A beta-hemolytic <em>Streptococci</em> (GAS)�.***For secondary prevention of rheumatic fever (prevention of recurrent rheumatic fever attacks) or poststreptococcal glomerulonephritis.***For the treatment of chronic carriers of group A beta-hemolytic <em>Streptococci</em> (GAS)� (bacterial colonization eradication).***For diphtheria prophylaxis�.***For the treatment of syphilis (<em>Treponema pallidum</em>), including neurosyphilis�. <br />        NOTE: Pregnant women with syphilis in any stage who report with penicillin allergy should be desensitized and treated with penicillin.<br />NOTE: The Jarisch-Herxheimer reaction may occur within the first 24 hours of therapy***For the treatment of primary, secondary, or early latent (less than 1 year duration) syphilis.***For the treatment of late latent (greater than 1 year duration) syphilis or latent syphilis of unknown duration.***For the treatment of late or tertiary syphilis (patients with gumma and cardiovascular syphilis). <br />          NOTE: The CDC recommends ruling out neurosyphilis prior to treatment.<br />       ***For the follow up treatment of neurosyphilis�. <br />          NOTE: Benzathine penicillin is NOT indicated for treatment of neurosyphilis but only as follow-up after therapy with aqueous penicillin G. Aqueous penicillin G injection is recommended. However, optimum treatment schedules for neurosyphilis have not been established. The dosage regimens recommended for neurosyphilis are shorter than the regimen used for late syphilis in the absence of neurosyphilis.<br />       ***For the treatment of congenital syphilis (<em>Treponema pallidum</em>). <br />          NOTE: Current CDC guidelines should be consulted to determine the appropriate course of treatment in neonates born to mothers with syphilis. Therapy is based on physical examination, serum quantitive nontreponemal serologic titer, and whether or not the mother was treated properly before delivery. <br />       ","***Viral infection***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Intravenous administration***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Renal failure, renal impairment***Pregnancy***Breast-feeding***Geriatric***Infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['714438'],pazopanib,"***For the treatment of advanced renal cell cancer.***For the treatment of advanced soft-tissue sarcoma in patients who have received prior chemotherapy. <br />        NOTE: Efficacy of pazopanib for the treatment of adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated.<br />     ***For the treatment of unresectable, locally advanced, or metastatic gastrointestinal stromal tumors (GIST), after progression on or intolerance to both imatinib and sunitinib�.","***General Information***Geriatric, hepatic disease, hepatotoxicity***Angina, myocardial infarction, stroke***Heart failure, hypertension***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, thyroid disease***Bleeding, GI bleeding, intracranial bleeding***Hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP)***Surgery, wound dehiscence***Hypothyroidism***Proteinuria***Children, infants, neonates***Asian patients, neutropenia, serious rash, thrombocytopenia***Pregnancy***Pneumonitis***Contraception requirements, infertility, male-mediated teratogenicity, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['22968']['4083'],dienogest/estradiol valerate,"***For routine contraception.***For the treatment of menorrhagia (heavy and/or prolonged menstrual bleeding) in females who also desire contraception.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Breast-feeding, obstetric delivery***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia, pancreatitis***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, hypertension, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Surgery***Headache, migraine***Depression***Children, infants, neonates***Breast cancer***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Geriatric***Angioedema, hereditary angioedema***Systemic lupus erythematosus (SLE)***Chloasma***Contact lenses, glaucoma, visual disturbance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['337523'],ixabepilone,"***For the treatment of breast cancer. <br />  NOTE: Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting.<br /***For the treatment of metastatic or locally advanced breast cancer that is resistant to an anthracycline and a taxane, or that is taxane resistant and for patients whom further anthracycline therapy is contraindicated, in combination with capecitabine.***For the treatment of metastatic or locally advanced breast cancer that is resistant or refractory to anthracyclines, taxanes, and capecitabine.","***Polyoxyethylated castor oil hypersensitivity***Bone marrow suppression, neutropenia, thrombocytopenia***Hepatic disease, jaundice***Diabetes mellitus, peripheral neuropathy***Cardiac arrhythmias, cardiac disease, ventricular dysfunction***Children***Alcoholism, driving or operating machinery, substance abuse***Geriatric***Pregnancy***Breast-feeding***Radiation therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sipuleucel-T,"***For the treatment of asymptomatic or minimally symptomatic metastatic, castrate resistant (hormone refractory), prostate cancer. <br />        NOTE: Approximately 3 days prior to each infusion of sipuleucel-T, a standard leukapheresis procedure is to be done. If the patient is unable to receive an infusion of sipuleucel-T and treatment is to be continued, the patient will need to undergo an additional leukapheresis procedure.<br />NOTE: Prior to infusion of sipuleucel-T, match the patient's identity with the patient identifiers on both the Cell Product Disposition Form and the sipuleucel-T infusion bag","***General Information***Cardiac disease, infusion-related reactions, pulmonary disease***Chemotherapy, immunosuppression***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['274771'],nelarabine,***For the treatment of T-cell leukemia/lymphoma.***For the treatment of T-cell leukemia/lymphoma in patients at first relapse or with refractory disease�.***For the treatment of T-cell leukemia/lymphoma in patients who have not responded to or have relapsed following treatment with at least 2 chemotherapy regimens.***For the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL)�.***Formoterol; Mometasone,"***Chemotherapy, driving or operating machinery, geriatric, neurological disease, neurotoxicity, peripheral neuropathy, radiation therapy, seizures***Bone marrow suppression, fungal infection, herpes infection, infection, varicella, viral infection***Dental disease, dental work***Intramuscular injections***Hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia***Hepatic disease***Renal failure, renal impairment***Pregnancy***Breast-feeding***Accidental exposure, ocular exposure***Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6218'],lactulose,"***For the treatment of hepatic encephalopathy (portal-systemic encephalopathy, PSE).***For the treatment of constipation, including constipation related to barium retention.",***Galactose-free diet***Surgery***Diabetes mellitus***Geriatric***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10379'],testosterone,***For the treatment of delayed puberty in males.***For palliative treatment of breast cancer that is inoperable in women.***For the treatment of postpubertal cryptorchidism�.***For the treatment of microphallus�.***For the treatment of anemia� in patients with chronic renal failure.***For female-to-male gender change (trans-sexualism�).***For the treatment of lichen sclerosus�.***For the treatment of AIDS-associated wasting syndrome�.,"***Benzoic acid hypersensitivity, benzyl alcohol hypersensitivity, polyoxyethylated castor oil hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis, soya lecithin hypersensitivity***Magnetic resonance imaging (MRI)***Intramuscular administration, intravenous administration***Breast cancer, geriatric, prostate cancer, prostatic hypertrophy***Cardiac disease, coronary artery disease, heart failure, hepatic disease, myocardial infarction, renal disease, stroke***Obesity, pulmonary disease***Polycythemia***Accidental exposure, females***Contraception requirements, labor, obstetric delivery, pregnancy, reproductive risk***Breast-feeding***Diabetes mellitus***Hypercalcemia***Pulmonary oil microembolism***Nasal polyps, nasal septal perforation, nasal surgery, nasal trauma, rhinorrhea, Sjogren's syndrome***Children, infants, neonates***Substance abuse***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,levothyroxine sodium,"***For the treatment of primary hypothyroidism with or without goiter due to diminished or absent thyroid function caused by functional deficiency, primary atrophy, partial or complete absence of the thyroid gland, or from the effects of surgery, radiation, or an antithyroid agent, and for the treatment of secondary (pituitary) or tertiary (hypothalamic) hypothyroidism.***For the treatment of myxedema coma.***For thyroid stimulating hormone (TSH) suppression in thyroid nodules, euthyroid goiters, and well-differentiated thyroid cancer.***Formoterol; Mometasone","***General Information***Adrenal insufficiency***Hypopituitarism***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, coronary artery disease, hypertension, myocardial infarction***Diabetes mellitus***Obesity treatment***Infertility***Osteoporosis***Pregnancy***Breast-feeding***Dysphagia***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed,"***For simultaneous diphtheria prophylaxis, tetanus prophylaxis, and pertussis prophylaxis.***For prophylaxis against diphtheria and tetanus for patients with large, contaminated wounds who also need the pertussis component.","***Children, infants, neonates, premature neonates***Intraarterial administration, intravenous administration, subcutaneous administration***Guillain-Barre syndrome***Latex hypersensitivity***Coma, encephalopathy, neurological disease, seizure disorder, seizures***Fever, shock***Anticoagulant therapy, bleeding, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Infection***Immunosuppression***Pregnancy***Breast-feeding***Syncope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['21212'],clarithromycin,"***For the treatment of acute exacerbations of chronic bronchitis.***For the treatment of community-acquired pneumonia (CAP).***For the treatment of sinusitis.***For the treatment of uncomplicated skin and skin structure infections.***For the treatment of acute otitis media.***For the treatment of disseminated Mycobacterium avium complex infection (MAC) <em> </em>in HIV-positive patients.***For <em>Mycobacterium avium </em>complex (MAC) prophylaxis in HIV-infected patients.***For primary <em>Mycobacterium avium</em> complex (MAC) prophylaxis.***For secondary <em>Mycobacterium avium</em> complex (MAC) prophylaxis in patients with disseminated disease, after treatment of the acute illness.***For Helicobacter pylori (H. pylori) eradication in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />        NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.  The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Prevpac monograph).  <br />NOTE: Clarithromycin resistance rates for H. pylori strains in the US are 13%. In patients who fail therapy, susceptibility testing should be done, if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin containing regimen is recommended.<br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. After H. pylori eradication, long term tumor regression is observed in 60% to 90% of patients.***For bacterial endocarditis prophylaxis�.***For the treatment of pertussis (whooping cough)� caused by <em>Bordetella pertussis</em>.***For postexposure pertussis prophylaxis�.***For the treatment of bartonellosis� (<em>Bartonella bacilliformis)</em> and other <em>Bartonella sp.</em>� infections in HIV-infected patients.***For the treatment of angiomatosis infections�, peliosis hepatis�, bacteremia�, and osteomyelitis� caused by <em>Bartonella sp.</em>�.***For long term suppression� of infections caused by <em>Bartonella sp.</em>� in patients with relapse or reinfection with less than 200 CD4 cells/mm3.***For the treatment of pharyngitis (primary rheumatic fever prophylaxis�) or tonsillitis caused by susceptible strains of <em>Streptococcus pyogenes</em> (group A beta-hemolytic streptococci). <br />  NOTE: Clarithromycin is generally effective at eradication of S. pyogenes from the nasopharynx, however, data on the efficacy of preventing rheumatic fever are unknown. The antibiotic of choice for treatment and prevention of streptococcal infection and prophylaxis of rheumatic fever is penicillin administered either intramuscularly or orally.<br />NOTE: The American Heart Association (AHA) recommends secondary prophylaxis for 10 years or until age 40 (whichever is longer) for patients who have experienced rheumatic fever with carditis and have residual heart disease (persistent valvular disease). For patients who have experienced rheumatic fever with carditis, but have no residual heart disease, the AHA recommends prophylaxis for 10 years or until age 21 (whichever is longer). For patients who have experienced rheumatic fever without carditis, the AHA recommends prophylaxis for 5 years or until age 21 (whichever is longer)***Formoterol; Mometasone","***General Information***Viral infection***Macrolide hypersensitivity***Pregnancy***Breast-feeding***Hepatic disease, hepatitis, jaundice***Renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Colostomy, ileostomy***Children, infants, neonates***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, mortality, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes, ventricular arrhythmias***Myasthenia gravis***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,donepezil hydrochloride,***For the treatment of Alzheimer's disease.***For the treatment of mild to moderate Alzheimer's disease.***For the treatment of moderate to severe Alzheimer's disease.***For the treatment of vascular dementia�.***For the short-term treatment (up to 90 days) of acute cognitive deficits following ischemic stroke�.***For the treatment of dementia with Lewy bodies�.***Formoterol***Formoterol; Mometasone,"***General Information***Abrupt discontinuation***Alcoholism, AV block, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, sick sinus syndrome, syncope, thyroid disease***Diarrhea, GI bleeding, GI disease, peptic ulcer disease, vomiting***Hepatic disease***Asthma, chronic obstructive pulmonary disease (COPD), pulmonary disease***Bladder obstruction***Seizure disorder, seizures***Pregnancy***Breast-feeding***Children, infants, neonates***Surgery***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['72302'],ropinirole,***For the treatment of Parkinson's disease.***For conversion from immediate-release to extended-release tablets.***For the treatment of restless legs syndrome (RLS).,"***General Information***Pregnancy***Breast-feeding***Children***Cardiac disease, hypertension, hypotension, orthostatic hypotension, syncope***Geriatric, psychosis***Dialysis, renal failure, renal impairment***Hepatic disease***Tobacco smoking***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion, narcolepsy, sleep apnea***Abrupt discontinuation***Melanoma***Impulse control symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['38400'],atomoxetine,***For the treatment of attention-deficit hyperactivity disorder (ADHD).,"***General Information***Pheochromocytoma***MAOI therapy***Hepatic disease, hepatitis, jaundice***Closed-angle glaucoma***Constipation, GI obstruction, ileus, prostatic hypertrophy, urinary retention***Seizure disorder, seizures***Driving or operating machinery, ethanol intoxication***Bipolar disorder, depression, mania, psychosis***Alcoholism, arteriosclerosis, bradycardia, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, congenital heart disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, stroke, tachycardia, thyroid disease, ventricular arrhythmias, ventricular dysfunction***Children, growth inhibition, suicidal ideation***Dehydration, hypovolemia, orthostatic hypotension, syncope***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['14851'],vigabatrin,"***For use as monotherapy in the treatment of infantile spasms in pediatric patients for whom the potential benefits outweigh the potential risk of vision loss. <br />  NOTE: Vision loss in infants and children may not be detected until it is severe. Vision assessment is recommended at baseline (no later than 4 weeks after vigabatrin initiation), at least every 3 months during therapy, and approximately 3 to 6 months after vigabatrin discontinuation.<br /***For the adjunctive treatment of refractory complex partial seizures. <br />        NOTE: Vision assessment is recommended at baseline (no later than 4 weeks after vigabatrin initiation), at least every 3 months during therapy, and approximately 3 to 6 months after vigabatrin discontinuation.<br />     ***Formoterol; Mometasone","***General Information***Requires an experienced clinician, visual impairment***Depression, suicidal ideation***Abrupt discontinuation***Driving or operating machinery***Hepatic decompensation, hepatic disease***Renal impairment***Geriatric***Children, infants, neonates***Substance abuse***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine,"***For simultaneous diphtheria prophylaxis, tetanus prophylaxis, pertussis prophylaxis, and poliovirus prophylaxis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children whose previous DTaP vaccine doses have been with Infanrix and/or Pediarix for the first three doses and Infanrix for the fourth dose.","***Intraarterial administration, intravenous administration, subcutaneous administration***Guillain-Barre syndrome***Neomycin hypersensitivity, polymyxin hypersensitivity, polysorbate 80 hypersensitivity***Latex hypersensitivity***Coma, encephalopathy, fever, neurological disease, seizure disorder, seizures***Shock***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Immunosuppression***Infection***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,interferon gamma-1b,"***For the treatment of chronic granulomatous disease to reduce the frequency and severity of serious infections. <br />        NOTE: Interferon gamma-1b has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of severe, malignant osteopetrosis to delay the time to disease progression. <br />        NOTE: Interferon gamma-1b has been designated an orphan drug by the FDA for this indication.<br />     ","***Pulmonary fibrosis***Bone marrow suppression, immunosuppression***Infants, neonates***Angina, cardiac arrhythmias, cardiac disease, heart failure, myocardial infarction***Driving or operating machinery, seizure disorder***E. coli protein hypersensitivity, latex hypersensitivity, mannitol hypersensitivity***Hepatic disease***Renal failure, renal impairment***Pregnancy***Breast-feeding***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['73710'],paricalcitol,"***For the prevention and treatment of secondary hyperparathyroidism and resultant metabolic bone disease (renal osteodystrophy�). <br />        NOTE: Dosage adjustments should be determined based on serum calcium, serum phosphorous, and serum or plasma iPTH concentrations. Initially and following a dosage adjustment, serum calcium, serum phosphorous, and serum or plasma iPTH concentrations should be monitored at least every 2 weeks for 3 months, monthly for 3 months, and then every 3 months thereafter.<br />     ***For initial dosing and dosage titration in pre-dialysis patients with Stage 3 or 4 chronic kidney disease. <br />  NOTE: In general, the dose should be adjusted no more frequently than every 2 to 4 weeks in adults and every 4 weeks in pediatric patients. In clinical trials of paricalcitol in adults, the average weekly dose was 9.6 mcg in patients taking once daily and 9.5 mcg in patients taking 3 times per week.<br /***For initial dosing and dosage titration in patients with Stage 5 chronic kidney disease on dialysis.***For initial dosing and dosage titration in patients with stage 5 chronic kidney disease on dialysis (National Kidney Foundation Guidelines). <br />  NOTE: Serum calcium concentration should be less than 9.5 mg/dL in patients with a serum iPTH less than 1000 pg/mL. In patients with a serum iPTH greater 1000 pg/mL, the serum calcium concentration should be less than 10 mg/dL. Serum phosphorous concentration should be less than 5.5 mg/dL and the calcium-phosphorous product should be less than 55.<br />Dosage adjustments should be determined based on serum calcium, serum phosphorous, and plasma iPTH concentrations. Initially and during dosage titration, monitor serum calcium and phosphorous concentrations every 2 weeks for 1 month and then monthly. Plasma iPTH concentration should be monitored monthly for 3 months then every 3 months once target iPTH concentrations are achieved (150 to 300 pg/mL)","***Hypercalcemia***Hypervitaminosis D***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['819300'],golimumab,"***For the treatment of moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate.***For the treatment of active ankylosing spondylitis (AS).***For the treatment of active psoriatic arthritis (PsA).***For the treatment of moderately to severely active ulcerative colitis to induce and maintain clinical response, to improve endoscopic appearance of the mucosa during induction, to induce clinical remission, and to achieve and sustain clinical remission in induction responders in adults who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine.","***Hepatitis, hepatitis B exacerbation***Bone marrow suppression, corticosteroid therapy, diabetes mellitus, fungal infection, immunosuppression, infection, influenza, mycobacterial infection, sepsis, surgery, tuberculosis, viral infection***Cholangitis, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, leukemia, lymphoma, new primary malignancy, skin cancer, ulcerative colitis***Heart failure***Guillain-Barre syndrome, multiple sclerosis, optic neuritis***Agranulocytosis, leukopenia, neutropenia, thrombocytopenia***Latex hypersensitivity***Vaccination***Infants, neonates, pregnancy***Breast-feeding***Geriatric***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3008'],cyclosporine,"***For kidney transplant rejection prophylaxis.***For kidney transplant rejection prophylaxis in combination with sirolimus and corticosteroids in patients who are considered low to moderate immunologic risk.***For kidney transplant rejection prophylaxis in combination with sirolimus and corticosteroids in patients who are considered high immunologic risk. <br />          NOTE: Black transplant recipients, repeat renal transplant recipients who lost a previous allograft for immunologic reason, or patients with high-panel reactive antibodies (PRA; peak PRA level greater than 80%) are considered high immunologic risk.<br />NOTE: The protocol-specified target Cmin range for cyclosporine was 200 to 300 ng/mL up to week 2, 150 to 200 ng/mL for weeks 2 to 26, and 100 to 150 ng/mL for weeks 26 to 52, and for sirolimus was 10 to 15 ng/mL***For the treatment of severe, plaque-type psoriasis in immunocompetent patients who failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated.***For the treatment of severe rheumatoid arthritis (RA) in patients unresponsive to conventional therapy, alone or in combination with methotrexate when the disease has not adequately responded to methotrexate.***For early rheumatoid arthritis (RA).***For the treatment of xerophthalmia by increasing tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.***For the treatment of heart transplant rejection prophylaxis, liver transplant rejection prophylaxis, and the treatment of acute and chronic graft-versus-host disease (GVHD)� and graft-versus-host disease (GVHD) prophylaxis�. <br />        NOTE: In general, children may undergo the same dosing regimen as adults but often require and tolerate higher doses.<br />NOTE: In the prevention of organ transplant rejection, cyclosporine is intended to be used in combination with corticosteroid therapy***For the treatment of severe atopic dermatitis�.***For the treatment of severe aplastic anemia�.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP)�.***For the treatment of myasthenia gravis� in patients who are poorly controlled with cholinesterase inhibitor therapy.***For the treatment of psoriatic arthritis�.***For the treatment of lupus nephritis� in patients with systemic lupus erythematosus (SLE) unresponsive to conventional therapy, or for the treatment of children with idiopathic nephrotic syndrome�.","***General Information***Fungal infection, herpes infection, immunosuppression, infection, requires a specialized care setting, requires an experienced clinician, varicella, viral infection***Herpes simplex keratitis (dendritic keratitis), ocular infection***Lymphoma, new primary malignancy, radiation therapy, skin cancer, sunlight (UV) exposure***Nephrotoxicity, renal disease, renal failure, renal impairment***Hyperkalemia, hypertension***Electrolyte imbalance***Polyoxyethylated castor oil hypersensitivity***Children, infants***Pregnancy***Breast-feeding***Geriatric***Alcoholism, biliary tract disease, hepatic disease, jaundice***Gout, hyperuricemia***Encephalopathy, hypomagnesemia***Vaccination***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['68244'],lamivudine,"***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***For the treatment of chronic hepatitis B infection.***For the treatment of chronic hepatitis B infection in HIV-negative patients.***For the treatment of chronic hepatitis B infection in HIV-positive patients.***For human immunodeficiency virus (HIV) prophylaxis�.***For HIV prophylaxis after occupational exposure to HIV.***For HIV prophylaxis after non-occupational HIV exposure, including sexual assault. <br />  NOTE: Higher risk exposures for which prophylaxis is recommended include exposure of vagina, rectum, eye, mouth, or other mucous membrane, nonintact skin, or percutaneous contact with blood, semen, vaginal secretions, rectal secretions, breast milk, or any body fluid that is visibly contaminated with blood when the source is known to be HIV-positive. Exposures to a source patient with unknown HIV status should be assessed on a case-by-case basis.<br /***For perinatal human immunodeficiency virus (HIV) prophylaxis� in neonates at high risk for HIV acquisition. <br />  NOTE: Empiric therapy with a 3-drug combination antiretroviral (ARV) regimen, consisting of zidovudine, lamivudine, and nevirapine at treatment doses, is a treatment option recommended for neonates with presumed HIV exposure or those at high risk for perinatal HIV transmission (neonates born to HIV-infected mothers: who have not received antepartum or intrapartum ARV treatment, who have received only intrapartum ARV treatment, who have suboptimal viral suppression near delivery, who have acute or primary HIV infection during pregnancy or breastfeeding, who have unknown HIV status, or who have known ARV drug-resistant virus). ARV therapy should be initiated as close to the time of birth as possible, preferably within 6 to 12 hours of delivery.<br /","***General Information***Hepatitis B and HIV coinfection, hepatitis B exacerbation, HIV serum status***Alcoholism, females, hepatic disease, Hepatotoxicity or Lactic Acidosis, obesity, organ transplant***Geriatric***Peripheral neuropathy***Renal failure, renal impairment***Children, infants, neonates, pancreatitis***Pregnancy***Breast-feeding***Human immunodeficiency virus (HIV) infection resistance***Diabetes mellitus***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['861634'],pitavastatin,"***For the treatment of hypercholesterolemia, hyperlipoproteinemia, and/or hypertriglyceridemia as an adjunct to dietary control.***For reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglyceride concentrations, and to increase HDL-cholesterol in patients with primary hypercholesterolemia or mixed dyslipidemia.***For the regression of coronary atherosclerosis in patients with acute coronary syndrome (ACS).","***General Information***Alcoholism, cholestasis, hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Dialysis, electrolyte imbalance, endocrine disease, females, hypotension, hypothyroidism, infection, myopathy, organ transplant, renal disease, renal failure, renal impairment, rhabdomyolysis, seizure disorder, surgery, trauma***Diabetes mellitus***Contraception requirements, pregnancy***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ketotifen fumarate,"***For the temporary prevention of ocular pruritus due to allergic conjunctivitis.***For the treatment of allergic conditions including allergic rhinitis�, atopic dermatitis�, and acute or chronic urticaria�.","***Children, infants, neonates***Contact lenses***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,moxifloxacin hydrochloride,"***For the treatment of acute bacterial exacerbation of chronic bronchitis.***For the treatment of acute bacterial sinusitis.***For the treatment of mild to moderate community-acquired pneumonia (CAP).***For the treatment of skin and skin structure infections.***For uncomplicated skin and skin structure infections due to <em>Staphylococcus aureus</em> (MSSA) and <em>Streptococcus pyogenes</em>.***For complicated skin and skin structure infections due to <em>Enterobacter cloacae</em>, <em>Escherichia coli</em>, <em>Klebsiella pneumoniae</em>, or <em>Staphylococcus aureus</em> (MSSA).***For the treatment of complicated intraabdominal infections including polymicrobial infections such as abscesses.***For the treatment of bacterial conjunctivitis (including chlamydial conjunctivitis) due to susceptible organisms.***For the treatment of plague, including pneumonic and septicemic plague, and plague prophylaxis due to susceptible isolates.***For the treatment of tuberculosis infection� caused by <em>Mycobacterium tuberculosis�</em> in combination with other antituberculosis agents as a second line agent. <br />        NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., &gt;= 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, IDSA, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. Directly observed therapy (DOT) should be used for all regimens administered 1, 2, 3, or 5 times per week. The initial treatment regimen should include four drugs unless the likelihood of INH or rifampin resistance is low (i.e., &lt; 4%), in which case an initial regimen of INH, rifampin, and pyrazinamide may be considered. HIV-infected patients should always receive induction therapy with four drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate.   For multi-drug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, the CDC recommends treatment for 18�24 months after culture conversion in patients with bacteriologic confirmation and for &gt;= 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months in MDR-TB.<br />     ***For the treatment of Mycobacterium avium complex infection� (MAC) in HIV-infected patients.***For the treatment of anthrax�.***For the treatment of systemic anthrax infection.***For the treatment of cutaneous anthrax infection.***For the treatment of bacterial gastroenteritis� and infectious diarrhea�.***For salmonellosis� in HIV-infected patients.***For shigellosis� in HIV-infected patients.***For the treatment of campylobacteriosis� in HIV-infected patients.***For surgical infection prophylaxis�.***For ophthalmic surgical prophylaxis�.***For the treatment of recurrent or persistent non-gonococcal urethritis (NGU)�.***For the treatment of pelvic inflammatory disease (PID)�.***For anthrax prophylaxis� after exposure to <em>Bacillus anthracis</em> (postexposure prophylaxis, PEP).***Formoterol***Formoterol; Mometasone","***Viral infection***Quinolone hypersensitivity***Corticosteroid therapy, organ transplant, tendinitis, tendinopathy, tendon pain, tendon rupture***Alcoholism, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Cerebrovascular disease, neurotoxicity, peripheral neuropathy, seizure disorder***Myasthenia gravis***Hepatic disease, hepatitis, hepatotoxicity, jaundice***Diabetes mellitus***Sunlight (UV) exposure***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Geriatric***Pregnancy***Breast-feeding***Sexually transmitted disease***Children, infants, neonates***Sodium restriction***Contact lenses***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,formoterol fumarate,"***For the maintenance prevention of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.","***Monotherapy treatment of asthma***Paradoxical bronchospasm***Acute bronchospasm, asthma-related death***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, tachycardia***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia, hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***Labor, pregnancy***Breast-feeding***MAOI therapy***Geriatric***Children, infants***Milk protein hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,azelaic acid,***For the treatment of mild-to-moderate inflammatory acne vulgaris.***For the treatment of inflammatory pustules and papules of mild-to-moderate acne rosacea.***For the treatment of melasma�.***For the treatment of lentigo maligna� in which surgery is contraindicated.***For the treatment of cutaneous malignant melanoma�.,"***General Information***Occlusive dressing, ocular exposure***Pregnancy***Breast-feeding***Children, infants, neonates***Herpes infection***Asthma, deterioration of asthma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['37418', '67158']",sumatriptan,***For the acute treatment of migraine attacks with or without aura. <br />        NOTE: Sumatriptan is not indicated for hemiplegic or basilar migraine.<br />     ***For the acute treatment of cluster headache.,"***General Information***Sumatriptan hypersensitivity***Acute myocardial infarction, angina, arteriosclerosis, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, hypercholesterolemia, obesity, tobacco smoking, vasospastic angina, Wolff-Parkinson-White syndrome***Hypertension***Cerebrovascular disease, intracranial bleeding, stroke***Basilar/hemiplegic migraine***Intravenous administration***Pregnancy***Breast-feeding***Hepatic disease***Renal disease, renal failure, renal impairment***Children***Geriatric***Driving or operating machinery***Colitis, peripheral vascular disease, Raynaud's phenomenon***Seizure disorder, seizures***Visual disturbance***MAOI therapy***Magnetic resonance imaging (MRI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ondansetron); (ondansetron hydrochloride,***For chemotherapy-induced nausea/vomiting prophylaxis (CINV prophylaxis) and radiation-induced nausea/vomiting prophylaxis (RINV prophylaxis).***For post-operative nausea/vomiting (PONV) prophylaxis.***For the treatment of post-operative nausea/vomiting (PONV)�.***For hyperemesis gravidarum� (severe pregnancy-induced nausea/vomiting) unresponsive to other antiemetics.***For the short-term treatment of nausea/vomiting associated with acute gastroenteritis�.***For the treatment of pruritus� secondary to cholestasis.***For the maintenance treatment of alcohol dependence�.***For the treatment of cyclic vomiting syndrome�.***Formoterol***Formoterol; Mometasone,"***General Information***Hepatic disease, hepatitis***Dolasetron hypersensitivity, granisetron hypersensitivity, ondansetron hypersensitivity, palonosetron hypersensitivity***Phenylketonuria***GI obstruction, ileus***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Children***Infants, neonates***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1116632'],ticagrelor,"***For arterial thromboembolism prophylaxis in patients with acute coronary syndrome (ACS) (unstable angina, acute myocardial infarction), including in patients undergoing percutaneous coronary intervention (PCI).","***General Information***Bleeding, coronary artery bypass graft surgery (CABG), GI bleeding, intracranial bleeding, surgery***Hepatic disease***Labor, obstetric delivery, pregnancy***Breast-feeding***Abrupt discontinuation***Children, infants, neonates***AV block, bradycardia, sick sinus syndrome, syncope***Aspirin coadministration***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,tiotropium bromide,"***For the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and to reduce exacerbations of COPD.***For the long-term maintenance treatment of asthma.","***General Information***Milk protein hypersensitivity***Acute bronchospasm***Closed-angle glaucoma, contact lenses, ocular exposure, ophthalmic administration***Anticholinergic medications, bladder obstruction, prostatic hypertrophy, urinary retention, urinary tract obstruction***Cardiac arrhythmias***Renal impairment***Driving or operating machinery***Geriatric***Pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['28439'],lamotrigine,"***For the treatment of partial seizures with or without secondary generalization. <br />        NOTE: Lamotrigine should be initiated at a low dose, with gradual increases according to the dose escalation guidelines provided by the manufacturer. This may minimize the occurrence of a severe, and potentially life-threatening skin rash, which has been associated with lamotrigine administration.<br />NOTE: Therapeutic plasma concentrations have not been established. In general, dosage should be based upon clinical response.<br />NOTE: Discontinuation of lamotrigine should be done in a step-wise fashion over at least 2 weeks (approximately 50% dosage reduction per week), unless safety concerns warrant a more rapid withdrawal***For monotherapy of partial seizures in patients currently receiving treatment with a single enzyme-inducing anti-epileptic drug (AED) (e.g., carbamazepine, phenobarbital, phenytoin, primidone) NOT to include valproate.***For monotherapy of partial seizures in patients  currently receiving treatment with valproate.***For adjunctive therapy to other anticonvulsants in the treatment of partial seizures.***For monotherapy of partial seizures in patients currently receiving treatment with a single anti-epileptic drug (AED)  OTHER than carbamazepine, phenytoin, phenobarbital, primidone, or valproate. <br />  NOTE: Safety and effectiveness of extended-release tablets have not been established as initial monotherapy or for simultaneous conversion to monotherapy from 2 or more concomitant AEDs.<br /***For adjunctive therapy to other anticonvulsants in the treatment of primary generalized tonic-clonic seizures. <br />        NOTE: Lamotrigine should be initiated at a low dose, with gradual increases according to the dose escalation guidelines provided by the manufacturer. This may minimize the occurrence of a severe, and potentially life-threatening skin rash, which has been associated with lamotrigine administration.<br />NOTE: Therapeutic plasma concentrations have not been established. In general, dosage should be based upon clinical response.<br />NOTE: Discontinuation of lamotrigine should be done in a step-wise fashion over at least 2 weeks (approximately 50% dosage reduction per week), unless safety concerns warrant a more rapid withdrawal***For adjunctive therapy to other anticonvulsants in the treatment of generalized seizures of Lennox-Gastaut syndrome. <br />        NOTE: Lamotrigine should be initiated at a low dose, with gradual increases according to the dose escalation guidelines provided by the manufacturer. This may minimize the occurrence of a severe, and potentially life-threatening skin rash, which has been associated with lamotrigine administration.<br />NOTE: Therapeutic plasma concentrations have not been established. In general, dosage should be based upon clinical response.<br />NOTE: Discontinuation of lamotrigine should be done in a step-wise fashion over at least 2 weeks (approximately 50% dosage reduction per week), unless safety concerns warrant a more rapid withdrawal***For the long-term maintenance treatment of bipolar disorder (bipolar I disorder) to delay the occurrence of mood episodes (i.e., depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy. <br />        NOTE: Do not exceed initial and subsequent dose escalations of lamotrigine due to increased risk of rash. Periodically re-assess the need for continued treatment. Lamotrigine should not be abruptly discontinued; taper downward roughly 50% per week for 2 weeks unless safety issues require a more rapid dose reduction.<br />     ***For the treatment of absence seizures�.***For long-term prophylaxis of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT)�.","***General Information***Serious rash***Depression, suicidal ideation***Abrupt discontinuation***Driving or operating machinery***Hepatic disease***Dialysis, renal disease, renal failure, renal impairment***Cardiac disease, heart failure***Black patients***Geriatric***Children, infants, neonates***Folate deficiency, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bupropion hydrochloride,"***For the treatment of major depression.***For the prevention of seasonal major depressive disorder episodes associated with seasonal affective disorder (SAD).***For use as an adjunct to psychosocial interventions in the management of tobacco cessation (smoking cessation).***For use alone to aide in tobacco cessation.***For aide with tobacco cessation using bupropion in combination with a nicotine transdermal system (NTS).***For the treatment of attention-deficit hyperactivity disorder (ADHD)�.***For use as monotherapy of attention-deficit hyperactivity disorder (ADHD)� in adults.***For the symptomatic treatment of neuropathic pain� due to various causes, including pain associated with peripheral diabetic neuropathy� or postherpetic neuralgia�.***Formoterol; Mometasone","***General Information***Alcoholism, anorexia nervosa, benzodiazepine withdrawal, brain tumor, bulimia nervosa, diabetes mellitus, head trauma, hypoglycemia, hyponatremia, hypoxemia, intracranial mass, obesity treatment, seizure disorder, seizures, stroke, substance abuse***Children, suicidal ideation***Tics, Tourette's syndrome***Behavioral changes, bipolar disorder, depression, mania, psychiatric event, schizophrenia***MAOI therapy***Neonates, pregnancy***Breast-feeding***Hepatic disease***Renal disease, renal failure, renal impairment***Acute myocardial infarction, cardiac disease, heart failure, hypertension, tobacco smoking***Geriatric***Driving or operating machinery, ethanol intoxication***Closed-angle glaucoma, increased intraocular pressure***Abrupt discontinuation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['480167'],lapatinib,"***For the treatment of breast cancer. <br />        NOTE: Confirm normal left ventricular ejection fraction (LVEF) before starting lapatinib. Also, evaluate LVEF during treatment, as decreases in LVEF have been reported, and the lapatinib dose may need to be reduced.<br />     ***For the treatment of patients with advanced or metastatic breast cancer, in combination with capecitabine, whose tumor overexpresses the HER2 protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. <br />          NOTE: Patients should exhibit disease progression on trastuzumab prior to initiating combination therapy with lapatinib and capecitabine. In a randomized, open-label study of HER2-positive metastatic breast cancer patients (n = 540), median progression free survival (PFS) and overall survival (OS) for lapatinib plus capecitabine was less than for patients treated with trastuzumab plus capecitabine (PFS: 6.6 months vs. 8 months, HR 1.3, 95% CI, 1.04 to 1.64; OS: HR 1.34, 95% CI, 0.95 to 1.92). In another randomized, open-label study of women with HER2-positive metastatic breast cancer, first-line treatment with lapatinib plus taxane-based chemotherapy also had a shorter median PFS compared with trastuzumab plus taxane-based chemotherapy (n = 652) (9 months vs. 11.3 months; HR 1.37; 95% CI, 1.13 to 1.65).<br />       ***For the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor and for whom hormonal therapy is indicated, in combination with letrozole.***For the treatment of HER2-positive, trastuzumab-refractory metastatic breast cancer� in combination with trastuzumab.","***General Information***Serious rash***Cardiac disease, heart failure, hypertension***Hepatic disease, hepatotoxicity***Alcoholism, bradycardia, cardiac arrhythmias, coronary artery disease, diabetes mellitus, females, geriatric, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Pneumonitis, pulmonary disease***Asian patients, Black patients, Caucasian patients, Hispanic patients***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['1100699', '1100703']",linagliptin,***For the treatment of type 2 diabetes mellitus in combination with diet and exercise. <br />        NOTE: Linagliptin is used as monotherapy or in combination with other drugs used to treat type 2 diabetes mellitus.<br />     ***Formoterol; Mometasone,"***Exfoliative dermatitis, history of angioedema, serious rash***Diabetic ketoacidosis, type 1 diabetes mellitus***Burns, fever, infection, surgery, trauma***Adrenal insufficiency, hypoglycemia, hypothyroidism, malnutrition, pituitary insufficiency, renal impairment***Diarrhea, gastroparesis, GI obstruction, ileus, vomiting***Hypercortisolism, hyperglycemia, hyperthyroidism***Pancreatitis***Arthralgia***Heart failure***Pregnancy***Breast-feeding***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['857974', '1546030']",saxagliptin,***For the treatment of type 2 diabetes mellitus in combination with diet and exercise.***Formoterol; Mometasone,"***Exfoliative dermatitis, history of angioedema, serious rash***Diabetic ketoacidosis, type 1 diabetes mellitus***Burns, fever, infection, surgery, trauma***Diarrhea, gastroparesis, GI obstruction, ileus, vomiting***Pancreatitis***Hypercortisolism, hyperglycemia, hyperthyroidism***Adrenal insufficiency, hypoglycemia, hypothyroidism, malnutrition, pituitary insufficiency***Cardiac disease, heart failure***Renal disease, renal failure, renal impairment***Arthralgia***Geriatric***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['20352'],carvedilol,"***For the treatment of heart failure (ischemic origin or cardiomyopathy).***For mild, moderate, or severe heart failure in adult patients (ischemic origin or cardiomyopathy) as a single agent or in conjunction with digoxin, diuretics, hydralazine, or ACE inhibitor therapy.***For patients with severe heart failure (NYHA Class III/IV) and referred for cardiac transplantation�.***For the treatment of heart failure in pediatric patients� (ischemic origin or cardiomyopathy) usually in conjunction with digoxin, diuretics, or ACE inhibitor therapy.***For reduction of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (ejection fraction of 40% or higher) following acute myocardial infarction.***For the treatment of essential hypertension, either as a single agent or in combination with other antihypertensive agents.***For the treatment of angina�.***For heart rate control in patients with atrial fibrillation� or atrial flutter�.","***Angioedema, beta-blocker hypersensitivity***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***Pheochromocytoma, vasospastic angina***Acute heart failure, AV block, bradycardia, cardiogenic shock, hypotension, orthostatic hypotension, pulmonary edema, sick sinus syndrome, ventricular dysfunction***Cerebrovascular disease***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Surgery***Hepatic disease***Peripheral vascular disease, renal disease, renal failure, renal impairment***Depression***Psoriasis***Myasthenia gravis***Geriatric***Diabetes mellitus, hypoglycemia***Contact lenses***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['35296', '262418']",ramipril,"***For reduction of cardiovascular mortality, myocardial infarction (myocardial infarction prophylaxis) and stroke (stroke prophylaxis) in adults 55 years or older who are at high risk of developing major cardiovascular events.***For the treatment of stable patients who have demonstrated clinical signs of congestive heart failure within the first few days following acute myocardial infarction (postmyocardial infarction).***For the treatment of hypertension.***For the treatment of persistent albuminuria� in patients with diabetic nephropathy� or in at-risk hypertensive patients�.","***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, Black patients, hereditary angioedema***Diabetes mellitus, hyperkalemia, renal artery stenosis, renal disease, renal failure, renal impairment***Autoimmune disease, bone marrow suppression, collagen-vascular disease, immunosuppression, scleroderma, systemic lupus erythematosus (SLE)***Hepatic disease, jaundice***Dialysis, hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hyponatremia, hypotension, hypovolemia***Neonates, pregnancy***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['60548'],exenatide,***For the treatment of type 2 diabetes mellitus in combination with diet and exercise.,"***General Information***Diabetic ketoacidosis, type 1 diabetes mellitus***Burns, diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Crohn's disease, gastroparesis, GI disease, inflammatory bowel disease, ulcerative colitis***Hypoglycemia***Dehydration, dialysis, kidney transplant, renal disease, renal failure, renal impairment***Tobacco smoking***Pregnancy***Breast-feeding***Children, infants***Pancreatitis***Medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), thyroid cancer, thyroid C-cell tumors***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fenofibric acid,"***For use as an adjunct to diet in the treatment of hyperlipoproteinemia or hypertriglyceridemia. <br />        NOTE: Patients should be placed on an appropriate lipid-lowering diet before and while receiving fenofibric acid. Excess body weight, excess alcohol intake, dietary indiscretion, and poor glycemic control are important factors in conditions of elevated triglycerides and should be addressed prior to instituting fenofibric acid therapy.<br />NOTE: Fenofibric acid is not indicated for patients who have elevated chylomicrons and triglycerides, but who have normal VLDL concentrations.<br />NOTE: One delayed-release capsule of fenofibric acid 135 mg produces plasma concentrations equivalent to one 200 mg capsule of micronized fenofibrate administered under fed conditions.<br />***For the treatment of severe hypertriglyceridemia.***For the treatment of primary hyperlipidemia or mixed dyslipidemia (e.g., to reduce elevated LDL-C, total cholesterol, triglycerides and apolipoprotein B and to increase HDL-C).","***General Information***Dialysis, renal disease, renal failure, renal impairment***Cholelithiasis, gallbladder disease***Biliary cirrhosis, hepatic disease***Pancreatitis***Cardiac disease***Anticoagulant therapy, thromboembolic disease***Geriatric***Diabetes mellitus***Hypothyroidism***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,brimonidine tartrate/timolol maleate,***For the treatment of glaucoma or ocular hypertension.,"***General Information***MAOI therapy***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***AV block, bradycardia, cardiac disease, cardiogenic shock, coronary artery disease, heart failure, hypotension, peripheral vascular disease, Raynaud's phenomenon, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Diabetes mellitus, hypoglycemia***Cerebrovascular disease***Hyperthyroidism, thyrotoxicosis***Depression***Thromboangiitis obliterans (Buerger's disease)***Orthostatic hypotension***Myasthenia gravis***Surgery***Hepatic disease***Renal impairment***Contact lenses***Corneal abrasion, ocular infection***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3008'],cyclosporine,"***For kidney transplant rejection prophylaxis.***For kidney transplant rejection prophylaxis in combination with sirolimus and corticosteroids in patients who are considered low to moderate immunologic risk.***For kidney transplant rejection prophylaxis in combination with sirolimus and corticosteroids in patients who are considered high immunologic risk. <br />          NOTE: Black transplant recipients, repeat renal transplant recipients who lost a previous allograft for immunologic reason, or patients with high-panel reactive antibodies (PRA; peak PRA level greater than 80%) are considered high immunologic risk.<br />NOTE: The protocol-specified target Cmin range for cyclosporine was 200 to 300 ng/mL up to week 2, 150 to 200 ng/mL for weeks 2 to 26, and 100 to 150 ng/mL for weeks 26 to 52, and for sirolimus was 10 to 15 ng/mL***For the treatment of severe, plaque-type psoriasis in immunocompetent patients who failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated.***For the treatment of severe rheumatoid arthritis (RA) in patients unresponsive to conventional therapy, alone or in combination with methotrexate when the disease has not adequately responded to methotrexate.***For early rheumatoid arthritis (RA).***For the treatment of xerophthalmia by increasing tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.***For the treatment of heart transplant rejection prophylaxis, liver transplant rejection prophylaxis, and the treatment of acute and chronic graft-versus-host disease (GVHD)� and graft-versus-host disease (GVHD) prophylaxis�. <br />        NOTE: In general, children may undergo the same dosing regimen as adults but often require and tolerate higher doses.<br />NOTE: In the prevention of organ transplant rejection, cyclosporine is intended to be used in combination with corticosteroid therapy***For the treatment of severe atopic dermatitis�.***For the treatment of severe aplastic anemia�.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP)�.***For the treatment of myasthenia gravis� in patients who are poorly controlled with cholinesterase inhibitor therapy.***For the treatment of psoriatic arthritis�.***For the treatment of lupus nephritis� in patients with systemic lupus erythematosus (SLE) unresponsive to conventional therapy, or for the treatment of children with idiopathic nephrotic syndrome�.","***General Information***Fungal infection, herpes infection, immunosuppression, infection, requires a specialized care setting, requires an experienced clinician, varicella, viral infection***Herpes simplex keratitis (dendritic keratitis), ocular infection***Lymphoma, new primary malignancy, radiation therapy, skin cancer, sunlight (UV) exposure***Nephrotoxicity, renal disease, renal failure, renal impairment***Hyperkalemia, hypertension***Electrolyte imbalance***Polyoxyethylated castor oil hypersensitivity***Children, infants***Pregnancy***Breast-feeding***Geriatric***Alcoholism, biliary tract disease, hepatic disease, jaundice***Gout, hyperuricemia***Encephalopathy, hypomagnesemia***Vaccination***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3108'],dapsone,"***For the treatment of dermatitis herpetiformis.***For the treatment leprosy (Hansen's disease).***For multibacillary leprosy.***For paucibacillary leprosy.***For the treatment of acne vulgaris.***For the treatment of actinomycotic mycetoma�.***For actinomycotic mycetoma� caused by <em>Actinomadura madurae</em>� or <em>Streptomyces somaliensis</em>�.***For actinomycotic mycetoma� caused by <em>Nocardia</em> sp.�.***For the treatment of granuloma annulare�.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP)�.***For the treatment of polychondritis�.***For the treatment of mild to moderate Pneumocystis pneumonia (PCP)�.***For Pneumocystis pneumonia (PCP) prophylaxis�.***For primary PCP prophylaxis� in HIV-infected patients.***For secondary PCP prophylaxis� in HIV-infected patients after PCP treatment.***For primary toxoplasmosis prophylaxis� in HIV-infected patients, specifically prevention of toxoplasmic encephalitis (TE)� due to <em>Toxoplasmosis gondii</em>.***For the treatment of pyoderma gangrenosum�.***For the treatment of subcorneal pustular dermatosis�.","***Anemia, G6PD deficiency, methemoglobin reductase deficiency***Hepatic disease***Pregnancy***Breast-feeding***Children, infants, neonates***Sulfonamide hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,metformin hydrochloride/rosiglitazone maleate,"***For the treatment of type 2 diabetes mellitus uncontrolled by diet and exercise. <br />        NOTE: All patients should start the rosiglitazone component of metformin; rosiglitazone (Avandamet) at the lowest recommended dose. Further increases in the dose of rosiglitazone should be accompanied by careful monitoring for adverse events related to fluid retention.<br />NOTE: When adding rosiglitazone to metformin in patients with heart disease (with or without symptoms) and diabetes, monitor patients closely for signs of weight gain, peripheral edema, or congestive heart failure. Rosiglitazone should be initiated at the lowest dose and increased gradually after at least three months of therapy. The risk of these symptoms is increased when higher doses of rosiglitazone are used in combination with insulin in patients at risk of congestive heart failure. Rosiglitazone should not be added to metformin therapy in patients with New York Heart Association Class III or IV heart failure; metformin should not be used in patients with congestive heart failure requiring pharmacological therapy. Metformin; rosiglitazone should be discontinued if any deterioration in cardiac status occurs during therapy***For use when initial treatment with metformin alone does not result in adequate glycemic control.***For use when initial treatment with rosiglitazone alone does not result in adequate glycemic control.***For use when switching from rosiglitazone plus metformin as separate tablets to the single, combination tablet.***Formoterol; Mometasone","***General Information***Diabetic ketoacidosis, type 1 diabetes mellitus***Acute heart failure, acute myocardial infarction, angina, cardiac disease, cardiogenic shock, edema, heart failure, myocardial infarction, peripheral edema, pulmonary edema***Acidemia, hypovolemia, hypoxemia, lactic acidosis, metabolic acidosis, sepsis***Renal disease, renal failure, renal impairment***Alcoholism, ethanol ingestion, ethanol intoxication, hepatic disease, jaundice***Diarrhea, vomiting***Radiographic contrast administration***Burns, dehydration, fever, infection, surgery, trauma***Adrenal insufficiency, gastroparesis, GI obstruction, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypothyroidism, ileus, malnutrition, pituitary insufficiency***Anemia, pernicious anemia***Bone fractures, osteoporosis***Contraception requirements, menstrual irregularity, polycystic ovary syndrome***Pregnancy***Breast-feeding***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['23043'],difluprednate,***For the treatment of postoperative ocular pain and postoperative ocular inflammation.***For the treatment of endogenous anterior uveitis.,"***Corticosteroid hypersensitivity, glycerin hypersensitivity, polysorbate 80 hypersensitivity***Fungal infection, herpes simplex keratitis (dendritic keratitis), mycobacterial infection, ocular infection, varicella, viral infection***Glaucoma, increased intraocular pressure, open-angle glaucoma***Cataracts, diabetes mellitus***Corneal abrasion***Contact lenses***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['72625'],duloxetine,"***For the treatment of major depression.***For the treatment of generalized anxiety disorder (GAD).***For the treatment of pain associated with diabetic neuropathy.***For the treatment of pain associated with fibromyalgia.***For the treatment of chronic musculoskeletal pain (e.g., chronic low back pain and chronic pain due to osteoarthritis).***For the treatment of stress urinary incontinence� (SUI) in adult females.","***Abrupt discontinuation***Closed-angle glaucoma, increased intraocular pressure***Bipolar disorder, mania***Children, growth inhibition, suicidal ideation***MAOI therapy***Electroconvulsive therapy (ECT), seizure disorder***Cardiac disease, hypertension, hypotension, orthostatic hypotension, syncope***Dehydration, hyponatremia, hypovolemia***Alcoholism, hepatic disease, hepatitis, hepatotoxicity, jaundice***Serious rash***Anticoagulant therapy, bleeding, thrombolytic therapy***Renal failure, renal impairment***Urinary retention***Driving or operating machinery, ethanol ingestion***Diabetes mellitus***Eclampsia, neonates, obstetric delivery, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['15657'],decitabine,"***For the treatment myelodysplastic syndrome (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.***For the treatment of chronic myelogenous leukemia (CML)�.","***Anemia, bone marrow suppression, fungal infection, herpes infection, infection, neutropenia, thrombocytopenia, varicella, viral infection***Hepatic disease, renal impairment***Contraception requirements, male-mediated teratogenicity, reproductive risk***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['847083'],ustekinumab,***For the treatment of moderate to severe plaque psoriasis in those patients who are candidates for phototherapy or systemic therapy.***For the treatment of active psoriatic arthritis with or without methotrexate.***For the treatment of moderately to severely active Crohn's disease in adult patients who have had an inadequate response to or are unable to tolerate immunomodulators or corticosteroids or TNF blockers.***For the induction treatment of Crohn's disease.***For the maintenance treatment of Crohn's disease.,"***Desensitization procedures***Diabetes mellitus, immunosuppression, infection, influenza, sepsis, surgery, tuberculosis***Neoplastic disease***Vaccination***Sunlight (UV) exposure***Children, infants, neonates***Pregnancy***Breast-feeding***Geriatric***Latex hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,doxorubicin hydrochloride liposome,"***For the treatment of HIV-related Kaposi's sarcoma in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to other therapy.***For the treatment of ovarian cancer that has progressed or recurred after platinum-based chemotherapy. <br />        NOTE: Doxil has been designated an orphan drug by the FDA for this indication.<br />NOTE: Refractory disease is defined as progression while on therapy or within 6 months of completing treatment***For the treatment of relapsed or refractory multiple myeloma in patients who have received at least 1 prior therapy, in combination with bortezomib.***For the treatment of locally advanced or metastatic breast cancer�. <br />        NOTE: In a phase III trial comparing conventional doxorubicin to liposomal doxorubicin (Myocet; not available in the United States), the estimated median cumulative lifetime dose of doxorubicin for the first appearance of cardiotoxicity was &gt; 2220 mg/m2 for the liposomal doxorubicin and 480 mg/m2 for conventional doxorubicin.<br />     ***For the treatment of refractory or transformed cutaneous T-cell lymphoma (CTCL)�, including mycosis fungoides� and Sezary syndrome�.","***Anthracycline hypersensitivity***Infusion-related reactions***Cardiac disease, cardiomyopathy, cardiotoxicity, females, heart failure***Anemia, bone marrow suppression, infection, leukopenia, neutropenia, thrombocytopenia***Children, infants, neonates***Extravasation***Hepatic disease***Contraception requirements, male-mediated teratogenicity, pregnancy***Breast-feeding***New primary malignancy***Infertility***Ensure correct formulation selection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,tranylcypromine sulfate,***For use in treatment-resistant depression.***For the treatment of refractory panic disorder�.***For the treatment of refractory social phobia (social anxiety disorder)�.***For treatment of neurogenic orthostatic hypotension� in combination with increased dietary tyramine intake.,"***General Information***Alcoholism, coadministration with other CNS depressants, ethanol ingestion, MAOI therapy***Abrupt discontinuation, substance abuse***Pheochromocytoma***Hepatic disease, hepatitis***Seizure disorder, seizures***Anticholinergic medications, driving or operating machinery***Asthma, bronchitis***Diabetes mellitus***Hyperthyroidism***Dental work, spinal anesthesia, surgery***Anxiety, bipolar disorder, mania, psychosis, schizophrenia***Children, suicidal ideation***Acute myocardial infarction, angina, cardiac disease, cerebrovascular disease, head trauma, headache, hypertension, hypertensive crisis, increased intracranial pressure, intracranial bleeding, stroke***Radiographic contrast administration***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['495881'],sorafenib,"***For the treatment of advanced renal cell cancer.***For the treatment of unresectable hepatocellular cancer (HCC). <br />        NOTE: Sorafenib has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of locally recurrent or metastatic, progressive, differentiated thyroid cancer that is refractory to treatment with radioactive iodine.***For the treatment of advanced malignant melanoma�.***For the treatment of advanced, including locally unresectable and metastatic, malignant melanoma�.***For the treatment of advanced, including locally unresectable and metastatic, malignant melanoma� in combination with carboplatin and paclitaxel.***For the treatment of advanced, including locally unresectable and metastatic, malignant melanoma� in combination with dacarbazine or temozolomide.","***General Information***Lung cancer***Bleeding, GI bleeding, intracranial bleeding***Hepatic disease, hepatitis***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation***Surgery***Pregnancy***Breast-feeding***Children, infants, neonates***Hypertension***Skin disease***GI perforation***Thyroid disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7393']['36567'],niacin/simvastatin,"***For the reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B, non-HDL cholesterol, or triglyceride concentrations, and to increase HDL-cholesterol in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa or IIb hyperlipoproteinemia); or to treat Fredrickson Type IV (hypertriglyceridemia, increased VLDL). <br />  NOTE: Because of the risk of hepatotoxicity related with sustained-release or time-release niacin preparations or immediate-release (crystalline) niacin, the combination product niacin; simvastatin should only be substituted for equivalent doses of niacin extended release (Niaspan).<br /","***General Information***Alcoholism, cholestasis, hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Electrolyte imbalance, endocrine disease, females, hypotension, hypothyroidism, infection, myopathy, renal disease, renal failure, renal impairment, rhabdomyolysis, seizure disorder, surgery, trauma***Peptic ulcer disease***Gout***Hypophosphatemia***Diabetes mellitus***Anticoagulant therapy, bleeding, coagulopathy, thrombocytopenia***Asian patients***Geriatric***Contraception requirements, pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['819911'],besifloxacin,***For the treatment of bacterial conjunctivitis due to susceptible organisms.,"***General Information***Quinolone hypersensitivity***Contact lenses***Fungal infection, infection***Geriatric***Infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['993449'],denosumab,***For the treatment of osteoporosis in men and postmenopausal women at high risk for fracture. <br />        NOTE: Denosumab should be administered by a health care professional. Different products are indicated for different treatments; take care to select the right product for prescribing and avoid duplication.<br />NOTE: Patients at a high risk for fracture are those with a history of osteoporotic fracture or with multiple risk factors for fracture. Denosumab is also appropriate for those patients who have failed or are intolerant to other available osteoporosis therapy***For the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.***For osteoporosis prophylaxis in men at high risk for bone fractures after receiving androgen deprivation therapy for nonmetastatic prostate cancer and in women at high risk for bone fractures after receiving adjuvant aromatase inhibitor therapy for breast cancer. <br />        NOTE: Denosumab should be administered by a health care professional. Different products are indicated for different treatments; take care to select the right product when prescribing and avoid duplication.<br />     ***For the treatment of giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.***For the treatment of hypercalcemia of malignancy that is refractory to bisphosphonate therapy.***Formoterol; Mometasone,"***General Information***Dialysis, hypocalcemia, renal failure, renal impairment, vitamin D deficiency***Diabetes mellitus, immunosuppression, infection, surgery, tuberculosis***Angioedema, latex hypersensitivity, urticaria***Eczema***Neoplastic disease***Chemotherapy, corticosteroid therapy, dental disease, dental work***Pancreatitis***Bone fractures***Children, infants***Pregnancy***Contraception requirements, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ranitidine hydrochloride,"***For the self-medication of non-ulcer dyspepsia (acid indigestion), pyrosis (heartburn), and sour stomach.***For prophylaxis.***For treatment.***For the treatment of gastroesophageal reflux disease (GERD). <br />        NOTE: While ranitidine may be effective in patients with less severe GERD, proton pump inhibitors (PPIs) offer more rapid symptom relief and better healing.<br />     ***For short-term treatment (acute healing phase).***For maintenance treatment� (relapse prevention).***For the treatment of erosive esophagitis.***For endoscopically diagnosed erosive esophagitis.***For the treatment of pathologic GI hypersecretory conditions such as Zollinger-Ellison syndrome, systemic mastocytosis, or multiple endocrine adenoma syndrome.***For the treatment of peptic ulcer disease (duodenal ulcer or gastric ulcer) or gastritis�. <br />        NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br />NOTE: If gastritis or ulceration is due to NSAID therapy, every effort should be made to discontinue the NSAID***For short-term treatment of active benign gastric ulcer, active duodenal ulcer or gastritis�.***For maintenance therapy after treatment phase is complete.***For Helicobacter pylori (H. pylori) eradication� in the treatment of patients with peptic ulcer disease, dyspepsia, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />          NOTE: The American College of Gastroenterology (ACG) recommends 10�14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole; the same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: Ranitidine is not effective as a single agent for the eradication of H. pylori. Quadruple regimens that include an H2-blocker as an anti-secretory agent are FDA-approved, but are associated with lower compliance and efficacy rates than other recommended regimens.  An H2-blocker should not be substituted for a PPI in any current H. pylori treatment regimen unless the patient cannot tolerate a PPI.<br />NOTE: In populations where H. pylori infection is common (&gt;= 10%), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Helidac monograph).  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60�90% of patients.***For acid aspiration prophylaxis� prior to anesthesia. <br />        NOTE: Routine use of H2-blockers prior to surgery to decrease the risks of pulmonary aspiration in patients who have no apparent increased risk for pulmonary aspiration is not recommended. Consult current practice guidelines.<br />     ***For NSAID-induced ulcer prophylaxis�.***For stress gastritis prophylaxis� in critically-ill patients. <br />        NOTE: The 2008 Surviving Sepsis Campaign guidelines recommend H2-blockers or proton pump inhibitors be used in patients with sepsis or septic shock to prevent gastritis.<br />     ***For the treatment of acute, severe urticaria� or angioedema� associated with systemic symptoms in combination with an H1-blocker.***For the prevention of urticaria� and other histamine-mediated reactions� to specific types of chemotherapy (e.g., paclitaxel).","***General Information***H2-blocker hypersensitivity***Gastric cancer***Infection***Hepatic disease***Renal disease, renal failure, renal impairment***Children, infants, neonates, premature neonates***Pregnancy***Breast-feeding***Porphyria***Tobacco smoking***Bradycardia, cardiac disease***Geriatric***Vitamin B12 deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['35829'],ranolazine,"***For the treatment of chronic angina. <br />        NOTE: The concomitant use of ranolazine and CYP3A inducers or strong CYP3A inhibitors is contraindicated.<br />NOTE: The effects of ranolazine on angina frequency and exercise tolerance are considerably smaller in women than in men***For the treatment of acute coronary syndromes in patients with acute myocardial infarction, NSTEMI�.***For the treatment of acute coronary syndromes in patients with unstable angina�.***Formoterol***Formoterol; Mometasone","***General Information***Hepatic disease***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Females***Renal failure, renal impairment***Driving or operating machinery, syncope***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['711942'],eltrombopag,***For the treatment of thrombocytopenia.***For the initiation and maintenance of interferon-based therapy in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy.***For the treatment of severe aplastic anemia in patients who have had an insufficient response to immunosuppressive therapy.,"***Hepatic decompensation, hepatic disease, hepatitis C infection, hepatotoxicity, hypoalbuminemia***Renal impairment***Bone marrow suppression***Anticoagulant therapy, bleeding***Thromboembolic disease***Neoplastic disease***Cataracts***Asian patients***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['15202'],argatroban,"***For use as an anticoagulant in the treatment of thrombosis (i.e., deep venous thrombosis (DVT), pulmonary embolism) or for venous thromboembolism (VTE) prophylaxis (i.e., deep venous thrombosis (DVT) prophylaxis, pulmonary embolism prophylaxis) in patients with heparin-induced thrombocytopenia (HIT). <br />        NOTE: Before administering argatroban, discontinue heparin therapy and obtain a baseline aPTT.<br />     ***For conversion to oral anticoagulant therapy in patients receiving argatroban. <br />          NOTE: Initiate warfarin therapy using the expected daily dose of warfarin; a loading dose of warfarin should not be used.<br />NOTE: There is potential for combined effects on the INR with coadministration of argatroban and warfarin. The relationship between the INR obtained on combined therapy and the INR obtained on warfarin alone is dependent on both the dose of argatroban and the thromboplastin reagent used***For coronary artery thrombosis prophylaxis or treatment during percutaneous coronary intervention (PCI) in patients who have or who are at risk of developing heparin-induced thrombocytopenia.***For use as adjunctive therapy to thrombolytic agents in the treatment of ST-elevation myocardial infarction (STEMI)� (i.e., acute myocardial infarction�).***For the treatment of disseminated intravascular coagulation (DIC)�.***Formoterol; Mometasone","***Hepatic disease***Aneurysm, bleeding, coagulopathy, diverticulitis, endocarditis, GI bleeding, hemophilia, hypertension, inflammatory bowel disease, intracranial bleeding, intramuscular injections, lumbar puncture, menstruation, peptic ulcer disease, renal disease, retroperitoneal bleeding, spinal anesthesia, stroke, surgery, trauma***Abrupt discontinuation, angina***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluticasone propionate/salmeterol,***For the maintenance treatment of asthma.***For the maintenance treatment of chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis or emphysema.***Formoterol***Formoterol; Mometasone,"***General Information***Angioedema, milk protein hypersensitivity***Acute bronchospasm, asthma-related death, respiratory insufficiency, status asthmaticus***Corticosteroid therapy***Paradoxical bronchospasm***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation***Diabetes mellitus, hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***Hypothalamic-pituitary-adrenal (HPA) suppression***Immunosuppression, tuberculosis***Hepatic disease***Osteoporosis***Cataracts, glaucoma, increased intraocular pressure***Labor, pregnancy***Breast-feeding***Children, growth inhibition, increased intracranial pressure, infants***MAOI therapy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,carvedilol phosphate,"***For the treatment of heart failure (ischemic origin or cardiomyopathy).***For mild, moderate, or severe heart failure in adult patients (ischemic origin or cardiomyopathy) as a single agent or in conjunction with digoxin, diuretics, hydralazine, or ACE inhibitor therapy.***For patients with severe heart failure (NYHA Class III/IV) and referred for cardiac transplantation�.***For the treatment of heart failure in pediatric patients� (ischemic origin or cardiomyopathy) usually in conjunction with digoxin, diuretics, or ACE inhibitor therapy.***For reduction of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (ejection fraction of 40% or higher) following acute myocardial infarction.***For the treatment of essential hypertension, either as a single agent or in combination with other antihypertensive agents.***For the treatment of angina�.***For heart rate control in patients with atrial fibrillation� or atrial flutter�.","***Angioedema, beta-blocker hypersensitivity***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***Pheochromocytoma, vasospastic angina***Acute heart failure, AV block, bradycardia, cardiogenic shock, hypotension, orthostatic hypotension, pulmonary edema, sick sinus syndrome, ventricular dysfunction***Cerebrovascular disease***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Surgery***Hepatic disease***Peripheral vascular disease, renal disease, renal failure, renal impairment***Depression***Psoriasis***Myasthenia gravis***Geriatric***Diabetes mellitus, hypoglycemia***Contact lenses***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluticasone propionate/salmeterol,***For the maintenance treatment of asthma.***For the maintenance treatment of chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis or emphysema.***Formoterol***Formoterol; Mometasone,"***General Information***Angioedema, milk protein hypersensitivity***Acute bronchospasm, asthma-related death, respiratory insufficiency, status asthmaticus***Corticosteroid therapy***Paradoxical bronchospasm***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation***Diabetes mellitus, hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***Hypothalamic-pituitary-adrenal (HPA) suppression***Immunosuppression, tuberculosis***Hepatic disease***Osteoporosis***Cataracts, glaucoma, increased intraocular pressure***Labor, pregnancy***Breast-feeding***Children, growth inhibition, increased intracranial pressure, infants***MAOI therapy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sumatriptan succinate,***For the acute treatment of migraine attacks with or without aura. <br />        NOTE: Sumatriptan is not indicated for hemiplegic or basilar migraine.<br />     ***For the acute treatment of cluster headache.,"***General Information***Sumatriptan hypersensitivity***Acute myocardial infarction, angina, arteriosclerosis, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, hypercholesterolemia, obesity, tobacco smoking, vasospastic angina, Wolff-Parkinson-White syndrome***Hypertension***Cerebrovascular disease, intracranial bleeding, stroke***Basilar/hemiplegic migraine***Intravenous administration***Pregnancy***Breast-feeding***Hepatic disease***Renal disease, renal failure, renal impairment***Children***Geriatric***Driving or operating machinery***Colitis, peripheral vascular disease, Raynaud's phenomenon***Seizure disorder, seizures***Visual disturbance***MAOI therapy***Magnetic resonance imaging (MRI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8727'],progesterone,"***For the treatment of amenorrhea.***For the prevention of endometrial hyperplasia associated with conjugated estrogen replacement therapy in postmenopausal women who have an intact uterus.***For the treatment of dysfunctional uterine bleeding secondary to hormonal imbalance.***For the treatment of infertility or for the prevention of early pregnancy failure� (e.g., miscarriage) in women with corpus luteum insufficiency�. <br />        NOTE: The optimal dose and route of progesterone administration has not been determined. Vaginal progesterone is often used preferentially over the intramuscular formulation secondary to comparable efficacy and decreased side effects (e.g., pain at the injection site, sterile abscess formation).<br />     ***For the treatment of symptoms associated with premenstrual syndrome (PMS)�.***For preterm delivery prophylaxis�.","***Breast cancer, cervical cancer, endometrial cancer, endometrial hyperplasia, new primary malignancy, ovarian cancer, uterine cancer, vaginal cancer***Hepatic disease***Benzyl alcohol hypersensitivity, intravenous administration, pulmonary oil microembolism, sesame oil hypersensitivity***Infertility***Ectopic pregnancy, incomplete abortion, pregnancy***Breast-feeding***Children, infants, neonates***Cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, visual disturbance***Diabetes mellitus, hyperlipidemia***Asthma, cardiac disease, renal disease***Depression, migraine, seizure disorder***Infection, inflammation***Peanut hypersensitivity***Driving or operating machinery***Dementia, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,naproxen sodium/sumatriptan,***For the treatment of acute migraine attacks with or without aura.***Formoterol; Mometasone,"***General Information***MAOI therapy***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Acute myocardial infarction, angina, arteriosclerosis, cardiac arrhythmias, cardiac disease, cerebrovascular disease, colitis, coronary artery bypass graft surgery (CABG), coronary artery disease, diabetes mellitus, hypercholesterolemia, intracranial bleeding, myocardial infarction, obesity, peripheral vascular disease, Raynaud's phenomenon, stroke, tachycardia, thromboembolism, tobacco smoking, vasospastic angina, Wolff-Parkinson-White syndrome***Basilar/hemiplegic migraine***Hypertension***Labor, pregnancy***Breast-feeding***Hepatic disease***Geriatric***Dehydration, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Cardiomyopathy, edema, heart failure***Seizure disorder, seizures***Driving or operating machinery***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, Crohn's disease, GI bleeding, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, thrombocytopenia***Anemia***Intramuscular injections***Dental disease, dental work",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,trazodone hydrochloride,***For the treatment of major depression.***For the treatment of insomnia�.***For the maintenance treatment of alcohol dependence�.***For the treatment of panic disorder� or agoraphobia�.***For the treatment of generalized anxiety disorder (GAD)�.,"***Children, suicidal ideation***Bipolar disorder, mania***MAOI therapy***Acute myocardial infarction, alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, dehydration, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, syncope, thyroid disease***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Hepatic disease***Renal failure, renal impairment***Hyponatremia***Closed-angle glaucoma, increased intraocular pressure***Anticoagulant therapy, bleeding, thrombolytic therapy***Priapism***Electroconvulsive therapy (ECT)***Abrupt discontinuation***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fondaparinux sodium,"***For the treatment of acute pulmonary embolism (PE) or acute deep venous thrombosis (DVT) in conjunction with warfarin.***For deep venous thrombosis (DVT) prophylaxis or pulmonary embolism prophylaxis (PE prophylaxis).***For DVT or PE prophylaxis following orthopedic surgery including hip fracture surgery, hip replacement surgery or knee replacement surgery.***For DVT or PE prophylaxis following abdominal surgery in patients who are risk for thromboembolic complications. <br />          NOTE: Patients at risk are those undergoing surgery with general anesthesia lasting &gt; 45 minutes who are 1) &gt; 60 years or 2) &gt; 40 years with at least one of the following: neoplastic disease, obesity, chronic obstructive pulmonary disease, inflammatory bowel disease, history of DVT or PE, or congestive heart failure.<br />       ***For coronary artery thrombosis prophylaxis� and the prevention of ischemic complications in patients with acute coronary syndrome (ACS)�.***For patients with ST-segment elevation acute myocardial infarction� (STEMI).***For patients with unstable angina� or non-ST-segment elevation myocardial infarction (NSTEMI)�.***For the treatment of superficial vein thrombosis� in the legs.","***General Information***Bleeding, endocarditis, epidural anesthesia, GI bleeding, lumbar puncture, spinal anesthesia, stroke, surgery***Intramuscular administration***Geriatric***Heparin-induced thrombocytopenia (HIT), thrombocytopenia***Renal disease, renal failure, renal impairment***Aneurysm, diabetic retinopathy, diverticulitis, hemophilia, hepatic disease, hypertension, idiopathic thrombocytopenic purpura (ITP), inflammatory bowel disease, menstruation, peptic ulcer disease, vaginal bleeding***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Anticoagulant therapy, thrombolytic therapy***Dental disease, dental work***Angioedema***Intramuscular injections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,propylene glycol,***For the temporary relief of xerophthalmia and minor ocular irritation.,"***Contact lenses***Corneal abrasion, ocular infection, ocular trauma, visual disturbance***Pregnancy***Children, infants, neonates***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['787390'],tapentadol,"***For the treatment of severe pain.***For the management of chronic severe pain, including severe neuropathic pain associated with diabetic peripheral neuropathy, in patients who require daily, around-the-clock, long-term opioid treatment. <br />  NOTE: Extended-release tapentadol tablets should be reserved for patients in whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Discontinue all other tapentadol products, tramadol products, and around-the-clock opioid drugs upon initiation of tapentadol extended-release tablets.<br />NOTE: The use of initial dosages higher than 50 mg PO twice daily should be reserved for opioid-tolerant patients. Opioid-tolerant patients are defined as those taking, for a minimum of 1 week, 60 mg or more oral morphine daily, 30 mg or more oral oxycodone daily, 8 mg or more oral hydromorphone daily, 25 mg or more oral oxymorphone daily, 25 mcg or more transdermal fentanyl per hour, 60 mg or more oral hydrocodone daily, or an equivalent dose of another opioid***For the treatment of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.","***General Information***Accidental exposure, ethanol ingestion, ethanol intoxication, parenteral administration, potential for overdose or poisoning, requires an experienced clinician***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, coma, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Opioid-naive patients***MAOI therapy***Acute abdomen, constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Driving or operating machinery***CNS depression, head trauma, increased intracranial pressure, intracranial mass, psychosis***Seizure disorder, seizures***Renal failure, renal impairment***Abrupt discontinuation***Hepatic disease***Children, infants, neonates***Geriatric***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Infertility, reproductive risk***Angina, cardiac arrhythmias, cardiac disease, dehydration, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock***Adrenal insufficiency, hypothyroidism, myxedema***Bladder obstruction, oliguria, prostatic hypertrophy, urethral stricture, urinary retention***Biliary tract disease, pancreatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,beclomethasone dipropionate monohydrate,***For the maintenance treatment of asthma as prophylactic therapy.***For relief of seasonal or perennial allergic rhinitis.***For relief of vasomotor rhinitis (nonallergic rhinitis).***For the prevention of recurrence of nasal polyps after surgical removal.***For the maintenance treatment of chronic obstructive pulmonary disease (COPD)� such as chronic bronchitis� or emphysema�.***For exercise-induced bronchospasm prophylaxis�.,"***General Information***Acute bronchospasm, status asthmaticus***Paradoxical bronchospasm***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, surgery***Fungal infection, herpes infection, infection, measles, tuberculosis, varicella, viral infection***Malnutrition, osteoporosis, tobacco smoking***Nasal septal perforation, nasal surgery, nasal trauma***Infants, neonates, pregnancy***Breast-feeding***Children, growth inhibition, increased intracranial pressure***Diabetes mellitus, hyperglycemia***Cataracts, glaucoma, increased intraocular pressure, ocular exposure, visual disturbance***Corticosteroid hypersensitivity***Depression, psychosis, suicidal ideation***Hepatic disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['480639', '1516803']",alvimopan,"***For the acceleration of time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis (i.e., postoperative ileus prophylaxis).***For the treatment of opiate agonist-induced constipation�.","***General Information***Myocardial infarction, requires a specialized care setting***GI obstruction***Hepatic disease***Renal disease***Pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['11636']['4083'],drospirenone/estradiol,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae) in women with an intact uterus.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Adrenal insufficiency, hyperkalemia, hyponatremia, renal failure, renal impairment***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['195085']['276237'],efavirenz/emtricitabine/tenofovir disoproxil fumarate,"***For the treatment of human immunodeficiency virus (HIV) infection. <br />        NOTE: Efavirenz; emtricitabine; tenofovir is not indicated for the treatment of chronic hepatitis B virus (HBV) infection, and the safety and efficacy of treatment have not been established in patients co-infected with HBV and HIV.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Females, hepatotoxicity or lactic acidosis, lactic acidosis, obesity***Pregnancy***Breast-feeding***Hypercholesterolemia, hypertriglyceridemia***Children, infants, neonates***Alcoholism, bipolar disorder, depression, driving or operating machinery, mania, psychosis, substance abuse, suicidal ideation***Exfoliative dermatitis, serious rash***Seizure disorder, seizures***Asian patients, Black patients, Hispanic patients, human immunodeficiency virus (HIV) infection resistance***Hepatic disease, hepatitis, hepatitis B and HIV coinfection, hepatitis B exacerbation***Bone fractures, hypophosphatemia, renal disease, renal failure, renal impairment***Osteomalacia, osteoporosis***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Hepatitis C and HIV coinfection***Bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1112973'],belatacept,"***For kidney transplant rejection prophylaxis in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids. <br />        NOTE: Obtain Epstein-Barr virus (EBV) serology BEFORE belatacept administration. Belatacept is contraindicated for use by patients who are EBV seronegative or who have unknown EBV serostatus.<br />     ","***Requires a specialized care setting, requires an experienced clinician***Diabetes mellitus, infection, tuberculosis***Immunosuppression, new primary malignancy, post-transplant lymphoproliferative disorder (PTLD), progressive multifocal leukoencephalopathy, sunlight (UV) exposure***Children, infants, neonates***Pregnancy***Breast-feeding***Liver transplant, mortality***Thromboembolic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2191', '1545984']",ceftazidime,"***For the treatment of intraabdominal infections, including peritonitis.***For peritonitis in patients undergoing peritoneal dialysis.***For the treatment of bone and joint infections, including osteomyelitis.***For the treatment of lower respiratory tract infections, including pneumonia such as community-acquired pneumonia (CAP) and nosocomial pneumonia.***For the treatment of urinary tract infection (UTI).***For the treatment of very severe life-threatening infections, such as bacteremia and sepsis.***For the treatment of gynecologic infections, including endometritis and pelvic cellulitis.***For the treatment of central nervous system infections, including meningitis.***For the treatment of skin and skin structure infections, including diabetic foot ulcer.***For the management of pulmonary infections in patients with cystic fibrosis.***For the empiric treatment of febrile neutropenia�.***For the treatment of melioidosis� due to <em>Burkholderia pseudomallei</em>.***For the treatment of infective endocarditis�.","***General Information***Cephalosporin hypersensitivity, penicillin hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Coagulopathy, vitamin K deficiency***Renal failure, renal impairment***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['82122'],levofloxacin,"***For the treatment of acute bacterial sinusitis.***For the treatment of urinary tract infection (UTI), including pyelonephritis.***For treatment of mild to moderate complicated UTI or acute pyelonephritis.***For treatment of mild to moderate uncomplicated UTI.***For the treatment of acute bacterial exacerbation of chronic bronchitis.***For the treatment of lower respiratory tract infections, including community-acquired pneumonia (CAP) and nosocomial pneumonia.***For the treatment of nosocomial, ventilator-associated pneumonia (VAP) or hospital-acquired pneumonia (HAP).***For the treatment of community-acquired pneumonia (CAP).***For the treatment of bacterial conjunctivitis.***For anthrax prophylaxis after exposure to Bacillus anthracis (postexposure prophylaxis, PEP).***For the treatment of plague infection, including pneumonic and septicemic plague, due to exposure to <em>Yersinia pestis</em> and for plague prophylaxis. <br />        NOTE: Streptomycin or gentamicin are the drugs of choice to treat plague in most patients. Gentamicin is the preferred treatment agent in exposed pregnant women. Tetracyclines or a quinolone are the treatments of choice for plague in the mass casualty setting and for prophylaxis, including pregnant women.<br />     ***For the treatment of complicated or uncomplicated mild to moderate skin and skin structure infections including an abscess, cellulitis, furunculosis, impetigo, pyoderma, wound infections, or diabetic foot ulcer�.***For the treatment of catheter-related skin and skin structure infections� (exit site� and tunnel infections�) in continuous ambulatory peritoneal dialysis (CAPD) pediatric patients.***For the treatment of tuberculosis infection� caused by <em>Mycobacterium tuberculosis</em>� infection in combination with other antituberculosis agents as second line therapy. <br />  NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., at least 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, IDSA, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. Directly observed therapy (DOT) should be used for all regimens administered 1, 2, 3, or 5 times per week. The initial treatment regimen should include four drugs unless the likelihood of INH or rifampin resistance is low (i.e., less than 4%), in which case an initial regimen of INH, rifampin, and pyrazinamide may be considered. HIV-infected patients should always receive induction therapy with four drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate.   For multi-drug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, the CDC recommends treatment for 18 to 24 months after culture conversion in patients with bacteriologic confirmation and for at least 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months in MDR-TB.<br /***For the treatment of Mycobacterium avium complex infection� (MAC) in HIV-infected patients.***For the treatment of non-gonococcal urethritis (NGU)� or chlamydia infection� including cervicitis� or urethritis�.***For the treatment of chronic bacterial prostatitis or epididymitis�.***For acute epididymitis�.***For the treatment of chronic bacterial prostatitis.***For the treatment of pelvic inflammatory disease (PID)�.***For use in combination with amoxicillin and rabeprazole for Helicobacter pylori (H. pylori) eradication�. <br />  NOTE: For patients unable to reach the acceptable 80% or more eradication rate with conventional therapy, a combination including levofloxacin is recommended as a third choice therapy. Selection of this type of rescue therapy should be based on antimicrobial susceptibility testing.<br /***For the treatment of salmonellosis� in HIV-infected patients.***For the treatment of anthrax�.***For the treatment of cutaneous anthrax infection�.***For the treatment of systemic anthrax infection�.***For the treatment of uncomplicated typhoid fever� caused by <em>Salmonella typhi</em>.***For the empiric treatment of febrile neutropenia� as part of combination therapy.***For surgical infection prophylaxis�.***For the treatment of shigellosis� in HIV-infected patients.***For the treatment of campylobacteriosis� in HIV-infected patients.***For the treatment of sepsis�.***For the treatment of moderate or severe traveler's diarrhea�.","***General Information***Quinolone hypersensitivity***Corticosteroid therapy, organ transplant, tendinitis, tendinopathy, tendon pain, tendon rupture***Cerebrovascular disease, depression, neurotoxicity, peripheral neuropathy, seizure disorder***Myasthenia gravis***Alcoholism, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Renal failure, renal impairment***Dehydration***Hepatic disease, hepatitis, hepatotoxicity, jaundice***Diabetes mellitus***Sunlight (UV) exposure***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Geriatric***Pregnancy***Breast-feeding***Sexually transmitted disease***Children, infants, neonates***Contact lenses***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ceftaroline fosamil,***For the treatment of acute bacterial skin and skin structure infections (ABSSSI) due to susceptible organisms.***For the treatment of bacterial community-acquired pneumonia due to susceptible organisms.***For the treatment of sepsis�.,"***Carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Antimicrobial resistance, viral infection***Dialysis, renal failure, renal impairment***Coagulopathy, hypoprothrombinemia, vitamin K deficiency***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['60212']['2382'],atovaquone/proguanil hydrochloride,"***For the treatment of acute, uncomplicated malaria due to <em>P. falciparum</em> or <em>P. vivax</em>�.***For <em>P. falciparum</em> malaria prophylaxis, including in areas where chloroquine resistance has been reported.","***General Information***Pulmonary edema, renal failure, renal impairment***Diarrhea, GI disease, vomiting***Pregnancy***Breast-feeding***Asian patients, Black patients, hepatic disease***Children, infants***Geriatric***Driving or operating machinery***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['38454'],trandolapril,***For the treatment of hypertension.***For the treatment of heart failure post acute myocardial infarction or left-ventricular dysfunction post acute myocardial infarction.,"***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, Black patients, hereditary angioedema***Diabetes mellitus, hyperkalemia, renal artery stenosis, renal disease, renal failure, renal impairment***Autoimmune disease, bone marrow suppression, collagen-vascular disease, immunosuppression, neutropenia, scleroderma, systemic lupus erythematosus (SLE)***Aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hyponatremia, hypotension, hypovolemia***Dialysis, hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Hepatic disease, jaundice***Surgery***Neonates, pregnancy***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,propafenone hydrochloride,"***For the treatment of sustained ventricular tachycardia that is deemed to be life-threatening. <br />        NOTE: Dosage should be initiated in the hospital setting.<br />     ***For the conversion to� and/or maintenance of sinus rhythm in patients with supraventricular arrhythmias in patients without structural heart disease.***For the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation or atrial flutter associated with disabling symptoms.***For paroxysmal supraventricular tachycardia (PSVT) prophylaxis in patients with AV reentrant tachycardias, including patients with Wolff-Parkinson-White (WPW) syndrome�.***For conversion to� sinus rhythm in patients with recent-onset atrial fibrillation.***Formoterol***Formoterol; Mometasone","***AV block, bradycardia, cardiogenic shock, electrolyte imbalance, heart failure, hyperkalemia, hypotension, sick sinus syndrome***Alcoholism, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, mortality, myocardial infarction, QT prolongation, thyroid disease***Brugada syndrome***Renal failure, renal impairment***Hepatic disease***Acute bronchospasm, asthma, chronic obstructive pulmonary disease (COPD)***Pregnancy***Myasthenia gravis***Breast-feeding***Systemic lupus erythematosus (SLE)***Infertility***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6472']['7393'],lovastatin/niacin,"***For the treatment of primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb hyperlipoproteinemia) in patients receiving lovastatin or niacin and who require further TG-lowering and/or HDL-raising. <br />        NOTE: Equivalent doses of Advicor may be substituted for niacin-equivalent doses of Niaspan, but should not be substituted for other niacin preparations. Since extended-release and regular-release dosage forms of niacin are not bioequivalent, the manufacturer recommends that patients previously receiving niacin products (other than Niaspan) be titrated with Niaspan prior to switching to Advicor.<br />     ","***General Information***Peptic ulcer disease***Alcoholism, cholestasis, gallbladder disease, hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Anticoagulant therapy, bleeding, coagulopathy, surgery, thrombocytopenia***Electrolyte imbalance, endocrine disease, hypotension, infection, myopathy, renal disease, renal failure, renal impairment, rhabdomyolysis, seizure disorder, trauma***Acute myocardial infarction, angina, driving or operating machinery, orthostatic hypotension***Diabetes mellitus***Gout***Hypophosphatemia***Geriatric***Contraception requirements, pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['14851'],vigabatrin,"***For use as monotherapy in the treatment of infantile spasms in pediatric patients for whom the potential benefits outweigh the potential risk of vision loss. <br />  NOTE: Vision loss in infants and children may not be detected until it is severe. Vision assessment is recommended at baseline (no later than 4 weeks after vigabatrin initiation), at least every 3 months during therapy, and approximately 3 to 6 months after vigabatrin discontinuation.<br /***For the adjunctive treatment of refractory complex partial seizures. <br />        NOTE: Vision assessment is recommended at baseline (no later than 4 weeks after vigabatrin initiation), at least every 3 months during therapy, and approximately 3 to 6 months after vigabatrin discontinuation.<br />     ***Formoterol; Mometasone","***General Information***Requires an experienced clinician, visual impairment***Depression, suicidal ideation***Abrupt discontinuation***Driving or operating machinery***Hepatic decompensation, hepatic disease***Renal impairment***Geriatric***Children, infants, neonates***Substance abuse***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,eprosartan mesylate,"***For the treatment of hypertension, either alone or in combination with other antihypertensive agents.","***Hypotension, hypovolemia***Heart failure, renal artery stenosis, renal disease, renal failure, renal impairment***Hepatic disease***Hyperkalemia***ACE-inhibitor induced angioedema, angioedema***Black patients***Surgery***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['233272'],bexarotene,"***For the treatment cutaneous T-cell lymphoma (CTCL), including mycosis fungoides. <br />  NOTE: Bexarotene has been designated an orphan drug by the FDA for this indication.<br /***For the treatment of cutaneous manifestations of CTCL in patients who are refractory to at least 1 prior systemic therapy.***For the treatment of cutaneous lesions of stage IA or IB CTCL in patients who have refractory or persistent disease after other therapies or who have not tolerated other therapies.***For the treatment of advanced non-small cell lung cancer (NSCLC)�.***For the treatment of AIDS-related Kaposi's sarcoma�.***For the treatment of metastatic breast cancer�.***For the treatment of severe plaque psoriasis�.","***Retinoid hypersensitivity***Diabetes mellitus***Alcoholism, biliary tract disease, pancreatitis***Cholestasis, hepatic disease, hepatotoxicity***Hypothyroidism, thyroid disease***Leukopenia, neutropenia***Cataracts***Sunlight (UV) exposure***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia***Pregnancy***Contraception requirements, male-mediated teratogenicity, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,palonosetron hydrochloride,***For chemotherapy-induced nausea/vomiting prophylaxis (CINV prophylaxis).***For acute chemotherapy-induced nausea/vomiting (CINV) prophylaxis associated with initial and repeat courses of highly emetogenic cancer chemotherapy.***For chemotherapy-induced nausea/vomiting (CINV) prophylaxis associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.***For post-operative nausea/vomiting (PONV) prophylaxis for up to 24 hours after surgery. <br />        NOTE: Efficacy beyond 24 hours has not been established.<br />     ,"***Dolasetron hypersensitivity, granisetron hypersensitivity, ondansetron hypersensitivity, palonosetron hypersensitivity***Pregnancy***Breast-feeding***Neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,propafenone hydrochloride,"***For the treatment of sustained ventricular tachycardia that is deemed to be life-threatening. <br />        NOTE: Dosage should be initiated in the hospital setting.<br />     ***For the conversion to� and/or maintenance of sinus rhythm in patients with supraventricular arrhythmias in patients without structural heart disease.***For the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation or atrial flutter associated with disabling symptoms.***For paroxysmal supraventricular tachycardia (PSVT) prophylaxis in patients with AV reentrant tachycardias, including patients with Wolff-Parkinson-White (WPW) syndrome�.***For conversion to� sinus rhythm in patients with recent-onset atrial fibrillation.***Formoterol***Formoterol; Mometasone","***AV block, bradycardia, cardiogenic shock, electrolyte imbalance, heart failure, hyperkalemia, hypotension, sick sinus syndrome***Alcoholism, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, mortality, myocardial infarction, QT prolongation, thyroid disease***Brugada syndrome***Renal failure, renal impairment***Hepatic disease***Acute bronchospasm, asthma, chronic obstructive pulmonary disease (COPD)***Pregnancy***Myasthenia gravis***Breast-feeding***Systemic lupus erythematosus (SLE)***Infertility***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,insulin lispro,"***For the treatment of type 1 diabetes mellitus.***For the treatment of type 2 diabetes mellitus that is inadequately managed by diet, exercise, and oral hypoglycemics. <br />        NOTE: A consensus algorithm issued by the ADA and the European Association for the Study of Diabetes lists basal or intermediate-acting insulin as a second line or third line agent in patients with type 2 diabetes not controlled on oral drugs; metformin is the initial recommended therapy in all type 2 diabetics without contraindications. Once insulin is added, therapy can be intensified (e.g., addition of prandial insulin) to achieve optimal glycemic control. In patients that are receiving a sulfonylurea, the sulfonylurea should be discontinued when insulin therapy is initiated.<br />     ***For the treatment of diabetic ketoacidosis�.***For the treatment of uncomplicated diabetic ketoacidosis� (DKA) when continuous IV administration is not possible.***Formoterol; Mometasone","***General Information***Diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Hepatic disease, renal failure, renal impairment***Diabetic ketoacidosis, hyperosmolar hyperglycemic state (HHS)***Continuous subcutaneous insulin infusion (CSII) administration***Hypoglycemia***Hypokalemia***Cresol hypersensitivity***Neonates, pregnancy***Breast-feeding***Tobacco smoking***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,interferon beta-1a,***For the treatment of remitting-relapsing forms of multiple sclerosis (MS) to slow physical disability and to decrease the frequency of clinical exacerbations. <br />        NOTE: Interferon beta-1a (Avonex) has been designated as an orphan drug by the FDA for this indication.<br />NOTE: Safety and efficacy have not been established in patients with chronic progressive multiple sclerosis***For the treatment of chronic hepatitis C infection� in treatment naive patients. <br />        NOTE: Interferon beta-1a has been designated as an orphan drug by the FDA for this indication.<br />     ,"***Albumin hypersensitivity, hamster protein hypersensitivity***Latex hypersensitivity***Subcutaneous administration***Angina, cardiac arrhythmias, cardiac disease, heart failure, myocardial infarction***Bone marrow suppression***Alcoholism, hepatic disease, jaundice***Pregnancy***Breast-feeding***Children***Depression, psychosis, suicidal ideation***Seizure disorder***Autoimmune disease, thyroid disease***Hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['787390'],tapentadol,"***For the treatment of severe pain.***For the management of chronic severe pain, including severe neuropathic pain associated with diabetic peripheral neuropathy, in patients who require daily, around-the-clock, long-term opioid treatment. <br />  NOTE: Extended-release tapentadol tablets should be reserved for patients in whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Discontinue all other tapentadol products, tramadol products, and around-the-clock opioid drugs upon initiation of tapentadol extended-release tablets.<br />NOTE: The use of initial dosages higher than 50 mg PO twice daily should be reserved for opioid-tolerant patients. Opioid-tolerant patients are defined as those taking, for a minimum of 1 week, 60 mg or more oral morphine daily, 30 mg or more oral oxycodone daily, 8 mg or more oral hydromorphone daily, 25 mg or more oral oxymorphone daily, 25 mcg or more transdermal fentanyl per hour, 60 mg or more oral hydrocodone daily, or an equivalent dose of another opioid***For the treatment of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.","***General Information***Accidental exposure, ethanol ingestion, ethanol intoxication, parenteral administration, potential for overdose or poisoning, requires an experienced clinician***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, coma, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Opioid-naive patients***MAOI therapy***Acute abdomen, constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Driving or operating machinery***CNS depression, head trauma, increased intracranial pressure, intracranial mass, psychosis***Seizure disorder, seizures***Renal failure, renal impairment***Abrupt discontinuation***Hepatic disease***Children, infants, neonates***Geriatric***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Infertility, reproductive risk***Angina, cardiac arrhythmias, cardiac disease, dehydration, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock***Adrenal insufficiency, hypothyroidism, myxedema***Bladder obstruction, oliguria, prostatic hypertrophy, urethral stricture, urinary retention***Biliary tract disease, pancreatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluticasone propionate,"***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses, including the treatment of alopecia areata, discoid lupus erythematosus, generalized exfoliative dermatitis, cutaneous lichen planus, lichen simplex chronicus, lichen striatus, nodular prurigo, pompholyx (dyshidrosis), pemphigus, polymorphous light eruption, psoriasis, seborrheic dermatitis, severe contact dermatitis, severe Rhus dermatitis (due to plants like poison ivy), and xerosis.***For the treatment of eczema, including atopic dermatitis.***For the management of symptoms associated with seasonal or perennial allergic rhinitis, including allergic conjunctivitis.***For the management of nasal symptoms associated with vasomotor rhinitis (perennial nonallergic rhinitis).***For the maintenance treatment of asthma.***For the treatment of nasal polyps.***For exercise-induced bronchospasm prophylaxis�.***Formaldehyde hypersensitivit","***General Information***Corticosteroid hypersensitivity, milk protein hypersensitivity***Acute bronchospasm, status asthmaticus***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion, surgery***Diabetes mellitus***Nasal septal perforation, nasal surgery, nasal trauma***Fungal infection, herpes infection, infection, measles, tuberculosis, varicella, viral infection***Malnutrition, osteoporosis, tobacco smoking***Geriatric***Hepatic disease***Acne rosacea, acne vulgaris, perioral dermatitis, peripheral vascular disease, skin atrophy***Cataracts, glaucoma, increased intraocular pressure, ocular exposure***Formaldehyde hypersensitivity***Children, growth inhibition, increased intracranial pressure, infants***Pregnancy***Breast-feeding***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['57308'],topotecan,"***For the treatment of patients with metastatic ovarian cancer with disease progression on or after initial or subsequent chemotherapy. <br />  NOTE: Patients must have a neutrophil count &gt; 1500 cells/mm3 and a platelet count &gt; 100,000 cells/mm3 before topotecan initiation. Do NOT give subsequent courses of topotecan until the neutrophil count is &gt; 1000 cells/mm3, the platelet count is &gt; 100,000 cells/mm3, and the hemoglobin concentration is &gt; 9 g/dL (transfusion may be necessary).<br /***For the treatment of small cell lung cancer (SCLC). <br />        NOTE: Patients must have a neutrophil count &gt; 1500 cells/mm3 and a platelet count &gt; 100,000 cells/mm3 before topotecan initiation. Do NOT give subsequent courses of topotecan until the neutrophil count is &gt; 1000 cells/mm3, the platelet count is &gt; 100,000 cells/mm3, and the hemoglobin concentration is &gt; 9 g/dL (transfusion may be necessary).<br />     ***For platinum-sensitive small cell lung cancer (SCLC) who progressed at least 60 days after initiation of first-line chemotherapy.***For relapsed small cell lung cancer (SCLC) in patients with a prior complete or partial response and who are at least 45 days from the end of first-line chemotherapy.***For chemotherapy-naive, extensive-stage SCLC in combination with paclitaxel�.***For chemotherapy-naive, extensive-stage SCLC sequentially after treatment with cisplatin and etoposide�.***For the treatment of stage IV-B recurrent or persistent cervical cancer that is not amendable to curative treatment with surgery and/or radiation therapy. <br />        NOTE: Patients must have a neutrophil count &gt; 1500 cells/mm3 and a platelet count &gt; 100,000 cells/mm3 before topotecan initiation. Do NOT give subsequent courses of topotecan until the neutrophil count is &gt; 1000 cells/mm3, the platelet count is &gt; 100,000 cells/mm3, and the hemoglobin concentration is &gt; 9 g/dL (transfusion may be necessary).<br />     ***For the treatment of metastatic rhabdomyosarcoma� in combination with cyclophosphamide and vincristine alternating with VAC.***For the treatment of non-small cell lung cancer (NSCLC)�.***For the treatment of previously untreated advanced non-small cell lung cancer (NSCLC) in combination with gemcitabine�.***For the second-line treatment of advanced non-small cell lung cancer in combination with gemcitabine�.","***Gelatin hypersensitivity, mannitol hypersensitivity***Anemia, bone marrow suppression, herpes infection, infection, neutropenia, radiation therapy, thrombocytopenia, varicella, viral infection***Dehydration, diarrhea***Lung cancer, pulmonary fibrosis***Extravasation***Children, infants, neonates***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10390'],tetrabenazine,***For the treatment of chorea associated with Huntington's Disease (Huntington's Chorea). <br />        NOTE: The FDA has designated tetrabenazine an orphan drug for this indication.<br />     ***Formoterol***Formoterol; Mometasone,"***General Information***Depression, suicidal ideation***CNS depression, coma, neurological disease***Alcoholism, driving or operating machinery***Pregnancy***Breast-feeding***Bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, dehydration, diabetes mellitus, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, thyroid disease***Parkinson's disease***Children***Renal disease, renal failure, renal impairment***Hepatic disease***Surgery***Fever***Breast cancer, hyperprolactinemia, infertility***Dysphagia***MAOI therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['343047'],atazanavir,"***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents. <br />        NOTE: When transitioning between formulations, a change in dose may be necessary. Consult dosing for each specific formulation prior to prescribing.<br />     ***For the treatment of HIV in protease inhibitor-experienced patients.***For the treatment of HIV in anti-retroviral treatment-naive patients.***For human immunodeficiency virus (HIV) prophylaxis� after occupational exposure.***Formoterol; Mometasone","***General Information***Infants, neonates***Geriatric***AV block***Females, lactic acidosis, obesity***Pregnancy***Breast-feeding***Human immunodeficiency virus (HIV) infection resistance***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia***Hepatic disease, hepatitis, jaundice***Hepatitis B and HIV coinfection***Bleeding, hemophilia***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, pancreatitis***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Cholelithiasis, nephrolithiasis***Dialysis, renal disease, renal impairment***Serious rash***Phenylketonuria***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2551']['3264'],ciprofloxacin/dexamethasone,***For the treatment of acute otitis media due to susceptible organisms in children with tympanostomy tubes aged 6 months and older.***For the treatment of acute otitis externa due to susceptible organisms.,"***Ophthalmic administration, parenteral administration***Corticosteroid hypersensitivity, quinolone hypersensitivity***Ear discharge, fungal infection, herpes infection, mycobacterial infection, varicella, viral infection***Pregnancy***Breast-feeding***Infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10379'],testosterone,***For the treatment of delayed puberty in males.***For palliative treatment of breast cancer that is inoperable in women.***For the treatment of postpubertal cryptorchidism�.***For the treatment of microphallus�.***For the treatment of anemia� in patients with chronic renal failure.***For female-to-male gender change (trans-sexualism�).***For the treatment of lichen sclerosus�.***For the treatment of AIDS-associated wasting syndrome�.,"***Benzoic acid hypersensitivity, benzyl alcohol hypersensitivity, polyoxyethylated castor oil hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis, soya lecithin hypersensitivity***Magnetic resonance imaging (MRI)***Intramuscular administration, intravenous administration***Breast cancer, geriatric, prostate cancer, prostatic hypertrophy***Cardiac disease, coronary artery disease, heart failure, hepatic disease, myocardial infarction, renal disease, stroke***Obesity, pulmonary disease***Polycythemia***Accidental exposure, females***Contraception requirements, labor, obstetric delivery, pregnancy, reproductive risk***Breast-feeding***Diabetes mellitus***Hypercalcemia***Pulmonary oil microembolism***Nasal polyps, nasal septal perforation, nasal surgery, nasal trauma, rhinorrhea, Sjogren's syndrome***Children, infants, neonates***Substance abuse***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1094833'],ipilimumab,"***For the treatment of malignant melanoma.***For the treatment of unresectable or metastatic melanoma, as a single-agent.***For the first-line treatment of unresectable or metastatic melanoma, in combination with dacarbazine�.***For the treatment of unresectable or metastatic melanoma, following no more than 1 prior therapy, in combination with sargramostim (GM-CSF)�.***For the treatment of unresectable or metastatic melanoma, in combination with nivolumab�. <br />  NOTE: Nivolumab is FDA approved in combination with ipilimumab for the treatment of unresectable or metastatic malignant melanoma.<br /***For the adjuvant treatment of cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, in patients who have undergone complete resection, including total lymphadenectomy.","***Colitis, Crohn's disease, diarrhea, inflammatory bowel disease, ulcerative colitis***Serious rash***Hepatic disease, hepatitis***Guillain-Barre syndrome, myasthenia gravis, peripheral neuropathy***Adrenal insufficiency, hyperthyroidism, hypophysitis, hypopituitarism, hypothyroidism, thyroid disease***Renal disease***Pancreatitis***Iritis, ocular disease, uveitis***Rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus (SLE)***Immunosuppression, organ transplant***Pregnancy***Contraception requirements, reproductive risk***Breast-feeding***Immune-mediated reactions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clavulanate potassium/ticarcillin disodium,"***For the treatment of lower respiratory tract infections, including pneumonia.***For the treatment of moderate to severe infection including bacteremia, sepsis, skin and skin structure infections, pericarditis�, intraabdominal infections (e.g., peritonitis), urinary tract infection (UTI), bone and joint infections, gynecologic infections (e.g., endometritis) due to susceptible bacteria.***For the treatment of acute pulmonary exacerbations� in patients with cystic fibrosis�.***For the treatment of of acute pulmonary exacerbations� in pediatric patients with cystic fibrosis�.***For the empiric treatment of febrile neutropenia�.***For the treatment of febrile neutropenia in adults.***For the treatment of febrile neutropenia in pediatric patients.","***General Information***Viral infection***Renal disease, renal failure, renal impairment***Electrolyte imbalance, hypokalemia***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, cystic fibrosis, eczema, penicillin hypersensitivity***Coagulopathy, hemophilia***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Diabetes mellitus***Geriatric, heart failure, sodium restriction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1091836'],roflumilast,***For the prevention of COPD exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.,"***Hepatic disease***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Acute bronchospasm***Anxiety, depression, insomnia, suicidal ideation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,paliperidone palmitate,***For the treatment of schizophrenia.***For the treatment of schizoaffective disorder as monotherapy or as an adjunct to mood stabilizers and/or antidepressants.***For the treatment of mania� associated with bipolar disorder�.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.,"***General Information***Intravenous administration, subcutaneous administration***Tardive dyskinesia***Acute myocardial infarction, alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, syncope, thyroid disease***CNS depression, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Suicidal ideation***Agranulocytosis, hematological disease, leukopenia, neutropenia, thrombotic thrombocytopenic purpura (TTP)***Renal failure, renal impairment***Hepatic disease***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, obesity***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia***Seizure disorder, seizures***Neurological disease, Parkinson's disease***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Cystic fibrosis, dysphagia, esophageal stricture, gastroesophageal reflux disease (GERD), gastroparesis, GI obstruction, inflammatory bowel disease, peritonitis***Priapism***Dementia, geriatric, stroke***Abrupt discontinuation***Breast cancer, hyperprolactinemia, infertility***Neonates, pregnancy, pregnancy testing***Breast-feeding***Children, infants***Brain tumor, Reye's syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bupropion hydrochloride,"***For the treatment of major depression.***For the prevention of seasonal major depressive disorder episodes associated with seasonal affective disorder (SAD).***For use as an adjunct to psychosocial interventions in the management of tobacco cessation (smoking cessation).***For use alone to aide in tobacco cessation.***For aide with tobacco cessation using bupropion in combination with a nicotine transdermal system (NTS).***For the treatment of attention-deficit hyperactivity disorder (ADHD)�.***For use as monotherapy of attention-deficit hyperactivity disorder (ADHD)� in adults.***For the symptomatic treatment of neuropathic pain� due to various causes, including pain associated with peripheral diabetic neuropathy� or postherpetic neuralgia�.***Formoterol; Mometasone","***General Information***Alcoholism, anorexia nervosa, benzodiazepine withdrawal, brain tumor, bulimia nervosa, diabetes mellitus, head trauma, hypoglycemia, hyponatremia, hypoxemia, intracranial mass, obesity treatment, seizure disorder, seizures, stroke, substance abuse***Children, suicidal ideation***Tics, Tourette's syndrome***Behavioral changes, bipolar disorder, depression, mania, psychiatric event, schizophrenia***MAOI therapy***Neonates, pregnancy***Breast-feeding***Hepatic disease***Renal disease, renal failure, renal impairment***Acute myocardial infarction, cardiac disease, heart failure, hypertension, tobacco smoking***Geriatric***Driving or operating machinery, ethanol intoxication***Closed-angle glaucoma, increased intraocular pressure***Abrupt discontinuation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,brimonidine tartrate,"***For the treatment of open-angle glaucoma or ocular hypertension. <br />        NOTE: The original Alphagan brand product (0.2% and 0.5% brimonidine, preserved with benzalkonium chloride) has been discontinued in the US; however, the FDA has approved a generic equivalent of the 0.2% product in June 2003. The Alphagan P brand product (0.1% and 0.15% brimonidine, preserved with Purite) remains available.<br />     ***For the treatment of persistent (nontransient) facial erythema of acne rosacea.","***Cardiac disease, cerebrovascular disease, coronary artery disease***Contact lenses***Depression, orthostatic hypotension, Raynaud's phenomenon, scleroderma, Sjogren's syndrome, thromboangiitis obliterans (Buerger's disease)***Hepatic disease, renal impairment***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"human papillomavirus bivalent (types 16, 18) vaccine, recombinant",***For human papillomavirus (HPV) infection prophylaxis.,"***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Children, geriatric, infants, neonates***Latex hypersensitivity***Fever***Pregnancy***Breast-feeding***Agammaglobulinemia, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Syncope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cisatracurium besylate,"***For neuromuscular blockade, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the ICU.***For endotracheal intubation. <br />          NOTE: Because of its intermediate onset of action, cisatracurium is not recommended for rapid sequence endotracheal intubation (i.e., where intubation is rapidly performed to minimize the time the airway is unprotected).<br />       ***For adjunct therapy in acute respiratory distress syndrome (ARDS)�.***For the prevention of shaking chills� induced by therapeutic hypothermia following cardiac arrest.","***General Information***Lung cancer, myasthenia gravis, myopathy, neuromuscular disease***Chronic obstructive pulmonary disease (COPD), pulmonary disease, respiratory depression***Burns***Acid/base imbalance, dehydration, electrolyte imbalance, hypermagnesemia, hypocalcemia, hypokalemia, hyponatremia, metabolic alkalosis, respiratory acidosis***Intramuscular administration***Malignant hyperthermia***Labor, obstetric delivery, pregnancy***Breast-feeding***Benzyl alcohol hypersensitivity, children, neonates***Neuromuscular blocking agent hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ondansetron hydrochloride,***For chemotherapy-induced nausea/vomiting prophylaxis (CINV prophylaxis) and radiation-induced nausea/vomiting prophylaxis (RINV prophylaxis).***For post-operative nausea/vomiting (PONV) prophylaxis.***For the treatment of post-operative nausea/vomiting (PONV)�.***For hyperemesis gravidarum� (severe pregnancy-induced nausea/vomiting) unresponsive to other antiemetics.***For the short-term treatment of nausea/vomiting associated with acute gastroenteritis�.***For the treatment of pruritus� secondary to cholestasis.***For the maintenance treatment of alcohol dependence�.***For the treatment of cyclic vomiting syndrome�.***Formoterol***Formoterol; Mometasone,"***General Information***Hepatic disease, hepatitis***Dolasetron hypersensitivity, granisetron hypersensitivity, ondansetron hypersensitivity, palonosetron hypersensitivity***Phenylketonuria***GI obstruction, ileus***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Children***Infants, neonates***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],estradiol,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For systemic treatment of the vasomotor symptoms (hot flashes) and genitourinary symptoms of menopause.***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For estrogen replacement for premenopausal women with primary ovarian failure or female hypogonadism.***For the palliative treatment of advanced inoperable prostate cancer.***For the palliative treatment of breast cancer that is inoperable and progressive in selected men and postmenopausal women.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates***Intravenous administration***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,leuprolide acetate,"***For the palliative treatment of advanced prostate cancer, particularly when orchiectomy or estrogen therapy are not indicated or are unacceptable.***For the management of endometriosis including pain relief and reduction of endometriotic lesions.***For the treatment of central precocious puberty (idiopathic or neurogenic) in children. <br />        NOTE: Leuprolide has been designated an orphan drug by the FDA for this indication.<br />NOTE: Downregulation is determined by GnRH agonist stimulation test, sex steroid concentrations, and Tanner staging. Give consideration to discontinuing treatment before 11 years of age in girls and 12 years of age in boys***For the preoperative treatment of anemia due to uterine leiomyomata (fibroids) in combination with iron supplementation when iron therapy alone fails to correct the anemia.***For the treatment of benign prostatic hyperplasia (BPH)�.***For the adjuvant treatment of premenopausal women with hormone receptor-positive breast cancer�.***For the treatment of nonspecific symptoms associated with premenstrual syndrome (PMS)�.***For inhibiting premature leuteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation and subsequent in vitro fertilization (IVF) or other assisted reproductive technology (ART) for the treatment of infertility�. <br />        NOTE: Drugs such as ganirelix and cetrorelix are now more commonly used and are FDA-approved for this purpose. Leuprolide should only be used by a qualified infertility specialist. Withhold HCG administration in cases where the ovaries are abnormally enlarged to reduce the chance of inducing ovarian hyperstimulation syndrome (OHSS).<br />     ***For prevention of stuttering priapism� (i.e., recurrent priapism).***Formoterol***Formoterol; Mometasone","***Benzyl alcohol hypersensitivity***Gonadotropin-Releasing Hormone (GnRH) analogs hypersensitivity***Renal impairment, spinal cord compression, urinary tract obstruction***Pituitary insufficiency***Dysfunctional uterine bleeding, menstruation, vaginal bleeding***Children, geriatric, osteoporosis***Females, pregnancy***Breast-feeding***Cardiac disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, stroke, tobacco smoking***Diabetes mellitus, hyperglycemia***Alcoholism, cardiac arrhythmias, coronary artery disease, heart failure, hepatic disease, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, thyroid disease***Brain tumor, cerebrovascular disease, seizure disorder***Depression, suicidal ideation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10379'],testosterone,***For the treatment of delayed puberty in males.***For palliative treatment of breast cancer that is inoperable in women.***For the treatment of postpubertal cryptorchidism�.***For the treatment of microphallus�.***For the treatment of anemia� in patients with chronic renal failure.***For female-to-male gender change (trans-sexualism�).***For the treatment of lichen sclerosus�.***For the treatment of AIDS-associated wasting syndrome�.,"***Benzoic acid hypersensitivity, benzyl alcohol hypersensitivity, polyoxyethylated castor oil hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis, soya lecithin hypersensitivity***Magnetic resonance imaging (MRI)***Intramuscular administration, intravenous administration***Breast cancer, geriatric, prostate cancer, prostatic hypertrophy***Cardiac disease, coronary artery disease, heart failure, hepatic disease, myocardial infarction, renal disease, stroke***Obesity, pulmonary disease***Polycythemia***Accidental exposure, females***Contraception requirements, labor, obstetric delivery, pregnancy, reproductive risk***Breast-feeding***Diabetes mellitus***Hypercalcemia***Pulmonary oil microembolism***Nasal polyps, nasal septal perforation, nasal surgery, nasal trauma, rhinorrhea, Sjogren's syndrome***Children, infants, neonates***Substance abuse***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,rosiglitazone maleate,***For the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control. <br />  NOTE: Rosiglitazone is not effective for type 1 diabetes mellitus.<br /***Formoterol; Mometasone,"***General Information***Diabetic ketoacidosis, type 1 diabetes mellitus***Hypoglycemia***Acute heart failure, angina, cardiac disease, edema, heart failure, myocardial infarction, peripheral edema, pulmonary edema***Anemia***Hepatic disease, jaundice***Bone fractures, osteoporosis***Geriatric***Contraception requirements, menstrual irregularity, polycystic ovary syndrome***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['327361'],adalimumab,"***For the treatment of moderate to severe rheumatoid arthritis to reduce signs and symptoms of the disease, to induce a major clinical response, to inhibit the progression of structural damage, and to improve physical function.***For the treatment of moderately to severely active polyarticular juvenile idiopathic arthritis as monotherapy or with methotrexate to reduce signs and symptoms of the disease.***For reducing the signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis. <br />        NOTE: Adalimumab may be used alone or in combination with a disease-modifying anti-rheumatic drug (DMARD). Methotrexate, glucocorticoids, salicylates, NSAIDs, analgesics, or other DMARDs may be continued during treatment.<br />     ***For reducing the signs and symptoms of active ankylosing spondylitis. <br />        NOTE: Adalimumab may be used alone or in combination with a disease-modifying anti-rheumatic drug (DMARD). Methotrexate, glucocorticoids, salicylates, NSAIDs, analgesics, or other DMARDs may be continued during treatment.<br />     ***For the treatment of moderate to severe, chronic plaque psoriasis in patients who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. <br />        NOTE: Only administer adalimumab to patients who will be closely monitored and who will have regular follow-up visits with a physician.<br />NOTE: Adalimumab receipt for greater than 1 year has not been evaluated in controlled clinical trials***For reducing the signs and symptoms and inducing and maintaining clinical remission of moderate to severe Crohn's disease in patients who have had an inadequate response to conventional therapy. <br />        NOTE: Adalimumab may also be used for reducing the signs and symptoms and inducing clinical remission in adult patients if they have lost response to or are intolerant to infliximab.<br />NOTE: Adalimumab may be given with aminosalicylates, corticosteroids, and/or immunomodulatory agents such as 6-mercaptopurine and azathioprine.<br />NOTE: Adalimumab receipt for greater than 1 year has not been evaluated in controlled clinical trials***For inducing and maintaining clinical remission of moderate to severe ulcerative colitis in patients who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine, or 6-mercaptopurine (6-MP). <br />        NOTE: The effectiveness of adalimumab has not been established in patients who have lost response to or were intolerant to TNF blockers.<br />     ***For the treatment of moderate to severe hidradenitis suppurativa.***For the treatment of non-infectious uveitis (including intermediate, posterior, and panuveitis).***Formoterol; Mometasone","***Latex hypersensitivity***Hepatitis, hepatitis B exacerbation***Bone marrow suppression, corticosteroid therapy, diabetes mellitus, fungal infection, immunosuppression, infection, mycobacterial infection, sepsis, surgery, tuberculosis, viral infection***Cholangitis, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, new primary malignancy***Children***Vaccination***Geriatric***Infants, neonates, pregnancy***Breast-feeding***Heart failure***Multiple sclerosis, neurological disease***Human anti-chimeric antibody (HACA)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['7880', '235379']",pancrelipase,"***For the management of exocrine pancreatic insufficiency, such as in patients with cystic fibrosis, chronic pancreatitis, or other conditions.***For the management of exocrine pancreatic insufficiency due to pancreatectomy.***For enteral feeding tube occlusion�.","***Porcine protein hypersensitivity***Viral infection***Dysphagia, esophageal stricture***Gout, hyperuricemia, renal impairment***Fibrosing colonopathy, GI obstruction, inflammatory bowel disease, surgery***Pregnancy***Breast-feeding***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,omega-3-acid ethyl esters,"***For use as an adjunct to diet to reduce hypertriglyceridemia (i.e., defined as triglyceride blood concentrations >= 500 mg/dL). <br />        NOTE: Patients should be placed on an appropriate lipid-lowering diet and should continue this diet during treatment.<br />     ***For use as an adjunct to simvastatin therapy� for the treatment of hypertriglyceridemia.","***Fish hypersensitivity***Hypercholesterolemia***Anticoagulant therapy, thrombolytic therapy***Atrial fibrillation***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluticasone propionate,"***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses, including the treatment of alopecia areata, discoid lupus erythematosus, generalized exfoliative dermatitis, cutaneous lichen planus, lichen simplex chronicus, lichen striatus, nodular prurigo, pompholyx (dyshidrosis), pemphigus, polymorphous light eruption, psoriasis, seborrheic dermatitis, severe contact dermatitis, severe Rhus dermatitis (due to plants like poison ivy), and xerosis.***For the treatment of eczema, including atopic dermatitis.***For the management of symptoms associated with seasonal or perennial allergic rhinitis, including allergic conjunctivitis.***For the management of nasal symptoms associated with vasomotor rhinitis (perennial nonallergic rhinitis).***For the maintenance treatment of asthma.***For the treatment of nasal polyps.***For exercise-induced bronchospasm prophylaxis�.***Formaldehyde hypersensitivit","***General Information***Corticosteroid hypersensitivity, milk protein hypersensitivity***Acute bronchospasm, status asthmaticus***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion, surgery***Diabetes mellitus***Nasal septal perforation, nasal surgery, nasal trauma***Fungal infection, herpes infection, infection, measles, tuberculosis, varicella, viral infection***Malnutrition, osteoporosis, tobacco smoking***Geriatric***Hepatic disease***Acne rosacea, acne vulgaris, perioral dermatitis, peripheral vascular disease, skin atrophy***Cataracts, glaucoma, increased intraocular pressure, ocular exposure***Formaldehyde hypersensitivity***Children, growth inhibition, increased intracranial pressure, infants***Pregnancy***Breast-feeding***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['7880', '235379']",pancrelipase,"***For the management of exocrine pancreatic insufficiency, such as in patients with cystic fibrosis, chronic pancreatitis, or other conditions.***For the management of exocrine pancreatic insufficiency due to pancreatectomy.***For enteral feeding tube occlusion�.","***Porcine protein hypersensitivity***Viral infection***Dysphagia, esophageal stricture***Gout, hyperuricemia, renal impairment***Fibrosing colonopathy, GI obstruction, inflammatory bowel disease, surgery***Pregnancy***Breast-feeding***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,paroxetine hydrochloride,"***For the treatment of major depression.***For the treatment of generalized anxiety disorder (GAD).***For the treatment of premenstrual dysphoric disorder (PMDD).***For the treatment of moderate to severe hot flashes associated with menopause, including in women who have been treated for breast cancer.***For the treatment of obsessive-compulsive disorder (OCD).***For the treatment of panic disorder, with or without agoraphobia.***For the treatment of posttraumatic stress disorder (PTSD).***For the treatment of social phobia (social anxiety disorder).***For the treatment of premature ejaculation�.","***General Information***Abrupt discontinuation***Bipolar disorder, mania***Children, growth inhibition, suicidal ideation***MAOI therapy***Electroconvulsive therapy (ECT), seizure disorder, seizures***Dehydration, hyponatremia, hypovolemia***Renal failure, renal impairment***Hepatic disease***Anticoagulant therapy, bleeding, thrombolytic therapy***Cardiac disease, congenital heart disease***Bone fractures, osteoporosis***Closed-angle glaucoma, increased intraocular pressure***Akathisia***Anorexia nervosa***Driving or operating machinery, ethanol ingestion***Neonates, pregnancy***Breast-feeding***Anticholinergic medications, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sodium chloride,"***For the treatment of dehydration or hypovolemia, including during diabetic ketoacidosis, cardiopulmonary resuscitation, and shock (e.g., septic shock, anaphylactic shock, cardiogenic shock).***For the treatment of hyponatremia. <br />        NOTE: In general, initial correction of acute or symptomatic hyponatremia should be undertaken with hypertonic 3% Sodium Chloride Injection. Asymptomatic, chronic hyponatremia should be corrected with isotonic 0.9% Sodium Chloride Injection. <br />     ***For mucolysis and sputum induction in patients with cystic fibrosis.***For the treatment of nasal congestion and dryness.***For nutritional supplementation.***For temporary relief of corneal edema (i.e., ocular inflammation).***For the treatment of increased intracranial pressure�.***For the inpatient management of viral bronchiolitis�.***Formoterol; Mometasone","***Cardiac disease, diabetic ketoacidosis, edema, heart failure, hyperaldosteronism, hyperchloremia, hypernatremia, hypertension, hypervolemia, metabolic acidosis, renal artery stenosis, renal disease, renal failure, renal impairment***Alcoholism, females, hyponatremia, hypoxemia, malnutrition***Hepatic disease***Hemolysis***Pregnancy***Breast-feeding***Neonates, premature neonates***Requires an experienced clinician***Visual impairment***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ranitidine hydrochloride,"***For the self-medication of non-ulcer dyspepsia (acid indigestion), pyrosis (heartburn), and sour stomach.***For prophylaxis.***For treatment.***For the treatment of gastroesophageal reflux disease (GERD). <br />        NOTE: While ranitidine may be effective in patients with less severe GERD, proton pump inhibitors (PPIs) offer more rapid symptom relief and better healing.<br />     ***For short-term treatment (acute healing phase).***For maintenance treatment� (relapse prevention).***For the treatment of erosive esophagitis.***For endoscopically diagnosed erosive esophagitis.***For the treatment of pathologic GI hypersecretory conditions such as Zollinger-Ellison syndrome, systemic mastocytosis, or multiple endocrine adenoma syndrome.***For the treatment of peptic ulcer disease (duodenal ulcer or gastric ulcer) or gastritis�. <br />        NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br />NOTE: If gastritis or ulceration is due to NSAID therapy, every effort should be made to discontinue the NSAID***For short-term treatment of active benign gastric ulcer, active duodenal ulcer or gastritis�.***For maintenance therapy after treatment phase is complete.***For Helicobacter pylori (H. pylori) eradication� in the treatment of patients with peptic ulcer disease, dyspepsia, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />          NOTE: The American College of Gastroenterology (ACG) recommends 10�14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole; the same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: Ranitidine is not effective as a single agent for the eradication of H. pylori. Quadruple regimens that include an H2-blocker as an anti-secretory agent are FDA-approved, but are associated with lower compliance and efficacy rates than other recommended regimens.  An H2-blocker should not be substituted for a PPI in any current H. pylori treatment regimen unless the patient cannot tolerate a PPI.<br />NOTE: In populations where H. pylori infection is common (&gt;= 10%), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Helidac monograph).  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60�90% of patients.***For acid aspiration prophylaxis� prior to anesthesia. <br />        NOTE: Routine use of H2-blockers prior to surgery to decrease the risks of pulmonary aspiration in patients who have no apparent increased risk for pulmonary aspiration is not recommended. Consult current practice guidelines.<br />     ***For NSAID-induced ulcer prophylaxis�.***For stress gastritis prophylaxis� in critically-ill patients. <br />        NOTE: The 2008 Surviving Sepsis Campaign guidelines recommend H2-blockers or proton pump inhibitors be used in patients with sepsis or septic shock to prevent gastritis.<br />     ***For the treatment of acute, severe urticaria� or angioedema� associated with systemic symptoms in combination with an H1-blocker.***For the prevention of urticaria� and other histamine-mediated reactions� to specific types of chemotherapy (e.g., paclitaxel).","***General Information***H2-blocker hypersensitivity***Gastric cancer***Infection***Hepatic disease***Renal disease, renal failure, renal impairment***Children, infants, neonates, premature neonates***Pregnancy***Breast-feeding***Porphyria***Tobacco smoking***Bradycardia, cardiac disease***Geriatric***Vitamin B12 deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['993449'],denosumab,***For the treatment of osteoporosis in men and postmenopausal women at high risk for fracture. <br />        NOTE: Denosumab should be administered by a health care professional. Different products are indicated for different treatments; take care to select the right product for prescribing and avoid duplication.<br />NOTE: Patients at a high risk for fracture are those with a history of osteoporotic fracture or with multiple risk factors for fracture. Denosumab is also appropriate for those patients who have failed or are intolerant to other available osteoporosis therapy***For the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.***For osteoporosis prophylaxis in men at high risk for bone fractures after receiving androgen deprivation therapy for nonmetastatic prostate cancer and in women at high risk for bone fractures after receiving adjuvant aromatase inhibitor therapy for breast cancer. <br />        NOTE: Denosumab should be administered by a health care professional. Different products are indicated for different treatments; take care to select the right product when prescribing and avoid duplication.<br />     ***For the treatment of giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.***For the treatment of hypercalcemia of malignancy that is refractory to bisphosphonate therapy.***Formoterol; Mometasone,"***General Information***Dialysis, hypocalcemia, renal failure, renal impairment, vitamin D deficiency***Diabetes mellitus, immunosuppression, infection, surgery, tuberculosis***Angioedema, latex hypersensitivity, urticaria***Eczema***Neoplastic disease***Chemotherapy, corticosteroid therapy, dental disease, dental work***Pancreatitis***Bone fractures***Children, infants***Pregnancy***Contraception requirements, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['85762'],ritonavir,"***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***For human immunodeficiency virus (HIV) prophylaxis� after nonoccupational exposure. <br />  NOTE: Higher risk exposures for which prophylaxis is recommended include exposure of vagina, rectum, eye, mouth, or other mucous membrane, nonintact skin, or percutaneous contact with blood, semen, vaginal secretions, rectal secretions, breast milk, or any body fluid that is visibly contaminated with blood when the source is known to be HIV-positive. Exposures to a source patient with unknown HIV status should be assessed on a case-by-case basis.<br /***Formoterol***Formoterol; Mometasone","***General Information***Ritonavir coadministration with other drugs***Hepatic disease, hepatitis, hepatitis B and HIV coinfection, jaundice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"rotavirus vaccine, live, oral","***For the prophylaxis of gastroenteritis caused by rotavirus infection. <br />  NOTE: On May 14, 2010, the FDA stated that Rotarix use may be resumed and that RotaTeq use may be continued. On March 22, 2010, the FDA recommended temporary suspension of Rotarix administration to patients, as DNA from porcine circovirus type 1 (PCV1) is present in the Rotarix formulation. The recommended action was a precautionary measure. The PCV1 DNA is present in the cell bank and seed from which the Rotarix vaccine is derived, which means that the DNA from PCV1 has been present since the early stages of the vaccine�s development including during clinical studies. In addition to PCV1 in Rotarix, RotaTeq has DNA fragments from both PCV1 and PCV2. However, the FDA has no evidence that PCV1 or PCV2 pose a safety risk in humans, and neither is known to cause infection or illness in humans. As available evidence supports the safety of Rotarix and RotaTeq, no medical follow-up is needed for patients who have been vaccinated with either vaccine.<br />NOTE: The safety and efficacy of administering Rotarix for the first dose and another rotavirus vaccine for the second dose or vice versa have not been established.***For infection caused by G1, G2, G3, and G4. <br />          NOTE: Infants who have had rotavirus gastroenteritis before receiving the full course of rotavirus vaccinations should still initiate or complete the 3-dose schedule because the initial infection frequently provides only partial immunity. No data are available on post-exposure prophylaxis with rotavirus vaccine. <br />       ***For infection caused by G1, G3, G4, and G9. <br />          NOTE: Safety and efficacy when administered after exposure to rotavirus have not been evaluated.<br />       ","***Latex hypersensitivity***Parenteral administration***Infants, neonates***Diarrhea, fever, gastroenteritis, respiratory infection, vomiting***GI disease, intussusception***Acquired immunodeficiency syndrome (AIDS), agammaglobulinemia, bone marrow suppression, chemotherapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, leukemia, lymphoma, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['195085'],efavirenz,***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***For human immunodeficiency virus (HIV) prophylaxis� after occupational exposure.***Formoterol***Formoterol; Mometasone,"***General Information***Pregnancy***Breast-feeding***Hepatic disease, hepatitis, hepatitis B and HIV coinfection***Hypercholesterolemia, hypertriglyceridemia***Alcoholism, bipolar disorder, depression, driving or operating machinery, mania, psychosis, substance abuse, suicidal ideation***Children, serious rash***Asian patients, Black patients, Hispanic patients, human immunodeficiency virus (HIV) infection resistance***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Seizure disorder, seizures***Hepatitis C and HIV coinfection***Bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,gabapentin enacarbil,"***For the adjunctive treatment of partial seizures with or without secondary generalized tonic-clonic seizures.***For neuropathic pain associated with postherpetic neuralgia (PHN).***For the treatment of moderate to severe primary restless legs syndrome (RLS). <br />        NOTE: Gabapentin enacarbil is not recommended for patients who are required to sleep during the day and remain awake at night.<br />NOTE: immediate-release and extended-release gabapentin formulations are not interchangeable; also, Gralise is not interchangeable with Horizant due to differing chemical forms and pharmacokinetic properties***For the treatment of amyotrophic lateral sclerosis (ALS)�. <br />        NOTE: Gabapentin has been granted orphan drug status by the FDA for this indication.<br />     ***For the treatment of tremor�.***For the treatment of orthostatic tremor�.***For the treatment of essential tremor�.***For the treatment of nystagmus�.***For the treatment of acquired pendular nystagmus�.***For the treatment of congenital nystagmus�.***For the treatment of paroxysmal symptoms and spasticity� due to multiple sclerosis�.***For the treatment of hot flashes� due to menopause� or in women who have been treated for breast cancer.***For reducing hot flashes� associated with natural menopause�.***For reducing hot flashes� in women with breast cancer.***For the treatment of pruritus�.***For the treatment of uremic pruritus� in hemodialysis patients.***For the treatment of brachioradial pruritus�.***For the treatment of fibromyalgia�.***For the treatment of singultus (hiccups)�.***For the treatment of dysautonomia� following severe traumatic brain injury.***For long-term prophylaxis of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT)�.***For the treatment of painful diabetic neuropathy�.","***General Information***Depression, suicidal ideation***Dialysis, renal failure, renal impairment***Driving or operating machinery***Pregnancy***Breast-feeding***Children, infants, neonates***Seizure disorder, seizures***Abrupt discontinuation***Geriatric***Substance abuse***Angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dabigatran etexilate mesylate,***For stroke prophylaxis and systemic embolism prophylaxis in patients with non-valvular atrial fibrillation.***For the treatment of deep venous thrombosis (DVT) and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for 5�10 days.***For deep venous thrombosis (DVT) prophylaxis and pulmonary embolism prophylaxis.***For deep venous thrombosis (DVT) prophylaxis and pulmonary embolism prophylaxis in patients undergoing total hip replacement surgery.***For deep venous thrombosis (DVT) prophylaxis and pulmonary embolism prophylaxis in patients undergoing total knee replacement surgery�.***For the reduction in risk of recurrence of deep venous thrombosis (DVT) and pulmonary embolism in patients who have been previously treated.,"***General Information***Anticoagulant therapy, bleeding***Abrupt discontinuation***Surgery***Dialysis, renal failure, renal impairment***Geriatric***Children, infants, neonates***Labor, obstetric delivery, pregnancy***Breast-feeding***Mechanical heart valves, prosthetic heart valves***Epidural anesthesia, lumbar puncture, spinal anesthesia***Intramuscular injections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['161']['2670', '235412', '1545976']",acetaminophen/codeine phosphate,***For the treatment of mild pain to moderate pain.***For the treatment of nonproductive cough�.,"***General Information***Acetaminophen hypersensitivity, opiate agonist hypersensitivity, sulfite hypersensitivity***Constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, pulmonary disease, respiratory depression***Abrupt discontinuation***Alcoholism, ethanol intoxication, hepatic disease, hepatitis, potential for overdose or poisoning***Substance abuse***Head trauma, increased intracranial pressure***Cardiac arrhythmias, cardiac disease, hypotension, hypovolemia***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, renal impairment, urethral stricture, urinary retention***Geriatric***Adenoidectomy, children, infants, neonates, neuromuscular disease, obesity, respiratory infection, sleep apnea, tonsillectomy***Anemia, G6PD deficiency***Bone marrow suppression, immunosuppression, infection***Driving or operating machinery***Asian patients, Black patients, Caucasian patients, Hispanic patients***Adrenal insufficiency, hypothyroidism, myxedema***MAOI therapy***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8588'],aminobenzoate potassium,"***For the treatment of dermatomyositis, linear scleroderma, morphea (localized scleroderma), pemphigus, or Peyronie's disease.","***Para-aminobenzoic acid, PABA hypersensitivity***Renal disease, renal impairment***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3254'],desonide,"***For the treatment of mild to moderate inflammatory manifestations of corticosteroid-responsive dermatitis such as contact dermatitis, exfoliative dermatitis, <em>Rhus dermatitis</em> due to plants like poison ivy, or seborrheic dermatitis (facial and intertriginous areas), discoid lupus erythematosus (facial and intertriginous areas), eczema, granuloma annulare, intertrigo, cutaneous lichen planus, lichen simplex chronicus, polymorphous light eruption, anogenital or senilis pruritus, psoriasis (facial and intertriginous areas), or xerosis (inflammatory phase). <br />        NOTE: Occlusive dressings may be required for chronic or severe cases of lichen simplex chronicus, psoriasis, eczema, or chronic hand eczema. More potent topical corticosteroids and/or occlusive dressings may be necessary for the treatment of discoid lupus erythematosus, lichen planus, granuloma annulare, psoriatic plaques, and psoriasis of the palms, soles, elbows, or knees.<br />     ***For the treatment of mild to moderate atopic dermatitis. <br />        NOTE: Occlusive dressings may be required for chronic or severe cases of atopic dermatitis.<br />     ","***General Information***Corticosteroid hypersensitivity***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Diabetes mellitus***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, tuberculosis, varicella, viral infection***Ocular exposure, ophthalmic administration***Geriatric, skin atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,loteprednol etabonate,"***For the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.***For the treatment of steroid responsive ophthalmic diseases including acute allergic conjunctivitis, acne rosacea, giant papillary conjunctivitis (GPC), iritis, keratitis, and cyclitis. <br />        NOTE: Alrex is only indicated for seasonal allergic conjunctivitis.<br />     ***For the treatment of postoperative ocular inflammation following ocular surgery.***For the treatment of postoperative ocular pain following ocular surgery.***For use as an alternative corticosteroid for the treatment of uveitis�. <br />        NOTE: Lotemax should not be used in patients who require a more potent corticosteroid for uveitis. Lotemax is less effective than prednisolone 1% in the treatment of acute anterior uveitis. Overall, 72% of patients treated with Lotemax experienced resolution of anterior chamber cell by day 28, compared to 87% of patients treated with prednisolone; however, the incidence of patients with clinically significant increases in IOP (&gt;= 10 mmHg) was 1% with Lotemax versus 6% with prednisolone.<br />     ","***Corticosteroid hypersensitivity, glycerin hypersensitivity***Fungal infection, herpes infection, herpes simplex keratitis (dendritic keratitis), mycobacterial infection, ocular infection, varicella, viral infection***Glaucoma, open-angle glaucoma***Cataracts, diabetes mellitus***Corneal abrasion***Contact lenses***Pregnancy***Breast-feeding***Children***Increased intraocular pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,propranolol hydrochloride,"***For the treatment of chronic stable angina.***For heart rate control in patients with atrial fibrillation and/or atrial flutter.***For the treatment of paroxysmal supraventricular tachycardia (PSVT) or for paroxysmal supraventricular tachycardia (PSVT) prophylaxis.***For the treatment of an evolving acute myocardial infarction. <br />  NOTE: For ST-elevation myocardial infarction, oral beta-blocker therapy should be initiated in the first 24 hours for patients who do not have signs of cardiac failure, evidence of low output, increased risk for cardiogenic shock, or other contraindications for beta-blocker therapy.<br /***For reduction of cardiovascular mortality in stable patients who have sustained a myocardial infarction.***For the treatment of hypertension.***For the treatment of idiopathic hypertrophic subaortic stenosis (IHSS).***For management of pheochromocytoma, including preoperative control of tachycardia before surgery, in conjunction with an alpha-blocker.***For migraine prophylaxis.***For migraine prophylaxis in pediatric patients�.***For migraine prophylaxis in adults.***For the management of tremor.***For the management of essential tremor.***For the management of lithium-induced tremor�.***For the management of essential tremor in pediatric patients.***For the treatment of a proliferating infantile hemangioma requiring systemic therapy. <br />  To reduce the risk of hypoglycemia, administer propranolol immediately after or concurrently with a feeding. Avoid fasting; if inevitable, hold medication or support with a product such as Pedialyte or glucose-containing IV fluids.  Vital signs and cardiorespiratory exam or ECG should be obtained at baseline. Obtain blood pressure and heart rate measurements at 1 and 2 hours after the initial dose and any significant dose increase (e.g., more than 0.5 mg/kg/day).  Experts have recommended propranolol therapy continue until full involution of the lesion has occurred or the patient is at least 1 year of age; recurrences have been reported with early discontinuation. At the end of therapy, gradually taper propranolol over 2 to 4 weeks.      If hemangiomas recur, treatment may reinitiated.<br /***For the treatment of unstable angina�.***For the treatment of anxiety� or panic attacks�.***For the short-term symptomatic management of thyrotoxicosis� and thyroid storm�.***For the short-term symptomatic management of thyrotoxicosis� and thyroid storm� in pediatric patients.***For the short term management of thyrotoxicosis� or thyroid storm in adults�.***For the treatment of hypertension and the subsequent decline in renal function associated with scleroderma renal crisis (SRC)�.***For the treatment of portal hypertension� and/or variceal bleeding prophylaxis� in patients with esophageal varices�.***For the prevention of first variceal bleed (primary variceal bleeding prophylaxis).***For prevention of recurrence of variceal bleed (secondary variceal bleeding prophylaxis).***For the treatment of chronic agitation� or aggressive behavior.***For the prevention and management of hypercyanotic episodes associated with tetralogy of Fallot (i.e., tetralogy spells�).***For the attenuation of hypermetabolism in patients with severe burns�.***For the attenuation of hypermetabolism in adult patients with severe burns.***For the attenuation of hypermetabolism in pediatric patients with severe burns.***For the treatment of heart failure� (ischemic origin or cardiomyopathy�) usually in conjunction with digoxin, diuretics, or ACE inhibitor therapy in children and infants.***For the maintenance of sinus rhythm in patients with supraventricular arrhythmias�, including Wolff-Parkinson-White (WPW) syndrome� and junctional ectopic tachycardia� (JET).***Formoterol; Mometasone","***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***Acute heart failure, AV block, bradycardia, cardiogenic shock, hypotension, pheochromocytoma, pulmonary edema, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Wolff-Parkinson-White syndrome***Cerebrovascular disease, PHACE syndrome, stroke***Diabetes mellitus, hypoglycemia***Hepatic disease***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Beta-blocker hypersensitivity***Raynaud's phenomenon***Myasthenia gravis, myopathy***Depression***Driving or operating machinery***Renal failure, renal impairment***Psoriasis***Surgery***Children, infants, neonates, premature neonates***Obstetric delivery, pregnancy***Breast-feeding***Geriatric***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,loteprednol etabonate,"***For the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.***For the treatment of steroid responsive ophthalmic diseases including acute allergic conjunctivitis, acne rosacea, giant papillary conjunctivitis (GPC), iritis, keratitis, and cyclitis. <br />        NOTE: Alrex is only indicated for seasonal allergic conjunctivitis.<br />     ***For the treatment of postoperative ocular inflammation following ocular surgery.***For the treatment of postoperative ocular pain following ocular surgery.***For use as an alternative corticosteroid for the treatment of uveitis�. <br />        NOTE: Lotemax should not be used in patients who require a more potent corticosteroid for uveitis. Lotemax is less effective than prednisolone 1% in the treatment of acute anterior uveitis. Overall, 72% of patients treated with Lotemax experienced resolution of anterior chamber cell by day 28, compared to 87% of patients treated with prednisolone; however, the incidence of patients with clinically significant increases in IOP (&gt;= 10 mmHg) was 1% with Lotemax versus 6% with prednisolone.<br />     ","***Corticosteroid hypersensitivity, glycerin hypersensitivity***Fungal infection, herpes infection, herpes simplex keratitis (dendritic keratitis), mycobacterial infection, ocular infection, varicella, viral infection***Glaucoma, open-angle glaucoma***Cataracts, diabetes mellitus***Corneal abrasion***Contact lenses***Pregnancy***Breast-feeding***Children***Increased intraocular pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,metformin hydrochloride/saxagliptin,***For the treatment of type 2 diabetes mellitus in combination with diet and exercise when treatment with both saxagliptin and metformin is appropriate.***Formoterol; Mometasone,"***Exfoliative dermatitis, history of angioedema, serious rash***Diabetic ketoacidosis, type 1 diabetes mellitus***Acidemia, hypoxemia, lactic acidosis, metabolic acidosis***Acute heart failure, acute myocardial infarction, cardiac disease, cardiogenic shock, heart failure***Renal disease, renal failure, renal impairment***Radiographic contrast administration***Alcoholism, ethanol ingestion, ethanol intoxication, hepatic disease***Burns, dehydration, fever, infection, sepsis, surgery, trauma***Anemia, pernicious anemia, vitamin B12 deficiency***Pancreatitis***Adrenal insufficiency, diarrhea, gastroparesis, GI obstruction, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypothyroidism, ileus, malnutrition, pituitary insufficiency, vomiting***Geriatric***Arthralgia***Polycystic ovary syndrome, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3992'],epinephrine,"***For the treatment of anaphylaxis. <br />        NOTE: Epinephrine absorption is rapid and complete if administered IM in the anterolateral aspect of the thigh. Subcutaneous epinephrine is not routinely recommended due to delayed absorption. <br />     ***For the treatment of acute bronchospasm (e.g., asthma exacerbation) and/or status asthmaticus.***For bronchospasm prophylaxis.***For the treatment of laryngotracheobronchitis (croup).***For the treatment of acute, severe urticaria or angioedema associated with systemic symptoms.***For use in cardiopulmonary resuscitation (CPR), specifically, for the treatment of cardiac arrest (pulseless electrical activity or ventricular asystole), or as an adjunct to electrical defibrillation in the treatment of ventricular fibrillation/pulseless ventricular tachycardia.***For the treatment of hypotension associated with septic shock.***For the treatment or prevention of surgical bleeding along a surgical incision.***For the treatment of open-angle glaucoma.***For the treatment of nasal congestion.***For mydriasis induction and maintenance during intraocular surgery.***For the emergency treatment of symptomatic bradycardia�.***For the treatment of acute chloroquine overdose� in combination with diazepam.***Formoterol***Formoterol; Mometasone","***General Information***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, coronary artery disease, hemorrhagic shock, hypovolemia, pulmonary edema, shock***Sulfite hypersensitivity***Closed-angle glaucoma***Extravasation, infection, intraarterial administration***Cerebrovascular disease, organic brain syndrome***Hypertension***Hyperthyroidism, pheochromocytoma, thyroid disease, thyrotoxicosis***Diabetes mellitus***Labor, obstetric delivery, pregnancy***Breast-feeding***Ophthalmic administration***Parkinson's disease***Renal disease***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['69722'],zanamivir,"***For the treatment of uncomplicated influenza A virus infection or influenza B virus infection.***For seasonal influenza prophylaxis for infections due to influenza A or influenza B virus.***For the treatment of novel influenza A viruses associated with severe human disease�, including avian influenza A virus infection�.***For prophylaxis of novel influenza A viruses associated with severe human disease�, including avian influenza prophylaxis�.","***General Information***Angioedema, milk protein hypersensitivity***Viral infection***Cardiac disease, geriatric***Renal failure, renal impairment***Asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Administration via nebulizer***Vaccination***Children, Reye's syndrome***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1114195'],rivaroxaban,"***For stroke prophylaxis and systemic embolism prophylaxis in patients with nonvalvular atrial fibrillation.***For the treatment of deep venous thrombosis (DVT) or pulmonary embolism. <br />        NOTE: Initiation of rivaroxaban is not recommended acutely as an alternative to unfractionated heparin in patients with pulmonary embolism who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.<br />     ***For deep venous thrombosis (DVT) prophylaxis and pulmonary embolism prophylaxis.***For reduction in risk of recurrence of deep venous thrombosis (DVT) and/or pulmonary embolism (PE) in patients at continued risk for DVT and/or PE after completion of initial treatment.***For deep venous thrombosis (DVT) prophylaxis, which may lead to pulmonary embolism PE, in patients undergoing knee or hip replacement surgery.","***General Information***Bleeding, epidural anesthesia, lumbar puncture, spinal anesthesia, surgery***Anticoagulant therapy***Coagulopathy, hepatic disease***Renal failure, renal impairment***Abrupt discontinuation***Geriatric***Prosthetic heart valves***Labor, obstetric delivery, pregnancy***Breast-feeding***Reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed","***For simultaneous diphtheria prophylaxis, tetanus prophylaxis, and pertussis prophylaxis.***For prophylaxis against diphtheria and tetanus for patients with large, contaminated wounds who also need the pertussis component.","***Children, infants, neonates, premature neonates***Intraarterial administration, intravenous administration, subcutaneous administration***Guillain-Barre syndrome***Latex hypersensitivity***Coma, encephalopathy, neurological disease, seizure disorder, seizures***Fever, shock***Anticoagulant therapy, bleeding, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Infection***Immunosuppression***Pregnancy***Breast-feeding***Syncope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['85762'],ritonavir,"***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***For human immunodeficiency virus (HIV) prophylaxis� after nonoccupational exposure. <br />  NOTE: Higher risk exposures for which prophylaxis is recommended include exposure of vagina, rectum, eye, mouth, or other mucous membrane, nonintact skin, or percutaneous contact with blood, semen, vaginal secretions, rectal secretions, breast milk, or any body fluid that is visibly contaminated with blood when the source is known to be HIV-positive. Exposures to a source patient with unknown HIV status should be assessed on a case-by-case basis.<br /***Formoterol***Formoterol; Mometasone","***General Information***Ritonavir coadministration with other drugs***Hepatic disease, hepatitis, hepatitis B and HIV coinfection, jaundice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['712566'],ofatumumab,"***For the treatment of chronic lymphocytic leukemia (CLL). <br />  NOTE: The FDA has designated ofatumumab as an orphan drug for the treatment of CLL.<br /***For the treatment of CLL refractory to fludarabine and alemtuzumab.***For the treatment of fludarabine-refractory CLL with bulky (larger than 5 cm) lymphadenopathy�.***For the first-line treatment of CLL in combination with chlorambucil in patients for whom fludarabine is considered inappropriate.***For extended treatment in patients who have a complete or partial response after at least 2 lines of therapy for recurrent or progressive CLL.***For the treatment of relapsed CLL in combination with fludarabine and cyclophosphamide.***For the treatment of non-Hodgkin's lymphoma (NHL)�.***For the treatment of relapsed or refractory diffuse large B-cell lymphoma in transplant eligible patients, in combination with dexamethasone, cytarabine, and cisplatin (DHAP regimen).","***Infusion-related reactions***Progressive multifocal leukoencephalopathy***Hepatitis, hepatitis B exacerbation***Agranulocytosis, anemia, neutropenia, sepsis, thrombocytopenia***Tumor lysis syndrome (TLS)***Infants, neonates, vaccination***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,leuprolide acetate,"***For the palliative treatment of advanced prostate cancer, particularly when orchiectomy or estrogen therapy are not indicated or are unacceptable.***For the management of endometriosis including pain relief and reduction of endometriotic lesions.***For the treatment of central precocious puberty (idiopathic or neurogenic) in children. <br />        NOTE: Leuprolide has been designated an orphan drug by the FDA for this indication.<br />NOTE: Downregulation is determined by GnRH agonist stimulation test, sex steroid concentrations, and Tanner staging. Give consideration to discontinuing treatment before 11 years of age in girls and 12 years of age in boys***For the preoperative treatment of anemia due to uterine leiomyomata (fibroids) in combination with iron supplementation when iron therapy alone fails to correct the anemia.***For the treatment of benign prostatic hyperplasia (BPH)�.***For the adjuvant treatment of premenopausal women with hormone receptor-positive breast cancer�.***For the treatment of nonspecific symptoms associated with premenstrual syndrome (PMS)�.***For inhibiting premature leuteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation and subsequent in vitro fertilization (IVF) or other assisted reproductive technology (ART) for the treatment of infertility�. <br />        NOTE: Drugs such as ganirelix and cetrorelix are now more commonly used and are FDA-approved for this purpose. Leuprolide should only be used by a qualified infertility specialist. Withhold HCG administration in cases where the ovaries are abnormally enlarged to reduce the chance of inducing ovarian hyperstimulation syndrome (OHSS).<br />     ***For prevention of stuttering priapism� (i.e., recurrent priapism).***Formoterol***Formoterol; Mometasone","***Benzyl alcohol hypersensitivity***Gonadotropin-Releasing Hormone (GnRH) analogs hypersensitivity***Renal impairment, spinal cord compression, urinary tract obstruction***Pituitary insufficiency***Dysfunctional uterine bleeding, menstruation, vaginal bleeding***Children, geriatric, osteoporosis***Females, pregnancy***Breast-feeding***Cardiac disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, stroke, tobacco smoking***Diabetes mellitus, hyperglycemia***Alcoholism, cardiac arrhythmias, coronary artery disease, heart failure, hepatic disease, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, thyroid disease***Brain tumor, cerebrovascular disease, seizure disorder***Depression, suicidal ideation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['69036'],rufinamide,***For the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.***For the adjunctive treatment of refractory partial seizures�.,"***General Information***Depression, suicidal ideation***Short QT syndrome***Abrupt discontinuation***Driving or operating machinery***Dialysis***Hepatic disease***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hepatitis A vaccine,***For hepatitis A prophylaxis.***For primary immunization (Havrix or Vaqta).***For post-exposure hepatitis A prophylaxis�.***For patients traveling to regions that have high or intermediate hepatitis A endemicity�.,"***General Information***Latex hypersensitivity, neomycin hypersensitivity***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Fever, infection***Agammaglobulinemia, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Pregnancy***Breast-feeding***Intravenous administration, subcutaneous administration***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['3521', '203015']",aspirin/dipyridamole,***For stroke prophylaxis in patients who have sustained a previous transient ischemic attack (TIA) or completed ischemic stroke due to thrombosis.,"***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, tartrazine dye hypersensitivity, urticaria***Anemia, esophagitis, gastritis, GI bleeding, peptic ulcer disease, tobacco smoking***Angina, coronary artery disease, myocardial infarction***Abrupt discontinuation, surgery***Agranulocytosis, bone marrow suppression, coagulopathy, immunosuppression, neutropenia, thrombocytopenia, vitamin K deficiency***Head trauma, increased intracranial pressure, intracranial bleeding***Intramuscular injections***G6PD deficiency***Hepatic disease, hypoprothrombinemia***Orthostatic hypotension***Renal disease, renal failure, renal impairment, systemic lupus erythematosus (SLE)***Syncope***Diabetes mellitus***Gout, hyperuricemia***Children, infants, neonates, Reye's syndrome, viral infection***Labor, obstetric delivery, pregnancy***Breast-feeding***Alcoholism***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diltiazem hydrochloride,"***For the treatment of hypertension.***For the treatment of chronic stable angina.***For the treatment of variant angina (Prinzmetal's angina).***For the treatment of paroxysmal supraventricular tachycardia (PSVT) or control of ventricular rate in atrial flutter or atrial fibrillation.***For the short-term treatment of rapid ventricular rate secondary to atrial arrhythmias� in adolescents, children, and infants.***For long-term control of ventricular rate in atrial flutter� or atrial fibrillation�.***For the relief of ongoing ischemia in patients with unstable angina� or after acute non-ST-segment elevation myocardial infarction� in the absence of congestive heart failure, pulmonary congestion, left ventricular dysfunction, or AV block, when beta-blockers are ineffective or contraindicated.***For the treatment of idiopathic dilated cardiomyopathy�.***For migraine prophylaxis�.***For the treatment of proteinuria� associated with diabetic nephropathy�.","***Acute myocardial infarction, bradycardia, cardiogenic shock, heart failure, ventricular dysfunction***Hypotension***AV block***Sick sinus syndrome***Lown-Ganong-Levine syndrome, ventricular tachycardia, Wolff-Parkinson-White syndrome***Hepatic disease***Aortic stenosis***Gastroesophageal reflux disease (GERD), hiatal hernia***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2194', '11415']",cefuroxime,"***For the treatment of mild-to-moderate acute bacterial exacerbations of chronic bronchitis.***For the treatment of skin and skin structure infections.***For mild to moderate uncomplicated skin and skin structure infections.***For serious skin and skin structure infections.***For the treatment of impetigo. <br />        NOTE: Oral tablets and suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis.<br />     ***For the treatment of urinary tract infection (UTI).***For the treatment of bone and joint infections.***For the treatment of pharyngitis. <br />        NOTE: Oral tablets and suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis.<br />     ***For the treatment of gonorrhea.***For cervicitis or urethritis due to <em>N. gonorrhoeae</em> or rectal gonorrhea in females or urethritis in males.***For disseminated gonococcal infection due to <em>N. gonorrhoeae</em>.***For the treatment of early Lyme disease (erythema migrans). <br />        NOTE: Oral tablets and suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis.<br />     ***For the treatment of acute otitis media. <br />        NOTE: Oral tablets and suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis.<br />     ***For the treatment of bacteremia.***For the treatment of meningitis.***For surgical infection prophylaxis.***For the treatment of tonsillitis. <br />        NOTE: Oral tablets and suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis.<br />     ***For the treatment of sinusitis. <br />        NOTE: Oral tablets and suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis.<br />     ***For the treatment of pneumonia, including community-acquired pneumonia (CAP), and pleural empyema.***For the treatment of intraabdominal infections�, including biliary tract infections� such as cholecystitis�.","***Antimicrobial resistance, viral infection***Cephalosporin hypersensitivity, penicillin hypersensitivity***Renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Breast-feeding***Pregnancy***Diabetes mellitus***Infants, neonates, premature neonates***Phenylketonuria***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,divalproex sodium,"***For the monotherapy or adjunct treatment of simple absence seizures, complex absence seizures, or complex partial seizures, and adjunctively for other seizure types that include absence or partial complex seizures (e.g., tonic-clonic seizures, myoclonic seizures).***For the treatment of acute mania associated with bipolar disorder, with or without psychotic features.***For migraine prophylaxis.***For the treatment of refractory status epilepticus�. <br />  NOTE: Valproate has been used for emergency treatment of seizures where other agents have failed, or, when other medications are not readily available or when phenytoin is contraindicated.<br /***For the treatment of persistent singultus (hiccups)�.***For the treatment of severe behavioral disturbances, such as agitation�.***For severe behavioral disturbances� (e.g., aggression, agitation�, explosive temper) occurring with attention-deficit hyperactivity disorder (ADHD)�.***For the symptomatic treatment of acquired pendular nystagmus�.***For the treatment of painful diabetic neuropathy�.","***General Information***Encephalopathy***Serious rash***Mitochondrial disease***Carnitine deficiency, hepatic disease, hepatotoxicity, hypoalbuminemia, organic brain syndrome***Pancreatitis***Children, infants, neonates***Depression, suicidal ideation***Bleeding, coagulopathy, surgery, thrombocytopenia***Renal failure, renal impairment***Human immunodeficiency virus (HIV) infection***Driving or operating machinery, ethanol ingestion***Colostomy, diarrhea, ileostomy***Head trauma***Abrupt discontinuation***Contraception requirements, pregnancy, reproductive risk***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,abiraterone acetate,"***For the treatment of metastatic prostate cancer.***For the treatment of metastatic high risk hormone-sensitive prostate cancer, in combination with prednisone and androgen-deprivation therapy.***For the treatment of metastatic castration-resistant prostate cancer, in combination with prednisone.","***Hepatic disease, hepatitis, hepatotoxicity***Cardiac disease, heart failure, hypertension, hypokalemia, myocardial infarction, ventricular arrhythmias***Adrenal insufficiency, infection, surgery***Females, pregnancy***Contraception requirements, infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['89013'],aripiprazole,***For the treatment of schizophrenia.***For the acute treatment of mania and mixed episodes and maintenance treatment of bipolar disorder (Bipolar I Disorder).***For the treatment of agitation associated with schizophrenia or bipolar mania.***For the adjunctive treatment of major depression.***For the short-term treatment of irritability associated with autistic disorder.***For the treatment of Tourette's syndrome.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.***Formoterol***Formoterol; Mometasone,"***General Information***Bipolar disorder, mania***Agranulocytosis, hematological disease, leukopenia, neutropenia***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, syncope, thyroid disease***Cerebrovascular disease, seizure disorder, seizures***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Dysphagia***Children, suicidal ideation***Impulse control symptoms***Diabetes mellitus, hyperglycemia***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, obesity***Tardive dyskinesia***Neurological disease, Parkinson's disease***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Poor metabolizers***Abrupt discontinuation***Dementia, geriatric, stroke***Neonates, pregnancy, pregnancy testing***Breast-feeding***Phenylketonuria***Magnetic resonance imaging (MRI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1098413'],vandetanib,"***For the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. <br />        NOTE: Carefully consider the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease because of the treatment-related risks of vandetanib.<br />     ","***Renal disease, renal failure, renal impairment***Hypertension***Hepatic disease***Heart failure***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, geriatric, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, requires an experienced clinician, torsade de pointes***Bleeding, GI bleeding***Driving or operating machinery***Sunlight (UV) exposure***Pneumonitis, pulmonary disease***Encephalopathy***Hypothyroidism***Serious rash***Diarrhea***Stroke***Pregnancy***Contraception requirements, infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['276237']['1102270'],emtricitabine/rilpivirine/tenofovir disoproxil fumarate,"***For the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-naive patients with HIV RNA concentrations 100,000 copies/mL or less at treatment initiation and certain virologically-stable (HIV RNA less than 50 copies/mL) treatment-experienced patients. <br />  NOTE: Prior to initiating therapy, health care providers are advised to consider the following findings from clinical trials: virologic failures occurred more frequently in patients with baseline HIV RNA concentrations more than 100,000 copies/mL than in patients with concentrations 100,000 copies/mL or less; patients with CD4 counts less than 200 cells/mm3 experienced more virologic failures than those with counts 200 cells/mm3 or more (regardless of HIV RNA concentrations); virologic failures associated with resistance and cross-resistance to the NNRTI class occurred more frequently in rilpivirine-treated patients than efavirenz-treated patients; a higher rate of tenofovir and lamivudine/emtricitabine resistance developed in rilpivirine-treated patients than in efavirenz-treated patients.<br />NOTE: Treatment-experienced patients should meet the following criteria: switching from their 1st or 2nd antiretroviral regimen; have displayed consistent viral suppression (HIV RNA less than 50 copies/mL) for at least 6 months prior to switching; no history of virologic failure; no current or past history of resistance to emtricitabine, rilpivirine, or tenofovir. To assess potential virologic failure/rebound, additional HIV RNA monitoring is recommended for these patients.<br />NOTE: Emtricitabine; rilpivirine; tenofovir disoproxil fumarate is not indicated for the treatment of chronic hepatitis B virus (HBV) infection, and the safety and efficacy of treatment have not been established in patients co-infected with HBV and HIV***For human immunodeficiency virus (HIV) prophylaxis� after occupational exposure to HIV.***Formoterol***Formoterol; Mometasone","***General Information***Alcoholism, females, hepatic disease, hepatomegaly, hepatotoxicity or lactic acidosis, obesity***Hepatitis, hepatitis B and HIV coinfection, hepatitis B exacerbation, hepatitis C and HIV coinfection***Depression, suicidal ideation***Bone fractures, hypophosphatemia, renal failure, renal impairment***Pregnancy***Breast-feeding***Human immunodeficiency virus (HIV) infection resistance***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Osteomalacia, osteoporosis***QT prolongation, torsade de pointes***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia***Children, infants, neonates***Serious rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['25789']['84108'],glimepiride/rosiglitazone maleate,"***For the treatment of type 2 diabetes mellitus uncontrolled by diet and exercise alone. <br />  NOTE: Patients treated with glimepiride; rosiglitazone should be monitored for cardiovascular adverse events. The use of combination glimepiride; rosiglitazone with insulin has not been studied and is not recommended by the manufacturer.<br />NOTE: When adding rosiglitazone to glimepiride in patients with or without symptomatic heart disease and diabetes, monitor closely for signs of weight gain, peripheral edema, or congestive heart failure. In general, rosiglitazone should be initiated at the lowest dose and increased gradually after at least 3 months of therapy. The risk of these symptoms is increased when higher doses of rosiglitazone are used in combination with a sulfonylurea or insulin in patients at risk of congestive heart failure. Rosiglitazone should not be added to glimepiride therapy in patients with New York Heart Association Class III or IV heart failure. Discontinue the drug if any deterioration in cardiac status occurs during therapy***For when treatment with a sulfonylurea or rosiglitazone alone does not result in adequate glycemic control.***For patients already receiving a combination of glimepiride and rosiglitazone who desire to switch to the combination tablet.***Formoterol; Mometasone","***General Information***Acute heart failure, cardiac disease, edema, heart failure, myocardial infarction, peripheral edema, pulmonary edema***Diabetic ketoacidosis, type 1 diabetes mellitus***Sulfonylurea hypersensitivity***Sulfonamide hypersensitivity***Adrenal insufficiency, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypothyroidism, pituitary insufficiency***Hepatic disease, jaundice***Renal failure, renal impairment***Anemia, G6PD deficiency, hemolytic anemia***Bone fractures, osteoporosis***Geriatric***Menstrual irregularity, polycystic ovary syndrome***Obstetric delivery, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diclofenac epolamine,"***For the treatment of osteoarthritis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the treatment of rheumatoid arthritis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the treatment of ankylosing spondylitis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the acute treatment of migraine with or without aura. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />NOTE: Diclofenac is not indicated for migraine prophylaxis***For the treatment of mild pain or moderate pain. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For primary dysmenorrhea or for mild or moderate pain associated with nonrheumatic inflammatory conditions, bone pain�, arthralgia�, myalgia�, and vascular or migraine headache�. <br />          NOTE: Voltaren XR is not indicated for the management of acute painful conditions.<br />       ***For the treatment of acute mild or moderate pain.***For the topical treatment of acute mild pain or moderate pain due to minor strains, sprains, and contusions. <br />          NOTE: Carefully consider the potential benefits and risks of the diclofenac patch. If the patch will be used, use the lowest effective dose for the shortest possible duration.<br />       ***For the treatment of postoperative ocular inflammation following cataract extraction.***For the reduction of photophobia and ocular pain following corneal refractive surgery.***For the treatment of moderate to severe pain alone or in combination with opioid analgesics.***For the treatment of actinic keratosis.***For the prevention of heterotopic ossification�.***Formoterol; Mometasone","***Acute bronchospasm, asthma, bovine protein hypersensitivity, gelatin hypersensitivity, nasal polyps, NSAID hypersensitivity, polysorbate 80 hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Contact lenses, ocular surgery, rheumatoid arthritis***Anemia***Dental disease, dental work***Hepatic disease, jaundice, porphyria***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, renal impairment, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Labor, pregnancy***Breast-feeding***Burns, eczema, exfoliative dermatitis, heating pad, occlusive dressing, ocular exposure, skin abrasion***Benzyl alcohol hypersensitivity, sunlight (UV) exposure***Coronary artery bypass graft surgery (CABG)***Accidental exposure***Phenylketonuria***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,epoprostenol sodium,***For the treatment of pulmonary hypertension.***For long-term intravenous treatment of adult patients with NYHA Class III or IV primary pulmonary hypertension or adults with pulmonary hypertension due to scleroderma (systemic sclerosis).***For treatment of pulmonary arterial hypertension in pediatric patients�.***For short-term treatment of pulmonary hypertension using inhaled (nebulized)� therapy.***For acute vasodilator testing in pulmonary hypertension diagnosis�.,"***Abrupt discontinuation***Hypotension***Heart failure***Bleeding***Pulmonary edema***Thromboembolic disease***Labor, obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dalteparin sodium,"***For the treatment of venous thromboembolism (VTE) including acute deep venous thrombosis (DVT) or pulmonary embolism.***For extended treatment of symptomatic proximal DVT or pulmonary embolism in patients with cancer to reduce the recurrence of VTE. <br />          NOTE: Safety and efficacy of more than 6 months of treatment have not been established.<br />       ***For the treatment of DVT� or pulmonary embolism�.***For the treatment of DVT� or pulmonary embolism� in pregnant females.***For thrombosis prophylaxis. <br />        NOTE: Mechanical methods of prophylaxis should be used in patients who are at high risk of bleeding or as an adjunct to anticoagulant-based prophylaxis.<br />     ***For arterial thromboembolism prophylaxis� in patients after prosthetic heart valves surgery.***For venous thromboembolism (VTE) prophylaxis deep venous thrombosis (DVT) prophylaxis or pulmonary embolism prophylaxis.***For deep venous thrombosis (DVT) prophylaxis in pregnant females. <br />          NOTE: In all pregnant women with a history of DVT, the use of graduated elastic compression stockings is recommended both antenatally and postpartum.<br />       ***For thrombosis prophylaxis in pregnant patients with prosthetic heart valves�.***For thrombosis prophylaxis in low-risk patients receiving anticoagulation with vitamin K antagonists (VKA) who require an interruption in VKA dosing (e.g., prior to an invasive procedure)�. <br />          NOTE: Patients considered to be at low-risk for thromboembolism include: no VTE within the previous 3 months, atrial fibrillation without a history of stroke or other risk factors, or a bileaflet mechanical valve in the aortic position.<br />       ***For thrombosis prophylaxis in moderate-risk patients receiving anticoagulation with vitamin K antagonists (VKA) who require an interruption in VKA dosing (e.g., prior to an invasive procedure)�.***For thrombosis prophylaxis in high-risk patients receiving anticoagulation with vitamin K antagonists (VKA) who require an interruption in VKA dosing (e.g., prior to an invasive procedure)�. <br />          NOTE: Patients considered to be at high-risk for VTE include those patients with a history of VTE within the previous 3 months, a mechanical cardiac valve in the mitral position, or an old model cardiac valve (ball/cage).<br />       ***For thrombosis prophylaxis and/or for pulmonary embolism prophylaxis in patients at increased risk after sustaining an acute MI (e.g., ST segment elevation MI, severe LV dysfunction, CHF, history of systemic or pulmonary embolism, 2D echo evidence of mural thrombus, or atrial fibrillation).***For arterial thromboembolism prophylaxis� in patients with atrial fibrillation who are undergoing elective cardioversion.***For coronary artery thrombosis prophylaxis and the prevention of ischemic complications in patients with acute coronary syndrome (ACS).***For patients with ST-segment elevation myocardial infarction (STEMI)� or Q-wave acute myocardial infarction (AMI)�. <br />          NOTE: Studies comparing dalteparin with UFH in patients with STEMI also receiving a fibrinolytic have been completed; however, further study is needed before dalteparin can be routinely recommended for this indication.<br />       ***For patients with unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI), or non-Q-wave myocardial infarction, including those patients undergoing percutaneous coronary intervention (PCI)�. <br />          NOTE: The terminology used to classify patients presenting with acute chest pain has changed in recent years. Patients presenting with acute chest pain are classified as having ACS with or without ST segment elevation. The terms ST segment elevation MI (STEMI), non-ST-segment elevation MI (NSTEMI), and unstable angina (UA) are used to further differentiate patients with ACS and are consistent with the terminology used in the 2002 ACC/AHA guidelines for the management of patients with UA and NSTEMI. For the purposes of treatment, NSTEMI and UA are distinguishable and often referred to as non-ST segment elevation ACS (NSTE ACS). For the purposes of patient management and treatment, Q-wave MI and non-Q-wave MI are no longer used to classify patients with acute chest pain. It should be noted that the majority of patients with STEMI do have Q-wave MIs; likewise, the majority of patients with NSTEMI do have non-Q-wave MIs. <br />       ***For the treatment of cerebral thromboembolism� (e.g., cerebral venous sinus thrombosis).***For the prevention of pregnancy loss and/or thrombosis in patients with antiphospholipid antibody syndrome� (APLA).","***Heparin hypersensitivity, porcine protein hypersensitivity***Heparin-induced thrombocytopenia (HIT), thrombocytopenia***Anticoagulant therapy, renal disease, renal failure, renal impairment***Aneurysm, bleeding, coagulopathy, diabetic retinopathy, diverticulitis, endocarditis, epidural anesthesia, GI bleeding, hemophilia, hepatic disease, hypertension, idiopathic thrombocytopenic purpura (ITP), inflammatory bowel disease, lumbar puncture, menstruation, peptic ulcer disease, spinal anesthesia, stroke, surgery***Intramuscular injections***Geriatric***Prosthetic heart valves***Infants, neonates***Thrombolytic therapy***Dental disease, dental work***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['25033'],cefixime,"***For the treatment of mild to moderate pharyngitis, tonsillitis, or bronchitis caused by susceptible organisms.***For the treatment of uncomplicated urinary tract infection (UTI).***For the treatment of mild to moderate otitis media.***For the treatment of uncomplicated gonorrhea (e.g., vulvovaginitis, cervicitis, urethritis).***For the treatment of typhoid fever� caused by multidrug-resistant <em>Salmonella typhi</em>.***For the treatment of acute bacterial sinusitis�.***For the treatment of community-acquired pneumonia�.***For the treatment of acute pyelonephritis�.***For the treatment of patients with low-risk febrile neutropenia�.","***General Information***Cephalosporin hypersensitivity, penicillin hypersensitivity***Dialysis, renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Infants, neonates***Coagulopathy, vitamin K deficiency***Phenylketonuria***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,paroxetine hydrochloride,"***For the treatment of major depression.***For the treatment of generalized anxiety disorder (GAD).***For the treatment of premenstrual dysphoric disorder (PMDD).***For the treatment of moderate to severe hot flashes associated with menopause, including in women who have been treated for breast cancer.***For the treatment of obsessive-compulsive disorder (OCD).***For the treatment of panic disorder, with or without agoraphobia.***For the treatment of posttraumatic stress disorder (PTSD).***For the treatment of social phobia (social anxiety disorder).***For the treatment of premature ejaculation�.","***General Information***Abrupt discontinuation***Bipolar disorder, mania***Children, growth inhibition, suicidal ideation***MAOI therapy***Electroconvulsive therapy (ECT), seizure disorder, seizures***Dehydration, hyponatremia, hypovolemia***Renal failure, renal impairment***Hepatic disease***Anticoagulant therapy, bleeding, thrombolytic therapy***Cardiac disease, congenital heart disease***Bone fractures, osteoporosis***Closed-angle glaucoma, increased intraocular pressure***Akathisia***Anorexia nervosa***Driving or operating machinery, ethanol ingestion***Neonates, pregnancy***Breast-feeding***Anticholinergic medications, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1895'],drospirenone/ethinyl estradiol/levomefolate calcium,"***For routine contraception and to increase folate levels in women who desire to use oral contraception.***For the treatment of premenstrual dysphoric disorder (PMDD) in women who desire to use an oral contraceptive.***For the treatment of moderate acne vulgaris in women who also desire to use an oral contraceptive.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception.***Formoterol; Mometasone","***Adrenal insufficiency, electrolyte imbalance, hyperkalemia, renal failure, renal impairment***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, hypertension, myocardial infarction, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Breast cancer***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Surgery***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Headache, migraine***Depression***Hypothyroidism, thyroid disease***Pernicious anemia, vitamin B12 deficiency***Contact lenses, glaucoma, visual disturbance***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Obesity***Systemic lupus erythematosus (SLE)***Children, infants, neonates***Angioedema, hereditary angioedema***Chloasma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,morphine sulfate/naltrexone hydrochloride,"***For the treatment of chronic severe pain in patients who require daily, around-the-clock, long-term opioid treatment. <br />  NOTE: Extended-release morphine; naltrexone should be reserved for patients in whom alternative treatment options (e.g., nonopioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Discontinue all other around-the-clock opioid drugs upon initiation of morphine; naltrexone.<br />NOTE: The 100 mg/4 mg strength of morphine; naltrexone is for use in opioid-tolerant patients only. Opioid-tolerant patients are defined as those taking, for a minimum of 1 week, &gt;= 60 mg oral morphine daily, &gt;= 30 mg oral oxycodone daily, &gt;= 8 mg oral hydromorphone daily, &gt;= 25 mg oral oxymorphone daily, &gt;= 25 mcg transdermal fentanyl per hour, or an equivalent dose of another opioid.***For use as the first opioid analgesic or in patients who are not opioid-tolerant.***For conversion from other oral morphine formulations.***For conversion from other opioid agonist analgesics.","***General Information***Opiate agonist hypersensitivity***Accidental exposure, alcoholism, ethanol ingestion, parenteral administration, potential for overdose or poisoning, requires an experienced clinician***Depression, substance abuse***Asthma, bronchitis, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, emphysema, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Opioid-naive patients***MAOI therapy***Abrupt discontinuation***Dental work, surgery***Acute abdomen, constipation, diarrhea, gastroparesis, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Biliary tract disease, pancreatitis***CNS depression, coma, head trauma, increased intracranial pressure, intracranial mass, psychosis, seizure disorder***Adrenal insufficiency, hypothyroidism, myxedema***Angina, cardiac arrhythmias, cardiac disease, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock, syncope***Bladder obstruction, prostatic hypertrophy, renal disease, urethral stricture***Hepatic disease, renal impairment***Driving or operating machinery***Children***Geriatric***Labor, neonatal opioid withdrawal syndrome, neonates, obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,eribulin mesylate,"***For the treatment of patients with breast cancer.***For the treatment of metastatic breast cancer in patients who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease, including both an anthracycline and a taxane in either the adjuvant or metastatic setting.***For the treatment of soft-tissue sarcoma. <br />        Eribulin has been designated by the FDA as an orphan drug for the treatment of advanced soft-tissue sarcoma.<br />     ***For the treatment of unresectable or metastatic liposarcoma in patients who have received a prior anthracycline-containing regimen.***Formoterol***Formoterol; Mometasone","***Neutropenia, thrombocytopenia***Peripheral neuropathy***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Hepatic disease, hepatotoxicity***Renal disease, renal impairment***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3264'],dexamethasone,"***For the treatment of adrenocortical function abnormalities, such as adrenocortical insufficiency, congenital adrenal hyperplasia, chronic primary (Addison's disease) or secondary adrenocortical insufficiency, or adrenogenital syndrome.***For hypothalamic-pituitary-adrenal (HPA) suppression diagnosis (e.g., dexamethasone suppression tests).***For use as a test for Cushing's syndrome.***For use as a test to distinguish Cushing's syndrome secondary to pituitary ACTH excess from Cushing's syndrome secondary to other causes.***For the treatment of allergic conditions, such as acute anaphylaxis, anaphylactoid reactions, anaphylactic shock, angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, or serum sickness reactions.***For acute anaphylaxis or anaphylactoid reactions.***For anaphylactic shock.***For the systemic treatment of other allergic disorders including angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, or serum sickness.***For the treatment of cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.***For treatment of cerebral edema in pediatric patients.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of kidney transplant rejection in conjunction with other immunosuppressants or for the treatment of acute graft-versus-host disease (GVHD).***For the reduction of edema and inflammation associated with selected cases of otitis externa.***For the treatment of pruritus and inflammatory effects of corticosteroid-responsive dermatologic disorders, including dermatitis, alopecia areata, atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis (including Rhus dermatitis due to poison ivy, poison oak, poison sumac), discoid lupus erythematosus, eczema, exfoliative dermatitis, granuloma annulare, keloids, lichen planus, lichen simplex chronicus or neurodermatitis, necrobiosis lipoidica diabeticorum, pemphigus, polymorphous light eruption, plaque psoriasis, cutaneous T-cell lymphoma (CTCL) or mycosis fungoides, severe seborrheic dermatitis, urticaria, and severe erythema multiforme or Stevens-Johnson syndrome.***For systemic treatment of inflammatory and allergic dermatoses (e.g., severe dermatitis, psoriasis, or exfoliative dermatitis, erythema multiforme, or Stevens-Johnson syndrome).***For intralesional or soft-tissue treatment of specific corticosteroid-responsive skin or soft-tissue lesions.***For adjunctive therapy in the treatment of rheumatic disorders including acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, synovitis of osteoarthritis, and for psoriatic arthritis; or for the treatment of acute episodes or exacerbation of nonrheumatic inflammatory conditions including acute and subacute bursitis, epicondylitis, acute non-specific tenosynovitis, and cystic tumors of an aponeurosis tendon (ganglia).***For the treatment of hematologic disorders such as secondary thrombocytopenia in adults, autoimmune hemolytic anemia, erythroblastopenia, congenital hypoplastic anemia, and thrombocytopenia associated with immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of acute asthma� exacerbation.***For the treatment of hypercalcemia related to sarcoidosis or cancer, or for the treatment of nonsuppurative thyroiditis, or for severe cases of myasthenia gravis not controlled by antimyasthenic agents alone.***For the treatment of hypercalcemia related to cancer or for the treatment of nonsuppurative thyroiditis in pediatric patients.***For the treatment of nephrotic syndrome to induce diuresis or decrease proteinuria.***For the treatment of Hodgkin lymphoma.***For the treatment of non-Hodgkin's lymphoma (NHL).***For the palliative treatment of NHL.***For the treatment of relapsed or refractory, aggressive NHL in transplant eligible patients, in combination with gemcitabine and cisplatin (and rituximab for CD20-positive disease)�.***For the treatment of relapsed or refractory diffuse large B-cell lymphoma in transplant eligible patients, in combination with cisplatin and cytarabine (DHAP regimen) and ofatumumab�.***For the treatment of acute lymphocytic leukemia (ALL).***For the treatment of multiple myeloma.***For the treatment of multiple myeloma in patients who have received at least 1 prior therapy, in combination with lenalidomide.***For the treatment of patients with newly diagnosed multiple myeloma, in combination with lenalidomide.***For newly diagnosed multiple myeloma as induction therapy prior to autologous stem-cell transplantation, in combination with doxorubicin and vincristine�.***For newly diagnosed multiple myeloma, in combination with thalidomide.***For newly diagnosed multiple myeloma as induction therapy prior to autologous stem-cell transplantation, in combination with bortezomib�.***For newly diagnosed multiple myeloma as induction therapy prior to autologous stem-cell transplantation, in combination with bortezomib and thalidomide�.***For the treatment of multiple myeloma in patients who have received at least 2 prior therapies (including bortezomib and an immunomodulatory agent), in combination with panobinostat and bortezomib.***For the treatment of relapsed multiple myeloma in patients who have received 1 to 3 prior lines of therapy, in combination with carfilzomib and lenalidomide.***For the treatment multiple myeloma in patients who have received at least 1 prior therapy, in combination with daratumumab and bortezomib.***For the treatment of multiple myeloma in patients who have received at least 1 prior therapy, in combination with daratumumab and lenalidomide.***For the treatment of newly diagnosed multiple myeloma, in combination with bortezomib and lenalidomide�.***For the treatment of multiple myeloma in patients who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor, in combination with pomalidomide and daratumumab.***For the treatment of acute exacerbations of multiple sclerosis.***For the treatment of inflammatory bowel disease during critical periods of ulcerative colitis and regional enteritis (Crohn's disease).***For the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment inflammation of the globe, such as allergic conjunctivitis, eyelid acne rosacea, superficial punctate keratitis, herpes zoster ocular infection associated keratitis, iritis, cyclitis, vernal keratoconjunctivitis, selected infective viral conjunctivitis or postoperative ocular inflammation when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal abrasion, corneal ulcer, or corneal injury from chemical or thermal burns, or penetration of foreign bodies; systemic treatment may be indicated for uveitis, sympathetic ophthalmia, and ocular inflammatory conditions unresponsive to topical corticosteroids.***For the treatment of non-infectious uveitis affecting the posterior segment of the eye in adults.***For the treatment of diabetic macular edema.***For the treatment of macular edema following retinal vein occlusion, including branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).***For the prevention of extubation failure in pediatric patients at increased risk for laryngeal edema (i.e., laryngeal edema prophylaxis�).***For use as an adjunct in the management of extradural malignant spinal cord compression� (MSCC�) associated with metastatic disease.***For the adjunctive treatment of bacterial meningitis� (non-tuberculous).***For the treatment of chemotherapy-induced nausea/vomiting� (CINV�) and for chemotherapy-induced nausea/vomiting prophylaxis�.***For the treatment of respiratory conditions including aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), Loeffler's syndrome, or noncardiogenic pulmonary edema�.***For the treatment of acute respiratory distress syndrome (ARDS)�.***For the treatment of laryngotracheobronchitis (croup)�.***For hyaline membrane disease prophylaxis�, for the purpose of fetal lung maturation to prophylax against anticipated neonatal respiratory distress syndrome (RDS)� in premature infants.***For the prevention of chronic lung disease (CLD)� in mechanically ventilated neonates.***For therapy in selected cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis�, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, symptomatic sarcoidosis, vasculitis�, or Wegener's granulomatosis�; also for the treatment of neurologic or myocardial involvement associated with trichinosis.***For the treatment of acute altitude sickness�, including the treatment of high altitude cerebral edema.***For altitude sickness prophylaxis<strong>***For the adjunctive treatment of infertility� in combination with clomiphene therapy.***For the treatment of post-operative nausea/vomiting (PONV)�.***For post-operative nausea/vomiting (PONV) prophylaxis�.***For the treatment of bronchiolitis�.***For the treatment of Waldenstrom macroglobulinemia�.***For the treatment of newly diagnosed Waldenstrom macroglobulinemia, in combination with rituximab and cyclophosphamide�.***For the treatment of newly diagnosed Waldenstrom macroglobulinemia, in combination with bortezomib and rituximab�.***For the treatment of amyloidosis�.***For the treatment of systemic amyloid light-chain amyloidosis, in combination with lenalidomide and cyclophosphamide�.***For the treatment of systemic amyloid light-chain amyloidosis, in combination with lenalidomide and melphalan�.","***Epidural administration***Abrupt discontinuation, corneal abrasion, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, growth inhibition, increased intracranial pressure***Immunosuppression***Surgery***Acne rosacea, acne vulgaris, fungal infection, herpes infection, herpes simplex keratitis (dendritic keratitis), infection, measles, ocular infection, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Myocardial infarction***Heart failure, hypertension***Osteoporosis***Diabetes mellitus***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hypothyroidism, psychosis, renal disease, seizure disorder***Myasthenia gravis***Coagulopathy, thromboembolic disease***Cataracts, glaucoma, increased intraocular pressure, myopia, ocular exposure, open-angle glaucoma, rupture of posterior ocular lens capsule, visual disturbance***Pregnancy***Neonates, premature neonates***Breast-feeding***Vaccination***Asthma, benzyl alcohol hypersensitivity, sulfite hypersensitivity***Corticosteroid hypersensitivity***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4337'],fentanyl,"***For the control of moderate pain or severe pain.***For intraoperative or procedural management of severe pain, for use only in a monitored anesthesia care setting in the hospital.***For control of postoperative pain in the recovery room.***For the management of chronic severe pain in opioid-tolerant patients who require daily, around-the-clock, long-term opioid treatment.***For the management of severe breakthrough cancer pain in opioid-tolerant patients.***For short-term management of acute postoperative pain in the hospital setting using a fentanyl iontophoretic transdermal system (ITS) for patient-controlled analgesia.***For adjuvant management of general anesthesia maintenance and intraoperative pain control.***For minor surgical procedures and for use in the immediate postoperative period.***For major surgery, providing analgesia and some relief from the stress response. <br />          NOTE: Respiratory depression at this dosage level requires artificial ventilation.<br />       ***For open heart surgery and other complicated procedures where surgery is prolonged and the stress response would be detrimental to the patient's well-being.***For general anesthesia induction when attenuation of the responses to surgical stress is especially important such as during major surgery like open heart surgery or complicated neurological or orthopedic procedures.***For analgesia and/or sedation maintenance� in mechanically-ventilated intensive care patients.***For sedation and analgesia prior to rapid-sequence intubation (RSI)�.***For the management of dyspnea� in patients with end-stage cancer or lung disease.***For procedural sedation� of non-intubated patients during diagnostic, surgical, or other procedures.","***General Information***Dental work, headache, migraine, opioid-naive patients, surgery***Constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Accidental exposure***MAOI therapy***Potential for overdose or poisoning, requires a specialized care setting, requires an experienced clinician***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, urethral stricture, urinary retention***Brain tumor, CNS depression, head trauma, increased intracranial pressure, seizure disorder, seizures***Angina, bradycardia, cardiac arrhythmias, cardiac disease, heart failure, hypotension, orthostatic hypotension, shock***Children, infants, neonates, premature neonates***Labor, neonatal opioid withdrawal syndrome, pregnancy***Breast-feeding***Females***Geriatric***Biliary tract disease, pancreatitis***Abrupt discontinuation***Driving or operating machinery***Anticoagulant therapy, coagulopathy, epidural administration, infection, intrathecal administration, thrombocytopenia***Opiate agonist hypersensitivity***Ambient temperature increase, fever, heating pad, skin abrasion, sunlight (UV) exposure***Ocular exposure***Dental disease, diabetes mellitus, stomatitis***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Adrenal insufficiency, hypothyroidism, myxedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['191831', '1790539', '1927283']",infliximab,"***For the treatment of Crohn's disease.***For moderately to severely active Crohn's disease to reduce of signs and symptoms and to induce and maintain clinical remission in patients who have an inadequate response to conventional therapy.***For patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous or rectovaginal fistula(s) and for the maintenance of fistula closure.***For moderately to severely active ulcerative colitis in patients who have had an inadequate response to conventional therapy.***For the treatment of moderate to severe rheumatoid arthritis in combination with methotrexate.***For the treatment of active ankylosing spondylitis.***For the treatment of chronic severe (i.e., extensive and/or disabling) plaque psoriasis.***For the treatment of active psoriatic arthritis (PsA) with or without methotrexate.***For the treatment of uveitis� associated with Behcet's syndrome�.","***General Information***Human anti-chimeric antibody (HACA), infusion-related reactions, murine protein hypersensitivity***Hepatitis***Bone marrow suppression, corticosteroid therapy, diabetes mellitus, fungal infection, herpes infection, immunosuppression, infection, mycobacterial infection, sepsis, tuberculosis, viral infection***Heart failure***Cervical cancer, lymphoma, new primary malignancy, skin cancer***Chronic obstructive pulmonary disease (COPD), tobacco smoking***Guillain-Barre syndrome, multiple sclerosis, neurological disease, optic neuritis, seizure disorder, seizures, vasculitis***Hematological disease, leukopenia, neutropenia, thrombocytopenia***Hepatotoxicity, jaundice***Autoimmune disease***Vaccination***Infants, neonates, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydrocodone bitartrate/ibuprofen,"***For the short-term (generally less than 10 days) treatment of acute, moderate pain. <br />        NOTE: Hydrocodone; ibuprofen is not indicated for the treatment of conditions such as rheumatoid arthritis or osteoarthritis.<br />The 2009 American Geriatrics Society (AGS) Practical Guidelines recommend avoiding NSAIDs in older persons with persistent pain EXCEPT in patients who have failed other therapies and have a favorable benefit vs. risks assessment; extreme caution, ongoing therapy evaluation, and concurrent PPI or misoprostol use are also advised***Formoterol; Mometasone","***General Information***Alcoholism, anticoagulant therapy, chemotherapy, constipation, corticosteroid therapy, GI bleeding, GI disease, GI obstruction, GI perforation, ileus, inflammatory bowel disease, peptic ulcer disease, tobacco smoking, ulcerative colitis***Diarrhea***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, driving or operating machinery, pulmonary disease, respiratory depression, respiratory insufficiency, status asthmaticus***Hepatic disease, jaundice***Bladder obstruction, diabetes mellitus, edema, heart failure, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, sepsis, systemic lupus erythematosus (SLE), urethral stricture, urinary retention***Nasal polyps, NSAID hypersensitivity, opiate agonist hypersensitivity, polysorbate 80 hypersensitivity, salicylate hypersensitivity, urticaria***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, infection, neutropenia, thrombocytopenia***Anemia***Intramuscular injections***Dental disease, dental work***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, hypertension, hypotension, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Coronary artery bypass graft surgery (CABG), surgery***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Biliary tract disease***Abrupt discontinuation***Substance abuse***Head trauma, increased intracranial pressure***Seizure disorder***Geriatric***Adrenal insufficiency, hypothyroidism, myxedema***Infertility, reproductive risk***Accidental exposure, potential for overdose or poisoning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['21241'],clobazam,***For adjunct therapy to other anticonvulsants in the treatment of Lennox-Gastaut syndrome. <br />  NOTE: Clobazam has been designated an orphan drug for this indication by the FDA.<br /,"***Benzodiazepine hypersensitivity***Depression, suicidal ideation***Coadministration with other CNS depressants, driving or operating machinery, respiratory depression***Avoid ethanol ingestion, ethanol intoxication, substance abuse***Abrupt discontinuation***Dialysis, renal failure, renal impairment***Hepatic disease, poor metabolizers***Geriatric***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['72302'],ropinirole,***For the treatment of Parkinson's disease.***For conversion from immediate-release to extended-release tablets.***For the treatment of restless legs syndrome (RLS).,"***General Information***Pregnancy***Breast-feeding***Children***Cardiac disease, hypertension, hypotension, orthostatic hypotension, syncope***Geriatric, psychosis***Dialysis, renal failure, renal impairment***Hepatic disease***Tobacco smoking***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion, narcolepsy, sleep apnea***Abrupt discontinuation***Melanoma***Impulse control symptoms",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['283809'],travoprost,***For the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.,"***Closed-angle glaucoma***Iritis, sunlight (UV) exposure, uveitis***Aphakia***Contact lenses***Corneal abrasion, keratitis, ocular infection, ocular surgery, ocular trauma***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albuterol sulfate,"***For the treatment of acute bronchospasm (e.g., asthma) and bronchospasm prophylaxis.***For bronchospasm associated reversible obstructive airway disease (i.e., asthma).***For exercise-induced bronchospasm prophylaxis.***For the adjunctive emergency acute treatment of hyperkalemia�.***For the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD)� including chronic bronchitis� and emphysema�.","***General Information***Albuterol hypersensitivity, levalbuterol hypersensitivity, milk protein hypersensitivity***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, tachycardia, thyroid disease***Geriatric***Hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyrotoxicosis***Diabetes mellitus, diabetic ketoacidosis***Deterioration of asthma, paradoxical bronchospasm***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Renal impairment***MAOI therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],estradiol,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For systemic treatment of the vasomotor symptoms (hot flashes) and genitourinary symptoms of menopause.***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For estrogen replacement for premenopausal women with primary ovarian failure or female hypogonadism.***For the palliative treatment of advanced inoperable prostate cancer.***For the palliative treatment of breast cancer that is inoperable and progressive in selected men and postmenopausal women.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates***Intravenous administration***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['679314'],paliperidone,***For the treatment of schizophrenia.***For the treatment of schizoaffective disorder as monotherapy or as an adjunct to mood stabilizers and/or antidepressants.***For the treatment of mania� associated with bipolar disorder�.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.,"***General Information***Intravenous administration, subcutaneous administration***Tardive dyskinesia***Acute myocardial infarction, alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, syncope, thyroid disease***CNS depression, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Suicidal ideation***Agranulocytosis, hematological disease, leukopenia, neutropenia, thrombotic thrombocytopenic purpura (TTP)***Renal failure, renal impairment***Hepatic disease***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, obesity***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia***Seizure disorder, seizures***Neurological disease, Parkinson's disease***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Cystic fibrosis, dysphagia, esophageal stricture, gastroesophageal reflux disease (GERD), gastroparesis, GI obstruction, inflammatory bowel disease, peritonitis***Priapism***Dementia, geriatric, stroke***Abrupt discontinuation***Breast cancer, hyperprolactinemia, infertility***Neonates, pregnancy, pregnancy testing***Breast-feeding***Children, infants***Brain tumor, Reye's syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['298665'],nepafenac,***For the treatment of ocular pain and postoperative ocular inflammation following cataract surgery.,"***NSAID hypersensitivity, salicylate hypersensitivity***Anticoagulant therapy, coagulopathy, diabetes mellitus, hemophilia, ocular disease, ocular surgery, rheumatoid arthritis***Children, infants, neonates***Pregnancy***Breast-feeding***Asthma***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hepatitis A &amp; hepatitis B (recombinant) vaccine,***For hepatitis A prophylaxis and hepatitis B prophylaxis.,"***General Information***Neomycin hypersensitivity, yeast hypersensitivity***Anticoagulant therapy, coagulopathy, hemophilia, intravenous administration, thrombocytopenia, vitamin K deficiency***Cardiac disease, fever, infection***Chemotherapy, human immunodeficiency virus (HIV) infection, immunosuppression***Children, infants, neonates***Geriatric***Pregnancy***Breast-feeding***Latex hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,loteprednol etabonate,"***For the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.***For the treatment of steroid responsive ophthalmic diseases including acute allergic conjunctivitis, acne rosacea, giant papillary conjunctivitis (GPC), iritis, keratitis, and cyclitis. <br />        NOTE: Alrex is only indicated for seasonal allergic conjunctivitis.<br />     ***For the treatment of postoperative ocular inflammation following ocular surgery.***For the treatment of postoperative ocular pain following ocular surgery.***For use as an alternative corticosteroid for the treatment of uveitis�. <br />        NOTE: Lotemax should not be used in patients who require a more potent corticosteroid for uveitis. Lotemax is less effective than prednisolone 1% in the treatment of acute anterior uveitis. Overall, 72% of patients treated with Lotemax experienced resolution of anterior chamber cell by day 28, compared to 87% of patients treated with prednisolone; however, the incidence of patients with clinically significant increases in IOP (&gt;= 10 mmHg) was 1% with Lotemax versus 6% with prednisolone.<br />     ","***Corticosteroid hypersensitivity, glycerin hypersensitivity***Fungal infection, herpes infection, herpes simplex keratitis (dendritic keratitis), mycobacterial infection, ocular infection, varicella, viral infection***Glaucoma, open-angle glaucoma***Cataracts, diabetes mellitus***Corneal abrasion***Contact lenses***Pregnancy***Breast-feeding***Children***Increased intraocular pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cefuroxime axetil,"***For the treatment of mild-to-moderate acute bacterial exacerbations of chronic bronchitis.***For the treatment of skin and skin structure infections.***For mild to moderate uncomplicated skin and skin structure infections.***For serious skin and skin structure infections.***For the treatment of impetigo. <br />        NOTE: Oral tablets and suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis.<br />     ***For the treatment of urinary tract infection (UTI).***For the treatment of bone and joint infections.***For the treatment of pharyngitis. <br />        NOTE: Oral tablets and suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis.<br />     ***For the treatment of gonorrhea.***For cervicitis or urethritis due to <em>N. gonorrhoeae</em> or rectal gonorrhea in females or urethritis in males.***For disseminated gonococcal infection due to <em>N. gonorrhoeae</em>.***For the treatment of early Lyme disease (erythema migrans). <br />        NOTE: Oral tablets and suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis.<br />     ***For the treatment of acute otitis media. <br />        NOTE: Oral tablets and suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis.<br />     ***For the treatment of bacteremia.***For the treatment of meningitis.***For surgical infection prophylaxis.***For the treatment of tonsillitis. <br />        NOTE: Oral tablets and suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis.<br />     ***For the treatment of sinusitis. <br />        NOTE: Oral tablets and suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis.<br />     ***For the treatment of pneumonia, including community-acquired pneumonia (CAP), and pleural empyema.***For the treatment of intraabdominal infections�, including biliary tract infections� such as cholecystitis�.","***Antimicrobial resistance, viral infection***Cephalosporin hypersensitivity, penicillin hypersensitivity***Renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Breast-feeding***Pregnancy***Diabetes mellitus***Infants, neonates, premature neonates***Phenylketonuria***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,epoetin alfa,"***For the treatment of anemia.***For anemia due to chronic kidney disease to decrease the need for red blood cell transfusion. <br />          NOTE: Epoetin alfa has been designated an orphan drug by the FDA for this indication.<br />       ***For zidovudine-induced anemia in HIV-infected patients with circulating endogenous erythropoietin concentrations of 500 mUnits/mL or less who are receiving a dose of zidovudine of 4,200 mg/week or less. <br />          NOTE: Epoetin alfa has been designated an orphan drug by the FDA for this indication.<br />       ***For anemia in patients with non-myeloid malignancies where the anemia is due to the effect of concomitantly administered chemotherapy and at least 2 additional months of chemotherapy is planned.***For anemia of prematurity�, in combination with iron supplementation. <br />          NOTE: Epoetin alfa has been designated an orphan drug by the FDA for this indication.<br />       ***For anemia associated with myelodysplastic syndrome� (MDS). <br />          NOTE: Epoetin alfa has been designated an orphan drug by the FDA for this indication.<br />       ***For anemia secondary to combination ribavirin and interferon-alfa therapy in patients infected with hepatitis C virus�.***For the treatment of hypoxic-ischemic encephalopathy (HIE)�.","***General Information***Red cell aplasia***Angina, anticoagulant therapy, cardiac disease, dialysis, heart failure, hemoglobin concentration greater than 11 g/dl, mortality, myocardial infarction, renal failure, renal impairment, stroke***Hypertension***Seizure disorder, seizures***Porphyria***Hyperkalemia***Coronary artery bypass graft surgery (CABG), surgery, thromboembolism***Coagulopathy, cystic fibrosis, folate deficiency, hematological disease, hyperparathyroidism, hypersplenism, infection, leukemia, osteitis, sickle cell disease, vitamin B12 deficiency***Iron-deficiency anemia***Pregnancy***Breast-feeding***Benzyl alcohol hypersensitivity, infants, neonates***Neoplastic disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5640'],ibuprofen,"***For the treatment of rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA).***For the treatment of dysmenorrhea.***For the treatment of severe pain in hospitalized patients.***For the treatment of mild pain to moderate pain.***For the treatment of mild to moderate pain in hospitalized patients.***For self-treatment of minor aches and pains due to the common cold, toothache, muscular aches or backache (musculoskeletal pain), and the minor pains of arthritis.***For the treatment of fever.***For the treatment of headache.***For self-treatment of headache.***For the treatment of pain due to acute migraine.***For the treatment of osteoarthritis; ankylosing spondylitis�; acute gouty arthritis�; or psoriatic arthritis�.***For patients with cystic fibrosis� to slow the rate of decline in lung function.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, Crohn's disease, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery bypass graft surgery (CABG), coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Geriatric***Labor, obstetric delivery, pregnancy***Infertility, reproductive risk***Breast-feeding***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['194881'],brinzolamide,***For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.,"***General Information***Sulfonamide hypersensitivity***Renal disease, renal impairment***Hepatic disease***Closed-angle glaucoma***Pregnancy***Breast-feeding***Children***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['36453'],sevoflurane,***For use in general anesthesia induction during inpatient or outpatient surgery. <br />        NOTE: Sevoflurane has a nonpungent odor and does not cause respiratory irritability; it is suitable for mask induction in children and adults.<br />NOTE: Dosage of sevoflurane must be individualized based on patient response***For general anesthesia maintenance during inpatient or outpatient surgery. <br />        NOTE: Sevoflurane can be administered with any type of anesthesia circuit. Determine the concentration of sevoflurane being delivered from a vaporizer during anesthesia. The administration of general anesthesia must be individualized based on the patient's response.<br />NOTE: No specific premedication is either indicated or contraindicated with sevoflurane. The decision as to whether or not to premedicate and the choice of premedication is left to the discretion of the anesthesiologist***Formoterol***Formoterol; Mometasone,"***Halogenated anesthetics hypersensitivity, malignant hyperthermia***Head trauma, increased intracranial pressure, intracranial mass***Myasthenia gravis***Neuromuscular disease***Children, infants, neonates, seizure disorder, seizures***Renal failure, renal impairment***Accidental exposure, labor, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Geriatric, hypotension",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7393'],niacin,"***For the treatment of clinical manifestations of pellagra.***For nutritional supplementation to meet the recommended dietary allowance (RDA).***For use as adjunctive therapy to diet to reduce elevated total cholesterol (TC), LDL-cholesterol (LDL-C), apolipoprotein B (Apo B), and triglyceride (TG) concentrations, and to increase HDL-cholesterol (HDL-C) in patients with primary hyperlipoproteinemia and mixed dyslipidemia; in combination with a bile acid binding resin to reduce elevated TC and LDL-C concentrations in adult patients with primary hyperlipoproteinemia; as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis with inadequate response to diet. <br />        NOTE: Nicotinic acid is active as a hypolipidemic agent but nicotinamide (niacinamide) is not. Do not use nicotinamide to treat hyperlipidemias.<br />     ***For patients with a history of coronary artery disease (CAD) and hyperlipidemia, in combination with a bile acid binding resin, to slow progression or promote regression of atherosclerosis.***For use in combination with an HMG-CoA reductase inhibitor (statin) for the regression of atherosclerosis�.***For adjunctive therapy in the treatment of peripheral vascular disease (PVD)� and circulatory disorders. <br />  NOTE: Nicotinic acid is active as a vasodilatory agent but nicotinamide (niacinamide) does not have vasodilatory properties. Do not use nicotinamide to treat PVD.<br /***For adjunctive therapy in the treatment of tinnitus�.","***General Information***Alcoholism, gallbladder disease, hepatic disease***Peptic ulcer disease***Acute myocardial infarction, angina, driving or operating machinery, hypotension, orthostatic hypotension***Gout***Hypophosphatemia***Rhabdomyolysis***Diabetes mellitus***Children, infants, neonates***Pregnancy***Breast-feeding***Renal disease, renal failure, renal impairment***Anticoagulant therapy, bleeding, coagulopathy, surgery, thrombocytopenia***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sunitinib malate,"***For the treatment of renal cell cancer (RCC).***For the adjuvant treatment of renal cell cancer (RCC) in patients at high risk of recurrence following nephrectomy.***For the treatment of advanced renal cell cancer (RCC).***For the treatment of gastrointestinal stromal tumors (GIST) after disease progression on or intolerance to imatinib.***For the treatment of unresectable, locally advanced or metastatic, progressive, well-differentiated pancreatic neuroendocrine tumor (NET).***Formoterol***Formoterol; Mometasone","***Pregnancy***Breast-feeding***Hepatic disease***Diabetes mellitus, hypoglycemia***Angina, cardiac disease, cardiomyopathy, coronary artery bypass graft surgery (CABG), heart failure, myocardial infarction, stroke***Alcoholism, bradycardia, cardiac arrhythmias, coronary artery disease, females, geriatric, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, thyroid disease***Hypertension***Bleeding***Dental disease, dental work***Contraception requirements, infertility, pregnancy testing, reproductive risk***Hyperthyroidism, hypothyroidism***Surgery***Proteinuria, renal failure***Tumor lysis syndrome (TLS)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,follitropin beta,"***For the treatment of infertility in females. <br />        NOTE: Prior to the treatment, women should have a complete gynecologic and endocrinologic evaluation. The possibility of pregnancy should be ruled out and the fertility status of the male partner should be evaluated. <br />NOTE: During FSH treatment and during a 2 week post-treatment period, patients should be examined at least every other day for signs of excessive ovarian stimulation. Ovarian hyperstimulation syndrome (OHSS) usually occurs after discontinuation of FSH and reaches its maximum at about 7 to 10 days post-ovulation.***For the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure.***For the development of multiple follicles in the ovulatory female patient participating in an Assisted Reproductive Technology (ART) program.***For the induction of pregnancy in the ovulatory female patient undergoing controlled ovarian stimulation as part of an In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) cycle. <br />          NOTE: Women should have a diagnosis of the cause of infertility.<br />       ***For the treatment of infertility in males (for the stimulation of spermatogenesis in males with primary or secondary hypogonadotropic hypogonadism and resultant oligospermia). <br />  NOTE: Pretreatment with hCG is required prior to combination treatment with r-FSH. Various hCG dosages have been advocated; continue hCG for a period sufficient to achieve normal serum testosterone concentrations. Such pretreatment may require 3 to 6 months.<br />NOTE: Complete a medical and endocrinologic evaluation before starting follitropin beta or follitropin alfa. Exclude primary testicular failure and confirm hypogonadotropic hypogonadism. Lastly, evaluate the fertility status of the female partner.<br />NOTE: Serum testosterone concentrations and semen analysis are used for clinical monitoring of spermatogenesis","***General Information***Neomycin hypersensitivity, streptomycin hypersensitivity***Children***Driving or operating machinery***Asthma***Adrenal insufficiency, pituitary adenoma, thyroid disease***Ethanol intoxication, tobacco smoking***Testicular failure***Ovarian failure***Endometriosis, uterine leiomyomata, vaginal bleeding***Geriatric***Breast cancer, ovarian cancer, ovarian cyst, uterine cancer***Ascites, polycystic ovary syndrome***Ectopic pregnancy, pregnancy***Breast-feeding***Myocardial infarction, obesity, stroke, thromboembolic disease, thrombophlebitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,insulin detemir (rDNA origin),"***For the treatment of type 1 diabetes mellitus or type 2 diabetes mellitus.***For the treatment of type 1 diabetes mellitus.***For the treatment of type 2 diabetes mellitus inadequately managed by diet, exercise, and oral hypoglycemics.***Formoterol; Mometasone","***Cresol hypersensitivity***Diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Hepatic disease, renal failure, renal impairment***Coma, continuous subcutaneous insulin infusion (CSII) administration, diabetic ketoacidosis, hyperosmolar hyperglycemic state (HHS), intramuscular administration, intravenous administration***Hypoglycemia***Hypokalemia***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Tobacco smoking***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['15996'],mirtazapine,"***For the treatment of major depression, including the maintenance of response in patients with a major depressive disorder.***For the treatment of resting tremor�, benign familial tremor� (essential tremor�) or for the treatment of levodopa-induced dyskinesias�.***For the treatment of pruritus�.***For the treatment of intractable pruritus�.***For the treatment of nocturnal itch associated with chronic pruritus�.***Formoterol***Formoterol; Mometasone","***General Information***Abrupt discontinuation***Children, suicidal ideation***MAOI therapy***Bipolar disorder, mania***Agranulocytosis, bone marrow suppression, neutropenia***Acute myocardial infarction, angina, cardiac disease, cerebrovascular disease, hypovolemia, myocardial infarction, orthostatic hypotension, QT prolongation, stroke***Dehydration, hyponatremia***Seizure disorder***Renal failure, renal impairment***Hepatic disease, jaundice***Diabetes mellitus, hypercholesterolemia, hypertriglyceridemia***Prostatic hypertrophy***Closed-angle glaucoma, increased intraocular pressure***Akathisia***Driving or operating machinery, ethanol ingestion***Neonates, pregnancy***Breast-feeding***Geriatric***Lactase deficiency, phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['183379'],rivastigmine,***For the treatment of mild to moderate Parkinson's disease dementia (PDD).***For the treatment of Alzheimer's disease.***For the treatment of mild to moderate Alzheimer's disease.***For the treatment of severe Alzheimer's disease.***For the treatment of Dementia with Lewy bodies�.***For the treatment of vascular dementia�.,"***Carbamate hypersensitivity***Abrupt discontinuation***Driving or operating machinery***Females, vomiting***Diarrhea, GI bleeding, GI disease, GI obstruction, ileus, peptic ulcer disease***Hepatic disease***Renal failure, renal impairment***Asthma, chronic obstructive pulmonary disease (COPD)***AV block, bradycardia, cardiac arrhythmias, cardiac disease, hypotension, sick sinus syndrome, syncope***Bladder obstruction, urinary tract obstruction***Head trauma, increased intracranial pressure, seizure disorder, seizures***Anticholinergic medications***Pregnancy***Breast-feeding***Children***Surgery***Tobacco smoking***Geriatric***Magnetic resonance imaging (MRI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,rivastigmine tartrate,***For the treatment of mild to moderate Parkinson's disease dementia (PDD).***For the treatment of Alzheimer's disease.***For the treatment of mild to moderate Alzheimer's disease.***For the treatment of severe Alzheimer's disease.***For the treatment of Dementia with Lewy bodies�.***For the treatment of vascular dementia�.,"***Carbamate hypersensitivity***Abrupt discontinuation***Driving or operating machinery***Females, vomiting***Diarrhea, GI bleeding, GI disease, GI obstruction, ileus, peptic ulcer disease***Hepatic disease***Renal failure, renal impairment***Asthma, chronic obstructive pulmonary disease (COPD)***AV block, bradycardia, cardiac arrhythmias, cardiac disease, hypotension, sick sinus syndrome, syncope***Bladder obstruction, urinary tract obstruction***Head trauma, increased intracranial pressure, seizure disorder, seizures***Anticholinergic medications***Pregnancy***Breast-feeding***Children***Surgery***Tobacco smoking***Geriatric***Magnetic resonance imaging (MRI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1.25 mL diluent) (peginterferon alfa-2b,"***For treatment of hepatitis C infection in patients with compensated liver disease. <br />        NOTE: No safety and efficacy data on treatment for longer than 1 year exist.<br />NOTE: Serum HCV RNA concentrations should be assessed after 24 weeks of treatment. Indications are based on achieving undetectable HCV RNA after 24 or 48 weeks of treatment and maintaining a sustained virologic response (SVR) 24 weeks after the last dose***For chronic hepatitis C as monotherapy in adults who have not been previously treated with interferon alfa. <br />          NOTE: Combination therapy is preferred over monotherapy, unless a contraindication or significant intolerance exists, as it provides substantially better response rates.<br />       ***For acute hepatitis C�.***For the treatment of chronic hepatitis C genotype 1 infection as part of combination therapy.***For the treatment of chronic hepatitis C genotype 2 infection as part of combination therapy.***For the treatment of chronic hepatitis C genotype 3 infection as part of combination therapy.***For the treatment of chronic hepatitis C genotype 4 infection as part of combination therapy.***For the treatment of chronic hepatitis C genotypes 5� or 6� infection as part of combination therapy.***For the adjuvant treatment of malignant melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy.***For treatment of chronic hepatitis B infection�.","***E. coli protein hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis, serious rash***Alcoholism, bipolar disorder, depression, driving or operating machinery, encephalopathy, mania, neurologic events, peripheral neuropathy, psychiatric event, psychosis, seizure disorder, seizures, substance abuse, suicidal ideation***Infection***Anemia, aplastic anemia, bleeding, bone marrow suppression, human immunodeficiency virus (HIV) infection, neutropenia, organ transplant, sickle cell disease, thalassemia, thrombocytopenia***Ethanol ingestion, hepatic decompensation, hepatic disease, hepatitis, hepatitis C and HIV coinfection, jaundice***Autoimmune disease, idiopathic thrombocytopenic purpura (ITP), psoriasis, rheumatoid arthritis, systemic lupus erythematosus (SLE), thrombotic thrombocytopenic purpura (TTP)***Graves' disease, hyperthyroidism, hypothyroidism, thyroid disease***Diabetes mellitus, hyperglycemia, hypoglycemia***Angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, hypertension, myocardial infarction, stroke***Pneumonitis, pulmonary disease, pulmonary hypertension, respiratory insufficiency, sarcoidosis***Dialysis, renal failure, renal impairment***Colitis, ischemic colitis, ulcerative colitis***Hypertriglyceridemia, pancreatitis***Diabetic retinopathy, ocular disease, optic neuritis, papilledema, retinal bleeding, retinal detachment, visual disturbance***Geriatric***Contraception requirements, pregnancy, use with ribavirin***Infertility, menstrual irregularity***Breast-feeding***Children, growth inhibition, infants, neonates***Dental disease, dental work***Hepatitis B exacerbation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['17767']['5487'],amlodipine/hydrochlorothiazide/valsartan,"***For the treatment of hypertension. <br />        NOTE: Amlodipine; hydrochlorothiazide; HCTZ; valsartan is not indicated for the initial therapy of hypertension.<br />     ***For add-on or switch therapy in patients not adequately controlled on any two of the following antihypertensive classes: calcium channel blockers, angiotensin receptor blockers, or diuretics.***For patients already receiving amlodipine, hydrochlorothiazide and valsartan who desire to switch to the combination tablet.***Formoterol***Formoterol; Mometasone","***General Information***Dihydropyridine hypersensitivity***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Angina, coronary artery disease***Acute myocardial infarction, aortic stenosis, bradycardia, cardiogenic shock, cardiomyopathy, heart failure, hypotension, hypovolemia, mitral stenosis, surgery, ventricular dysfunction***Anuria, renal artery stenosis, renal impairment***Hepatic disease***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia, hyponatremia***Diabetes mellitus, hyperglycemia***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***ACE-inhibitor induced angioedema, angioedema***Black patients***Gastroesophageal reflux disease (GERD), hiatal hernia***Orthostatic hypotension, sympathectomy, syncope***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,alendronate sodium,"***For the treatment of osteoporosis.***For osteoporosis prophylaxis in postmenopausal women.***For the treatment of Paget's disease in symptomatic patients or patients with alkaline phosphatase levels at least twice the upper limit of normal, or those at risk from complications..***For the treatment of malignant hypercalcemia�.","***General Information***Achalasia, dysphagia, esophageal stricture, esophagitis, gastritis, gastroesophageal reflux disease (GERD), GI disease, GI perforation, hiatal hernia, inability to stand or sit upright***Geriatric***Hypocalcemia, vitamin D deficiency***Renal failure, renal impairment***Children, infants, neonates***Pregnancy***Breast-feeding***Phosphonate hypersensitivity***Sunlight (UV) exposure***Anemia, chemotherapy, coagulopathy, corticosteroid therapy, dental disease, dental work, infection***Cardiac disease, heart failure, hypertension, sodium restriction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mycophenolic acid,"***For kidney transplant rejection prophylaxis with or without antithymocyte induction.***For heart transplant rejection prophylaxis. <br />        NOTE: The safety and efficacy of mycophenolate in combination with sirolimus following withdrawal of initial calcineurin inhibitor therapy (cyclosporine or tacrolimus) have not been established. A study was stopped because of a higher than expected incidence of grade IIIA acute rejection in patients switched from calcineurin inhibitors in combination with mycophenolate to sirolimus in combination with mycophenolate 12 weeks after heart transplantation. Specifically, acute rejection occurred within 5 weeks of calcineurin inhibitor discontinuation in 4 of 7 patients randomized to get sirolimus, mycophenolate, and corticosteroids whereas none of the 8 patients randomized to continue getting a calcineurin inhibitor, mycophenolate, and corticosteroids had acute rejection. The study was designed to investigate whether renal function benefit could be achieved with sirolimus substitution of calcineurin inhibitor therapy.<br />     ***For liver transplant rejection prophylaxis.***For the treatment of refractory acute kidney transplant rejection�. <br />  NOTE: The pharmacokinetic parameters of mycophenolic acid are unchanged in patients who have renal transplant rejection. No dosage change or cessation of mycophenolate is needed.<br /***For the treatment of rheumatoid arthritis�.***For the prophylaxis or treatment of acute graft-versus-host disease (GVHD)�.***For the treatment of lupus nephritis�.***For the treatment of atopic dermatitis�.***For the adjuvant treatment of pemphigus� (pemphigus vulgaris� and pemphigus foliaceus�).***For the treatment of myasthenia gravis�.***For the treatment of uveitis�.***For the treatment of psoriasis�.","***General Information***GI disease, peptic ulcer disease***Renal failure, renal impairment, uremia***Diabetes mellitus***Cholestasis, gallbladder disease, hepatic disease, hepatic encephalopathy, hepatitis, hypoalbuminemia***Diarrhea***Fungal infection, herpes infection, immunosuppression, infection, progressive multifocal leukoencephalopathy, requires a specialized care setting, requires an experienced clinician, varicella, viral infection***Anemia, bone marrow suppression, leukopenia, neutropenia, red cell aplasia, thrombocytopenia***Geriatric***Children, infants***Contraception requirements, pregnancy, pregnancy testing, reproductive risk***Breast-feeding***Accidental exposure, ocular exposure***Lactase deficiency, phenylketonuria***Lymphoma, new primary malignancy, skin cancer, sunlight (UV) exposure***Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mometasone furoate,"***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses including alopecia areata, atopic dermatitis, contact dermatitis, dermatitis, discoid lupus erythematosus, eczema, exfoliative dermatitis, granuloma annulare, keloids, lichen planus, lichen simplex, lichen striatus, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pruritus, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, xerosis, and severe <em>Rhus dermatitis</em> due to plants like poison ivy. <br />  NOTE: Occlusive dressings may be required for chronic or severe cases of lichen simplex chronicus, psoriasis, eczema, atopic dermatitis, or chronic hand eczema. More potent topical corticosteroids and/or occlusive dressings may be necessary for the treatment of discoid lupus erythematosus, lichen planus, granuloma annulare, psoriatic plaques, and psoriasis of the palms, soles, elbows, or knees.<br /***For maintenance treatment of asthma.***For the management of nasal symptoms associated with seasonal or perennial allergic rhinitis (e.g., nasal congestion).***For seasonal allergic rhinitis prophylaxis.***For the treatment of nasal polyps.***For sinus patency maintenance after ethmoid sinus surgery in patients with chronic sinusitis.***For exercise-induced bronchospasm prophylaxis�.","***Corticosteroid hypersensitivity***Milk protein hypersensitivity***Acute bronchospasm, paradoxical bronchospasm, status asthmaticus***Skin atrophy***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion, surgery***Children, growth inhibition, increased intracranial pressure, infants, neonates***Diabetes mellitus, hyperglycemia, peripheral vascular disease***Nasal septal perforation, nasal surgery, nasal trauma***Cataracts, glaucoma, increased intraocular pressure, ocular exposure, visual disturbance***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, tuberculosis, varicella, viral infection***Pregnancy***Breast-feeding***Sunlight (UV) exposure***Hepatic disease***Osteoporosis***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6069'],ivermectin,"***For the treatment of onchocerciasis due to <em>Onchocerca volvulus</em> infection.***For the treatment of strongyloidiasis due to <em>Strongyloides stercoralis</em> infection.***For the treatment of pediculosis including pediculosis capitis, pediculosis corporis�, and pediculosis pubis�.***For the treatment of inflammatory lesions of acne rosacea.***For the treatment of scabies� infections, including crusted (Norwegian) scabies�.***For the treatment of scabies�.***For the treatment of crusted scabies� (i.e., Norwegian scabies�) infection, superinfected scabies, or resistant scabies.***For the treatment of Bancroft's filariasis� caused by <em>Wuchereria bancrofti</em>�.***For the secondary treatment of cutaneous larva currens� or cutaneous larva migrans�.","***General Information***Asthma***Hepatic disease***Geriatric***Human immunodeficiency virus (HIV) infection, immunosuppression***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"measles, mumps, and rubella virus vaccine live","***For measles prophylaxis, mumps prophylaxis, and rubella prophylaxis. <br />        NOTE: Vaccination with MMR is recommended for persons susceptible to measles, mumps, and rubella. Adults born before 1957 are considered immune.<br />     ***For post-exposure measles prophylaxis�.","***General Information***Intramuscular administration, intravenous administration***Egg hypersensitivity, neomycin hypersensitivity***Albumin hypersensitivity, gelatin hypersensitivity***Idiopathic thrombocytopenic purpura (ITP), infection, thrombocytopenia***Seizure disorder***Infants, neonates***Acquired immunodeficiency syndrome (AIDS), agammaglobulinemia, bone marrow suppression, chemotherapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, IgA deficiency, immunosuppression, leukemia, lymphoma, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Pregnancy***Breast-feeding***Fever, respiratory infection, tuberculosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['194279'],palivizumab,***For respiratory syncytial virus (RSV) infection prophylaxis in pediatric patients at high risk of RSV disease.,"***General Information***Coagulopathy, thrombocytopenia***Acute bronchospasm, hypotension, murine protein hypersensitivity***Human anti-human antibody (HAHA)***Pregnancy***Breast-feeding***Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['194337'],vorinostat,"***For the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have progressive, persistent, or recurrent disease on or following 2 systemic therapies.***For the treatment of relapsed or refractory multiple myeloma�, in combination with bortezomib.***Formoterol***Formoterol; Mometasone","***Hepatic disease***Anemia, thrombocytopenia***Anticoagulant therapy, thromboembolic disease***Dehydration, diarrhea, GI bleeding, vomiting***Diabetes mellitus, hyperglycemia***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Pregnancy***Breast-feeding***Children, infants, neonates***Accidental exposure, ocular exposure***Dental disease, dental work***Renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,zoster vaccine live,***For varicella (chickenpox) infection prophylaxis to provide active immunity against the varicella (chickenpox) virus in susceptible adults and children >= 12 months old.***For varicella prophylaxis for outbreak control� of local epidemics of wild-type varicella virus in susceptible persons following varicella exposure.***For herpes zoster (shingles) infection prophylaxis among patients who have had varicella exposure either naturally or through vaccination.,"***Gelatin hypersensitivity, neomycin hypersensitivity***Intramuscular administration, intravenous administration***Fever, respiratory infection, tuberculosis***Acquired immunodeficiency syndrome (AIDS), agammaglobulinemia, bone marrow suppression, chemotherapy, corticosteroid therapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, IgA deficiency, immunosuppression, leukemia, lymphoma, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2019']['6375'],carbidopa/levodopa,"***For the treatment of idiopathic Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.***For the treatment of motor fluctuations in patients with advanced Parkinson's disease.***For the treatment of restless legs syndrome (RLS)�.***For the treatment of amblyopia�.","***General Information***Abrupt discontinuation, hyperthermia, mental status changes, surgery***Cardiac arrhythmias, cardiac disease, myocardial infarction, orthostatic hypotension***Asthma, emphysema, pulmonary disease***Hepatic disease, renal disease***GI obstruction, GI perforation, intussusception, peptic ulcer disease***Depression, psychosis, seizure disorder, suicidal ideation***MAOI therapy***Diabetes mellitus***Closed-angle glaucoma***Melanoma***Pregnancy***Breast-feeding***Children, infants, neonates***Pheochromocytoma***Impulse control symptoms***Driving or operating machinery***Peripheral neuropathy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['141704'],everolimus,"***For the treatment of patients with advanced renal cell cancer (RCC).***For the treatment of patients with advanced renal cell cancer who have failed treatment with sunitinib or sorafenib.***For the treatment of advanced renal cell cancer (RCC) in combination with lenvatinib, following one prior anti-angiogenic therapy.***For kidney transplant rejection prophylaxis in patients at low-moderate immunologic risk. <br />        NOTE: The safety and efficacy of everolimus have not been established in patients at high immunologic risk.<br />     ***For the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) in patients who require therapeutic intervention but are not candidates for curative surgical resection.***For the treatment of patients with unresectable, locally advanced, or metastatic neuroendocrine tumor (NET) or carcinoid tumors. ***For the treatment of progressive neuroendocrine tumor (NET) of pancreatic origin (also known as PNET) in patients with unresectable, locally advanced or metastatic disease.***For the treatment of progressive, well-differentiated, non-functional neuroendocrine tumor (NET) of gastrointestinal or lung origin (also known as carcinoid) in patients with unresectable, locally advanced or metastatic disease. <br />          NOTE: Everolimus is not indicated for the treatment of patients with functional carcinoid tumors.<br />       ***For the treatment of breast cancer.***For the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women who have failed treatment with letrozole or anastrozole, in combination with exemestane.***For the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer in postmenopausal women with secondary aromatase inhibitor resistance, in combination with tamoxifen�.***For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with vinorelbine and trastuzumab�.***For the treatment of renal angiomyolipoma and tuberous sclerosis complex not requiring immediate surgery.***For liver transplant rejection prophylaxis.***For the treatment of relapsed or refractory Waldenstrom macroglobulinemia�.","***General Information***Pleural effusion, pneumonitis, pulmonary fibrosis***Fungal infection, infection***Immunosuppression, lymphoma, new primary malignancy, skin cancer, sunlight (UV) exposure***Nephrotoxicity, renal impairment***Renal artery thrombosis, renal graft thrombosis, renal vein thrombosis***Diabetes mellitus, hyperglycemia, hyperlipidemia, hypertriglyceridemia***Hepatic disease***Vaccination***Heart transplant, mortality***Surgery, wound dehiscence***Geriatric***Lactase deficiency***Pregnancy***Contraception requirements, infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['358257'],tolvaptan,"***For the treatment of clinically significant hypervolemic and euvolemic hyponatremia (i.e., serum sodium < 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including in patients with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH). <br />  NOTE: Only initiate or re-initiate tolvaptan in a hospital where serum sodium concentrations can be closely monitored. Too rapid correction can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, changes in affect, spastic quadriparesis, seizures, coma, and death.<br />NOTE: Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan.<br />NOTE: A clear symptomatic or survival benefit with tolvaptan therapy has not been established","***General Information***Alcoholism, malnutrition, osmotic demyelination syndrome, requires a specialized care setting***Hypovolemia***Anuria***Hepatic disease***Dehydration***Hyperkalemia***Geriatric***Pregnancy***Breast-feeding***Children, infants, neonates***Autosomal dominant polycystic kidney disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['763450'],rilonacept,***For the treatment of cryopyrin-associated periodic syndromes (CAPS) including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS).,"***Acquired immunodeficiency syndrome (AIDS), bone marrow suppression, diabetes mellitus, hepatitis, human immunodeficiency virus (HIV) infection, immunosuppression, infection, tuberculosis***Children, infants, neonates***Pregnancy***Breast-feeding***Asthma***Geriatric***Hamster protein hypersensitivity***Intramuscular administration, intravenous administration***Vaccination***Hypercholesterolemia, hypertriglyceridemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,abobotulinumtoxinA,***For the treatment of cervical dystonia.***For the treatment of glabellar lines (facial wrinkles or vertical lines between the eyebrows).***For the treatment of spasticity.***For the treatment of upper limb spasticity.***For the treatment of lower limb spasticity.***For the treatment of blepharospasm� and hemifacial spasm�.***For the treatment of bilateral blepharospasm�.***For the treatment of unilateral blepharospasm� and hemifacial spasm�.***For the treatment of axillary hyperhidrosis� (excessive sweating).,"***General Information***Requires an experienced clinician***Albumin hypersensitivity, bovine protein hypersensitivity***Infection***Dysphagia, respiratory insufficiency***Cerebral palsy, children, distant spread of toxin effects***Amyotrophic lateral sclerosis (ALS), autonomic neuropathy, inflammation, myasthenia gravis, myopathy, neuromuscular disease***Geriatric***Pregnancy***Breast-feeding***Diabetes mellitus***Viral infection***Cardiac disease***Driving or operating machinery***Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['25025'],finasteride,"***For the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, to reduce the risk of acute urinary retention, and to reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy.***For the treatment of male pattern hair loss (i.e., androgenetic alopecia), in patients with mild to moderate hair loss of the vertex and anterior mid-scalp area.***For the second-line treatment of hirsutism�.***For prostate cancer prophylaxis�.","***Females, pregnancy***Breast-feeding***Children, infants***Hepatic disease***Prostate cancer, urinary tract obstruction***Blood donation***Geriatric***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albuterol sulfate,"***For the treatment of acute bronchospasm (e.g., asthma) and bronchospasm prophylaxis.***For bronchospasm associated reversible obstructive airway disease (i.e., asthma).***For exercise-induced bronchospasm prophylaxis.***For the adjunctive emergency acute treatment of hyperkalemia�.***For the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD)� including chronic bronchitis� and emphysema�.","***General Information***Albuterol hypersensitivity, levalbuterol hypersensitivity, milk protein hypersensitivity***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, tachycardia, thyroid disease***Geriatric***Hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyrotoxicosis***Diabetes mellitus, diabetic ketoacidosis***Deterioration of asthma, paradoxical bronchospasm***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Renal impairment***MAOI therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,oxycodone hydrochloride,"***For the treatment of severe pain.***For the treatment of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.***For the management of chronic severe pain in patients who require daily, around-the-clock, long-term opioid treatment. <br />          NOTE: Extended-release oxycodone should be reserved for patients in whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would otherwise provide inadequate pain management. Discontinue all other around-the-clock opioid drugs upon initiation of oxycodone extended-release tablets or capsules. <br />NOTE: Extended-release oxycodone 60 or 80 mg tablets, a single tablet dose more than 40 mg, or a total tablet daily dose more than 80 mg should be reserved for opioid-tolerant patients. A single extended-release oxycodone capsule dose of 36 mg (equivalent to 40 mg oxycodone hydrochloride) or more or a total capsule daily dose of 72 mg (equivalent to 80 mg oxycodone hydrochloride) or more should be reserved for opioid-tolerant patients. Adult patients who are opioid tolerant are those receiving, for a minimum of 1 week, 60 mg or more oral morphine daily, 30 mg or more oral oxycodone daily, 8 mg or more oral hydromorphone daily, 25 mg or more oral oxymorphone daily, 25 mcg or more transdermal fentanyl per hour, 60 mg or more oral hydrocodone per day, or an equivalent dose of another opioid. Extended-release oxycodone tablets should only be used in pediatric patients 11 years or older receiving opioids for at least 5 consecutive days and taking a minimum of 20 mg per day of oxycodone or its equivalent for 2 days immediately preceding dosing with extended-release oxycodone.***For the treatment of painful diabetic neuropathy�.","***Accidental exposure, ethanol ingestion, ethanol intoxication, parenteral administration, potential for overdose or poisoning, requires an experienced clinician***Acute abdomen, constipation, diarrhea, diverticulitis, dysphagia, esophageal stricture, gastric cancer, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, coma, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Opioid-naive patients, surgery***Biliary tract disease, pancreatitis***Abrupt discontinuation***CNS depression, head trauma, increased intracranial pressure, intracranial mass, psychosis***Angina, cardiac arrhythmias, cardiac disease, dehydration, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, urethral stricture, urinary retention***Seizure disorder, seizures***Geriatric***Children, infants, neonates***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Infertility, reproductive risk***Driving or operating machinery***Opiate agonist hypersensitivity***Adrenal insufficiency, hypothyroidism, myxedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['9344'],ribavirin,"***For the treatment of respiratory syncytial virus (RSV) infection.***For the treatment of chronic hepatitis C infection in patients with compensated liver disease. <br />        NOTE: Ribavirin monotherapy is not effective for hepatitis C infection. <br />NOTE: Therapy should be discontinued in patients who develop hepatic decompensation during treatment***For the treatment of chronic hepatitis C infection in combination with interferon alfa-2b alone. <br />          NOTE: Consider response prognostic factors, HCV genotype, viral load, and disease progression evidence such as hepatic inflammation and fibrosis when deciding to treat a pediatric patient. Weigh treatment benefits against potential safety risks identified in clinical trials.<br />       ***For the treatment of chronic hepatitis C infection in combination with a peginterferon alfa product alone. <br />          NOTE: Guidelines recommend the use of a peginterferon product plus ribavirin as part of a combination regimen depending on patient factors and genotype. <br />       ***For the treatment of chronic hepatitis C infection genotype 1 in combination with a nucleotide analog NS5B polymerase inhibitor or NS3/4A protease inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infections in patients with hepatocellular carcinoma awaiting liver transplant as well as patients with decompensated cirrhosis who may or may not be candidates for liver transplantation�.***For the treatment of  recurrent hepatitis C infection in patients after liver transplantation�.***For the treatment of chronic hepatitis C infection genotype 2 in combination with a nucleotide analog NS5B polymerase inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infection genotype 3 in combination with a nucleotide analog NS5B polymerase inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infection genotype 4 in combination with a nucleotide analog NS5B polymerase inhibitor or NS3/4A protease inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infection genotypes 5 or 6 in combination with a nucleotide analog NS5B polymerase inhibitor and/or a peginterferon alfa product�.***For the treatment of viral hemorrhagic fever (VHF)�, including hemorrhagic fever with renal syndrome (HFRS)� secondary to Hantaan virus infection�. <br />        NOTE: Ribavirin has been designated an orphan drug by the FDA for hemorrhagic fever with renal syndrome (HFRS).<br />     ***For Lassa fever prophylaxis�.***For the treatment of adenovirus infection�, including pneumonitis�, hepatitis�, hemorrhagic cystitis�, and nephritis�.***For the treatment of viral encephalitis�.***For subacute measles encephalitis� (SME).***For subacute sclerosing panencephalitis� (SSPE) caused by the measles virus�.***For encephalitis� caused by the Nipah virus�.***For encephalitis� caused by the West Nile virus�.***For the treatment of West Nile virus infection�, including meningitis� and encephalitis�. <br />  NOTE: Other than supportive care, there is no established treatment for West Nile virus infection. The use of ribavirin is suggested by in vitro data only.<br /***For the treatment of Severe Acute Respiratory Syndrome (SARS)�.***For the treatment of Crimean-Congo virus hemorrhagic fever (CCVHF)� or Lassa fever infection�. <br />        NOTE: The use of ribavirin for hemorrhagic fever with renal syndrome (HFRS) secondary to Crimean-Congo virus is supported by in vitro data.<br />***For Crimean-Congo virus hemorrhagic fever (CCVHF) prophylaxis�.","***General Information***Requires an experienced clinician, respiratory depression, respiratory insufficiency***Contact lenses, ocular exposure***Contraception requirements, male-mediated teratogenicity, pregnancy, pregnancy testing, reproductive risk***Infertility***Breast-feeding***Anemia, angina, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, heart failure, hemolytic anemia, myocardial infarction***Infection***Hemoglobinopathy, sickle cell disease, thalassemia***Geriatric***Hepatic disease, hepatitis, hepatitis C and HIV coinfection, influenza, organ transplant, ribavirin monotherapy, viral infection***Children, growth inhibition, infants, neonates***Pancreatitis***Dialysis, renal failure, renal impairment***Thyroid disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['784649'],asenapine,"***For the  treatment of schizophrenia.***For the treatment of bipolar disorder (bipolar I disorder), including mania or mixed episodes.***For the treatment of severe behavioral or psychological symptoms of dementia�.***Formoterol***Formoterol; Mometasone","***General Information***CNS depression, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Agranulocytosis, hematological disease, leukopenia, neutropenia***Suicidal ideation***Abrupt discontinuation***Tardive dyskinesia***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, syncope, tachycardia, thyroid disease***Seizure disorder, seizures***Hepatic disease***Ambient temperature increase, anticholinergic medications, dehydration, hyperthermia, hypothermia, strenuous exercise***Dysphagia***Neurological disease, Parkinson's disease***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia***Obesity***Breast cancer, hyperprolactinemia, infertility***Dementia, geriatric, stroke***Neonates, pregnancy, pregnancy testing***Substance abuse***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pneumococcal vaccine polyvalent,"***For pneumococcal prophylaxis .***For routine prophylaxis of infants and children as part of the primary childhood immunization schedule.***For routine prophylaxis of healthy adults, adolescents, and children 6 years and older.***For prophylaxis of patients at least 2 years of age with risk factors.***For prophylaxis in patients who will undergo elective splenectomy, cochlear implant surgery, organ transplantation, chemotherapy, or other immunosuppressive therapy. <br />          NOTE: If vaccination before the procedure is not feasible, give the vaccine as soon as possible after surgery.<br />       ***For routine prophylaxis of healthy geriatric patients. <br />          NOTE: The Advisory Committee on Immunization Practices (ACIP) recommends all patients at least 65 years of age receive routine vaccination with both Prevnar 13 and Pneumovax 23.<br />       ***For prophylaxis of adults 19 years and older with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants. <br />          NOTE: The Advisory Committee on Immunization Practices (ACIP) recommends adults 19 years and older with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants receive vaccination with both Prevnar 13 and Pneumovax 23.<br />       ***For otitis media prophylaxis in infants and children younger than 6 years.","***General Information***Intravenous administration***Fever***Idiopathic thrombocytopenic purpura (ITP)***Cardiac disease, pulmonary disease***Chemotherapy, Hodgkin's disease, immunosuppression, organ transplant, radiation therapy***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Children, infants***Neonates, premature neonates***Pregnancy***Breast-feeding***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['18631'],azithromycin,"***For the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis in patients with COPD caused by susceptible strains of <em>Haemophilus influenza</em>, <em>Moraxella catarrhalis</em>, or <em>Streptococcus pneumoniae</em>.***For the treatment of acute otitis media. <br />        NOTE: Various dosing regimens are FDA-approved. Because macrolides, including azithromycin, have limited efficacy against both H. influenzae and S. pneumoniae, these agents are not included in the preferred or alternative options recommended by the American Academy of Pediatrics (AAP) in the treatment guidelines for acute otitis media.<br />     ***For the treatment of bacterial conjunctivitis caused by susceptible strains of <em>CDC coryneform group G, H. influenzae, S. aureus, S. mitis group, and S. pneumoniae</em>.***For the treatment of community-acquired pneumonia (CAP).***For the treatment of uncomplicated skin and skin structure infections caused by <em>S. aureus, S. pyogenes</em> or <em>S. agalactiae</em>.***For the treatment of pelvic inflammatory disease (PID).***For the treatment of gonorrhea.***For the treatment of uncomplicated gonorrhea of the cervix, urethra, rectum, and pharynx.***For the treatment of disseminated (e.g., bacteremia, arthritis) gonococcal infection�, including meningitis� and endocarditis�.***For the treatment of gonococcal conjunctivitis�.***For the treatment of chancroid due to <em>Haemophilus ducreyi</em>.***For the treatment of Mycobacterium avium complex infection (MAC).***For Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients.***For primary Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients.***For secondary Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients with disseminated disease, after treatment of the acute illness.***For the treatment of acute bacterial sinusitis. <br />        NOTE: Due to the high rate of resistance among S. pneumoniae isolates, macrolides are not recommended as empiric therapy. Amoxicillin/clavulanate is recommended as the first-line empiric therapy.<br />     ***For the treatment of non-gonococcal urethiritis (NGU) and chlamydia infection, including infant pneumonia�. <br />        NOTE: For ophthalmia neonatorum caused by C. trachomatis, see ophthalmia neonatorum indication.<br />     ***For the treatment of non-gonococcal urethritis (NGU) and other urogenital infections (e.g., cervicitis, urethritis, proctitis).***For the treatment of pneumonia caused by <em>Chlamydia trachomatis</em> in neonates and infants�.***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis (primary rheumatic fever prophylaxis�) and tonsillitis. <br />        NOTE: For secondary prophylaxis of rheumatic fever, the American Heart Association (AHA) recommends prophylaxis for 10 years or until age 40 (whichever is longer) for patients who have experienced rheumatic fever with carditis and have residual heart disease (persistent valvular disease). For patients who have experienced rheumatic fever with carditis, but have no residual heart disease, the AHA recommends prophylaxis for 10 years or until age 21 (whichever is longer). For patients who have experienced rheumatic fever without carditis, the AHA recommends prophylaxis for 5 years or until age 21 (whichever is longer).<br />     ***For the treatment of primary, secondary, or early latent syphilis� (caused by <em>Treponema pallidum</em>) in nonpregnant, penicillin-allergic patients. <br />        NOTE: A Jarisch-Herxheimer reaction may occur within the first 24 hours of therapy.<br />NOTE: While the HIV guidelines recommend non-penicillin alternatives for the treatment of syphilis in HIV-infected patients, their efficacy has not been evaluated and should only be used with close clinical and serologic monitoring***For the treatment of chronic prostatitis� due to <em>Ureaplasma urealyticum</em>.***For the treatment of Legionnaire's disease�.***For the treatment of shigellosis� diarrhea.***For the treatment of shigellosis� diarrhea in non-immunocompromised patients.***For the treatment of shigellosis� in HIV-infected patients.***For the treatment of mild-to-moderate campylobacteriosis� in HIV-infected patients.***For the treatment of toxoplasmosis�, including toxoplasmic encephalitis�, in HIV-positive patients.***For the treatment of early Lyme disease�.***For the treatment of early Lyme disease� in adults.***For the treatment of early Lyme disease� in children and adolescents.***For the treatment of dental infection� or dentoalveolar infection�, including periodontitis�, acute dental abscess (apical)�, and dental abscess (periapical)�.***For adult chronic periodontitis� after scaling and root planing.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage in patients with beta-lactam allergy.***For bacterial endocarditis prophylaxis�.***For the treatment of babesiosis� in combination with atovaquone.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For use in improving pulmonary function in cystic fibrosis� patients chronically infected with <em>Pseudomonas aeruginosa</em>.***For the treatment of mild scrub typhus� due to Orientia tsutsugamushi� (formerly Rickettsia tsutsugamushi�).***For the treatment of pertussis (whooping cough)� caused by <em>Bordetella pertussis</em> or for postexposure pertussis prophylaxis�. <br />  NOTE: For postexposure prophylaxis, administer to close contacts within 3 weeks of exposure, especially in high-risk patients (e.g., pregnant women in third trimester, infants younger than 12 months). Symptomatic contacts (coughing) should be treated as if they have pertussis.<br /***For the treatment of cholera�.***For the treatment of uncomplicated typhoid fever�.***For the treatment of bartonellosis� (<em>Bartonella bacilliformis)</em> and other <em>Bartonella </em>sp.� infections in HIV-infected patients.***For the treatment of angiomatosis infections�, peliosis hepatis�, bacteremia�, and osteomyelitis� caused by <em>Bartonella </em>sp.�.***For long term suppression� of infections caused by <em>Bartonella </em>sp.� in HIV-infected patients with relapse or reinfection and with CD4 count less than 200 cells/mm3.***For the treatment of ophthalmia neonatorum� due to <em>C. trachomatis</em>.***For the treatment of lymphogranuloma venereum� caused by <em>C. trachomatis</em>.***For chlamydial infection prophylaxis� and gonorrhea prophylaxis� in victims of sexual assault.***For the treatment of moderate or severe traveler's diarrhea�.***Formoterol***Formoterol; Mometasone","***General Information***Viral infection***Macrolide hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis***Hepatic disease, hepatitis, jaundice***Renal failure, renal impairment***Colitis, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Geriatric***Pregnancy***Breast-feeding***Infants, neonates***Sunlight (UV) exposure***Sodium restriction***Contact lenses***Myasthenia gravis***Sexually transmitted disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['72965'],letrozole,"***For the treatment of breast cancer. <br />  NOTE: The American Society of Clinical Oncology recommends that all postmenopausal women with hormone receptor-positive early breast cancer receive adjuvant aromatase inhibitor therapy. Options include 5 years of an aromatase inhibitor or sequential therapy with 2 to 3 years or 5 years of tamoxifen followed by 2 to 3 years or 5 years of an aromatase inhibitor. The optimal duration of therapy and regimen is not known.<br /***For adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.***For extended treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. <br />          NOTE: The effectiveness of letrozole in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated for a median of 24 months. Further data are needed to determine long-term outcomes.<br />       ***For first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor status unknown with locally advanced or metastatic disease.***For the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.***For the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated in combination with lapatinib.***For the treatment of infertility� in women due to anovulation, irregular ovulation, or luteal phase defects, including women with polycystic ovary syndrome (PCOS). <br />        NOTE: Ensure that patients are not pregnant prior to initiating letrozole. While the outcomes of pregnancies in one cohort study demonstrate a similar rate of miscarriage and ectopic pregnancy in women who took letrozole versus other drugs for ovarian stimulation , the manufacturer of letrozole urges physicians to ensure that letrozole is not used in women who may become or are pregnant; birth defects have been reported in the children of women who were receiving letrozole during pregnancy.<br />     ***For an increase in height in boys with idiopathic short stature� or constitutional delayed puberty�.***For boys with idiopathic short stature�.***For boys with constitutional delayed puberty�.***For the treatment of endometriosis� refractory to other medical or surgical treatments.","***Biliary cirrhosis, hepatic disease***Osteoporosis***Hypercholesterolemia***Children***Pregnancy***Contraception requirements, infertility, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,eletriptan hydrobromide,***For the treatment of acute migraine attacks with or without aura. <br />        NOTE: Eletriptan should not be used within 24 hours of an ergot-based medication or 72 hours of treatment with any known potent CYP3A4 inhibitors (see Drug Interactions).<br />     ,"***General Information***Basilar/hemiplegic migraine***Acute myocardial infarction, angina, arteriosclerosis, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, hypercholesterolemia, obesity, tobacco smoking, vasospastic angina, Wolff-Parkinson-White syndrome***Hypertension***Colitis, peripheral vascular disease, Raynaud's phenomenon***Cerebrovascular disease, intracranial bleeding, stroke***Driving or operating machinery***Hepatic disease***Geriatric***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10612'],tinidazole,"***For the treatment of giardiasis.***For the treatment of intestinal amebiasis.***For amebic involvement of the liver.***For the treatment of trichomoniasis.***For the treatment of bacterial vaginosis. <br />        NOTE: Prior to treatment of bacterial vaginosis, other commonly associated pathogens such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhea, Candida albicans, and Herpes simplex virus should be ruled out.<br />     ***For the treatment of acute ulcerative gingivitis�.***For the treatment of recurrent and persistent non-gonococcal urethritis (NGU)�.***For bacterial vaginosis prophylaxis� and trichomoniasis prophylaxis� in victims of sexual assault.","***Viral infection***Bone marrow suppression, hematological disease***Pregnancy***Breast-feeding***New primary malignancy***Alcoholism, ethanol intoxication***Hepatic disease***Renal failure***Neurological disease, peripheral neuropathy, seizure disorder***Fungal infection***Geriatric***Children, infants***Sexually transmitted disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['341248']['36567'],ezetimibe/simvastatin,"***For use as an adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipoproteinemia AND for reduction of elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.","***General Information***Alcoholism, cholestasis, hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Electrolyte imbalance, endocrine disease, females, hypotension, hypothyroidism, infection, myopathy, organ transplant, renal disease, renal failure, renal impairment, rhabdomyolysis, seizure disorder, surgery, trauma***Geriatric***Pregnancy***Breast-feeding***Children, infants, neonates***Asian patients***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['17767']['69749'],amlodipine/valsartan,"***For the treatment of hypertension. <br />        NOTE: The combination product (Exforge) is available as 5/160 mg, 5/320 mg, 10/160 mg, or 10/320 mg tablets of amlodipine/valsartan.<br />     ***For initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals.***For substitution after titration of amlodipine and valsartan as single agents.","***Dihydropyridine hypersensitivity***Acute myocardial infarction, coronary artery disease***Aortic stenosis, bradycardia, cardiogenic shock, heart failure, hypotension, hypovolemia, surgery, ventricular dysfunction***Renal artery stenosis, renal impairment***Geriatric, hepatic disease***Hyperkalemia***ACE-inhibitor induced angioedema, angioedema***Black patients***Gastroesophageal reflux disease (GERD), hiatal hernia***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['341248'],ezetimibe,"***For use as adjunctive therapy to diet and exercise for the reduction of elevated total cholesterol, LDL-cholesterol, Apo-B, and non-HDL-cholesterol in patients with primary (heterozygous familial and non-familial) hyperlipidemia; reduction of elevated sitosterol and campesterol in patients with homozygous familial sitosterolemia; in combination with atorvastatin or simvastatin for reduction of elevated total cholesterol and LDL-cholesterol in patients with homozygous familial hypercholesterolemia:. <br />        NOTE: The effects of ezetimibe given either alone or in addition to an HMG-CoA reductase inhibitor or fenofibrate on cardiovascular morbidity and mortality have not been established.<br />     ***For monotherapy.***For use in combination with a HMG-CoA reductase inhibitor (statin"").***For use in combination with fenofibrate as adjunctive therapy to diet for the treatment of hypercholesterolemia in patients with mixed hyperlipoproteinemia. <br />          NOTE: Administration of ezetimibe with fenofibrate is effective in improving serum total cholesterol",LDL cholesterol,Apo-B,"and non-HDL cholesterol concentrations in patients with mixed hyperlipidemia compared to monotherapy with either treatment. The percent decrease in triglycerides and percent increase in HDL-cholesterol for ezetimibe coadministered with fenofibrate are comparable to values achieved by fenofibrate monotherapy.<br />       """,***General Information***Hepatic disease***Myopathy***Geriatric***Pregnancy***Breast-feeding***Children,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,varicella virus vaccine live,***For varicella (chickenpox) infection prophylaxis to provide active immunity against the varicella (chickenpox) virus in susceptible adults and children >= 12 months old.***For varicella prophylaxis for outbreak control� of local epidemics of wild-type varicella virus in susceptible persons following varicella exposure.***For herpes zoster (shingles) infection prophylaxis among patients who have had varicella exposure either naturally or through vaccination.,"***Gelatin hypersensitivity, neomycin hypersensitivity***Intramuscular administration, intravenous administration***Fever, respiratory infection, tuberculosis***Acquired immunodeficiency syndrome (AIDS), agammaglobulinemia, bone marrow suppression, chemotherapy, corticosteroid therapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, IgA deficiency, immunosuppression, leukemia, lymphoma, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,BCG live,"***For the treatment and prophylaxis of bladder cancer <em>in situ</em> (CIS) or the prophylaxis of primary or recurrent stage Ta or T1 papillary tumors following transurethral resection. <br />        NOTE: The optimal dose and treatment regimen has not been determined. Therefore, dosing may vary from protocol to protocol. If questions arise, clinicians should consult the appropriate references to verify the dose.<br />NOTE: There are no data to support the interchangeability of the BCG live products.<br />NOTE: Neither TICE BCG nor TheraCys are recommended for stage TaG1 papillary tumors unless the patient is judged to be at high risk of tumor recurrence","***Infection, trauma***Mycobacterial infection, tuberculosis***Aneurysm, fever, hematuria, prosthetic heart valves, urinary tract infection (UTI)***Acquired immunodeficiency syndrome (AIDS), bone marrow suppression, chemotherapy, corticosteroid therapy, diabetes mellitus, human immunodeficiency virus (HIV) infection, immunosuppression, leukemia, lymphoma, myasthenia gravis, radiation therapy, renal failure, severe combined immunodeficiency (SCID)***Accidental exposure***Latex hypersensitivity***Intravenous administration, subcutaneous administration***Irritable bladder***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['18343']['847728'],artemether/lumefantrine,"***For the treatment of malaria in patients with acute, uncomplicated infections due to <em>Plasmodium falciparum</em>.","***General Information***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Children, infants, neonates***Pregnancy***Breast-feeding***Geriatric***Hepatic disease, renal failure, renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2540']['5690', '1545986']",cilastatin/imipenem,"***For the treatment of intraabdominal infections (e.g., perforated appendicitis, peritonitis).***For the treatment of peritonitis in patients undergoing peritoneal dialysis�.***For the treatment of urinary tract infection (UTI).***For the treatment of lower respiratory tract infections (e.g., pneumonia, community-acquired pneumonia (CAP), nosocomial pneumonia).***For the treatment of skin and skin structure infections (e.g., abscesses, cellulitis, infected diabetic foot ulcer, wound infections).***For the treatment of bone and joint infections.***For the treatment of gynecologic infections.***For the treatment of sepsis.***For the treatment of endocarditis.***For the empiric treatment of febrile neutropenia�.***For the treatment of febrile neutropenia in adults.***For the treatment of febrile neutropenia in pediatric patients.***For the treatment of pulmonary exacerbations in patients with cystic fibrosis�.***For the treatment of systemic anthrax� infection.","***General Information***Carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Head trauma, neurological disease, seizure disorder, seizures***Dialysis, renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Amide local anesthetic hypersensitivity, AV block, shock***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,alendronate sodium/cholecalciferol,***For the treatment of osteoporosis in postmenopausal women and to increase bone mass in adult men with osteoporosis.,"***General Information***Lactase deficiency***Achalasia, dysphagia, esophageal stricture, esophagitis, gastritis, gastroesophageal reflux disease (GERD), GI disease, GI perforation, hiatal hernia, inability to stand or sit upright***Geriatric***Corticosteroid therapy***Hypocalcemia, vitamin D deficiency***Hyperphosphatemia***Hypercalcemia, hypervitaminosis D***Nephrolithiasis, renal failure, renal impairment***Children***Hypoparathyroidism***Pregnancy***Breast-feeding***Phosphonate hypersensitivity***Sunlight (UV) exposure***Anemia, chemotherapy, coagulopathy, dental disease, dental work, infection***Malabsorption syndrome***Leukemia, lymphoma, sarcoidosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1114326'],indacaterol,"***For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.***Formoterol***Formoterol; Mometasone","***General Information***Asthma, monotherapy treatment of asthma***Acute bronchospasm, asthma-related death, paradoxical bronchospasm, status asthmaticus***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, tachycardia***Hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***Diabetes mellitus, diabetic ketoacidosis***Milk protein hypersensitivity***MAOI therapy***Hepatic disease***Children, infants***Labor, obstetric delivery, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['196102'],basiliximab,"***For acute kidney transplant rejection prophylaxis when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids. <br />        NOTE: Basiliximab should only be administered once it has been determined that the patient will receive the graft and concomitant immunosuppression.<br />NOTE: Do not give the second basiliximab dose on day 4 after transplantation if graft loss or a severe hypersensitivity reaction occurs after the initial dose.<br />NOTE: Patients previously administered basiliximab should only be re-exposed to a subsequent course of therapy with extreme caution. The potential risks of another treatment course, specifically those associated with immunosuppression and/or the occurrence of anaphylaxis/anaphylactoid reactions, are not known***For acute liver transplant rejection prophylaxis� when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.","***Fungal infection, herpes infection, infection, lymphoma, neoplastic disease, requires a specialized care setting, requires an experienced clinician, varicella, viral infection***Pregnancy***Breast-feeding***Children***Human anti-murine antibody (HAMA), mannitol hypersensitivity, murine protein hypersensitivity***Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['73178', '848723']",iloperidone,***For the treatment of schizophrenia.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.***Formoterol***Formoterol; Mometasone,"***General Information***CNS depression, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Agranulocytosis, hematological disease, leukopenia, neutropenia***Suicidal ideation***Abrupt discontinuation***Tardive dyskinesia***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Cerebrovascular disease, hypovolemia, orthostatic hypotension***Seizure disorder, seizures***Hepatic disease, poor metabolizers***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Dysphagia***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, obesity***Priapism***Breast cancer, hyperprolactinemia, infertility***Neonates, pregnancy, pregnancy testing***Breast-feeding***Children, infants***Substance abuse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2540']['5690', '1545986']",cilastatin/imipenem,"***For the treatment of intraabdominal infections (e.g., perforated appendicitis, peritonitis).***For the treatment of peritonitis in patients undergoing peritoneal dialysis�.***For the treatment of urinary tract infection (UTI).***For the treatment of lower respiratory tract infections (e.g., pneumonia, community-acquired pneumonia (CAP), nosocomial pneumonia).***For the treatment of skin and skin structure infections (e.g., abscesses, cellulitis, infected diabetic foot ulcer, wound infections).***For the treatment of bone and joint infections.***For the treatment of gynecologic infections.***For the treatment of sepsis.***For the treatment of endocarditis.***For the empiric treatment of febrile neutropenia�.***For the treatment of febrile neutropenia in adults.***For the treatment of febrile neutropenia in pediatric patients.***For the treatment of pulmonary exacerbations in patients with cystic fibrosis�.***For the treatment of systemic anthrax� infection.","***General Information***Carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Head trauma, neurological disease, seizure disorder, seizures***Dialysis, renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Amide local anesthetic hypersensitivity, AV block, shock***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1012892'],fingolimod,***For the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. <br />        NOTE: Doses greater than 0.5 mg once daily are associated with a greater incidence of adverse reactions without additional benefit.<br />     ***Formoterol***Formoterol; Mometasone,"***General Information***Diabetes mellitus, uveitis***Asthma, chronic obstructive pulmonary disease (COPD), respiratory insufficiency***Hepatic disease***Alcoholism, angina, AV block, bradycardia, cardiac arrest, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, females, geriatric, heart failure, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, sick sinus syndrome, sleep apnea, stroke, syncope, thyroid disease***Acquired immunodeficiency syndrome (AIDS), chemotherapy, corticosteroid therapy, human immunodeficiency virus (HIV) infection, immunosuppression, leukemia, lymphoma***Hypertension***Children, infants, neonates***Pregnancy***Breast-feeding***Encephalopathy, progressive multifocal leukoencephalopathy***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"1mL diluent) (interferon alfa-2b, recombinant","***For the treatment of hairy-cell leukemia.***For the adjuvant treatment of malignant melanoma in patients who are disease free and at high risk for systemic recurrence within 56 days of surgery.***For the treatment of aggressive, follicular non-Hodgkin's lymphoma (NHL) in conjunction with an anthracycline-containing combination chemotherapy regimen.***For the treatment of condylomata acuminata (genital or venereal warts), due to the human papillomavirus (HPV) infection, involving the external surfaces of the genital and perianal areas.***For the treatment of AIDS-related Kaposi's sarcoma. <br />        NOTE: Interferon alfa-2b should not be used for the treatment of visceral AIDS-related Kaposi's sarcoma associated with rapidly progressive disease.<br />NOTE: Interferon alfa-2b has been designated an orphan drug by the FDA for this indication***For the treatment of chronic hepatitis B infection in patients with compensated liver disease. <br />        NOTE: Patients who have been serum HBsAg positive for at least 6 months and have evidence of HBV replication (serum HBeAg positive) with elevated serum ALT are candidates for treatment.<br />NOTE: Evaluate liver function tests, HBeAg, and HBsAg before treatment initiation, at therapy cessation, and at both 3 and 6 months after therapy cessation. In clinical studies, 15 of 38 responding adults lost HBeAg 1 to 6 months after interferon alfa-2b cessation. Further, 7 of 12 responding adults lost HBsAg 1 to 6 months after interferon alfa-2b cessation***For the treatment of hepatitis C infection in patients with compensated liver disease.***For the treatment of West Nile virus infection� (i.e., symptomatic flavivirus infections). <br />  NOTE: Other than supportive care, there is no established treatment for symptomatic flavivirus infections. The use of interferon alfa-2b for the treatment of West Nile virus is suggested by in vitro data only.<br />***For the treatment of St. Louis encephalitis� (i.e., symptomatic flavivirus infections).***For the first-line treatment of Philadelphia chromosome positive, chronic phase, chronic myelogenous leukemia (CML)�, in combination with cytarabine.***For the treatment of renal cell cancer� in combination with bevacizumab for previously untreated metastatic disease. <br />        NOTE: Bevacizumab is FDA-approved for this indication.<br />     ***For the maintenance treatment for multiple myeloma�.***For the treatment of hypereosinophilic syndrome�.***For the treatment of hemangioma� of infancy or pulmonary hemangiomatosis�.***For the treatment of adult T-cell leukemia/lymphoma� in combination with zidovudine in patients infected with human T-lymphotropic virus type I (HTLV-I).","***Acute bronchospasm, albumin hypersensitivity, E. coli protein hypersensitivity, urticaria***Alcoholism, depression, driving or operating machinery, psychiatric event, seizure disorder, substance abuse, suicidal ideation***Stroke, thrombophlebitis***Anemia, angina, cardiac arrhythmias, cardiac disease, chronic obstructive pulmonary disease (COPD), heart failure, myocardial infarction, neoplastic disease, pulmonary disease, use with ribavirin***Diabetes mellitus, diabetic ketoacidosis***Geriatric***Ascites, bleeding, hepatic disease, hepatic encephalopathy, hepatitis, immunosuppression, jaundice, organ transplant***Children, growth inhibition, infants, neonates***Colitis, pancreatitis, ulcerative colitis***Kaposi's sarcoma***Autoimmune disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus (SLE), thrombocytopenia***Infection, neutropenia***Bone marrow suppression, radiation therapy***Renal failure, renal impairment***Intramuscular injections***Dental disease, dental work***Hyperthyroidism, hypothyroidism, thyroid disease***Pregnancy***Breast-feeding***Coronary artery disease, diabetic retinopathy, hyperlipidemia, hypertension, non-arteritic anterior ischemic optic neuropathy, ocular disease, visual disturbance***Hepatitis B exacerbation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3008'],cyclosporine,"***For kidney transplant rejection prophylaxis.***For kidney transplant rejection prophylaxis in combination with sirolimus and corticosteroids in patients who are considered low to moderate immunologic risk.***For kidney transplant rejection prophylaxis in combination with sirolimus and corticosteroids in patients who are considered high immunologic risk. <br />          NOTE: Black transplant recipients, repeat renal transplant recipients who lost a previous allograft for immunologic reason, or patients with high-panel reactive antibodies (PRA; peak PRA level greater than 80%) are considered high immunologic risk.<br />NOTE: The protocol-specified target Cmin range for cyclosporine was 200 to 300 ng/mL up to week 2, 150 to 200 ng/mL for weeks 2 to 26, and 100 to 150 ng/mL for weeks 26 to 52, and for sirolimus was 10 to 15 ng/mL***For the treatment of severe, plaque-type psoriasis in immunocompetent patients who failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated.***For the treatment of severe rheumatoid arthritis (RA) in patients unresponsive to conventional therapy, alone or in combination with methotrexate when the disease has not adequately responded to methotrexate.***For early rheumatoid arthritis (RA).***For the treatment of xerophthalmia by increasing tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.***For the treatment of heart transplant rejection prophylaxis, liver transplant rejection prophylaxis, and the treatment of acute and chronic graft-versus-host disease (GVHD)� and graft-versus-host disease (GVHD) prophylaxis�. <br />        NOTE: In general, children may undergo the same dosing regimen as adults but often require and tolerate higher doses.<br />NOTE: In the prevention of organ transplant rejection, cyclosporine is intended to be used in combination with corticosteroid therapy***For the treatment of severe atopic dermatitis�.***For the treatment of severe aplastic anemia�.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP)�.***For the treatment of myasthenia gravis� in patients who are poorly controlled with cholinesterase inhibitor therapy.***For the treatment of psoriatic arthritis�.***For the treatment of lupus nephritis� in patients with systemic lupus erythematosus (SLE) unresponsive to conventional therapy, or for the treatment of children with idiopathic nephrotic syndrome�.","***General Information***Fungal infection, herpes infection, immunosuppression, infection, requires a specialized care setting, requires an experienced clinician, varicella, viral infection***Herpes simplex keratitis (dendritic keratitis), ocular infection***Lymphoma, new primary malignancy, radiation therapy, skin cancer, sunlight (UV) exposure***Nephrotoxicity, renal disease, renal failure, renal impairment***Hyperkalemia, hypertension***Electrolyte imbalance***Polyoxyethylated castor oil hypersensitivity***Children, infants***Pregnancy***Breast-feeding***Geriatric***Alcoholism, biliary tract disease, hepatic disease, jaundice***Gout, hyperuricemia***Encephalopathy, hypomagnesemia***Vaccination***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2019']['60307'],carbidopa/entacapone/levodopa,***For the treatment of idiopathic Parkinson's disease.,"***General Information***Abrupt discontinuation, hyperthermia, mental status changes, surgery***MAOI therapy***Depression, psychosis, seizure disorder, suicidal ideation***Geriatric***Closed-angle glaucoma***Cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, myocardial infarction, thromboembolic disease, ventricular arrhythmias***GI bleeding, peptic ulcer disease***Driving or operating machinery***Asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease, status asthmaticus***Renal disease, renal failure, renal impairment***Diabetes mellitus, endocrine disease***Biliary cirrhosis, biliary obstruction, biliary tract disease, hepatic disease, jaundice***Melanoma***Orthostatic hypotension, syncope***Pregnancy***Breast-feeding***Children, infants, neonates***Pheochromocytoma***Impulse control symptoms***Prostate cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Latrodectus Mactans) (black widow spider antivenin (equine),"***For the management of black widow spider bites (<em>Latrodectus mactans</em>) or other <em>Latrodectus</em> species bites. <br />        NOTE: Patients should be observed for serum sickness for an average of 8�12 days following administration of antivenin.<br />     ***For sensitivity testing prior to antivenin administration. <br />          NOTE: Black widow spider antivenin is prepared from horse serum; skin or conjunctival sensitivity testing should be performed in all patients prior to treatment. For all sensitivity testing, Epinephrine and other emergency measures should be available in case of a severe reaction.<br />       ***For the treatment of black widow spider bites with antivenin following sensitivity testing. <br />          NOTE: If possible, the patient should be hospitalized.<br />NOTE: Due to the risk of anaphylactic reactions, the use of antivenin may be deferred in otherwise healthy patients between the ages of 16 and 60 years.<br />NOTE: Symptomatic treatment (e.g., calcium gluconate, warm baths, morphine) in otherwise healthy individuals may be sufficient. Applying a tourniquet or attempting to remove the venom by incision and suction provides no clinical benefit***For desensitization prior to administration of antivenin should allergy history be positive or if sensitivity tests are mildly or questionably positive.","***Equine protein hypersensitivity, requires a specialized care setting***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['37776'],temozolomide,***For the treatment of glioblastoma multiforme.***For the treatment of refractory anaplastic astrocytoma in patients who have experienced disease progression on a chemotherapy regimen containing a nitrosourea or procarbazine.***For the treatment of malignant glioma�. <br />        NOTE: Temozolomide has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of high-grade glioma in pediatric patients�.***For the treatment of newly diagnosed diffuse intrinsic brainstem glioma in pediatric patients�.***For the first-line treatment of metastatic malignant melanoma�. <br />        NOTE: Temozolomide has been designated an orphan drug by the FDA for this indication.<br />     ,"***Aplastic anemia, bone marrow suppression, females, geriatric, neutropenia, thrombocytopenia***Dacarbazine (DTIC) hypersensitivity, gelatin hypersensitivity, mannitol hypersensitivity, serious rash, urticaria***Hepatic disease, hepatotoxicity***Renal disease, renal impairment***Infection***Children, infants, neonates***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,octreotide acetate,"***For the treatment of acromegaly. <br />        NOTE: Octreotide has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of symptoms associated with carcinoid tumors, specifically, diarrhea and cutaneous flushing. <br />  NOTE: Octreotide has been designated an orphan drug by the FDA for this indication.�<br /***For the treatment of symptoms associated with vasoactive intestinal peptide tumors (e.g., VIPoma) (i.e., to reduce plasma concentrations of vasoactive intestinal peptide). <br />        NOTE: Octreotide has been designated an orphan drug by the FDA for this indication.<br />     ***For the management of intractable diarrhea� or ileostomy-associated diarrhea�.***For the management of chemotherapy-induced diarrhea� in pediatric patients.***For the control of diarrhea secondary to AIDS-associated enteropathy�.***For the treatment of dumping syndrome�.***For the treatment of short bowel syndrome�.***For the treatment of enterocutaneous fistula�.***For reducing output from a pancreatic fistula�.***For adjunct therapy to endoscopic variceal ligation in the treatment of upper GI bleeding� or variceal bleeding� in patients with esophageal varices�.***For the treatment of hyperthyroidism� secondary to thyrotropinoma�.***For the treatment of hypoglycemia in patients with hyperinsulinism, including patients with benign or malignant insulinoma�.***For the treatment of neurogenic orthostatic hypotension�.***For the treatment of hepatorenal syndrome� in combination with midodrine and albumin.***For the treatment of acute cluster headache�.","***General Information***Biliary obstruction, biliary tract disease, cholangitis, cholelithiasis, gallbladder disease***Pancreatitis***Hepatic disease***Dialysis, renal failure***Diabetes mellitus, gastroparesis, hyperglycemia, hypoglycemia***Goiter, hypothyroidism***Fat malabsorption, vitamin B12 deficiency***Pregnancy***Breast-feeding***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, electrolyte imbalance, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Growth inhibition, infants, necrotizing enterocolitis, neonates, premature neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clindamycin phosphate/tretinoin,***For the treatment of acne vulgaris caused by <em>Propionibacterium acnes</em>.,"***General Information***Clindamycin hypersensitivity, retinoid hypersensitivity***Colitis, Crohn's disease, diarrhea, gastroenteritis, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Sunburn, sunlight (UV) exposure***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1111103'],fidaxomicin,***For the treatment of pseudomembranous colitis or <em>Clostridium difficile</em>-associated diarrhea (CDAD).,"***Children, infants, neonates***Pregnancy***Breast-feeding***Macrolide hypersensitivity***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['9601', '9603']",scopolamine,"***For the treatment of nausea/vomiting.***For nausea/vomiting prophylaxis due to motion sickness.***For use in aspiration prophylaxis prior to anesthesia and intubation; for treatment of bradycardia during surgery.***For obstetric amnesia induction.***For procedural sedation.***For use as a sedative or tranquilizer for sedation induction.***For the adjunct treatment of alcohol withdrawal (i.e., delirium tremens).***For the treatment of mania.***For cycloplegia induction or mydriasis induction during ophthalmologic examination.***For the treatment of iritis or uveitis.***For the treatment of sialorrhea�.","***General Information***Anticholinergic medications***Closed-angle glaucoma, contact lenses, open-angle glaucoma***Prostatic hypertrophy, urinary tract obstruction***Gastroesophageal reflux disease (GERD), GI obstruction, hiatal hernia, ileus, toxic megacolon, ulcerative colitis***Asthma, chronic obstructive pulmonary disease (COPD)***Autonomic neuropathy, myasthenia gravis***Cardiac arrhythmias, coronary artery disease, heart failure, hypertension, hyperthyroidism***Hepatic disease***Renal impairment***Pregnancy***Breast-feeding***Geriatric***Magnetic resonance imaging (MRI)***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,betamethasone dipropionate,"***For the treatment of acute graft-versus-host disease (GVHD).***For the treatment of nonsuppurative thyroiditis.***For the treatment of acute exacerbations of multiple sclerosis.***For the management of symptomatic sarcoidosis or for the treatment of hypercalcemia associated with cancer or sarcoidosis.***For the treatment of allergic disorders including anaphylaxis or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema (or for laryngeal edema prophylaxis), drug hypersensitivity reactions, serum sickness, severe perennial or seasonal allergic rhinitis, severe urticaria, or for the treatment of urticarial transfusion reactions. <br />        NOTE: Betamethasone should be administered IM or IV initially in the treatment of anaphylaxis or anaphylactoid reactions, angioedema, and acute noninfectious laryngeal edema or to prevent impending risk of laryngeal edema.<br />     ***For the treatment of urticarial transfusion reactions.***For the treatment of immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of hematologic disorders including secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), and congenital hypoplastic anemia.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of inflammatory bowel disease including Crohn's disease (regional gastroenteritis) and ulcerative colitis.***For the induction of diuresis or remission of proteinuria in the nephrotic syndrome.***For the treatment of nasal polyps.***For the treatment of severe cases of myasthenia gravis not controlled by antimyasthenic agents alone.***For adjunctive therapy in the treatment of rheumatic disorders e.g., acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), osteoarthritis, polychondritis�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of nonrheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the treatment of moderate-to-severe inflammation and pruritus due to corticosteroid-responsive dermatologic disorders such as alopecia areata, cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis, generalized exfoliative dermatitis, nummular dermatitis, seborrheic dermatitis, eczema, granuloma annulare, keloids, lichen planus, lichen simplex chronicus, lichen striatus, subacute cutaneous and discoid lupus erythematosus, pretibial myxedema, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, psoriasis, <em>Rhus dermatitis</em> (due to poison ivy, poison oak, or poison sumac), sarcoidosis, Stevens-Johnson syndrome, sunburn, or urticaria. <br />        NOTE: Systemic corticosteroids may be necessary for some conditions based on the type and severity of the disorder (e.g., Stevens-Johnson syndrome) or inadequate response to topical therapy; intralesional injections may also be appropriate for select conditions.<br />     ***For the treatment of plaque psoriasis.***For the treatment of seborrheic dermatitis.***For hyaline membrane disease prophylaxis�, for the purpose of fetal lung maturation to prophylax against anticipated neonatal respiratory distress syndrome (RDS)� in premature infants.***For palliative management of leukemia and lymphoma in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), or for the treatment of multiple myeloma�.***For maintenance therapy in selected cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis�, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, conjunctivitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For the treatment of respiratory inflammatory conditions including airway-obstructing hemangioma� in infants, aspiration pneumonitis, berylliosis, bronchial asthma, chronic obstructive pulmonary disease (COPD), laryngotracheobronchitis (croup), Loeffler's syndrome, or non-cardiogenic pulmonary edema�, or for bronchospasm prophylaxis. <br />        NOTE: Betamethasone should be administered parenterally initially in the treatment of severe manifestations of these diseases, particularly where airway obstruction is present.<br />     ","***Abrupt discontinuation, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, growth inhibition, increased intracranial pressure, infants, neonates***Immunosuppression***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Edema, heart failure, hypertension***Osteoporosis***Diabetes mellitus***Crohn's disease, diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hyperthyroidism, hypothyroidism, psychosis, renal disease, seizure disorder, thyroid disease***Myasthenia gravis***Idiopathic thrombocytopenic purpura (ITP), thromboembolic disease***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Epidural administration, intravenous administration***Corticosteroid hypersensitivity***Head trauma***Skin atrophy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['60307'],entacapone,***For adjuvant therapy to levodopa/carbidopa for the treatment of end-of-dose 'wearing off' in patients with idiopathic Parkinson's disease.,"***General Information***Biliary obstruction, hepatic disease, jaundice***Abrupt discontinuation***Hypotension, syncope***Pregnancy***Driving or operating machinery***Breast-feeding***Impulse control symptoms***Children***Psychosis***Melanoma***Surgery***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant",***For human papillomavirus (HPV) infection prophylaxis.***For HPV infection prophylaxis in adult females outside of FDA-approved populations�.,"***Yeast hypersensitivity***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Syncope***Agammaglobulinemia, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Fever***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydromorphone hydrochloride,"***For the relief of moderate pain or severe pain.***For the relief of acute and chronic moderate pain or severe pain.***For the management of chronic severe pain in opioid-tolerant patients who require daily, around-the-clock, long-term opioid treatment. <br />          NOTE: Extended-release hydromorphone should be reserved for patients in whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would otherwise provide inadequate pain management. Discontinue all other around-the-clock opioid drugs upon initiation of hydromorphone extended-release tablets.<br />NOTE: Opioid-tolerant patients are defined as those taking, for a minimum of 1 week, &gt;= 60 mg oral morphine daily, &gt;= 30 mg oral oxycodone daily, &gt;= 8 mg oral hydromorphone daily, &gt;= 25 mg oral oxymorphone daily, &gt;= 25 mcg transdermal fentanyl per hour, or an equivalent dose of another opioid","***Acute abdomen, constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, surgery, ulcerative colitis***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, emphysema, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Opioid-naive patients***Abrupt discontinuation***Coma, head trauma, increased intracranial pressure, intracranial mass, seizure disorder, seizures***Angina, cardiac arrhythmias, cardiac disease, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal impairment, urethral stricture, urinary retention***Geriatric***Children, infants, neonates***Biliary tract disease, gallbladder disease, pancreatitis***Neonatal opioid withdrawal syndrome, pregnancy***Labor, obstetric delivery***Breast-feeding***Driving or operating machinery***Epidural administration***Opiate agonist hypersensitivity***Lactase deficiency, latex hypersensitivity, paraben hypersensitivity, sulfite hypersensitivity***Adrenal insufficiency, hypothyroidism, myxedema***Intravenous administration***Accidental exposure, ethanol ingestion, ethanol intoxication, potential for overdose or poisoning, requires an experienced clinician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['258494'],exemestane,"***For the treatment of breast cancer in postmenopausal women.***For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. <br />  NOTE: Exemestane is not indicated for the treatment of breast cancer in premenopausal women.<br /***For the adjuvant treatment of estrogen receptor-positive early breast cancer in postmenopausal women who have already received 2 to 3 years of tamoxifen therapy, and who are switched to exemestane for completion of a total of 5 consecutive years of adjuvant hormonal therapy. <br />  NOTE: Exemestane is not indicated for the treatment of breast cancer in premenopausal women.<br /***For the treatment of estrogen receptor positive, HER2 negative, locally advanced or metastatic breast cancer in postmenopausal women refractory to letrozole or anastrozole, in combination with everolimus�. <br />  NOTE: Everolimus (Afinitor) is FDA-approved for use in combination with exemestane for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women who have failed treatment with letrozole or anastrozole.<br /","***Osteoporosis***Vitamin D deficiency***Pregnancy***Contraception requirements, infertility, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['325642'],ertapenem,"***For the treatment of community-acquired pneumonia including cases with concurrent bacteremia.***For the treatment of complicated intraabdominal infections.***For the treatment of complicated skin and skin structure infections, including diabetic foot infections (diabetic foot ulcer).***For the treatment of complicated urinary tract infection (UTI) (pyelonephritis), including cases with concurrent bacteremia.***For the treatment of acute pelvic infections, including postpartum endomyometritis, septic abortion, and post surgical gynecologic infections.***For surgical infection prophylaxis for elective colorectal surgery.","***Viral infection***Amide local anesthetic hypersensitivity***Carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Dialysis, renal failure, renal impairment***Brain tumor, myoclonic seizures, seizures***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Infants***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['475968'],liraglutide,"***For the treatment of type 2 diabetes mellitus and to reduce the risk of cardiovascular events (e.g., non-fatal myocardial infarction or non-fatal stroke), including reduction of cardiovascular mortality, in type 2 DM patients who also have established cardiovascular disease.***For the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity.","***General Information***History of angioedema, serious hypersensitivity reactions or anaphylaxis***Medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), thyroid cancer, thyroid C-cell tumors***Diabetic ketoacidosis, type 1 diabetes mellitus***Burns, diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Gastroparesis***Hypoglycemia***Renal impairment***Alcoholism, cholelithiasis, gallbladder disease, pancreatitis***Hepatic disease***Pregnancy***Breast-feeding***Children, infants***Depression, suicidal ideation***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4917'],nitroglycerin,"***For the treatment of angina.***For acute angina pectoris or for acute angina pectoris prophylaxis (i.e., situations likely to provoke an anginal attack).***For chronic angina pectoris. <br />          NOTE: A nitrate-free interval is necessary to avoid the development of drug tolerance; although a minimum interval has not been clearly established, 10 to 12 hours/day has been sufficient with other nitroglycerin formulations.<br />       ***For the treatment of pain associated with anal fissures.***For the treatment of pain associated with anal fissures� and hemorrhoids�.***For controlled hypotension induction during anesthesia; for IV treatment of acute congestive heart failure or pulmonary edema, acute angina pectoris or unstable angina, acute myocardial infarction, or acute pulmonary hypertension�; or for treatment of severe hypertension, postoperative hypertension, perioperative hypertension (e.g., during cardiac surgery), or hypertensive emergency.***For use as a uterine relaxant to aid in extraction of a retained placenta�.***For the treatment of extravasation� of vasoactive medications.","***General Information***Nitrate hypersensitivity***Head trauma, increased intracranial pressure, intracranial bleeding***Anemia***Aortic stenosis, cardiac tamponade, cardiomyopathy, constrictive pericarditis, mitral stenosis, shock***Acute myocardial infarction, dehydration, hypotension, hypovolemia, orthostatic hypotension***Geriatric***Hepatic disease***Abrupt discontinuation***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Pregnancy***Breast-feeding***GI disease***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],estradiol,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For systemic treatment of the vasomotor symptoms (hot flashes) and genitourinary symptoms of menopause.***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For estrogen replacement for premenopausal women with primary ovarian failure or female hypogonadism.***For the palliative treatment of advanced inoperable prostate cancer.***For the palliative treatment of breast cancer that is inoperable and progressive in selected men and postmenopausal women.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates***Intravenous administration***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"hepatitis A vaccine, inactivated",***For hepatitis A prophylaxis.***For primary immunization (Havrix or Vaqta).***For post-exposure hepatitis A prophylaxis�.***For patients traveling to regions that have high or intermediate hepatitis A endemicity�.,"***General Information***Latex hypersensitivity, neomycin hypersensitivity***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Fever, infection***Agammaglobulinemia, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Pregnancy***Breast-feeding***Intravenous administration, subcutaneous administration***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/etonogestrel,"***For routine contraception under the following conditions.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to hormonal contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to hormonal contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***General Information***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Contraceptive devices***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, obesity, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Geriatric***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema***Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['591622'],varenicline,***For use as an adjunct to psychosocial interventions for tobacco cessation (smoking cessation).,"***Angioedema, serious rash***Behavioral changes, bipolar disorder, depression, psychiatric event, schizophrenia, suicidal ideation***Driving or operating machinery, ethanol ingestion, ethanol intoxication***Seizures***Cardiac disease, myocardial infarction or stroke***Dialysis, renal failure, renal impairment***Geriatric***Pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['358258'],bortezomib,"***For the treatment of multiple myeloma. <br />        NOTE: The FDA has designated bortezomib as an orphan drug for this indication.<br />     ***For previously untreated multiple myeloma, in combination with melphalan and prednisone.***For the treatment of relapsed multiple myeloma.***For the treatment of relapsed or refractory multiple myeloma in patients who have received at least 1 prior therapy, in combination with doxorubicin liposomal�. <br />          NOTE: Doxorubicin Liposomal is FDA approved in combination with bortezomib for the treatment of relapsed or refractory multiple myeloma in patients who have received at least 1 prior therapy besides bortezomib.<br />       ***For newly diagnosed multiple myeloma as induction therapy prior to autologous stem-cell transplantation, in combination with dexamethasone�.***For newly diagnosed multiple myeloma as induction therapy prior to autologous stem-cell transplantation, in combination with thalidomide and dexamethasone�.***For the treatment of relapsed multiple myeloma in patients who have previously responded to treatment with bortezomib (either alone or in combination) and have relapsed at least 6 months after completing prior bortezomib treatment.***For the treatment of relapsed or refractory multiple myeloma, in combination with vorinostat�.***For the treatment of multiple myeloma in patients who have received at least 2 prior therapies (including bortezomib and an immunomodulatory agent), in combination with panobinostat and dexamethasone�. <br />          NOTE: Panobinostat is FDA approved in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in patients who have received at least 2 prior therapies (including bortezomib and an immunomodulatory agent).<br />       ***For the treatment of multiple myeloma in patients who received at least 1 prior therapy, in combination with daratumumab and dexamethasone�. <br />          NOTE: Daratumumab is FDA approved in combination with bortezomib and dexamethasone for this indication.<br />       ***For the treatment of newly diagnosed multiple myeloma, in combination with lenalidomide and dexamethasone�.***For the treatment of previously untreated multiple myeloma in patients ineligible for autologous stem-cell transplantation, in combination with daratumumab, melphalan, and prednisone�.***For the treatment of mantle cell lymphoma (MCL). <br />  NOTE: The FDA has designated bortezomib as an orphan drug for this indication.<br /***For the treatment of relapsed MCL in patients who have received at least 1 prior therapy.***For the treatment of previously untreated MCL, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (Velcade only). <br />  NOTE: The subcutaneous route may be the preferred route of administration in patients with pre-existing peripheral neuropathy or who have a high risk of developing peripheral neuropathy.<br /***For the treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma (NHL)�. <br />        NOTE: The FDA has designated bortezomib as an orphan drug for this indication.<br />     ***For the treatment of Waldenstrom macroglobulinemia�.***For the treatment of newly diagnosed Waldenstrom macroglobulinemia, in combination with dexamethasone and rituximab�.***Formoterol; Mometasone","***Mannitol hypersensitivity***Intrathecal administration***Peripheral neuropathy***Dehydration, hypotension, orthostatic hypotension, syncope***Cardiac disease, heart failure, pulmonary disease***Tumor lysis syndrome (TLS)***Anemia, bleeding, GI bleeding, herpes infection, intracranial bleeding, neutropenia, thrombocytopenia***Hepatic disease, hepatitis***Diabetes mellitus***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,zoledronic acid,"***For the treatment of hypercalcemia of malignancy (i.e., albumin-corrected serum calcium 12 mg/dL or higher).***For the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. <br />  NOTE: When used for bone metastases of prostate cancer, the disease should have progressed after treatment with at least one hormonal therapy.<br />NOTE: To avoid hypocalcemia and maintain proper status, patients should also receive an oral calcium supplement of 500 mg and a multiple vitamin containing 400 International Units of Vitamin D every day during treatment***For the treatment of active Paget's disease. <br />        NOTE: To reduce the risk of hypocalcemia, all patients should receive an intake of 1500 mg elemental calcium daily in divided doses (750 mg two times a day, or 500 mg three times a day) and 800 International Units vitamin D daily, particularly in the 2 weeks following drug administration.<br />     ***For the treatment of osteoporosis.***For secondary fracture prophylaxis in high-risk patients (i.e., recent low-trauma hip fracture).***For the treatment of glucocorticoid-induced osteoporosis in men and women taking systemic glucocorticoids (i.e., oral prednisone 7.5 mg/day or more, or equivalent) and expected to continue glucocorticoid therapy for 12 months or longer.***For osteoporosis prophylaxis.***For the prevention of glucocorticoid-induced osteoporosis in men and women taking systemic glucocorticoids (i.e., oral prednisone 7.5 mg/day or more, or equivalent) and expected to continue glucocorticoid therapy for 12 months or longer.***For the adjuvant treatment of early breast cancer� in women with postmenopausal reproductive hormone levels.","***General Information***Acute bronchospasm, asthma, phosphonate hypersensitivity***Dehydration, diarrhea, fever, hypovolemia, vomiting***Diabetes mellitus, hypertension, multiple myeloma, renal disease, renal failure, renal impairment***Cardiac arrhythmias, electrolyte imbalance, hypocalcemia, hypomagnesemia, hypophosphatemia, seizures***Pregnancy***Breast-feeding***Children, infants, neonates***Anemia, chemotherapy, coagulopathy, corticosteroid therapy, dental disease, dental work, infection***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['15996'],mirtazapine,"***For the treatment of major depression, including the maintenance of response in patients with a major depressive disorder.***For the treatment of resting tremor�, benign familial tremor� (essential tremor�) or for the treatment of levodopa-induced dyskinesias�.***For the treatment of pruritus�.***For the treatment of intractable pruritus�.***For the treatment of nocturnal itch associated with chronic pruritus�.***Formoterol***Formoterol; Mometasone","***General Information***Abrupt discontinuation***Children, suicidal ideation***MAOI therapy***Bipolar disorder, mania***Agranulocytosis, bone marrow suppression, neutropenia***Acute myocardial infarction, angina, cardiac disease, cerebrovascular disease, hypovolemia, myocardial infarction, orthostatic hypotension, QT prolongation, stroke***Dehydration, hyponatremia***Seizure disorder***Renal failure, renal impairment***Hepatic disease, jaundice***Diabetes mellitus, hypercholesterolemia, hypertriglyceridemia***Prostatic hypertrophy***Closed-angle glaucoma, increased intraocular pressure***Akathisia***Driving or operating machinery, ethanol ingestion***Neonates, pregnancy***Breast-feeding***Geriatric***Lactase deficiency, phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,tolterodine tartrate,"***For the treatment of an overactive bladder (OAB) with symptoms of urinary frequency, urinary urgency, or urge-related urinary incontinence.","***General Information***Prostatic hypertrophy, renal disease, renal failure, renal impairment, urinary retention, urinary tract obstruction***Closed-angle glaucoma, contact lenses***Anticholinergic medications, gastroesophageal reflux disease (GERD), gastroparesis, GI obstruction, ileus, pyloric stenosis, toxic megacolon, ulcerative colitis***Hepatic disease***Driving or operating machinery***Autonomic neuropathy, myasthenia gravis***Pregnancy***Breast-feeding***Children, infants, neonates***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mometasone furoate,"***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses including alopecia areata, atopic dermatitis, contact dermatitis, dermatitis, discoid lupus erythematosus, eczema, exfoliative dermatitis, granuloma annulare, keloids, lichen planus, lichen simplex, lichen striatus, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pruritus, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, xerosis, and severe <em>Rhus dermatitis</em> due to plants like poison ivy. <br />  NOTE: Occlusive dressings may be required for chronic or severe cases of lichen simplex chronicus, psoriasis, eczema, atopic dermatitis, or chronic hand eczema. More potent topical corticosteroids and/or occlusive dressings may be necessary for the treatment of discoid lupus erythematosus, lichen planus, granuloma annulare, psoriatic plaques, and psoriasis of the palms, soles, elbows, or knees.<br /***For maintenance treatment of asthma.***For the management of nasal symptoms associated with seasonal or perennial allergic rhinitis (e.g., nasal congestion).***For seasonal allergic rhinitis prophylaxis.***For the treatment of nasal polyps.***For sinus patency maintenance after ethmoid sinus surgery in patients with chronic sinusitis.***For exercise-induced bronchospasm prophylaxis�.","***Corticosteroid hypersensitivity***Milk protein hypersensitivity***Acute bronchospasm, paradoxical bronchospasm, status asthmaticus***Skin atrophy***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion, surgery***Children, growth inhibition, increased intracranial pressure, infants, neonates***Diabetes mellitus, hyperglycemia, peripheral vascular disease***Nasal septal perforation, nasal surgery, nasal trauma***Cataracts, glaucoma, increased intraocular pressure, ocular exposure, visual disturbance***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, tuberculosis, varicella, viral infection***Pregnancy***Breast-feeding***Sunlight (UV) exposure***Hepatic disease***Osteoporosis***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8588'],losartan potassium,"***For the treatment of hypertension, either alone or in combination with other antihypertensive agents.***For stroke prophylaxis in hypertensive patients with left ventricular hypertrophy (LVH). <br />        NOTE: There is evidence that this benefit does not apply to Black patients.<br />     ***For the treatment of proteinuria or diabetic nephropathy.***For the treatment of chronic heart failure�.","***General Information***Hepatic disease***Heart failure, renal artery stenosis***Hypotension, hypovolemia***Hyperkalemia***ACE-inhibitor induced angioedema, angioedema***Black patients***Pregnancy***Breast-feeding***Children***Surgery***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,haemophilus b conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine,"***For combined Haemophilus influenzae type b prophylaxis and hepatitis B prophylaxis. <br />        NOTE: Infants born of hepatitis B surface antigen-positive (HBsAg-positive) mothers should NOT receive Comvax at birth but instead should be vaccinated with a passive-active regimen that includes the administration of hepatitis B immune globulin (HBIG) and hepatitis B vaccine (recombinant) at birth given according to a particular schedule. Also, infants born to mothers of unknown HBsAg status should receive hepatitis B vaccine (recombinant) at birth given according to a particular schedule. The subsequent administration of Comvax for completion of the hepatitis B vaccination series in infants who are born to HBsAg positive mothers and receive HBIG, or to complete vaccination in infants born to mothers of unknown status, has not been studied.<br />     ","***Latex hypersensitivity, yeast hypersensitivity***Fever, infection***Agammaglobulinemia, corticosteroid therapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Intravenous administration, subcutaneous administration***Children, infants, neonates***Geriatric***Pregnancy***Breast-feeding***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,rizatriptan benzoate,***For the treatment of acute migraine attacks with or without aura. <br />  NOTE: Rizatriptan is not approved for prophylactic migraine therapy or for the treatment of hemiplegic or basilar migraines or cluster headaches.<br /***For acute treatment of migraine with or without aura using rizatriptan as a single agent.***For treatment of migraine in patients who are receiving concomitant therapy with propranolol.,"***General Information***Colitis, peripheral vascular disease, Raynaud's phenomenon***Acute myocardial infarction, angina, arteriosclerosis, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, hypercholesterolemia, obesity, tobacco smoking, vasospastic angina, Wolff-Parkinson-White syndrome***Hypertension***Cerebrovascular disease, intracranial bleeding, stroke***Basilar/hemiplegic migraine***Pregnancy***Breast-feeding***Hepatic disease***Dialysis, renal disease, renal failure, renal impairment***Children, infants, neonates***Phenylketonuria***Driving or operating machinery***Geriatric***MAOI therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,calcium citrate/docosahexaenoic acid (DHA)/docusate sodium/ferrous fumarate/iron carbonyl/vitamin B6 (pyridoxine hydrochloride)/vitamin B9 (folic acid)/vitamin D3 (cholecalciferol)/vitamin E (dl-alpha tocopheryl acetate),"***For nutritional supplementation of females of child-bearing potential during pre-conception, pregnancy or lactation.***Formoterol; Mometasone","***General Information***Accidental exposure, children, infants***Anticoagulant therapy, bleeding***Breast-feeding, pregnancy***Pernicious anemia, vitamin B12 deficiency megaloblastic anemia***Hemochromatosis, hemosiderosis, hepatic disease, sideroblastic anemia, thalassemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,insulin aspart protamine (rDNA origin)/insulin aspart (rDNA origin),"***For the treatment of type 1 diabetes mellitus or for type 2 diabetes mellitus inadequately managed by diet, exercise, and oral hypoglycemics.***Formoterol; Mometasone","***General Information***Diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Hepatic disease, renal failure, renal impairment***Coma, continuous subcutaneous insulin infusion (CSII) administration, diabetic ketoacidosis, hyperosmolar hyperglycemic state (HHS), intravenous administration***Hypoglycemia***Hypokalemia***Cresol hypersensitivity***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Children, infants***Tobacco smoking***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['275635'],desloratadine,"***For the relief of nasal and non-nasal symptoms of seasonal or perennial allergic rhinitis.***For the treatment of symptoms of chronic idiopathic urticaria (e.g., relief of pruritus, reduction in the size and number of hives).","***General Information***Asthma***Hepatic disease, renal failure, renal impairment***Infants, neonates***Pregnancy***Breast-feeding***Driving or operating machinery***Phenylketonuria***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dorzolamide hydrochloride,***For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.,"***General Information***Carbonic anhydrase inhibitor hypersensitivity, sulfonamide hypersensitivity***Closed-angle glaucoma***Contact lenses***Corneal abrasion, ocular infection***Hepatic disease***Geriatric, renal impairment***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,metformin hydrochloride/sitagliptin,"***For the treatment of type 2 diabetes mellitus uncontrolled by diet and exercise and when treatment with one antidiabetic agent alone does not result in adequate control. <br />        NOTE: During concurrent use of metformin; sitagliptin and insulin or sulfonylureas, it may be necessary to lower the dose of insulin or the sulfonylurea to minimize the risk of hypoglycemia.<br />     ***For use when switching from metformin plus sitagliptin as separate tablets to the single, combination tablet.***For use when initial treatment with metformin alone does not result in adequate glycemic control.***For use when initial treatment with sitagliptin alone does not result in adequate glycemic control.***Formoterol; Mometasone","***Exfoliative dermatitis, history of angioedema, serious rash***Diabetic ketoacidosis, type 1 diabetes mellitus***Acidemia, hypoxemia, lactic acidosis, metabolic acidosis***Pancreatitis***Adrenal insufficiency, diarrhea, fever, gastroparesis, GI obstruction, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypothyroidism, ileus, malnutrition, pituitary insufficiency, vomiting***Renal disease, renal failure, renal impairment***Acute heart failure, acute myocardial infarction, cardiac disease, cardiogenic shock, heart failure***Geriatric***Alcoholism, ethanol intoxication, hepatic disease***Radiographic contrast administration***Burns, dehydration, infection, sepsis, surgery, trauma***Anemia, pernicious anemia, vitamin B12 deficiency***Arthralgia***Polycystic ovary syndrome, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,naftifine hydrochloride,"***For the treatment of tinea cruris.***For the treatment of interdigital tinea pedis.***For the treatment of tinea corporis.***For the treatment of distal subungual onychomycosis� or white superficial onychomycosis� (tinea unguium) due to susceptible dermatophytes (i.e., <em>Trichophyton rubrum</em>) or <em>Candida</em> species in patients unable to tolerate oral antifungal therapy.","***Accidental exposure, ocular exposure***Occlusive dressing***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"rotavirus vaccine, live, oral, pentavalent","***For the prophylaxis of gastroenteritis caused by rotavirus infection. <br />  NOTE: On May 14, 2010, the FDA stated that Rotarix use may be resumed and that RotaTeq use may be continued. On March 22, 2010, the FDA recommended temporary suspension of Rotarix administration to patients, as DNA from porcine circovirus type 1 (PCV1) is present in the Rotarix formulation. The recommended action was a precautionary measure. The PCV1 DNA is present in the cell bank and seed from which the Rotarix vaccine is derived, which means that the DNA from PCV1 has been present since the early stages of the vaccine�s development including during clinical studies. In addition to PCV1 in Rotarix, RotaTeq has DNA fragments from both PCV1 and PCV2. However, the FDA has no evidence that PCV1 or PCV2 pose a safety risk in humans, and neither is known to cause infection or illness in humans. As available evidence supports the safety of Rotarix and RotaTeq, no medical follow-up is needed for patients who have been vaccinated with either vaccine.<br />NOTE: The safety and efficacy of administering Rotarix for the first dose and another rotavirus vaccine for the second dose or vice versa have not been established.***For infection caused by G1, G2, G3, and G4. <br />          NOTE: Infants who have had rotavirus gastroenteritis before receiving the full course of rotavirus vaccinations should still initiate or complete the 3-dose schedule because the initial infection frequently provides only partial immunity. No data are available on post-exposure prophylaxis with rotavirus vaccine. <br />       ***For infection caused by G1, G3, G4, and G9. <br />          NOTE: Safety and efficacy when administered after exposure to rotavirus have not been evaluated.<br />       ","***Latex hypersensitivity***Parenteral administration***Infants, neonates***Diarrhea, fever, gastroenteritis, respiratory infection, vomiting***GI disease, intussusception***Acquired immunodeficiency syndrome (AIDS), agammaglobulinemia, bone marrow suppression, chemotherapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, leukemia, lymphoma, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mesalamine,***For the treatment of active ulcerative proctitis.***For the treatment of ulcerative colitis or Crohn's disease�.***For induction of remission of mild to moderate active ulcerative colitis or Crohn's disease�.***For maintenance of remission of ulcerative colitis.,"***General Information***5-aminosalicylates hypersensitivity, salicylate hypersensitivity***Renal disease, renal failure, renal impairment***Hepatitis, myocarditis, pericarditis, pneumonitis***Geriatric***Pregnancy***Breast-feeding***GI obstruction, pyloric stenosis***Sulfite hypersensitivity***Hepatic disease***Children, infants, neonates***Phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2019']['6375'],carbidopa/levodopa,"***For the treatment of idiopathic Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.***For the treatment of motor fluctuations in patients with advanced Parkinson's disease.***For the treatment of restless legs syndrome (RLS)�.***For the treatment of amblyopia�.","***General Information***Abrupt discontinuation, hyperthermia, mental status changes, surgery***Cardiac arrhythmias, cardiac disease, myocardial infarction, orthostatic hypotension***Asthma, emphysema, pulmonary disease***Hepatic disease, renal disease***GI obstruction, GI perforation, intussusception, peptic ulcer disease***Depression, psychosis, seizure disorder, suicidal ideation***MAOI therapy***Diabetes mellitus***Closed-angle glaucoma***Melanoma***Pregnancy***Breast-feeding***Children, infants, neonates***Pheochromocytoma***Impulse control symptoms***Driving or operating machinery***Peripheral neuropathy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['325646'],aliskiren,***For the treatment of hypertension either as monotherapy or in combination with other antihypertensive agents.,"***ACE-inhibitor induced angioedema, angioedema, Black patients, hereditary angioedema, surgery***Myocardial infarction***Aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease, hyponatremia, hypotension, hypovolemia***Heart failure, renal artery stenosis, renal failure, renal impairment***Hyperkalemia, hypokalemia***Biliary cirrhosis, hepatic disease***Diabetes mellitus***Children, infants, neonates***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hepatitis B vaccine (recombinant),***For hepatitis B prophylaxis.***For prophylaxis of hepatitis B using Recombivax HB.***For prophylaxis of hepatitis B using Engerix-B.***For booster vaccination using Engerix-B.***For prophylaxis of hepatitis B using Heplisav-B.,"***General Information***Yeast hypersensitivity***Neonates, premature neonates***Anticoagulant therapy, coagulopathy, hemophilia, intravenous administration, subcutaneous administration, thrombocytopenia, vitamin K deficiency***Cardiac disease, fever, infection***Chemotherapy, human immunodeficiency virus (HIV) infection, immunosuppression***Dialysis, renal disease, renal failure***Pregnancy***Breast-feeding***Latex hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,moxifloxacin hydrochloride,"***For the treatment of acute bacterial exacerbation of chronic bronchitis.***For the treatment of acute bacterial sinusitis.***For the treatment of mild to moderate community-acquired pneumonia (CAP).***For the treatment of skin and skin structure infections.***For uncomplicated skin and skin structure infections due to <em>Staphylococcus aureus</em> (MSSA) and <em>Streptococcus pyogenes</em>.***For complicated skin and skin structure infections due to <em>Enterobacter cloacae</em>, <em>Escherichia coli</em>, <em>Klebsiella pneumoniae</em>, or <em>Staphylococcus aureus</em> (MSSA).***For the treatment of complicated intraabdominal infections including polymicrobial infections such as abscesses.***For the treatment of bacterial conjunctivitis (including chlamydial conjunctivitis) due to susceptible organisms.***For the treatment of plague, including pneumonic and septicemic plague, and plague prophylaxis due to susceptible isolates.***For the treatment of tuberculosis infection� caused by <em>Mycobacterium tuberculosis�</em> in combination with other antituberculosis agents as a second line agent. <br />        NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., &gt;= 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, IDSA, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. Directly observed therapy (DOT) should be used for all regimens administered 1, 2, 3, or 5 times per week. The initial treatment regimen should include four drugs unless the likelihood of INH or rifampin resistance is low (i.e., &lt; 4%), in which case an initial regimen of INH, rifampin, and pyrazinamide may be considered. HIV-infected patients should always receive induction therapy with four drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate.   For multi-drug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, the CDC recommends treatment for 18�24 months after culture conversion in patients with bacteriologic confirmation and for &gt;= 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months in MDR-TB.<br />     ***For the treatment of Mycobacterium avium complex infection� (MAC) in HIV-infected patients.***For the treatment of anthrax�.***For the treatment of systemic anthrax infection.***For the treatment of cutaneous anthrax infection.***For the treatment of bacterial gastroenteritis� and infectious diarrhea�.***For salmonellosis� in HIV-infected patients.***For shigellosis� in HIV-infected patients.***For the treatment of campylobacteriosis� in HIV-infected patients.***For surgical infection prophylaxis�.***For ophthalmic surgical prophylaxis�.***For the treatment of recurrent or persistent non-gonococcal urethritis (NGU)�.***For the treatment of pelvic inflammatory disease (PID)�.***For anthrax prophylaxis� after exposure to <em>Bacillus anthracis</em> (postexposure prophylaxis, PEP).***Formoterol***Formoterol; Mometasone","***Viral infection***Quinolone hypersensitivity***Corticosteroid therapy, organ transplant, tendinitis, tendinopathy, tendon pain, tendon rupture***Alcoholism, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Cerebrovascular disease, neurotoxicity, peripheral neuropathy, seizure disorder***Myasthenia gravis***Hepatic disease, hepatitis, hepatotoxicity, jaundice***Diabetes mellitus***Sunlight (UV) exposure***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Geriatric***Pregnancy***Breast-feeding***Sexually transmitted disease***Children, infants, neonates***Sodium restriction***Contact lenses***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dexmethylphenidate hydrochloride,***For the treatment of attention-deficit hyperactivity disorder (ADHD).,"***General Information***Anxiety, bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Tics, Tourette's syndrome***Glaucoma, visual disturbance***Abrupt discontinuation, alcoholism, anorexia nervosa, obesity treatment, substance abuse***Hypertension, tachycardia, ventricular arrhythmias***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular dysfunction***Cerebrovascular disease, stroke***Children, growth inhibition, infants***Hyperthyroidism, thyrotoxicosis***Seizure disorder, seizures***Pregnancy***Breast-feeding***Driving or operating machinery***Surgery***Radiographic contrast administration***Hepatic disease***Geriatric***MAOI therapy***Peripheral vascular disease, Raynaud's phenomenon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,haemophilus b conjugate vaccine (meningococcal protein conjugate),***For Haemophilus influenzae type b prophylaxis.,"***Intravenous administration***Latex hypersensitivity***Infants, neonates, premature neonates***Pregnancy***Breast-feeding***Agammaglobulinemia, corticosteroid therapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, leukemia, lymphoma, neoplastic disease, severe combined immunodeficiency (SCID)***Guillain-Barre syndrome***Fever, infection***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Native American patients",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['275635']['8896'],desloratadine/pseudoephedrine sulfate,***For the treatment of seasonal allergic rhinitis and accompanying nasal congestion.***Formoterol***Formoterol; Mometasone,"***General Information***Closed-angle glaucoma, diabetes mellitus, hyperthyroidism, increased intraocular pressure, prostatic hypertrophy, urinary retention***Hepatic disease***Renal failure, renal impairment***Geriatric***MAOI therapy***Angina, cardiac arrhythmias, cardiac disease, coronary artery disease, hypertension, myocardial infarction, tachycardia***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['75635', '288688']",eptifibatide,"***For the adjunctive treatment of patients undergoing percutaneous coronary intervention (PCI), including those undergoing coronary stenting, to prevent cardiac ischemic complications (e.g., myocardial infarction prophylaxis).***For the treatment of patients with acute coronary syndrome (unstable angina or acute myocardial infarction, NSTEMI), including patients who are to be managed medically, and for those undergoing percutaneous coronary intervention (PCI).***For the treatment of patients with acute myocardial infarction, STEMI� undergoing percutaneous coronary intervention (PCI).","***Bleeding, coagulopathy, hypertension, intramuscular injections, stroke, surgery, trauma, venipuncture***Anticoagulant therapy, thrombolytic therapy***Dialysis, renal disease, renal failure, renal impairment***Geriatric***Thrombocytopenia***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ascorbic acid/polyethylene glycol 3350/potassium chloride/sodium ascorbate/sodium chloride/sodium sulfate,"***For use as a bowel evacuant to clean the colon prior to colonoscopy or barium enema X-ray examination (bowel preparation). <br />        NOTE: Patients should be well hydrated before, during, and after the colon preparation. The first bowel movement should occur approximately 1 hour after the start of solution administration.<br />     ***For dosing in adults and/or adolescents.***For dosing in children and older infants.***For the treatment of chronic constipation�. <br />        NOTE: This product should be used for 2 weeks or less or as directed by the prescriber.<br />     ","***General Information***Abdominal pain, acute abdomen, appendicitis, colitis, dehydration, GI obstruction, GI perforation, ileus, inflammatory bowel disease, toxic megacolon, ulcerative colitis, vomiting***Electrolyte imbalance, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, seizure disorder, seizures***Children, infants, neonates***Pregnancy***Breast-feeding***Coma, dementia, dysphagia, esophageal stricture, gag reflex depression***Angina, cardiac arrhythmias, cardiomyopathy, heart failure, myocardial infarction, QT prolongation***Renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,insulin aspart (rDNA origin),"***For the treatment of type 1 diabetes mellitus.***For the treatment of type 1 diabetes in adult patients.***For the treatment of type 1 diabetes in pediatric patients.***For the treatment of type 2 diabetes mellitus inadequately managed by diet, exercise, and oral hypoglycemics.***For the treatment of type 2 diabetes mellitus in adult patients.***For the treatment of type 2 diabetes mellitus� in pediatric patients�.***For the treatment of diabetic ketoacidosis� (DKA).***Formoterol; Mometasone","***General Information***Diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Hepatic disease, renal failure, renal impairment***Diabetic ketoacidosis, hyperosmolar hyperglycemic state (HHS)***Continuous subcutaneous insulin infusion (CSII) administration***Hypoglycemia***Hypokalemia***Intravenous administration***Cresol hypersensitivity***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Tobacco smoking***Geriatric***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['614373'],deferasirox,***For the treatment of chronic iron toxicity.***For the initiation of therapy for chronic iron toxicity secondary to transfusional iron overload (transfusional hemisiderosis).***For maintenance therapy for chronic iron toxicity secondary to transfusional iron overload (transfusional hemosiderosis).***For initiation of therapy for chronic iron toxicity in non-transfusion dependent thalassemia syndromes with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of liver dry weight and serum ferritin more than 300 mcg/L.***For maintenance of therapy for chronic iron toxicity in non-transfusion dependent thalassemia syndromes and a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram liver dry weight and serum ferritin more than 300 mcg/L.,"***Nephrotoxicity, proteinuria, renal disease, renal failure, renal impairment***Hepatic decompensation, hepatic disease, hepatitis, hepatotoxicity***Agranulocytosis, anemia, bone marrow suppression, neutropenia, thrombocytopenia***Myelodysplastic syndrome (MDS), neoplastic disease***Anticoagulant therapy, corticosteroid therapy, GI bleeding, GI perforation, peptic ulcer disease***Angioedema, serious hypersensitivity reactions or anaphylaxis, serious rash***Cataracts, glaucoma, hearing impairment, visual disturbance***Children, infants, neonates***Geriatric***Pregnancy***Driving or operating machinery***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['302379'],omalizumab,"***For moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroid. <br />        NOTE: Total IgE concentrations are elevated during treatment and remain elevated for up to 1 year after treatment is discontinued; therefore, serum IgE concentrations during treatment cannot be used as a guide for dosage determination. Periodically reassess the need for continued therapy based upon the patient's disease severity and level of asthma control.<br />     ***For baseline serum IgE 30 to 100 International Units/mL.***For baseline serum IgE 101 to 200 International Units/mL.***For baseline serum IgE 201 to 300 International Units/mL.***For baseline serum IgE 301 to 400 International Units/mL.***For baseline serum IgE 401 to 500 International Units/mL.***For baseline serum IgE 501 to 600 International Units/mL.***For baseline serum IgE 601 to 700 International Units/mL.***For baseline serum IgE 701 to 900 International Units/mL.***For baseline serum IgE 901 to 1,100 International Units/mL.***For baseline serum IgE 1,101 to 1,200 International Units/mL.***For baseline serum IgE 1,201 to 1,300 International Units/mL.***For the treatment of chronic idiopathic urticaria in patients who remain symptomatic despite H1 antihistamine treatment.***For the treatment of seasonal allergic rhinitis�. <br />  NOTE: Total IgE concentrations are elevated during treatment and remain elevated for up to 1 year after treatment is discontinued. The monitoring of IgE concentrations during treatment cannot be used as a guide for dosage determination. If treatment is interrupted for less than 1 year, the restarting dose should be based on serum IgE levels obtained at the initial dosage determination. Dosage should be adjusted for significant changes in body weight.<br /","***Hamster protein hypersensitivity, omalizumab hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis***Acute bronchospasm, corticosteroid therapy, peripheral neuropathy, respiratory insufficiency, status asthmaticus, vasculitis***Neoplastic disease, new primary malignancy***Vaccination***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['593411', '621590']",sitagliptin,***For the treatment of type 2 diabetes mellitus in combination with diet and exercise. <br />        NOTE: Sitagliptin is used as monotherapy or in combination with other drugs used to treat type 2 diabetes mellitus.<br />     ***Formoterol; Mometasone,"***Exfoliative dermatitis, history of angioedema, serious rash***Diabetic ketoacidosis, type 1 diabetes mellitus***Burns, fever, infection, surgery, trauma***Diarrhea, gastroparesis, GI obstruction, ileus, vomiting***Hypercortisolism, hyperglycemia, hyperthyroidism***Adrenal insufficiency, hypoglycemia, hypothyroidism, malnutrition, pituitary insufficiency***Renal failure, renal impairment***Pancreatitis***Arthralgia***Heart failure***Pregnancy***Breast-feeding***Geriatric***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,formoterol fumarate dihydrate/mometasone furoate,"***For the maintenance treatment of asthma.***For the maintenance treatment of chronic obstructive pulmonary disease (COPD)�, such as chronic bronchitis� or emphysema�.","***General Information***Acute bronchospasm, asthma-related death, status asthmaticus***Corticosteroid hypersensitivity***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, long QT syndrome, myocardial infarction, potential for overdose or poisoning, QT prolongation***Fungal infection, herpes infection, infection, measles, tuberculosis, varicella, viral infection***Corticosteroid therapy, corticosteroid withdrawal, hypothalamic-pituitary-adrenal (HPA) suppression***Malnutrition, osteoporosis, tobacco smoking***Cataracts, glaucoma, increased intraocular pressure***Diabetes mellitus, diabetic ketoacidosis***Aneurysm, hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***MAOI therapy***Children, growth inhibition, increased intracranial pressure, infants, neonates***Geriatric***Labor, pregnancy***Breast-feeding***Hepatic disease***Paradoxical bronchospasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sildenafil citrate,***For the treatment of erectile dysfunction (ED).***For the treatment of erectile dysfunction and lower urinary tract symptoms (LUTS) in combination with alfuzosin.***For the treatment of pulmonary hypertension.***For childhood primary and secondary pulmonary hypertension�.***For the treatment of severe pulmonary hypertension�.***For use as a pulmonary vasodilator to predict treatment response in patients with pulmonary hypertension�.***For severe pulmonary hypertension� in combination with iloprost.***For weaning of inhaled nitric oxide (iNO) in patients with pulmonary hypertension�.***For the treatment of anorgasmy� or sexual dysfunction� in patients receiving antidepressant therapy.***For the treatment of sexual dysfunction� in females receiving antidepressant therapy.***For the treatment of sexual dysfunction� in males receiving antidepressant therapy.***For the treatment of Raynaud's phenomenon� resistant to vasodilator therapy.***For altitude sickness prophylaxis<strong>***For the treatment of persistent pulmonary hypertension of the newborn� (PPHN).***For adjunctive therapy for PPHN using the oral route of administration.***For adjunctive therapy for PPHN using the intravenous route of administration.,"***General Information***Nitrate/nitrite therapy***Geriatric, hepatic disease, renal impairment***Angina, aortic stenosis, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypertension, hypotension, idiopathic hypertrophic subaortic stenosis, myocardial infarction, stroke***Leukemia, multiple myeloma, penile structural abnormality, polycythemia, priapism***Human immunodeficiency virus (HIV) infection***Coagulopathy, peptic ulcer disease***Non-arteritic anterior ischemic optic neuropathy, retinitis pigmentosa, visual disturbance***Pregnancy***Breast-feeding***Neonates, premature neonates***Abrupt discontinuation, children, infants***Gastroesophageal reflux disease (GERD), hiatal hernia***Sickle cell disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,minocycline hydrochloride,"***For the treatment of relapsing fever due to <em>Borrelia recurrentis</em>.***For the treatment of chancroid due to <em>Haemophilus ducreyi</em>.***For the treatment of Campylobacter fetus infections.***For the treatment of acute intestinal amebiasis as an adjunct to amebicides.***For the treatment of lower respiratory tract infections and upper respiratory tract infections.***For the treatment of skin and skin structure infections due to <em>Staphylococcus aureus</em>. <br />        NOTE: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection. <br />     ***For the treatment of Rickettsial infections (e.g., murine typhus, Q fever, Rocky Mountain spotted fever, Rickettsial pox).***For the treatment of uncomplicated gonorrhea infections, including urethritis.***For the treatment of psittacosis.***For the treatment of lymphogranuloma venereum caused by <em>Chlamydia trachomatis</em>.***For the treatment of non-gonococcal urethritis (NGU) and chlamydia infection, including trachoma and chlamydial conjunctivitis.***For the treatment of urethral, endocervical, or rectal infections.***For the treatment of other chlamydia infections, including trachoma and inclusion bacterial conjunctivitis.***For the treatment of syphilis when penicillin is contraindicated.***For the treatment of granuloma inguinale (Donovanosis) due to <em>Klebsiella granulomatis</em>.***For the treatment of bartonellosis.***For the treatment of brucellosis in combination with streptomycin.***For the treatment of urinary tract infection (UTI).***For the treatment of plague after exposure to <em>Yersinia pestis</em>.***For the treatment of tularemia following exposure to <em>Francisella tularensis</em>.***For the treatment of cholera.***For the treatment of acne vulgaris.***For the treatment of non-nodular moderate to severe acne vulgaris.***For the treatment of infections caused by <em>Actinomyces israelii</em> (actinomycosis), <em>Bacillus anthracis</em> (anthrax), <em>Clostridium</em> sp. (clostridial diseases), necrotizing ulcerative gingivitis (Fusospirochetosis or Vincent's infection), <em>Listeria monocytogenes</em> (listeriosis), or <em>Treponema pertenue</em> (yaws) when penicillin is contraindicated.***For the treatment meningitis due to <em>Neisseria meningitidis</em>.***For the treatment of the meningococcal carrier state (i.e., for meningococcal infection prophylaxis).***For the treatment of Mycobacterium marinum infection.***For the treatment of rheumatoid arthritis�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis in combination with conventional treatment (e.g., scaling and root planing).***For aggressive periodontitis (juvenile periodontitis)�.***For use as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult chronic periodontitis.***For the treatment of bullous pemphigus�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated bone and joint infections� or an orthopedic device-related infection�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated osteomyelitis�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated prosthetic device infections�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated spinal implant infections�.","***General Information***Serious rash, tetracyclines hypersensitivity***Hepatic disease, hepatitis, hepatotoxicity***Autoimmune disease***Renal failure, renal impairment***Increased intracranial pressure, papilledema, pseudotumor cerebri, visual disturbance***Sunlight (UV) exposure***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***AV block, cardiac disease***Children, infants, neonates***Sexually transmitted disease***Geriatric***Dental work***Pregnancy***Breast-feeding***Infertility, reproductive risk***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,caspofungin acetate,"***For the treatment of candidemia and invasive candidiasis.***For the treatment of chronic disseminated (hepatosplenic) candidiasis�.***For the treatment of invasive aspergillosis in patients who are refractory to or intolerant of other antifungal therapies.***For the treatment of esophageal candidiasis.***For the treatment of respiratory infections (i.e., pneumonia and pleural space infections).***For the treatment of <em>Candida</em> pneumonia and pleural space infections.***For the treatment of <em>Aspergillus</em> pneumonia and pleural space infections in patients who are refractory to or intolerant of other antifungal therapies.***For the treatment of intraabdominal infections (i.e., peritonitis, intraabdominal abscess).***For the treatment of intraabdominal candidiasis.***For the treatment of intraabdominal aspergillosis in patients who are refractory to or intolerant of other antifungal therapies.***For the treatment of bone and joint infections, including osteomyelitis and infectious arthritis.***For the treatment of <em>Candida</em> osteomyelitis� or infectious arthritis�.***For the treatment of <em>Aspergillus</em> osteomyelitis or infectious arthritis in patients who are refractory to or intolerant of other antifungal therapies.***For empirical therapy for presumed fungal infection in patients with febrile neutropenia.***For the treatment of oropharyngeal candidiasis (thrush)�.***For the treatment of cardiovascular system infections, including endocarditis�, suppurative thrombophlebitis�, and infected pacemaker�, implantable cardiac defibrillator (ICD)�, or ventricular assist devices (VAD)�.***For the treatment of <em>Candida</em> cardiovascular system infections�.***For the treatment of <em>Aspergillus</em> cardiovascular system infections in patients who are refractory to or intolerant of other antifungal therapies.***For candidiasis prophylaxis� and aspergillosis prophylaxis� in high-risk patients.","***General Information***Cholestasis, hepatic disease, hepatitis, jaundice***Infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,formoterol fumarate,"***For the maintenance prevention of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.","***Monotherapy treatment of asthma***Paradoxical bronchospasm***Acute bronchospasm, asthma-related death***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, tachycardia***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia, hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***Labor, pregnancy***Breast-feeding***MAOI therapy***Geriatric***Children, infants***Milk protein hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1148495'],crizotinib,***For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)- or ROS1- positive as detected by an FDA-approved test.***Formoterol***Formoterol; Mometasone,"***General Information***Pneumonitis***Hepatic disease***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Children, infants, neonates***Renal failure, renal impairment***Driving or operating machinery, optic neuritis, visual disturbance***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['36567'],simvastatin,"***For the treatment of hypercholesterolemia, hyperlipoproteinemia, and/or hypertriglyceridemia, as an adjunct to dietary control.***For reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglyceride concentrations, and to increase HDL-cholesterol in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson types IIa or IIb); or to treat Fredrickson Type IV (hypertriglyceridemia, increased VLDL) or Fredrickson Type III (primary dysbetalipoproteinemia) hyperlipoproteinemias.***For the treatment of patients with homozygous familial hypercholesterolemia.***For myocardial infarction prophylaxis or stroke prophylaxis in patients at high risk of coronary events due to existing coronary heart disease, diabetes, peripheral vessel disease, or history of stroke or other cerebrovascular disease.***For slowing the progression of coronary atherosclerosis�.***For cerebral vasospasm prophylaxis� after aneurysmal subarachnoid hemorrhage.","***General Information***Alcoholism, cholestasis, hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Electrolyte imbalance, endocrine disease, females, hypotension, hypothyroidism, infection, myopathy, organ transplant, renal disease, renal failure, renal impairment, rhabdomyolysis, seizure disorder, surgery, trauma***Asian patients***Diabetes mellitus***Contraception requirements, pregnancy***Breast-feeding***Geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['325646']['5487'],aliskiren/hydrochlorothiazide,"***For the treatment of hypertension.***For the initial therapy of hypertension in patients likely to require multiple medications to achieve their blood pressure goals. <br />          NOTE: Aliskiren; hydrochlorothiazide, HCTZ is not recommended for use as initial therapy in patients with intravascular volume depletion.<br />       ***For the treatment of patients already receiving aliskiren and hydrochlorothiazide who desire to switch to the combination tablet.***For add-on or switch therapy in patients not adequately controlled on aliskiren or hydrochlorothiazide alone.***Formoterol***Formoterol; Mometasone","***General Information***ACE-inhibitor induced angioedema, angioedema, Black patients, hereditary angioedema, surgery***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, heart failure, hypovolemia, renal artery stenosis, renal failure, renal impairment***Aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease, hyponatremia, hypotension, orthostatic hypotension, sympathectomy, syncope***Acid/base imbalance, electrolyte imbalance, hypercalcemia, hyperkalemia, hypochloremia, hypokalemia, hypomagnesemia, metabolic alkalosis***Diabetes mellitus***Hepatic disease***Jaundice, pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Geriatric***Children, infants, neonates***Pregnancy***Sunlight (UV) exposure***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['282446'],posaconazole,"***For the treatment of mucocutaneous candidiasis.***For the treatment of esophageal candidiasis�.***For the treatment of oropharyngeal candidiasis (thrush).***For candidiasis prophylaxis and for aspergillosis prophylaxis in high-risk patients due to severe immunosuppression, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy.***For secondary esophageal candidiasis prophylaxis� in HIV-infected patients.***For the treatment of invasive aspergillosis�, including invasive pulmonary�, CNS�, and cutaneous aspergillosis�, as well as <em>Aspergillus</em> sinusitis�, tracheobronchitis�, endocarditis�, pericarditis�, myocarditis�, osteomyelitis�, infectious arthritis�, eye infections� (fungal keratitis�, endophthalmitis�), and aspergilloma�.***For the treatment of allergic bronchopulmonary aspergillosis� as alternative therapy.***For the treatment of periorbital cellulitis� due to <em>Rhizopus</em> sp.�.***For the treatment of disseminated histoplasmosis� in HIV-infected patients.***For the treatment of meningeal coccidioidomycosis� or mild coccidioidomycoses infections (focal pneumonia) in HIV-infected patients.***For the treatment of refractory fusariosis� due to <em>Fusarium</em> sp.�.***For secondary coccidioidomycosis prophylaxis� (chronic maintenance therapy�) after treatment of coccidioidomycosis in HIV-infected patients.***For the treatment of cryptococcosis�.***Formoterol***Formoterol; Mometasone","***General Information***Azole antifungals hypersensitivity***Hepatic disease, hepatitis***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Obesity***Renal impairment***Diarrhea, vomiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['29046', '1546022']",lisinopril,***For the treatment of hypertension.***For the treatment of heart failure.***For the treatment of persistent albuminuria� in patients with diabetic nephropathy� or in at-risk hypertensive patients�.***For migraine prophylaxis�.***For the treatment of proteinuria� in pediatric patients with IgA nephropathy�.,"***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, Black patients, hereditary angioedema***Diabetes mellitus, hyperkalemia, renal artery stenosis, renal disease, renal failure, renal impairment***Autoimmune disease, bone marrow suppression, collagen-vascular disease, immunosuppression, scleroderma, systemic lupus erythematosus (SLE)***Dialysis, hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Acute myocardial infarction, aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hyponatremia, hypotension, hypovolemia***Surgery***Jaundice***Neonates, pregnancy***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4462'],fluocinonide,"***For the treatment of pruritus and topical inflammation associated with corticosteroid-responsive dermatoses such as alopecia areata, atopic dermatitis, cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), contact dermatitis, severe <em>Rhus dermatitis</em> (due to plants like poison ivy), discoid lupus erythematosus, generalized exfoliative dermatitis, granuloma annulare, keloids, lichen planus, lichen simplex, lichen striatus, severe eczema (including severe hyperkeratotic eczema, severe nummular eczema, and severe eczematous conditions of the hands or feet), keloids, necrobiosis lipoidica diabeticorum, pemphigoid, pompholyx (dyshidrosis), nodular prurigo, pemphigus, pityriasis rosea, severe pruritus, psoriasis, sarcoidosis, seborrheic dermatitis, sunburn, or urticaria. <br />        NOTE: Systemic therapy or intralesional injection of corticosteroids may be necessary for some conditions based on the type and severity of the disorder or inadequate response to topical therapy.<br />     ***For the treatment of plaque-type psoriasis affecting up to 10% of the body surface area (BSA).","***Corticosteroid hypersensitivity***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Diabetes mellitus***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Fungal infection, herpes infection, infection, measles, peripheral vascular disease, tuberculosis, varicella, viral infection***Acne rosacea, acne vulgaris, cataracts, glaucoma, ocular exposure, ophthalmic administration, perioral dermatitis***Geriatric, skin atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['187832'],pregabalin,***For the symptomatic treatment of neuropathic pain.***For pain associated with peripheral diabetic neuropathy (DPN).***For pain associated with postherpetic neuralgia (PHN).***For the adjunctive treatment of partial seizures (with or without secondary generalization).***For the treatment of fibromyalgia.***For the treatment of social phobia (social anxiety disorder)�.***For the treatment of generalized anxiety disorder (GAD)�.,"***Angioedema***Depression, suicidal ideation***CNS depression, driving or operating machinery, ethanol intoxication***Substance abuse***Abrupt discontinuation***Renal failure, renal impairment***Geriatric***Children, infants***Diabetes mellitus, heart failure***Myopathy, rhabdomyolysis***Glaucoma, ocular disease***Labor, obstetric delivery, pregnancy***Breast-feeding***Reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mometasone furoate,"***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses including alopecia areata, atopic dermatitis, contact dermatitis, dermatitis, discoid lupus erythematosus, eczema, exfoliative dermatitis, granuloma annulare, keloids, lichen planus, lichen simplex, lichen striatus, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pruritus, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, xerosis, and severe <em>Rhus dermatitis</em> due to plants like poison ivy. <br />  NOTE: Occlusive dressings may be required for chronic or severe cases of lichen simplex chronicus, psoriasis, eczema, atopic dermatitis, or chronic hand eczema. More potent topical corticosteroids and/or occlusive dressings may be necessary for the treatment of discoid lupus erythematosus, lichen planus, granuloma annulare, psoriatic plaques, and psoriasis of the palms, soles, elbows, or knees.<br /***For maintenance treatment of asthma.***For the management of nasal symptoms associated with seasonal or perennial allergic rhinitis (e.g., nasal congestion).***For seasonal allergic rhinitis prophylaxis.***For the treatment of nasal polyps.***For sinus patency maintenance after ethmoid sinus surgery in patients with chronic sinusitis.***For exercise-induced bronchospasm prophylaxis�.","***Corticosteroid hypersensitivity***Milk protein hypersensitivity***Acute bronchospasm, paradoxical bronchospasm, status asthmaticus***Skin atrophy***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion, surgery***Children, growth inhibition, increased intracranial pressure, infants, neonates***Diabetes mellitus, hyperglycemia, peripheral vascular disease***Nasal septal perforation, nasal surgery, nasal trauma***Cataracts, glaucoma, increased intraocular pressure, ocular exposure, visual disturbance***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, tuberculosis, varicella, viral infection***Pregnancy***Breast-feeding***Sunlight (UV) exposure***Hepatic disease***Osteoporosis***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['853491'],canakinumab,"***For the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).***For the treatment of active systemic juvenile idiopathic arthritis (SJIA).***For the treatment of tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), and familial mediterranean fever (FMF).","***Hepatitis, human immunodeficiency virus (HIV) infection, immunosuppression, infection, tuberculosis***Neoplastic disease***Vaccination***Hepatic disease, renal impairment***Pregnancy***Breast-feeding***Children, infants, neonates***Intramuscular administration, intravenous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,imatinib mesylate,"***For the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML).***For the treatment of newly diagnosed chronic-phase Ph+ CML.***For the treatment of chronic-phase Ph+ CML after the failure of interferon-alfa therapy.***For pediatric patients with chronic phase Ph+ CML whose disease has recurred after hematopoietic stem cell transplant or who are resistant to interferon-alfa therapy�.***For the treatment of accelerated-phase or blast crisis Ph+ CML after the failure of interferon-alfa therapy.***For the treatment of Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL).***For the treatment of relapsed or refractory Ph+ ALL.***For the treatment of newly diagnosed Ph+ ALL, in combination with chemotherapy.***For the treatment of Kit (CD117) positive gastrointestinal stromal tumors (GIST). <br />        NOTE: Imatinib has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of Kit (CD117) positive unresectable and/or metastatic GIST.***For the adjuvant treatment of Kit (CD117) positive GIST after complete gross resection.***For the treatment of hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIPL1L1-PDGFR alpha fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIPL1L-PDGFR alpha fusion kinase negative or unknown.***For the treatment of myelodysplastic syndrome (MDS)/myeloproliferative disease (MPD) associated with the PDGFR (platelet-derived growth factor receptor) gene rearrangements. <br />        Prior to starting therapy, test for platelet-derived growth factor receptor (PDGFR) gene re-arrangements using a FDA-approved test.<br />     ***For the treatment of aggressive systemic mastocytosis (ASM) without D816V c-Kit mutation or with c-Kit mutation status unknown. <br />        Prior to starting therapy, test for D816V c-Kit mutation status using a FDA-approved test.<br />     ***For the treatment of unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (DFSP). <br />  NOTE: The dosage of imatinib should be increased by at least 50% and clinical response closely monitored in patients receiving imatinib with a potent cytochrome P450 inducer such as rifampin or phenytoin (see Drug Interactions).<br /***For the treatment of desmoid tumor� or aggressive fibromatosis� not amenable to surgery or radiotherapy.","***Diabetes mellitus, hypertension, nephrotoxicity, renal impairment***Cardiac disease, heart failure, renal disease, ventricular dysfunction***Bleeding, bone marrow suppression, fungal infection, GI bleeding, herpes infection, immunosuppression, infection, neutropenia, thrombocytopenia, varicella, viral infection***Hepatic disease, jaundice***Hemochromatosis***Children, growth inhibition, infants, neonates***Driving or operating machinery***Ascites, edema, geriatric, pericardial effusion, pleural effusion, pulmonary edema***Pregnancy***Contraception requirements, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['325646']['17767'],aliskiren/amlodipine/hydrochlorothiazide,***For the treatment of hypertension. <br />        NOTE: Aliskiren; amlodipine; hydrochlorothiazide is not indicated for initial therapy of hypertension.<br />     ***Formoterol***Formoterol; Mometasone,"***General Information***Anuria, hypovolemia, renal artery stenosis, renal failure, renal impairment***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***ACE-inhibitor induced angioedema, angioedema, Black patients, hereditary angioedema, surgery***Breast-feeding***Aortic stenosis, hyponatremia, hypotension, orthostatic hypotension, sympathectomy***Angina, coronary artery disease, myocardial infarction***Biliary cirrhosis, hepatic disease***Heart failure***Systemic lupus erythematosus (SLE)***Geriatric***Acid/base imbalance, electrolyte imbalance, hyperaldosteronism, hypercalcemia, hyperkalemia, hypochloremia, hypokalemia, hypomagnesemia, metabolic alkalosis***Diabetes mellitus***Children, infants, neonates***Pregnancy***Gastroesophageal reflux disease (GERD), hiatal hernia***Gout, hyperuricemia***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,zolpidem tartrate,"***For the treatment of insomnia.***For the short-term treatment of insomnia characterized by difficulty with sleep initiation.***For insomnia characterized by difficulties with sleep onset and/or sleep maintenance.***For middle-of-the night awakening that is followed by difficulty returning to sleep.***For increasing awareness and responsiveness in patients with disorders of consciousness due to traumatic brain injury� (TBI�) or nontraumatic brain injury� (e.g., head trauma� or hypoxia, respectively).","***Angioedema***Depression, suicidal ideation***Behavioral changes, CNS depression, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion, females***Abrupt discontinuation, alcoholism, substance abuse***Encephalopathy, hepatic disease***Chronic obstructive pulmonary disease (COPD), myasthenia gravis, pulmonary disease, respiratory depression, sleep apnea***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,betamethasone dipropionate,"***For the treatment of acute graft-versus-host disease (GVHD).***For the treatment of nonsuppurative thyroiditis.***For the treatment of acute exacerbations of multiple sclerosis.***For the management of symptomatic sarcoidosis or for the treatment of hypercalcemia associated with cancer or sarcoidosis.***For the treatment of allergic disorders including anaphylaxis or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema (or for laryngeal edema prophylaxis), drug hypersensitivity reactions, serum sickness, severe perennial or seasonal allergic rhinitis, severe urticaria, or for the treatment of urticarial transfusion reactions. <br />        NOTE: Betamethasone should be administered IM or IV initially in the treatment of anaphylaxis or anaphylactoid reactions, angioedema, and acute noninfectious laryngeal edema or to prevent impending risk of laryngeal edema.<br />     ***For the treatment of urticarial transfusion reactions.***For the treatment of immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of hematologic disorders including secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), and congenital hypoplastic anemia.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of inflammatory bowel disease including Crohn's disease (regional gastroenteritis) and ulcerative colitis.***For the induction of diuresis or remission of proteinuria in the nephrotic syndrome.***For the treatment of nasal polyps.***For the treatment of severe cases of myasthenia gravis not controlled by antimyasthenic agents alone.***For adjunctive therapy in the treatment of rheumatic disorders e.g., acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), osteoarthritis, polychondritis�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of nonrheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the treatment of moderate-to-severe inflammation and pruritus due to corticosteroid-responsive dermatologic disorders such as alopecia areata, cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis, generalized exfoliative dermatitis, nummular dermatitis, seborrheic dermatitis, eczema, granuloma annulare, keloids, lichen planus, lichen simplex chronicus, lichen striatus, subacute cutaneous and discoid lupus erythematosus, pretibial myxedema, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, psoriasis, <em>Rhus dermatitis</em> (due to poison ivy, poison oak, or poison sumac), sarcoidosis, Stevens-Johnson syndrome, sunburn, or urticaria. <br />        NOTE: Systemic corticosteroids may be necessary for some conditions based on the type and severity of the disorder (e.g., Stevens-Johnson syndrome) or inadequate response to topical therapy; intralesional injections may also be appropriate for select conditions.<br />     ***For the treatment of plaque psoriasis.***For the treatment of seborrheic dermatitis.***For hyaline membrane disease prophylaxis�, for the purpose of fetal lung maturation to prophylax against anticipated neonatal respiratory distress syndrome (RDS)� in premature infants.***For palliative management of leukemia and lymphoma in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), or for the treatment of multiple myeloma�.***For maintenance therapy in selected cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis�, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, conjunctivitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For the treatment of respiratory inflammatory conditions including airway-obstructing hemangioma� in infants, aspiration pneumonitis, berylliosis, bronchial asthma, chronic obstructive pulmonary disease (COPD), laryngotracheobronchitis (croup), Loeffler's syndrome, or non-cardiogenic pulmonary edema�, or for bronchospasm prophylaxis. <br />        NOTE: Betamethasone should be administered parenterally initially in the treatment of severe manifestations of these diseases, particularly where airway obstruction is present.<br />     ","***Abrupt discontinuation, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, growth inhibition, increased intracranial pressure, infants, neonates***Immunosuppression***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Edema, heart failure, hypertension***Osteoporosis***Diabetes mellitus***Crohn's disease, diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hyperthyroidism, hypothyroidism, psychosis, renal disease, seizure disorder, thyroid disease***Myasthenia gravis***Idiopathic thrombocytopenic purpura (ITP), thromboembolic disease***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Epidural administration, intravenous administration***Corticosteroid hypersensitivity***Head trauma***Skin atrophy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine","***For meningococcal infection prophylaxis due to <em>Neisseria meningitidis</em> serogroups A, C, Y, and W-135. <br />  NOTE: The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of all persons 11�18 years of age, preferably with 1 dose at age 11 or 12 years and a booster dose at 16 years.<br /","***General Information***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Fever, infection***Agammaglobulinemia, chemotherapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Pregnancy***Breast-feeding***Geriatric***Guillain-Barre syndrome***Infants, neonates, premature neonates***Syncope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mometasone furoate monohydrate,"***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses including alopecia areata, atopic dermatitis, contact dermatitis, dermatitis, discoid lupus erythematosus, eczema, exfoliative dermatitis, granuloma annulare, keloids, lichen planus, lichen simplex, lichen striatus, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pruritus, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, xerosis, and severe <em>Rhus dermatitis</em> due to plants like poison ivy. <br />  NOTE: Occlusive dressings may be required for chronic or severe cases of lichen simplex chronicus, psoriasis, eczema, atopic dermatitis, or chronic hand eczema. More potent topical corticosteroids and/or occlusive dressings may be necessary for the treatment of discoid lupus erythematosus, lichen planus, granuloma annulare, psoriatic plaques, and psoriasis of the palms, soles, elbows, or knees.<br /***For maintenance treatment of asthma.***For the management of nasal symptoms associated with seasonal or perennial allergic rhinitis (e.g., nasal congestion).***For seasonal allergic rhinitis prophylaxis.***For the treatment of nasal polyps.***For sinus patency maintenance after ethmoid sinus surgery in patients with chronic sinusitis.***For exercise-induced bronchospasm prophylaxis�.","***Corticosteroid hypersensitivity***Milk protein hypersensitivity***Acute bronchospasm, paradoxical bronchospasm, status asthmaticus***Skin atrophy***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion, surgery***Children, growth inhibition, increased intracranial pressure, infants, neonates***Diabetes mellitus, hyperglycemia, peripheral vascular disease***Nasal septal perforation, nasal surgery, nasal trauma***Cataracts, glaucoma, increased intraocular pressure, ocular exposure, visual disturbance***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, tuberculosis, varicella, viral infection***Pregnancy***Breast-feeding***Sunlight (UV) exposure***Hepatic disease***Osteoporosis***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['25025'],finasteride,"***For the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, to reduce the risk of acute urinary retention, and to reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy.***For the treatment of male pattern hair loss (i.e., androgenetic alopecia), in patients with mild to moderate hair loss of the vertex and anterior mid-scalp area.***For the second-line treatment of hirsutism�.***For prostate cancer prophylaxis�.","***Females, pregnancy***Breast-feeding***Children, infants***Hepatic disease***Prostate cancer, urinary tract obstruction***Blood donation***Geriatric***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,influenza virus vaccine,***For annual seasonal influenza prophylaxis.,"***General Information***Intravenous administration, subcutaneous administration***Fever, respiratory infection***Egg hypersensitivity, kanamycin hypersensitivity, latex hypersensitivity, neomycin hypersensitivity***Guillain-Barre syndrome***Geriatric***Children, infants***Pregnancy***Breast-feeding***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Acquired immunodeficiency syndrome (AIDS), agammaglobulinemia, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Syncope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"measles, mumps, rubella and varicella virus vaccine live","***For measles prophylaxis, mumps prophylaxis, rubella prophylaxis, and varicella (chickenpox) infection prophylaxis.","***General Information***Egg hypersensitivity***Albumin hypersensitivity, gelatin hypersensitivity, neomycin hypersensitivity***Intramuscular administration, intravenous administration***Fever, infection, tuberculosis***Acquired immunodeficiency syndrome (AIDS), agammaglobulinemia, bone marrow suppression, chemotherapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, IgA deficiency, immunosuppression, leukemia, lymphoma, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Pregnancy***Breast-feeding***Geriatric, infants***Seizure disorder***Thrombocytopenia***Viral infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,phenelzine sulfate,"***For use in treatment-resistant depression, including atypical depression.***For the treatment of panic disorder�.***For the treatment of social phobia (social anxiety disorder)�.","***General Information***Alcoholism, coadministration with other CNS depressants, ethanol ingestion, MAOI therapy***Pheochromocytoma***Hepatic disease, hepatitis***Anuria, renal disease, renal failure, renal impairment***Seizure disorder, seizures***Driving or operating machinery***Asthma, bronchitis***Diabetes mellitus***Hyperthyroidism***Dental work, spinal anesthesia, surgery***Abrupt discontinuation, substance abuse***Anxiety, bipolar disorder, mania, psychosis, schizophrenia***Children, suicidal ideation***Acute myocardial infarction, angina, cardiac disease, cerebrovascular disease, head trauma, headache, heart failure, hypertension, hypertensive crisis, hypotension, increased intracranial pressure, intracranial bleeding, orthostatic hypotension, stroke***Radiographic contrast administration***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,interferon beta-1b,***For treatment of multiple sclerosis (MS). <br />        NOTE: The specific activity of interferon beta-1b is approximately 32 million International Units/mg.<br />NOTE: Interferon beta-1b has been designated as an orphan drug by the FDA for this indication.<br />NOTE: Patients in whom efficacy has been demonstrated include those who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis***For relapsing-remitting forms of MS to decrease the frequency of clinical exacerbations.***For secondary progressive MS� to delay neurological deterioration.,"***Pregnancy***Heart failure***Albumin hypersensitivity, E. coli protein hypersensitivity, mannitol hypersensitivity***Breast-feeding***Children, infants, neonates***Depression, suicidal ideation***Bone marrow suppression***Hyperthyroidism, hypothyroidism, thyroid disease***Hepatic disease, hepatitis***Seizures***Hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP)***Latex hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,montelukast sodium,"***For the chronic treatment and prevention of the symptoms of asthma, either as monotherapy or as add-on therapy in patients whose persistent mild-moderate asthma is inadequately controlled with inhaled corticosteroids. <br />  NOTE: Montelukast is not a rescue medication; it should not be used for the treatment of an acute asthmatic attack or acute bronchospasm. However, montelukast may be continued during the treatment of an acute asthmatic event.<br /***For exercise-induced bronchospasm prophylaxis.***For the treatment of allergic rhinitis. <br />        Expert opinions regard the leukotriene receptor antagonists (LTRAs) as options in the treatment of allergic rhinitis, particularly when the patient has comorbid asthma. Montelukast has the strongest data for these indications of the LRTAs. However, in patients with allergic rhinitis (seasonal or other) alone, intranasal corticosteroids are generally considered first-line therapy, since treatment results with LTRAs appear to be similar to standard treatments such as antihistamines, and inferior to intranasal corticosteroids. <br />     ***For perennial allergic rhinitis.***For seasonal allergic rhinitis.***For the treatment of aspirin-induced asthma�.***For the treatment of atopic dermatitis�.***For the adjunctive treatment of chronic urticaria� or chronic idiopathic urticaria�.***For the treatment of mild to moderate obstructive sleep apnea�.","***General Information***Acute bronchospasm, status asthmaticus***Phenylketonuria***Depression, suicidal ideation***Pregnancy***Breast-feeding***Infants, neonates***Alcoholism, hepatic disease, hepatitis, jaundice***Corticosteroid withdrawal***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,coagulation factor VIIa (recombinant),"***For the treatment of congenital hemophilia A or hemophilia B with inhibitors.***For the treatment of acute bleeding episodes in patients with hemophilia A or hemophilia B with inhibitors.***For perioperative management of bleeding in hemophilia A or hemophilia B patients with inhibitors. <br />          NOTE: Factor VIIa has been designated an orphan drug by the FDA for this indication.<br />       ***For the treatment of acquired hemophilia.***For the treatment of acute bleeding episodes in patients with acquired hemophilia.***For the perioperative management of bleeding in patients with acquired hemophilia.***For the treatment of congenital factor VII deficiency.***For the treatment of acute bleeding episodes in patients with congenital factor VII deficiency.***For perioperative management of bleeding in patients with congenital factor VII deficiency.***For the treatment of Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.***For the treatment of acute bleeding in patients with Glanzmann's thrombasthenia.***For management of perioperative bleeding in patients with Glanzmann's thrombasthenia.***For the treatment of severe von Willebrand's disease�.***For the treatment of hemorrhage in patients with coumarin toxicity�.","***General Information***Bovine protein hypersensitivity, hamster protein hypersensitivity, murine protein hypersensitivity***Arteriosclerosis, disseminated intravascular coagulation (DIC), hepatic disease, sepsis, thromboembolic disease, thromboembolism, trauma***Obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4917'],nitroglycerin,"***For the treatment of angina.***For acute angina pectoris or for acute angina pectoris prophylaxis (i.e., situations likely to provoke an anginal attack).***For chronic angina pectoris. <br />          NOTE: A nitrate-free interval is necessary to avoid the development of drug tolerance; although a minimum interval has not been clearly established, 10 to 12 hours/day has been sufficient with other nitroglycerin formulations.<br />       ***For the treatment of pain associated with anal fissures.***For the treatment of pain associated with anal fissures� and hemorrhoids�.***For controlled hypotension induction during anesthesia; for IV treatment of acute congestive heart failure or pulmonary edema, acute angina pectoris or unstable angina, acute myocardial infarction, or acute pulmonary hypertension�; or for treatment of severe hypertension, postoperative hypertension, perioperative hypertension (e.g., during cardiac surgery), or hypertensive emergency.***For use as a uterine relaxant to aid in extraction of a retained placenta�.***For the treatment of extravasation� of vasoactive medications.","***General Information***Nitrate hypersensitivity***Head trauma, increased intracranial pressure, intracranial bleeding***Anemia***Aortic stenosis, cardiac tamponade, cardiomyopathy, constrictive pericarditis, mitral stenosis, shock***Acute myocardial infarction, dehydration, hypotension, hypovolemia, orthostatic hypotension***Geriatric***Hepatic disease***Abrupt discontinuation***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Pregnancy***Breast-feeding***GI disease***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['69749'],valsartan,***For the treatment of hypertension.***For the reduction of cardiovascular mortality in stable patients with left ventricular failure or left ventricular dysfunction (LVD) following acute myocardial infarction. <br />        NOTE: The VALIANT trial has demonstrated comparable efficacy of valsartan versus captopril to reduce cardiovascular mortality in postmyocardial infarction patients with cardiac failure and/or left ventricular dysfunction. This study has also reported that the combination of valsartan with captopril increased the adverse events rate without improving survival.<br />     ***For the treatment of heart failure (NYHA Class II thru IV).,"***General Information***Heart failure, hypotension, hypovolemia, renal artery stenosis, renal failure, renal impairment***Hepatic disease***Hyperkalemia***ACE-inhibitor induced angioedema, angioedema***Black patients***Pregnancy***Breast-feeding***Children, infants, neonates***Surgery***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydromorphone hydrochloride,"***For the relief of moderate pain or severe pain.***For the relief of acute and chronic moderate pain or severe pain.***For the management of chronic severe pain in opioid-tolerant patients who require daily, around-the-clock, long-term opioid treatment. <br />          NOTE: Extended-release hydromorphone should be reserved for patients in whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would otherwise provide inadequate pain management. Discontinue all other around-the-clock opioid drugs upon initiation of hydromorphone extended-release tablets.<br />NOTE: Opioid-tolerant patients are defined as those taking, for a minimum of 1 week, &gt;= 60 mg oral morphine daily, &gt;= 30 mg oral oxycodone daily, &gt;= 8 mg oral hydromorphone daily, &gt;= 25 mg oral oxymorphone daily, &gt;= 25 mcg transdermal fentanyl per hour, or an equivalent dose of another opioid","***Acute abdomen, constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, surgery, ulcerative colitis***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, emphysema, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Opioid-naive patients***Abrupt discontinuation***Coma, head trauma, increased intracranial pressure, intracranial mass, seizure disorder, seizures***Angina, cardiac arrhythmias, cardiac disease, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal impairment, urethral stricture, urinary retention***Geriatric***Children, infants, neonates***Biliary tract disease, gallbladder disease, pancreatitis***Neonatal opioid withdrawal syndrome, pregnancy***Labor, obstetric delivery***Breast-feeding***Driving or operating machinery***Epidural administration***Opiate agonist hypersensitivity***Lactase deficiency, latex hypersensitivity, paraben hypersensitivity, sulfite hypersensitivity***Adrenal insufficiency, hypothyroidism, myxedema***Intravenous administration***Accidental exposure, ethanol ingestion, ethanol intoxication, potential for overdose or poisoning, requires an experienced clinician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,tolterodine tartrate,"***For the treatment of an overactive bladder (OAB) with symptoms of urinary frequency, urinary urgency, or urge-related urinary incontinence.","***General Information***Prostatic hypertrophy, renal disease, renal failure, renal impairment, urinary retention, urinary tract obstruction***Closed-angle glaucoma, contact lenses***Anticholinergic medications, gastroesophageal reflux disease (GERD), gastroparesis, GI obstruction, ileus, pyloric stenosis, toxic megacolon, ulcerative colitis***Hepatic disease***Driving or operating machinery***Autonomic neuropathy, myasthenia gravis***Pregnancy***Breast-feeding***Children, infants, neonates***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,rabies vaccine,"***For rabies prophylaxis.***For preexposure immunization and booster doses in high-risk groups. <br />  NOTE: Pre-exposure vaccination does not negate the need for post-exposure treatment should a potential rabies exposure occur, it simply reduces the doses of treatment needed post-exposure.<br /***For postexposure vaccination of previously unvaccinated persons with altered immunocompetence.***For postexposure vaccination of previously vaccinated persons. <br />  NOTE: Previously vaccinated patients include those who received a complete vaccination series (pre- or postexposure prophylaxis) with a cell-culture vaccine or who previously had a documented adequate rabies virus-neutralizing antibody titer after vaccination with other types of vaccines. If the immune status of a previously vaccinated person is not known, the full post-exposure series is recommended; in such cases, if a protective serum titer (from a sample collected before vaccine administration ) can be demonstrated, then the treatment can be discontinued after at least 2 doses. <br /***For postexposure vaccination of previously unvaccinated immunocompetent persons.","***Albumin hypersensitivity, bovine protein hypersensitivity, egg hypersensitivity, neomycin hypersensitivity***Intraarterial administration, intravenous administration, subcutaneous administration***Viral infection***Acquired immunodeficiency syndrome (AIDS), agammaglobulinemia, corticosteroid therapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Guillain-Barre syndrome***Pregnancy***Breast-feeding***Infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fosaprepitant dimeglumine,"***For chemotherapy-induced nausea/vomiting prophylaxis (CINV prophylaxis).***For acute and delayed chemotherapy-induced nausea/vomiting (CINV) prophylaxis associated with highly-emetogenic chemotherapy.***For chemotherapy-induced nausea/vomiting (CINV) prophylaxis associated with moderately-emetogenic chemotherapy.***For post-operative nausea/vomiting (PONV) prophylaxis. <br />  NOTE: Chronic, continuous use of aprepitant/fosaprepitant is not recommended because it has not been studied, and the drug interaction profile may change during chronic continuous use.<br /","***General Information***Hypotension, infusion-related reactions, polysorbate 80 hypersensitivity***Hepatic disease***Anticoagulant therapy***Children, infants, neonates***Contraception requirements, contraceptive devices***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['136411'],sildenafil,***For the treatment of erectile dysfunction (ED).***For the treatment of erectile dysfunction and lower urinary tract symptoms (LUTS) in combination with alfuzosin.***For the treatment of pulmonary hypertension.***For childhood primary and secondary pulmonary hypertension�.***For the treatment of severe pulmonary hypertension�.***For use as a pulmonary vasodilator to predict treatment response in patients with pulmonary hypertension�.***For severe pulmonary hypertension� in combination with iloprost.***For weaning of inhaled nitric oxide (iNO) in patients with pulmonary hypertension�.***For the treatment of anorgasmy� or sexual dysfunction� in patients receiving antidepressant therapy.***For the treatment of sexual dysfunction� in females receiving antidepressant therapy.***For the treatment of sexual dysfunction� in males receiving antidepressant therapy.***For the treatment of Raynaud's phenomenon� resistant to vasodilator therapy.***For altitude sickness prophylaxis<strong>***For the treatment of persistent pulmonary hypertension of the newborn� (PPHN).***For adjunctive therapy for PPHN using the oral route of administration.***For adjunctive therapy for PPHN using the intravenous route of administration.,"***General Information***Nitrate/nitrite therapy***Geriatric, hepatic disease, renal impairment***Angina, aortic stenosis, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypertension, hypotension, idiopathic hypertrophic subaortic stenosis, myocardial infarction, stroke***Leukemia, multiple myeloma, penile structural abnormality, polycythemia, priapism***Human immunodeficiency virus (HIV) infection***Coagulopathy, peptic ulcer disease***Non-arteritic anterior ischemic optic neuropathy, retinitis pigmentosa, visual disturbance***Pregnancy***Breast-feeding***Neonates, premature neonates***Abrupt discontinuation, children, infants***Gastroesophageal reflux disease (GERD), hiatal hernia***Sickle cell disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['1232150', '1304475']",aflibercept,***For the treatment of neovascular (wet) age-related macular degeneration (AMD).***For the treatment of macular edema following retinal vein occlusion (including central or branch retinal vein occlusion).***For the treatment of diabetic macular edema (DME) or for the treatment of diabetic retinopathy in patients with DME.***For the treatment of proliferative diabetic retinopathy�.***For the treatment of choroidal neovascularization (CNV)� due to presumed ocular histoplasmosis syndrome (POHS).,"***General Information***Ocular infection***Inflammation***Glaucoma, increased intraocular pressure***Ocular surgery***Driving or operating machinery***Children, infants, neonates***Pregnancy***Contraception requirements, infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1819'],buprenorphine,"***For the treatment of moderate pain or severe pain.***For treatment of chronic severe pain in patients who require daily, around-the-clock, long-term opioid treatment. <br />          NOTE: Transdermal and buccal buprenorphine should be reserved for patients in whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Discontinue all other around-the-clock opioid drugs upon initiation of transdermal buprenorphine. <br />NOTE: Transdermal buprenorphine doses of 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour, and 20 mcg/hour are for use in opioid-experienced patients only.<br />NOTE: Buccal doses of 600 mcg, 750 mcg, and 900 mcg are for use following titration from lower doses of the buccal film***For the treatment of opiate agonist dependence, including opiate agonist withdrawal symptoms.***For the prevention of undue symptoms of opiate agonist withdrawal during induction of opiate agonist dependence treatment.***For maintenance treatment of opiate agonist dependence.***For maintenance treatment of opioid agonist dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine-containing product (i.e., doses of no more than 8 mg per day of Subutex or Suboxone sublingual tablet equivalent or generic equivalent).***For the management of neonatal abstinence syndrome�.***Formoterol***Formoterol; Mometasone","***Opiate agonist hypersensitivity***Accidental exposure, alcoholism, depression, implant insertion and removal complications, potential for overdose or poisoning, requires an experienced clinician, substance abuse***Abrupt discontinuation***Dental work, surgery***Anxiety***Acute abdomen, constipation, diarrhea, GI obstruction, ileus, inflammatory bowel disease, toxic megacolon, ulcerative colitis***Children, infants***Acute intoxication of CNS depressants, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), CNS depression, coadministration with other CNS depressants, cor pulmonale, driving or operating machinery, emphysema, ethanol intoxication, heart failure, obesity, psychosis, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Coma, head trauma, hypoxemia, increased intracranial pressure, intracranial mass***Labor, neonatal opioid withdrawal syndrome, neonates, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Bladder obstruction, oliguria, prostatic hypertrophy, renal failure, renal impairment, urethral stricture, urinary retention, urinary tract obstruction***Biliary cirrhosis, biliary obstruction, biliary tract disease, gallbladder disease, pancreatitis***Acute heart failure, acute myocardial infarction, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Fever, heating pad, sunlight (UV) exposure***Hypotension, hypovolemia, orthostatic hypotension***Seizure disorder, seizures***Opioid-naive patients, pain***Geriatric***Adrenal insufficiency, hypothyroidism, myxedema***Infection, intramuscular administration***Scleroderma***Infertility, reproductive risk***Intravenous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,1.25mL diluent) (peginterferon alfa-2b,"***For treatment of hepatitis C infection in patients with compensated liver disease. <br />        NOTE: No safety and efficacy data on treatment for longer than 1 year exist.<br />NOTE: Serum HCV RNA concentrations should be assessed after 24 weeks of treatment. Indications are based on achieving undetectable HCV RNA after 24 or 48 weeks of treatment and maintaining a sustained virologic response (SVR) 24 weeks after the last dose***For chronic hepatitis C as monotherapy in adults who have not been previously treated with interferon alfa. <br />          NOTE: Combination therapy is preferred over monotherapy, unless a contraindication or significant intolerance exists, as it provides substantially better response rates.<br />       ***For acute hepatitis C�.***For the treatment of chronic hepatitis C genotype 1 infection as part of combination therapy.***For the treatment of chronic hepatitis C genotype 2 infection as part of combination therapy.***For the treatment of chronic hepatitis C genotype 3 infection as part of combination therapy.***For the treatment of chronic hepatitis C genotype 4 infection as part of combination therapy.***For the treatment of chronic hepatitis C genotypes 5� or 6� infection as part of combination therapy.***For the adjuvant treatment of malignant melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy.***For treatment of chronic hepatitis B infection�.","***E. coli protein hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis, serious rash***Alcoholism, bipolar disorder, depression, driving or operating machinery, encephalopathy, mania, neurologic events, peripheral neuropathy, psychiatric event, psychosis, seizure disorder, seizures, substance abuse, suicidal ideation***Infection***Anemia, aplastic anemia, bleeding, bone marrow suppression, human immunodeficiency virus (HIV) infection, neutropenia, organ transplant, sickle cell disease, thalassemia, thrombocytopenia***Ethanol ingestion, hepatic decompensation, hepatic disease, hepatitis, hepatitis C and HIV coinfection, jaundice***Autoimmune disease, idiopathic thrombocytopenic purpura (ITP), psoriasis, rheumatoid arthritis, systemic lupus erythematosus (SLE), thrombotic thrombocytopenic purpura (TTP)***Graves' disease, hyperthyroidism, hypothyroidism, thyroid disease***Diabetes mellitus, hyperglycemia, hypoglycemia***Angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, hypertension, myocardial infarction, stroke***Pneumonitis, pulmonary disease, pulmonary hypertension, respiratory insufficiency, sarcoidosis***Dialysis, renal failure, renal impairment***Colitis, ischemic colitis, ulcerative colitis***Hypertriglyceridemia, pancreatitis***Diabetic retinopathy, ocular disease, optic neuritis, papilledema, retinal bleeding, retinal detachment, visual disturbance***Geriatric***Contraception requirements, pregnancy, use with ribavirin***Infertility, menstrual irregularity***Breast-feeding***Children, growth inhibition, infants, neonates***Dental disease, dental work***Hepatitis B exacerbation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['10627', '220333']",tobramycin,"***For the treatment of bone and joint infections, skin and skin structure infections (burn wound infection), and meningitis. <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight.<br />     ***For intrathecal� or intraventricular� administration in patients with meningitis.***For treatment of lower respiratory tract infections, including community-acquired pneumonia (CAP) and nosocomial pneumonia. <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight.<br />     ***For the treatment of external infections of the eye including, of blepharitis, blepharoconjunctivitis, bacterial conjunctivitis, dacryocystitis, keratitis, keratoconjunctivitis, and acute meibomianitis.***For the treatment of complicated or recurrent urinary tract infection (UTI). <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight.<br />     ***For the treatment of intraabdominal infections, including peritonitis. <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight.<br />     ***For peritoneal dialysis-associated peritonitis in patients with end-stage renal disease.***For the treatment of bacteremia and sepsis. <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight.<br />     ***For the empiric treatment of febrile neutropenia�.***For the treatment of febrile neutropenia in adults.***For the treatment of febrile neutropenia in pediatric patients.***For surgical infection prophylaxis�.***Formoterol; Mometasone","***General Information***Dehydration, nephrotoxicity, renal disease, renal failure, renal impairment***Hearing impairment, neurotoxicity, ototoxicity, tinnitus***Aminoglycoside hypersensitivity***Botulism, electrolyte imbalance, myasthenia gravis, neuromuscular disease, parkinsonism, respiratory depression, respiratory insufficiency***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Acute bronchospasm, corneal abrasion***Pregnancy***Breast-feeding***Neonates, premature neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5487']['69749'],hydrochlorothiazide/valsartan,***For the treatment of hypertension.***For initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals.***For substitution after titration of valsartan and hydrochlorothiazide (HCTZ).***For patients who do not respond to monotherapy with valsartan.***For patients who do not respond to monotherapy with hydrochlorothiazide (HCTZ).***Formoterol***Formoterol; Mometasone,"***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, heart failure, renal artery stenosis, renal disease, renal failure, renal impairment***Hepatic disease***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***ACE-inhibitor induced angioedema, angioedema***Surgery***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia, hyponatremia***Pregnancy***Breast-feeding***Children***Diabetes mellitus, hyperglycemia***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['325646']['17767'],aliskiren/amlodipine,"***For the treatment of hypertension, either alone or in combination with other antihypertensive agents.***For initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals.***For patients already receiving aliskiren and amlodipine who desire to switch to the combination tablet or patients not adequately controlled on aliskiren or amlodipine alone.","***General Information***ACE-inhibitor induced angioedema, angioedema, Black patients, hereditary angioedema, surgery***Aortic stenosis, hyponatremia, hypotension, hypovolemia***Angina, coronary artery disease, myocardial infarction***Renal artery stenosis, renal failure, renal impairment***Biliary cirrhosis, hepatic disease***Gastroesophageal reflux disease (GERD), hiatal hernia***Heart failure***Diabetes mellitus***Hyperkalemia, hypokalemia***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,metoclopramide hydrochloride,"***For post-operative nausea/vomiting (PONV) and post-operative nausea/vomiting (PONV) prophylaxis.***For emetogenic chemotherapy-induced nausea/vomiting and chemotherapy-induced nausea/vomiting prophylaxis.***For the treatment of symptomatic gastroesophageal reflux disease (GERD).***For the treatment of idiopathic or postsurgical gastroparesis� or diabetic gastroparesis.***For the treatment of acute, severe migraine� prior to administration of dihydroergotamine (DHE) to offset DHE-induced nausea; or in patients who do not respond to dihydroergotamine; or as an alternative to other migraine therapies.***For the treatment of persistent singultus (hiccups)�.***For lactation induction�.***For use as a radiation sensitizer in combination with radiation therapy in the treatment of patients with non-small cell lung cancer (NSCLC)�.***For pregnancy-induced nausea/vomiting�.***For the facilitation of gastric emptying in neonates with feeding intolerance�.","***Paraben hypersensitivity, procainamide hypersensitivity***GI bleeding, GI obstruction, GI perforation***Cardiac disease, heart failure, hypertension, pheochromocytoma***Parkinsonism, Parkinson's disease, seizure disorder, seizures, tardive dyskinesia***Abrupt discontinuation, depression, driving or operating machinery***Children, G6PD deficiency, infants, methemoglobin reductase deficiency, methemoglobinemia, neonates***Renal failure, renal impairment***Breast cancer, infertility***Pregnancy***Breast-feeding***Malignant hyperthermia***Geriatric***Hepatic disease, poor metabolizers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,betamethasone dipropionate,"***For the treatment of acute graft-versus-host disease (GVHD).***For the treatment of nonsuppurative thyroiditis.***For the treatment of acute exacerbations of multiple sclerosis.***For the management of symptomatic sarcoidosis or for the treatment of hypercalcemia associated with cancer or sarcoidosis.***For the treatment of allergic disorders including anaphylaxis or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema (or for laryngeal edema prophylaxis), drug hypersensitivity reactions, serum sickness, severe perennial or seasonal allergic rhinitis, severe urticaria, or for the treatment of urticarial transfusion reactions. <br />        NOTE: Betamethasone should be administered IM or IV initially in the treatment of anaphylaxis or anaphylactoid reactions, angioedema, and acute noninfectious laryngeal edema or to prevent impending risk of laryngeal edema.<br />     ***For the treatment of urticarial transfusion reactions.***For the treatment of immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of hematologic disorders including secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), and congenital hypoplastic anemia.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of inflammatory bowel disease including Crohn's disease (regional gastroenteritis) and ulcerative colitis.***For the induction of diuresis or remission of proteinuria in the nephrotic syndrome.***For the treatment of nasal polyps.***For the treatment of severe cases of myasthenia gravis not controlled by antimyasthenic agents alone.***For adjunctive therapy in the treatment of rheumatic disorders e.g., acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), osteoarthritis, polychondritis�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of nonrheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the treatment of moderate-to-severe inflammation and pruritus due to corticosteroid-responsive dermatologic disorders such as alopecia areata, cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis, generalized exfoliative dermatitis, nummular dermatitis, seborrheic dermatitis, eczema, granuloma annulare, keloids, lichen planus, lichen simplex chronicus, lichen striatus, subacute cutaneous and discoid lupus erythematosus, pretibial myxedema, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, psoriasis, <em>Rhus dermatitis</em> (due to poison ivy, poison oak, or poison sumac), sarcoidosis, Stevens-Johnson syndrome, sunburn, or urticaria. <br />        NOTE: Systemic corticosteroids may be necessary for some conditions based on the type and severity of the disorder (e.g., Stevens-Johnson syndrome) or inadequate response to topical therapy; intralesional injections may also be appropriate for select conditions.<br />     ***For the treatment of plaque psoriasis.***For the treatment of seborrheic dermatitis.***For hyaline membrane disease prophylaxis�, for the purpose of fetal lung maturation to prophylax against anticipated neonatal respiratory distress syndrome (RDS)� in premature infants.***For palliative management of leukemia and lymphoma in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), or for the treatment of multiple myeloma�.***For maintenance therapy in selected cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis�, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, conjunctivitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For the treatment of respiratory inflammatory conditions including airway-obstructing hemangioma� in infants, aspiration pneumonitis, berylliosis, bronchial asthma, chronic obstructive pulmonary disease (COPD), laryngotracheobronchitis (croup), Loeffler's syndrome, or non-cardiogenic pulmonary edema�, or for bronchospasm prophylaxis. <br />        NOTE: Betamethasone should be administered parenterally initially in the treatment of severe manifestations of these diseases, particularly where airway obstruction is present.<br />     ","***Abrupt discontinuation, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, growth inhibition, increased intracranial pressure, infants, neonates***Immunosuppression***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Edema, heart failure, hypertension***Osteoporosis***Diabetes mellitus***Crohn's disease, diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hyperthyroidism, hypothyroidism, psychosis, renal disease, seizure disorder, thyroid disease***Myasthenia gravis***Idiopathic thrombocytopenic purpura (ITP), thromboembolic disease***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Epidural administration, intravenous administration***Corticosteroid hypersensitivity***Head trauma***Skin atrophy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,potassium citrate,"***For the management of renal tubular acidosis (RTA) with calcium nephrolithiasis (renal calculus); hypocitraturic calcium oxalate nephrolithiasis of any etiology; or uric acid nephrolithiasis (with or without calcium stones). <br />  NOTE: The treatment regimen includes hydration (urine volume 2 L/day or more) and dietary sodium restriction.<br />NOTE: Monitor 24-hour urinary citrate concentrations and/or urinary pH to evaluate initial dosage or dosage adjustments, and then every 4 months during maintenance therapy. The goal of therapy in adults is to restore normal urinary citrate (greater than 320 mg/day, and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to 6 to 7.<br />NOTE: In patients with severe renal tubular acidosis or chronic diarrheal syndrome where urinary citrate may be very low (less than 100 mg/day), potassium citrate may be relatively ineffective in raising urinary citrate; a higher dose may be required to produce a satisfactory response. In patients with renal tubular acidosis in whom urinary pH may be high, potassium citrate produces a relatively small rise in urinary pH.<br />NOTE: The manufacturer advises monitoring of serum electrolytes (sodium, potassium, chloride and carbon dioxide), serum creatinine (SCr), and CBC every 4 months during therapy with potassium citrate extended-release tablets (Urocit-K). Treatment should be discontinued if there is hyperkalemia, a significant rise in serum creatinine, or a significant fall in blood hematocrit or hemoglobin***For the management of distal renal tubular acidosis (RTA) in children�.***For the treatment or prevention of hypokalemia�. <br />  NOTE: In oral dosing for hypokalemia, potassium chloride is the salt of choice (see Potassium Salts monograph) due to better GI absorption than other potassium salts such as potassium citrate.<br />NOTE: Hypokalemia is generally defined as a serum potassium concentration less than 3.5 mEq/L; however, serum potassium concentrations do not always correlate with cellular potassium levels. The National Council on Potassium in Clinical Practice recommends that serum potassium concentrations 4 mEq/L or more be achieved and maintained in patients with hypertension, heart failure, and cardiac arrhythmias. In addition, the Council recommends potassium supplementation for patients with potential for diuretic-induced potassium loss (e.g., thiazide or loop diuretics), patients with high sodium intake (or unwilling to reduce salt intake), and patients with reduced GI intake (e.g., GI disturbances, laxative abuse)***For the prevention of hypokalemia�.***For the treatment of hypokalemia�.***Formoterol; Mometasone","***General Information***Adrenal insufficiency, burns, dehydration, diabetes mellitus, diarrhea, geriatric, hyperkalemia, hypocalcemia, metabolic alkalosis, renal disease, renal failure, renal impairment***Atrial fibrillation, atrial flutter, cardiac arrhythmias, digitalis toxicity, heart failure, hypertension, ventricular arrhythmias, ventricular fibrillation, ventricular tachycardia***Esophageal stricture, gastroparesis, GI obstruction, ileus, peptic ulcer disease***Urinary tract infection (UTI)***Muscle cramps***Hepatic disease***Chronic obstructive pulmonary disease (COPD)***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1102129'],boceprevir,"***For the treatment of chronic hepatitis C infection (HCV, genotype 1) in adults with compensated liver disease. <br />        �NOTE: Boceprevir must be administered in combination with peginterferon alfa and ribavirin; never administer as monotherapy.<br />     ***Formoterol; Mometasone","***General Information***Male-mediated teratogenicity, pregnancy***Breast-feeding***Anemia***Agranulocytosis, neutropenia***Hepatitis C and HIV coinfection***Hepatic disease, hypoalbuminemia, thrombocytopenia***Organ transplant***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,octreotide acetate,"***For the treatment of acromegaly. <br />        NOTE: Octreotide has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of symptoms associated with carcinoid tumors, specifically, diarrhea and cutaneous flushing. <br />  NOTE: Octreotide has been designated an orphan drug by the FDA for this indication.�<br /***For the treatment of symptoms associated with vasoactive intestinal peptide tumors (e.g., VIPoma) (i.e., to reduce plasma concentrations of vasoactive intestinal peptide). <br />        NOTE: Octreotide has been designated an orphan drug by the FDA for this indication.<br />     ***For the management of intractable diarrhea� or ileostomy-associated diarrhea�.***For the management of chemotherapy-induced diarrhea� in pediatric patients.***For the control of diarrhea secondary to AIDS-associated enteropathy�.***For the treatment of dumping syndrome�.***For the treatment of short bowel syndrome�.***For the treatment of enterocutaneous fistula�.***For reducing output from a pancreatic fistula�.***For adjunct therapy to endoscopic variceal ligation in the treatment of upper GI bleeding� or variceal bleeding� in patients with esophageal varices�.***For the treatment of hyperthyroidism� secondary to thyrotropinoma�.***For the treatment of hypoglycemia in patients with hyperinsulinism, including patients with benign or malignant insulinoma�.***For the treatment of neurogenic orthostatic hypotension�.***For the treatment of hepatorenal syndrome� in combination with midodrine and albumin.***For the treatment of acute cluster headache�.","***General Information***Biliary obstruction, biliary tract disease, cholangitis, cholelithiasis, gallbladder disease***Pancreatitis***Hepatic disease***Dialysis, renal failure***Diabetes mellitus, gastroparesis, hyperglycemia, hypoglycemia***Goiter, hypothyroidism***Fat malabsorption, vitamin B12 deficiency***Pregnancy***Breast-feeding***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, electrolyte imbalance, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Growth inhibition, infants, necrotizing enterocolitis, neonates, premature neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pseudoephedrine hydrochloride,"***For the temporary relief of the symptoms of sinus and nasal congestion due to the common cold, allergic rhinitis or other upper respiratory allergies or conditions, including eustachian tube congestion.***For otalgia prophylaxis� prior to air-pressure changes induced by jet-travel.***For the treatment of urinary incontinence� in adult patients with stress incontinence due to urethral sphincter weakness.***Formoterol***Formoterol; Mometasone","***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, heart failure, hypertension, MAOI therapy, substance abuse, tachycardia***Bronchitis, closed-angle glaucoma, diabetes mellitus, emphysema, hyperthyroidism, urinary retention***Renal failure, renal impairment***Dysphagia, GI obstruction***Pregnancy***Breast-feeding***Geriatric***Children, infants***Phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8588'],hydrochlorothiazide/losartan potassium,"***For the treatment of hypertension. <br />        NOTE: Hyzaar is available as 50�12.5 mg, 100�12.5 mg, and 100�25 mg dosage strengths for losartan and hydrochlorothiazide, respectively. Individualize dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, Hyzaar can be substituted.<br />     ***For patients who do not respond to monotherapy.***For severe hypertension.***For stroke prophylaxis in hypertensive patients with left ventricular hypertrophy (LVH). <br />        NOTE: There is evidence that this benefit does not apply to Black patients.<br />NOTE: Hyzaar is available as 50�12.5 mg, 100�12.5 mg, and 100�25 mg dosage strengths for losartan and hydrochlorothiazide, respectively. Individualize dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, Hyzaar can be substituted***Formoterol***Formoterol; Mometasone","***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, heart failure, renal artery stenosis, renal disease, renal failure, renal impairment***Hepatic disease***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***ACE-inhibitor induced angioedema, angioedema***Surgery***Pregnancy***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia, hyponatremia***Breast-feeding***Children, infants, neonates***Diabetes mellitus, hyperglycemia***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,indinavir sulfate,***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***Formoterol; Mometasone,"***General Information***Dehydration, nephrolithiasis***Hepatitis, hepatitis B and HIV coinfection***Hepatic disease***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia***Labor, neonates***Pregnancy***Breast-feeding***Children, infants***Hemophilia***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, pancreatitis***Human immunodeficiency virus (HIV) infection resistance***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome, tuberculosis***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['141704'],everolimus,"***For the treatment of patients with advanced renal cell cancer (RCC).***For the treatment of patients with advanced renal cell cancer who have failed treatment with sunitinib or sorafenib.***For the treatment of advanced renal cell cancer (RCC) in combination with lenvatinib, following one prior anti-angiogenic therapy.***For kidney transplant rejection prophylaxis in patients at low-moderate immunologic risk. <br />        NOTE: The safety and efficacy of everolimus have not been established in patients at high immunologic risk.<br />     ***For the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) in patients who require therapeutic intervention but are not candidates for curative surgical resection.***For the treatment of patients with unresectable, locally advanced, or metastatic neuroendocrine tumor (NET) or carcinoid tumors. ***For the treatment of progressive neuroendocrine tumor (NET) of pancreatic origin (also known as PNET) in patients with unresectable, locally advanced or metastatic disease.***For the treatment of progressive, well-differentiated, non-functional neuroendocrine tumor (NET) of gastrointestinal or lung origin (also known as carcinoid) in patients with unresectable, locally advanced or metastatic disease. <br />          NOTE: Everolimus is not indicated for the treatment of patients with functional carcinoid tumors.<br />       ***For the treatment of breast cancer.***For the treatment of hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women who have failed treatment with letrozole or anastrozole, in combination with exemestane.***For the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer in postmenopausal women with secondary aromatase inhibitor resistance, in combination with tamoxifen�.***For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with vinorelbine and trastuzumab�.***For the treatment of renal angiomyolipoma and tuberous sclerosis complex not requiring immediate surgery.***For liver transplant rejection prophylaxis.***For the treatment of relapsed or refractory Waldenstrom macroglobulinemia�.","***General Information***Pleural effusion, pneumonitis, pulmonary fibrosis***Fungal infection, infection***Immunosuppression, lymphoma, new primary malignancy, skin cancer, sunlight (UV) exposure***Nephrotoxicity, renal impairment***Renal artery thrombosis, renal graft thrombosis, renal vein thrombosis***Diabetes mellitus, hyperglycemia, hyperlipidemia, hypertriglyceridemia***Hepatic disease***Vaccination***Heart transplant, mortality***Surgery, wound dehiscence***Geriatric***Lactase deficiency***Pregnancy***Contraception requirements, infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sertraline hydrochloride,***For the treatment of major depression.***For the treatment of major depression in adults.***For the treatment of major depression� in pediatric patients.***For the treatment of social phobia (social anxiety disorder).***For the treatment of obsessive-compulsive disorder (OCD).***For the treatment of posttraumatic stress disorder (PTSD).***For the treatment of panic disorder.***For the treatment of premenstrual dysphoric disorder (PMDD).***For the treatment of generalized anxiety disorder (GAD)�.***For the treatment of separation anxiety disorder�.***For the treatment of hot flashes� due to menopause� or in women who have been treated for breast cancer.***For women experiencing hot flashes� as a symptom of menopause�.***For hot flashes� in women treated for breast cancer or for an increased risk of breast cancer.***For the treatment of premature ejaculation�.***For the treatment of pruritus� due to cholestatic liver disease.***Formoterol***Formoterol; Mometasone,"***General Information***Abrupt discontinuation***Children, growth inhibition, suicidal ideation***Bipolar disorder, mania***MAOI therapy***Electroconvulsive therapy (ECT), seizure disorder***Dehydration, hyponatremia, hypovolemia***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Hepatic disease***Anticoagulant therapy, bleeding, thrombolytic therapy***Bone fractures, osteoporosis***Closed-angle glaucoma, increased intraocular pressure***Akathisia***Anorexia nervosa***Driving or operating machinery, ethanol ingestion***Neonates, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,zoledronic acid,"***For the treatment of hypercalcemia of malignancy (i.e., albumin-corrected serum calcium 12 mg/dL or higher).***For the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. <br />  NOTE: When used for bone metastases of prostate cancer, the disease should have progressed after treatment with at least one hormonal therapy.<br />NOTE: To avoid hypocalcemia and maintain proper status, patients should also receive an oral calcium supplement of 500 mg and a multiple vitamin containing 400 International Units of Vitamin D every day during treatment***For the treatment of active Paget's disease. <br />        NOTE: To reduce the risk of hypocalcemia, all patients should receive an intake of 1500 mg elemental calcium daily in divided doses (750 mg two times a day, or 500 mg three times a day) and 800 International Units vitamin D daily, particularly in the 2 weeks following drug administration.<br />     ***For the treatment of osteoporosis.***For secondary fracture prophylaxis in high-risk patients (i.e., recent low-trauma hip fracture).***For the treatment of glucocorticoid-induced osteoporosis in men and women taking systemic glucocorticoids (i.e., oral prednisone 7.5 mg/day or more, or equivalent) and expected to continue glucocorticoid therapy for 12 months or longer.***For osteoporosis prophylaxis.***For the prevention of glucocorticoid-induced osteoporosis in men and women taking systemic glucocorticoids (i.e., oral prednisone 7.5 mg/day or more, or equivalent) and expected to continue glucocorticoid therapy for 12 months or longer.***For the adjuvant treatment of early breast cancer� in women with postmenopausal reproductive hormone levels.","***General Information***Acute bronchospasm, asthma, phosphonate hypersensitivity***Dehydration, diarrhea, fever, hypovolemia, vomiting***Diabetes mellitus, hypertension, multiple myeloma, renal disease, renal failure, renal impairment***Cardiac arrhythmias, electrolyte imbalance, hypocalcemia, hypomagnesemia, hypophosphatemia, seizures***Pregnancy***Breast-feeding***Children, infants, neonates***Anemia, chemotherapy, coagulopathy, corticosteroid therapy, dental disease, dental work, infection***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['719872'],raltegravir,"***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***For human immunodeficiency virus (HIV) prophylaxis�.***For human immunodeficiency virus (HIV) prophylaxis� after occupational exposure.***For human immunodeficiency virus (HIV) prophylaxis� after nonoccupational exposure, including sexual assault. <br />  NOTE: Higher risk exposures for which prophylaxis is recommended include exposure of vagina, rectum, eye, mouth, or other mucous membrane, nonintact skin, or percutaneous contact with blood, semen, vaginal secretions, rectal secretions, breast milk, or any body fluid that is visibly contaminated with blood when the source is known to be HIV-positive. Exposures to a source patient with unknown HIV status should be assessed on a case-by-case basis.<br /","***General Information***Breast-feeding***Human immunodeficiency virus (HIV) infection resistance***Hepatic disease, hepatitis, hepatitis B and HIV coinfection, hepatitis C and HIV coinfection***Pregnancy***Lactase deficiency, phenylketonuria***Geriatric***Depression, suicidal ideation***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Serious rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mometasone furoate,"***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses including alopecia areata, atopic dermatitis, contact dermatitis, dermatitis, discoid lupus erythematosus, eczema, exfoliative dermatitis, granuloma annulare, keloids, lichen planus, lichen simplex, lichen striatus, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pruritus, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, xerosis, and severe <em>Rhus dermatitis</em> due to plants like poison ivy. <br />  NOTE: Occlusive dressings may be required for chronic or severe cases of lichen simplex chronicus, psoriasis, eczema, atopic dermatitis, or chronic hand eczema. More potent topical corticosteroids and/or occlusive dressings may be necessary for the treatment of discoid lupus erythematosus, lichen planus, granuloma annulare, psoriatic plaques, and psoriasis of the palms, soles, elbows, or knees.<br /***For maintenance treatment of asthma.***For the management of nasal symptoms associated with seasonal or perennial allergic rhinitis (e.g., nasal congestion).***For seasonal allergic rhinitis prophylaxis.***For the treatment of nasal polyps.***For sinus patency maintenance after ethmoid sinus surgery in patients with chronic sinusitis.***For exercise-induced bronchospasm prophylaxis�.","***Corticosteroid hypersensitivity***Milk protein hypersensitivity***Acute bronchospasm, paradoxical bronchospasm, status asthmaticus***Skin atrophy***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion, surgery***Children, growth inhibition, increased intracranial pressure, infants, neonates***Diabetes mellitus, hyperglycemia, peripheral vascular disease***Nasal septal perforation, nasal surgery, nasal trauma***Cataracts, glaucoma, increased intraocular pressure, ocular exposure, visual disturbance***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, tuberculosis, varicella, viral infection***Pregnancy***Breast-feeding***Sunlight (UV) exposure***Hepatic disease***Osteoporosis***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['358255'],aprepitant,"***For chemotherapy-induced nausea/vomiting prophylaxis (CINV prophylaxis).***For acute and delayed chemotherapy-induced nausea/vomiting (CINV) prophylaxis associated with highly-emetogenic chemotherapy.***For chemotherapy-induced nausea/vomiting (CINV) prophylaxis associated with moderately-emetogenic chemotherapy.***For post-operative nausea/vomiting (PONV) prophylaxis. <br />  NOTE: Chronic, continuous use of aprepitant/fosaprepitant is not recommended because it has not been studied, and the drug interaction profile may change during chronic continuous use.<br /","***General Information***Hypotension, infusion-related reactions, polysorbate 80 hypersensitivity***Hepatic disease***Anticoagulant therapy***Children, infants, neonates***Contraception requirements, contraceptive devices***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['662281'],nilotinib,***For the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). <br />        NOTE: Nilotinib has been designated an orphan drug by the FDA for the treatment of CML.<br />     ***For the treatment of chronic phase Ph+ CML in patients resistant or intolerant to prior therapy that included imatinib.***For the treatment of newly diagnosed chronic phase Ph+ CML.***For the treatment of accelerated phase Ph+ CML in patients resistant or intolerant to prior therapy that included imatinib.***For the treatment of chronic phase Ph+ CML in patients resistant or intolerant to prior tyrosine-kinase inhibitor therapy.***Formoterol***Formoterol; Mometasone,"***Cardiac disease, cerebrovascular disease, heart failure, myocardial infarction, occlusive vascular disease***Anemia, neutropenia, thrombocytopenia***Alcoholism, angina, bradycardia, cardiac arrhythmias, coronary artery disease, diabetes mellitus, geriatric, hypertension, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, mortality, QT prolongation, thyroid disease***Hepatic disease***Pancreatitis***Galactose-free diet, lactase deficiency***Gelatin hypersensitivity***Total gastrectomy***Dehydration, leukocytosis, tumor lysis syndrome (TLS)***Ascites, edema, pericardial effusion, pleural effusion, pulmonary edema***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia***Hyperglycemia, hypoglycemia***Bleeding***Pregnancy***Contraception requirements, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,phentermine hydrochloride,"***For the short-term treatment of obesity, used as an adjunct to behavior modifications including dietary modification and appropriate exercise.***Formoterol***Formoterol; Mometasone","***General Information***Angina, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypertension, pulmonary hypertension, stroke, valvular heart disease***Hyperthyroidism, thyroid disease***MAOI therapy***Anxiety, insomnia, mania, psychosis, schizophrenia***Driving or operating machinery, ethanol ingestion***Diabetes mellitus***Anorexia nervosa, substance abuse***Abrupt discontinuation***Closed-angle glaucoma***Geriatric, renal failure, renal impairment***Pregnancy***Breast-feeding***Children, infants***Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,enoxaparin sodium,"***For the treatment of venous thromboembolism (VTE) including acute deep venous thrombosis (DVT) or pulmonary embolism (PE).***For inpatient treatment of DVT with or without PE.***For the outpatient treatment of acute DVT not associated with PE, in conjunction with warfarin.***For the treatment of DVT or PE in pregnant females�.***For the treatment of DVT or PE in patients with cancer�.***For thrombosis prophylaxis. <br />        NOTE: Mechanical methods of prophylaxis should be used in patients who are at high risk of bleeding or as an adjunct to anticoagulant-based prophylaxis.<br />     ***For arterial thromboembolism prophylaxis� in patients after prosthetic heart valves� surgery.***For venous thromboembolism (VTE) prophylaxis including deep venous thrombosis (DVT) prophylaxis or pulmonary embolism prophylaxis.***For thrombosis prophylaxis in patients with obesity�.***For deep venous thrombosis (DVT) prophylaxis in pregnant females. <br />          NOTE: In all pregnant women with a history of DVT, the use of graduated elastic stockings (ES) is recommended both antenatally and postpartum.<br />       ***For thrombosis prophylaxis in pregnant patients with prosthetic heart valves�.***For thrombosis prophylaxis in low-risk patients receiving anticoagulation with vitamin K antagonists (VKA) who require an interruption in VKA dosing (e.g., prior to an invasive procedure)�. <br />          NOTE: Patients considered to be at low-risk for thromboembolism include: no VTE within the previous 3 months, atrial fibrillation without a history of stroke or other risk factors, or a bileaflet mechanical valve in the aortic position.<br />       ***For thrombosis prophylaxis in moderate-risk patients receiving anticoagulation with vitamin K antagonists (VKA) who require an interruption in VKA dosing (e.g., prior to an invasive procedure)�.***For thrombosis prophylaxis in high-risk patients receiving anticoagulation with vitamin K antagonists (VKA) who require an interruption in VKA dosing (e.g., prior to an invasive procedure)�. <br />          NOTE: Patients considered to be at high-risk for thromboembolism include patients with a history of VTE within the previous 3 months, a mechanical cardiac valve in the mitral position, or an old model cardiac valve (ball/cage).<br />       ***For thrombosis prophylaxis and/or for pulmonary embolism prophylaxis in patients at increased risk after sustaining an acute MI (e.g., ST segment elevation MI, severe LV dysfunction, CHF, history of systemic or pulmonary embolism, 2D echo evidence of mural thrombus, or atrial fibrillation).***For arterial thromboembolism prophylaxis� in patients with atrial fibrillation who are undergoing elective cardioversion.***For the treatment of cerebral thromboembolism� (e.g., cerebral venous sinus thrombosis�).***For coronary artery thrombosis prophylaxis and the prevention of ischemic complications in patients with acute coronary syndrome (ACS), including patients undergoing percutaneous coronary intervention (PCI)�. <br />        NOTE: Adhere precisely to the intervals recommended between enoxaparin doses to minimize the risk of bleeding following the vascular instrumentation during the treatment of angina that is unstable, non-Q-wave myocardial infarction, and acute ST-segment elevation myocardial infarction. It is important to achieve hemostasis at the puncture site after PCI. In case a closure device is used, the sheath can be removed immediately. If a manual compression method is used, remove the sheath 6 hours after the last enoxaparin dose. If enoxaparin is to be continued, the next scheduled dose should be given no sooner than 6�8 hours after sheath removal. Observe the procedure site for signs of bleeding or of hematoma formation.<br />     ***For patients with acute myocardial infarction with ST-segment elevation (ST-segment elevation myocardial infarction or STEMI). <br />          NOTE: In the pivotal clinical study, the enoxaparin treatment duration was 8 days or until hospital discharge, whichever came first. An optimal duration of treatment is not known, but it is likely to be longer than 8 days.<br />       ***For patients with unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI), or non-Q-wave myocardial infarction.***For the prevention of pregnancy loss and/or thrombosis in patients with antiphospholipid antibody syndrome� (APLA).","***Benzyl alcohol hypersensitivity, heparin hypersensitivity, porcine protein hypersensitivity***Heparin-induced thrombocytopenia (HIT), thrombocytopenia***Aneurysm, bleeding, coagulopathy, diabetic retinopathy, diverticulitis, endocarditis, GI bleeding, hemophilia, hepatic disease, hypertension, idiopathic thrombocytopenic purpura (ITP), inflammatory bowel disease, peptic ulcer disease, renal disease, stroke, surgery***Intramuscular injections***Prosthetic heart valves***Pregnancy***Breast-feeding***Anticoagulant therapy, thrombolytic therapy***Dialysis, renal failure, renal impairment***Females, geriatric***Obesity***Children, infants, neonates***Epidural anesthesia, lumbar puncture, spinal anesthesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,atropine sulfate,"***For the treatment of bradyasystolic cardiac arrest.***For pre-operative use to decrease secretions (i.e., aspiration prophylaxis), as well as block cardiovagal reflexes and/or succinylcholine-induced arrhythmias, during surgery.***For the treatment of cholinergic crisis (e.g., chemical nerve agent or organophosphate insecticide toxicity). <br />        NOTE: Start atropine as soon as symptoms of toxicity occur. A survey of accidental auto-injections of atropine in children found that even relatively large doses (up to 0.175 mg/kg) were not associated with mortality or life-threatening complications (i.e., seizures, arrhythmias). In 48% of children (116/240), systemic atropine effects were noted, with 8% experiencing severe atropinization. Severity of atropinization was dose-related in a non-linear fashion.<br />     ***For cholinesterase inhibitor-induced muscarinic effects prophylaxis when anticholinesterase agents (i.e., neostigmine, physostigmine, pyridostigmine) are used to reverse the neuromuscular blockade produced by curariform agents.***For adjunctive treatment of GI disorders caused by cholinergic stimulation, such as duodenal ulcer, irritable bowel syndrome, or GI hypermotility and diarrhea.***For mydriasis induction or cycloplegia induction.***For the treatment of iritis or uveitis.***For the treatment of symptomatic bradycardia� (e.g., vasovagal response, AV block, or bradyarrhythmias). <br />        NOTE: Atropine may be administered in higher initial doses for bradycardia resulting from acetylcholinesterase-inhibiting agents; large total doses may be required.<br />     ***For the treatment of moderate amblyopia�.***For management of early-onset irinotecan-induced diarrhea�.***For the prevention of bradycardia and reduction of oral secretions during rapid-sequence intubation�.","***General Information***Driving or operating machinery***Acute myocardial infarction, angina, bleeding, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypertension, hyperthyroidism, mitral stenosis, myocardial infarction, tachycardia, thyrotoxicosis***Heart transplant***Asthma, chronic lung disease (CLD), chronic obstructive pulmonary disease (COPD), respiratory infection***Hepatic disease***Bladder obstruction, prostatic hypertrophy, renal failure, renal impairment, urinary retention, urinary tract obstruction***Autonomic neuropathy, myasthenia gravis***Achalasia, colostomy, diarrhea, esophagitis, gastroesophageal reflux disease (GERD), GI disease, GI obstruction, hiatal hernia, ileostomy, ileus, peptic ulcer disease, pseudomembranous colitis, pyloric stenosis, toxic megacolon, ulcerative colitis***Closed-angle glaucoma, contact lenses, glaucoma, increased intraocular pressure, synechia***Ambient temperature increase, dehydration, fever, strenuous exercise***Children, infants, neonates***Pregnancy***Breast-feeding***Dental disease***Anticholinergic medications, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1895'],fosamprenavir calcium,***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***For the treatment of HIV in protease inhibitor-experienced patients.***For the treatment of HIV in protease inhibitor-naive patients.***For human immunodeficiency virus (HIV) prophylaxis� after occupational exposure.***Formoterol; Mometasone,"***General Information***Sulfonamide hypersensitivity***Hepatitis, hepatitis B and HIV coinfection***Hepatic disease***Hypercholesterolemia, hypertriglyceridemia, myocardial infarction***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia***Hemophilia***Infants, neonates, premature neonates***Pregnancy***Breast-feeding***Human immunodeficiency virus (HIV) infection resistance***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Geriatric***Hemolytic anemia***Serious rash***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,brentuximab vedotin,"***For the treatment of classical Hodgkin lymphoma. <br />        NOTE: Brentuximab has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of previously untreated stage III or IV classical Hodgkin lymphoma, in combination with chemotherapy.***For the treatment of systemic anaplastic large-cell lymphoma after failure of at least 1 prior multi-agent chemotherapy regimen. <br />  Note: Brentuximab vedotin has been designated an orphan drug by the FDA for the treatment of anaplastic large-cell lymphoma.<br /***For the treatment of cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma, in patients who have received prior systemic therapy. <br />  Note: Brentuximab vedotin has been designated an orphan drug by the FDA for the treatment of CTCL and mycosis fungoides.<br /","***Pneumonitis, pulmonary disease, respiratory distress syndrome***Peripheral neuropathy***Anemia, geriatric, neutropenia, thrombocytopenia***Tumor lysis syndrome (TLS)***Progressive multifocal leukoencephalopathy***Renal impairment***Hepatic disease***Infection, sepsis***Infusion-related reactions***Colitis, GI bleeding, GI disease, GI obstruction, GI perforation, ileus, peptic ulcer disease***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,corticorelin ovine triflutate,***For the differential diagnosis of pituitary or ectopic production of corticotropin (ACTH) in patients with ACTH-dependent Cushing's syndrome.,"***Ovine protein hypersensitivity***Intramuscular administration, subcutaneous administration***Dialysis, renal failure***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['83818'],irbesartan,"***For the treatment of hypertension.***For the treatment of proteinuria or diabetic nephropathy. <br />  NOTE: Based on the Irbesartan Diabetic Nephropathy Trial, irbesartan is FDA-approved for the treatment of diabetic nephropathy (defined as elevated serum creatinine and proteinuria greater than 300 mg/day) in patients with type 2 diabetes and hypertension. In this population, irbesartan reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or progression to end-stage renal disease (i.e., need for dialysis or renal transplantation).<br /","***Hypotension, hypovolemia***Heart failure, renal artery stenosis***Hyperkalemia***Hepatic disease***ACE-inhibitor induced angioedema, angioedema***Black patients***Surgery***Pregnancy***Breast-feeding***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cimetidine hydrochloride,"***For the treatment of gastroesophageal reflux disease (GERD) or esophagitis associated with gastroesophageal reflux disease (GERD).***For the self-medication of pyrosis (heartburn), acid dyspepsia (acid indigestion), or sour stomach.***For the treatment of peptic ulcer disease (duodenal ulcer or gastric ulcer). <br />        NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br />     ***For acute treatment.***For maintenance therapy of refractory duodenal ulcer or gastric ulcer in patients with peptic ulcer disease.***For Helicobacter pylori (H. pylori) eradication in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />        NOTE: The American College of Gastroenterology (ACG) recommends 10�14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole; the same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.�<br />NOTE: Famotidine is not effective as a single agent for the eradication of H. pylori. Quadruple regimens that include an H2-blocker as an anti-secretory agent are FDA-approved, but are associated with lower compliance and efficacy rates than other recommended regimens.  An H2-blocker should not be substituted for a PPI in any current H. pylori treatment regimen unless the patient cannot tolerate a PPI.�<br />NOTE: In populations where H. pylori infection is common (&gt;= 10%), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Helidac monograph).  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60�90% of patients.***For the treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome, systemic mastocytosis, and multiple endocrine adenoma syndrome.***For the treatment of upper GI bleeding or acute gastritis.***For stress gastritis prophylaxis in critically-ill patients.***For acid aspiration prophylaxis� prior to intubation or anesthesia.***For NSAID-induced ulcer prophylaxis�.***For the treatment of acute, severe urticaria� or angioedema� associated with systemic symptoms in combination with an H1-blocker.***For the prevention of urticaria and other histamine-mediated reactions to specific types of chemotherapy� (e.g., paclitaxel).***Formoterol; Mometasone","***General Information***Benzyl alcohol hypersensitivity, H2-blocker hypersensitivity***Intravenous administration***Gastric cancer***Infection***Hepatic disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Neonates***Tobacco smoking***Immunosuppression***Geriatric***Vitamin B12 deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,chlorpromazine hydrochloride,"***For the treatment of schizophrenia.***For the treatment of nausea/vomiting.***For the adjunctive treatment of tetanus.***For the treatment of intractable singultus (hiccups).***For the treatment of acute intermittent porphyria.***For the treatment of acute psychosis in acutely agitated schizophrenic patients.***For the treatment of severe behavioral problems associated with oppositional defiant disorder or other disruptive behavioral disorders, or for attention-deficit hyperactivity disorder (ADHD) in pediatric patients who show excessive motor activity with accompanying conduct disorders.***For the treatment of acute migraine�.***For the treatment of agitation� or delirium� in hospitalized patients without underlying psychiatric illness.***For the treatment of neonatal abstinence syndrome�. <br />        NOTE: The use of chlorpromazine in infants under the age of 6 months should be limited to illnesses where the use of the medication could be potentially lifesaving.<br />NOTE: Although chlorpromazine is included in current guidelines established by the American Academy of Pediatrics, its use is limited due to occasional adverse effects such as hypothermia, decreased seizure threshold, and eosinophilia***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.","***Asthma, benzyl alcohol hypersensitivity, phenothiazine hypersensitivity, sulfite hypersensitivity***Agranulocytosis, bone marrow suppression, fever, hematological disease, infection, leukopenia, neutropenia***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion, head trauma***Dental work, surgery***Intracranial mass, seizure disorder, seizures***Tardive dyskinesia***Anticholinergic medications, closed-angle glaucoma, ileus, prostatic hypertrophy, urinary retention***Alcoholism, angina, AV block, bradycardia, bundle-branch block, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, parenteral administration, QT prolongation, tachycardia, thyroid disease, torsade de pointes***Pulmonary disease***Encephalopathy, hepatic disease, jaundice***Labor, neonates, obstetric delivery, pregnancy, pregnancy testing***Breast-feeding***Children, infants, Reye's syndrome***Breast cancer, hyperprolactinemia, infertility***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Sunlight (UV) exposure***Accidental exposure***Abrupt discontinuation***Renal failure***Ocular disease***Chemotherapy, GI obstruction, vomiting***Tobacco smoking***Suicidal ideation***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Radiographic contrast administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],estradiol,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For systemic treatment of the vasomotor symptoms (hot flashes) and genitourinary symptoms of menopause.***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For estrogen replacement for premenopausal women with primary ovarian failure or female hypogonadism.***For the palliative treatment of advanced inoperable prostate cancer.***For the palliative treatment of breast cancer that is inoperable and progressive in selected men and postmenopausal women.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates***Intravenous administration***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3254'],desonide,"***For the treatment of mild to moderate inflammatory manifestations of corticosteroid-responsive dermatitis such as contact dermatitis, exfoliative dermatitis, <em>Rhus dermatitis</em> due to plants like poison ivy, or seborrheic dermatitis (facial and intertriginous areas), discoid lupus erythematosus (facial and intertriginous areas), eczema, granuloma annulare, intertrigo, cutaneous lichen planus, lichen simplex chronicus, polymorphous light eruption, anogenital or senilis pruritus, psoriasis (facial and intertriginous areas), or xerosis (inflammatory phase). <br />        NOTE: Occlusive dressings may be required for chronic or severe cases of lichen simplex chronicus, psoriasis, eczema, or chronic hand eczema. More potent topical corticosteroids and/or occlusive dressings may be necessary for the treatment of discoid lupus erythematosus, lichen planus, granuloma annulare, psoriatic plaques, and psoriasis of the palms, soles, elbows, or knees.<br />     ***For the treatment of mild to moderate atopic dermatitis. <br />        NOTE: Occlusive dressings may be required for chronic or severe cases of atopic dermatitis.<br />     ","***General Information***Corticosteroid hypersensitivity***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Diabetes mellitus***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, tuberculosis, varicella, viral infection***Ocular exposure, ophthalmic administration***Geriatric, skin atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albuterol sulfate,"***For the treatment of acute bronchospasm (e.g., asthma) and bronchospasm prophylaxis.***For bronchospasm associated reversible obstructive airway disease (i.e., asthma).***For exercise-induced bronchospasm prophylaxis.***For the adjunctive emergency acute treatment of hyperkalemia�.***For the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD)� including chronic bronchitis� and emphysema�.","***General Information***Albuterol hypersensitivity, levalbuterol hypersensitivity, milk protein hypersensitivity***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, tachycardia, thyroid disease***Geriatric***Hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyrotoxicosis***Diabetes mellitus, diabetic ketoacidosis***Deterioration of asthma, paradoxical bronchospasm***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Renal impairment***MAOI therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['68244']['11413'],lamivudine/zidovudine,"***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***For human immunodeficiency virus (HIV) prophylaxis�.***For human immunodeficiency virus (HIV) prophylaxis� after occupational exposure.***For human immunodeficiency virus (HIV) prophylaxis� after nonoccupational exposure, including sexual assault. <br />  NOTE: Higher risk exposures for which prophylaxis is recommended include exposure of vagina, rectum, eye, mouth, or other mucous membrane, nonintact skin, or percutaneous contact with blood, semen, vaginal secretions, rectal secretions, breast milk, or any body fluid that is visibly contaminated with blood when the source is known to be HIV-positive. Exposures to a source patient with unknown HIV status should be assessed on a case-by-case basis.<br /","***General Information***Children, infants, neonates***Renal failure, renal impairment***Anemia, bone marrow suppression, folate deficiency, neutropenia, radiation therapy, vitamin B12 deficiency***Alcoholism, females, hepatic disease, hepatotoxicity or lactic acidosis, obesity***Hepatitis B and HIV coinfection, hepatitis B exacerbation***Dental disease, dental work***Pancreatitis***Peripheral neuropathy***Pregnancy***Breast-feeding***Human immunodeficiency virus (HIV) infection resistance***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Myopathy***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['197'],acetylcysteine,"***For the prevention of hepatotoxicity after an acute acetaminophen overdose or repeated ingestion of supratherapeutic doses. <br />  NOTE: The Rumack-Matthew nomogram should be used to estimate the hepatotoxicity potential from an acute acetaminophen (APAP) overdose in patients with a known APAP concentration, a known APAP ingestion time, and who present within 8 hours of the overdose. For patients whose serum APAP concentrations fall above the possible"" toxicity line on the nomogram",initiate treatment within 8 hours of suspected APAP ingestion for maximal protection against hepatic injury. Give activated charcoal as soon as possible after ingestion to prevent APAP absorption. For regular-release APAP overdoses,obtain serum drug concentration at least 4 hours post-ingestion; concentrations obtained earlier than 4 hours may not represent maximum APAP concentrations. For extended-release APAP overdoses,if the initial APAP serum concentration was below the possible toxicity line,obtain a second concentration 8 to 10 hours post-ingestion. The efficacy of acetylcysteine diminishes progressively after 8 hours post-ingestion. Beginning treatment 15 to 24 hours post-ingestion results in limited efficacy; however,it does not appear to worsen the condition and should not be withheld since the reported time of ingestion may not be correct. If the time of ingestion is unknown,or the serum APAP concentration is not available,cannot be interpreted,or is not available within 8 hours of APAP ingestion,acetylcysteine should be administered immediately regardless of the quantity reported to have been ingested. If greater than 24 hours has elapsed since the APAP ingestion,the clinician should determine the appropriateness of acetylcysteine administration based on the patients liver status and clinical presentation.<br />NOTE: The Rumack-Matthew nomogram is ineffective at predicting hepatotoxicity in patients who have ingested repeated supratherapeutic doses of acetaminophen over an extended period of time. In these patients,treatment should be guided by information obtained from laboratory tests,including: acetaminophen serum concentrations,liver function tests (LFTs),serum creatinine,BUN,electrolytes,bilirubin,blood glucose,and INR. Assistance may be obtained by contacting your regional poison control center at 1�800�222�1222 or the acetaminophen overdose center at 1�800�525�6115.***For adjunctive treatment of chronic bronchopulmonary disorders such as chronic obstructive pulmonary disease (COPD),including chronic bronchitis,emphysema,tuberculosis,bronchiectasis,and primary amyloidosis of the lung.***For mucolysis of viscous or inspissated mucous secretions in patients with pulmonary conditions (e.g.,pneumonia,bronchitis,cystic fibrosis,atelectasis due to mucous obstruction,and post-traumatic chest conditions) and for use during tracheostomy care,anaesthesia,"and diagnostic bronchograms.***For diagnostic bronchial studies.***For nephrotoxicity prophylaxis� against radiographic-contrast-induced reductions in renal function in those patients with preexisting renal insufficiency (SCr > 1.2mg/dl or CrCl < 60 ml/min) or who are otherwise at risk for radiocontrast-induced nephropathy.***For the treatment of giant papillary conjunctivitis (GPC)�.***For the treatment of distal intestinal obstruction syndrome (DIOS)� (previously called meconium ileus equivalent).""","***General Information***Acute bronchospasm, asthma, gag reflex depression, respiratory insufficiency***Esophageal varices, GI bleeding, peptic ulcer disease, vomiting***Children, infants, neonates***Pregnancy***Breast-feeding***Heart failure, hypertension, renal disease"
,bisoprolol fumarate/hydrochlorothiazide,***For the treatment of hypertension in patients who do not respond to monotherapy.***Formoterol***Formoterol; Mometasone,"***Beta-blocker hypersensitivity, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, renal disease, renal failure, renal impairment***Abrupt discontinuation***Depression***AV block, bradycardia, cardiogenic shock, heart failure, pulmonary edema, sick sinus syndrome, ventricular dysfunction***Cerebrovascular disease***Hyperthyroidism, thyroid disease, thyrotoxicosis***Diabetes mellitus, hyperglycemia***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Peripheral vascular disease, pheochromocytoma, Raynaud's phenomenon, vasospastic angina***Hepatic disease***Psoriasis***Myasthenia gravis***Surgery***Electrolyte imbalance, hypercalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***Pancreatitis***Gout, hyperuricemia***Hypercholesterolemia, hypertriglyceridemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Preeclampsia, pregnancy***Breast-feeding***Children, infants, neonates***Driving or operating machinery***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mesalamine,***For the treatment of active ulcerative proctitis.***For the treatment of ulcerative colitis or Crohn's disease�.***For induction of remission of mild to moderate active ulcerative colitis or Crohn's disease�.***For maintenance of remission of ulcerative colitis.,"***General Information***5-aminosalicylates hypersensitivity, salicylate hypersensitivity***Renal disease, renal failure, renal impairment***Hepatitis, myocarditis, pericarditis, pneumonitis***Geriatric***Pregnancy***Breast-feeding***GI obstruction, pyloric stenosis***Sulfite hypersensitivity***Hepatic disease***Children, infants, neonates***Phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clindamycin phosphate/tretinoin,***For the treatment of acne vulgaris caused by <em>Propionibacterium acnes</em>.,"***General Information***Clindamycin hypersensitivity, retinoid hypersensitivity***Colitis, Crohn's disease, diarrhea, gastroenteritis, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Sunburn, sunlight (UV) exposure***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clindamycin phosphate,"***For the treatment of serious infections such as bacteremia.***For the treatment of lower respiratory tract infections (e.g., pleural empyema, anaerobic pneumonia, aspiration pneumonia, community-acquired pneumonia, and lung abscess) due to susceptible organisms<strong>***For the treatment of intraabdominal infections, including intraabdominal abscess and peritonitis.***For the treatment of peritonitis in patients receiving peritoneal dialysis.***For the treatment of skin and skin structure infections, including impetigo, ecthyma, cellulitis, erysipelas, infectious neonatal pustulosis, bite wounds, and complicated skin and skin structure infections such as necrotizing infections, gas gangrene, and diabetic foot ulcer.***For the treatment of impetigo or ecthyma.***For the treatment of necrotizing infections of the skin, fascia, and muscle (i.e. gas gangrene).***For the treatment of animal bite wounds.***For the treatment of diabetic foot ulcer.***For the treatment of gynecologic infections, including endometritis and pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of acute pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of bacterial vaginosis.***For the treatment of acne vulgaris.***For the treatment of bone and joint infections, including osteomyelitis and septic/infectious arthritis, or an orthopedic device-related infection�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated prosthetic joint infections�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated spinal implant infections�.***For the treatment of of uncomplicated acute otitis media�.***For the treatment of acute bacterial sinusitis�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis� in combination with conventional treatment (e.g., scaling and root planing) as well as acute dental abscess (apical)� and/or dental abscess (periapical)�.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage in patients with beta-lactam allergy.***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis� (rheumatic fever prophylaxis�) and for bacterial colonization eradication� in chronic carriers of group A beta-hemolytic <em>Streptococci</em> (GAS)�.***For the treatment of chronic pharyngeal carriers of group A streptococci (i.e., bacterial colonization eradication�).***For surgical infection prophylaxis�.***For bacterial endocarditis prophylaxis�.***For the treatment of anthrax�.***For the treatment of cutaneous anthrax infection.***For the treatment of systemic anthrax infection.***For anthrax prophylaxis� after exposure to Bacillus anthracis (postexposure prophylaxis, PEP).***For the treatment of toxoplasmosis�, including toxoplasmic encephalitis�.***For secondary toxoplasmosis prophylaxis� in HIV-infected patients intolerant of sulfa drugs.***For the treatment of Pneumocystis pneumonia (PCP)� in HIV-infected patients.***For the treatment of malaria� due <em>Plasmodium falciparum</em>.***For the treatment of babesiosis�.***For perinatal Group B streptococcal bacterial infection prophylaxis� in patients allergic to penicillin and cephalosporins.***Formoterol; Mometasone","***Asthma, atopy, clindamycin hypersensitivity, lincomycin hypersensitivity, serious rash, tartrazine dye hypersensitivity***Fungal infection***Diarrhea, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Neonates***Hepatic disease***Pregnancy***Breast-feeding***Ocular exposure***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10753'],tretinoin,"***For the treatment of acne vulgaris.***For adjunctive treatment of photoaging including palliation of fine facial wrinkles, facial mottled hyperpigmentation (i.e., 'liver spots'), and facial skin roughness.***For the treatment of acute promyelocytic leukemia (APL). <br />        NOTE: Retinoic acid-APL (RA-APL) syndrome characterized by fever, dyspnea, acute respiratory distress, weight gain, radiographic pulmonary infiltrates, pleural and pericardial effusions, edema, and hepatic, renal, and multi-organ failure requires prompt treatment with high-dose steroids (e.g., dexamethasone 10 mg IV every 12 hours for 3 days or until the resolution of symptoms). RA-APL syndrome may occur with or without leukocytosis.<br />     ***For remission induction treatment in patients with APL who are refractory to or who have relapsed from anthracycline chemotherapy or who have a contraindication to anthracycline-based therapy.***For maintenance therapy following induction and consolidation therapy�.***For remission induction and consolidation treatment in patients with newly diagnosed, low-risk APL in combination with arsenic trioxide�.***For remission induction treatment in patients with newly diagnosed APL, in combination with idarubicin�.***For consolidation treatment following tretinoin and idarubicin induction therapy in patients with newly diagnosed APL, in combination with idarubicin-containing chemotherapy�.***For the treatment of melasma�.***For the treatment of diseases of keratinization� (e.g., actinic keratosis�, ichthyosis�, keloids�, keratosis follicularis�); acne rosacea�; skin hyperpigmentation�.***For the treatment of AIDS-related Kaposi's sarcoma�.***Formoterol; Mometasone","***Requires a specialized care setting, requires an experienced clinician, respiratory insufficiency***Retinoid hypersensitivity***Paraben hypersensitivity***Fish hypersensitivity***Acute promyelocytic leukemia differentiation syndrome***Leukocytosis***Skin photosensitivity disorder, sunburn, sunlight (UV) exposure***Eczema***Hepatic disease***Contraception requirements, pregnancy, pregnancy testing, reproductive risk***Breast-feeding***Children, infants, neonates***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia***Accidental exposure, ocular exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,alfentanil hydrochloride,"***For use during general anesthesia induction and general anesthesia maintenance. <br />        NOTE: Appropriately reduce the initial alfentanil dose for elderly and debilitated patients. In one clinical trial, the dose of alfentanil required to produce anesthesia as determined by appearance of delta waves in EEG was 40% lower in geriatric patients than the dose needed for healthy young patients. Consider the effect of the initial dose when determining supplemental doses.<br />NOTE: Use lean body weight to calculate the alfentanil dose for patients who weigh more than 20% above their ideal total body weight***For patients spontaneously breathing/assisted ventilation.***For patients with assisted or controlled ventilation to attenuate the response to laryngoscopy and intubation.***For patients with assisted or controlled ventilation to provide continued attenuation of response to intubation and incision. <br />          NOTE: Required infusion rates are variable and should be titrated to the desired clinical effect.�<br />       ***For conscious sedation maintenance or monitored anesthesia care (MAC) in the sedated, responsive, and spontaneously breathing patient.***For the epidural management of postoperative, severe pain� in the intensive care setting.","***General Information***Constipation, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, pulmonary disease, requires a specialized care setting, requires an experienced clinician, respiratory depression, respiratory insufficiency***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal impairment, urethral stricture, urinary retention***Head trauma, increased intracranial pressure, seizure disorder, seizures***Angina, cardiac disease, heart failure, hypotension, hypovolemia***Children, infants, neonates***Labor, obstetric delivery, pregnancy***Breast-feeding***Females***Geriatric***Biliary tract disease***Abrupt discontinuation***Alcoholism, depression, substance abuse***Driving or operating machinery***Epidural administration***Opiate agonist hypersensitivity***Accidental exposure, potential for overdose or poisoning***MAOI therapy***Adrenal insufficiency, hypothyroidism, myxedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['39786'],venlafaxine,"***For the treatment of major depression.***For the treatment of generalized anxiety disorder (GAD).***For the treatment of social phobia (social anxiety disorder).***For the treatment of panic disorder (with or without agoraphobia).***For the treatment of obsessive-compulsive disorder (OCD)�.***For the treatment of hot flashes� due to menopause� or in women who have been treated for breast cancer.***For women experiencing hot flashes� due to natural menopause�.***For hot flashes� in women with a history of, or high risk of, breast cancer, including those receiving adjuvant treatments like tamoxifen.***For the treatment of premenstrual dysphoric disorder (PMDD)�.***For the treatment of fibromyalgia�.***For the treatment of painful diabetic neuropathy�.***For migraine prophylaxis�.***For the treatment of hot flashes� due to prostate cancer� and associated induced androgen deficiency� ('andropause�') in men who have had surgical or medication induced castration.***Formoterol***Formoterol; Mometasone","***General Information***Desvenlafaxine hypersensitivity, venlafaxine hypersensitivity***Abrupt discontinuation***Bipolar disorder, mania***Children, growth inhibition, suicidal ideation***MAOI therapy***Electroconvulsive therapy (ECT), seizure disorder, seizures***Dehydration, hyponatremia, hypovolemia***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Dialysis, renal disease, renal failure, renal impairment***Hepatic disease***Anticoagulant therapy, bleeding, thrombolytic therapy***Closed-angle glaucoma, increased intraocular pressure***Eosinophilic pneumonia***Driving or operating machinery***Eclampsia, neonates, obstetric delivery, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,risedronate sodium,"***For the treatment of Paget's disease (osteitis deformans) to induce remission in patients who have serum alkaline phosphatase concentrations at least twice the upper limit of normal, or are symptomatic, or are at risk for future complications of their disease.***For the treatment of osteoporosis.***For osteoporosis prophylaxis.***For the treatment of osteolytic bone metastases� in patients with multiple myeloma.","***General Information***Asthma, phosphonate hypersensitivity***Hyperparathyroidism, hypocalcemia, vitamin D deficiency***Achalasia, dysphagia, esophageal stricture, esophagitis, gastritis, gastroesophageal reflux disease (GERD), GI disease, hiatal hernia, inability to stand or sit upright***Children***Pregnancy***Breast-feeding***Renal failure, renal impairment***Geriatric***Anemia, chemotherapy, coagulopathy, corticosteroid therapy, dental disease, dental work, infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,benzoyl peroxide/clindamycin phosphate,"***For the treatment of acne vulgaris. <br />        NOTE: There are reports of an increase of P. acnes resistance to clindamycin in the treatment of acne. In patients with P. acnes resistant to clindamycin, the clindamycin component may provide no additional benefit beyond benzoyl peroxide alone.<br />     ***For the treatment of moderate to severe acne rosacea�.","***General Information***Benzoic acid hypersensitivity, clindamycin hypersensitivity, lincomycin hypersensitivity***Eczema, ocular exposure, skin abrasion, skin disease, sunburn, sunlight (UV) exposure***Children, infants, neonates***Colitis, Crohn's disease, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clindamycin phosphate,"***For the treatment of serious infections such as bacteremia.***For the treatment of lower respiratory tract infections (e.g., pleural empyema, anaerobic pneumonia, aspiration pneumonia, community-acquired pneumonia, and lung abscess) due to susceptible organisms<strong>***For the treatment of intraabdominal infections, including intraabdominal abscess and peritonitis.***For the treatment of peritonitis in patients receiving peritoneal dialysis.***For the treatment of skin and skin structure infections, including impetigo, ecthyma, cellulitis, erysipelas, infectious neonatal pustulosis, bite wounds, and complicated skin and skin structure infections such as necrotizing infections, gas gangrene, and diabetic foot ulcer.***For the treatment of impetigo or ecthyma.***For the treatment of necrotizing infections of the skin, fascia, and muscle (i.e. gas gangrene).***For the treatment of animal bite wounds.***For the treatment of diabetic foot ulcer.***For the treatment of gynecologic infections, including endometritis and pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of acute pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of bacterial vaginosis.***For the treatment of acne vulgaris.***For the treatment of bone and joint infections, including osteomyelitis and septic/infectious arthritis, or an orthopedic device-related infection�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated prosthetic joint infections�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated spinal implant infections�.***For the treatment of of uncomplicated acute otitis media�.***For the treatment of acute bacterial sinusitis�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis� in combination with conventional treatment (e.g., scaling and root planing) as well as acute dental abscess (apical)� and/or dental abscess (periapical)�.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage in patients with beta-lactam allergy.***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis� (rheumatic fever prophylaxis�) and for bacterial colonization eradication� in chronic carriers of group A beta-hemolytic <em>Streptococci</em> (GAS)�.***For the treatment of chronic pharyngeal carriers of group A streptococci (i.e., bacterial colonization eradication�).***For surgical infection prophylaxis�.***For bacterial endocarditis prophylaxis�.***For the treatment of anthrax�.***For the treatment of cutaneous anthrax infection.***For the treatment of systemic anthrax infection.***For anthrax prophylaxis� after exposure to Bacillus anthracis (postexposure prophylaxis, PEP).***For the treatment of toxoplasmosis�, including toxoplasmic encephalitis�.***For secondary toxoplasmosis prophylaxis� in HIV-infected patients intolerant of sulfa drugs.***For the treatment of Pneumocystis pneumonia (PCP)� in HIV-infected patients.***For the treatment of malaria� due <em>Plasmodium falciparum</em>.***For the treatment of babesiosis�.***For perinatal Group B streptococcal bacterial infection prophylaxis� in patients allergic to penicillin and cephalosporins.***Formoterol; Mometasone","***Asthma, atopy, clindamycin hypersensitivity, lincomycin hypersensitivity, serious rash, tartrazine dye hypersensitivity***Fungal infection***Diarrhea, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Neonates***Hepatic disease***Pregnancy***Breast-feeding***Ocular exposure***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,metformin hydrochloride/pioglitazone,"***For the treatment of type 2 diabetes mellitus in combination with diet and exercise and when treatment with  both metformin and pioglitazone is appropriate. <br />  NOTE: Metformin; pioglitazone is not for use in patients with type 1 diabetes or diabetic ketoacidosis.<br />NOTE: When metformin; pioglitazone is used in combination with insulin or an insulin secretagogue, a lower dose of the insulin or insulin secretagogue may be needed in order to reduce the risk of hypoglycemia. In patients taking insulin and metformin; pioglitazone who experience hypoglycemia, reduce the dose of insulin by 10 to 25%. Individualize any further adjustments based on glycemic response.<br />NOTE: When adding pioglitazone to metformin in patients with or without symptomatic heart disease and diabetes, monitor closely for signs of weight gain, peripheral edema, or congestive heart failure. In general, pioglitazone should be initiated at the lowest dose and increased gradually after at least three months of therapy. The risk of these symptoms is increased when higher doses of pioglitazone are used in combination with insulin in patients at risk of congestive heart failure. Pioglitazone should not be used in patients with New York Heart Association Class III or IV heart failure; metformin should not be used in patients with congestive heart failure requiring pharmacological therapy. Metformin; pioglitazone should be discontinued if any deterioration in cardiac status occurs during therapy.<br />NOTE: Liver function tests (serum alanine and aspartate aminotransferases, alkaline phosphatase, and total bilirubin) should be obtained prior to initiating metformin; pioglitazone (see Contraindications/Precautions)***For use when initial treatment with metformin alone or pioglitazone alone does not result in adequate glycemic control.***For use when switching from pioglitazone plus metformin as separate tablets to the single, combination tablet.***Formoterol; Mometasone","***General Information***Diabetic ketoacidosis, type 1 diabetes mellitus***Acidemia, acute myocardial infarction, cardiogenic shock, dehydration, hypoxemia, lactic acidosis, metabolic acidosis, sepsis***Diarrhea, vomiting***Renal disease, renal failure, renal impairment***Acute heart failure, cardiac disease, edema, heart failure, peripheral edema, pulmonary edema***Alcoholism, ethanol ingestion, ethanol intoxication, hepatic disease***Radiographic contrast administration***Burns, fever, infection, surgery, trauma***Adrenal insufficiency, gastroparesis, GI obstruction, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypothyroidism, ileus, malnutrition, pituitary insufficiency***Anemia, pernicious anemia***Bone fractures, osteoporosis***Contraception requirements, menstrual irregularity, polycystic ovary syndrome, pregnancy***Breast-feeding***Bladder cancer, new primary malignancy***Geriatric***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/levonorgestrel,"***For routine contraception.***For extended continuous routine contraception.***For use as postcoital contraception within 72 hours of unprotected intercourse, or known or suspected contraceptive failure, in females who have no known contraindications to oral contraceptives, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['27169'],leflunomide,"***For the treatment of rheumatoid arthritis to reduce signs and symptoms, to inhibit structural damage as evidenced by radiographic erosions and joint space narrowing, and to improve physical function.***For use in combination with methotrexate� for patients with active disease despite treatment with methotrexate alone.***For the treatment of juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA)�. <br />        NOTE: The safety and efficacy of leflunomide for pediatric patients with polyarticular course JRA has not been fully evaluated.<br />     ","***General Information***Serious rash***Alcoholism, hepatic disease, hepatitis, hepatotoxicity, jaundice***Agranulocytosis, bone marrow suppression, chemotherapy, immunosuppression, infection, tuberculosis***Vaccination***Diabetes mellitus, geriatric, peripheral neuropathy***Eosinophilic pneumonia, pneumonitis, pulmonary disease, pulmonary fibrosis, sarcoidosis***Renal failure, renal impairment***Hypertension***Pregnancy***Contraception requirements, male-mediated teratogenicity, pregnancy testing, reproductive risk***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clobetasol propionate,"***For the treatment of moderate-to-severe inflammatory manifestations, including pruritus, of corticosteroid-responsive dermatologic disorders such as alopecia areata, atopic dermatitis, contact dermatitis, generalized exfoliative dermatitis, Rhus dermatitis due to plants like poison ivy, seborrheic dermatitis, eczema (including severe hyperkeratotic eczema, severe nummular eczema, and severe eczematous conditions of the hands or feet), granuloma annulare, keloids, cutaneous lichen planus, lichen simplex chronicus, lichen striatus, subacute cutaneous and discoid lupus erythematosus, pretibial myxedema, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, sarcoidosis, sunburn, or urticaria. <br />        NOTE: Acute exudative inflammation, as occurs with poison ivy, may be best treated with a non-emollient cream or gel formulation, which are drying. Dry, scaly dermatoses may be best treated with emollient creams or ointments. Lower potency corticosteroids should be used on the face and intertriginous areas.<br />NOTE: Systemic therapy or intralesional injection of corticosteroids may be necessary for some conditions based on the type and severity of the disorder or inadequate response to topical therapy***For the treatment of plaque-type psoriasis.***For the alternative treatment of recalcitrant oral vesiculoerosive disease� including oral lichen planus�, mucous membrane pemphigus�, aphthous ulcer� and chronic oral erythema multiforme�.***For the treatment of vulvar lichen sclerosus�.***For the alternative treatment of vision-threatening periocular capillary hemangioma� in infancy and early childhood.","***Corticosteroid hypersensitivity***Cushing's syndrome, hepatic disease, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Diabetes mellitus***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Fungal infection, herpes infection, infection, measles, peripheral vascular disease, varicella, viral infection***Acne rosacea, acne vulgaris, cataracts, glaucoma, ocular exposure, ophthalmic administration, perioral dermatitis***Geriatric, skin atrophy***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mesalamine,***For the treatment of active ulcerative proctitis.***For the treatment of ulcerative colitis or Crohn's disease�.***For induction of remission of mild to moderate active ulcerative colitis or Crohn's disease�.***For maintenance of remission of ulcerative colitis.,"***General Information***5-aminosalicylates hypersensitivity, salicylate hypersensitivity***Renal disease, renal failure, renal impairment***Hepatitis, myocarditis, pericarditis, pneumonitis***Geriatric***Pregnancy***Breast-feeding***GI obstruction, pyloric stenosis***Sulfite hypersensitivity***Hepatic disease***Children, infants, neonates***Phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4177'],etomidate,"***For general anesthesia induction.***For the supplementation of subpotent anesthetic agents (e.g., nitrous oxide) during general anesthesia maintenance for short operative procedures such as obstetric anesthesia for dilation and curettage or cervical conization.","***Sepsis***Intraarterial administration***Geriatric, hypertension***Hypovolemia, trauma***Esophageal varices, hepatic disease***Renal impairment***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,zolpidem tartrate,"***For the treatment of insomnia.***For the short-term treatment of insomnia characterized by difficulty with sleep initiation.***For insomnia characterized by difficulties with sleep onset and/or sleep maintenance.***For middle-of-the night awakening that is followed by difficulty returning to sleep.***For increasing awareness and responsiveness in patients with disorders of consciousness due to traumatic brain injury� (TBI�) or nontraumatic brain injury� (e.g., head trauma� or hypoxia, respectively).","***Angioedema***Depression, suicidal ideation***Behavioral changes, CNS depression, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion, females***Abrupt discontinuation, alcoholism, substance abuse***Encephalopathy, hepatic disease***Chronic obstructive pulmonary disease (COPD), myasthenia gravis, pulmonary disease, respiratory depression, sleep apnea***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,chlorpheniramine polistirex/hydrocodone polistirex,***For the relief of cough and upper respiratory symptoms associated with allergic rhinitis or the common cold.,"***General Information***Bladder obstruction, constipation, GI obstruction, ileus, inflammatory bowel disease, prostatic hypertrophy, ulcerative colitis, urinary retention***Diarrhea***Opiate agonist hypersensitivity***Driving or operating machinery***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, ethanol ingestion, pulmonary disease, respiratory depression***Hepatic disease***Diabetes mellitus, heart failure, hypertension, oliguria, renal disease, systemic lupus erythematosus (SLE), urethral stricture***Pregnancy***Children, infants, neonates***Breast-feeding***Biliary tract disease***Abrupt discontinuation***Substance abuse***Head trauma, increased intracranial pressure***Seizure disorder***Closed-angle glaucoma, contact lenses***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,insulin glulisine (rDNA origin),"***For the treatment of type 1 diabetes mellitus.***For the treatment of type 2 diabetes mellitus that is inadequately managed by diet, exercise, and oral hypoglycemics.***Formoterol; Mometasone","***General Information***Diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Hepatic disease, renal failure, renal impairment***Coma, diabetic ketoacidosis, hyperosmolar hyperglycemic state (HHS)***Continuous subcutaneous insulin infusion (CSII) administration***Hypoglycemia***Hypokalemia***Intravenous administration***Cresol hypersensitivity***Pregnancy***Breast-feeding***Tobacco smoking***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['16818'],acitretin,"***For the treatment of adults with severe, recalcitrant psoriasis, including plaque, guttate, erythrodermic, palmar-plantar and pustular types.***For the treatment of lichen planus�.***For the treatment of hyperkeratotic dermatitis of the palms (eczema� keratoticum).","***Ethanol ingestion, male-mediated teratogenicity, pregnancy, pregnancy testing***Blood donation***Breast-feeding***Renal failure, renal impairment***Hepatic disease***Hyperostosis***Contact lenses, driving or operating machinery, visual disturbance***Retinoid hypersensitivity***Alcoholism, cardiac disease, diabetes mellitus, hypercholesterolemia, hyperglycemia, hypertriglyceridemia, obesity, pancreatitis***Children, infants, neonates***Sunlight (UV) exposure***Depression, suicidal ideation***Increased intracranial pressure, papilledema***Requires an experienced clinician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],desogestrel/ethinyl estradiol,"***For routine contraception.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�,  abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Edema, hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,indocyanine green,"***For use as a diagnostic aid in cardiac function diagnosis, to determine cardiac output using indicator-dilution studies. <br />        NOTE: An average of 5 dilution curves are needed for a diagnostic cardiac catheterization. The total amount of indocyanine green administered should be less than 2 mg/kg.<br />NOTE: See prescribing information for creating calibrating dye curves to quantitate the patient-specific dilution curves.<br />NOTE: Indocyanine green should be mixed with the Sterile Water for Injection solvent provided. The resulting solution should be used within 6 hours of preparation and should not be used if a precipitate is present. It is recommended that the syringe used for the injection of the dye be rinsed with Sterile Water for Injection; however, 0.9% Sodium Chloride Injection should be used in all other parts of the catheterization procedure***For use as a diagnostic aid in determining hepatobiliary system dysfunction diagnosis. <br />        NOTE: The patient should be studied in a fasting, basal state.<br />     ***For use as a diagnostic agent during ophthalmic angiography. <br />  NOTE: The peak absorption and emission of indocyanine green lie in a region of 800 to 850 nm where transmission of energy by the pigment epithelium is more efficient than in the region of visible light energy.<br />NOTE: Indocyanine green is useful in both absorption and fluorescence infrared angiography of the choroidal vasculature when using appropriate filters and film in a fundus camera","***General Information***Iodine hypersensitivity***Dialysis, renal failure, uremia***Neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['31447'],nabilone,"***For treatment of refractory chemotherapy-induced nausea/vomiting (CINV) and for chemotherapy-induced nausea/vomiting prophylaxis (CINV prophylaxis). <br />        NOTE: According to the American Society of Clinical Oncologists, cannabinoids should be reserved for patients who are intolerant or refractory to first-line therapy (i.e., 5-HT3 serotonin receptor antagonists, NKI receptor antagonists, and dexamethasone). <br />     ***For the treatment of chorea associated with Huntington's Disease (Huntington's Chorea)�.","***General Information***Angina, cardiac arrhythmias, cardiac disease, coronary artery disease, hypertension, orthostatic hypotension***Bipolar disorder, depression, mania, psychosis, schizophrenia***Driving or operating machinery***Alcoholism, substance abuse***Hepatic disease, renal disease, renal failure, renal impairment***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,rasagiline mesylate,***For the treatment of Parkinson's disease.,"***General Information***Alcoholism, cerebrovascular disease, ethanol ingestion, hypertension, hypertensive crisis***MAOI therapy***Coadministration with other CNS depressants, driving or operating machinery***Orthostatic hypotension***Psychosis, schizophrenia***Impulse control symptoms***Hepatic disease***Renal failure, renal impairment***Abrupt discontinuation***Melanoma***Pregnancy***Breast-feeding***Children, infants***Geriatric***Dental work, surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,certolizumab pegol,"***For the treatment of Crohn's disease.***For patients with fistulizing Crohn's disease�.***For patients who are unresponsive or intolerant to infliximab�.***For the treatment of moderately to severely active rheumatoid arthritis.***For the treatment of active psoriatic arthritis.***For the treatment of active ankylosing spondylitis.***For the treatment of moderate to severe, chronic plaque psoriasis� in patients who are candidates for systemic therapy or phototherapy.","***General Information***Intravenous administration, latex hypersensitivity***Guillain-Barre syndrome, multiple sclerosis, neurological disease***Heart failure***Hepatitis***Acquired immunodeficiency syndrome (AIDS), bone marrow suppression, corticosteroid therapy, diabetes mellitus, fungal infection, immunosuppression, infection, influenza, mycobacterial infection, sepsis, surgery, tuberculosis, viral infection***New primary malignancy***Infants, neonates, pregnancy***Breast-feeding***Children***Vaccination***Geriatric***Human anti-chimeric antibody (HACA)***Coagulopathy***Leukopenia, thrombocytopenia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6922'],metronidazole,"***For the treatment of trichomoniasis.***For the treatment of bacterial vaginosis (e.g., <em>Gardnerella vaginalis</em>, <em>Mycoplasma hominis</em>�, and anaerobic bacteria such as <em>Prevotella sp.</em> and <em>Mobiluncus</em> sp.).***For the treatment of pelvic inflammatory disease (PID) in combination with other antibiotics.***For the treatment of amebiasis.***For intestinal disease (acute amebic dysentery) due to <em>Entamoeba histolytica</em>.***For hepatic abscess due to <em>Entamoeba histolytica</em>.***For amebiasis due to <em>Entamoeba polecki</em>�.***For the treatment of serious anaerobic infections (e.g., skin and skin structure infections [e.g. diabetic foot ulcer], CNS infection including meningitis and brain abscess, bone and joint infections, endocarditis, bacteremia, and gynecologic infections [e.g. endometritis, endomyometritis]).***For the treatment of acne rosacea.***For the treatment of serious anaerobic intraabdominal infections, including intraabdominal abscess, peritonitis, perforated appendicitis, necrotizing enterocolitis, and biliary tract infections such as cholangitis and cholecystitis.***For the treatment of perforated appendicitis� in pediatric patients.***For the treatment of serious anaerobic lower respiratory tract infections, including pleural empyema, pneumonia, and lung abscess.***For bacterial vaginosis prophylaxis� or trichomoniasis prophylaxis� in victims of sexual assault.***For the treatment of recurrent and persistent non-gonococcal urethritis (NGU)�.***For the treatment of dental infection�, including dentoalveolar infection� and periodontitis�.***For adolescent periodontitis� or adult chronic periodontitis� after scaling and root planing.***For adolescent aggressive periodontitis� or adult refractory chronic periodontitis� in combination with amoxicillin after scaling and root planing.***For adult refractory chronic periodontitis� in combination with ciprofloxacin after scaling and root planing in �-lactam allergic patients.***For the treatment of guinea worm disease� (dracunculiasis�).***For surgical infection prophylaxis, including bowel preparation� in patients undergoing colorectal surgery.***For bowel preparation� in patients undergoing colorectal surgery.***For the treatment of antibiotic-associated pseudomembranous colitis� due to <em>Clostridium difficile</em>.***For the treatment of antibiotic-associated pseudomembranous colitis� due to <em>Clostridium difficile </em>in adults.***For the treatment of antibiotic-associated pseudomembranous colitis� due to <em>Clostridium difficile i</em>n pediatric patients.***For the treatment of Crohn's disease� associated with colonic and/or perianal involvement.***For Helicobacter pylori (H. pylori) eradication� in the treatment of patients with duodenal ulcer� disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />  NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.  The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: Metronidazole-resistant strains of H. pylori are prevalent in the US (approximately 25%), and primarily occur in patients previously treated with metronidazole. Therapy with at least two antimicrobials is necessary to limit the development of metronidazole resistance. Patients who have persistence of H. pylori following therapy may have metronidazole-resistant H. pylori infection.<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Prevpac monograph).  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60% to 90% of patients.***For the treatment of pruritus� secondary to cholestasis.***For the treatment of giardiasis�.","***Hematological disease***Dialysis, renal failure, renal impairment***Bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***New primary malignancy***Pregnancy***Breast-feeding***Alcoholism, ethanol ingestion, ethanol intoxication***Fungal infection***Crohn's disease***Ocular exposure***Geriatric***Sexually transmitted disease***Hepatic disease, hepatic encephalopathy***Cockayne syndrome***Corticosteroid therapy, edema, sodium restriction***Laboratory test interference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['657797'],temsirolimus,"***For the treatment of advanced renal cell cancer. <br />  NOTE: Prophylactic diphenhydramine 25 to 50 mg IV, or a similar antihistamine, approximately 30 minutes before the start of each temsirolimus dose is recommended.<br /***For the treatment of heavily pretreated, relapsed or refractory mantle cell lymphoma (MCL)�.***For the treatment of relapsed or refractory high-grade malignant glioma�.***For the treatment of relapsed or refractory neuroblastoma� in pediatric patients.***For the treatment of relapsed or refractory rhabdomyosarcoma�.***For the treatment of recurrent glioblastoma multiforme�.","***Pregnancy***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['623033'],lubiprostone,"***For the treatment of chronic idiopathic constipation (e.g., 6 month or longer history of less than 3 spontaneous bowel movements per week, with at least 25% of bowel movements with hard stools, sensation of incomplete evacuation, or straining).***For the treatment of irritable bowel syndrome with constipation (IBS-C) in females.***For the treatment of opiate agonist-induced constipation in patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dose escalation.","***General Information***Abdominal pain, cholelithiasis, Crohn's disease, diverticulitis, fecal impaction, gastric cancer, GI disease, GI obstruction, inflammatory bowel disease***Diarrhea, hypotension, syncope, vomiting***Pregnancy***Breast-feeding***Children***Hepatic disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,conjugated estrogens,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), or dyspareunia, whether menopause is natural or surgical (e.g., due to oophorectomy).***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For treatment of premenopausal females with estrogen deficiency due to hypogonadism.***For treatment of hypoestrogenism due to primary ovarian failure.***For the short-term treatment of abnormal or dysfunctional uterine bleeding caused by hormonal imbalance in the absence of organic pathology.***For the palliative treatment of breast cancer that has metastasized, in appropriately selected men or women.***For the palliative treatment of advanced inoperable prostate cancer.***Formoterol; Mometasone","***Angioedema, benzyl alcohol hypersensitivity, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['4451', '227633']",flucytosine,"***For the treatment of candidemia and disseminated (non-CNS) candidiasis. <br />        NOTE: For candidemia or disseminated candidiasis, an echinocandin or fluconazole is the preferred therapy.<br />     ***For the treatment of <em>Candida</em> infections of the cardiovascular system, including endocarditis and infected pacemaker�, implantable cardiac defibrillator (ICD)�, or ventricular assist devices (VAD)�.***For the treatment of urinary tract infection (UTI), including symptomatic cystitis, caused by <em>Candida</em> sp. (e.g. candiduria).***For the treatment of pyelonephritis caused by <em>Candida</em> sp..***For the treatment of cryptococcosis, including disseminated disease, CNS disease (e.g., cryptococcal meningitis) and severe pulmonary infection. <br />        NOTE: Flucytosine in combination with amphotericin B is the preferred induction therapy for cryptococcal meningitis, severe pulmonary cryptococcosis, and cryptococcemia.<br />     ***For the treatment of <em>Candida</em> meningitis�.***For the treatment of endophthalmitis� caused by <em>Candida</em> sp..***For the treatment of chromomycosis� in combination with amphotericin B.","***Renal disease, renal failure, renal impairment***Bone marrow suppression, hematological disease***Hepatotoxicity***Radiation therapy***Electrolyte imbalance, hypokalemia***Sunlight (UV) exposure***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['73689'],febuxostat,"***For the chronic management of hyperuricemia in patients with gout. <br />        NOTE: In clinical trials, gout flare was commonly reported after febuxostat initiation; prophylactic therapy with an NSAID or colchicine for up to 6 months may be beneficial.<br />     ","***General Information***Serious rash***Cardiac disease, myocardial infarction, stroke***Hepatic disease***Renal impairment***Chemotherapy, Lesch-Nyhan syndrome, neoplastic disease, secondary hyperuricemia***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mexiletine hydrochloride,***For the treatment of life threatening ventricular arrhythmias such as ventricular tachycardia.***For the treatment of neuropathic pain� syndromes.***For the treatment of pain associated with diabetic neuropathy�.***For the treatment of neuropathic pain�.,"***AV block, bradycardia, cardiogenic shock***Hypotension***Acute myocardial infarction, cardiac arrhythmias, heart failure, hepatic disease, hepatotoxicity, mortality, myocardial infarction, ventricular dysfunction***Renal disease, renal failure, renal impairment***Parkinson's disease, seizure disorder***Agranulocytosis, leukopenia***Pregnancy***Breast-feeding***Tobacco smoking***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['816346'],dexlansoprazole,"***For the symptomatic treatment of non-erosive gastroesophageal reflux disease (GERD), including treatment of pyrosis (heartburn) related to GERD. <br />        NOTE: Dexlansoprazole is not used for occasional heartburn.<br />***For the treatment of erosive esophagitis.***For the initial healing of all grades of erosive esophagitis. <br />  NOTE: Two 30 mg delayed-release orally disintegrating tablets (SoluTabs) are not interchangable with a single 60 mg delayed-release capsule. The SoluTabs are not approved for the initial treatment of erosive esophagitis.<br /***For maintenance of healed erosive esophagitis and relief of pyrosis (heartburn).***For the treatment of proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) in the differential diagnosis of eosinophilic esophagitis (EoE)�.","***Proton pump inhibitors (PPIs) hypersensitivity***Vitamin B12 deficiency***Hepatic disease***Gastric cancer***Bone fractures, geriatric, osteoporosis***Hypomagnesemia, long QT syndrome***Diarrhea, pseudomembranous colitis***Rebound acid hypersecretion***Pregnancy***Breast-feeding***Laboratory test interference***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"tirofiban hydrochloride,""","***Aneurysm, aortic dissection, arteriovenous malformation, bleeding, coagulopathy, epidural anesthesia, hypertension, intracranial bleeding, intracranial mass, intramuscular injections, lumbar puncture, pericarditis, spinal anesthesia, stroke, surgery, trauma, venipuncture***Anticoagulant therapy, thrombolytic therapy***Thrombocytopenia***Geriatric***Dialysis, renal disease, renal failure, renal impairment***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,phenoxybenzamine hydrochloride,"***For the treatment of excessive sweating and hypertension associated with pheochromocytoma.***For the treatment of peripheral vasospastic disorders (e.g., Raynaud's phenomenon�, acrocyanosis�, or frostbite�).***For the treatment of urinary symptoms associated with benign prostatic hyperplasia (BPH)�.","***General Information***Coronary artery disease, heart failure***Cerebrovascular disease, renal disease***Shock***Respiratory infection***Pregnancy***Geriatric***Breast-feeding***Dental disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,betamethasone valerate,"***For the treatment of acute graft-versus-host disease (GVHD).***For the treatment of nonsuppurative thyroiditis.***For the treatment of acute exacerbations of multiple sclerosis.***For the management of symptomatic sarcoidosis or for the treatment of hypercalcemia associated with cancer or sarcoidosis.***For the treatment of allergic disorders including anaphylaxis or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema (or for laryngeal edema prophylaxis), drug hypersensitivity reactions, serum sickness, severe perennial or seasonal allergic rhinitis, severe urticaria, or for the treatment of urticarial transfusion reactions. <br />        NOTE: Betamethasone should be administered IM or IV initially in the treatment of anaphylaxis or anaphylactoid reactions, angioedema, and acute noninfectious laryngeal edema or to prevent impending risk of laryngeal edema.<br />     ***For the treatment of urticarial transfusion reactions.***For the treatment of immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of hematologic disorders including secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), and congenital hypoplastic anemia.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of inflammatory bowel disease including Crohn's disease (regional gastroenteritis) and ulcerative colitis.***For the induction of diuresis or remission of proteinuria in the nephrotic syndrome.***For the treatment of nasal polyps.***For the treatment of severe cases of myasthenia gravis not controlled by antimyasthenic agents alone.***For adjunctive therapy in the treatment of rheumatic disorders e.g., acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), osteoarthritis, polychondritis�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of nonrheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the treatment of moderate-to-severe inflammation and pruritus due to corticosteroid-responsive dermatologic disorders such as alopecia areata, cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis, generalized exfoliative dermatitis, nummular dermatitis, seborrheic dermatitis, eczema, granuloma annulare, keloids, lichen planus, lichen simplex chronicus, lichen striatus, subacute cutaneous and discoid lupus erythematosus, pretibial myxedema, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, psoriasis, <em>Rhus dermatitis</em> (due to poison ivy, poison oak, or poison sumac), sarcoidosis, Stevens-Johnson syndrome, sunburn, or urticaria. <br />        NOTE: Systemic corticosteroids may be necessary for some conditions based on the type and severity of the disorder (e.g., Stevens-Johnson syndrome) or inadequate response to topical therapy; intralesional injections may also be appropriate for select conditions.<br />     ***For the treatment of plaque psoriasis.***For the treatment of seborrheic dermatitis.***For hyaline membrane disease prophylaxis�, for the purpose of fetal lung maturation to prophylax against anticipated neonatal respiratory distress syndrome (RDS)� in premature infants.***For palliative management of leukemia and lymphoma in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), or for the treatment of multiple myeloma�.***For maintenance therapy in selected cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis�, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, conjunctivitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For the treatment of respiratory inflammatory conditions including airway-obstructing hemangioma� in infants, aspiration pneumonitis, berylliosis, bronchial asthma, chronic obstructive pulmonary disease (COPD), laryngotracheobronchitis (croup), Loeffler's syndrome, or non-cardiogenic pulmonary edema�, or for bronchospasm prophylaxis. <br />        NOTE: Betamethasone should be administered parenterally initially in the treatment of severe manifestations of these diseases, particularly where airway obstruction is present.<br />     ","***Abrupt discontinuation, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, growth inhibition, increased intracranial pressure, infants, neonates***Immunosuppression***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Edema, heart failure, hypertension***Osteoporosis***Diabetes mellitus***Crohn's disease, diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hyperthyroidism, hypothyroidism, psychosis, renal disease, seizure disorder, thyroid disease***Myasthenia gravis***Idiopathic thrombocytopenic purpura (ITP), thromboembolic disease***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Epidural administration, intravenous administration***Corticosteroid hypersensitivity***Head trauma***Skin atrophy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['167'],acetazolamide,"***For the treatment of glaucoma.***For the adjunctive treatment of open-angle glaucoma.***For the treatment of secondary glaucoma and pre-operatively for acute angle-closure glaucoma.***For use as an alternative agent in the treatment of absence seizures. <br />        NOTE: The extended release preparation is not recommended for use as an anticonvulsant.<br />     ***For the treatment of acute altitude sickness.***For altitude sickness prophylaxis, including prevention of high altitude cerebral edema.***For the treatment of edema secondary to congestive heart failure or drug therapy.***For use as an adjunctive agent to reverse metabolic alkalosis� in mechanically ventilated patients. <br />        NOTE: Appropriate correction of underlying fluid and electrolyte imbalances (e.g., administration of saline fluids, potassium chloride) should be instituted prior to acetazolamide administration. In patients with excessive carbon dioxide retention (e.g., COPD), reversal of metabolic alkalosis may assist the process of weaning from mechanical ventilation, by reducing compensatory carbon dioxide retention.<br />     ***For use in urinary alkalinization�.***For the treatment of familial periodic paralysis�.***For the treatment of central vestibular nystagmus�.","***General Information***Carbonic anhydrase inhibitor hypersensitivity, sulfonamide hypersensitivity***Hepatic disease***Acid/base imbalance, acidemia, adrenal insufficiency, anuria, dialysis, electrolyte imbalance, hyperchloremia, hypokalemia, hyponatremia, metabolic acidosis, renal disease, renal failure, renal impairment***Closed-angle glaucoma***Emphysema, infection, pulmonary disease, respiratory acidosis***Agranulocytosis, bone marrow suppression***Sunlight (UV) exposure***Pregnancy***Breast-feeding***Driving or operating machinery***Children, growth inhibition, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,calcipotriene,"***For the treatment of plaque psoriasis. <br />        NOTE: According to the American Academy of Dermatology (AAD), combining calcipotriene with a topical corticosteroid is more effective than either treatment alone. In addition, fewer adverse events were reported with combination therapy in most clinical studies.<br />     ***For the treatment of chronic, moderate scalp psoriasis.","***General Information***Hypercalcemia, hypercalciuria, hypervitaminosis D, nephrolithiasis, occlusive dressing***Accidental exposure, ocular exposure***Children, infants, neonates***Sunlight (UV) exposure***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,triptorelin pamoate,***For the palliative treatment of advanced prostate cancer.***For the treatment of central precocious puberty.***For the treatment of premenopausal women with hormone-sensitive advanced breast cancer�.***For pituitary downregulation in women undergoing controlled ovarian hyperstimulation and subsequent in vitro fertilization (IVF) or other assisted reproductive technology (ART) for the treatment of infertility�.***For the treatment of endometriosis�.***For the treatment of hirsutism�.,"***Gonadotropin-Releasing Hormone (GnRH) analogs hypersensitivity***Pregnancy***Breast-feeding***Renal impairment, spinal cord compression, urinary tract obstruction***Hepatic disease***Pituitary insufficiency***Dysfunctional uterine bleeding, menstruation, vaginal bleeding***Osteoporosis***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Brain tumor, cerebrovascular disease, seizure disorder***Depression, psychiatric event, suicidal ideation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sertaconazole nitrate,***For the topical treatment of interdigital tinea pedis in immunocompetent patients.,"***Azole antifungals hypersensitivity***Onychomycosis***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dolasetron mesylate,"***For chemotherapy-induced nausea/vomiting prophylaxis (CINV prophylaxis). <br />        NOTE: In December 2010, the FDA announced that because of the risk of QT prolongation, dolasetron injection is longer indicated for chemotherapy-induced nausea/vomiting (CINV) prophylaxis.<br />     ***For the treatment of post-operative nausea/vomiting (PONV).***For post-operative nausea/vomiting (PONV) prophylaxis.","***Dolasetron hypersensitivity, granisetron hypersensitivity, ondansetron hypersensitivity, palonosetron hypersensitivity***Alcoholism, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, nausea/vomiting, QT prolongation, renal impairment, sick sinus syndrome, thyroid disease***Children, infants, neonates***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clomipramine hydrochloride,***For treatment of obsessive-compulsive disorder (OCD).***For the treatment of behavioral symptoms associated with autistic disorder�.***For the treatment of premature ejaculation�.,"***Carbamazepine hypersensitivity, serious rash, tricyclic antidepressant hypersensitivity***MAOI therapy***Acute myocardial infarction, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, long QT syndrome, myocardial infarction, orthostatic hypotension, QT prolongation, tachycardia***Children, suicidal ideation***Bipolar disorder, mania, schizophrenia***Alcoholism, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Electroconvulsive therapy (ECT), seizure disorder, seizures***Hepatic disease, poor metabolizers***Surgery***Anticholinergic medications, ileus, prostatic hypertrophy, urinary retention***Closed-angle glaucoma, increased intraocular pressure***Contact lenses***Agranulocytosis, leukopenia***Hyperthyroidism, hypothyroidism, thyroid disease***Diabetes mellitus, pheochromocytoma***Radiographic contrast administration***Sunlight (UV) exposure***Renal failure, renal impairment***Abrupt discontinuation***Geriatric***Neonates, pregnancy***Breast-feeding***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['620216'],maraviroc,***For the treatment of CCR5-tropic human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***For human immunodeficiency virus (HIV) prophylaxis� after occupational HIV exposure.,"***General Information***Infection***Fever, hepatic disease, hepatitis, hepatitis B and HIV coinfection, hepatitis C and HIV coinfection, hepatotoxicity, serious rash***Cardiac disease, myocardial infarction***Orthostatic hypotension***Dialysis, renal failure, renal impairment***Children, infants, neonates***Geriatric***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Human immunodeficiency virus (HIV) infection resistance***Pregnancy***Breast-feeding***Asian patients",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10184'],sulfanilamide,***For the treatment of vulvovaginal candidiasis due to <em>Candida albicans</em>.,"***Sulfonamide hypersensitivity***Carbonic anhydrase inhibitor hypersensitivity, sulfonylurea hypersensitivity, thiazide diuretic hypersensitivity***G6PD deficiency***Hepatic disease, renal failure, renal impairment***Children, infants, neonates***Pregnancy***Breast-feeding***Porphyria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3327'],diazoxide,"***For the treatment of hypertensive emergency. <br />        NOTE: Diazoxide is not effective in treating hypertension resulting from pheochromocytoma or monoamine oxidase inhibitor therapy. Because diazoxide increases cardiac output, it may be harmful if used in patients with hypertension secondary to aortic coarctation or arteriovenous shunt.<br />     ***For the treatment of secondary hypoglycemia following the established diagnosis of a primary condition when other specific medical therapy or surgical management has been unsuccessful or is not feasible. <br />        NOTE: Diazoxide should be used only after a diagnosis of hypoglycemia due to one of the following conditions has been definitely established. For adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. For children and infants: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. Diazoxide may be used preoperatively temporarily, and postoperatively, if hypoglycemia persists.<br />     ","***Diabetes mellitus, hepatic disease, hypoglycemia, hypokalemia***Cardiac disease, cerebrovascular disease, coronary artery disease, heart failure, renal disease, tachycardia***Uremia***Congenital diaphragmatic hernia, infants, neonates, pulmonary hypertension, respiratory distress syndrome, sepsis***Aortic coarctation, arteriovenous shunt***Pheochromocytoma***Renal impairment***Sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Labor, obstetric delivery, pregnancy***Breast-feeding***Gout, hyperuricemia***Extravasation, intramuscular administration, subcutaneous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albuterol sulfate,"***For the treatment of acute bronchospasm (e.g., asthma) and bronchospasm prophylaxis.***For bronchospasm associated reversible obstructive airway disease (i.e., asthma).***For exercise-induced bronchospasm prophylaxis.***For the adjunctive emergency acute treatment of hyperkalemia�.***For the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD)� including chronic bronchitis� and emphysema�.","***General Information***Albuterol hypersensitivity, levalbuterol hypersensitivity, milk protein hypersensitivity***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, tachycardia, thyroid disease***Geriatric***Hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyrotoxicosis***Diabetes mellitus, diabetic ketoacidosis***Deterioration of asthma, paradoxical bronchospasm***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Renal impairment***MAOI therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1388'],lindane,"***For the treatment of scabies caused by <em>Sarcoptes scabiei </em>in patients who cannot tolerate or have failed treatment with other approved therapies. <br />        NOTE: Scabies management should include microscopic evaluation of skin scrapings to confirm the diagnosis, evaluation and treatment of sexual contacts simultaneously, and washing of clothing, used bedding and towels in very hot water (or dry-cleaning such items).<br />     ***For the treatment of pediculosis caused by <em>Pediculus capitis</em> (head lice) or <em>Phthirus pubis</em> (crab lice or pediculosis pubis). <br />        NOTE: Lindane shampoo is indicated for the treatment of lice only in patients who cannot tolerate or have failed treatment with other approved therapies. Lice management should include visual inspection to ensure patient is currently infested with live lice (empty egg casings or 'nits' can remain on hair shaft long after true infestation); manual removal of nits using a comb designed for this purpose and/or individual removal with tweezers followed by close examination of the hair and scalp; evaluation and treatment of sexual contacts simultaneously, and washing of clothing, used bedding and towels in very hot water. Personal articles that cannot be washed may be dry-cleaned, sealed in a plastic bag for 4 weeks, or sprayed with a product specifically designed for this purpose.<br />     ","***General Information***Accidental exposure, neurotoxicity, occlusive dressing, ocular exposure, seizures***Alcoholism, brain tumor, head trauma, hepatic disease, human immunodeficiency virus (HIV) infection, seizure disorder***Atopy, burns, crusted (Norwegian) scabies, eczema, exfoliative dermatitis, inflammation, psoriasis, skin abrasion, skin disease***Children, geriatric, infants, neonates, premature neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,antihemophilic factor (recombinant),"***For the prevention and control of hemorrhage in patients with hemophilia A (classical hemophilia). <br />        NOTE: Humate, Kogenate, and ReFacto have been designated by the FDA as orphan drugs for the prophylaxis and management of hemorrhage or hemarthrosis in patients with hemophilia A.<br /> <br />NOTE: Guidelines for the treatment of acute bleeding and prevention of bleeding during surgery vary. For all indications, the dose of antihemophilic factor should be individualized taking into consideration the seriousness of the bleed or procedure, the clinical status of the patient, and the factor VIII activity concentration***For minor bleeding including early muscle bleed, early hemarthrosis, and oral bleeds.***For moderate bleeding including advanced muscle bleed, extensive hemarthrosis, hematoma, and mild head trauma.***For life- or limb-threatening bleeding including surgical bleeding, gastrointestinal bleeding, neck, tongue or pharyngeal hematoma with potential for airway compromise, intracranial, intraabdominal, or intrathoracic bleeding, or fractures.***For bleeding in patients with hemophilia A and factor VIII inhibitor titers less than 10 Bethesda Units and with low anamnestic responses.***For the perioperative management of surgical bleeding (surgical bleeding prophylaxis) in patients with hemophilia A.***For routine bleeding prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A.***For the management of hemorrhage or hemarthrosis in patients with von Willebrand's disease (vWD). <br />        NOTE: Humate-P has been designated by the FDA as orphan drugs for this indication.<br />     ***For major hemorrhage in patients with mild vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma or traumatic hemorrhage).***For minor hemorrhage in patients with moderate to severe vWD type I, type II, and type III (e.g., epistaxis, oral bleeding, or menorrhagia).***For major hemorrhage in patients with moderate to severe vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For major hemorrhage in patients with vWD type II and III (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For surgical bleeding prophylaxis during major or minor procedures in patients with vWD in whom desmopressin is either ineffective or contraindicated. <br />          NOTE: Alphanate and Humate-P have been designated by the FDA as orphan drugs for this indication.<br />       ","***General Information***Pregnancy***Breast-feeding***Thromboembolic disease***Hepatitis, infection, viral infection***Anemia***Bovine protein hypersensitivity, hamster protein hypersensitivity, latex hypersensitivity, mannitol hypersensitivity, murine protein hypersensitivity, polysorbate 80 hypersensitivity***Porcine protein hypersensitivity***Human immunodeficiency virus (HIV) infection***Cardiac disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['733', '221058']",ampicillin,"***For the treatment of meningitis due to susceptible organisms. <br />        NOTE: The Infectious Diseases Society of America (IDSA) recommends ampicillin as an option for the definitive treatment of Streptococcus pneumoniae with penicillin MICs &lt; 0.1 mcg/ml, Neisseria meningitides with MICs &lt; 0.1 mcg/ml, Beta-lactamase negative Haemophilus influenzae, ampicillin susceptible Enterococcus sp. (plus gentamicin), Listeria monocytogenes, and Streptococcus agalactiae. They also recommend ampicillin as empiric therapy in patients &lt; 1 month of age (with cefotaxime or an aminoglycoside) or &gt; 50 years old (with vancomycin and a 3rd generation cephalosporin).<br />     ***For the treatment of infective endocarditis.***For the treatment of severe infections, including bacteremia.***For the treatment of upper respiratory tract infections and lower respiratory tract infections, including community-acquired pneumonia. <br />        NOTE: The manufacturer suggests that higher doses may be used for severe infections. For example, see Dosage for septicemia, meningitis, and endocarditis for higher dosage recommendations.<br />     ***For the treatment of skin and skin structure infections (e.g. cellulitis). <br />        NOTE: The manufacturer suggests that higher doses may be used for severe infections. For example, see Dosage for septicemia, meningitis, and endocarditis for higher dosage recommendations.<br />     ***For the treatment of genitourinary tract infections, including urinary tract infection (UTI) (e.g. cystitis and pyelonephritis). <br />        NOTE: The manufacturer suggests that higher doses may be used for severe infections. For example, see Dosage for septicemia, meningitis, and endocarditis for higher dosage recommendations.<br />     ***For the treatment of gastrointestinal infections (e.g. enterocolitis, gastroenteritis), including those due to <em>Salmonella typhii </em>(typhoid fever), other <em>Salmonella </em>sp<em>.</em> (salmonellosis), <em>Shigella </em>sp<em>.</em> (dysentery/shigellosis). <br />        NOTE: The manufacturer suggests that higher doses may be used for severe infections. For example, see Dosage for septicemia, meningitis, and endocarditis for higher dosage recommendations.<br />     ***For management of <em>Salmonella typhii</em> chronic carrier patients�.***For the treatment of leptospirosis�.***For bacterial endocarditis prophylaxis�.***For perinatal Group B streptococcal bacterial infection prophylaxis�.***For surgical infection prophylaxis� in patients undergoing liver transplantation.***For the treatment of systemic anthrax� infection.","***General Information***Dialysis, renal disease, renal failure, renal impairment***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, eczema, penicillin hypersensitivity, serious rash, urticaria***Mononucleosis***Antimicrobial resistance***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Sexually transmitted disease***Infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['25789']['33738'],glimepiride/pioglitazone,"***For the treatment of type 2 diabetes mellitus uncontrolled by diet and exercise alone. <br />  NOTE: The safety and efficacy of glimepiride; pioglitazone combination tablets as initial therapy for type 2 diabetes have not been established.<br />NOTE: Patients treated with glimepiride; pioglitazone should be monitored for cardiovascular adverse events. When pioglitazone is used in combination with insulin, the combination therapy should be discontinued in patients who do not respond as manifested by a reduction in HbA1c or insulin dose after 4�5 months of therapy or who develop any significant adverse events.<br />NOTE: When adding pioglitazone to glimepiride in patients with or without symptomatic heart disease and diabetes, monitor closely for signs of weight gain, peripheral edema, or congestive heart failure. In general, pioglitazone should be initiated at the lowest dose and increased gradually after at least three months of therapy. The risk of these symptoms is increased when higher doses of pioglitazone are used in combination with a sulfonylurea or insulin in patients at risk of congestive heart failure. Pioglitazone should not be added to glimepiride therapy in patients with New York Heart Association Class III or IV heart failure. Glimepiride; Pioglitazone should be discontinued if any deterioration in cardiac status occurs during therapy***For use when initial treatment with a sulfonylurea alone does not result in adequate glycemic control.***For use when initial treatment with pioglitazone alone does not result in adequate glycemic control.***For patients already receiving a combination of glimepiride and pioglitazone, and desire to switch to the combination tablet.***For patients already receiving a combination of a different sulfonylurea and pioglitazone, and desire to switch to the combination tablet.***Formoterol; Mometasone","***General Information***Acute heart failure, cardiac disease, edema, heart failure, peripheral edema, pulmonary edema***Diabetic ketoacidosis, type 1 diabetes mellitus***Sulfonylurea hypersensitivity***Sulfonamide hypersensitivity***Adrenal insufficiency, autonomic neuropathy, hypoglycemia, pituitary insufficiency, thyroid disease***Fever, infection, surgery, trauma***Hepatic disease***Renal failure, renal impairment***Anemia, G6PD deficiency, hemolytic anemia***Bladder cancer, new primary malignancy***Bone fractures, osteoporosis***Geriatric***Contraception requirements, menstrual irregularity, polycystic ovary syndrome***Neonates, obstetric delivery, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/levonorgestrel,"***For routine contraception.***For extended continuous routine contraception.***For use as postcoital contraception within 72 hours of unprotected intercourse, or known or suspected contraceptive failure, in females who have no known contraindications to oral contraceptives, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,miconazole nitrate/white petrolatum/zinc oxide,***For the adjuvant treatment of diaper dermatitis complicated by documented candidiasis in immunocompetent pediatric patients.,"***General Information***Ophthalmic administration, vaginal administration***Azole antifungals hypersensitivity***Immunosuppression***Neonates***Antimicrobial resistance***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,metformin hydrochloride/pioglitazone,"***For the treatment of type 2 diabetes mellitus in combination with diet and exercise and when treatment with  both metformin and pioglitazone is appropriate. <br />  NOTE: Metformin; pioglitazone is not for use in patients with type 1 diabetes or diabetic ketoacidosis.<br />NOTE: When metformin; pioglitazone is used in combination with insulin or an insulin secretagogue, a lower dose of the insulin or insulin secretagogue may be needed in order to reduce the risk of hypoglycemia. In patients taking insulin and metformin; pioglitazone who experience hypoglycemia, reduce the dose of insulin by 10 to 25%. Individualize any further adjustments based on glycemic response.<br />NOTE: When adding pioglitazone to metformin in patients with or without symptomatic heart disease and diabetes, monitor closely for signs of weight gain, peripheral edema, or congestive heart failure. In general, pioglitazone should be initiated at the lowest dose and increased gradually after at least three months of therapy. The risk of these symptoms is increased when higher doses of pioglitazone are used in combination with insulin in patients at risk of congestive heart failure. Pioglitazone should not be used in patients with New York Heart Association Class III or IV heart failure; metformin should not be used in patients with congestive heart failure requiring pharmacological therapy. Metformin; pioglitazone should be discontinued if any deterioration in cardiac status occurs during therapy.<br />NOTE: Liver function tests (serum alanine and aspartate aminotransferases, alkaline phosphatase, and total bilirubin) should be obtained prior to initiating metformin; pioglitazone (see Contraindications/Precautions)***For use when initial treatment with metformin alone or pioglitazone alone does not result in adequate glycemic control.***For use when switching from pioglitazone plus metformin as separate tablets to the single, combination tablet.***Formoterol; Mometasone","***General Information***Diabetic ketoacidosis, type 1 diabetes mellitus***Acidemia, acute myocardial infarction, cardiogenic shock, dehydration, hypoxemia, lactic acidosis, metabolic acidosis, sepsis***Diarrhea, vomiting***Renal disease, renal failure, renal impairment***Acute heart failure, cardiac disease, edema, heart failure, peripheral edema, pulmonary edema***Alcoholism, ethanol ingestion, ethanol intoxication, hepatic disease***Radiographic contrast administration***Burns, fever, infection, surgery, trauma***Adrenal insufficiency, gastroparesis, GI obstruction, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypothyroidism, ileus, malnutrition, pituitary insufficiency***Anemia, pernicious anemia***Bone fractures, osteoporosis***Contraception requirements, menstrual irregularity, polycystic ovary syndrome, pregnancy***Breast-feeding***Bladder cancer, new primary malignancy***Geriatric***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,leuprolide acetate,"***For the palliative treatment of advanced prostate cancer, particularly when orchiectomy or estrogen therapy are not indicated or are unacceptable.***For the management of endometriosis including pain relief and reduction of endometriotic lesions.***For the treatment of central precocious puberty (idiopathic or neurogenic) in children. <br />        NOTE: Leuprolide has been designated an orphan drug by the FDA for this indication.<br />NOTE: Downregulation is determined by GnRH agonist stimulation test, sex steroid concentrations, and Tanner staging. Give consideration to discontinuing treatment before 11 years of age in girls and 12 years of age in boys***For the preoperative treatment of anemia due to uterine leiomyomata (fibroids) in combination with iron supplementation when iron therapy alone fails to correct the anemia.***For the treatment of benign prostatic hyperplasia (BPH)�.***For the adjuvant treatment of premenopausal women with hormone receptor-positive breast cancer�.***For the treatment of nonspecific symptoms associated with premenstrual syndrome (PMS)�.***For inhibiting premature leuteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation and subsequent in vitro fertilization (IVF) or other assisted reproductive technology (ART) for the treatment of infertility�. <br />        NOTE: Drugs such as ganirelix and cetrorelix are now more commonly used and are FDA-approved for this purpose. Leuprolide should only be used by a qualified infertility specialist. Withhold HCG administration in cases where the ovaries are abnormally enlarged to reduce the chance of inducing ovarian hyperstimulation syndrome (OHSS).<br />     ***For prevention of stuttering priapism� (i.e., recurrent priapism).***Formoterol***Formoterol; Mometasone","***Benzyl alcohol hypersensitivity***Gonadotropin-Releasing Hormone (GnRH) analogs hypersensitivity***Renal impairment, spinal cord compression, urinary tract obstruction***Pituitary insufficiency***Dysfunctional uterine bleeding, menstruation, vaginal bleeding***Children, geriatric, osteoporosis***Females, pregnancy***Breast-feeding***Cardiac disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, stroke, tobacco smoking***Diabetes mellitus, hyperglycemia***Alcoholism, cardiac arrhythmias, coronary artery disease, heart failure, hepatic disease, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, thyroid disease***Brain tumor, cerebrovascular disease, seizure disorder***Depression, suicidal ideation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['17652'],amcinonide,"***For the treatment of moderate to severe corticosteroid-responsive dermatoses, like alopecia areata, atopic dermatitis, severe contact dermatitis, or severe <em>Rhus</em> dermatitis (due to plants like poison ivy), discoid lupus erythematosus, granuloma annulare, cutaneous lichen planus, lichen simplex chronicus, severe lichen striatus, severe eczema (including severe hyperkeratotic eczema, severe nummular eczema, and severe eczematous conditions of the hands or feet), exfoliative dermatitis, keloids, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, severe pruritus, sarcoidosis, sunburn, or urticaria.","***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, growth inhibition, increased intracranial pressure, infants, neonates***Diabetes mellitus***Corticosteroid hypersensitivity***Fungal infection, herpes infection, infection, measles, varicella, viral infection***Acne rosacea, acne vulgaris, ocular exposure, ophthalmic administration, perioral dermatitis***Geriatric, peripheral vascular disease, skin atrophy***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,glatiramer acetate,***For the treatment of relapsing forms of multiple sclerosis. <br />        NOTE: Glatiramer has been designated an orphan drug by the FDA for this indication.<br />     ,"***Intravenous administration, mannitol hypersensitivity***Immunosuppression, infection, vaccination***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['35619'],rifaximin,***For the treatment of patients with traveler's diarrhea caused by noninvasive strains of <em>E. coli</em>.***For reducing the risk of overt hepatic encephalopathy recurrence.***For the treatment of irritable bowel syndrome (IBS) with diarrhea.***For the traveler's diarrhea prophylaxis�.***For the treatment of diverticulitis�.***For recurrent acute diverticulitis� in combination with mesalamine.***For symptomatic remission of uncomplicated diverticulitis� in combination with mesalamine.***For the treatment of active Crohn's disease�.***For the treatment of pseudomembranous colitis� due to <em>Clostridium difficile</em>.,"***Rifamycin hypersensitivity***Colitis, diarrhea, dysentery, fever, GI bleeding, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1011650'],pegloticase,"***For the treatment of chronic gout in patients refractory to conventional therapy (treatment-failure gout). <br />  NOTE: Pegloticase is not recommended for asymptomatic hyperuricemia.<br />NOTE: In clinical trials, all study patients were premedicated with an oral antihistamine, IV corticosteroid, and acetaminophen prior to each dose and received prophylaxis for gout flares with an NSAID and/or colchicine starting 1 week prior to initiating therapy unless not tolerated or otherwise contraindicated","***General Information***Asian patients, Black patients, G6PD deficiency, hemolysis, methemoglobinemia***Hyperuricemia, infusion-related reactions, requires a specialized care setting, requires an experienced clinician, serious hypersensitivity reactions or anaphylaxis***Heart failure***Breast-feeding***Children, infants, neonates***Pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['3554', '151358']",disulfiram,***For the maintenance treatment of alcohol dependence.,"***General Information***Ethanol ingestion, ethanol intoxication***Pregnancy***Breast-feeding***Hematological disease, hepatic disease, hepatitis, jaundice***Diabetes mellitus, hypothyroidism, renal disease, seizure disorder***Acute myocardial infarction, cardiac disease, psychosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mesalamine,***For the treatment of active ulcerative proctitis.***For the treatment of ulcerative colitis or Crohn's disease�.***For induction of remission of mild to moderate active ulcerative colitis or Crohn's disease�.***For maintenance of remission of ulcerative colitis.,"***General Information***5-aminosalicylates hypersensitivity, salicylate hypersensitivity***Renal disease, renal failure, renal impairment***Hepatitis, myocarditis, pericarditis, pneumonitis***Geriatric***Pregnancy***Breast-feeding***GI obstruction, pyloric stenosis***Sulfite hypersensitivity***Hepatic disease***Children, infants, neonates***Phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['40114'],guanfacine,"***For the treatment of hypertension.***For the treatment of attention-deficit hyperactivity disorder (ADHD), as monotherapy or as adjunctive therapy to a psychostimulant.","***General Information***Acute myocardial infarction, AV block, bradycardia, cardiac disease, cerebrovascular disease, coronary artery disease, dehydration, hypotension, orthostatic hypotension, syncope***Hepatic disease, renal disease, renal failure, renal impairment***Abrupt discontinuation***Geriatric***Depression***Driving or operating machinery, ethanol ingestion***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['996051'],cabazitaxel,"***For the treatment of castration-resistant metastatic prostate cancer in patients who have previously been treated with a docetaxel-containing regimen, in combination with prednisone.","***Polysorbate 80 hypersensitivity, serious hypersensitivity reactions or anaphylaxis, taxane hypersensitivity***Anemia, bone marrow suppression, neutropenia, thrombocytopenia***Hepatic disease***Abdominal pain, anticoagulant therapy, constipation, corticosteroid therapy, diarrhea, GI bleeding, GI perforation, ileus, vomiting***Radiation therapy***Dehydration, renal failure, sepsis***Chronic lung disease (CLD), pneumonitis, respiratory distress syndrome***Geriatric***Children***Pregnancy***Contraception requirements, infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['72962', '1299922']",docetaxel,"***For the treatment of breast cancer.***For locally advanced or metastatic breast cancer after failure of previous chemotherapy.***For the treatment of metastatic breast cancer after failure of prior anthracycline-containing chemotherapy in combination with capecitabine�. <br />          NOTE: Capecitabine is FDA approved for use in combination with docetaxel for the treatment of metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.<br />       ***For adjuvant treatment of operable node-positive breast cancer in combination with cyclophosphamide and doxorubicin.***For adjuvant treatment of operable stage I to III invasive breast cancer in combination with cyclophosphamide�.***For adjuvant treatment of operable node-positive or high-risk node-negative (tumor greater than 2 cm) breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy�.***For adjuvant treatment of HER2 overexpressing, node-positive or node negative (ER/PR negative or with one high-risk feature) breast cancer, in combination with trastuzumab and carboplatin (TCH regimen)�. <br />          NOTE: Trastuzumab is FDA approved for the adjuvant treatment of HER2 overexpressing, node-positive or node negative (ER/PR negative or with one high-risk feature) breast cancer, in combination with docetaxel and carboplatin.<br />       ***For adjuvant treatment of node-positive breast cancer in sequence with fluorouracil, epirubicin, and cyclophosphamide (FEC-D regimen)�.***For first-line treatment of metastatic breast cancer�.***For HER2-positive metastatic breast cancer in combination with trastuzumab�. <br />          NOTE: Trastuzumab is FDA approved for use in combination with docetaxel for the treatment of metastatic HER-2 positive breast cancer<br />       ***For patients who have not previously received chemotherapy for metastatic or inoperable locally recurrent HER2-negative breast cancer, in combination with bevacizumab�.***For first-line treatment of HER2-positive metastatic breast cancer in combination with pertuzumab and trastuzumab�. <br />          NOTE: Pertuzumab is FDA approved in combination with trastuzumab and docetaxel for the first-line treatment of HER2-positive metastatic breast cancer.<br />       ***For the treatment of non-small cell lung cancer (NSCLC).***For advanced or metastatic non-small cell lung cancer (NSCLC) after the failure of prior platinum containing chemotherapy.***For first-line treatment of unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with cisplatin in patients who have not received prior chemotherapy.***For first-line treatment of unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with carboplatin�.***For first-line treatment of unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with gemcitabine�.***For the treatment of metastatic prostate cancer.***For the treatment of hormone-refractory, metastatic prostate cancer in combination with prednisone.***For the treatment of hormone-refractory, metastatic prostate cancer in combination with estramustine�.***For the first-line treatment of metastatic, hormone-sensitive prostate cancer in selected patients, in combination with androgen-deprivation therapy�.***For the treatment of gastric cancer.***For advanced gastric cancer, including adenocarcinoma of the gastroesophageal junction, in combination with cisplatin and 5-fluorouracil in patients who have not received prior chemotherapy for advanced disease.***For the treatment of advanced gastric cancer as a single agent�.***For the treatment of head and neck cancer.***For induction treatment of locally advanced inoperable squamous cell head and neck cancer in combination with cisplatin and 5-fluorouracil (5-FU).***For induction treatment of locally advanced (unresectable disease, low surgical cure, or organ preservation) squamous cell head and neck cancer in combination with cisplatin and 5-fluorouracil (5-FU). <br />          NOTE: Survival was significantly improved among patients who got the 3 drugs (see Dosage below) as compared with receipt of only cisplatin 100 mg/m2 IV on day 1 and 5- fluorouracil 1000 mg/m2/day by continuous IV infusion for 5 days. Specifically, the relative risk of death was 30% lower. Also, the median overall survival was 70.6 months as compared with 30.1 months for patients receiving only cisplatin and 5-fluorouracil. Three to 8 weeks after the start of the last cycle, all patients in both treatment arms who did not have progressive disease got carboplatin (AUC 1.5 weekly for 7 doses) and radiation therapy (2 Gy per day, 5 days per week for 7 weeks) followed by surgery, if appropriate.<br />       ***For the treatment of ovarian cancer�.***For refractory advanced ovarian cancer�.***For the first-line adjuvant treatment of Stage Ic through IV ovarian cancer and peritoneal cancers in combination with carboplatin�.***For the treatment of metastatic malignant melanoma�.","***Bone marrow suppression, herpes infection, infection, neutropenia, radiation therapy, thrombocytopenia, varicella, viral infection***Biliary tract disease, hepatic disease, jaundice***Acute bronchospasm, hypotension, polysorbate 80 hypersensitivity, serious hypersensitivity reactions or anaphylaxis, taxane hypersensitivity***Dental disease, dental work***Ascites, cardiac tamponade, edema, fluid retention, peripheral edema, pleural effusion***Accidental exposure, ocular exposure***Children, infants, neonates***Geriatric***Vaccination***Intramuscular injections***Ocular disease***Driving or operating machinery, ethanol ingestion, ethanol intoxication***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3322'],diazepam,"***For the treatment of anxiety disorders or for the short-term relief of the symptoms of anxiety.***For the treatment of acute alcohol withdrawal.***For the treatment of muscle spasm due to local pathology such as muscle or joint inflammation or trauma; athetosis; stiff-man syndrome; tetanus; or spasticity due to upper motor neuron diseases such as cerebral palsy.***For the treatment of status epilepticus or for treatment of drug-induced seizures. <br />        NOTE: Many clinicians now prefer IV lorazepam over IV diazepam for the acute treatment of seizures.<br />     ***For adjunctive treatment of seizures other than status epilepticus in selected, refractory patients with partial seizures or generalized tonic-clonic seizures who require intermittent use of diazepam to control bouts of increased seizure activity.***For amnesia induction or for preprocedure sedation induction.***For the treatment of benzodiazepine withdrawal�.***For febrile seizure prophylaxis�.***For the treatment of agitation� in intensive care unit patients.***For the treatment of acute chloroquine overdose� in combination with epinephrine.***For the treatment of insomnia�.","***Benzodiazepine hypersensitivity***Extravasation, intraarterial administration***Bipolar disorder, depression, mania, psychosis, suicidal ideation***Abrupt discontinuation, substance abuse***Seizure disorder, seizures, status epilepticus***CNS depression, coma, driving or operating machinery, ethanol intoxication, shock***Children, infants, neonates***Closed-angle glaucoma***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, pulmonary disease, respiratory depression, respiratory insufficiency, sleep apnea***Labor, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease, hepatitis, jaundice***Neutropenia***Renal failure, renal impairment***Myasthenia gravis, neuromuscular disease, Parkinson's disease***Dementia, geriatric***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['103', '1546028']",mercaptopurine,"***For the treatment of acute lymphocytic leukemia (ALL).***For maintenance treatment of acute myelogenous leukemia (AML)�, in combination with other chemotherapeutic agents.***For the treatment of chronic myelogenous leukemia (CML)�.***For the treatment of Crohn's disease� or ulcerative colitis�.***Formoterol; Mometasone","***Anemia, bone marrow suppression, leukopenia, neutropenia, requires an experienced clinician, thiopurine methyltransferase (TPMT) deficiency, thrombocytopenia***Hepatic disease, hepatotoxicity***Hyperuricemia, renal impairment, tumor lysis syndrome (TLS)***Vaccination***Autoimmune disease, immunosuppression, infection, inflammatory bowel disease, new primary malignancy***Sunlight (UV) exposure***Children, hypoglycemia, infants***Intrauterine fetal death, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amphotericin B lipid complex,"***For the treatment of CNS infections, including meningitis, in patients refractory to or intolerant of amphotericin B deoxycholate. <br />  NOTE: For CNS infections caused by Cryptococcus, see Cryptococcus meningitis.<br /***For the treatment of CNS infections caused by <em>Aspergillus</em> sp..***For the treatment of CNS infections caused by <em>Blastomyces dermatitidis</em>�.***For the treatment of candidemia and invasive candidiasis (non-CNS) in patients refractory to or intolerant of amphotericin B deoxycholate.***For the treatment of chronic disseminated (hepatosplenic candidiasis).***For the treatment of invasive aspergillosis in patients who are refractory to or intolerant of amphotericin B deoxycholate. <br />        NOTE: For CNS disease, see meningitis indication.<br />     ***For the treatment of fungal ophthalmic infection, including endophthalmitis, caused by <em>Aspergillus</em> sp. in patients who are refractory to or intolerant of amphotericin B deoxycholate.***For the treatment of cardiovascular system infections, including endocarditis, myocarditis, pericarditis, suppurative thrombophlebitis�, and infected pacemaker�, implantable cardiac defibrillator (ICD)�, or ventricular assist devices (VAD)� in patients who are refractory to or intolerant of other antifungal therapies.***For the treatment of <em>Candida</em> cardiovascular system infections.***For the treatment of <em>Aspergillus</em> cardiovascular system infections.***For the treatment of respiratory infections (i.e., pneumonia, tracheobronchitis, sinusitis) in patients who are refractory to or intolerant of amphotericin B deoxycholate.***For the treatment of <em>Candida</em> pneumonia.***For the treatment of invasive pulmonary, sinus, or tracheobronchial aspergillosis.***For the treatment of intraabdominal infections (i.e., peritonitis, intraabdominal abscess) in patients who are refractory to or intolerant of amphotericin B deoxycholate.***For the treatment of intraabdominal candidiasis.***For the treatment of <em>Aspergillus</em> peritonitis.***For the treatment of bone and joint infections, including osteomyelitis and infectious arthritis, in patients who are refractory to or intolerant of amphotericin B deoxycholate.***For the treatment of <em>Candida</em> osteomyelitis or infectious arthritis.***For the treatment of <em>Aspergillus</em> osteomyelitis or infectious arthritis.***For the treatment of pulmonary and disseminated cryptococcosis, including cryptococcal meningitis, in patients who are refractory to or intolerant of amphotericin B deoxycholate.***For the treatment of moderately severe to severe disseminated (nonmeningeal) or invasive pulmonary blastomycosis in patients refractory to or intolerant of amphotericin B deoxycholate. <br />        NOTE: For CNS disease, see meningitis indication.<br />     ***For the treatment of severe disseminated (nonmeningeal) or diffuse pulmonary coccidioidomycosis in patients refractory to or intolerant of amphotericin B deoxycholate.***For the treatment of moderately severe to severe disseminated (nonmeningeal) or pulmonary histoplasmosis in patients refractory to or intolerant of amphotericin B deoxycholate.***For the treatment of pulmonary histoplasmosis.***For the treatment of disseminated (nonmeningeal) histoplasmosis.***For the treatment of esophageal candidiasis� in HIV-infected patients.***For empirical therapy for presumed fungal infection in patients with febrile neutropenia� or non-neutropenic patients at high risk for fungal infection� (e.g., critically ill patients with risk factors for invasive candidiasis and no other known cause of fever).***For the treatment of visceral leishmaniasis�, including antimony-resistant, caused by <em>Leishmania infantum</em>.***For chronic maintenance therapy (secondary prophylaxis)� of visceral leishmaniasis in HIV-infected patients.","***General Information***Renal disease, renal failure, renal impairment***Hepatic disease***Anemia, hematological disease, leukopenia, thrombocytopenia***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypocalcemia, hypokalemia, hypomagnesemia***Cardiac disease, hypertension, hypotension***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding***Infusion-related reactions",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,arformoterol tartrate,"***For the maintenance treatment of bronchoconstriction associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.***Formoterol***Formoterol; Mometasone","***General Information***Angioedema, urticaria***Acute bronchospasm, asthma, asthma-related death, monotherapy treatment of asthma***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation***Diabetes mellitus, hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***Children, infants***Hepatic disease***Labor, obstetric delivery***Pregnancy***Breast-feeding***MAOI therapy***Paradoxical bronchospasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clopidogrel bisulfate,"***For arterial thromboembolism prophylaxis (i.e., myocardial infarction prophylaxis, stroke prophylaxis, thrombosis prophylaxis). <br />  NOTE: Patients identified as CYP2C19 poor metabolizers have a diminished antiplatelet response to clopidogrel. A higher dosage regimen (600 mg PO loading dose followed by 150 mg PO daily) increases antiplatelet response, however an appropriate dosage regimen for this patient population has not been established in clinical outcome trials.<br /***For patients with recent ischemic stroke, transient ischemic attack (TIA), or myocardial infarction, or established coronary artery disease or peripheral arterial disease.***For patients with unstable angina or acute myocardial infarction, NSTEMI (non-ST-elevation myocardial infarction).***For patients with acute myocardial infarction, STEMI (ST-segment elevation MI).***For pediatric arterial thromboembolism prophylaxis� (i.e., thrombosis prophylaxis�, secondary stroke prophylaxis� following arterial ischemic stroke� or transient ischemic attack (TIA)�), including following cardiac surgery� and in other cardiac conditions with a risk for arterial thrombosis (e.g., Kawasaki disease�):. <br />          NOTE: In children with recurrent arterial ischemic stroke or TIAs who fail or are intolerant of aspirin, clopidogrel is recommended as an alternative antiplatelet agent.  <br />NOTE: In children with Kawasaki disease who have severe coronary involvement, clopidogrel is recommended to be used with aspirin***For patients undergoing percutaneous coronary intervention (PCI). <br />  NOTE: Premature discontinuation of dual antiplatelet therapy after stent placement increases the risk of stent thrombosis. The mortality rate of stent thrombosis is 20�45%. <br /***For patients undergoing coronary artery bypass graft surgery (cardiac surgery�).","***General Information***Bleeding, GI bleeding, intracranial bleeding, peptic ulcer disease, surgery, trauma***Hepatic disease***Renal disease, renal failure, renal impairment***Poor metabolizers***Pregnancy***Breast-feeding***Geriatric***Children, infants, neonates***Abrupt discontinuation***Thrombotic thrombocytopenic purpura (TTP)***Thienopyridine hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['190521']['68244'],abacavir/lamivudine/zidovudine,***For the treatment of human immunodeficiency virus (HIV) infection.,"***General Information***Abacavir hypersensitivity, serious hypersensitivity reactions or anaphylaxis***Geriatric***Children, infants, neonates***Renal failure, renal impairment***Anemia, bone marrow suppression, folate deficiency, neutropenia, radiation therapy, vitamin B12 deficiency***Dental disease, dental work***Alcoholism, females, hepatic disease, hepatotoxicity or lactic acidosis, obesity***Hepatitis B and HIV coinfection, hepatitis B exacerbation***Pregnancy***Breast-feeding***Human immunodeficiency virus (HIV) infection resistance***Myopathy***Peripheral neuropathy***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Cardiac disease, myocardial infarction***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5487']['83818'],hydrochlorothiazide/irbesartan,"***For the treatment of hypertension in patients who do not respond to monotherapy and/or as initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. <br />        Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, heart failure, renal artery stenosis, renal disease, renal failure, renal impairment***Hepatic disease***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***ACE-inhibitor induced angioedema, angioedema***Surgery***Pregnancy***Breast-feeding***Children***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia, hyponatremia***Diabetes mellitus, hyperglycemia***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['190521'],abacavir,***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***For human immunodeficiency virus (HIV) prophylaxis� after occupational HIV exposure.,"***General Information***Abacavir hypersensitivity, serious hypersensitivity reactions or anaphylaxis***Cardiac disease, myocardial infarction***Alcoholism, females, hepatic disease, hepatotoxicity or lactic acidosis, obesity***Pregnancy***Breast-feeding***Infants, neonates***Human immunodeficiency virus (HIV) infection resistance***Geriatric***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Hepatitis B and HIV coinfection***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['140587'],celecoxib,"***For the relief of the signs and symptoms of osteoarthritis.***For the relief of the signs and symptoms of rheumatoid arthritis.***For the relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA) including pauciarticular, polyarticular juvenile idiopathic arthritis.***For the treatment of acute moderate pain or severe pain and dysmenorrhea.***For moderate-to-severe pain associated with orthopedic surgery.***For the relief of the signs and symptoms of ankylosing spondylitis.***Formoterol; Mometasone","***Sulfonamide hypersensitivity***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking***Hepatic disease, jaundice***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, heart failure, hypertension, myocardial infarction, peripheral edema, peripheral vascular disease, renal disease, stroke, tachycardia, thromboembolism, thrombophlebitis***Coronary artery bypass graft surgery (CABG)***Anemia***Bone marrow suppression, immunosuppression***Black patients***Children, infants, neonates***Labor, obstetric delivery, pregnancy***Breast-feeding***Dehydration, hypovolemia, renal failure, renal impairment***Geriatric***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,conjugated estrogens,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), or dyspareunia, whether menopause is natural or surgical (e.g., due to oophorectomy).***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For treatment of premenopausal females with estrogen deficiency due to hypogonadism.***For treatment of hypoestrogenism due to primary ovarian failure.***For the short-term treatment of abnormal or dysfunctional uterine bleeding caused by hormonal imbalance in the absence of organic pathology.***For the palliative treatment of breast cancer that has metastasized, in appropriately selected men or women.***For the palliative treatment of advanced inoperable prostate cancer.***Formoterol; Mometasone","***Angioedema, benzyl alcohol hypersensitivity, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,meperidine hydrochloride,"***For the treatment of moderate pain to severe pain. <br />        NOTE: Chronic use of meperidine is not recommended due to an increased risk of neurotoxicity (e.g., seizures) secondary to accumulation of the meperidine metabolite, normeperidine.<br />NOTE: Pain severity and patient response should guide dosage***For obstetric analgesia during labor and delivery.***For preoperative sedation induction.***For general anesthesia maintenance. <br />        NOTE: Dosage needed will depend on premedication and anesthesia utilized, nature and duration of procedure, and patient characteristics.<br />     ***For obstetric anesthesia�.***For the treatment of acute, severe headache� or migraine�.***For the treatment of shaking chills� induced by intravenous infusions of amphotericin B or for postoperative shivering�.","***Opiate agonist hypersensitivity***MAOI therapy***Acute abdomen, constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Biliary tract disease***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, status asthmaticus***Alcoholism, depression, substance abuse***Head trauma, increased intracranial pressure***Glaucoma***CNS depression, hepatic disease, renal impairment, seizure disorder, seizures***Angina, atrial flutter, cardiac arrhythmias, cardiac disease, dehydration, heart failure, hypotension, hypovolemia, pheochromocytoma***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, sickle cell disease, urinary retention***Geriatric***Children, infants, intramuscular administration, neonates***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Driving or operating machinery***Abrupt discontinuation***Anticoagulant therapy, coagulopathy, epidural administration, infection, intrathecal administration, intravenous administration, thrombocytopenia***Adrenal insufficiency, hypothyroidism, myxedema***Accidental exposure, potential for overdose or poisoning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['161']['2670', '235412', '1545976']",acetaminophen/codeine phosphate,***For the treatment of mild pain to moderate pain.***For the treatment of nonproductive cough�.,"***General Information***Acetaminophen hypersensitivity, opiate agonist hypersensitivity, sulfite hypersensitivity***Constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, pulmonary disease, respiratory depression***Abrupt discontinuation***Alcoholism, ethanol intoxication, hepatic disease, hepatitis, potential for overdose or poisoning***Substance abuse***Head trauma, increased intracranial pressure***Cardiac arrhythmias, cardiac disease, hypotension, hypovolemia***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, renal impairment, urethral stricture, urinary retention***Geriatric***Adenoidectomy, children, infants, neonates, neuromuscular disease, obesity, respiratory infection, sleep apnea, tonsillectomy***Anemia, G6PD deficiency***Bone marrow suppression, immunosuppression, infection***Driving or operating machinery***Asian patients, Black patients, Caucasian patients, Hispanic patients***Adrenal insufficiency, hypothyroidism, myxedema***MAOI therapy***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,norethindrone acetate,***For the treatment of secondary amenorrhea or dysfunctional uterine bleeding due to hormonal imbalance in the absence of organic pathology such as submucous fibroids or uterine cancer.***For routine contraception. <br />        NOTE: Ortho-Micronor and NOR-QD are not considered bioequivalent and are not substitutable for each other.<br />NOTE: These products have not been studied for and are not indicated for use in emergency contraception***For the treatment of endometriosis.***For the prevention of endometrial changes associated with estrogen replacement therapy in postmenopausal women.,"***General Information***Human immunodeficiency virus (HIV) infection***Hepatic disease***Incomplete abortion, vaginal bleeding***Breast cancer***Ectopic pregnancy, pregnancy***Breast-feeding***Diabetes mellitus***Hyperlipidemia***Cerebrovascular disease, myocardial infarction, stroke, thromboembolic disease, thrombophlebitis, tobacco smoking***Asthma, renal disease***Depression, migraine, seizure disorder***Ovarian cyst***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['596205'],ramelteon,***For the treatment of chronic or transient insomnia characterized by difficulty with sleep onset.,"***General Information***Angioedema, lactase deficiency***Hepatic disease***Chronic obstructive pulmonary disease (COPD), sleep apnea***Bipolar disorder, depression, schizophrenia, suicidal ideation***Neurological disease, seizure disorder***Alcoholism, driving or operating machinery, ethanol intoxication***Labor, obstetric delivery, pregnancy***Breast-feeding***Endocrine disease, hyperprolactinemia, infertility***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ibritumomab tiuxetan,"***For the treatment of CD20-positive non-Hodgkin's lymphoma (NHL), in combination with rituximab.***For the treatment of previously untreated follicular NHL in patients who achieve a partial or complete response to first-line chemotherapy. <br />          NOTE: Initiate the yttrium-90-ibritumomab therapeutic regimen 6 to 12 weeks after the last dose of first-line chemotherapy. Do not start therapy until the platelet count is &gt;= 150,000 cells/mm3.<br />       ***For the treatment of relapsed or refractory low-grade or follicular B-cell NHL.***Formoterol; Mometasone","***General Information***Altered biodistribution of Indium-111***Anemia, anticoagulant therapy, bleeding, bone marrow suppression, coagulopathy, leukopenia, neutropenia, thrombocytopenia***Infusion-related reactions***Pregnancy***Breast-feeding***Accidental exposure, extravasation***Vaccination***Exfoliative dermatitis, serious rash***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['233698'],dronedarone,"***For reduction in the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation. <br />  NOTE: Dronedarone is contraindicated in patients with permanent atrial fibrillation who will not or cannot be cardioverted to normal sinus rhythm. The use of dronedarone in these patients has resulted in increases in death, stroke, and heart failure hospitalizations when compared to placebo. <br /","***General Information***Heart failure, hypovolemia***Atrial fibrillation***Amiodarone-induced liver toxicity, hepatic disease***Amiodarone-induced lung toxicity***Electrolyte imbalance, hypokalemia, hypomagnesemia***Alcoholism, AV block, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, hypertension, hypocalcemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, sick sinus syndrome, thyroid disease, torsade de pointes***Asian patients***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydralazine hydrochloride/isosorbide dinitrate,***For the adjunctive treatment of heart failure in patients self-identified as black taking standard heart failure therapy.,"***General Information***Nitrate hypersensitivity***Renal disease, renal failure, renal impairment, systemic lupus erythematosus (SLE)***Hypotension, hypovolemia, orthostatic hypotension, syncope***Driving or operating machinery***Acute myocardial infarction, angina, cardiomyopathy, coronary artery disease***Geriatric***Head trauma, increased intracranial pressure, intracranial bleeding***Closed-angle glaucoma***Anemia***Hyperthyroidism***Hepatic disease***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,azilsartan medoxomil/chlorthalidone,"***For the treatment of hypertension, either alone or in combination with other antihypertensive agents. <br />        NOTE: Correct volume depletion prior to administration of azilsartan; chlorthalidone, especially in patients treated with high doses of diuretics or those with impaired renal function.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Anuria, heart failure, renal artery stenosis, renal failure, renal impairment***Hypovolemia***Pregnancy***Breast-feeding***Electrolyte imbalance, hepatic disease, hyperkalemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis***Gout, hyperuricemia***Geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,methylnaltrexone bromide,"***For the treatment of opiate agonist-induced constipation (OIC) in patients with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care, and also for the treatment of OIC in patients taking opioids for chronic non-cancer pain (including patients with chronic pain related to prior cancer or its treatment who do not require frequent [e.g., weekly] opioid dosage escalation).***For the management of nausea/vomiting� related to morphine.***For the treatment of pruritus� related to morphine.***For the management of urinary retention� from opioids.","***GI obstruction***Diarrhea***Children, infants, neonates***Intravenous administration***Geriatric, renal disease, renal impairment***Hepatic disease***Pregnancy***Breast-feeding***Crohn's disease, GI perforation, neoplastic disease, peptic ulcer disease, ulcerative colitis***Acute opioid withdrawal",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,conjugated estrogens/medroxyprogesterone acetate,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), or dyspareunia in women with an intact uterus.***For osteoporosis prophylaxis due to menopause (either natural or surgical) in women with an intact uterus.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10753'],tretinoin,"***For the treatment of acne vulgaris.***For adjunctive treatment of photoaging including palliation of fine facial wrinkles, facial mottled hyperpigmentation (i.e., 'liver spots'), and facial skin roughness.***For the treatment of acute promyelocytic leukemia (APL). <br />        NOTE: Retinoic acid-APL (RA-APL) syndrome characterized by fever, dyspnea, acute respiratory distress, weight gain, radiographic pulmonary infiltrates, pleural and pericardial effusions, edema, and hepatic, renal, and multi-organ failure requires prompt treatment with high-dose steroids (e.g., dexamethasone 10 mg IV every 12 hours for 3 days or until the resolution of symptoms). RA-APL syndrome may occur with or without leukocytosis.<br />     ***For remission induction treatment in patients with APL who are refractory to or who have relapsed from anthracycline chemotherapy or who have a contraindication to anthracycline-based therapy.***For maintenance therapy following induction and consolidation therapy�.***For remission induction and consolidation treatment in patients with newly diagnosed, low-risk APL in combination with arsenic trioxide�.***For remission induction treatment in patients with newly diagnosed APL, in combination with idarubicin�.***For consolidation treatment following tretinoin and idarubicin induction therapy in patients with newly diagnosed APL, in combination with idarubicin-containing chemotherapy�.***For the treatment of melasma�.***For the treatment of diseases of keratinization� (e.g., actinic keratosis�, ichthyosis�, keloids�, keratosis follicularis�); acne rosacea�; skin hyperpigmentation�.***For the treatment of AIDS-related Kaposi's sarcoma�.***Formoterol; Mometasone","***Requires a specialized care setting, requires an experienced clinician, respiratory insufficiency***Retinoid hypersensitivity***Paraben hypersensitivity***Fish hypersensitivity***Acute promyelocytic leukemia differentiation syndrome***Leukocytosis***Skin photosensitivity disorder, sunburn, sunlight (UV) exposure***Eczema***Hepatic disease***Contraception requirements, pregnancy, pregnancy testing, reproductive risk***Breast-feeding***Children, infants, neonates***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia***Accidental exposure, ocular exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6373'],levonorgestrel,"***For routine contraception.***For use as postcoital contraception within 72 hours of unprotected intercourse or known or suspected contraceptive failure - for use in females who have no known contraindications to use, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of menorrhagia (heavy menstrual bleeding).***For the treatment of endometriosis� in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception.","***General Information***Ectopic pregnancy, intrauterine fetal death, pregnancy, pregnancy testing***Breast-feeding***Cervical cancer, incomplete abortion, uterine cancer, vaginal bleeding***Breast cancer***Menstrual irregularity, ovarian cyst***Diabetes mellitus***Children***Hepatic disease, hepatocellular cancer, jaundice***Asian patients***Obstetric delivery***Requires an experienced clinician, uterine leiomyomata***Acquired immunodeficiency syndrome (AIDS), cervicitis, endometritis, infection, leukemia, vaginal discharge, vaginitis***Human immunodeficiency virus (HIV) infection, sexually transmitted disease***Bradycardia, seizure disorder, syncope***Obesity***Anticoagulant therapy, coagulopathy***Cerebrovascular disease, hypertension, myocardial infarction, stroke, thromboembolic disease, thrombophlebitis, tobacco smoking, valvular heart disease***Headache, migraine, visual disturbance***Renal disease***Magnetic resonance imaging (MRI)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,paclitaxel protein-bound,"***For the treatment of breast cancer.***For metastatic breast cancer after the failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy. <br />          NOTE: Prior therapy should have included an anthracycline unless clinically contraindicated.�<br />       ***For the treatment of taxane-refractory metastatic breast cancer�.***For the treatment of previously untreated metastatic breast cancer�.***For the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who are not candidates for curative surgery or radiation, in combination with carboplatin.***For the first-line treatment of metastatic pancreatic cancer in combination with gemcitabine.","***General Information***Taxane hypersensitivity***Bone marrow suppression, neutropenia, thrombocytopenia***Peripheral neuropathy***Geriatric***Hepatic disease, jaundice***Infertility, male-mediated teratogenicity, pregnancy***Breast-feeding***Radiation therapy***Children, infants, neonates***Biliary obstruction, fever, sepsis***Pneumonitis***Ensure correct formulation selection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clobetasol propionate,"***For the treatment of moderate-to-severe inflammatory manifestations, including pruritus, of corticosteroid-responsive dermatologic disorders such as alopecia areata, atopic dermatitis, contact dermatitis, generalized exfoliative dermatitis, Rhus dermatitis due to plants like poison ivy, seborrheic dermatitis, eczema (including severe hyperkeratotic eczema, severe nummular eczema, and severe eczematous conditions of the hands or feet), granuloma annulare, keloids, cutaneous lichen planus, lichen simplex chronicus, lichen striatus, subacute cutaneous and discoid lupus erythematosus, pretibial myxedema, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, sarcoidosis, sunburn, or urticaria. <br />        NOTE: Acute exudative inflammation, as occurs with poison ivy, may be best treated with a non-emollient cream or gel formulation, which are drying. Dry, scaly dermatoses may be best treated with emollient creams or ointments. Lower potency corticosteroids should be used on the face and intertriginous areas.<br />NOTE: Systemic therapy or intralesional injection of corticosteroids may be necessary for some conditions based on the type and severity of the disorder or inadequate response to topical therapy***For the treatment of plaque-type psoriasis.***For the alternative treatment of recalcitrant oral vesiculoerosive disease� including oral lichen planus�, mucous membrane pemphigus�, aphthous ulcer� and chronic oral erythema multiforme�.***For the treatment of vulvar lichen sclerosus�.***For the alternative treatment of vision-threatening periocular capillary hemangioma� in infancy and early childhood.","***Corticosteroid hypersensitivity***Cushing's syndrome, hepatic disease, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Diabetes mellitus***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Fungal infection, herpes infection, infection, measles, peripheral vascular disease, varicella, viral infection***Acne rosacea, acne vulgaris, cataracts, glaucoma, ocular exposure, ophthalmic administration, perioral dermatitis***Geriatric, skin atrophy***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['623400'],lacosamide,***For the treatment of partial seizures.***For use as monotherapy for partial seizures.***For adjunctive treatment of partial seizures.,"***General Information***Depression, suicidal ideation***Acute myocardial infarction, AV block, bradycardia, Brugada syndrome, cardiac disease, heart failure, myocardial infarction, sick sinus syndrome***Atrial fibrillation, atrial flutter, dehydration, hypovolemia, orthostatic hypotension, syncope***Substance abuse***Abrupt discontinuation***Driving or operating machinery***Dialysis, renal disease, renal failure, renal impairment***Hepatic disease***Labor, pregnancy***Breast-feeding***Phenylketonuria***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2683'],colchicine,***For the prevention and treatment of gout flares (gouty arthritis).***For the prevention of gout flares (gout prophylaxis).***For the treatment of acute gout flares.***For familial Mediterranean fever prophylaxis.***For the treatment of primary amyloidosis� not associated with familial Mediterranean fever.***For the treatment of primary biliary cirrhosis�.***For the treatment of hepatic cirrhosis�.***For the treatment of dermatitis herpetiformis� or Paget's disease� of bone.***For the treatment of Behcet's syndrome�.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP)�.***For the management of pseudogout�.***For the treatment of pseudogout�.***For prevention of pseudogout�.***For the treatment of inflammation in recurrent pericarditis�.***For the treatment of idiopathic pulmonary fibrosis�.,"***Biliary obstruction, cardiac disease, hepatic disease, renal disease, renal impairment***Dialysis***Alcoholism, GI disease***Bone marrow suppression***Dental disease***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,antihemophilic factor (recombinant),"***For the prevention and control of hemorrhage in patients with hemophilia A (classical hemophilia). <br />        NOTE: Humate, Kogenate, and ReFacto have been designated by the FDA as orphan drugs for the prophylaxis and management of hemorrhage or hemarthrosis in patients with hemophilia A.<br /> <br />NOTE: Guidelines for the treatment of acute bleeding and prevention of bleeding during surgery vary. For all indications, the dose of antihemophilic factor should be individualized taking into consideration the seriousness of the bleed or procedure, the clinical status of the patient, and the factor VIII activity concentration***For minor bleeding including early muscle bleed, early hemarthrosis, and oral bleeds.***For moderate bleeding including advanced muscle bleed, extensive hemarthrosis, hematoma, and mild head trauma.***For life- or limb-threatening bleeding including surgical bleeding, gastrointestinal bleeding, neck, tongue or pharyngeal hematoma with potential for airway compromise, intracranial, intraabdominal, or intrathoracic bleeding, or fractures.***For bleeding in patients with hemophilia A and factor VIII inhibitor titers less than 10 Bethesda Units and with low anamnestic responses.***For the perioperative management of surgical bleeding (surgical bleeding prophylaxis) in patients with hemophilia A.***For routine bleeding prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A.***For the management of hemorrhage or hemarthrosis in patients with von Willebrand's disease (vWD). <br />        NOTE: Humate-P has been designated by the FDA as orphan drugs for this indication.<br />     ***For major hemorrhage in patients with mild vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma or traumatic hemorrhage).***For minor hemorrhage in patients with moderate to severe vWD type I, type II, and type III (e.g., epistaxis, oral bleeding, or menorrhagia).***For major hemorrhage in patients with moderate to severe vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For major hemorrhage in patients with vWD type II and III (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For surgical bleeding prophylaxis during major or minor procedures in patients with vWD in whom desmopressin is either ineffective or contraindicated. <br />          NOTE: Alphanate and Humate-P have been designated by the FDA as orphan drugs for this indication.<br />       ","***General Information***Pregnancy***Breast-feeding***Thromboembolic disease***Hepatitis, infection, viral infection***Anemia***Bovine protein hypersensitivity, hamster protein hypersensitivity, latex hypersensitivity, mannitol hypersensitivity, murine protein hypersensitivity, polysorbate 80 hypersensitivity***Porcine protein hypersensitivity***Human immunodeficiency virus (HIV) infection***Cardiac disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bisoprolol fumarate,***For the treatment of hypertension.***For the treatment of heart failure�.***For the treatment of angina�.***For heart rate control in patients who have atrial fibrillation<strong>,"***Abrupt discontinuation***Depression***Acute heart failure, AV block, bradycardia, cardiogenic shock, pulmonary edema, sick sinus syndrome, ventricular dysfunction***Cerebrovascular disease***Hyperthyroidism, thyroid disease, thyrotoxicosis***Diabetes mellitus***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Peripheral vascular disease, pheochromocytoma, Raynaud's phenomenon, vasospastic angina***Hepatic disease, renal disease, renal failure, renal impairment***Psoriasis***Myasthenia gravis***Hypotension, surgery***Geriatric***Pregnancy***Breast-feeding***Children***Beta-blocker hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,lisdexamfetamine dimesylate,***For the treatment of attention-deficit hyperactivity disorder (ADHD).***For the treatment of moderate to severe binge-eating disorder (BED).***Formoterol; Mometasone,"***General Information***Alcoholism, substance abuse***Bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Hypertension, tachycardia***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, stroke, syncope, valvular heart disease, ventricular arrhythmias, ventricular dysfunction***Hyperthyroidism, thyrotoxicosis***MAOI therapy***Glaucoma, visual disturbance***Tics, Tourette's syndrome***Driving or operating machinery***Radiographic contrast administration, seizure disorder, seizures***Surgery***Hypercortisolism***Hepatic disease, renal failure, renal impairment***Priapism***Peripheral vascular disease, Raynaud's phenomenon***Anorexia nervosa, bulimia nervosa, obesity treatment***Abrupt discontinuation***Growth inhibition, infants***Labor, neonates, obstetric delivery, pregnancy, premature labor***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,coagulation factor IX (recombinant),"***For the management of hemophilia B (congenital factor IX deficiency or Christmas disease). <br />        NOTE: Many Factor IX products have been designated orphan drugs by the FDA for this indication.<br />NOTE: Guidelines for the treatment of acute bleeding and prevention of bleeding during surgery vary. For all indications, the dose of factor IX should be individualized, taking into consideration the seriousness of the bleed or procedure, the clinical status of the patient, and the baseline factor IX activity concentration***For routine bleeding prophylaxis.***For the control of hemorrhage including surgical bleeding and hemarthrosis.","***General Information***Factor IX inhibitors***Hamster protein hypersensitivity, murine protein hypersensitivity***Hepatitis, infection***Disseminated intravascular coagulation (DIC), fibrinolysis, hepatic disease, neonates, surgery, thromboembolic disease***Pregnancy***Breast-feeding***Human immunodeficiency virus (HIV) infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['8339', '1546000']['37617']",piperacillin/tazobactam,"***For the treatment of moderate to severe complicated and uncomplicated skin and skin structure infections (e.g., cellulitis, skin abscesses, ischemic diabetic foot ulcer).***For the treatment of intraabdominal infections, including peritonitis, appendicitis complicated by rupture or intraabdominal abscess, and biliary tract infections such as cholangitis and cholecystitis.***For intraabdominal infections using conventional dosing.***For intraabdominal infections using extended-infusion dosing�.***For the treatment of pneumonia, including community-acquired pneumonia (CAP) and nosocomial pneumonia, as well as pleural empyema.***For pneumonia using conventional dosing.***For pneumonia using extended-infusion dosing�.***For the treatment of moderate to severe infections including pelvic inflammatory disease (PID) and endometritis.***For the treatment of pyelonephritis� and complicated urinary tract infection (UTI)� caused by susceptible organisms.***For surgical infection prophylaxis� for patients undergoing liver transplantation.***For the treatment of acute pulmonary exacerbations in patients with cystic fibrosis�.***For acute pulmonary exacerbations in patients with cystic fibrosis using conventional dosing.***For acute pulmonary exacerbations in patients with cystic fibrosis using extended-infusion dosing.***For the treatment of bacteremia� and septicemia�.***For bacteremia and septicemia using conventional dosing.***For bacteremia and septicemia using extended-infusion dosing.***For the empiric treatment of febrile neutropenia�.***For febrile neutropenia in adults using conventional dosing.***For febrile neutropenia in pediatric patients using extended-infusion dosing.***For febrile neutropenia in pediatric patients using conventional dosing.","***General Information***Critical illness, dialysis, renal failure, renal impairment***Urinary tract infection (UTI)***Biliary obstruction***Electrolyte imbalance, heart failure, hypokalemia, neonates, sodium restriction***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, cystic fibrosis, penicillin hypersensitivity, serious rash***Anticoagulant therapy, bleeding, coagulopathy, hemophilia, leukopenia***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Geriatric***Diabetes mellitus***Sexually transmitted disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2231', '1299782']",cephalexin,"***For the treatment of upper respiratory tract infections, including tonsillitis and/or pharyngitis secondary to <em>Streptococcus pyogenes</em> (i.e., primary rheumatic fever prophylaxis).***For the treatment of lower respiratory tract infections (e.g., pneumonia, community-acquired pneumonia).***For the treatment skin and skin structure infections (e.g., cellulitis, impetigo) due to susceptible organisms.***For the treatment of otitis media.***For the treatment of bone and joint infections (i.e., osteomyelitis, infectious arthritis).***For the treatment of genitourinary infection (i.e., urinary tract infection (UTI), cystitis, prostatitis).***For bacterial endocarditis prophylaxis�.","***Antimicrobial resistance, viral infection***Cephalosporin hypersensitivity, penicillin hypersensitivity***Renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Breast-feeding***Pregnancy***Coagulopathy, vitamin K deficiency***Diabetes mellitus***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amphetamine aspartate monohydrate/amphetamine sulfate/dextroamphetamine saccharate/dextroamphetamine sulfate,***For the treatment of attention-deficit hyperactivity disorder (ADHD).***For the treatment of narcolepsy.***Formoterol***Formoterol; Mometasone,"***General Information***Alcoholism, substance abuse***Bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Hypertension, tachycardia***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular arrhythmias, ventricular dysfunction***Cerebrovascular disease, stroke***Children, growth inhibition, infants***Hyperthyroidism, thyrotoxicosis***Glaucoma, visual disturbance***Breast-feeding***Neonates, pregnancy***Tics, Tourette's syndrome***Driving or operating machinery***Seizure disorder, seizures***Surgery***Radiographic contrast administration***Abrupt discontinuation***Geriatric***Hypercortisolism***Hepatic disease, renal impairment***MAOI therapy***Peripheral vascular disease, Raynaud's phenomenon***Anorexia nervosa, bulimia nervosa, obesity treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bupropion hydrobromide,"***For the treatment of major depression.***For the prevention of seasonal major depressive disorder episodes associated with seasonal affective disorder (SAD).***For use as an adjunct to psychosocial interventions in the management of tobacco cessation (smoking cessation).***For use alone to aide in tobacco cessation.***For aide with tobacco cessation using bupropion in combination with a nicotine transdermal system (NTS).***For the treatment of attention-deficit hyperactivity disorder (ADHD)�.***For use as monotherapy of attention-deficit hyperactivity disorder (ADHD)� in adults.***For the symptomatic treatment of neuropathic pain� due to various causes, including pain associated with peripheral diabetic neuropathy� or postherpetic neuralgia�.***Formoterol; Mometasone","***General Information***Alcoholism, anorexia nervosa, benzodiazepine withdrawal, brain tumor, bulimia nervosa, diabetes mellitus, head trauma, hypoglycemia, hyponatremia, hypoxemia, intracranial mass, obesity treatment, seizure disorder, seizures, stroke, substance abuse***Children, suicidal ideation***Tics, Tourette's syndrome***Behavioral changes, bipolar disorder, depression, mania, psychiatric event, schizophrenia***MAOI therapy***Neonates, pregnancy***Breast-feeding***Hepatic disease***Renal disease, renal failure, renal impairment***Acute myocardial infarction, cardiac disease, heart failure, hypertension, tobacco smoking***Geriatric***Driving or operating machinery, ethanol intoxication***Closed-angle glaucoma, increased intraocular pressure***Abrupt discontinuation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,levoleucovorin,"***For methotrexate toxicity prophylaxis.***For the palliative treatment of advanced metastatic colorectal cancer, in combination with 5-fluorouracil. <br />        NOTE: The FDA has designated levoleucovorin as an orphan drug for use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum.<br />     ","***Folic acid hypersensitivity, mannitol hypersensitivity***Pernicious anemia, vitamin B12 deficiency megaloblastic anemia***Seizure disorder***Renal disease, renal impairment***Dehydration, diarrhea, geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10763'],triamterene,"***For the treatment of peripheral edema states (e.g., heart failure, idiopathic edema, nephrotic syndrome, ascites due to hepatic cirrhosis, secondary hyperaldosteronism), hypertension�, or hypokalemia.***For the treatment of symptoms of bloating and weight gain associated with premenstrual syndrome (PMS)�.***Formoterol; Mometasone","***General Information***Anuria, diabetes mellitus, hyperkalemia, renal disease, renal failure, renal impairment***Hyponatremia***Acid/base imbalance, metabolic acidosis, respiratory acidosis***Hepatic disease***Gout, hyperuricemia, nephrolithiasis***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,conjugated estrogens,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), or dyspareunia, whether menopause is natural or surgical (e.g., due to oophorectomy).***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For treatment of premenopausal females with estrogen deficiency due to hypogonadism.***For treatment of hypoestrogenism due to primary ovarian failure.***For the short-term treatment of abnormal or dysfunctional uterine bleeding caused by hormonal imbalance in the absence of organic pathology.***For the palliative treatment of breast cancer that has metastasized, in appropriately selected men or women.***For the palliative treatment of advanced inoperable prostate cancer.***Formoterol; Mometasone","***Angioedema, benzyl alcohol hypersensitivity, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10180']['10829'],sulfamethoxazole/trimethoprim,"***For the treatment of urinary tract infection (UTI), including pyelonephritis and cystitis.***For the treatment of Pneumocystis pneumonia (PCP).***For Pneumocystis pneumonia (PCP) prophylaxis in individuals who are immunosuppressed and considered to be at an increased risk.***For primary PCP prophylaxis in HIV-infected patients.***For secondary PCP prophylaxis in HIV-infected patients.***For primary PCP prophylaxis in immunocompromised patients with primary immunodeficiency disease (especially severe combined immunodeficiency disease), lymphoreticular malignancies (especially acute lymphatic leukemia and human T-cell lymphotropic virus-associated leukemia or lymphoma), organ transplantation (especially lung or heart-lung), and solid tumors, particularly brain tumors.***For primary PCP prophylaxis in recipients of bone marrow allografts.***For the treatment of otitis media due to susceptible strains of <em>Haemophilus influenzae</em> or <em>Streptococcus pneumoniae</em>.***For otitis media with otorrhea due to community-acquired methicillin-resistant <em>Staphylococcus aureus</em>�.***For the treatment of acute exacerbations of chronic bronchitis.***For the treatment of gastroenteritis, infectious diarrhea, and gastrointestinal infections.***For the treatment of cholera� caused by <em>Vibrio cholerae</em>.***For the treatment of cyclosporiasis� due to <em>Cyclospora cayetanensis</em>.***For the treatment of shigellosis.***For the treatment of isosporiasis� in HIV-positive patients.***For chronic maintenance therapy (secondary prophylaxis) of isosporiasis� in HIV-positive patients.***For the treatment of salmonellosis� in HIV-infected patients.***For the treatment of traveler's diarrhea due to enterotoxigenic <em>E. coli</em>.***For urinary tract infection (UTI) prophylaxis�.***For bacterial infection prophylaxis� in HIV-infected children and infants.***For secondary prophylaxis� in HIV-infected children and infants with > 2 invasive bacterial infections in a 1-year period.***For primary prophylaxis� to reduce opportunistic infection in HIV-infected children (regardless of CD4 count).***For toxoplasmosis prophylaxis�, specifically prevention of toxoplasmic encephalitis (TE) due to <em>Toxoplasma gondii</em>.***For primary prophylaxis� in HIV-infected patients.***For chronic maintenance therapy� (secondary prophylaxis�) after acute toxoplasmosis infection.***For the treatment of Legionnaire's disease� caused by <em>Legionella pneumophila</em>.***For the treatment of actinomycotic mycetoma�.***For actinomycotic mycetoma� caused by <em>Actinomadura pelletierii</em>, <em>Actinomadura madurae</em>, <em>Streptomyces somaliensis</em>.***For actinomycotic mycetoma� caused by <em>Nocardia brasiliensis</em>, <em>Nocardia asteroides</em>, or <em>Nocardia otitidiscaviarum</em>.***For the treatment of nocardiosis� caused by <em>Nocardia</em> sp..***For the treatment of pertussis (whooping cough)� caused by <em>Bordetella pertussis</em> or for postexposure pertussis prophylaxis�. <br />        NOTE: For postexposure prophylaxis, administer to close contacts within 3 weeks of exposure, especially in high-risk patients (e.g., women in 3rd trimester, infants).<br />     ***For the treatment of bacteremia� and catheter-associated infections�.***For prevention of bacteremia� (i.e., bacteremia prophylaxis�) or spontaneous bacterial peritonitis� (i.e., peritonitis prophylaxis�) in patients with cirrhosis and ascites.***For the treatment of typhoid fever� due to <em>Salmonella typhi</em>.***For acute infections.***For chronic carriers.***For the treatment of <em>Staphylococcus aureus</em> infections�, including endocarditis�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus </em>(MRSA)<em>�</em> skin and skin structure infections�, including cellulitis�.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of therapy-resistant pediculosis� capitis (head lice infestation) due to <em>Pediculus capitis�</em>.***For the treatment of melioidosis� and for postexposure prophylaxis.***For sulfonamide desensitization� in patients requiring sulfamethoxazole; trimethoprim therapy.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated bone and joint infections�, including osteomyelitis� and septic/infectious arthritis�, or an orthopedic device-related infection�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated osteomyelitis�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated septic arthritis�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated prosthetic joint infections�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated spinal implant infections�.***For surgical infection prophylaxis�.***For the treatment of CNS infections�, including meningitis�, brain abscess�, subdural empyema�, spinal epidural abscess�, and septic thrombosis of the cavernous or dural venous sinus�.***Formoterol***Formoterol; Mometasone","***General Information***Carbonic anhydrase inhibitor hypersensitivity, sulfite hypersensitivity, sulfonamide hypersensitivity, sulfonylurea hypersensitivity, thiazide diuretic hypersensitivity, trimethoprim hypersensitivity***Agranulocytosis, bone marrow suppression, folate deficiency, folate deficiency megaloblastic anemia, G6PD deficiency, hemolysis, thrombocytopenia***Hyperkalemia, hyponatremia, renal disease, renal failure, renal impairment***Hepatic disease***Porphyria***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Hypothyroidism***Acquired immunodeficiency syndrome (AIDS)***Infants, neonates***Pregnancy***Breast-feeding***Antimicrobial resistance, viral infection***Hypoglycemia, malnutrition***Sunlight (UV) exposure***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, myocardial infarction, QT prolongation, thyroid disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4917'],nitroglycerin,"***For the treatment of angina.***For acute angina pectoris or for acute angina pectoris prophylaxis (i.e., situations likely to provoke an anginal attack).***For chronic angina pectoris. <br />          NOTE: A nitrate-free interval is necessary to avoid the development of drug tolerance; although a minimum interval has not been clearly established, 10 to 12 hours/day has been sufficient with other nitroglycerin formulations.<br />       ***For the treatment of pain associated with anal fissures.***For the treatment of pain associated with anal fissures� and hemorrhoids�.***For controlled hypotension induction during anesthesia; for IV treatment of acute congestive heart failure or pulmonary edema, acute angina pectoris or unstable angina, acute myocardial infarction, or acute pulmonary hypertension�; or for treatment of severe hypertension, postoperative hypertension, perioperative hypertension (e.g., during cardiac surgery), or hypertensive emergency.***For use as a uterine relaxant to aid in extraction of a retained placenta�.***For the treatment of extravasation� of vasoactive medications.","***General Information***Nitrate hypersensitivity***Head trauma, increased intracranial pressure, intracranial bleeding***Anemia***Aortic stenosis, cardiac tamponade, cardiomyopathy, constrictive pericarditis, mitral stenosis, shock***Acute myocardial infarction, dehydration, hypotension, hypovolemia, orthostatic hypotension***Geriatric***Hepatic disease***Abrupt discontinuation***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Pregnancy***Breast-feeding***GI disease***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clobetasol propionate,"***For the treatment of moderate-to-severe inflammatory manifestations, including pruritus, of corticosteroid-responsive dermatologic disorders such as alopecia areata, atopic dermatitis, contact dermatitis, generalized exfoliative dermatitis, Rhus dermatitis due to plants like poison ivy, seborrheic dermatitis, eczema (including severe hyperkeratotic eczema, severe nummular eczema, and severe eczematous conditions of the hands or feet), granuloma annulare, keloids, cutaneous lichen planus, lichen simplex chronicus, lichen striatus, subacute cutaneous and discoid lupus erythematosus, pretibial myxedema, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, sarcoidosis, sunburn, or urticaria. <br />        NOTE: Acute exudative inflammation, as occurs with poison ivy, may be best treated with a non-emollient cream or gel formulation, which are drying. Dry, scaly dermatoses may be best treated with emollient creams or ointments. Lower potency corticosteroids should be used on the face and intertriginous areas.<br />NOTE: Systemic therapy or intralesional injection of corticosteroids may be necessary for some conditions based on the type and severity of the disorder or inadequate response to topical therapy***For the treatment of plaque-type psoriasis.***For the alternative treatment of recalcitrant oral vesiculoerosive disease� including oral lichen planus�, mucous membrane pemphigus�, aphthous ulcer� and chronic oral erythema multiforme�.***For the treatment of vulvar lichen sclerosus�.***For the alternative treatment of vision-threatening periocular capillary hemangioma� in infancy and early childhood.","***Corticosteroid hypersensitivity***Cushing's syndrome, hepatic disease, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Diabetes mellitus***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Fungal infection, herpes infection, infection, measles, peripheral vascular disease, varicella, viral infection***Acne rosacea, acne vulgaris, cataracts, glaucoma, ocular exposure, ophthalmic administration, perioral dermatitis***Geriatric, skin atrophy***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sodium phosphate dibasic anhydrous/sodium phosphate monobasic monohydrate,"***For use as a bowel evacuant to clean the colon prior to colonoscopy (bowel preparation).***For treatment of constipation. <br />  NOTE: Each 118 mL and 197 mL bottle contains 4,400 mg of sodium. NOTE: Each 59 mL bottle (pediatric formulation) contains 2,200 mg of sodium.<br /***For the treatment of hypophosphatemia. <br />  NOTE: Serum phosphorus cutoff values represent adult concentrations. Normal serum phosphorus concentrations are higher in children, and thus cutoff values for children will be higher. Hypophosphatemia in children is generally defined as a serum phosphorus concentration less than 4 mg/dL; severe hypophosphatemia is generally defined as serum phosphorus concentrations less than 1 to 1.5 mg/dL. However, there is no consensus definition for degrees of hypophosphatemia in children.  <br />NOTE: Guidelines generally recommend the use of sodium phosphate for potassium serum concentration more than 4 mg/dL and potassium phosphate for potassium serum concentration less than 4 mg/dL. <br />NOTE: Sodium phosphate injection contains 3 mmol of phosphorus per mL equivalent to 4 mEq of sodium per mL; 1 mmol of phosphorus weighs 31 mg***For the treatment of mild hypophosphatemia (i.e., phosphorus serum concentration 2 to 2.5 mg/dL).***For the treatment of moderate hypophosphatemia (i.e., phosphorus serum concentration 1 to 2 mg/dL).***For the treatment of severe hypophosphatemia (i.e., phosphorus serum concentration less than 1 mg/dL).***For nutritional supplementation to prevent hypophosphatemia in patients receiving parenteral nutrition (PN). <br />  NOTE: Supplementation of phosphate in PN may be limited by physical incompatibility, particularly in neonates who have higher calcium and phosphate requirements.<br /","***General Information***Colitis, GI obstruction, hypovolemia, nephrotoxicity, renal disease, renal failure, renal impairment***Abdominal pain, acute abdomen, appendicitis, esophageal stricture, gastroparesis, GI bleeding, GI perforation, hypothyroidism, ileus, inflammatory bowel disease, scleroderma, surgery, toxic megacolon, ulcerative colitis***Acute myocardial infarction, angina, arrhythmia exacerbation, ascites, cardiac arrhythmias, cardiomyopathy, coronary artery bypass graft surgery (CABG), heart failure, QT prolongation, sodium restriction***Dehydration, electrolyte imbalance, hypernatremia, hyperphosphatemia, hypocalcemia, hypokalemia, vomiting***Alcoholism, hyponatremia, seizure disorder, seizures***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['32592'],oxaliplatin,"***For the treatment of colorectal cancer.***For the treatment of advanced colorectal cancer in combination with 5-fluorouracil (5-FU) and leucovorin (LV), with or without bevacizumab (FOLFOX4 with or without bevacizumab). <br />          NOTE: Bevacizumab is FDA-approved in combination with IV 5-fluorouracil based chemotherapy for the first- or second-line treatment of patients with metastatic colorectal cancer (mCRC), and in combination with fluoropyrimidine and irinotecan- or oxaliplatin-based chemotherapy for the second-line treatment of patients with mCRC who have progressed on a first-line bevacizumab-containing regimen.<br />       ***For adjuvant treatment of patients with stage 3 colorectal cancer who have undergone complete resection of the primary tumor in combination with 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOX4).***For the first line treatment of advanced colorectal cancer in combination with irinotecan and 5-fluorouracil-based chemotherapy (FOLFOXIRI)�.***For first- and second-line treatment of advanced colorectal cancer in combination with capecitabine (XELOX or CapeOX)�.***For the first line treatment of metastatic colorectal cancer in combination with capecitabine and bevacizumab (XELOX or CapeOx, with bevacizumab)�.***For the adjuvant treatment of stage 3 (Dukes C) colon cancer in combination with capecitabine (XELOX or CapeOx)�.***For the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC), in combination with cetuximab, leucovorin, and 5-fluorouracil (mFOLFOX6 plus cetuximab)�. <br />          NOTE: Response rates to cetuximab do not correlate with either the percentage of EGFR-positive cells or the intensity of EGFR expression.<br />       ***For the adjuvant treatment of colorectal cancer, in combination with leucovorin and 5-fluorouracil (5-FU) (FLOX).***For the adjuvant treatment of colorectal cancer, in combination with leucovorin and 5-fluorouracil (5-FU) (mFOLFOX6).***For the treatment of metastatic colorectal cancer in combination with leucovorin and 5-fluorouracil (5-FU), with or without bevacizumab (mFOLFOX6 with or without bevacizumab). <br />          NOTE: Bevacizumab is FDA approved for the treatment of metastatic colorectal cancer in combination with 5-FU based chemotherapy and oxaliplatin is FDA approved for advanced colorectal cancer in combination with infusional 5-FU and leucovorin.<br />       ***For the first line treatment of metastatic colorectal cancer in combination with leucovorin, 5-fluorouracil (5-FU), and panitumumab in patients with wild-type KRAS (exon 2 in codons 12 or 13) (FOLFOX4 plus panitumumab). <br />          NOTE: Panitumumab is FDA approved for the treatment of metastatic colorectal cancer in combination with FOLFOX chemotherapy and oxaliplatin is FDA approved for advanced colorectal cancer in combination with infusional 5-FU and leucovorin.<br />       ***For the first line treatment of metastatic colorectal cancer in combination with leucovorin, 5-fluorouracil (5-FU), and panitumumab in patients with wild-type KRAS (exon 2 in codons 12 or 13) (mFOLFOX6 plus panitumumab). <br />          NOTE: Panitumumab is FDA approved for the treatment of metastatic colorectal cancer in combination with FOLFOX chemotherapy, and oxaliplatin is FDA approved for advanced colorectal cancer in combination with infusional 5-FU and leucovorin.<br />       ***For the treatment of gastric cancer�.***For the treatment of advanced gastric cancer� in combination with epirubicin and capecitabine or 5-fluorouracil.***For the treatment of advanced gastric cancer� in combination with 5-fluorouracil.***For the adjuvant treatment of stage II�IIIB gastric cancer� in combination with capecitabine.***For the treatment of advanced ovarian cancer�.***For the treatment of advanced or metastatic breast cancer�.***For the treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL)� in combination with cytarabine and dexamethasone, with or without rituximab.***For the treatment of recurrent, advanced head and neck cancer� in combination with 5-fluorouracil-based chemotherapy.***For the treatment of pancreatic cancer�.***For the first line treatment of locally advanced and metastatic pancreatic cancer in combination with gemcitabine.***For the second line treatment of gemcitabine-refractory advanced pancreatic cancer in combination with 5-fluorouracil-based chemotherapy.***For the first-line treatment of metastatic pancreatic cancer� in combination with irinotecan, fluorouracil, and leucovorin (FOLFIRINOX).***For the treatment of advanced or metastatic biliary tract cancer�.***For the treatment of cisplatin-refractory or relapsed germ cell cancer (testicular cancer�).***For the treatment of malignant pleural mesothelioma�.***Formoterol***Formoterol; Mometasone","***Platinum compound hypersensitivity, serious hypersensitivity reactions or anaphylaxis***Peripheral neuropathy***Bone marrow suppression, chemotherapy, herpes infection, infection, neutropenia, radiation therapy, thrombocytopenia, varicella, viral infection***Hepatic disease, hepatotoxicity***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, electrolyte imbalance, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Encephalopathy***Chronic lung disease (CLD), pneumonitis, pulmonary disease, pulmonary fibrosis***Myopathy, rhabdomyolysis***Geriatric***Pregnancy***Contraception requirements, infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,timolol maleate,"***For the treatment of hypertension.***For reduction of cardiovascular mortality and to reduce the risk of reinfarction (i.e., myocardial infarction prophylaxis) after an acute myocardial infarction in patients who are clinically stable.***For migraine prophylaxis.***For the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.***For the management of chronic stable angina�.***For the treatment of essential tremor�.","***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***AV block, bradycardia, cardiogenic shock, heart failure, hypotension, pheochromocytoma, pulmonary edema, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Cerebrovascular disease***Diabetes mellitus***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Surgery***Hepatic disease***Geriatric, peripheral vascular disease***Dialysis, renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Raynaud's phenomenon***Depression***Psoriasis***Myasthenia gravis***Contact lenses***Children, infants, neonates***Beta-blocker hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,polyethylene glycol 3350/potassium chloride/sodium bicarbonate/sodium chloride,"***For use as a bowel evacuant to clean the colon prior to colonoscopy or barium enema X-ray examination (bowel preparation). <br />        NOTE: Patients should be well hydrated before, during, and after the colon preparation. The first bowel movement should occur approximately 1 hour after the start of solution administration.<br />     ***For dosing in adults and/or adolescents.***For dosing in children and older infants.***For the treatment of chronic constipation�. <br />        NOTE: This product should be used for 2 weeks or less or as directed by the prescriber.<br />     ","***General Information***Abdominal pain, acute abdomen, appendicitis, colitis, dehydration, GI obstruction, GI perforation, ileus, inflammatory bowel disease, toxic megacolon, ulcerative colitis, vomiting***Electrolyte imbalance, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, seizure disorder, seizures***Children, infants, neonates***Pregnancy***Breast-feeding***Coma, dementia, dysphagia, esophageal stricture, gag reflex depression***Angina, cardiac arrhythmias, cardiomyopathy, heart failure, myocardial infarction, QT prolongation***Renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,azilsartan medoxomil,"***For the treatment of hypertension, either alone or in combination with other antihypertensive agents.","***Hypovolemia***Heart failure, renal artery stenosis, renal impairment***ACE-inhibitor induced angioedema, angioedema***Black patients***Children, infants, neonates***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['11413'],zidovudine,"***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents. <br />        NOTE: Antiretroviral drug resistance testing is recommended prior to initiation of therapy in anti-retroviral treatment naive patients and prior to changing therapy for treatment failure. <br />NOTE: The following abbreviations are used: nucleoside reverse transcriptase inhibitors (NRTIs); non-nucleoside reverse transcriptase inhibitors (NNRTIs); protease inhibitor (PI)***For perinatal human immunodeficiency virus (HIV) prophylaxis. <br />        NOTE: Post-partum chemoprophylaxis with zidovudine is recommended for all HIV-exposed infants to reduce perinatal transmission of HIV.<br />     ***For human immunodeficiency virus (HIV) prophylaxis�.***For HIV prophylaxis after occupational exposure to HIV.***For HIV prophylaxis after non-occupational HIV exposure, including sexual assault. <br />  NOTE: Higher risk exposures for which prophylaxis is recommended include exposure of vagina, rectum, eye, mouth, or other mucous membrane, nonintact skin, or percutaneous contact with blood, semen, vaginal secretions, rectal secretions, breast milk, or any body fluid that is visibly contaminated with blood when the source is known to be HIV-positive. Exposures to a source patient with unknown HIV status should be assessed on a case-by-case basis.<br /***For the treatment of adult T-cell leukemia/lymphoma� in combination with interferon alfa in patients infected with human T-lymphotropic virus type I (HTLV-I)�.","***General Information***Anemia, bone marrow suppression, chemotherapy, neutropenia, radiation therapy***Dental disease, dental work***Hepatitis, hepatitis B and HIV coinfection***Alcoholism, females, hepatic disease, hepatotoxicity or lactic acidosis, obesity***Pregnancy***Breast-feeding***Infants, neonates***Renal failure, renal impairment***Myopathy***Human immunodeficiency virus (HIV) infection resistance***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Intramuscular administration, subcutaneous administration***Hepatitis C and HIV coinfection***Latex hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,acyclovir sodium,"***For the treatment of neonatal herpes simplex virus infection.***For the treatment of viral encephalitis.***For herpes simplex encephalitis.***For varicella-zoster encephalitis�.***For encephalitis due to B virus (cercopithecine herpesvirus) infection� as an alternative to valacyclovir.***For the treatment of herpes labialis (i.e., cold sores) or herpes fibrilis caused by herpes simplex virus.***For the treatment of recurrent herpes labialis in immunocompetent adults.***For the treatment of varicella (chickenpox) infection.***For the treatment of varicella (chickenpox) infection in immunocompetent patients.***For the treatment of for varicella (chickenpox) infection in immunocompromised patients.***For the treatment of herpes zoster (shingles) infection. <br />        NOTE: For CNS infections, see encephalitis.<br />     ***For the treatment of herpes zoster (shingles) infection in bone marrow and organ transplant patients, patients receiving chemotherapy, and other immunocompromised patients.***For the treatment of herpes zoster (shingles) infection in immunocompetent patients.***For the treatment of herpes genitalis caused by herpes simplex virus.***For the treatment of initial herpes genitalis infection.***For the treatment of recurrent herpes genitalis.***For chronic suppression therapy of recurrent herpes genitalis (i.e., herpes genitalis prophylaxis).***For the treatment of complicated herpes simplex virus infection (e.g., disseminated disease�, pneumonitis�, infection in immunocompromised hosts, and infections requiring hospitalization). <br />        NOTE: For congenital herpes, see neonatal herpes simplex virus infection; for CNS disease, see encephalitis.<br />     ***For neonatal herpes simplex virus infection prophylaxis� (i.e., suppressive therapy) in neonates with any neonatal herpes simplex disease classification.***For chronic suppression of recurrent herpes labialis� (i.e., herpes labialis prophylaxis�).***For herpes simplex infection prophylaxis� in immunocompromised hosts.***For primary herpes simplex infection prophylaxis in HSV-seropositive recipients of a bone marrow transplant�.***For primary herpes simplex infection prophylaxis in immunocompromised hosts who are HSV-seropositive patients�.***For primary varicella (chickenpox) infection prophylaxis� in HIV-infected patients with significant exposure to chickenpox or shingles for patients who have no history of either condition or, if available, negative antibody to varicella-zoster virus (VZV).***For cytomegalovirus (CMV) disease prophylaxis�.***For prevention of CMV disease� in immunocompromised patients.***For prevention of CMV disease� in CMV-seropositive patients receiving bone marrow transplantation.***For CMV disease prophylaxis� in adults receiving renal transplantation.***For the treatment of hairy leukoplakia� in HIV-positive adults.***For the adjunctive treatment of Bell's palsy�in combination with steroids.***For secondary herpes simplex ocular infection prophylaxis�.***For the treatment of acute herpes zoster ocular infection� (herpes zoster ophthalmicus�) in immunocompetent patients.***For the treatment of acute retinal necrosis (ARN)� due to varicella-zoster virus in HIV-infected patients.","***Acyclovir hypersensitivity, famciclovir hypersensitivity, ganciclovir hypersensitivity, milk protein hypersensitivity, penciclovir hypersensitivity, valacyclovir hypersensitivity, valganciclovir hypersensitivity***Dehydration, renal failure, renal impairment***Neurological disease, seizure disorder***Geriatric***Pregnancy***Breast-feeding***Children, infants, neonates***Ophthalmic administration***Extravasation, intramuscular administration, subcutaneous administration***Obesity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['33738'],pioglitazone,***For the treatment of type 2 diabetes mellitus. <br />        NOTE: Pioglitazone is not effective for type 1 diabetes mellitus.<br />     ***Formoterol; Mometasone,"***General Information***Diabetic ketoacidosis***Hypoglycemia***Acute heart failure, cardiac disease, edema, heart failure, peripheral edema, pulmonary edema***Hepatic disease***Bladder cancer, new primary malignancy***Bone fractures, osteoporosis***Geriatric***Contraception requirements, menstrual irregularity, polycystic ovary syndrome***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,nefazodone hydrochloride,***For the treatment of major depression.***For the treatment of panic disorder� or for social phobia (social anxiety disorder)�.***For the treatment of posttraumatic stress disorder (PTSD)�.***For the treatment of premenstrual dysphoric disorder (PMDD)�.***Formoterol; Mometasone,"***General Information***Bipolar disorder, mania***Hepatic disease, hepatotoxicity, jaundice***Children, suicidal ideation***MAOI therapy***Electroconvulsive therapy (ECT)***Angina, bradycardia, cardiac disease, cerebrovascular disease, dehydration, hypertension, hypotension, hypovolemia, myocardial infarction, stroke***Infants, neonates, pregnancy***Breast-feeding***Geriatric***Seizures***Surgery***Driving or operating machinery***Closed-angle glaucoma, increased intraocular pressure***Abrupt discontinuation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amikacin sulfate,"***For treatment of serious infections such as bone and joint infections, skin and skin structure infections (e.g., burn wound infection), intraabdominal infections (e.g., peritonitis), urinary tract infection (UTI) (e.g., pyelonephritis), and central nervous system infections (e.g., meningitis).***For intraventricular� administration in patients with meningitis.***For the treatment of peritoneal dialysis-associated peritonitis in patients with end-stage renal disease.***For the treatment of lower respiratory tract infections such as pneumonia, including community-acquired pneumonia (CAP) and nosocomial pneumonia.***For the treatment of bacteremia and sepsis.***For the treatment of pulmonary exacerbations in patients with cystic fibrosis� (CF).***For the empiric treatment of febrile neutropenia�.***For the treatment of febrile neutropenia in adults.***For the treatment of febrile neutropenia in pediatric patients.***For the treatment of Mycobacterium avium complex infection� (MAC) or tuberculosis infection�.***For the treatment of Mycobacterium avium complex (MAC)�.***For the treatment of tuberculosis infection� due to susceptible strains of Mycobacterium tuberculosis as second line therapy, according to guidances of the American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), Centers for Disease Control and Prevention (CDC), and World Health Organization (WHO).***For the treatment of actinomycotic mycetoma� or nocardiosis� caused by Nocardia sp..***For the treatment of infective endocarditis�.","***General Information***Dehydration, nephrotoxicity, renal disease, renal failure, renal impairment***Hearing impairment, neurotoxicity, ototoxicity, tinnitus***Aminoglycoside hypersensitivity***Botulism, electrolyte imbalance, myasthenia gravis, neuromuscular blockade, neuromuscular disease, parkinsonism, respiratory depression, respiratory insufficiency***Diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Neonates, premature neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8703'],fenofibrate,"***For use as an adjunct to diet for the treatment of adult patients with severe hypertriglyceridemia. <br />  NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.     <br />NOTE: Markedly elevated levels of serum triglycerides (e.g., &gt; 2000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.  ***For use as an adjunct to diet to reduce elevated LDL-cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase HDL-cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. <br />        NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.   ","***General Information***Cardiac disease***Biliary cirrhosis, cholelithiasis, gallbladder disease, hepatic disease***Dialysis, renal disease, renal failure, renal impairment***Anticoagulant therapy***Thromboembolic disease***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding***Diabetes mellitus***Hypothyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluorescein sodium,"***For radiographic examination (i.e., diagnostic angiography or angioscopy) of the retina and iris vasculature.***For staining the anterior segment of the eye for eye trauma diagnosis.***For staining the anterior segment of the eye for contact lens fitting.***For staining the anterior segment of the eye for post-ophthalmic surgery wound closure assessment following anterior chamber reformation.***For staining the anterior segment of the eye for lacrimal drainage diagnosis.","***Extravasation, intraarterial administration, intramuscular administration, intrathecal administration***Asthma, eczema, urticaria***Contact lenses***Cardiac disease, dialysis, myocardial infarction, renal impairment, stroke***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sodium ferric gluconate complex,"***For the treatment of iron-deficiency anemia.***For iron replacement (iron-deficiency anemia) to maintain hemoglobin in patients with hemodialysis-dependent chronic kidney disease (Triferic).***For the treatment of iron-deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental epoetin alfa therapy. <br />          NOTE: In patients with iron-deficiency anemia receiving hemodialysis and supplemental epoetin alfa therapy, sufficient intravenous iron should be administered to maintain a serum ferritin of greater than 200 ng/mL and transferrin saturation (TSAT) greater than 20%. The administration of IV iron is not routinely recommended if serum ferritin exceeds 500 ng/mL. Dosages in excess of iron needs may lead to accumulation of iron in iron storage sites. Serum iron concentrations greater than 300 mcg/dL may indicate iron poisoning.<br />NOTE: Serum iron concentrations should be interpreted cautiously in the 24 hours following sodium ferric gluconate complex administration as many laboratory assays will falsely overestimate serum- or transferrin-bound iron by measuring iron still bound to the sodium ferric gluconate complex. Additionally, when assessing iron overload, use caution when interpreting serum ferritin concentrations in the week following sodium ferric gluconate complex administration. During clinical studies, serum ferritin exhibited a non-specific rise which persisted for 5 days","***General Information***Cardiac disease, geriatric, hypotension***Intramuscular administration***Hemochromatosis, hemoglobinopathy, hemosiderosis***Hepatic disease***Pregnancy***Breast-feeding***Benzyl alcohol hypersensitivity, children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,levocetirizine dihydrochloride,***For the treatment of symptoms associated with seasonal allergic rhinitis or perennial allergic rhinitis.***For the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria.***For the symptomatic treatment of atopic dermatitis�.,"***Hydroxyzine hypersensitivity***Dialysis, renal failure, renal impairment***Driving or operating machinery***Infants, neonates***Pregnancy***Breast-feeding***Bladder obstruction, prostatic hypertrophy, urinary retention***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['118886'],verteporfin,"***For the treatment of macular degeneration. <br />        NOTE: During clinical trials, the average number of yearly treatments in patients with age-related macular degeneration was 3.5 in the first year after diagnosis, 2.4 in the second, 1.3 in the third, 0.4 in the fourth, and 0.1 in the fifth year; in patients with pathologic myopia: the average number of treatments was 3.5 in the first year after diagnosis, 1.8 in the second, 0.4 in the third, 0.2 in the fourth, and 0.1 in the fifth. For patients with presumed ocular histoplasmosis, the average number of treatments per year was 2.9 in the first year after diagnosis, 1.2 in the second, 0.2 in the third and 0.1 in the fourth.<br />     ***For the treatment of classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (wet form), ocular histoplasmosis, or pathologic myopia and for the treatment of predominantly occult subfoveal choroidal neovascularization�.***For the treatment of age-related macular degeneration in patients with predominantly occult subfoveal choroidal neovascularization� and recent presumed disease progression.***For the treatment of central serous chorioretinopathy (CSC)�.***Formoterol; Mometasone","***General Information***Egg hypersensitivity, porphyria, porphyrin hypersensitivity***Dental work, skin photosensitivity disorder, sunlight (UV) exposure, surgery***Extravasation***Accidental exposure, ocular exposure***Hepatic disease***Radiation therapy***Geriatric***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['167'],acetazolamide,"***For the treatment of glaucoma.***For the adjunctive treatment of open-angle glaucoma.***For the treatment of secondary glaucoma and pre-operatively for acute angle-closure glaucoma.***For use as an alternative agent in the treatment of absence seizures. <br />        NOTE: The extended release preparation is not recommended for use as an anticonvulsant.<br />     ***For the treatment of acute altitude sickness.***For altitude sickness prophylaxis, including prevention of high altitude cerebral edema.***For the treatment of edema secondary to congestive heart failure or drug therapy.***For use as an adjunctive agent to reverse metabolic alkalosis� in mechanically ventilated patients. <br />        NOTE: Appropriate correction of underlying fluid and electrolyte imbalances (e.g., administration of saline fluids, potassium chloride) should be instituted prior to acetazolamide administration. In patients with excessive carbon dioxide retention (e.g., COPD), reversal of metabolic alkalosis may assist the process of weaning from mechanical ventilation, by reducing compensatory carbon dioxide retention.<br />     ***For use in urinary alkalinization�.***For the treatment of familial periodic paralysis�.***For the treatment of central vestibular nystagmus�.","***General Information***Carbonic anhydrase inhibitor hypersensitivity, sulfonamide hypersensitivity***Hepatic disease***Acid/base imbalance, acidemia, adrenal insufficiency, anuria, dialysis, electrolyte imbalance, hyperchloremia, hypokalemia, hyponatremia, metabolic acidosis, renal disease, renal failure, renal impairment***Closed-angle glaucoma***Emphysema, infection, pulmonary disease, respiratory acidosis***Agranulocytosis, bone marrow suppression***Sunlight (UV) exposure***Pregnancy***Breast-feeding***Driving or operating machinery***Children, growth inhibition, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,succinylcholine chloride,"***For neuromuscular blockade.***For neuromuscular blockade during short surgical procedures.***For neuromuscular blockade during long surgical procedures.***For the facilitation of endotracheal intubation. <br />        NOTE: In pediatric patients, the use of a nondepolarizing neuromuscular blocker is preferred to avoid the rare risk of succinylcholine-induced acute rhabdomyolysis with hyperkalemia and asystole. In pediatric patients, succinylcholine should be reserved for emergency procedures or when IV access is not available.<br />     ***For control of muscle contractions during electroconvulsive therapy (ECT)�.","***General Information***Bradycardia, children, Guillain-Barre syndrome, hyperkalemia, infants, malignant hyperthermia, myopathy, neonates, rhabdomyolysis***Burns, digitalis toxicity, trauma***Glaucoma, ocular surgery, ocular trauma***Labor, obstetric delivery, pregnancy***Breast-feeding***Anemia, cardiac disease, cholinesterase inhibitor toxicity, edema, hepatic disease, infection, malnutrition, myxedema, peptic ulcer disease, pseudocholinesterase deficiency, renal disease***Myasthenia gravis, neuromuscular disease, obesity***Requires a specialized care setting, requires an experienced clinician, respiratory insufficiency***Neuromuscular blocking agent hypersensitivity***Asthma, chronic obstructive pulmonary disease (COPD), pulmonary disease, respiratory depression***Acid/base imbalance, adrenal insufficiency, dehydration, electrolyte imbalance, hypercalcemia, hypermagnesemia, hypocalcemia, hypokalemia, hypothermia, metabolic acidosis, metabolic alkalosis, respiratory acidosis, respiratory alkalosis***Increased intracranial pressure***Bone fractures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,abacavir sulfate/lamivudine,***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.,"***General Information***Abacavir hypersensitivity, serious hypersensitivity reactions or anaphylaxis***Geriatric***Children, infants, neonates***Human immunodeficiency virus (HIV) infection resistance***Peripheral neuropathy***Alcoholism, females, hepatic disease, Hepatotoxicity or Lactic Acidosis, obesity***Hepatitis B and HIV coinfection, hepatitis B exacerbation***Pregnancy***Breast-feeding***Renal failure, renal impairment***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Cardiac disease, myocardial infarction***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['139994'],oprelvekin,***For the prevention of severe chemotherapy-induced thrombocytopenia and to reduce the need for platelet transfusions following myelosuppressive chemotherapy in patients with non-myeloid malignancies who are at high risk of severe thrombocytopenia. <br />        NOTE: Oprelvekin has been designated an orphan drug by the FDA for this indication.<br />     ,"***Acute bronchospasm, angioedema, oprelvekin hypersensitivity, urticaria***Chemotherapy***Renal disease, renal failure, renal impairment***Anemia, electrolyte imbalance, heart failure, hypokalemia, pulmonary edema, ventricular dysfunction***Ascites, pericardial effusion, pleural effusion***Brain tumor, children, driving or operating machinery, increased intracranial pressure, infants, intracranial mass, papilledema, visual disturbance***Atrial fibrillation, atrial flutter, cardiac arrhythmias, cardiac disease, cerebrovascular disease, geriatric, stroke***Pregnancy***Breast-feeding***Leukemia, multiple myeloma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/ferrous fumarate/norethindrone acetate,"***For routine contraception.***For the treatment of moderate acne vulgaris related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Pregnancy***Gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Diabetes mellitus***Hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, pancreatitis***Systemic lupus erythematosus (SLE)***Surgery***Asthma, headache, hypertension, migraine, seizure disorder***Depression***Contact lenses, glaucoma, visual disturbance***Breast cancer***Hypercalcemia, hypocalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Obesity***Chloasma***Angioedema, hereditary angioedema***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['274786'],telithromycin,"***For the treatment of mild or moderate community-acquired pneumonia (CAP). <br />  NOTE: Telithromycin was originally approved for sinusitis and bronchitis, but the FDA has subsequently withdrawn these approvals.<br /***Formoterol***Formoterol; Mometasone","***General Information***Macrolide hypersensitivity***Viral infection***Alcoholism, hepatic disease, hepatitis, jaundice, renal failure, renal impairment***Pregnancy***Bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Breast-feeding***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis***Children, infants, neonates***Geriatric***Myasthenia gravis***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dolasetron mesylate,"***For chemotherapy-induced nausea/vomiting prophylaxis (CINV prophylaxis). <br />        NOTE: In December 2010, the FDA announced that because of the risk of QT prolongation, dolasetron injection is longer indicated for chemotherapy-induced nausea/vomiting (CINV) prophylaxis.<br />     ***For the treatment of post-operative nausea/vomiting (PONV).***For post-operative nausea/vomiting (PONV) prophylaxis.","***Dolasetron hypersensitivity, granisetron hypersensitivity, ondansetron hypersensitivity, palonosetron hypersensitivity***Alcoholism, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, nausea/vomiting, QT prolongation, renal impairment, sick sinus syndrome, thyroid disease***Children, infants, neonates***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,tamoxifen citrate,"***For the treatment of breast cancer. <br />        NOTE: Evidence indicates that patients whose tumors are estrogen receptor (ER) positive are more likely to benefit from tamoxifen therapy.<br />     ***For metastatic breast cancer in men and pre- and post-menopausal women.***For ductal carcinoma in situ (DCIS) following breast surgery and radiation therapy to reduce the risk of invasive breast cancer.***For hormone receptor-positive, HER2-negative metastatic breast cancer in postmenopausal women with secondary aromatase inhibitor resistance, in combination with everolimus�.***For breast cancer prophylaxis in women who are at high risk (5-year risk >= 1.67%) for developing the disease. <br />        NOTE: There are no data available regarding the effect of tamoxifen on breast cancer incidence in women with inherited mutations (i.e., BRCA1 or BRCA2).<br />NOTE: Clinical guidelines recommend discussing the option of breast cancer chemoprevention only with those women who are at high risk for developing the disease. The potential harm of this therapy outweighs the benefit in women with low or average risk of breast cancer.***For women with certain risk factor combinations predicting a 5-year risk >= 1.67% for developing breast cancer. <br />          NOTE: The Gail Model is to be used to estimate a woman's risk to develop breast cancer. US health care professionals may obtain a Gail Model Risk Assessment Tool by calling (800)�34�LIFE�4.<br />       ***For the treatment of malignant melanoma�.***For the first-line treatment of metastatic malignant melanoma in combination with dacarbazine, cisplatin, and carmustine�.***For the treatment of metastatic malignant melanoma in combination with other agents�.***For the treatment of malignant glioma�.***For the treatment of relapsed or refractory ovarian cancer�.***For the treatment of desmoid tumor� or fibromatosis�.***For stimulation of ovulation in the treatment of infertility�.***For the prevention or treatment of mastalgia� and/or gynecomastia�.***For the treatment of mastalgia�.***For the treatment of mastalgia� and or gynecomastia� in men with prostate cancer.***For the treatment of postmenopausal osteoporosis�.***For the treatment of McCune-Albright Syndrome� and precocious puberty�.***For the treatment of bipolar disorder� (bipolar I disorder) in patients displaying mania or mixed episodes with or without psychotic features.***Formoterol***Formoterol; Mometasone","***General Information***Anticoagulant therapy, chemotherapy, stroke, thromboembolism***Menstrual irregularity, pregnancy***Breast-feeding***Endometrial cancer, endometrial hyperplasia, new primary malignancy, uterine cancer***Bone marrow suppression, leukopenia, neutropenia, thrombocytopenia***Intramuscular injections***Hypercholesterolemia, hyperlipoproteinemia***Cataracts, visual disturbance***Hypercalcemia***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['68244'],lamivudine,"***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***For the treatment of chronic hepatitis B infection.***For the treatment of chronic hepatitis B infection in HIV-negative patients.***For the treatment of chronic hepatitis B infection in HIV-positive patients.***For human immunodeficiency virus (HIV) prophylaxis�.***For HIV prophylaxis after occupational exposure to HIV.***For HIV prophylaxis after non-occupational HIV exposure, including sexual assault. <br />  NOTE: Higher risk exposures for which prophylaxis is recommended include exposure of vagina, rectum, eye, mouth, or other mucous membrane, nonintact skin, or percutaneous contact with blood, semen, vaginal secretions, rectal secretions, breast milk, or any body fluid that is visibly contaminated with blood when the source is known to be HIV-positive. Exposures to a source patient with unknown HIV status should be assessed on a case-by-case basis.<br /***For perinatal human immunodeficiency virus (HIV) prophylaxis� in neonates at high risk for HIV acquisition. <br />  NOTE: Empiric therapy with a 3-drug combination antiretroviral (ARV) regimen, consisting of zidovudine, lamivudine, and nevirapine at treatment doses, is a treatment option recommended for neonates with presumed HIV exposure or those at high risk for perinatal HIV transmission (neonates born to HIV-infected mothers: who have not received antepartum or intrapartum ARV treatment, who have received only intrapartum ARV treatment, who have suboptimal viral suppression near delivery, who have acute or primary HIV infection during pregnancy or breastfeeding, who have unknown HIV status, or who have known ARV drug-resistant virus). ARV therapy should be initiated as close to the time of birth as possible, preferably within 6 to 12 hours of delivery.<br /","***General Information***Hepatitis B and HIV coinfection, hepatitis B exacerbation, HIV serum status***Alcoholism, females, hepatic disease, Hepatotoxicity or Lactic Acidosis, obesity, organ transplant***Geriatric***Peripheral neuropathy***Renal failure, renal impairment***Children, infants, neonates, pancreatitis***Pregnancy***Breast-feeding***Human immunodeficiency virus (HIV) infection resistance***Diabetes mellitus***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['35623'],riluzole,***For the treatment of amyotrophic lateral sclerosis (ALS).***For the treatment of chorea associated with Huntington's Disease (Huntington's Chorea)�.,"***Hepatic disease***Hematological disease, neutropenia***Pneumonitis, pulmonary disease***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,delavirdine mesylate,***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***Formoterol; Mometasone,"***General Information***Hepatic disease***Pregnancy***Breast-feeding***Children, infants, neonates***Exfoliative dermatitis***Achlorhydria***Human immunodeficiency virus (HIV) infection resistance***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Hepatitis, hepatitis B and HIV coinfection***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mesalamine,***For the treatment of active ulcerative proctitis.***For the treatment of ulcerative colitis or Crohn's disease�.***For induction of remission of mild to moderate active ulcerative colitis or Crohn's disease�.***For maintenance of remission of ulcerative colitis.,"***General Information***5-aminosalicylates hypersensitivity, salicylate hypersensitivity***Renal disease, renal failure, renal impairment***Hepatitis, myocarditis, pericarditis, pneumonitis***Geriatric***Pregnancy***Breast-feeding***GI obstruction, pyloric stenosis***Sulfite hypersensitivity***Hepatic disease***Children, infants, neonates***Phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,insulin glargine,"***For the treatment of type 1 diabetes mellitus and type 2 diabetes mellitus.***For the treatment of type 1 diabetes mellitus.***For the treatment of type 2 diabetes mellitus inadequately managed by diet, exercise, and oral hypoglycemics.***For the treatment of transient neonatal diabetes mellitus�.***Formoterol; Mometasone","***Diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Hepatic disease, renal failure, renal impairment***Coma, continuous subcutaneous insulin infusion (CSII) administration, diabetic ketoacidosis, hyperosmolar hyperglycemic state (HHS), intravenous administration***Hypoglycemia***Hypokalemia***Cresol hypersensitivity***Pregnancy***Breast-feeding***Tobacco smoking***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['167'],acetazolamide,"***For the treatment of glaucoma.***For the adjunctive treatment of open-angle glaucoma.***For the treatment of secondary glaucoma and pre-operatively for acute angle-closure glaucoma.***For use as an alternative agent in the treatment of absence seizures. <br />        NOTE: The extended release preparation is not recommended for use as an anticonvulsant.<br />     ***For the treatment of acute altitude sickness.***For altitude sickness prophylaxis, including prevention of high altitude cerebral edema.***For the treatment of edema secondary to congestive heart failure or drug therapy.***For use as an adjunctive agent to reverse metabolic alkalosis� in mechanically ventilated patients. <br />        NOTE: Appropriate correction of underlying fluid and electrolyte imbalances (e.g., administration of saline fluids, potassium chloride) should be instituted prior to acetazolamide administration. In patients with excessive carbon dioxide retention (e.g., COPD), reversal of metabolic alkalosis may assist the process of weaning from mechanical ventilation, by reducing compensatory carbon dioxide retention.<br />     ***For use in urinary alkalinization�.***For the treatment of familial periodic paralysis�.***For the treatment of central vestibular nystagmus�.","***General Information***Carbonic anhydrase inhibitor hypersensitivity, sulfonamide hypersensitivity***Hepatic disease***Acid/base imbalance, acidemia, adrenal insufficiency, anuria, dialysis, electrolyte imbalance, hyperchloremia, hypokalemia, hyponatremia, metabolic acidosis, renal disease, renal failure, renal impairment***Closed-angle glaucoma***Emphysema, infection, pulmonary disease, respiratory acidosis***Agranulocytosis, bone marrow suppression***Sunlight (UV) exposure***Pregnancy***Breast-feeding***Driving or operating machinery***Children, growth inhibition, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1102261'],telaprevir,"***For the treatment of chronic hepatitis C infection (HCV, genotype 1) in adults with compensated liver disease. <br />        NOTE: MUST be administered in combination with peginterferon alfa and ribavirin; never administer as monotherapy. If peginterferon alfa or ribavirin are discontinued for any reason, then telaprevir must also be discontinued.<br />     ***Formoterol; Mometasone","***General Information***Male-mediated teratogenicity, pregnancy***Breast-feeding***Serious rash***Anemia***Hepatitis C and HIV coinfection***Liver transplant***Hepatic disease***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"synthetic conjugated estrogens, B","***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), or dyspareunia, whether menopause is natural or surgical (e.g., due to oophorectomy).***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For treatment of premenopausal females with estrogen deficiency due to hypogonadism.***For treatment of hypoestrogenism due to primary ovarian failure.***For the short-term treatment of abnormal or dysfunctional uterine bleeding caused by hormonal imbalance in the absence of organic pathology.***For the palliative treatment of breast cancer that has metastasized, in appropriately selected men or women.***For the palliative treatment of advanced inoperable prostate cancer.***Formoterol; Mometasone","***Angioedema, benzyl alcohol hypersensitivity, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,lurasidone hydrochloride,***For the treatment of schizophrenia.***For the treatment of depression associated with bipolar I disorder (bipolar depression).***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.,"***General Information***Agranulocytosis, hematological disease, leukopenia, neutropenia***Seizure disorder, seizures***Children, suicidal ideation***Tardive dyskinesia***Abrupt discontinuation***Cardiac disease, cerebrovascular disease, heart failure, hypotension, hypovolemia, myocardial infarction, orthostatic hypotension, syncope***Hepatic disease***Renal disease, renal failure, renal impairment***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Neurological disease, Parkinson's disease***Dysphagia***Diabetes mellitus, diabetic ketoacidosis, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, obesity***Dementia, geriatric, stroke***Breast cancer, hyperprolactinemia, infertility***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Substance abuse***Neonates, pregnancy, pregnancy testing***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['283821'],rasburicase,"***For the prevention and treatment of hyperuricemia in patients with leukemia, lymphoma, or solid tumors who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. <br />  NOTE: The FDA has designated rasburicase as an orphan drug for the treatment of malignancy-associated or chemotherapy-induced hyperuricemia.<br /","***Interference with uric acid measurements***Acute bronchospasm, hypotension, mannitol hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis, shock, urticaria, yeast hypersensitivity***G6PD deficiency, hemolytic anemia, methemoglobin reductase deficiency, methemoglobinemia***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['734064'],desvenlafaxine,"***For the treatment of major depression.***For the treatment of vasomotor symptoms (e.g., hot flashes�) associated with menopause�.","***General Information***Desvenlafaxine hypersensitivity, venlafaxine hypersensitivity***Abrupt discontinuation***Bipolar disorder, mania***Children, suicidal ideation***MAOI therapy***Electroconvulsive therapy (ECT), seizure disorder***Dehydration, hyponatremia, hypovolemia***Cardiac disease, cerebrovascular disease, hypertension***Hepatic disease***Renal failure, renal impairment***Anticoagulant therapy, bleeding, thrombolytic therapy***Closed-angle glaucoma, increased intraocular pressure***Eosinophilic pneumonia***Driving or operating machinery, ethanol ingestion***Eclampsia, neonates, obstetric delivery, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,alfuzosin hydrochloride,***For the symptomatic treatment of benign prostatic hyperplasia (BPH).***For the treatment of erectile dysfunction (ED)� in combination with sildenafil in patients with lower urinary tract symptoms (LUTS) suggestive of BPH.,"***General Information***Hepatic disease***Angina, coronary artery disease, orthostatic hypotension, syncope***Geriatric***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Surgery***Prostate cancer***Children, infants, neonates***Pregnancy***Breast-feeding***Renal disease, renal failure, renal impairment***Ocular surgery***Priapism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6218'],lactulose,"***For the treatment of hepatic encephalopathy (portal-systemic encephalopathy, PSE).***For the treatment of constipation, including constipation related to barium retention.",***Galactose-free diet***Surgery***Diabetes mellitus***Geriatric***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,methylphenidate hydrochloride,***For the treatment of attention-deficit hyperactivity disorder (ADHD).***For once-daily product dosing.***For the treatment of narcolepsy.***For the treatment of major depression� or post-stroke depression refractory to other therapies. <br />        NOTE: The use of stimulants for the treatment of depressive disorders is usually limited to treatment-refractory cases or when standard medical therapies are not tolerated. Stimulants may aggravate coexisting anxiety or agitation in depressed patients.<br />     ,"***General Information***Hereditary fructose intolerance***Anxiety, bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Tics, Tourette's syndrome***Glaucoma, visual disturbance***Abrupt discontinuation, alcoholism, substance abuse***Hypertension***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular arrhythmias, ventricular dysfunction***Cerebrovascular disease, stroke***Children, growth inhibition***Hyperthyroidism***Seizure disorder, seizures***Neonates, pregnancy***Breast-feeding***Driving or operating machinery***Surgery***Radiographic contrast administration***Dysphagia, esophageal stricture, GI obstruction, ileus***Hepatic disease***Geriatric***MAOI therapy***Peripheral vascular disease, Raynaud's phenomenon***Chemical leukoderma, skin hypopigmentation, vitiligo***Phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8703'],fenofibrate,"***For use as an adjunct to diet for the treatment of adult patients with severe hypertriglyceridemia. <br />  NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.     <br />NOTE: Markedly elevated levels of serum triglycerides (e.g., &gt; 2000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.  ***For use as an adjunct to diet to reduce elevated LDL-cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase HDL-cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. <br />        NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.   ","***General Information***Cardiac disease***Biliary cirrhosis, cholelithiasis, gallbladder disease, hepatic disease***Dialysis, renal disease, renal failure, renal impairment***Anticoagulant therapy***Thromboembolic disease***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding***Diabetes mellitus***Hypothyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['6854', '227717']",methoxsalen,"***For the treatment of cutaneous T-cell lymphoma (CTCL).***For the palliative treatment of the skin manifestations of CTCL unresponsive to other forms of treatment, used with the UVAR XTS or CELLEX photopheresis system.***For the treatment of idiopathic vitiligo (in conjunction with UVA). <br />        NOTE: Idiopathic vitiligo is reversible but not equally reversible in every patient. Repigmentation will vary in completeness, onset time, and duration. Repigmentation occurs more rapidly in fleshy areas such as the face, abdomen, and buttocks and less rapidly over less fleshy areas such as the dorsum of the hands or feet.<br />     ***For the treatment of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy and is diagnosed by biopsy; alopecia� areata; atopic dermatitis�; eczema�; lichen planus�; and for increased tolerance of skin to sunlight�. <br />        NOTE: Methoxsalen soft gelatin capsules and hard gelatin capsules are not interchangeable. The mean J/cm2 for the soft gelatin capsules is substantially less than that required for the hard gelatin capsules due to pharmacokinetic differences (see Pharmacokinetics). Evaluate each patient by determining the minimum phototoxic dose and phototoxic peak time after drug administration before photochemotherapy onset with Oxsoralen-Ultra.<br />NOTE: In the event that the weight of a patient changes during treatment such that he/she falls into an adjacent weight range/dose category, no change in the methoxsalen dose is usually required. If, in the physician's opinion, however, a weight change is sufficiently great to modify the drug dose, then adjust the UVA exposure time.<br />NOTE: If a patient's generalized psoriasis is not responding or if the condition appears to be worsening during treatment, consider the possibility of a generalized phototoxic reaction, which may be confirmed by the improvement of the condition following temporary discontinuance of this therapy for two weeks. If no improvement occurs during treatment interruption, this patient may be considered a treatment failure.<br />NOTE: The number of doses per week of methoxsalen capsules will be determined by the patient's schedule of UVA exposures. The severity and extent of the patient's erythema may be used to determine whether the next exposure should be shortened, omitted, or maintained at the previous dosage.<br />NOTE: If the patient flares during maintenance treatment (i.e., develops psoriasis on more than 5% of the originally involved areas of the body), his maintenance treatment schedule may be changed to the preceding maintenance or clearing schedule. The patient may be kept on his schedule until again 95% clear. If the original maintenance treatment schedule is unable to control the psoriasis, the schedule may be changed to a more frequent regimen***Formoterol; Mometasone","***Albinism, porphyria, skin photosensitivity disorder, systemic lupus erythematosus (SLE), xeroderma pigmentosum***Requires an experienced clinician***Melanoma, new primary malignancy, radiation therapy, skin cancer***Hepatic disease***Aphakia, cataracts, ocular disease***Burns, sunlight (UV) exposure***Cardiac disease, geriatric***Pregnancy***Contraception requirements, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['24605'],etodolac,"***For the treatment of mild pain or moderate pain including arthralgia, myalgia, dental pain, or bone pain. <br />        NOTE: Dosage should be individualized according to patient response.<br />     ***For the the management of the signs and symptoms of osteoarthritis or rheumatoid arthritis. <br />        NOTE: Dosage should be individualized according to patient response.<br />     ***For the the management of the signs and symptoms of juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA).***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease, jaundice***Dehydration, diabetes mellitus, edema, heart failure, hypertension, renal disease, renal failure, renal impairment, rheumatoid arthritis, sepsis, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Coagulopathy, hematological disease, hemophilia, surgery, thrombocytopenia***Bone marrow suppression, immunosuppression, neutropenia***Anemia***Intramuscular injections***Dental disease, dental work***Children, infants, neonates***Labor, pregnancy***Breast-feeding***Coronary artery bypass graft surgery (CABG)***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,potassium chloride,"***For the treatment of hypokalemia and hypokalemia prevention.***For the treatment of hypokalemia or digoxin toxicity (arrhythmias or ECG changes) associated with hypokalemia. <br />          NOTE: Hypokalemia is generally defined as a serum potassium concentration &lt; 3.5 mEq/L; however, serum potassium concentrations do not always correlate with cellular potassium levels. The National Council on Potassium in Clinical Practice recommends that serum potassium concentrations &gt;= 4 mEq/L be achieved and maintained in patients with hypertension, heart failure, and cardiac arrhythmias.<br />NOTE: Although extremely variable and based on clinical conditions of the patient, serum potassium decreases an average of 0.3 mmol/L for each 100-mmol reduction in total body stores. To avoid inducing hyperkalemia when correcting potassium loss, it is recommended to utilize the low end of this estimate and administer a moderate dose (orally, if possible) over a period of days to weeks to fully correct the potassium deficit. Among patients in an intensive care unit treated for acute hypokalemia, 20 mEq/hr potassium chloride IV resulted in a mean increase in the serum potassium concentration of 0.25 mmol/L***For the prevention of hypokalemia. <br />  NOTE: Hypokalemia is generally defined as a serum potassium concentration &lt; 3.5 mEq/L; however, serum potassium concentrations do not always correlate with cellular potassium levels. The National Council on Potassium in Clinical Practice recommends that serum potassium concentrations &gt;= 4 mEq/L be achieved and maintained in patients with hypertension, heart failure, and cardiac arrhythmias. In addition, the Council recommends potassium supplementation for patients with potential for diuretic-induced potassium loss (e.g., thiazide or loop diuretics), patients with high sodium intake (or unwilling to reduce salt intake), and patients with reduced GI intake (e.g., GI disturbances, laxative abuse).<br /***Formoterol; Mometasone","***General Information***Adrenal insufficiency, burns, dehydration, diabetic ketoacidosis, geriatric, hyperkalemia, metabolic acidosis, premature neonates, renal disease, renal failure, renal impairment***Atrial fibrillation, atrial flutter, AV block, cardiac arrhythmias, digitalis toxicity, heart failure, ventricular arrhythmias, ventricular fibrillation, ventricular tachycardia***Esophageal stricture, gastroparesis, GI obstruction, ileus, peptic ulcer disease***Pregnancy***Breast-feeding***Hepatic disease, metabolic alkalosis, respiratory alkalosis***Extravasation, thrombophlebitis***Muscle channelopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,promethazine hydrochloride,"***For the prevention of motion sickness.***For the treatment of active nausea/vomiting, including post-operative nausea/vomiting (PONV) and for�post-operative nausea/vomiting (PONV) prophylaxis.***For the treatment of allergic manifestations, such as pruritus.***For the treatment of allergic rhinitis�.***For sedation induction.***For sedation in obstetrics.***For relief of apprehension and to induce quiet sleep from which the patient can be easily aroused.***For preoperative or postoperative procedural sedation, as an adjunct to analgesics.***For the treatment of acute peripheral vestibular nystagmus�.***For pregnancy-induced nausea/vomiting�, including hyperemesis gravidarum�.","***General Information***Agranulocytosis, bone marrow suppression, coma, jaundice, phenothiazine hypersensitivity***Extravasation, intraarterial administration, intravenous administration, subcutaneous administration, tissue necrosis***Seizure disorder***Acute bronchospasm, asthma, chronic obstructive pulmonary disease (COPD), respiratory depression, sleep apnea, sulfite hypersensitivity***Hepatic disease, hepatic encephalopathy***Children, dehydration, infants, neonates, Reye's syndrome***Labor, obstetric delivery, pregnancy***Breast-feeding***Contact lenses, glaucoma***Bladder obstruction, GI obstruction, ileus, prostatic hypertrophy, urinary retention***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Radiographic contrast administration***CNS depression, driving or operating machinery, ethanol intoxication***Diabetes mellitus***Anticholinergic medications, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8794'],propylthiouracil,***For the treatment of hyperthyroidism (due to Graves' disease<strong>***For the treatment of thyrotoxicosis� (thyroid storm�).,"***General Information***Agranulocytosis, bone marrow suppression, fever***Hepatitis, hepatotoxicity, jaundice***Children, infants***Neonates, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,norepinephrine bitartrate,"***For the treatment of acute hypotension, cardiogenic shock, sepsis, or septic shock.***For the treatment of upper GI bleeding.***Formoterol***Formoterol; Mometasone","***Hypovolemia***Mesenteric thrombosis***Cyclopropane anesthesia, halothane anesthesia***Hypertension, hyperthyroidism***Extravasation, geriatric, peripheral vascular disease, tissue necrosis***MAOI therapy***Asthma, sulfite hypersensitivity***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6470'],lorazepam,"***For the short-term management of anxiety.***For the short-term treatment of insomnia due to anxiety or transient situational stress.***For procedural sedation or preoperative sedation induction.***For operative amnesia induction in adult patients.***For preoperative sedation induction and/or relief of preoperative anxiety in adult patients.***For amnesia induction� and anxiety relief in pediatric patients.***For the treatment of status epilepticus. <br />        NOTE: The intramuscular route is not preferred for the treatment of status epilepticus because therapeutic concentrations may not be achieved as quickly compared to using the intravenous route. However, if an intravenous port is not available, the intramuscular route may be useful.<br />     ***For sedation maintenance� in mechanically-ventilated patients, to alleviate agitation� and/or anxiety.***For the treatment of alcohol withdrawal�.***For acute alcohol-related seizure prophylaxis�.***For the treatment and prevention of the symptoms of alcohol withdrawal�.***For chemotherapy-induced nausea/vomiting prophylaxis� as an adjunct to antiemetics.","***Benzodiazepine hypersensitivity, benzyl alcohol hypersensitivity***Bipolar disorder, depression, mania, psychosis, suicidal ideation***Status epilepticus***Intraarterial administration***Alcoholism, chronic obstructive pulmonary disease (COPD), CNS depression, coadministration with other CNS depressants, congenital heart disease, ethanol intoxication, pulmonary disease, pulmonary hypertension, respiratory depression, respiratory insufficiency, sleep apnea, status asthmaticus***Driving or operating machinery***Closed-angle glaucoma***Hepatic disease, hepatic encephalopathy, renal failure, renal impairment***Abrupt discontinuation, benzodiazepine dependence, seizure disorder, substance abuse***Neuromuscular disease, Parkinson's disease***GI disease***Dementia, geriatric***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates, premature neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2019'],carbidopa,"***For the treatment of idiopathic Parkinson's disease (paralysis agitans), post-encephalitic parkinsonism, or symptomatic parkinsonism following CNS injury due to carbon monoxide or manganese intoxication. <br />  NOTE: Carbidopa is given in combination with levodopa for all indications. Monitor patients closely during initial carbidopa or levodopa dosage titration and when other antiparkinson medication is added. Maintain carbidopa doses of at least 70 to 100 mg/day; patients receiving less than 70 to 100 mg/day of carbidopa may experience nausea and vomiting. Therapy should be individualized and adjusted based on clinical response.<br /***For patients already on carbidopa-levodopa combination therapy who need an increase in the carbidopa dosage.***For individual titration of carbidopa and levodopa dosage in the occasional patient who requires individually titrated dosages of these two drugs.","***General Information***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,methylphenidate hydrochloride,***For the treatment of attention-deficit hyperactivity disorder (ADHD).***For once-daily product dosing.***For the treatment of narcolepsy.***For the treatment of major depression� or post-stroke depression refractory to other therapies. <br />        NOTE: The use of stimulants for the treatment of depressive disorders is usually limited to treatment-refractory cases or when standard medical therapies are not tolerated. Stimulants may aggravate coexisting anxiety or agitation in depressed patients.<br />     ,"***General Information***Hereditary fructose intolerance***Anxiety, bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Tics, Tourette's syndrome***Glaucoma, visual disturbance***Abrupt discontinuation, alcoholism, substance abuse***Hypertension***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular arrhythmias, ventricular dysfunction***Cerebrovascular disease, stroke***Children, growth inhibition***Hyperthyroidism***Seizure disorder, seizures***Neonates, pregnancy***Breast-feeding***Driving or operating machinery***Surgery***Radiographic contrast administration***Dysphagia, esophageal stricture, GI obstruction, ileus***Hepatic disease***Geriatric***MAOI therapy***Peripheral vascular disease, Raynaud's phenomenon***Chemical leukoderma, skin hypopigmentation, vitiligo***Phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clindamycin palmitate hydrochloride,"***For the treatment of serious infections such as bacteremia.***For the treatment of lower respiratory tract infections (e.g., pleural empyema, anaerobic pneumonia, aspiration pneumonia, community-acquired pneumonia, and lung abscess) due to susceptible organisms<strong>***For the treatment of intraabdominal infections, including intraabdominal abscess and peritonitis.***For the treatment of peritonitis in patients receiving peritoneal dialysis.***For the treatment of skin and skin structure infections, including impetigo, ecthyma, cellulitis, erysipelas, infectious neonatal pustulosis, bite wounds, and complicated skin and skin structure infections such as necrotizing infections, gas gangrene, and diabetic foot ulcer.***For the treatment of impetigo or ecthyma.***For the treatment of necrotizing infections of the skin, fascia, and muscle (i.e. gas gangrene).***For the treatment of animal bite wounds.***For the treatment of diabetic foot ulcer.***For the treatment of gynecologic infections, including endometritis and pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of acute pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of bacterial vaginosis.***For the treatment of acne vulgaris.***For the treatment of bone and joint infections, including osteomyelitis and septic/infectious arthritis, or an orthopedic device-related infection�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated prosthetic joint infections�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated spinal implant infections�.***For the treatment of of uncomplicated acute otitis media�.***For the treatment of acute bacterial sinusitis�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis� in combination with conventional treatment (e.g., scaling and root planing) as well as acute dental abscess (apical)� and/or dental abscess (periapical)�.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage in patients with beta-lactam allergy.***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis� (rheumatic fever prophylaxis�) and for bacterial colonization eradication� in chronic carriers of group A beta-hemolytic <em>Streptococci</em> (GAS)�.***For the treatment of chronic pharyngeal carriers of group A streptococci (i.e., bacterial colonization eradication�).***For surgical infection prophylaxis�.***For bacterial endocarditis prophylaxis�.***For the treatment of anthrax�.***For the treatment of cutaneous anthrax infection.***For the treatment of systemic anthrax infection.***For anthrax prophylaxis� after exposure to Bacillus anthracis (postexposure prophylaxis, PEP).***For the treatment of toxoplasmosis�, including toxoplasmic encephalitis�.***For secondary toxoplasmosis prophylaxis� in HIV-infected patients intolerant of sulfa drugs.***For the treatment of Pneumocystis pneumonia (PCP)� in HIV-infected patients.***For the treatment of malaria� due <em>Plasmodium falciparum</em>.***For the treatment of babesiosis�.***For perinatal Group B streptococcal bacterial infection prophylaxis� in patients allergic to penicillin and cephalosporins.***Formoterol; Mometasone","***Asthma, atopy, clindamycin hypersensitivity, lincomycin hypersensitivity, serious rash, tartrazine dye hypersensitivity***Fungal infection***Diarrhea, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Neonates***Hepatic disease***Pregnancy***Breast-feeding***Ocular exposure***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clindamycin phosphate,"***For the treatment of serious infections such as bacteremia.***For the treatment of lower respiratory tract infections (e.g., pleural empyema, anaerobic pneumonia, aspiration pneumonia, community-acquired pneumonia, and lung abscess) due to susceptible organisms<strong>***For the treatment of intraabdominal infections, including intraabdominal abscess and peritonitis.***For the treatment of peritonitis in patients receiving peritoneal dialysis.***For the treatment of skin and skin structure infections, including impetigo, ecthyma, cellulitis, erysipelas, infectious neonatal pustulosis, bite wounds, and complicated skin and skin structure infections such as necrotizing infections, gas gangrene, and diabetic foot ulcer.***For the treatment of impetigo or ecthyma.***For the treatment of necrotizing infections of the skin, fascia, and muscle (i.e. gas gangrene).***For the treatment of animal bite wounds.***For the treatment of diabetic foot ulcer.***For the treatment of gynecologic infections, including endometritis and pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of acute pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of bacterial vaginosis.***For the treatment of acne vulgaris.***For the treatment of bone and joint infections, including osteomyelitis and septic/infectious arthritis, or an orthopedic device-related infection�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated prosthetic joint infections�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated spinal implant infections�.***For the treatment of of uncomplicated acute otitis media�.***For the treatment of acute bacterial sinusitis�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis� in combination with conventional treatment (e.g., scaling and root planing) as well as acute dental abscess (apical)� and/or dental abscess (periapical)�.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage in patients with beta-lactam allergy.***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis� (rheumatic fever prophylaxis�) and for bacterial colonization eradication� in chronic carriers of group A beta-hemolytic <em>Streptococci</em> (GAS)�.***For the treatment of chronic pharyngeal carriers of group A streptococci (i.e., bacterial colonization eradication�).***For surgical infection prophylaxis�.***For bacterial endocarditis prophylaxis�.***For the treatment of anthrax�.***For the treatment of cutaneous anthrax infection.***For the treatment of systemic anthrax infection.***For anthrax prophylaxis� after exposure to Bacillus anthracis (postexposure prophylaxis, PEP).***For the treatment of toxoplasmosis�, including toxoplasmic encephalitis�.***For secondary toxoplasmosis prophylaxis� in HIV-infected patients intolerant of sulfa drugs.***For the treatment of Pneumocystis pneumonia (PCP)� in HIV-infected patients.***For the treatment of malaria� due <em>Plasmodium falciparum</em>.***For the treatment of babesiosis�.***For perinatal Group B streptococcal bacterial infection prophylaxis� in patients allergic to penicillin and cephalosporins.***Formoterol; Mometasone","***Asthma, atopy, clindamycin hypersensitivity, lincomycin hypersensitivity, serious rash, tartrazine dye hypersensitivity***Fungal infection***Diarrhea, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Neonates***Hepatic disease***Pregnancy***Breast-feeding***Ocular exposure***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10355'],temazepam,***For the short-term treatment of insomnia.,"***General Information***Benzodiazepine hypersensitivity***Bipolar disorder, depression, mania, myasthenia gravis, Parkinson's disease, psychosis, suicidal ideation***Pain***Alcoholism, driving or operating machinery, ethanol ingestion, ethanol intoxication***Chronic obstructive pulmonary disease (COPD), CNS depression, coadministration with other CNS depressants, pulmonary disease, respiratory depression, respiratory insufficiency, sleep apnea***Abrupt discontinuation, benzodiazepine dependence, seizure disorder, seizures, status epilepticus, substance abuse***Closed-angle glaucoma***Porphyria***Infants, labor, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease***Renal failure, renal impairment***Dementia, geriatric***Children, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,metformin hydrochloride,"***For treatment of type 2 diabetes mellitus.***For monotherapy or for use in combination with an insulin secretogue (e.g., sulfonylurea) or insulin.***For conversion to metformin monotherapy from other antidiabetic agents.***For the adjunct treatment of patients with hyperinsulinemia secondary to polycystic ovary syndrome� (PCOS), including the treatment of infertility� in these patients.***For the delay of clinical puberty and early menarche in females with precocious puberty�.***For the prolongation of pubertal growth� and to prevent the delay of early menarche in low birth weight females with early-normal onset of puberty.***For the treatment of gestational diabetes� in patients not controlled by diet-therapy alone.","***General Information***Diabetic ketoacidosis, type 1 diabetes mellitus***Acidemia, hypoxemia, lactic acidosis, metabolic acidosis***Diarrhea, vomiting***Renal disease, renal failure, renal impairment***Acute heart failure, acute myocardial infarction, cardiac disease, cardiogenic shock, heart failure***Alcoholism, ethanol ingestion, ethanol intoxication, hepatic disease***Radiographic contrast administration***Burns, dehydration, fever, infection, sepsis, surgery, trauma***Adrenal insufficiency, gastroparesis, GI obstruction, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypothyroidism, ileus, malnutrition, pituitary insufficiency***Pernicious anemia***Geriatric***Polycystic ovary syndrome, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3098'],dacarbazine,"***For the treatment of metastatic malignant melanoma.***For the single-agent treatment of metastatic melanoma.***For the first-line treatment of unresectable or metastatic melanoma, in combination with ipilimumab�.***For the treatment of Hodgkin lymphoma.***For the second-line treatment of Hodgkin lymphoma, in combination with other agents.***For the treatment of previously untreated advanced classical Hodgkin lymphoma, in combination with brentuximab vedotin, doxorubicin, and vinblastine�. <br />  NOTE: Brentuximab vedotin is FDA approved in combination with chemotherapy (e.g., doxorubicin, vinblastine, and dacarbazine) for the treatment of previously untreated stage III or IV classical Hodgkin lymphoma.<br /***For the treatment of unresectable or metastatic osteogenic sarcoma�, in combination with mesna, ifosfamide, and doxorubicin.***For the treatment of of unresectable or metastatic Ewing's sarcoma�, in combination with mesna, ifosfamide, and doxorubicin.***For the treatment of unresectable or metastatic rhabdomyosarcoma�, in combination with mesna, ifosfamide, and doxorubicin.***For the the first-line treatment of unresectable or metastatic soft-tissue sarcoma�, in combination with mesna, ifosfamide, and doxorubicin.***For the treatment of carcinomatous meningitis� due to melanoma.***For the treatment of advanced neuroblastoma�, in combination with other chemotherapy agents.","***Dacarbazine (DTIC) hypersensitivity***Bone marrow suppression, herpes infection, infection, neutropenia, radiation therapy, requires an experienced clinician, thrombocytopenia, varicella, viral infection***Intramuscular injections***Extravasation, intramuscular administration, subcutaneous administration***Dental disease, dental work***Hepatic disease, hepatic necrosis, hepatotoxicity, renal impairment***Accidental exposure, ocular exposure***Vaccination***New primary malignancy***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['21766'],crotamiton,***For the treatment of scabies caused by <em>Sarcoptes scabiei</em>.***For the treatment of pruritus.,"***General Information***Accidental exposure, ocular exposure***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4719'],gemfibrozil,"***For use as an adjunct to diet for the treatment of hyperlipoproteinemia and hypertriglyceridemia.***For hypertriglyceridemia including Type IV (elevated triglycerides, VLDL) and Type V (elevated triglycerides, chylomicrons, VLDL) in patients who have significant risk of coronary artery disease or pancreatitis, and have not responded to diet. <br />          NOTE: Gemfibrozil is not indicated for patients with Type I (rare) hyperlipoproteinemia who have elevated chylomicrons, triglycerides, but who have normal VLDL concentrations. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I (rare), IV, and V (rare) hyperlipoproteinemia.<br />       ***For second-line therapy for type IIb hypercholesterolemia (elevated cholesterol, triglycerides, LDL, VLDL) in patients with low HDL (< 35 mg/dl) and without evidence of coronary artery disease.","***General Information***Biliary cirrhosis, cholelithiasis, gallbladder disease, hepatic disease***Renal disease, renal failure, renal impairment***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['28031', '202826']",itraconazole,"***For the treatment of invasive aspergillosis including invasive pulmonary, CNS, and cutaneous aspergillosis, as well as <em>Aspergillus</em> sinusitis, tracheobronchitis, endocarditis, pericarditis, myocarditis, osteomyelitis, infectious arthritis, and aspergilloma in patients who are intolerant of or refractory to amphotericin B therapy. <br />        Note: Itraconazole is recommended as alternative therapy for invasive aspergillosis by the Infectious Diseases Society of America (IDSA).<br />     ***For primary treatment of allergic bronchopulmonary aspergillosis.***For primary treatment of <em>Aspergillus</em> peritonitis.***For the treatment of blastomycosis. <br />        NOTE: For CNS infections, see meningitis.<br />NOTE: Obtain itraconazole serum concentrations after at least 2 weeks of therapy to ensure adequate drug exposure***For mild to moderate pulmonary or disseminated extrapulmonary blastomycosis.***For blastomycosis in immunosuppressed patients.***For moderately severe or severe pulmonary or disseminated extrapulmonary blastomycosis.***For the treatment of histoplasmosis. <br />        NOTE: For CNS infections, see meningitis.<br />     ***For the treatment of acute symptomatic pulmonary histoplasmosis.***For the treatment of chronic pulmonary histoplasmosis.***For the treatment of chronic progressive disseminated histoplasmosis.***For use as maintenance (consolidation) therapy in the treatment of moderately severe to severe disseminated histoplasmosis (<em>Histoplasma capsulatum</em>) in HIV-infected patients.***For use as induction and maintenance (consolidation) therapy in the treatment of mild disseminated histoplasmosis in HIV-infected patients.***For the treatment of onychomycosis due to dermatophytes (tinea unguium) in immunocompetent patients. <br />        NOTE: Due to the serious adverse reactions associated with itraconazole, nail specimens should be sent for laboratory testing to confirm the diagnosis prior to beginning itraconazole therapy.<br />     ***For fingernail involvement only.***For toenail involvement with or without fingernail involvement.***For the treatment of mucocutaneous candidiasis. <br />        NOTE: Itraconazole oral solution only is FDA-approved for esophageal and/or oral candidiasis. The manufacturer states that patients with severe neutropenia were not studied. The oral solution is not recommended for treatment of these indications in patients who are at immediate risk for systemic candidiasis.<br />     ***For the treatment of esophageal candidiasis.***For the treatment of oropharyngeal candidiasis (thrush).***For the treatment of oropharyngeal candidiasis unresponsive or refractory to fluconazole.***For treatment of nonalbicans or recurrent vulvovaginal candidiasis� (VVC).***For the treatment of meningitis�.***For the treatment of cryptococcosis� and meningitis� caused by <em>Cryptococcus sp.�</em> in HIV-infected patients as consolidation therapy after successful induction therapy.***For the treatment of CNS infection� or meningitis� due to <em>Blastomyces dermatitidis</em>.***For the treatment of meningitis� with <em>Coccidioides sp.</em>� in HIV-infected patients.***For the treatment of disseminated coccidioidomycosis�. <br />        NOTE: For CNS infections, see meningitis.<br />     ***For the treatment of mild coccidioidomycosis� (focal pneumonia or positive coccidioidal serologic test alone) in HIV-infected patients.***For treatment of severe, nonmeningeal coccidioidomycosis� (diffuse pulmonary or severely ill patients with extrathoracic disseminated disease) in HIV-infected patients during the acute phase.***For the treatment of cutaneous or systemic sporotrichosis�.***For the treatment of tinea corporis�.***For the empiric treatment of suspected invasive candidiasis� in neutropenic patients.***For the treatment of penicilliosis� (<em>Penicilliosis marneffei</em>�) in HIV-infected patients.***For the treatment of mild penicilliosis� in HIV-infected patients.***For the treatment of acute penicilliosis� in severely ill HIV-infected patients.***For candidiasis prophylaxis� in high-risk patients.***For candidiasis prophylaxis� in high-risk cancer patients and those with chemotherapy-induced neutropenia.***For secondary oropharyngeal candidiasis prophylaxis� in HIV-infected patients.***For vulvovaginal candidiasis prophylaxis� in patients with recurrent infection.***For secondary esophageal candidiasis prophylaxis� in HIV-infected patients.***For the treatment or secondary prophylaxis of disseminated (non-ocular) infections associated with microsporidiosis� and attributed to <em>Trachipleistophora</em> or <em>Anncaliia</em>. <br />  NOTE: According to the HIV treatment guidelines, initiating antiretroviral therapy (ART) before severe immunosuppression develops is key to preventing chronic microsporidiosis, as infection most commonly occurs in patients with CD4 counts less than 100 cells/mm3. Other preventative measures for patients with CD4 counts less than 200 cells/mm3 include: avoid untreated water sources; avoid consuming undercooked meat or seafood; limit exposure to animals known to be infected with microsporidia.<br />NOTE: All patients infected with microsporidiosis should be offered ART as part of the initial treatment***For maintenance therapy� (secondary coccidioidomycosis prophylaxis�) after treatment of coccidioidomycosis in HIV-infected patients .***For primary histoplasmosis prophylaxis� in HIV-infected patients or for secondary histoplasmosis prophylaxis� in HIV-infected patients, after treatment of the acute infection.***For primary and secondary penicilliosis prophylaxis� in HIV-infected patients.***For secondary cryptococcosis prophylaxis� (chronic maintenance therapy) for meningitis caused by <em>Cryptococcus</em> sp.  in HIV-infected patients<strong><em>�</em***For aspergillosis prophylaxis�.***For the treatment of fungal keratitis�.***For the treatment of tinea capitis�.***For the treatment of tinea pedis�.***Formoterol***Formoterol; Mometasone","***Hepatic disease, hepatotoxicity***Chronic obstructive pulmonary disease (COPD), coronary artery disease, dialysis, heart failure, pulmonary disease, pulmonary edema, valvular heart disease, ventricular dysfunction***Alcoholism, cardiac arrhythmias, diabetes mellitus, females, hypocalcemia, hypokalemia, hypomagnesemia, itraconazole coadministration with other drugs, long QT syndrome, myocardial infarction, QT prolongation, thyroid disease, ventricular arrhythmias***Cystic fibrosis***Achlorhydria, human immunodeficiency virus (HIV) infection, hypochlorhydria***Peripheral neuropathy***Hearing impairment***Driving or operating machinery***Neutropenia***Pregnancy***Breast-feeding***Children, infants, neonates***Azole antifungals hypersensitivity***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7975'],penicillamine,***For the treatment of Wilson's disease (hepatolenticular degeneration).***For the treatment of cystinuria.***For the treatment of arsenic toxicity.***For the treatment of rheumatoid arthritis.***For the treatment of juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA)�.***For the treatment of lead toxicity�.***For the treatment of rapidly progressive scleroderma (systemic sclerosis)�.,"***Fever, penicillamine hypersensitivity, penicillin hypersensitivity, requires an experienced clinician, serious rash***Agranulocytosis, aplastic anemia, bone marrow suppression, hematological disease, neutropenia***Pemphigus vulgaris***Hematuria, nephrolithiasis, nephrotoxicity, proteinuria, renal failure, renal impairment***Caesarean section, pregnancy***Breast-feeding***Diabetes mellitus, hypoglycemia***Cholestasis, hepatitis, hepatotoxicity, jaundice***Geriatric***Children***Myasthenia gravis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dextromethorphan hydrobromide/promethazine hydrochloride,***For the temporary relief of cough and upper respiratory symptoms associated with allergy or the common cold.,"***General Information***Agranulocytosis, bone marrow suppression, jaundice, phenothiazine hypersensitivity***Bladder obstruction, closed-angle glaucoma, contact lenses, ileus, prostatic hypertrophy, urinary retention***Head trauma, increased intracranial pressure***Asthma, chronic obstructive pulmonary disease (COPD), respiratory depression, sleep apnea***Hepatic disease***CNS depression, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Seizure disorder, seizures***Cardiac arrhythmias, cardiac disease***Sunlight (UV) exposure***Diabetes mellitus***Atopy, children, dehydration, infants, neonates, Reye's syndrome***Obstetric delivery, pregnancy***Breast-feeding***Radiographic contrast administration***MAOI therapy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6980'],minocycline,"***For the treatment of relapsing fever due to <em>Borrelia recurrentis</em>.***For the treatment of chancroid due to <em>Haemophilus ducreyi</em>.***For the treatment of Campylobacter fetus infections.***For the treatment of acute intestinal amebiasis as an adjunct to amebicides.***For the treatment of lower respiratory tract infections and upper respiratory tract infections.***For the treatment of skin and skin structure infections due to <em>Staphylococcus aureus</em>. <br />        NOTE: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection. <br />     ***For the treatment of Rickettsial infections (e.g., murine typhus, Q fever, Rocky Mountain spotted fever, Rickettsial pox).***For the treatment of uncomplicated gonorrhea infections, including urethritis.***For the treatment of psittacosis.***For the treatment of lymphogranuloma venereum caused by <em>Chlamydia trachomatis</em>.***For the treatment of non-gonococcal urethritis (NGU) and chlamydia infection, including trachoma and chlamydial conjunctivitis.***For the treatment of urethral, endocervical, or rectal infections.***For the treatment of other chlamydia infections, including trachoma and inclusion bacterial conjunctivitis.***For the treatment of syphilis when penicillin is contraindicated.***For the treatment of granuloma inguinale (Donovanosis) due to <em>Klebsiella granulomatis</em>.***For the treatment of bartonellosis.***For the treatment of brucellosis in combination with streptomycin.***For the treatment of urinary tract infection (UTI).***For the treatment of plague after exposure to <em>Yersinia pestis</em>.***For the treatment of tularemia following exposure to <em>Francisella tularensis</em>.***For the treatment of cholera.***For the treatment of acne vulgaris.***For the treatment of non-nodular moderate to severe acne vulgaris.***For the treatment of infections caused by <em>Actinomyces israelii</em> (actinomycosis), <em>Bacillus anthracis</em> (anthrax), <em>Clostridium</em> sp. (clostridial diseases), necrotizing ulcerative gingivitis (Fusospirochetosis or Vincent's infection), <em>Listeria monocytogenes</em> (listeriosis), or <em>Treponema pertenue</em> (yaws) when penicillin is contraindicated.***For the treatment meningitis due to <em>Neisseria meningitidis</em>.***For the treatment of the meningococcal carrier state (i.e., for meningococcal infection prophylaxis).***For the treatment of Mycobacterium marinum infection.***For the treatment of rheumatoid arthritis�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis in combination with conventional treatment (e.g., scaling and root planing).***For aggressive periodontitis (juvenile periodontitis)�.***For use as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult chronic periodontitis.***For the treatment of bullous pemphigus�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated bone and joint infections� or an orthopedic device-related infection�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated osteomyelitis�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated prosthetic device infections�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated spinal implant infections�.","***General Information***Serious rash, tetracyclines hypersensitivity***Hepatic disease, hepatitis, hepatotoxicity***Autoimmune disease***Renal failure, renal impairment***Increased intracranial pressure, papilledema, pseudotumor cerebri, visual disturbance***Sunlight (UV) exposure***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***AV block, cardiac disease***Children, infants, neonates***Sexually transmitted disease***Geriatric***Dental work***Pregnancy***Breast-feeding***Infertility, reproductive risk***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['68503'],ziconotide,"***For the relief of chronic, severe pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatments such as systemic analgesics, adjunctive therapies, or intrathecal morphine. <br />        NOTE: Dosage should be titrated according to the pain severity, patient response, and adverse event occurrence. Reduced initial dosages should be considered for elderly patients and for patients receiving CNS depressants.<br />     ***For spasticity� associated with spinal cord injury�.","***Epidural administration, intravenous administration, spinal cord compression***Driving or operating machinery, ethanol intoxication***Behavioral changes, bipolar disorder, depression, neurologic events, psychiatric event, psychosis, schizophrenia, suicidal ideation***Seizures***Immunosuppression, infection***Bleeding, coagulopathy, hematological disease, hemophilia, thrombocytopenia, von Willebrand's disease***Dementia, geriatric***Cardiac arrhythmias, cardiac disease, syncope***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['115238'],becaplermin,"***For the treatment of lower extremity diabetic neuropathic ulcers (e.g., diabetic foot ulcer) that extend into the subcutaneous tissue or beyond and have an adequate blood supply. <br />  NOTE: Becaplermin is used as an adjunct to good ulcer care practices including initial sharp debridement, pressure relief, and infection control.<br />NOTE: The safety and efficacy of becaplermin treatment beyond 20 weeks have not been determined.<br />NOTE: The diabetic ulcers had failed to heal after at least 8 weeks of other treatment, and the median ulcer size at baseline ranged from 1.4 to 3.5 cm2; 95% of the ulcers measured in area up to 10 cm2***For wound management� of full thickness, single, fingertip injuries with a wound area of at least 1.5 cm<sup>2</sup> with or without phalangeal exposure; distal to the distal interphalangeal joint; and not involving the flexor tendon insertion.***For surgical, abdominal wound dehiscence�.***For the treatment of chronic, full thickness decubitus ulcer� in combination with good wound care. <br />        NOTE: The efficacy of becaplermin has not been established for the treatment of pressure ulcers.<br />     ","***General Information***Cresol hypersensitivity, paraben hypersensitivity***Mortality, neoplastic disease, new primary malignancy***Pregnancy***Breast-feeding***Children, infants, neonates***Corticosteroid therapy, infection***Peripheral vascular disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6038'],isoniazid,"***For the treatment of infections due to <em>Mycobacterium</em> sp., including tuberculosis infection. <br />        NOTE: All patients receiving isoniazid therapy should also receive pyridoxine daily. <br />     ***For the treatment of tuberculosis infection in combination with other antitubercular agents. <br />          NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., at least 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, IDSA, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. Directly observed therapy (DOT) should be used for all regimens administered 1, 2, 3, or 5 times per week and in all pediatric patients. The initial treatment regimen should include four drugs unless the likelihood of isoniazid or rifampin resistance is low (i.e., less than 4%), in which case an initial regimen of isoniazid, rifampin, and pyrazinamide may be considered. HIV positive patients should always receive induction therapy with four drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate.  For multi-drug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, the CDC recommends treatment for 18 to 24 months after culture conversion in patients with bacteriologic confirmation and for at least 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months in MDR-TB. The WHO also provides an alternative set of international dosing guidelines.<br />       ***For the treatment of infections due to susceptible nontuberculous <em>Mycobacterium </em>sp.�. <br />          NOTE: Selection of agents should be guided by in vitro susceptibility tests. While some species such as M. kansasii are usually susceptible to INH, other Mycobacterium sp. (e.g., M. avium-intracellulare) are broadly resistant.<br />       ***For tuberculosis prophylaxis or latent tuberculosis infection (LTBI). <br />        NOTE: Directly observed therapy (DOT) should be employed when weekly or twice-weekly dose regimens are used. <br />     ***For tuberculosis prophylaxis in non-immunocompromised patients.***For tuberculosis prophylaxis in HIV-infected patients when a newly-positive skin test (5 mm or more) is confirmed or when the patient has been in contact with someone with active isoniazid-sensitive tuberculosis regardless of skin test result. <br />          NOTE: Active tuberculosis must be excluded prior to beginning prophylaxis. <br />       ***For the reduction of severe tremor� associated with multiple sclerosis.***Formoterol; Mometasone","***General Information***Alcoholism, Black patients, females, geriatric, hepatic disease, hepatitis, hepatotoxicity, Hispanic patients, jaundice***Diabetes mellitus, human immunodeficiency virus (HIV) infection, malnutrition, peripheral neuropathy, renal failure, renal impairment***Seizure disorder***Pregnancy***Breast-feeding***Acne vulgaris***MAOI therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,valproic acid,"***For the monotherapy or adjunct treatment of simple absence seizures, complex absence seizures, or complex partial seizures, and adjunctively for other seizure types that include absence or partial complex seizures (e.g., tonic-clonic seizures, myoclonic seizures).***For the treatment of acute mania associated with bipolar disorder, with or without psychotic features.***For migraine prophylaxis.***For the treatment of refractory status epilepticus�. <br />  NOTE: Valproate has been used for emergency treatment of seizures where other agents have failed, or, when other medications are not readily available or when phenytoin is contraindicated.<br /***For the treatment of persistent singultus (hiccups)�.***For the treatment of severe behavioral disturbances, such as agitation�.***For severe behavioral disturbances� (e.g., aggression, agitation�, explosive temper) occurring with attention-deficit hyperactivity disorder (ADHD)�.***For the symptomatic treatment of acquired pendular nystagmus�.***For the treatment of painful diabetic neuropathy�.","***General Information***Encephalopathy***Serious rash***Mitochondrial disease***Carnitine deficiency, hepatic disease, hepatotoxicity, hypoalbuminemia, organic brain syndrome***Pancreatitis***Children, infants, neonates***Depression, suicidal ideation***Bleeding, coagulopathy, surgery, thrombocytopenia***Renal failure, renal impairment***Human immunodeficiency virus (HIV) infection***Driving or operating machinery, ethanol ingestion***Colostomy, diarrhea, ileostomy***Head trauma***Abrupt discontinuation***Contraception requirements, pregnancy, reproductive risk***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,quinidine gluconate,"***For conversion to and/or maintenance of sinus rhythm in patients with atrial fibrillation, atrial flutter, or ventricular tachycardia; or for the treatment of paroxysmal supraventricular tachycardia (PSVT); or for paroxysmal supraventricular tachycardia (PSVT) prophylaxis in patients with reentrant tachycardias, including patients with Wolff-Parkinson-White (WPW) syndrome. <br />        NOTE: Most adult patients require 10 to 20 mg/kg/day, expressed as quinidine base. Dosages should be adjusted to produce a serum quinidine concentration of 2 to 6 mcg/mL. Quinidine sulfate, quinidine gluconate, and quinidine polygalacturonate (no longer commercially available) contain 83%, 62%, and 80% quinidine base, respectively.<br />     ***For the treatment of severe malaria.***For the treatment of persistent singultus (hiccups)�.***Formoterol***Formoterol; Mometasone","***AV block, bundle-branch block, digitalis toxicity***Heart failure***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, mortality, myocardial infarction, QT prolongation, thyroid disease***Hypotension***Asthma, fever, mefloquine hypersensitivity, quinidine hypersensitivity, quinine hypersensitivity***Myasthenia gravis***Hepatic disease, renal failure, renal impairment***Labor, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['161']['10689'],acetaminophen/tramadol hydrochloride,***For the short term (5 days or less) treatment of acute moderate pain.***For diabetic neuropathy�.,"***General Information***Acetaminophen hypersensitivity, opiate agonist hypersensitivity***Head trauma, increased intracranial pressure, infection, seizure disorder, seizures***Alcoholism, hepatic disease, hepatitis***MAOI therapy***Depression, hepatotoxicity, potential for overdose or poisoning, suicidal ideation***Coadministration with other CNS depressants, respiratory depression***Acute abdomen, biliary tract disease, constipation, diarrhea, GI disease, GI obstruction, ileus, pancreatitis, ulcerative colitis***Acute intoxication of CNS depressants, avoid ethanol ingestion, ethanol intoxication***Substance abuse***Abrupt discontinuation***Renal failure, renal impairment***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Geriatric***Adenoidectomy, asthma, children, infants, neonates, neuromuscular disease, obesity, pulmonary disease, respiratory infection, sleep apnea, tonsillectomy***Driving or operating machinery***Anemia, G6PD deficiency***Bone marrow suppression, immunosuppression, neutropenia***Adrenal insufficiency, hypothyroidism, myxedema***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5552'],hydroxyurea,"***For the treatment of resistant chronic myelogenous leukemia (CML).***For the treatment of locally advanced squamous cell head and neck cancer (excluding the lip) in combination with chemoradiation therapy.***For the treatment of sickle cell disease (i.e., to reduce the frequency of painful crises and to reduce the need for blood transfusions in patients with recurrent moderate to severe painful crises). <br />        The FDA has designated hydroxyurea as an orphan drug for the treatment of sickle cell anemia.<br />     ***For the treatment of acute myelogenous leukemia (AML)�.***For the treatment of advanced non-small cell lung cancer (NSCLC)�, in combination with chemotherapy.***For the treatment of polycythemia vera�.***For the prevention of thrombosis in patients with essential thrombocytosis�.***For the treatment of psoriasis�.***For the adjuvant treatment of high-grade malignant glioma�, as part of the 8-in-1 regimen.***For the adjuvant treatment of medulloblastoma�, in combination with radiotherapy and following procarbazine.***For the adjuvant treatment of primitive neuroectodermal tumor�, as part of the 8-in-1 chemotherapy regimen.***Formoterol; Mometasone","***General Information***Anemia, bone marrow suppression, leukopenia, neutropenia, thrombocytopenia***New primary malignancy, radiation therapy, sunlight (UV) exposure, vasculitis***Geriatric, hepatic disease, renal disease, renal impairment***Human immunodeficiency virus (HIV) infection***Vaccination***Pernicious anemia***Laboratory test interference***Intrauterine fetal death, pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, pregnancy testing, reproductive risk***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydroxyzine pamoate,"***For the short-term treatment of anxiety, tension, and psychomotor agitation in conditions of emotional stress.***For the treatment of pruritus due to histamine-mediated conditions or due to allergic conditions like chronic urticaria (e.g., chronic idiopathic urticaria), atopic dermatitis or contact dermatitis.***For post-operative nausea/vomiting (PONV) and post-operative nausea/vomiting (PONV) prophylaxis.***For procedural sedation or adjunctively for pre-and postoperative or pre-and post-partum therapy to permit dosage reduction of narcotic analgesia.***For the short term treatment of insomnia�.***For the treatment of allergic rhinitis� and for allergic rhinitis prophylaxis�.***Formoterol***Formoterol; Mometasone","***Hydroxyzine hypersensitivity***Asthma, chronic obstructive pulmonary disease (COPD)***Bradycardia, cardiac disease, electrolyte imbalance, heart failure, hypokalemia, hypomagnesemia, long QT syndrome, myocardial infarction, QT prolongation, torsade de pointes, ventricular arrhythmias***Closed-angle glaucoma, contact lenses***Ileus, prostatic hypertrophy, urinary retention***Dialysis, renal failure, renal impairment***Biliary cirrhosis, hepatic disease***Labor, pregnancy***Breast-feeding***Infants, neonates, premature neonates***Anticholinergic medications, geriatric***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion, ethanol intoxication***Intravenous administration, subcutaneous administration, tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3393'],diflunisal,"***For the treatment of acute or chronic osteoarthritis.***For the treatment of acute or chronic rheumatoid arthritis.***For the acute or long-term management of mild pain or moderate pain including arthralgia�, bone pain�, dental pain�, dysmenorrhea�, headache�, migraine�, and myalgia�.***Formoterol; Mometasone","***Acute bronchospasm, asthma, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, gastritis, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Dehydration, diabetes mellitus, edema, heart failure, hyperaldosteronism, hypertension, hypovolemia, renal disease, renal failure, renal impairment, sepsis, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Anemia, bone marrow suppression, coagulopathy, hemophilia, immunosuppression, neutropenia, thrombocytopenia, thrombolytic therapy***Intramuscular injections***Biliary tract disease, hepatic disease, jaundice***Dental disease, dental work, surgery***Labor, obstetric delivery, pregnancy***Breast-feeding***Influenza, varicella, viral infection***Coronary artery bypass graft surgery (CABG)***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,haloperidol decanoate,"***For the treatment of schizophrenia.***For the treatment of severe behavioral problems associated with oppositional defiant disorder or other disruptive behavioral disorders, or for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients who show excessive motor activity with accompanying conduct disorders.***For the treatment of tics and vocal utterances associated with Tourette's syndrome.***For the treatment of acute psychosis in acutely agitated schizophrenic patients with moderately severe to very severe symptoms.***For the treatment of acute mania�.***For the treatment of irritability associated with autistic disorder�.***For use as a second-line agent for rescue treatment of chemotherapy-induced nausea/vomiting�.***For the treatment of agitation� or delirium�.***For agitation� or delirium� in adult patients with no underlying psychiatric illness.***For the treatment of delirium� in the pediatric intensive care unit (PICU).***For the treatment of persistent singultus (hiccups)�.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.","***General Information***Alcoholism, angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, intravenous administration, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, thyroid disease, torsade de pointes***Agranulocytosis, hematological disease, leukopenia, neutropenia***CNS depression, coma***Tardive dyskinesia***Neurological disease, Parkinson's disease***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Seizure disorder, seizures***Dysphagia***Pulmonary disease***Hepatic disease, jaundice***Closed-angle glaucoma, increased intraocular pressure, visual disturbance***Prostatic hypertrophy, urinary retention***Dementia, geriatric, stroke***Thyrotoxicosis***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Tobacco smoking***Abrupt discontinuation***Breast cancer, hyperprolactinemia, infertility***Neonates, pregnancy, pregnancy testing***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pravastatin sodium,"***For the treatment of hypercholesterolemia, hyperlipoproteinemia, and/or hypertriglyceridemia as an adjunct to dietary control.***For myocardial infarction prophylaxis or stroke prophylaxis.***For secondary prevention of and reduction of cardiovascular mortality and acute coronary events, stroke, TIA, coronary revascularization procedures, and atherosclerosis progression in patients with coronary artery disease.***For primary prevention in patients with hypercholesterolemia but without coronary artery disease to reduce the risk of MI, reduce the need for myocardial revascularization, and/or to reduce the risk of cardiovascular mortality.***For cerebral vasospasm prophylaxis� after aneurysmal subarachnoid hemorrhage.","***General Information***Alcoholism, hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Electrolyte imbalance, endocrine disease, females, hypotension, hypothyroidism, infection, myopathy, organ transplant, renal disease, renal failure, renal impairment, rhabdomyolysis, seizure disorder, surgery, trauma***Diabetes mellitus***Pregnancy***Contraception requirements, reproductive risk***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2105', '343027']",carmustine,"***For the treatment of brain tumors including malignant glioma and glioblastoma multiforme.***For the treatment of brain tumors including malignant glioma, glioblastoma, medulloblastoma, astrocytoma, ependymoma, and brain metastases. <br />  NOTE: Carmustine injection has been designated an orphan drug by the FDA for the treatment of intracranial malignancies.<br /***For the treatment of newly-diagnosed high grade malignant glioma as an adjunct to surgery and radiation and as an adjunct to surgery in patients with recurrent glioblastoma multiforme. <br />  NOTE: Carmustine implantable wafer has been designated an orphan drug by the FDA for the treatment of malignant glioma.<br /***For the treatment of multiple myeloma in combination with prednisone.***For the treatment of relapsed or refractory Hodgkin lymphoma or non-Hodgkin's lymphoma (NHL), in combination with other approved drugs.***For the first-line treatment of metastatic malignant melanoma in combination with dacarbazine, cisplatin, and tamoxifen�. <br />        NOTE: Since the major toxicity associated with carmustine administration is delayed bone marrow suppression, blood counts should be monitored weekly for at least 6 weeks after a dose and courses of carmustine should not be given more frequently than every 6 weeks.<br />     ***For the treatment of cutaneous T-cell lymphoma (CTCL)� (aka mycosis fungoides�).***For stem cell transplant preparation, in combination with other chemotherapy agents�.***Formoterol; Mometasone","***General Information***Anemia, aseptic meningitis, bleeding, bone marrow suppression, infection, leukopenia, neutropenia, thrombocytopenia***Pulmonary fibrosis, pulmonary toxicity***New primary malignancy***Extravasation***Intraarterial administration***Seizures***Wound dehiscence***Increased intracranial pressure***Renal disease, renal failure, renal impairment***Hepatic disease, hepatotoxicity***Children***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['519'],allopurinol,"***For the treatment of signs and symptoms of primary or secondary gout (i.e., acute attacks, tophi, joint destruction, uric acid lithiasis, and/or uric acid nephropathy). <br />        NOTE:�The lowest effective dose of allopurinol should be used to decrease the incidence of side effects.<br />NOTE: In transferring a patient from a uricosuric agent to allopurinol, the dose of the uricosuric agent should be gradually reduced over a period of several weeks and the allopurinol dose gradually increased to the required dose needed to maintain a normal serum uric acid concentration.<br />NOTE: Continuation of colchicine and/or anti-inflammatory agents is recommended during adjustment of the allopurinol dose until the serum uric acid concentration has been normalized and no acute gouty attacks have occurred for several months***For the prevention of acute hyperuricemia during chemotherapy or radiation treatment of leukemia, lymphoma, or solid tumors that may cause tumor lysis syndrome. <br />        NOTE: Intravenous allopurinol has been designated an orphan drug by the FDA for this indication.<br />NOTE: The correct dose and frequency of dosage for maintaining the serum uric acid concentration within the normal range are best determined by using the serum uric acid concentration as an index. Allopurinol is not recommended for the treatment of asymptomatic hyperuricemia. Discontinue allopurinol when the potential for overproduction of uric acid is no longer present***For the treatment of recurrent calcium oxalate nephrolithiasis (renal calculus) in males whose daily uric acid excretion exceeds 800 mg/day and in females whose daily uric acid excretion exceeds 750 mg/day. <br />        NOTE: Carefully assess each patient's situation initially and periodically to determine if treatment is beneficial and if the benefits outweigh the risks.<br />NOTE: Patients may also benefit from dietary changes such as an increased intake of oral fluids and dietary fiber and a decreased intake of animal protein, sodium, refined sugars, oxalate-rich foods, and excessive calcium","***General Information***Serious rash***Renal disease, renal failure, renal impairment***Hepatic disease, hepatotoxicity***Anticoagulant therapy, bone marrow suppression***Driving or operating machinery***Pregnancy***Breast-feeding***Infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],desogestrel/ethinyl estradiol,"***For routine contraception.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�,  abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Edema, hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3322'],diazepam,"***For the treatment of anxiety disorders or for the short-term relief of the symptoms of anxiety.***For the treatment of acute alcohol withdrawal.***For the treatment of muscle spasm due to local pathology such as muscle or joint inflammation or trauma; athetosis; stiff-man syndrome; tetanus; or spasticity due to upper motor neuron diseases such as cerebral palsy.***For the treatment of status epilepticus or for treatment of drug-induced seizures. <br />        NOTE: Many clinicians now prefer IV lorazepam over IV diazepam for the acute treatment of seizures.<br />     ***For adjunctive treatment of seizures other than status epilepticus in selected, refractory patients with partial seizures or generalized tonic-clonic seizures who require intermittent use of diazepam to control bouts of increased seizure activity.***For amnesia induction or for preprocedure sedation induction.***For the treatment of benzodiazepine withdrawal�.***For febrile seizure prophylaxis�.***For the treatment of agitation� in intensive care unit patients.***For the treatment of acute chloroquine overdose� in combination with epinephrine.***For the treatment of insomnia�.","***Benzodiazepine hypersensitivity***Extravasation, intraarterial administration***Bipolar disorder, depression, mania, psychosis, suicidal ideation***Abrupt discontinuation, substance abuse***Seizure disorder, seizures, status epilepticus***CNS depression, coma, driving or operating machinery, ethanol intoxication, shock***Children, infants, neonates***Closed-angle glaucoma***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, pulmonary disease, respiratory depression, respiratory insufficiency, sleep apnea***Labor, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease, hepatitis, jaundice***Neutropenia***Renal failure, renal impairment***Myasthenia gravis, neuromuscular disease, Parkinson's disease***Dementia, geriatric***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diclofenac sodium/misoprostol,***For the treatment of the signs and symptoms of osteoarthritis in patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications.***For the treatment of the signs and symptoms of rheumatoid arthritis in patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications.***Formoterol; Mometasone,"***General Information***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, geriatric, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Dental disease, dental work***Intramuscular injections***Acute bronchospasm, asthma, lactase deficiency, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Hepatic disease, jaundice, porphyria***Renal disease, renal failure, renal impairment***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, dehydration, diabetes mellitus, heart failure, hypertension, hypovolemia, myocardial infarction, peripheral vascular disease, rheumatoid arthritis, stroke, systemic lupus erythematosus (SLE), tachycardia, thromboembolism***Children***Labor, pregnancy, reproductive risk***Breast-feeding***Inflammatory bowel disease***Coronary artery bypass graft surgery (CABG)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3407'],digoxin,"***For ventricular rate control in patients with chronic atrial fibrillation and/or atrial flutter�; or for the treatment of narrow-complex paroxysmal supraventricular tachycardia (PSVT)� or for paroxysmal supraventricular tachycardia (PSVT) prophylaxis� in patients without a delta wave on ECG during sinus rhythm; or for the treatment of congestive heart failure. <br />        NOTE: In patients with undetectable serum digoxin concentrations, the total loading dose should be based on lean body weight and clinical response, and divided into several doses administered at 4- to 8-hour intervals. Higher doses (i.e., concentrations) may be required for treating arrhythmias than for treating heart failure. Patients with moderate-severe renal insufficiency should receive smaller loading doses than patients with normal renal function due to a reduced volume of distribution.<br />NOTE: Maintenance doses should be based on lean body weight, clinical response, and renal function. Higher doses (i.e., concentrations) may be required for treating arrhythmias than for treating heart failure. Lower doses should be considered for geriatric patients, patients with impaired renal function, and in patients whose lean weight is an abnormally small fraction of their total body mass because of obesity or edema. In 1 small study of men with NYHA class II or III heart failure who were in normal sinus rhythm, left ventricular function improved significantly on a dose of 0.125 mg/day that produced mean serum concentrations of 0.8 ng/mL but doses of 0.25 mg/day and corresponding higher concentrations of 1.5 ng/mL did not produce further improvement over the lower dosage. In another small study of men with NYHA class II or III heart failure who were in normal sinus rhythm, left ventricular ejection fraction improved significantly when digoxin was increased from a mean dose of 0.2 mg/day (mean trough 0.67 ng/mL) to a mean dose of 0.39 mg/day (mean trough 1.22 ng/mL); however, no significant changes were observed in heart failure score or exercise tolerance***For the transplacental treatment of fetal supraventricular tachyarrhythmias�.","***Acute myocardial infarction, Adams-Stokes syndrome, AV block, bradycardia, cardiomyopathy, cor pulmonale, hyperthyroidism, hypothyroidism, hypoxemia, myocarditis, myxedema, pulmonary disease, sick sinus syndrome***Carotid sinus hypersensitivity, ventricular arrhythmias, ventricular fibrillation, ventricular tachycardia, Wolff-Parkinson-White syndrome***Renal disease, renal failure, renal impairment***Geriatric***Hepatic disease***Constrictive pericarditis, idiopathic hypertrophic subaortic stenosis***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypocalcemia, hypokalemia, hypomagnesemia***Hypertension***Infants, neonates, premature neonates***Pregnancy***Breast-feeding***Diarrhea, malabsorption syndrome***Intramuscular administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['1256', '202559']",azathioprine,"***For kidney transplant rejection prophylaxis. <br />        NOTE: Complete blood counts including platelet counts are advised weekly during the first month of treatment, twice monthly for the second and third months of treatment, then monthly; more frequent monitoring may be necessary if the dose is altered or other therapy changes occur. Prompt reduction in dosage or temporary withdrawal of the drug may be necessary if there is a rapid fall in or persistently low leukocyte count or if other evidence of bone marrow depression exists. Early drug discontinuation is advisable for patients with abnormal CBC results that do not respond to dose reduction.<br />     ***For the treatment of active rheumatoid arthritis (RA) to reduce signs and symptoms. <br />        NOTE: Consider alternative therapies for patients who have low or absent thiopurine S-methyltransferase (TPMT) activity (see Contraindications). Dosage reduction is recommended in patients with reduced TPMT activity.<br />NOTE: Aspirin, nonsteroidal anti-inflammatory drugs, and/or low dose glucocorticoids may be continued during treatment with azathioprine. Use of azathioprine with disease modifying antirheumatic drugs cannot be recommended; combined use has not been studied.<br />NOTE: Patients with rheumatoid arthritis previously treated with alkylating agents such as cyclophosphamide, chlorambucil, or melphalan may have a prohibitive risk of neoplasia if treated with azathioprine***For the treatment of serious manifestations of Behcet's syndrome�.***For the treatment of refractory Crohn's disease�.***For the treatment of steroid-resistant or steroid-dependent ulcerative colitis�.***For the treatment of lupus nephritis�.***For the treatment of systemic lupus erythematosus (SLE)�.***For the treatment of dermatomyositis� or polymyositis�.***For the treatment of Wegener's granulomatosis�.***For the treatment of immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP)�.***For the treatment of myasthenia gravis� in patients who are poorly controlled with cholinesterase inhibitor therapy.***For remission maintenance of autoimmune hepatitis�.***For the treatment of idiopathic pulmonary fibrosis�.***For the treatment of atopic dermatitis�.***For the treatment of psoriasis�. <br />        NOTE: Azathioprine should generally be reserved for psoriatic patients who have failed multiple other therapies due to the potential for severe adverse effects.<br />     ***Formoterol; Mometasone","***General Information***Black patients, Caucasian patients, thiopurine methyltransferase (TPMT) deficiency***Bone marrow suppression***Intramuscular injections***Hepatic disease***Inflammatory bowel disease, lymphoma, new primary malignancy, requires an experienced clinician, rheumatoid arthritis, sunlight (UV) exposure***Renal disease, renal impairment***Pregnancy***Breast-feeding***Children, vaccination***Immunosuppression, infection, progressive multifocal leukoencephalopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dexmethylphenidate hydrochloride,***For the treatment of attention-deficit hyperactivity disorder (ADHD).,"***General Information***Anxiety, bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Tics, Tourette's syndrome***Glaucoma, visual disturbance***Abrupt discontinuation, alcoholism, anorexia nervosa, obesity treatment, substance abuse***Hypertension, tachycardia, ventricular arrhythmias***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular dysfunction***Cerebrovascular disease, stroke***Children, growth inhibition, infants***Hyperthyroidism, thyrotoxicosis***Seizure disorder, seizures***Pregnancy***Breast-feeding***Driving or operating machinery***Surgery***Radiographic contrast administration***Hepatic disease***Geriatric***MAOI therapy***Peripheral vascular disease, Raynaud's phenomenon",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydroxyzine hydrochloride,"***For the short-term treatment of anxiety, tension, and psychomotor agitation in conditions of emotional stress.***For the treatment of pruritus due to histamine-mediated conditions or due to allergic conditions like chronic urticaria (e.g., chronic idiopathic urticaria), atopic dermatitis or contact dermatitis.***For post-operative nausea/vomiting (PONV) and post-operative nausea/vomiting (PONV) prophylaxis.***For procedural sedation or adjunctively for pre-and postoperative or pre-and post-partum therapy to permit dosage reduction of narcotic analgesia.***For the short term treatment of insomnia�.***For the treatment of allergic rhinitis� and for allergic rhinitis prophylaxis�.***Formoterol***Formoterol; Mometasone","***Hydroxyzine hypersensitivity***Asthma, chronic obstructive pulmonary disease (COPD)***Bradycardia, cardiac disease, electrolyte imbalance, heart failure, hypokalemia, hypomagnesemia, long QT syndrome, myocardial infarction, QT prolongation, torsade de pointes, ventricular arrhythmias***Closed-angle glaucoma, contact lenses***Ileus, prostatic hypertrophy, urinary retention***Dialysis, renal failure, renal impairment***Biliary cirrhosis, hepatic disease***Labor, pregnancy***Breast-feeding***Infants, neonates, premature neonates***Anticholinergic medications, geriatric***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion, ethanol intoxication***Intravenous administration, subcutaneous administration, tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amiodarone hydrochloride,"***For the treatment of life-threatening recurrent ventricular fibrillation or hemodynamically unstable (symptomatic) sustained ventricular tachycardia, including post-myocardial infarction (MI) patients. <br />        NOTE: See resuscitation indication for ECC/AHA dosage and administration guidelines for ventricular fibrillation or pulseless ventricular tachycardia.<br />NOTE: Amiodarone is FDA-approved for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy***For the treatment of ventricular arrhythmias during cardiopulmonary resuscitation� (CPR).***For cardiac arrest associated with ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) unresponsive to CPR.***For hemodynamically stable ventricular tachycardia (monomorphic or polymorphic) or wide-complex tachycardia of unknown origin during CPR (perfusing ventricular arrhythmias).***For the treatment of atrial fibrillation�, atrial flutter�, or paroxysmal supraventricular tachycardia (PSVT)�.***For primary atrial fibrillation prophylaxis� in patients receiving cardiac surgery�. <br />        NOTE: Amiodarone is listed as an alternative treatment option to other frontline treatment strategies (e.g., beta-blockers) for the prevention of atrial fibrillation after coronary artery bypass graft (CABG) surgery. <br />     ***For the prevention of sudden cardiac death in patients with heart failure�.***Formoterol***Formoterol; Mometasone","***Iodine hypersensitivity***Cardiogenic shock, heart failure, hypotension, hypovolemia, ventricular dysfunction***Alcoholism, arrhythmia exacerbation, AV block, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, hypertension, hypocalcemia, long QT syndrome, malnutrition, mortality, myocardial infarction, QT prolongation, requires an experienced clinician***Amiodarone-induced lung toxicity, chronic obstructive pulmonary disease (COPD), pneumonitis, pulmonary disease, pulmonary fibrosis, respiratory distress syndrome, respiratory insufficiency, surgery***Amiodarone-induced liver toxicity, hepatic disease, hepatitis, hepatotoxicity***Diarrhea, electrolyte imbalance, hypokalemia, hypomagnesemia***Goiter, hyperthyroidism, hypothyroidism, thyroid disease, thyrotoxicosis***Cataracts, Fabry disease, optic neuritis, visual disturbance***Geriatric***Neurological disease, peripheral neuropathy***Sunlight (UV) exposure***Halothane anesthesia***Benzyl alcohol hypersensitivity, children, infants, neonates***Pregnancy***Breast-feeding***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2623', '202859']",clotrimazole,"***For the treatment of candidiasis, specifically mucocutaneous candidiasis (i.e., oropharyngeal candidiasis (thrush), vulvovaginal candidiasis).***For the treatment of oropharyngeal candidiasis (thrush).***For the treatment of vulvovaginal candidiasis (VVC).***For candidiasis prophylaxis to reduce the incidence of oropharyngeal candidiasis in immunocompromised patients undergoing chemotherapy or radiotherapy in the treatment of leukemia or solid tumors, or in allograft transplant patients who are receiving corticosteroid therapy.***For the treatment of tinea corporis, tinea cruris, and tinea pedis.***For the treatment of fungal otitis externa�.","***Onychomycosis***Pregnancy***Breast-feeding***Contraceptive devices, menstruation***Azole antifungals hypersensitivity***Abdominal pain, diabetes mellitus, fever, human immunodeficiency virus (HIV) infection, immunosuppression, vaginal discharge***Children, infants, neonates***Ocular exposure, ophthalmic administration***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1227'],auranofin,"***For the treatment of active rheumatoid arthritis in patients who have had an insufficient therapeutic response to or are intolerant of an adequate trial of full doses of at least one nonsteroidal anti-inflammatory drug. <br />        NOTE: Add auranofin to a comprehensive baseline program that includes non-drug therapies.<br />NOTE: Improvement may not be observed before 6 months of use. Gold cannot reverse existing structural damage; best efficacy may occur in patients with active synovitis.<br />NOTE: Discontinuation of injectable gold and initiation of auranofin 6 mg PO daily led to similar disease control 6 months after the switch from injectable to oral gold receipt as compared with patients who remained on injectable gold.<br />NOTE: Obtain a complete blood count (CBC) with differential and platelet count, urinalysis, and renal and hepatic function tests before auranofin initiation. During therapy, obtain a CBC with differential and platelet count and urinalysis at least monthly","***General Information***Benzyl alcohol hypersensitivity***Lactase deficiency***Agranulocytosis, anemia, bleeding, bone marrow suppression, diarrhea, exfoliative dermatitis, gold toxicity, hematological disease, hematuria, hepatic disease, inflammatory bowel disease, leukopenia, necrotizing enterocolitis, neutropenia, proteinuria, pulmonary fibrosis, renal disease, renal failure, renal impairment, requires an experienced clinician, serious rash, stomatitis, thrombocytopenia***Breast-feeding***Pregnancy***Children, infants***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydroxyzine hydrochloride,"***For the short-term treatment of anxiety, tension, and psychomotor agitation in conditions of emotional stress.***For the treatment of pruritus due to histamine-mediated conditions or due to allergic conditions like chronic urticaria (e.g., chronic idiopathic urticaria), atopic dermatitis or contact dermatitis.***For post-operative nausea/vomiting (PONV) and post-operative nausea/vomiting (PONV) prophylaxis.***For procedural sedation or adjunctively for pre-and postoperative or pre-and post-partum therapy to permit dosage reduction of narcotic analgesia.***For the short term treatment of insomnia�.***For the treatment of allergic rhinitis� and for allergic rhinitis prophylaxis�.***Formoterol***Formoterol; Mometasone","***Hydroxyzine hypersensitivity***Asthma, chronic obstructive pulmonary disease (COPD)***Bradycardia, cardiac disease, electrolyte imbalance, heart failure, hypokalemia, hypomagnesemia, long QT syndrome, myocardial infarction, QT prolongation, torsade de pointes, ventricular arrhythmias***Closed-angle glaucoma, contact lenses***Ileus, prostatic hypertrophy, urinary retention***Dialysis, renal failure, renal impairment***Biliary cirrhosis, hepatic disease***Labor, pregnancy***Breast-feeding***Infants, neonates, premature neonates***Anticholinergic medications, geriatric***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion, ethanol intoxication***Intravenous administration, subcutaneous administration, tissue necrosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydrocortisone acetate/pramoxine hydrochloride,"***For the temporary relief of skin inflammation, pain, and pruritus associated with corticosteroid-responsive dermatitis, including psoriasis, anorectal inflammation, pain, pruritus, and swelling associated with hemorrhoids, proctitis, cryptitis, anal fissures, postoperative pain, and pruritus ani.***For the adjunctive treatment of chronic ulcerative colitis� when disease is limited to the distal portion of the rectum (e.g., proctosigmoiditis).","***Fungal infection, herpes infection, infection, peripheral vascular disease, tuberculosis, viral infection***Hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, infants, neonates***Geriatric, skin atrophy***Diabetes mellitus***Cataracts, glaucoma, ocular exposure, ophthalmic administration***Pregnancy***Breast-feeding***Hepatic disease***Fistula, GI obstruction, GI perforation, peritonitis, ulcerative colitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4053'],erythromycin,"***For the treatment of acne vulgaris.***For mild to moderately severe lower respiratory tract infections (e.g., pneumonia, bronchitis) caused by susceptible organisms.***For the treatment of Legionnaire's disease (caused by <em>Legionella pneumophila</em>).***For the treatment of mild to moderately severe upper respiratory tract infections (e.g., pharyngitis, tonsillitis), including group A beta-hemolytic streptococcal (GAS) pharyngitis (primary rheumatic fever prophylaxis).***For upper respiratory tract infections and GAS pharyngitis (primary rheumatic fever prophylaxis).***For prevention of recurrent attacks of rheumatic fever (i.e., secondary rheumatic fever prophylaxis).***For the treatment of listeriosis.***For the treatment of chlamydia infection and non-gonococcal urethritis.***For the treatment of non-gonococcal urethritis (NGU) or chlamydial infections including urogenital infections (urethritis, cervicitis, proctitis) and infant pneumonia.***For the treatment of chlamydial conjunctivitis or ophthalmia neonatorum caused by <em>Chlamydia trachomatis</em>.***For the treatment of lymphogranuloma venereum� caused by <em>Chlamydia trachomatis</em>.***For the prevention of ophthalmia neonatorum (i.e., ophthalmia neonatorum prophylaxis) due to <em>Neisseria gonorrhoeae</em><em> </em>or<em> Chlamydia trachomatis</em>.***For the treatment of pneumonia caused by <em>Chlamydia trachomatis</em> in neonates and infants.***For the adjunctive treatment of diphtheria to prevent establishment of carrier state and for <em>Corynebacterium diphtheriae</em> bacterial colonization eradication.***For the treatment of close contacts of patients with diphtheria (i.e., diphtheria prophylaxis�).***For the treatment of acute pelvic inflammatory disease (PID).***For acute pelvic inflammatory disease (PID) caused by <em>Neisseria gonorrhoeae</em>.***For the treatment of pertussis (whooping cough) caused by <em>Bordetella pertussis</em> or for postexposure pertussis prophylaxis. <br />  NOTE: For postexposure prophylaxis, administer to close contacts within 3 weeks of exposure, especially in high-risk patients (e.g., women in third trimester, infants &lt; 12 months).<br /***For the treatment of primary syphilis (caused by <em>Treponema pallidum</em>) in penicillin-allergic, nonpregnant patients.***For bowel preparation in combination with neomycin in patients undergoing colorectal surgery.***For the treatment of superficial ophthalmic infection involving the conjunctiva and/or cornea.***For the treatment of chancroid� due to <em>Haemophilus ducreyi</em>.***For the treatment of disseminated gonorrhea�. <br />  NOTE: Erythromycin is not recommended in adults, adolescents, or children 8 years and older or in patients weighing 45 kg or more due to resistance of N. gonorrheae against erythromycin in the United States. Single-dose azithromycin in combination with ceftriaxone is the preferred therapy in these populations. <br /***For the facilitation of gastric emptying in patients with delayed gastrointestinal motility  (e.g., gastroparesis�).***For the treatment of idiopathic or postsurgical gastroparesis� or diabetic gastroparesis�.***For the facilitation of gastric emptying� in patients with feeding intolerance�.***For the treatment of early Lyme disease�.***For the treatment of skin and skin structure infections including impetigo and burn wound infection�.***For the treatment of erythrasma (caused by <em>Corynebacterium minutissimum</em>).***For the treatment of tetanus� (caused by <em>Clostridium tetani</em>) when penicillin or tetracycline is contraindicated or not tolerated.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of cholera�.***For the treatment of bartonellosis� (<em>Bartonella bacilliformis)</em> and other <em>Bartonella sp.</em>� infections in HIV-infected patients.***For the treatment of angiomatosis infections�, peliosis hepatis�, bacteremia�, and osteomyelitis� caused by <em>Bartonella sp.</em>�.***For long term suppression� of infections caused by <em>Bartonella sp.</em>� in HIV-infected patients with relapse or reinfections with < 200 CD4 cells/mm3.***For pneumococcal prophylaxis� in penicillin-allergic patients with sickle cell disease�.***For the treatment of infantile acne�.***For the oral treatment of infantile acne.***For the topical treatment of infantile acne.***Formoterol***Formoterol; Mometasone","***General Information***Viral infection***Macrolide hypersensitivity***Hepatic disease***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Hearing impairment***Benzyl alcohol hypersensitivity, neonates***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Seizure disorder***Myasthenia gravis***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,influenza vaccine,***For annual seasonal influenza prophylaxis.,"***General Information***Intravenous administration, subcutaneous administration***Fever, respiratory infection***Egg hypersensitivity, kanamycin hypersensitivity, latex hypersensitivity, neomycin hypersensitivity***Guillain-Barre syndrome***Geriatric***Children, infants***Pregnancy***Breast-feeding***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Acquired immunodeficiency syndrome (AIDS), agammaglobulinemia, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Syncope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],estradiol,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For systemic treatment of the vasomotor symptoms (hot flashes) and genitourinary symptoms of menopause.***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For estrogen replacement for premenopausal women with primary ovarian failure or female hypogonadism.***For the palliative treatment of advanced inoperable prostate cancer.***For the palliative treatment of breast cancer that is inoperable and progressive in selected men and postmenopausal women.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates***Intravenous administration***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['9997'],spironolactone,"***For the treatment of hypertension.***For the treatment of hypokalemia.***For hypokalemia prevention in patients taking digoxin.***For the treatment of heart failure.***For the treatment of edema (e.g., due to nephrotic syndrome, congestive heart failure, or hepatic cirrhosis).***For primary hyperaldosteronism diagnosis.***For the treatment of primary hyperaldosteronism.***For the treatment of pulmonary edema� due to chronic lung disease (CLD)�.***For the treatment of symptoms of bloating and weight gain associated with premenstrual syndrome (PMS)�.***For the treatment of polycystic ovary syndrome�.***For the treatment of female hirsutism�.***For the treatment of acne vulgaris�.***Formoterol; Mometasone","***Adrenal insufficiency, anuria, diabetes mellitus, hyperkalemia, renal disease, renal failure, renal impairment***Acid/base imbalance, metabolic acidosis, metabolic alkalosis, respiratory acidosis***Ascites, biliary cirrhosis, hepatic disease***Menstrual irregularity***New primary malignancy, tumorigenicity***Prostate cancer***Driving or operating machinery***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4815']['6809'],glyburide/metformin hydrochloride,"***For the treatment of type 2 diabetes mellitus uncontrolled by diet alone.***For use as initial antidiabetic therapy in previously untreated patients.***For use when initial treatment with either glyburide or metformin alone do not result in adequate glycemic control.***For patients already on a combination of sulfonylurea-metformin who desire to switch to the combination tablet.***For use in combination with a thiazolidinedione (e.g., rosiglitazone, pioglitazone), in patients already receiving Glucovance therapy and who require additional glycemic control.","***Sulfonylurea hypersensitivity***Sulfonamide hypersensitivity***Diabetic ketoacidosis, type 1 diabetes mellitus***Acidemia, hypoxemia, lactic acidosis, metabolic acidosis***Diarrhea, vomiting***Renal disease, renal failure, renal impairment***Acute heart failure, acute myocardial infarction, cardiac disease, cardiogenic shock, heart failure***Alcoholism, ethanol ingestion, ethanol intoxication, hepatic disease***Radiographic contrast administration***Burns, dehydration, fever, infection, sepsis, surgery, trauma***Adrenal insufficiency, gastroparesis, GI obstruction, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypothyroidism, ileus, malnutrition, pituitary insufficiency***Geriatric***Neonates, obstetric delivery, polycystic ovary syndrome, pregnancy***Breast-feeding***Children***Pernicious anemia***G6PD deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8987'],pyrazinamide,***For the treatment of tuberculosis infection in combination with other antitubercular agents.,"***General Information***Alcoholism, hepatic disease, hepatitis, jaundice***Gout, hyperuricemia***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"meningococcal polysaccharide vaccine, groups A, C, Y and W-135 combined","***For meningococcal infection prophylaxis due to Neisseria meningitidis serogroup A, C, Y, and W-135.","***Latex hypersensitivity, thimerosal hypersensitivity***Fever, infection***Agammaglobulinemia, corticosteroid therapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Intramuscular administration, intravenous administration***Children, infants, neonates***Pregnancy***Breast-feeding***Guillain-Barre syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,etoposide phosphate,"***For the treatment of testicular cancer.***For the treatment of refractory testicular cancer, in combination with other chemotherapeutic agents.***For the treatment of small cell lung cancer (SCLC).***For the first-line treatment of SCLC, in combination with other chemotherapeutic agents.***For the treatment of extensive disease SCLC in combination with carboplatin�.***For the treatment of limited disease SCLC in combination with carboplatin and radiation therapy�.***For the treatment of newly-diagnosed small cell lung cancer (SCLC) in combination with cyclophosphamide and doxorubicin.***For the treatment of non-small cell lung cancer (NSCLC)�.***For the adjuvant treatment of resected stage IB�III non-small cell lung cancer (NSCLC) in combination with cisplatin�.***For the treatment of stage IIIB non-small cell lung cancer (NSCLC) in combination with cisplatin and concurrent radiotherapy�.***For the treatment of high-risk gestational trophoblastic disease�.***For the treatment of acute lymphocytic leukemia (ALL)�.***For the treatment of relapsed or refractory ALL, in combination with cyclophosphamide and clofarabine�.***For the treatment of relapsed or refractory acute lymphocytic leukemia (ALL) in combination with ifosfamide, carboplatin, and rituximab�.***For the treatment of refractory acute myelogenous leukemia (AML)� in combination with mitoxantrone and cytarabine.***For the treatment of Hodgkin lymphoma�.***For the treatment of Hodgkin lymphoma as part of the Stanford V regimen.***For the treatment of Hodgkin lymphoma as part of the BEACOPP regimen.***For the treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL)� in combination with ifosfamide and carboplatin.***For stem cell transplant preparation and bone marrow ablation�.***For stem cell mobilization in combination with ifosfamide and carboplatin, in transplant eligible patients with non-Hodgkin's lymphoma.***For stem cell transplant preparation and bone marrow ablation for allogeneic hematopoietic stem cell transplantation, in combination with total body irradiation�.***For the treatment of neuroblastoma�.***For the treatment of intermediate-risk neuroblastoma in combination with carboplatin, cyclophosphamide, doxorubicin�.***For the treatment of localized and unresectable neuroblastoma in combination with cisplatin, alternating with cyclophosphamide, vincristine, and doxorubicin�.***For the treatment of refractory desmoid tumor� and fibromatosis�.***For the first-line treatment of unresectable, advanced thymoma�.***For the first-line treatment of unresectable, advanced thymoma in combination with cisplatin�.***For the first-line treatment of unresectable, advanced thymoma in combination with cisplatin and ifosfamide�.***For the first-line treatment of unresectable, advanced thymic carcinoma�, in combination with cisplatin and ifosfamide.***For the treatment of poor-risk relapsed Wilms' tumor in combination with ifosfamide and carboplatin�.***For the treatment of newly diagnosed Ewing's sarcoma� family tumors, in combination with ifosfamide, alternating with vincristine, doxorubicin, and cyclophosphamide.","***Infusion-related reactions***Bleeding, bone marrow suppression, infection, neutropenia, requires an experienced clinician, thrombocytopenia***Extravasation***Hepatic disease, hypoalbuminemia***Renal disease, renal impairment***New primary malignancy***Geriatric***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['19831'],budesonide,"***For the management of nasal symptoms associated with perennial vasomotor rhinitis.***For the management of nasal symptoms associated with allergic rhinitis.***For maintenance treatment of asthma as prophylactic therapy (bronchospasm prophylaxis). <br />        NOTE: Budesonide is not indicated for the treatment of acute bronchospasm.<br />     ***For mild to moderate Crohn's disease involving the ileum and/or ascending colon.***For active disease in patients not previously receiving oral prednisolone.***For active disease in patients previously receiving oral prednisolone.***For maintenance of clinical remission for up to 3 months. <br />  NOTE: A Crohn�s Disease Activity Index (CDAI) less than 150 after 8 weeks of treatment for active disease is recommended before maintenance treatment is initiated.<br /***For the induction of remission in patients with active, mild to moderate ulcerative colitis.***For the treatment of laryngotracheobronchitis (croup)�.***For the treatment of collagenous colitis� (a form of microscopic colitis).***For exercise-induced bronchospasm prophylaxis�.","***General Information***Acute bronchospasm, milk protein hypersensitivity, status asthmaticus***Fungal infection, herpes infection, immunosuppression, infection, ocular infection, tuberculosis, viral infection***Measles, varicella***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Abrupt discontinuation, adrenal insufficiency, corticosteroid withdrawal, hypothalamic-pituitary-adrenal (HPA) suppression***Gastroenteritis, surgery, trauma***Cushing's syndrome, hypercortisolism***Nasal septal perforation, nasal surgery, nasal trauma***Malnutrition, osteoporosis, tobacco smoking***Edema, heart failure, hypertension***Diabetes mellitus, hyperglycemia, hyperthyroidism, hypothyroidism, psychosis, renal disease, seizure disorder, thyroid disease***Diverticulitis, GI disease, GI perforation, hepatic disease, peptic ulcer disease***Cataracts, glaucoma, increased intraocular pressure, visual disturbance***Myasthenia gravis***Corticosteroid hypersensitivity***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,desmopressin acetate,"***For the management of patients with central diabetes insipidus (neurohypophyseal diabetes insipidus) including polydipsia and polyuria which occurs following head surgery or trauma.***For the treatment of primary nocturnal enuresis.***For the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.***For the management of spontaneous bleeding or trauma-induced hemorrhage (e.g., hemarthrosis, intramuscular hematomas, or mucosal bleeding, uremic bleeding�) or for bleeding prophylaxis (e.g., surgical bleeding) in selected patients.***Formoterol; Mometasone","***General Information***Renal disease, renal failure, renal impairment***Children, cystic fibrosis, diarrhea, electrolyte imbalance, fever, hyponatremia, infection, vomiting***Angina, cardiac disease, coronary artery disease, heart failure, hypertension, increased intracranial pressure, thromboembolic disease, urinary retention***Von Willebrand's disease***Nasal surgery, nasal trauma***Geriatric***Pregnancy***Breast-feeding***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,tramadol hydrochloride,"***For the treatment of moderate pain or moderately severe pain.***For moderate chronic pain or moderately severe chronic pain in patients requiring continuous, around-the-clock treatment for an extended period of time.***For the adjuvant treatment of arthralgia� associated with osteoarthritis�.***For the treatment of diabetic neuropathy�.***For postherpetic neuralgia�.***For the treatment of postoperative shivering�.","***Lactase deficiency***Opiate agonist hypersensitivity, polysorbate 80 hypersensitivity***Accidental exposure, acute intoxication of CNS depressants, ethanol ingestion, ethanol intoxication, potential for overdose or poisoning***Asthma, coadministration with other CNS depressants, respiratory depression***Head trauma, increased intracranial pressure, seizure disorder, seizures***Acute abdomen, biliary tract disease, constipation, diarrhea, GI disease, GI obstruction, ileus, pancreatitis, ulcerative colitis***Alcoholism, depression, substance abuse, suicidal ideation***Abrupt discontinuation***Renal disease, renal failure, renal impairment***Hepatic disease***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Infertility, reproductive risk***Geriatric***Adenoidectomy, children, infants, neonates, neuromuscular disease, obesity, pulmonary disease, sleep apnea, tonsillectomy***Driving or operating machinery***MAOI therapy***Phenylketonuria***Adrenal insufficiency, hypothyroidism, myxedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['720825'],silodosin,***For the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). <br />        NOTE: Silodosin is not indicated for the treatment of hypertension.<br />     ,"***General Information***Driving or operating machinery***Hypotension, orthostatic hypotension, syncope***Renal disease, renal failure, renal impairment***Geriatric***Prostate cancer***Hepatic disease***Females, pregnancy***Children, infants, neonates***Ocular surgery***Breast-feeding***Priapism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dextromethorphan polistirex,"***For temporary relief of cough; especially useful for non-productive cough due to minor throat and bronchial irritation associated with the common cold, inhaled irritants, or chronic bronchitis.***For the treatment of painful diabetic neuropathy�.","***Asthma, emphysema, tobacco smoking***Hepatic disease***Children, infants***Pregnancy***Breast-feeding***Driving or operating machinery***MAOI therapy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,econazole nitrate,"***For the treatment of tinea cruris, tinea corporis, or tinea versicolor caused by susceptible fungi.***For the treatment of cutaneous candidiasis.***For the treatment of tinea pedis caused by susceptible fungi.","***Ophthalmic administration, vaginal administration***Pregnancy***Breast-feeding***Children, infants, neonates***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,tizanidine hydrochloride,"***For the acute and intermittent management of increased muscle tone associated with spasticity (including spasticity related to multiple sclerosis or spinal cord injury). <br />        NOTE: Because of its short duration, tizanidine should be reserved for activities and times when spasticity control is most important. Use tizanidine with caution when spasticity is beneficial to obtain increased function or to sustain posture and balance during movement.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Hypotension***Renal failure, renal impairment***Hepatic disease***Driving or operating machinery***Psychosis***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Abrupt discontinuation***Labor, obstetric delivery, pregnancy***Breast-feeding***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,polyethylene glycol 3350/potassium chloride/sodium bicarbonate/sodium chloride/sodium sulfate,"***For use as a bowel evacuant to clean the colon prior to colonoscopy or barium enema X-ray examination (bowel preparation). <br />        NOTE: Patients should be well hydrated before, during, and after the colon preparation. The first bowel movement should occur approximately 1 hour after the start of solution administration.<br />     ***For dosing in adults and/or adolescents.***For dosing in children and older infants.***For the treatment of chronic constipation�. <br />        NOTE: This product should be used for 2 weeks or less or as directed by the prescriber.<br />     ","***General Information***Abdominal pain, acute abdomen, appendicitis, colitis, dehydration, GI obstruction, GI perforation, ileus, inflammatory bowel disease, toxic megacolon, ulcerative colitis, vomiting***Electrolyte imbalance, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, seizure disorder, seizures***Children, infants, neonates***Pregnancy***Breast-feeding***Coma, dementia, dysphagia, esophageal stricture, gag reflex depression***Angina, cardiac arrhythmias, cardiomyopathy, heart failure, myocardial infarction, QT prolongation***Renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydrocortisone acetate/pramoxine hydrochloride,"***For the temporary relief of skin inflammation, pain, and pruritus associated with corticosteroid-responsive dermatitis, including psoriasis, anorectal inflammation, pain, pruritus, and swelling associated with hemorrhoids, proctitis, cryptitis, anal fissures, postoperative pain, and pruritus ani.***For the adjunctive treatment of chronic ulcerative colitis� when disease is limited to the distal portion of the rectum (e.g., proctosigmoiditis).","***Fungal infection, herpes infection, infection, peripheral vascular disease, tuberculosis, viral infection***Hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, infants, neonates***Geriatric, skin atrophy***Diabetes mellitus***Cataracts, glaucoma, ocular exposure, ophthalmic administration***Pregnancy***Breast-feeding***Hepatic disease***Fistula, GI obstruction, GI perforation, peritonitis, ulcerative colitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,antihemophilic factor (human),"***For the prevention and control of hemorrhage in patients with hemophilia A (classical hemophilia). <br />        NOTE: Humate, Kogenate, and ReFacto have been designated by the FDA as orphan drugs for the prophylaxis and management of hemorrhage or hemarthrosis in patients with hemophilia A.<br /> <br />NOTE: Guidelines for the treatment of acute bleeding and prevention of bleeding during surgery vary. For all indications, the dose of antihemophilic factor should be individualized taking into consideration the seriousness of the bleed or procedure, the clinical status of the patient, and the factor VIII activity concentration***For minor bleeding including early muscle bleed, early hemarthrosis, and oral bleeds.***For moderate bleeding including advanced muscle bleed, extensive hemarthrosis, hematoma, and mild head trauma.***For life- or limb-threatening bleeding including surgical bleeding, gastrointestinal bleeding, neck, tongue or pharyngeal hematoma with potential for airway compromise, intracranial, intraabdominal, or intrathoracic bleeding, or fractures.***For bleeding in patients with hemophilia A and factor VIII inhibitor titers less than 10 Bethesda Units and with low anamnestic responses.***For the perioperative management of surgical bleeding (surgical bleeding prophylaxis) in patients with hemophilia A.***For routine bleeding prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A.***For the management of hemorrhage or hemarthrosis in patients with von Willebrand's disease (vWD). <br />        NOTE: Humate-P has been designated by the FDA as orphan drugs for this indication.<br />     ***For major hemorrhage in patients with mild vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma or traumatic hemorrhage).***For minor hemorrhage in patients with moderate to severe vWD type I, type II, and type III (e.g., epistaxis, oral bleeding, or menorrhagia).***For major hemorrhage in patients with moderate to severe vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For major hemorrhage in patients with vWD type II and III (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For surgical bleeding prophylaxis during major or minor procedures in patients with vWD in whom desmopressin is either ineffective or contraindicated. <br />          NOTE: Alphanate and Humate-P have been designated by the FDA as orphan drugs for this indication.<br />       ","***General Information***Pregnancy***Breast-feeding***Thromboembolic disease***Hepatitis, infection, viral infection***Anemia***Bovine protein hypersensitivity, hamster protein hypersensitivity, latex hypersensitivity, mannitol hypersensitivity, murine protein hypersensitivity, polysorbate 80 hypersensitivity***Porcine protein hypersensitivity***Human immunodeficiency virus (HIV) infection***Cardiac disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clobetasol propionate,"***For the treatment of moderate-to-severe inflammatory manifestations, including pruritus, of corticosteroid-responsive dermatologic disorders such as alopecia areata, atopic dermatitis, contact dermatitis, generalized exfoliative dermatitis, Rhus dermatitis due to plants like poison ivy, seborrheic dermatitis, eczema (including severe hyperkeratotic eczema, severe nummular eczema, and severe eczematous conditions of the hands or feet), granuloma annulare, keloids, cutaneous lichen planus, lichen simplex chronicus, lichen striatus, subacute cutaneous and discoid lupus erythematosus, pretibial myxedema, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, sarcoidosis, sunburn, or urticaria. <br />        NOTE: Acute exudative inflammation, as occurs with poison ivy, may be best treated with a non-emollient cream or gel formulation, which are drying. Dry, scaly dermatoses may be best treated with emollient creams or ointments. Lower potency corticosteroids should be used on the face and intertriginous areas.<br />NOTE: Systemic therapy or intralesional injection of corticosteroids may be necessary for some conditions based on the type and severity of the disorder or inadequate response to topical therapy***For the treatment of plaque-type psoriasis.***For the alternative treatment of recalcitrant oral vesiculoerosive disease� including oral lichen planus�, mucous membrane pemphigus�, aphthous ulcer� and chronic oral erythema multiforme�.***For the treatment of vulvar lichen sclerosus�.***For the alternative treatment of vision-threatening periocular capillary hemangioma� in infancy and early childhood.","***Corticosteroid hypersensitivity***Cushing's syndrome, hepatic disease, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Diabetes mellitus***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Fungal infection, herpes infection, infection, measles, peripheral vascular disease, varicella, viral infection***Acne rosacea, acne vulgaris, cataracts, glaucoma, ocular exposure, ophthalmic administration, perioral dermatitis***Geriatric, skin atrophy***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,antihemophilic factor (recombinant),"***For the prevention and control of hemorrhage in patients with hemophilia A (classical hemophilia). <br />        NOTE: Humate, Kogenate, and ReFacto have been designated by the FDA as orphan drugs for the prophylaxis and management of hemorrhage or hemarthrosis in patients with hemophilia A.<br /> <br />NOTE: Guidelines for the treatment of acute bleeding and prevention of bleeding during surgery vary. For all indications, the dose of antihemophilic factor should be individualized taking into consideration the seriousness of the bleed or procedure, the clinical status of the patient, and the factor VIII activity concentration***For minor bleeding including early muscle bleed, early hemarthrosis, and oral bleeds.***For moderate bleeding including advanced muscle bleed, extensive hemarthrosis, hematoma, and mild head trauma.***For life- or limb-threatening bleeding including surgical bleeding, gastrointestinal bleeding, neck, tongue or pharyngeal hematoma with potential for airway compromise, intracranial, intraabdominal, or intrathoracic bleeding, or fractures.***For bleeding in patients with hemophilia A and factor VIII inhibitor titers less than 10 Bethesda Units and with low anamnestic responses.***For the perioperative management of surgical bleeding (surgical bleeding prophylaxis) in patients with hemophilia A.***For routine bleeding prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A.***For the management of hemorrhage or hemarthrosis in patients with von Willebrand's disease (vWD). <br />        NOTE: Humate-P has been designated by the FDA as orphan drugs for this indication.<br />     ***For major hemorrhage in patients with mild vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma or traumatic hemorrhage).***For minor hemorrhage in patients with moderate to severe vWD type I, type II, and type III (e.g., epistaxis, oral bleeding, or menorrhagia).***For major hemorrhage in patients with moderate to severe vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For major hemorrhage in patients with vWD type II and III (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For surgical bleeding prophylaxis during major or minor procedures in patients with vWD in whom desmopressin is either ineffective or contraindicated. <br />          NOTE: Alphanate and Humate-P have been designated by the FDA as orphan drugs for this indication.<br />       ","***General Information***Pregnancy***Breast-feeding***Thromboembolic disease***Hepatitis, infection, viral infection***Anemia***Bovine protein hypersensitivity, hamster protein hypersensitivity, latex hypersensitivity, mannitol hypersensitivity, murine protein hypersensitivity, polysorbate 80 hypersensitivity***Porcine protein hypersensitivity***Human immunodeficiency virus (HIV) infection***Cardiac disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydralazine hydrochloride,***For the treatment of hypertension.***For the treatment of hypertensive emergency or hypertensive urgency.***For the treatment of hypertension associated with severe preeclampsia or eclampsia.***For the treatment of congestive heart failure� in patients with systolic dysfunction.,"***Slow acetylation, systemic lupus erythematosus (SLE)***Renal failure, renal impairment***Acute myocardial infarction, angina, coronary artery disease, heart failure, myocardial infarction, rheumatic heart disease***Increased intracranial pressure, stroke***Pregnancy***Breast-feeding***Driving or operating machinery***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6845'],methocarbamol,"***For use as an adjunct to rest, physical therapy, and other measures for the relief of musculoskeletal pain associated with acute, painful musculoskeletal conditions. <br />        NOTE: Methocarbamol does not directly relax tense skeletal muscles.<br />     ***For the treatment of tetanus.","***Latex hypersensitivity***Renal disease, renal failure, renal impairment***Seizure disorder***Children, infants, neonates***Driving or operating machinery***Extravasation***Pregnancy***Breast-feeding***Geriatric***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,zolpidem tartrate,"***For the treatment of insomnia.***For the short-term treatment of insomnia characterized by difficulty with sleep initiation.***For insomnia characterized by difficulties with sleep onset and/or sleep maintenance.***For middle-of-the night awakening that is followed by difficulty returning to sleep.***For increasing awareness and responsiveness in patients with disorders of consciousness due to traumatic brain injury� (TBI�) or nontraumatic brain injury� (e.g., head trauma� or hypoxia, respectively).","***Angioedema***Depression, suicidal ideation***Behavioral changes, CNS depression, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion, females***Abrupt discontinuation, alcoholism, substance abuse***Encephalopathy, hepatic disease***Chronic obstructive pulmonary disease (COPD), myasthenia gravis, pulmonary disease, respiratory depression, sleep apnea***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,rho(D) immune globulin intravenous (human),"***For Rh isoimmunization prophylaxis in Rh<sub>0</sub> [D]-negative patient and to ensure subsequent erythroblastosis fetalis prophylaxis in females with present and future pregnancies. <br />        NOTE: Never administer Rh0 [D] immune globulin to the neonate; administer to the mother only.<br />NOTE: The woman must not be sensitized to the Rh0 [D] antigen. The immune globulin is used to prevent the formation of anti-Rh0 [D] antibody.<br />NOTE: Rh0 [D] immune globulin prophylaxis for all obstetric indications is not indicated if either the father or the fetus is known to be Rh0 [D] negative. If the Rh status of the father and fetus are unknown, assume the fetus to be Rh0 [D] positive, and administer Rh0 [D] immune globulin to the mother.<br />NOTE: Passively acquired anti-Rh0 [D] may be detected in maternal or neonatal blood if antibody screening tests are performed after Rh0 [D] immune globulin administration. The presence of passively acquired anti-Rh0 [D] does not preclude further antepartum or postpartum prophylaxis with Rh0 [D] immune globulin. A woman who had a large fetomaternal hemorrhage late in pregnancy or after delivery may test Rh positive even though she is really Rh negative. Administer Rh0 [D] immune globulin if there is any doubt about the mother's Rh type. A screening test to detect fetal red blood cells may be helpful***For the suppression of Rh isoimmunization in Rh<sub>0</sub> [D]-negative patients who are exposed to Rh<sub>0</sub> [D]-positive red blood cells or Rh<sub>0</sub> [D]-positive blood products secondary to blood transfusion. <br />          NOTE: One prefilled syringe of HyperRHO S/D Full-Dose, of Rhophylac, or of RhoGAM has at least 1500 international units of Rh0 [D] antibody and will suppress the immunizing potential of 15 ml of Rh0 [D] positive packed red blood cells or the equivalent of 30 ml of whole blood. One 300 mcg vial of WinRho SDF has at least 1500 international units of Rh0 [D] antibody and will suppress the immunizing potential of 17 ml of Rh0 [D] positive packed red blood cells.<br />NOTE: The amount of incompatible blood transfusion should be determined by an approved assay such as the modified Kleihauer-Betke acid elution stain technique.<br />NOTE: Rh immunization can occur after exposure to less than 1 ml of Rh-positive red blood cells. <br />NOTE: Monitor patients by clinical and laboratory methods because of the risk for a hemolytic reaction.<br /***For the treatment of immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP) in non-splenectomized, Rh0 [D] antigen-positive patients. <br />        NOTE: Alternative treatments should be used in patients with hemoglobin concentrations less than 8 g/dl due to the risk of increasing the severity of anemia.<br />     ","***Anemia, hemolysis, hemolytic anemia, renal impairment, requires a specialized care setting***IgA deficiency***Anticoagulant therapy, coagulopathy, hemophilia, intramuscular administration, intravenous administration, thrombocytopenia, vitamin K deficiency***Agammaglobulinemia, hypogammaglobulinemia***Pregnancy***Children, infants, neonates***Breast-feeding***Diabetes mellitus***Geriatric, hepatitis, infection, leukemia, lymphoma, systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['31448'],nabumetone,***For the acute and chronic treatment of rheumatoid arthritis or osteoarthritis.***For the treatment of ankylosing spondylitis�.***Formoterol; Mometasone,"***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Dental disease, dental work***Intramuscular injections***Hepatic disease, jaundice***Dehydration, diabetes mellitus, heart failure, hypertension, hypovolemia, peripheral edema, renal disease, renal failure, renal impairment, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Children***Labor, pregnancy***Breast-feeding***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Coronary artery bypass graft surgery (CABG)***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,selenium sulfide,***For the treatment of dandruff and seborrheic dermatitis and associated pruritus and flaking.***For the treatment of tinea versicolor.***For the treatment of psoriasis�.***For the adjunctive treatment of tinea capitis�.,"***Accidental exposure, ocular exposure***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,polyethylene glycol 3350/potassium chloride/sodium bicarbonate/sodium chloride,"***For use as a bowel evacuant to clean the colon prior to colonoscopy or barium enema X-ray examination (bowel preparation). <br />        NOTE: Patients should be well hydrated before, during, and after the colon preparation. The first bowel movement should occur approximately 1 hour after the start of solution administration.<br />     ***For dosing in adults and/or adolescents.***For dosing in children and older infants.***For the treatment of chronic constipation�. <br />        NOTE: This product should be used for 2 weeks or less or as directed by the prescriber.<br />     ","***General Information***Abdominal pain, acute abdomen, appendicitis, colitis, dehydration, GI obstruction, GI perforation, ileus, inflammatory bowel disease, toxic megacolon, ulcerative colitis, vomiting***Electrolyte imbalance, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, seizure disorder, seizures***Children, infants, neonates***Pregnancy***Breast-feeding***Coma, dementia, dysphagia, esophageal stricture, gag reflex depression***Angina, cardiac arrhythmias, cardiomyopathy, heart failure, myocardial infarction, QT prolongation***Renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1894'],calcitriol,"***For the treatment of hypocalcemia and secondary hyperparathyroidism and resultant metabolic bone disease (renal osteodystrophy) in patients with chronic kidney disease (CKD).***For initial dosing and dosage titration in adult predialysis patients with Stage 3 or 4 CKD or pediatric predialysis patients with Stage 2 to 4 CKD. <br />          NOTE: Serum calcium, phosphorus, alkaline phosphatase, and creatinine concentrations should be determined initially, monthly for 6 months, then periodically. Serum iPTH should be monitored initially and then every 3 to 4 months. During dosage titration, calcium concentrations should be monitored at least twice weekly.<br />NOTE: Calcitriol is indicated when serum 25-(OH)-vitamin D is more than 30 ng/mL and plasma iPTH concentrations are more than 70 pg/mL (Stage 3 in adults; Stage 2 to 3 in pediatric patients) or more than 110 pg/mL (Stage 4); serum calcium concentrations should be less than 9.5 mg/dL (adults) or 10 mg/dL (pediatric patients) and serum phosphorous concentrations should be should be less than 4.6 mg/dL for adults and at age appropriate levels for pediatric patients.***For initial dosing and dosage titration in patients with Stage 5 CKD on dialysis (FDA-approved labeling).***For initial dosing and dosage titration  in patients with Stage 5 CKD on dialysis (National Kidney Foundation Guidelines)�. <br />          NOTE: Serum phosphorous concentrations should be less than 5.5 mg/dL (adults and adolescents) or less than 6.5 mg/dL (infants and children) and the calcium-phosphorous product should be less than 55 (adults and adolescents) or less than 65 (infants and children). Serum calcium concentrations should be less than 9.5 mg/dL (adults) or 10 mg/dL (pediatric patients) in patients with a serum iPTH of 1000 pg/mL or less. In patients with a serum iPTH more than 1000 pg/mL, the serum calcium concentration should be less than 10 mg/dL (adults) or 10.5 mg/dL (pediatric patients). <br />       ***For the treatment of patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism and pseudohypoparathyroidism manifesting as hypocalcemia.***For the treatment of mild to moderate plaque psoriasis. <br />        NOTE: According to the American Academy of Dermatology (AAD), combining calcitriol with a topical corticosteroid is more effective than either treatment alone. In addition, fewer adverse events were reported with combination therapy in most clinical studies.<br />     ***For the management of hypocalcemia associated with vitamin D deficiency�. <br />  NOTE: For hypocalcemia associated with chronic kidney disease, see hyperparathyroidism indication.<br /***For the treatment of vitamin D-dependent rickets�.***For the treatment of familial hypophosphatemia�.***For the treatment of postmenopausal osteoporosis�.***For osteoporosis prophylaxis� in recipients of chronic corticosteroid therapy.***For the treatment of osteopetrosis�.","***General Information***Hypercalcemia, hypervitaminosis D, occlusive dressing, renal failure***Accidental exposure, ocular exposure***Hyperphosphatemia***Arteriosclerosis, cardiac disease***Geriatric***Dehydration***Sarcoidosis***Sunlight (UV) exposure***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,minocycline hydrochloride,"***For the treatment of relapsing fever due to <em>Borrelia recurrentis</em>.***For the treatment of chancroid due to <em>Haemophilus ducreyi</em>.***For the treatment of Campylobacter fetus infections.***For the treatment of acute intestinal amebiasis as an adjunct to amebicides.***For the treatment of lower respiratory tract infections and upper respiratory tract infections.***For the treatment of skin and skin structure infections due to <em>Staphylococcus aureus</em>. <br />        NOTE: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection. <br />     ***For the treatment of Rickettsial infections (e.g., murine typhus, Q fever, Rocky Mountain spotted fever, Rickettsial pox).***For the treatment of uncomplicated gonorrhea infections, including urethritis.***For the treatment of psittacosis.***For the treatment of lymphogranuloma venereum caused by <em>Chlamydia trachomatis</em>.***For the treatment of non-gonococcal urethritis (NGU) and chlamydia infection, including trachoma and chlamydial conjunctivitis.***For the treatment of urethral, endocervical, or rectal infections.***For the treatment of other chlamydia infections, including trachoma and inclusion bacterial conjunctivitis.***For the treatment of syphilis when penicillin is contraindicated.***For the treatment of granuloma inguinale (Donovanosis) due to <em>Klebsiella granulomatis</em>.***For the treatment of bartonellosis.***For the treatment of brucellosis in combination with streptomycin.***For the treatment of urinary tract infection (UTI).***For the treatment of plague after exposure to <em>Yersinia pestis</em>.***For the treatment of tularemia following exposure to <em>Francisella tularensis</em>.***For the treatment of cholera.***For the treatment of acne vulgaris.***For the treatment of non-nodular moderate to severe acne vulgaris.***For the treatment of infections caused by <em>Actinomyces israelii</em> (actinomycosis), <em>Bacillus anthracis</em> (anthrax), <em>Clostridium</em> sp. (clostridial diseases), necrotizing ulcerative gingivitis (Fusospirochetosis or Vincent's infection), <em>Listeria monocytogenes</em> (listeriosis), or <em>Treponema pertenue</em> (yaws) when penicillin is contraindicated.***For the treatment meningitis due to <em>Neisseria meningitidis</em>.***For the treatment of the meningococcal carrier state (i.e., for meningococcal infection prophylaxis).***For the treatment of Mycobacterium marinum infection.***For the treatment of rheumatoid arthritis�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis in combination with conventional treatment (e.g., scaling and root planing).***For aggressive periodontitis (juvenile periodontitis)�.***For use as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult chronic periodontitis.***For the treatment of bullous pemphigus�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated bone and joint infections� or an orthopedic device-related infection�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated osteomyelitis�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated prosthetic device infections�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated spinal implant infections�.","***General Information***Serious rash, tetracyclines hypersensitivity***Hepatic disease, hepatitis, hepatotoxicity***Autoimmune disease***Renal failure, renal impairment***Increased intracranial pressure, papilledema, pseudotumor cerebri, visual disturbance***Sunlight (UV) exposure***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***AV block, cardiac disease***Children, infants, neonates***Sexually transmitted disease***Geriatric***Dental work***Pregnancy***Breast-feeding***Infertility, reproductive risk***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,methadone hydrochloride,"***For the treatment of opiate agonist withdrawal during detoxification treatment. <br />        NOTE: Patients need to show withdrawal symptoms but no signs of sedation or intoxication.<br />NOTE: For the treatment of narcotic addiction in detoxification programs, methadone may be dispensed only by pharmacies and clinics approved by the FDA and state authorities according to treatment requirements stipulated in the Federal Methadone Regulations.<br />NOTE: Detoxification shall not exceed 21 days or be repeated earlier than 4 weeks after completion of a preceding course.<br />NOTE: Loss of opioid tolerance should be considered for a patient who has not taken opioids for more than 5 days***For the maintenance treatment of opiate agonist dependence.***For the management of iatrogenic opiate agonist dependence in pediatric patients�.***For the treatment of moderate pain or severe pain.***For the treatment of chronic severe pain in patients who require daily, around-the-clock, long-term opioid treatment. <br />          NOTE: Methadone tablets or oral solution should be reserved for patients in whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would otherwise provide inadequate pain management. Discontinue all other around-the-clock opioid drugs upon initiation of methadone. <br />       ***For the treatment of moderate to severe pain not responsive to non-narcotic analgesics.","***General Information***Dental work, pain, surgery***Angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, thyroid disease***Alcoholism, depression, substance abuse***Anxiety***Biliary tract disease, constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, pancreatitis, ulcerative colitis***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Brain tumor, CNS depression, coma, head trauma, increased intracranial pressure, intracranial mass***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, urethral stricture, urinary retention***Seizure disorder, seizures***Geriatric***Adrenal insufficiency, hypothyroidism, myxedema***Infants, neonates***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Driving or operating machinery***Opiate agonist hypersensitivity***Accidental exposure, opioid-naive patients, potential for overdose or poisoning***Abrupt discontinuation***MAOI therapy***Requires an experienced clinician***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,betaine anhydrous,"***For the adjunct treatment of homocystinuria in order to reduce plasma homocysteine levels; including in those patients with deficiencies or defects in 1) cystathionine beta-synthase (CBS); 2) 5,10-methylenetetrahydrofolate reductase (MTHFR); and 3) cobalamin cofactor metabolism (cbl). <br />        NOTE: Betaine is designated as an orphan drug by the FDA for this indication.<br />NOTE: In patients with CBS-deficiency, monitor plasma methionine concentrations.<br />NOTE: Response to treatment is usually evident within 1 week, and steady state is reached within roughly 1 month",***General Information***Hypermethioninemia***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,For age 7 years and older) (tetanus and diphtheria toxoids adsorbed,"***For diphtheria prophylaxis and tetanus prophylaxis.***For primary immunization against diphtheria and tetanus in infants and children 6 weeks up to 7 years of age. <br />          NOTE: If a child has a valid contraindication to pertussis vaccine (i.e., allergy), DT should be used to complete the vaccination series. Vaccinate preterm infants according to their chronological age from birth.<br />       ***For booster immunization against diphtheria and tetanus in children up to 7 years of age that have completed primary immunization (see above).***For primary immunization against diphtheria and tetanus in adults and children >= 7 years of age.***For booster immunization against diphtheria and tetanus in adults and children >= 7 years of age. <br />          NOTE: A single dose of Tdap instead of Td for booster immunization against tetanus, diphtheria, and pertussis is recommended for adolescents 11�18 years of age who have completed the recommended childhood DTP/DTaP vaccination series and have not received Td. If Td was received at 11�12 years of age, a single Tdap dose is recommended 5 years later, but a shorter time interval is acceptable (see Diphtheria/Tetanus Toxoids; Pertussis vaccine, DTP monograph).<br />NOTE: If Tdap has not been received or if at least 10 years have elapsed since Td administration, a single dose of Tdap instead of Td for booster immunization against tetanus, diphtheria, and pertussis is recommended for all adults 19�64 years of age; an interval of at least 10 years between Td and Tdap administration is advised but is not essential. Only 1 dose of Tdap has been evaluated; use Td for subsequent booster immunizations (see Diphtheria/Tetanus Toxoids; Pertussis vaccine, DTP monograph)***For prophylaxis against diphtheria and tetanus for patients with large, contaminated wounds. <br />          NOTE: Td is preferred over single-antigen tetanus toxoid to enhance diphtheria protection. A preferred alternative may be Boostrix, Tdap for patients 10�18 years of age or Adacel for patients at least 11 years of age (see Diphtheria/Tetanus Toxoids; Pertussis vaccine, DTP monograph).<br />NOTE: If primary immunization is complete and the last dose was less than 10 years ago, a dose is not needed for minor, uncontaminated wounds. Avulsions, wounds from missiles, a crushing injury, punctures, burns, frostbite, and wounds with dirt, feces, soil, or saliva are considered to be large or contaminated","***Latex hypersensitivity, thimerosal hypersensitivity***Bovine protein hypersensitivity***Pregnancy***Breast-feeding***Infants, neonates***Anticoagulant therapy, bleeding, coagulopathy, hemophilia, intraarterial administration, intravenous administration, subcutaneous administration, thrombocytopenia, vitamin K deficiency***Fever, infection, shock***Immunosuppression***Guillain-Barre syndrome***Premature neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],estradiol,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For systemic treatment of the vasomotor symptoms (hot flashes) and genitourinary symptoms of menopause.***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For estrogen replacement for premenopausal women with primary ovarian failure or female hypogonadism.***For the palliative treatment of advanced inoperable prostate cancer.***For the palliative treatment of breast cancer that is inoperable and progressive in selected men and postmenopausal women.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates***Intravenous administration***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,vincristine sulfate,"***For the treatment of acute lymphocytic leukemia (ALL).***For the treatment of neuroblastoma.***For the treatment of Hodgkin lymphoma.***For the treatment of Hodgkin lymphoma as part of the Stanford V regimen.***For the treatment of Hodgkin lymphoma as part of the BEACOPP regimen.***For the treatment of non-Hodgkin's lymphoma (NHL).***For the treatment of rhabdomyosarcoma.***For the treatment of metastatic rhabdomyosarcoma in combination with cyclophosphamide and topotecan alternating with VAC�.***For the first-line treatment of rhabdomyosarcoma in children and adolescents in combination with ifosfamide, dactinomycin, and doxorubicin�.***For rhabdomyosarcoma.***For the treatment of Wilms' tumor.***For the treatment of previously untreated, low-grade malignant glioma� in combination with carboplatin.***For the treatment of high-risk gestational trophoblastic disease�.***For the treatment of immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP)�.***For the treatment of newly-diagnosed small cell lung cancer (SCLC)� in combination with cyclophosphamide and doxorubicin.***For induction therapy prior to autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma�, in combination with doxorubicin and dexamethasone.***For the treatment of head and neck cancer�.***For the treatment of unresectable, advanced thymoma�, in combination with cisplatin, doxorubicin, and cyclophosphamide.***For the treatment of AIDS-related Kaposi's sarcoma in combination with bleomycin and doxorubicin�.","***Pregnancy***Breast-feeding***Geriatric, hyponatremia, neurological disease, neurotoxicity***Biliary tract disease, hepatic disease, ileus***Bone marrow suppression, herpes infection, infection, radiation therapy, varicella, viral infection***Hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, tumor lysis syndrome (TLS)***Accidental exposure, ocular exposure***Extravasation, intramuscular administration, subcutaneous administration***Intrathecal administration***Vaccination***Requires an experienced clinician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydrocortisone butyrate,"***For the treatment of primary adrenocortical insufficiency (e.g., Addison's Disease, congenital adrenal hyperplasia or CAH) or secondary adrenocortical insufficiency.***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing minor surgery or with a minor illness (e.g., inguinal hernia repair, colonoscopy, mild febrile illness, gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing moderate surgery or with a moderate illness (e.g., open cholecystectomy, hemicolectomy, significant febrile illness, pneumonia, severe gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing major surgery, or with other acute stressors (e.g., major cardiothoracic surgery, Whipple procedure, liver resection, pancreatitis, acute systemic infection, shock).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency and a critical illness (e.g., shock).***For the treatment of acute adrenocortical insufficiency.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency with other acute stressors (e.g., febrile illness with a temperature more than 38.5 degrees Celsius, gastroenteritis with dehydration, major trauma):.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency undergoing surgery accompanied by general anesthesia.***For use in nonspecific proctitis, postirradiation (factitial) proctitis, cryptitis, or for other non-specific inflammatory conditions of the anorectum.***For the treatment of inflammatory bowel disease (Crohn's disease or ulcerative colitis).***For adjunctive treatment of Crohn's disease or ulcerative colitis using oral or parenteral therapy.***For adjunctive rectal treatment of chronic ulcerative colitis, particularly if disease limited to the distal portion of the rectum.***For the relief of inflammation, pruritus ani, and swelling associated with hemorrhoids.***For the treatment of allergic disorders including anaphylaxis, anaphylactic shock, or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, transfusion-related reactions, serum sickness, severe perennial or seasonal allergic rhinitis, or urticaria.***For the non-emergent treatment of hypersensitivity or allergic conditions.***For the urgent treatment of severe conditions such as anaphylaxis, angioedema, acute noninfectious laryngeal edema, or urticarial transfusion-related reactions.***For the treatment of corticosteroid-responsive dermatologic disorders (e.g., alopecia areata, atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis including Rhus dermatitis due to poison ivy, poison oak, poison sumac, discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pompholyx (dyshidrosis), pruritus, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, xerosis).***For mild-to-moderate corticosteroid responsive dermatoses.***For mild to moderate atopic dermatitis.***For the systemic treatment of severe inflammatory dermatoses, like severe exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, or psoriasis unresponsive to topical treatment.***For adjunctive therapy in the treatment of rheumatic disorders including acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of non-rheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the short-term treatment of hypercalcemia associated with neoplastic disease.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the management of nephrotic syndrome to induce diuresis or decrease proteinuria.***For the treatment of neurologic or myocardial involvement associated with trichinosis.***For the treatment of nonsuppurative thyroiditis.***For rheumatic and related disorders such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, symptomatic sarcoidosis, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive hematologic disorders, like immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia, and congenital hypoplastic anemia; OR for the palliative treatment of neoplastic disease in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), or multiple myeloma�.***For the treatment of respiratory inflammatory conditions including bronchial asthma, aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), Loeffler's syndrome, or noncardiogenic pulmonary edema�.***For the treatment of septic shock� and/or hypotension� in patients whose blood pressure is poorly responsive to adequate fluid resuscitation and vasopressor therapy.***For the prevention of chronic lung disease (CLD)� in mechanically ventilated patients.***For the treatment of refractory neonatal hypoglycemia�.***For the treatment of corticosteroid-responsive ophthalmic disorders, including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.","***Abrupt discontinuation, Cushing's syndrome, skin abrasion***Growth inhibition, increased intracranial pressure***Immunosuppression***Fungal infection, infection***Acne rosacea, acne vulgaris, herpes infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Heart failure, hypertension***Osteoporosis***Diabetes mellitus***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hypothyroidism, psychosis, renal disease, seizure disorder***Myasthenia gravis***Coagulopathy, hemophilia, thromboembolic disease***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Neonates, premature neonates***Benzyl alcohol hypersensitivity, corticosteroid hypersensitivity***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Skin atrophy***Geriatric***Epidural administration, intrathecal administration***Pheochromocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,midazolam hydrochloride,"***For procedural sedation and amnesia induction.***For sedation and amnesia induction before short diagnostic procedures or endoscopy.***For preoperative sedation induction, amnesia induction, and to control preoperative anxiety.***For general anesthesia induction and general anesthesia maintenance. <br />        NOTE: Midazolam should be administered as an inducing agent only by those trained in anesthesia.<br />     ***For sedation maintenance in mechanically-ventilated patients�, to alleviate agitation� and/or anxiety.***For the treatment of status epilepticus� refractory to standard therapy.***For the treatment of alcohol withdrawal�, including symptomatic treatment of delirium tremens�.","***General Information***Benzodiazepine hypersensitivity, benzyl alcohol hypersensitivity, epidural administration, extravasation, intraarterial administration, intrathecal administration***Intravenous administration, requires a specialized care setting, requires an experienced clinician, respiratory depression, respiratory insufficiency***Children, hypotension, in utero exposure, infants, neonates, premature neonates, seizures***Abrupt discontinuation***Dementia, geriatric***Driving or operating machinery, ethanol ingestion, ethanol intoxication***Apnea, chronic obstructive pulmonary disease (COPD), CNS depression, coadministration with other CNS depressants, congenital heart disease, dental work, pulmonary disease, sleep apnea, status asthmaticus***Neuromuscular disease, Parkinson's disease, psychosis***Bipolar disorder, mania***Cardiac disease, dehydration, electrolyte imbalance, hypovolemia, shock***Hepatic disease, hepatic encephalopathy, obesity, renal failure, renal impairment***Closed-angle glaucoma***Labor, obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,polyethylene glycol 3350,***For the treatment of constipation.***For the treatment of fecal impaction�.***For use as a bowel evacuant to clean the colon prior to colonoscopy (bowel preparation)�.,"***General Information***Abdominal pain, acute abdomen, diarrhea, GI bleeding, GI obstruction, GI perforation, ileus, toxic megacolon, vomiting***Dementia, dysphagia, esophageal stricture, gag reflex depression***Renal disease***Pregnancy***Breast-feeding***Neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,allopurinol sodium,"***For the treatment of signs and symptoms of primary or secondary gout (i.e., acute attacks, tophi, joint destruction, uric acid lithiasis, and/or uric acid nephropathy). <br />        NOTE:�The lowest effective dose of allopurinol should be used to decrease the incidence of side effects.<br />NOTE: In transferring a patient from a uricosuric agent to allopurinol, the dose of the uricosuric agent should be gradually reduced over a period of several weeks and the allopurinol dose gradually increased to the required dose needed to maintain a normal serum uric acid concentration.<br />NOTE: Continuation of colchicine and/or anti-inflammatory agents is recommended during adjustment of the allopurinol dose until the serum uric acid concentration has been normalized and no acute gouty attacks have occurred for several months***For the prevention of acute hyperuricemia during chemotherapy or radiation treatment of leukemia, lymphoma, or solid tumors that may cause tumor lysis syndrome. <br />        NOTE: Intravenous allopurinol has been designated an orphan drug by the FDA for this indication.<br />NOTE: The correct dose and frequency of dosage for maintaining the serum uric acid concentration within the normal range are best determined by using the serum uric acid concentration as an index. Allopurinol is not recommended for the treatment of asymptomatic hyperuricemia. Discontinue allopurinol when the potential for overproduction of uric acid is no longer present***For the treatment of recurrent calcium oxalate nephrolithiasis (renal calculus) in males whose daily uric acid excretion exceeds 800 mg/day and in females whose daily uric acid excretion exceeds 750 mg/day. <br />        NOTE: Carefully assess each patient's situation initially and periodically to determine if treatment is beneficial and if the benefits outweigh the risks.<br />NOTE: Patients may also benefit from dietary changes such as an increased intake of oral fluids and dietary fiber and a decreased intake of animal protein, sodium, refined sugars, oxalate-rich foods, and excessive calcium","***General Information***Serious rash***Renal disease, renal failure, renal impairment***Hepatic disease, hepatotoxicity***Anticoagulant therapy, bone marrow suppression***Driving or operating machinery***Pregnancy***Breast-feeding***Infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['5487']['29046', '1546022']",hydrochlorothiazide/lisinopril,"***For the treatment of hypertension in patients who do not respond to monotherapy. <br />        NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, Black patients, hereditary angioedema***Dialysis, hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Hepatic disease***Aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hypotension, hypovolemia***Orthostatic hypotension, sympathectomy, syncope***Surgery***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia, hyponatremia***Anuria, autoimmune disease, bone marrow suppression, collagen-vascular disease, immunosuppression, renal artery stenosis, renal disease, renal failure, renal impairment, scleroderma, systemic lupus erythematosus (SLE)***Gout, hyperuricemia***Diabetes mellitus, hyperglycemia***Pregnancy***Breast-feeding***Children***Pancreatitis***Geriatric***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydrocodone bitartrate/ibuprofen,"***For the short-term (generally less than 10 days) treatment of acute, moderate pain. <br />        NOTE: Hydrocodone; ibuprofen is not indicated for the treatment of conditions such as rheumatoid arthritis or osteoarthritis.<br />The 2009 American Geriatrics Society (AGS) Practical Guidelines recommend avoiding NSAIDs in older persons with persistent pain EXCEPT in patients who have failed other therapies and have a favorable benefit vs. risks assessment; extreme caution, ongoing therapy evaluation, and concurrent PPI or misoprostol use are also advised***Formoterol; Mometasone","***General Information***Alcoholism, anticoagulant therapy, chemotherapy, constipation, corticosteroid therapy, GI bleeding, GI disease, GI obstruction, GI perforation, ileus, inflammatory bowel disease, peptic ulcer disease, tobacco smoking, ulcerative colitis***Diarrhea***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, driving or operating machinery, pulmonary disease, respiratory depression, respiratory insufficiency, status asthmaticus***Hepatic disease, jaundice***Bladder obstruction, diabetes mellitus, edema, heart failure, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, sepsis, systemic lupus erythematosus (SLE), urethral stricture, urinary retention***Nasal polyps, NSAID hypersensitivity, opiate agonist hypersensitivity, polysorbate 80 hypersensitivity, salicylate hypersensitivity, urticaria***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, infection, neutropenia, thrombocytopenia***Anemia***Intramuscular injections***Dental disease, dental work***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, hypertension, hypotension, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Coronary artery bypass graft surgery (CABG), surgery***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Biliary tract disease***Abrupt discontinuation***Substance abuse***Head trauma, increased intracranial pressure***Seizure disorder***Geriatric***Adrenal insufficiency, hypothyroidism, myxedema***Infertility, reproductive risk***Accidental exposure, potential for overdose or poisoning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,phenylephrine hydrochloride/promethazine hydrochloride,"***For the temporary relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.***Formoterol***Formoterol; Mometasone","***General Information***Sulfite hypersensitivity***Agranulocytosis, bone marrow suppression, jaundice, phenothiazine hypersensitivity***Driving or operating machinery***Geriatric***Closed-angle glaucoma, contact lenses, increased intraocular pressure, open-angle glaucoma***Bladder obstruction, prostatic hypertrophy, renal disease, renal failure, renal impairment, urethral stricture, urinary retention***GI disease, GI obstruction, ileus***Aneurysm, arteriosclerosis, cerebrovascular disease, head trauma, increased intracranial pressure, intracranial bleeding, organic brain syndrome, stroke***Acute myocardial infarction, angina, atrial fibrillation, atrial flutter, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, heart failure, hypertension, myocardial infarction, tachycardia, ventricular fibrillation, ventricular tachycardia***Peripheral vascular disease***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, sleep apnea, status asthmaticus, tobacco smoking***Hepatic disease***Seizure disorder, seizures***Children, dehydration, infants, neonates, respiratory depression, Reye's syndrome***Labor, obstetric delivery, pregnancy***Breast-feeding***Accidental exposure, sunlight (UV) exposure***Radiographic contrast administration***Surgery***Hyperthyroidism, thyroid disease, thyrotoxicosis***Diabetes mellitus***MAOI therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,antihemophilic factor/von Willebrand factor complex (human),"***For the prevention and control of hemorrhage in patients with hemophilia A (classical hemophilia). <br />        NOTE: Humate, Kogenate, and ReFacto have been designated by the FDA as orphan drugs for the prophylaxis and management of hemorrhage or hemarthrosis in patients with hemophilia A.<br /> <br />NOTE: Guidelines for the treatment of acute bleeding and prevention of bleeding during surgery vary. For all indications, the dose of antihemophilic factor should be individualized taking into consideration the seriousness of the bleed or procedure, the clinical status of the patient, and the factor VIII activity concentration***For minor bleeding including early muscle bleed, early hemarthrosis, and oral bleeds.***For moderate bleeding including advanced muscle bleed, extensive hemarthrosis, hematoma, and mild head trauma.***For life- or limb-threatening bleeding including surgical bleeding, gastrointestinal bleeding, neck, tongue or pharyngeal hematoma with potential for airway compromise, intracranial, intraabdominal, or intrathoracic bleeding, or fractures.***For bleeding in patients with hemophilia A and factor VIII inhibitor titers less than 10 Bethesda Units and with low anamnestic responses.***For the perioperative management of surgical bleeding (surgical bleeding prophylaxis) in patients with hemophilia A.***For routine bleeding prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A.***For the management of hemorrhage or hemarthrosis in patients with von Willebrand's disease (vWD). <br />        NOTE: Humate-P has been designated by the FDA as orphan drugs for this indication.<br />     ***For major hemorrhage in patients with mild vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma or traumatic hemorrhage).***For minor hemorrhage in patients with moderate to severe vWD type I, type II, and type III (e.g., epistaxis, oral bleeding, or menorrhagia).***For major hemorrhage in patients with moderate to severe vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For major hemorrhage in patients with vWD type II and III (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For surgical bleeding prophylaxis during major or minor procedures in patients with vWD in whom desmopressin is either ineffective or contraindicated. <br />          NOTE: Alphanate and Humate-P have been designated by the FDA as orphan drugs for this indication.<br />       ","***General Information***Pregnancy***Breast-feeding***Thromboembolic disease***Hepatitis, infection, viral infection***Anemia***Bovine protein hypersensitivity, hamster protein hypersensitivity, latex hypersensitivity, mannitol hypersensitivity, murine protein hypersensitivity, polysorbate 80 hypersensitivity***Porcine protein hypersensitivity***Human immunodeficiency virus (HIV) infection***Cardiac disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cefditoren pivoxil,"***For the treatment of acute bacterial exacerbations of chronic bronchitis.***For the treatment of community-acquired pneumonia caused by <em>H. influenzae</em> (beta-lactamase negative), <em>H. influenzae</em> (beta-lactamase positive), <em>H. parainfluenzae</em> (including beta-lactamase-producing strains), <em>S. pneumoniae</em> (penicillin-susceptible strains only), or <em>M. catarrhalis</em> (including beta-lactamase-producing strains).***For pharyngitis/tonsillitis caused by <em>Streptococcus pyogenes</em>. <br />        NOTE: The American Heart Association does not recommended cefditoren as routine therapy for Group A Streptococcal pharyngitis therapy to prevent rheumatic fever.<br />     ***For uncomplicated skin and skin structure infections due to <em>S. aureus</em> (MSSA) including beta-lactamase-producing strains and <em>S. pyogenes</em> (group A beta-hemolytic streptococci).","***General Information***Antimicrobial resistance, viral infection***Carnitine deficiency***Milk protein hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Cephalosporin hypersensitivity, penicillin hypersensitivity***Renal failure, renal impairment***Hepatic disease***Pregnancy***Breast-feeding***Children, infants, neonates***Coagulopathy, vitamin K deficiency***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,phytonadione,"***For treatment of hemorrhagic disease of the newborn (HDN).***For hemorrhagic disease of the newborn (HDN) prophylaxis. <br />        NOTE: The use of prophylactic vitamin K1 administration is common in the US and recommended by the American Academy of Pediatrics; however, this practice is controversial in other countries.<br />     ***For nutritional supplementation to prevent vitamin K deficiency and/or hypoprothrombinemia.***For the adequate intake (AI) of vitamin K in healthy individuals. <br />          NOTE: Updated by the IOM Food and Nutrition Board in 2001. No RDA has been established.<br />       ***For the treatment of hemorrhage or bleeding prophylaxis in patients with coumarin toxicity (i.e., warfarin-induced hypoprothrombinemia). <br />        NOTE: Although doses of 10 mg or more of vitamin K are effective, use of large doses can lead to warfarin resistance for up to a week after vitamin K is discontinued. Therefore, unless the patient has serious bleeding or the INR is more than 10, lower doses of vitamin K are generally recommended and have been shown to effectively reduce the INR. Since oral vitamin K is effective for lowering the INR, it is the route of choice unless rapid reversal of the INR is critical, in which case vitamin K can be administered by slow IV infusion. <br />     ***For osteoporosis prophylaxis�.","***General Information***Biliary tract disease, hepatic disease, jaundice***Hypoprothrombinemia, thromboembolic disease***Anticoagulant therapy***Pregnancy***Breast-feeding***Intramuscular administration, intravenous administration, serious hypersensitivity reactions or anaphylaxis***Benzyl alcohol hypersensitivity, neonates, polysorbate 80 hypersensitivity, premature neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['59763'],stavudine,***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.,"***General Information***Pancreatitis***Alcoholism, females, hepatic disease, hepatotoxicity or lactic acidosis, obesity***Hepatitis B and HIV coinfection***Geriatric, Guillain-Barre syndrome, neuromuscular disease, peripheral neuropathy***Dialysis, renal failure, renal impairment***Pregnancy***Breast-feeding***Human immunodeficiency virus (HIV) infection resistance***Autoimmune disease, Graves' disease, immune reconstitution syndrome***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clobetasol propionate,"***For the treatment of moderate-to-severe inflammatory manifestations, including pruritus, of corticosteroid-responsive dermatologic disorders such as alopecia areata, atopic dermatitis, contact dermatitis, generalized exfoliative dermatitis, Rhus dermatitis due to plants like poison ivy, seborrheic dermatitis, eczema (including severe hyperkeratotic eczema, severe nummular eczema, and severe eczematous conditions of the hands or feet), granuloma annulare, keloids, cutaneous lichen planus, lichen simplex chronicus, lichen striatus, subacute cutaneous and discoid lupus erythematosus, pretibial myxedema, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, sarcoidosis, sunburn, or urticaria. <br />        NOTE: Acute exudative inflammation, as occurs with poison ivy, may be best treated with a non-emollient cream or gel formulation, which are drying. Dry, scaly dermatoses may be best treated with emollient creams or ointments. Lower potency corticosteroids should be used on the face and intertriginous areas.<br />NOTE: Systemic therapy or intralesional injection of corticosteroids may be necessary for some conditions based on the type and severity of the disorder or inadequate response to topical therapy***For the treatment of plaque-type psoriasis.***For the alternative treatment of recalcitrant oral vesiculoerosive disease� including oral lichen planus�, mucous membrane pemphigus�, aphthous ulcer� and chronic oral erythema multiforme�.***For the treatment of vulvar lichen sclerosus�.***For the alternative treatment of vision-threatening periocular capillary hemangioma� in infancy and early childhood.","***Corticosteroid hypersensitivity***Cushing's syndrome, hepatic disease, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Diabetes mellitus***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Fungal infection, herpes infection, infection, measles, peripheral vascular disease, varicella, viral infection***Acne rosacea, acne vulgaris, cataracts, glaucoma, ocular exposure, ophthalmic administration, perioral dermatitis***Geriatric, skin atrophy***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,buprenorphine hydrochloride,"***For the treatment of moderate pain or severe pain.***For treatment of chronic severe pain in patients who require daily, around-the-clock, long-term opioid treatment. <br />          NOTE: Transdermal and buccal buprenorphine should be reserved for patients in whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Discontinue all other around-the-clock opioid drugs upon initiation of transdermal buprenorphine. <br />NOTE: Transdermal buprenorphine doses of 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour, and 20 mcg/hour are for use in opioid-experienced patients only.<br />NOTE: Buccal doses of 600 mcg, 750 mcg, and 900 mcg are for use following titration from lower doses of the buccal film***For the treatment of opiate agonist dependence, including opiate agonist withdrawal symptoms.***For the prevention of undue symptoms of opiate agonist withdrawal during induction of opiate agonist dependence treatment.***For maintenance treatment of opiate agonist dependence.***For maintenance treatment of opioid agonist dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine-containing product (i.e., doses of no more than 8 mg per day of Subutex or Suboxone sublingual tablet equivalent or generic equivalent).***For the management of neonatal abstinence syndrome�.***Formoterol***Formoterol; Mometasone","***Opiate agonist hypersensitivity***Accidental exposure, alcoholism, depression, implant insertion and removal complications, potential for overdose or poisoning, requires an experienced clinician, substance abuse***Abrupt discontinuation***Dental work, surgery***Anxiety***Acute abdomen, constipation, diarrhea, GI obstruction, ileus, inflammatory bowel disease, toxic megacolon, ulcerative colitis***Children, infants***Acute intoxication of CNS depressants, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), CNS depression, coadministration with other CNS depressants, cor pulmonale, driving or operating machinery, emphysema, ethanol intoxication, heart failure, obesity, psychosis, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Coma, head trauma, hypoxemia, increased intracranial pressure, intracranial mass***Labor, neonatal opioid withdrawal syndrome, neonates, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Bladder obstruction, oliguria, prostatic hypertrophy, renal failure, renal impairment, urethral stricture, urinary retention, urinary tract obstruction***Biliary cirrhosis, biliary obstruction, biliary tract disease, gallbladder disease, pancreatitis***Acute heart failure, acute myocardial infarction, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Fever, heating pad, sunlight (UV) exposure***Hypotension, hypovolemia, orthostatic hypotension***Seizure disorder, seizures***Opioid-naive patients, pain***Geriatric***Adrenal insufficiency, hypothyroidism, myxedema***Infection, intramuscular administration***Scleroderma***Infertility, reproductive risk***Intravenous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2626'],clozapine,***For the treatment of refractory schizophrenia that has failed to respond adequately to appropriate courses of standard antipsychotic agents; also to reduce the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder.***For the treatment of bipolar disorder�.***Formoterol***Formoterol; Mometasone,"***General Information***Agranulocytosis, bone marrow suppression, chemotherapy, fever, infection, leukemia, leukopenia, neutropenia***Seizure disorder, seizures***CNS depression, coadministration with other CNS depressants, coma***Neurological disease, Parkinson's disease, tardive dyskinesia***Anticholinergic medications, closed-angle glaucoma, constipation, fecal impaction, GI obstruction, ileus, prostatic hypertrophy, urinary retention***Driving or operating machinery***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, myocarditis, orthostatic hypotension, QT prolongation, syncope, tachycardia, thyroid disease, torsade de pointes, ventricular arrhythmias***Pulmonary disease, thromboembolic disease***Dialysis, renal disease, renal failure***Hepatic disease, hepatitis, hepatotoxicity, jaundice, poor metabolizers***Dementia, geriatric, stroke***Neonates, pregnancy, pregnancy testing***Breast-feeding***Surgery***Children, infants***Diabetes mellitus, diabetic ketoacidosis, hypercholesterolemia, hyperglycemia, hyperlipidemia, hyperosmolar hyperglycemic state (HHS), hypertriglyceridemia, obesity***Abrupt discontinuation***Tobacco smoking***Phenylketonuria***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Dysphagia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"15 mg, 30 mg, 60 mg, 100 mg) (phenobarbital","***For the treatment of status epilepticus. <br />        NOTE: The full antiepileptic effect of phenobarbital is not immediate. IV benzodiazepines, (e.g., lorazepam or diazepam) should be given initially.<br />     ***For the maintenance treatment of all types of seizures, including but not limited to partial seizures, myoclonic seizures, tonic-clonic seizures, or neonatal seizures not responding to other anticonvulsants.***For the short-term treatment of insomnia.***For procedural sedation and relief of preoperative anxiety.***For sedation maintenance, to relieve anxiety, tension, and apprehension.***For the treatment of hyperbilirubinemia�.***For the treatment of hyperbilirubinemia due to chronic cholestasis.***For the treatment of hyperbilirubinemia in neonates.***For the treatment of hyperbilirubinemia due to type II Crigler-Najjar syndrome.***For neonatal abstinence syndrome�.","***Agranulocytosis, barbiturate hypersensitivity, carbamazepine hypersensitivity, exfoliative dermatitis, hydantoin hypersensitivity***Pain***Depression, suicidal ideation***Cardiac disease, heart failure, hypertension, hypotension, intraarterial administration, intravenous administration, shock, subcutaneous administration***Chronic obstructive pulmonary disease (COPD), pulmonary disease, respiratory depression, sleep apnea***Abrupt discontinuation, seizure disorder, seizures, status epilepticus, substance abuse***Alcoholism, CNS depression, driving or operating machinery, ethanol ingestion, mental status changes***Geriatric***Hepatic disease, hepatic encephalopathy***Anuria, dialysis, renal failure, renal impairment***Porphyria***Anticoagulant therapy***Osteomalacia, osteoporosis***Children, infants, neonates, premature neonates***Labor, obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7646'],omeprazole/sodium bicarbonate,***For the treatment of active duodenal ulcer.***For the short-term treatment of active benign gastric ulcer.***For the treatment of gastroesophageal reflux disease (GERD).***For symptomatic treatment of non-erosive GERD.***For nocturnal acid breakthrough�.***For the treatment of erosive esophagitis (erosive GERD).***For stress gastritis prophylaxis in critically ill patients.***For the treatment of frequent pyrosis (heartburn).***For the treatment of proton pump inhibitor�responsive esophageal eosinophilia (PPI-REE) in the differential diagnosis of eosinophilic esophagitis (EoE)�.,"***General Information***Proton pump inhibitors (PPIs) hypersensitivity***Bartter's syndrome, corticosteroid therapy, Cushing's syndrome, hyperaldosteronism, hypocalcemia, hypokalemia, metabolic alkalosis, respiratory alkalosis***Cardiac disease, heart failure, hypernatremia, hypertension, peripheral edema, pulmonary edema, renal disease, renal failure, renal impairment, sodium restriction***Hepatic disease***Asian patients***Gastric cancer***Vitamin B12 deficiency***Children, infants, neonates***Pregnancy***Breast-feeding***Diarrhea, pseudomembranous colitis***Bone fractures, geriatric, osteoporosis***Hypomagnesemia, long QT syndrome***Rebound acid hypersecretion***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,neomycin sulfate,"***For use in preoperative bowel preparation for patients undergoing colorectal surgery.***For the adjunctive treatment of hepatic encephalopathy or hepatic coma.***For the treatment of superficial skin and skin structure infections (i.e., minor cuts and wounds) due to susceptible organisms.***For the treatment of infectious diarrhea� or bacterial overgrowth syndrome�.","***Colitis, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Dehydration, hearing impairment, neonates, nephrotoxicity, neurotoxicity, ototoxicity, renal disease, renal impairment***Botulism, myasthenia gravis, neuromuscular blockade, neuromuscular disease, parkinsonism, respiratory depression, respiratory insufficiency***Pregnancy***Breast-feeding***Aminoglycoside hypersensitivity***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],desogestrel/ethinyl estradiol,"***For routine contraception.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�,  abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Edema, hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ganirelix acetate,***For inhibiting premature leutenizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation and subsequent in vitro fertilization (IVF) or other assisted reproductive technology (ART) for the treatment of infertility. <br />        NOTE: Withhold HCG administration in cases where the ovaries are abnormally enlarged to reduce the chance of inducing ovarian hyperstimulation syndrome (OHSS).<br />     ,"***Latex hypersensitivity***Ovarian failure***Ovarian cyst, polycystic ovary syndrome***Geriatric***Hepatic disease, renal impairment***Pregnancy***Breast-feeding***Children***Ethanol intoxication, tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5640'],ibuprofen,"***For the treatment of rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA).***For the treatment of dysmenorrhea.***For the treatment of severe pain in hospitalized patients.***For the treatment of mild pain to moderate pain.***For the treatment of mild to moderate pain in hospitalized patients.***For self-treatment of minor aches and pains due to the common cold, toothache, muscular aches or backache (musculoskeletal pain), and the minor pains of arthritis.***For the treatment of fever.***For the treatment of headache.***For self-treatment of headache.***For the treatment of pain due to acute migraine.***For the treatment of osteoarthritis; ankylosing spondylitis�; acute gouty arthritis�; or psoriatic arthritis�.***For patients with cystic fibrosis� to slow the rate of decline in lung function.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, Crohn's disease, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery bypass graft surgery (CABG), coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Geriatric***Labor, obstetric delivery, pregnancy***Infertility, reproductive risk***Breast-feeding***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['24605'],etodolac,"***For the treatment of mild pain or moderate pain including arthralgia, myalgia, dental pain, or bone pain. <br />        NOTE: Dosage should be individualized according to patient response.<br />     ***For the the management of the signs and symptoms of osteoarthritis or rheumatoid arthritis. <br />        NOTE: Dosage should be individualized according to patient response.<br />     ***For the the management of the signs and symptoms of juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA).***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease, jaundice***Dehydration, diabetes mellitus, edema, heart failure, hypertension, renal disease, renal failure, renal impairment, rheumatoid arthritis, sepsis, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Coagulopathy, hematological disease, hemophilia, surgery, thrombocytopenia***Bone marrow suppression, immunosuppression, neutropenia***Anemia***Intramuscular injections***Dental disease, dental work***Children, infants, neonates***Labor, pregnancy***Breast-feeding***Coronary artery bypass graft surgery (CABG)***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8691'],primidone,"***For use as an alternative to other anticonvulsants for the management of generalized tonic-clonic seizures, or for the management of complex partial seizures (e.g., psychomotor seizures).***For the treatment of essential tremor�.","***Agranulocytosis, barbiturate hypersensitivity, carbamazepine hypersensitivity, exfoliative dermatitis, hydantoin hypersensitivity***Depression, suicidal ideation***Chronic obstructive pulmonary disease (COPD), pulmonary disease, respiratory depression, sleep apnea***Abrupt discontinuation, seizure disorder, seizures, status epilepticus***Alcoholism, CNS depression, driving or operating machinery, ethanol intoxication, mental status changes***Geriatric***Hepatic disease, hepatic encephalopathy***Anuria, dialysis, renal failure, renal impairment***Porphyria***Anticoagulant therapy***Osteomalacia, osteoporosis***Neonates, premature neonates***Labor, obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albumin (human),"***For the treatment of shock due to hypovolemia. <br />        NOTE: Dosage should be based on patient response as indicated by blood pressure, degree of pulmonary congestion, and hematocrit.<br />     ***For adjunctive treatment of severe burns.***For the treatment of nephrosis in nephrotic syndrome.***For treatment of hypoproteinemia.***For adjunctive use with exchange transfusion in the treatment of hyperbilirubinemia and erythroblastosis fetalis.","***Albumin hypersensitivity***Anemia, heart failure, hypertension***Renal disease***Hypernatremia***Burns***Viral infection***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1388'],lindane,"***For the treatment of scabies caused by <em>Sarcoptes scabiei </em>in patients who cannot tolerate or have failed treatment with other approved therapies. <br />        NOTE: Scabies management should include microscopic evaluation of skin scrapings to confirm the diagnosis, evaluation and treatment of sexual contacts simultaneously, and washing of clothing, used bedding and towels in very hot water (or dry-cleaning such items).<br />     ***For the treatment of pediculosis caused by <em>Pediculus capitis</em> (head lice) or <em>Phthirus pubis</em> (crab lice or pediculosis pubis). <br />        NOTE: Lindane shampoo is indicated for the treatment of lice only in patients who cannot tolerate or have failed treatment with other approved therapies. Lice management should include visual inspection to ensure patient is currently infested with live lice (empty egg casings or 'nits' can remain on hair shaft long after true infestation); manual removal of nits using a comb designed for this purpose and/or individual removal with tweezers followed by close examination of the hair and scalp; evaluation and treatment of sexual contacts simultaneously, and washing of clothing, used bedding and towels in very hot water. Personal articles that cannot be washed may be dry-cleaned, sealed in a plastic bag for 4 weeks, or sprayed with a product specifically designed for this purpose.<br />     ","***General Information***Accidental exposure, neurotoxicity, occlusive dressing, ocular exposure, seizures***Alcoholism, brain tumor, head trauma, hepatic disease, human immunodeficiency virus (HIV) infection, seizure disorder***Atopy, burns, crusted (Norwegian) scabies, eczema, exfoliative dermatitis, inflammation, psoriasis, skin abrasion, skin disease***Children, geriatric, infants, neonates, premature neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,quinine sulfate,"***For the treatment of malaria.***For the treatment of malaria caused by <em>P. falciparum</em>, including chloroquine-resistant strains.***For the treatment of malaria caused by chloroquine-resistant strains of <em>P. vivax�</em>.***For the treatment of babesiosis�.***Formoterol***Formoterol; Mometasone","***Muscle cramps***Children, infants, neonates***Geriatric***Pregnancy***Breast-feeding***Hypoglycemia***Optic neuritis, tinnitus***G6PD deficiency***Hemolytic-uremic syndrome, thrombocytopenia, thrombotic thrombocytopenic purpura (TTP)***Intramuscular injections***Blackwater fever***Mefloquine hypersensitivity, quinidine hypersensitivity, quinine hypersensitivity***Myasthenia gravis***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2623', '202859']",clotrimazole,"***For the treatment of candidiasis, specifically mucocutaneous candidiasis (i.e., oropharyngeal candidiasis (thrush), vulvovaginal candidiasis).***For the treatment of oropharyngeal candidiasis (thrush).***For the treatment of vulvovaginal candidiasis (VVC).***For candidiasis prophylaxis to reduce the incidence of oropharyngeal candidiasis in immunocompromised patients undergoing chemotherapy or radiotherapy in the treatment of leukemia or solid tumors, or in allograft transplant patients who are receiving corticosteroid therapy.***For the treatment of tinea corporis, tinea cruris, and tinea pedis.***For the treatment of fungal otitis externa�.","***Onychomycosis***Pregnancy***Breast-feeding***Contraceptive devices, menstruation***Azole antifungals hypersensitivity***Abdominal pain, diabetes mellitus, fever, human immunodeficiency virus (HIV) infection, immunosuppression, vaginal discharge***Children, infants, neonates***Ocular exposure, ophthalmic administration***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,alpha1-proteinase inhibitor (human),***For chronic augmentation and maintenance therapy in adults with emphysema due to alpha-1 proteinase inhibitor (A1PI) deficiency.,"***General Information***IgA deficiency***Viral infection***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Intra-articular) (triamcinolone hexacetonide,"***For bronchospasm prophylaxis or maintenance therapy in patients who require chronic treatment with corticosteroids for control of bronchial asthma.***For the treatment of severe or incapacitating allergic conditions such as asthma that are intractable to adequate trials of conventional treatment.***For the treatment of symptoms of seasonal and perennial allergic rhinitis.***For the treatment of severe or incapacitating allergic conditions that are intractable to adequate trials of conventional treatment.***For the treatment of ocular inflammation (i.e., sympathetic ophthalmia and ocular inflammatory conditions unresponsive to topical corticosteroids), temporal arteritis, and uveitis.***For visualization during ocular surgery (i.e., vitrectomy).***For the treatment of acute rheumatic carditis, berylliosis, temporal arteritis�, or systemic lupus erythematosus (SLE). <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses (e.g., alopecia areata, atopic dermatitis, contact dermatitis including <em>Rhus dermatitis</em> due to poison ivy, poison oak, poison sumac, subacute cutaneous or discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex chronicus, mycosis fungoides, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, psoriasis, sarcoidosis, seborrheic dermatitis, sunburn, or xerosis). <br />        NOTE: Occlusive dressings may be necessary for chronic or severe cases of psoriasis or other recalcitrant conditions.<br />     ***For the treatment of ulcerative or inflammatory oral lesions including aphthous ulcer, desquamative gingivitis�, and oral lichen planus�.***For the treatment of severe or incapacitating allergic conditions such as atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions, bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome) that are intractable to adequate trials of conventional treatment and for the treatment of idiopathic eosinophilic pneumonias.***For the treatment of symptomatic sarcoidosis.***For the treatment of primary (Addison's disease) or secondary adrenocortical insufficiency. <br />        NOTE: Hydrocortisone and cortisone are the preferred agents for these conditions.<br />     ***For the treatment of congenital adrenal hyperplasia.***For the treatment of hypercalcemia associated with cancer.***For the treatment of nonsuppurative thyroiditis.***For the treatment of a critical period of regional enteritis and ulcerative colitis.***For the treatment of autoimmune hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, or selected cases of secondary thrombocytopenia.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of acute exacerbations of multiple sclerosis. <br />        NOTE: Corticosteroids are effective in speeding the resolution of acute exacerbations, but they do not affect the ultimate outcome or natural history of the disease.<br />     ***For the treatment of cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.***For the treatment of proteinuria or to induce diuresis in idiopathic nephrotic syndrome or lupus erythematosus.***For the treatment of an acute episode or exacerbation of ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA) as adjunctive therapy for short-term administration.***For the treatment of dermatomyositis or polymyositis.***For the relief of inflammation and for immunosuppression associated with a variety of disorders, like Hodgkin lymphoma. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the palliative treatment of leukemias and lymphomas.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of diabetic macular edema�.***For the relief of inflammation associated with synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; gout with acute gouty arthritis; epicondylitis; acute non-specific tenosynovitis; polychondritis�; posttraumatic osteoarthritis. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of osteoarthritis pain of the knee. <br />  NOTE: Zilretta is not interchangeable with other formulations of triamcinolone acetonide.<br /","***Epidural administration, intramuscular administration, intrathecal administration, intravenous administration, subcutaneous administration***Acute bronchospasm, status asthmaticus***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hyperthyroidism, hypothalamic-pituitary-adrenal (HPA) suppression, hypothyroidism, increased intracranial pressure, occlusive dressing, skin abrasion***Head trauma***Growth inhibition, osteoporosis***Surgery***Fungal infection, infection, viral infection***Tuberculosis***Immunosuppression***Herpes infection, measles, varicella***Glaucoma***Acne rosacea, acne vulgaris***Peripheral vascular disease***Nasal septal perforation, nasal surgery, nasal trauma***Myocardial infarction***Heart failure, hypertension***Diabetes mellitus***Skin atrophy***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Myasthenia gravis***Psychosis, seizure disorder***Coagulopathy, hemophilia, thromboembolic disease***Cataracts, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Vaccination***Breast-feeding***Tartrazine dye hypersensitivity***Neonates, premature neonates***Idiopathic thrombocytopenic purpura (ITP)***Corticosteroid hypersensitivity***Geriatric***Renal disease, renal impairment***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2410'],chlorzoxazone,"***For adjunctive therapy to rest, physical therapy, and other measures for the relief of musculoskeletal pain associated with acute, painful musculoskeletal conditions.","***General Information***Alcoholism, CNS depression, driving or operating machinery, ethanol intoxication***Fever, hepatic disease, hepatitis, jaundice, vomiting***Renal failure, renal impairment***Geriatric***Pregnancy***Breast-feeding***Neurological disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,vecuronium bromide,"***For neuromuscular blockade or endotracheal intubation.***For facilitation of endotracheal intubation, including rapid-sequence intubation.***For neuromuscular blockade as an adjunct to general anesthesia induction in patients anesthetized with enflurane or isoflurane.***For neuromuscular blockade as an adjunct to surgical anesthesia following succinylcholine assisted endotracheal intubation.","***General Information***Requires a specialized care setting, requires an experienced clinician, respiratory insufficiency***Bromide hypersensitivity***Acid/base imbalance, adrenal insufficiency, dehydration, electrolyte imbalance, hypercalcemia, hypermagnesemia, hypocalcemia, hypokalemia, hypothermia, metabolic alkalosis, respiratory acidosis***Asthma, chronic obstructive pulmonary disease (COPD), pulmonary disease***Lung cancer, myasthenia gravis, myopathy, neuromuscular disease, obesity***Cardiac disease, edema***Hepatic disease***Burns***Renal failure, uremia***Malignant hyperthermia***Labor, obstetric delivery, pregnancy***Breast-feeding***Geriatric***Neuromuscular blocking agent hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['40575'],zileuton,"***For the prophylaxis and chronic treatment of patients with asthma. <br />        NOTE: Liver function tests (LFTs) should be conducted at baseline then once monthly for 3 months, then every 2 to 3 months for the remainder of the first year and periodically thereafter.<br />     ***For the treatment of inflammation associated with rheumatoid arthritis�.***For the treatment of ulcerative colitis�.***For the treatment of aspirin-induced asthma�.***For exercise-induced bronchospasm prophylaxis�.***Formoterol; Mometasone","***General Information***Alcoholism, hepatic disease***Children, infants, neonates***Acute bronchospasm, status asthmaticus***Fever, infection***Pregnancy***Breast-feeding***Suicidal ideation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ganciclovir sodium,"***For induction treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including HIV-infected patients.***For cytomegalovirus (CMV) disease prophylaxis in patients at risk for CMV disease.***For prophylaxis in allogeneic hematopoietic cell transplant (HCT) recipients.***For solid organ transplant recipients who are CMV-seropositive or CMV-seronegative receiving an organ from a CMV-seropositive donor. <br />          NOTE: Treatment regimens are organ, transplant center, and recipient specific; CMV hyperimmune globulin may be added to the ganciclovir regimen and/or the duration of IV therapy may vary from 14 days to 6 months, with total ganciclovir treatment duration of 3 to 6 months.<br />       ***For solid organ transplant recipients who are CMV-seropositive and receiving immunosuppressive induction therapy (i.e., transplant rejection treatment) with antithymocyte globulin (ATG)�.***For preemptive therapy in hematopoietic cell transplant (HCT) recipients who are less than 100 days post HCT�.***For preemptive therapy in hematopoietic cell transplant (HCT) recipients who are more than 100 days post HCT�.***For the treatment of acute herpes simplex keratitis (dendritic keratitis). <br />        NOTE: Ganciclovir ophthalmic gel is an FDA-designated orphan drug for this indication.<br />     ***For chronic suppressive therapy of cytomegalovirus (CMV) disease, including CMV retinitis (i.e., secondary cytomegalovirus (CMV) retinitis prophylaxis) in HIV-infected patients. <br />        NOTE: Ganciclovir intravenous injection has been designated an orphan drug by the FDA for CMV retinitis.<br />NOTE: The HIV guidelines generally do not recommend ganciclovir for chronic suppressive therapy following acute CMV disease other than retinitis in adults and adolescents. In infants and children, chronic suppressive therapy is recommended after disseminated disease, neurologic disease, retinitis, or gastrointestinal disease with relapse.<br />NOTE: For patients who experience progression of CMV retinitis while receiving maintenance therapy, re-induction treatment with the same drug used for maintenance followed by reinstitution of maintenance therapy is recommended.***For the treatment of viral encephalitis�.***For varicella-zoster (herpes zoster) encephalitis� as an alternative to acyclovir.***For the treatment of cytomegalovirus (CMV) encephalitis� and for the treatment of cytomegalovirus (CMV) neurological disease� (including encephalitis�) in HIV-infected patients.***For encephalitis� due to B virus (cercopithecine herpesvirus) infection� as an alternative to valacyclovir.***For the treatment of cytomegalovirus (CMV)-associated gastrointestinal disease� (e.g., esophagitis�, gastroenteritis�, or colitis�).***For the treatment of cytomegalovirus (CMV) pneumonitis�.***For the treatment of symptomatic congenital cytomegalovirus (CMV) disease�.***For the treatment of acute retinal necrosis (ARN)� due to varicella-zoster virus  in HIV-infected patients.***For the treatment of progressive outer retinal necrosis (PORN)� due to varicella zoster virus (VZV)� in HIV-infected patients.***For the treatment of severe human herpesvirus 8 (HHV-8) infection� and associated diseases in HIV-infected patients, including multicentric Castleman disease� (MCD) and primary effusion lymphoma� (PEL).***For multicentric Castleman disease (MCD)�.***For the treatment of herpes simplex virus infection� or varicella (chickenpox) infection� due to varicella-zoster virus in hospitalized immunocompromised patients unable to take oral therapy. <br />        NOTE: For CNS disease, see encephalitis.<br />     ***For the treatment of neonatal herpes simplex virus infection�.***For the treatment of encephalitis caused by human herpesvirus 6 (HHV-6) infection� in immunocompromised patients.","***Acyclovir hypersensitivity, famciclovir hypersensitivity, ganciclovir hypersensitivity, penciclovir hypersensitivity, valacyclovir hypersensitivity, valganciclovir hypersensitivity***Anemia, bone marrow suppression, chemotherapy, leukopenia, neutropenia, radiation therapy, thrombocytopenia***Intramuscular administration, subcutaneous administration***Dehydration, geriatric, renal failure, renal impairment***Accidental exposure, neoplastic disease, ocular exposure***Children, infants, neonates***Infertility, reproductive risk***Antimicrobial resistance***Contraception requirements, male-mediated teratogenicity, pregnancy, pregnancy testing***Breast-feeding***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluphenazine decanoate,"***For the treatment of schizophrenia.***For the treatment of acute agitated behavior (e.g., acute psychosis) when rapid control of acute symptoms is desired or for use when the oral route is not feasible.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.","***Benzyl alcohol hypersensitivity, paraben hypersensitivity, phenothiazine hypersensitivity, sesame oil hypersensitivity, tartrazine dye hypersensitivity***Agranulocytosis, bone marrow suppression, fever, hematological disease, infection, leukopenia, neutropenia***Intravenous administration***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion, head trauma***Dental work, surgery***Intracranial mass, seizure disorder, seizures***Tardive dyskinesia***Anticholinergic medications, closed-angle glaucoma, ileus, prostatic hypertrophy, urinary retention***Alcoholism, angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, pulmonary disease, QT prolongation, thyroid disease***Children, infants, neonates, Reye's syndrome***Encephalopathy, hepatic disease, jaundice***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Sunlight (UV) exposure***Accidental exposure***Abrupt discontinuation***Renal failure***Ocular disease***Chemotherapy, GI obstruction, vomiting***Tobacco smoking***Labor, obstetric delivery, pregnancy, pregnancy testing***Breast-feeding***Breast cancer, hyperprolactinemia, infertility***Radiographic contrast administration***Suicidal ideation***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['6387']['10391', '91189']",lidocaine/tetracaine,"***For use as local anesthesia to provide topical anesthesia to normal intact skin.***For superficial dermatological procedures such as excision, electrodesiccation, and shave biopsy of skin lesions.***For superficial venous access.***For superficial dermatological procedures such as dermal filler injection, pulsed dye laser therapy, and facial laser resurfacing.***For laser-assisted tattoo removal.","***General Information***Amide local anesthetic hypersensitivity, ester local anesthetic hypersensitivity, para-aminobenzoic acid, PABA hypersensitivity, paraben hypersensitivity***Magnetic resonance imaging (MRI)***Accidental exposure, children, infants***Labor, obstetric delivery, pregnancy***Breast-feeding***Burns, eczema, occlusive dressing, skin abrasion***Ocular exposure***Pseudocholinesterase deficiency***Geriatric***Cardiac disease, heart failure, hepatic disease, hepatic encephalopathy, hepatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/ferrous fumarate/norethindrone acetate,"***For routine contraception.***For the treatment of moderate acne vulgaris related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Pregnancy***Gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Diabetes mellitus***Hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, pancreatitis***Systemic lupus erythematosus (SLE)***Surgery***Asthma, headache, hypertension, migraine, seizure disorder***Depression***Contact lenses, glaucoma, visual disturbance***Breast cancer***Hypercalcemia, hypocalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Obesity***Chloasma***Angioedema, hereditary angioedema***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5032']['8896'],guaifenesin/pseudoephedrine hydrochloride,"***For the treatment of cough and nasal congestion, including relief of eustachian tube congestion, associated with the common cold, sinusitis, or other upper respiratory conditions.***Formoterol***Formoterol; Mometasone","***General Information***MAOI therapy***Asthma, bronchitis, emphysema, tobacco smoking***Fever***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, heart failure, hypertension, myocardial infarction, tachycardia***Closed-angle glaucoma, diabetes mellitus, hyperthyroidism, peripheral vascular disease, prostatic hypertrophy, urinary retention***Renal failure, renal impairment***Children, infants***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['114477'],levetiracetam,***For the adjunctive treatment of partial seizures. <br />        NOTE: Treatment may be initiated with IV or PO therapy.<br />     ***For the adjunctive treatment of myoclonic seizures in those with juvenile myoclonic epilepsy.***For the adjunctive treatment of primary generalized tonic-clonic seizures in those with idiopathic generalized epilepsy.***For the first-line treatment of convulsive status epilepticus�.***For seizure prophylaxis�.***For seizure prophylaxis� after traumatic brain injury.***Formoterol; Mometasone,"***General Information***Abrupt discontinuation***Dialysis, renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Driving or operating machinery***Depression, suicidal ideation***Psychosis, schizophrenia***Geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,colestipol hydrochloride,"***For the treatment of primary hypercholesterolemia (elevated LDL cholesterol hyperlipoproteinemia) in conjunction with dietary control in patients with hypertriglyceridemia; for the treatment of diarrhea� due to increased bile acids after surgery; for the treatment of pruritus� associated with partial biliary obstruction.***For the treatment of digoxin overdose�, digitoxin overdose�, or digitoxin toxicity�. <br />        NOTE: Colestipol binds both digoxin and digitoxin in the GI tract in the case of overdose. Because digitoxin undergoes enterohepatic circulation, colestipol is also effective in the treatment of digitoxin toxicity.<br />     ","***Biliary cirrhosis, biliary obstruction, cholelithiasis***Constipation, dysphagia, GI obstruction, hemorrhoids, ileus***Hypertriglyceridemia***Coagulopathy***Hypothyroidism***Renal disease***Phenylketonuria***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8588'],diclofenac potassium,"***For the treatment of osteoarthritis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the treatment of rheumatoid arthritis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the treatment of ankylosing spondylitis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the acute treatment of migraine with or without aura. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />NOTE: Diclofenac is not indicated for migraine prophylaxis***For the treatment of mild pain or moderate pain. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For primary dysmenorrhea or for mild or moderate pain associated with nonrheumatic inflammatory conditions, bone pain�, arthralgia�, myalgia�, and vascular or migraine headache�. <br />          NOTE: Voltaren XR is not indicated for the management of acute painful conditions.<br />       ***For the treatment of acute mild or moderate pain.***For the topical treatment of acute mild pain or moderate pain due to minor strains, sprains, and contusions. <br />          NOTE: Carefully consider the potential benefits and risks of the diclofenac patch. If the patch will be used, use the lowest effective dose for the shortest possible duration.<br />       ***For the treatment of postoperative ocular inflammation following cataract extraction.***For the reduction of photophobia and ocular pain following corneal refractive surgery.***For the treatment of moderate to severe pain alone or in combination with opioid analgesics.***For the treatment of actinic keratosis.***For the prevention of heterotopic ossification�.***Formoterol; Mometasone","***Acute bronchospasm, asthma, bovine protein hypersensitivity, gelatin hypersensitivity, nasal polyps, NSAID hypersensitivity, polysorbate 80 hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Contact lenses, ocular surgery, rheumatoid arthritis***Anemia***Dental disease, dental work***Hepatic disease, jaundice, porphyria***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, renal impairment, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Labor, pregnancy***Breast-feeding***Burns, eczema, exfoliative dermatitis, heating pad, occlusive dressing, ocular exposure, skin abrasion***Benzyl alcohol hypersensitivity, sunlight (UV) exposure***Coronary artery bypass graft surgery (CABG)***Accidental exposure***Phenylketonuria***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['343048'],treprostinil,"***For the treatment of pulmonary hypertension.***For the treatment of pulmonary arterial hypertension (WHO Group 1) to diminish symptoms associated with exercise.***For patients transitioning from epoprostenol to intravenous or subcutaneous treprostinil. <br />          NOTE: The transition from epoprostenol to treprostinil should take place in a hospital with continuous observation to response (e.g., walking distance and signs and symptoms of disease progression).<br />       ***For patients transitioning from intravenous or subcutaneous treprostinil to oral treprostinil.***For temporary subcutaneous or intravenous treprostinil infusion in patients unable to take oral treprostinil due to a planned, short-term treatment interruption.***For the treatment of severe intermittent claudication� in patients with Fontaine classes IIb�III symptoms.","***General Information***Intravenous administration***Abrupt discontinuation***Asthma, chronic obstructive pulmonary disease (COPD), pulmonary disease***Hypotension***Bleeding***Hepatic disease, hepatitis***Renal disease, renal failure, renal impairment***Geriatric***Diverticulitis***Alcoholism***Labor, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fludrocortisone acetate,"***For the treatment of primary and secondary adrenocortical insufficiency in Addison's disease and salt-losing adrenogenital syndrome. <br />        NOTE: Dosage depends on disease severity and patient response. Close monitoring is necessary for signs indicating possible dosage adjustment such as remissions or exacerbations of the disease and stressors like surgery, infection, or trauma.<br />NOTE: All classic congenital adrenal hyperplasia patients should be treated with fludrocortisone at diagnosis in the newborn period***For the treatment of neurogenic orthostatic hypotension�.","***Cardiac disease, heart failure, hepatic disease, hypertension, renal disease***Myocardial infarction***Cataracts***Fungal infection, infection, measles, tuberculosis, varicella***Coagulopathy, Cushing's syndrome, diabetes mellitus, diverticulitis, geriatric, GI disease, herpes infection, hypothyroidism, myasthenia gravis, osteoporosis, psychosis, seizure disorder, ulcerative colitis***Surgery***Children, infants***Pregnancy***Breast-feeding***Corticosteroid hypersensitivity***Lactase deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['11516'],doxercalciferol,"***For the treatment of secondary hyperparathyroidism and resultant bone disease (renal osteodystrophy�).***For initial dosing and dosage titration in pre-dialysis patients with Stage 3 or Stage 4 chronic kidney disease (CrCl 15 to 59 mL/min/1.73m2).***For initial dosing and dosage titration in predialysis patients with Stage 3 or 4 chronic kidney disease (National Kidney Foundation guidelines). <br />  NOTE: Doxercalciferol is indicated when serum 25-(OH)-vitamin D are greater than 30 ng/mL and plasma iPTH concentrations are greater than 70 pg/mL (Stage 3) or greater than 110 pg/mL (Stage 4); serum calcium concentrations should be less than 9.5 mg/dL and serum phosphorous concentrations should be less than 4.6 mg/dL.<br /***For patients with Stage 5 chronic kidney disease on dialysis.***For initial dosing and dosage adjustments for patients with Stage 5 chronic kidney disease on dialysis (National Kidney Foundation Guidelines). <br />          NOTE: Serum phosphorous concentrations should be less than 5.5 mg/dL and the Calcium-Phosphorous product should be less than 55. Serum calcium concentrations should be less than 9.5 mg/dL in patients with a serum iPTH less than 1000 pg/mL. In patients with a serum iPTH greater than 1000 pg/mL, the serum calcium concentration should be less than 10 mg/dL.<br />       ",***General Information***Hypercalcemia***Children***Hypervitaminosis D***Hepatic disease***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['3264']['10627', '220333']",dexamethasone/tobramycin,"***For the treatment of corticosteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ophthalmic infection or a risk of bacterial infection exists, including bacterial conjunctivitis, chronic anterior uveitis, and corneal injury (corneal abrasion) from chemical, radiation or thermal burns, or penetration of foreign bodies.","***General Information***Aminoglycoside hypersensitivity, corticosteroid hypersensitivity***Contact lenses***Fungal infection, mycobacterial infection, ocular infection, varicella, viral infection***Diabetes mellitus, increased intraocular pressure, myopia, open-angle glaucoma***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['83947'],tazarotene,"***For the treatment of stable plaque psoriasis. <br />  NOTE: According to the American Academy of Dermatology (AAD), tazarotene is best used in combination with a topical corticosteroid for the treatment of psoriasis. Combination therapy may produce a synergistic effect, increase duration of treatment benefit and length of remission, and potentially decrease steroid-induced atrophy.<br /***For the topical treatment of acne vulgaris.***For adjunctive treatment of fine facial wrinkles and facial mottled hyperpigmentation (i.e., 'liver spots') and hypopigmentation associated with photoaging.","***General Information***Pregnancy***Breast-feeding***Children, infants, neonates***Eczema***Retinoid hypersensitivity***Benzyl alcohol hypersensitivity***Skin cancer, skin photosensitivity disorder, sunburn, sunlight (UV) exposure***Accidental exposure, occlusive dressing, ocular exposure***Contraception requirements, females, pregnancy testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10379'],testosterone,***For the treatment of delayed puberty in males.***For palliative treatment of breast cancer that is inoperable in women.***For the treatment of postpubertal cryptorchidism�.***For the treatment of microphallus�.***For the treatment of anemia� in patients with chronic renal failure.***For female-to-male gender change (trans-sexualism�).***For the treatment of lichen sclerosus�.***For the treatment of AIDS-associated wasting syndrome�.,"***Benzoic acid hypersensitivity, benzyl alcohol hypersensitivity, polyoxyethylated castor oil hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis, soya lecithin hypersensitivity***Magnetic resonance imaging (MRI)***Intramuscular administration, intravenous administration***Breast cancer, geriatric, prostate cancer, prostatic hypertrophy***Cardiac disease, coronary artery disease, heart failure, hepatic disease, myocardial infarction, renal disease, stroke***Obesity, pulmonary disease***Polycythemia***Accidental exposure, females***Contraception requirements, labor, obstetric delivery, pregnancy, reproductive risk***Breast-feeding***Diabetes mellitus***Hypercalcemia***Pulmonary oil microembolism***Nasal polyps, nasal septal perforation, nasal surgery, nasal trauma, rhinorrhea, Sjogren's syndrome***Children, infants, neonates***Substance abuse***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1999'],carbachol,***For intraocular miosis induction during surgery and to reduce increased intraocular pressure during the first 24 hours after cataract surgery.***For lowering intraocular pressure in the treatment of glaucoma. <br />        NOTE: For topical ophthalmic use only. Not for injection.<br />     ,"***Asthma***Peptic ulcer disease***Iritis***Retinal detachment***Contact lenses***Corneal abrasion***Acute heart failure, cardiac disease, hypertension, hypotension, myocardial infarction***Parkinson's disease***Urinary tract obstruction***Hyperthyroidism***Driving or operating machinery***Pregnancy***Breast-feeding***Children, infants, neonates***Latex hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4136'],ethotoin,***For the treatment of generalized tonic-clonic seizures and complex-partial seizures (as a second line or adjunct therapy). <br />        NOTE: Ethotoin is usually administered with other anticonvulsants.<br />     ,"***General Information***Depression, suicidal ideation***Hypoglycemia, hyponatremia, petit mal (absence) seizures***Barbiturate hypersensitivity, carbamazepine hypersensitivity, hydantoin hypersensitivity***Agranulocytosis, anemia, bleeding, hematological disease, infection, leukopenia, thrombocytopenia***Hepatic disease, jaundice***Abrupt discontinuation, status epilepticus***Neonates, obstetric delivery, pregnancy, vitamin K deficiency***Breast-feeding***Geriatric***Dental work***Diabetes mellitus***Driving or operating machinery***Osteomalacia, osteoporosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10865'],ketorolac tromethamine,"***For the reduction of postoperative ocular inflammation and ocular pain following cataract ocular surgery or corneal refractive surgery .***For the reduction of postoperative ocular inflammation and ocular pain following cataract surgery.***For the reduction of ocular pain and burning/stinging following corneal refractive surgery.***For the treatment of ocular pruritus due seasonal allergic conjunctivitis.***For the short-term treatment of moderate pain or moderately severe pain that requires analgesia at the opioid level, including bone pain�, dental pain�, arthralgia�, and myalgia�.***For the short-term treatment of moderately severe pain.***For the short-term treatment of moderate pain.***For the treatment of acute, severe headache�, including migraine�.***Formoterol; Mometasone","***Limit duration of use***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, serious hypersensitivity reactions or anaphylaxis, urticaria***Bleeding, surgery***Alcoholism, chemotherapy, Crohn's disease, GI bleeding, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease, hypoalbuminemia, jaundice***Dehydration, diabetes mellitus, edema, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery bypass graft surgery (CABG), coronary artery disease, heart failure, hypertension, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Anemia, bone marrow suppression, hematological disease, immunosuppression, intracranial bleeding, neutropenia, thrombocytopenia***Keratitis, ocular disease, ocular surgery***Contact lenses***Epidural administration, intrathecal administration***Children, infants, neonates***Caesarean section, labor, obstetric delivery, pregnancy***Breast-feeding***Ocular exposure***Geriatric***Lactase deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['10627', '220333']",tobramycin,"***For the treatment of bone and joint infections, skin and skin structure infections (burn wound infection), and meningitis. <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight.<br />     ***For intrathecal� or intraventricular� administration in patients with meningitis.***For treatment of lower respiratory tract infections, including community-acquired pneumonia (CAP) and nosocomial pneumonia. <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight.<br />     ***For the treatment of external infections of the eye including, of blepharitis, blepharoconjunctivitis, bacterial conjunctivitis, dacryocystitis, keratitis, keratoconjunctivitis, and acute meibomianitis.***For the treatment of complicated or recurrent urinary tract infection (UTI). <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight.<br />     ***For the treatment of intraabdominal infections, including peritonitis. <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight.<br />     ***For peritoneal dialysis-associated peritonitis in patients with end-stage renal disease.***For the treatment of bacteremia and sepsis. <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight.<br />     ***For the empiric treatment of febrile neutropenia�.***For the treatment of febrile neutropenia in adults.***For the treatment of febrile neutropenia in pediatric patients.***For surgical infection prophylaxis�.***Formoterol; Mometasone","***General Information***Dehydration, nephrotoxicity, renal disease, renal failure, renal impairment***Hearing impairment, neurotoxicity, ototoxicity, tinnitus***Aminoglycoside hypersensitivity***Botulism, electrolyte imbalance, myasthenia gravis, neuromuscular disease, parkinsonism, respiratory depression, respiratory insufficiency***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Acute bronchospasm, corneal abrasion***Pregnancy***Breast-feeding***Neonates, premature neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,calcium formate/copper oxide/ferrous asparto glycinate/magnesium oxide/potassium iodine/vitamin A (beta-carotene)/vitamin B1 (thiamine mononitrate)/vitamin B2 (riboflavin)/vitamin B3 (niacinamide)/vitamin B6 (pyridoxine hydrochloride)/vitamin B7 (biotin)/vitamin B9 (folic acid)/vitamin B12 (cyanocobalamin)/vitamin C (ascorbic acid)/vitamin D3 (cholecalciferol)/vitamin E (dl-alpha tocopheryl acetate)/zinc oxide,"***For nutritional supplementation of females of child-bearing potential during pre-conception, pregnancy or lactation.***Formoterol; Mometasone","***General Information***Accidental exposure, children, infants***Anticoagulant therapy, bleeding***Breast-feeding, pregnancy***Pernicious anemia, vitamin B12 deficiency megaloblastic anemia***Hemochromatosis, hemosiderosis, hepatic disease, sideroblastic anemia, thalassemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,betaxolol hydrochloride,***For the treatment of hypertension.***For the treatment of chronic open-angle glaucoma and ocular hypertension. <br />        NOTE: Beta-blockers are generally less effective in the treatment of angle-closure glaucoma than for open angle-glaucoma.�<br />     ,"***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***AV block, bradycardia, cardiogenic shock, heart failure, pheochromocytoma, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Diabetes mellitus***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Surgery***Dialysis, renal disease, renal failure, renal impairment***Neonates, pregnancy***Breast-feeding***Driving or operating machinery***Cerebrovascular disease, peripheral vascular disease, Raynaud's phenomenon***Depression***Psoriasis***Myasthenia gravis***Contact lenses***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,chenodiol,"***For treatment of cholelithiasis via the dissolution of radiolucent cholesterol gallstones. <br />  NOTE: Chenodiol is indicated for use in patients with radiolucent stones who are ineligible for surgery because of systemic disease or age. Successful dissolution of stones is more likely in patients presenting with small or floatable stones; for patients with non-floatable stones, the risk of unsuccessful medical treatment should be weighed against the risk of postponed surgical intervention.<br />NOTE: Chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones","***General Information***Bile acid agents hypersensitivity***Surgery***Biliary cirrhosis, biliary obstruction, biliary tract disease, biliary-GI fistula, cholangitis, cholestasis, gallbladder disease, pancreatitis***Hepatic disease***Diarrhea***New primary malignancy***Hypercholesterolemia***Children***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,etidronate disodium,"***For the treatment of moderate to severe Paget's disease.***For the treatment of heterotopic ossification. <br />        NOTE: Retreatment has not been studied.<br />     ***For heterotopic ossification resulting from spinal cord injury.***For heterotopic ossification following total hip arthroplasty.***For the treatment of hypercalcemia associated with malignant neoplasms. <br />        NOTE: Etidronate has been designated an orphan drug by the FDA for this indication.<br />     ***For osteoporosis�.***For the treatment of postmenopausal osteoporosis�.***For prevention of corticosteroid-induced osteoporosis (i.e., osteoporosis prophylaxis�).","***General Information***Asthma, phosphonate hypersensitivity***Osteomalacia***Pregnancy***Breast-feeding***Children***Achalasia, colitis, dysphagia, esophageal stricture, esophagitis, gastritis, gastroesophageal reflux disease (GERD), GI disease, GI perforation, hiatal hernia, inability to stand or sit upright, peptic ulcer disease***Renal failure, renal impairment***Hyperparathyroidism, hypocalcemia, vitamin D deficiency***Anemia, chemotherapy, coagulopathy, corticosteroid therapy, dental disease, dental work, infection***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1819']['7242'],buprenorphine/naloxone,***For the treatment of opiate agonist dependence.***For maintenance treatment in patients with opioid dependence.***Formoterol***Formoterol; Mometasone,"***General Information***Opiate agonist hypersensitivity***Abrupt discontinuation, intravenous administration, parenteral administration, substance abuse***Dental work, surgery***Anxiety***Constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, toxic megacolon, ulcerative colitis***Accidental exposure, children, infants***Activities requiring coordination and concentration, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), CNS depression, coadministration with other CNS depressants, cor pulmonale, driving or operating machinery, emphysema, ethanol intoxication, heart failure, pulmonary disease, respiratory depression, respiratory insufficiency, suicidal ideation***Coma, head trauma, hypoxemia, increased intracranial pressure, intracranial mass***Labor, neonatal opioid withdrawal syndrome, neonates, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, urethral stricture, urinary retention, urinary tract obstruction***Biliary cirrhosis, biliary obstruction, biliary tract disease, gallbladder disease***Opioid-naive patients***Geriatric***Adrenal insufficiency, hypothyroidism, myxedema***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['41493'],meloxicam,***For the relief of the signs and symptoms of osteoarthritis.***For the relief of the signs and symptoms of rheumatoid arthritis.***For the relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA).***Formoterol; Mometasone,"***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, heart failure, hypertension, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Coronary artery bypass graft surgery (CABG)***Alcoholism, anticoagulant therapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking***Hepatic disease, jaundice***Dehydration, hypovolemia, peripheral edema, renal disease, renal failure, renal impairment***Anemia***Bone marrow suppression, immunosuppression, neutropenia***Geriatric***Infertility, reproductive risk***Labor, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,verapamil hydrochloride,"***For the treatment of ischemic heart disease including variant angina (Prinzmetal's angina), unstable angina, and chronic stable angina.***For rapid conversion of narrow-complex paroxysmal supraventricular tachycardia (PSVT) (including those associated with accessory bypass tracts such as Wolff-Parkinson-White or Lown-Ganong-Levine) to sinus rhythm.***For paroxysmal supraventricular tachycardia (PSVT) prophylaxis due to re-entry.***For the treatment of atrial flutter or atrial fibrillation.***For the acute, temporary ventricular rate control in cases of atrial flutter or atrial fibrillation except when associated with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome.***For ventricular rate control in patients with chronic atrial flutter and/or atrial fibrillation in combination with digoxin.***For ventricular rate control in patients with chronic atrial flutter or atrial fibrillation.***For the treatment of hypertension.***For migraine prophylaxis�.***For the treatment of acute mania�.***For the treatment of intermittent claudication� due to peripheral vascular disease (PVD)�.***For the relief of ongoing ischemia after acute myocardial infarction� in the absence of congestive heart failure, left ventricular dysfunction, or AV block, when beta-blockers are ineffective or contraindicated.","***General Information***Acute myocardial infarction, bradycardia, cardiogenic shock, heart failure, ventricular dysfunction***Lown-Ganong-Levine syndrome, ventricular tachycardia, Wolff-Parkinson-White syndrome***Hypotension***AV block, sick sinus syndrome***Hepatic disease, renal disease, renal failure, renal impairment***Cardiomyopathy***Aortic stenosis***Myasthenia gravis, neuromuscular disease***Constipation, fecal impaction, gastroesophageal reflux disease (GERD), GI obstruction, hiatal hernia, ileus***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,carglumic acid,"***For the treatment of hyperammonemia in patients with N-acetylglutamate synthase deficiency both as an adjunctive therapy for the treatment of acute hyperammonemia and as maintenance therapy for chronic hyperammonemia. <br />        NOTE: Treat any episode of acute symptomatic hyperammonemia as a life-threatening emergency. Uncontrolled hyperammonemia can rapidly result in brain injury/damage or death, and prompt use of all therapies necessary to reduce plasma ammonia concentrations is essential. During acute hyperammonemic episodes, concomitant administration of carglumic acid with other ammonia lowering therapies such as alternate pathway medications, hemodialysis, and dietary protein restriction/hypercaloric intake to block ammonia generating catabolic pathways is recommended.<br />NOTE: During maintenance therapy, the concomitant use of other ammonia lowering therapies and protein restriction may be reduced or discontinued based on plasma ammonia concentrations. Maintain plasma ammonia concentrations within normal range for age via individual dose adjustment.<br />NOTE: Manage hyperammonemia due to NAGS deficiency in coordination with medical personnel experienced in metabolic disorders. Ongoing monitoring of plasma ammonia concentrations, neurological status, laboratory tests, and clinical responses in patients receiving carglumic acid is crucial to assess patient response to treatment.<br />NOTE: Carglumic acid is designated as an orphan drug for the treatment of N-acetylglutamate synthase deficiency",***Pregnancy***Breast-feeding***Geriatric,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/levonorgestrel,"***For routine contraception.***For extended continuous routine contraception.***For use as postcoital contraception within 72 hours of unprotected intercourse, or known or suspected contraceptive failure, in females who have no known contraindications to oral contraceptives, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5492'],hydrocortisone,"***For the treatment of primary adrenocortical insufficiency (e.g., Addison's Disease, congenital adrenal hyperplasia or CAH) or secondary adrenocortical insufficiency.***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing minor surgery or with a minor illness (e.g., inguinal hernia repair, colonoscopy, mild febrile illness, gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing moderate surgery or with a moderate illness (e.g., open cholecystectomy, hemicolectomy, significant febrile illness, pneumonia, severe gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing major surgery, or with other acute stressors (e.g., major cardiothoracic surgery, Whipple procedure, liver resection, pancreatitis, acute systemic infection, shock).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency and a critical illness (e.g., shock).***For the treatment of acute adrenocortical insufficiency.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency with other acute stressors (e.g., febrile illness with a temperature more than 38.5 degrees Celsius, gastroenteritis with dehydration, major trauma):.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency undergoing surgery accompanied by general anesthesia.***For use in nonspecific proctitis, postirradiation (factitial) proctitis, cryptitis, or for other non-specific inflammatory conditions of the anorectum.***For the treatment of inflammatory bowel disease (Crohn's disease or ulcerative colitis).***For adjunctive treatment of Crohn's disease or ulcerative colitis using oral or parenteral therapy.***For adjunctive rectal treatment of chronic ulcerative colitis, particularly if disease limited to the distal portion of the rectum.***For the relief of inflammation, pruritus ani, and swelling associated with hemorrhoids.***For the treatment of allergic disorders including anaphylaxis, anaphylactic shock, or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, transfusion-related reactions, serum sickness, severe perennial or seasonal allergic rhinitis, or urticaria.***For the non-emergent treatment of hypersensitivity or allergic conditions.***For the urgent treatment of severe conditions such as anaphylaxis, angioedema, acute noninfectious laryngeal edema, or urticarial transfusion-related reactions.***For the treatment of corticosteroid-responsive dermatologic disorders (e.g., alopecia areata, atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis including Rhus dermatitis due to poison ivy, poison oak, poison sumac, discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pompholyx (dyshidrosis), pruritus, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, xerosis).***For mild-to-moderate corticosteroid responsive dermatoses.***For mild to moderate atopic dermatitis.***For the systemic treatment of severe inflammatory dermatoses, like severe exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, or psoriasis unresponsive to topical treatment.***For adjunctive therapy in the treatment of rheumatic disorders including acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of non-rheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the short-term treatment of hypercalcemia associated with neoplastic disease.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the management of nephrotic syndrome to induce diuresis or decrease proteinuria.***For the treatment of neurologic or myocardial involvement associated with trichinosis.***For the treatment of nonsuppurative thyroiditis.***For rheumatic and related disorders such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, symptomatic sarcoidosis, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive hematologic disorders, like immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia, and congenital hypoplastic anemia; OR for the palliative treatment of neoplastic disease in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), or multiple myeloma�.***For the treatment of respiratory inflammatory conditions including bronchial asthma, aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), Loeffler's syndrome, or noncardiogenic pulmonary edema�.***For the treatment of septic shock� and/or hypotension� in patients whose blood pressure is poorly responsive to adequate fluid resuscitation and vasopressor therapy.***For the prevention of chronic lung disease (CLD)� in mechanically ventilated patients.***For the treatment of refractory neonatal hypoglycemia�.***For the treatment of corticosteroid-responsive ophthalmic disorders, including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.","***Abrupt discontinuation, Cushing's syndrome, skin abrasion***Growth inhibition, increased intracranial pressure***Immunosuppression***Fungal infection, infection***Acne rosacea, acne vulgaris, herpes infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Heart failure, hypertension***Osteoporosis***Diabetes mellitus***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hypothyroidism, psychosis, renal disease, seizure disorder***Myasthenia gravis***Coagulopathy, hemophilia, thromboembolic disease***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Neonates, premature neonates***Benzyl alcohol hypersensitivity, corticosteroid hypersensitivity***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Skin atrophy***Geriatric***Epidural administration, intrathecal administration***Pheochromocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,promethazine hydrochloride,"***For the prevention of motion sickness.***For the treatment of active nausea/vomiting, including post-operative nausea/vomiting (PONV) and for�post-operative nausea/vomiting (PONV) prophylaxis.***For the treatment of allergic manifestations, such as pruritus.***For the treatment of allergic rhinitis�.***For sedation induction.***For sedation in obstetrics.***For relief of apprehension and to induce quiet sleep from which the patient can be easily aroused.***For preoperative or postoperative procedural sedation, as an adjunct to analgesics.***For the treatment of acute peripheral vestibular nystagmus�.***For pregnancy-induced nausea/vomiting�, including hyperemesis gravidarum�.","***General Information***Agranulocytosis, bone marrow suppression, coma, jaundice, phenothiazine hypersensitivity***Extravasation, intraarterial administration, intravenous administration, subcutaneous administration, tissue necrosis***Seizure disorder***Acute bronchospasm, asthma, chronic obstructive pulmonary disease (COPD), respiratory depression, sleep apnea, sulfite hypersensitivity***Hepatic disease, hepatic encephalopathy***Children, dehydration, infants, neonates, Reye's syndrome***Labor, obstetric delivery, pregnancy***Breast-feeding***Contact lenses, glaucoma***Bladder obstruction, GI obstruction, ileus, prostatic hypertrophy, urinary retention***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Radiographic contrast administration***CNS depression, driving or operating machinery, ethanol intoxication***Diabetes mellitus***Anticholinergic medications, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ursodiol,"***For treatment of cholelithiasis via the dissolution of radiolucent cholesterol gallstones.***For gallstone dissolution via use of ursodiol alone.***For treating single radiolucent gallstones of 4�20 mm diameter by combining ursodiol therapy with lithotripsy (e.g., Medstone).***For gallstone prophylaxis during rapid weight loss.***For the treatment of cholestatic hepatobiliary disorders and their symptoms (e.g., pruritus�).***For the treatment of primary biliary cirrhosis (PBC). <br />          NOTE: Ursodiol is designated an orphan drug by the FDA for this indication.<br />       ***For the treatment of cholestasis� secondary to cystic fibrosis�.***For the treatment of intrahepatic cholestasis of pregnancy (ICP)�.***For the treatment of primary sclerosing cholangitis (PSC)�.***For use as an adjunct to prevent biliary stent occlusion� after surgical placement to palliate malignant biliary obstruction secondary to pancreatic cancer.***For adjunctive treatment of biliary atresia or chronic cholestasis (e.g., genetic bile acid biosynthesis disorder).***For the treatment of non-alcoholic steatosis-hepatitis (NASH)�.","***General Information***Bile acid agents hypersensitivity***Ascites, biliary obstruction, biliary tract disease, biliary-GI fistula, bleeding, cholangitis, encephalopathy, esophageal varices, jaundice, pancreatitis***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['598'],alprostadil,"***For the treatment of neonates with congenital heart defects to maintain the patency of the ductus arteriosus (ductus arteriosus maintenance) until palliative or corrective surgery can be performed.***For the treatment of erectile dysfunction (ED). <br />        NOTE: Per ED guidelines, second-line treatment options for ED treatment include intracavernous injection and intra-urethral therapy. Intracavernous injection therapy is the most effective nonsurgical treatment for ED, with predictable and sustained response. However, it is invasive and caries notable side-effects including priapism and penile fibrosis. Careful dose selection, proper patient education, and continued monitoring by a prescribing physician is warranted for successful non-oral treatment of ED. Follow-up visits for ED patients, regardless of therapy, are necessary to determine whether therapy continues to be effective and whether cardiovascular health has significantly changed.<br />     ***For erectile dysfunction due to vasculogenic, psychogenic, or mixed causes or following post-radical prostatectomy�.***For erectile dysfunction due to neurogenic origin.***For the treatment of ED in combination with other vasoactive agents (i.e., papaverine, phentolamine)�.","***General Information***Benzyl alcohol hypersensitivity, children, infants, neonates***Apnea, premature neonates, requires a specialized care setting, respiratory depression***GI obstruction***Respiratory distress syndrome***Cardiac disease, driving or operating machinery, hypotension, syncope***Anticoagulant therapy, bleeding, coagulopathy***Balanitis, hypospadia, penile implants, penile structural abnormality, Peyronie's disease, urethral stricture, urethritis***Leukemia, multiple myeloma, polycythemia, priapism, sickle cell disease, thrombocytosis***Geriatric, renal impairment***Contraception requirements, females, labor, pregnancy, sexually transmitted disease***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['35617', '262139']",rifapentine,"***For the treatment of tuberculosis infection (i.e., active pulmonary tuberculosis) in conjunction with at least one other antituberculosis agent. <br />  NOTE: Rifapentine MUST be used in combination with other antituberculosis agents; DO NOT administer as monotherapy.<br />NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., at least 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, IDSA, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. Directly observed therapy (DOT) should be used for all regimens administered 1, 2, 3, or 5 times per week. The initial treatment regimen should include four drugs unless the likelihood of INH or rifampin resistance is low (i.e., &lt; 4%), in which case an initial regimen of INH, rifampin, and pyrazinamide may be considered. HIV-infected patients should always receive induction therapy with four drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate.   For multi-drug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, the CDC recommends treatment for 18�24 months after culture conversion in patients with bacteriologic confirmation and for at least 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months in MDR-TB***For tuberculosis prophylaxis or the treatment of latent tuberculosis infection (LTBI) in patients at high risk for progressing to tuberculosis disease. <br />        NOTE: Rifapentine MUST ALWAYS be used in combination with isoniazid when treating latent tuberculosis.<br />     ","***General Information***Viral infection***Rifamycin hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Hepatic disease***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric***Human immunodeficiency virus (HIV) infection***Porphyria***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,morphine sulfate,"***For the relief of acute and chronic moderate pain or severe pain. <br />        NOTE: There is substantial interpatient variability in the relative potency of different opioid drugs and products. FDA-approved labeling defines adult opioid-tolerant patients as those who take the following per day for a minimum of 1 week: oral morphine 60 mg or more; oral oxycodone 30 mg or more; oral hydromorphone 8 mg or more; oral oxymorphone 25 mg or more; 60 mg oral hydrocodone or more; transdermal fentanyl 25 mcg or more per hour; or another opioid at an equivalent dose. <br />     ***For acute moderate to severe pain related to major orthopedic surgery of the lower extremity.***For acute moderate to severe pain related to lower abdominal or pelvic surgery.***For acute moderate to severe pain related to cesarean section after delivery and clamping of the umbilical cord.***For the management of chronic severe pain in patients who require daily, around-the-clock, long-term opioid treatment. <br />  NOTE: Reserve extended-release morphine for when alternative options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would otherwise provide inadequate pain management. Discontinue all other around-the-clock opioids upon initiation.  <br />NOTE: Do not use the following morphine products in opioid-naive patients: 60 mg, 90 mg, or 120 mg biphasic-release capsules (Avinza); 100 mg, 130 mg, 150 mg, or 200 mg extended-release capsules (Kadian); 100 mg or 200 mg controlled-release tablets (MS Contin); 100 mg extended-release tablets (Morphabond). In this population, use could result in fatal respiratory depression. Use of a single dose of more than 60 mg, or a total daily dose more than 120 mg, should be limited to opioid-tolerant patients.   <br />NOTE: There is substantial interpatient variability in the relative potency of different opioid drugs and products. FDA-approved labeling defines adult opioid-tolerant patients as those who take the following per day for a minimum of 1 week: oral morphine 60 mg or more; oral oxycodone 30 mg or more; oral hydromorphone 8 mg or more; oral oxymorphone 25 mg or more; oral hydrocodone 60 mg or more; transdermal fentanyl 25 mcg or more per hour; or another opioid at an equivalent dose.***For the treatment of diarrhea.***For the treatment of noninfectious diarrhea. <br />  WARNING: Proper product selection is critical. Deodorized opium tincture 10 mg/mL solution is 25 times more concentrated than camphorated opium tincture 0.4 mg/mL solution. Serious patient harm may occur with incorrect product selection.<br /***For control of diarrhea� secondary to AIDS-associated enteropathy.***For the management of dyspnea�.***For the adjuvant treatment of acute pulmonary edema�.***For acute myocardial infarction� or unstable angina� and to provide potentially beneficial cardiovascular effects.***For procedural sedation� before short diagnostic procedures or endoscopy. <br />        NOTE: Morphine should be administered as an inducing agent only by those trained in anesthesia.<br />     ***For sedation during rapid-sequence intubation�.***For the treatment of painful diabetic neuropathy�.","***Opiate agonist hypersensitivity***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, coma, cor pulmonale, emphysema, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Ethanol ingestion, ethanol intoxication***Anticoagulant therapy, coagulopathy, infection, intramuscular administration, intrathecal administration, intravenous administration, requires a specialized care setting, requires an experienced clinician, subcutaneous administration***Accidental exposure, opioid-naive patients, potential for overdose or poisoning***Abrupt discontinuation***Acute abdomen, constipation, diarrhea, GI bleeding, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Biliary tract disease***Arteriosclerosis, brain tumor, CNS depression, head trauma, increased intracranial pressure, seizure disorder, seizures, status epilepticus, strychnine toxicity***Angina, atrial fibrillation, atrial flutter, cardiac arrhythmias, cardiac disease, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal impairment, urethral stricture, urinary retention***Children, infants, neonates***Geriatric***Driving or operating machinery***MAOI therapy***Adrenal insufficiency, hypothyroidism, myxedema***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['161']['7804'],acetaminophen/oxycodone,"***For the treatment of moderate pain to moderately-severe pain.***For the treatment of acute pain severe enough to require opioid treatment and for which alternative treatment options (e.g., non-opioid analgesics) are inadequate.","***General Information***Acetaminophen hypersensitivity, opiate agonist hypersensitivity, sulfite hypersensitivity***Acute abdomen, constipation, dysphagia, esophageal stricture, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Accidental exposure, asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Abrupt discontinuation***Substance abuse***CNS depression, head trauma, increased intracranial pressure, intracranial mass, psychosis***Cardiac arrhythmias, cardiac disease, hypotension, hypovolemia, orthostatic hypotension***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, renal impairment, urethral stricture, urinary retention***Alcoholism, hepatic disease, hepatitis, hepatotoxicity, potential for overdose or poisoning***Geriatric***Children, infants, neonates***G6PD deficiency***Bone marrow suppression, immunosuppression, infection***Driving or operating machinery***Biliary tract disease, pancreatitis***Adrenal insufficiency, hypothyroidism, myxedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5032'],guaifenesin,"***For the treatment of cough associated with colds and minor upper respiratory tract infections and for loosening phlegm and thin bronchial secretions to aid in clearing bronchial passages and making coughs more productive.***For the treatment of cervical factor infertility�, including cervical mucus thickening induced by clomiphene treatment.","***General Information***Asthma, bronchitis, emphysema, heart failure, tobacco smoking***Fever***Children, infants***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['22299'],daptomycin,"***For the treatment of <em>Staphylococcus aureus</em> bacteremia.***For the treatment of complicated skin and skin structure infections, including infections caused by methicillin-resistant <em>Staphylococcus aureus</em> (MRSA).***For the treatment of endocarditis.***For the treatment of infections due to vancomycin-resistant enterococci (VRE)�.***For the treatment of MRSA-associated bone and joint infections�, including osteomyelitis� and septic/infectious arthritis�, or an orthopedic device-related infection�.***For the treatment of MRSA-associated osteomyelitis�.***For the treatment of MRSA-associated septic arthritis�.***For the treatment of MRSA-associated prosthetic device infections�.***For the treatment of MRSA-associated spinal implant infections�.***For the empiric treatment of febrile neutropenia�.","***General Information***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Myopathy, rhabdomyolysis***Peripheral neuropathy***Pregnancy***Breast-feeding***Infants, neonates***Geriatric***Eosinophilic pneumonia***Renal failure, renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydrocortisone acetate,"***For the treatment of primary adrenocortical insufficiency (e.g., Addison's Disease, congenital adrenal hyperplasia or CAH) or secondary adrenocortical insufficiency.***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing minor surgery or with a minor illness (e.g., inguinal hernia repair, colonoscopy, mild febrile illness, gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing moderate surgery or with a moderate illness (e.g., open cholecystectomy, hemicolectomy, significant febrile illness, pneumonia, severe gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing major surgery, or with other acute stressors (e.g., major cardiothoracic surgery, Whipple procedure, liver resection, pancreatitis, acute systemic infection, shock).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency and a critical illness (e.g., shock).***For the treatment of acute adrenocortical insufficiency.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency with other acute stressors (e.g., febrile illness with a temperature more than 38.5 degrees Celsius, gastroenteritis with dehydration, major trauma):.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency undergoing surgery accompanied by general anesthesia.***For use in nonspecific proctitis, postirradiation (factitial) proctitis, cryptitis, or for other non-specific inflammatory conditions of the anorectum.***For the treatment of inflammatory bowel disease (Crohn's disease or ulcerative colitis).***For adjunctive treatment of Crohn's disease or ulcerative colitis using oral or parenteral therapy.***For adjunctive rectal treatment of chronic ulcerative colitis, particularly if disease limited to the distal portion of the rectum.***For the relief of inflammation, pruritus ani, and swelling associated with hemorrhoids.***For the treatment of allergic disorders including anaphylaxis, anaphylactic shock, or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, transfusion-related reactions, serum sickness, severe perennial or seasonal allergic rhinitis, or urticaria.***For the non-emergent treatment of hypersensitivity or allergic conditions.***For the urgent treatment of severe conditions such as anaphylaxis, angioedema, acute noninfectious laryngeal edema, or urticarial transfusion-related reactions.***For the treatment of corticosteroid-responsive dermatologic disorders (e.g., alopecia areata, atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis including Rhus dermatitis due to poison ivy, poison oak, poison sumac, discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pompholyx (dyshidrosis), pruritus, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, xerosis).***For mild-to-moderate corticosteroid responsive dermatoses.***For mild to moderate atopic dermatitis.***For the systemic treatment of severe inflammatory dermatoses, like severe exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, or psoriasis unresponsive to topical treatment.***For adjunctive therapy in the treatment of rheumatic disorders including acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of non-rheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the short-term treatment of hypercalcemia associated with neoplastic disease.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the management of nephrotic syndrome to induce diuresis or decrease proteinuria.***For the treatment of neurologic or myocardial involvement associated with trichinosis.***For the treatment of nonsuppurative thyroiditis.***For rheumatic and related disorders such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, symptomatic sarcoidosis, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive hematologic disorders, like immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia, and congenital hypoplastic anemia; OR for the palliative treatment of neoplastic disease in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), or multiple myeloma�.***For the treatment of respiratory inflammatory conditions including bronchial asthma, aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), Loeffler's syndrome, or noncardiogenic pulmonary edema�.***For the treatment of septic shock� and/or hypotension� in patients whose blood pressure is poorly responsive to adequate fluid resuscitation and vasopressor therapy.***For the prevention of chronic lung disease (CLD)� in mechanically ventilated patients.***For the treatment of refractory neonatal hypoglycemia�.***For the treatment of corticosteroid-responsive ophthalmic disorders, including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.","***Abrupt discontinuation, Cushing's syndrome, skin abrasion***Growth inhibition, increased intracranial pressure***Immunosuppression***Fungal infection, infection***Acne rosacea, acne vulgaris, herpes infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Heart failure, hypertension***Osteoporosis***Diabetes mellitus***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hypothyroidism, psychosis, renal disease, seizure disorder***Myasthenia gravis***Coagulopathy, hemophilia, thromboembolic disease***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Neonates, premature neonates***Benzyl alcohol hypersensitivity, corticosteroid hypersensitivity***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Skin atrophy***Geriatric***Epidural administration, intrathecal administration***Pheochromocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,velaglucerase alfa,***For long-term enzyme replacement therapy in patients with type 1 Gaucher disease.,"***Infusion-related reactions, risk of serious hypersensitivity reactions or anaphylaxis***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA)/ferrous fumarate/polysaccharide iron complex/vitamin B6 (pyridoxine hydrochloride)/vitamin B9 (folic acid)/vitamin C (sodium ascorbate),"***For nutritional supplementation of females of child-bearing potential during pre-conception, pregnancy or lactation.***Formoterol; Mometasone","***General Information***Accidental exposure, children, infants***Anticoagulant therapy, bleeding***Breast-feeding, pregnancy***Pernicious anemia, vitamin B12 deficiency megaloblastic anemia***Hemochromatosis, hemosiderosis, hepatic disease, sideroblastic anemia, thalassemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6628'],mannitol,"***For the adjunctive treatment of edema. <br />  NOTE: In patients with marked decreased renal function, or those believed to have inadequate renal function, an initial test dose of 0.2 g/kg IV over 3 to 5 minutes should be given to produce a urine output of at least 30 to 50 ml/hr for 2 to 3 hours; this dose may be repeated if there is no improvement in urine output. If urine output does not increase after a second test dose, mannitol should not be used.<br /***For the prevention or treatment of acute renal failure (oliguria). <br />        NOTE: Data supporting the routine use of mannitol in the treatment or prevention of acute renal failure are lacking. However, mannitol may be useful in the prevention of acute renal failure for select situations if administered prior to the insult to the kidney. <br />NOTE: In patients with marked oliguria, or those believed to have inadequate renal function, an initial test dose of 0.2 g/kg IV over 3�5 minutes should be given to produce a urine output of at least 30�50 ml/hr for 2�3 hours; this dose may be repeated if there is no improvement in urine output. If urine output does not increase after a second test dose, mannitol should not be used***For the treatment of acute renal failure (oliguria).***For the treatment of post-operative acute renal failure (oliguria) after cardiac surgery.***For the prevention of acute renal failure (oliguria).***For the prevention of acute renal failure (oliguria) during cardiovascular or other types of surgery.***For the prevention of acute renal failure (oliguria) in patients undergoing renal transplantation.***For the prevention of acute renal failure (oliguria) in patients with rhabdomyolysis.***For the prevention of acute renal failure (oliguria) in patients with hemolytic transfusion reactions.***For the treatment of cerebral edema or increased intracranial pressure.***For the reduction of increased intraocular pressure.***For toxin excretion enhancement (e.g., urinary excretion of salicylates, barbiturates, bromides, lithium).***For antihemolytic urologic irrigation for transurethral prostatic resection or other transurethral surgical procedures.***For the assessment of bronchial hyper-responsiveness and bronchospasm diagnosis in patients who do not have clinically apparent asthma.***Formoterol; Mometasone","***Intracranial bleeding***Heart failure, pulmonary edema***Anuria, dehydration, electrolyte imbalance, hypovolemia, renal disease, renal failure***Geriatric***Labor, obstetric delivery, pregnancy***Breast-feeding***Gelatin hypersensitivity, mannitol hypersensitivity***Acute myocardial infarction, aneurysm, hypertension, stroke***Acute bronchospasm, asthma, requires an experienced clinician***Angina, pneumothorax, respiratory infection, surgery***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['10627', '220333']",tobramycin,"***For the treatment of bone and joint infections, skin and skin structure infections (burn wound infection), and meningitis. <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight.<br />     ***For intrathecal� or intraventricular� administration in patients with meningitis.***For treatment of lower respiratory tract infections, including community-acquired pneumonia (CAP) and nosocomial pneumonia. <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight.<br />     ***For the treatment of external infections of the eye including, of blepharitis, blepharoconjunctivitis, bacterial conjunctivitis, dacryocystitis, keratitis, keratoconjunctivitis, and acute meibomianitis.***For the treatment of complicated or recurrent urinary tract infection (UTI). <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight.<br />     ***For the treatment of intraabdominal infections, including peritonitis. <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight.<br />     ***For peritoneal dialysis-associated peritonitis in patients with end-stage renal disease.***For the treatment of bacteremia and sepsis. <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight.<br />     ***For the empiric treatment of febrile neutropenia�.***For the treatment of febrile neutropenia in adults.***For the treatment of febrile neutropenia in pediatric patients.***For surgical infection prophylaxis�.***Formoterol; Mometasone","***General Information***Dehydration, nephrotoxicity, renal disease, renal failure, renal impairment***Hearing impairment, neurotoxicity, ototoxicity, tinnitus***Aminoglycoside hypersensitivity***Botulism, electrolyte imbalance, myasthenia gravis, neuromuscular disease, parkinsonism, respiratory depression, respiratory insufficiency***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Acute bronchospasm, corneal abrasion***Pregnancy***Breast-feeding***Neonates, premature neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/ferrous fumarate/norethindrone acetate,"***For routine contraception.***For the treatment of moderate acne vulgaris related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Pregnancy***Gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Diabetes mellitus***Hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, pancreatitis***Systemic lupus erythematosus (SLE)***Surgery***Asthma, headache, hypertension, migraine, seizure disorder***Depression***Contact lenses, glaucoma, visual disturbance***Breast cancer***Hypercalcemia, hypocalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Obesity***Chloasma***Angioedema, hereditary angioedema***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,magnesium sulfate/potassium sulfate/sodium sulfate,"***For use as a bowel evacuant to clean the colon prior to colonoscopy (bowel preparation). <br />  NOTE: On the day before the colonoscopy, a light breakfast or clear liquids may be consumed. On the day of the colonoscopy, only clear liquids should be consumed. Avoid red and purple liquids, milk, and alcoholic beverages.<br /","***Colitis, gag reflex depression, gastroparesis, GI obstruction, GI perforation, ileus, inflammatory bowel disease, pyloric stenosis, toxic megacolon, ulcerative colitis***Dehydration, electrolyte imbalance, gout, hyperuricemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, vomiting***Angina, cardiac arrhythmias, cardiomyopathy, heart failure, myocardial infarction, QT prolongation***Seizure disorder***Renal impairment***Elderly***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,desmopressin acetate,"***For the management of patients with central diabetes insipidus (neurohypophyseal diabetes insipidus) including polydipsia and polyuria which occurs following head surgery or trauma.***For the treatment of primary nocturnal enuresis.***For the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.***For the management of spontaneous bleeding or trauma-induced hemorrhage (e.g., hemarthrosis, intramuscular hematomas, or mucosal bleeding, uremic bleeding�) or for bleeding prophylaxis (e.g., surgical bleeding) in selected patients.***Formoterol; Mometasone","***General Information***Renal disease, renal failure, renal impairment***Children, cystic fibrosis, diarrhea, electrolyte imbalance, fever, hyponatremia, infection, vomiting***Angina, cardiac disease, coronary artery disease, heart failure, hypertension, increased intracranial pressure, thromboembolic disease, urinary retention***Von Willebrand's disease***Nasal surgery, nasal trauma***Geriatric***Pregnancy***Breast-feeding***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,heparin sodium,"***For the treatment of deep venous thrombosis (DVT) or pulmonary embolism; for the treatment of arterial thromboembolism including cerebral thromboembolism; or for the treatment of mural thrombosis.***For thrombosis prophylaxis.***For thrombosis prophylaxis, including arterial thromboembolism prophylaxis, during extracorporeal circulation in patients undergoing open heart or other cardiovascular surgery.***For coronary artery thrombosis prophylaxis during percutaneous coronary intervention (PCI) in patients not receiving abciximab therapy.***For deep venous thrombosis (DVT) prophylaxis.***For mural thrombosis prophylaxis in patients with an acute transmural anterior myocardial infarction.***For arterial thromboembolism prophylaxis in patients with prosthetic heart valves.***For thrombosis prophylaxis and/or for pulmonary embolism prophylaxis in patients at increased risk after sustaining an acute MI (e.g., Q-wave infarction, severe LV dysfunction, CHF, history of systemic or pulmonary embolism, 2D echo evidence of mural thrombus, or atrial fibrillation).***For thrombosis prophylaxis, including arterial thromboembolism prophylaxis, during hemodialysis.***For coronary artery thrombosis prophylaxis during percutaneous coronary intervention (PCI) in patients receiving abciximab concomitantly.***For deep venous thrombosis (DVT) prophylaxis in pregnant females.***For intravascular catheter occlusion prophylaxis. <br />        NOTE: The amount of heparin solution in each single dose is sufficient to prevent clotting within the lumen of the indwelling catheter for up to 24 hours. If the catheter is used for withdrawal of repeated blood samples for laboratory tests and the presence of heparin is likely to interfere with the test, the in situ heparin flush should be cleared from the catheter by aspirating and discarding a volume of solution equivalent to that of the indwelling catheter before the desired blood sample is drawn. If the drug to be administered is incompatible with heparin, the entire catheter or lumen should be flushed with sterile water or normal saline before and after the medication is administered. Following the second flush, the heparin flush solution may be reinstilled into the set.<br />     ***For the prevention of pregnancy loss and/or thrombosis in patients with antiphospholipid antibody syndrome (APLA).***For the treatment of disseminated intravascular coagulation (DIC).***For the treatment of unstable angina. <br />        NOTE: In 2009, the USP adopted new reference standards and manufacturing controls for heparin that result in a 10% reduction in the potency. This change in heparin potency may have clinical significance in situations that require dosage adjustments and more frequent monitoring, especially when aggressive anticoagulation is needed, including pediatric patients undergoing extracorporeal membrane oxygenation, adults and children undergoing cardiopulmonary bypass, and the treatment or prevention of life-threatening thromboses. Healthcare providers should exercise clinical judgement when deciding what dose to administer and continue to individualize heparin dosing. Higher doses may be required to achieve and maintain the desired anticoagulant effect in some patients.<br />     ***For the treatment of an evolving acute myocardial infarction (AMI) (i.e., coronary artery thrombosis�) in patients who have received thrombolytic therapy with alteplase (tPA), reteplase (r-PA), or tenecteplase (TNK-tPA).. <br />        NOTE: In 2009, the USP adopted new reference standards and manufacturing controls for heparin that result in a 10% reduction in the potency. This change in heparin potency may have clinical significance in situations that require dosage adjustments and more frequent monitoring, especially when aggressive anticoagulation is needed, including pediatric patients undergoing extracorporeal membrane oxygenation, adults and children undergoing cardiopulmonary bypass, and the treatment or prevention of life-threatening thromboses. Healthcare providers should exercise clinical judgement when deciding what dose to administer and continue to individualize heparin dosing. Higher doses may be required to achieve and maintain the desired anticoagulant effect in some patients.<br />     ***For patients receiving streptokinase or anistreplase (APSAC) concurrently.***Formoterol; Mometasone","***General Information***Asthma, benzyl alcohol hypersensitivity, corn hypersensitivity, heparin hypersensitivity, porcine protein hypersensitivity, sulfite hypersensitivity***Heparin-induced thrombocytopenia (HIT), thrombocytopenia***Aneurysm, bleeding, coagulopathy, diverticulitis, endocarditis, head trauma, hemophilia, hypertension, hypotension, inflammatory bowel disease, lumbar puncture, menstruation, peptic ulcer disease, spinal anesthesia, surgery, vaginal bleeding***Intracranial bleeding***Fever, infection, myocardial infarction, neoplastic disease, thrombophlebitis***Disseminated intravascular coagulation (DIC), hepatic disease, renal disease***Infants, neonates, premature neonates***Geriatric***Intramuscular administration, intramuscular injections***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['658708'],ecallantide,***For the treatment of acute attacks of hereditary angioedema (HAE).,"***Ecallantide hypersensitivity, requires an experienced clinician, serious hypersensitivity reactions or anaphylaxis***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],desogestrel/ethinyl estradiol,"***For routine contraception.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�,  abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Edema, hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3264']['7299'],dexamethasone/neomycin sulfate/polymyxin B sulfate,"***For steroid-responsive inflammatory ocular inflammation conditions (e.g., uveitis, bacterial conjunctivitis, corneal abrasion) for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. <br />        NOTE: Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies.<br />     ","***General Information***Fungal infection, herpes simplex keratitis (dendritic keratitis), mycobacterial infection, varicella, viral infection***Aminoglycoside hypersensitivity, corticosteroid hypersensitivity, neomycin hypersensitivity, polymyxin hypersensitivity***Cataracts, glaucoma, herpes infection, increased intraocular pressure, ocular infection, ocular surgery, visual disturbance***Abrupt discontinuation, corticosteroid withdrawal***Intramuscular administration, intravenous administration***Children, infants, neonates***Pregnancy***Breast-feeding***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bupropion hydrochloride,"***For the treatment of major depression.***For the prevention of seasonal major depressive disorder episodes associated with seasonal affective disorder (SAD).***For use as an adjunct to psychosocial interventions in the management of tobacco cessation (smoking cessation).***For use alone to aide in tobacco cessation.***For aide with tobacco cessation using bupropion in combination with a nicotine transdermal system (NTS).***For the treatment of attention-deficit hyperactivity disorder (ADHD)�.***For use as monotherapy of attention-deficit hyperactivity disorder (ADHD)� in adults.***For the symptomatic treatment of neuropathic pain� due to various causes, including pain associated with peripheral diabetic neuropathy� or postherpetic neuralgia�.***Formoterol; Mometasone","***General Information***Alcoholism, anorexia nervosa, benzodiazepine withdrawal, brain tumor, bulimia nervosa, diabetes mellitus, head trauma, hypoglycemia, hyponatremia, hypoxemia, intracranial mass, obesity treatment, seizure disorder, seizures, stroke, substance abuse***Children, suicidal ideation***Tics, Tourette's syndrome***Behavioral changes, bipolar disorder, depression, mania, psychiatric event, schizophrenia***MAOI therapy***Neonates, pregnancy***Breast-feeding***Hepatic disease***Renal disease, renal failure, renal impairment***Acute myocardial infarction, cardiac disease, heart failure, hypertension, tobacco smoking***Geriatric***Driving or operating machinery, ethanol intoxication***Closed-angle glaucoma, increased intraocular pressure***Abrupt discontinuation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,vardenafil hydrochloride,***For the treatment of erectile dysfunction (ED) including ED associated with diabetes or after radical prostatectomy.,"***General Information***Nitrate/nitrite therapy***Hepatic disease, renal disease, renal failure, renal impairment***Geriatric***Alcoholism, angina, aortic stenosis, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, idiopathic hypertrophic subaortic stenosis, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, stroke, thyroid disease***Leukemia, multiple myeloma, penile structural abnormality, polycythemia, priapism, sickle cell disease***Human immunodeficiency virus (HIV) infection***Non-arteritic anterior ischemic optic neuropathy, retinitis pigmentosa, visual disturbance***Pregnancy***Breast-feeding***Children, infants, neonates***Gastroesophageal reflux disease (GERD), hiatal hernia***Coagulopathy, peptic ulcer disease***Hearing impairment, tinnitus***Phenylketonuria***Hereditary fructose intolerance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,polymyxin B sulfate/trimethoprim,"***For the treatment of ocular infections, including bacterial conjunctivitis and blepharoconjunctivitis, caused by susceptible strains of bacteria.","***Polymyxin hypersensitivity, trimethoprim hypersensitivity***Infection***Contact lenses***Infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diphenhydramine hydrochloride,"***For the treatment of urticaria, pruritus, or supportive treatment of allergic reactions; also for treating symptoms (e.g., rhinorrhea, sneezing) associated with allergic rhinitis or the common cold, and for cough caused by minor throat and bronchial irritation.***For prevention and treatment of allergic rhinitis, urticaria, pruritus, or allergic reactions under prescription of a healthcare professional.***For non-prescription self-treatment of symptoms associated with allergic rhinitis or the common cold.***For non-prescription self-treatment of cough caused by minor throat and bronchial irritation.***For the prevention and treatment of motion sickness or vertigo.***For the treatment of insomnia.***For the treatment of parkinsonism or Parkinson's disease.***For the treatment of drug-induced extrapyramidal symptoms.***For the treatment of local reactions to insect bites or stings, allergic contact dermatitis, or Rhus dermatitis due to poison ivy/oak/sumac.***For the treatment of acute peripheral vestibular nystagmus�.","***Asthma, chronic obstructive pulmonary disease (COPD)***Children, infants, neonates***Pregnancy***Breast-feeding***Closed-angle glaucoma, contact lenses, increased intraocular pressure***Bladder obstruction, GI obstruction, ileus, prostatic hypertrophy, urinary retention***Hepatic disease***Cardiac disease, hypertension***Driving or operating machinery***Accidental exposure, ocular exposure, potential for overdose or poisoning***Anticholinergic medications, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,liotrix (T3;T4),"***For the treatment of hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism (congenital hypothyroidism), myxedema, and ordinary hypothyroidism in patients of any age (pediatrics, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism.***For thyroid suppression testing as an aid for hyperthyroidism diagnosis in patients with signs of mild hyperthyroidism in whom baseline laboratory tests appear normal, or to demonstrate thyroid gland autonomy in patients with Grave's ophthalmology.***Formoterol; Mometasone","***Tartrazine dye hypersensitivity***Thyrotoxicosis***Adrenal insufficiency***Hypopituitarism***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, coronary artery disease, hypertension, surgery***Geriatric***Diabetes mellitus***Pregnancy***Breast-feeding***Obesity treatment***Infertility***Osteoporosis***Infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['60223', '153184']",adapalene,***For the treatment of acne vulgaris.,"***Pregnancy***Breast-feeding***Eczema, skin abrasion, sunburn, sunlight (UV) exposure***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['28031', '202826']",itraconazole,"***For the treatment of invasive aspergillosis including invasive pulmonary, CNS, and cutaneous aspergillosis, as well as <em>Aspergillus</em> sinusitis, tracheobronchitis, endocarditis, pericarditis, myocarditis, osteomyelitis, infectious arthritis, and aspergilloma in patients who are intolerant of or refractory to amphotericin B therapy. <br />        Note: Itraconazole is recommended as alternative therapy for invasive aspergillosis by the Infectious Diseases Society of America (IDSA).<br />     ***For primary treatment of allergic bronchopulmonary aspergillosis.***For primary treatment of <em>Aspergillus</em> peritonitis.***For the treatment of blastomycosis. <br />        NOTE: For CNS infections, see meningitis.<br />NOTE: Obtain itraconazole serum concentrations after at least 2 weeks of therapy to ensure adequate drug exposure***For mild to moderate pulmonary or disseminated extrapulmonary blastomycosis.***For blastomycosis in immunosuppressed patients.***For moderately severe or severe pulmonary or disseminated extrapulmonary blastomycosis.***For the treatment of histoplasmosis. <br />        NOTE: For CNS infections, see meningitis.<br />     ***For the treatment of acute symptomatic pulmonary histoplasmosis.***For the treatment of chronic pulmonary histoplasmosis.***For the treatment of chronic progressive disseminated histoplasmosis.***For use as maintenance (consolidation) therapy in the treatment of moderately severe to severe disseminated histoplasmosis (<em>Histoplasma capsulatum</em>) in HIV-infected patients.***For use as induction and maintenance (consolidation) therapy in the treatment of mild disseminated histoplasmosis in HIV-infected patients.***For the treatment of onychomycosis due to dermatophytes (tinea unguium) in immunocompetent patients. <br />        NOTE: Due to the serious adverse reactions associated with itraconazole, nail specimens should be sent for laboratory testing to confirm the diagnosis prior to beginning itraconazole therapy.<br />     ***For fingernail involvement only.***For toenail involvement with or without fingernail involvement.***For the treatment of mucocutaneous candidiasis. <br />        NOTE: Itraconazole oral solution only is FDA-approved for esophageal and/or oral candidiasis. The manufacturer states that patients with severe neutropenia were not studied. The oral solution is not recommended for treatment of these indications in patients who are at immediate risk for systemic candidiasis.<br />     ***For the treatment of esophageal candidiasis.***For the treatment of oropharyngeal candidiasis (thrush).***For the treatment of oropharyngeal candidiasis unresponsive or refractory to fluconazole.***For treatment of nonalbicans or recurrent vulvovaginal candidiasis� (VVC).***For the treatment of meningitis�.***For the treatment of cryptococcosis� and meningitis� caused by <em>Cryptococcus sp.�</em> in HIV-infected patients as consolidation therapy after successful induction therapy.***For the treatment of CNS infection� or meningitis� due to <em>Blastomyces dermatitidis</em>.***For the treatment of meningitis� with <em>Coccidioides sp.</em>� in HIV-infected patients.***For the treatment of disseminated coccidioidomycosis�. <br />        NOTE: For CNS infections, see meningitis.<br />     ***For the treatment of mild coccidioidomycosis� (focal pneumonia or positive coccidioidal serologic test alone) in HIV-infected patients.***For treatment of severe, nonmeningeal coccidioidomycosis� (diffuse pulmonary or severely ill patients with extrathoracic disseminated disease) in HIV-infected patients during the acute phase.***For the treatment of cutaneous or systemic sporotrichosis�.***For the treatment of tinea corporis�.***For the empiric treatment of suspected invasive candidiasis� in neutropenic patients.***For the treatment of penicilliosis� (<em>Penicilliosis marneffei</em>�) in HIV-infected patients.***For the treatment of mild penicilliosis� in HIV-infected patients.***For the treatment of acute penicilliosis� in severely ill HIV-infected patients.***For candidiasis prophylaxis� in high-risk patients.***For candidiasis prophylaxis� in high-risk cancer patients and those with chemotherapy-induced neutropenia.***For secondary oropharyngeal candidiasis prophylaxis� in HIV-infected patients.***For vulvovaginal candidiasis prophylaxis� in patients with recurrent infection.***For secondary esophageal candidiasis prophylaxis� in HIV-infected patients.***For the treatment or secondary prophylaxis of disseminated (non-ocular) infections associated with microsporidiosis� and attributed to <em>Trachipleistophora</em> or <em>Anncaliia</em>. <br />  NOTE: According to the HIV treatment guidelines, initiating antiretroviral therapy (ART) before severe immunosuppression develops is key to preventing chronic microsporidiosis, as infection most commonly occurs in patients with CD4 counts less than 100 cells/mm3. Other preventative measures for patients with CD4 counts less than 200 cells/mm3 include: avoid untreated water sources; avoid consuming undercooked meat or seafood; limit exposure to animals known to be infected with microsporidia.<br />NOTE: All patients infected with microsporidiosis should be offered ART as part of the initial treatment***For maintenance therapy� (secondary coccidioidomycosis prophylaxis�) after treatment of coccidioidomycosis in HIV-infected patients .***For primary histoplasmosis prophylaxis� in HIV-infected patients or for secondary histoplasmosis prophylaxis� in HIV-infected patients, after treatment of the acute infection.***For primary and secondary penicilliosis prophylaxis� in HIV-infected patients.***For secondary cryptococcosis prophylaxis� (chronic maintenance therapy) for meningitis caused by <em>Cryptococcus</em> sp.  in HIV-infected patients<strong><em>�</em***For aspergillosis prophylaxis�.***For the treatment of fungal keratitis�.***For the treatment of tinea capitis�.***For the treatment of tinea pedis�.***Formoterol***Formoterol; Mometasone","***Hepatic disease, hepatotoxicity***Chronic obstructive pulmonary disease (COPD), coronary artery disease, dialysis, heart failure, pulmonary disease, pulmonary edema, valvular heart disease, ventricular dysfunction***Alcoholism, cardiac arrhythmias, diabetes mellitus, females, hypocalcemia, hypokalemia, hypomagnesemia, itraconazole coadministration with other drugs, long QT syndrome, myocardial infarction, QT prolongation, thyroid disease, ventricular arrhythmias***Cystic fibrosis***Achlorhydria, human immunodeficiency virus (HIV) infection, hypochlorhydria***Peripheral neuropathy***Hearing impairment***Driving or operating machinery***Neutropenia***Pregnancy***Breast-feeding***Children, infants, neonates***Azole antifungals hypersensitivity***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['17767']['73494'],amlodipine/telmisartan,***For the treatment of hypertension. <br />        NOTE: Correct volume and/or sodium depletion prior to initiation of amlodipine; telmisartan therapy.<br />     ***For initial therapy of hypertension in patients who are likely to need multiple drugs to achieve their blood pressure goals.***For substitution after titration of amlodipine and telmisartan as single agents.***For add-on therapy in patients not adequately controlled on amlodipine (or another dihydropyridine calcium channel blocker) alone or telmisartan (or another angiotensin receptor blocker) alone.,"***General Information***Dihydropyridine hypersensitivity***Acute myocardial infarction, angina, coronary artery disease***Aortic stenosis, bradycardia, cardiogenic shock, heart failure, hypotension, hypovolemia, surgery, ventricular dysfunction***Renal artery stenosis, renal impairment***Hepatic disease***Geriatric***Hyperkalemia***ACE-inhibitor induced angioedema, angioedema***Black patients***Gastroesophageal reflux disease (GERD), hiatal hernia***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,flurbiprofen sodium,"***For the treatment of rheumatoid arthritis.***For the treatment of osteoarthritis.***For intraoperative miosis inhibition.***For the treatment of ankylosing spondylitis�.***For the treatment of dysmenorrhea�.***For the acute treatment of migraine� headache.***For migraine prophylaxis�.***For the preservation of bone around dental implants�.***For the treatment of mild pain and moderate pain including arthralgia, myalgia, bone pain�, and dental pain�.***For the treatment of postoperative ocular inflammation�.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Bone marrow suppression, coagulopathy, hemophilia, immunosuppression, neutropenia, ocular surgery, surgery, thrombocytopenia***Anemia***Dental disease, dental work***Hepatic disease, jaundice***Diabetes mellitus, rheumatoid arthritis***Renal disease, renal failure, renal impairment***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, edema, heart failure, hypertension, myocardial infarction, peripheral vascular disease, stroke, thromboembolism***Coronary artery bypass graft surgery (CABG)***Geriatric***Labor, obstetric delivery, pregnancy***Breast-feeding***Visual disturbance***Poor metabolizers",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1202'],atenolol,"***For the treatment of angina pectoris.***For the treatment of chronic stable angina.***For the treatment of unstable angina�.***For the treatment of hypertension.***For the treatment of acute myocardial infarction, STEMI and for the reduction of cardiovascular mortality and secondary myocardial infarction prophylaxis. <br /***For paroxysmal supraventricular tachycardia (PSVT) prophylaxis� in patients with recurrent PSVT due to AV reentry.***For migraine prophylaxis�.***For the adjunct treatment of alcohol withdrawal�.***For the treatment of tremor�.***For the treatment of lithium-induced tremor�.***For the treatment of essential tremor�.***For heart rate control in patients with atrial fibrillation<strong>","***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***AV block, bradycardia, cardiogenic shock, heart failure, hypotension, pheochromocytoma, pulmonary edema, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Cerebrovascular disease***Diabetes mellitus***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Surgery***Dialysis, renal disease, renal failure, renal impairment***Labor, obstetric delivery, pregnancy***Breast-feeding***Driving or operating machinery***Peripheral vascular disease, Raynaud's phenomenon***Depression***Psoriasis***Myasthenia gravis***Geriatric***Beta-blocker hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluorometholone acetate,"***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis, ocular burns or trauma due to corneal injury resulting from chemical, thermal or penetration trauma, giant papillary conjunctivitis (GPC), keratitis, postoperative ocular inflammation, vernal keratoconjunctivitis, and chronic anterior uveitis. <br />  NOTE: The benefit of diminution of edema and inflammation from the use of ocular corticosteroids and the inherent risk of infection in certain conditions must be considered. Duration of treatment may vary with type of lesion and therapeutic response. Renewal of prescriptions beyond 20 mL of suspension or 8 grams of ointment should be made by a physician after re-examination with the aid of magnification. Care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of therapy should be carried out by gradually decreasing the frequency of applications.<br /","***General Information***Herpes infection, herpes simplex keratitis (dendritic keratitis), varicella, viral infection***Fungal infection, mycobacterial infection***Contact lenses***Glaucoma***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['3521', '203015']",dipyridamole,"***For arterial thromboembolism prophylaxis.***For use in coronary artery disease diagnosis (i.e., dipyridamole-stress echocardiography).***For secondary prophylaxis of transient ischemic attack (TIA)� in combination with aspirin.***For the treatment of dilated cardiomyopathy�.***For the treatment of proteinuria� associated with membranous glomerulonephritis.***For myocardial infarction prophylaxis� in patients who have sustained a prior myocardial infarction (MI).","***Hypotension, orthostatic hypotension, syncope***Angina***Asthma***Labor, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease***Geriatric***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10865'],lodoxamide tromethamine,"***For the treatment of ocular inflammatory states such as vernal conjunctivitis, vernal keratitis, or vernal keratoconjunctivitis.","***General Information***Contact lenses***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['644101'],idursulfase,***For the treatment of mucopolysaccharidosis II (Hunter syndrome). <br />        NOTE: Idursulfase has been designated as an orphan drug for this indication by the FDA.<br />     ,"***Angioedema, hypotension, infusion-related reactions, serious hypersensitivity reactions or anaphylaxis***Acute bronchospasm, asthma, fever, respiratory depression, respiratory infection, respiratory insufficiency***Cardiac disease, heart failure, pulmonary edema***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,perflutren protein-type A microspheres,***For use during echocardiography to enhance ultrasound imaging by opacifying the left ventricle and improving the delineation of the left ventricular endocardial borders. <br />  NOTE: Diagnostic echocardiography procedures that involve the use of this product should be carried out under the direction of a licensed practitioner having a thorough knowledge of the procedure and the safe use of the product.<br /,"***Intraarterial administration***Albumin hypersensitivity***Viral infection***Acute myocardial infarction, cardiopulmonary reaction, coronary artery disease, heart failure, ventricular arrhythmias***Arteriovenous shunt***Children, congenital heart disease, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['68092'],lanreotide,"***For the long-term treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. <br />        NOTE: Lanreotide has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumor (NET). <br />        NOTE: Lanreotide has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of carcinoid syndrome, to reduce the frequency of short-acting somatostatin analog rescue therapy. <br />        NOTE: Lanreotide has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of hyperthyroidism� secondary to thyrotropinoma.","***Bradycardia, cardiac disease***Diabetes mellitus***Gallbladder disease***Hepatic disease***Hypothyroidism, thyroid disease***Pregnancy***Infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,C1 esterase inhibitor (human),"***For routine angioedema prophylaxis in patients with hereditary angioedema.***For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE). <br />        NOTE: Advise patients who may self administer Berinert for acute laryngeal HAE attacks to immediately seek medical attention in an appropriate healthcare facility after Berinert receipt because of the potential for airway obstruction.<br />     ","***General Information***Central venous catheter placement, obesity, thromboembolic disease***Viral infection***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diflorasone diacetate,"***For the treatment of moderate to severe corticosteroid-responsive dermatoses, like alopecia areata, atopic dermatitis, severe contact dermatitis, or severe <em>Rhus</em> dermatitis (due to plants like poison ivy), discoid lupus erythematosus, granuloma annulare, cutaneous lichen planus, lichen simplex chronicus, severe lichen striatus, severe eczema (including severe hyperkeratotic eczema, severe nummular eczema, and severe eczematous conditions of the hands or feet), exfoliative dermatitis, keloids, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, severe pruritus, sarcoidosis, sunburn, or urticaria. <br />        NOTE: Systemic therapy or intralesional injection of corticosteroids may be necessary for some conditions based on the type and severity of the disorder or inadequate response to topical therapy.<br />     ***For the treatment of moderate to severe chronic plaque-type psoriasis.***For the treatment of vulvar lichen sclerosus�.***For the treatment of cutaneous T-cell lymphoma (CTCL)� (aka mycosis fungoides�).","***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Diabetes mellitus***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Fungal infection, herpes infection, infection, measles, peripheral vascular disease, tuberculosis, varicella, viral infection***Acne rosacea, acne vulgaris, cataracts, glaucoma, ocular exposure, ophthalmic administration, perioral dermatitis***Geriatric, skin atrophy***Corticosteroid hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,azelaic acid,***For the treatment of mild-to-moderate inflammatory acne vulgaris.***For the treatment of inflammatory pustules and papules of mild-to-moderate acne rosacea.***For the treatment of melasma�.***For the treatment of lentigo maligna� in which surgery is contraindicated.***For the treatment of cutaneous malignant melanoma�.,"***General Information***Occlusive dressing, ocular exposure***Pregnancy***Breast-feeding***Children, infants, neonates***Herpes infection***Asthma, deterioration of asthma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,potassium chloride,"***For the treatment of hypokalemia and hypokalemia prevention.***For the treatment of hypokalemia or digoxin toxicity (arrhythmias or ECG changes) associated with hypokalemia. <br />          NOTE: Hypokalemia is generally defined as a serum potassium concentration &lt; 3.5 mEq/L; however, serum potassium concentrations do not always correlate with cellular potassium levels. The National Council on Potassium in Clinical Practice recommends that serum potassium concentrations &gt;= 4 mEq/L be achieved and maintained in patients with hypertension, heart failure, and cardiac arrhythmias.<br />NOTE: Although extremely variable and based on clinical conditions of the patient, serum potassium decreases an average of 0.3 mmol/L for each 100-mmol reduction in total body stores. To avoid inducing hyperkalemia when correcting potassium loss, it is recommended to utilize the low end of this estimate and administer a moderate dose (orally, if possible) over a period of days to weeks to fully correct the potassium deficit. Among patients in an intensive care unit treated for acute hypokalemia, 20 mEq/hr potassium chloride IV resulted in a mean increase in the serum potassium concentration of 0.25 mmol/L***For the prevention of hypokalemia. <br />  NOTE: Hypokalemia is generally defined as a serum potassium concentration &lt; 3.5 mEq/L; however, serum potassium concentrations do not always correlate with cellular potassium levels. The National Council on Potassium in Clinical Practice recommends that serum potassium concentrations &gt;= 4 mEq/L be achieved and maintained in patients with hypertension, heart failure, and cardiac arrhythmias. In addition, the Council recommends potassium supplementation for patients with potential for diuretic-induced potassium loss (e.g., thiazide or loop diuretics), patients with high sodium intake (or unwilling to reduce salt intake), and patients with reduced GI intake (e.g., GI disturbances, laxative abuse).<br /***Formoterol; Mometasone","***General Information***Adrenal insufficiency, burns, dehydration, diabetic ketoacidosis, geriatric, hyperkalemia, metabolic acidosis, premature neonates, renal disease, renal failure, renal impairment***Atrial fibrillation, atrial flutter, AV block, cardiac arrhythmias, digitalis toxicity, heart failure, ventricular arrhythmias, ventricular fibrillation, ventricular tachycardia***Esophageal stricture, gastroparesis, GI obstruction, ileus, peptic ulcer disease***Pregnancy***Breast-feeding***Hepatic disease, metabolic alkalosis, respiratory alkalosis***Extravasation, thrombophlebitis***Muscle channelopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['733003'],plerixafor,"***For peripheral blood stem cell (PBSC) mobilization for collection and subsequent autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma, in combination with a granulocyte colony stimulating factor (G-CSF). <br />NOTE: The FDA has designated plerixafor as an orphan drug to improve the yield of progenitor cells in the apheresis product for subsequent stem cell transplantation following myelosuppressive or myeloablative chemotherapy<br /","***Hypotension, shock***Leukemia***Renal disease, renal impairment***Thrombocytopenia***Pregnancy***Breast-feeding***Leukocytosis***Contraception requirements, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,prednisolone acetate,"***For primary (Addison's disease) or secondary adrenocortical insufficiency or for the treatment of congenital adrenal hyperplasia.***For the treatment of nonsuppurative thyroiditis.***For the management of symptomatic sarcoidosis.***For the treatment of corticosteroid-responsive dermatitis and dermatologic disorders such as atopic dermatitis or eczema, bullous dermatitis herpetiformis, contact dermatitis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe psoriasis, severe seborrheic dermatitis, or severe erythema multiforme or Stevens-Johnson syndrome.***For the treatment of corticosteroid-responsive respiratory disorders including aspiration pneumonitis, berylliosis, Loeffler's syndrome, or idiopathic pulmonary fibrosis.***For the treatment of asthma.***For a moderate to severe asthma exacerbation in the emergency department or the hospital.***For an acute asthma exacerbation on an outpatient basis.***For long-term prevention of symptoms in severe persistent asthma.***For the treatment of inflammatory bowel disease including critical periods of ulcerative colitis or regional enteritis (Crohn's disease).***For the treatment of hematologic disorders with thrombocytopenia including immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), or secondary thrombocytopenia.***For the treatment of acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), or congenital hypoplastic anemia.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of kidney transplant rejection or for kidney transplant rejection prophylaxis in conjunction with other immunosuppressants.***For the treatment of acute exacerbations of multiple sclerosis.***For the treatment of nephrotic syndrome.***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis, allergic marginal corneal ulcer, anterior segment inflammation, bacterial conjunctivitis, chorioretinitis, choroiditis, cyclitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus) with appropriate antiviral therapy, iritis, non-specific keratitis or superficial punctate keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, vernal keratoconjunctivitis, or for corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies.***For topical ophthalmic treatment of corticosteroid-responsive eye disorders.***For systemic treatment of corticosteroid-responsive eye disorders unresponsive to topical ophthalmic treatment or for conditions usually requiring systemic treatment, such as sympathetic ophthalmia or optic neuritis.***For adjunctive therapy in the treatment of rheumatic disorders including ankylosing spondylitis, gout with gouty arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, psoriatic arthritis, or rheumatoid arthritis; ALSO for the treatment of acute episodes or exacerbation of nonrheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the treatment of selected cases of collagen disorders and mixed connective tissue disease�, such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, polyarteritis nodosa, relapsing polychondritis, polymyalgia rheumatica, certain cases of vasculitis, or Wegener's granulomatosis�.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.***For the treatment of mild to moderate laryngotracheobronchitis (croup)�.***For palliative management of leukemia and lymphoma in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), or multiple myeloma�; also may be used as an adjunct in managing hypercalcemia of malignancy.***For the treatment of acute interstitial nephritis (AIN)�.***For the treatment of Severe Acute Respiratory Syndrome (SARS)�.***For the management of heart transplant rejection prophylaxis�.***For the treatment of Bell's palsy�.***For the treatment of exacerbations of chronic obstructive pulmonary disease (COPD)�.***For the treatment of Kawasaki disease�.","***General Information***Corticosteroid hypersensitivity***Intravenous administration***Infection, surgery***Fungal infection***Herpes infection, measles, tuberculosis, varicella, viral infection***Myocardial infarction***Heart failure, hypertension***Cataracts, glaucoma, visual disturbance***Diverticulitis, GI disease, hepatic disease, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Diabetes mellitus, hyperthyroidism, hypothyroidism, osteoporosis, psychosis, renal disease, seizure disorder, thyroid disease***Myasthenia gravis***Coagulopathy, thromboembolic disease***Pregnancy***Breast-feeding***Children, growth inhibition, increased intracranial pressure, infants***Abrupt discontinuation, hypothalamic-pituitary-adrenal (HPA) suppression***Sulfite hypersensitivity***Tartrazine dye hypersensitivity***Benzyl alcohol hypersensitivity, neonates, premature neonates***Cushing's syndrome***Vaccination***Corneal abrasion, increased intraocular pressure, myopia, open-angle glaucoma***Geriatric***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8703'],fenofibrate,"***For use as an adjunct to diet for the treatment of adult patients with severe hypertriglyceridemia. <br />  NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.     <br />NOTE: Markedly elevated levels of serum triglycerides (e.g., &gt; 2000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.  ***For use as an adjunct to diet to reduce elevated LDL-cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase HDL-cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. <br />        NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.   ","***General Information***Cardiac disease***Biliary cirrhosis, cholelithiasis, gallbladder disease, hepatic disease***Dialysis, renal disease, renal failure, renal impairment***Anticoagulant therapy***Thromboembolic disease***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding***Diabetes mellitus***Hypothyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6574'],omeprazole); (omeprazole magnesium,"***For the short-term, self-treatment of frequent dyspepsia or pyrosis (heartburn) that occurs 2 or more times per week.***For the treatment of erosive esophagitis (erosive GERD).***For the treatment of non-erosive gastroesophageal reflux disease (GERD).***For the short-term treatment of active benign gastric ulcer. <br />        NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br />     ***For the short-term treatment of active duodenal ulcer. <br />  NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br /***For Helicobacter pylori (H. pylori) eradication in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />        NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.   The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with nonulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Prevpac monograph).  <br />NOTE: A large body of data exists to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long-term tumor regression is observed in 60 to 90% of patients.***For the long-term treatment of gastric hypersecretory conditions, including Zollinger-Ellison syndrome, systemic mastocytosis, and multiple endocrine adenoma syndrome.***For stress gastritis prophylaxis� in critically-ill patients. <br />        NOTE: For those patients with risk factors qualifying them for stress ulcer prophylaxis (SUP), the H2 antagonists, cytoprotective agents, and some PPIs are adequate choices. Optimum duration is unclear, but it is reasonable to provide therapy while risk factors are present, the patient is in a critical care unit, or for a least 1 week after onset of critical illness. <br />     ***For NSAID-induced ulcer prophylaxis�.***For the treatment of proton pump inhibitor�responsive esophageal eosinophilia (PPI-REE) in the differential diagnosis of eosinophilic esophagitis (EoE)�.","***General Information***Proton pump inhibitors (PPIs) hypersensitivity***Hepatic disease***Asian patients***Gastric cancer***Diarrhea, pseudomembranous colitis***Vitamin B12 deficiency***Bone fractures, geriatric, osteoporosis***Hypomagnesemia, long QT syndrome***Rebound acid hypersecretion***Pregnancy***Breast-feeding***Abdominal pain, dysphagia, GI bleeding, vomiting***Children, infants, neonates***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4917'],nitroglycerin,"***For the treatment of angina.***For acute angina pectoris or for acute angina pectoris prophylaxis (i.e., situations likely to provoke an anginal attack).***For chronic angina pectoris. <br />          NOTE: A nitrate-free interval is necessary to avoid the development of drug tolerance; although a minimum interval has not been clearly established, 10 to 12 hours/day has been sufficient with other nitroglycerin formulations.<br />       ***For the treatment of pain associated with anal fissures.***For the treatment of pain associated with anal fissures� and hemorrhoids�.***For controlled hypotension induction during anesthesia; for IV treatment of acute congestive heart failure or pulmonary edema, acute angina pectoris or unstable angina, acute myocardial infarction, or acute pulmonary hypertension�; or for treatment of severe hypertension, postoperative hypertension, perioperative hypertension (e.g., during cardiac surgery), or hypertensive emergency.***For use as a uterine relaxant to aid in extraction of a retained placenta�.***For the treatment of extravasation� of vasoactive medications.","***General Information***Nitrate hypersensitivity***Head trauma, increased intracranial pressure, intracranial bleeding***Anemia***Aortic stenosis, cardiac tamponade, cardiomyopathy, constrictive pericarditis, mitral stenosis, shock***Acute myocardial infarction, dehydration, hypotension, hypovolemia, orthostatic hypotension***Geriatric***Hepatic disease***Abrupt discontinuation***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Pregnancy***Breast-feeding***GI disease***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10169'],sodium sulfacetamide,"***For the treatment of conjunctivitis, corneal ulcer and other superficial ophthalmic infections caused by susceptible organisms, and as adjunctive treatment in systemic sulfonamide therapy of chlamydial conjunctivitis including trachoma and inclusion conjunctivitis.***For the topical treatment of scaling dermatoses, such as seborrheic dermatitis, and seborrhea sicca.***For the treatment of secondary bacterial skin and skin structure infections due to organisms susceptible to sulfonamides.***For the treatment of acne vulgaris.","***Ocular surgery, ocular trauma***Fungal infection, viral infection***Carbonic anhydrase inhibitor hypersensitivity, sulfonamide hypersensitivity, sulfonylurea hypersensitivity, thiazide diuretic hypersensitivity***Children, infants, neonates***Breast-feeding***Pregnancy***Sunlight (UV) exposure***Renal disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6922'],metronidazole,"***For the treatment of trichomoniasis.***For the treatment of bacterial vaginosis (e.g., <em>Gardnerella vaginalis</em>, <em>Mycoplasma hominis</em>�, and anaerobic bacteria such as <em>Prevotella sp.</em> and <em>Mobiluncus</em> sp.).***For the treatment of pelvic inflammatory disease (PID) in combination with other antibiotics.***For the treatment of amebiasis.***For intestinal disease (acute amebic dysentery) due to <em>Entamoeba histolytica</em>.***For hepatic abscess due to <em>Entamoeba histolytica</em>.***For amebiasis due to <em>Entamoeba polecki</em>�.***For the treatment of serious anaerobic infections (e.g., skin and skin structure infections [e.g. diabetic foot ulcer], CNS infection including meningitis and brain abscess, bone and joint infections, endocarditis, bacteremia, and gynecologic infections [e.g. endometritis, endomyometritis]).***For the treatment of acne rosacea.***For the treatment of serious anaerobic intraabdominal infections, including intraabdominal abscess, peritonitis, perforated appendicitis, necrotizing enterocolitis, and biliary tract infections such as cholangitis and cholecystitis.***For the treatment of perforated appendicitis� in pediatric patients.***For the treatment of serious anaerobic lower respiratory tract infections, including pleural empyema, pneumonia, and lung abscess.***For bacterial vaginosis prophylaxis� or trichomoniasis prophylaxis� in victims of sexual assault.***For the treatment of recurrent and persistent non-gonococcal urethritis (NGU)�.***For the treatment of dental infection�, including dentoalveolar infection� and periodontitis�.***For adolescent periodontitis� or adult chronic periodontitis� after scaling and root planing.***For adolescent aggressive periodontitis� or adult refractory chronic periodontitis� in combination with amoxicillin after scaling and root planing.***For adult refractory chronic periodontitis� in combination with ciprofloxacin after scaling and root planing in �-lactam allergic patients.***For the treatment of guinea worm disease� (dracunculiasis�).***For surgical infection prophylaxis, including bowel preparation� in patients undergoing colorectal surgery.***For bowel preparation� in patients undergoing colorectal surgery.***For the treatment of antibiotic-associated pseudomembranous colitis� due to <em>Clostridium difficile</em>.***For the treatment of antibiotic-associated pseudomembranous colitis� due to <em>Clostridium difficile </em>in adults.***For the treatment of antibiotic-associated pseudomembranous colitis� due to <em>Clostridium difficile i</em>n pediatric patients.***For the treatment of Crohn's disease� associated with colonic and/or perianal involvement.***For Helicobacter pylori (H. pylori) eradication� in the treatment of patients with duodenal ulcer� disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />  NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.  The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: Metronidazole-resistant strains of H. pylori are prevalent in the US (approximately 25%), and primarily occur in patients previously treated with metronidazole. Therapy with at least two antimicrobials is necessary to limit the development of metronidazole resistance. Patients who have persistence of H. pylori following therapy may have metronidazole-resistant H. pylori infection.<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Prevpac monograph).  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60% to 90% of patients.***For the treatment of pruritus� secondary to cholestasis.***For the treatment of giardiasis�.","***Hematological disease***Dialysis, renal failure, renal impairment***Bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***New primary malignancy***Pregnancy***Breast-feeding***Alcoholism, ethanol ingestion, ethanol intoxication***Fungal infection***Crohn's disease***Ocular exposure***Geriatric***Sexually transmitted disease***Hepatic disease, hepatic encephalopathy***Cockayne syndrome***Corticosteroid therapy, edema, sodium restriction***Laboratory test interference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,prochlorperazine edisylate,"***For treatment of nausea/vomiting.***For preoperative nausea control.***For the management of the manifestations of psychotic disorders such as schizophrenia.***For the short-term treatment of non-psychotic anxiety.***For the treatment of intractable, severe migraine� unresponsive to other therapies, or prior to administration of intravenous dihydroergotamine (DHE) to offset DHE-induced nausea.","***Phenothiazine hypersensitivity***Agranulocytosis, neutropenia***Tardive dyskinesia***Neurological disease, Parkinson's disease***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion***Hypotension, orthostatic hypotension***Alcoholism, angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, pulmonary disease, QT prolongation, thyroid disease***Hepatic disease, jaundice***Radiographic contrast administration, seizure disorder***Glaucoma, prostatic hypertrophy, urinary retention***GI obstruction, ileus***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Breast cancer, hyperprolactinemia, infertility***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Children, infants, Reye's syndrome, surgery***Dementia, geriatric, stroke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['662019'],pralatrexate,"***For the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL), a form of non-Hodgkin's lymphoma (NHL). <br />  NOTE: To reduce the incidence and severity of adverse reactions, patients should receive folic acid and vitamin B12 supplementation. Folic acid 1 to 1.25 mg PO daily should begin 10 days prior to the first dose of pralatrexate and continue during the full course of therapy, until 30 days after the last dose of pralatrexate. Vitamin B12 1000 mcg IM should begin within 10 weeks prior to the first dose of pralatrexate and should be repeated every 8 to 10 weeks during therapy. Subsequent vitamin B12 injections may be given the same day as pralatrexate.<br /","***Anemia, bone marrow suppression, neutropenia, thrombocytopenia***Renal disease, renal impairment, serious rash***Hepatic disease***Stomatitis***Tumor lysis syndrome (TLS)***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,coagulation factor VIII complex (human)/von Willebrand factor (human),"***For the prevention and control of hemorrhage in patients with hemophilia A (classical hemophilia). <br />        NOTE: Humate, Kogenate, and ReFacto have been designated by the FDA as orphan drugs for the prophylaxis and management of hemorrhage or hemarthrosis in patients with hemophilia A.<br /> <br />NOTE: Guidelines for the treatment of acute bleeding and prevention of bleeding during surgery vary. For all indications, the dose of antihemophilic factor should be individualized taking into consideration the seriousness of the bleed or procedure, the clinical status of the patient, and the factor VIII activity concentration***For minor bleeding including early muscle bleed, early hemarthrosis, and oral bleeds.***For moderate bleeding including advanced muscle bleed, extensive hemarthrosis, hematoma, and mild head trauma.***For life- or limb-threatening bleeding including surgical bleeding, gastrointestinal bleeding, neck, tongue or pharyngeal hematoma with potential for airway compromise, intracranial, intraabdominal, or intrathoracic bleeding, or fractures.***For bleeding in patients with hemophilia A and factor VIII inhibitor titers less than 10 Bethesda Units and with low anamnestic responses.***For the perioperative management of surgical bleeding (surgical bleeding prophylaxis) in patients with hemophilia A.***For routine bleeding prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A.***For the management of hemorrhage or hemarthrosis in patients with von Willebrand's disease (vWD). <br />        NOTE: Humate-P has been designated by the FDA as orphan drugs for this indication.<br />     ***For major hemorrhage in patients with mild vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma or traumatic hemorrhage).***For minor hemorrhage in patients with moderate to severe vWD type I, type II, and type III (e.g., epistaxis, oral bleeding, or menorrhagia).***For major hemorrhage in patients with moderate to severe vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For major hemorrhage in patients with vWD type II and III (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For surgical bleeding prophylaxis during major or minor procedures in patients with vWD in whom desmopressin is either ineffective or contraindicated. <br />          NOTE: Alphanate and Humate-P have been designated by the FDA as orphan drugs for this indication.<br />       ","***General Information***Pregnancy***Breast-feeding***Thromboembolic disease***Hepatitis, infection, viral infection***Anemia***Bovine protein hypersensitivity, hamster protein hypersensitivity, latex hypersensitivity, mannitol hypersensitivity, murine protein hypersensitivity, polysorbate 80 hypersensitivity***Porcine protein hypersensitivity***Human immunodeficiency virus (HIV) infection***Cardiac disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['161']['5489', '221107']",acetaminophen/hydrocodone bitartrate,***For the treatment of moderate pain to moderately severe pain. <br />  NOTE: FDA-approved dosages vary depending on product. Do not exceed a total daily dose of 4 grams of acetaminophen from ALL sources. <br /,"***General Information***Acetaminophen hypersensitivity, opiate agonist hypersensitivity***Acute abdomen, biliary tract disease, constipation, GI disease, GI obstruction, ileus, inflammatory bowel disease, pancreatitis, ulcerative colitis***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, coma, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Abrupt discontinuation***Alcoholism, ethanol ingestion, ethanol intoxication, hepatic disease, hepatitis, hepatotoxicity, malnutrition***Depression, substance abuse***CNS depression, head trauma, increased intracranial pressure, intracranial mass, psychosis***Angina, cardiac arrhythmias, cardiac disease, dehydration, hypotension, hypovolemia, orthostatic hypotension, shock***Bladder obstruction, oliguria, prostatic hypertrophy, renal impairment, urethral stricture, urinary retention***Geriatric***Children, infants, neonates***G6PD deficiency***Bone marrow suppression, immunosuppression, infection, neutropenia***Driving or operating machinery***Adrenal insufficiency, hypothyroidism, myxedema***Accidental exposure, potential for overdose or poisoning***Seizure disorder, seizures***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,warfarin sodium,"***For general dosing information in patients requiring warfarin anticoagulation. <br />        NOTE: Clinical practice guidelines recommend against the routine use of pharmacogenetic testing for guiding dosing in patients initiating warfarin therapy.<br />     ***For treatment of deep venous thrombosis (DVT) or pulmonary embolism and deep vein thrombosis (DVT) prophylaxis or pulmonary embolism prophylaxis.***For the treatment and further prevention of DVT or pulmonary embolism (PE) after the initial, acute phase of treatment.***For DVT prophylaxis in patients undergoing total hip or knee replacement surgery or hip fracture surgery�.***For DVT prophylaxis in patients with long-term indwelling central venous catheters to prevent axillary-subclavian venous thrombosis�.***For thrombosis prophylaxis (i.e., arterial thromboembolism prophylaxis, stroke prophylaxis, or coronary artery thrombosis prophylaxis). <br />        NOTE: For information regarding prophylaxis in orthopedic surgery or with central venous catheters, see 'deep venous thrombosis (DVT) prophylaxis'.<br />     ***For coronary artery thrombosis prophylaxis in high or very high-risk patients with stable angina� or chronic coronary artery disease�.***For thrombosis prophylaxis in patients with atrial fibrillation.***For thrombosis prophylaxis in patients with atrial fibrillation or atrial flutter who are undergoing cardioversion.***For thrombosis prophylaxis in patients with prosthetic heart valves.***For thrombosis prophylaxis in patients with mechanical prosthetic heart valves and a history of bleeding while receiving warfarin therapy.***For stroke prophylaxis in patients with cerebral venous sinus thrombosis (CVST) after primary treatment with heparin or LMWH.***For thrombosis prophylaxis in patients with valvular heart disease.***For stroke prophylaxis in patients with dilated cardiomyopathy (DCM), particularly in the subgroup of patients with concomitant atrial fibrillation or with a prior history of systemic embolization.***For secondary myocardial infarction prophylaxis (i.e., prevention of a subsequent myocardial infarction or coronary artery thrombosis prophylaxis) or for stroke prophylaxis in high-risk postmyocardial infarction patients (e.g., patients with acute MI complicated by severe LV dysfunction, CHF, atrial fibrillation, previous emboli, or 2D echocardiograph evidence of mural thrombosis).***For the coronary artery thrombosis prophylaxis in patients with unstable angina�.***For prophylaxis of arterial and/or venous thromboembolism in patients with antiphospholipid antibody syndrome.***For thromboprophylaxis� in patients with heart failure� who are in sinus rhythm.","***Coumarin anticoagulants hypersensitivity***Anemia, aneurysm, aortic dissection, atrial fibrillation, bleeding, cardiac disease, cerebrovascular disease, eclampsia, endocarditis, epidural anesthesia, GI bleeding, head trauma, hematological disease, hemophilia, hypertension, intracranial bleeding, leukemia, lumbar puncture, neoplastic disease, peptic ulcer disease, pericardial effusion, pericarditis, polycythemia vera, preeclampsia, renal disease, renal failure, renal impairment, retinal bleeding, spinal anesthesia, stroke, surgery, vasculitis***Asian patients***Dental work***Diabetes mellitus***Heparin-induced thrombocytopenia (HIT), idiopathic thrombocytopenic purpura (ITP)***Heart failure***Cholestasis, hepatic disease, hepatitis, jaundice***Intramuscular injections***Protein C deficiency, protein S deficiency***Vitamin C deficiency***Anorexia nervosa, bulimia nervosa, vitamin K deficiency***Alcoholism, dementia, psychosis***Fever, hyperthyroidism, infection***Diarrhea, hyperlipidemia, hypothyroidism, peripheral edema***Tobacco smoking***Geriatric***Labor, obstetric delivery, pregnancy***Children, infants, neonates***Breast-feeding***Contraception requirements, pregnancy testing, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7243'],naltrexone,***For the maintenance treatment of alcohol dependence.***For relapse prevention following opioid detoxification in patients with opiate agonist dependence.***For the opiate agonist withdrawal induction� during detoxification. <br />        NOTE: Rapid and ultrarapid opiate detoxification should only be done in a controlled setting under the supervision of a physician experienced in the management of opiate withdrawal. Severe withdrawal symptoms and death have been reported in patients undergoing ultrarapid opiate detoxification.<br />     ***For rapid opiate detoxification�.***For ultrarapid opiate detoxification�.***For the treatment of pruritus�.***For uremic pruritus�.***For use as an adjunct to psychosocial interventions for tobacco cessation� (smoking cessation�).,"***General Information***Hepatic disease, hepatitis***Depression, suicidal ideation***Acute opioid withdrawal***Surgery***Respiratory depression***Potential for overdose or poisoning***Renal impairment***Pregnancy***Breast-feeding***Children, infants, neonates***Driving or operating machinery***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Females, intravenous administration, obesity, subcutaneous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,docusate sodium,***For the prevention or treatment of  constipation.,"***General Information***Abdominal pain, GI bleeding, vomiting***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['9524'],sulfasalazine,"***For the treatment of mild to moderate ulcerative colitis; as adjunctive therapy in the treatment of severe ulcerative colitis; and to prolong the remission period between acute attacks of ulcerative colitis.***For the treatment of rheumatoid arthritis in patients who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs.***For the treatment of juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA) that has responded poorly to salicylates or other nonsteroidal anti-inflammatory drugs (NSAIDs).***For the treatment of Crohn's disease�, particularly patients with colonic involvement.","***General Information***5-aminosalicylates hypersensitivity, carbonic anhydrase inhibitor hypersensitivity, salicylate hypersensitivity, sulfonamide hypersensitivity, sulfonylurea hypersensitivity, thiazide diuretic hypersensitivity***Folate deficiency megaloblastic anemia, G6PD deficiency, hematological disease***Hepatic disease, jaundice***Porphyria***Dehydration, hypovolemia, renal failure, renal impairment, urinary tract obstruction***Asthma***Pregnancy***Breast-feeding, infants, neonates***Infertility***Children***GI obstruction***Sunlight (UV) exposure***Immunosuppression, infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clindamycin phosphate,"***For the treatment of serious infections such as bacteremia.***For the treatment of lower respiratory tract infections (e.g., pleural empyema, anaerobic pneumonia, aspiration pneumonia, community-acquired pneumonia, and lung abscess) due to susceptible organisms<strong>***For the treatment of intraabdominal infections, including intraabdominal abscess and peritonitis.***For the treatment of peritonitis in patients receiving peritoneal dialysis.***For the treatment of skin and skin structure infections, including impetigo, ecthyma, cellulitis, erysipelas, infectious neonatal pustulosis, bite wounds, and complicated skin and skin structure infections such as necrotizing infections, gas gangrene, and diabetic foot ulcer.***For the treatment of impetigo or ecthyma.***For the treatment of necrotizing infections of the skin, fascia, and muscle (i.e. gas gangrene).***For the treatment of animal bite wounds.***For the treatment of diabetic foot ulcer.***For the treatment of gynecologic infections, including endometritis and pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of acute pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of bacterial vaginosis.***For the treatment of acne vulgaris.***For the treatment of bone and joint infections, including osteomyelitis and septic/infectious arthritis, or an orthopedic device-related infection�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated prosthetic joint infections�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated spinal implant infections�.***For the treatment of of uncomplicated acute otitis media�.***For the treatment of acute bacterial sinusitis�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis� in combination with conventional treatment (e.g., scaling and root planing) as well as acute dental abscess (apical)� and/or dental abscess (periapical)�.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage in patients with beta-lactam allergy.***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis� (rheumatic fever prophylaxis�) and for bacterial colonization eradication� in chronic carriers of group A beta-hemolytic <em>Streptococci</em> (GAS)�.***For the treatment of chronic pharyngeal carriers of group A streptococci (i.e., bacterial colonization eradication�).***For surgical infection prophylaxis�.***For bacterial endocarditis prophylaxis�.***For the treatment of anthrax�.***For the treatment of cutaneous anthrax infection.***For the treatment of systemic anthrax infection.***For anthrax prophylaxis� after exposure to Bacillus anthracis (postexposure prophylaxis, PEP).***For the treatment of toxoplasmosis�, including toxoplasmic encephalitis�.***For secondary toxoplasmosis prophylaxis� in HIV-infected patients intolerant of sulfa drugs.***For the treatment of Pneumocystis pneumonia (PCP)� in HIV-infected patients.***For the treatment of malaria� due <em>Plasmodium falciparum</em>.***For the treatment of babesiosis�.***For perinatal Group B streptococcal bacterial infection prophylaxis� in patients allergic to penicillin and cephalosporins.***Formoterol; Mometasone","***Asthma, atopy, clindamycin hypersensitivity, lincomycin hypersensitivity, serious rash, tartrazine dye hypersensitivity***Fungal infection***Diarrhea, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Neonates***Hepatic disease***Pregnancy***Breast-feeding***Ocular exposure***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2177', '1545975']",cefadroxil,"***For the treatment of urinary tract infection (UTI), including cystitis.***For the treatment of skin and skin structure infections including impetigo.***For the treatment of group A beta-hemolytic streptococcal pharyngitis (primary rheumatic fever prophylaxis�) or tonsillitis.","***General Information***Viral infection***Cephalosporin hypersensitivity, penicillin hypersensitivity***Renal disease, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Coagulopathy, vitamin K deficiency***Intramuscular injections***Neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10865'],ketorolac tromethamine,"***For the reduction of postoperative ocular inflammation and ocular pain following cataract ocular surgery or corneal refractive surgery .***For the reduction of postoperative ocular inflammation and ocular pain following cataract surgery.***For the reduction of ocular pain and burning/stinging following corneal refractive surgery.***For the treatment of ocular pruritus due seasonal allergic conjunctivitis.***For the short-term treatment of moderate pain or moderately severe pain that requires analgesia at the opioid level, including bone pain�, dental pain�, arthralgia�, and myalgia�.***For the short-term treatment of moderately severe pain.***For the short-term treatment of moderate pain.***For the treatment of acute, severe headache�, including migraine�.***Formoterol; Mometasone","***Limit duration of use***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, serious hypersensitivity reactions or anaphylaxis, urticaria***Bleeding, surgery***Alcoholism, chemotherapy, Crohn's disease, GI bleeding, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease, hypoalbuminemia, jaundice***Dehydration, diabetes mellitus, edema, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery bypass graft surgery (CABG), coronary artery disease, heart failure, hypertension, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Anemia, bone marrow suppression, hematological disease, immunosuppression, intracranial bleeding, neutropenia, thrombocytopenia***Keratitis, ocular disease, ocular surgery***Contact lenses***Epidural administration, intrathecal administration***Children, infants, neonates***Caesarean section, labor, obstetric delivery, pregnancy***Breast-feeding***Ocular exposure***Geriatric***Lactase deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['18631'],azithromycin,"***For the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis in patients with COPD caused by susceptible strains of <em>Haemophilus influenza</em>, <em>Moraxella catarrhalis</em>, or <em>Streptococcus pneumoniae</em>.***For the treatment of acute otitis media. <br />        NOTE: Various dosing regimens are FDA-approved. Because macrolides, including azithromycin, have limited efficacy against both H. influenzae and S. pneumoniae, these agents are not included in the preferred or alternative options recommended by the American Academy of Pediatrics (AAP) in the treatment guidelines for acute otitis media.<br />     ***For the treatment of bacterial conjunctivitis caused by susceptible strains of <em>CDC coryneform group G, H. influenzae, S. aureus, S. mitis group, and S. pneumoniae</em>.***For the treatment of community-acquired pneumonia (CAP).***For the treatment of uncomplicated skin and skin structure infections caused by <em>S. aureus, S. pyogenes</em> or <em>S. agalactiae</em>.***For the treatment of pelvic inflammatory disease (PID).***For the treatment of gonorrhea.***For the treatment of uncomplicated gonorrhea of the cervix, urethra, rectum, and pharynx.***For the treatment of disseminated (e.g., bacteremia, arthritis) gonococcal infection�, including meningitis� and endocarditis�.***For the treatment of gonococcal conjunctivitis�.***For the treatment of chancroid due to <em>Haemophilus ducreyi</em>.***For the treatment of Mycobacterium avium complex infection (MAC).***For Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients.***For primary Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients.***For secondary Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients with disseminated disease, after treatment of the acute illness.***For the treatment of acute bacterial sinusitis. <br />        NOTE: Due to the high rate of resistance among S. pneumoniae isolates, macrolides are not recommended as empiric therapy. Amoxicillin/clavulanate is recommended as the first-line empiric therapy.<br />     ***For the treatment of non-gonococcal urethiritis (NGU) and chlamydia infection, including infant pneumonia�. <br />        NOTE: For ophthalmia neonatorum caused by C. trachomatis, see ophthalmia neonatorum indication.<br />     ***For the treatment of non-gonococcal urethritis (NGU) and other urogenital infections (e.g., cervicitis, urethritis, proctitis).***For the treatment of pneumonia caused by <em>Chlamydia trachomatis</em> in neonates and infants�.***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis (primary rheumatic fever prophylaxis�) and tonsillitis. <br />        NOTE: For secondary prophylaxis of rheumatic fever, the American Heart Association (AHA) recommends prophylaxis for 10 years or until age 40 (whichever is longer) for patients who have experienced rheumatic fever with carditis and have residual heart disease (persistent valvular disease). For patients who have experienced rheumatic fever with carditis, but have no residual heart disease, the AHA recommends prophylaxis for 10 years or until age 21 (whichever is longer). For patients who have experienced rheumatic fever without carditis, the AHA recommends prophylaxis for 5 years or until age 21 (whichever is longer).<br />     ***For the treatment of primary, secondary, or early latent syphilis� (caused by <em>Treponema pallidum</em>) in nonpregnant, penicillin-allergic patients. <br />        NOTE: A Jarisch-Herxheimer reaction may occur within the first 24 hours of therapy.<br />NOTE: While the HIV guidelines recommend non-penicillin alternatives for the treatment of syphilis in HIV-infected patients, their efficacy has not been evaluated and should only be used with close clinical and serologic monitoring***For the treatment of chronic prostatitis� due to <em>Ureaplasma urealyticum</em>.***For the treatment of Legionnaire's disease�.***For the treatment of shigellosis� diarrhea.***For the treatment of shigellosis� diarrhea in non-immunocompromised patients.***For the treatment of shigellosis� in HIV-infected patients.***For the treatment of mild-to-moderate campylobacteriosis� in HIV-infected patients.***For the treatment of toxoplasmosis�, including toxoplasmic encephalitis�, in HIV-positive patients.***For the treatment of early Lyme disease�.***For the treatment of early Lyme disease� in adults.***For the treatment of early Lyme disease� in children and adolescents.***For the treatment of dental infection� or dentoalveolar infection�, including periodontitis�, acute dental abscess (apical)�, and dental abscess (periapical)�.***For adult chronic periodontitis� after scaling and root planing.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage in patients with beta-lactam allergy.***For bacterial endocarditis prophylaxis�.***For the treatment of babesiosis� in combination with atovaquone.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For use in improving pulmonary function in cystic fibrosis� patients chronically infected with <em>Pseudomonas aeruginosa</em>.***For the treatment of mild scrub typhus� due to Orientia tsutsugamushi� (formerly Rickettsia tsutsugamushi�).***For the treatment of pertussis (whooping cough)� caused by <em>Bordetella pertussis</em> or for postexposure pertussis prophylaxis�. <br />  NOTE: For postexposure prophylaxis, administer to close contacts within 3 weeks of exposure, especially in high-risk patients (e.g., pregnant women in third trimester, infants younger than 12 months). Symptomatic contacts (coughing) should be treated as if they have pertussis.<br /***For the treatment of cholera�.***For the treatment of uncomplicated typhoid fever�.***For the treatment of bartonellosis� (<em>Bartonella bacilliformis)</em> and other <em>Bartonella </em>sp.� infections in HIV-infected patients.***For the treatment of angiomatosis infections�, peliosis hepatis�, bacteremia�, and osteomyelitis� caused by <em>Bartonella </em>sp.�.***For long term suppression� of infections caused by <em>Bartonella </em>sp.� in HIV-infected patients with relapse or reinfection and with CD4 count less than 200 cells/mm3.***For the treatment of ophthalmia neonatorum� due to <em>C. trachomatis</em>.***For the treatment of lymphogranuloma venereum� caused by <em>C. trachomatis</em>.***For chlamydial infection prophylaxis� and gonorrhea prophylaxis� in victims of sexual assault.***For the treatment of moderate or severe traveler's diarrhea�.***Formoterol***Formoterol; Mometasone","***General Information***Viral infection***Macrolide hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis***Hepatic disease, hepatitis, jaundice***Renal failure, renal impairment***Colitis, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Geriatric***Pregnancy***Breast-feeding***Infants, neonates***Sunlight (UV) exposure***Sodium restriction***Contact lenses***Myasthenia gravis***Sexually transmitted disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pyridostigmine bromide,"***For the treatment of myasthenia gravis. <br />        NOTE: Failure of patients to show clinical improvement may reflect underdosage OR overdosage. Overdosage of pyridostigmine may result in a life-threatening cholinergic crisis, which is characterized by increasing muscle weakness. Extreme muscle weakness is also characteristic of myasthenic crisis. Thus, differentiation on a symptomatic basis between cholinergic crisis and myasthenic crisis may be difficult. Differentiation is extremely important, as increases in pyridostigmine doses could have grave consequences in the presence of cholinergic crisis or of a refractory state.<br />     ***For neuromuscular blockade reversal, specifically, neuromuscular blockade secondary to non-depolarizing agents. <br />        NOTE: Intravenous pyridostigmine should only be administered by or under the supervision of experienced clinicians familiar with the use of agents that reverse or antagonize the effects of neuromuscular blocking agents. Administer pyridostigmine after spontaneous recovery of neuromuscular function has begun.<br />NOTE: Maintain adequate patient ventilation and a patent airway until complete recovery of normal respiration is assured.<br />NOTE: Electrolyte imbalances, diseases that lead to electrolyte imbalance such as adrenal cortical insufficiency, and certain drugs (see Drug Interactions) have been shown to alter neuromuscular blockade. Consider these possibilities in regard to the restoration of neuromuscular function***For adjunctive use in the treatment of Soman nerve gas exposure prophylaxis (for use only when administered prior to a threat of exposure to Soman gas). <br />        NOTE: This indication is FDA-approved for use only by US military personnel. Pyridostigmine is to be used in conjunction with other protective measures including chemical protective masks and battle dress garments.<br />     ***Formoterol; Mometasone","***General Information***Bladder obstruction, GI obstruction, ileus, urinary tract obstruction***Bromide hypersensitivity***Cholinesterase inhibitor toxicity***Asthma, bradycardia, cardiac arrhythmias, peptic ulcer disease***Hyperthyroidism***Seizure disorder***Benzyl alcohol hypersensitivity, neonates***Renal impairment***Pregnancy***Breast-feeding***Children***Adrenal insufficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pralidoxime chloride,"***For use as an antidote to organophosphate insecticide toxicity.***For the treatment of cholinesterase inhibitor toxicity secondary to agents used in the treatment of myasthenia gravis (e.g., neostigmine, pyridostigmine).","***Myasthenia gravis***Renal disease, renal impairment***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,medroxyprogesterone acetate,"***For the treatment of secondary amenorrhea.***For the treatment of dysfunctional uterine bleeding due to hormonal imbalance, in the absence of organic pathology such as fibroids or uterine cancer.***For routine contraception.***For the treatment of endometriosis-associated pain.***For the treatment of inoperable, recurrent, and metastatic endometrial cancer or renal cell cancer.***For the prevention of endometrial hyperplasia associated with estrogen replacement therapy in postmenopausal women with an intact uterus.***For the treatment of hypoventilation due to obesity-hypoventilation syndrome� (Pickwickian syndrome�).***For the treatment of hot flashes� due to menopause�.***For use to reduce the rate of decline in bone mineral density and to control biochemical indices of mild primary hyperparathyroidism� in postmenopausal women.***For the management of paraphilia� (atypical or extreme compulsive sexual behaviors�) in men.***For the treatment of hot flashes� due to prostate cancer� and associated induced androgen deficiency� (andropause�"") in men who have had surgical or medication induced castration.""","***History of angioedema***Intravenous administration***Breast cancer, cervical cancer, endometrial cancer, endometrial hyperplasia, new primary malignancy, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Diabetes mellitus***Cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, visual disturbance***Hyperlipidemia***Ectopic pregnancy, infertility, pregnancy***Incomplete abortion, menstrual irregularity***Cholestasis, hepatic disease, jaundice***Breast-feeding***Asthma, renal disease***Depression, migraine, seizure disorder***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, sexually transmitted disease***Dementia, geriatric***Hypocalcemia, porphyria, systemic lupus erythematosus (SLE)***Alcoholism, anorexia nervosa, corticosteroid therapy, osteopenia, osteoporosis***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,erythromycin stearate,"***For the treatment of acne vulgaris.***For mild to moderately severe lower respiratory tract infections (e.g., pneumonia, bronchitis) caused by susceptible organisms.***For the treatment of Legionnaire's disease (caused by <em>Legionella pneumophila</em>).***For the treatment of mild to moderately severe upper respiratory tract infections (e.g., pharyngitis, tonsillitis), including group A beta-hemolytic streptococcal (GAS) pharyngitis (primary rheumatic fever prophylaxis).***For upper respiratory tract infections and GAS pharyngitis (primary rheumatic fever prophylaxis).***For prevention of recurrent attacks of rheumatic fever (i.e., secondary rheumatic fever prophylaxis).***For the treatment of listeriosis.***For the treatment of chlamydia infection and non-gonococcal urethritis.***For the treatment of non-gonococcal urethritis (NGU) or chlamydial infections including urogenital infections (urethritis, cervicitis, proctitis) and infant pneumonia.***For the treatment of chlamydial conjunctivitis or ophthalmia neonatorum caused by <em>Chlamydia trachomatis</em>.***For the treatment of lymphogranuloma venereum� caused by <em>Chlamydia trachomatis</em>.***For the prevention of ophthalmia neonatorum (i.e., ophthalmia neonatorum prophylaxis) due to <em>Neisseria gonorrhoeae</em><em> </em>or<em> Chlamydia trachomatis</em>.***For the treatment of pneumonia caused by <em>Chlamydia trachomatis</em> in neonates and infants.***For the adjunctive treatment of diphtheria to prevent establishment of carrier state and for <em>Corynebacterium diphtheriae</em> bacterial colonization eradication.***For the treatment of close contacts of patients with diphtheria (i.e., diphtheria prophylaxis�).***For the treatment of acute pelvic inflammatory disease (PID).***For acute pelvic inflammatory disease (PID) caused by <em>Neisseria gonorrhoeae</em>.***For the treatment of pertussis (whooping cough) caused by <em>Bordetella pertussis</em> or for postexposure pertussis prophylaxis. <br />  NOTE: For postexposure prophylaxis, administer to close contacts within 3 weeks of exposure, especially in high-risk patients (e.g., women in third trimester, infants &lt; 12 months).<br /***For the treatment of primary syphilis (caused by <em>Treponema pallidum</em>) in penicillin-allergic, nonpregnant patients.***For bowel preparation in combination with neomycin in patients undergoing colorectal surgery.***For the treatment of superficial ophthalmic infection involving the conjunctiva and/or cornea.***For the treatment of chancroid� due to <em>Haemophilus ducreyi</em>.***For the treatment of disseminated gonorrhea�. <br />  NOTE: Erythromycin is not recommended in adults, adolescents, or children 8 years and older or in patients weighing 45 kg or more due to resistance of N. gonorrheae against erythromycin in the United States. Single-dose azithromycin in combination with ceftriaxone is the preferred therapy in these populations. <br /***For the facilitation of gastric emptying in patients with delayed gastrointestinal motility  (e.g., gastroparesis�).***For the treatment of idiopathic or postsurgical gastroparesis� or diabetic gastroparesis�.***For the facilitation of gastric emptying� in patients with feeding intolerance�.***For the treatment of early Lyme disease�.***For the treatment of skin and skin structure infections including impetigo and burn wound infection�.***For the treatment of erythrasma (caused by <em>Corynebacterium minutissimum</em>).***For the treatment of tetanus� (caused by <em>Clostridium tetani</em>) when penicillin or tetracycline is contraindicated or not tolerated.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of cholera�.***For the treatment of bartonellosis� (<em>Bartonella bacilliformis)</em> and other <em>Bartonella sp.</em>� infections in HIV-infected patients.***For the treatment of angiomatosis infections�, peliosis hepatis�, bacteremia�, and osteomyelitis� caused by <em>Bartonella sp.</em>�.***For long term suppression� of infections caused by <em>Bartonella sp.</em>� in HIV-infected patients with relapse or reinfections with < 200 CD4 cells/mm3.***For pneumococcal prophylaxis� in penicillin-allergic patients with sickle cell disease�.***For the treatment of infantile acne�.***For the oral treatment of infantile acne.***For the topical treatment of infantile acne.***Formoterol***Formoterol; Mometasone","***General Information***Viral infection***Macrolide hypersensitivity***Hepatic disease***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Hearing impairment***Benzyl alcohol hypersensitivity, neonates***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Seizure disorder***Myasthenia gravis***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dexmedetomidine hydrochloride,***For sedation induction and sedation maintenance.***For sedation induction and maintenance (<= 24 hours) of initially intubated and mechanically ventilated patients during treatment in an intensive care setting.***For sedation induction and maintenance of non-intubated patients prior to and/or during surgical and other procedures.,"***AV block, bradycardia, cardiac disease, diabetes mellitus, hypotension, hypovolemia, sick sinus syndrome, ventricular dysfunction***Hypertension***Abrupt discontinuation***Hepatic disease***Dialysis, renal disease, renal failure, renal impairment***Geriatric***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Requires a specialized care setting, requires an experienced clinician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3264']['7299'],dexamethasone/neomycin sulfate/polymyxin B sulfate,"***For steroid-responsive inflammatory ocular inflammation conditions (e.g., uveitis, bacterial conjunctivitis, corneal abrasion) for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. <br />        NOTE: Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies.<br />     ","***General Information***Fungal infection, herpes simplex keratitis (dendritic keratitis), mycobacterial infection, varicella, viral infection***Aminoglycoside hypersensitivity, corticosteroid hypersensitivity, neomycin hypersensitivity, polymyxin hypersensitivity***Cataracts, glaucoma, herpes infection, increased intraocular pressure, ocular infection, ocular surgery, visual disturbance***Abrupt discontinuation, corticosteroid withdrawal***Intramuscular administration, intravenous administration***Children, infants, neonates***Pregnancy***Breast-feeding***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,emedastine difumarate,"***For the temporary relief of the signs and symptoms (e.g., ocular pruritus) of allergic conjunctivitis.","***Contact lenses***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2551'],ciprofloxacin,"***For the treatment of urinary tract infection (UTI), including acute uncomplicated cystitis and pyelonephritis.***For the treatment of acute, uncomplicated UTI (acute cystitis).***For the treatment of mild to moderate UTIs and for the treatment of severe and/or complicated UTIs, including pyelonephritis.***For the treatment of lower respiratory tract infections, including bronchitis, community-acquired pneumonia (CAP), and nosocomial pneumonia. <br />        NOTE: Ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. <br />     ***For the treatment of nosocomial, ventialator-associated pneumonia (VAP) or hospital-acquired pneumonia (HAP).***For the treatment of community-acquired pneumonia (CAP).***For the treatment of acute exacerbations of chronic bronchitis.***For the treatment of skin and skin structure infections, including diabetic foot ulcer, surgical incision site infections, animal bite wounds, and necrotizing infections.***For the treatment of diabetic foot ulcer.***For the treatment of surgical incision site infections.***For the treatment of animal bite wounds.***For the treatment of necrotizing infections of the skin, fascia, and muscle.***For the treatment of enteric infections, including acute gastroenteritis and infectious diarrhea.***For the treatment of uncomplicated gonorrhea (e.g., cervicitis and urethritis).***For the treatment of mild to moderate acute sinusitis.***For the treatment of prostatitis caused by susceptible organisms.***For acute prostatitis�.***For chronic bacterial prostatitis.***For the treatment of complicated intraabdominal infections in combination with metronidazole.***For empiric treatment of patients with febrile neutropenia as part of combination therapy.***For febrile neutropenia in adults.***For febrile neutropenia in pediatric patients�.***For the treatment of bacterial conjunctivitis.***For the treatment of ophthalmic infection associated with corneal ulcer.***For anthrax prophylaxis after exposure to Bacillus anthracis (postexposure prophylaxis, PEP).***For the treatment of plague infection.***For treatment in a contained casualty setting.***For treatment in a mass casualty setting.***For plague prophylaxis following exposure to <em>Yersinia pestis</em>.***For the treatment of acute otitis externa due to susceptible isolates of <em>Pseudomonas aeruginosa</em> or <em>Staphylococcus aureus</em>.***For the treatment of bone and joint infections (i.e., osteomyelitis, prosthetic joint infections, infectious arthritis).***For the treatment of bilateral otitis media with effusion in pediatric patients undergoing tympanostomy tube placement.***For the treatment of typhoid fever due to <em>Salmonella typhi</em>.***For the treatment of shigellosis.***For the treatment of campylobacteriosis.***For the treatment of acute systemic brucellosis� caused by <em>Brucella melitensis</em>.***For the treatment of chancroid� due to <em>Haemophilus ducreyi</em>.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of <em>Neisseria meningitidis</em>� nasal carrier state (i.e., for meningococcal infection prophylaxis�).***For the treatment of dental infection�, including dentoalveolar infection� and periodontitis�.***For adult chronic periodontitis� after scaling and root planing.***For adult refractory chronic periodontitis� in combination with metronidazole after scaling and root planing in beta-lactam allergic patients.***For the treatment of anthrax�.***For the treatment of cutaneous anthrax.***For the treatment of systemic anthrax infection.***For the treatment of cholera�.***For the treatment of tularemia� infection or for postexposure tularemia prophylaxis�.***For an individual patient� or in a contained casualty setting�. <br />          NOTE: Streptomycin is the drug of choice to treat tularemia in most patients; gentamicin is the preferred agent in pregnant women.<br />       ***For a mass casualty setting� and for tularemia prophylaxis� after exposure to <em>Francisella tularensis</em>. <br />          NOTE: Doxycycline is the treatment of choice for tularemia in the most patients. Ciprofloxacin is the drug of choice for pregnant women; if ciprofloxacin is contraindicated, doxycycline should be used.<br />       ***For use as maintenance treatment of melioidosis� due to <em>Burkholderia pseudomallei�</em>.***For surgical infection prophylaxis�.***For the treatment of acute pulmonary exacerbations in cystic fibrosis� (CF) patients.***For bacterial infection prophylaxis� in patients with cirrhosis and GI bleeding.***For the treatment of CAPD-associated peritonitis�.***For the treatment of exit-site� and tunnel infections� in CAPD patients.***For the treatment of infective endocarditis�.***For the treatment of Mycobacterium avium complex infection� (MAC) in HIV-infected patients.***For the treatment of salmonellosis�.***For the treatment of moderate or severe traveler's diarrhea�.***For the treatment of isosporiasis� (<em>Isospora belli</em>) in HIV-infected patients.***For the treatment of sepsis�.","***Viral infection***Quinolone hypersensitivity***Corticosteroid therapy, organ transplant, tendinitis, tendinopathy, tendon pain, tendon rupture***Alcoholism, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Cerebrovascular disease, neurotoxicity, peripheral neuropathy, seizure disorder***Myasthenia gravis***Diabetes mellitus***Dialysis, renal disease, renal failure, renal impairment***Dehydration***Hepatic disease, hepatitis, hepatotoxicity, jaundice***Sunlight (UV) exposure***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Sexually transmitted disease***Geriatric***Children, infants, neonates***Contact lenses***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mepivacaine hydrochloride,"***For use as local anesthesia or regional anesthesia. <br />        NOTE: Doses listed below are those considered necessary to produce a successful block and should be regarded as guidelines. Individual variations in onset and duration may occur.<br />     ***For cervical nerve block, brachial plexus block, intercostal nerve block, or pudendal nerve block.***For epidural anesthesia or caudal anesthesia.***For dental anesthesia via infiltration anesthesia.***For infiltration anesthesia.***For paracervical block.***For peripheral nerve block for the management of severe pain.","***General Information***Intraarterial administration, intrathecal administration, intravenous administration***Head and neck anesthesia***Ocular surgery***Anticoagulant therapy, coagulopathy, infection, neurological disease, sepsis, thrombocytopenia***AV block, cardiac disease, dehydration, hypotension, hypovolemia, myasthenia gravis, QT prolongation, shock***Amide local anesthetic hypersensitivity, paraben hypersensitivity***Geriatric***Hepatic disease***Eclampsia, fetal distress, fetal prematurity, labor, obstetric delivery, paracervical nerve block, pregnancy, pudendal nerve block***Breast-feeding***Continuous intraarticular infusion administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ciprofloxacin hydrochloride/hydrocortisone,***For the treatment of acute otitis externa due to susceptible organisms.,"***Ophthalmic administration, parenteral administration***Corticosteroid hypersensitivity, latex hypersensitivity, quinolone hypersensitivity***Ear discharge, fungal infection, herpes infection, mycobacterial infection, tympanic membrane perforation, varicella, viral infection***Pregnancy***Benzyl alcohol hypersensitivity***Breast-feeding***Infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/levonorgestrel,"***For routine contraception.***For extended continuous routine contraception.***For use as postcoital contraception within 72 hours of unprotected intercourse, or known or suspected contraceptive failure, in females who have no known contraindications to oral contraceptives, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,goserelin acetate,"***For the treatment of breast cancer in selected females. <br />        NOTE: The Zoladex 3-month (10.8 mg depot) implant is contraindicated for use in females because sufficient clinical data are not available to support reliable suppression of serum estradiol.<br />     ***For the palliative treatment of advanced breast cancer in pre- or perimenopausal women with estrogen-receptor positive disease.***For early (Stage II), estrogen-receptor positive breast cancer� in pre- or perimenopausal women.***For the treatment of endometriosis.***For use as an endometrial thinning agent prior to endometrial ablation for dysfunctional uterine bleeding. <br />        NOTE: The Zoladex 3-month (10.8 mg depot) implant is contraindicated for use in females because sufficient clinical data are not available to support reliable suppression of serum estradiol.<br />     ***For the palliative treatment of advanced prostate cancer, particularly when orchiectomy or estrogen therapy are not indicated or are unacceptable.***For locally confined Stage T2b-T4 (Stage B2-C) prostate cancer in combination with flutamide and radiation therapy.***For medical management of uterine leiomyomata� (fibroids). <br />        NOTE: The Zoladex 3-month (10.8 mg depot) implant is contraindicated for use in females because sufficient clinical data are not available to support reliable suppression of serum estradiol.<br />     ***For the treatment of benign prostatic hyperplasia (BPH)�.***Formoterol***Formoterol; Mometasone","***Gonadotropin-Releasing Hormone (GnRH) analogs hypersensitivity***Dysfunctional uterine bleeding, females, vaginal bleeding***Menstruation, pregnancy***Breast-feeding***Spinal cord compression, urinary tract obstruction***Osteoporosis***Pituitary insufficiency***Children, infants, neonates***Alcoholism, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hepatic disease, hypercholesterolemia, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, obesity, QT prolongation, stroke, thyroid disease, tobacco smoking***Diabetes mellitus, hyperglycemia***Anticoagulant therapy, body weight less than 60 kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,glycopyrrolate,"***For use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; reduce gastric acid production and acidity (aspiration prophylaxis); and to block vagal inhibitory reflexes during intubation and induction of anesthesia.***For the treatment of sialorrhea.***For severe chronic sialorrhea (chronic drooling) associated with neurologic conditions such as cerebral palsy in pediatric patients.***For clozapine-induced sialorrhea� in adults.***For the treatment of cardiac arrhythmias (e.g., bradycardia) that occur intraoperatively and are drug-induced or are associated with visceral traction stimulation of vagal reflexes.***For cholinesterase inhibitor-induced muscarinic effects prophylaxis when anticholinesterase agents (i.e., neostigmine, physostigmine, pyridostigmine) are used to reverse neuromuscular blockade produced by curariform agents.***For the treatment of peptic or duodenal ulcer. <br />        NOTE: Due to the potential for side effects, as well as the availability of more effective alternatives, glycopyrrolate is rarely used for this indication.<br />     ***For the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis or emphysema.***For the treatment of irritable bowel syndrome� and/or diarrhea�.","***Benzyl alcohol hypersensitivity, milk protein hypersensitivity***Latex hypersensitivity***Ambient temperature increase***Closed-angle glaucoma, ocular exposure***Prostatic hypertrophy, urinary retention, urinary tract obstruction***Autonomic neuropathy, myasthenia gravis***Achalasia, biliary-GI fistula, constipation, diarrhea, esophagitis, gastroesophageal reflux disease (GERD), GI bleeding, GI obstruction, hemorrhagic shock, hiatal hernia, ileus, pyloric stenosis, toxic megacolon, ulcerative colitis***Hepatic disease, renal failure, renal impairment***Cardiac arrhythmias, coronary artery disease, heart failure, hypertension, hyperthyroidism, tachycardia, ventricular tachycardia***Pregnancy***Breast-feeding***Children, Down's syndrome, infants, neonates***Driving or operating machinery***Acute bronchospasm***Paradoxical bronchospasm***Anticholinergic medications, dementia, geriatric***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['25138'],fluorescein,"***For radiographic examination (i.e., diagnostic angiography or angioscopy) of the retina and iris vasculature.***For staining the anterior segment of the eye for eye trauma diagnosis.***For staining the anterior segment of the eye for contact lens fitting.***For staining the anterior segment of the eye for post-ophthalmic surgery wound closure assessment following anterior chamber reformation.***For staining the anterior segment of the eye for lacrimal drainage diagnosis.","***Extravasation, intraarterial administration, intramuscular administration, intrathecal administration***Asthma, eczema, urticaria***Contact lenses***Cardiac disease, dialysis, myocardial infarction, renal impairment, stroke***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,theophylline anhydrous,"***For treatment of reversible airways obstruction (i.e., for bronchospasm prophylaxis) associated with asthma or chronic obstructive pulmonary disease (COPD) (e.g., emphysema or chronic bronchitis). <br />        NOTE: Calculate initial mg/kg dose based on ideal body weight as theophylline distributes poorly into body fat. <br />     ***For adjunct treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases (e.g., COPD) along with inhaled beta-2 selective agonists and systemic corticosteroids.***For maintenance therapy of asthma or COPD using oral dosage.***For the treatment of acute exacerbations� of reversible airways obstruction (including status asthmaticus) in patients who are not responding to first-line therapies. <br />        NOTE: Although reference texts continue to list this indication, several studies have failed to demonstrate a benefit of theophylline in the management of acute bronchospasm. The FDA no longer includes acute bronchospasm as an approved indication. Most clinicians do not feel theophylline is warranted in the treatment of acute bronchospasm unless the patient is not responding to other treatments. The National Asthma Education and Prevention Program does not recommend theophylline for acute exacerbations because it appears to provide no additional benefit to optimal inhaled beta-2-agonist therapy and may increase risk of adverse effects.<br />     ***For the treatment of neonatal apnea of prematurity when non-pharmacologic therapies are ineffective. <br />        NOTE: Caffeine is the preferred agent for this indication (see Caffeine monograph); theophylline is used as an alternative.<br />     ***For the treatment of sleep apnea� in patients with chronic heart failure-induced systolic dysfunction.***Formoterol***Formoterol; Mometasone","***General Information***Cardiac arrhythmias, cardiac disease, cor pulmonale, coronary artery disease, heart failure, myocardial infarction***Hypothyroidism, pulmonary edema, sepsis, shock***Cystic fibrosis, hyperthyroidism***Acidemia***Cholestasis, hepatic disease, hepatitis, infants, neonates, renal impairment***Tobacco smoking***Fever, hypoxemia***Gastritis, gastroesophageal reflux disease (GERD), hiatal hernia, peptic ulcer disease***Prostatic hypertrophy***Pregnancy***Breast-feeding***Corn hypersensitivity***Seizure disorder***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['56946'],paclitaxel,"***For the treatment of breast cancer.***For metastatic breast cancer after the failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy.***For adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.***For first line treatment of metastatic breast cancer that overexpresses the HER2 protein in combination with trastuzumab.***For patients who have not previously received chemotherapy for metastatic HER2-negative breast cancer, in combination with bevacizumab�.***For the front-line treatment of HER2-overexpressing metastatic breast cancer in combination with carboplatin and trastuzumab�.***For the neoadjuvant treatment of HER2-positive breast cancer with trastuzumab, in sequence with fluorouracil, epirubicin, and cyclophosphamide (FEC regimen) plus trastuzumab�.***For the first line treatment of metastatic breast cancer in combination with carboplatin�.***For second line treatment of AIDS-related Kaposi's sarcoma. <br />        NOTE: Paclitaxel has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of non-small cell lung cancer (NSCLC).***For first line treatment of NSCLC, in combination with cisplatin, in patients who are not candidates for potentially curative surgery and/or radiation therapy.***For the treatment of advanced or metastatic NSCLC in combination with carboplatin�.***For the treatment of advanced or metastatic NSCLC in combination with gemcitabine�.***For the treatment of ovarian cancer.***For first line treatment of ovarian cancer in combination with cisplatin.***For the first line treatment of ovarian cancer in combination with carboplatin�.***For refractory or metastatic ovarian cancer.***For the first line treatment of optimally debulked, stage III ovarian cancer as an intraperitoneal and intravenous infusion in combination with intraperitoneal cisplatin�.***For the first line treatment of advanced transitional-cell bladder cancer�, in combination with carboplatin.***For the treatment of unresectable or metastatic squamous cell esophageal cancer�, in combination with cisplatin.***For the treatment of advanced squamous cell head and neck cancer�, in combination with carboplatin and radiotherapy.***For peripheral blood stem cell (PBSC) mobilization� in hematologic malignancies.***For the treatment of advanced or recurrent endometrial cancer in combination with doxorubicin and cisplatin�.***For the first line treatment of unresectable, advanced thymoma�, in combination with carboplatin.***For the first line treatment of unresectable, advanced thymic carcinoma�, in combination with carboplatin.***For the treatment of small cell lung cancer (SCLC)�.***For chemotherapy-naive, extensive-stage SCLC in combination with topotecan�.***For the treatment of relapsed SCLC as a single agent�.***For the treatment of relapsed SCLC in combination with carboplatin�.***For the neoadjuvant treatment of locally advanced or metastatic penile cancer� in combination with cisplatin and ifosfamide.","***Polyoxyethylated castor oil hypersensitivity, serious hypersensitivity reactions or anaphylaxis, taxane hypersensitivity***Bone marrow suppression, herpes infection, infection, Kaposi's sarcoma, neutropenia, requires a specialized care setting, requires an experienced clinician, thrombocytopenia, varicella, viral infection***Angina, AV block, bradycardia, cardiac arrhythmias, cardiac disease, heart failure, myocardial infarction***Peripheral neuropathy***Geriatric***Hepatic disease***Pregnancy***Breast-feeding***Radiation therapy***Intramuscular injections***Dental disease, dental work***Alcoholism, driving or operating machinery***Children***Extravasation, intramuscular administration, subcutaneous administration***Accidental exposure, ocular exposure***Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3992'],epinephrine,"***For the treatment of anaphylaxis. <br />        NOTE: Epinephrine absorption is rapid and complete if administered IM in the anterolateral aspect of the thigh. Subcutaneous epinephrine is not routinely recommended due to delayed absorption. <br />     ***For the treatment of acute bronchospasm (e.g., asthma exacerbation) and/or status asthmaticus.***For bronchospasm prophylaxis.***For the treatment of laryngotracheobronchitis (croup).***For the treatment of acute, severe urticaria or angioedema associated with systemic symptoms.***For use in cardiopulmonary resuscitation (CPR), specifically, for the treatment of cardiac arrest (pulseless electrical activity or ventricular asystole), or as an adjunct to electrical defibrillation in the treatment of ventricular fibrillation/pulseless ventricular tachycardia.***For the treatment of hypotension associated with septic shock.***For the treatment or prevention of surgical bleeding along a surgical incision.***For the treatment of open-angle glaucoma.***For the treatment of nasal congestion.***For mydriasis induction and maintenance during intraocular surgery.***For the emergency treatment of symptomatic bradycardia�.***For the treatment of acute chloroquine overdose� in combination with diazepam.***Formoterol***Formoterol; Mometasone","***General Information***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, coronary artery disease, hemorrhagic shock, hypovolemia, pulmonary edema, shock***Sulfite hypersensitivity***Closed-angle glaucoma***Extravasation, infection, intraarterial administration***Cerebrovascular disease, organic brain syndrome***Hypertension***Hyperthyroidism, pheochromocytoma, thyroid disease, thyrotoxicosis***Diabetes mellitus***Labor, obstetric delivery, pregnancy***Breast-feeding***Ophthalmic administration***Parkinson's disease***Renal disease***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,alclometasone dipropionate,"***For the treatment of mild to moderate inflammatory manifestations of corticosteroid-responsive dermatitis such as atopic dermatitis, contact dermatitis, exfoliative dermatitis, <em>Rhus</em> <em>dermatitis</em> due to plants like poison ivy, or seborrheic dermatitis (facial and intertriginous areas), discoid lupus erythematosus (facial and intertriginous areas), eczema, granuloma annulare, intertrigo, cutaneous lichen planus, lichen simplex chronicus, polymorphous light eruption, anogenital or senilis pruritus, psoriasis (facial and intertriginous areas), or xerosis (inflammatory phase). <br />        NOTE: Occlusive dressings may be required for chronic or severe cases of lichen simplex chronicus, psoriasis, eczema, atopic dermatitis, or chronic hand eczema. More potent topical corticosteroids and/or occlusive dressings may be necessary for the treatment of discoid lupus erythematosus, lichen planus, granuloma annulare, psoriatic plaques, and psoriasis of the palms, soles, elbows, or knees.<br />     ","***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, tuberculosis, varicella, viral infection***Ocular exposure***Geriatric, skin atrophy***Diabetes mellitus***Corticosteroid hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,benzoyl peroxide/erythromycin,***For the treatment of acne vulgaris.,"***Eczema, skin abrasion, skin disease, sunburn, sunlight (UV) exposure***Benzoic acid hypersensitivity, macrolide hypersensitivity***Diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Myasthenia gravis***Accidental exposure, ocular exposure***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8703'],fenofibrate,"***For use as an adjunct to diet for the treatment of adult patients with severe hypertriglyceridemia. <br />  NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.     <br />NOTE: Markedly elevated levels of serum triglycerides (e.g., &gt; 2000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.  ***For use as an adjunct to diet to reduce elevated LDL-cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase HDL-cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. <br />        NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.   ","***General Information***Cardiac disease***Biliary cirrhosis, cholelithiasis, gallbladder disease, hepatic disease***Dialysis, renal disease, renal failure, renal impairment***Anticoagulant therapy***Thromboembolic disease***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding***Diabetes mellitus***Hypothyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,milrinone lactate,"***For the short-term intravenous treatment of patients with acute decompensated heart failure. <br />        NOTE: Experience with IV milrinone has primarily been in patients receiving digoxin and diuretics. There is no experience in controlled trials with IV milrinone infusions &gt; 48 hours. Whether given orally or by IV infusion, milrinone has not been shown to be safe or effective in long-term (i.e., &gt; 48 hours) treatment of patients with heart failure. In a multicenter trial of 1088 patients with NYHA Class III and IV heart failure, long-term oral milrinone was associated with no improvement in heart failure symptoms and an increased risk of hospitalization and death. Patients with Class IV heart failure had an increased risk of life-threatening cardiovascular events including hypotension and syncope. There is no evidence that long-term milrinone given intravenously does not carry a similar risk.<br />NOTE: The ACC/AHA guidelines for management of chronic heart failure recommend that intermittent intravenous positive inotropic therapy has no proven value in patients with Stage C chronic heart failure (Class III recommendation); however, the guidelines suggest that continuous intravenous inotrope infusions may be considered for palliation of symptoms in patients with end-stage heart failure (i.e., Stage D).  In one study of patients hospitalized with worsened systolic heart failure (92% NYHA Class III or IV), a 48 hour infusion of milrinone did not reduce in-hospital mortality, the number of hospital days for cardiovascular events, or the composite study endpoint (death or hospital readmission rate), but resulted in increased adverse effects when compared to placebo; the study excluded patients who required continuous IV inotropic support***For the treatment of cerebral vasospasm� after aneurysmal subarachnoid hemorrhage.","***General Information***Idiopathic hypertrophic subaortic stenosis, valvular heart disease***Atrial fibrillation, atrial flutter, electrolyte imbalance, hypotension, hypovolemia, orthostatic hypotension, syncope***Acute myocardial infarction***Renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dantrolene sodium,"***For treatment of chronic spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). <br />        NOTE: Dantrolene is not indicated for the treatment of skeletal muscle spasm resulting from rheumatic disorders.<br />NOTE: Stop dantrolene if no observable benefit is derived after a total of 45 days of treatment. Brief withdrawal of dantrolene for 2�4 days may help to detect subtle but meaningful spasticity improvement with dantrolene***For malignant hyperthermia.***For treatment of an acute malignant hyperthermia crisis.***For prevention of malignant hyperthermia in susceptible patients undergoing surgery.***For the treatment of neuroleptic malignant syndrome�. <br />        NOTE: Response to dantrolene in this condition has not always been successful.<br />     ***For succinylcholine-induced muscle fasciculations and post-op myalgia�.","***General Information***Myopathy, neuromuscular disease***Females, hepatic disease, hepatitis, hepatotoxicity, multiple sclerosis***Cardiac disease***Chronic obstructive pulmonary disease (COPD), pulmonary disease***Sunlight (UV) exposure***Pregnancy***Breast-feeding***Driving or operating machinery***Extravasation***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7435'],nisoldipine,***For the treatment of hypertension.***For the treatment of ischemic heart disease including variant angina� (Prinzmetal's angina) and stable angina� pectoris.,"***Dihydropyridine hypersensitivity***Aortic stenosis***Acute myocardial infarction, coronary artery disease, hypotension***Cardiogenic shock***Hepatic disease***Heart failure, ventricular dysfunction***Bradycardia***Pregnancy***Breast-feeding***Children***Gastroesophageal reflux disease (GERD), hiatal hernia***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amitriptyline hydrochloride,***For the treatment of major depression.***For the treatment of social phobia (social anxiety disorder)� or panic disorder�.***For the treatment of painful diabetic neuropathy�.***For the treatment of postherpetic neuralgia�.***For migraine prophylaxis�.***For the treatment of fibromyalgia�.***For the treatment of insomnia�.***For the treatment of persistent singultus (hiccups)�.***For the treatment of primary nocturnal enuresis�.***For the adjunct treatment of bulimia nervosa�.,"***Carbamazepine hypersensitivity, tricyclic antidepressant hypersensitivity***MAOI therapy***Acute myocardial infarction, bradycardia, cardiac arrhythmias, cardiac disease, congenital heart disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation***Children, suicidal ideation***Bipolar disorder, mania, schizophrenia***Alcoholism, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Electroconvulsive therapy (ECT), seizure disorder, seizures***Hepatic disease***Surgery***Anticholinergic medications, ileus, prostatic hypertrophy, urinary retention***Closed-angle glaucoma, increased intraocular pressure***Contact lenses***Agranulocytosis, leukopenia***Hyperthyroidism, hypothyroidism, thyroid disease***Diabetes mellitus, pheochromocytoma***Radiographic contrast administration***Sunlight (UV) exposure***Abrupt discontinuation***Geriatric***Neonates, pregnancy***Breast-feeding***Tobacco smoking***Intravenous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['31819'],nitazoxanide,"***For the treatment of infectious diarrhea due to susceptible organisms, including <em>Cryptosporidium parvum</em> (cryptosporidiosis) and <em>Giardia lamblia</em> (giardiasis).***For the treatment of diarrhea caused by <em>Cryptosporidium parvum</em> (cryptosporidiosis).***For the treatment of diarrhea caused by <em>Giardia lamblia</em> (giardiasis).***For the treatment of diarrhea caused by <em>Giardia intestinalis�</em> and <em>Entamoeba histolytica�</em> and/or <em>E. dispar�</em>.***For the treatment of gastrointestinal infections caused by Enterocytozoon bieneusi� (microsporidiosis�) in HIV-infected patients.***For the treatment of diarrhea due to rotavirus infection�.***For the treatment of pseudomembranous colitis� due to <em>Clostridium difficile</em>.","***General Information***Biliary tract disease, hepatic disease, renal disease, renal failure, renal impairment***Diabetes mellitus***Driving or operating machinery***Pregnancy***Breast-feeding***Children, infants, neonates***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, immunosuppression***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['114477'],levetiracetam,***For the adjunctive treatment of partial seizures. <br />        NOTE: Treatment may be initiated with IV or PO therapy.<br />     ***For the adjunctive treatment of myoclonic seizures in those with juvenile myoclonic epilepsy.***For the adjunctive treatment of primary generalized tonic-clonic seizures in those with idiopathic generalized epilepsy.***For the first-line treatment of convulsive status epilepticus�.***For seizure prophylaxis�.***For seizure prophylaxis� after traumatic brain injury.***Formoterol; Mometasone,"***General Information***Abrupt discontinuation***Dialysis, renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Driving or operating machinery***Depression, suicidal ideation***Psychosis, schizophrenia***Geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,methamphetamine hydrochloride,"***For treatment of attention-deficit hyperactivity disorder (ADHD) characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.***For adjunctive, short-term treatment of exogenous obesity in patients whose obesity is refractory to repeated diets, group programs, and other drugs.***For the treatment of narcolepsy�.***Formoterol***Formoterol; Mometasone","***Lactase deficiency***Alcoholism, substance abuse***Hypertension, tachycardia***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular arrhythmias, ventricular dysfunction***Cerebrovascular disease, stroke***Tics, Tourette's syndrome***Bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Hyperthyroidism, thyrotoxicosis***Glaucoma, visual disturbance***Seizure disorder, seizures***Radiographic contrast administration***Surgery***Driving or operating machinery***Diabetes mellitus***Hypercortisolism***Peripheral vascular disease, Raynaud's phenomenon***Anorexia nervosa, bulimia nervosa, obesity treatment***Neonates, pregnancy***Breast-feeding***Geriatric***Children, growth inhibition, infants***Abrupt discontinuation***MAOI therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['460132'],darunavir,"***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***For human immunodeficiency virus (HIV) prophylaxis�.***For human immunodeficiency virus (HIV) prophylaxis� after occupational exposure.***For human immunodeficiency virus (HIV) prophylaxis� after nonoccupational exposure, including sexual assault. <br />  NOTE: Higher risk exposures for which prophylaxis is recommended include exposure of vagina, rectum, eye, mouth, or other mucous membrane, nonintact skin, or percutaneous contact with blood, semen, vaginal secretions, rectal secretions, breast milk, or any body fluid that is visibly contaminated with blood when the source is known to be HIV-positive. Exposures to a source patient with unknown HIV status should be assessed on a case-by-case basis.<br /***Formoterol; Mometasone","***General Information***Sulfonamide hypersensitivity***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Hepatic disease, hepatitis, hepatitis B and HIV coinfection, hepatitis C and HIV coinfection, jaundice***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia***Bleeding, hemophilia***Pregnancy***Breast-feeding***Children, infants, neonates***Hyperlipidemia, hypertriglyceridemia, pancreatitis***Human immunodeficiency virus (HIV) infection resistance***Serious rash***Pregnancy testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8463'],podofilox,"***For the treatment of external warts (condylomata acuminata) due to human papillomavirus (HPV) infection. <br />        NOTE: Podofilox 0.5% gel may be used to treat external genital or perianal warts. The 0.5% topical solution may be used to treat external genital warts; however, it is not indicated for use in the perianal area.<br />     ","***General Information***Accidental exposure, ocular exposure***Children, infants, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['21090'],ciclopirox,"***For the topical treatment of mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to <em>Trichophyton rubrum </em>in immunocompetent patients. <br />        NOTE: Ciclopirox should be used in conjunction with a comprehensive management program for onychomycosis which includes removal of the unattached, infected nails (as frequently as monthly) by a health care professional and weekly trimming of the nails by the patient.<br />     ***For the topical treatment of seborrheic dermatitis of the scalp.***For the topical treatment of tinea corporis, tinea cruris, or tinea pedis (<em>Epidermophyton floccosum</em>; <em>Microsporum canis</em>; <em>Trichophyton mentagrophytes</em>; <em>Trichophyton rubrum</em>); tinea versicolor (<em>Malassezia furfur</em>); or cutaneous candidiasis due to <em>Candida albicans</em>.","***Skin abrasion***Ocular exposure***Onychomycosis***Corticosteroid therapy, human immunodeficiency virus (HIV) infection, immunosuppression, organ transplant, seizure disorder***Diabetes mellitus, peripheral vascular disease***Geriatric***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['897018'],dalfampridine,"***For improved walking (i.e., improved walking speed) in patients with multiple sclerosis. <br />        NOTE: Benefit was noted as an increase in walking speed, and benefit was observed across all 4 major types of multiple sclerosis disease course.<br />NOTE: In trials, most patients were also taking immunomodulatory drugs such as interferons, glatiramer acetate, or natalizumab. The magnitude of improvement in walking ability was independent of concomitant treatment with an immunomodulatory drug","***Seizure disorder, seizures***Renal disease, renal failure, renal impairment***Children***Breast-feeding***Pregnancy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,anagrelide hydrochloride,"***For the treatment of thrombocytosis due to myeloproliferative disorders such as essential thrombocythemia, polycythemia vera, or chronic myelogenous leukemia (CML). <br />        NOTE: Anagrelide has been designated an orphan drug by the FDA for these indications.<br />NOTE: To monitor effectiveness and prevent thrombocytopenia, platelet counts should be performed every 2 days during the first week of treatment and at least weekly thereafter until the desired maintenance dosage is reached","***Renal failure, renal impairment***Hepatic disease***Heart failure***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Bleeding***Eosinophilic pneumonia, pneumonitis***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,meperidine hydrochloride,"***For the treatment of moderate pain to severe pain. <br />        NOTE: Chronic use of meperidine is not recommended due to an increased risk of neurotoxicity (e.g., seizures) secondary to accumulation of the meperidine metabolite, normeperidine.<br />NOTE: Pain severity and patient response should guide dosage***For obstetric analgesia during labor and delivery.***For preoperative sedation induction.***For general anesthesia maintenance. <br />        NOTE: Dosage needed will depend on premedication and anesthesia utilized, nature and duration of procedure, and patient characteristics.<br />     ***For obstetric anesthesia�.***For the treatment of acute, severe headache� or migraine�.***For the treatment of shaking chills� induced by intravenous infusions of amphotericin B or for postoperative shivering�.","***Opiate agonist hypersensitivity***MAOI therapy***Acute abdomen, constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Biliary tract disease***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, status asthmaticus***Alcoholism, depression, substance abuse***Head trauma, increased intracranial pressure***Glaucoma***CNS depression, hepatic disease, renal impairment, seizure disorder, seizures***Angina, atrial flutter, cardiac arrhythmias, cardiac disease, dehydration, heart failure, hypotension, hypovolemia, pheochromocytoma***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, sickle cell disease, urinary retention***Geriatric***Children, infants, intramuscular administration, neonates***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Driving or operating machinery***Abrupt discontinuation***Anticoagulant therapy, coagulopathy, epidural administration, infection, intrathecal administration, intravenous administration, thrombocytopenia***Adrenal insufficiency, hypothyroidism, myxedema***Accidental exposure, potential for overdose or poisoning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['632'],mitomycin,***For treatment of gastric cancer.***For the treatment of pancreatic cancer.***For use as an adjunct to ab externo ocular surgery for glaucoma.***For the treatment of colorectal cancer�.***For the treatment of liver metastases from colorectal cancer�.***For the treatment of peritoneal carcinomatosis of colorectal cancer�.***For the treatment of anal cancer� in combination with fluorouracil and radiation.***For the treatment of advanced head and neck cancer� in combination with 5-fluorouracil and radiation therapy.***For the adjuvant treatment of superficial bladder cancer� in patients at high risk for recurrence.***For the treatment of cervical cancer� in combination with cisplatin.***For the treatment of malignant mesothelioma�.***For the treatment of malignant pleural mesothelioma administered locally in the pleural cavity in combination with cisplatin�.***For the treatment of malignant peritoneal mesothelioma in combination with cisplatin�.***For the treatment of biliary tract cancer�.***For the treatment of unresectable intrahepatic cholangiocarcinoma in combination with cisplatin and doxorubicin�.***For the treatment of unresectable intrahepatic cholangiocarcinoma�.***Formoterol; Mometasone,"***General Information***Bleeding, bone marrow suppression, coagulopathy, herpes infection, infection, leukopenia, neutropenia, radiation therapy, requires a specialized care setting, requires an experienced clinician, thrombocytopenia, varicella, viral infection***Dental disease, dental work***Intramuscular injections***Extravasation, intramuscular administration, subcutaneous administration***Anemia, hemolytic-uremic syndrome, renal failure, renal impairment***Acute bronchospasm, pulmonary disease, pulmonary fibrosis, respiratory insufficiency, surgery***Infertility, male-mediated teratogenicity, pregnancy***Breast-feeding***Children, infants***Accidental exposure, ocular exposure***Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,naphazoline hydrochloride/pheniramine maleate,"***For the temporary relief of ocular pruritus and conjunctival hyperemia caused by pollen, ragweed, grass, and animal hair and dander.","***Closed-angle glaucoma***Cardiac disease, hypertension***Prostatic hypertrophy***Pregnancy***Breast-feeding***Children, infants***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,alglucosidase alfa,***For the treatment of acid alpha-glucosidase deficiency (Pompe disease). <br />        NOTE: Alglucosidase alfa was designated as an orphan drug for the treatment of Pompe disease in 1997.<br />NOTE: Initiation of alglucosidase alfa therapy in the earliest stages of the disease process is associated with the most clinical benefit***For the treatment of infantile-onset acid alpha-glucosidase deficiency (Pompe disease).***For the treatment of late-onset (non-infantile) acid alpha-glucosidase deficiency (Pompe disease) .,"***General Information***Alglucosidase alfa hypersensitivity, infusion-related reactions, serious hypersensitivity reactions or anaphylaxis***Cardiac disease, cardiomyopathy, heart failure, respiratory insufficiency, sepsis, surgery***Pregnancy***Breast-feeding***Geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2396'],chlorothiazide,"***For the treatment of hypertension.***For use as an adjunctive agent to treat peripheral edema associated with congestive heart failure, hepatic cirrhosis (ascites), corticosteroid therapy, or estrogen therapy; or to treat edema associated with renal dysfunction including nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.***For the treatment of idiopathic hypercalciuria� in children.***Formoterol***Formoterol; Mometasone","***General Information***Sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, renal disease, renal failure, renal impairment***Hepatic disease***Acid/base imbalance, electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia, hyponatremia***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***Diabetes mellitus, hyperglycemia***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Extravasation, intramuscular administration, subcutaneous administration***Sunlight (UV) exposure***Preeclampsia, pregnancy***Breast-feeding***Children, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,remifentanil hydrochloride,"***For general anesthesia induction (through intubation). <br />        NOTE: Remifentanil should not be used as the sole agent for general anesthesia because loss of consciousness cannot be assured and because of a high incidence of apnea, muscle rigidity, and tachycardia.<br />     ***For general anesthesia maintenance . <br />        NOTE: Remifentanil should not be used as the sole agent for general anesthesia because loss of consciousness cannot be assured and because of a high incidence of apnea, muscle rigidity, and tachycardia.<br />     ***For total intravenous anesthesia (TIVA).***For the management of moderate pain and severe pain.***For sedation and analgesia prior to non-emergent endotracheal intubation� or rapid-sequence intubation (RSI)�.***For procedural sedation�.","***General Information***Opiate agonist hypersensitivity***Abrupt discontinuation***Acute abdomen, constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Obesity***Chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, ethanol ingestion, ethanol intoxication, pulmonary disease, requires a specialized care setting, requires an experienced clinician, respiratory depression, respiratory insufficiency***Angina, bradycardia, cardiac disease, heart failure, hypotension, hypovolemia***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, urethral stricture, urinary retention***Epidural administration, intrathecal administration***Head trauma, increased intracranial pressure, seizure disorder, seizures***Geriatric***Biliary tract disease***Alcoholism, depression, substance abuse***Driving or operating machinery***Females***Neonates***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Accidental exposure, potential for overdose or poisoning***Adrenal insufficiency, hypothyroidism, myxedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1292'],baclofen,"***For the treatment of spasticity, muscle spasm (not due to rheumatic conditions), myoclonus, and muscle rigidity in multiple sclerosis and spinal cord injury or diseases. <br />        NOTE: The efficacy of oral baclofen has not been established in stroke, cerebral palsy, and Parkinson's disease, and, therefore, is not recommended by the manufacturer for use in these disease states.<br />     ***For severe spasticity due to multiple sclerosis, cerebral palsy, spinal cord injury, or traumatic brain injury; or in patients unresponsive to oral baclofen therapy or those who experience intolerable side effects at effective oral doses. <br />          NOTE: Intrathecal baclofen has been designated an orphan drug by the FDA for this indication.<br />       ***For the treatment of persistent singultus (hiccups)�.***For the treatment of trigeminal neuralgia�.***For the treatment of central vestibular nystagmus�.***For prevention of stuttering priapism� (i.e., recurrent priapism).***For the adjunct treatment of symptomatic gastroesophageal reflux disease (GERD)� in refractory patients.","***General Information***Abrupt discontinuation***Intrathecal administration***Cerebral palsy, head trauma, intracranial bleeding, stroke***Geriatric***Bipolar disorder, depression, psychosis, schizophrenia***Diabetes mellitus***Seizure disorder, seizures***Dialysis, renal failure, renal impairment***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Children, infants***Epidural administration, intramuscular administration, intravenous administration, subcutaneous administration***Anticoagulant therapy, coagulopathy, infection, thrombocytopenia***Dental disease***Pregnancy***Breast-feeding***Phenylketonuria***Ovarian cyst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,colistin sulfate/hydrocortisone acetate/neomycin sulfate/thonzonium bromide,"***For the treatment of superficial bacterial infections of the external auditory canal (i.e., otitis externa) caused by susceptible organisms, and for the treatment of infections of mastoidectomy and fenestration cavities caused by susceptible organisms.","***General Information***Aminoglycoside hypersensitivity, neomycin hypersensitivity***Herpes infection, varicella, viral infection***Hearing impairment, renal disease, tympanic membrane perforation***Ocular exposure***Colitis, diarrhea, pseudomembranous colitis***Pregnancy***Breast-feeding***Infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mepivacaine hydrochloride,"***For use as local anesthesia or regional anesthesia. <br />        NOTE: Doses listed below are those considered necessary to produce a successful block and should be regarded as guidelines. Individual variations in onset and duration may occur.<br />     ***For cervical nerve block, brachial plexus block, intercostal nerve block, or pudendal nerve block.***For epidural anesthesia or caudal anesthesia.***For dental anesthesia via infiltration anesthesia.***For infiltration anesthesia.***For paracervical block.***For peripheral nerve block for the management of severe pain.","***General Information***Intraarterial administration, intrathecal administration, intravenous administration***Head and neck anesthesia***Ocular surgery***Anticoagulant therapy, coagulopathy, infection, neurological disease, sepsis, thrombocytopenia***AV block, cardiac disease, dehydration, hypotension, hypovolemia, myasthenia gravis, QT prolongation, shock***Amide local anesthetic hypersensitivity, paraben hypersensitivity***Geriatric***Hepatic disease***Eclampsia, fetal distress, fetal prematurity, labor, obstetric delivery, paracervical nerve block, pregnancy, pudendal nerve block***Breast-feeding***Continuous intraarticular infusion administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['42331'],misoprostol,"***For NSAID-induced ulcer prophylaxis in patients receiving NSAIDs and at high risk for gastric ulceration (e.g., elderly, past history of ulcer, concomitant debilitating disease, or concomitant systemic corticosteroid use). <br />        NOTE: Misoprostol is indicated to prevent NSAID-induced gastric ulcers but has not been shown to prevent duodenal ulcers.<br />     ***For the short-term treatment of active duodenal ulcer� or gastric ulcer� unrelated to NSAID use.***For kidney transplant rejection prophylaxis� in patients who are currently receiving cyclosporine and prednisone.***For pregnancy termination�.***For pregnancy termination in combination with mifepristone, at 49 days (7 weeks) or less of gestation dated from the first day of the last menstrual period.***For pregnancy termination� prior to the 63rd day of pregnancy in combination with intramuscular methotrexate.***For pregnancy termination� during the second trimester of pregnancy.***For cervical ripening induction� and labor induction� for obstetric delivery of a term pregnancy, or for labor induction following intrauterine fetal death�.***For the prevention and/or treatment of postpartum bleeding�.***For the prevention of postpartum bleeding� when other uterotonic agents are not available.***For the treatment of postpartum bleeding� due to uterine atony when unresponsive to massage and other uterotonic agents are not available, or when unresponsive to massage and other uterotonic agents.***For the medical management of early pregnancy failure�. <br />        NOTE: Consult the contraindications section of the monograph before use.<br />     ","***General Information***Abnormal fetal position, caesarean section, contraception requirements, ectopic pregnancy, fetal distress, herpes infection, incomplete abortion, labor, multiparity, obstetric delivery, placenta previa, pregnancy, pregnancy testing, reproductive risk, vaginal administration, vaginal bleeding, vasa previa***Infertility***Breast-feeding, diarrhea***Children***Dehydration, inflammatory bowel disease, ulcerative colitis***Renal disease***Cardiac disease***Fever, infection, sepsis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6038']['8987'],isoniazid/pyrazinamide/rifampin,"***For the initial phase of short-course pulmonary tuberculosis infection treatment in patients already on a fixed dose regimen. <br />  NOTE: Each tablet contains 50 mg isoniazid, 300 mg pyrazinamide, and 120 mg rifampin.<br />NOTE: Concurrent administration of pyridoxine (B6) is recommended.<br />NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., at least 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, IDSA, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. Directly observed therapy (DOT) should be used for all regimens administered 1, 2, 3, or 5 times per week and in all pediatric patients. The initial treatment regimen should include 4 drugs unless the likelihood of INH or rifampin resistance is low (i.e., less than 4%), in which case an initial regimen of INH, rifampin, and pyrazinamide may be considered. HIV positive patients should always receive induction therapy with 4 drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate. ***Formoterol; Mometasone","***General Information***Alcoholism, Black patients, females, geriatric, hepatic disease, hepatitis, hepatotoxicity, Hispanic patients, jaundice***Rifamycin hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Contact lenses***Peripheral neuropathy, renal failure, renal impairment***Diabetes mellitus***MAOI therapy***Visual disturbance***Gout, hyperuricemia***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,somatropin (rDNA origin),"***For the treatment of growth hormone deficiency, growth failure, or short stature.***For replacement therapy in adults with growth hormone deficiency (GHD) for either childhood onset (secondary to congenital, genetic, acquired, or idiopathic causes) or adult onset (endogenous or associated with multiple hormone deficiencies, i.e., hypopituitarism, as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma).***For the long-term treatment of growth failure in children who have growth hormone deficiency due to inadequate growth hormone secretion.***For growth failure due to Prader-Willi syndrome.***For the long-term treatment of growth failure in children born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 to 4.***For growth failure associated with chronic renal failure up to the time of transplantation.***For short stature associated with Turner's syndrome.***For short stature in children with SHOX (short stature homeobox-containing gene) deficiency.***For short stature in children with Noonan Syndrome.***For idiopathic short stature.***For the treatment of HIV-associated failure to thrive in children, AIDS-associated wasting syndrome, or cachexia.***For the treatment of HIV-associated adipose redistribution syndrome (HARS)�.***For the treatment of short bowel syndrome in patients receiving specialized nutrition support as directed by a health care professional.***Formoterol; Mometasone","***General Information***Cresol hypersensitivity, glycerin hypersensitivity, history of angioedema, risk of serious hypersensitivity reactions or anaphylaxis***Epiphyseal closure***Children, renal impairment, renal osteodystrophy***Benzyl alcohol hypersensitivity, neonates***Chemotherapy, neoplastic disease, new primary malignancy, radiation therapy***Respiratory insufficiency, surgery, trauma***Obesity***Respiratory infection, sleep apnea***Diabetes mellitus, diabetic retinopathy***Scoliosis***Adrenal insufficiency, hypothyroidism***Increased intracranial pressure***Pregnancy***Breast-feeding***Otitis media***Geriatric***Females***Pancreatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,prochlorperazine maleate,"***For treatment of nausea/vomiting.***For preoperative nausea control.***For the management of the manifestations of psychotic disorders such as schizophrenia.***For the short-term treatment of non-psychotic anxiety.***For the treatment of intractable, severe migraine� unresponsive to other therapies, or prior to administration of intravenous dihydroergotamine (DHE) to offset DHE-induced nausea.","***Phenothiazine hypersensitivity***Agranulocytosis, neutropenia***Tardive dyskinesia***Neurological disease, Parkinson's disease***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion***Hypotension, orthostatic hypotension***Alcoholism, angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, pulmonary disease, QT prolongation, thyroid disease***Hepatic disease, jaundice***Radiographic contrast administration, seizure disorder***Glaucoma, prostatic hypertrophy, urinary retention***GI obstruction, ileus***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Breast cancer, hyperprolactinemia, infertility***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Children, infants, Reye's syndrome, surgery***Dementia, geriatric, stroke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['28889'],loratadine,"***For the relief of symptoms associated with seasonal or perennial allergic rhinitis, and for management of chronic idiopathic urticaria or other histamine-mediated allergic symptoms (e.g., hives, pruritus).***For adjunctive exercise-induced bronchospasm prophylaxis� in patients with allergies.","***General Information***Asthma***Phenylketonuria***Driving or operating machinery***Hepatic disease***Renal failure, renal impairment***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,disopyramide phosphate,"***For the treatment of documented, life-threatening arrhythmias such as sustained ventricular tachycardia.***For maintenance of sinus rhythm in patients with atrial fibrillation� or atrial flutter�.","***General Information***Hyperkalemia, hypokalemia***Cardiogenic shock, cardiomyopathy, heart failure***Myasthenia gravis***Alcoholism, AV block, bradycardia, bundle-branch block, cardiac arrhythmias, cardiac disease, coronary artery disease, females, hypertension, hypocalcemia, hypomagnesemia, long QT syndrome, malnutrition, mortality, myocardial infarction, QT prolongation, sick sinus syndrome, thyroid disease, ventricular arrhythmias, Wolff-Parkinson-White syndrome***Bladder obstruction, glaucoma, prostatic hypertrophy, urinary retention***Diabetes mellitus***Renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Hepatic disease***Contact lenses***Anticholinergic medications, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['40575'],zileuton,"***For the prophylaxis and chronic treatment of patients with asthma. <br />        NOTE: Liver function tests (LFTs) should be conducted at baseline then once monthly for 3 months, then every 2 to 3 months for the remainder of the first year and periodically thereafter.<br />     ***For the treatment of inflammation associated with rheumatoid arthritis�.***For the treatment of ulcerative colitis�.***For the treatment of aspirin-induced asthma�.***For exercise-induced bronchospasm prophylaxis�.***Formoterol; Mometasone","***General Information***Alcoholism, hepatic disease***Children, infants, neonates***Acute bronchospasm, status asthmaticus***Fever, infection***Pregnancy***Breast-feeding***Suicidal ideation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,immune globulin subcutaneous (human),"***For hepatitis A prophylaxis.***For postexposure prophylaxis.***For patients traveling to regions that have high or intermediate hepatitis A endemicity.***For measles prophylaxis to prevent or modify measles in an unvaccinated patient who has not previously had measles and who was exposed within the past 6 days. <br />  NOTE: For most persons 12 months and older who are exposed to measles, use of MMR or measles vaccine within 72 hours of exposure is preferred to using immune globulin (except pregnant women and others for whom the vaccine is contraindicated). Any person exposed to measles who lacks evidence of measles immunity and to whom immune globulin (IG) is administered should subsequently receive MMR vaccine but not earlier than 6 months after IMIG administration or 8 months after IGIV administration (provided the vaccine is not contraindicated).<br /***For varicella (chickenpox) infection prophylaxis.***For rubella prophylaxis in exposed, susceptible pregnant women who will not consider a therapeutic abortion. <br />        NOTE: The routine use of IMIG for rubella prophylaxis in early pregnancy is of dubious value and cannot be justified.<br />     ***For immunoglobulin deficiency. <br />  NOTE: Immune globulin may prevent serious infection in patients with immunoglobulin deficiencies if circulating IgG concentrations of approximately 200 mg/100 mL plasma are maintained.<br /","***Intravenous administration***Pregnancy***Breast-feeding***Agammaglobulinemia, hypogammaglobulinemia, IgA deficiency***Viral infection***Anticoagulant therapy, bleeding, coagulopathy, hemophilia, thrombocytopenia***Vaccination***Children***Coronary artery disease, geriatric, heart failure, hypertriglyceridemia, hyponatremia, obesity, thromboembolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,divalproex sodium,"***For the monotherapy or adjunct treatment of simple absence seizures, complex absence seizures, or complex partial seizures, and adjunctively for other seizure types that include absence or partial complex seizures (e.g., tonic-clonic seizures, myoclonic seizures).***For the treatment of acute mania associated with bipolar disorder, with or without psychotic features.***For migraine prophylaxis.***For the treatment of refractory status epilepticus�. <br />  NOTE: Valproate has been used for emergency treatment of seizures where other agents have failed, or, when other medications are not readily available or when phenytoin is contraindicated.<br /***For the treatment of persistent singultus (hiccups)�.***For the treatment of severe behavioral disturbances, such as agitation�.***For severe behavioral disturbances� (e.g., aggression, agitation�, explosive temper) occurring with attention-deficit hyperactivity disorder (ADHD)�.***For the symptomatic treatment of acquired pendular nystagmus�.***For the treatment of painful diabetic neuropathy�.","***General Information***Encephalopathy***Serious rash***Mitochondrial disease***Carnitine deficiency, hepatic disease, hepatotoxicity, hypoalbuminemia, organic brain syndrome***Pancreatitis***Children, infants, neonates***Depression, suicidal ideation***Bleeding, coagulopathy, surgery, thrombocytopenia***Renal failure, renal impairment***Human immunodeficiency virus (HIV) infection***Driving or operating machinery, ethanol ingestion***Colostomy, diarrhea, ileostomy***Head trauma***Abrupt discontinuation***Contraception requirements, pregnancy, reproductive risk***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,estradiol cypionate,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For systemic treatment of the vasomotor symptoms (hot flashes) and genitourinary symptoms of menopause.***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For estrogen replacement for premenopausal women with primary ovarian failure or female hypogonadism.***For the palliative treatment of advanced inoperable prostate cancer.***For the palliative treatment of breast cancer that is inoperable and progressive in selected men and postmenopausal women.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates***Intravenous administration***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,torsemide,"***For the treatment of edema.***For edema associated with congestive heart failure.***For edema associated with chronic renal failure.***For the adjunctive treatment of ascites (e.g., due to hepatic cirrhosis) either alone or in combination with spironolactone or amiloride. <br />        NOTE: Loop diuretics, preferably in combination with an aldosterone antagonist or a potassium-sparing diuretic (e.g., spironolactone or amiloride), are used for the treatment of ascites.<br />     ***For the treatment of hypertension.***Formoterol; Mometasone","***Sulfonamide hypersensitivity, sulfonylurea hypersensitivity, thiazide diuretic hypersensitivity***Hepatic disease***Anuria, hypovolemia, sympathectomy, syncope***Electrolyte imbalance, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, ventricular arrhythmias***Acute myocardial infarction***Renal disease, renal failure, renal impairment***Hearing impairment***Gout, hyperuricemia***Diabetes mellitus, hyperglycemia***Pregnancy***Breast-feeding***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ulipristal acetate,***For postcoital contraception after unprotected intercourse or a known or suspected contraceptive failure.***For the treatment of uterine leiomyomata� (uterine fibroids�).,"***General Information***Ectopic pregnancy, pregnancy, pregnancy testing***Contraception requirements, menstrual irregularity***Breast-feeding***Hepatic disease***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, sexually transmitted disease***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,benazepril hydrochloride,***For the treatment of hypertension.***For the treatment of persistent albuminuria� in patients with diabetic nephropathy� or in at-risk hypertensive patients�.***For the treatment of heart failure�.,"***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, Black patients, hereditary angioedema***Hyperkalemia, renal artery stenosis, renal failure, renal impairment***Agranulocytosis, bone marrow suppression, immunosuppression, neutropenia, scleroderma, systemic lupus erythematosus (SLE)***Aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hyponatremia, hypotension, hypovolemia***Dialysis, hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Hepatic disease, jaundice***Surgery***Neonates, pregnancy***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['3264']['10627', '220333']",dexamethasone/tobramycin,"***For the treatment of corticosteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ophthalmic infection or a risk of bacterial infection exists, including bacterial conjunctivitis, chronic anterior uveitis, and corneal injury (corneal abrasion) from chemical, radiation or thermal burns, or penetration of foreign bodies.","***General Information***Aminoglycoside hypersensitivity, corticosteroid hypersensitivity***Contact lenses***Fungal infection, mycobacterial infection, ocular infection, varicella, viral infection***Diabetes mellitus, increased intraocular pressure, myopia, open-angle glaucoma***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10865'],ketorolac tromethamine,"***For the reduction of postoperative ocular inflammation and ocular pain following cataract ocular surgery or corneal refractive surgery .***For the reduction of postoperative ocular inflammation and ocular pain following cataract surgery.***For the reduction of ocular pain and burning/stinging following corneal refractive surgery.***For the treatment of ocular pruritus due seasonal allergic conjunctivitis.***For the short-term treatment of moderate pain or moderately severe pain that requires analgesia at the opioid level, including bone pain�, dental pain�, arthralgia�, and myalgia�.***For the short-term treatment of moderately severe pain.***For the short-term treatment of moderate pain.***For the treatment of acute, severe headache�, including migraine�.***Formoterol; Mometasone","***Limit duration of use***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, serious hypersensitivity reactions or anaphylaxis, urticaria***Bleeding, surgery***Alcoholism, chemotherapy, Crohn's disease, GI bleeding, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease, hypoalbuminemia, jaundice***Dehydration, diabetes mellitus, edema, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery bypass graft surgery (CABG), coronary artery disease, heart failure, hypertension, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Anemia, bone marrow suppression, hematological disease, immunosuppression, intracranial bleeding, neutropenia, thrombocytopenia***Keratitis, ocular disease, ocular surgery***Contact lenses***Epidural administration, intrathecal administration***Children, infants, neonates***Caesarean section, labor, obstetric delivery, pregnancy***Breast-feeding***Ocular exposure***Geriatric***Lactase deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,goserelin acetate,"***For the treatment of breast cancer in selected females. <br />        NOTE: The Zoladex 3-month (10.8 mg depot) implant is contraindicated for use in females because sufficient clinical data are not available to support reliable suppression of serum estradiol.<br />     ***For the palliative treatment of advanced breast cancer in pre- or perimenopausal women with estrogen-receptor positive disease.***For early (Stage II), estrogen-receptor positive breast cancer� in pre- or perimenopausal women.***For the treatment of endometriosis.***For use as an endometrial thinning agent prior to endometrial ablation for dysfunctional uterine bleeding. <br />        NOTE: The Zoladex 3-month (10.8 mg depot) implant is contraindicated for use in females because sufficient clinical data are not available to support reliable suppression of serum estradiol.<br />     ***For the palliative treatment of advanced prostate cancer, particularly when orchiectomy or estrogen therapy are not indicated or are unacceptable.***For locally confined Stage T2b-T4 (Stage B2-C) prostate cancer in combination with flutamide and radiation therapy.***For medical management of uterine leiomyomata� (fibroids). <br />        NOTE: The Zoladex 3-month (10.8 mg depot) implant is contraindicated for use in females because sufficient clinical data are not available to support reliable suppression of serum estradiol.<br />     ***For the treatment of benign prostatic hyperplasia (BPH)�.***Formoterol***Formoterol; Mometasone","***Gonadotropin-Releasing Hormone (GnRH) analogs hypersensitivity***Dysfunctional uterine bleeding, females, vaginal bleeding***Menstruation, pregnancy***Breast-feeding***Spinal cord compression, urinary tract obstruction***Osteoporosis***Pituitary insufficiency***Children, infants, neonates***Alcoholism, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hepatic disease, hypercholesterolemia, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, obesity, QT prolongation, stroke, thyroid disease, tobacco smoking***Diabetes mellitus, hyperglycemia***Anticoagulant therapy, body weight less than 60 kg",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['27781'],iopromide,***For use as contrast in angiography.***For use as a contrast in cerebral arteriography.***For use as a contrast in angiocardiography including left ventriculography and coronary arteriography.***For use as contrast in aortography.***For use as a contrast in visceral angiography.***For use as a contrast in peripheral arteriography.***For use as a contrast in peripheral venography.***For use as a contrast in excretory urography.***For use as contrast during computed tomography (CT) imaging of the head and body to evaluate for neoplastic and non-neoplastic lesions.***For computed tomography (CT) imaging of the head.***For computed tomography (CT) imaging of the body.,"***Intrathecal administration***Asthma, atopy, iodine hypersensitivity, radiopaque contrast media hypersensitivity***Dehydration, diabetes mellitus, females, hepatic disease, renal disease, renal failure, renal impairment***Cardiac disease, pulmonary hypertension, QT prolongation, valvular heart disease***Heart failure***Coagulopathy, thromboembolic disease***Serious rash***Sickle cell disease***Multiple myeloma***Hyperthyroidism, hypothyroidism, thyroid disease, thyrotoxicosis***Myasthenia gravis***Pheochromocytoma***Extravasation***Emphysema, pulmonary disease***Radiation exposure***Children, infants, neonates, premature neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['25120', '1546428']",flunisolide,***For the maintenance treatment of asthma as bronchospasm prophylaxis.***For relief of the nasal symptoms of seasonal or perennial allergic rhinitis.,"***General Information***Acute bronchospasm, status asthmaticus***Adrenal insufficiency, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, surgery***Children, growth inhibition, increased intracranial pressure, infants, neonates***Fungal infection, herpes infection, infection, trauma, tuberculosis***Cataracts, glaucoma, increased intraocular pressure***Osteoporosis***Pregnancy***Breast-feeding***Geriatric***Corticosteroid hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,rifampin,"***For the treatment of all forms of active tuberculosis infection in combination with other antitubercular agents. <br />        NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., at least 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, IDSA, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. Directly observed therapy (DOT) should be used for all regimens administered 1, 2, 3, or 5 times per week and in all pediatric patients. The initial treatment regimen should include 4 drugs unless the likelihood of isoniazid or rifampin resistance is low (i.e., less than 4%), in which case an initial regimen of isoniazid, rifampin, and pyrazinamide may be considered. HIV-positive patients should always receive induction therapy with 4 drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate.   For multi-drug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, the CDC recommends treatment for 18 to 24 months after culture conversion in patients with bacteriologic confirmation and for at least 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months in MDR-TB. The WHO also provides an alternative set of international dosing guidelines.<br />     ***For the treatment of asymptomatic carriers of <em>Neisseria meningitidis</em> to eliminate meningococci from the nasopharynx (meningococcal infection prophylaxis). <br />        NOTE: The Centers for Disease Control (CDC) recommends antimicrobial chemoprophylaxis for close contacts of a person with invasive meningococcal disease. Close contacts include: household contacts, child-care center contacts, and anyone directly exposed to patient's oral secretions (e.g., kissing, mouth-to-mouth resuscitation, airway management [e.g., endotracheal tube management]) in the 7 days before symptom onset, and travelers who had direct contact with respiratory secretions from an index-patient or for anyone seated directly next to an index-patient on a prolonged flight (i.e., 8 hours or more). Rifampin is not indicated for treatment of active meningococcal infection.<br />     ***For use as an alternative to isoniazid regimens for tuberculosis prophylaxis� or latent tuberculosis infection (LTBI).***For Haemophilus influenzae type B prophylaxis� in carriers who are at high risk of transmitting the disease to children ages 4 years and less.***For the treatment of leprosy (Hansen's disease)� in combination with dapsone.***For the treatment of multibacillary leprosy�.***For the treatment of paucibacillary leprosy�.***For the treatment of endocarditis�. <br />  NOTE: For the treatment of methicillin-resistant Staphylococcus aureus (MRSA), rifampin should not be used as a single agent. Rifampin is not recommended as an addition to vancomycin for native valve endocarditis.<br /***For endocarditis� due to <em>Staphylococcus aureus</em> in patients with prosthetic valves.***For right-sided endocarditis� secondary to <em>Staphylococcus aureus</em> in intravenous drug abusers.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated bone and joint infections�, including osteomyelitis�, or an orthopedic device-related infection�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated osteomyelitis.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated prosthetic joint infections.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated spinal implant infections.***For the treatment of bartonellosis� (<em>Bartonella bacilliformis</em>) and other <em>Bartonella sp.</em>� infections in HIV-infected patients.***For the treatment of pruritus� secondary to cholestasis.***For the treatment of central nervous system infections�, including meningitis�, ventriculitis�, cerebrospinal fluid (CSF) shunt infections, brain abscess�, subdural empyema�, spinal epidural abscess�, or septic thrombosis of the cavernous or dural venous sinus�.***For the treatment of persistent <em>Staphylococcus aureus</em> (MRSA) bacteremia� and vancomycin failure�. <br />  NOTE: Routine use of rifampin for MRSA bacteremia is not recommended.<br /","***General Information***Rifamycin hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis***Antimicrobial resistance***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Alcoholism, hepatic disease, hepatitis, jaundice***Contact lenses***Pregnancy***Breast-feeding***Porphyria***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Diabetes mellitus***Extravasation, intramuscular administration, subcutaneous administration***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,promethazine hydrochloride,"***For the prevention of motion sickness.***For the treatment of active nausea/vomiting, including post-operative nausea/vomiting (PONV) and for�post-operative nausea/vomiting (PONV) prophylaxis.***For the treatment of allergic manifestations, such as pruritus.***For the treatment of allergic rhinitis�.***For sedation induction.***For sedation in obstetrics.***For relief of apprehension and to induce quiet sleep from which the patient can be easily aroused.***For preoperative or postoperative procedural sedation, as an adjunct to analgesics.***For the treatment of acute peripheral vestibular nystagmus�.***For pregnancy-induced nausea/vomiting�, including hyperemesis gravidarum�.","***General Information***Agranulocytosis, bone marrow suppression, coma, jaundice, phenothiazine hypersensitivity***Extravasation, intraarterial administration, intravenous administration, subcutaneous administration, tissue necrosis***Seizure disorder***Acute bronchospasm, asthma, chronic obstructive pulmonary disease (COPD), respiratory depression, sleep apnea, sulfite hypersensitivity***Hepatic disease, hepatic encephalopathy***Children, dehydration, infants, neonates, Reye's syndrome***Labor, obstetric delivery, pregnancy***Breast-feeding***Contact lenses, glaucoma***Bladder obstruction, GI obstruction, ileus, prostatic hypertrophy, urinary retention***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Radiographic contrast administration***CNS depression, driving or operating machinery, ethanol intoxication***Diabetes mellitus***Anticholinergic medications, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,oxycodone hydrochloride,"***For the treatment of severe pain.***For the treatment of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.***For the management of chronic severe pain in patients who require daily, around-the-clock, long-term opioid treatment. <br />          NOTE: Extended-release oxycodone should be reserved for patients in whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would otherwise provide inadequate pain management. Discontinue all other around-the-clock opioid drugs upon initiation of oxycodone extended-release tablets or capsules. <br />NOTE: Extended-release oxycodone 60 or 80 mg tablets, a single tablet dose more than 40 mg, or a total tablet daily dose more than 80 mg should be reserved for opioid-tolerant patients. A single extended-release oxycodone capsule dose of 36 mg (equivalent to 40 mg oxycodone hydrochloride) or more or a total capsule daily dose of 72 mg (equivalent to 80 mg oxycodone hydrochloride) or more should be reserved for opioid-tolerant patients. Adult patients who are opioid tolerant are those receiving, for a minimum of 1 week, 60 mg or more oral morphine daily, 30 mg or more oral oxycodone daily, 8 mg or more oral hydromorphone daily, 25 mg or more oral oxymorphone daily, 25 mcg or more transdermal fentanyl per hour, 60 mg or more oral hydrocodone per day, or an equivalent dose of another opioid. Extended-release oxycodone tablets should only be used in pediatric patients 11 years or older receiving opioids for at least 5 consecutive days and taking a minimum of 20 mg per day of oxycodone or its equivalent for 2 days immediately preceding dosing with extended-release oxycodone.***For the treatment of painful diabetic neuropathy�.","***Accidental exposure, ethanol ingestion, ethanol intoxication, parenteral administration, potential for overdose or poisoning, requires an experienced clinician***Acute abdomen, constipation, diarrhea, diverticulitis, dysphagia, esophageal stricture, gastric cancer, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, coma, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Opioid-naive patients, surgery***Biliary tract disease, pancreatitis***Abrupt discontinuation***CNS depression, head trauma, increased intracranial pressure, intracranial mass, psychosis***Angina, cardiac arrhythmias, cardiac disease, dehydration, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, urethral stricture, urinary retention***Seizure disorder, seizures***Geriatric***Children, infants, neonates***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Infertility, reproductive risk***Driving or operating machinery***Opiate agonist hypersensitivity***Adrenal insufficiency, hypothyroidism, myxedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cyclopentolate hydrochloride/phenylephrine hydrochloride,***For mydriasis induction for ophthalmic diagnostic procedures.,"***General Information***Closed-angle glaucoma, geriatric, increased intraocular pressure***Parenteral administration***MAOI therapy***Cardiac disease, hypertension, hyperthyroidism***Contact lenses***Cerebral palsy, children, Down's syndrome, head trauma, infants, neonates, premature neonates, seizure disorder***Pregnancy***Breast-feeding***Driving or operating machinery, sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],drospirenone/ethinyl estradiol,"***For routine contraception.***For the treatment of acne vulgaris in women who also desire oral contraception.***For the treatment of premenstrual dysphoric disorder (PMDD) in women who also desire oral contraception.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception.***For the treatment or adjuvant treatment of conditions such as amenorrhea�, hirsutism�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who desire oral contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Adrenal insufficiency, electrolyte imbalance, hyperkalemia, renal disease, renal failure, renal impairment***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia, pancreatitis***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, hypertension, myocardial infarction, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,follitropin alfa,"***For the treatment of infertility in females. <br />        NOTE: Prior to the treatment, women should have a complete gynecologic and endocrinologic evaluation. The possibility of pregnancy should be ruled out and the fertility status of the male partner should be evaluated. <br />NOTE: During FSH treatment and during a 2 week post-treatment period, patients should be examined at least every other day for signs of excessive ovarian stimulation. Ovarian hyperstimulation syndrome (OHSS) usually occurs after discontinuation of FSH and reaches its maximum at about 7 to 10 days post-ovulation.***For the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure.***For the development of multiple follicles in the ovulatory female patient participating in an Assisted Reproductive Technology (ART) program.***For the induction of pregnancy in the ovulatory female patient undergoing controlled ovarian stimulation as part of an In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) cycle. <br />          NOTE: Women should have a diagnosis of the cause of infertility.<br />       ***For the treatment of infertility in males (for the stimulation of spermatogenesis in males with primary or secondary hypogonadotropic hypogonadism and resultant oligospermia). <br />  NOTE: Pretreatment with hCG is required prior to combination treatment with r-FSH. Various hCG dosages have been advocated; continue hCG for a period sufficient to achieve normal serum testosterone concentrations. Such pretreatment may require 3 to 6 months.<br />NOTE: Complete a medical and endocrinologic evaluation before starting follitropin beta or follitropin alfa. Exclude primary testicular failure and confirm hypogonadotropic hypogonadism. Lastly, evaluate the fertility status of the female partner.<br />NOTE: Serum testosterone concentrations and semen analysis are used for clinical monitoring of spermatogenesis","***General Information***Neomycin hypersensitivity, streptomycin hypersensitivity***Children***Driving or operating machinery***Asthma***Adrenal insufficiency, pituitary adenoma, thyroid disease***Ethanol intoxication, tobacco smoking***Testicular failure***Ovarian failure***Endometriosis, uterine leiomyomata, vaginal bleeding***Geriatric***Breast cancer, ovarian cancer, ovarian cyst, uterine cancer***Ascites, polycystic ovary syndrome***Ectopic pregnancy, pregnancy***Breast-feeding***Myocardial infarction, obesity, stroke, thromboembolic disease, thrombophlebitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cefazolin sodium,"***For the treatment of upper respiratory tract infections, lower respiratory tract infections (e.g. pneumonia), skin and skin structure infections, bone and joint infections, and biliary tract infections caused by susceptible organisms.***For the treatment of urinary tract infection (UTI).***For treatment of a complicated urinary tract infection (UTI).***For treatment of an uncomplicated urinary tract infection (UTI).***For the treatment of infective endocarditis.***For surgical infection prophylaxis.***For ophthalmic surgical infection prophylaxis�.***For the treatment of prostatitis and epididymitis due to susceptible organisms .***For the treatment of bacteremia.***For bacterial endocarditis prophylaxis�.***For perinatal Group B streptococcal bacterial infection prophylaxis� in patients allergic to penicillin.","***General Information***Antimicrobial resistance, viral infection***Cephalosporin hypersensitivity, penicillin hypersensitivity***Renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Coagulopathy, vitamin K deficiency***Neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amphetamine aspartate monohydrate/amphetamine sulfate/dextroamphetamine saccharate/dextroamphetamine sulfate,***For the treatment of attention-deficit hyperactivity disorder (ADHD).***For the treatment of narcolepsy.***Formoterol***Formoterol; Mometasone,"***General Information***Alcoholism, substance abuse***Bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Hypertension, tachycardia***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular arrhythmias, ventricular dysfunction***Cerebrovascular disease, stroke***Children, growth inhibition, infants***Hyperthyroidism, thyrotoxicosis***Glaucoma, visual disturbance***Breast-feeding***Neonates, pregnancy***Tics, Tourette's syndrome***Driving or operating machinery***Seizure disorder, seizures***Surgery***Radiographic contrast administration***Abrupt discontinuation***Geriatric***Hypercortisolism***Hepatic disease, renal impairment***MAOI therapy***Peripheral vascular disease, Raynaud's phenomenon***Anorexia nervosa, bulimia nervosa, obesity treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,heparin sodium,"***For the treatment of deep venous thrombosis (DVT) or pulmonary embolism; for the treatment of arterial thromboembolism including cerebral thromboembolism; or for the treatment of mural thrombosis.***For thrombosis prophylaxis.***For thrombosis prophylaxis, including arterial thromboembolism prophylaxis, during extracorporeal circulation in patients undergoing open heart or other cardiovascular surgery.***For coronary artery thrombosis prophylaxis during percutaneous coronary intervention (PCI) in patients not receiving abciximab therapy.***For deep venous thrombosis (DVT) prophylaxis.***For mural thrombosis prophylaxis in patients with an acute transmural anterior myocardial infarction.***For arterial thromboembolism prophylaxis in patients with prosthetic heart valves.***For thrombosis prophylaxis and/or for pulmonary embolism prophylaxis in patients at increased risk after sustaining an acute MI (e.g., Q-wave infarction, severe LV dysfunction, CHF, history of systemic or pulmonary embolism, 2D echo evidence of mural thrombus, or atrial fibrillation).***For thrombosis prophylaxis, including arterial thromboembolism prophylaxis, during hemodialysis.***For coronary artery thrombosis prophylaxis during percutaneous coronary intervention (PCI) in patients receiving abciximab concomitantly.***For deep venous thrombosis (DVT) prophylaxis in pregnant females.***For intravascular catheter occlusion prophylaxis. <br />        NOTE: The amount of heparin solution in each single dose is sufficient to prevent clotting within the lumen of the indwelling catheter for up to 24 hours. If the catheter is used for withdrawal of repeated blood samples for laboratory tests and the presence of heparin is likely to interfere with the test, the in situ heparin flush should be cleared from the catheter by aspirating and discarding a volume of solution equivalent to that of the indwelling catheter before the desired blood sample is drawn. If the drug to be administered is incompatible with heparin, the entire catheter or lumen should be flushed with sterile water or normal saline before and after the medication is administered. Following the second flush, the heparin flush solution may be reinstilled into the set.<br />     ***For the prevention of pregnancy loss and/or thrombosis in patients with antiphospholipid antibody syndrome (APLA).***For the treatment of disseminated intravascular coagulation (DIC).***For the treatment of unstable angina. <br />        NOTE: In 2009, the USP adopted new reference standards and manufacturing controls for heparin that result in a 10% reduction in the potency. This change in heparin potency may have clinical significance in situations that require dosage adjustments and more frequent monitoring, especially when aggressive anticoagulation is needed, including pediatric patients undergoing extracorporeal membrane oxygenation, adults and children undergoing cardiopulmonary bypass, and the treatment or prevention of life-threatening thromboses. Healthcare providers should exercise clinical judgement when deciding what dose to administer and continue to individualize heparin dosing. Higher doses may be required to achieve and maintain the desired anticoagulant effect in some patients.<br />     ***For the treatment of an evolving acute myocardial infarction (AMI) (i.e., coronary artery thrombosis�) in patients who have received thrombolytic therapy with alteplase (tPA), reteplase (r-PA), or tenecteplase (TNK-tPA).. <br />        NOTE: In 2009, the USP adopted new reference standards and manufacturing controls for heparin that result in a 10% reduction in the potency. This change in heparin potency may have clinical significance in situations that require dosage adjustments and more frequent monitoring, especially when aggressive anticoagulation is needed, including pediatric patients undergoing extracorporeal membrane oxygenation, adults and children undergoing cardiopulmonary bypass, and the treatment or prevention of life-threatening thromboses. Healthcare providers should exercise clinical judgement when deciding what dose to administer and continue to individualize heparin dosing. Higher doses may be required to achieve and maintain the desired anticoagulant effect in some patients.<br />     ***For patients receiving streptokinase or anistreplase (APSAC) concurrently.***Formoterol; Mometasone","***General Information***Asthma, benzyl alcohol hypersensitivity, corn hypersensitivity, heparin hypersensitivity, porcine protein hypersensitivity, sulfite hypersensitivity***Heparin-induced thrombocytopenia (HIT), thrombocytopenia***Aneurysm, bleeding, coagulopathy, diverticulitis, endocarditis, head trauma, hemophilia, hypertension, hypotension, inflammatory bowel disease, lumbar puncture, menstruation, peptic ulcer disease, spinal anesthesia, surgery, vaginal bleeding***Intracranial bleeding***Fever, infection, myocardial infarction, neoplastic disease, thrombophlebitis***Disseminated intravascular coagulation (DIC), hepatic disease, renal disease***Infants, neonates, premature neonates***Geriatric***Intramuscular administration, intramuscular injections***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,idarubicin hydrochloride,"***For induction therapy or post-remission therapy in adults with acute myelogenous leukemia (AML) in combination with cytarabine, Ara-C. <br />  NOTE: Idarubicin has been designated an orphan drug by the FDA for this indication.<br /***For the treatment of acute promyelocytic leukemia (APL).***For the treatment of APL, in combination with other approved antileukemic agents.***For remission induction treatment in patients with newly diagnosed APL, in combination with tretinoin�.***For consolidation treatment following tretinoin and idarubicin induction therapy in patients with newly diagnosed APL, in combination with tretinoin-containing chemotherapy�.***For the treatment of acute lymphocytic leukemia (ALL)�. <br />  �NOTE: Idarubicin has been designated an orphan drug by the FDA for ALL in pediatric patients.<br /***For the treatment of relapsed or refractory ALL, in combination with cytarabine�.***For the treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL)�, in combination with chemotherapy.***For the treatment of myeloid blast crisis chronic myelogenous leukemia (CML)�, in combination with cytarabine or imatinib and cytarabine. <br />  NOTE: Idarubicin has been designated an orphan drug by the FDA for this indication.<br /***Formoterol***Formoterol; Mometasone","***Anthracycline hypersensitivity***Bone marrow suppression, herpes infection, infection, neutropenia, requires a specialized care setting, requires an experienced clinician, thrombocytopenia, varicella, viral infection***Dental disease, dental work***Intramuscular injections***Extravasation, intramuscular administration, subcutaneous administration***Hepatic disease, jaundice***Renal impairment***Pregnancy***Breast-feeding***Hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, tumor lysis syndrome (TLS)***Acute myocardial infarction, alcoholism, angina, bradycardia, cardiac arrhythmias, cardiac disease, cardiotoxicity, children, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hypertension, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, maximum cumulative lifetime dose, myocardial infarction, QT prolongation, radiation therapy, thyroid disease, ventricular dysfunction***Accidental exposure, ocular exposure***Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['73044'],repaglinide,***For the treatment of type 2 diabetes mellitus uncontrolled by diet and exercise alone.,"***General Information***Hypoglycemia***Diabetic ketoacidosis, type 1 diabetes mellitus***Fever, infection, surgery, trauma***Hepatic disease***Geriatric***Pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['598'],alprostadil,"***For the treatment of neonates with congenital heart defects to maintain the patency of the ductus arteriosus (ductus arteriosus maintenance) until palliative or corrective surgery can be performed.***For the treatment of erectile dysfunction (ED). <br />        NOTE: Per ED guidelines, second-line treatment options for ED treatment include intracavernous injection and intra-urethral therapy. Intracavernous injection therapy is the most effective nonsurgical treatment for ED, with predictable and sustained response. However, it is invasive and caries notable side-effects including priapism and penile fibrosis. Careful dose selection, proper patient education, and continued monitoring by a prescribing physician is warranted for successful non-oral treatment of ED. Follow-up visits for ED patients, regardless of therapy, are necessary to determine whether therapy continues to be effective and whether cardiovascular health has significantly changed.<br />     ***For erectile dysfunction due to vasculogenic, psychogenic, or mixed causes or following post-radical prostatectomy�.***For erectile dysfunction due to neurogenic origin.***For the treatment of ED in combination with other vasoactive agents (i.e., papaverine, phentolamine)�.","***General Information***Benzyl alcohol hypersensitivity, children, infants, neonates***Apnea, premature neonates, requires a specialized care setting, respiratory depression***GI obstruction***Respiratory distress syndrome***Cardiac disease, driving or operating machinery, hypotension, syncope***Anticoagulant therapy, bleeding, coagulopathy***Balanitis, hypospadia, penile implants, penile structural abnormality, Peyronie's disease, urethral stricture, urethritis***Leukemia, multiple myeloma, polycythemia, priapism, sickle cell disease, thrombocytosis***Geriatric, renal impairment***Contraception requirements, females, labor, pregnancy, sexually transmitted disease***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,apraclonidine hydrochloride,"***For the prevention or treatment of postsurgical increased intraocular pressure following argon laser trabeculoplasty, argon laser iridotomy, or Nd:YAG posterior capsulotomy. <br /***For short-term adjunctive treatment of increased intraocular pressure in glaucoma patients on maximally tolerated medical therapy who require additional intraocular pressure reduction. <br />        NOTE: Maximally tolerated medical therapy for intraocular hypertension may include a topical beta-adrenergic blocking agent, a sympathomimetic, a systemic carbonic anhydrase inhibitor and/or a parasympathomimetic agent.<br />     ","***General Information***Contact lenses***Acute myocardial infarction, cardiac disease, cerebrovascular disease, coronary artery disease, hypertension, Raynaud's phenomenon, syncope, thromboangiitis obliterans (Buerger's disease)***Renal disease, renal failure, renal impairment***Hepatic disease***Pregnancy***Breast-feeding***Children, infants, neonates***MAOI therapy***Depression***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,colistin sulfate/hydrocortisone acetate/neomycin sulfate/thonzonium bromide,"***For the treatment of superficial bacterial infections of the external auditory canal (i.e., otitis externa) caused by susceptible organisms, and for the treatment of infections of mastoidectomy and fenestration cavities caused by susceptible organisms.","***General Information***Aminoglycoside hypersensitivity, neomycin hypersensitivity***Herpes infection, varicella, viral infection***Hearing impairment, renal disease, tympanic membrane perforation***Ocular exposure***Colitis, diarrhea, pseudomembranous colitis***Pregnancy***Breast-feeding***Infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['274964'],ciclesonide,"***For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis.***For seasonal allergic rhinitis.***For perennial allergic rhinitis.***For the maintenance treatment of asthma as prophylactic therapy.***For patients previously receiving bronchodilators alone.***For patients previously receiving inhaled corticosteroids.***For patients previously receiving oral corticosteroids. <br />          NOTE: The manufacturer recommends that prednisone should be reduced no faster than 2.5 mg/day weekly, beginning after at least 1 week of therapy with ciclesonide. Patients should be carefully monitored for signs of asthma instability, including monitoring of serial objective measures of airflow, and for signs of adrenal insufficiency during steroid taper and following discontinuation of oral corticosteroid therapy.<br />       ***For the maintenance treatment of asthma in children�.***For exercise-induced bronchospasm prophylaxis�.","***Corticosteroid hypersensitivity***Acute bronchospasm, status asthmaticus***Adrenal insufficiency, hypothalamic-pituitary-adrenal (HPA) suppression***Fungal infection, herpes infection, infection, tuberculosis, viral infection***Vaccination***Measles, varicella***Children, growth inhibition, increased intracranial pressure***Infants, neonates, pregnancy***Breast-feeding***Cushing's syndrome***Nasal septal perforation, nasal surgery, nasal trauma***Osteoporosis***Geriatric***Cataracts, glaucoma, increased intraocular pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"tuberculin purified protein derivative, diluted","***For tuberculosis diagnosis (e.g., diagnosis of latent tuberculosis infection (LTBI) or tuberculosis (TB) disease).***Formoterol; Mometasone","***General Information***Intramuscular administration, intravenous administration, subcutaneous administration***Corticosteroid therapy, Hodgkin's disease, immunosuppression, leukemia, lymphoma, neoplastic disease, radiation therapy, sarcoidosis***Fungal infection, herpes infection, infection, measles, tuberculosis, vaccination, varicella, viral infection***Burns, diabetes mellitus, malabsorption syndrome, malnutrition, renal failure, surgery, total gastrectomy***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Children, infants, neonates***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/ferrous fumarate/norethindrone acetate,"***For routine contraception.***For the treatment of moderate acne vulgaris related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Pregnancy***Gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Diabetes mellitus***Hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, pancreatitis***Systemic lupus erythematosus (SLE)***Surgery***Asthma, headache, hypertension, migraine, seizure disorder***Depression***Contact lenses, glaucoma, visual disturbance***Breast cancer***Hypercalcemia, hypocalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Obesity***Chloasma***Angioedema, hereditary angioedema***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,apraclonidine hydrochloride,"***For the prevention or treatment of postsurgical increased intraocular pressure following argon laser trabeculoplasty, argon laser iridotomy, or Nd:YAG posterior capsulotomy. <br /***For short-term adjunctive treatment of increased intraocular pressure in glaucoma patients on maximally tolerated medical therapy who require additional intraocular pressure reduction. <br />        NOTE: Maximally tolerated medical therapy for intraocular hypertension may include a topical beta-adrenergic blocking agent, a sympathomimetic, a systemic carbonic anhydrase inhibitor and/or a parasympathomimetic agent.<br />     ","***General Information***Contact lenses***Acute myocardial infarction, cardiac disease, cerebrovascular disease, coronary artery disease, hypertension, Raynaud's phenomenon, syncope, thromboangiitis obliterans (Buerger's disease)***Renal disease, renal failure, renal impairment***Hepatic disease***Pregnancy***Breast-feeding***Children, infants, neonates***MAOI therapy***Depression***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['5464', '486164']",hyaluronidase,"***For use as an adjuvant to increase the absorption and dispersion of other drugs (e.g., local anesthesia, including infiltration anesthesia).***For use as an adjunct for ophthalmic anesthesia�.***For hypodermoclysis.***For use as an adjunct in subcutaneous urography for improving resorption of urographic radiopaque contrast agents.***For use as an antidote for extravasation� of selected drugs, examples include: antineoplastic agents (e.g., vinca alkaloids), osmotic fluids, (e.g., total parenteral nutrition, 10% or greater dextrose injection, calcium salts, mannitol, potassium salts, sodium bicarbonate, aminophylline, radiocontrast media, or hypertonic saline), or irritants (e.g., diazepam, nafcillin, phenytoin, thiopental, or vasopressin). <br />  NOTE: Use only in the treatment of extravasations where hyaluronidase has been shown to be of benefit. Hyaluronidase is not generally recommended for use as an antidote for extravasation of ischemic agents (e.g., dopamine or alpha-agonists).<br />NOTE: Use hyaluronidase as an adjunct to medical management of extravasation; co-therapies may include hot or cold compresses (extravasating agent dependent), elevation of the affected limb, surgical debridement, and wound care.<br />NOTE: A preliminary hypersensitivity test dose can be performed prior to use***For the treatment of vitreous hemorrhage�. <br />        NOTE: A preliminary hypersensitivity test dose can be performed prior to use.<br />     ***For the treatment of diabetic retinopathy�. <br />  NOTE: A preliminary hypersensitivity test dose can be performed prior to use.<br /","***Hyaluronidase hypersensitivity***Extravasation, intravenous administration***Ocular exposure, ocular surgery***Infection***Children, hypervolemia, infants***Pregnancy***Breast-feeding***Viral infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['473387'],ferumoxytol,***For the treatment of iron-deficiency anemia in patients with chronic kidney disease or intolerance or unsatisfactory response to oral iron.***For use as a magnetic resonance imaging (MRI)� contrast agent.,"***Dialysis, hypotension***Requires a specialized care setting, risk of serious hypersensitivity reactions or anaphylaxis***Hemochromatosis, hemoglobinopathy, hemosiderosis***Magnetic resonance imaging (MRI)***Hepatic disease***Geriatric***Laboratory test interference***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['55681'],rimexolone,***For the treatment of postoperative ocular inflammation.***For the treatment of anterior uveitis.***For the treatment of vernal keratoconjunctivitis�.***For use as an adjunct in the treatment of rheumatoid arthritis� involving the knee joint.,"***Fungal infection, herpes simplex keratitis (dendritic keratitis), infection, mycobacterial infection, varicella, viral infection***Cataracts, glaucoma, visual disturbance***Pregnancy***Breast-feeding***Children, infants, neonates***Corticosteroid hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,esmolol hydrochloride,"***For short-term control of supraventricular tachyarrhythmias, including sinus tachycardia or paroxysmal supraventricular tachycardia (PSVT), or to control ventricular rate in patients with atrial fibrillation or atrial flutter.***For the treatment of perioperative hypertension and/or tachycardia; or for the treatment of postoperative hypertension and/or tachycardia.***For the treatment of hypertensive urgency� or hypertensive emergency�.***For the treatment of acute myocardial infarction�.***For the treatment of unstable angina�.","***General Information***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Abrupt discontinuation***Acute heart failure, AV block, bradycardia, cardiogenic shock, hypotension, pheochromocytoma, pulmonary edema, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Cerebrovascular disease***Peripheral vascular disease, Raynaud's phenomenon***Diabetes mellitus***Hyperthyroidism, thyroid disease, thyrotoxicosis***Myasthenia gravis***Renal disease, renal failure, renal impairment***Extravasation***Geriatric***Labor, obstetric delivery, pregnancy***Breast-feeding***Beta-blocker hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['274332'],nateglinide,***For the treatment of type 2 diabetes mellitus that is not controlled by diet and exercise alone.,"***Diabetic ketoacidosis, type 1 diabetes mellitus***Hypoglycemia***Fever, infection, surgery, trauma***Hepatic disease***Pregnancy***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10379'],testosterone,***For the treatment of delayed puberty in males.***For palliative treatment of breast cancer that is inoperable in women.***For the treatment of postpubertal cryptorchidism�.***For the treatment of microphallus�.***For the treatment of anemia� in patients with chronic renal failure.***For female-to-male gender change (trans-sexualism�).***For the treatment of lichen sclerosus�.***For the treatment of AIDS-associated wasting syndrome�.,"***Benzoic acid hypersensitivity, benzyl alcohol hypersensitivity, polyoxyethylated castor oil hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis, soya lecithin hypersensitivity***Magnetic resonance imaging (MRI)***Intramuscular administration, intravenous administration***Breast cancer, geriatric, prostate cancer, prostatic hypertrophy***Cardiac disease, coronary artery disease, heart failure, hepatic disease, myocardial infarction, renal disease, stroke***Obesity, pulmonary disease***Polycythemia***Accidental exposure, females***Contraception requirements, labor, obstetric delivery, pregnancy, reproductive risk***Breast-feeding***Diabetes mellitus***Hypercalcemia***Pulmonary oil microembolism***Nasal polyps, nasal septal perforation, nasal surgery, nasal trauma, rhinorrhea, Sjogren's syndrome***Children, infants, neonates***Substance abuse***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bepotastine besilate,***For the treatment of itching (ocular pruritus) associated with signs and symptoms of allergic conjunctivitis.,"***Contact lenses***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7623'],ofloxacin,"***For the treatment of urinary tract infection (UTI), including uncomplicated (cystitis) or complicated infections.***For the treatment of gonorrhea and chlamydia infection including cervicitis or urethritis as well as non-gonococcal urethritis.***For acute, uncomplicated gonococcal urethritis or cervicitis caused by <em>N. gonorrhoeae</em>.***For non-gonococcal urethritis (NGU) or cervicitis caused by <em>C. trachomatis</em>.***For the treatment of mixed infection cervicitis or urethritis caused by <em>C. trachomatis</em> and <em>N. gonorrhoeae</em>.***For the treatment of pelvic inflammatory disease (PID).***For the treatment of bacterial prostatitis due to <em>E. coli</em>.***For the treatment of otitis media.***For acute otitis media in children with tympanostomy tubes due to <em>H. influenzae</em> (beta-lactamase negative), <em>H. influenzae</em> (beta-lactamase positive), <em>M. catarrhalis</em>, <em>P. aeruginosa</em>, <em>S. aureus</em>, or <em>S. pneumoniae</em>.***For chronic suppurative otitis media in adults and adolescents with perforated tympanic membranes due to <em>P. mirabilis</em>, <em>P. aeruginosa</em>, or <em>S. aureus</em>.***For the treatment of otitis externa due to <em>E. coli</em>, <em>P. aeruginosa,</em> and <em>S. aureus</em>.***For the treatment of lower respiratory tract infections (e.g. acute exacerbations of chronic bronchitis, community-acquired pneumonia) due to susceptible organisms.***For the treatment of skin and skin structure infections due to susceptible organisms.***For the treatment of acute epididymitis�.***For the treatment of meningococcal carriers (i.e., for meningococcal infection prophylaxis�).***For the treatment of moderate or severe traveler's diarrhea�.***For the treatment of plague� infection due to exposure to <em>Yersinia pestis</em>�.***For an individual patient� or in a contained casualty setting�. <br />          NOTE: Streptomycin is the drug of choice to treat plague in most patients; gentamicin is the preferred agent in pregnant women.<br />       ***For a mass casualty setting�. <br />          NOTE: Doxycycline is the treatment of choice for plague in the mass casualty setting.<br />       ***For plague prophylaxis� following exposure to <em>Yersinia pestis</em>�. <br />        NOTE: Doxycycline is the treatment of choice for plague prophylaxis.<br />     ***For the treatment of typhoid fever� caused by <em>Salmonella typhi</em>.***For uncomplicated typhoid fever�.***For severe typhoid fever�.***For the treatment of tuberculosis infection� in patients with multi-drug resistant<em> Myocbacterium tuberculosis</em>. <br />  NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., at least 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, IDSA, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. Directly observed therapy (DOT) should be used for all regimens administered 1, 2, 3, or 5 times per week. The initial treatment regimen should include 4 drugs unless the likelihood of INH or rifampin resistance is low (i.e., less than 4%), in which case an initial regimen of INH, rifampin, and pyrazinamide may be considered. HIV-infected patients should always receive induction therapy with 4 drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate.   For multidrug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, the CDC recommends treatment for 18�24 months after culture conversion in patients with bacteriologic confirmation and for at least 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months in MDR-TB.<br /***Formoterol***Formoterol; Mometasone","***General Information***Viral infection***Quinolone hypersensitivity***Corticosteroid therapy, organ transplant, tendinitis, tendinopathy, tendon pain, tendon rupture***Acute myocardial infarction, alcoholism, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, thyroid disease, torsade de pointes***Cerebrovascular disease, neurotoxicity, peripheral neuropathy, seizure disorder***Myasthenia gravis***Renal failure, renal impairment***Dehydration***Hepatic disease, hepatitis, hepatotoxicity, jaundice***Diabetes mellitus***Sunlight (UV) exposure***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Geriatric***Pregnancy***Breast-feeding***Sexually transmitted disease***Children, infants, neonates***Contact lenses***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,levobunolol hydrochloride,***For the treatment of chronic open-angle glaucoma or ocular hypertension.,"***AV block, bradycardia, cardiac disease, cardiogenic shock, coronary artery disease, heart failure, hypotension, peripheral vascular disease, Raynaud's phenomenon, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Cerebrovascular disease***Pheochromocytoma***Hyperthyroidism, thyroid disease, thyrotoxicosis***Diabetes mellitus***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema***Sulfite hypersensitivity***Hepatic disease***Myasthenia gravis***Surgery***Geriatric***Closed-angle glaucoma***Pregnancy***Breast-feeding***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pegademase bovine,***For the treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase (ADA) deficiency.,"***General Information***Coagulopathy, thrombocytopenia***Infection***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fenofibric acid,"***For use as an adjunct to diet in the treatment of hyperlipoproteinemia or hypertriglyceridemia. <br />        NOTE: Patients should be placed on an appropriate lipid-lowering diet before and while receiving fenofibric acid. Excess body weight, excess alcohol intake, dietary indiscretion, and poor glycemic control are important factors in conditions of elevated triglycerides and should be addressed prior to instituting fenofibric acid therapy.<br />NOTE: Fenofibric acid is not indicated for patients who have elevated chylomicrons and triglycerides, but who have normal VLDL concentrations.<br />NOTE: One delayed-release capsule of fenofibric acid 135 mg produces plasma concentrations equivalent to one 200 mg capsule of micronized fenofibrate administered under fed conditions.<br />***For the treatment of severe hypertriglyceridemia.***For the treatment of primary hyperlipidemia or mixed dyslipidemia (e.g., to reduce elevated LDL-C, total cholesterol, triglycerides and apolipoprotein B and to increase HDL-C).","***General Information***Dialysis, renal disease, renal failure, renal impairment***Cholelithiasis, gallbladder disease***Biliary cirrhosis, hepatic disease***Pancreatitis***Cardiac disease***Anticoagulant therapy, thromboembolic disease***Geriatric***Diabetes mellitus***Hypothyroidism***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,antihemophilic factor (recombinant),"***For the prevention and control of hemorrhage in patients with hemophilia A (classical hemophilia). <br />        NOTE: Humate, Kogenate, and ReFacto have been designated by the FDA as orphan drugs for the prophylaxis and management of hemorrhage or hemarthrosis in patients with hemophilia A.<br /> <br />NOTE: Guidelines for the treatment of acute bleeding and prevention of bleeding during surgery vary. For all indications, the dose of antihemophilic factor should be individualized taking into consideration the seriousness of the bleed or procedure, the clinical status of the patient, and the factor VIII activity concentration***For minor bleeding including early muscle bleed, early hemarthrosis, and oral bleeds.***For moderate bleeding including advanced muscle bleed, extensive hemarthrosis, hematoma, and mild head trauma.***For life- or limb-threatening bleeding including surgical bleeding, gastrointestinal bleeding, neck, tongue or pharyngeal hematoma with potential for airway compromise, intracranial, intraabdominal, or intrathoracic bleeding, or fractures.***For bleeding in patients with hemophilia A and factor VIII inhibitor titers less than 10 Bethesda Units and with low anamnestic responses.***For the perioperative management of surgical bleeding (surgical bleeding prophylaxis) in patients with hemophilia A.***For routine bleeding prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A.***For the management of hemorrhage or hemarthrosis in patients with von Willebrand's disease (vWD). <br />        NOTE: Humate-P has been designated by the FDA as orphan drugs for this indication.<br />     ***For major hemorrhage in patients with mild vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma or traumatic hemorrhage).***For minor hemorrhage in patients with moderate to severe vWD type I, type II, and type III (e.g., epistaxis, oral bleeding, or menorrhagia).***For major hemorrhage in patients with moderate to severe vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For major hemorrhage in patients with vWD type II and III (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For surgical bleeding prophylaxis during major or minor procedures in patients with vWD in whom desmopressin is either ineffective or contraindicated. <br />          NOTE: Alphanate and Humate-P have been designated by the FDA as orphan drugs for this indication.<br />       ","***General Information***Pregnancy***Breast-feeding***Thromboembolic disease***Hepatitis, infection, viral infection***Anemia***Bovine protein hypersensitivity, hamster protein hypersensitivity, latex hypersensitivity, mannitol hypersensitivity, murine protein hypersensitivity, polysorbate 80 hypersensitivity***Porcine protein hypersensitivity***Human immunodeficiency virus (HIV) infection***Cardiac disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['343048'],treprostinil,"***For the treatment of pulmonary hypertension.***For the treatment of pulmonary arterial hypertension (WHO Group 1) to diminish symptoms associated with exercise.***For patients transitioning from epoprostenol to intravenous or subcutaneous treprostinil. <br />          NOTE: The transition from epoprostenol to treprostinil should take place in a hospital with continuous observation to response (e.g., walking distance and signs and symptoms of disease progression).<br />       ***For patients transitioning from intravenous or subcutaneous treprostinil to oral treprostinil.***For temporary subcutaneous or intravenous treprostinil infusion in patients unable to take oral treprostinil due to a planned, short-term treatment interruption.***For the treatment of severe intermittent claudication� in patients with Fontaine classes IIb�III symptoms.","***General Information***Intravenous administration***Abrupt discontinuation***Asthma, chronic obstructive pulmonary disease (COPD), pulmonary disease***Hypotension***Bleeding***Hepatic disease, hepatitis***Renal disease, renal failure, renal impairment***Geriatric***Diverticulitis***Alcoholism***Labor, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,nedocromil sodium,***For the treatment of asthma. <br />        NOTE: Nedocromil sodium is intended for regular maintenance treatment and should not be used for relief of symptoms in an acute asthmatic attack.<br />     ***For maintenance therapy and bronchospasm prophylaxis in mild to moderate chronic asthma.***For exercise-induced bronchospasm prophylaxis�.***For the treatment of itching related to allergic ocular disorders such as allergic conjunctivitis.,"***Acute bronchospasm, status asthmaticus***Pregnancy***Breast-feeding***Contact lenses***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8588'],penicillin G potassium,"***For the treatment of serious infections caused by susceptible organisms, including pleural empyema and bacteremia.***For the treatment of serious meningococcal infections.***For the treatment of bacteremia due to <em>Pasteurella multocida</em>.***For the treatment of gram-negative bacilliary infections.***For the treatment of serious streptococcal infections.***For the treatment of serious staphylococcal infections.***For the treatment of infections due to <em>Clostridium </em>sp., including botulism (adjunctive to antitoxin), gas gangrene, and tetanus (adjunctive therapy).***For the treatment of inhalation anthrax infection caused by susceptible strains of <em>Bacillus anthracis</em>. <br />        NOTE: In the setting where high concentrations of B. anthracis organisms are present, the treatment of infections with a penicillin-type drug alone is a concern due to the risk of a beta-lactamase induction event, which would significantly increase the MIC.<br />     ***For endocarditis or pericarditis.***For the treatment of endocarditis due to penicillin-susceptible viridans streptococci and <em>Streptococcus bovis</em> (MIC of 0.1 mcg/mL or less).***For the treatment of endocarditis due to strains of viridans streptococci and <em>Streptococcus bovis</em> relatively resistant to penicillin G (MIC greater than 0.12 mcg/mL and less than 0.5 mcg/mL).***For the treatment of endocarditis due to viridans streptococci with a MIC of 0.5 mcg/mL or greater or due to enterococci.***For the treatment of staphylococcal endocarditis.***For the treatment of endocarditis due to <em>Erysipelothrix insidiosa</em>.***For the treatment of gonococcal endocarditis.***For the treatment of meningococcal endocarditis.***For the treatment of meningitis.***For the treatment of streptococcal meningitis.***For the treatment of meningococcal meningitis.***For the treatment of staphylococcal meningitis.***For the treatment of <em>Listeria</em> meningitis.***For the treatment of gonococcal meningitis.***For the treatment of meningitis due to <em>Pasteurella multocida</em>.***For the treatment of disseminated gonorrhea, including infectious arthritis, due to <em>Neisseria gonorrhoeae</em> when the infecting strain has been tested and found to be susceptible to penicillin. <br />        NOTE: For meningitis infections, see meningitis dosing. For endocarditis infections, see endocarditis dosing.<br />     ***For the treatment of listeriosis.***For the treatment of diphtheria and for the elimination of the diphtheria carrier state.***For the treatment of rat-bite fever or Haverhill fever due to <em>Spirillum minus</em> or <em>Streptobacillus moniliformis</em>.***For the treatment of actinomycosis.***For the treatment of fusospirochetosis or Vincent's infection, including necrotizing ulcerative gingivitis, oropharynx infections, lower respiratory tract infections, and genital infections caused by <em>Fusobacterium</em> sp..***For the treatment of pneumonia, including community-acquired pneumonia.***For the treatment of disseminated Lyme disease� (i.e., neuroborreliosis, carditis, recurrent/persistent arthritis). <br />  NOTE: Penicillin G is recommended as an alternative to ceftriaxone for the treatment of early Lyme disease with acute neurological disease, for the initial treatment of hospitalized patients with Lyme carditis, and for late manifestations of Lyme disease.<br /***For the treatment of leptospirosis� due to <em>Leptospira </em>sp..***For the treatment of syphilis, including congenital syphilis and neurosyphilis or syphilitic eye disease� (e.g., uveitis�, neuroretinitis�, or optic neuritis�). <br />        NOTE: If follow-up/compliance unsure, desensitize patient and treat with penicillin.<br />NOTE: Pregnant women with syphilis in any stage who report with penicillin allergy should be desensitized and treated with penicillin***For neurosyphilis or syphilitic eye disease� (e.g., uveitis�, neuroretinitis�, or optic neuritis�).***For congenital syphilis. <br />          NOTE: Current CDC guidelines should be consulted to determine the appropriate course of treatment in neonates born to mothers with syphilis. Therapy is based on physical examination, serum quantitative nontreponemal serologic titer, and whether or not the mother was treated properly before delivery. <br />       ***For perinatal Group B streptococcal bacterial infection prophylaxis�.***For the treatment of serious streptococcal or staphylococcal infections, including necrotizing skin and skin structure infections� and erysipelas�.","***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Infants, neonates, renal failure, renal impairment***Electrolyte imbalance***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3102'],danazol,"***For the treatment of endometriosis.***For mild cases.***For moderate to severe cases.***For the treatment of fibrocystic breast disease.***For angioedema prophylaxis in patients with hereditary angioedema.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP)�.***For the treatment of mastalgia� associated with premenstrual syndrome (PMS)�; or for PMS-associated bloating and weight gain, anxiety, depressive symptoms, and/or global complaints.***For emergency postcoital contraception�.","***Cardiac disease, migraine, renal disease, renal failure, renal impairment, seizure disorder***Hepatic disease, hepatotoxicity, jaundice, peliosis hepatis***Porphyria***Contraception requirements, pregnancy, pregnancy testing***Breast-feeding***Vaginal bleeding***Breast cancer***Geriatric, prostatic hypertrophy***Increased intracranial pressure, papilledema, pseudotumor cerebri***Stroke, thromboembolic disease, thromboembolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cyclopentolate hydrochloride,***For mydriasis induction and cycloplegia induction for ophthalmic diagnostic procedures.,"***Closed-angle glaucoma, Down's syndrome, glaucoma***Contact lenses***Children, seizure disorder, seizures***Infants***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['25789'],glimepiride,***For the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise; for use as monotherapy or in combination with other appropriate antidiabetic medications.,"***General Information***Sulfonylurea hypersensitivity***Sulfonamide hypersensitivity***Diabetic ketoacidosis, type 1 diabetes mellitus***Adrenal insufficiency, autonomic neuropathy, hepatic disease, renal disease, renal failure, renal impairment, thyroid disease***Infection, surgery, trauma***Neonates, obstetric delivery, pregnancy***Breast-feeding***Children***G6PD deficiency***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,benzoyl peroxide/clindamycin phosphate,"***For the treatment of acne vulgaris. <br />        NOTE: There are reports of an increase of P. acnes resistance to clindamycin in the treatment of acne. In patients with P. acnes resistant to clindamycin, the clindamycin component may provide no additional benefit beyond benzoyl peroxide alone.<br />     ***For the treatment of moderate to severe acne rosacea�.","***General Information***Benzoic acid hypersensitivity, clindamycin hypersensitivity, lincomycin hypersensitivity***Eczema, ocular exposure, skin abrasion, skin disease, sunburn, sunlight (UV) exposure***Children, infants, neonates***Colitis, Crohn's disease, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,methylphenidate hydrochloride,***For the treatment of attention-deficit hyperactivity disorder (ADHD).***For once-daily product dosing.***For the treatment of narcolepsy.***For the treatment of major depression� or post-stroke depression refractory to other therapies. <br />        NOTE: The use of stimulants for the treatment of depressive disorders is usually limited to treatment-refractory cases or when standard medical therapies are not tolerated. Stimulants may aggravate coexisting anxiety or agitation in depressed patients.<br />     ,"***General Information***Hereditary fructose intolerance***Anxiety, bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Tics, Tourette's syndrome***Glaucoma, visual disturbance***Abrupt discontinuation, alcoholism, substance abuse***Hypertension***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular arrhythmias, ventricular dysfunction***Cerebrovascular disease, stroke***Children, growth inhibition***Hyperthyroidism***Seizure disorder, seizures***Neonates, pregnancy***Breast-feeding***Driving or operating machinery***Surgery***Radiographic contrast administration***Dysphagia, esophageal stricture, GI obstruction, ileus***Hepatic disease***Geriatric***MAOI therapy***Peripheral vascular disease, Raynaud's phenomenon***Chemical leukoderma, skin hypopigmentation, vitiligo***Phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,irinotecan hydrochloride,"***For the treatment of metastatic colorectal cancer. <br />        NOTE: The use of irinotecan in combination with 5-FU/leucovorin regimens administered for 4 to 5 consecutive days every 4 weeks are not recommended due to an increased risk of toxicity, including death; use of these regimens should be limited to clinical trials.<br />     ***For the treatment of metastatic colorectal cancer in combination with 5-fluorouracil (5-FU) and leucovorin (IFL).***For the treatment of metastatic colorectal cancer that has recurred or progressed after 5-fluorouracil (5-FU) based therapy, as monotherapy.***For the treatment of previously treated KRAS wild-type, EGFR-expressing, metastatic colorectal cancer in combination with cetuximab�. <br />          NOTE: In combination with irinotecan, cetuximab is FDA-approved for the treatment of ironetacn-refractory, EGFR-expressing metastatic colorectal cancer.<br />       ***For the treatment of metastatic colorectal cancer, in combination with leucovorin and 5-fluorouracil (5-FU) (FOLFIRI).***For the treatment of BRAF mutation-positive, RAS wild-type, metastatic colorectal cancer, in combination with vemurafenib and cetuximab�.***For the second-line treatment of metastatic colorectal cancer, in combination with oxaliplatin (IROX).***For the treatment of extensive small cell lung cancer (SCLC)� in combination with cisplatin.***For the treatment of gastric cancer�.***For the treatment of resectable locally advanced gastric cancer in combination with cisplatin�.***For the treatment of previously untreated advanced gastric cancer in combination with 5-fluorouracil�.***For the treatment of refractory advanced gastric cancer in combination with capecitabine�.***For the first-line treatment of metastatic pancreatic cancer� in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFIRINOX).***For the monotherapy treatment of recurrent malignant glioma�. <br />        NOTE: Concomitant use of an enzyme-inducing antiepileptic drug (EIAED) alters the metabolism and elimination of irinotecan and its active metabolite, SN-38. Irinotecan dose adjustment is needed to achieve therapeutic concentrations.<br />     ***For the treatment of recurrent or relapsed glioblastoma multiforme in combination with bevacizumab�. <br />        NOTE: Concomitant use of an enzyme-inducing antiepileptic drug (EIAED) alters the metabolism and elimination of irinotecan and its active metabolite, SN-38. Irinotecan dose adjustment is needed to achieve therapeutic concentrations.<br />     ***For the treatment of rhabdomyosarcoma�, in combination with chemotherapy.***For the treatment of non-small cell lung cancer (NSCLC)� in combination with cisplatin.","***Radiation therapy***Anemia, bone marrow suppression, neutropenia, thrombocytopenia***Poor metabolizers***Chronic lung disease (CLD), pneumonitis***Dehydration, diarrhea, GI obstruction***Geriatric***Biliary tract disease, hepatic disease***Extravasation***Accidental exposure***Children***Pregnancy***Infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['46967'],beractant,"***For the prevention of neonatal respiratory distress syndrome (RDS) in premature infants and for the treatment of neonatal respiratory distress syndrome (RDS). <br />  NOTE: Beractant is indicated for prevention and treatment (�rescue�) of Respiratory Distress Syndrome (RDS) in premature infants. In premature infants less than 1,250 g birth weight or with evidence of surfactant deficiency, give beractant as soon as possible, preferably within 15 minutes of birth. To treat infants with RDS confirmed by X-ray and requiring mechanical ventilation, give beractant as soon as possible, preferably by 8 hours of age.<br />NOTE: The manufacturer has not conducted controlled trials examining the use of beractant in premature neonates with a birth weight of &lt; 600 g or &gt; 1,750 g; however, dosage recommendations based on weight ranges for premature neonates weighing from 600 g up to 2,000 g are included in the full prescribing information***For the treatment of acute respiratory distress syndrome (ARDS)�.",***Bovine protein hypersensitivity***Bradycardia***Sepsis***Neonates***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6902'],methylprednisolone,"***For the treatment of status asthmaticus.***For the treatment of asthma.***For a moderate to severe asthma exacerbation in the emergency department or the hospital.***For an acute asthma exacerbation on an outpatient basis.***For long-term prevention of symptoms in severe persistent asthma.***For the treatment of the acute respiratory distress syndrome (ARDS).***For the management of symptomatic sarcoidosis.***For the treatment of inflammatory bowel disease during critical periods of ulcerative colitis and regional enteritis (Crohn's disease).***For the treatment of allergic disorders including anaphylaxis or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, serum sickness, severe perennial or seasonal allergic rhinitis, or urticaria.***For non-emergent treatment of hypersensitivity or allergic conditions.***For the urgent treatment of severe conditions like anaphylaxis, angioedema, or urticarial transfusion-related reactions.***For the treatment of corticosteroid-responsive dermatologic disorders (e.g., alopecia areata, atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis including Rhus dermatitis due to poison ivy, poison oak, poison sumac, discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex, mycosis fungoides, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pruritus, psoriasis, seborrheic dermatitis, or xerosis).***For mild-moderate corticosteroid responsive dermatoses.***For severe inflammatory dermatoses, like exfoliative dermatitis, erythema multiforme or Stevens-Johnson syndrome, or psoriasis not responding to topical therapy.***For the treatment of acute exacerbations of multiple sclerosis.***For the treatment of myasthenia gravis in patients who are poorly controlled with cholinesterase inhibitor therapy.***For the treatment of hypercalcemia associated with certain types of cancer.***For the treatment of non-neoplastic hematologic disorders including immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), and congenital hypoplastic anemia.***For the treatment of adrenocortical function abnormalities, such as adrenocortical insufficiency, congenital adrenal hyperplasia (CAH), chronic primary (Addison's disease) or secondary adrenocortical insufficiency, or adrenogenital syndrome.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of nonsuppurative thyroiditis.***For the treatment of acute kidney transplant rejection.***For the treatment of respiratory conditions including airway-obstructing hemangioma� in infants, aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), Loeffler's syndrome, or noncardiogenic pulmonary edema�.***For chronic oral management of non-asthmatic respiratory conditions.***For parenteral management of non-asthmatic respiratory conditions when oral dosing not feasible or severity or compromised airway warrants.***For chronic maintenance therapy for idiopathic pulmonary fibrosis�.***For the treatment of laryngotracheobronchitis (croup)�.***For the treatment of acute spinal cord injury�.***For adjunctive therapy in the treatment of rheumatic disorders including acute gouty arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, psoriatic arthritis, or rheumatoid arthritis, or for the treatment of acute episodes or exacerbation of nonrheumatic inflammatory conditions including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the treatment of selected cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, vasculitis�, or Wegener's granulomatosis�.***For routine treatment.***For life-threatening manifestations including diffuse proliferative glomerulonephritis (i.e., lupus nephritis�), cerebritis, or hemolytic disease.***For the palliative management of leukemia and lymphoma in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), or multiple myeloma�.***For the treatment of Pneumocystis pneumonia (PCP)� in HIV patients as adjunctive therapy.***For the treatment of Severe Acute Respiratory Syndrome (SARS)�.***For the treatment of acute interstitial nephritis (AIN)�.***For the treatment of acute graft-versus-host disease (GVHD)�.***For the treatment of heart transplant rejection�.***For the systemic treatment of ophthalmic disorders including allergic conjunctivitis, allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.***For the treatment of IVIG-refractory Kawasaki disease�.","***General Information***Epidural administration, intramuscular administration, intrathecal administration, intravenous administration***Fungal infection, infection, measles, mycobacterial infection, sepsis, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Heart failure, hypertension***Cataracts, glaucoma, increased intraocular pressure, visual disturbance***Diabetes mellitus, herpes infection, osteoporosis, psychosis, renal disease, seizure disorder***Myasthenia gravis***Diverticulitis, GI disease, hepatic disease, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Coagulopathy, idiopathic thrombocytopenic purpura (ITP), thromboembolic disease***Pregnancy***Breast-feeding***Children, growth inhibition, increased intracranial pressure, infants***Cushing's syndrome***Abrupt discontinuation, hypothalamic-pituitary-adrenal (HPA) suppression***Neonates, premature neonates***Corticosteroid hypersensitivity***Hyperthyroidism, hypothyroidism, thyroid disease***Geriatric***Immunosuppression***Vaccination***Head trauma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5487']['9997'],hydrochlorothiazide/spironolactone,"***For the treatment of edema associated with cirrhosis of the liver, congestive heart failure, or the nephrotic syndrome. <br />        NOTE: The dosage must be determined by individual titration of the separate components. Spironolactone; hydrochlorothiazide is not indicated for initial therapy. Since the onset of action of spironolactone is gradual, partially explained by the long half-life of canrenone (active metabolite), several days should elapse between dosage adjustments. Dose requirements may change over time due to patient specific factors.<br />NOTE: Spironolactone should not be used to prevent anticipated hypokalemia from hydrochlorothiazide. Most patients will not develop hypokalemia with hydrochlorothiazide doses of 12.5�25 mg daily.<br />NOTE: Spironolactone addition to hydrochlorothiazide has yielded a greater natriuretic effect for patients with a low urinary sodium amount and a high urine potassium amount. Negligible benefit was obtained for patients with a low urine sodium and potassium amount.<br />NOTE: Patients with cirrhosis may only need spironolactone due to secondary hyperaldosteronism being an important cause of sodium and water retention. Increasing the dose of hydrochlorothiazide may result in intravascular volume depletion. Intermittent large volume paracentesis may be more appropriate for ascites management.<br />NOTE: Treatment of the underlying disease along with restriction of sodium and fluid intake is paramount***For the treatment of essential hypertension. <br />        NOTE: Spironolactone should not be used to prevent anticipated hypokalemia from hydrochlorothiazide. Most patients will not develop hypokalemia with hydrochlorothiazide doses of 12.5�25 mg daily.<br />NOTE: Hydrochlorothiazide has a relatively flat dose-response curve with little difference in the fraction of excreted sodium between the daily dosage range of 12.5�50 mg. Higher doses usually do not increase efficacy but do increase the risk of adverse effects. Spironolactone is indicated for the treatment of essential hypertension, usually in combination with other antihypertensives (e.g., HCTZ, ACE inhibitors)***For the treatment of chronic lung disease (CLD)�. <br />        NOTE: Spironolactone has been shown to be a tumorigen in rats. Unnecessary use of this drug should be avoided.<br />NOTE: There is currently no comparative information regarding the use of spironolactone with HCTZ versus HCTZ alone.<br />NOTE: Due to the need to individualize drug doses in pediatric patients, fixed-dose combination products should generally be avoided. The separate components should be titrated to optimize clinical response***Formoterol***Formoterol; Mometasone","***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Electrolyte imbalance***Adrenal insufficiency, anuria, diabetes mellitus, hyperkalemia, hypomagnesemia, hyponatremia, renal failure, renal impairment***Hypercalcemia, hyperparathyroidism***Hepatic disease***Gout, hyperuricemia***Hypercholesterolemia, hypertriglyceridemia***Systemic lupus erythematosus (SLE)***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***Preeclampsia, pregnancy***Breast-feeding***Children***Menstrual irregularity***Water intoxication***Sunlight (UV) exposure***New primary malignancy, tumorigenicity***Driving or operating machinery***Geriatric***Prostate cancer",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,oxiconazole nitrate,"***For the topical treatment of the following dermal infections: tinea corporis, tinea cruris, and tinea pedis due to <em>Epidermophyton floccosum, Trichophyton mentagrophytes</em><em>,</em> or <em>Trichophyton rubrum</em>.***For the topical treatment of tinea versicolor due to <em>Malassezia furfur</em>.","***Azole antifungals hypersensitivity***Onychomycosis***Ocular exposure, ophthalmic administration, vaginal administration***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['474128'],telbivudine,"***For the treatment of chronic hepatitis B infection in patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. <br />  NOTE: The indication is based on virologic, serologic, biochemical, and histologic responses after one year of treatment in nucleoside-treatment-naive patients with HBeAg-positive and HBeAg-negative chronic hepatitis B with compensated liver disease.<br />NOTE: Resistance may develop with prolonged treatment in patients with incomplete viral suppression; therefore, only initiate telbivudine therapy if pre-treatment HBV DNA and ALT measurements are known and meet recommended starting levels. For HBeAg-positive patients, HBV DNA should be &lt; 9 log10 copies/ml and ALT should be &gt;= 2x upper limits of normal prior to treatment with telbivudine. For HBeAg-negative patients, HBV DNA should be &lt; 7 log10 copies/ml prior to treatment","***General Information***Dialysis, geriatric, renal disease, renal failure, renal impairment***Alcoholism, females, hepatic disease, hepatotoxicity or lactic acidosis, obesity***Hepatitis B exacerbation***Pregnancy***Breast-feeding***Children, infants, neonates***Hepatitis B and HIV coinfection, human immunodeficiency virus (HIV) infection, human immunodeficiency virus (HIV) infection resistance***Liver transplant***Antimicrobial resistance***Black patients, Hispanic patients",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['19552', '1546020']",cefprozil,***For the treatment of mild to moderate pharyngitis or tonsillitis.***For the treatment of acute bacterial exacerbation of chronic bronchitis.***For the treatment of otitis media.***For the treatment of uncomplicated skin and skin structure infections.***For the treatment of acute sinusitis.,"***General Information***Phenylketonuria***Renal failure, renal impairment***Cephalosporin hypersensitivity, penicillin hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Coagulopathy, vitamin K deficiency***Pregnancy***Breast-feeding***Infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diflorasone diacetate,"***For the treatment of moderate to severe corticosteroid-responsive dermatoses, like alopecia areata, atopic dermatitis, severe contact dermatitis, or severe <em>Rhus</em> dermatitis (due to plants like poison ivy), discoid lupus erythematosus, granuloma annulare, cutaneous lichen planus, lichen simplex chronicus, severe lichen striatus, severe eczema (including severe hyperkeratotic eczema, severe nummular eczema, and severe eczematous conditions of the hands or feet), exfoliative dermatitis, keloids, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, severe pruritus, sarcoidosis, sunburn, or urticaria. <br />        NOTE: Systemic therapy or intralesional injection of corticosteroids may be necessary for some conditions based on the type and severity of the disorder or inadequate response to topical therapy.<br />     ***For the treatment of moderate to severe chronic plaque-type psoriasis.***For the treatment of vulvar lichen sclerosus�.***For the treatment of cutaneous T-cell lymphoma (CTCL)� (aka mycosis fungoides�).","***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Diabetes mellitus***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Fungal infection, herpes infection, infection, measles, peripheral vascular disease, tuberculosis, varicella, viral infection***Acne rosacea, acne vulgaris, cataracts, glaucoma, ocular exposure, ophthalmic administration, perioral dermatitis***Geriatric, skin atrophy***Corticosteroid hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydrocortisone acetate,"***For the treatment of primary adrenocortical insufficiency (e.g., Addison's Disease, congenital adrenal hyperplasia or CAH) or secondary adrenocortical insufficiency.***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing minor surgery or with a minor illness (e.g., inguinal hernia repair, colonoscopy, mild febrile illness, gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing moderate surgery or with a moderate illness (e.g., open cholecystectomy, hemicolectomy, significant febrile illness, pneumonia, severe gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing major surgery, or with other acute stressors (e.g., major cardiothoracic surgery, Whipple procedure, liver resection, pancreatitis, acute systemic infection, shock).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency and a critical illness (e.g., shock).***For the treatment of acute adrenocortical insufficiency.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency with other acute stressors (e.g., febrile illness with a temperature more than 38.5 degrees Celsius, gastroenteritis with dehydration, major trauma):.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency undergoing surgery accompanied by general anesthesia.***For use in nonspecific proctitis, postirradiation (factitial) proctitis, cryptitis, or for other non-specific inflammatory conditions of the anorectum.***For the treatment of inflammatory bowel disease (Crohn's disease or ulcerative colitis).***For adjunctive treatment of Crohn's disease or ulcerative colitis using oral or parenteral therapy.***For adjunctive rectal treatment of chronic ulcerative colitis, particularly if disease limited to the distal portion of the rectum.***For the relief of inflammation, pruritus ani, and swelling associated with hemorrhoids.***For the treatment of allergic disorders including anaphylaxis, anaphylactic shock, or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, transfusion-related reactions, serum sickness, severe perennial or seasonal allergic rhinitis, or urticaria.***For the non-emergent treatment of hypersensitivity or allergic conditions.***For the urgent treatment of severe conditions such as anaphylaxis, angioedema, acute noninfectious laryngeal edema, or urticarial transfusion-related reactions.***For the treatment of corticosteroid-responsive dermatologic disorders (e.g., alopecia areata, atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis including Rhus dermatitis due to poison ivy, poison oak, poison sumac, discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pompholyx (dyshidrosis), pruritus, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, xerosis).***For mild-to-moderate corticosteroid responsive dermatoses.***For mild to moderate atopic dermatitis.***For the systemic treatment of severe inflammatory dermatoses, like severe exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, or psoriasis unresponsive to topical treatment.***For adjunctive therapy in the treatment of rheumatic disorders including acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of non-rheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the short-term treatment of hypercalcemia associated with neoplastic disease.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the management of nephrotic syndrome to induce diuresis or decrease proteinuria.***For the treatment of neurologic or myocardial involvement associated with trichinosis.***For the treatment of nonsuppurative thyroiditis.***For rheumatic and related disorders such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, symptomatic sarcoidosis, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive hematologic disorders, like immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia, and congenital hypoplastic anemia; OR for the palliative treatment of neoplastic disease in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), or multiple myeloma�.***For the treatment of respiratory inflammatory conditions including bronchial asthma, aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), Loeffler's syndrome, or noncardiogenic pulmonary edema�.***For the treatment of septic shock� and/or hypotension� in patients whose blood pressure is poorly responsive to adequate fluid resuscitation and vasopressor therapy.***For the prevention of chronic lung disease (CLD)� in mechanically ventilated patients.***For the treatment of refractory neonatal hypoglycemia�.***For the treatment of corticosteroid-responsive ophthalmic disorders, including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.","***Abrupt discontinuation, Cushing's syndrome, skin abrasion***Growth inhibition, increased intracranial pressure***Immunosuppression***Fungal infection, infection***Acne rosacea, acne vulgaris, herpes infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Heart failure, hypertension***Osteoporosis***Diabetes mellitus***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hypothyroidism, psychosis, renal disease, seizure disorder***Myasthenia gravis***Coagulopathy, hemophilia, thromboembolic disease***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Neonates, premature neonates***Benzyl alcohol hypersensitivity, corticosteroid hypersensitivity***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Skin atrophy***Geriatric***Epidural administration, intrathecal administration***Pheochromocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,atropine sulfate/diphenoxylate hydrochloride,***For adjunctive therapy in the management of diarrhea including AIDS-associated diarrhea� with no identifiable infectious agent.,"***General Information***Dehydration, electrolyte imbalance***Pregnancy***Breast-feeding***Substance abuse***Hepatic disease, jaundice***Ulcerative colitis***Gastroenteritis, infection***Pseudomembranous colitis***Children, Down's syndrome, infants, neonates***MAOI therapy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,copper sulfate/ferrous fumarate/manganese sulfate/polysaccharide iron complex/vitamin B1 (thiamine mononitrate)/vitamin B2 (riboflavin)/vitamin B3 (niacinamide)/vitamin B5 (calcium pantothenate)/vitamin B6 (pyridoxine hydrochloride)/vitamin B9 (folic acid)/vitamin B12 (cyanocobalamin concentrate)/vitamin C (sodium ascorbate)/zinc sulfate,"***For nutritional supplementation of females of child-bearing potential during pre-conception, pregnancy or lactation.***Formoterol; Mometasone","***General Information***Accidental exposure, children, infants***Anticoagulant therapy, bleeding***Breast-feeding, pregnancy***Pernicious anemia, vitamin B12 deficiency megaloblastic anemia***Hemochromatosis, hemosiderosis, hepatic disease, sideroblastic anemia, thalassemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['475969'],etravirine,***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in treatment-experienced patients with evidence of HIV replication despite ongoing antiretroviral therapy.***For human immunodeficiency virus (HIV) prophylaxis� after occupational exposure to HIV.,"***General Information***Hepatic disease***Hepatitis, hepatitis B and HIV coinfection***Children, infants, neonates***Geriatric***Human immunodeficiency virus (HIV) infection resistance***Pregnancy***Breast-feeding***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Females, serious rash***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,potassium chloride,"***For the treatment of hypokalemia and hypokalemia prevention.***For the treatment of hypokalemia or digoxin toxicity (arrhythmias or ECG changes) associated with hypokalemia. <br />          NOTE: Hypokalemia is generally defined as a serum potassium concentration &lt; 3.5 mEq/L; however, serum potassium concentrations do not always correlate with cellular potassium levels. The National Council on Potassium in Clinical Practice recommends that serum potassium concentrations &gt;= 4 mEq/L be achieved and maintained in patients with hypertension, heart failure, and cardiac arrhythmias.<br />NOTE: Although extremely variable and based on clinical conditions of the patient, serum potassium decreases an average of 0.3 mmol/L for each 100-mmol reduction in total body stores. To avoid inducing hyperkalemia when correcting potassium loss, it is recommended to utilize the low end of this estimate and administer a moderate dose (orally, if possible) over a period of days to weeks to fully correct the potassium deficit. Among patients in an intensive care unit treated for acute hypokalemia, 20 mEq/hr potassium chloride IV resulted in a mean increase in the serum potassium concentration of 0.25 mmol/L***For the prevention of hypokalemia. <br />  NOTE: Hypokalemia is generally defined as a serum potassium concentration &lt; 3.5 mEq/L; however, serum potassium concentrations do not always correlate with cellular potassium levels. The National Council on Potassium in Clinical Practice recommends that serum potassium concentrations &gt;= 4 mEq/L be achieved and maintained in patients with hypertension, heart failure, and cardiac arrhythmias. In addition, the Council recommends potassium supplementation for patients with potential for diuretic-induced potassium loss (e.g., thiazide or loop diuretics), patients with high sodium intake (or unwilling to reduce salt intake), and patients with reduced GI intake (e.g., GI disturbances, laxative abuse).<br /***Formoterol; Mometasone","***General Information***Adrenal insufficiency, burns, dehydration, diabetic ketoacidosis, geriatric, hyperkalemia, metabolic acidosis, premature neonates, renal disease, renal failure, renal impairment***Atrial fibrillation, atrial flutter, AV block, cardiac arrhythmias, digitalis toxicity, heart failure, ventricular arrhythmias, ventricular fibrillation, ventricular tachycardia***Esophageal stricture, gastroparesis, GI obstruction, ileus, peptic ulcer disease***Pregnancy***Breast-feeding***Hepatic disease, metabolic alkalosis, respiratory alkalosis***Extravasation, thrombophlebitis***Muscle channelopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,tranexamic acid,"***For bleeding prophylaxis.***For short-term use to reduce or prevent hemorrhage and reduce the need for replacement therapy during and after tooth extraction in hemophilia A and hemophilia B patients.***For bleeding prophylaxis following ocular trauma (hyphema)�.***For intracranial bleeding prophylaxis� after traumatic brain injury.***For the treatment of cyclic menorrhagia (heavy menstrual bleeding). <br />        NOTE: Prior to initiating therapy, exclude any endometrial pathology that can be associated with heavy menstrual bleeding.<br />     ***For the treatment of epistaxis� in patients with hereditary hemorrhagic telangiectasia.***For angioedema prophylaxis� in patients with hereditary angioedema.***For orthopedic surgical bleeding prophylaxis� in primary total hip or knee arthroplasty.***For the topical use of tranexamic acid for orthopedic surgical bleeding prophylaxis in primary total hip or knee arthroplasty.***For the intravenous use of tranexamic acid for orthopedic surgical bleeding prophylaxis in primary total hip or knee arthroplasty.","***General Information***Leukemia, thromboembolic disease***Intracranial bleeding***Visual disturbance***Pregnancy***Breast-feeding***Children, infants***Geriatric***Renal failure, renal impairment***Disseminated intravascular coagulation (DIC)***Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4492'],fluorouracil,"***For the treatment of colorectal cancer. <br />        NOTE: Dosage should be based upon body surface area using actual body weight unless patient is obese or has significant fluid retention. In these cases the dose should be based upon the ideal weight or dry weight.<br />NOTE: Fluorouracil has been given in a large number of different dosages and schedules. The correct dose of fluorouracil will vary from protocol to protocol. Clinicians should consult the appropriate references to verify the dose***For the adjuvant treatment of colon cancer in combination with leucovorin (Roswell Park)�.***For adjuvant treatment of high-risk stage II or stage III rectal cancer in combination with radiation therapy.***For the treatment of metastatic colorectal cancer in combination with irinotecan and leucovorin, with or without bevacizumab (FOLFIRI with or without bevacizumab)�. <br />          NOTE: Both bevacizumab and irinotecan are FDA approved for the treatment of metastatic colorectal cancer in combination with leucovorin and 5-FU.<br />NOTE: Outside of a clinical trial, irinotecan should only be given in combination with weekly 5-FU/leucovorin bolus regimens or continuous infusion 5-FU/leucovorin as listed below. Use of irinotecan in combination with 5-FU/leucovorin regimens administered for 4 to 5 consecutive days every 4 weeks are not recommended due to an increased risk of toxicity, including death; use of these regimens should be limited to controlled clinical trials***For the treatment of advanced colorectal cancer in combination with leucovorin (LV) and oxaliplatin with or without bevacizumab (FOLFOX4 with or without bevacizumab)�. <br />          NOTE: Bevacizumab is FDA approved for the treatment of metastatic colorectal cancer in combination with 5-FU based chemotherapy and oxaliplatin is FDA approved for advanced colorectal cancer in combination with infusional 5-FU and leucovorin.<br />       ***For the treatment of metastatic colorectal cancer in combination with leucovorin, irinotecan, and bevacizumab (IFL plus bevacizumab)�. <br />          NOTE: Bevacizumab is FDA approved for the treatment of metastatic colorectal cancer, in combination with leucovorin, 5-FU, and irinotecan (IFL)<br />       ***For the adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor, in combination with leucovorin and oxaliplatin (FOLFOX4)�. <br />          NOTE: Oxaliplatin is FDA approved for the adjuvant treatment of colorectal cancer in combination with 5-FU and leucovorin.<br />       ***For the treatment of metastatic colorectal cancer in combination with leucovorin and oxaliplatin, with or without bevacizumab (mFOLFOX6 with or without bevacizumab)�. <br />          NOTE: Bevacizumab is FDA approved for the treatment of metastatic colorectal cancer in combination with 5-FU based chemotherapy and oxaliplatin is FDA approved for advanced colorectal cancer in combination with infusional 5-FU and leucovorin.<br />       ***For the adjuvant treatment of colon cancer in combination with leucovorin (Mayo Clinic)�.***For the adjuvant treatment of colorectal cancer, in combination with leucovorin and oxaliplatin (mFOLFOX6)�. <br />          NOTE: Oxaliplatin is FDA approved for the adjuvant treatment of colorectal cancer in combination with 5-FU and leucovorin.<br />       ***For the adjuvant treatment of colorectal cancer, in combination with leucovorin and oxaliplatin (FLOX)�. <br />          NOTE: Oxaliplatin is FDA approved for the adjuvant treatment of colorectal cancer in combination with 5-FU and leucovorin.<br />       ***For the first line treatment of metastatic colorectal cancer in combination with leucovorin, oxaliplatin, and panitumumab in patients with wild-type KRAS (exon 2 in codons 12 or 13) (FOLFOX4 plus panitumumab)�. <br />          NOTE: Panitumumab is FDA approved for the treatment of metastatic colorectal cancer in combination with FOLFOX chemotherapy, and oxaliplatin is FDA approved for advanced colorectal cancer in combination with infusional 5-FU and leucovorin.<br />       ***For the first line treatment of metastatic colorectal cancer in combination with leucovorin, oxaliplatin, and panitumumab in patients with wild-type KRAS (exon 2 in codons 12 or 13) (mFOLFOX6 plus panitumumab)�. <br />          NOTE: Panitumumab is FDA approved for the treatment of metastatic colorectal cancer in combination with FOLFOX chemotherapy, and oxaliplatin is FDA approved for advanced colorectal cancer in combination with infusional 5-FU and leucovorin.<br />       ***For the first-line treatment of KRAS wild-type, EGFR-expressing metastatic colorectal cancer in combination with leucovorin and irinotecan, in combination with cetuximab (FOLFIRI plus cetuximab)�. <br />          NOTE: Cetuximab is FDA approved for the treatment of�KRAS wild-type, EGRF-expressing metastatic colorectal cancer in combination with FOLFIRI.<br />       ***For the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC), in combination with cetuximab, leucovorin, and oxaliplatin (mFOLFOX6 plus cetuximab)�. <br />          NOTE: Response rates to cetuximab do not correlate with either the percentage of EGFR-positive cells or the intensity of EGFR expression.<br />       ***For the first line treatment of advanced colorectal cancer in combination with irinotecan and oxaliplatin-based chemotherapy (FOLFOXIRI)�.***For the treatment of gastric cancer. <br />        NOTE: Dosage should be based upon body surface area using actual body weight unless patient is obese or has significant fluid retention. In these cases the dose should be based upon the ideal weight or dry weight.<br />     ***For the treatment of<strong>***For the perioperative treatment of gastric cancer in combination with epirubicin and cisplatin�.***For the treatment of breast cancer. <br />        NOTE: Dosage should be based upon body surface area using actual body weight unless patient is obese or has significant fluid retention. In these cases the dose should be based upon the ideal weight or dry weight.<br />     ***For the treatment of breast cancer in patients with evidence of axillary node involvement following resection of the primary tumor in combination with cyclophosphamide and epirubicin.***For the neoadjuvant treatment of HER2-positive breast cancer with fluorouracil and cyclophosphamide (FEC regimen) in sequence, and in combination, with paclitaxel and trastuzumab�.***For the treatment of metastatic breast cancer in combination with epirubicin and cyclophosphamide.***For the adjuvant treatment of early breast cancer, in combination with methotrexate and cyclophosphamide (CMF)�.***For the treatment of actinic keratosis (solar keratosis).***For the treatment of superficial basal cell carcinoma.***For the treatment of anal cancer�.***For the treatment of anal cancer in combination with mitomycin and radiation therapy.***For the treatment of anal cancer in combination with cisplatin and radiation therapy.***For the treatment of pancreatic cancer�. <br />        NOTE: Dosage should be based upon body surface area using actual body weight unless patient is obese or has significant fluid retention. In these cases the dose should be based upon the ideal weight or dry weight.<br />     ***For the treatment of pancreatic cancer in combination with other chemotherapy agents.***For the second-line treatment of gemcitabine-refractory advanced pancreatic cancer in combination with oxaliplatin�.***For the first-line treatment of metastatic pancreatic cancer� in combination with oxaliplatin, leucovorin, and irinotecan (FOLFIRINOX).***For the treatment of head and neck cancer�. <br />        NOTE: Dosage should be based upon body surface area using actual body weight unless patient is obese or has significant fluid retention. In these cases the dose should be based upon the ideal weight or dry weight.<br />     ***For the treatment of advanced or recurrent head and neck cancer in combination with cisplatin�.***For the treatment of advanced nasopharyngeal head and neck cancer in combination with cisplatin and radiotherapy�.***For induction treatment of inoperable locally advanced squamous cell head and neck cancer in combination with docetaxel and cisplatin�. <br />          NOTE: Docetaxel is FDA-approved for this indication.<br />       ***For induction treatment of locally advanced squamous cell head and neck cancer in combination with docetaxel and cisplatin for unresectable disease, low surgical cure, or organ preservation�. <br />  NOTE: Docetaxel is FDA-approved for this indication.<br />NOTE: Survival was significantly improved among patients who got the 3 drugs (see Dosage below) as compared with receipt of only cisplatin 100 mg/m2 IV on day 1 and 5- fluorouracil 1000 mg/m2/day by continuous IV infusion for 5 days. Specifically, the relative risk of death was 30% lower. Also, the median overall survival was 70.6 months as compared with 30.1 months for patients receiving only cisplatin and 5-fluorouracil. Three to 8 weeks after the start of the last cycle, all patients in both treatment arms who did not have progressive disease got carboplatin (AUC 1.5 weekly for 7 doses) and radiation therapy (2 Gy per day, 5 days per week for 7 weeks) followed by surgery, if appropriate***For the treatment of advanced-stage squamous cell carcinoma of the head and neck in combination with carboplatin and radiation therapy�.***For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in combination with carboplatin�.***For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck cancer in combination with carboplatin and cetuximab�.***For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck cancer in combination with cisplatin and cetuximab�.","***General Information***Bleeding, bone marrow suppression, infection, leukopenia, radiation therapy, thrombocytopenia***Diarrhea, GI bleeding, malnutrition, stomatitis, vomiting***Dihydropyrimidine dehydrogenase (DPD) deficiency, renal impairment***Biliary tract disease, hepatic disease, jaundice***Accidental exposure, ocular exposure***Occlusive dressing, skin abrasion***Sunlight (UV) exposure***Pregnancy***Breast-feeding***Intrathecal administration***Vaccination***Dental disease, dental work***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,metformin hydrochloride/repaglinide,***For the treatment of type 2 diabetes mellitus uncontrolled by diet and exercise.,"***General Information***Diabetic ketoacidosis, type 1 diabetes mellitus***Acidemia, hypoxemia, lactic acidosis, metabolic acidosis***Diarrhea, vomiting***Acute heart failure, acute myocardial infarction, cardiac disease, cardiogenic shock, heart failure***Renal disease, renal failure, renal impairment***Alcoholism, ethanol ingestion, ethanol intoxication, hepatic disease***Geriatric***Radiographic contrast administration***Burns, dehydration, fever, infection, sepsis, surgery, trauma***Adrenal insufficiency, hypoglycemia, hypothyroidism, malnutrition, pituitary insufficiency***Gastroparesis, GI obstruction, ileus***Hypercortisolism, hyperglycemia, hyperthyroidism***Children***Pernicious anemia***Polycystic ovary syndrome, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sevelamer hydrochloride,***For the management of hyperphosphatemia in patients with stage 5 chronic kidney disease (CKD) on dialysis.,"***General Information***Constipation, dysphagia, fecal impaction, GI obstruction, GI perforation, ileus, surgery***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,acetic acid,***For the treatment of otitis externa.***For urologic irrigation to prevent growth and proliferation of susceptible urinary pathogens (especially ammonia-forming bacteria) in patients with prolonged placement of an indwelling urethral catheter.***For topical adjunctive wound management� of selected superficial wounds to reduce the growth of <em>Pseudomonas aeruginosa</em>.,"***General Information***Parenteral administration, transurethral resection of the prostate***Ophthalmic administration***Tympanic membrane perforation***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6135'],ketoconazole,"***For the treatment of chromomycosis in patients who have failed or who are intolerant to other therapies. <br />  NOTE: Due to the potential for serious adverse events (i.e., fatal hepatotoxicity, adrenal insufficiency, harmful drug interactions), oral ketoconazole should only be used to treat serious fungal infections when no other antifungal therapies are available. <br /***For the treatment of blastomycosis, coccidioidomycosis, histoplasmosis, and paracoccidioidomycosis in patients who have failed or who are intolerant to other therapies. <br />  NOTE: Due to the potential for serious adverse events (i.e., fatal hepatotoxicity, adrenal insufficiency, harmful drug interactions), oral ketoconazole should only be used to treat serious fungal infections when no other antifungal therapies are available. <br /***For treatment of mucocutaneous candidiasis.***For the treatment of dandruff, to control flaking, scaling, or itching.***For the treatment of seborrheic dermatitis.***For the treatment of tinea corporis or tinea cruris.***For the treatment of tinea pedis.***For the treatment of tinea versicolor.***For the treatment of advanced prostate cancer�.***Formoterol***Formoterol; Mometasone","***Achlorhydria, human immunodeficiency virus (HIV) infection, hypochlorhydria***Ethanol ingestion, hepatic disease, hepatitis, hepatotoxicity***Bradycardia, cardiac arrhythmias, diabetes mellitus, females, heart failure, hypocalcemia, hypokalemia, hypomagnesemia, ketoconazole coadministration with other drugs, long QT syndrome, QT prolongation, torsade de pointes, ventricular arrhythmias***Adrenal insufficiency, surgery***Azole antifungals hypersensitivity***Pregnancy***Breast-feeding***Ocular exposure***Tobacco smoking***Driving or operating machinery***Geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,phenytoin sodium,"***For the treatment of status epilepticus.***For the treatment of tonic-clonic seizures or partial seizures.***For maintenance dosing to treat tonic-clonic or complex partial seizures.***For non-emergent treatment to increase phenytoin serum concentrations in a patient currently receiving phenytoin, but who has subtherapeutic serum concentrations; or to initiate phenytoin therapy for seizures in non-emergent situations.***For seizure prophylaxis due to specific neurologic conditions, including neurosurgery, head trauma� or traumatic brain injury�, or subarachnoid hemorrhage�.***For seizure prophylaxis following traumatic brain injury� or head trauma� or for seizure prophylaxis or treatment during neurosurgery.***For the treatment of serious cardiac arrhythmias secondary to digoxin toxicity�.***For seizure prophylaxis� during antenatal care in pregnant females with eclampsia� or severe preeclampsia�.","***Barbiturate hypersensitivity, carbamazepine hypersensitivity, hydantoin hypersensitivity, succinimide hypersensitivity***Asian patients, serious rash***Depression, suicidal ideation***Abrupt discontinuation***Hypoglycemia, hyponatremia, petit mal (absence) seizures***Hepatic disease, hepatotoxicity, hypoalbuminemia, jaundice***Agranulocytosis, bone marrow suppression, hematological disease, porphyria***Hodgkin's disease, lymphoma***Adams-Stokes syndrome, AV block, bradycardia, bundle-branch block, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypotension, infusion-related reactions, intravenous administration***Intramuscular administration***Alcoholism, ethanol ingestion, ethanol intoxication***Driving or operating machinery, encephalopathy, psychosis***Renal disease, renal failure, renal impairment***Diabetes mellitus***Hypothyroidism, thyroid disease***Bone fractures, osteomalacia, osteoporosis***Myasthenia gravis***Dental disease***Extravasation***Geriatric***Neonates, obstetric delivery, pregnancy, vitamin K deficiency***Breast-feeding***Contraception requirements, reproductive risk***Radiation therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,gadopentetate dimeglumine,"***For use as contrast enhancement in magnetic resonance imaging (MRI) to visualize lesions with abnormal vascularity within the central nervous system (brain, spine, and associated tissues), head, neck, and body (excluding the heart).","***General Information***Magnetic resonance imaging (MRI)***Asthma, atopy, radiopaque contrast media hypersensitivity***Diabetes mellitus, dialysis, geriatric, hypertension, nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy), renal disease, renal failure, renal impairment***Extravasation***Pregnancy***Breast-feeding***Sickle cell disease***Children, infants, neonates, premature neonates***Seizure disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,betamethasone acetate/betamethasone sodium phosphate,"***For the treatment of acute graft-versus-host disease (GVHD).***For the treatment of nonsuppurative thyroiditis.***For the treatment of acute exacerbations of multiple sclerosis.***For the management of symptomatic sarcoidosis or for the treatment of hypercalcemia associated with cancer or sarcoidosis.***For the treatment of allergic disorders including anaphylaxis or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema (or for laryngeal edema prophylaxis), drug hypersensitivity reactions, serum sickness, severe perennial or seasonal allergic rhinitis, severe urticaria, or for the treatment of urticarial transfusion reactions. <br />        NOTE: Betamethasone should be administered IM or IV initially in the treatment of anaphylaxis or anaphylactoid reactions, angioedema, and acute noninfectious laryngeal edema or to prevent impending risk of laryngeal edema.<br />     ***For the treatment of urticarial transfusion reactions.***For the treatment of immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of hematologic disorders including secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), and congenital hypoplastic anemia.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of inflammatory bowel disease including Crohn's disease (regional gastroenteritis) and ulcerative colitis.***For the induction of diuresis or remission of proteinuria in the nephrotic syndrome.***For the treatment of nasal polyps.***For the treatment of severe cases of myasthenia gravis not controlled by antimyasthenic agents alone.***For adjunctive therapy in the treatment of rheumatic disorders e.g., acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), osteoarthritis, polychondritis�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of nonrheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the treatment of moderate-to-severe inflammation and pruritus due to corticosteroid-responsive dermatologic disorders such as alopecia areata, cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis, generalized exfoliative dermatitis, nummular dermatitis, seborrheic dermatitis, eczema, granuloma annulare, keloids, lichen planus, lichen simplex chronicus, lichen striatus, subacute cutaneous and discoid lupus erythematosus, pretibial myxedema, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, psoriasis, <em>Rhus dermatitis</em> (due to poison ivy, poison oak, or poison sumac), sarcoidosis, Stevens-Johnson syndrome, sunburn, or urticaria. <br />        NOTE: Systemic corticosteroids may be necessary for some conditions based on the type and severity of the disorder (e.g., Stevens-Johnson syndrome) or inadequate response to topical therapy; intralesional injections may also be appropriate for select conditions.<br />     ***For the treatment of plaque psoriasis.***For the treatment of seborrheic dermatitis.***For hyaline membrane disease prophylaxis�, for the purpose of fetal lung maturation to prophylax against anticipated neonatal respiratory distress syndrome (RDS)� in premature infants.***For palliative management of leukemia and lymphoma in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), or for the treatment of multiple myeloma�.***For maintenance therapy in selected cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis�, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, conjunctivitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For the treatment of respiratory inflammatory conditions including airway-obstructing hemangioma� in infants, aspiration pneumonitis, berylliosis, bronchial asthma, chronic obstructive pulmonary disease (COPD), laryngotracheobronchitis (croup), Loeffler's syndrome, or non-cardiogenic pulmonary edema�, or for bronchospasm prophylaxis. <br />        NOTE: Betamethasone should be administered parenterally initially in the treatment of severe manifestations of these diseases, particularly where airway obstruction is present.<br />     ","***Abrupt discontinuation, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, growth inhibition, increased intracranial pressure, infants, neonates***Immunosuppression***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Edema, heart failure, hypertension***Osteoporosis***Diabetes mellitus***Crohn's disease, diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hyperthyroidism, hypothyroidism, psychosis, renal disease, seizure disorder, thyroid disease***Myasthenia gravis***Idiopathic thrombocytopenic purpura (ITP), thromboembolic disease***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Epidural administration, intravenous administration***Corticosteroid hypersensitivity***Head trauma***Skin atrophy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4278'],famotidine,"***For self-medication of pyrosis (heartburn), acid dyspepsia (acid indigestion), or sour stomach, either for prophylaxis or for symptomatic relief.***For maximum strength prevention or relief of symptoms.***For the treatment of gastroesophageal reflux disease (GERD) or esophagitis associated with gastroesophageal reflux disease (GERD).***For the treatment of peptic ulcer disease (duodenal ulcer or gastric ulcer). <br />        NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br />     ***For acute treatment.***For maintenance therapy of duodenal ulcer after the initial treatment phase has been completed.***For Helicobacter pylori (H. pylori) eradication in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�.***For pathologic GI hypersecretory conditions such as Zollinger-Ellison syndrome, systemic mastocytosis, or multiple endocrine adenoma syndrome.***For NSAID-induced ulcer prophylaxis�.***For stress gastritis prophylaxis� in critically-ill patients.***For acid aspiration prophylaxis� prior to anesthesia.","***General Information***H2-blocker hypersensitivity***Gastric cancer, GI bleeding***Infection***Hepatic disease, QT prolongation, renal disease, renal failure, renal impairment***Children, infants, neonates***Breast-feeding***Pregnancy***Tobacco smoking***Phenylketonuria***Geriatric***Vitamin B12 deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,rho(D) immune globulin (human),"***For Rh isoimmunization prophylaxis in Rh<sub>0</sub> [D]-negative patient and to ensure subsequent erythroblastosis fetalis prophylaxis in females with present and future pregnancies. <br />        NOTE: Never administer Rh0 [D] immune globulin to the neonate; administer to the mother only.<br />NOTE: The woman must not be sensitized to the Rh0 [D] antigen. The immune globulin is used to prevent the formation of anti-Rh0 [D] antibody.<br />NOTE: Rh0 [D] immune globulin prophylaxis for all obstetric indications is not indicated if either the father or the fetus is known to be Rh0 [D] negative. If the Rh status of the father and fetus are unknown, assume the fetus to be Rh0 [D] positive, and administer Rh0 [D] immune globulin to the mother.<br />NOTE: Passively acquired anti-Rh0 [D] may be detected in maternal or neonatal blood if antibody screening tests are performed after Rh0 [D] immune globulin administration. The presence of passively acquired anti-Rh0 [D] does not preclude further antepartum or postpartum prophylaxis with Rh0 [D] immune globulin. A woman who had a large fetomaternal hemorrhage late in pregnancy or after delivery may test Rh positive even though she is really Rh negative. Administer Rh0 [D] immune globulin if there is any doubt about the mother's Rh type. A screening test to detect fetal red blood cells may be helpful***For the suppression of Rh isoimmunization in Rh<sub>0</sub> [D]-negative patients who are exposed to Rh<sub>0</sub> [D]-positive red blood cells or Rh<sub>0</sub> [D]-positive blood products secondary to blood transfusion. <br />          NOTE: One prefilled syringe of HyperRHO S/D Full-Dose, of Rhophylac, or of RhoGAM has at least 1500 international units of Rh0 [D] antibody and will suppress the immunizing potential of 15 ml of Rh0 [D] positive packed red blood cells or the equivalent of 30 ml of whole blood. One 300 mcg vial of WinRho SDF has at least 1500 international units of Rh0 [D] antibody and will suppress the immunizing potential of 17 ml of Rh0 [D] positive packed red blood cells.<br />NOTE: The amount of incompatible blood transfusion should be determined by an approved assay such as the modified Kleihauer-Betke acid elution stain technique.<br />NOTE: Rh immunization can occur after exposure to less than 1 ml of Rh-positive red blood cells. <br />NOTE: Monitor patients by clinical and laboratory methods because of the risk for a hemolytic reaction.<br /***For the treatment of immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP) in non-splenectomized, Rh0 [D] antigen-positive patients. <br />        NOTE: Alternative treatments should be used in patients with hemoglobin concentrations less than 8 g/dl due to the risk of increasing the severity of anemia.<br />     ","***Anemia, hemolysis, hemolytic anemia, renal impairment, requires a specialized care setting***IgA deficiency***Anticoagulant therapy, coagulopathy, hemophilia, intramuscular administration, intravenous administration, thrombocytopenia, vitamin K deficiency***Agammaglobulinemia, hypogammaglobulinemia***Pregnancy***Children, infants, neonates***Breast-feeding***Diabetes mellitus***Geriatric, hepatitis, infection, leukemia, lymphoma, systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6922'],metronidazole,"***For the treatment of trichomoniasis.***For the treatment of bacterial vaginosis (e.g., <em>Gardnerella vaginalis</em>, <em>Mycoplasma hominis</em>�, and anaerobic bacteria such as <em>Prevotella sp.</em> and <em>Mobiluncus</em> sp.).***For the treatment of pelvic inflammatory disease (PID) in combination with other antibiotics.***For the treatment of amebiasis.***For intestinal disease (acute amebic dysentery) due to <em>Entamoeba histolytica</em>.***For hepatic abscess due to <em>Entamoeba histolytica</em>.***For amebiasis due to <em>Entamoeba polecki</em>�.***For the treatment of serious anaerobic infections (e.g., skin and skin structure infections [e.g. diabetic foot ulcer], CNS infection including meningitis and brain abscess, bone and joint infections, endocarditis, bacteremia, and gynecologic infections [e.g. endometritis, endomyometritis]).***For the treatment of acne rosacea.***For the treatment of serious anaerobic intraabdominal infections, including intraabdominal abscess, peritonitis, perforated appendicitis, necrotizing enterocolitis, and biliary tract infections such as cholangitis and cholecystitis.***For the treatment of perforated appendicitis� in pediatric patients.***For the treatment of serious anaerobic lower respiratory tract infections, including pleural empyema, pneumonia, and lung abscess.***For bacterial vaginosis prophylaxis� or trichomoniasis prophylaxis� in victims of sexual assault.***For the treatment of recurrent and persistent non-gonococcal urethritis (NGU)�.***For the treatment of dental infection�, including dentoalveolar infection� and periodontitis�.***For adolescent periodontitis� or adult chronic periodontitis� after scaling and root planing.***For adolescent aggressive periodontitis� or adult refractory chronic periodontitis� in combination with amoxicillin after scaling and root planing.***For adult refractory chronic periodontitis� in combination with ciprofloxacin after scaling and root planing in �-lactam allergic patients.***For the treatment of guinea worm disease� (dracunculiasis�).***For surgical infection prophylaxis, including bowel preparation� in patients undergoing colorectal surgery.***For bowel preparation� in patients undergoing colorectal surgery.***For the treatment of antibiotic-associated pseudomembranous colitis� due to <em>Clostridium difficile</em>.***For the treatment of antibiotic-associated pseudomembranous colitis� due to <em>Clostridium difficile </em>in adults.***For the treatment of antibiotic-associated pseudomembranous colitis� due to <em>Clostridium difficile i</em>n pediatric patients.***For the treatment of Crohn's disease� associated with colonic and/or perianal involvement.***For Helicobacter pylori (H. pylori) eradication� in the treatment of patients with duodenal ulcer� disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />  NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.  The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: Metronidazole-resistant strains of H. pylori are prevalent in the US (approximately 25%), and primarily occur in patients previously treated with metronidazole. Therapy with at least two antimicrobials is necessary to limit the development of metronidazole resistance. Patients who have persistence of H. pylori following therapy may have metronidazole-resistant H. pylori infection.<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Prevpac monograph).  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60% to 90% of patients.***For the treatment of pruritus� secondary to cholestasis.***For the treatment of giardiasis�.","***Hematological disease***Dialysis, renal failure, renal impairment***Bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***New primary malignancy***Pregnancy***Breast-feeding***Alcoholism, ethanol ingestion, ethanol intoxication***Fungal infection***Crohn's disease***Ocular exposure***Geriatric***Sexually transmitted disease***Hepatic disease, hepatic encephalopathy***Cockayne syndrome***Corticosteroid therapy, edema, sodium restriction***Laboratory test interference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,C1 esterase inhibitor (human),"***For routine angioedema prophylaxis in patients with hereditary angioedema.***For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE). <br />        NOTE: Advise patients who may self administer Berinert for acute laryngeal HAE attacks to immediately seek medical attention in an appropriate healthcare facility after Berinert receipt because of the potential for airway obstruction.<br />     ","***General Information***Central venous catheter placement, obesity, thromboembolic disease***Viral infection***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,meperidine hydrochloride,"***For the treatment of moderate pain to severe pain. <br />        NOTE: Chronic use of meperidine is not recommended due to an increased risk of neurotoxicity (e.g., seizures) secondary to accumulation of the meperidine metabolite, normeperidine.<br />NOTE: Pain severity and patient response should guide dosage***For obstetric analgesia during labor and delivery.***For preoperative sedation induction.***For general anesthesia maintenance. <br />        NOTE: Dosage needed will depend on premedication and anesthesia utilized, nature and duration of procedure, and patient characteristics.<br />     ***For obstetric anesthesia�.***For the treatment of acute, severe headache� or migraine�.***For the treatment of shaking chills� induced by intravenous infusions of amphotericin B or for postoperative shivering�.","***Opiate agonist hypersensitivity***MAOI therapy***Acute abdomen, constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Biliary tract disease***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, status asthmaticus***Alcoholism, depression, substance abuse***Head trauma, increased intracranial pressure***Glaucoma***CNS depression, hepatic disease, renal impairment, seizure disorder, seizures***Angina, atrial flutter, cardiac arrhythmias, cardiac disease, dehydration, heart failure, hypotension, hypovolemia, pheochromocytoma***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, sickle cell disease, urinary retention***Geriatric***Children, infants, intramuscular administration, neonates***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Driving or operating machinery***Abrupt discontinuation***Anticoagulant therapy, coagulopathy, epidural administration, infection, intrathecal administration, intravenous administration, thrombocytopenia***Adrenal insufficiency, hypothyroidism, myxedema***Accidental exposure, potential for overdose or poisoning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,choriogonadotropin alfa,"***For the treatment of male infants and children with prepubertal cryptorchidism not caused by anatomical obstruction. <br />        NOTE: HCG appears to be more effective at inducing testicular descent in those infants and children with palpable testes in the high scrotal, prescrotal, or inguinal regions. Intra-abdominal testes are especially refractory to HCG treatment. While hormonal therapy is traditionally instituted after the age of 4 years, there are several studies that include male children of younger ages, and there is some evidence that treatment prior to age 2 years may be beneficial in terms of long-term outcomes. Consult specialized references for the most current recommendations.<br />     ***For the treatment of select cases of hypogonadotropic hypogonadism.***For the routine treatment of hypogonadotropic hypogonadism in adult and adolescent males.***For the stimulation of spermatogenesis in males with primary or secondary hypogonadotropic hypogonadism and resultant oligospermia. <br />          NOTE: Pretreatment with human chorionic gonadotropin (HCG) is required prior to combination treatment with menotropins or follitropin. Various dosage regimens have been advocated.<br />       ***For adjunctive treatment of anovulation in females with infertility not due to primary ovarian failure, including in women undergoing assisted reproductive technology (ART). <br />        NOTE: HCG must be withheld if there is an excessive ovarian response, as evidenced by abnormally enlarged ovaries, multiple follicular development, or excessive estradiol production. Consult specialized references.<br />     ***For induction of ovulation in females treated with clomiphene who have an appropriate follicular response but a failure to ovulate.***For induction of ovulation following treatment with menotropins or follitropin in females with infertility.***For luteal phase support� of infertile female patients with hypogonadotropic hypogonadism after they have completed a typical ovulation induction protocol with FSH/LH (menotropins).***For induction of final oocyte maturation in preparation for oocyte harvest in females undergoing IVF or other ART procedures following follitropin treatment.***For the treatment of Kaposi's sarcoma�.","***Hamster protein hypersensitivity***Benzyl alcohol hypersensitivity, neonates***Children, precocious puberty***Asthma, cardiac disease, migraine, renal disease, seizure disorder, thromboembolic disease, thrombophlebitis***Dysfunctional uterine bleeding, endometrial cancer, endometriosis, neoplastic disease, ovarian cancer, prostate cancer, uterine leiomyomata***Adrenal insufficiency, ovarian failure, pituitary adenoma, thyroid disease***Ascites, ovarian cyst, polycystic ovary syndrome***Geriatric***Pregnancy***Breast-feeding***Obesity***Ethanol intoxication, tobacco smoking***Hepatic disease, renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,erythromycin lactobionate,"***For the treatment of acne vulgaris.***For mild to moderately severe lower respiratory tract infections (e.g., pneumonia, bronchitis) caused by susceptible organisms.***For the treatment of Legionnaire's disease (caused by <em>Legionella pneumophila</em>).***For the treatment of mild to moderately severe upper respiratory tract infections (e.g., pharyngitis, tonsillitis), including group A beta-hemolytic streptococcal (GAS) pharyngitis (primary rheumatic fever prophylaxis).***For upper respiratory tract infections and GAS pharyngitis (primary rheumatic fever prophylaxis).***For prevention of recurrent attacks of rheumatic fever (i.e., secondary rheumatic fever prophylaxis).***For the treatment of listeriosis.***For the treatment of chlamydia infection and non-gonococcal urethritis.***For the treatment of non-gonococcal urethritis (NGU) or chlamydial infections including urogenital infections (urethritis, cervicitis, proctitis) and infant pneumonia.***For the treatment of chlamydial conjunctivitis or ophthalmia neonatorum caused by <em>Chlamydia trachomatis</em>.***For the treatment of lymphogranuloma venereum� caused by <em>Chlamydia trachomatis</em>.***For the prevention of ophthalmia neonatorum (i.e., ophthalmia neonatorum prophylaxis) due to <em>Neisseria gonorrhoeae</em><em> </em>or<em> Chlamydia trachomatis</em>.***For the treatment of pneumonia caused by <em>Chlamydia trachomatis</em> in neonates and infants.***For the adjunctive treatment of diphtheria to prevent establishment of carrier state and for <em>Corynebacterium diphtheriae</em> bacterial colonization eradication.***For the treatment of close contacts of patients with diphtheria (i.e., diphtheria prophylaxis�).***For the treatment of acute pelvic inflammatory disease (PID).***For acute pelvic inflammatory disease (PID) caused by <em>Neisseria gonorrhoeae</em>.***For the treatment of pertussis (whooping cough) caused by <em>Bordetella pertussis</em> or for postexposure pertussis prophylaxis. <br />  NOTE: For postexposure prophylaxis, administer to close contacts within 3 weeks of exposure, especially in high-risk patients (e.g., women in third trimester, infants &lt; 12 months).<br /***For the treatment of primary syphilis (caused by <em>Treponema pallidum</em>) in penicillin-allergic, nonpregnant patients.***For bowel preparation in combination with neomycin in patients undergoing colorectal surgery.***For the treatment of superficial ophthalmic infection involving the conjunctiva and/or cornea.***For the treatment of chancroid� due to <em>Haemophilus ducreyi</em>.***For the treatment of disseminated gonorrhea�. <br />  NOTE: Erythromycin is not recommended in adults, adolescents, or children 8 years and older or in patients weighing 45 kg or more due to resistance of N. gonorrheae against erythromycin in the United States. Single-dose azithromycin in combination with ceftriaxone is the preferred therapy in these populations. <br /***For the facilitation of gastric emptying in patients with delayed gastrointestinal motility  (e.g., gastroparesis�).***For the treatment of idiopathic or postsurgical gastroparesis� or diabetic gastroparesis�.***For the facilitation of gastric emptying� in patients with feeding intolerance�.***For the treatment of early Lyme disease�.***For the treatment of skin and skin structure infections including impetigo and burn wound infection�.***For the treatment of erythrasma (caused by <em>Corynebacterium minutissimum</em>).***For the treatment of tetanus� (caused by <em>Clostridium tetani</em>) when penicillin or tetracycline is contraindicated or not tolerated.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of cholera�.***For the treatment of bartonellosis� (<em>Bartonella bacilliformis)</em> and other <em>Bartonella sp.</em>� infections in HIV-infected patients.***For the treatment of angiomatosis infections�, peliosis hepatis�, bacteremia�, and osteomyelitis� caused by <em>Bartonella sp.</em>�.***For long term suppression� of infections caused by <em>Bartonella sp.</em>� in HIV-infected patients with relapse or reinfections with < 200 CD4 cells/mm3.***For pneumococcal prophylaxis� in penicillin-allergic patients with sickle cell disease�.***For the treatment of infantile acne�.***For the oral treatment of infantile acne.***For the topical treatment of infantile acne.***Formoterol***Formoterol; Mometasone","***General Information***Viral infection***Macrolide hypersensitivity***Hepatic disease***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Hearing impairment***Benzyl alcohol hypersensitivity, neonates***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Seizure disorder***Myasthenia gravis***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10379'],testosterone,***For the treatment of delayed puberty in males.***For palliative treatment of breast cancer that is inoperable in women.***For the treatment of postpubertal cryptorchidism�.***For the treatment of microphallus�.***For the treatment of anemia� in patients with chronic renal failure.***For female-to-male gender change (trans-sexualism�).***For the treatment of lichen sclerosus�.***For the treatment of AIDS-associated wasting syndrome�.,"***Benzoic acid hypersensitivity, benzyl alcohol hypersensitivity, polyoxyethylated castor oil hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis, soya lecithin hypersensitivity***Magnetic resonance imaging (MRI)***Intramuscular administration, intravenous administration***Breast cancer, geriatric, prostate cancer, prostatic hypertrophy***Cardiac disease, coronary artery disease, heart failure, hepatic disease, myocardial infarction, renal disease, stroke***Obesity, pulmonary disease***Polycythemia***Accidental exposure, females***Contraception requirements, labor, obstetric delivery, pregnancy, reproductive risk***Breast-feeding***Diabetes mellitus***Hypercalcemia***Pulmonary oil microembolism***Nasal polyps, nasal septal perforation, nasal surgery, nasal trauma, rhinorrhea, Sjogren's syndrome***Children, infants, neonates***Substance abuse***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,phendimetrazine tartrate,***For the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. <br />        NOTE: Recommended for patients with an initial body mass index (BMI) of 30 kg/m2 or higher and who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone.<br />     ***Formoterol***Formoterol; Mometasone,"***General Information***Anxiety, mania, psychosis***Hyperthyroidism, thyroid disease***Glaucoma***Cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypertension, stroke, valvular heart disease***Pulmonary hypertension***Abrupt discontinuation, depression***Alcoholism, anorexia nervosa, substance abuse, suicidal ideation***Children, infants, neonates***Pregnancy***Breast-feeding***Diabetes mellitus***Driving or operating machinery, geriatric***Surgery***MAOI therapy***Renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],desogestrel/ethinyl estradiol,"***For routine contraception.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�,  abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Edema, hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5640']['8896'],ibuprofen/pseudoephedrine hydrochloride,"***For the temporary relief of nasal congestion, sinus congestion, fever, sore throat, body aches (mild pain), and/or headache pain caused by allergies (hay fever), the common cold or flu, and sinusitis.***Formoterol***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, peptic ulcer disease, tobacco smoking, ulcerative colitis***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, heart failure, hypertension, MAOI therapy, myocardial infarction, stroke, substance abuse, tachycardia***Coronary artery bypass graft surgery (CABG)***Closed-angle glaucoma, diabetes mellitus, hepatic disease, hyperthyroidism, jaundice, prostatic hypertrophy, renal disease, renal failure, renal impairment, systemic lupus erythematosus (SLE), urinary retention***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, thrombocytopenia***Anemia***Intramuscular injections***Dental disease, dental work***Children, infants, varicella***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['475230'],degarelix,***For the treatment of advanced prostate cancer. <br />  NOTE: Two strengths are available. The 120 mg strength (used for the initial dose) contains 120 mg in 3 mL once reconstituted. The 80 mg strength (used for the maintenance dose) contains 80 mg in 4 mL once reconstituted. Double check the vial strength to ensure accuracy prior to administering.<br /,"***General Information***Children***Mannitol hypersensitivity***Intravenous administration***Hepatic disease***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Renal disease, renal failure, renal impairment***Osteoporosis***Pregnancy***Angioedema, urticaria***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dihydroergotamine mesylate,"***For the acute treatment of migraine with or without aura and the acute treatment of cluster headache episodes.***For orthostatic hypotension�.***For the treatment of orthostatic hypotension�.***For prevention of orthostatic hypotension (i.e., orthostatic hypotension prophylaxis�) associated with spinal or epidural anesthesia.","***Ergot alkaloid hypersensitivity***Basilar/hemiplegic migraine, stroke***Angina, arteriosclerosis, cardiac disease, coronary artery disease, diabetes mellitus, geriatric, hypercholesterolemia, hypertension, myocardial infarction, obesity, peripheral vascular disease, peripheral vasoconstriction or ischemia, Raynaud's phenomenon, sepsis, thromboangiitis obliterans (Buerger's disease), thrombophlebitis, tobacco smoking***Biliary tract disease, cholestasis, hepatic disease***Renal disease, renal failure, renal impairment***Eclampsia, labor, obstetric delivery, preeclampsia, pregnancy***Breast-feeding***Intramuscular administration***Children, infants***Pulmonary disease, pulmonary fibrosis, retroperitoneal fibrosis, valvular heart disease***Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,butoconazole nitrate,***For the treatment of vulvovaginal candidiasis (VVC).,"***Onychomycosis***Pregnancy***Breast-feeding***Azole antifungals hypersensitivity***Contraceptive devices, menstruation***Abdominal pain, diabetes mellitus, fever, human immunodeficiency virus (HIV) infection, immunosuppression, vaginal discharge***Children, infants, neonates***Ocular exposure, ophthalmic administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['74667'],zaleplon,***For the short-term (generally 7 to 10 days) treatment of insomnia.,"***Angioedema, salicylate hypersensitivity, tartrazine dye hypersensitivity***Hepatic disease***Asian patients***Depression***Asthma, chronic obstructive pulmonary disease (COPD), respiratory depression, respiratory insufficiency, sleep apnea***Substance abuse***Behavioral changes, CNS depression, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Geriatric***Pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['376', '1040019']",corticotropin,"***For the treatment of infantile spasms.***For the treatment of acute exacerbations of multiple sclerosis.***For the adjunctive treatment of an acute episode or exacerbation of psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), and ankylosing spondylitis.***For the treatment of symptomatic sarcoidosis.***For the treatment of ophthalmic diseases, such as keratitis, iritis, iridocyclitis, diffuse posterior uveitis, choroiditis, optic neuritis, chorioretinitis, and anterior segment inflammation.***For the induction of diuresis or remission of proteinuria in the nephrotic syndrome.***For the treatment of dermatologic and allergic states, including severe erythema multiforme, Stevens-Johnson syndrome, or serum sickness, or for collagen diseases such as systemic lupus erythematosus (SLE) or systemic dermatomyositis (polymyositis).","***Corticosteroid hypersensitivity, porcine protein hypersensitivity***Intravenous administration***Fungal infection, herpes infection, infection, ocular infection, tuberculosis***Vaccination***Cardiac disease, heart failure, hypertension***Diverticulitis, peptic ulcer disease, ulcerative colitis***Scleroderma, surgery***Adrenal insufficiency, Cushing's syndrome, hypercortisolism, hypothalamic-pituitary-adrenal (HPA) suppression***Myasthenia gravis, psychosis, seizure disorder***Diabetes mellitus, hypothyroidism***Hypernatremia, hypokalemia, renal impairment***Thromboembolic disease***Geriatric, osteoporosis, postmenopausal females***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluticasone propionate,"***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses, including the treatment of alopecia areata, discoid lupus erythematosus, generalized exfoliative dermatitis, cutaneous lichen planus, lichen simplex chronicus, lichen striatus, nodular prurigo, pompholyx (dyshidrosis), pemphigus, polymorphous light eruption, psoriasis, seborrheic dermatitis, severe contact dermatitis, severe Rhus dermatitis (due to plants like poison ivy), and xerosis.***For the treatment of eczema, including atopic dermatitis.***For the management of symptoms associated with seasonal or perennial allergic rhinitis, including allergic conjunctivitis.***For the management of nasal symptoms associated with vasomotor rhinitis (perennial nonallergic rhinitis).***For the maintenance treatment of asthma.***For the treatment of nasal polyps.***For exercise-induced bronchospasm prophylaxis�.***Formaldehyde hypersensitivit","***General Information***Corticosteroid hypersensitivity, milk protein hypersensitivity***Acute bronchospasm, status asthmaticus***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion, surgery***Diabetes mellitus***Nasal septal perforation, nasal surgery, nasal trauma***Fungal infection, herpes infection, infection, measles, tuberculosis, varicella, viral infection***Malnutrition, osteoporosis, tobacco smoking***Geriatric***Hepatic disease***Acne rosacea, acne vulgaris, perioral dermatitis, peripheral vascular disease, skin atrophy***Cataracts, glaucoma, increased intraocular pressure, ocular exposure***Formaldehyde hypersensitivity***Children, growth inhibition, increased intracranial pressure, infants***Pregnancy***Breast-feeding***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['402316'],miglustat,***For the treatment of mild to moderate type 1 Gaucher disease in patients for whom enzyme replacement therapy is not an option.,"***General Information***Renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Infertility, male-mediated teratogenicity***Peripheral neuropathy***Dehydration, diarrhea, electrolyte imbalance, tremor***Geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fexofenadine hydrochloride,***For the treatment of allergic rhinitis (hay fever).***For the treatment of chronic idiopathic urticaria.,"***Terfenadine hypersensitivity***Phenylketonuria***Renal disease, renal failure, renal impairment***Geriatric***Pregnancy***Breast-feeding***Driving or operating machinery***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cromolyn sodium,"***For use as an adjunct in the management of patients with asthma.***For exercise-induced bronchospasm prophylaxis or the prevention of bronchospasm induced by other known precipitating factors.***For treatment of the nasal symptoms associated with allergic rhinitis including runny/itching nose, sneezing, and allergic nasal congestion; and for allergic rhinitis prophylaxis.***For the treatment of allergic ocular disorders such as allergic conjunctivitis, allergic keratoconjunctivitis, giant papillary conjunctivitis (GPC), vernal keratitis, vernal keratoconjunctivitis.***For the treatment of systemic mastocytosis.***For the treatment of chronic inflammatory bowel disease� (e.g., ulcerative colitis�), for initial suppression and for maintenance therapy to prevent relapse.***For the prevention of symptoms associated with food allergy�.","***General Information***Acute bronchospasm, status asthmaticus***Cardiac arrhythmias, cardiac disease, coronary artery disease***Contact lenses***Lactase deficiency***Hepatic disease, renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['73494'],telmisartan,"***For the treatment of hypertension, either alone or in combination with other antihypertensive agents.***For stroke prophylaxis, myocardial infarction prophylaxis, and reduction of cardiovascular mortality in adults 55 years of age and older who are at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.***For the treatment of proteinuria� or diabetic nephropathy�.","***Hypotension, hypovolemia***Heart failure, renal artery stenosis***Hepatic disease***ACE-inhibitor induced angioedema, angioedema***Hyperkalemia***Black patients***Pregnancy***Breast-feeding***Children***Surgery***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydroxyprogesterone caproate,"***For preterm delivery prophylaxis in females with a singleton pregnancy who have a history of singleton spontaneous preterm birth.***For the treatment of inoperable, recurrent, and metastatic endometrial cancer.***For the treatment of amenorrhea (primary or secondary) or for dysfunctional uterine bleeding due to hormonal imbalance in the absence of organic pathology.","***Intravenous administration***Benzyl alcohol hypersensitivity, polyoxyethylated castor oil hypersensitivity***Thromboembolic disease, thromboembolism, thrombophlebitis***Breast cancer, cervical cancer, uterine cancer, vaginal cancer***Vaginal bleeding***Cardiac disease, hypertension, preeclampsia***Diabetes mellitus***Depression, migraine, seizure disorder***Asthma, renal disease***Labor, pregnancy***Cholestasis, hepatic disease, hepatocellular cancer, jaundice***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6218'],lactulose,"***For the treatment of hepatic encephalopathy (portal-systemic encephalopathy, PSE).***For the treatment of constipation, including constipation related to barium retention.",***Galactose-free diet***Surgery***Diabetes mellitus***Geriatric***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6135'],ketoconazole,"***For the treatment of chromomycosis in patients who have failed or who are intolerant to other therapies. <br />  NOTE: Due to the potential for serious adverse events (i.e., fatal hepatotoxicity, adrenal insufficiency, harmful drug interactions), oral ketoconazole should only be used to treat serious fungal infections when no other antifungal therapies are available. <br /***For the treatment of blastomycosis, coccidioidomycosis, histoplasmosis, and paracoccidioidomycosis in patients who have failed or who are intolerant to other therapies. <br />  NOTE: Due to the potential for serious adverse events (i.e., fatal hepatotoxicity, adrenal insufficiency, harmful drug interactions), oral ketoconazole should only be used to treat serious fungal infections when no other antifungal therapies are available. <br /***For treatment of mucocutaneous candidiasis.***For the treatment of dandruff, to control flaking, scaling, or itching.***For the treatment of seborrheic dermatitis.***For the treatment of tinea corporis or tinea cruris.***For the treatment of tinea pedis.***For the treatment of tinea versicolor.***For the treatment of advanced prostate cancer�.***Formoterol***Formoterol; Mometasone","***Achlorhydria, human immunodeficiency virus (HIV) infection, hypochlorhydria***Ethanol ingestion, hepatic disease, hepatitis, hepatotoxicity***Bradycardia, cardiac arrhythmias, diabetes mellitus, females, heart failure, hypocalcemia, hypokalemia, hypomagnesemia, ketoconazole coadministration with other drugs, long QT syndrome, QT prolongation, torsade de pointes, ventricular arrhythmias***Adrenal insufficiency, surgery***Azole antifungals hypersensitivity***Pregnancy***Breast-feeding***Ocular exposure***Tobacco smoking***Driving or operating machinery***Geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Single-Dose Packets) (azithromycin,"***For the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis in patients with COPD caused by susceptible strains of <em>Haemophilus influenza</em>, <em>Moraxella catarrhalis</em>, or <em>Streptococcus pneumoniae</em>.***For the treatment of acute otitis media. <br />        NOTE: Various dosing regimens are FDA-approved. Because macrolides, including azithromycin, have limited efficacy against both H. influenzae and S. pneumoniae, these agents are not included in the preferred or alternative options recommended by the American Academy of Pediatrics (AAP) in the treatment guidelines for acute otitis media.<br />     ***For the treatment of bacterial conjunctivitis caused by susceptible strains of <em>CDC coryneform group G, H. influenzae, S. aureus, S. mitis group, and S. pneumoniae</em>.***For the treatment of community-acquired pneumonia (CAP).***For the treatment of uncomplicated skin and skin structure infections caused by <em>S. aureus, S. pyogenes</em> or <em>S. agalactiae</em>.***For the treatment of pelvic inflammatory disease (PID).***For the treatment of gonorrhea.***For the treatment of uncomplicated gonorrhea of the cervix, urethra, rectum, and pharynx.***For the treatment of disseminated (e.g., bacteremia, arthritis) gonococcal infection�, including meningitis� and endocarditis�.***For the treatment of gonococcal conjunctivitis�.***For the treatment of chancroid due to <em>Haemophilus ducreyi</em>.***For the treatment of Mycobacterium avium complex infection (MAC).***For Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients.***For primary Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients.***For secondary Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients with disseminated disease, after treatment of the acute illness.***For the treatment of acute bacterial sinusitis. <br />        NOTE: Due to the high rate of resistance among S. pneumoniae isolates, macrolides are not recommended as empiric therapy. Amoxicillin/clavulanate is recommended as the first-line empiric therapy.<br />     ***For the treatment of non-gonococcal urethiritis (NGU) and chlamydia infection, including infant pneumonia�. <br />        NOTE: For ophthalmia neonatorum caused by C. trachomatis, see ophthalmia neonatorum indication.<br />     ***For the treatment of non-gonococcal urethritis (NGU) and other urogenital infections (e.g., cervicitis, urethritis, proctitis).***For the treatment of pneumonia caused by <em>Chlamydia trachomatis</em> in neonates and infants�.***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis (primary rheumatic fever prophylaxis�) and tonsillitis. <br />        NOTE: For secondary prophylaxis of rheumatic fever, the American Heart Association (AHA) recommends prophylaxis for 10 years or until age 40 (whichever is longer) for patients who have experienced rheumatic fever with carditis and have residual heart disease (persistent valvular disease). For patients who have experienced rheumatic fever with carditis, but have no residual heart disease, the AHA recommends prophylaxis for 10 years or until age 21 (whichever is longer). For patients who have experienced rheumatic fever without carditis, the AHA recommends prophylaxis for 5 years or until age 21 (whichever is longer).<br />     ***For the treatment of primary, secondary, or early latent syphilis� (caused by <em>Treponema pallidum</em>) in nonpregnant, penicillin-allergic patients. <br />        NOTE: A Jarisch-Herxheimer reaction may occur within the first 24 hours of therapy.<br />NOTE: While the HIV guidelines recommend non-penicillin alternatives for the treatment of syphilis in HIV-infected patients, their efficacy has not been evaluated and should only be used with close clinical and serologic monitoring***For the treatment of chronic prostatitis� due to <em>Ureaplasma urealyticum</em>.***For the treatment of Legionnaire's disease�.***For the treatment of shigellosis� diarrhea.***For the treatment of shigellosis� diarrhea in non-immunocompromised patients.***For the treatment of shigellosis� in HIV-infected patients.***For the treatment of mild-to-moderate campylobacteriosis� in HIV-infected patients.***For the treatment of toxoplasmosis�, including toxoplasmic encephalitis�, in HIV-positive patients.***For the treatment of early Lyme disease�.***For the treatment of early Lyme disease� in adults.***For the treatment of early Lyme disease� in children and adolescents.***For the treatment of dental infection� or dentoalveolar infection�, including periodontitis�, acute dental abscess (apical)�, and dental abscess (periapical)�.***For adult chronic periodontitis� after scaling and root planing.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage in patients with beta-lactam allergy.***For bacterial endocarditis prophylaxis�.***For the treatment of babesiosis� in combination with atovaquone.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For use in improving pulmonary function in cystic fibrosis� patients chronically infected with <em>Pseudomonas aeruginosa</em>.***For the treatment of mild scrub typhus� due to Orientia tsutsugamushi� (formerly Rickettsia tsutsugamushi�).***For the treatment of pertussis (whooping cough)� caused by <em>Bordetella pertussis</em> or for postexposure pertussis prophylaxis�. <br />  NOTE: For postexposure prophylaxis, administer to close contacts within 3 weeks of exposure, especially in high-risk patients (e.g., pregnant women in third trimester, infants younger than 12 months). Symptomatic contacts (coughing) should be treated as if they have pertussis.<br /***For the treatment of cholera�.***For the treatment of uncomplicated typhoid fever�.***For the treatment of bartonellosis� (<em>Bartonella bacilliformis)</em> and other <em>Bartonella </em>sp.� infections in HIV-infected patients.***For the treatment of angiomatosis infections�, peliosis hepatis�, bacteremia�, and osteomyelitis� caused by <em>Bartonella </em>sp.�.***For long term suppression� of infections caused by <em>Bartonella </em>sp.� in HIV-infected patients with relapse or reinfection and with CD4 count less than 200 cells/mm3.***For the treatment of ophthalmia neonatorum� due to <em>C. trachomatis</em>.***For the treatment of lymphogranuloma venereum� caused by <em>C. trachomatis</em>.***For chlamydial infection prophylaxis� and gonorrhea prophylaxis� in victims of sexual assault.***For the treatment of moderate or severe traveler's diarrhea�.***Formoterol***Formoterol; Mometasone","***General Information***Viral infection***Macrolide hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis***Hepatic disease, hepatitis, jaundice***Renal failure, renal impairment***Colitis, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Geriatric***Pregnancy***Breast-feeding***Infants, neonates***Sunlight (UV) exposure***Sodium restriction***Contact lenses***Myasthenia gravis***Sexually transmitted disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5781'],indomethacin,"***For the treatment of mild pain, moderate pain, or severe pain, such as arthralgia, myalgia, bursitis, or tendinitis.***For the treatment of mild to moderate acute pain.***For the treatment of moderate to severe pain.***For treatment of acute gouty arthritis. <br />        NOTE: Sustained-release capsules should not be used for this condition.<br />     ***For treatment of a hemodynamically significant patent ductus arteriosus (PDA) in premature infants.***For treatment of moderate to severe rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA)�, osteoarthritis, or ankylosing spondylitis. <br />        NOTE: If minor adverse effects develop as the dosage is increased, rapidly reduce the dose to a tolerated dose and closely observe the patient. If severe adverse reactions occur, stop indomethacin.<br />     ***For treatment of idiopathic or viral pericarditis�. <br />        NOTE: Use of NSAIDs are contraindicated in pericarditis after myocardial infarction; NSAIDs retard myocardial scar formation and the incidence of rupture may increase.<br />     ***For treatment of headache�.***For prophylaxis of chronic cluster headache�.***For the prevention of heterotopic ossification�.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Aortic coarctation, bleeding, congenital heart disease, infection, intracranial bleeding, necrotizing enterocolitis, neonates***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, hemorrhoids, peptic ulcer disease, tobacco smoking, ulcerative colitis***Bone marrow suppression, coagulopathy, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Visual disturbance***Hepatic disease, jaundice***Dental disease, dental work***Dehydration, hyperkalemia, renal disease, renal failure, renal impairment***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hypertension, myocardial infarction, peripheral vascular disease, stroke, thromboembolism***Coronary artery bypass graft surgery (CABG)***Depression, driving or operating machinery, headache, Parkinson's disease, seizure disorder***Labor, pregnancy***Breast-feeding***Geriatric***Children, infants***Intramuscular injections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,levothyroxine sodium,"***For the treatment of primary hypothyroidism with or without goiter due to diminished or absent thyroid function caused by functional deficiency, primary atrophy, partial or complete absence of the thyroid gland, or from the effects of surgery, radiation, or an antithyroid agent, and for the treatment of secondary (pituitary) or tertiary (hypothalamic) hypothyroidism.***For the treatment of myxedema coma.***For thyroid stimulating hormone (TSH) suppression in thyroid nodules, euthyroid goiters, and well-differentiated thyroid cancer.***Formoterol; Mometasone","***General Information***Adrenal insufficiency***Hypopituitarism***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, coronary artery disease, hypertension, myocardial infarction***Diabetes mellitus***Obesity treatment***Infertility***Osteoporosis***Pregnancy***Breast-feeding***Dysphagia***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cromolyn sodium,"***For use as an adjunct in the management of patients with asthma.***For exercise-induced bronchospasm prophylaxis or the prevention of bronchospasm induced by other known precipitating factors.***For treatment of the nasal symptoms associated with allergic rhinitis including runny/itching nose, sneezing, and allergic nasal congestion; and for allergic rhinitis prophylaxis.***For the treatment of allergic ocular disorders such as allergic conjunctivitis, allergic keratoconjunctivitis, giant papillary conjunctivitis (GPC), vernal keratitis, vernal keratoconjunctivitis.***For the treatment of systemic mastocytosis.***For the treatment of chronic inflammatory bowel disease� (e.g., ulcerative colitis�), for initial suppression and for maintenance therapy to prevent relapse.***For the prevention of symptoms associated with food allergy�.","***General Information***Acute bronchospasm, status asthmaticus***Cardiac arrhythmias, cardiac disease, coronary artery disease***Contact lenses***Lactase deficiency***Hepatic disease, renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ammonium lactate,***For the treatment of ichthyosis vulgaris.***For the treatment of xerosis.,"***Skin abrasion, sunlight (UV) exposure***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['723', '1297882']",amoxicillin,"***For the treatment of upper respiratory tract infections (e.g., pharyngitis, tonsillitis).***For the treatment of tonsillitis and/or pharyngitis (rheumatic fever prophylaxis) secondary to <em>Streptococcus pyogenes</em>.***For the treatment of acute otitis media. <br />  NOTE: The American Academy of Pediatrics (AAP) does not recommend doses less than 80 mg/kg/day PO for the treatment of otitis media. Patients failing to respond within 48 to 72 hours should be re-evaluated by a healthcare provider. Amoxicillin; clavulanate is the preferred therapy for children who have received amoxicillin within the past 30 days or who have purulent conjunctivitis or a history of recurrent acute otitis media unresponsive to amoxicillin.<br /***For the treatment of skin and skin structure infections (e.g., cellulitis).***For mild to moderate infections caused by highly susceptible organisms.***For severe infections or infections caused by less susceptible organisms.***For the treatment of lower respiratory tract infections (e.g., pneumonia, community-acquired pneumonia, bronchitis).***For the treatment of urinary tract infection (UTI) including cystitis.***For mild to moderate infections caused by highly susceptible organisms.***For severe infections or infections caused by less susceptible organisms.***For the treatment of Lyme disease�.***For patients with erythema migrans�.***For early-stage Lyme disease�. <br />          NOTE: Used as an alternative to tetracycline or penicillin V in children &lt; 9 years of age or as an alternative to tetracycline in pregnant or lactating women.<br />       ***For Lyme arthritis�.***For the treatment of pregnant women with chlamydia infection� including cervicitis� and urethritis�.***For the treatment of dental infection�, including dentoalveolar infection�.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage.***For adolescent aggressive periodontitis� or adult refractory chronic periodontitis� in combination with metronidazole after scaling and root planing.***For bacterial endocarditis prophylaxis�.***For the treatment of typhoid fever� due to <em>Salmonella typhii</em>.***For Helicobacter pylori (H. pylori) eradication� in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />  NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.  The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: Resistance rates of H. pylori to metronidazole in the US are 25%; whereas amoxicillin resistance is rare.  Resistance rates for H. pylori to clarithromycin in the US are 13%.<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Prevpac monograph)  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60% to 90% of patients.***For treatment of cutaneous anthrax� infection due to exposure to <em>Bacillus anthracis</em> or as oral follow-up therapy for severe anthrax.***For anthrax prophylaxis� after exposure to <em>Bacillus anthracis</em>.","***General Information***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, eczema, penicillin hypersensitivity, urticaria***Dialysis, renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Children, infants, neonates, premature neonates***Geriatric***Pregnancy***Breast-feeding***Phenylketonuria***Mononucleosis***Sexually transmitted disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['14584'],etonogestrel,"***For routine contraception. <br />        NOTE: Safety and efficacy are expected to be the same for adolescents post-menarche as for women &gt; 18 years.<br />NOTE: Etonogestrel has not been studied in women who weigh &gt; 130% of their ideal body weight.<br />NOTE: If deviating from the recommended time of insertion, rule out pregnancy and instruct the patient to use back-up non-hormonal contraception for 7 days after implant insertion.<br />NOTE: Etonogestrel implants can be removed at any time***For the treatment of endometriosis-associated pain�.","***General Information***Ectopic pregnancy, pregnancy***Breast-feeding***Cervical cancer, ovarian cyst, vaginal bleeding***Breast cancer***Human immunodeficiency virus (HIV) infection***Diabetes mellitus***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice***Hyperlipidemia***Cerebrovascular disease, migraine, myocardial infarction, stroke, surgery, thromboembolic disease, thrombophlebitis, tobacco smoking***Coronary artery disease, edema, heart failure, hypertension, renal disease, renal failure, renal impairment***Depression***Seizure disorder***Contact lenses***Obesity***Geriatric***Children, infants, neonates***Intramuscular administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['83947'],tazarotene,"***For the treatment of stable plaque psoriasis. <br />  NOTE: According to the American Academy of Dermatology (AAD), tazarotene is best used in combination with a topical corticosteroid for the treatment of psoriasis. Combination therapy may produce a synergistic effect, increase duration of treatment benefit and length of remission, and potentially decrease steroid-induced atrophy.<br /***For the topical treatment of acne vulgaris.***For adjunctive treatment of fine facial wrinkles and facial mottled hyperpigmentation (i.e., 'liver spots') and hypopigmentation associated with photoaging.","***General Information***Pregnancy***Breast-feeding***Children, infants, neonates***Eczema***Retinoid hypersensitivity***Benzyl alcohol hypersensitivity***Skin cancer, skin photosensitivity disorder, sunburn, sunlight (UV) exposure***Accidental exposure, occlusive dressing, ocular exposure***Contraception requirements, females, pregnancy testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,somatropin (rDNA origin),"***For the treatment of growth hormone deficiency, growth failure, or short stature.***For replacement therapy in adults with growth hormone deficiency (GHD) for either childhood onset (secondary to congenital, genetic, acquired, or idiopathic causes) or adult onset (endogenous or associated with multiple hormone deficiencies, i.e., hypopituitarism, as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma).***For the long-term treatment of growth failure in children who have growth hormone deficiency due to inadequate growth hormone secretion.***For growth failure due to Prader-Willi syndrome.***For the long-term treatment of growth failure in children born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 to 4.***For growth failure associated with chronic renal failure up to the time of transplantation.***For short stature associated with Turner's syndrome.***For short stature in children with SHOX (short stature homeobox-containing gene) deficiency.***For short stature in children with Noonan Syndrome.***For idiopathic short stature.***For the treatment of HIV-associated failure to thrive in children, AIDS-associated wasting syndrome, or cachexia.***For the treatment of HIV-associated adipose redistribution syndrome (HARS)�.***For the treatment of short bowel syndrome in patients receiving specialized nutrition support as directed by a health care professional.***Formoterol; Mometasone","***General Information***Cresol hypersensitivity, glycerin hypersensitivity, history of angioedema, risk of serious hypersensitivity reactions or anaphylaxis***Epiphyseal closure***Children, renal impairment, renal osteodystrophy***Benzyl alcohol hypersensitivity, neonates***Chemotherapy, neoplastic disease, new primary malignancy, radiation therapy***Respiratory insufficiency, surgery, trauma***Obesity***Respiratory infection, sleep apnea***Diabetes mellitus, diabetic retinopathy***Scoliosis***Adrenal insufficiency, hypothyroidism***Increased intracranial pressure***Pregnancy***Breast-feeding***Otitis media***Geriatric***Females***Pancreatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,somatropin (rDNA origin),"***For the treatment of growth hormone deficiency, growth failure, or short stature.***For replacement therapy in adults with growth hormone deficiency (GHD) for either childhood onset (secondary to congenital, genetic, acquired, or idiopathic causes) or adult onset (endogenous or associated with multiple hormone deficiencies, i.e., hypopituitarism, as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma).***For the long-term treatment of growth failure in children who have growth hormone deficiency due to inadequate growth hormone secretion.***For growth failure due to Prader-Willi syndrome.***For the long-term treatment of growth failure in children born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 to 4.***For growth failure associated with chronic renal failure up to the time of transplantation.***For short stature associated with Turner's syndrome.***For short stature in children with SHOX (short stature homeobox-containing gene) deficiency.***For short stature in children with Noonan Syndrome.***For idiopathic short stature.***For the treatment of HIV-associated failure to thrive in children, AIDS-associated wasting syndrome, or cachexia.***For the treatment of HIV-associated adipose redistribution syndrome (HARS)�.***For the treatment of short bowel syndrome in patients receiving specialized nutrition support as directed by a health care professional.***Formoterol; Mometasone","***General Information***Cresol hypersensitivity, glycerin hypersensitivity, history of angioedema, risk of serious hypersensitivity reactions or anaphylaxis***Epiphyseal closure***Children, renal impairment, renal osteodystrophy***Benzyl alcohol hypersensitivity, neonates***Chemotherapy, neoplastic disease, new primary malignancy, radiation therapy***Respiratory insufficiency, surgery, trauma***Obesity***Respiratory infection, sleep apnea***Diabetes mellitus, diabetic retinopathy***Scoliosis***Adrenal insufficiency, hypothyroidism***Increased intracranial pressure***Pregnancy***Breast-feeding***Otitis media***Geriatric***Females***Pancreatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,medroxyprogesterone acetate,"***For the treatment of secondary amenorrhea.***For the treatment of dysfunctional uterine bleeding due to hormonal imbalance, in the absence of organic pathology such as fibroids or uterine cancer.***For routine contraception.***For the treatment of endometriosis-associated pain.***For the treatment of inoperable, recurrent, and metastatic endometrial cancer or renal cell cancer.***For the prevention of endometrial hyperplasia associated with estrogen replacement therapy in postmenopausal women with an intact uterus.***For the treatment of hypoventilation due to obesity-hypoventilation syndrome� (Pickwickian syndrome�).***For the treatment of hot flashes� due to menopause�.***For use to reduce the rate of decline in bone mineral density and to control biochemical indices of mild primary hyperparathyroidism� in postmenopausal women.***For the management of paraphilia� (atypical or extreme compulsive sexual behaviors�) in men.***For the treatment of hot flashes� due to prostate cancer� and associated induced androgen deficiency� (andropause�"") in men who have had surgical or medication induced castration.""","***History of angioedema***Intravenous administration***Breast cancer, cervical cancer, endometrial cancer, endometrial hyperplasia, new primary malignancy, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Diabetes mellitus***Cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, visual disturbance***Hyperlipidemia***Ectopic pregnancy, infertility, pregnancy***Incomplete abortion, menstrual irregularity***Cholestasis, hepatic disease, jaundice***Breast-feeding***Asthma, renal disease***Depression, migraine, seizure disorder***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, sexually transmitted disease***Dementia, geriatric***Hypocalcemia, porphyria, systemic lupus erythematosus (SLE)***Alcoholism, anorexia nervosa, corticosteroid therapy, osteopenia, osteoporosis***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,trientine hydrochloride,***For the treatment of Wilson's disease (hepatolenticular degeneration).,"***General Information***Pregnancy***Breast-feeding***Children, infants, neonates***Gelatin hypersensitivity***Anemia, hemochromatosis, iron-deficiency anemia, sideroblastic anemia***Geriatric***Biliary cirrhosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dornase alfa,***For mucolysis in patients with cystic fibrosis in conjunction with standard therapies to improve pulmonary function.***For mucolysis in the management of atelectasis� and/or pulmonary mucus plugging in non-cystic fibrosis disease states�. <br />        NOTE: Limited data is available for the use of dornase alpha in non-cystic fibrosis disease states. The optimal dose for these conditions has not been determined.�<br />     ,"***General Information***Hamster protein hypersensitivity***Breast-feeding***Pregnancy***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bleomycin sulfate,"***For the treatment of Hodgkin lymphoma. <br />  NOTE: Because of the possibility of an anaphylactoid reaction, lymphoma patients are usually given 2 units or less IV, IM, or subcutaneous for the first two doses or as a test dose, followed by a 24-hour observation. If no acute reactions occur, the regular doses may be given.<br /***For the treatment of Hodgkin lymphoma as part of the Stanford V regimen.***For the treatment of Hodgkin lymphoma as part of the BEACOPP regimen.***For the treatment of non-Hodgkin's lymphoma (NHL).***For the treatment of cervical cancer, head and neck cancer, or vulvar cancer (specifically squamous cell cancer).***For the treatment of testicular cancer, including embryonal cell, choriocarcinoma, and teratocarcinoma.***For the treatment of penile cancer.***For the treatment of locally advanced or metastatic penile cancer in combination with cisplatin and methotrexate.***For the treatment of squamous cell penile cancer.***For the treatment of malignant pleural effusion.***For the treatment of osteogenic sarcoma�.***For the treatment of AIDS-related Kaposi's sarcoma in combination with doxorubicin and vincristine�.***For the treatment of malignant ascites�.***For the treatment of verruca vulgaris� (i.e., common warts) or verruca plantaris� (i.e., plantar warts).***For the treatment of hemangioma�.***Formoterol; Mometasone","***Bleomycin hypersensitivity, fever, idiosyncratic reaction, requires a specialized care setting, requires an experienced clinician, serious hypersensitivity reactions or anaphylaxis***Geriatric, infection, maximum cumulative lifetime dose, pulmonary disease, pulmonary fibrosis, pulmonary toxicity, radiation therapy, tobacco smoking***Surgery***Renal failure, renal impairment***Pregnancy***Breast-feeding***Peripheral vascular disease, Raynaud's phenomenon***Extravasation, intramuscular administration, subcutaneous administration***Accidental exposure, ocular exposure***Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/levonorgestrel,"***For routine contraception.***For extended continuous routine contraception.***For use as postcoital contraception within 72 hours of unprotected intercourse, or known or suspected contraceptive failure, in females who have no known contraindications to oral contraceptives, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,calcium acetate,"***For the treatment of hypocalcemia.***For the treatment of acute hypocalcemia. <br />          NOTE: IV dosages should be used in patients with tetany.�<br />NOTE: Monitor ionized serum calcium concentrations to individualize dosage.<br />NOTE: For the treatment of ionized hypocalcemia during CPR, see dosing for CPR.***For hypocalcemia secondary to citrated blood infusion.***For the treatment of hyperkalemia, hypermagnesemia, and ionized hypocalcemia.***For the treatment of life-threatening cardiac arrhythmias or during cardiopulmonary resuscitation (CPR)� (cardiac arrest�) associated with suspected or documented hyperkalemia, hypermagnesemia, or ionized hypocalcemia. <br />          NOTE: Calcium salts are NOT recommended for routine treatment of cardiac arrest.   No benefit has been demonstrated during cardiac arrest and hypercalcemia may occur following calcium administration.<br />       ***For the treatment of severe hyperkalemia (serum potassium > 7 mEq/L) or hypermagnesemia associated with toxic ECG changes.***For adjunctive therapy in the treatment of CNS depression due to hypermagnesemia.***For nutritional supplementation.***For nutritional supplementation to prevent hypocalcemia in patients receiving total parenteral nutrition (TPN).***For the treatment of hyperphosphatemia, especially in patients with chronic renal failure or end stage renal disease. <br />        NOTE: Calcium carbonate (see separate calcium carbonate monograph) has been designated as an orphan drug by the FDA for this indication.�<br />     ***For the treatment of verapamil toxicity or calcium antagonist toxicity (e.g., myocardial depression, hypotension, cardiac conduction defects or cardiac arrhythmias).***For exchange transfusion-induced hypocalcemia prophylaxis�.","***General Information***Hypercalcemia***Hypercalciuria***Sarcoidosis***Extravasation, intramuscular administration, subcutaneous administration***Cardiac arrhythmias, digitalis toxicity, ventricular fibrillation***Dehydration***Diarrhea***Hyperphosphatemia, hypoparathyroidism***Vitamin D toxicity***Pregnancy***Breast-feeding***Necrotizing enterocolitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2555'],cisplatin,"***For the treatment of bladder cancer.***For the treatment of bladder cancer as a single agent.***For the neoadjuvant treatment of muscle-invasive bladder cancer in combination with methotrexate, doxorubicin, and vinblastine�.***For the first-line treatment of advanced or metastatic bladder cancer, in combination with vinblastine, doxorubicin, and methotrexate�.***For the first-line treatment of locally advanced or metastatic transitional-cell bladder cancer, in combination with gemcitabine�.***For malignant mesothelioma.***For the treatment of unresectable malignant pleural mesothelioma, in combination with pemetrexed.***For the treatment of malignant mesothelioma in combination with gemcitabine�.***For the treatment of malignant peritoneal mesothelioma in combination with mitomycin C�.***For the treatment of previously untreated advanced, unresectable malignant pleural mesothelioma, in combination with pemetrexed and bevacizumab�.***For the treatment of ovarian cancer.***For advanced ovarian cancer in combination with paclitaxel.***For the first-line treatment of optimally debulked, stage III ovarian cancer in combination with intraperitoneal and intravenous paclitaxel�.***For the treatment of testicular cancer.***For the treatment of non-small cell lung cancer (NSCLC).***For first-line treatment of non-small cell lung cancer (NSCLC) in combination with paclitaxel in patients who are not candidates for potentially curative surgery and/or radiation therapy.***For first-line treatment of unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with docetaxel in patients who have not received prior chemotherapy.***For advanced, unresectable stage III or IV non-small cell lung cancer (NSCLC) in combination with vinorelbine.***For first-line treatment of inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) in combination with gemcitabine.***For first-line therapy of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in combination with pemetrexed.***For adjuvant treatment of resected non-small cell lung cancer (NSCLC) in combination with vinorelbine�.***For the first-line treatment of inoperable, stage II or III NSCLC, in combination with vinblastine and radiotherapy�.***For adjuvant treatment of resected stage IB�III non-small-cell lung cancer (NSCLC) in combination with vinblastine�.***For the adjuvant treatment of resected stage IB�III non-small cell lung cancer (NSCLC) in combination with etoposide�.***For the treatment of stage IIIB non-small cell lung cancer (NSCLC) in combination with etoposide and concurrent radiotherapy�.***For the first-line treatment of inoperable stage III or IV NSCLC in combination with mitomycin and vinblastine or ifosfamide�.***For the first-line treatment of advanced non-small cell lung cancer (NSCLC) in combination with vinorelbine and cetuximab�.***For the treatment of advanced non-small cell lung cancer (NSCLC) in combination with irinotecan�.***For the treatment of advanced or recurrent endometrial cancer� in combination with doxorubicin and paclitaxel.***For the treatment of gastric cancer�.***For the treatment of previously untreated patients with metastatic gastric or gastroesophageal junction adenocarcinoma in combination with trastuzumab and 5-fluorouracil or capecitabine�.***For the perioperative treatment of gastric cancer in combination with epirubicin and 5-fluorouracil�.***For the treatment of advanced gastric cancer in combination with capecitabine�.***For the treatment of advanced gastric cancer in combination with epirubicin and capecitabine or fluorouracil (5-FU)�.***For the treatment of advanced gastric cancer, including adenocarcinoma of the gastroesophageal junction, in combination with docetaxel and 5-fluorouracil in patients who have not received prior chemotherapy for advanced disease�. <br />  NOTE: Docetaxel is FDA-approved for the treatment of gastric cancer as part of the TCF (docetaxel, cisplatin, fluorouracil) regimen.<br /***For the treatment of high-risk gestational trophoblastic disease�.***For the treatment of non-Hodgkin's lymphoma (NHL)�.***For salvage treatment in NHL, in combination with high-dose cytarabine and dexamethasone�.***For the treatment of relapsed or refractory, aggressive NHL in transplant eligible patients, in combination with gemcitabine and dexamethasone (and rituximab for CD20-positive disease)�.***For the treatment of relapsed or refractory diffuse large B-cell lymphoma in transplant eligible patients, in combination with dexamethasone and cytarabine (DHAP regimen) and ofatumumab�.***For the first-line treatment of metastatic malignant melanoma� in combination with vinblastine and dacarbazine.***For the treatment of localized and unresectable neuroblastoma� in combination with etoposide, alternating with cyclophosphamide, vincristine, and doxorubicin.***For the treatment of penile cancer�.***For the treatment of locally advanced or metastatic penile cancer in combination with methotrexate and bleomycin�.***For the neoadjuvant treatment of locally advanced or metastatic carcinoma of the penis in combination with paclitaxel and ifosfamide�.***For the treatment of head and neck cancer�.***For the treatment of advanced or recurrent head and neck cancer in combination with fluorouracil�.***For the treatment of previously untreated resectable squamous cell head and neck cancer of the larynx�.***For the treatment of previously untreated unresectable squamous cell head and neck cancer, excluding cancers of the nasopharynx, paranasal sinus, or parotid gland�.***For the treatment of previously untreated squamous cell head and neck cancer of the oral cavity, oropharynx, hypopharynx, or larynx�.***For the treatment of advanced nasopharyngeal head and neck cancer in combination with fluorouracil and radiotherapy�.***For induction treatment of inoperable, locally advanced squamous cell head and neck cancer in combination with docetaxel and 5-fluorouracil (5-FU)�. <br />          NOTE: Docetaxel is FDA-approved for this indication.<br />       ***For induction treatment of locally advanced squamous cell head and neck cancer in combination with docetaxel and 5-fluorouracil (5-FU) for unresectable disease, low surgical cure, or organ preservation�. <br />          NOTE: Docetaxel FDA-approved for this indication.<br />NOTE: Survival was significantly improved among patients who got the 3 drugs as compared with receipt of only cisplatin 100 mg/m2 IV on day 1 and 5-fluorouracil 1000 mg/m2/day by continuous IV infusion for 5 days. Specifically, the relative risk of death was 30% lower. Also, the median overall survival was 70.6 months as compared with 30.1 months for patients receiving only cisplatin and 5-fluorouracil. Three to 8 weeks after the start of the last cycle, all patients in both treatment arms who did not have progressive disease got carboplatin (AUC 1.5 weekly x 7 doses) and radiation therapy (2 Gy per day, 5 days per week for 7 weeks) followed by surgery, if appropriate***For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in combination with cetuximab�.***For the first-line treatment of recurrent locoregional or metastatic squamous cell carcinoma of the head and neck in combination with cetuximab and fluorouracil�. <br />          NOTE: Cetuximab is FDA-approved for this indication.<br />       ***For the treatment of anal cancer in combination with 5-fluorouracil and radiation therapy�.***For the treatment of biliary tract cancer� in combination with gemcitabine.***For the treatment of hepatocellular cancer�.***For the treatment of advanced stage hepatocellular carcinoma in combination with doxorubicin�.***For the treatment of advanced hepatocellular carcinoma�.***For the treatment of unresectable, advanced thymoma�.***For unresectable, advanced thymoma in combination with cyclophosphamide and doxorubicin�.***For unresectable, advanced thymoma in combination with cyclophosphamide, doxorubicin, and vincristine�.***For unresectable, advanced thymoma in combination with etoposide and ifosfamide�.***For unresectable, advanced thymoma in combination with etoposide�.***For the first-line treatment of unresectable, advanced thymic carcinoma�, in combination with etoposide and ifosfamide.***For the treatment of peripheral T-cell lymphoma (PTCL)�.***For the first-line treatment of PTCL in combination with gemcitabine, prednisone, and thalidomide�.","***Platinum compound hypersensitivity, serious hypersensitivity reactions or anaphylaxis***Bone marrow suppression, neutropenia, radiation therapy, requires a specialized care setting, requires an experienced clinician, thrombocytopenia***Peripheral neuropathy***Children, hearing impairment, infants, neonates, ototoxicity***Herpes infection, infection, varicella, viral infection***Dental disease, dental work***Dehydration, hypokalemia, hypomagnesemia, nephrotoxicity, renal disease, renal failure, renal impairment***Hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, tumor lysis syndrome (TLS)***Pregnancy***Breast-feeding***Extravasation, intramuscular administration, subcutaneous administration***Geriatric***Accidental exposure, ocular exposure***Vaccination***Chemotherapy-induced nausea/vomiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,granisetron hydrochloride,"***For chemotherapy-induced nausea/vomiting (CINV) and chemotherapy-induced nausea/vomiting prophylaxis.***For chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days.***For acute and delayed chemotherapy induced nausea/vomiting (CINV) prophylaxis associated with moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide chemotherapy regimens, in combination with other antiemetics.***For chemotherapy-induced nausea/vomiting (CINV) prophylaxis, including for high-dose cisplatin.***For chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving highly emetogenic chemotherapy (HEC), in combination with fosaprepitant and dexamethasone�.***For radiation-induced nausea/vomiting prophylaxis.***For the treatment of post-operative nausea/vomiting (PONV)�.***For post-operative nausea/vomiting (PONV) prophylaxis�.***Formoterol***Formoterol; Mometasone","***Dolasetron hypersensitivity, granisetron hypersensitivity, ondansetron hypersensitivity, palonosetron hypersensitivity***Benzyl alcohol hypersensitivity, neonates***Constipation, GI obstruction, ileus, surgery***Sunlight (UV) exposure***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Bipolar disorder, depression, pain***Heating pad***Anticoagulant therapy, bleeding***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fosinopril sodium/hydrochlorothiazide,"***For the treatment of hypertension. <br />        NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, asthma, atopy, Black patients, hereditary angioedema***Dialysis, hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Hepatic disease***Heart failure, hyponatremia, hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***Aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease***Surgery***Anuria, autoimmune disease, bone marrow suppression, collagen-vascular disease, immunosuppression, renal artery stenosis, renal disease, renal failure, renal impairment, scleroderma, systemic lupus erythematosus (SLE)***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia***Gout, hyperuricemia***Diabetes mellitus, hyperglycemia***Pancreatitis***Pregnancy***Breast-feeding***Children***Geriatric***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/norgestimate,"***For routine contraception.***For the treatment of severe acne vulgaris in females who have no known contraindications to oral contraceptives, desire contraception, and have achieved menarche.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Ectopic pregnancy, pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children, infants, neonates***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['228833'],gadoversetamide,***For use with magnetic resonance imaging (MRI) to enhance visualization of abnormal vascularity within the central nervous system (CNS) and liver and detect blood-brain barrier disruptions.,"***Diabetes mellitus, dialysis, geriatric, hypertension, nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy), renal disease, renal failure, renal impairment***Magnetic resonance imaging (MRI)***Asthma, atopy, radiopaque contrast media hypersensitivity***Extravasation***Sickle cell disease***Pregnancy***Breast-feeding***Laboratory test interference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['53654'],nevirapine,"***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents. <br />  NOTE: Although the FDA-approved labeling recommends reinitiation of lead-in dosing for patients who have interrupted therapy for more than 7 days, the HIV guidelines recommend that children who interrupt therapy for 14 days or less should be restarted on full-dose nevirapine. If dosing is interrupted for more than 14 days, dosing should be restarted with the lead-in dosing for 14 days, followed by full-dose escalation. <br /***For perinatal human immunodeficiency virus (HIV) prophylaxis� in neonates at high risk for HIV acquisition. <br />        NOTE: All HIV exposed infants should receive post-partum prophylaxis initiated as close to the time of birth as possible, preferably within 6 to 12 hours of delivery. Combination antiretroviral regimens are recommended for infants at high risk. Neonates at high risk for perinatal HIV transmission include those born to HIV-infected mothers: who have not received antepartum or intrapartum antiretroviral treatment, who have received only intrapartum antiretroviral treatment, who have suboptimal viral suppression near delivery, who have unknown HIV status, or who have known ARV drug-resistant virus.<br />","***General Information***Hepatic disease, hepatitis, hepatitis B and HIV coinfection, hepatotoxicity***Nevirapine hypersensitivity, serious rash***Pregnancy***Breast-feeding***Females***Black patients, Hispanic patients, human immunodeficiency virus (HIV) infection resistance***Dialysis***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Children, infants, neonates***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,nortriptyline hydrochloride,***For the treatment of major depression . <br /***For the treatment of social phobia (social anxiety disorder)� or panic disorder�.***For migraine prophylaxis�.***For the treatment of premenstrual dysphoric disorder (PMDD)�.***For the treatment of nocturnal enuresis�.***For the treatment of postherpetic neuralgia�.***For the treatment of painful diabetic neuropathy�.***For use as an adjunct to psychosocial interventions in the management of tobacco cessation� (smoking cessation�).,"***Carbamazepine hypersensitivity, tricyclic antidepressant hypersensitivity***MAOI therapy***Acute myocardial infarction, bradycardia, Brugada syndrome, cardiac arrhythmias, cardiac disease, congenital heart disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, orthostatic hypotension, QT prolongation***Children, suicidal ideation***Bipolar disorder, mania, schizophrenia***Alcoholism, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Electroconvulsive therapy (ECT), seizure disorder, seizures***Hepatic disease***Surgery***Anticholinergic medications, ileus, prostatic hypertrophy, urinary retention***Closed-angle glaucoma, increased intraocular pressure***Contact lenses***Agranulocytosis, leukopenia***Hyperthyroidism, hypothyroidism***Diabetes mellitus, pheochromocytoma***Radiographic contrast administration***Sunlight (UV) exposure***Abrupt discontinuation***Geriatric***Pregnancy***Breast-feeding***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,vitamin A palmitate,***For nutritional supplementation of vitamin A according to recommended reference dietary intakes. <br />        NOTE: Patients with malabsorption syndromes will require higher doses than those listed here to maintain adequate nutritional status and prevent deficiency of vitamin A. Use a product that contains a water soluble form of vitamin A for better absorption. <br />NOTE: 3.3 International Units retinol = 1 mcg RAE***For the treatment of vitamin A deficiency.***For the treatment of xerophthalmia secondary to deficiency of vitamin A.***For fat malabsorption diagnosis.***For vitamin A supplementation in children with measles.***For the prevention of loss of visual field in patients with retinitis pigmentosa�.***For the treatment of keratinization disorders such as ichthyosis�.,"***Intravenous administration***Hepatic disease, hyperlipidemia, hypervitaminosis A, malnutrition***Pregnancy***Breast-feeding***Acne vulgaris***Neonates, polysorbate 80 hypersensitivity, premature neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1147220'],vemurafenib,"***For the treatment of unresectable or metastatic malignant melanoma in patients with the BRAF V600E mutation. <br />        NOTE: Confirm the BRAF V600E mutation prior to starting therapy using a FDA-approved test; vemurafenib is not indicated in patients with wild-type BRAF melanoma.<br />     ***For the treatment of Erdheim-Chester Disease (ECD) in patients with the BRAF V600E mutation. <br />  NOTE: Vemurafenib has been designated an orphan drug by the FDA for the treatment of ECD.<br /***For the treatment of BRAF mutation-positive, RAS wild-type, metastatic colorectal cancer, in combination with irinotecan and cetuximab�.***Formoterol***Formoterol; Mometasone","***General Information***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***New primary malignancy, skin cancer, sunburn***Sunlight (UV) exposure***Coagulopathy, hepatic disease***Iritis***Fever, hypotension***Serious rash***Radiation therapy***Renal failure***Dupuytren's contracture, plantar fibromatosis***Pregnancy***Contraception requirements, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['296'],adenosine,"***For the treatment of stable reentry supraventricular tachycardia or paroxysmal supraventricular tachycardia (PSVT), including PSVT in patients with Wolff-Parkinson-White (WPW) syndrome.***For use as an adjunct to thallium-201 myocardial perfusion imaging for coronary artery disease diagnosis in patients unable to exercise adequately.***For acute vasodilator testing in pulmonary hypertension diagnosis�.***For wide-complex tachycardia diagnosis� and conversion of wide-complex tachycardia of supraventricular origin� in hemodynamically stable patients.","***General Information***Atrial fibrillation, atrial flutter, ventricular tachycardia, Wolff-Parkinson-White syndrome***Asystole, AV block, bradycardia, bundle-branch block, sick sinus syndrome***Autonomic neuropathy, hypotension, hypovolemia, pericardial effusion, pericarditis, valvular heart disease***Angina, cardiac arrest, myocardial infarction, respiratory arrest, ventricular arrhythmias***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema***Geriatric***Pregnancy***Breast-feeding***Heart transplant***Seizure disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cosyntropin,"***For adrenocortical insufficiency diagnosis. <br />  NOTE: See Therapeutic Drug Monitoring for further information regarding adrenocortical deficiency diagnosis.<br />NOTE: Patients taking cortisone, hydrocortisone, or spironolactone should omit pre-test doses",***General Information***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydroxyethyl starch 130/0.4/sodium chloride,"***For use as a plasma expander in cardiopulmonary bypass surgery and in the treatment of shock due to hypovolemia caused by hemorrhage, surgery, trauma, sepsis, or burns. <br />        NOTE: Dosage and infusion rate depend on amount of fluid loss and must be individualized.<br />     ***For enhancement of granulocyte yield during continuous-flow centrifugation leukapheresis procedures.***Formoterol; Mometasone","***Corn hypersensitivity, hydroxyethyl cellulose hypersensitivity***Coagulopathy, intracranial bleeding, surgery, thrombocytopenia, von Willebrand's disease***Anuria, dialysis, heart failure, mortality, oliguria, pulmonary edema, renal disease, renal failure, renal impairment, sepsis, sodium restriction***Hepatic disease***Pancreatitis***Pregnancy***Breast-feeding***Neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,paroxetine mesylate,"***For the treatment of major depression.***For the treatment of generalized anxiety disorder (GAD).***For the treatment of premenstrual dysphoric disorder (PMDD).***For the treatment of moderate to severe hot flashes associated with menopause, including in women who have been treated for breast cancer.***For the treatment of obsessive-compulsive disorder (OCD).***For the treatment of panic disorder, with or without agoraphobia.***For the treatment of posttraumatic stress disorder (PTSD).***For the treatment of social phobia (social anxiety disorder).***For the treatment of premature ejaculation�.","***General Information***Abrupt discontinuation***Bipolar disorder, mania***Children, growth inhibition, suicidal ideation***MAOI therapy***Electroconvulsive therapy (ECT), seizure disorder, seizures***Dehydration, hyponatremia, hypovolemia***Renal failure, renal impairment***Hepatic disease***Anticoagulant therapy, bleeding, thrombolytic therapy***Cardiac disease, congenital heart disease***Bone fractures, osteoporosis***Closed-angle glaucoma, increased intraocular pressure***Akathisia***Anorexia nervosa***Driving or operating machinery, ethanol ingestion***Neonates, pregnancy***Breast-feeding***Anticholinergic medications, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['4603', '202991']",furosemide,***For the treatment of peripheral edema or edema associated with heart failure or nephrotic syndrome.***For the management of pulmonary edema or prevention of adverse hemodynamic effects associated with blood product transfusions�.***For the adjunctive treatment of acute pulmonary edema.***For the prevention of adverse hemodynamic effects and/or pulmonary edema associated with blood product transfusions�.***For adjunctive treatment of edema in patients with acute or chronic renal failure (renal impairment).***For the treatment of hypertension.***For adjunctive treatment of hypertensive urgency� or hypertensive emergency�.***For the acute treatment of hypercalcemia� associated with neoplastic disease in combination with intravenous saline.***For the treatment of ascites� in combination with spironolactone or amiloride.***Formoterol; Mometasone,"***Sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Acid/base imbalance, electrolyte imbalance, hypocalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis***Diabetes mellitus, hyperglycemia***Diarrhea, heart failure, ventricular arrhythmias***Acute myocardial infarction***Anuria, hypovolemia, renal disease, renal failure, renal impairment***Hypotension, orthostatic hypotension, sympathectomy, syncope***Systemic lupus erythematosus (SLE)***Gout, hyperuricemia***Hearing impairment***Pancreatitis***Preeclampsia, pregnancy***Breast-feeding***Children, infants, neonates, premature neonates***Ascites, hepatic disease, hepatic encephalopathy***Prostatic hypertrophy, urethral stricture, urinary retention***Thyroid disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['229369']['229367'],dalfopristin/quinupristin,***For the treatment of complicated skin and skin structure infections.***For the treatment of serious or life-threatening infections such as bacteremia�.***Formoterol; Mometasone,"***Streptogramin hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Children, infants, neonates***Pregnancy***Breast-feeding***Hepatic disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,terazosin hydrochloride,"***For the treatment of hypertension. <br />        NOTE: A landmark clinical trial (ALLHAT), published in 2000, compared another alpha-blocker, doxazosin, to chlorthalidone in the treatment of high-risk hypertensive patients. In this study, only the diuretic significantly reduced the risk of combined cardiovascular disease events, especially heart failure. These results led to discontinuation of the alpha-blocker treatment arm of the study.<br />     ***For the treatment of symptomatic benign prostatic hyperplasia (BPH).","***Angina, orthostatic hypotension, syncope***Geriatric***Pregnancy***Breast-feeding***Ocular surgery***Priapism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dextroamphetamine sulfate,"***For the treatment of attention-deficit hyperactivity disorder (ADHD). <br />        NOTE: Dosage should be individualized; use lowest effective dose after stabilization. Lack of response to one stimulant does not predict a response to other stimulants. ADHD is a chronic condition that will require ongoing management and monitoring. Sixty to eighty percent of children will continue to need treatment in adulthood. The effect of behavioral therapy is controversial; however, combined drug and behavioral therapy has been shown to be more effective than behavioral therapy alone. In many cases, drug treatment alone showed a consistent dose-sensitive effect in improving core ADHD symptoms. Treatment strategies must be individualized for patients based on psychosocial and comorbid factors. Stimulants have been shown to be effective first-line agents in the treatment of ADHD.   <br />NOTE: Avoid late evening doses to help prevent insomnia. Reduce dose if anorexia or insomnia occur***For the treatment of narcolepsy.***For the short-term treatment (i.e., 3 to 6 weeks) of exogenous obesity� in adults.***For the treatment of hypothalamic obesity� after craniopharyngioma surgical resection.***Formoterol***Formoterol; Mometasone","***General Information***Alcoholism, substance abuse***Bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Hypertension, tachycardia***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular arrhythmias, ventricular dysfunction***Cerebrovascular disease, stroke***Glaucoma, visual disturbance***Hyperthyroidism, thyrotoxicosis***Neonates, pregnancy***Breast-feeding***Tics, Tourette's syndrome***Driving or operating machinery***Seizure disorder, seizures***Surgery***Radiographic contrast administration***Abrupt discontinuation***Hypercortisolism***Geriatric***Hepatic disease, renal impairment***Children, growth inhibition, infants***MAOI therapy***Peripheral vascular disease, Raynaud's phenomenon***Anorexia nervosa, bulimia nervosa, obesity treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cevimeline hydrochloride,***For the treatment of xerostomia associated with Sjogren's syndrome.,"***Driving or operating machinery, glaucoma, iritis***Asthma, bronchitis, chronic obstructive pulmonary disease (COPD)***Angina, cardiac arrhythmias, cardiac disease, myocardial infarction***Cholelithiasis, nephrolithiasis***Pregnancy***Breast-feeding***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3041'],cytarabine,"***For the first-line treatment of Philadelphia chromosome positive, chronic phase, CML, in combination with interferon alfa-2b�.***For the treatment of relapsed or refractory Hodgkin lymphoma�.***For the treatment of non-Hodgkin's lymphoma (NHL)�.***For the salvage treatment of NHL, in combination with cisplatin and dexamethasone�.***For the treatment of relapsed or refractory NHL, in combination with other chemotherapy agents�.***For the treatment of relapsed or refractory diffuse large B-cell lymphoma in transplant eligible patients, in combination with dexamethasone and cisplatin (DHAP regimen) and ofatumumab�.","***General Information***Abdominal pain, anemia, bone marrow suppression, chemotherapy-induced nausea/vomiting, diarrhea, hepatotoxicity, herpes infection, infection, leukopenia, oral ulceration, requires a specialized care setting, requires an experienced clinician, thrombocytopenia, varicella, viral infection***Dental disease, dental work***Intramuscular injections***Geriatric, neurological disease, renal impairment***Hepatic disease***Hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, tumor lysis syndrome (TLS)***Pregnancy***Breast-feeding***Benzyl alcohol hypersensitivity, neonates***Accidental exposure, ocular exposure***Children, vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diclofenac sodium,"***For the treatment of osteoarthritis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the treatment of rheumatoid arthritis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the treatment of ankylosing spondylitis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the acute treatment of migraine with or without aura. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />NOTE: Diclofenac is not indicated for migraine prophylaxis***For the treatment of mild pain or moderate pain. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For primary dysmenorrhea or for mild or moderate pain associated with nonrheumatic inflammatory conditions, bone pain�, arthralgia�, myalgia�, and vascular or migraine headache�. <br />          NOTE: Voltaren XR is not indicated for the management of acute painful conditions.<br />       ***For the treatment of acute mild or moderate pain.***For the topical treatment of acute mild pain or moderate pain due to minor strains, sprains, and contusions. <br />          NOTE: Carefully consider the potential benefits and risks of the diclofenac patch. If the patch will be used, use the lowest effective dose for the shortest possible duration.<br />       ***For the treatment of postoperative ocular inflammation following cataract extraction.***For the reduction of photophobia and ocular pain following corneal refractive surgery.***For the treatment of moderate to severe pain alone or in combination with opioid analgesics.***For the treatment of actinic keratosis.***For the prevention of heterotopic ossification�.***Formoterol; Mometasone","***Acute bronchospasm, asthma, bovine protein hypersensitivity, gelatin hypersensitivity, nasal polyps, NSAID hypersensitivity, polysorbate 80 hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Contact lenses, ocular surgery, rheumatoid arthritis***Anemia***Dental disease, dental work***Hepatic disease, jaundice, porphyria***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, renal impairment, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Labor, pregnancy***Breast-feeding***Burns, eczema, exfoliative dermatitis, heating pad, occlusive dressing, ocular exposure, skin abrasion***Benzyl alcohol hypersensitivity, sunlight (UV) exposure***Coronary artery bypass graft surgery (CABG)***Accidental exposure***Phenylketonuria***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,homatropine methylbromide/hydrocodone bitartrate,***For cough suppression.,"***Constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Biliary tract disease***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, ethanol ingestion, pulmonary disease, respiratory depression, respiratory insufficiency***Abrupt discontinuation***Alcoholism, substance abuse***Head trauma, increased intracranial pressure***Angina, cardiac arrhythmias, cardiac disease, heart failure, hypotension, hypovolemia***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, urethral stricture, urinary retention***Labor, obstetric delivery, pregnancy***Breast-feeding***Seizure disorder, seizures***Dementia, geriatric***Children, infants, neonates***Driving or operating machinery***Opiate agonist hypersensitivity***Adrenal insufficiency, hypothyroidism***Closed-angle glaucoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['69634'],sargramostim,"***For neutropenia prophylaxis.***For the treatment of HIV-induced� or drug therapy-induced� neutropenia (e.g., ganciclovir-induced neutropenia� or zidovudine-induced neutropenia�) in immunosuppressed patients or those with HIV disease to decrease the risk of bacterial infections.***For peripheral blood stem cell (PBSC) mobilization for collection by leukapheresis.***For chemotherapy-induced neutropenia prophylaxis.***For the treatment of severe aplastic anemia�.***For the treatment of malignant melanoma�.***For the adjuvant treatment of malignant melanoma following surgery for stage III or IV melanoma in patients at high-risk for recurrence�.***For the treatment of unresectable or metastatic malignant melanoma following no more than 1 prior therapy, in combination with ipilimumab�.***For the treatment of Crohn's disease�.***For the treatment of acute radiation exposure, to increase survival, in patients who receive myelosuppressive doses of radiation.","***Leukocytosis, thrombocytosis***Leukemia***Mannitol hypersensitivity, yeast hypersensitivity***Capillary leak syndrome, edema, heart failure, pericardial effusion, peripheral edema, pleural effusion***Cardiac arrhythmias, cardiac disease***Hepatic disease, renal disease, renal impairment***Chemotherapy, radiation therapy***Benzyl alcohol hypersensitivity, neonates***Risk of serious hypersensitivity reactions or anaphylaxis***Pulmonary disease, pulmonary toxicity***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fexofenadine hydrochloride,***For the treatment of allergic rhinitis (hay fever).***For the treatment of chronic idiopathic urticaria.,"***Terfenadine hypersensitivity***Phenylketonuria***Renal disease, renal failure, renal impairment***Geriatric***Pregnancy***Breast-feeding***Driving or operating machinery***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1292'],baclofen,"***For the treatment of spasticity, muscle spasm (not due to rheumatic conditions), myoclonus, and muscle rigidity in multiple sclerosis and spinal cord injury or diseases. <br />        NOTE: The efficacy of oral baclofen has not been established in stroke, cerebral palsy, and Parkinson's disease, and, therefore, is not recommended by the manufacturer for use in these disease states.<br />     ***For severe spasticity due to multiple sclerosis, cerebral palsy, spinal cord injury, or traumatic brain injury; or in patients unresponsive to oral baclofen therapy or those who experience intolerable side effects at effective oral doses. <br />          NOTE: Intrathecal baclofen has been designated an orphan drug by the FDA for this indication.<br />       ***For the treatment of persistent singultus (hiccups)�.***For the treatment of trigeminal neuralgia�.***For the treatment of central vestibular nystagmus�.***For prevention of stuttering priapism� (i.e., recurrent priapism).***For the adjunct treatment of symptomatic gastroesophageal reflux disease (GERD)� in refractory patients.","***General Information***Abrupt discontinuation***Intrathecal administration***Cerebral palsy, head trauma, intracranial bleeding, stroke***Geriatric***Bipolar disorder, depression, psychosis, schizophrenia***Diabetes mellitus***Seizure disorder, seizures***Dialysis, renal failure, renal impairment***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Children, infants***Epidural administration, intramuscular administration, intravenous administration, subcutaneous administration***Anticoagulant therapy, coagulopathy, infection, thrombocytopenia***Dental disease***Pregnancy***Breast-feeding***Phenylketonuria***Ovarian cyst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amphotericin B liposome,"***For the treatment of CNS infections, including meningitis, in patients refractory to or intolerant of amphotericin B deoxycholate. <br />        NOTE: For CNS infections caused by Cryptococcus, see Cryptococcus meningitis.<br />     ***For the treatment of CNS infections caused by <em>Candida</em> sp..***For the treatment of CNS infections caused by  <em>Aspergillus sp</em>..***For the treatment of CNS infections caused by <em>Blastomyces dermatitidis</em>�.***For the treatment of CNS infections caused by <em>Histoplasma capsulatum</em>�.***For the treatment of candidemia and invasive candidiasis (non-CNS) in patients refractory to or intolerant of amphotericin B deoxycholate. <br />        NOTE: For CNS disease, see meningitis indication.<br />     ***For the treatment of chronic disseminated (hepatosplenic) candidiasis.***For the treatment of invasive aspergillosis in patients refractory to or intolerant of amphotericin B deoxycholate. <br />        NOTE: For CNS disease, see meningitis indication.<br />     ***For the treatment of fungal ophthalmic infection, including endophthalmitis and chorioretinitis, in patients refractory to or intolerant of amphotericin B deoxycholate.***For the treatment of <em>Candida </em>endophthalmitis and chorioretinitis.***For the treatment of <em>Aspergillus</em> endophthalmitis.***For the treatment of cardiovascular system infections, including endocarditis, myocarditis, pericarditis, suppurative thrombophlebitis�, and infected pacemaker�, implantable cardiac defibrillator (ICD)�, or ventricular assist devices (VAD)� in patients refractory to or intolerant of amphotericin B deoxycholate.***For the treatment of <em>Candida</em> cardiovascular system infections.***For the treatment of <em>Aspergillus</em> cardiovascular system infections.***For the treatment of respiratory infections (i.e., pneumonia, tracheobronchitis, sinusitis) in patients refractory to or intolerant of amphotericin B deoxycholate.***For the treatment of <em>Candida</em> pneumonia.***For the treatment of invasive pulmonary, sinus, or tracheobronchial aspergillosis.***For the treatment of intraabdominal infections (i.e., peritonitis, intraabdominal abscess) in patients refractory to or intolerant of amphotericin B deoxycholate.***For the treatment of intraabdominal candidiasis.***For the treatment of <em>Aspergillus</em> peritonitis.***For the treatment of bone and joint infections, including osteomyelitis and infectious arthritis, in patients refractory to or intolerant of amphotericin B deoxycholate.***For the treatment of <em>Candida</em> osteomyelitis or infectious arthritis.***For the treatment of <em>Aspergillus</em> osteomyelitis or infectious arthritis.***For empirical therapy for presumed fungal infection in patients with febrile neutropenia.***For the treatment of cryptococcal meningitis. <br />        NOTE: LAmB has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of esophageal candidiasis� in HIV-infected patients.***For fungal prophylaxis� (e.g., candidiasis prophylaxis�, aspergillosis prophylaxis�) in high-risk patients.***For the treatment of disseminated (nonmeningeal) or pulmonary cryptococcosis�. <br />        NOTE: For the treatment of CNS infections, see cryptococcal meningitis.<br />     ***For the treatment of moderately severe to severe disseminated (nonmeningeal) or invasive pulmonary blastomycosis�. <br />        For CNS disease, see meningitis indication.<br />     ***For the treatment of severe disseminated (nonmeningeal) or diffuse pulmonary coccidioidomycosis� in HIV-infected patients.***For the treatment of moderately severe to severe disseminated (nonmeningeal) or pulmonary histoplasmosis�. <br />        NOTE: LAmB has been designated an orphan drug by the FDA for this indication.<br />NOTE: For CNS infections, see meningitis indication***For the treatment of pulmonary histoplasmosis.***For the treatment of disseminated (nonmeningeal) histoplasmosis.***For the treatment of acute penicilliosis� infection in severely ill HIV-infected patients.","***General Information***Renal disease, renal failure, renal impairment***Hepatic disease***Anemia, hematological disease, leukopenia, thrombocytopenia***Electrolyte imbalance, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia***Cardiac disease, hypertension, hypotension, tachycardia***Geriatric***Neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['42635'],iron dextran,***For the treatment of iron-deficiency anemia in patients in whom oral iron administration is unsatisfactory or impossible.***For nutritional supplementation� and to prevent iron deficiency in patients receiving long-term total parenteral nutrition.,"***Iron dextran hypersensitivity, serious hypersensitivity reactions or anaphylaxis***Ankylosing spondylitis, asthma, atopy, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Cardiac disease, hypotension, intravenous administration***Anemia, hemochromatosis, hemoglobinopathy, hemosiderosis***Dialysis, renal disease, renal failure***Hepatic disease***Infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7417'],nifedipine,"***For the treatment of ischemic heart disease including variant angina (Prinzmetal's angina) and chronic stable angina pectoris.***For the treatment of hypertension.***For acute hypertensive episodes including hypertensive urgency and hypertensive emergency in pediatric patients�. <br />          NOTE: Per the FDA and manufacturers, immediate-release nifedipine dosage forms should not be used to treat hypertension and should only be used to treat patients with chronic stable angina or vasospastic angina. The immediate-release nifedipine formulation has been associated with serious side effects (see Precautions and Adverse Reactions) when used to treat adult patients with hypertension, hypertensive urgency, hypertensive emergency, or coexisting myocardial infarction. Although the use of immediate-release nifedipine for the treatment of acute hypertensive episodes is still relatively common practice in pediatric patients, considerable controversy exists and caution should be used.<br />       ***For migraine prophylaxis�.***For the treatment of proteinuria� associated with diabetic nephropathy�.***For the treatment of persistent singultus (hiccups)�.***For the inhibition of uterine contractions in premature labor�. <br />        NOTE: Clinical practice guidelines recommend the use of a first line tocolytic (i.e., beta agonist, calcium channel blocker, or NSAID) for short-term use (up to 48 hours) to allow for administration of antenatal corticosteroids to enhance fetal lung maturation, magnesium sulfate for fetal neuroprotection, or transport to a tertiary facility, if indicated. There is no evidence that tocolytic therapy alone has any favorable effect on neonatal outcomes. Maintenance therapy with tocolytics is ineffective for preventing preterm birth and improving neonatal outcomes and is not recommended.<br />     ***For the treatment of achalasia�.***For the treatment of high altitude pulmonary edema associated with altitude sickness�.***For altitude sickness prophylaxis<strong>","***General Information***Dihydropyridine hypersensitivity***Pregnancy***Breast-feeding***Acute myocardial infarction, bradycardia, cardiogenic shock, coronary artery disease, heart failure, hypotension, ventricular dysfunction***Geriatric***Aortic stenosis***Colostomy, constipation, diabetes mellitus, diverticulitis, esophageal stricture, gastric cancer, gastroesophageal reflux disease (GERD), GI obstruction, hiatal hernia, hypothyroidism, ileus, inflammatory bowel disease, obesity***Children, infants***Hepatic disease***Lactase deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,granisetron hydrochloride,"***For chemotherapy-induced nausea/vomiting (CINV) and chemotherapy-induced nausea/vomiting prophylaxis.***For chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days.***For acute and delayed chemotherapy induced nausea/vomiting (CINV) prophylaxis associated with moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide chemotherapy regimens, in combination with other antiemetics.***For chemotherapy-induced nausea/vomiting (CINV) prophylaxis, including for high-dose cisplatin.***For chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving highly emetogenic chemotherapy (HEC), in combination with fosaprepitant and dexamethasone�.***For radiation-induced nausea/vomiting prophylaxis.***For the treatment of post-operative nausea/vomiting (PONV)�.***For post-operative nausea/vomiting (PONV) prophylaxis�.***Formoterol***Formoterol; Mometasone","***Dolasetron hypersensitivity, granisetron hypersensitivity, ondansetron hypersensitivity, palonosetron hypersensitivity***Benzyl alcohol hypersensitivity, neonates***Constipation, GI obstruction, ileus, surgery***Sunlight (UV) exposure***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Bipolar disorder, depression, pain***Heating pad***Anticoagulant therapy, bleeding***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,poractant alfa,"***For the rescue treatment of neonatal respiratory distress syndrome (RDS). <br />        NOTE: Curosurf is indicated for the treatment (rescue"") of respiratory distress syndrome (RDS) in premature infants. The safety and efficacy of administering poractant alfa &gt; 15 hours after the initial diagnosis of neonatal respiratory distress syndrome (RDS) has not been established.<br />NOTE: Adequate data are not available on the use of poractant alfa in conjunction with experimental therapies of RDS (e.g.","high-frequency ventilation)***For the treatment of acute respiratory distress syndrome (ARDS)� secondary to near-drowning�.""","***General Information***Porcine protein hypersensitivity***Acid/base imbalance, anemia, bradycardia, hypoglycemia, hypotension, hypothermia***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,secobarbital sodium,***For use in preoperative sedation induction.***For the short-term treatment of insomnia.,"***Agranulocytosis, barbiturate hypersensitivity, carbamazepine hypersensitivity, hydantoin hypersensitivity***Pain***Depression, mental status changes, suicidal ideation***Chronic obstructive pulmonary disease (COPD), pulmonary disease, respiratory depression, sleep apnea***Abrupt discontinuation, seizure disorder, seizures, status epilepticus, substance abuse***Alcoholism, CNS depression, driving or operating machinery, ethanol ingestion, hypotension***Geriatric***Hepatic disease, hepatic encephalopathy***Renal failure, renal impairment***Porphyria***Anticoagulant therapy***Osteomalacia, osteoporosis***Children, infants, neonates, premature neonates***Labor, obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2623', '202859']",clotrimazole,"***For the treatment of candidiasis, specifically mucocutaneous candidiasis (i.e., oropharyngeal candidiasis (thrush), vulvovaginal candidiasis).***For the treatment of oropharyngeal candidiasis (thrush).***For the treatment of vulvovaginal candidiasis (VVC).***For candidiasis prophylaxis to reduce the incidence of oropharyngeal candidiasis in immunocompromised patients undergoing chemotherapy or radiotherapy in the treatment of leukemia or solid tumors, or in allograft transplant patients who are receiving corticosteroid therapy.***For the treatment of tinea corporis, tinea cruris, and tinea pedis.***For the treatment of fungal otitis externa�.","***Onychomycosis***Pregnancy***Breast-feeding***Contraceptive devices, menstruation***Azole antifungals hypersensitivity***Abdominal pain, diabetes mellitus, fever, human immunodeficiency virus (HIV) infection, immunosuppression, vaginal discharge***Children, infants, neonates***Ocular exposure, ophthalmic administration***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,morphine sulfate,"***For the relief of acute and chronic moderate pain or severe pain. <br />        NOTE: There is substantial interpatient variability in the relative potency of different opioid drugs and products. FDA-approved labeling defines adult opioid-tolerant patients as those who take the following per day for a minimum of 1 week: oral morphine 60 mg or more; oral oxycodone 30 mg or more; oral hydromorphone 8 mg or more; oral oxymorphone 25 mg or more; 60 mg oral hydrocodone or more; transdermal fentanyl 25 mcg or more per hour; or another opioid at an equivalent dose. <br />     ***For acute moderate to severe pain related to major orthopedic surgery of the lower extremity.***For acute moderate to severe pain related to lower abdominal or pelvic surgery.***For acute moderate to severe pain related to cesarean section after delivery and clamping of the umbilical cord.***For the management of chronic severe pain in patients who require daily, around-the-clock, long-term opioid treatment. <br />  NOTE: Reserve extended-release morphine for when alternative options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would otherwise provide inadequate pain management. Discontinue all other around-the-clock opioids upon initiation.  <br />NOTE: Do not use the following morphine products in opioid-naive patients: 60 mg, 90 mg, or 120 mg biphasic-release capsules (Avinza); 100 mg, 130 mg, 150 mg, or 200 mg extended-release capsules (Kadian); 100 mg or 200 mg controlled-release tablets (MS Contin); 100 mg extended-release tablets (Morphabond). In this population, use could result in fatal respiratory depression. Use of a single dose of more than 60 mg, or a total daily dose more than 120 mg, should be limited to opioid-tolerant patients.   <br />NOTE: There is substantial interpatient variability in the relative potency of different opioid drugs and products. FDA-approved labeling defines adult opioid-tolerant patients as those who take the following per day for a minimum of 1 week: oral morphine 60 mg or more; oral oxycodone 30 mg or more; oral hydromorphone 8 mg or more; oral oxymorphone 25 mg or more; oral hydrocodone 60 mg or more; transdermal fentanyl 25 mcg or more per hour; or another opioid at an equivalent dose.***For the treatment of diarrhea.***For the treatment of noninfectious diarrhea. <br />  WARNING: Proper product selection is critical. Deodorized opium tincture 10 mg/mL solution is 25 times more concentrated than camphorated opium tincture 0.4 mg/mL solution. Serious patient harm may occur with incorrect product selection.<br /***For control of diarrhea� secondary to AIDS-associated enteropathy.***For the management of dyspnea�.***For the adjuvant treatment of acute pulmonary edema�.***For acute myocardial infarction� or unstable angina� and to provide potentially beneficial cardiovascular effects.***For procedural sedation� before short diagnostic procedures or endoscopy. <br />        NOTE: Morphine should be administered as an inducing agent only by those trained in anesthesia.<br />     ***For sedation during rapid-sequence intubation�.***For the treatment of painful diabetic neuropathy�.","***Opiate agonist hypersensitivity***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, coma, cor pulmonale, emphysema, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Ethanol ingestion, ethanol intoxication***Anticoagulant therapy, coagulopathy, infection, intramuscular administration, intrathecal administration, intravenous administration, requires a specialized care setting, requires an experienced clinician, subcutaneous administration***Accidental exposure, opioid-naive patients, potential for overdose or poisoning***Abrupt discontinuation***Acute abdomen, constipation, diarrhea, GI bleeding, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Biliary tract disease***Arteriosclerosis, brain tumor, CNS depression, head trauma, increased intracranial pressure, seizure disorder, seizures, status epilepticus, strychnine toxicity***Angina, atrial fibrillation, atrial flutter, cardiac arrhythmias, cardiac disease, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal impairment, urethral stricture, urinary retention***Children, infants, neonates***Geriatric***Driving or operating machinery***MAOI therapy***Adrenal insufficiency, hypothyroidism, myxedema***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7781'],oxazepam,***For the treatment of anxiety.***For the treatment of mild to moderate anxiety in children.***For treatment of acute alcohol withdrawal.***For the treatment of insomnia�.,"***Benzodiazepine hypersensitivity, tartrazine dye hypersensitivity***Bipolar disorder, depression, mania, psychosis, suicidal ideation***Chronic obstructive pulmonary disease (COPD), CNS depression, coadministration with other CNS depressants, pulmonary disease, respiratory depression, respiratory insufficiency, sleep apnea***Abrupt discontinuation, benzodiazepine dependence, seizure disorder, seizures, status epilepticus, substance abuse***Myasthenia gravis***Porphyria***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease***Renal failure, renal impairment***Cardiac arrhythmias, cardiac disease, cerebrovascular disease, hypotension, orthostatic hypotension, stroke***Parkinson's disease***Children, infants***Closed-angle glaucoma***Dementia, geriatric***Alcoholism, driving or operating machinery, ethanol ingestion, ethanol intoxication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,triamcinolone acetonide,"***For bronchospasm prophylaxis or maintenance therapy in patients who require chronic treatment with corticosteroids for control of bronchial asthma.***For the treatment of severe or incapacitating allergic conditions such as asthma that are intractable to adequate trials of conventional treatment.***For the treatment of symptoms of seasonal and perennial allergic rhinitis.***For the treatment of severe or incapacitating allergic conditions that are intractable to adequate trials of conventional treatment.***For the treatment of ocular inflammation (i.e., sympathetic ophthalmia and ocular inflammatory conditions unresponsive to topical corticosteroids), temporal arteritis, and uveitis.***For visualization during ocular surgery (i.e., vitrectomy).***For the treatment of acute rheumatic carditis, berylliosis, temporal arteritis�, or systemic lupus erythematosus (SLE). <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses (e.g., alopecia areata, atopic dermatitis, contact dermatitis including <em>Rhus dermatitis</em> due to poison ivy, poison oak, poison sumac, subacute cutaneous or discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex chronicus, mycosis fungoides, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, psoriasis, sarcoidosis, seborrheic dermatitis, sunburn, or xerosis). <br />        NOTE: Occlusive dressings may be necessary for chronic or severe cases of psoriasis or other recalcitrant conditions.<br />     ***For the treatment of ulcerative or inflammatory oral lesions including aphthous ulcer, desquamative gingivitis�, and oral lichen planus�.***For the treatment of severe or incapacitating allergic conditions such as atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions, bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome) that are intractable to adequate trials of conventional treatment and for the treatment of idiopathic eosinophilic pneumonias.***For the treatment of symptomatic sarcoidosis.***For the treatment of primary (Addison's disease) or secondary adrenocortical insufficiency. <br />        NOTE: Hydrocortisone and cortisone are the preferred agents for these conditions.<br />     ***For the treatment of congenital adrenal hyperplasia.***For the treatment of hypercalcemia associated with cancer.***For the treatment of nonsuppurative thyroiditis.***For the treatment of a critical period of regional enteritis and ulcerative colitis.***For the treatment of autoimmune hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, or selected cases of secondary thrombocytopenia.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of acute exacerbations of multiple sclerosis. <br />        NOTE: Corticosteroids are effective in speeding the resolution of acute exacerbations, but they do not affect the ultimate outcome or natural history of the disease.<br />     ***For the treatment of cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.***For the treatment of proteinuria or to induce diuresis in idiopathic nephrotic syndrome or lupus erythematosus.***For the treatment of an acute episode or exacerbation of ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA) as adjunctive therapy for short-term administration.***For the treatment of dermatomyositis or polymyositis.***For the relief of inflammation and for immunosuppression associated with a variety of disorders, like Hodgkin lymphoma. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the palliative treatment of leukemias and lymphomas.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of diabetic macular edema�.***For the relief of inflammation associated with synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; gout with acute gouty arthritis; epicondylitis; acute non-specific tenosynovitis; polychondritis�; posttraumatic osteoarthritis. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of osteoarthritis pain of the knee. <br />  NOTE: Zilretta is not interchangeable with other formulations of triamcinolone acetonide.<br /","***Epidural administration, intramuscular administration, intrathecal administration, intravenous administration, subcutaneous administration***Acute bronchospasm, status asthmaticus***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hyperthyroidism, hypothalamic-pituitary-adrenal (HPA) suppression, hypothyroidism, increased intracranial pressure, occlusive dressing, skin abrasion***Head trauma***Growth inhibition, osteoporosis***Surgery***Fungal infection, infection, viral infection***Tuberculosis***Immunosuppression***Herpes infection, measles, varicella***Glaucoma***Acne rosacea, acne vulgaris***Peripheral vascular disease***Nasal septal perforation, nasal surgery, nasal trauma***Myocardial infarction***Heart failure, hypertension***Diabetes mellitus***Skin atrophy***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Myasthenia gravis***Psychosis, seizure disorder***Coagulopathy, hemophilia, thromboembolic disease***Cataracts, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Vaccination***Breast-feeding***Tartrazine dye hypersensitivity***Neonates, premature neonates***Idiopathic thrombocytopenic purpura (ITP)***Corticosteroid hypersensitivity***Geriatric***Renal disease, renal impairment***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clemastine fumarate,"***For the treatment of symptoms associated with the common cold or allergic rhinitis including sneezing, rhinorrhea, itching of the nose or throat, and itchy, watery eyes (ocular pruritus).***For the relief of mild uncomplicated allergic skin manifestations (e.g., pruritus) of urticaria and angioedema.","***Asthma, chronic obstructive pulmonary disease (COPD)***Children, infants, neonates***Pregnancy***Breast-feeding***Closed-angle glaucoma, contact lenses***Bladder obstruction, GI obstruction, ileus, prostatic hypertrophy, urinary retention***Hepatic disease***Cardiac disease***Driving or operating machinery***Anticholinergic medications, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,selenium sulfide,***For the treatment of dandruff and seborrheic dermatitis and associated pruritus and flaking.***For the treatment of tinea versicolor.***For the treatment of psoriasis�.***For the adjunctive treatment of tinea capitis�.,"***Accidental exposure, ocular exposure***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,asparaginase erwinia chrysanthemi,"***For the treatment of acute lymphocytic leukemia (ALL) in combination with other chemotherapeutic agents in patients who have developed hypersensitivity to E. coli-derived asparaginase. <br />        NOTE: Asparaginase Erwinia chrysanthemi may be substituted for either pegaspargase or native E. coli asparaginase; however, dosage regimens differ.<br />NOTE: L- Asparaginase Escherichia coli and Pegaspargase are discussed in separate monographs. Use care in selecting the proper product to avoid medication errors","***General Information***Pancreatitis***Bleeding***Thromboembolic disease***Hepatic disease***Breast-feeding***Diabetes mellitus, hyperglycemia***Pregnancy***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,nalbuphine hydrochloride,"***For the relief of moderate pain to severe pain and for pain associated with obstetric labor and delivery. <br />  NOTE: For pain, doses should be titrated to the desired analgesic effect. Reduced initial dosages should be considered for geriatric patients and for patients at increased risk for respiratory depression, including patients receiving other CNS depressants.<br />NOTE: Nalbuphine 10 mg IV is considered equianalgesic to morphine 10 mg IV.<br />NOTE: Nalbuphine is not the analgesic of choice for opiate-tolerant patients because of the risk of withdrawal. If the previous analgesic was morphine, meperidine, codeine, or other opioid with similar duration of activity, administer 25% of the anticipated nalbuphine dose and closely observe the patient for withdrawal symptoms (e.g., abdominal cramps, nausea, vomiting, rhinorrhea, anxiety, piloerection). If the patient tolerates the reduced dosage, the nalbuphine dose may be slowly increased until the desired level of analgesia is achieved. If an opioid-tolerant patient has unduly troublesome opioid withdrawal symptoms upon nalbuphine administration, slow intravenous administration of small increments of morphine may be used as needed for symptom relief***For preanesthesia and adjunctive use in general anesthesia induction and general anesthesia maintenance. <br />        NOTE: Only persons specifically trained in the use of intravenous anesthetics and in the management of the respiratory effects of potent opioids should administer nalbuphine.<br />     ","***Opiate agonist hypersensitivity, paraben hypersensitivity***Constipation, diarrhea, GI disease, GI obstruction, inflammatory bowel disease, ulcerative colitis***Acute myocardial infarction, angina, cardiac disease, heart failure, ventricular dysfunction***Biliary tract disease***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, infection, pulmonary disease, respiratory depression, respiratory insufficiency, uremia***Head trauma, increased intracranial pressure, intracranial mass***Children***Geriatric***Infants, labor, obstetric delivery, pregnancy***Breast-feeding***Abrupt discontinuation, alcoholism, substance abuse***Hepatic disease, renal failure, renal impairment***Driving or operating machinery***Adrenal insufficiency, hypothyroidism, myxedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5093'],haloperidol,"***For the treatment of schizophrenia.***For the treatment of severe behavioral problems associated with oppositional defiant disorder or other disruptive behavioral disorders, or for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients who show excessive motor activity with accompanying conduct disorders.***For the treatment of tics and vocal utterances associated with Tourette's syndrome.***For the treatment of acute psychosis in acutely agitated schizophrenic patients with moderately severe to very severe symptoms.***For the treatment of acute mania�.***For the treatment of irritability associated with autistic disorder�.***For use as a second-line agent for rescue treatment of chemotherapy-induced nausea/vomiting�.***For the treatment of agitation� or delirium�.***For agitation� or delirium� in adult patients with no underlying psychiatric illness.***For the treatment of delirium� in the pediatric intensive care unit (PICU).***For the treatment of persistent singultus (hiccups)�.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.","***General Information***Alcoholism, angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, intravenous administration, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, thyroid disease, torsade de pointes***Agranulocytosis, hematological disease, leukopenia, neutropenia***CNS depression, coma***Tardive dyskinesia***Neurological disease, Parkinson's disease***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Seizure disorder, seizures***Dysphagia***Pulmonary disease***Hepatic disease, jaundice***Closed-angle glaucoma, increased intraocular pressure, visual disturbance***Prostatic hypertrophy, urinary retention***Dementia, geriatric, stroke***Thyrotoxicosis***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Tobacco smoking***Abrupt discontinuation***Breast cancer, hyperprolactinemia, infertility***Neonates, pregnancy, pregnancy testing***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,metaproterenol sulfate,"***For the treatment of asthma, acute bronchospasm, or for the treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis or emphysema.","***General Information***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, pheochromocytoma, QT prolongation, seizures, tachycardia***Labor, pregnancy***Breast-feeding***Children, infants, neonates***Seizure disorder***MAOI therapy***Hyperthyroidism, thyroid disease, thyrotoxicosis***Diabetes mellitus***Deterioration of asthma, paradoxical bronchospasm***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7975'],penicillamine,***For the treatment of Wilson's disease (hepatolenticular degeneration).***For the treatment of cystinuria.***For the treatment of arsenic toxicity.***For the treatment of rheumatoid arthritis.***For the treatment of juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA)�.***For the treatment of lead toxicity�.***For the treatment of rapidly progressive scleroderma (systemic sclerosis)�.,"***Fever, penicillamine hypersensitivity, penicillin hypersensitivity, requires an experienced clinician, serious rash***Agranulocytosis, aplastic anemia, bone marrow suppression, hematological disease, neutropenia***Pemphigus vulgaris***Hematuria, nephrolithiasis, nephrotoxicity, proteinuria, renal failure, renal impairment***Caesarean section, pregnancy***Breast-feeding***Diabetes mellitus, hypoglycemia***Cholestasis, hepatitis, hepatotoxicity, jaundice***Geriatric***Children***Myasthenia gravis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,thrombin (bovine origin),"***For hemostasis of small vessels and capillaries associated with surgical bleeding (i.e., as in plastic surgery, dental extractions, skin grafting, and neurosurgery).***For the treatment of pseudoaneurysms (false aneurysms)�. <br />        NOTE: The majority of the reports for the percutaneous injection of thrombin involve pseudoaneurysm in association with the femoral artery; however, thrombosis of pseudoaneurysms at other anatomical locations has also been successful.<br />NOTE: In patients with a previous exposure to thrombin (topical or intravascular), a skin-prick test to rule out hypersensitivity to thrombin is recommended (see Administration).","***Bleeding, thromboembolism***Accidental exposure, intravenous administration, parenteral administration***Bovine protein hypersensitivity, hamster protein hypersensitivity, mannitol hypersensitivity***Children, infants***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8814'],epoprostenol,***For the treatment of pulmonary hypertension.***For long-term intravenous treatment of adult patients with NYHA Class III or IV primary pulmonary hypertension or adults with pulmonary hypertension due to scleroderma (systemic sclerosis).***For treatment of pulmonary arterial hypertension in pediatric patients�.***For short-term treatment of pulmonary hypertension using inhaled (nebulized)� therapy.***For acute vasodilator testing in pulmonary hypertension diagnosis�.,"***Abrupt discontinuation***Hypotension***Heart failure***Bleeding***Pulmonary edema***Thromboembolic disease***Labor, obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10109'],streptomycin,"***For the treatment of brucellosis in combination with other antimicrobials.***For brucellosis caused by <em>Brucella</em> sp. in combination with tetracycline.***For the treatment of gram-negative bacillary bacteremia, meningitis, or lower respiratory tract infections (e.g., pneumonia) in combination with other antimicrobials.***For the treatment of urinary tract infection (UTI) due to <em>E. coli</em>, <em>Proteus </em>sp., <em>E. aerogenes</em>, <em>K. pneumoniae</em>, or <em>E. faecalis</em> in combination with other antimicrobials.***For the treatment of chancroid or granuloma inguinale in combination with other antimicrobials.***For the treatment of infective endocarditis. <br />  NOTE: Serum streptomycin concentrations should be used to guide dosage adjustments. A 'dosing' weight should be used to calculate initial dosages in patients weighing more than their ideal body weight. Adjust the streptomycin dose to maintain peak serum concentrations of 20 to 35 mcg/mL and trough concentrations of less than 10 mcg/mL. Avoid streptomycin use in patients with a CrCl less than 50 mL/minute.<br /***For treatment of tuberculosis infection caused by <em>Mycobacterium tuberculosis</em> in combination with other antituberculosis agents as second line therapy. <br />        NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., at least 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, IDSA, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. Directly observed therapy (DOT) should be used for all regimens administered 1, 2,3, or 5 times per week. The initial treatment regimen should include four drugs unless the likelihood of INH or rifampin resistance is low (i.e., &lt; 4%), in which case an initial regimen of INH, rifampin, and pyrazinamide may be considered. HIV positive patients should always receive induction therapy with four drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate.   For multi-drug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, the CDC recommends treatment for 18�24 months after culture conversion in patients with bacteriologic confirmation and for at least 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months in MDR-TB.<br />     ***For the treatment of tuberculosis when isoniazid cannot be used or for strains of <em>Mycobacterium tuberculosis</em> resistant to isoniazid.***For the treatment of tuberculosis in patients unable to take rifamycins or due to strains of <em>Mycobacterium tuberculosis</em> resistant to the rifamycins alone or in combination with other drug resistance.***For the treatment of plague infection due to exposure to <em>Yersinia pestis</em> in an individual patient or in a contained casualty setting. <br />        NOTE: It is recommended that pregnant women be treated with gentamicin as a first-line agent; streptomycin has been associated with deafness in children following fetal exposure and should be avoided if possible.<br />     ***For the initial treatment of tularemia infection due to exposure to <em>Francisella tularensis</em>.***For the treatment of infection due to Mycobacterium avium complex infection� (MAC) in HIV-infected patients.***For the treatment of actinomycotic mycetoma�.***For actinomycotic mycetoma� caused by <em>Actinomadura madurae</em> or <em>Streptomyces somaliensis</em>.***For actinomycotic mycetoma� caused by <em>Actinomadura pelletierii</em> or <em>Nocardia brasiliensis</em>.","***Viral infection***Intravenous administration***Dehydration, hearing impairment, neonates, nephrotoxicity, ototoxicity, renal disease, renal failure, renal impairment, requires a specialized care setting, tinnitus***Botulism, infants, myasthenia gravis, neuromuscular blockade, neurotoxicity, parkinsonism, respiratory depression, respiratory insufficiency***Pregnancy***Breast-feeding***Aminoglycoside hypersensitivity***Sexually transmitted disease***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,levorphanol tartrate,***For the treatment of severe pain that requires an opioid analgesic and for which alternative treatments are inadequate.,"***Opiate agonist hypersensitivity***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, coma, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***CNS depression, head trauma, increased intracranial pressure, intracranial mass, psychosis***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, dehydration, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock***Hepatic disease***Biliary tract disease, pancreatitis***Driving or operating machinery***Acute abdomen, constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, renal impairment, urethral stricture, urinary retention***Adrenal insufficiency, hypothyroidism, myxedema***Geriatric***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Abrupt discontinuation***Children, infants, neonates***Infertility, reproductive risk***Seizure disorder, seizures***Accidental exposure, ethanol ingestion, ethanol intoxication, potential for overdose or poisoning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2101'],aspirin/carisoprodol,"***For the short-term treatment of acute, painful musculoskeletal conditions (e.g., musculoskeletal pain) as an adjunct to rest, physical therapy, and other measures for pain relief.***For the short-term treatment of acute, painful musculoskeletal conditions (e.g., muscle spasm) as an adjunct to rest, physical therapy, and other measures for pain relief. <br />        NOTE: Aspirin; carisoprodol should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for longer term use has not been established and because acute, painful musculoskeletal conditions are generally of short duration.<br />     ","***Hematological disease, porphyria***Asthma, carbamate hypersensitivity, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Anemia, G6PD deficiency***Anticoagulant therapy, gastritis, peptic ulcer disease***Intramuscular injections***GI bleeding***CNS depression, driving or operating machinery***Abrupt discontinuation, substance abuse***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, influenza, neonates, Reye's syndrome, varicella***Hepatic disease, renal disease, renal failure, renal impairment***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['161'],acetaminophen,"***For the treatment of fever. <br />        NOTE: Acetaminophen should not be used for self-medication of marked fever (greater than 39.5 degrees C or 103.1 degrees F), fever persisting longer than 3 days, or recurrent fever, unless directed by a physician.<br />     ***For the treatment of mild pain or for the temporary relief of headache, myalgia, back pain, musculoskeletal pain, dental pain (e.g., toothache), dysmenorrhea, arthralgia, or minor aches and pains associated with the common cold or flu. <br />        NOTE: Acetaminophen should not be used for self-medication of pain for longer than 10 days in adults or 5 days in children.<br />     ***For the treatment of moderate pain to severe pain with adjunctive opioid analgesics.***For minor osteoarthritis pain.***For the treatment of headache pain due to acute migraine�.","***Acetaminophen hypersensitivity***Alcoholism, ethanol intoxication, hepatic disease, hepatitis, hepatotoxicity, hypovolemia, malnutrition, potential for overdose or poisoning***Renal disease, renal failure, renal impairment***G6PD deficiency***Bone marrow suppression, immunosuppression, infection, neutropenia***Tobacco smoking***Children, infants, neonates***Pregnancy***Breast-feeding***Phenylketonuria***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluoxetine hydrochloride,***For the treatment of major depression.***For the treatment of depression with a daily dosage formulation.***For the once-weekly maintenance treatment of depression.***For acute treatment of treatment-resistant depression in combination with olanzapine.***For acute  treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in combination with olanzapine.***For the treatment of obsessive-compulsive disorder (OCD).***For the treatment of panic disorder with or without agoraphobia.***For the treatment of bulimia nervosa.***For the treatment of premenstrual dysphoric disorder (PMDD).***For the treatment of generalized anxiety disorder (GAD)�.***For the treatment of social phobia (social anxiety disorder)�.***For the treatment of posttraumatic stress disorder (PTSD)�.***For the treatment of anorexia nervosa�.***For the treatment of obesity�.***For the treatment of borderline personality disorder�.***For the treatment of autistic disorder�.***For the treatment of separation anxiety disorder�.***For the treatment of fibromyalgia�.***For the treatment of neurogenic orthostatic hypotension�.***For the treatment of premature ejaculation�.***For the treatment of hot flashes� in women with breast cancer experiencing symptoms of menopause�.***For migraine prophylaxis�.***For the treatment of selective mutism� in children who have failed an adequate trial of psychotherapy.***Formoterol***Formoterol; Mometasone,"***General Information***Abrupt discontinuation***Electroconvulsive therapy (ECT), seizure disorder***Children, growth inhibition, suicidal ideation***MAOI therapy***Bipolar disorder, mania***Hepatic disease***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diarrhea, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, poor metabolizers, QT prolongation, thyroid disease, ventricular arrhythmias***Dehydration, hyponatremia, hypovolemia***Anticoagulant therapy, bleeding, thrombolytic therapy***Closed-angle glaucoma, increased intraocular pressure***Driving or operating machinery, ethanol ingestion***Diabetes mellitus***Akathisia***Anorexia nervosa***Bone fractures, osteoporosis***Neonates, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mefloquine hydrochloride,"***For the treatment of mild to moderate malaria.***For the treatment of mild to moderate malaria caused by mefloquine-susceptible strains of <em>P. falciparum</em>.***For the treatment of mild to moderate malaria caused by <em>P. vivax</em>.***For the treatment of cerebral malaria�.***For malaria prophylaxis against <em>P. falciparum</em> and <em>P. vivax</em> malaria, including prophylaxis of chloroquine-resistant strains of <em>P. falciparum</em>.***Formoterol***Formoterol; Mometasone","***General Information***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Driving or operating machinery, neurologic events, seizure disorder, seizures, tinnitus***Hepatic disease***Mefloquine hypersensitivity, quinidine hypersensitivity, quinine hypersensitivity***Pregnancy***Breast-feeding***Anxiety, behavioral changes, depression, psychiatric event, psychosis, schizophrenia, suicidal ideation***Ocular disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,neomycin sulfate/polymyxin B sulfate,***For bacteriuria prophylaxis and bacteremia prophylaxis via continuous prophylactic irrigation of the intact urinary bladder in patients with indwelling catheters.,"***General Information***Aminoglycoside hypersensitivity, neomycin hypersensitivity, polymyxin hypersensitivity***Botulism, dehydration, geriatric, hearing impairment, myasthenia gravis, neuromuscular disease, parkinsonism, renal disease, renal impairment, respiratory insufficiency, surgery***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4508'],flutamide,***For the treatment of prostate cancer.***For the treatment of locally confined Stage B2-C and Stage D2 prostate cancer in combination with leuteinizing hormone-releasing hormone (LHRH) analogs and radiation therapy.***For the treatment of Stage B2�C prostate cancer in combination with goserelin and radiation therapy.***For the treatment of locally confined Stage D2 metastatic prostate cancer in combination with leuteinizing hormone-releasing hormone (LHRH) analogs.,"***Hepatic disease***G6PD deficiency, hemoglobinopathy, tobacco smoking***Females, polycystic ovary syndrome, pregnancy***Lactase deficiency***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['7539', '8701']",penicillin G procaine,"***For the treatment of moderately severe pneumococcal pneumonia, moderately severe to severe staphylococcal infections, and moderately severe to severe group A streptococcal (GAS) infections (tonsillitis, erysipelas, scarlet fever, upper respiratory tract infections, skin and skin structure infections).***For the treatment of subacute bacterial endocarditis due to penicillin-susceptible Group A streptococci.***For the treatment of fusospirochetosis or Vincent's infection (necrotizing ulcerative gingivitis or pharyngitis).***For the treatment of diphtheria.***For diphtheria carrier state.***For the treatment of diphtheria.***For the treatment of rat-bite fever.***For anthrax prophylaxis after exposure to <em>Bacillus anthracis</em> (postexposure prophylaxis, PEP).***For the treatment of syphilis, including neurosyphilis; yaws (<em>Treponema pallidum</em> ssp. <em>pertenue</em>); pinta (<em>Treponema carateum</em>); and bejel (<em>Treponema pallidum</em> ssp. <em>endemicum</em>). <br />        NOTE: The Jarisch-Herxheimer reaction may occur within the first 24 hours of therapy.<br />     ***For the treatment of primary, secondary, or early latent (less than 1 year duration) syphilis, yaws , pinta , and bejel.***For the treatment of late latent (greater than 1 year duration) syphilis, yaws, pinta, and bejel.***For the treatment of tertiary syphilis (patients with gumma and cardiovascular syphilis), yaws, pinta, and bejel.***For the treatment of neurosyphilis.***For the treatment of congenital syphilis. <br />          NOTE: Current CDC guidelines should be consulted to determine the appropriate course of treatment in neonates born to mothers with syphilis. Therapy is based on physical examination, serum quantitive nontreponemal serologic titer, and whether or not the mother was treated properly before delivery. <br />       ","***Viral infection***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Intravenous administration***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Renal failure, renal impairment***Breast-feeding***Pregnancy***Geriatric***Infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['7539', '8701']",penicillin G benzathine/penicillin G procaine,"***For the treatment of moderately severe to severe upper respiratory tract infections, scarlet fever, erysipelas, skin and skin structure infections, and soft-tissue infections due to susceptible streptococci. <br />  NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia.<br /***For the treatment of moderately severe pneumonia and otitis media due to susceptible pneumococci. <br />        NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage.<br />     ","***Viral infection***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Syphilis***Intravenous administration***Ester local anesthetic hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Renal disease, renal impairment***Pregnancy***Breast-feeding***Infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydrocortisone acetate/pramoxine hydrochloride,"***For the temporary relief of skin inflammation, pain, and pruritus associated with corticosteroid-responsive dermatitis, including psoriasis, anorectal inflammation, pain, pruritus, and swelling associated with hemorrhoids, proctitis, cryptitis, anal fissures, postoperative pain, and pruritus ani.***For the adjunctive treatment of chronic ulcerative colitis� when disease is limited to the distal portion of the rectum (e.g., proctosigmoiditis).","***Fungal infection, herpes infection, infection, peripheral vascular disease, tuberculosis, viral infection***Hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, infants, neonates***Geriatric, skin atrophy***Diabetes mellitus***Cataracts, glaucoma, ocular exposure, ophthalmic administration***Pregnancy***Breast-feeding***Hepatic disease***Fistula, GI obstruction, GI perforation, peritonitis, ulcerative colitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['224905'],trastuzumab,"***For the treatment of patients with HER2-positive breast cancer. <br />        NOTE: Patients should be selected based on the presence of HER2 protein overexpression or HER2 gene amplification in tumor specimens. Information on FDA-approved tests for the detection of HER2 protein overexpression and HER2 gene amplification is available at http://www.fda.gov/CompanionDiagnostics. Tests should be specific for breast cancers due to differences in breast vs. gastric histopathology, including incomplete membrane staining and more frequent heterogeneous expression of HER2 seen in gastric cancers.<br />     ***For the treatment of HER2-positive metastatic breast cancer in patients who have failed one or more chemotherapy regimens for metastatic disease as monotherapy.***For the treatment of HER2-positive metastatic breast cancer, in combination with docetaxel�.***For the treatment of HER2-positive metastatic breast cancer, in combination with vinorelbine�.***For adjuvant treatment of HER2-positive, node-positive or node-negative (ER/PR negative or with one high-risk feature) breast cancer in combination with paclitaxel, following completion of doxorubicin and cyclophosphamide chemotherapy (AC-TH).***For adjuvant treatment of HER2-positive, node-positive or node-negative (ER/PR negative or with one high-risk feature) breast cancer in combination with docetaxel, after completion of doxorubicin and cyclophosphamide chemotherapy (AC-TH).***For adjuvant treatment of HER2-positive, node-positive or node-negative (ER/PR negative or with one high-risk feature) breast cancer as monotherapy, following multimodality anthracycline-based chemotherapy.***For adjuvant treatment of HER2-positive, node-positive or node negative (ER/PR negative or with one high-risk feature) breast cancer, in combination with carboplatin and docetaxel (TCH).***For the front-line treatment of HER2-overexpressing metastatic breast cancer, in combination with carboplatin and paclitaxel�.***For the treatment of HER2-positive, trastuzumab-refractory metastatic breast cancer, in combination with lapatinib�.***For the treatment of HER2-positive, hormone receptor-positive metastatic breast cancer, in combination with anastrozole�.***For the neoadjuvant treatment of HER2-positive breast cancer sequential to and in combination with doxorubicin, paclitaxel, and CMF chemotherapy�.***For the neoadjuvant treatment of HER2-positive breast cancer in sequence, and in combination, with paclitaxel and FEC chemotherapy�.***For first-line treatment of HER2-positive metastatic breast cancer in combination with pertuzumab and docetaxel�. <br />          NOTE: Pertuzumab is FDA approved in combination with trastuzumab and docetaxel for the first-line treatment of HER2-positive metastatic breast cancer.<br />       ***For the first-line treatment of HER2-positive metastatic breast cancer, in combination with paclitaxel.***For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with vinorelbine and everolimus�.***For the treatment of patients with previously untreated HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma, in combination with cisplatin and 5-fluorouracil or capecitabine. <br />        NOTE: Patients should be selected based on the presence of HER2 protein overexpression or HER2 gene amplification in tumor specimens. Information on FDA-approved tests for the detection of HER2 protein overexpression and HER2 gene amplification is available at http://www.fda.gov/CompanionDiagnostics. Tests should be specific for gastric cancers due to differences in breast vs. gastric histopathology, including incomplete membrane staining and more frequent heterogeneous expression of HER2 seen in gastric cancers.<br />     ","***Angioedema, hypotension, infusion-related reactions, respiratory distress syndrome***Asthma, chronic lung disease (CLD), chronic obstructive pulmonary disease (COPD), pneumonitis, pulmonary disease, pulmonary fibrosis, pulmonary toxicity***Cardiac arrhythmias, cardiac disease, cardiomyopathy, geriatric, heart failure, hypertension, ventricular dysfunction***Benzyl alcohol hypersensitivity***Human anti-human antibody (HAHA)***Chemotherapy, neutropenia***Pregnancy***Contraception requirements, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7299'],gramicidin/neomycin sulfate/polymyxin B sulfate,"***For the treatment of superficial ophthalmic infection of the external eye and its adnexa including bacterial conjunctivitis, keratitis, keratoconjunctivitis, blepharitis, and blepharoconjunctivitis.***For ophthalmic surgical infection prophylaxis�.","***General Information***Aminoglycoside hypersensitivity, neomycin hypersensitivity, polymyxin hypersensitivity***Contact lenses***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['296'],adenosine,"***For the treatment of stable reentry supraventricular tachycardia or paroxysmal supraventricular tachycardia (PSVT), including PSVT in patients with Wolff-Parkinson-White (WPW) syndrome.***For use as an adjunct to thallium-201 myocardial perfusion imaging for coronary artery disease diagnosis in patients unable to exercise adequately.***For acute vasodilator testing in pulmonary hypertension diagnosis�.***For wide-complex tachycardia diagnosis� and conversion of wide-complex tachycardia of supraventricular origin� in hemodynamically stable patients.","***General Information***Atrial fibrillation, atrial flutter, ventricular tachycardia, Wolff-Parkinson-White syndrome***Asystole, AV block, bradycardia, bundle-branch block, sick sinus syndrome***Autonomic neuropathy, hypotension, hypovolemia, pericardial effusion, pericarditis, valvular heart disease***Angina, cardiac arrest, myocardial infarction, respiratory arrest, ventricular arrhythmias***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema***Geriatric***Pregnancy***Breast-feeding***Heart transplant***Seizure disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4337'],fentanyl,"***For the control of moderate pain or severe pain.***For intraoperative or procedural management of severe pain, for use only in a monitored anesthesia care setting in the hospital.***For control of postoperative pain in the recovery room.***For the management of chronic severe pain in opioid-tolerant patients who require daily, around-the-clock, long-term opioid treatment.***For the management of severe breakthrough cancer pain in opioid-tolerant patients.***For short-term management of acute postoperative pain in the hospital setting using a fentanyl iontophoretic transdermal system (ITS) for patient-controlled analgesia.***For adjuvant management of general anesthesia maintenance and intraoperative pain control.***For minor surgical procedures and for use in the immediate postoperative period.***For major surgery, providing analgesia and some relief from the stress response. <br />          NOTE: Respiratory depression at this dosage level requires artificial ventilation.<br />       ***For open heart surgery and other complicated procedures where surgery is prolonged and the stress response would be detrimental to the patient's well-being.***For general anesthesia induction when attenuation of the responses to surgical stress is especially important such as during major surgery like open heart surgery or complicated neurological or orthopedic procedures.***For analgesia and/or sedation maintenance� in mechanically-ventilated intensive care patients.***For sedation and analgesia prior to rapid-sequence intubation (RSI)�.***For the management of dyspnea� in patients with end-stage cancer or lung disease.***For procedural sedation� of non-intubated patients during diagnostic, surgical, or other procedures.","***General Information***Dental work, headache, migraine, opioid-naive patients, surgery***Constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Accidental exposure***MAOI therapy***Potential for overdose or poisoning, requires a specialized care setting, requires an experienced clinician***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, urethral stricture, urinary retention***Brain tumor, CNS depression, head trauma, increased intracranial pressure, seizure disorder, seizures***Angina, bradycardia, cardiac arrhythmias, cardiac disease, heart failure, hypotension, orthostatic hypotension, shock***Children, infants, neonates, premature neonates***Labor, neonatal opioid withdrawal syndrome, pregnancy***Breast-feeding***Females***Geriatric***Biliary tract disease, pancreatitis***Abrupt discontinuation***Driving or operating machinery***Anticoagulant therapy, coagulopathy, epidural administration, infection, intrathecal administration, thrombocytopenia***Opiate agonist hypersensitivity***Ambient temperature increase, fever, heating pad, skin abrasion, sunlight (UV) exposure***Ocular exposure***Dental disease, diabetes mellitus, stomatitis***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Adrenal insufficiency, hypothyroidism, myxedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,thyrotropin alfa,***For use in patients with thyroid cancer.***For use as an adjunctive diagnostic tool for serum thyroglobulin testing (with or without radioiodine imaging) in the follow-up of patients with well-differentiated thyroid cancer who have undergone thyroidectomy. <br />          NOTE: Thyrotropin has been designated an orphan drug by the FDA for this indication.<br />       ***For adjunctive treatment in radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid disease.,"***Hamster protein hypersensitivity***Requires an experienced clinician***Acute myocardial infarction, angina, cardiac disease, coronary artery disease, geriatric, hyperthyroidism***Females, migraine, stroke, tobacco smoking***Dialysis, renal failure***Pregnancy***Breast-feeding***Children, infants***Intravenous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bupivacaine liposome,***For post-surgical local analgesia.,"***Epidural administration, intrathecal administration, intravenous administration***Continuous intraarticular infusion administration***Hepatic disease***Cardiac disease***Amide local anesthetic hypersensitivity***Renal disease, renal failure, renal impairment***Children, infants, neonates***Labor, obstetric delivery, paracervical nerve block, pregnancy***Breast-feeding***Requires an experienced clinician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['47579'],cabergoline,"***For the treatment of hyperprolactinemia, either idiopathic or due to a pituitary adenoma.***For the treatment of motor fluctuations associated with Parkinson's disease�.***For the treatment of restless legs syndrome (RLS)�.","***Ergot alkaloid hypersensitivity***Hepatic disease***Driving or operating machinery***Hypotension***Hypertension***Constrictive pericarditis, pleural effusion, pulmonary fibrosis***Valvular heart disease***Dementia, psychosis, schizophrenia***Depression***Impulse control symptoms***Eclampsia, preeclampsia, pregnancy***Breast-feeding***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1808'],bumetanide,"***For the treatment of peripheral edema, or edema associated with heart failure or nephrotic syndrome.***For the treatment of hypertension�.***For the acute treatment of hypercalcemia� associated with neoplastic disease in combination with intravenous saline.***For the treatment of ascites�.***Formoterol; Mometasone","***Sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Acid/base imbalance, electrolyte imbalance, hypocalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis***Hepatic disease, hepatic encephalopathy***Diabetes mellitus, hyperglycemia***Anuria, dehydration, hypovolemia, oliguria, renal disease, renal failure, renal impairment***Hypotension, orthostatic hypotension, sympathectomy, syncope***Gout, hyperuricemia***Diarrhea, heart failure, ventricular arrhythmias***Acute myocardial infarction***Hearing impairment, tinnitus***Pancreatitis***Eclampsia, preeclampsia, pregnancy***Breast-feeding***Children, infants, jaundice, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10803'],trifluridine,"***For the treatment of herpes simplex keratitis (dendritic keratitis), including primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus type 1 and herpes simplex virus type 2, and for the treatment of epithelial keratitis that has not responded clinically to idoxuridine or when ocular toxicity or hypersensitivity to idoxuridine has occurred.***For the treatment of viral conjunctivitis� associated with vaccinia virus�.***For the treatment of acyclovir-resistant mucocutaneous herpes simplex virus infection�, including herpes genitalis�, in HIV-infected patients.","***General Information***Children, geriatric, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7426'],nimodipine,"***For the reduction of the incidence and severity of ischemic deficits associated with subarachnoid hemorrhage (SAH) from ruptured berry aneurysms (regardless of post-ictus neurological condition, includes all Hunt and Hess Grades I-V).***For migraine prophylaxis�.","***Hepatic disease***Pregnancy***Acute myocardial infarction, bradycardia, cardiogenic shock, heart failure, ventricular dysfunction***Hypotension***Intraarterial administration, intracorporeal administration, intramuscular administration, intrathecal administration, intravenous administration***Geriatric***Children***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amantadine hydrochloride,"***For the treatment of idiopathic parkinsonism or Parkinson's disease.***For the treatment of dyskinesia associated with Parkinson's disease in patients receiving levodopa-based therapy, with or without concomitant dopaminergic medications.***For the treatment of drug-induced extrapyramidal symptoms (EPS).***For the treatment of uncomplicated influenza A virus infection.***For seasonal influenza prophylaxis for infections due to influenza A virus.***For the treatment of chorea associated with Huntington's Disease (Huntington's Chorea)�.***For the treatment of multiple-sclerosis associated fatigue�.***For the treatment of neuroleptic malignant syndrome�.","***General Information***Amantadine hypersensitivity, rimantadine hypersensitivity***Dialysis, renal failure, renal impairment***Heart failure, orthostatic hypotension, peripheral edema, syncope***Seizure disorder***Depression, psychosis, schizophrenia, substance abuse, suicidal ideation***Impulse control symptoms***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion, narcolepsy, sleep apnea***Hepatic disease***Eczema***Closed-angle glaucoma***Melanoma***Abrupt discontinuation***Pregnancy***Infertility***Breast-feeding***Anticholinergic medications, geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,daunorubicin hydrochloride,***For the treatment of acute myelogenous leukemia (AML) as remission induction or consolidation therapy in combination with other chemotherapy agents.***For the treatment of acute lymphocytic leukemia (ALL) as remission induction therapy in combination with other chemotherapy agents.***Formoterol***Formoterol; Mometasone,"***General Information***Anthracycline hypersensitivity***Bone marrow suppression, herpes infection, infection, neutropenia, requires a specialized care setting, requires an experienced clinician, thrombocytopenia, varicella, viral infection***Radiation therapy***Dental disease, dental work***Extravasation, intramuscular administration, subcutaneous administration***Intramuscular injections***Hepatic disease, jaundice***Renal failure, renal impairment***Hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, tumor lysis syndrome (TLS)***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cardiotoxicity, coronary artery disease, diabetes mellitus, geriatric, heart failure, hypertension, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, maximum cumulative lifetime dose, myocardial infarction, QT prolongation, thyroid disease***Accidental exposure, ocular exposure***Vaccination***Pregnancy***Breast-feeding***Children, infants***Females",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fexofenadine hydrochloride,***For the treatment of allergic rhinitis (hay fever).***For the treatment of chronic idiopathic urticaria.,"***Terfenadine hypersensitivity***Phenylketonuria***Renal disease, renal failure, renal impairment***Geriatric***Pregnancy***Breast-feeding***Driving or operating machinery***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,propranolol hydrochloride,"***For the treatment of chronic stable angina.***For heart rate control in patients with atrial fibrillation and/or atrial flutter.***For the treatment of paroxysmal supraventricular tachycardia (PSVT) or for paroxysmal supraventricular tachycardia (PSVT) prophylaxis.***For the treatment of an evolving acute myocardial infarction. <br />  NOTE: For ST-elevation myocardial infarction, oral beta-blocker therapy should be initiated in the first 24 hours for patients who do not have signs of cardiac failure, evidence of low output, increased risk for cardiogenic shock, or other contraindications for beta-blocker therapy.<br /***For reduction of cardiovascular mortality in stable patients who have sustained a myocardial infarction.***For the treatment of hypertension.***For the treatment of idiopathic hypertrophic subaortic stenosis (IHSS).***For management of pheochromocytoma, including preoperative control of tachycardia before surgery, in conjunction with an alpha-blocker.***For migraine prophylaxis.***For migraine prophylaxis in pediatric patients�.***For migraine prophylaxis in adults.***For the management of tremor.***For the management of essential tremor.***For the management of lithium-induced tremor�.***For the management of essential tremor in pediatric patients.***For the treatment of a proliferating infantile hemangioma requiring systemic therapy. <br />  To reduce the risk of hypoglycemia, administer propranolol immediately after or concurrently with a feeding. Avoid fasting; if inevitable, hold medication or support with a product such as Pedialyte or glucose-containing IV fluids.  Vital signs and cardiorespiratory exam or ECG should be obtained at baseline. Obtain blood pressure and heart rate measurements at 1 and 2 hours after the initial dose and any significant dose increase (e.g., more than 0.5 mg/kg/day).  Experts have recommended propranolol therapy continue until full involution of the lesion has occurred or the patient is at least 1 year of age; recurrences have been reported with early discontinuation. At the end of therapy, gradually taper propranolol over 2 to 4 weeks.      If hemangiomas recur, treatment may reinitiated.<br /***For the treatment of unstable angina�.***For the treatment of anxiety� or panic attacks�.***For the short-term symptomatic management of thyrotoxicosis� and thyroid storm�.***For the short-term symptomatic management of thyrotoxicosis� and thyroid storm� in pediatric patients.***For the short term management of thyrotoxicosis� or thyroid storm in adults�.***For the treatment of hypertension and the subsequent decline in renal function associated with scleroderma renal crisis (SRC)�.***For the treatment of portal hypertension� and/or variceal bleeding prophylaxis� in patients with esophageal varices�.***For the prevention of first variceal bleed (primary variceal bleeding prophylaxis).***For prevention of recurrence of variceal bleed (secondary variceal bleeding prophylaxis).***For the treatment of chronic agitation� or aggressive behavior.***For the prevention and management of hypercyanotic episodes associated with tetralogy of Fallot (i.e., tetralogy spells�).***For the attenuation of hypermetabolism in patients with severe burns�.***For the attenuation of hypermetabolism in adult patients with severe burns.***For the attenuation of hypermetabolism in pediatric patients with severe burns.***For the treatment of heart failure� (ischemic origin or cardiomyopathy�) usually in conjunction with digoxin, diuretics, or ACE inhibitor therapy in children and infants.***For the maintenance of sinus rhythm in patients with supraventricular arrhythmias�, including Wolff-Parkinson-White (WPW) syndrome� and junctional ectopic tachycardia� (JET).***Formoterol; Mometasone","***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***Acute heart failure, AV block, bradycardia, cardiogenic shock, hypotension, pheochromocytoma, pulmonary edema, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Wolff-Parkinson-White syndrome***Cerebrovascular disease, PHACE syndrome, stroke***Diabetes mellitus, hypoglycemia***Hepatic disease***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Beta-blocker hypersensitivity***Raynaud's phenomenon***Myasthenia gravis, myopathy***Depression***Driving or operating machinery***Renal failure, renal impairment***Psoriasis***Surgery***Children, infants, neonates, premature neonates***Obstetric delivery, pregnancy***Breast-feeding***Geriatric***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,agalsidase beta,***For the treatment of Fabry disease. <br />        NOTE: Agalsidase beta has been designated as an orphan drug for this indication by the FDA.<br />NOTE: When to start treatment and the optimal duration of treatment is unknown. Recent guidelines recommend that enzyme replacement therapy be started in all patients with Fabry disease with clinical signs and symptoms and in carriers with substantial disease manifestations,"***General Information***Mannitol hypersensitivity***Cardiac disease***Children, infants, neonates***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,haemophilus b conjugate vaccine (tetanus toxoid conjugate),***For Haemophilus influenzae type b prophylaxis.,"***Intravenous administration***Latex hypersensitivity***Infants, neonates, premature neonates***Pregnancy***Breast-feeding***Agammaglobulinemia, corticosteroid therapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, leukemia, lymphoma, neoplastic disease, severe combined immunodeficiency (SCID)***Guillain-Barre syndrome***Fever, infection***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Native American patients",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5492']['7299'],hydrocortisone/neomycin sulfate/polymyxin B sulfate,"***For the treatment of superficial bacterial infections of the external auditory canal (i.e., otitis externa) caused by susceptible organisms, and for the treatment of infections of mastoidectomy and fenestration caused by susceptible organisms.***For the treatment of corticosteroid-responsive inflammatory ocular conditions and where bacterial ophthalmic infection or a risk of bacterial ophthalmic infection exists (e.g., inflammation of palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in bacterial conjunctivitis is accepted to obtain a decrease in edema and inflammation; also in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign objects).***For the treatment of corticosteroid-responsive dermatitis with secondary infection.","***General Information***Aminoglycoside hypersensitivity, neomycin hypersensitivity***Fungal infection, herpes infection, tuberculosis, varicella, viral infection***Renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Ocular exposure***Otitis media, tympanic membrane perforation***Hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing***Pregnancy***Asthma, sulfite hypersensitivity***Breast-feeding***Glaucoma, surgery***Contact lenses***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mafenide acetate,***For the adjunctive therapy of patients with second or third degree burns for the prophylaxis of burn wound infection.,"***Sulfonamide hypersensitivity***Renal failure, renal impairment***Pulmonary disease, respiratory insufficiency***Asthma***G6PD deficiency***Fungal infection***Pregnancy***Breast-feeding***Infants, neonates, premature neonates***Accidental exposure, intramuscular administration, intravenous administration, ocular exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['10600', '1546004']",timolol,"***For the treatment of hypertension.***For reduction of cardiovascular mortality and to reduce the risk of reinfarction (i.e., myocardial infarction prophylaxis) after an acute myocardial infarction in patients who are clinically stable.***For migraine prophylaxis.***For the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.***For the management of chronic stable angina�.***For the treatment of essential tremor�.","***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***AV block, bradycardia, cardiogenic shock, heart failure, hypotension, pheochromocytoma, pulmonary edema, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Cerebrovascular disease***Diabetes mellitus***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Surgery***Hepatic disease***Geriatric, peripheral vascular disease***Dialysis, renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Raynaud's phenomenon***Depression***Psoriasis***Myasthenia gravis***Contact lenses***Children, infants, neonates***Beta-blocker hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['42316', '235991']",tacrolimus,"***For liver transplant rejection prophylaxis.***For kidney transplant rejection prophylaxis. <br />        NOTE: Do not administer concomitantly with cyclosporine. Additionally, use with sirolimus is not recommended in kidney transplant recipients. <br />NOTE: According to renal transplant guidelines, tacrolimus is the suggested first-line calcineurin inhibitor (CNI) to be used for initial maintenance immunosuppression with an antiproliferative agent such as mycophenolate plus or minus corticosteroids. The CNI is suggested to be started before or at the time of transplantation rather than delayed until graft function onset. Further, the CNI is suggested to be continued rather than withdrawn during long-term maintenance therapy.***For conversion from tacrolimus immediate-release products in combination with other immunosuppresants. <br />          NOTE: Tacrolimus immediate-release capsules (administered twice daily), extended-release capsules (Astagraf XL; administered once daily,) and extended-release tablets (Envarsus XR; administered once daily) are not interchangeable or substitutable. <br />       ***For the management of heart transplant rejection prophylaxis. <br />        NOTE: Tacrolimus is recommended to be used in conjunction with azathioprine or mycophenolate mofetil. Adjunct therapy with adrenal corticosteroids is recommended early post transplant.<br />     ***For the treatment of atopic dermatitis.***For short-term or intermittent long-term treatment of moderate-to-severe atopic dermatitis. <br />          NOTE: Topical tacrolimus is a second line agent to treat atopic dermatitis in patients unresponsive to or intolerant of other first line agents; long-term safety has not been established.<br />NOTE: If no improvement occurs after 6 weeks of treatment or if exacerbation of atopic dermatitis occurs, treatment should be stopped and other therapeutic options considered***For the maintenance of disease stabilization� in patients with moderate-to-severe atopic dermatitis. <br />  NOTE: Precautions apply to the chronic use of topical tacrolimus in children and adolescents; FDA-approved labeling warns against continuous long-term use of topical calcineurin inhibitors in any age group.<br /***For the treatment of acute liver transplant rejection�.***For the treatment of acute kidney transplant rejection�.***For pancreas transplant rejection prophylaxis�.***For the management of pancreas/kidney or solitary pancreas transplant rejection prophylaxis� and refractory kidney and/or pancreas transplant rejection�.***For islet transplantation rejection prophylaxis�.***For the management of heart transplant rejection�.***For the rescue treatment for lung transplant rejection� or the management of lung transplant rejection prophylaxis�.***For the management of small bowel transplant rejection prophylaxis�.***For the treatment of graft-versus-host disease (GVHD)� in combination with other immunosuppressants. <br />        NOTE: Tacrolimus has been designated an orphan drug by the FDA for this indication.<br />     ***For graft-versus-host disease (GVHD) prophylaxis�.***For the treatment of chronic allergic contact dermatitis�.***For the treatment of psoriasis�.***For the treatment of severe, recalcitrant, plaque-type psoriasis�.***For the treatment of facial or intertriginous psoriasis. <br />          NOTE: According to the American Academy of Dermatology (AAD), topical tacrolimus is not generally effective for the treatment of chronic plaque psoriasis.<br />       ***For the treatment of severe, refractory uveitis�.***For the treatment of steroid- and cyclosporine-resistant nephrotic syndrome�.***For the induction of remission of moderately to severely active ulcerative colitis� in patients with either steroid-dependent or steroid-resistant disease. <br />        NOTE: Most patients used medications containing 5-aminosalicylic acid or steroids.<br />     ***For the treatment of vulvar lichen sclerosus�.***For the treatment of lupus nephritis�.***Formoterol***Formoterol; Mometasone","***General Information***Fungal infection, herpes infection, infection, requires a specialized care setting, requires an experienced clinician, varicella, viral infection***Immunosuppression, lymphoma, mononucleosis, new primary malignancy, skin cancer***Liver transplant***Children, infants, neonates***Oliguria, renal disease, renal failure, renal impairment***Hepatic disease***Hyperkalemia, hypertension***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, females, geriatric, heart failure, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Seizure disorder, seizures***Black patients, diabetes mellitus, hyperglycemia***Intravenous administration, polyoxyethylated castor oil hypersensitivity***Pregnancy***Breast-feeding***Vaccination***Sunlight (UV) exposure***Occlusive dressing, ocular exposure***Exfoliative dermatitis, ichthyosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4337'],fentanyl,"***For the control of moderate pain or severe pain.***For intraoperative or procedural management of severe pain, for use only in a monitored anesthesia care setting in the hospital.***For control of postoperative pain in the recovery room.***For the management of chronic severe pain in opioid-tolerant patients who require daily, around-the-clock, long-term opioid treatment.***For the management of severe breakthrough cancer pain in opioid-tolerant patients.***For short-term management of acute postoperative pain in the hospital setting using a fentanyl iontophoretic transdermal system (ITS) for patient-controlled analgesia.***For adjuvant management of general anesthesia maintenance and intraoperative pain control.***For minor surgical procedures and for use in the immediate postoperative period.***For major surgery, providing analgesia and some relief from the stress response. <br />          NOTE: Respiratory depression at this dosage level requires artificial ventilation.<br />       ***For open heart surgery and other complicated procedures where surgery is prolonged and the stress response would be detrimental to the patient's well-being.***For general anesthesia induction when attenuation of the responses to surgical stress is especially important such as during major surgery like open heart surgery or complicated neurological or orthopedic procedures.***For analgesia and/or sedation maintenance� in mechanically-ventilated intensive care patients.***For sedation and analgesia prior to rapid-sequence intubation (RSI)�.***For the management of dyspnea� in patients with end-stage cancer or lung disease.***For procedural sedation� of non-intubated patients during diagnostic, surgical, or other procedures.","***General Information***Dental work, headache, migraine, opioid-naive patients, surgery***Constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Accidental exposure***MAOI therapy***Potential for overdose or poisoning, requires a specialized care setting, requires an experienced clinician***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, urethral stricture, urinary retention***Brain tumor, CNS depression, head trauma, increased intracranial pressure, seizure disorder, seizures***Angina, bradycardia, cardiac arrhythmias, cardiac disease, heart failure, hypotension, orthostatic hypotension, shock***Children, infants, neonates, premature neonates***Labor, neonatal opioid withdrawal syndrome, pregnancy***Breast-feeding***Females***Geriatric***Biliary tract disease, pancreatitis***Abrupt discontinuation***Driving or operating machinery***Anticoagulant therapy, coagulopathy, epidural administration, infection, intrathecal administration, thrombocytopenia***Opiate agonist hypersensitivity***Ambient temperature increase, fever, heating pad, skin abrasion, sunlight (UV) exposure***Ocular exposure***Dental disease, diabetes mellitus, stomatitis***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Adrenal insufficiency, hypothyroidism, myxedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,interferon beta-1b,***For treatment of multiple sclerosis (MS). <br />        NOTE: The specific activity of interferon beta-1b is approximately 32 million International Units/mg.<br />NOTE: Interferon beta-1b has been designated as an orphan drug by the FDA for this indication.<br />NOTE: Patients in whom efficacy has been demonstrated include those who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis***For relapsing-remitting forms of MS to decrease the frequency of clinical exacerbations.***For secondary progressive MS� to delay neurological deterioration.,"***Pregnancy***Heart failure***Albumin hypersensitivity, E. coli protein hypersensitivity, mannitol hypersensitivity***Breast-feeding***Children, infants, neonates***Depression, suicidal ideation***Bone marrow suppression***Hyperthyroidism, hypothyroidism, thyroid disease***Hepatic disease, hepatitis***Seizures***Hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP)***Latex hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,desirudin,"***For deep venous thrombosis (DVT) prophylaxis in patients undergoing elective hip replacement surgery.***For patients with acute coronary syndromes (acute myocardial infarction, NSTEMI; acute myocardial infarction, STEMI; unstable angina)�.***For prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA)�.","***General Information***Bleeding, epidural anesthesia, lumbar puncture, spinal anesthesia, trauma***Aneurysm, coagulopathy, diabetic retinopathy, diverticulitis, endocarditis, GI bleeding, hemophilia, hepatic disease, hypertension, inflammatory bowel disease, intracranial bleeding, menstruation, organ biopsy, peptic ulcer disease, renal disease, retinal bleeding, retroperitoneal bleeding, stroke, surgery, vitamin K deficiency***Renal failure, renal impairment***Intramuscular administration, intramuscular injections***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fexofenadine hydrochloride/pseudoephedrine hydrochloride,"***For the temporary relief of symptoms due to seasonal allergic rhinitis or the common cold, including sneezing, rhinorrhea, itching of the nose or throat, nasal congestion, and itchy, watery eyes.***Formoterol***Formoterol; Mometasone","***Terfenadine hypersensitivity***Renal disease, renal failure, renal impairment***Driving or operating machinery***Closed-angle glaucoma, diabetes mellitus, hyperthyroidism, prostatic hypertrophy, urinary retention***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, heart failure, hypertension, myocardial infarction, tachycardia***MAOI therapy***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mecasermin (rDNA origin),"***For the long-term treatment of growth failure in children with severe primary insulin-like growth factor (IGF-1) deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. <br />  NOTE: Severe primary IGF-1 deficiency is defined as a height standard deviation score of -3 or less, basal IGF-1 standard deviation score of -3 or less, and normal or elevated GH. Severe primary IGF-1 deficiency includes patients with mutations in the GH receptor (GHR), post-GHR signaling pathway, and IGF-1 gene defects. These patients are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment.<br /***For the slowing of the progression of muscle paralysis associated with amyotrophic lateral sclerosis (ALS)�.","***General Information***Benzyl alcohol hypersensitivity, neonates***Intravenous administration***Neoplastic disease***Epiphyseal closure, scoliosis***Children***Corticosteroid therapy, hypothyroidism, malnutrition***Diabetes mellitus, driving or operating machinery, hypoglycemia***Sleep apnea***Increased intracranial pressure***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['7880', '235379']",pancrelipase,"***For the management of exocrine pancreatic insufficiency, such as in patients with cystic fibrosis, chronic pancreatitis, or other conditions.***For the management of exocrine pancreatic insufficiency due to pancreatectomy.***For enteral feeding tube occlusion�.","***Porcine protein hypersensitivity***Viral infection***Dysphagia, esophageal stricture***Gout, hyperuricemia, renal impairment***Fibrosing colonopathy, GI obstruction, inflammatory bowel disease, surgery***Pregnancy***Breast-feeding***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8588'],penicillin V potassium,"***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis (rheumatic fever prophylaxis) and for bacterial colonization eradication� in chronic carriers of group A beta-hemolytic Streptococci (GAS)�.***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis (rheumatic fever prophylaxis).***For secondary prevention of rheumatic fever (prevention of recurrent rheumatic fever attacks) or chorea.***For the treatment of chronic carriers of group A beta-hemolytic Streptococci (GAS)� (bacterial colonization eradication�).***For the treatment of mild to moderately severe skin and skin structure infections (e.g. erysipelas) due to <em>Streptococcus pyogenes</em> (group A beta-hemolytic streptococci) or mild skin and skin structure infections due to <em>Staphylococcus</em> sp..***For the treatment of scarlet fever due to <em>Streptococcus pyogenes</em> (group A beta-hemolytic streptococci).***For the treatment of necrotizing ulcerative gingivitis (fusospirochetosis or Vincent's infection).***For use in endocarditis prophylaxis.***For the treatment of acute otitis media.***For the treatment of actinomycosis�.***For the treatment of rat-bite fever�.***For pneumococcal prophylaxis� in recipients of a bone marrow transplant, including stem-cell transplant recipients, with chronic graft-versus-host disease (GVHD).***For penicillin desensitization� of patients with a positive penicillin allergy skin test who require penicillin therapy. <br />        NOTE: Fourteen oral doses are to be administered before any parenteral administration. Oral doses listed are further diluted in approximately 30 mL of water and administered every 15 minutes. The total time elapsed for the oral desensitization protocol is 3 hours and 45 minutes with a cumulative dose of 1.3 million units. After the administration of the 14th oral dose of the desensitization protocol is complete, the patient should be observed for 30 minutes before beginning parenteral therapy. Patients must be maintained on penicillin continuously for the duration of the course of therapy.<br />     ***For doses 1 to 7 of oral desensitization protocol.***For doses 8 to 10 of oral desensitization protocol.***For doses 11 to 14 of oral desensitization protocol.***For treatment of cutaneous anthrax� infection due to exposure to <em>Bacillus anthracis</em> or as oral follow-up therapy for severe anthrax.***For anthrax prophylaxis� after exposure to <em>Bacillus anthracis</em> (postexposure prophylaxis, PEP).","***General Information***Viral infection***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Phenylketonuria***Renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5487']['6918'],hydrochlorothiazide/metoprolol tartrate,"***For the treatment of hypertension in patients who do not respond to monotherapy. <br />        NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br />     ***Formoterol***Formoterol; Mometasone","***Beta-blocker hypersensitivity, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, renal disease, renal failure, renal impairment***Abrupt discontinuation***Depression***AV block, bradycardia, cardiogenic shock, heart failure, pulmonary edema, sick sinus syndrome, ventricular dysfunction, Wolff-Parkinson-White syndrome***Cerebrovascular disease***Hyperthyroidism, thyroid disease, thyrotoxicosis***Diabetes mellitus, hyperglycemia***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Peripheral vascular disease, Raynaud's phenomenon, vasospastic angina***Pheochromocytoma***Hepatic disease***Psoriasis***Myasthenia gravis***Hypotension, surgery***Electrolyte imbalance, hypercalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis***Hypovolemia, orthostatic hypotension, sympathectomy, syncope***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Hypercholesterolemia, hypertriglyceridemia***Preeclampsia, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fexofenadine hydrochloride/pseudoephedrine hydrochloride,"***For the temporary relief of symptoms due to seasonal allergic rhinitis or the common cold, including sneezing, rhinorrhea, itching of the nose or throat, nasal congestion, and itchy, watery eyes.***Formoterol***Formoterol; Mometasone","***Terfenadine hypersensitivity***Renal disease, renal failure, renal impairment***Driving or operating machinery***Closed-angle glaucoma, diabetes mellitus, hyperthyroidism, prostatic hypertrophy, urinary retention***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, heart failure, hypertension, myocardial infarction, tachycardia***MAOI therapy***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7597'],nystatin,"***For the treatment of cutaneous candidiasis (including adjunctive treatment for candidal diaper dermatitis), mucocutaneous candidiasis (i.e., oropharyngeal candidiasis (thrush), vulvovaginal candidiasis), and intestinal candidiasis (with or without coexisting vulvovaginal candidiasis).***For the treatment of oropharyngeal candidiasis (thrush).***For the treatment of cutaneous candidiasis or mucocutaneous candidiasis, or for adjunctive treatment for candidal diaper dermatitis.***For the treatment of vulvovaginal candidiasis (VVC).***For the treatment of intestinal candidiasis (with or without coexisting vulvovaginal candidiasis).",***Paraben hypersensitivity***Pregnancy***Breast-feeding***Diabetes mellitus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mafenide acetate,***For the adjunctive therapy of patients with second or third degree burns for the prophylaxis of burn wound infection.,"***Sulfonamide hypersensitivity***Renal failure, renal impairment***Pulmonary disease, respiratory insufficiency***Asthma***G6PD deficiency***Fungal infection***Pregnancy***Breast-feeding***Infants, neonates, premature neonates***Accidental exposure, intramuscular administration, intravenous administration, ocular exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,chlorpheniramine maleate/hydrocodone bitartrate/pseudoephedrine hydrochloride,"***For the relief of symptoms such as cough and/or nasal congestion associated with the common cold or upper respiratory allergies (e.g., allergic rhinitis).***Formoterol***Formoterol; Mometasone","***General Information***Constipation, diarrhea, GI obstruction, ileus, peptic ulcer disease, ulcerative colitis***Bladder obstruction, prostatic hypertrophy, renal impairment, urethral stricture, urinary retention***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, hypertension, myocardial infarction, tachycardia***Diabetes mellitus, hyperthyroidism***Closed-angle glaucoma, contact lenses***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, respiratory depression***Opiate agonist hypersensitivity***Driving or operating machinery***Hepatic disease***Children, infants, neonates***Labor, pregnancy***Breast-feeding***Substance abuse***Abrupt discontinuation***Head trauma, increased intracranial pressure***Anticholinergic medications, MAOI therapy***Adrenal insufficiency***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5487']['8787'],hydrochlorothiazide/propranolol hydrochloride,***For the treatment of hypertension. <br />        NOTE: Hydrochlorothiazide; propranolol is not indicated for the initial treatment of hypertension. The dosage must be determined by individual titration with the separate components.<br />     ***Formoterol***Formoterol; Mometasone,"***General Information***Abrupt discontinuation***Beta-blocker hypersensitivity, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Hyperthyroidism, thyroid disease, thyrotoxicosis***AV block, bradycardia, cardiogenic shock, heart failure, hypotension, pheochromocytoma, pulmonary edema, sick sinus syndrome, vasospastic angina***Wolff-Parkinson-White syndrome***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema***Cerebrovascular disease***Diabetes mellitus, hyperglycemia, hypoglycemia***Hypovolemia, orthostatic hypotension, sympathectomy, syncope***Anuria, renal disease, renal failure, renal impairment***Hepatic disease***Acid/base imbalance, electrolyte imbalance, hypercalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Driving or operating machinery***Peripheral vascular disease, Raynaud's phenomenon***Depression***Psoriasis***Myasthenia gravis***Surgery***Tobacco smoking***Geriatric***Children***Labor, obstetric delivery, preeclampsia, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albuterol sulfate,"***For the treatment of acute bronchospasm (e.g., asthma) and bronchospasm prophylaxis.***For bronchospasm associated reversible obstructive airway disease (i.e., asthma).***For exercise-induced bronchospasm prophylaxis.***For the adjunctive emergency acute treatment of hyperkalemia�.***For the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD)� including chronic bronchitis� and emphysema�.","***General Information***Albuterol hypersensitivity, levalbuterol hypersensitivity, milk protein hypersensitivity***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, tachycardia, thyroid disease***Geriatric***Hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyrotoxicosis***Diabetes mellitus, diabetic ketoacidosis***Deterioration of asthma, paradoxical bronchospasm***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Renal impairment***MAOI therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1369']['7226'],bendroflumethiazide/nadolol,"***For the treatment of hypertension in patients who do not respond to monotherapy. <br />        NOTE: Initially, individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Beta-blocker hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, renal disease, renal failure, renal impairment***Abrupt discontinuation***Depression***AV block, bradycardia, cardiogenic shock, heart failure, pulmonary edema, sick sinus syndrome, ventricular dysfunction***Cerebrovascular disease***Hyperthyroidism, thyroid disease***Diabetes mellitus, hyperglycemia***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Peripheral vascular disease, pheochromocytoma, Raynaud's phenomenon, vasospastic angina***Hepatic disease***Psoriasis***Myasthenia gravis***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***Surgery***Acid/base imbalance, electrolyte imbalance, hypercalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis***Pancreatitis***Hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Hypercholesterolemia, hypertriglyceridemia***Labor, obstetric delivery, preeclampsia, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"5 mg, 10 mg, 15 mg, 30 mg) (buspirone hydrochloride",***For the treatment of generalized anxiety disorder (GAD) or for the short-term relief of the symptoms of anxiety.,"***General Information***MAOI therapy***Benzodiazepine dependence***Akathisia***Renal failure, renal impairment***Hepatic disease***Driving or operating machinery, ethanol ingestion***Geriatric***Pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,glucagon (rDNA origin),"***For the treatment of severe hypoglycemia.***For the treatment of severe hypoglycemia in neonates.***For use in radiographic examination of the GI tract.***For the treatment of congenital hyperinsulinemia� (e.g., hyperinsulinemic hypoglycemia).***For the treatment of beta-blocker toxicity�, or for adjunctive treatment of calcium channel blocker toxicity (e.g., verapamil toxicity�).***For the emergency treatment of choking due to esophageal foreign body impaction�.","***General Information***Insulinoma, pheochromocytoma***Adrenal insufficiency, malnutrition***Cardiac disease, coronary artery disease***Children***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1242127'],glucarpidase,***For the treatment of methotrexate toxicity (methotrexate plasma concentration >1 micromole/liter) in patients with delayed methotrexate clearance due to impaired renal function. <br />        NOTE: Glucarpidase is not indicated for use in patients who exhibit the expected clearance of methotrexate defined as plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered.<br />NOTE: Glucarpidase is not indicated for use in patients with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate,***General Information***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bromocriptine mesylate,"***For the treatment of Parkinson's disease.***For the treatment of acromegaly.***For the treatment of prolactin-secreting pituitary adenoma or disorders associated with hyperprolactinemia including amenorrhea with or without galactorrhea, male hypogonadism, or female infertility.***For use as an adjunct to diet and exercise in the treatment of type 2 diabetes mellitus.***For the treatment of mastalgia� associated with premenstrual syndrome (PMS)�.***For the maintenance treatment of alcohol dependence�.***For the treatment of symptoms associated with cocaine withdrawal�.***For the treatment of symptoms associated with neuroleptic malignant syndrome�.","***General Information***Ergot alkaloid hypersensitivity***Abrupt discontinuation***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, coronary artery disease, hypertension, peripheral vascular disease***Hypotension, orthostatic hypotension***Bipolar disorder, dementia, depression, driving or operating machinery, schizophrenia***Hepatic disease***Surgery***Pulmonary fibrosis, retroperitoneal fibrosis***GI bleeding, peptic ulcer disease***Geriatric***Basilar/hemiplegic migraine***Renal disease, renal impairment***Diabetic ketoacidosis, type 1 diabetes mellitus***Eclampsia, preeclampsia, pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1242987'],vismodegib,***For the treatment of metastatic basal cell carcinoma or locally advanced basal cell carcinoma that has recurred following surgery or in patients who are not candidates for surgery or radiation.,"***Blood donation***Children, growth inhibition, infants, neonates***Intrauterine fetal death, pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,minocycline hydrochloride,"***For the treatment of relapsing fever due to <em>Borrelia recurrentis</em>.***For the treatment of chancroid due to <em>Haemophilus ducreyi</em>.***For the treatment of Campylobacter fetus infections.***For the treatment of acute intestinal amebiasis as an adjunct to amebicides.***For the treatment of lower respiratory tract infections and upper respiratory tract infections.***For the treatment of skin and skin structure infections due to <em>Staphylococcus aureus</em>. <br />        NOTE: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection. <br />     ***For the treatment of Rickettsial infections (e.g., murine typhus, Q fever, Rocky Mountain spotted fever, Rickettsial pox).***For the treatment of uncomplicated gonorrhea infections, including urethritis.***For the treatment of psittacosis.***For the treatment of lymphogranuloma venereum caused by <em>Chlamydia trachomatis</em>.***For the treatment of non-gonococcal urethritis (NGU) and chlamydia infection, including trachoma and chlamydial conjunctivitis.***For the treatment of urethral, endocervical, or rectal infections.***For the treatment of other chlamydia infections, including trachoma and inclusion bacterial conjunctivitis.***For the treatment of syphilis when penicillin is contraindicated.***For the treatment of granuloma inguinale (Donovanosis) due to <em>Klebsiella granulomatis</em>.***For the treatment of bartonellosis.***For the treatment of brucellosis in combination with streptomycin.***For the treatment of urinary tract infection (UTI).***For the treatment of plague after exposure to <em>Yersinia pestis</em>.***For the treatment of tularemia following exposure to <em>Francisella tularensis</em>.***For the treatment of cholera.***For the treatment of acne vulgaris.***For the treatment of non-nodular moderate to severe acne vulgaris.***For the treatment of infections caused by <em>Actinomyces israelii</em> (actinomycosis), <em>Bacillus anthracis</em> (anthrax), <em>Clostridium</em> sp. (clostridial diseases), necrotizing ulcerative gingivitis (Fusospirochetosis or Vincent's infection), <em>Listeria monocytogenes</em> (listeriosis), or <em>Treponema pertenue</em> (yaws) when penicillin is contraindicated.***For the treatment meningitis due to <em>Neisseria meningitidis</em>.***For the treatment of the meningococcal carrier state (i.e., for meningococcal infection prophylaxis).***For the treatment of Mycobacterium marinum infection.***For the treatment of rheumatoid arthritis�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis in combination with conventional treatment (e.g., scaling and root planing).***For aggressive periodontitis (juvenile periodontitis)�.***For use as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult chronic periodontitis.***For the treatment of bullous pemphigus�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated bone and joint infections� or an orthopedic device-related infection�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated osteomyelitis�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated prosthetic device infections�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated spinal implant infections�.","***General Information***Serious rash, tetracyclines hypersensitivity***Hepatic disease, hepatitis, hepatotoxicity***Autoimmune disease***Renal failure, renal impairment***Increased intracranial pressure, papilledema, pseudotumor cerebri, visual disturbance***Sunlight (UV) exposure***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***AV block, cardiac disease***Children, infants, neonates***Sexually transmitted disease***Geriatric***Dental work***Pregnancy***Breast-feeding***Infertility, reproductive risk***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,betaxolol hydrochloride,***For the treatment of hypertension.***For the treatment of chronic open-angle glaucoma and ocular hypertension. <br />        NOTE: Beta-blockers are generally less effective in the treatment of angle-closure glaucoma than for open angle-glaucoma.�<br />     ,"***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***AV block, bradycardia, cardiogenic shock, heart failure, pheochromocytoma, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Diabetes mellitus***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Surgery***Dialysis, renal disease, renal failure, renal impairment***Neonates, pregnancy***Breast-feeding***Driving or operating machinery***Cerebrovascular disease, peripheral vascular disease, Raynaud's phenomenon***Depression***Psoriasis***Myasthenia gravis***Contact lenses***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,triamcinolone acetonide,"***For bronchospasm prophylaxis or maintenance therapy in patients who require chronic treatment with corticosteroids for control of bronchial asthma.***For the treatment of severe or incapacitating allergic conditions such as asthma that are intractable to adequate trials of conventional treatment.***For the treatment of symptoms of seasonal and perennial allergic rhinitis.***For the treatment of severe or incapacitating allergic conditions that are intractable to adequate trials of conventional treatment.***For the treatment of ocular inflammation (i.e., sympathetic ophthalmia and ocular inflammatory conditions unresponsive to topical corticosteroids), temporal arteritis, and uveitis.***For visualization during ocular surgery (i.e., vitrectomy).***For the treatment of acute rheumatic carditis, berylliosis, temporal arteritis�, or systemic lupus erythematosus (SLE). <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses (e.g., alopecia areata, atopic dermatitis, contact dermatitis including <em>Rhus dermatitis</em> due to poison ivy, poison oak, poison sumac, subacute cutaneous or discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex chronicus, mycosis fungoides, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, psoriasis, sarcoidosis, seborrheic dermatitis, sunburn, or xerosis). <br />        NOTE: Occlusive dressings may be necessary for chronic or severe cases of psoriasis or other recalcitrant conditions.<br />     ***For the treatment of ulcerative or inflammatory oral lesions including aphthous ulcer, desquamative gingivitis�, and oral lichen planus�.***For the treatment of severe or incapacitating allergic conditions such as atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions, bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome) that are intractable to adequate trials of conventional treatment and for the treatment of idiopathic eosinophilic pneumonias.***For the treatment of symptomatic sarcoidosis.***For the treatment of primary (Addison's disease) or secondary adrenocortical insufficiency. <br />        NOTE: Hydrocortisone and cortisone are the preferred agents for these conditions.<br />     ***For the treatment of congenital adrenal hyperplasia.***For the treatment of hypercalcemia associated with cancer.***For the treatment of nonsuppurative thyroiditis.***For the treatment of a critical period of regional enteritis and ulcerative colitis.***For the treatment of autoimmune hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, or selected cases of secondary thrombocytopenia.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of acute exacerbations of multiple sclerosis. <br />        NOTE: Corticosteroids are effective in speeding the resolution of acute exacerbations, but they do not affect the ultimate outcome or natural history of the disease.<br />     ***For the treatment of cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.***For the treatment of proteinuria or to induce diuresis in idiopathic nephrotic syndrome or lupus erythematosus.***For the treatment of an acute episode or exacerbation of ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA) as adjunctive therapy for short-term administration.***For the treatment of dermatomyositis or polymyositis.***For the relief of inflammation and for immunosuppression associated with a variety of disorders, like Hodgkin lymphoma. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the palliative treatment of leukemias and lymphomas.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of diabetic macular edema�.***For the relief of inflammation associated with synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; gout with acute gouty arthritis; epicondylitis; acute non-specific tenosynovitis; polychondritis�; posttraumatic osteoarthritis. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of osteoarthritis pain of the knee. <br />  NOTE: Zilretta is not interchangeable with other formulations of triamcinolone acetonide.<br /","***Epidural administration, intramuscular administration, intrathecal administration, intravenous administration, subcutaneous administration***Acute bronchospasm, status asthmaticus***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hyperthyroidism, hypothalamic-pituitary-adrenal (HPA) suppression, hypothyroidism, increased intracranial pressure, occlusive dressing, skin abrasion***Head trauma***Growth inhibition, osteoporosis***Surgery***Fungal infection, infection, viral infection***Tuberculosis***Immunosuppression***Herpes infection, measles, varicella***Glaucoma***Acne rosacea, acne vulgaris***Peripheral vascular disease***Nasal septal perforation, nasal surgery, nasal trauma***Myocardial infarction***Heart failure, hypertension***Diabetes mellitus***Skin atrophy***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Myasthenia gravis***Psychosis, seizure disorder***Coagulopathy, hemophilia, thromboembolic disease***Cataracts, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Vaccination***Breast-feeding***Tartrazine dye hypersensitivity***Neonates, premature neonates***Idiopathic thrombocytopenic purpura (ITP)***Corticosteroid hypersensitivity***Geriatric***Renal disease, renal impairment***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['15202'],argatroban,"***For use as an anticoagulant in the treatment of thrombosis (i.e., deep venous thrombosis (DVT), pulmonary embolism) or for venous thromboembolism (VTE) prophylaxis (i.e., deep venous thrombosis (DVT) prophylaxis, pulmonary embolism prophylaxis) in patients with heparin-induced thrombocytopenia (HIT). <br />        NOTE: Before administering argatroban, discontinue heparin therapy and obtain a baseline aPTT.<br />     ***For conversion to oral anticoagulant therapy in patients receiving argatroban. <br />          NOTE: Initiate warfarin therapy using the expected daily dose of warfarin; a loading dose of warfarin should not be used.<br />NOTE: There is potential for combined effects on the INR with coadministration of argatroban and warfarin. The relationship between the INR obtained on combined therapy and the INR obtained on warfarin alone is dependent on both the dose of argatroban and the thromboplastin reagent used***For coronary artery thrombosis prophylaxis or treatment during percutaneous coronary intervention (PCI) in patients who have or who are at risk of developing heparin-induced thrombocytopenia.***For use as adjunctive therapy to thrombolytic agents in the treatment of ST-elevation myocardial infarction (STEMI)� (i.e., acute myocardial infarction�).***For the treatment of disseminated intravascular coagulation (DIC)�.***Formoterol; Mometasone","***Hepatic disease***Aneurysm, bleeding, coagulopathy, diverticulitis, endocarditis, GI bleeding, hemophilia, hypertension, inflammatory bowel disease, intracranial bleeding, intramuscular injections, lumbar puncture, menstruation, peptic ulcer disease, renal disease, retroperitoneal bleeding, spinal anesthesia, stroke, surgery, trauma***Abrupt discontinuation, angina***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['753346'],sinecatechins,"***For the treatment of external genital and perianal warts (Condylomata acuminata). <br />        NOTE: Sinecatechins ointment has not been evaluated for the treatment of urethral, intra-vaginal, cervical, rectal, or intra-anal human papilloma viral disease and is not recommended for these conditions.<br />NOTE: Sinecatechins ointment has not been evaluated for treatment beyond 16 weeks, for multiple treatment courses, or for use in immunocompromised patients","***General Information***Accidental exposure, ocular exposure, vaginal administration***Immunosuppression***Sunlight (UV) exposure***Contraceptive devices***Occlusive dressing***Geriatric***Pregnancy***Children, infants, neonates***Breast-feeding***Viral infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,buprenorphine hydrochloride,"***For the treatment of moderate pain or severe pain.***For treatment of chronic severe pain in patients who require daily, around-the-clock, long-term opioid treatment. <br />          NOTE: Transdermal and buccal buprenorphine should be reserved for patients in whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Discontinue all other around-the-clock opioid drugs upon initiation of transdermal buprenorphine. <br />NOTE: Transdermal buprenorphine doses of 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour, and 20 mcg/hour are for use in opioid-experienced patients only.<br />NOTE: Buccal doses of 600 mcg, 750 mcg, and 900 mcg are for use following titration from lower doses of the buccal film***For the treatment of opiate agonist dependence, including opiate agonist withdrawal symptoms.***For the prevention of undue symptoms of opiate agonist withdrawal during induction of opiate agonist dependence treatment.***For maintenance treatment of opiate agonist dependence.***For maintenance treatment of opioid agonist dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine-containing product (i.e., doses of no more than 8 mg per day of Subutex or Suboxone sublingual tablet equivalent or generic equivalent).***For the management of neonatal abstinence syndrome�.***Formoterol***Formoterol; Mometasone","***Opiate agonist hypersensitivity***Accidental exposure, alcoholism, depression, implant insertion and removal complications, potential for overdose or poisoning, requires an experienced clinician, substance abuse***Abrupt discontinuation***Dental work, surgery***Anxiety***Acute abdomen, constipation, diarrhea, GI obstruction, ileus, inflammatory bowel disease, toxic megacolon, ulcerative colitis***Children, infants***Acute intoxication of CNS depressants, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), CNS depression, coadministration with other CNS depressants, cor pulmonale, driving or operating machinery, emphysema, ethanol intoxication, heart failure, obesity, psychosis, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Coma, head trauma, hypoxemia, increased intracranial pressure, intracranial mass***Labor, neonatal opioid withdrawal syndrome, neonates, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Bladder obstruction, oliguria, prostatic hypertrophy, renal failure, renal impairment, urethral stricture, urinary retention, urinary tract obstruction***Biliary cirrhosis, biliary obstruction, biliary tract disease, gallbladder disease, pancreatitis***Acute heart failure, acute myocardial infarction, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Fever, heating pad, sunlight (UV) exposure***Hypotension, hypovolemia, orthostatic hypotension***Seizure disorder, seizures***Opioid-naive patients, pain***Geriatric***Adrenal insufficiency, hypothyroidism, myxedema***Infection, intramuscular administration***Scleroderma***Infertility, reproductive risk***Intravenous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,aminolevulinic acid hydrochloride,"***For the treatment of minimally to moderately severe actinic keratosis.***For the treatment of actinic keratosis lesions of the scalp or face.***For the treatment of actinic keratosis lesions of the upper extremities.***For use during surgery in patients with glioma (suspected World Health Organization Grades III and IV on preoperative imaging) as an adjunct for visualization of malignant glioma.***For the treatment basal cell carcinoma� and other non-melanoma skin cancers (i.e., cutaneous squamous cell cancer)�.***For ablation of high-grade dysplasia and early cancer in patients with Barrett's esophagus�.***For the treatment of head and neck cancer� including esophageal cancer�.","***Porphyria, porphyrin hypersensitivity, skin photosensitivity disorder***Accidental exposure, ocular exposure***Sunlight (UV) exposure***Pregnancy***Breast-feeding***Coagulopathy***Inflammation",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4179'],etoposide,"***For the treatment of testicular cancer.***For the treatment of refractory testicular cancer, in combination with other chemotherapeutic agents.***For the treatment of small cell lung cancer (SCLC).***For the first-line treatment of SCLC, in combination with other chemotherapeutic agents.***For the treatment of extensive disease SCLC in combination with carboplatin�.***For the treatment of limited disease SCLC in combination with carboplatin and radiation therapy�.***For the treatment of newly-diagnosed small cell lung cancer (SCLC) in combination with cyclophosphamide and doxorubicin.***For the treatment of non-small cell lung cancer (NSCLC)�.***For the adjuvant treatment of resected stage IB�III non-small cell lung cancer (NSCLC) in combination with cisplatin�.***For the treatment of stage IIIB non-small cell lung cancer (NSCLC) in combination with cisplatin and concurrent radiotherapy�.***For the treatment of high-risk gestational trophoblastic disease�.***For the treatment of acute lymphocytic leukemia (ALL)�.***For the treatment of relapsed or refractory ALL, in combination with cyclophosphamide and clofarabine�.***For the treatment of relapsed or refractory acute lymphocytic leukemia (ALL) in combination with ifosfamide, carboplatin, and rituximab�.***For the treatment of refractory acute myelogenous leukemia (AML)� in combination with mitoxantrone and cytarabine.***For the treatment of Hodgkin lymphoma�.***For the treatment of Hodgkin lymphoma as part of the Stanford V regimen.***For the treatment of Hodgkin lymphoma as part of the BEACOPP regimen.***For the treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL)� in combination with ifosfamide and carboplatin.***For stem cell transplant preparation and bone marrow ablation�.***For stem cell mobilization in combination with ifosfamide and carboplatin, in transplant eligible patients with non-Hodgkin's lymphoma.***For stem cell transplant preparation and bone marrow ablation for allogeneic hematopoietic stem cell transplantation, in combination with total body irradiation�.***For the treatment of neuroblastoma�.***For the treatment of intermediate-risk neuroblastoma in combination with carboplatin, cyclophosphamide, doxorubicin�.***For the treatment of localized and unresectable neuroblastoma in combination with cisplatin, alternating with cyclophosphamide, vincristine, and doxorubicin�.***For the treatment of refractory desmoid tumor� and fibromatosis�.***For the first-line treatment of unresectable, advanced thymoma�.***For the first-line treatment of unresectable, advanced thymoma in combination with cisplatin�.***For the first-line treatment of unresectable, advanced thymoma in combination with cisplatin and ifosfamide�.***For the first-line treatment of unresectable, advanced thymic carcinoma�, in combination with cisplatin and ifosfamide.***For the treatment of poor-risk relapsed Wilms' tumor in combination with ifosfamide and carboplatin�.***For the treatment of newly diagnosed Ewing's sarcoma� family tumors, in combination with ifosfamide, alternating with vincristine, doxorubicin, and cyclophosphamide.","***Infusion-related reactions***Bleeding, bone marrow suppression, infection, neutropenia, requires an experienced clinician, thrombocytopenia***Extravasation***Hepatic disease, hypoalbuminemia***Renal disease, renal impairment***New primary malignancy***Geriatric***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['6854', '227717']",methoxsalen,"***For the treatment of cutaneous T-cell lymphoma (CTCL).***For the palliative treatment of the skin manifestations of CTCL unresponsive to other forms of treatment, used with the UVAR XTS or CELLEX photopheresis system.***For the treatment of idiopathic vitiligo (in conjunction with UVA). <br />        NOTE: Idiopathic vitiligo is reversible but not equally reversible in every patient. Repigmentation will vary in completeness, onset time, and duration. Repigmentation occurs more rapidly in fleshy areas such as the face, abdomen, and buttocks and less rapidly over less fleshy areas such as the dorsum of the hands or feet.<br />     ***For the treatment of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy and is diagnosed by biopsy; alopecia� areata; atopic dermatitis�; eczema�; lichen planus�; and for increased tolerance of skin to sunlight�. <br />        NOTE: Methoxsalen soft gelatin capsules and hard gelatin capsules are not interchangeable. The mean J/cm2 for the soft gelatin capsules is substantially less than that required for the hard gelatin capsules due to pharmacokinetic differences (see Pharmacokinetics). Evaluate each patient by determining the minimum phototoxic dose and phototoxic peak time after drug administration before photochemotherapy onset with Oxsoralen-Ultra.<br />NOTE: In the event that the weight of a patient changes during treatment such that he/she falls into an adjacent weight range/dose category, no change in the methoxsalen dose is usually required. If, in the physician's opinion, however, a weight change is sufficiently great to modify the drug dose, then adjust the UVA exposure time.<br />NOTE: If a patient's generalized psoriasis is not responding or if the condition appears to be worsening during treatment, consider the possibility of a generalized phototoxic reaction, which may be confirmed by the improvement of the condition following temporary discontinuance of this therapy for two weeks. If no improvement occurs during treatment interruption, this patient may be considered a treatment failure.<br />NOTE: The number of doses per week of methoxsalen capsules will be determined by the patient's schedule of UVA exposures. The severity and extent of the patient's erythema may be used to determine whether the next exposure should be shortened, omitted, or maintained at the previous dosage.<br />NOTE: If the patient flares during maintenance treatment (i.e., develops psoriasis on more than 5% of the originally involved areas of the body), his maintenance treatment schedule may be changed to the preceding maintenance or clearing schedule. The patient may be kept on his schedule until again 95% clear. If the original maintenance treatment schedule is unable to control the psoriasis, the schedule may be changed to a more frequent regimen***Formoterol; Mometasone","***Albinism, porphyria, skin photosensitivity disorder, systemic lupus erythematosus (SLE), xeroderma pigmentosum***Requires an experienced clinician***Melanoma, new primary malignancy, radiation therapy, skin cancer***Hepatic disease***Aphakia, cataracts, ocular disease***Burns, sunlight (UV) exposure***Cardiac disease, geriatric***Pregnancy***Contraception requirements, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,orphenadrine citrate,"***For adjunctive therapy to rest, physical therapy, and other measures for the relief of musculoskeletal pain associated with acute, painful musculoskeletal conditions.***For use as an adjunct to physical therapy and other medications in the treatment of postencephalic, arteriosclerotic, or idiopathic parkinsonism�.","***General Information***Asthma, sulfite hypersensitivity***Myasthenia gravis***Achalasia, gastroesophageal reflux disease (GERD), GI obstruction, peptic ulcer disease, pyloric stenosis***Glaucoma***Bladder obstruction, prostatic hypertrophy, urinary tract obstruction***Cardiac arrhythmias, cardiac disease, dental disease, tachycardia***Hepatic disease, renal disease, renal impairment***Contact lenses***Pregnancy***Breast-feeding***Children***Anticholinergic medications, geriatric***Substance abuse***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5492'],acyclovir/hydrocortisone,***For the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time.,"***General Information***Fungal infection***Ophthalmic administration***Immunosuppression***Children, infants, neonates***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,oxybutynin chloride,"***For the treatment of an overactive bladder (OAB) with symptoms of urinary frequency, urinary urgency, or urinary incontinence due to involuntary detrusor muscle contractions (includes neurogenic bladder).","***Angioedema***Prostatic hypertrophy, urinary retention, urinary tract obstruction***Closed-angle glaucoma, contact lenses***Esophageal stricture, gastroesophageal reflux disease (GERD), gastroparesis, GI obstruction, hiatal hernia, ileus, pyloric stenosis, toxic megacolon, ulcerative colitis***Autonomic neuropathy, myasthenia gravis***Dementia***Parkinson's disease***Hepatic disease***Anticholinergic medications, driving or operating machinery, ethanol ingestion***Ambient temperature increase***Accidental exposure, tobacco smoking***Pregnancy***Breast-feeding***Geriatric***Infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['70223'],aldesleukin,***For the treatment of metastatic renal cell cancer or metastatic malignant melanoma. <br />        NOTE: Aldesleukin has been designated an orphan drug by the FDA for these indications.<br />     ***For the treatment of acute myelogenous leukemia (AML)�. <br />        NOTE: Aldesleukin has been designated an orphan drug by the FDA for this indication.<br />     ***For consolidation treatment in patients with AML following chemotherapy or autologous bone marrow transplantation�.***For treatment of relapsed or refractory AML�.***For the treatment of cutaneous T-cell lymphoma (CTCL)� including mycosis fungoides� and Sezary Syndrome�.***For the treatment of leprosy (Hansen's disease)�.***For the treatment of steroid-refractory chronic graft-versus-host disease (GVHD)�.***Formoterol; Mometasone,"***General Information***Cardiac disease, hepatic disease, organ transplant, pulmonary disease, renal disease, renal impairment, seizure disorder, seizures***Infection, mental status changes***Angina, cardiac arrhythmias, cardiac tamponade, coma, GI bleeding, GI perforation, lethargy, myocardial infarction, psychosis, renal failure, respiratory insufficiency, ventricular tachycardia***Autoimmune disease, Crohn's disease, diabetes mellitus, myasthenia gravis, scleroderma, thyroid disease, vasculitis***Pregnancy***Breast-feeding***Children, geriatric, infants, neonates***Vaccination***Capillary leak syndrome, requires a specialized care setting, requires an experienced clinician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6011'],isocarboxazid,***For use in treatment-resistant depression.,"***General Information***Alcoholism, coadministration with other CNS depressants, ethanol ingestion, MAOI therapy***Acute myocardial infarction, angina, cardiac disease, cerebrovascular disease, head trauma, headache, hypertension, hypertensive crisis, hypotension, increased intracranial pressure, intracranial bleeding, myocardial infarction, orthostatic hypotension***Pheochromocytoma***Hepatic disease, hepatotoxicity, jaundice***Renal disease, renal failure, renal impairment***Seizure disorder, seizures***Driving or operating machinery***Asthma, bronchitis***Diabetes mellitus***Hyperthyroidism***Dental work, spinal anesthesia, surgery***Anxiety, bipolar disorder, mania, psychosis, schizophrenia***Children, suicidal ideation***Abrupt discontinuation, substance abuse***Radiographic contrast administration***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,gentamicin sulfate,"***For the treatment of lower respiratory tract infections, including community-acquired pneumonia (CAP) and nosocomial pneumonia. <br />        NOTE: Serum gentamicin concentrations should be used to guide dosage adjustments. Dosage of aminoglycosides should be based on an estimate of lean body mass.<br />     ***For the treatment of meningitis, bone and joint infections, and intraabdominal infections (peritonitis). <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. In most patients, dosage of aminoglycosides should be based on an estimate of lean body mass.<br />     ***For intrathecal or intraventricular administration in patients with meningitis due to susceptible organisms.***For peritoneal dialysis-associated peritonitis� in patients with end-stage renal disease.***For the treatment of infective endocarditis. <br />  NOTE: Serum gentamicin concentrations should be used to guide dosage adjustments. Dosage of aminoglycosides should usually be based on an estimate of lean body mass.<br /***For the treatment of skin and skin structure infections (e.g., cellulitis, burn wound infection). <br />  NOTE: Serum gentamicin concentrations should be used to guide dosage adjustments. Dosage of aminoglycosides should usually be based on an estimate of lean body mass.<br /***For the treatment of minor bacterial skin infection including, folliculitis, furunculosis, impetigo, eczema, pyoderma gangrenosum, sycosis barbae, infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis, and infected excoriations.***For the treatment of blepharitis, blepharoconjunctivitis, bacterial conjunctivitis, corneal ulcer, dacryocystitis, keratitis, keratoconjunctivitis, and acute meibomianitis.***For the treatment of bacteremia and sepsis. <br />  NOTE: Serum concentrations should be used to guide dosage adjustments. In most patients, dosage of aminoglycosides should be based on an estimate of lean body mass.<br /***For the treatment of urinary tract infection (UTI).***For the treatment of pelvic inflammatory disease (PID)� with or without complications of tubo-ovarian abscess� .***For the treatment of plague� infection due to exposure to <em>Yersinia pestis</em> in an individual patient or in a contained casualty setting. <br />        NOTE: Streptomycin is the drug of choice to treat plague in most patients, however, because gentamicin is more widely available it is an acceptable alternative. Gentamicin is the preferred agent in pregnant women.<br />     ***For the initial treatment of tularemia� infection due to exposure to <em>Francisella tularensis</em>.***For tularemia� in an individual patient or in a contained casualty setting. <br />          NOTE: Streptomycin is the drug of choice to treat tularemia in most patients, however, because gentamicin is more widely available it is an acceptable alternative. Gentamicin is the preferred agent in pregnant women; if gentamicin is contraindicated streptomycin should be used.<br />       ***For tularemia� in a mass casualty setting or for tularemia prophylaxis�. <br />          NOTE: Doxycycline and ciprofloxacin are preferred agents in this setting.<br />       ***For surgical infection prophylaxis�.***For the treatment of chronic <em>Bartonella quintana�</em> bacteremia (bartonellosis�) in combination with doxycycline.***For the treatment of granuloma inguinale� (Donovanosis) due to Klebsiella granulomatis.***For the treatment of cephalosporin-resistant gonorrhea�.***For the empiric treatment of febrile neutropenia�. <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. In most patients, dosage of aminoglycosides should be based on an estimate of lean body mass.<br />     ***For the treatment of febrile neutropenia in adults.***For the treatment of febrile neutropenia in pediatric patients.***Formoterol; Mometasone","***Dehydration, nephrotoxicity, renal disease, renal failure, renal impairment***Hearing impairment, neurotoxicity, ototoxicity, tinnitus***Aminoglycoside hypersensitivity, sulfite hypersensitivity***Botulism, electrolyte imbalance, myasthenia gravis, neuromuscular disease, parkinsonism, respiratory depression, respiratory insufficiency***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Antimicrobial resistance, corneal abrasion, fungal infection, viral infection***Pregnancy***Breast-feeding***Sexually transmitted disease***Neonates, premature neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,granisetron hydrochloride,"***For chemotherapy-induced nausea/vomiting (CINV) and chemotherapy-induced nausea/vomiting prophylaxis.***For chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days.***For acute and delayed chemotherapy induced nausea/vomiting (CINV) prophylaxis associated with moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide chemotherapy regimens, in combination with other antiemetics.***For chemotherapy-induced nausea/vomiting (CINV) prophylaxis, including for high-dose cisplatin.***For chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving highly emetogenic chemotherapy (HEC), in combination with fosaprepitant and dexamethasone�.***For radiation-induced nausea/vomiting prophylaxis.***For the treatment of post-operative nausea/vomiting (PONV)�.***For post-operative nausea/vomiting (PONV) prophylaxis�.***Formoterol***Formoterol; Mometasone","***Dolasetron hypersensitivity, granisetron hypersensitivity, ondansetron hypersensitivity, palonosetron hypersensitivity***Benzyl alcohol hypersensitivity, neonates***Constipation, GI obstruction, ileus, surgery***Sunlight (UV) exposure***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Bipolar disorder, depression, pain***Heating pad***Anticoagulant therapy, bleeding***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4488'],floxuridine,"***For the treatment of colorectal cancer metastatic to the liver.***For the treatment of unresectable hepatocellular cancer�, in combination with radiotherapy.","***Bone marrow suppression, herpes infection, infection, leukopenia, neutropenia, radiation therapy, requires a specialized care setting, requires an experienced clinician, thrombocytopenia, varicella, viral infection***Dental disease, dental work***Intramuscular injections***Pregnancy***Breast-feeding***Hepatic disease, hepatitis***Renal impairment***Dihydropyrimidine dehydrogenase (DPD) deficiency***GI bleeding, malnutrition, stomatitis***Accidental exposure, ocular exposure***Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,levalbuterol hydrochloride,"***For the treatment of acute bronchospasm and bronchospasm prophylaxis associated with asthma.***For bronchospasm associated with asthma in pediatric patients.***For bronchospasm associated with asthma in adults.***For the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis.***For the adjunctive emergency acute treatment of hyperkalemia� until hemodialysis is available. <br />        NOTE: Beta-agonists can be effective treatments for hyperkalemia via beta-adrenergic induction of potassium (K+) uptake. However, they are a temporary adjunctive measure.<br />     ***For exercise-induced bronchospasm prophylaxis�.","***General Information***Albuterol hypersensitivity, angioedema, levalbuterol hypersensitivity***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, tachycardia***Renal failure, renal impairment***Hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***Diabetes mellitus***Deterioration of asthma, paradoxical bronchospasm***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***MAOI therapy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,butabarbital sodium,"***For preprocedure sedation induction.***For sedation maintenance (routine daytime sedation), to relieve anxiety, tension, and/or apprehension.***For the short-term treatment of insomnia in adults.","***Tartrazine dye hypersensitivity***Agranulocytosis, barbiturate hypersensitivity, carbamazepine hypersensitivity, exfoliative dermatitis, hydantoin hypersensitivity***Pain***Depression, mental status changes, suicidal ideation***Asthma, chronic obstructive pulmonary disease (COPD), pulmonary disease, respiratory depression, sleep apnea, status asthmaticus***Abrupt discontinuation, seizure disorder, seizures, status epilepticus, substance abuse***Alcoholism, CNS depression, driving or operating machinery, ethanol ingestion***Cardiac disease, hypotension***Anticoagulant therapy***Hepatic disease, hepatic encephalopathy***Renal failure, renal impairment***Porphyria***Osteomalacia, osteoporosis, renal disease***Children, infants***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['16681'],acarbose,"***For the treatment of type 2 diabetes mellitus in patients not controlled by diet alone; may be used as monotherapy or in combination with a sulfonylurea, metformin, or insulin. <br />        NOTE: If acarbose is used in combination with sulfonylureas or insulin, acarbose will cause a further lowering of blood sugar that may lead to hypoglycemia. Adjustments of the sulfonylurea or insulin may be necessary.<br />     ***For the adjunctive treatment of type 1 diabetes mellitus� in patients on insulin.***Formoterol; Mometasone","***General Information***Diabetic ketoacidosis***Hypoglycemia***Females, hepatic disease, hepatitis, jaundice***GI disease, GI obstruction, hiatal hernia, ileus, inflammatory bowel disease***Diarrhea, vomiting***Renal failure, renal impairment***Pregnancy***Breast-feeding***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,chlorpheniramine polistirex/hydrocodone polistirex,***For the relief of cough and upper respiratory symptoms associated with allergic rhinitis or the common cold.,"***General Information***Bladder obstruction, constipation, GI obstruction, ileus, inflammatory bowel disease, prostatic hypertrophy, ulcerative colitis, urinary retention***Diarrhea***Opiate agonist hypersensitivity***Driving or operating machinery***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, ethanol ingestion, pulmonary disease, respiratory depression***Hepatic disease***Diabetes mellitus, heart failure, hypertension, oliguria, renal disease, systemic lupus erythematosus (SLE), urethral stricture***Pregnancy***Children, infants, neonates***Breast-feeding***Biliary tract disease***Abrupt discontinuation***Substance abuse***Head trauma, increased intracranial pressure***Seizure disorder***Closed-angle glaucoma, contact lenses***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,centruroides (scorpion) immune F(ab&#39;)2 (equine),"***For the treatment of Centruroides scorpion sting in patients with clinically significant signs of envenomation. <br />        NOTE: Mild envenomation in adults usually causes local pain and does not require specific treatment. Clinically significant stings result in neurotoxicity (e.g., uncoordinated neuromotor hyperactivity, oculomotor and visual abnormalities, and respiratory compromise). Significant envenomation is more likely in young children. In North America, scorpions whose venom has medical consequences fall within one genus, Centruroides. In the United States there is a single neurotoxic species, Centruroides sculpturatus (previously known as C. exilicauda).<br />     ","***Equine protein hypersensitivity, infection, requires a specialized care setting***Cresol hypersensitivity***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bupivacaine hydrochloride,"***For local anesthesia or regional anesthesia. <br />        NOTE: Doses listed below are those considered necessary to produce a successful block and should be regarded as guidelines for use in adults. Individual variations in onset and duration may occur.<br />     ***For caudal anesthesia.***For infiltration anesthesia including dental anesthesia.***For epidural anesthesia (other than caudal block).***For peripheral nerve block.***For sympathetic nerve block.***For ophthalmic anesthesia (i.e., retrobulbar nerve block).***For spinal anesthesia. <br />        NOTE: The following doses are guidelines only. Lower doses may be required in elderly or debilitated patients<br />     ***For anesthesia in lower extremity and perineal procedures.","***General Information***Intraarterial administration, intrathecal administration, intravenous administration***Head and neck anesthesia***Ocular surgery***AV block, cardiac disease, cardiogenic shock, dehydration, hemorrhagic shock, hypotension, hypovolemia, myasthenia gravis, shock***Anticoagulant therapy, coagulopathy, epidural anesthesia, hypertension, infection, neurological disease, sepsis, thrombocytopenia***Bleeding, cardiac arrhythmias, children, geriatric, headache, infants, neonates, spinal anesthesia***Amide local anesthetic hypersensitivity, paraben hypersensitivity***Heart failure, hepatic disease***Eclampsia, fetal distress, fetal prematurity, labor, obstetric delivery, paracervical nerve block, pregnancy, pudendal nerve block***Breast-feeding***Continuous intraarticular infusion administration***Requires a specialized care setting, requires an experienced clinician***Malignant hyperthermia***Electrolyte imbalance, seizure disorder, seizures***Renal disease, renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Chewable) (amoxicillin,"***For the treatment of upper respiratory tract infections (e.g., pharyngitis, tonsillitis).***For the treatment of tonsillitis and/or pharyngitis (rheumatic fever prophylaxis) secondary to <em>Streptococcus pyogenes</em>.***For the treatment of acute otitis media. <br />  NOTE: The American Academy of Pediatrics (AAP) does not recommend doses less than 80 mg/kg/day PO for the treatment of otitis media. Patients failing to respond within 48 to 72 hours should be re-evaluated by a healthcare provider. Amoxicillin; clavulanate is the preferred therapy for children who have received amoxicillin within the past 30 days or who have purulent conjunctivitis or a history of recurrent acute otitis media unresponsive to amoxicillin.<br /***For the treatment of skin and skin structure infections (e.g., cellulitis).***For mild to moderate infections caused by highly susceptible organisms.***For severe infections or infections caused by less susceptible organisms.***For the treatment of lower respiratory tract infections (e.g., pneumonia, community-acquired pneumonia, bronchitis).***For the treatment of urinary tract infection (UTI) including cystitis.***For mild to moderate infections caused by highly susceptible organisms.***For severe infections or infections caused by less susceptible organisms.***For the treatment of Lyme disease�.***For patients with erythema migrans�.***For early-stage Lyme disease�. <br />          NOTE: Used as an alternative to tetracycline or penicillin V in children &lt; 9 years of age or as an alternative to tetracycline in pregnant or lactating women.<br />       ***For Lyme arthritis�.***For the treatment of pregnant women with chlamydia infection� including cervicitis� and urethritis�.***For the treatment of dental infection�, including dentoalveolar infection�.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage.***For adolescent aggressive periodontitis� or adult refractory chronic periodontitis� in combination with metronidazole after scaling and root planing.***For bacterial endocarditis prophylaxis�.***For the treatment of typhoid fever� due to <em>Salmonella typhii</em>.***For Helicobacter pylori (H. pylori) eradication� in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />  NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.  The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: Resistance rates of H. pylori to metronidazole in the US are 25%; whereas amoxicillin resistance is rare.  Resistance rates for H. pylori to clarithromycin in the US are 13%.<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Prevpac monograph)  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60% to 90% of patients.***For treatment of cutaneous anthrax� infection due to exposure to <em>Bacillus anthracis</em> or as oral follow-up therapy for severe anthrax.***For anthrax prophylaxis� after exposure to <em>Bacillus anthracis</em>.","***General Information***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, eczema, penicillin hypersensitivity, urticaria***Dialysis, renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Children, infants, neonates, premature neonates***Geriatric***Pregnancy***Breast-feeding***Phenylketonuria***Mononucleosis***Sexually transmitted disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,succinylcholine chloride,"***For neuromuscular blockade.***For neuromuscular blockade during short surgical procedures.***For neuromuscular blockade during long surgical procedures.***For the facilitation of endotracheal intubation. <br />        NOTE: In pediatric patients, the use of a nondepolarizing neuromuscular blocker is preferred to avoid the rare risk of succinylcholine-induced acute rhabdomyolysis with hyperkalemia and asystole. In pediatric patients, succinylcholine should be reserved for emergency procedures or when IV access is not available.<br />     ***For control of muscle contractions during electroconvulsive therapy (ECT)�.","***General Information***Bradycardia, children, Guillain-Barre syndrome, hyperkalemia, infants, malignant hyperthermia, myopathy, neonates, rhabdomyolysis***Burns, digitalis toxicity, trauma***Glaucoma, ocular surgery, ocular trauma***Labor, obstetric delivery, pregnancy***Breast-feeding***Anemia, cardiac disease, cholinesterase inhibitor toxicity, edema, hepatic disease, infection, malnutrition, myxedema, peptic ulcer disease, pseudocholinesterase deficiency, renal disease***Myasthenia gravis, neuromuscular disease, obesity***Requires a specialized care setting, requires an experienced clinician, respiratory insufficiency***Neuromuscular blocking agent hypersensitivity***Asthma, chronic obstructive pulmonary disease (COPD), pulmonary disease, respiratory depression***Acid/base imbalance, adrenal insufficiency, dehydration, electrolyte imbalance, hypercalcemia, hypermagnesemia, hypocalcemia, hypokalemia, hypothermia, metabolic acidosis, metabolic alkalosis, respiratory acidosis, respiratory alkalosis***Increased intracranial pressure***Bone fractures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['18993'],benzonatate,***For the symptomatic treatment of cough.***For the treatment of intractable singultus (hiccups)� unresponsive to standard therapies.***For topical anesthesia� of the oropharyngeal region prior to awake endotracheal intubation� or prior to endoscopy�. <br />  NOTE: This route should only be used by health care professionals trained in anesthesia and intubation. Specialized references should be consulted for specific procedures and administration techniques. Resuscitative equipment and drugs used in the management of adverse reactions should be immediately available.<br /,"***Ester local anesthetic hypersensitivity, paraben hypersensitivity***Children, infants, neonates, potential for overdose or poisoning***Driving or operating machinery***Labor, obstetric delivery, pregnancy***Breast-feeding***Para-aminobenzoic acid, PABA hypersensitivity***Dysphagia, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1148138'],icatibant,"***For the treatment of acute attacks of hereditary angioedema (HAE). <br />        NOTE: Given the potential for airway obstruction during acute laryngeal HAE attacks, patients should be advised to seek immediate medical attention in an appropriate health care facility in addition to icatibant treatment.<br />     ***For the treatment of ACE-inhibitor induced angioedema�.","***General Information***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2177', '1545975']",cefadroxil,"***For the treatment of urinary tract infection (UTI), including cystitis.***For the treatment of skin and skin structure infections including impetigo.***For the treatment of group A beta-hemolytic streptococcal pharyngitis (primary rheumatic fever prophylaxis�) or tonsillitis.","***General Information***Viral infection***Cephalosporin hypersensitivity, penicillin hypersensitivity***Renal disease, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Coagulopathy, vitamin K deficiency***Intramuscular injections***Neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,trimethobenzamide hydrochloride,"***For the control of nausea/vomiting of a known etiology (e.g., post-operative or gastroenteritis).","***Renal failure, renal impairment***Children, ester local anesthetic hypersensitivity, infants, intravenous administration, neonates, premature neonates***Agranulocytosis, bone marrow suppression, fever, jaundice***Pregnancy***Breast-feeding***Dehydration, electrolyte imbalance, encephalopathy, gastroenteritis, Reye's syndrome, viral infection***Geriatric***Appendicitis***Driving or operating machinery, ethanol intoxication***Hepatic disease, hepatotoxicity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,factor XIII concentrate (human),"***For routine bleeding prophylaxis in patients with congenital factor XIII deficiency. <br />        NOTE: Factor XIII concentrate has not been proven to have a direct benefit on the treatment of bleeding episodes.<br />NOTE: Dosage is based on patient weight, laboratory values, and the patient's overall clinical condition","***General Information***Thromboembolic disease***Infection***Labor, obstetric delivery, pregnancy***Breast-feeding***Factor XIII inhibitors",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydrocodone bitartrate/pseudoephedrine hydrochloride,***For the treatment of cough and nasal congestion due to the common cold.***Formoterol***Formoterol; Mometasone,"***General Information***Opiate agonist hypersensitivity***Asthma, bronchitis, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, emphysema, ethanol ingestion, respiratory depression***Acute abdomen, constipation, diarrhea, GI obstruction, ileus, ulcerative colitis***Bladder obstruction, prostatic hypertrophy, renal impairment, urethral stricture, urinary retention***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, hypertension, ventricular tachycardia***Diabetes mellitus, hyperthyroidism***Closed-angle glaucoma***Driving or operating machinery***Hepatic disease***Children, infants, neonates***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Substance abuse***Abrupt discontinuation***Head trauma, increased intracranial pressure***Anticholinergic medications, MAOI therapy***Adrenal insufficiency***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6835'],methimazole,"***For the treatment of hyperthyroidism, including Graves' disease or toxic multinodular goiter when surgery or radioactive iodine therapy (RAI) is not appropriate, or for symptomatic treatment in preparation for thyroidectomy or RAI.***For the treatment of thyrotoxicosis� (thyroid storm�).","***General Information***Agranulocytosis, aplastic anemia, bone marrow suppression, geriatric, leukopenia, neutropenia, serious rash, thrombocytopenia, vasculitis***Hepatic disease, hepatitis, hepatotoxicity, jaundice***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4316'],felodipine,***For the treatment of hypertension.***For the treatment of angina�.,"***Dihydropyridine hypersensitivity***Labor, pregnancy***Breast-feeding***Children***Hypotension***Acute myocardial infarction, bradycardia, cardiogenic shock, heart failure, ventricular dysfunction***Angina, coronary artery disease***Aortic stenosis***Hepatic disease***Gastroesophageal reflux disease (GERD), hiatal hernia***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1895'],fenoprofen calcium,"***For the treatment of rheumatoid arthritis.***For the treatment of osteoarthritis or ankylosing spondylitis�.***For migraine prophylaxis�.***For the treatment of arthralgia, myalgia, mild pain to moderate pain associated with nonrheumatic inflammatory conditions, bone pain�, dental pain�, or migraine� or other vascular headache�.***For the treatment of acute gouty arthritis�.***For the management of fever�.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease, jaundice***Diabetes mellitus, edema, heart failure, hypertension, renal disease, renal failure, renal impairment, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Intramuscular injections***Dental disease, dental work***Labor, obstetric delivery, pregnancy***Breast-feeding***Coronary artery bypass graft surgery (CABG)***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,triamcinolone acetonide,"***For bronchospasm prophylaxis or maintenance therapy in patients who require chronic treatment with corticosteroids for control of bronchial asthma.***For the treatment of severe or incapacitating allergic conditions such as asthma that are intractable to adequate trials of conventional treatment.***For the treatment of symptoms of seasonal and perennial allergic rhinitis.***For the treatment of severe or incapacitating allergic conditions that are intractable to adequate trials of conventional treatment.***For the treatment of ocular inflammation (i.e., sympathetic ophthalmia and ocular inflammatory conditions unresponsive to topical corticosteroids), temporal arteritis, and uveitis.***For visualization during ocular surgery (i.e., vitrectomy).***For the treatment of acute rheumatic carditis, berylliosis, temporal arteritis�, or systemic lupus erythematosus (SLE). <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses (e.g., alopecia areata, atopic dermatitis, contact dermatitis including <em>Rhus dermatitis</em> due to poison ivy, poison oak, poison sumac, subacute cutaneous or discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex chronicus, mycosis fungoides, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, psoriasis, sarcoidosis, seborrheic dermatitis, sunburn, or xerosis). <br />        NOTE: Occlusive dressings may be necessary for chronic or severe cases of psoriasis or other recalcitrant conditions.<br />     ***For the treatment of ulcerative or inflammatory oral lesions including aphthous ulcer, desquamative gingivitis�, and oral lichen planus�.***For the treatment of severe or incapacitating allergic conditions such as atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions, bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome) that are intractable to adequate trials of conventional treatment and for the treatment of idiopathic eosinophilic pneumonias.***For the treatment of symptomatic sarcoidosis.***For the treatment of primary (Addison's disease) or secondary adrenocortical insufficiency. <br />        NOTE: Hydrocortisone and cortisone are the preferred agents for these conditions.<br />     ***For the treatment of congenital adrenal hyperplasia.***For the treatment of hypercalcemia associated with cancer.***For the treatment of nonsuppurative thyroiditis.***For the treatment of a critical period of regional enteritis and ulcerative colitis.***For the treatment of autoimmune hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, or selected cases of secondary thrombocytopenia.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of acute exacerbations of multiple sclerosis. <br />        NOTE: Corticosteroids are effective in speeding the resolution of acute exacerbations, but they do not affect the ultimate outcome or natural history of the disease.<br />     ***For the treatment of cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.***For the treatment of proteinuria or to induce diuresis in idiopathic nephrotic syndrome or lupus erythematosus.***For the treatment of an acute episode or exacerbation of ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA) as adjunctive therapy for short-term administration.***For the treatment of dermatomyositis or polymyositis.***For the relief of inflammation and for immunosuppression associated with a variety of disorders, like Hodgkin lymphoma. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the palliative treatment of leukemias and lymphomas.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of diabetic macular edema�.***For the relief of inflammation associated with synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; gout with acute gouty arthritis; epicondylitis; acute non-specific tenosynovitis; polychondritis�; posttraumatic osteoarthritis. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of osteoarthritis pain of the knee. <br />  NOTE: Zilretta is not interchangeable with other formulations of triamcinolone acetonide.<br /","***Epidural administration, intramuscular administration, intrathecal administration, intravenous administration, subcutaneous administration***Acute bronchospasm, status asthmaticus***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hyperthyroidism, hypothalamic-pituitary-adrenal (HPA) suppression, hypothyroidism, increased intracranial pressure, occlusive dressing, skin abrasion***Head trauma***Growth inhibition, osteoporosis***Surgery***Fungal infection, infection, viral infection***Tuberculosis***Immunosuppression***Herpes infection, measles, varicella***Glaucoma***Acne rosacea, acne vulgaris***Peripheral vascular disease***Nasal septal perforation, nasal surgery, nasal trauma***Myocardial infarction***Heart failure, hypertension***Diabetes mellitus***Skin atrophy***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Myasthenia gravis***Psychosis, seizure disorder***Coagulopathy, hemophilia, thromboembolic disease***Cataracts, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Vaccination***Breast-feeding***Tartrazine dye hypersensitivity***Neonates, premature neonates***Idiopathic thrombocytopenic purpura (ITP)***Corticosteroid hypersensitivity***Geriatric***Renal disease, renal impairment***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diltiazem hydrochloride,"***For the treatment of hypertension.***For the treatment of chronic stable angina.***For the treatment of variant angina (Prinzmetal's angina).***For the treatment of paroxysmal supraventricular tachycardia (PSVT) or control of ventricular rate in atrial flutter or atrial fibrillation.***For the short-term treatment of rapid ventricular rate secondary to atrial arrhythmias� in adolescents, children, and infants.***For long-term control of ventricular rate in atrial flutter� or atrial fibrillation�.***For the relief of ongoing ischemia in patients with unstable angina� or after acute non-ST-segment elevation myocardial infarction� in the absence of congestive heart failure, pulmonary congestion, left ventricular dysfunction, or AV block, when beta-blockers are ineffective or contraindicated.***For the treatment of idiopathic dilated cardiomyopathy�.***For migraine prophylaxis�.***For the treatment of proteinuria� associated with diabetic nephropathy�.","***Acute myocardial infarction, bradycardia, cardiogenic shock, heart failure, ventricular dysfunction***Hypotension***AV block***Sick sinus syndrome***Lown-Ganong-Levine syndrome, ventricular tachycardia, Wolff-Parkinson-White syndrome***Hepatic disease***Aortic stenosis***Gastroesophageal reflux disease (GERD), hiatal hernia***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,esterified estrogens,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For treatment of premenopausal females with estrogen deficiency due to hypogonadism or primary ovarian failure.***For estrogen replacement therapy for female hypogonadism.***For females with primary ovarian failure.***For the palliative treatment of breast cancer that is inoperable and progressive in selected men and postmenopausal women. <br />        NOTE: Treatment is continued for at least 3 months. In the past, estrogens have been used for the palliative management of breast cancer. While these drugs are no longer used routinely for breast cancer, some reference texts still list this condition as an indication.<br />     ***For the treatment of advancing inoperable prostate cancer.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1242999'],axitinib,***For the treatment of renal cell cancer (RCC).***For the first-line treatment of advanced or metastatic renal cell cancer (RCC)�.***For the treatment of advanced renal cell cancer after failure of 1 prior systemic therapy.,"***Thromboembolic disease***Bleeding***Fistula, GI bleeding, GI perforation***Surgery***Hepatic disease***Hypertension***Hyperthyroidism, hypothyroidism, thyroid disease***Proteinuria***Infertility***Renal impairment***Encephalopathy***Cardiac disease, heart failure***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluphenazine hydrochloride,"***For the treatment of schizophrenia.***For the treatment of acute agitated behavior (e.g., acute psychosis) when rapid control of acute symptoms is desired or for use when the oral route is not feasible.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.","***Benzyl alcohol hypersensitivity, paraben hypersensitivity, phenothiazine hypersensitivity, sesame oil hypersensitivity, tartrazine dye hypersensitivity***Agranulocytosis, bone marrow suppression, fever, hematological disease, infection, leukopenia, neutropenia***Intravenous administration***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion, head trauma***Dental work, surgery***Intracranial mass, seizure disorder, seizures***Tardive dyskinesia***Anticholinergic medications, closed-angle glaucoma, ileus, prostatic hypertrophy, urinary retention***Alcoholism, angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, pulmonary disease, QT prolongation, thyroid disease***Children, infants, neonates, Reye's syndrome***Encephalopathy, hepatic disease, jaundice***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Sunlight (UV) exposure***Accidental exposure***Abrupt discontinuation***Renal failure***Ocular disease***Chemotherapy, GI obstruction, vomiting***Tobacco smoking***Labor, obstetric delivery, pregnancy, pregnancy testing***Breast-feeding***Breast cancer, hyperprolactinemia, infertility***Radiographic contrast administration***Suicidal ideation***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,citalopram hydrobromide,***For the treatment of major depression.***For the treatment of major depression in adult patients.***For the treatment of major depression� in pediatric patients.***For the treatment of social phobia (social anxiety disorder)�.***For the treatment of obsessive-compulsive disorder (OCD)�.***For the treatment of panic disorder� (with or without agoraphobia).***For the treatment of posttraumatic stress disorder (PTSD)�.***For the treatment of premenstrual dysphoric disorder (PMDD)�.***For the treatment of hot flashes� in women experiencing symptoms of menopause�.***Formoterol; Mometasone,"***Citalopram hypersensitivity, escitalopram hypersensitivity***Abrupt discontinuation***Bipolar disorder, mania***Children, growth inhibition, suicidal ideation***MAOI therapy***Electroconvulsive therapy (ECT), seizure disorder***Acute myocardial infarction, alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes, ventricular tachycardia***Dehydration, hyponatremia, hypovolemia***Renal failure, renal impairment***Hepatic disease, poor metabolizers***Anticoagulant therapy, bleeding, thrombolytic therapy***Bone fractures, osteoporosis***Closed-angle glaucoma, increased intraocular pressure***Akathisia***Anorexia nervosa***Driving or operating machinery, ethanol ingestion***Neonates, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1193326'],ruxolitinib,"***For the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. <br />  The FDA has designated ruxolitinib as an orphan drug for the treatment of polycythemia vera.<br /***For the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. <br />        NOTE: Patients experiencing significant decreases in platelet counts may be candidates for abrupt dose reductions and/or treatment interruptions. Consider risk to benefits ratio in patients maintained on 5 mg PO twice daily (minimum dose) as long-term use at this dose has failed to produce clinical response.<br />     ","***Thrombocytopenia***Anemia***Immunosuppression, neutropenia***Fungal infection, hepatitis, infection, mycobacterial infection, progressive multifocal leukoencephalopathy, tuberculosis, viral infection***Hepatic disease***Renal disease, renal failure, renal impairment***Abrupt discontinuation***New primary malignancy, skin cancer***Hypercholesterolemia, hypertriglyceridemia***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,calcium acetate,"***For the treatment of hypocalcemia.***For the treatment of acute hypocalcemia. <br />          NOTE: IV dosages should be used in patients with tetany.�<br />NOTE: Monitor ionized serum calcium concentrations to individualize dosage.<br />NOTE: For the treatment of ionized hypocalcemia during CPR, see dosing for CPR.***For hypocalcemia secondary to citrated blood infusion.***For the treatment of hyperkalemia, hypermagnesemia, and ionized hypocalcemia.***For the treatment of life-threatening cardiac arrhythmias or during cardiopulmonary resuscitation (CPR)� (cardiac arrest�) associated with suspected or documented hyperkalemia, hypermagnesemia, or ionized hypocalcemia. <br />          NOTE: Calcium salts are NOT recommended for routine treatment of cardiac arrest.   No benefit has been demonstrated during cardiac arrest and hypercalcemia may occur following calcium administration.<br />       ***For the treatment of severe hyperkalemia (serum potassium > 7 mEq/L) or hypermagnesemia associated with toxic ECG changes.***For adjunctive therapy in the treatment of CNS depression due to hypermagnesemia.***For nutritional supplementation.***For nutritional supplementation to prevent hypocalcemia in patients receiving total parenteral nutrition (TPN).***For the treatment of hyperphosphatemia, especially in patients with chronic renal failure or end stage renal disease. <br />        NOTE: Calcium carbonate (see separate calcium carbonate monograph) has been designated as an orphan drug by the FDA for this indication.�<br />     ***For the treatment of verapamil toxicity or calcium antagonist toxicity (e.g., myocardial depression, hypotension, cardiac conduction defects or cardiac arrhythmias).***For exchange transfusion-induced hypocalcemia prophylaxis�.","***General Information***Hypercalcemia***Hypercalciuria***Sarcoidosis***Extravasation, intramuscular administration, subcutaneous administration***Cardiac arrhythmias, digitalis toxicity, ventricular fibrillation***Dehydration***Diarrhea***Hyperphosphatemia, hypoparathyroidism***Vitamin D toxicity***Pregnancy***Breast-feeding***Necrotizing enterocolitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['6854', '227717']",methoxsalen,"***For the treatment of cutaneous T-cell lymphoma (CTCL).***For the palliative treatment of the skin manifestations of CTCL unresponsive to other forms of treatment, used with the UVAR XTS or CELLEX photopheresis system.***For the treatment of idiopathic vitiligo (in conjunction with UVA). <br />        NOTE: Idiopathic vitiligo is reversible but not equally reversible in every patient. Repigmentation will vary in completeness, onset time, and duration. Repigmentation occurs more rapidly in fleshy areas such as the face, abdomen, and buttocks and less rapidly over less fleshy areas such as the dorsum of the hands or feet.<br />     ***For the treatment of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy and is diagnosed by biopsy; alopecia� areata; atopic dermatitis�; eczema�; lichen planus�; and for increased tolerance of skin to sunlight�. <br />        NOTE: Methoxsalen soft gelatin capsules and hard gelatin capsules are not interchangeable. The mean J/cm2 for the soft gelatin capsules is substantially less than that required for the hard gelatin capsules due to pharmacokinetic differences (see Pharmacokinetics). Evaluate each patient by determining the minimum phototoxic dose and phototoxic peak time after drug administration before photochemotherapy onset with Oxsoralen-Ultra.<br />NOTE: In the event that the weight of a patient changes during treatment such that he/she falls into an adjacent weight range/dose category, no change in the methoxsalen dose is usually required. If, in the physician's opinion, however, a weight change is sufficiently great to modify the drug dose, then adjust the UVA exposure time.<br />NOTE: If a patient's generalized psoriasis is not responding or if the condition appears to be worsening during treatment, consider the possibility of a generalized phototoxic reaction, which may be confirmed by the improvement of the condition following temporary discontinuance of this therapy for two weeks. If no improvement occurs during treatment interruption, this patient may be considered a treatment failure.<br />NOTE: The number of doses per week of methoxsalen capsules will be determined by the patient's schedule of UVA exposures. The severity and extent of the patient's erythema may be used to determine whether the next exposure should be shortened, omitted, or maintained at the previous dosage.<br />NOTE: If the patient flares during maintenance treatment (i.e., develops psoriasis on more than 5% of the originally involved areas of the body), his maintenance treatment schedule may be changed to the preceding maintenance or clearing schedule. The patient may be kept on his schedule until again 95% clear. If the original maintenance treatment schedule is unable to control the psoriasis, the schedule may be changed to a more frequent regimen***Formoterol; Mometasone","***Albinism, porphyria, skin photosensitivity disorder, systemic lupus erythematosus (SLE), xeroderma pigmentosum***Requires an experienced clinician***Melanoma, new primary malignancy, radiation therapy, skin cancer***Hepatic disease***Aphakia, cataracts, ocular disease***Burns, sunlight (UV) exposure***Cardiac disease, geriatric***Pregnancy***Contraception requirements, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/levonorgestrel,"***For routine contraception.***For extended continuous routine contraception.***For use as postcoital contraception within 72 hours of unprotected intercourse, or known or suspected contraceptive failure, in females who have no known contraindications to oral contraceptives, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pentamidine isethionate,"***For the treatment of Pneumocystis pneumonia (PCP) in patients unresponsive to, allergic to, or who cannot tolerate co-trimoxazole.***For pneumocystis pneumonia (PCP) prophylaxis in high-risk, HIV-infected patients.***For primary PCP prophylaxis in HIV-infected patients.***For secondary PCP prophylaxis in HIV-infected patients after treatment for acute pneumocystis pneumonia.***For the treatment of visceral leishmaniasis� due to<em> Leishmania donovani</em>�. <br />        NOTE: Pentamidine is used as an alternative to stibogluconate for visceral leishmaniasis�.<br />     ***For the treatment of African trypanosomiasis (sleeping sickness)� due to <em>Trypanosoma brucei gambiense</em> without CNS involvement (first stage or hemolymphatic stage).","***Hypotension***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Diabetes mellitus, hyperglycemia, hypoglycemia, pancreatitis***Anemia, bone marrow suppression, radiation therapy***Intramuscular injections***Dental disease, dental work***Dehydration, renal disease***Hepatic disease***Asthma***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluoxetine hydrochloride,***For the treatment of major depression.***For the treatment of depression with a daily dosage formulation.***For the once-weekly maintenance treatment of depression.***For acute treatment of treatment-resistant depression in combination with olanzapine.***For acute  treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in combination with olanzapine.***For the treatment of obsessive-compulsive disorder (OCD).***For the treatment of panic disorder with or without agoraphobia.***For the treatment of bulimia nervosa.***For the treatment of premenstrual dysphoric disorder (PMDD).***For the treatment of generalized anxiety disorder (GAD)�.***For the treatment of social phobia (social anxiety disorder)�.***For the treatment of posttraumatic stress disorder (PTSD)�.***For the treatment of anorexia nervosa�.***For the treatment of obesity�.***For the treatment of borderline personality disorder�.***For the treatment of autistic disorder�.***For the treatment of separation anxiety disorder�.***For the treatment of fibromyalgia�.***For the treatment of neurogenic orthostatic hypotension�.***For the treatment of premature ejaculation�.***For the treatment of hot flashes� in women with breast cancer experiencing symptoms of menopause�.***For migraine prophylaxis�.***For the treatment of selective mutism� in children who have failed an adequate trial of psychotherapy.***Formoterol***Formoterol; Mometasone,"***General Information***Abrupt discontinuation***Electroconvulsive therapy (ECT), seizure disorder***Children, growth inhibition, suicidal ideation***MAOI therapy***Bipolar disorder, mania***Hepatic disease***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diarrhea, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, poor metabolizers, QT prolongation, thyroid disease, ventricular arrhythmias***Dehydration, hyponatremia, hypovolemia***Anticoagulant therapy, bleeding, thrombolytic therapy***Closed-angle glaucoma, increased intraocular pressure***Driving or operating machinery, ethanol ingestion***Diabetes mellitus***Akathisia***Anorexia nervosa***Bone fractures, osteoporosis***Neonates, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,thrombin (recombinant),"***For hemostasis of small vessels and capillaries associated with surgical bleeding (i.e., as in plastic surgery, dental extractions, skin grafting, and neurosurgery).***For the treatment of pseudoaneurysms (false aneurysms)�. <br />        NOTE: The majority of the reports for the percutaneous injection of thrombin involve pseudoaneurysm in association with the femoral artery; however, thrombosis of pseudoaneurysms at other anatomical locations has also been successful.<br />NOTE: In patients with a previous exposure to thrombin (topical or intravascular), a skin-prick test to rule out hypersensitivity to thrombin is recommended (see Administration).","***Bleeding, thromboembolism***Accidental exposure, intravenous administration, parenteral administration***Bovine protein hypersensitivity, hamster protein hypersensitivity, mannitol hypersensitivity***Children, infants***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3648'],droperidol,"***For nausea/vomiting prophylaxis associated with diagnostic procedures and for post-operative nausea/vomiting (PONV) prophylaxis. <br />        NOTE: Droperidol dosage must be individualized according to the patient's age, weight, physical condition and other drugs used during anesthesia.<br />     ***For sedation induction�.***For sedation induction in combination with local anesthetics and/or opiate agonists during procedures where general anesthesia is not required.***For sedation induction of the acutely agitated and/or violent patient (i.e., chemical restraint).***For use as an adjunct to general anesthesia induction� and general anesthesia maintenance�<a href=http://wps.goldstandard.com/WPSEditorial/_WPS/RefShow.aspx?rid=29764"" target=""RefShow""><strong>[29764***For treatment of anxiety� prior to induction of anesthesia (preanesthesia�). <br />        NOTE: Droperidol dosage must be individualized according to the patient's age",weight,physical condition,"and other drugs used during anesthesia.<br />     ***For the treatment of intractable migraine� headache with or without aura.***For the treatment of post-operative nausea/vomiting (PONV)�.""","***General Information***Phenothiazine hypersensitivity***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Epidural anesthesia, hypotension, orthostatic hypotension, spinal anesthesia***MAOI therapy***Hepatic disease, renal failure, renal impairment***Pheochromocytoma***Geriatric***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Seizure disorder, seizures***Parkinson's disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,
,torsemide,"***For the treatment of edema.***For edema associated with congestive heart failure.***For edema associated with chronic renal failure.***For the adjunctive treatment of ascites (e.g., due to hepatic cirrhosis) either alone or in combination with spironolactone or amiloride. <br />        NOTE: Loop diuretics, preferably in combination with an aldosterone antagonist or a potassium-sparing diuretic (e.g., spironolactone or amiloride), are used for the treatment of ascites.<br />     ***For the treatment of hypertension.***Formoterol; Mometasone","***Sulfonamide hypersensitivity, sulfonylurea hypersensitivity, thiazide diuretic hypersensitivity***Hepatic disease***Anuria, hypovolemia, sympathectomy, syncope***Electrolyte imbalance, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, ventricular arrhythmias***Acute myocardial infarction***Renal disease, renal failure, renal impairment***Hearing impairment***Gout, hyperuricemia***Diabetes mellitus, hyperglycemia***Pregnancy***Breast-feeding***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2231', '1299782']",cephalexin,"***For the treatment of upper respiratory tract infections, including tonsillitis and/or pharyngitis secondary to <em>Streptococcus pyogenes</em> (i.e., primary rheumatic fever prophylaxis).***For the treatment of lower respiratory tract infections (e.g., pneumonia, community-acquired pneumonia).***For the treatment skin and skin structure infections (e.g., cellulitis, impetigo) due to susceptible organisms.***For the treatment of otitis media.***For the treatment of bone and joint infections (i.e., osteomyelitis, infectious arthritis).***For the treatment of genitourinary infection (i.e., urinary tract infection (UTI), cystitis, prostatitis).***For bacterial endocarditis prophylaxis�.","***Antimicrobial resistance, viral infection***Cephalosporin hypersensitivity, penicillin hypersensitivity***Renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Breast-feeding***Pregnancy***Coagulopathy, vitamin K deficiency***Diabetes mellitus***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,venlafaxine hydrochloride,"***For the treatment of major depression.***For the treatment of generalized anxiety disorder (GAD).***For the treatment of social phobia (social anxiety disorder).***For the treatment of panic disorder (with or without agoraphobia).***For the treatment of obsessive-compulsive disorder (OCD)�.***For the treatment of hot flashes� due to menopause� or in women who have been treated for breast cancer.***For women experiencing hot flashes� due to natural menopause�.***For hot flashes� in women with a history of, or high risk of, breast cancer, including those receiving adjuvant treatments like tamoxifen.***For the treatment of premenstrual dysphoric disorder (PMDD)�.***For the treatment of fibromyalgia�.***For the treatment of painful diabetic neuropathy�.***For migraine prophylaxis�.***For the treatment of hot flashes� due to prostate cancer� and associated induced androgen deficiency� ('andropause�') in men who have had surgical or medication induced castration.***Formoterol***Formoterol; Mometasone","***General Information***Desvenlafaxine hypersensitivity, venlafaxine hypersensitivity***Abrupt discontinuation***Bipolar disorder, mania***Children, growth inhibition, suicidal ideation***MAOI therapy***Electroconvulsive therapy (ECT), seizure disorder, seizures***Dehydration, hyponatremia, hypovolemia***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Dialysis, renal disease, renal failure, renal impairment***Hepatic disease***Anticoagulant therapy, bleeding, thrombolytic therapy***Closed-angle glaucoma, increased intraocular pressure***Eosinophilic pneumonia***Driving or operating machinery***Eclampsia, neonates, obstetric delivery, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2176', '1450910']",cefaclor,"***For the treatment of upper respiratory tract infections caused by susceptible organisms. <br />        NOTE: Use the higher suggested dosages for severe infections, less susceptible strains of pathogens, and obese patients.<br />     ***For otitis media due to <em>S. pneumoniae</em>, <em>H. influenzae</em>, staphylococci, and <em>S. pyogenes</em>.***For pharyngitis or tonsillitis due to <em>S. pyogenes</em>. <br />          NOTE: The American Heart Association does not recommended cefaclor for routine therapy for Group A Streptococcal pharyngitis therapy to prevent rheumatic fever.<br />       ***For the treatment of lower respiratory tract infections caused by susceptible organisms including pneumonia due to <em>Streptococcus pneumoniae, Haemophilus influenzae</em>, and <em>Streptococcus pyogenes</em>. <br />        NOTE: Use higher suggested dosages for severe infections (e.g., pneumonia), less susceptible strains of pathogens, and obese patients.<br />     ***For the treatment of acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis.***For the treatment of uncomplicated skin and skin structure infections caused by susceptible organisms.***For the treatment of urinary tract infection (UTI) including pyelonephritis and cystitis.","***General Information***Antimicrobial resistance, viral infection***Cephalosporin hypersensitivity, penicillin hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Coagulopathy, vitamin K deficiency***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['83929'],abciximab,"***For percutaneous coronary intervention (PCI) (e.g., angioplasty, atherectomy, stent placement).***For use as an adjunct to percutaneous coronary intervention (PCI) for the prevention of cardiac ischemic complications, including prevention of myocardial infarction (i.e., myocardial infarction prophylaxis).***For the prevention of cardiac ischemic complications in patients with acute myocardial infarction, NSTEMI or unstable angina (UA) not responding to conventional medical therapy when percutaneous coronary intervention (PCI) is planned within 24 hours.***For the prevention of cardiac ischemic complications in patients with ST-elevation MI (STEMI)� undergoing percutaneous coronary intervention (PCI).***For the treatment of large coronary aneurysms with or without thrombus formation in children with Kawasaki disease�.***For the treatment of acute myocardial infarction, STEMI� secondary to coronary artery thrombosis in combination with reduced dose fibrinolytic therapy and heparin. <br />NOTE: Although the ACCP antithrombotic guidelines recommend against this strategy for treating acute myocardial infarction (Grade 1B recommendation), the AHA-ACC STEMI guidelines suggest that abciximab combined with half-dose reteplase or tenecteplase may be considered to prevent complications of STEMI (e.g., reinfarction) in selected patients with anterior infarction location, age &lt; 75 years, and no risk factors for bleeding (Class IIb recommendation).<br /","***Aneurysm, anticoagulant therapy, arteriovenous malformation, bleeding, coagulopathy, dextran therapy, GI bleeding, hypertension, intracranial bleeding, intracranial mass, intramuscular injections, retinal bleeding, stroke, surgery, thrombocytopenia, thrombolytic therapy, trauma, vasculitis, venipuncture***Human anti-murine antibody (HAMA), murine protein hypersensitivity***Abciximab hypersensitivity, human anti-chimeric antibody (HACA)***Pregnancy***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1243041'],ivacaftor,"***For the treatment of cystic fibrosis (CF) in patients who have one mutation in the <em>CFTR</em> gene that is responsive to ivacaftor. <br />  NOTE: If a patient's genotype is unknown, an FDA-cleared CF mutation test should be performed; some tests may require verification with bi-directional sequencing.<br /","***General Information***Hepatic disease***Renal disease, renal failure, renal impairment***Cataracts, children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,follitropin beta,"***For the treatment of infertility in females. <br />        NOTE: Prior to the treatment, women should have a complete gynecologic and endocrinologic evaluation. The possibility of pregnancy should be ruled out and the fertility status of the male partner should be evaluated. <br />NOTE: During FSH treatment and during a 2 week post-treatment period, patients should be examined at least every other day for signs of excessive ovarian stimulation. Ovarian hyperstimulation syndrome (OHSS) usually occurs after discontinuation of FSH and reaches its maximum at about 7 to 10 days post-ovulation.***For the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure.***For the development of multiple follicles in the ovulatory female patient participating in an Assisted Reproductive Technology (ART) program.***For the induction of pregnancy in the ovulatory female patient undergoing controlled ovarian stimulation as part of an In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) cycle. <br />          NOTE: Women should have a diagnosis of the cause of infertility.<br />       ***For the treatment of infertility in males (for the stimulation of spermatogenesis in males with primary or secondary hypogonadotropic hypogonadism and resultant oligospermia). <br />  NOTE: Pretreatment with hCG is required prior to combination treatment with r-FSH. Various hCG dosages have been advocated; continue hCG for a period sufficient to achieve normal serum testosterone concentrations. Such pretreatment may require 3 to 6 months.<br />NOTE: Complete a medical and endocrinologic evaluation before starting follitropin beta or follitropin alfa. Exclude primary testicular failure and confirm hypogonadotropic hypogonadism. Lastly, evaluate the fertility status of the female partner.<br />NOTE: Serum testosterone concentrations and semen analysis are used for clinical monitoring of spermatogenesis","***General Information***Neomycin hypersensitivity, streptomycin hypersensitivity***Children***Driving or operating machinery***Asthma***Adrenal insufficiency, pituitary adenoma, thyroid disease***Ethanol intoxication, tobacco smoking***Testicular failure***Ovarian failure***Endometriosis, uterine leiomyomata, vaginal bleeding***Geriatric***Breast cancer, ovarian cancer, ovarian cyst, uterine cancer***Ascites, polycystic ovary syndrome***Ectopic pregnancy, pregnancy***Breast-feeding***Myocardial infarction, obesity, stroke, thromboembolic disease, thrombophlebitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['59943'],imiquimod,"***For the treatment of external genital and perianal warts (i.e., condylomata acuminata) due to human papillomavirus (HPV) infection. <br />        NOTE: Imiquimod cream has not been evaluated for the treatment of urethral, intra-vaginal, cervical, rectal, or intra-anal human papilloma viral disease and is not recommended for these conditions. <br />     ***For the treatment of  actinic keratosis (AK).***For the treatment of clinically typical, non-hyperkeratotic, non-hypertrophic actinic keratosis (AK) on the face or scalp in immunocompetent adults.***For the treatment of clinically typical visible or palpable actinic keratosis (AK) on  the full face or balding scalp in immunocompetent adults.***For the treatment of superficial basal cell carcinoma. <br />        NOTE: The diagnosis of superficial basal cell carcinoma should be confirmed prior to beginning treatment with Aldara. The safety and efficacy of Aldara in other types of basal cell carcinoma, including nodular or morpheaform (fibrosing or sclerosing) types, Basal Cell Nevus Syndrome, or xeroderma pigmentosum has not been established.<br />     ***For the treatment of molluscum contagiosum�.***For the treatment of lentigo maligna�.***For the treatment of acyclovir-resistant mucocutaneous herpes simplex virus infection�, including herpes genitalis�, in HIV-infected patients.***For the treatment of vulvar intraepithelial neoplasia (VIN)�.","***Accidental exposure, benzyl alcohol hypersensitivity, ocular exposure, paraben hypersensitivity, surgery***Human immunodeficiency virus (HIV) infection, immunosuppression***Sunburn, sunlight (UV) exposure***Contraceptive devices***Occlusive dressing***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1102270'],rilpivirine,"***For use in combination with other antiretroviral agents to treat human immunodeficiency virus (HIV) infection in antiretroviral treatment-naive patients with HIV-1 RNA concentrations less than or equal to 100,000 copies/mL at treatment initiation.***For human immunodeficiency virus (HIV) prophylaxis� after occupational exposure to HIV.***Formoterol***Formoterol; Mometasone","***General Information***Pregnancy***Breast-feeding***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Human immunodeficiency virus (HIV) infection resistance***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia***Depression, suicidal ideation***Children, infants, neonates***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Hepatic disease, hepatitis B and HIV coinfection, hepatitis C and HIV coinfection***Serious rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],drospirenone/ethinyl estradiol,"***For routine contraception.***For the treatment of acne vulgaris in women who also desire oral contraception.***For the treatment of premenstrual dysphoric disorder (PMDD) in women who also desire oral contraception.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception.***For the treatment or adjuvant treatment of conditions such as amenorrhea�, hirsutism�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who desire oral contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Adrenal insufficiency, electrolyte imbalance, hyperkalemia, renal disease, renal failure, renal impairment***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia, pancreatitis***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, hypertension, myocardial infarction, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,norethindrone,***For the treatment of secondary amenorrhea or dysfunctional uterine bleeding due to hormonal imbalance in the absence of organic pathology such as submucous fibroids or uterine cancer.***For routine contraception. <br />        NOTE: Ortho-Micronor and NOR-QD are not considered bioequivalent and are not substitutable for each other.<br />NOTE: These products have not been studied for and are not indicated for use in emergency contraception***For the treatment of endometriosis.***For the prevention of endometrial changes associated with estrogen replacement therapy in postmenopausal women.,"***General Information***Human immunodeficiency virus (HIV) infection***Hepatic disease***Incomplete abortion, vaginal bleeding***Breast cancer***Ectopic pregnancy, pregnancy***Breast-feeding***Diabetes mellitus***Hyperlipidemia***Cerebrovascular disease, myocardial infarction, stroke, thromboembolic disease, thrombophlebitis, tobacco smoking***Asthma, renal disease***Depression, migraine, seizure disorder***Ovarian cyst***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4917'],nitroglycerin,"***For the treatment of angina.***For acute angina pectoris or for acute angina pectoris prophylaxis (i.e., situations likely to provoke an anginal attack).***For chronic angina pectoris. <br />          NOTE: A nitrate-free interval is necessary to avoid the development of drug tolerance; although a minimum interval has not been clearly established, 10 to 12 hours/day has been sufficient with other nitroglycerin formulations.<br />       ***For the treatment of pain associated with anal fissures.***For the treatment of pain associated with anal fissures� and hemorrhoids�.***For controlled hypotension induction during anesthesia; for IV treatment of acute congestive heart failure or pulmonary edema, acute angina pectoris or unstable angina, acute myocardial infarction, or acute pulmonary hypertension�; or for treatment of severe hypertension, postoperative hypertension, perioperative hypertension (e.g., during cardiac surgery), or hypertensive emergency.***For use as a uterine relaxant to aid in extraction of a retained placenta�.***For the treatment of extravasation� of vasoactive medications.","***General Information***Nitrate hypersensitivity***Head trauma, increased intracranial pressure, intracranial bleeding***Anemia***Aortic stenosis, cardiac tamponade, cardiomyopathy, constrictive pericarditis, mitral stenosis, shock***Acute myocardial infarction, dehydration, hypotension, hypovolemia, orthostatic hypotension***Geriatric***Hepatic disease***Abrupt discontinuation***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Pregnancy***Breast-feeding***GI disease***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1112990'],ezogabine,***For the adjunct treatment of partial seizures in patients who have had an inadequate response to several alternative treatments and for whom the potential benefits outweigh the risk of retinal abnormalities and potential decline in visual acuity. <br />        NOTE: Vision should be assessed at baseline and�every 6 months during therapy with ezogabine.<br />     ***Formoterol***Formoterol; Mometasone,"***Depression, suicidal ideation***Dementia, prostatic hypertrophy, urinary retention***Psychosis, schizophrenia***Driving or operating machinery***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Abrupt discontinuation***Substance abuse***Dialysis, renal failure, renal impairment***Hepatic disease***Visual impairment***Geriatric***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,calcipotriene,"***For the treatment of plaque psoriasis. <br />        NOTE: According to the American Academy of Dermatology (AAD), combining calcipotriene with a topical corticosteroid is more effective than either treatment alone. In addition, fewer adverse events were reported with combination therapy in most clinical studies.<br />     ***For the treatment of chronic, moderate scalp psoriasis.","***General Information***Hypercalcemia, hypercalciuria, hypervitaminosis D, nephrolithiasis, occlusive dressing***Accidental exposure, ocular exposure***Children, infants, neonates***Sunlight (UV) exposure***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5781'],indomethacin,"***For the treatment of mild pain, moderate pain, or severe pain, such as arthralgia, myalgia, bursitis, or tendinitis.***For the treatment of mild to moderate acute pain.***For the treatment of moderate to severe pain.***For treatment of acute gouty arthritis. <br />        NOTE: Sustained-release capsules should not be used for this condition.<br />     ***For treatment of a hemodynamically significant patent ductus arteriosus (PDA) in premature infants.***For treatment of moderate to severe rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA)�, osteoarthritis, or ankylosing spondylitis. <br />        NOTE: If minor adverse effects develop as the dosage is increased, rapidly reduce the dose to a tolerated dose and closely observe the patient. If severe adverse reactions occur, stop indomethacin.<br />     ***For treatment of idiopathic or viral pericarditis�. <br />        NOTE: Use of NSAIDs are contraindicated in pericarditis after myocardial infarction; NSAIDs retard myocardial scar formation and the incidence of rupture may increase.<br />     ***For treatment of headache�.***For prophylaxis of chronic cluster headache�.***For the prevention of heterotopic ossification�.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Aortic coarctation, bleeding, congenital heart disease, infection, intracranial bleeding, necrotizing enterocolitis, neonates***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, hemorrhoids, peptic ulcer disease, tobacco smoking, ulcerative colitis***Bone marrow suppression, coagulopathy, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Visual disturbance***Hepatic disease, jaundice***Dental disease, dental work***Dehydration, hyperkalemia, renal disease, renal failure, renal impairment***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hypertension, myocardial infarction, peripheral vascular disease, stroke, thromboembolism***Coronary artery bypass graft surgery (CABG)***Depression, driving or operating machinery, headache, Parkinson's disease, seizure disorder***Labor, pregnancy***Breast-feeding***Geriatric***Children, infants***Intramuscular injections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['40048'],carboplatin,"***For the treatment of ovarian cancer.***For the first-line treatment of ovarian cancer in combination with paclitaxel�.***For the first-line treatment of ovarian cancer in combination with docetaxel�.***For the first-line treatment of or palliative treatment of recurrent advanced ovarian cancer.***For treatment of non-small cell lung cancer (NSCLC)�.***For the treatment of advanced or metastatic NSCLC in combination with paclitaxel�.***For first-line treatment of inoperable, locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with gemcitabine�.***For first-line treatment of unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with docetaxel�.***For the first-line treatment of stage IIIB or IV non-small cell lung cancer (NSCLC) in combination with pemetrexed�.***For the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who are not candidates for curative surgery or radiation in combination with nanoparticle albumin-bound paclitaxel�. <br />          NOTE: Nanoparticle albumin-bound paclitaxel is FDA approved in combination with carboplatin for the first-line treatment of locally advanced or metastatic NSCLC.<br />       ***For treatment of head and neck cancer�.***For the treatment of advanced-stage squamous cell carcinoma of the head and neck in combination with 5-fluorouracil and radiation therapy�.***For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in combination with 5-fluorouracil�.***For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in combination with 5-fluorouracil and cetuximab�.***For the treatment of advanced squamous cell carcinoma of the head and neck in combination with paclitaxel and radiotherapy�.***For treatment of testicular cancer�.***For the treatment of testicular cancer in combination with etoposide and bleomycin�.***For the treatment of stage I seminoma�.***For the treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL)� in combination with ifosfamide and etoposide.***For stem cell transplant preparation�.***For stem cell transplant preparation, in combination with ifosfamide and etoposide, prior to autologous stem cell transplant for the treatment of relapsed or refractory germ cell tumor�.***For stem cell mobilization in combination with ifosfamide and etoposide, in transplant eligible patients with non-Hodgkin's lymphoma.***For the treatment of malignant glioma�.***For the treatment of recurrent grade III malignant glioma in combination with teniposide�.***For the treatment of previously untreated, low-grade malignant glioma in combination with vincristine�.***For the treatment of recurrent high-grade malignant glioma�.***For the first-line treatment of advanced transitional-cell bladder cancer�, in combination with paclitaxel.***For the treatment of breast cancer�.***For adjuvant treatment of patients with HER2 overexpressing node-positive or high-risk node negative breast cancer�, in combination with docetaxel and trastuzumab. <br />          NOTE: Trastuzumab is FDA approved for the treatment of HER2 overexpressing node-positive or high-risk node negative breast cancer in combination with carboplatin and docetaxel. Carboplatin is not FDA approved for the treatment of breast cancer.<br />       ***For the first-line treatment of metastatic breast cancer in combination with paclitaxel�.***For the front-line treatment of HER2-overexpressing metastatic breast cancer� in combination with paclitaxel and trastuzumab.***For the treatment of relapsed or refractory acute lymphocytic leukemia (ALL) in combination with ifosfamide, etoposide, and rituximab�.***For the treatment of poor-risk relapsed Wilms' tumor in combination with etoposide and ifosfamide�.***For the treatment of intermediate-risk neuroblastoma in combination with etoposide, cyclophosphamide, and doxorubicin�.***For the first-line treatment of unresectable, advanced thymoma�, in combination with paclitaxel.***For the first-line treatment of unresectable, advanced thymic carcinoma�, in combination with paclitaxel.***For the treatment of small cell lung cancer (SCLC)�.***For the treatment of extensive disease SCLC in combination with etoposide�.***For the treatment of limited-disease SCLC in combination with etoposide and radiation therapy�.***For the treatment of relapsed SCLC in combination with paclitaxel�.***For the treatment of glioblastoma multiforme� after failing prior bevacizumab-based therapy, in combination with irinotecan and bevacizumab.***For the treatment of previously untreated, advanced, unresectable pleural malignant mesothelioma, in combination with pemetrexed�.","***Platinum compound hypersensitivity, serious hypersensitivity reactions or anaphylaxis***Anemia, bleeding, bone marrow suppression, coagulopathy, herpes infection, infection, neutropenia, radiation therapy, thrombocytopenia, varicella, viral infection***Anuria, dialysis, renal failure, renal impairment***Children, hearing impairment***Peripheral neuropathy***Pregnancy***Breast-feeding***Requires a specialized care setting, requires an experienced clinician***Geriatric***Vomiting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8410'],alteplase,"***For the treatment of acute myocardial infarction with ST-elevation (STEMI) due to coronary artery thrombosis. <br />        NOTE: A dose of 150 mg of alteplase is no longer recommended due to an increased incidence of intracranial bleeding.<br />NOTE: Randomized controlled trials have demonstrated beneficial outcomes when fibrinolytic therapy is administered as early as possible after onset of STEMI symptoms (e.g., prehospital fibrinolysis or within 30 minutes of hospital arrival). When indicated for patients with acute myocardial infarction and ST-elevation (STEMI), fibrinolytic therapy may be administered within 12 hours following the onset of symptoms.  It is reasonable to administer fibrinolytic therapy within 24 hours of the onset of STEMI symptoms in patients who have continuing ischemic symptoms and ST elevation greater than 0.1 mV in at least 2 contiguous precordial leads or at least 2 adjacent limb leads.<br />NOTE: See heparin monograph for suggested dosing regimens during thrombolysis for acute myocardial infarction***For the intracoronary treatment of acute coronary artery thrombosis (i.e., abrupt closure) in the setting of percutaneous coronary intervention (PCI)�, in combination with repeat balloon dilation. <br />          NOTE: The relative efficacy of alteplase compared with other treatment strategies has not been systematically evaluated.<br />       ***For the treatment of acute pulmonary embolism.***For the treatment of acute ischemic stroke.***For acute ischemic stroke in pediatric patients�.***For reestablishing patency of an occluded IV catheter.***For the treatment of deep venous thrombosis (DVT)� using local administration of thrombolytics including catheter-directed thrombolysis (CDT) and intra-clot administration. <br />  NOTE: Clinical practice guidelines recommend anticoagulant therapy alone over catheter-directed thrombolysis (CDT) in patients with acute proximal DVT; however, guidelines do state that patients who are most likely to benefit from CDT are those with iliofemoral DVT, symptoms for less than 14 days, good functional status, life expectancy of more than 1 year, and a low risk of bleeding.<br /***For the treatment of peripheral arterial thromboembolism�.***For intravascular catheter occlusion prophylaxis�.***For the management of pleural effusion� or pleural empyema�.","***General Information***Hypertension***Aneurysm, anticoagulant therapy, arteriovenous malformation, bleeding, brain tumor, coagulopathy, coronary artery bypass graft surgery (CABG), diabetic retinopathy, endocarditis, GI bleeding, head trauma, intracranial bleeding, intracranial mass, organ biopsy, peptic ulcer disease, pericarditis, seizures, stroke, surgery, thrombocytopenia, trauma, venipuncture***Hepatic disease, renal disease, renal failure***Intramuscular injections***Infection, thrombophlebitis***Geriatric***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Atrial fibrillation, mitral stenosis, thrombosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dicyclomine hydrochloride,***For the treatment of irritable bowel syndrome and other functional disturbances of GI motility.,"***General Information***Intravenous administration***Anticholinergic medications***GI obstruction, ileus, toxic megacolon, ulcerative colitis***Esophagitis, gastroesophageal reflux disease (GERD), hiatal hernia***Glaucoma***Cardiac arrhythmias, coronary artery disease, heart failure, hemorrhagic shock, hypertension***Myasthenia gravis, peripheral neuropathy***Prostatic hypertrophy, urinary tract obstruction***Hepatic disease, renal disease***Hyperthyroidism***Driving or operating machinery***Contact lenses***Children, infants, neonates***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['25480'],gabapentin,"***For the adjunctive treatment of partial seizures with or without secondary generalized tonic-clonic seizures.***For neuropathic pain associated with postherpetic neuralgia (PHN).***For the treatment of moderate to severe primary restless legs syndrome (RLS). <br />        NOTE: Gabapentin enacarbil is not recommended for patients who are required to sleep during the day and remain awake at night.<br />NOTE: immediate-release and extended-release gabapentin formulations are not interchangeable; also, Gralise is not interchangeable with Horizant due to differing chemical forms and pharmacokinetic properties***For the treatment of amyotrophic lateral sclerosis (ALS)�. <br />        NOTE: Gabapentin has been granted orphan drug status by the FDA for this indication.<br />     ***For the treatment of tremor�.***For the treatment of orthostatic tremor�.***For the treatment of essential tremor�.***For the treatment of nystagmus�.***For the treatment of acquired pendular nystagmus�.***For the treatment of congenital nystagmus�.***For the treatment of paroxysmal symptoms and spasticity� due to multiple sclerosis�.***For the treatment of hot flashes� due to menopause� or in women who have been treated for breast cancer.***For reducing hot flashes� associated with natural menopause�.***For reducing hot flashes� in women with breast cancer.***For the treatment of pruritus�.***For the treatment of uremic pruritus� in hemodialysis patients.***For the treatment of brachioradial pruritus�.***For the treatment of fibromyalgia�.***For the treatment of singultus (hiccups)�.***For the treatment of dysautonomia� following severe traumatic brain injury.***For long-term prophylaxis of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT)�.***For the treatment of painful diabetic neuropathy�.","***General Information***Depression, suicidal ideation***Dialysis, renal failure, renal impairment***Driving or operating machinery***Pregnancy***Breast-feeding***Children, infants, neonates***Seizure disorder, seizures***Abrupt discontinuation***Geriatric***Substance abuse***Angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['3640', '1545992']",doxycycline,"***For the treatment of skin and skin structure infections, including cellulitis, due to <em>Staphylococcus aureus</em>. <br />        NOTE: Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infection.<br />     ***For the treatment of bacterial urinary tract infection (UTI).***For the treatment of upper respiratory tract infections (e.g., sinusitis).***For the treatment of lower respiratory tract infections (e.g., pneumonia, community-acquired pneumonia).***For the treatment of severe acne vulgaris as adjunctive therapy.***For the treatment of acne rosacea.***For the treatment of cholera.***For the treatment of brucellosis.***For the treatment of Rickettsial infections (e.g., Rickettsial pox, Rocky Mountain spotted fever, scrub typhus) including endemic murine typhus.***For the treatment of relapsing fever due to <em>Borrelia recurrentis</em>.***For the treatment of syphilis. <br />        NOTE: A Jarisch-Herxheimer reaction may occur within the first 24 hours of therapy.<br />NOTE: While clinical practice guidelines recommend non-penicillin alternatives for the treatment of syphilis in HIV-infected patients, their efficacy has not been evaluated and should only be used with close clinical and serologic monitoring***For primary, secondary, or early latent syphilis (caused by <em>Treponema pallidum</em>) in nonpregnant, penicillin-allergic patients.***For late latent syphilis in nonpregnant, penicillin-allergic patients.***For the treatment of psittacosis.***For the treatment of non-gonococcal urethritis (NGU) and chlamydia infection, including trachoma and inclusion bacterial conjunctivitis.***For the treatment of lymphogranuloma venereum caused by <em>Chlamydia trachomatis</em>.***For the treatment of granuloma inguinale (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of epididymitis and epididymo-orchitis.***For malaria prophylaxis in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains.***For the treatment of anthrax infection due to exposure to <em>Bacillus anthracis</em>.***For the treatment of cutaneous anthrax infection.***For the treatment of systemic anthrax infection.***For anthrax prophylaxis after exposure to <em>Bacillus anthracis</em> (postexposure prophylaxis, PEP).***For the treatment of plague infection due to exposure to <em>Yersinia pestis</em>.***For the treatment of plague infection in an individual patient or in a contained casualty setting.***For the treatment of plague infection in a mass casualty setting.***For the initial treatment of tularemia infection due to exposure to <em>Francisella tularensis </em>.***For the initial treatment of tularemia infection in individual patient or in a contained casualty setting. <br />          NOTE: Streptomycin is the drug of choice to treat tularemia in most patients; gentamicin is the preferred agent in pregnant women.<br />       ***For the initial treatment of tularemia infection in a mass casualty setting. <br />          NOTE: It is recommended that pregnant women be treated with ciprofloxacin as a first-line agent; doxycycline is a preferred treatment choice if ciprofloxacin is contraindicated.<br />       ***For the treatment of intestinal amebiasis as an adjunct to amebicides.***For the treatment of infections caused by sensitive organisms including actinomycosis (<em>Actinomyces israelii</em>), yaws (<em>Treponema pertenue</em>), necrotizing ulcerative gingivitis (Fusospirochetosis or Vincent's infection), and listeriosis (<em>Listeria monocytogenes</em>).***For the treatment of Q fever.***For the treatment of chancroid (<em>Haemophilus ducreyi</em>) infections.***For the treatment of bartonellosis (<em>Bartonella bacilliformis</em>) infections, including <em>Bartonella</em> endocarditis.***For the treatment of <em>Bartonella</em> sp. infections (bartonellosis) in HIV-infected patients.***For long term suppression� of infections caused by <em>Bartonella</em> sp. in HIV-infected patients with relapse or reinfection with CD4 count less than 200 cells/mm3.***For the treatment of enterocolitis�, biliary tract infections�, and intraabdominal infections�.***For the treatment of uncomplicated gonorrhea (e.g., cervicitis, urethritis, pharyngitis, proctitis�).***For the treatment of acute proctitis�.***For chlamydial infection prophylaxis� in victims of sexual assault.***For the treatment of chronic prostatitis� due to <em>Ureaplasma urealyticum</em>.***For the treatment of Lyme disease�, including erythema migrans�, Lyme arthritis�, Lyme carditis�, and Lyme meningitis�.***For early Lyme disease� (erythema migrans�).***For Lyme arthritis�.***For Lyme carditis�.***For early neurologic Lyme disease (i.e., Lyme meningitis� or cranial nerve palsy).***For Lyme disease prophylaxis�.***For the treatment of Legionnaire's disease� caused by <em>Legionella pneumophila</em>.***For the management of pleural effusion� as an alternative to injectable tetracycline or other agents.***For the treatment of malaria� due to <em>P. falciparum</em> or <em>P. vivax</em>.***For the treatment of pelvic inflammatory disease (PID)� and tubo-ovarian abscess�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis in combination with conventional treatment (e.g., scaling and root planing).***For aggressive juvenile periodontitis�.***For chronic adult periodontitis for a gain in clinical attachment, reduction in probing depth, and reduction in bleeding on probing.***For plague prophylaxis� following exposure to <em>Yersinia pestis</em>.***For tularemia prophylaxis� following exposure to <em>Francisella tularensis</em>.***For the treatment of Bancroft's filariasis� (elephantiasis) caused by <em>Wuchereria bancrofti</em>�.***For the treatment of melioidosis� due to <em>Burkholderia pseudomallei</em>.***For use as an adjunct in the treatment of <em>Burkholderia pseudomallei</em> bacteremia�.***For use as an adjunct in the treatment of localized melioidosis�.***For the treatment of leptospirosis� due to <em>Leptospira</em> sp.�.***For mild leptospirosis�.***For severe leptospirosis�.***For surgical infection prophylaxis� for gynecologic procedures.***For surgical infection prophylaxis� for hysterosalpingogram or chromotubation.***For surgical infection prophylaxis� for induced abortion/dilation and evacuation.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated bone and joint infections�, including osteomyelitis�, or orthopedic device-related infection�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated osteomyelitis�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated prosthetic device infections�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated spinal implant infections�.","***Tetracyclines hypersensitivity***Hepatic disease***Sunlight (UV) exposure***Asthma, sulfite hypersensitivity***Achlorhydria***Pregnancy***Breast-feeding***Children, infants, neonates***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Dental disease, periodontal disease***Chemotherapy, diabetes mellitus, human immunodeficiency virus (HIV) infection, immunosuppression***Antimicrobial resistance, fungal infection, viral infection***Increased intracranial pressure, obesity***Sexually transmitted disease***Geriatric***Serious rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,metformin hydrochloride/sitagliptin,"***For the treatment of type 2 diabetes mellitus uncontrolled by diet and exercise and when treatment with one antidiabetic agent alone does not result in adequate control. <br />        NOTE: During concurrent use of metformin; sitagliptin and insulin or sulfonylureas, it may be necessary to lower the dose of insulin or the sulfonylurea to minimize the risk of hypoglycemia.<br />     ***For use when switching from metformin plus sitagliptin as separate tablets to the single, combination tablet.***For use when initial treatment with metformin alone does not result in adequate glycemic control.***For use when initial treatment with sitagliptin alone does not result in adequate glycemic control.***Formoterol; Mometasone","***Exfoliative dermatitis, history of angioedema, serious rash***Diabetic ketoacidosis, type 1 diabetes mellitus***Acidemia, hypoxemia, lactic acidosis, metabolic acidosis***Pancreatitis***Adrenal insufficiency, diarrhea, fever, gastroparesis, GI obstruction, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypothyroidism, ileus, malnutrition, pituitary insufficiency, vomiting***Renal disease, renal failure, renal impairment***Acute heart failure, acute myocardial infarction, cardiac disease, cardiogenic shock, heart failure***Geriatric***Alcoholism, ethanol intoxication, hepatic disease***Radiographic contrast administration***Burns, dehydration, infection, sepsis, surgery, trauma***Anemia, pernicious anemia, vitamin B12 deficiency***Arthralgia***Polycystic ovary syndrome, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8076'],perphenazine,***For the treatment of schizophrenia.***For the treatment of severe nausea/vomiting.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.,"***Asthma, phenothiazine hypersensitivity, sulfite hypersensitivity***Agranulocytosis, bone marrow suppression, fever, hematological disease, infection, leukopenia, neutropenia***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion, head trauma***Dental work, surgery***Intracranial mass, seizure disorder, seizures***Tardive dyskinesia***Anticholinergic medications, closed-angle glaucoma, ileus, prostatic hypertrophy, urinary retention***Alcoholism, angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, pulmonary disease, QT prolongation, thyroid disease***Children, infants, Reye's syndrome***Encephalopathy, hepatic disease, jaundice***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Sunlight (UV) exposure***Accidental exposure***Abrupt discontinuation***Renal failure***Ocular disease***Chemotherapy, GI obstruction, vomiting***Tobacco smoking***Labor, neonates, obstetric delivery, pregnancy, pregnancy testing***Breast-feeding***Breast cancer, hyperprolactinemia, infertility***Radiographic contrast administration***Suicidal ideation***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,megestrol acetate,"***For the treatment of anorexia, cachexia, or unexplained weight loss in patients with acquired immunodeficiency syndrome (AIDS).***For the palliative treatment of advanced, inoperable, recurrent metastatic breast cancer.***For the palliative treatment of advanced, inoperable, recurrent metastatic endometrial cancer.***For the treatment of advanced hormone-refractory prostate cancer�.***For the for the treatment of metastatic renal cell cancer�.***For the treatment of endometriosis�-associated pain�.***For the treatment of hot flashes� in women with a history of breast cancer or in men with prostate cancer who have undergone androgen-deprivation therapy.","***General Information***Dysfunctional uterine bleeding, females, vaginal bleeding***Breast cancer, neoplastic disease***Adrenal insufficiency, Cushing's syndrome, diabetes mellitus, hyperglycemia, hypotension, hypothalamic-pituitary-adrenal (HPA) suppression, infection, surgery, vomiting***Thromboembolic disease, thrombophlebitis***Hepatic disease***Pregnancy***Breast-feeding***Children***Renal failure, renal impairment***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['20492'],ceftibuten,***For the treatment of acute bacterial exacerbations of chronic bronchitis.***For the treatment of pharyngitis and/or tonsillitis due to <em>S. pyogenes</em> (group A beta-hemolytic streptococci). <br />        NOTE: The American Heart Association does not recommended ceftibuten for routine therapy for Group A Streptococcal pharyngitis therapy to prevent rheumatic fever.<br />     ***For the treatment of otitis media.***For the treatment of pneumonia�.***For the treatment of bacillary dysentery� (shigellosis�).,"***General Information***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Cephalosporin hypersensitivity, penicillin hypersensitivity***Dialysis, renal failure, renal impairment***Coagulopathy, vitamin K deficiency***Pregnancy***Breast-feeding***Infants, neonates***Diabetes mellitus***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,labetalol hydrochloride,***For the treatment of hypertension.***For the treatment of hypertensive emergency.***For the treatment of hypertension associated with severe preeclampsia or eclampsia.***For controlled hypotension induction� with anesthesia to reduce the risk of hemorrhage during surgery.,"***General Information***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***AV block, bradycardia, cardiogenic shock, heart failure, hypotension, pulmonary edema, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Pheochromocytoma***Cerebrovascular disease***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema***Driving or operating machinery***Diabetes mellitus***Surgery***Hepatic disease***Pregnancy***Breast-feeding***Depression***Psoriasis***Myasthenia gravis***Geriatric***Children, infants, neonates***Beta-blocker hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8703'],fenofibrate,"***For use as an adjunct to diet for the treatment of adult patients with severe hypertriglyceridemia. <br />  NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.     <br />NOTE: Markedly elevated levels of serum triglycerides (e.g., &gt; 2000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.  ***For use as an adjunct to diet to reduce elevated LDL-cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase HDL-cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. <br />        NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.   ","***General Information***Cardiac disease***Biliary cirrhosis, cholelithiasis, gallbladder disease, hepatic disease***Dialysis, renal disease, renal failure, renal impairment***Anticoagulant therapy***Thromboembolic disease***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding***Diabetes mellitus***Hypothyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cromolyn sodium,"***For use as an adjunct in the management of patients with asthma.***For exercise-induced bronchospasm prophylaxis or the prevention of bronchospasm induced by other known precipitating factors.***For treatment of the nasal symptoms associated with allergic rhinitis including runny/itching nose, sneezing, and allergic nasal congestion; and for allergic rhinitis prophylaxis.***For the treatment of allergic ocular disorders such as allergic conjunctivitis, allergic keratoconjunctivitis, giant papillary conjunctivitis (GPC), vernal keratitis, vernal keratoconjunctivitis.***For the treatment of systemic mastocytosis.***For the treatment of chronic inflammatory bowel disease� (e.g., ulcerative colitis�), for initial suppression and for maintenance therapy to prevent relapse.***For the prevention of symptoms associated with food allergy�.","***General Information***Acute bronchospasm, status asthmaticus***Cardiac arrhythmias, cardiac disease, coronary artery disease***Contact lenses***Lactase deficiency***Hepatic disease, renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7597']['10759'],nystatin/triamcinolone acetonide,"***For the short-term (i.e., less than 2 weeks) treatment of inflammatory cutaneous candidiasis caused by <em>Candida albicans</em> and other <em>Candida</em> sp..","***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing***Children, infants***Pregnancy***Breast-feeding***Peripheral vascular disease, skin abrasion***Geriatric, skin atrophy***Ocular exposure***Benzyl alcohol hypersensitivity***Corticosteroid hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,chlorhexidine gluconate,***For the treatment of gingivitis.***For the adjuvant treatment and maintenance of adult periodontitis.***For use as skin antisepsis.***For the amelioration of oral stomatitis� and mucositis� associated with cytoreductive chemotherapy in patients preparing for bone marrow transplantation. <br />  NOTE: This drug is designated as an orphan drug for this indication by the FDA.<br /***For the treatment of denture stomatitis�.***For use as a skin cleanser in the treatment of acne vulgaris�.,"***Breast-feeding***Dental work***Infection, periodontal disease***Surgery***Ocular exposure***Pregnancy***Tympanic membrane perforation***Lumbar puncture, occlusive dressing, skin disease***Children, infants, neonates***Risk of serious hypersensitivity reactions or anaphylaxis***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6218'],lactulose,"***For the treatment of hepatic encephalopathy (portal-systemic encephalopathy, PSE).***For the treatment of constipation, including constipation related to barium retention.",***Galactose-free diet***Surgery***Diabetes mellitus***Geriatric***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['121191'],rituximab,"***For the treatment of non-Hodgkin's lymphoma (NHL).***For patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell NHL.***For first-line treatment of follicular, CD20-positive, B-cell NHL, in combination with chemotherapy.***For the treatment of follicular, CD20-positive NHL, in combination with ibritumomab tiuxetan.***For first-line treatment of diffuse large B-cell, CD20-positive non-Hodgkin's lymphoma (NHL), in combination with CHOP or other anthracycline-based chemotherapy regimen.***For the treatment of follicular NHL, in combination with CHOP chemotherapy�.***For the treatment of previously untreated follicular NHL, in combination with fludarabine and mitoxantrone�.***For the treatment of previously untreated indolent NHL (including follicular lymphoma), in combination with bendamustine�.***For the treatment of previously treated indolent NHL (including follicular lymphoma), in combination with bendamustine�.***For the first-line treatment of indolent NHL (including follicular lymphoma), in combination with lenalidomide�.***For the treatment of relapsed or refractory, aggressive, CD20-positive NHL in transplant eligible patients, in combination with gemcitabine, dexamethasone, and cisplatin�.***For the treatment of chronic lymphocytic leukemia (CLL). <br />        NOTE: Pneumocystis jiroveci pneumonia (PCP) and anti-herpetic viral prophylaxis is recommended for patients with CLL during treatment and for up to 12 months following treatment as appropriate.<br />     ***For the treatment of CD20-positive CLL, in combination with cyclophosphamide and fludarabine.***For the first-line treatment of CLL, in combination with fludarabine�.***For the first-line treatment of CLL in elderly patients, in combination with chlorambucil�.***For the treatment of CLL, in combination with cyclophosphamide and pentostatin�.***For the treatment of relapsed or refractory CLL, in combination with idelalisib and bendamustine�.***For reducing signs and symptoms of moderately- to severely-active rheumatoid arthritis in combination with methotrexate in patients who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. <br />  NOTE: In patients with rheumatoid arthritis, obtain a CBC at 2�4 month intervals during rituximab therapy.<br /***For the treatment of Wegener's granulomatosis and microscopic polyangiitis in combination with glucocorticoids. <br />  NOTE: Prophylaxis against Pneumocystis pneumonia (PCP) is recommended for patients with WG and MPA during treatment and for at least 6 months after the last rituximab infusion.<br />NOTE: Use of concomitant immunosuppressants other than corticosteroids has not been studied in patients with peripheral B-cell depletion after rituximab receipt***For the treatment of mantle cell lymphoma (MCL)�.***For the treatment of previously untreated advanced mantle cell lymphoma (MCL), in combination with CHOP chemotherapy�.***For the treatment of previously untreated advanced mantle cell lymphoma (MCL), in combination with hyper-CVAD chemotherapy�.***For the treatment of previously untreated mantle cell lymphoma (MCL), in combination with bendamustine�.***For the treatment of previously treated mantle cell lymphoma (MCL), in combination with bendamustine�.***For the treatment of mantle cell lymphoma (MCL), in combination with lenalidomide�.***For the treatment of acute lymphocytic leukemia (ALL)�.***For the treatment of CD20-positive acute lymphocytic leukemia (ALL)� in combination with hyper-CVAD chemotherapy.***For the treatment of relapsed or refractory acute lymphocytic leukemia (ALL) in combination with ifosfamide, etoposide, and carboplatin�.***For the treatment of refractory autoimmune hemolytic anemia�.***For the treatment of immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP)�.***For corticosteroid-refractory ITP�.***For previously untreated ITP� in combination with dexamethasone.***For the treatment of thrombotic thrombocytopenia purpura� (TTP).***For the treatment of acquired blood factor deficiency�.***For the treatment of severe pemphigus�.***For the treatment of multicentric Castleman disease (MCD)� associated with human herpesvirus 8 (HHV-8) infection� in HIV-infected patients.***For the treatment of relapsing-remitting multiple sclerosis�. <br />        NOTE: Consideration of the type of multiple sclerosis, primary progressive or relapsing-remitting, is important. Rituximab for primary progressive MS was studied in a phase 2/3 trial; the dose was 1000 mg IV at baseline and at weeks 2, 24, 26, 48, 50, 72, and 74. According to the manufacturer, the primary endpoint of time to disease progression was not met. The percentage of patients with confirmed disease progression at week 96 was 30.2 % for rituximab recipients and 38.5 % for placebo recipients.<br />     ***For the treatment of Burkitt's lymphoma� in combination with Hyper-CVAD chemotherapy.***For the treatment of steroid-refractory chronic graft-versus-host disease (GVHD)�.***For the treatment of lupus nephritis� in patients with systemic lupus erythematosus (SLE) unresponsive to conventional therapy.***For the treatment of Waldenstrom macroglobulinemia�.***For the treatment of newly diagnosed Waldenstrom macroglobulinemia, in combination with dexamethasone and cyclophosphamide�.***For the treatment of newly diagnosed Waldenstrom macroglobulinemia, in combination with bortezomib and dexamethasone�.***Formoterol; Mometasone","***Serious rash***Hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, renal failure, tumor lysis syndrome (TLS)***Infection, viral infection***Hepatitis B exacerbation***Immunosuppression, progressive multifocal leukoencephalopathy***Vaccination***Renal disease, renal impairment***GI obstruction, GI perforation***Anemia, neutropenia, thrombocytopenia***Angina, cardiac arrhythmias, cardiac disease***Infusion-related reactions, pulmonary disease***Geriatric***Children, infants, neonates***Pregnancy***Contraception requirements, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,triamcinolone acetonide,"***For bronchospasm prophylaxis or maintenance therapy in patients who require chronic treatment with corticosteroids for control of bronchial asthma.***For the treatment of severe or incapacitating allergic conditions such as asthma that are intractable to adequate trials of conventional treatment.***For the treatment of symptoms of seasonal and perennial allergic rhinitis.***For the treatment of severe or incapacitating allergic conditions that are intractable to adequate trials of conventional treatment.***For the treatment of ocular inflammation (i.e., sympathetic ophthalmia and ocular inflammatory conditions unresponsive to topical corticosteroids), temporal arteritis, and uveitis.***For visualization during ocular surgery (i.e., vitrectomy).***For the treatment of acute rheumatic carditis, berylliosis, temporal arteritis�, or systemic lupus erythematosus (SLE). <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses (e.g., alopecia areata, atopic dermatitis, contact dermatitis including <em>Rhus dermatitis</em> due to poison ivy, poison oak, poison sumac, subacute cutaneous or discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex chronicus, mycosis fungoides, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, psoriasis, sarcoidosis, seborrheic dermatitis, sunburn, or xerosis). <br />        NOTE: Occlusive dressings may be necessary for chronic or severe cases of psoriasis or other recalcitrant conditions.<br />     ***For the treatment of ulcerative or inflammatory oral lesions including aphthous ulcer, desquamative gingivitis�, and oral lichen planus�.***For the treatment of severe or incapacitating allergic conditions such as atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions, bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome) that are intractable to adequate trials of conventional treatment and for the treatment of idiopathic eosinophilic pneumonias.***For the treatment of symptomatic sarcoidosis.***For the treatment of primary (Addison's disease) or secondary adrenocortical insufficiency. <br />        NOTE: Hydrocortisone and cortisone are the preferred agents for these conditions.<br />     ***For the treatment of congenital adrenal hyperplasia.***For the treatment of hypercalcemia associated with cancer.***For the treatment of nonsuppurative thyroiditis.***For the treatment of a critical period of regional enteritis and ulcerative colitis.***For the treatment of autoimmune hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, or selected cases of secondary thrombocytopenia.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of acute exacerbations of multiple sclerosis. <br />        NOTE: Corticosteroids are effective in speeding the resolution of acute exacerbations, but they do not affect the ultimate outcome or natural history of the disease.<br />     ***For the treatment of cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.***For the treatment of proteinuria or to induce diuresis in idiopathic nephrotic syndrome or lupus erythematosus.***For the treatment of an acute episode or exacerbation of ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA) as adjunctive therapy for short-term administration.***For the treatment of dermatomyositis or polymyositis.***For the relief of inflammation and for immunosuppression associated with a variety of disorders, like Hodgkin lymphoma. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the palliative treatment of leukemias and lymphomas.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of diabetic macular edema�.***For the relief of inflammation associated with synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; gout with acute gouty arthritis; epicondylitis; acute non-specific tenosynovitis; polychondritis�; posttraumatic osteoarthritis. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of osteoarthritis pain of the knee. <br />  NOTE: Zilretta is not interchangeable with other formulations of triamcinolone acetonide.<br /","***Epidural administration, intramuscular administration, intrathecal administration, intravenous administration, subcutaneous administration***Acute bronchospasm, status asthmaticus***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hyperthyroidism, hypothalamic-pituitary-adrenal (HPA) suppression, hypothyroidism, increased intracranial pressure, occlusive dressing, skin abrasion***Head trauma***Growth inhibition, osteoporosis***Surgery***Fungal infection, infection, viral infection***Tuberculosis***Immunosuppression***Herpes infection, measles, varicella***Glaucoma***Acne rosacea, acne vulgaris***Peripheral vascular disease***Nasal septal perforation, nasal surgery, nasal trauma***Myocardial infarction***Heart failure, hypertension***Diabetes mellitus***Skin atrophy***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Myasthenia gravis***Psychosis, seizure disorder***Coagulopathy, hemophilia, thromboembolic disease***Cataracts, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Vaccination***Breast-feeding***Tartrazine dye hypersensitivity***Neonates, premature neonates***Idiopathic thrombocytopenic purpura (ITP)***Corticosteroid hypersensitivity***Geriatric***Renal disease, renal impairment***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],drospirenone/ethinyl estradiol,"***For routine contraception.***For the treatment of acne vulgaris in women who also desire oral contraception.***For the treatment of premenstrual dysphoric disorder (PMDD) in women who also desire oral contraception.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception.***For the treatment or adjuvant treatment of conditions such as amenorrhea�, hirsutism�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who desire oral contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Adrenal insufficiency, electrolyte imbalance, hyperkalemia, renal disease, renal failure, renal impairment***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia, pancreatitis***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, hypertension, myocardial infarction, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albuterol sulfate,"***For the treatment of acute bronchospasm (e.g., asthma) and bronchospasm prophylaxis.***For bronchospasm associated reversible obstructive airway disease (i.e., asthma).***For exercise-induced bronchospasm prophylaxis.***For the adjunctive emergency acute treatment of hyperkalemia�.***For the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD)� including chronic bronchitis� and emphysema�.","***General Information***Albuterol hypersensitivity, levalbuterol hypersensitivity, milk protein hypersensitivity***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, tachycardia, thyroid disease***Geriatric***Hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyrotoxicosis***Diabetes mellitus, diabetic ketoacidosis***Deterioration of asthma, paradoxical bronchospasm***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Renal impairment***MAOI therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dextromethorphan hydrobromide/quinidine sulfate,***For the treatment of pseudobulbar affect (PBA).***Formoterol***Formoterol; Mometasone,"***General Information***Bone marrow suppression, thrombocytopenia***Alcoholism, AV block, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, electrolyte imbalance, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, stroke, thyroid disease, torsade de pointes, ventricular dysfunction***Hepatic disease, hepatitis***MAOI therapy***Myasthenia gravis***Substance abuse***Renal disease, renal failure, renal impairment***Geriatric***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7597'],nystatin,"***For the treatment of cutaneous candidiasis (including adjunctive treatment for candidal diaper dermatitis), mucocutaneous candidiasis (i.e., oropharyngeal candidiasis (thrush), vulvovaginal candidiasis), and intestinal candidiasis (with or without coexisting vulvovaginal candidiasis).***For the treatment of oropharyngeal candidiasis (thrush).***For the treatment of cutaneous candidiasis or mucocutaneous candidiasis, or for adjunctive treatment for candidal diaper dermatitis.***For the treatment of vulvovaginal candidiasis (VVC).***For the treatment of intestinal candidiasis (with or without coexisting vulvovaginal candidiasis).",***Paraben hypersensitivity***Pregnancy***Breast-feeding***Diabetes mellitus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pancuronium bromide,***For neuromuscular blockade or endotracheal intubation.***For the treatment of refractory agitation� in the intensive care unit patient.***For the induction of neuromuscular blockade as an adjunct to general anesthesia induction.***For the facilitation of endotracheal intubation.,"***General Information***Requires an experienced clinician, respiratory insufficiency***Labor, obstetric delivery, pregnancy***Breast-feeding***Chronic obstructive pulmonary disease (COPD), pulmonary disease, respiratory depression***Bromide hypersensitivity, neuromuscular blocking agent hypersensitivity***Lung cancer, myasthenia gravis, myopathy, neuromuscular disease, obesity***Asthma, cardiac disease, edema***Acid/base imbalance, adrenal insufficiency, dehydration, electrolyte imbalance, hypercalcemia, hypermagnesemia, hypocalcemia, hypokalemia, hypothermia, metabolic alkalosis, respiratory acidosis***Malignant hyperthermia***Tachycardia***Renal failure, renal impairment***Biliary obstruction, hepatic disease***Burns***Neonates, premature neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,buspirone hydrochloride,***For the treatment of generalized anxiety disorder (GAD) or for the short-term relief of the symptoms of anxiety.,"***General Information***MAOI therapy***Benzodiazepine dependence***Akathisia***Renal failure, renal impairment***Hepatic disease***Driving or operating machinery, ethanol ingestion***Geriatric***Pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1000082'],alcaftadine,***For the prevention of ocular pruritus associated with allergic conjunctivitis.,"***General Information***Contact lenses***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['42319'],nizatidine,"***For self-medication of pyrosis (heartburn), acid dyspepsia (acid indigestion), or sour stomach.***For the treatment of gastroesophageal reflux disease (GERD), including endoscopically diagnosed esophagitis (erosive and ulcerative esophagitis) and GERD-associated pyrosis (heartburn).***For the treatment of duodenal ulcer. <br />        NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br />     ***For an active ulcer.***For maintenance therapy after the ulcer has healed.***For the treatment of an active benign gastric ulcer. <br />        NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br />     ***For Helicobacter pylori (H. pylori) eradication in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />        NOTE: The American College of Gastroenterology (ACG) recommends 10�14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole; the same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: Nizatidine is not effective as a single agent for the eradication of H. pylori. Quadruple regimens that include an H2-blocker as an anti-secretory agent are FDA-approved, but are associated with lower compliance and efficacy rates than other recommended regimens.  An H2-blocker should not be substituted for a PPI in any current H. pylori treatment regimen unless the patient cannot tolerate a PPI.NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Helidac monograph).  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60%�90% of patients.***For use in acid aspiration prophylaxis� prior to anesthesia.***For stress gastritis prophylaxis� in critically-ill patients.","***General Information***H2-blocker hypersensitivity***Dysphagia, gastric cancer***Infection***Pregnancy***Breast-feeding***Children, infants, neonates***Renal failure, renal impairment***Tobacco smoking***Geriatric***Vitamin B12 deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['278739'],pegvisomant,"***For the treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate. <br />        NOTE: Pegvisomant is similar in structure to growth hormone (GH) and therefore cross-reacts in commercially available GH assays. Treatment with pegvisomant should not be monitored or adjusted based on serum GH concentrations reported from these assays; monitoring and dosage adjustments should only be based on serum IGF-I concentrations.<br />     ","***General Information***Neoplastic disease***Hepatic disease***Hypercholesterolemia***Diabetes mellitus***Pregnancy***Breast-feeding***Children, infants, neonates***Intravenous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dextran 70/hypromellose,***For the temporary relief of xerophthalmia and minor ocular irritation.,"***Contact lenses***Corneal abrasion, ocular infection, ocular trauma, visual disturbance***Pregnancy***Children, infants, neonates***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,gentamicin sulfate,"***For the treatment of lower respiratory tract infections, including community-acquired pneumonia (CAP) and nosocomial pneumonia. <br />        NOTE: Serum gentamicin concentrations should be used to guide dosage adjustments. Dosage of aminoglycosides should be based on an estimate of lean body mass.<br />     ***For the treatment of meningitis, bone and joint infections, and intraabdominal infections (peritonitis). <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. In most patients, dosage of aminoglycosides should be based on an estimate of lean body mass.<br />     ***For intrathecal or intraventricular administration in patients with meningitis due to susceptible organisms.***For peritoneal dialysis-associated peritonitis� in patients with end-stage renal disease.***For the treatment of infective endocarditis. <br />  NOTE: Serum gentamicin concentrations should be used to guide dosage adjustments. Dosage of aminoglycosides should usually be based on an estimate of lean body mass.<br /***For the treatment of skin and skin structure infections (e.g., cellulitis, burn wound infection). <br />  NOTE: Serum gentamicin concentrations should be used to guide dosage adjustments. Dosage of aminoglycosides should usually be based on an estimate of lean body mass.<br /***For the treatment of minor bacterial skin infection including, folliculitis, furunculosis, impetigo, eczema, pyoderma gangrenosum, sycosis barbae, infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis, and infected excoriations.***For the treatment of blepharitis, blepharoconjunctivitis, bacterial conjunctivitis, corneal ulcer, dacryocystitis, keratitis, keratoconjunctivitis, and acute meibomianitis.***For the treatment of bacteremia and sepsis. <br />  NOTE: Serum concentrations should be used to guide dosage adjustments. In most patients, dosage of aminoglycosides should be based on an estimate of lean body mass.<br /***For the treatment of urinary tract infection (UTI).***For the treatment of pelvic inflammatory disease (PID)� with or without complications of tubo-ovarian abscess� .***For the treatment of plague� infection due to exposure to <em>Yersinia pestis</em> in an individual patient or in a contained casualty setting. <br />        NOTE: Streptomycin is the drug of choice to treat plague in most patients, however, because gentamicin is more widely available it is an acceptable alternative. Gentamicin is the preferred agent in pregnant women.<br />     ***For the initial treatment of tularemia� infection due to exposure to <em>Francisella tularensis</em>.***For tularemia� in an individual patient or in a contained casualty setting. <br />          NOTE: Streptomycin is the drug of choice to treat tularemia in most patients, however, because gentamicin is more widely available it is an acceptable alternative. Gentamicin is the preferred agent in pregnant women; if gentamicin is contraindicated streptomycin should be used.<br />       ***For tularemia� in a mass casualty setting or for tularemia prophylaxis�. <br />          NOTE: Doxycycline and ciprofloxacin are preferred agents in this setting.<br />       ***For surgical infection prophylaxis�.***For the treatment of chronic <em>Bartonella quintana�</em> bacteremia (bartonellosis�) in combination with doxycycline.***For the treatment of granuloma inguinale� (Donovanosis) due to Klebsiella granulomatis.***For the treatment of cephalosporin-resistant gonorrhea�.***For the empiric treatment of febrile neutropenia�. <br />        NOTE: Serum concentrations should be used to guide dosage adjustments. In most patients, dosage of aminoglycosides should be based on an estimate of lean body mass.<br />     ***For the treatment of febrile neutropenia in adults.***For the treatment of febrile neutropenia in pediatric patients.***Formoterol; Mometasone","***Dehydration, nephrotoxicity, renal disease, renal failure, renal impairment***Hearing impairment, neurotoxicity, ototoxicity, tinnitus***Aminoglycoside hypersensitivity, sulfite hypersensitivity***Botulism, electrolyte imbalance, myasthenia gravis, neuromuscular disease, parkinsonism, respiratory depression, respiratory insufficiency***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Antimicrobial resistance, corneal abrasion, fungal infection, viral infection***Pregnancy***Breast-feeding***Sexually transmitted disease***Neonates, premature neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10180']['10829'],sulfamethoxazole/trimethoprim,"***For the treatment of urinary tract infection (UTI), including pyelonephritis and cystitis.***For the treatment of Pneumocystis pneumonia (PCP).***For Pneumocystis pneumonia (PCP) prophylaxis in individuals who are immunosuppressed and considered to be at an increased risk.***For primary PCP prophylaxis in HIV-infected patients.***For secondary PCP prophylaxis in HIV-infected patients.***For primary PCP prophylaxis in immunocompromised patients with primary immunodeficiency disease (especially severe combined immunodeficiency disease), lymphoreticular malignancies (especially acute lymphatic leukemia and human T-cell lymphotropic virus-associated leukemia or lymphoma), organ transplantation (especially lung or heart-lung), and solid tumors, particularly brain tumors.***For primary PCP prophylaxis in recipients of bone marrow allografts.***For the treatment of otitis media due to susceptible strains of <em>Haemophilus influenzae</em> or <em>Streptococcus pneumoniae</em>.***For otitis media with otorrhea due to community-acquired methicillin-resistant <em>Staphylococcus aureus</em>�.***For the treatment of acute exacerbations of chronic bronchitis.***For the treatment of gastroenteritis, infectious diarrhea, and gastrointestinal infections.***For the treatment of cholera� caused by <em>Vibrio cholerae</em>.***For the treatment of cyclosporiasis� due to <em>Cyclospora cayetanensis</em>.***For the treatment of shigellosis.***For the treatment of isosporiasis� in HIV-positive patients.***For chronic maintenance therapy (secondary prophylaxis) of isosporiasis� in HIV-positive patients.***For the treatment of salmonellosis� in HIV-infected patients.***For the treatment of traveler's diarrhea due to enterotoxigenic <em>E. coli</em>.***For urinary tract infection (UTI) prophylaxis�.***For bacterial infection prophylaxis� in HIV-infected children and infants.***For secondary prophylaxis� in HIV-infected children and infants with > 2 invasive bacterial infections in a 1-year period.***For primary prophylaxis� to reduce opportunistic infection in HIV-infected children (regardless of CD4 count).***For toxoplasmosis prophylaxis�, specifically prevention of toxoplasmic encephalitis (TE) due to <em>Toxoplasma gondii</em>.***For primary prophylaxis� in HIV-infected patients.***For chronic maintenance therapy� (secondary prophylaxis�) after acute toxoplasmosis infection.***For the treatment of Legionnaire's disease� caused by <em>Legionella pneumophila</em>.***For the treatment of actinomycotic mycetoma�.***For actinomycotic mycetoma� caused by <em>Actinomadura pelletierii</em>, <em>Actinomadura madurae</em>, <em>Streptomyces somaliensis</em>.***For actinomycotic mycetoma� caused by <em>Nocardia brasiliensis</em>, <em>Nocardia asteroides</em>, or <em>Nocardia otitidiscaviarum</em>.***For the treatment of nocardiosis� caused by <em>Nocardia</em> sp..***For the treatment of pertussis (whooping cough)� caused by <em>Bordetella pertussis</em> or for postexposure pertussis prophylaxis�. <br />        NOTE: For postexposure prophylaxis, administer to close contacts within 3 weeks of exposure, especially in high-risk patients (e.g., women in 3rd trimester, infants).<br />     ***For the treatment of bacteremia� and catheter-associated infections�.***For prevention of bacteremia� (i.e., bacteremia prophylaxis�) or spontaneous bacterial peritonitis� (i.e., peritonitis prophylaxis�) in patients with cirrhosis and ascites.***For the treatment of typhoid fever� due to <em>Salmonella typhi</em>.***For acute infections.***For chronic carriers.***For the treatment of <em>Staphylococcus aureus</em> infections�, including endocarditis�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus </em>(MRSA)<em>�</em> skin and skin structure infections�, including cellulitis�.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of therapy-resistant pediculosis� capitis (head lice infestation) due to <em>Pediculus capitis�</em>.***For the treatment of melioidosis� and for postexposure prophylaxis.***For sulfonamide desensitization� in patients requiring sulfamethoxazole; trimethoprim therapy.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated bone and joint infections�, including osteomyelitis� and septic/infectious arthritis�, or an orthopedic device-related infection�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated osteomyelitis�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated septic arthritis�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated prosthetic joint infections�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated spinal implant infections�.***For surgical infection prophylaxis�.***For the treatment of CNS infections�, including meningitis�, brain abscess�, subdural empyema�, spinal epidural abscess�, and septic thrombosis of the cavernous or dural venous sinus�.***Formoterol***Formoterol; Mometasone","***General Information***Carbonic anhydrase inhibitor hypersensitivity, sulfite hypersensitivity, sulfonamide hypersensitivity, sulfonylurea hypersensitivity, thiazide diuretic hypersensitivity, trimethoprim hypersensitivity***Agranulocytosis, bone marrow suppression, folate deficiency, folate deficiency megaloblastic anemia, G6PD deficiency, hemolysis, thrombocytopenia***Hyperkalemia, hyponatremia, renal disease, renal failure, renal impairment***Hepatic disease***Porphyria***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Hypothyroidism***Acquired immunodeficiency syndrome (AIDS)***Infants, neonates***Pregnancy***Breast-feeding***Antimicrobial resistance, viral infection***Hypoglycemia, malnutrition***Sunlight (UV) exposure***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, myocardial infarction, QT prolongation, thyroid disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['32613'],oxaprozin,"***For the treatment of juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA).***For the treatment of moderate pain�, including arthralgia�, myalgia�, and bone pain�, and the management of the signs and symptoms of rheumatoid arthritis or osteoarthritis.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Intramuscular injections***Dental disease, dental work***Hepatic disease, jaundice, renal impairment***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants***Coronary artery bypass graft surgery (CABG)***Geriatric***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7597'],nystatin,"***For the treatment of cutaneous candidiasis (including adjunctive treatment for candidal diaper dermatitis), mucocutaneous candidiasis (i.e., oropharyngeal candidiasis (thrush), vulvovaginal candidiasis), and intestinal candidiasis (with or without coexisting vulvovaginal candidiasis).***For the treatment of oropharyngeal candidiasis (thrush).***For the treatment of cutaneous candidiasis or mucocutaneous candidiasis, or for adjunctive treatment for candidal diaper dermatitis.***For the treatment of vulvovaginal candidiasis (VVC).***For the treatment of intestinal candidiasis (with or without coexisting vulvovaginal candidiasis).",***Paraben hypersensitivity***Pregnancy***Breast-feeding***Diabetes mellitus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,divalproex sodium,"***For the monotherapy or adjunct treatment of simple absence seizures, complex absence seizures, or complex partial seizures, and adjunctively for other seizure types that include absence or partial complex seizures (e.g., tonic-clonic seizures, myoclonic seizures).***For the treatment of acute mania associated with bipolar disorder, with or without psychotic features.***For migraine prophylaxis.***For the treatment of refractory status epilepticus�. <br />  NOTE: Valproate has been used for emergency treatment of seizures where other agents have failed, or, when other medications are not readily available or when phenytoin is contraindicated.<br /***For the treatment of persistent singultus (hiccups)�.***For the treatment of severe behavioral disturbances, such as agitation�.***For severe behavioral disturbances� (e.g., aggression, agitation�, explosive temper) occurring with attention-deficit hyperactivity disorder (ADHD)�.***For the symptomatic treatment of acquired pendular nystagmus�.***For the treatment of painful diabetic neuropathy�.","***General Information***Encephalopathy***Serious rash***Mitochondrial disease***Carnitine deficiency, hepatic disease, hepatotoxicity, hypoalbuminemia, organic brain syndrome***Pancreatitis***Children, infants, neonates***Depression, suicidal ideation***Bleeding, coagulopathy, surgery, thrombocytopenia***Renal failure, renal impairment***Human immunodeficiency virus (HIV) infection***Driving or operating machinery, ethanol ingestion***Colostomy, diarrhea, ileostomy***Head trauma***Abrupt discontinuation***Contraception requirements, pregnancy, reproductive risk***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"lymphocyte immune globulin, anti-thymocyte globulin (equine)","***For the treatment of acute kidney transplant rejection.***For kidney transplant rejection prophylaxis.***For the treatment of patients with moderate to severe aplastic anemia who are not candidates for hematopoietic stem cell transplantation. <br />  NOTE: The usefulness of Atgam has not been demonstrated in patients who are suitable candidates for bone marrow transplantation or in patients with aplastic anemia secondary to neoplastic disease, storage disease, myelofibrosis, Fanconi's syndrome, or in patients known to have been exposed to myelotoxic agents or radiation.<br />NOTE: Patients may need prophylactic platelet transfusions to maintain platelets at clinically acceptable concentrations***For the treatment of heart transplant rejection�.***For heart transplant rejection prophylaxis�.***For stem cell transplant preparation� prior to allogeneic stem hematopoietic stem cell transplantation (SCT).***For the treatment of myelodysplastic syndrome (MDS)�. <br />        NOTE: Rabbit ATG (Thymoglobulin) has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of acute graft-versus-host disease (GVHD)� and graft-versus-host disease (GVHD) prophylaxis�.***Formoterol; Mometasone","***General Information***Fungal infection, herpes infection, infection, lymphoma, neoplastic disease, requires an experienced clinician, varicella, viral infection***Acute bronchospasm, equine protein hypersensitivity, hypotension, leporine protein hypersensitivity, serious hypersensitivity reactions or anaphylaxis***Leukopenia, thrombocytopenia***Vaccination***Pregnancy***Breast-feeding***Contraception requirements, reproductive risk***Thromboembolic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10865'],carboprost tromethamine,"***For pregnancy termination.***For pregnancy termination between weeks 13�20 gestation dated from the first day of the last menstrual period.***For second trimester pregnancy termination in women with intact intrauterine membranes. <br />          NOTE: Also see above for women in weeks 13�20 of gestation.<br />       ***For second trimester pregnancy termination when there is failure of expulsion of the fetus during the course of treatment by another method.***For second trimester pregnancy termination with the premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity.***For second trimester pregnancy termination when there is a requirement of a repeat intrauterine instillation of drug for expulsion of the fetus.***For second trimester pregnancy termination when there is an inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion.***For the treatment of postpartum bleeding due to uterine atony that is unresponsive to conventional management. <br />        NOTE: Conventional management includes oxytocin IV, uterine massage, uterine manipulation, and ergot preparations IM or IV, as appropriate.<br />     ***For the treatment of refractory hemorrhagic cystitis�. <br />        NOTE: Consider premedication to minimize bladder spasms (oxybutynin 5�10 mg PO with or without belladonna; opium suppositories).<br />     ","***Incomplete abortion, trauma***Benzyl alcohol hypersensitivity***Infection***Caesarean section, surgery***Chorioamnionitis***Cardiac disease, hypertension***Hypotension***Asthma, pulmonary disease***Anemia, diabetes mellitus, hepatic disease, jaundice, renal disease, seizure disorder***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['19831'],budesonide,"***For the management of nasal symptoms associated with perennial vasomotor rhinitis.***For the management of nasal symptoms associated with allergic rhinitis.***For maintenance treatment of asthma as prophylactic therapy (bronchospasm prophylaxis). <br />        NOTE: Budesonide is not indicated for the treatment of acute bronchospasm.<br />     ***For mild to moderate Crohn's disease involving the ileum and/or ascending colon.***For active disease in patients not previously receiving oral prednisolone.***For active disease in patients previously receiving oral prednisolone.***For maintenance of clinical remission for up to 3 months. <br />  NOTE: A Crohn�s Disease Activity Index (CDAI) less than 150 after 8 weeks of treatment for active disease is recommended before maintenance treatment is initiated.<br /***For the induction of remission in patients with active, mild to moderate ulcerative colitis.***For the treatment of laryngotracheobronchitis (croup)�.***For the treatment of collagenous colitis� (a form of microscopic colitis).***For exercise-induced bronchospasm prophylaxis�.","***General Information***Acute bronchospasm, milk protein hypersensitivity, status asthmaticus***Fungal infection, herpes infection, immunosuppression, infection, ocular infection, tuberculosis, viral infection***Measles, varicella***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Abrupt discontinuation, adrenal insufficiency, corticosteroid withdrawal, hypothalamic-pituitary-adrenal (HPA) suppression***Gastroenteritis, surgery, trauma***Cushing's syndrome, hypercortisolism***Nasal septal perforation, nasal surgery, nasal trauma***Malnutrition, osteoporosis, tobacco smoking***Edema, heart failure, hypertension***Diabetes mellitus, hyperglycemia, hyperthyroidism, hypothyroidism, psychosis, renal disease, seizure disorder, thyroid disease***Diverticulitis, GI disease, GI perforation, hepatic disease, peptic ulcer disease***Cataracts, glaucoma, increased intraocular pressure, visual disturbance***Myasthenia gravis***Corticosteroid hypersensitivity***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"NPH, human insulin isophane (rDNA origin)","***For the treatment of type 1 diabetes mellitus or for type 2 diabetes mellitus inadequately managed by diet, exercise, and oral hypoglycemics. <br />  NOTE: A consensus algorithm issued by the ADA and the European Association for the Study of Diabetes lists basal or intermediate-acting insulin as a second line or third line agent in patients with type 2 diabetes not controlled on oral drugs; metformin is the initial recommended therapy in all type 2 diabetics without contraindications. Once insulin is added, therapy can be intensified (e.g., addition of prandial insulin) to achieve optimal glycemic control. In patients who are receiving a sulfonylurea, the sulfonylurea should be discontinued when insulin therapy is initiated.<br /***For the treatment of gestational diabetes or for the treatment of patients with pre-existing diabetes mellitus (type 1 or type 2) who are now pregnant.***For pregnant patients with gestational-onset diabetes not controlled by diet-therapy alone.***For pregnant patients with preexisting diabetes prior to pregnancy.***Formoterol; Mometasone","***Diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Hepatic disease, renal failure, renal impairment***Coma, continuous subcutaneous insulin infusion (CSII) administration, diabetic ketoacidosis, hyperosmolar hyperglycemic state (HHS), intravenous administration***Hypoglycemia***Hypokalemia***Bovine protein hypersensitivity, cresol hypersensitivity, porcine protein hypersensitivity***Labor, obstetric delivery, pregnancy***Breast-feeding***Tobacco smoking***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],desogestrel/ethinyl estradiol,"***For routine contraception.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�,  abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Edema, hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8331'],pimozide,***For the treatment of Tourette's syndrome not responding to standard therapy.***For the treatment of delusions of parasitosis� not responding to standard therapy.***For the treatment of schizophrenia� not responding to standard therapy.***Formoterol; Mometasone,"***General Information***Tics***Agranulocytosis, hematological disease, leukopenia, neutropenia***Abrupt discontinuation***Tardive dyskinesia***Parkinson's disease***Alcoholism, autonomic neuropathy, bradycardia, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, diabetes mellitus, females, head trauma, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, thromboembolism, thyroid disease, torsade de pointes***Hepatic disease, poor metabolizers***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion***Anticholinergic medications, glaucoma, ileus, prostatic hypertrophy, urinary retention***Seizure disorder, seizures***Breast cancer, hyperprolactinemia, infertility***Renal disease, renal impairment***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Priapism***Dysphagia***Dementia, geriatric, stroke***Neonates, pregnancy, pregnancy testing***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluocinolone acetonide,"***For the treatment of mild to moderate inflammatory manifestations of corticosteroid-responsive dermatitis such as alopecia areata, atopic dermatitis, contact dermatitis, exfoliative dermatitis, Rhus dermatitis due to plants like poison ivy, or seborrheic dermatitis (facial and intertriginous areas), discoid lupus erythematosus (facial and intertriginous areas), eczema, granuloma annulare, intertrigo, cutaneous lichen planus, lichen simplex chronicus, polymorphous light eruption, pompholyx (dyshidrosis), nodular prurigo, anogenital or senilis pruritus, psoriasis (facial and intertriginous areas), or xerosis (inflammatory phase).***For atopic dermatitis.***For psoriasis of the scalp.***For seborrheic dermatitis of the scalp.***For the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.***For the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.***For the treatment of chronic eczematous otitis externa.","***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Ocular exposure, ophthalmic administration***Children, growth inhibition, increased intracranial pressure, infants, neonates***Fungal infection, herpes infection, herpes simplex keratitis (dendritic keratitis), infection, measles, ocular infection, varicella, viral infection***Acne rosacea, acne vulgaris, perioral dermatitis***Diabetes mellitus***Geriatric, skin atrophy***Pregnancy***Breast-feeding***Peanut hypersensitivity***Corticosteroid hypersensitivity***Glaucoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fentanyl citrate,"***For the control of moderate pain or severe pain.***For intraoperative or procedural management of severe pain, for use only in a monitored anesthesia care setting in the hospital.***For control of postoperative pain in the recovery room.***For the management of chronic severe pain in opioid-tolerant patients who require daily, around-the-clock, long-term opioid treatment.***For the management of severe breakthrough cancer pain in opioid-tolerant patients.***For short-term management of acute postoperative pain in the hospital setting using a fentanyl iontophoretic transdermal system (ITS) for patient-controlled analgesia.***For adjuvant management of general anesthesia maintenance and intraoperative pain control.***For minor surgical procedures and for use in the immediate postoperative period.***For major surgery, providing analgesia and some relief from the stress response. <br />          NOTE: Respiratory depression at this dosage level requires artificial ventilation.<br />       ***For open heart surgery and other complicated procedures where surgery is prolonged and the stress response would be detrimental to the patient's well-being.***For general anesthesia induction when attenuation of the responses to surgical stress is especially important such as during major surgery like open heart surgery or complicated neurological or orthopedic procedures.***For analgesia and/or sedation maintenance� in mechanically-ventilated intensive care patients.***For sedation and analgesia prior to rapid-sequence intubation (RSI)�.***For the management of dyspnea� in patients with end-stage cancer or lung disease.***For procedural sedation� of non-intubated patients during diagnostic, surgical, or other procedures.","***General Information***Dental work, headache, migraine, opioid-naive patients, surgery***Constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Accidental exposure***MAOI therapy***Potential for overdose or poisoning, requires a specialized care setting, requires an experienced clinician***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, urethral stricture, urinary retention***Brain tumor, CNS depression, head trauma, increased intracranial pressure, seizure disorder, seizures***Angina, bradycardia, cardiac arrhythmias, cardiac disease, heart failure, hypotension, orthostatic hypotension, shock***Children, infants, neonates, premature neonates***Labor, neonatal opioid withdrawal syndrome, pregnancy***Breast-feeding***Females***Geriatric***Biliary tract disease, pancreatitis***Abrupt discontinuation***Driving or operating machinery***Anticoagulant therapy, coagulopathy, epidural administration, infection, intrathecal administration, thrombocytopenia***Opiate agonist hypersensitivity***Ambient temperature increase, fever, heating pad, skin abrasion, sunlight (UV) exposure***Ocular exposure***Dental disease, diabetes mellitus, stomatitis***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Adrenal insufficiency, hypothyroidism, myxedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,colestipol hydrochloride,"***For the treatment of primary hypercholesterolemia (elevated LDL cholesterol hyperlipoproteinemia) in conjunction with dietary control in patients with hypertriglyceridemia; for the treatment of diarrhea� due to increased bile acids after surgery; for the treatment of pruritus� associated with partial biliary obstruction.***For the treatment of digoxin overdose�, digitoxin overdose�, or digitoxin toxicity�. <br />        NOTE: Colestipol binds both digoxin and digitoxin in the GI tract in the case of overdose. Because digitoxin undergoes enterohepatic circulation, colestipol is also effective in the treatment of digitoxin toxicity.<br />     ","***Biliary cirrhosis, biliary obstruction, cholelithiasis***Constipation, dysphagia, GI obstruction, hemorrhoids, ileus***Hypertriglyceridemia***Coagulopathy***Hypothyroidism***Renal disease***Phenylketonuria***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,nitrofurantoin macrocrystals,***For the treatment of uncomplicated urinary tract infection (UTI) including acute cystitis.***For long-term suppressive therapy for urinary tract infection (UTI) prophylaxis in patients predisposed to urinary tract infection.,"***General Information***Viral infection***Anuria, oliguria, renal disease, renal impairment***Anemia, G6PD deficiency, hemolytic anemia***Children, infants, neonates***Labor, obstetric delivery, pregnancy***Breast-feeding***Diabetes mellitus, electrolyte imbalance, optic neuritis, peripheral neuropathy, vitamin B12 deficiency***Hepatic disease, jaundice***Pulmonary disease***Geriatric***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10635'],tolbutamide,"***For adjunctive therapy in the treatment of type 2 diabetes mellitus, where hyperglycemia cannot be controlled by diet and exercise alone. <br />        NOTE: Oral hypoglycemic dosage should be individualized; periodic monitoring of blood glucose is necessary to determine the lowest effective dose.<br />NOTE: Special care needs to be taken if transferring a patient from chlorpropamide to tolbutamide therapy to avoid hypoglycemia.<br />NOTE: A direct transfer from insulin therapy can be made if the daily dosage of insulin is &lt;= 20 units. If transferring from insulin at a dosage &gt; 20 units/day, the dose of tolbutamide is given in conjunction with a % reduction in the amount of insulin, depending on the number of insulin units given daily","***General Information***Sulfonylurea hypersensitivity***Sulfonamide hypersensitivity***Fever, infection, surgery, trauma***Diabetic ketoacidosis, renal disease, renal failure, renal impairment, type 1 diabetes mellitus, uremia***Hepatic disease***Neonates, obstetric delivery, pregnancy***Breast-feeding***Children***Geriatric***G6PD deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mepenzolate bromide,"***For use as adjunctive therapy in the treatment of duodenal ulcer or gastric ulcer. <br />        NOTE: This drug not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.<br />     ***Formoterol; Mometasone","***Bromide hypersensitivity, tartrazine dye hypersensitivity***Geriatric***Contact lenses, glaucoma***Bladder obstruction, prostatic hypertrophy, urinary retention, urinary tract obstruction***Achalasia, esophagitis, gastroesophageal reflux disease (GERD), GI obstruction, hiatal hernia, ileus, pyloric stenosis, toxic megacolon, ulcerative colitis***Cardiac arrhythmias, cardiac disease, coronary artery disease, GI bleeding, heart failure, hemorrhagic shock, hypertension, hyperthyroidism, tachycardia***Autonomic neuropathy, myasthenia gravis***Hepatic disease, renal disease, renal impairment***Chronic obstructive pulmonary disease (COPD), pulmonary disease***Ambient temperature increase, dehydration***Driving or operating machinery, ethanol intoxication***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6387'],lidocaine,"***For the treatment of perfusing ventricular arrhythmias including ventricular fibrillation (VF) and ventricular tachycardia (VT) that may result during acute myocardial infarction or cardiac manipulation (e.g., cardiac surgery). <br />  NOTE: See resuscitation indication for dosage guidelines for VF or pulseless VT.<br />NOTE: Although not considered a drug of choice for ventricular arrhythmias, lidocaine may be used as an alternative antiarrhythmic in patients with preserved ventricular function and stable monomorphic VT. Lidocaine may also be used to treat polymorphic VT in patients with a normal QT interval (when electrolyte imbalance and ischemia are treated). If pulseless cardiac arrest associated with VF or VT, see separate dosage guidelines for the treatment ventricular arrhythmias during CPR.<br />NOTE: Lidocaine may be used to treat patients with polymorphic VT associated with QT prolongation (e.g., torsade de pointes).<br />NOTE: Monitor blood pressure and the electrocardiogram (ECG) during intravenous lidocaine administration***For topical anesthesia of skin and mucous membranes or stomatitis.***For prevention of dental pain� and for topical anesthesia of mucous membranes.***For laryngoscopy.***For nonurgent painful procedures including IV cannulation, venipuncture, lumbar puncture, or arterial puncture.***For the treatment of stage 1 thru 4 pressure ulcers, venous stasis ulcers, ulcerations of mixed vascular etiologies, diabetic skin ulcers, first and second degree burns, and post surgical incisions, cuts, and abrasions.***For endotracheal intubation.***For neonatal circumcision�.***For bronchoscopy.***For the treatment of pain associated with postherpetic neuralgia.***For ophthalmic anesthesia.***For local anesthesia including peripheral nerve block anesthesia. <br />        NOTE: In adults, the dosages for local anesthesia reported are general guidelines only. The actual dose depends on a variety of factors such as depth of anesthesia, extent of surgical procedure, degree of muscle relaxation required, duration of anesthesia and the patients' physical condition. See Lidocaine; epinephrine monograph for information concerning combination dosing.<br />     ***For dental anesthesia including mandibular nerve block and maxillary infiltration.***For infiltration anesthesia.***For intravenous regional anesthesia.***For pudendal nerve block.***For paravertebral block.***For intercostal nerve block.***For brachial plexus block.***For paracervical block.***For sympathetic nerve block.***For cervical stellate ganglion block.***For lumbar sympathetic block.***For epidural anesthesia. <br />        NOTE: The dose is determined by the number of dermatomes to anesthetized (2 to 3 mL/dermatome). The suggested concentrations and volumes serve as a guide, other volumes and concentrations may be used provided the maximum dose is not exceeded.<br />     ***For lumbar anesthesia.***For lumbar analgesia for severe pain.***For thoracic.***For caudal anesthesia.***For obstetric anesthesia.***For surgical anesthesia.***For spinal anesthesia.***For obstetrical low spinal or saddle block anesthesia.***For intraabdominal anesthesia.***For the treatment of ventricular arrhythmias during cardiopulmonary resuscitation� (CPR).***For the attenuation of increased intracranial pressure� during rapid-sequence intubation� or endotracheal tube suctioning�.***For the treatment of severe singultus (hiccups)�.***For the treatment of headache�.***For the treatment of acute headache� associated with migraine�.***For the treatment of cluster headache�.***For the symptomatic treatment of corticosteroid-dependent asthma�. <br />        NOTE: Initial bronchoconstriction can occur. In addition, lidocaine toxicity can result in tremors, hallucinations, seizures, and cardiac arrest. Caution is advised until long-term safety and efficacy can be established.<br />     ***For short-term prophylaxis of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing� (SUNCT).***For the treatment of painful diabetic neuropathy� in adults.","***General Information***Amide local anesthetic hypersensitivity, epidural anesthesia***Collagen-vascular disease***G6PD deficiency***Geriatric, heart failure, hepatic disease***Hypotension, pregnancy***Breast-feeding***Adams-Stokes syndrome, atrial fibrillation, atrial flutter, AV block, bradycardia, cardiogenic shock, hemorrhagic shock, hypovolemia, shock, Wolff-Parkinson-White syndrome***Renal disease, renal failure, renal impairment***Burns, eczema, heating pad, occlusive dressing, skin abrasion***Cataracts, ocular exposure, ocular trauma***Accidental exposure***Intraarterial administration, intrathecal administration, intravenous administration***Head and neck anesthesia***Ocular surgery***Anticoagulant therapy, bleeding, coagulopathy, infection, neurological disease, requires a specialized care setting, requires an experienced clinician, sepsis, spinal anesthesia, thrombocytopenia***Fetal distress, labor, obstetric delivery, pudendal nerve block***Continuous intraarticular infusion administration***Fetal prematurity, paracervical nerve block***Malignant hyperthermia***Children, infants, neonates, teething pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,chlorpromazine hydrochloride,"***For the treatment of schizophrenia.***For the treatment of nausea/vomiting.***For the adjunctive treatment of tetanus.***For the treatment of intractable singultus (hiccups).***For the treatment of acute intermittent porphyria.***For the treatment of acute psychosis in acutely agitated schizophrenic patients.***For the treatment of severe behavioral problems associated with oppositional defiant disorder or other disruptive behavioral disorders, or for attention-deficit hyperactivity disorder (ADHD) in pediatric patients who show excessive motor activity with accompanying conduct disorders.***For the treatment of acute migraine�.***For the treatment of agitation� or delirium� in hospitalized patients without underlying psychiatric illness.***For the treatment of neonatal abstinence syndrome�. <br />        NOTE: The use of chlorpromazine in infants under the age of 6 months should be limited to illnesses where the use of the medication could be potentially lifesaving.<br />NOTE: Although chlorpromazine is included in current guidelines established by the American Academy of Pediatrics, its use is limited due to occasional adverse effects such as hypothermia, decreased seizure threshold, and eosinophilia***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.","***Asthma, benzyl alcohol hypersensitivity, phenothiazine hypersensitivity, sulfite hypersensitivity***Agranulocytosis, bone marrow suppression, fever, hematological disease, infection, leukopenia, neutropenia***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion, head trauma***Dental work, surgery***Intracranial mass, seizure disorder, seizures***Tardive dyskinesia***Anticholinergic medications, closed-angle glaucoma, ileus, prostatic hypertrophy, urinary retention***Alcoholism, angina, AV block, bradycardia, bundle-branch block, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, parenteral administration, QT prolongation, tachycardia, thyroid disease, torsade de pointes***Pulmonary disease***Encephalopathy, hepatic disease, jaundice***Labor, neonates, obstetric delivery, pregnancy, pregnancy testing***Breast-feeding***Children, infants, Reye's syndrome***Breast cancer, hyperprolactinemia, infertility***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Sunlight (UV) exposure***Accidental exposure***Abrupt discontinuation***Renal failure***Ocular disease***Chemotherapy, GI obstruction, vomiting***Tobacco smoking***Suicidal ideation***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Radiographic contrast administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,prednisolone sodium phosphate,"***For primary (Addison's disease) or secondary adrenocortical insufficiency or for the treatment of congenital adrenal hyperplasia.***For the treatment of nonsuppurative thyroiditis.***For the management of symptomatic sarcoidosis.***For the treatment of corticosteroid-responsive dermatitis and dermatologic disorders such as atopic dermatitis or eczema, bullous dermatitis herpetiformis, contact dermatitis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe psoriasis, severe seborrheic dermatitis, or severe erythema multiforme or Stevens-Johnson syndrome.***For the treatment of corticosteroid-responsive respiratory disorders including aspiration pneumonitis, berylliosis, Loeffler's syndrome, or idiopathic pulmonary fibrosis.***For the treatment of asthma.***For a moderate to severe asthma exacerbation in the emergency department or the hospital.***For an acute asthma exacerbation on an outpatient basis.***For long-term prevention of symptoms in severe persistent asthma.***For the treatment of inflammatory bowel disease including critical periods of ulcerative colitis or regional enteritis (Crohn's disease).***For the treatment of hematologic disorders with thrombocytopenia including immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), or secondary thrombocytopenia.***For the treatment of acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), or congenital hypoplastic anemia.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of kidney transplant rejection or for kidney transplant rejection prophylaxis in conjunction with other immunosuppressants.***For the treatment of acute exacerbations of multiple sclerosis.***For the treatment of nephrotic syndrome.***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis, allergic marginal corneal ulcer, anterior segment inflammation, bacterial conjunctivitis, chorioretinitis, choroiditis, cyclitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus) with appropriate antiviral therapy, iritis, non-specific keratitis or superficial punctate keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, vernal keratoconjunctivitis, or for corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies.***For topical ophthalmic treatment of corticosteroid-responsive eye disorders.***For systemic treatment of corticosteroid-responsive eye disorders unresponsive to topical ophthalmic treatment or for conditions usually requiring systemic treatment, such as sympathetic ophthalmia or optic neuritis.***For adjunctive therapy in the treatment of rheumatic disorders including ankylosing spondylitis, gout with gouty arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, psoriatic arthritis, or rheumatoid arthritis; ALSO for the treatment of acute episodes or exacerbation of nonrheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the treatment of selected cases of collagen disorders and mixed connective tissue disease�, such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, polyarteritis nodosa, relapsing polychondritis, polymyalgia rheumatica, certain cases of vasculitis, or Wegener's granulomatosis�.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.***For the treatment of mild to moderate laryngotracheobronchitis (croup)�.***For palliative management of leukemia and lymphoma in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), or multiple myeloma�; also may be used as an adjunct in managing hypercalcemia of malignancy.***For the treatment of acute interstitial nephritis (AIN)�.***For the treatment of Severe Acute Respiratory Syndrome (SARS)�.***For the management of heart transplant rejection prophylaxis�.***For the treatment of Bell's palsy�.***For the treatment of exacerbations of chronic obstructive pulmonary disease (COPD)�.***For the treatment of Kawasaki disease�.","***General Information***Corticosteroid hypersensitivity***Intravenous administration***Infection, surgery***Fungal infection***Herpes infection, measles, tuberculosis, varicella, viral infection***Myocardial infarction***Heart failure, hypertension***Cataracts, glaucoma, visual disturbance***Diverticulitis, GI disease, hepatic disease, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Diabetes mellitus, hyperthyroidism, hypothyroidism, osteoporosis, psychosis, renal disease, seizure disorder, thyroid disease***Myasthenia gravis***Coagulopathy, thromboembolic disease***Pregnancy***Breast-feeding***Children, growth inhibition, increased intracranial pressure, infants***Abrupt discontinuation, hypothalamic-pituitary-adrenal (HPA) suppression***Sulfite hypersensitivity***Tartrazine dye hypersensitivity***Benzyl alcohol hypersensitivity, neonates, premature neonates***Cushing's syndrome***Vaccination***Corneal abrasion, increased intraocular pressure, myopia, open-angle glaucoma***Geriatric***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4053'],erythromycin,"***For the treatment of acne vulgaris.***For mild to moderately severe lower respiratory tract infections (e.g., pneumonia, bronchitis) caused by susceptible organisms.***For the treatment of Legionnaire's disease (caused by <em>Legionella pneumophila</em>).***For the treatment of mild to moderately severe upper respiratory tract infections (e.g., pharyngitis, tonsillitis), including group A beta-hemolytic streptococcal (GAS) pharyngitis (primary rheumatic fever prophylaxis).***For upper respiratory tract infections and GAS pharyngitis (primary rheumatic fever prophylaxis).***For prevention of recurrent attacks of rheumatic fever (i.e., secondary rheumatic fever prophylaxis).***For the treatment of listeriosis.***For the treatment of chlamydia infection and non-gonococcal urethritis.***For the treatment of non-gonococcal urethritis (NGU) or chlamydial infections including urogenital infections (urethritis, cervicitis, proctitis) and infant pneumonia.***For the treatment of chlamydial conjunctivitis or ophthalmia neonatorum caused by <em>Chlamydia trachomatis</em>.***For the treatment of lymphogranuloma venereum� caused by <em>Chlamydia trachomatis</em>.***For the prevention of ophthalmia neonatorum (i.e., ophthalmia neonatorum prophylaxis) due to <em>Neisseria gonorrhoeae</em><em> </em>or<em> Chlamydia trachomatis</em>.***For the treatment of pneumonia caused by <em>Chlamydia trachomatis</em> in neonates and infants.***For the adjunctive treatment of diphtheria to prevent establishment of carrier state and for <em>Corynebacterium diphtheriae</em> bacterial colonization eradication.***For the treatment of close contacts of patients with diphtheria (i.e., diphtheria prophylaxis�).***For the treatment of acute pelvic inflammatory disease (PID).***For acute pelvic inflammatory disease (PID) caused by <em>Neisseria gonorrhoeae</em>.***For the treatment of pertussis (whooping cough) caused by <em>Bordetella pertussis</em> or for postexposure pertussis prophylaxis. <br />  NOTE: For postexposure prophylaxis, administer to close contacts within 3 weeks of exposure, especially in high-risk patients (e.g., women in third trimester, infants &lt; 12 months).<br /***For the treatment of primary syphilis (caused by <em>Treponema pallidum</em>) in penicillin-allergic, nonpregnant patients.***For bowel preparation in combination with neomycin in patients undergoing colorectal surgery.***For the treatment of superficial ophthalmic infection involving the conjunctiva and/or cornea.***For the treatment of chancroid� due to <em>Haemophilus ducreyi</em>.***For the treatment of disseminated gonorrhea�. <br />  NOTE: Erythromycin is not recommended in adults, adolescents, or children 8 years and older or in patients weighing 45 kg or more due to resistance of N. gonorrheae against erythromycin in the United States. Single-dose azithromycin in combination with ceftriaxone is the preferred therapy in these populations. <br /***For the facilitation of gastric emptying in patients with delayed gastrointestinal motility  (e.g., gastroparesis�).***For the treatment of idiopathic or postsurgical gastroparesis� or diabetic gastroparesis�.***For the facilitation of gastric emptying� in patients with feeding intolerance�.***For the treatment of early Lyme disease�.***For the treatment of skin and skin structure infections including impetigo and burn wound infection�.***For the treatment of erythrasma (caused by <em>Corynebacterium minutissimum</em>).***For the treatment of tetanus� (caused by <em>Clostridium tetani</em>) when penicillin or tetracycline is contraindicated or not tolerated.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of cholera�.***For the treatment of bartonellosis� (<em>Bartonella bacilliformis)</em> and other <em>Bartonella sp.</em>� infections in HIV-infected patients.***For the treatment of angiomatosis infections�, peliosis hepatis�, bacteremia�, and osteomyelitis� caused by <em>Bartonella sp.</em>�.***For long term suppression� of infections caused by <em>Bartonella sp.</em>� in HIV-infected patients with relapse or reinfections with < 200 CD4 cells/mm3.***For pneumococcal prophylaxis� in penicillin-allergic patients with sickle cell disease�.***For the treatment of infantile acne�.***For the oral treatment of infantile acne.***For the topical treatment of infantile acne.***Formoterol***Formoterol; Mometasone","***General Information***Viral infection***Macrolide hypersensitivity***Hepatic disease***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Hearing impairment***Benzyl alcohol hypersensitivity, neonates***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Seizure disorder***Myasthenia gravis***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,betamethasone dipropionate,"***For the treatment of acute graft-versus-host disease (GVHD).***For the treatment of nonsuppurative thyroiditis.***For the treatment of acute exacerbations of multiple sclerosis.***For the management of symptomatic sarcoidosis or for the treatment of hypercalcemia associated with cancer or sarcoidosis.***For the treatment of allergic disorders including anaphylaxis or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema (or for laryngeal edema prophylaxis), drug hypersensitivity reactions, serum sickness, severe perennial or seasonal allergic rhinitis, severe urticaria, or for the treatment of urticarial transfusion reactions. <br />        NOTE: Betamethasone should be administered IM or IV initially in the treatment of anaphylaxis or anaphylactoid reactions, angioedema, and acute noninfectious laryngeal edema or to prevent impending risk of laryngeal edema.<br />     ***For the treatment of urticarial transfusion reactions.***For the treatment of immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of hematologic disorders including secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), and congenital hypoplastic anemia.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of inflammatory bowel disease including Crohn's disease (regional gastroenteritis) and ulcerative colitis.***For the induction of diuresis or remission of proteinuria in the nephrotic syndrome.***For the treatment of nasal polyps.***For the treatment of severe cases of myasthenia gravis not controlled by antimyasthenic agents alone.***For adjunctive therapy in the treatment of rheumatic disorders e.g., acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), osteoarthritis, polychondritis�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of nonrheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the treatment of moderate-to-severe inflammation and pruritus due to corticosteroid-responsive dermatologic disorders such as alopecia areata, cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis, generalized exfoliative dermatitis, nummular dermatitis, seborrheic dermatitis, eczema, granuloma annulare, keloids, lichen planus, lichen simplex chronicus, lichen striatus, subacute cutaneous and discoid lupus erythematosus, pretibial myxedema, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, psoriasis, <em>Rhus dermatitis</em> (due to poison ivy, poison oak, or poison sumac), sarcoidosis, Stevens-Johnson syndrome, sunburn, or urticaria. <br />        NOTE: Systemic corticosteroids may be necessary for some conditions based on the type and severity of the disorder (e.g., Stevens-Johnson syndrome) or inadequate response to topical therapy; intralesional injections may also be appropriate for select conditions.<br />     ***For the treatment of plaque psoriasis.***For the treatment of seborrheic dermatitis.***For hyaline membrane disease prophylaxis�, for the purpose of fetal lung maturation to prophylax against anticipated neonatal respiratory distress syndrome (RDS)� in premature infants.***For palliative management of leukemia and lymphoma in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), or for the treatment of multiple myeloma�.***For maintenance therapy in selected cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis�, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, conjunctivitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For the treatment of respiratory inflammatory conditions including airway-obstructing hemangioma� in infants, aspiration pneumonitis, berylliosis, bronchial asthma, chronic obstructive pulmonary disease (COPD), laryngotracheobronchitis (croup), Loeffler's syndrome, or non-cardiogenic pulmonary edema�, or for bronchospasm prophylaxis. <br />        NOTE: Betamethasone should be administered parenterally initially in the treatment of severe manifestations of these diseases, particularly where airway obstruction is present.<br />     ","***Abrupt discontinuation, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, growth inhibition, increased intracranial pressure, infants, neonates***Immunosuppression***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Edema, heart failure, hypertension***Osteoporosis***Diabetes mellitus***Crohn's disease, diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hyperthyroidism, hypothyroidism, psychosis, renal disease, seizure disorder, thyroid disease***Myasthenia gravis***Idiopathic thrombocytopenic purpura (ITP), thromboembolic disease***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Epidural administration, intravenous administration***Corticosteroid hypersensitivity***Head trauma***Skin atrophy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6475'],loxapine,***For the treatment of schizophrenia.***For the treatment of acute agitation associated with schizophrenia or bipolar disorder (bipolar I disorder).***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.,"***General Information***Thyroid disease***Hypocalcemia***CNS depression, coma***Cardiac disease, cerebrovascular disease, heart failure, hypotension, hypovolemia, myocardial infarction, orthostatic hypotension, syncope***Seizure disorder***Hepatic disease***Closed-angle glaucoma***Prostatic hypertrophy***Agranulocytosis, hematological disease, leukopenia, neutropenia***Neurological disease, Parkinson's disease***Tardive dyskinesia***Dementia, geriatric, stroke***Alcoholism***Neonates, pregnancy, pregnancy testing***Breast-feeding***Children***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Breast cancer, hyperprolactinemia, infertility***Acute bronchospasm, asthma, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease, requires a specialized care setting***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pramipexole dihydrochloride,***For the treatment of moderate to severe primary Restless Legs Syndrome (RLS).***For the treatment of the signs and symptoms of idiopathic Parkinson's disease.,"***Cardiac disease, orthostatic hypotension***Geriatric***Driving or operating machinery***Renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Children***Melanoma***Impulse control symptoms***Abrupt discontinuation***Psychosis, schizophrenia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,methohexital sodium,***For general anesthesia induction and general anesthesia maintenance. <br />        NOTE: Dosage must be individualized - the following doses are guidelines only.<br />     ,"***General Information***Agranulocytosis, barbiturate hypersensitivity, carbamazepine hypersensitivity, exfoliative dermatitis, hydantoin hypersensitivity***Porphyria***Adrenal insufficiency, anemia, myxedema, obesity, renal disease, uremia***Depression, mental status changes, suicidal ideation***Cardiac disease, heart failure, hypertension, hypotension, peripheral vascular disease, shock, tachycardia***Hepatic disease***Geriatric, pulmonary disease***Children, infants, neonates***Seizure disorder, seizures, status epilepticus***CNS depression, driving or operating machinery, ethanol intoxication***Labor, obstetric delivery, pregnancy***Breast-feeding***Chronic obstructive pulmonary disease (COPD), neuromuscular disease, requires a specialized care setting, requires an experienced clinician, respiratory depression, respiratory insufficiency, sleep apnea, status asthmaticus***Extravasation, intraarterial administration, subcutaneous administration***Hepatic encephalopathy***Renal failure, renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,aluminum chloride/ethyl alcohol,***For the prevention and treatment of hyperhidrosis. <br />        NOTE: The following dosage information pertains only to the use of prescription products. Please see individual recommendations for proper use for available non-prescription antiperspirants.<br />     ,"***General Information***Ocular exposure, skin abrasion***Children, infants, neonates***Pregnancy***Breast-feeding***Renal disease, renal failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hyaluronidase human,"***For use as an adjuvant to increase the absorption and dispersion of other drugs (e.g., local anesthesia, including infiltration anesthesia).***For use as an adjunct for ophthalmic anesthesia�.***For hypodermoclysis.***For use as an adjunct in subcutaneous urography for improving resorption of urographic radiopaque contrast agents.***For use as an antidote for extravasation� of selected drugs, examples include: antineoplastic agents (e.g., vinca alkaloids), osmotic fluids, (e.g., total parenteral nutrition, 10% or greater dextrose injection, calcium salts, mannitol, potassium salts, sodium bicarbonate, aminophylline, radiocontrast media, or hypertonic saline), or irritants (e.g., diazepam, nafcillin, phenytoin, thiopental, or vasopressin). <br />  NOTE: Use only in the treatment of extravasations where hyaluronidase has been shown to be of benefit. Hyaluronidase is not generally recommended for use as an antidote for extravasation of ischemic agents (e.g., dopamine or alpha-agonists).<br />NOTE: Use hyaluronidase as an adjunct to medical management of extravasation; co-therapies may include hot or cold compresses (extravasating agent dependent), elevation of the affected limb, surgical debridement, and wound care.<br />NOTE: A preliminary hypersensitivity test dose can be performed prior to use***For the treatment of vitreous hemorrhage�. <br />        NOTE: A preliminary hypersensitivity test dose can be performed prior to use.<br />     ***For the treatment of diabetic retinopathy�. <br />  NOTE: A preliminary hypersensitivity test dose can be performed prior to use.<br /","***Hyaluronidase hypersensitivity***Extravasation, intravenous administration***Ocular exposure, ocular surgery***Infection***Children, hypervolemia, infants***Pregnancy***Breast-feeding***Viral infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,immune globulin intravenous (human),"***For hepatitis A prophylaxis.***For postexposure prophylaxis.***For patients traveling to regions that have high or intermediate hepatitis A endemicity.***For measles prophylaxis to prevent or modify measles in an unvaccinated patient who has not previously had measles and who was exposed within the past 6 days. <br />  NOTE: For most persons 12 months and older who are exposed to measles, use of MMR or measles vaccine within 72 hours of exposure is preferred to using immune globulin (except pregnant women and others for whom the vaccine is contraindicated). Any person exposed to measles who lacks evidence of measles immunity and to whom immune globulin (IG) is administered should subsequently receive MMR vaccine but not earlier than 6 months after IMIG administration or 8 months after IGIV administration (provided the vaccine is not contraindicated).<br /***For varicella (chickenpox) infection prophylaxis.***For rubella prophylaxis in exposed, susceptible pregnant women who will not consider a therapeutic abortion. <br />        NOTE: The routine use of IMIG for rubella prophylaxis in early pregnancy is of dubious value and cannot be justified.<br />     ***For immunoglobulin deficiency. <br />  NOTE: Immune globulin may prevent serious infection in patients with immunoglobulin deficiencies if circulating IgG concentrations of approximately 200 mg/100 mL plasma are maintained.<br /","***Intravenous administration***Pregnancy***Breast-feeding***Agammaglobulinemia, hypogammaglobulinemia, IgA deficiency***Viral infection***Anticoagulant therapy, bleeding, coagulopathy, hemophilia, thrombocytopenia***Vaccination***Children***Coronary artery disease, geriatric, heart failure, hypertriglyceridemia, hyponatremia, obesity, thromboembolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['596'],alprazolam,"***For the treatment of  transient symptoms of anxiety, anxiety associated with depression, or generalized anxiety disorder (GAD).***For the treatment of panic disorder with or without agoraphobia.***For the treatment of anxiety and mood-symptoms associated with premenstrual syndrome (PMS)� or premenstrual dysphoric disorder (PMDD)� that are unresponsive to non-pharmacologic therapy.","***Benzodiazepine hypersensitivity***Abrupt discontinuation, benzodiazepine dependence, seizure disorder, seizures, status epilepticus, substance abuse***Anxiety***Bipolar disorder, depression, mania, psychosis, suicidal ideation***Chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, pulmonary disease, respiratory depression, sleep apnea***CNS depression, coma, driving or operating machinery, ethanol intoxication, shock***Closed-angle glaucoma***Myasthenia gravis***Parkinson's disease***Porphyria***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease, obesity***Renal failure, renal impairment***Dementia, geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amlodipine besylate,"***For the treatment of hypertension. <br />        NOTE: The maximum hypotensive effects may require several weeks to become fully manifest.<br />     ***For the treatment of coronary artery disease (CAD), including chronic stable angina, vasospastic angina (variant angina), and CAD documented by angiography and without heart failure or ejection fraction < 40%.","***General Information***Hypotension***Hepatic disease***Aortic stenosis***Acute myocardial infarction, coronary artery disease***Pregnancy***Breast-feeding***Children, infants, neonates***Gastroesophageal reflux disease (GERD), hiatal hernia***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,levocarnitine,***For the treatment carnitine deficiency.***For the treatment of primary systemic carnitine deficiency or for acute and chronic treatment of patients with an inborn error of metabolism that results in secondary carnitine deficiency. <br />          NOTE: Levocarnitine is designated an an orphan drug by the FDA for this indication.<br />       ***For the treatment of carnitine deficiency in neonates receiving total parenteral nutrition�.***For the prevention and treatment of carnitine deficiency in patients with end stage renal impairment who are undergoing dialysis. <br />        NOTE: Levocarnitine is designated an an orphan drug by the FDA for this indication.<br />     ***For the treatment of Alzheimer's disease�.***For the prevention of left ventricular dilation after anterior acute myocardial infarction�.***For the treatment of type 2 diabetes mellitus�.***For the treatment of various cardiomyopathy� states.***For the treatment of adult patients with heart failure� attributable to dilated cardiomyopathy�.***For the treatment of childhood cardiomyopathy�. <br />          NOTE: Levocarnitine is designated an an orphan drug for this indication.<br />       ***For the treatment of hyperlipoproteinemia�.***For the improvement of ergogenesis� in healthy adults.***For the treatment of male infertility� due to poor sperm quality.***For the treatment and prevention of valproate-induced hepatotoxicity� due to secondary carnitine deficiency in children. <br />        NOTE: Levocarnitine is designated an an orphan drug by the FDA for this indication.<br />     ,"***Diarrhea***Pregnancy***Seizure disorder***Cardiac disease, dialysis, hypertension, ventricular arrhythmias***Peripheral neuropathy***Renal failure, renal impairment***Hepatic disease***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7226'],nadolol,"***For the long-term management of angina pectoris.***For the treatment of hypertension, either alone or in combination with other antihypertensive agents, especially thiazide diuretics. ***For ventricular tachycardia prophylaxis�.***For heart rate control in patients with atrial fibrillation� or atrial flutter�.***For paroxysmal supraventricular tachycardia (PSVT) prophylaxis� in patients with recurrent PSVT due to AV reentry.***For migraine prophylaxis�.***For the treatment of portal hypertension� and/or variceal bleeding prophylaxis� in patients with esophageal varices�.***For the treatment of tremor�.***For the treatment of essential tremor�.***For the treatment of lithium-induced tremor�.***For the treatment of anxiety�.","***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***AV block, bradycardia, cardiogenic shock, heart failure, hypotension, pheochromocytoma, pulmonary edema, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Cerebrovascular disease***Diabetes mellitus***Surgery***Dialysis, renal disease, renal failure, renal impairment***Labor, obstetric delivery, pregnancy***Breast-feeding***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Peripheral vascular disease, Raynaud's phenomenon***Depression***Psoriasis***Myasthenia gravis***Geriatric***Beta-blocker hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['121243'],voriconazole,"***For the treatment of candidemia and other serious invasive candidiasis infections. <br />        NOTE: The manufacturer recommends use in nonneutropenic patients only.<br />     ***For the primary treatment of invasive aspergillosis.***For the treatment of CNS infections, including meningitis.***For the treatment of CNS infections caused by <em>Blastomyces dermatitidis</em><em>�</em>.***For the treatment of CNS infections caused by <em>Aspergillus</em> sp..***For the treatment of CNS infections caused by <em>Coccidioides</em> sp.�.***For the treatment of esophageal candidiasis.***For the treatment of cardiovascular system infections, including endocarditis, myocarditis, pericarditis, and infected pacemaker, implantable cardiac defibrillator (ICD), or ventricular assist devices (VAD).***For the treatment of <em>Candida</em> cardiovascular system infections�.***For the treatment of <em>Aspergillus</em> cardiovascular system infections.***For the treatment of invasive pulmonary aspergillosis and other <em>Aspergillus</em> respiratory infections (i.e., pneumonia, tracheobronchitis, sinusitis, aspergilloma).***For the treatment of intraabdominal infections (i.e., peritonitis, intraabdominal abscess).***For the treatment of intraabdominal candidiasis. <br />          NOTE: The manufacturer recommends use in nonneutropenic patients only.<br />       ***For the treatment of intraabdominal aspergillosis.***For the treatment of bone and joint infections (i.e., osteomyelitis and infectious arthritis) caused by <em>Aspergillus</em> sp..***For the treatment of fungal skin and skin structure infections.***For the treatment of disseminated cutaneous candidiasis. <br />          NOTE: The manufacturer recommends use in nonneutropenic patients only.<br />       ***For the treatment of cutaneous aspergillosis.***For the treatment of serious fungal infections caused by <em>Scedosporium apiospermum</em> (scedosporiosis) in patients intolerant of, or refractory to, other therapy.***For the treatment of serious fungal infections caused by <em>Fusarium</em> sp. (fusariosis) in patients intolerant of, or refractory to, other therapy.***For the treatment of fungal ophthalmic infection�, including endophthalmitis� and chorioretinitis�.***For the treatment of <em>Candida</em> endophthalmitis and chorioretinitis.***For the treatment of <em>Aspergillus</em> endophthalmitis.***For the treatment of fungal keratitis�.***For the treatment of oropharyngeal candidiasis (thrush)�.***For the treatment of allergic bronchopulmonary aspergillosis�.***For empiric treatment for presumed fungal infection in patients with febrile neutropenia�.***For fungal prophylaxis� (e.g., candidiasis prophylaxis�, aspergillosis prophylaxis�) in high-risk patients.***For the treatment of cryptococcosis�.***For the treatment of mild coccidioidomycosis� infections (focal pneumonia) in HIV-infected patients. <br />        NOTE: For CNS infections, see meningitis indication.<br />     ***For chronic suppressive therapy for coccidioidomycosis (secondary coccidioidomycosis prophylaxis�) in HIV-infected patients.***For the treatment of disseminated histoplasmosis�.***For the treatment of penicilliosis� in HIV-infected patients.***For the treatment of mild penicilliosis in HIV-infected patients.***For the treatment of acute penicilliosis� infection in severely ill HIV-infected patients.***Formoterol***Formoterol; Mometasone","***General Information***Azole antifungals hypersensitivity***Cholestasis, hepatic disease, hepatitis, jaundice***Dialysis, renal disease, renal failure, renal impairment***Chemotherapy, pancreatitis***Children, infants, neonates***Ocular disease***Lactase deficiency***Melanoma, sunlight (UV) exposure***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Asian patients, Black patients, Caucasian patients, poor metabolizers***Infusion-related reactions***Geriatric***Pregnancy***Breast-feeding***Contraception requirements, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clindamycin phosphate,"***For the treatment of serious infections such as bacteremia.***For the treatment of lower respiratory tract infections (e.g., pleural empyema, anaerobic pneumonia, aspiration pneumonia, community-acquired pneumonia, and lung abscess) due to susceptible organisms<strong>***For the treatment of intraabdominal infections, including intraabdominal abscess and peritonitis.***For the treatment of peritonitis in patients receiving peritoneal dialysis.***For the treatment of skin and skin structure infections, including impetigo, ecthyma, cellulitis, erysipelas, infectious neonatal pustulosis, bite wounds, and complicated skin and skin structure infections such as necrotizing infections, gas gangrene, and diabetic foot ulcer.***For the treatment of impetigo or ecthyma.***For the treatment of necrotizing infections of the skin, fascia, and muscle (i.e. gas gangrene).***For the treatment of animal bite wounds.***For the treatment of diabetic foot ulcer.***For the treatment of gynecologic infections, including endometritis and pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of acute pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of bacterial vaginosis.***For the treatment of acne vulgaris.***For the treatment of bone and joint infections, including osteomyelitis and septic/infectious arthritis, or an orthopedic device-related infection�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated prosthetic joint infections�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated spinal implant infections�.***For the treatment of of uncomplicated acute otitis media�.***For the treatment of acute bacterial sinusitis�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis� in combination with conventional treatment (e.g., scaling and root planing) as well as acute dental abscess (apical)� and/or dental abscess (periapical)�.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage in patients with beta-lactam allergy.***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis� (rheumatic fever prophylaxis�) and for bacterial colonization eradication� in chronic carriers of group A beta-hemolytic <em>Streptococci</em> (GAS)�.***For the treatment of chronic pharyngeal carriers of group A streptococci (i.e., bacterial colonization eradication�).***For surgical infection prophylaxis�.***For bacterial endocarditis prophylaxis�.***For the treatment of anthrax�.***For the treatment of cutaneous anthrax infection.***For the treatment of systemic anthrax infection.***For anthrax prophylaxis� after exposure to Bacillus anthracis (postexposure prophylaxis, PEP).***For the treatment of toxoplasmosis�, including toxoplasmic encephalitis�.***For secondary toxoplasmosis prophylaxis� in HIV-infected patients intolerant of sulfa drugs.***For the treatment of Pneumocystis pneumonia (PCP)� in HIV-infected patients.***For the treatment of malaria� due <em>Plasmodium falciparum</em>.***For the treatment of babesiosis�.***For perinatal Group B streptococcal bacterial infection prophylaxis� in patients allergic to penicillin and cephalosporins.***Formoterol; Mometasone","***Asthma, atopy, clindamycin hypersensitivity, lincomycin hypersensitivity, serious rash, tartrazine dye hypersensitivity***Fungal infection***Diarrhea, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Neonates***Hepatic disease***Pregnancy***Breast-feeding***Ocular exposure***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5487']['35208'],hydrochlorothiazide/quinapril hydrochloride,"***For the treatment of hypertension. <br />        NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, Black patients, hereditary angioedema***Dialysis, hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Hepatic disease***Gout, hyperuricemia***Diabetes mellitus, hyperglycemia***Cerebrovascular disease, coronary artery disease, heart failure, hyponatremia, hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***Surgery***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia***Anuria, collagen-vascular disease, immunosuppression, renal artery stenosis, renal failure, renal impairment, scleroderma, systemic lupus erythematosus (SLE)***Pregnancy***Breast-feeding***Children***Pancreatitis***Sunlight (UV) exposure***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,promethazine hydrochloride,"***For the prevention of motion sickness.***For the treatment of active nausea/vomiting, including post-operative nausea/vomiting (PONV) and for�post-operative nausea/vomiting (PONV) prophylaxis.***For the treatment of allergic manifestations, such as pruritus.***For the treatment of allergic rhinitis�.***For sedation induction.***For sedation in obstetrics.***For relief of apprehension and to induce quiet sleep from which the patient can be easily aroused.***For preoperative or postoperative procedural sedation, as an adjunct to analgesics.***For the treatment of acute peripheral vestibular nystagmus�.***For pregnancy-induced nausea/vomiting�, including hyperemesis gravidarum�.","***General Information***Agranulocytosis, bone marrow suppression, coma, jaundice, phenothiazine hypersensitivity***Extravasation, intraarterial administration, intravenous administration, subcutaneous administration, tissue necrosis***Seizure disorder***Acute bronchospasm, asthma, chronic obstructive pulmonary disease (COPD), respiratory depression, sleep apnea, sulfite hypersensitivity***Hepatic disease, hepatic encephalopathy***Children, dehydration, infants, neonates, Reye's syndrome***Labor, obstetric delivery, pregnancy***Breast-feeding***Contact lenses, glaucoma***Bladder obstruction, GI obstruction, ileus, prostatic hypertrophy, urinary retention***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Radiographic contrast administration***CNS depression, driving or operating machinery, ethanol intoxication***Diabetes mellitus***Anticholinergic medications, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,tranexamic acid,"***For bleeding prophylaxis.***For short-term use to reduce or prevent hemorrhage and reduce the need for replacement therapy during and after tooth extraction in hemophilia A and hemophilia B patients.***For bleeding prophylaxis following ocular trauma (hyphema)�.***For intracranial bleeding prophylaxis� after traumatic brain injury.***For the treatment of cyclic menorrhagia (heavy menstrual bleeding). <br />        NOTE: Prior to initiating therapy, exclude any endometrial pathology that can be associated with heavy menstrual bleeding.<br />     ***For the treatment of epistaxis� in patients with hereditary hemorrhagic telangiectasia.***For angioedema prophylaxis� in patients with hereditary angioedema.***For orthopedic surgical bleeding prophylaxis� in primary total hip or knee arthroplasty.***For the topical use of tranexamic acid for orthopedic surgical bleeding prophylaxis in primary total hip or knee arthroplasty.***For the intravenous use of tranexamic acid for orthopedic surgical bleeding prophylaxis in primary total hip or knee arthroplasty.","***General Information***Leukemia, thromboembolic disease***Intracranial bleeding***Visual disturbance***Pregnancy***Breast-feeding***Children, infants***Geriatric***Renal failure, renal impairment***Disseminated intravascular coagulation (DIC)***Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5492'],hydrocortisone,"***For the treatment of primary adrenocortical insufficiency (e.g., Addison's Disease, congenital adrenal hyperplasia or CAH) or secondary adrenocortical insufficiency.***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing minor surgery or with a minor illness (e.g., inguinal hernia repair, colonoscopy, mild febrile illness, gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing moderate surgery or with a moderate illness (e.g., open cholecystectomy, hemicolectomy, significant febrile illness, pneumonia, severe gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing major surgery, or with other acute stressors (e.g., major cardiothoracic surgery, Whipple procedure, liver resection, pancreatitis, acute systemic infection, shock).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency and a critical illness (e.g., shock).***For the treatment of acute adrenocortical insufficiency.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency with other acute stressors (e.g., febrile illness with a temperature more than 38.5 degrees Celsius, gastroenteritis with dehydration, major trauma):.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency undergoing surgery accompanied by general anesthesia.***For use in nonspecific proctitis, postirradiation (factitial) proctitis, cryptitis, or for other non-specific inflammatory conditions of the anorectum.***For the treatment of inflammatory bowel disease (Crohn's disease or ulcerative colitis).***For adjunctive treatment of Crohn's disease or ulcerative colitis using oral or parenteral therapy.***For adjunctive rectal treatment of chronic ulcerative colitis, particularly if disease limited to the distal portion of the rectum.***For the relief of inflammation, pruritus ani, and swelling associated with hemorrhoids.***For the treatment of allergic disorders including anaphylaxis, anaphylactic shock, or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, transfusion-related reactions, serum sickness, severe perennial or seasonal allergic rhinitis, or urticaria.***For the non-emergent treatment of hypersensitivity or allergic conditions.***For the urgent treatment of severe conditions such as anaphylaxis, angioedema, acute noninfectious laryngeal edema, or urticarial transfusion-related reactions.***For the treatment of corticosteroid-responsive dermatologic disorders (e.g., alopecia areata, atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis including Rhus dermatitis due to poison ivy, poison oak, poison sumac, discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pompholyx (dyshidrosis), pruritus, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, xerosis).***For mild-to-moderate corticosteroid responsive dermatoses.***For mild to moderate atopic dermatitis.***For the systemic treatment of severe inflammatory dermatoses, like severe exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, or psoriasis unresponsive to topical treatment.***For adjunctive therapy in the treatment of rheumatic disorders including acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of non-rheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the short-term treatment of hypercalcemia associated with neoplastic disease.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the management of nephrotic syndrome to induce diuresis or decrease proteinuria.***For the treatment of neurologic or myocardial involvement associated with trichinosis.***For the treatment of nonsuppurative thyroiditis.***For rheumatic and related disorders such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, symptomatic sarcoidosis, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive hematologic disorders, like immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia, and congenital hypoplastic anemia; OR for the palliative treatment of neoplastic disease in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), or multiple myeloma�.***For the treatment of respiratory inflammatory conditions including bronchial asthma, aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), Loeffler's syndrome, or noncardiogenic pulmonary edema�.***For the treatment of septic shock� and/or hypotension� in patients whose blood pressure is poorly responsive to adequate fluid resuscitation and vasopressor therapy.***For the prevention of chronic lung disease (CLD)� in mechanically ventilated patients.***For the treatment of refractory neonatal hypoglycemia�.***For the treatment of corticosteroid-responsive ophthalmic disorders, including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.","***Abrupt discontinuation, Cushing's syndrome, skin abrasion***Growth inhibition, increased intracranial pressure***Immunosuppression***Fungal infection, infection***Acne rosacea, acne vulgaris, herpes infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Heart failure, hypertension***Osteoporosis***Diabetes mellitus***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hypothyroidism, psychosis, renal disease, seizure disorder***Myasthenia gravis***Coagulopathy, hemophilia, thromboembolic disease***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Neonates, premature neonates***Benzyl alcohol hypersensitivity, corticosteroid hypersensitivity***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Skin atrophy***Geriatric***Epidural administration, intrathecal administration***Pheochromocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['55672'],rifabutin,"***For Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients with advanced disease.***For primary prophylaxis in HIV-infected patients.***For secondary prophylaxis in HIV-infected patients with disseminated disease, after treatment of the acute illness.***For the treatment of Mycobacterium avium complex infection� (MAC).***For the treatment of disseminated Mycobacterium avium complex (MAC)�. <br />          NOTE: Rifabutin has been designated an orphan drug for this indication.<br />       ***For the treatment of Mycobacterium avium complex (MAC)� pulmonary disease.***For the treatment of Mycobacterium avium complex (MAC)� in HIV-infected patients.***For the treatment of tuberculosis infection� as an alternative to rifampin in combination with other antitubercular agents. <br />        NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., at least 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, IDSA, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. Directly observed therapy (DOT) should be used for all regimens administered 2, 3, or 5 times per week and in all pediatric patients. The initial treatment regimen should include 4 drugs unless the likelihood of isoniazid or rifampin resistance is low (i.e., less than 4%), in which case an initial regimen of isoniazid, rifampin, and pyrazinamide may be considered. HIV-infected patients should always receive induction therapy with 4 drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate.   For multi-drug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, the CDC recommends treatment for 18 to 24 months after culture conversion in patients with bacteriologic confirmation and for at least 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months in MDR-TB. The WHO also provides an alternative set of international dosing guidelines.<br />NOTE: Rifabutin is used as an alternative to rifampin in regimens when patients are contraindicated to receive rifampin due to concomitant therapy with protease inhibitors or non-nucleoside reverse transcriptase inhibitors or in patients who have experienced intolerance to rifampin. The patient should be carefully monitored for potential rifabutin drug toxicity and decreased antiretroviral medication activity while receiving rifabutin with other antiretroviral agents.***For tuberculosis prophylaxis� as an alternative to isoniazid and rifampin regimens in HIV-infected patients. <br />  NOTE: Prophylaxis is recommended when a newly-positive skin test (5 mm or more) is confirmed or when the patient has been in contact with someone with active tuberculosis and there is a high probability of exposure to isoniazid-resistant tuberculosis. Rifabutin is used as an alternative to rifampin when patients are contraindicated to receive rifampin due to concomitant therapy with protease inhibitors or non-nucleoside reverse transcriptase inhibitors. The patient should be carefully monitored for potential rifabutin drug toxicity and decreased antiretroviral medication activity while receiving rifabutin with other antiretroviral agents. <br /","***Viral infection***Rifamycin hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Contact lenses***Pregnancy***Breast-feeding***Children***Geriatric***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Renal disease, renal failure, renal impairment***Hepatotoxicity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['139896'],enfuvirtide,***For the treatment of advanced human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in treatment-experienced patients with evidence of HIV replication despite ongoing antiretroviral therapy.***For human immunodeficiency virus (HIV) prophylaxis� after occupational HIV exposure.,"***General Information***Anticoagulant therapy, coagulopathy, hemophilia***Pulmonary disease, respiratory infection, substance abuse, tobacco smoking***Pregnancy***Breast-feeding***Children, infants, neonates***Human immunodeficiency virus (HIV) infection resistance***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Hepatitis B and HIV coinfection***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8703'],fenofibrate,"***For use as an adjunct to diet for the treatment of adult patients with severe hypertriglyceridemia. <br />  NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.     <br />NOTE: Markedly elevated levels of serum triglycerides (e.g., &gt; 2000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.  ***For use as an adjunct to diet to reduce elevated LDL-cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase HDL-cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. <br />        NOTE: Fenofibrate tablet and capsule formulations are not bioequivalent.<br />NOTE: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.   ","***General Information***Cardiac disease***Biliary cirrhosis, cholelithiasis, gallbladder disease, hepatic disease***Dialysis, renal disease, renal failure, renal impairment***Anticoagulant therapy***Thromboembolic disease***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding***Diabetes mellitus***Hypothyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,atropine sulfate/edrophonium chloride,"***For use in nondepolarizing neuromuscular blockade reversal or antagonism, or as an adjunctive treatment of respiratory depression due to curare overdosage.","***Glaucoma, posterior synechiae, synechia***GI obstruction, pyloric stenosis, toxic megacolon***Sulfite hypersensitivity***Bladder obstruction, prostatic hypertrophy, urinary retention, urinary tract obstruction***Asthma, chronic lung disease (CLD)***Myasthenia gravis***Acute myocardial infarction, angina, AV block, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypotension, myocardial infarction***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3255'],desoximetasone,"***For the relief of moderate-to-severe inflammatory manifestations, including pruritus, of corticosteroid responsive dermatoses including alopecia areata, atopic dermatitis, contact dermatitis, dermatitis, <em>Rhus</em> <em>dermatitis</em> due to plants like poison ivy, discoid lupus erythematosus, eczema, exfoliative dermatitis, granuloma annulare, keloids, lichen planus, lichen simplex, lichen striatus, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, and xerosis. <br />        NOTE: Systemic therapy or intralesional injection of corticosteroids may be necessary for some conditions based on the type and severity of the disorder or inadequate response to topical therapy.<br />     ","***General Information***Cataracts, glaucoma, ocular exposure, ophthalmic administration***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Geriatric, skin atrophy***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, tuberculosis, varicella, viral infection***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,yellow fever vaccine,***For yellow fever prophylaxis.,"***Fever***Egg hypersensitivity***Acquired immunodeficiency syndrome (AIDS), agammaglobulinemia, corticosteroid therapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, leukemia, lymphoma, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Myasthenia gravis***Geriatric***Infants, neonates***Pregnancy***Breast-feeding***Intramuscular administration, intravenous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albumin (human),"***For the treatment of shock due to hypovolemia. <br />        NOTE: Dosage should be based on patient response as indicated by blood pressure, degree of pulmonary congestion, and hematocrit.<br />     ***For adjunctive treatment of severe burns.***For the treatment of nephrosis in nephrotic syndrome.***For treatment of hypoproteinemia.***For adjunctive use with exchange transfusion in the treatment of hyperbilirubinemia and erythroblastosis fetalis.","***Albumin hypersensitivity***Anemia, heart failure, hypertension***Renal disease***Hypernatremia***Burns***Viral infection***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diltiazem hydrochloride,"***For the treatment of hypertension.***For the treatment of chronic stable angina.***For the treatment of variant angina (Prinzmetal's angina).***For the treatment of paroxysmal supraventricular tachycardia (PSVT) or control of ventricular rate in atrial flutter or atrial fibrillation.***For the short-term treatment of rapid ventricular rate secondary to atrial arrhythmias� in adolescents, children, and infants.***For long-term control of ventricular rate in atrial flutter� or atrial fibrillation�.***For the relief of ongoing ischemia in patients with unstable angina� or after acute non-ST-segment elevation myocardial infarction� in the absence of congestive heart failure, pulmonary congestion, left ventricular dysfunction, or AV block, when beta-blockers are ineffective or contraindicated.***For the treatment of idiopathic dilated cardiomyopathy�.***For migraine prophylaxis�.***For the treatment of proteinuria� associated with diabetic nephropathy�.","***Acute myocardial infarction, bradycardia, cardiogenic shock, heart failure, ventricular dysfunction***Hypotension***AV block***Sick sinus syndrome***Lown-Ganong-Levine syndrome, ventricular tachycardia, Wolff-Parkinson-White syndrome***Hepatic disease***Aortic stenosis***Gastroesophageal reflux disease (GERD), hiatal hernia***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],drospirenone/ethinyl estradiol,"***For routine contraception.***For the treatment of acne vulgaris in women who also desire oral contraception.***For the treatment of premenstrual dysphoric disorder (PMDD) in women who also desire oral contraception.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, who have achieved menarche and desire contraception.***For the treatment or adjuvant treatment of conditions such as amenorrhea�, hirsutism�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who desire oral contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Adrenal insufficiency, electrolyte imbalance, hyperkalemia, renal disease, renal failure, renal impairment***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia, pancreatitis***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, hypertension, myocardial infarction, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['283810'],bimatoprost,***For the reduction of elevated or increased intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.***For treatment of hypotrichosis of the eyelashes.,"***General Information***Closed-angle glaucoma***Aphakia, corneal abrasion, iritis, keratitis, ocular infection, ocular surgery, ocular trauma, uveitis***Contact lenses***Sunlight (UV) exposure***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,folic acid,"***For the treatment of folate deficiency megaloblastic anemia.***For the treatment of folate deficiency megaloblastic anemia or macrocytic anemia secondary to folic acid deficiency, hepatic disease, alcoholism, intestinal obstruction, or excessive hemolysis.***For the treatment of folate deficiency megaloblastic anemia in patients with tropical sprue.***For nutritional supplementation.***For the recommended dietary allowance (RDA) of folic acid in healthy individuals.***For supplementation in patients with sickle cell disease.***For the adjunct treatment of primary homocystinuria.***For methotrexate toxicity prophylaxis� in patients receiving methotrexate for rheumatoid arthritis.***For folate deficiency diagnosis�, to detect the presence of folate deficiency without concealing pernicious anemia in patients with megaloblastic anemia.***For neural tube defect prophylaxis�. <br />        NOTE: Because there is evidence that fetal neural tube defects can be prevented if folic acid therapy is initiated before pregnancy, the US Public Health Service (USPHS), American College of Obstetrics and Gynecology (ACOG) or FDA have recommend the following doses.<br />     ***For the prevention of fetal neural tube defects (NTDs) in women with a history of pregnancy complicated by fetal NTDs.","***Folic acid hypersensitivity***Pernicious anemia***Benzyl alcohol hypersensitivity, neonates, premature neonates***Pregnancy***Breast-feeding***Renal disease, renal failure, renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,nelfinavir mesylate,***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***Formoterol; Mometasone,"***General Information***Phenylketonuria***Hemophilia***Hepatic disease***Hepatitis B and HIV coinfection***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, pancreatitis***Children, infants, neonates***Pregnancy***Breast-feeding***Antimicrobial resistance***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4135'],ethosuximide,***For the treatment of generalized absence seizures.,"***Succinimide hypersensitivity***Depression, suicidal ideation***Abrupt discontinuation***Hepatic disease, hepatitis, jaundice***Porphyria***Renal disease***Agranulocytosis, bone marrow suppression, fever, hematological disease, infection***Avoid ethanol ingestion, driving or operating machinery***Children, infants, neonates***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,chorionic gonadotropin,"***For the treatment of male infants and children with prepubertal cryptorchidism not caused by anatomical obstruction. <br />        NOTE: HCG appears to be more effective at inducing testicular descent in those infants and children with palpable testes in the high scrotal, prescrotal, or inguinal regions. Intra-abdominal testes are especially refractory to HCG treatment. While hormonal therapy is traditionally instituted after the age of 4 years, there are several studies that include male children of younger ages, and there is some evidence that treatment prior to age 2 years may be beneficial in terms of long-term outcomes. Consult specialized references for the most current recommendations.<br />     ***For the treatment of select cases of hypogonadotropic hypogonadism.***For the routine treatment of hypogonadotropic hypogonadism in adult and adolescent males.***For the stimulation of spermatogenesis in males with primary or secondary hypogonadotropic hypogonadism and resultant oligospermia. <br />          NOTE: Pretreatment with human chorionic gonadotropin (HCG) is required prior to combination treatment with menotropins or follitropin. Various dosage regimens have been advocated.<br />       ***For adjunctive treatment of anovulation in females with infertility not due to primary ovarian failure, including in women undergoing assisted reproductive technology (ART). <br />        NOTE: HCG must be withheld if there is an excessive ovarian response, as evidenced by abnormally enlarged ovaries, multiple follicular development, or excessive estradiol production. Consult specialized references.<br />     ***For induction of ovulation in females treated with clomiphene who have an appropriate follicular response but a failure to ovulate.***For induction of ovulation following treatment with menotropins or follitropin in females with infertility.***For luteal phase support� of infertile female patients with hypogonadotropic hypogonadism after they have completed a typical ovulation induction protocol with FSH/LH (menotropins).***For induction of final oocyte maturation in preparation for oocyte harvest in females undergoing IVF or other ART procedures following follitropin treatment.***For the treatment of Kaposi's sarcoma�.","***Hamster protein hypersensitivity***Benzyl alcohol hypersensitivity, neonates***Children, precocious puberty***Asthma, cardiac disease, migraine, renal disease, seizure disorder, thromboembolic disease, thrombophlebitis***Dysfunctional uterine bleeding, endometrial cancer, endometriosis, neoplastic disease, ovarian cancer, prostate cancer, uterine leiomyomata***Adrenal insufficiency, ovarian failure, pituitary adenoma, thyroid disease***Ascites, ovarian cyst, polycystic ovary syndrome***Geriatric***Pregnancy***Breast-feeding***Obesity***Ethanol intoxication, tobacco smoking***Hepatic disease, renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5487']['6918'],hydrochlorothiazide/metoprolol tartrate,"***For the treatment of hypertension in patients who do not respond to monotherapy. <br />        NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br />     ***Formoterol***Formoterol; Mometasone","***Beta-blocker hypersensitivity, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, renal disease, renal failure, renal impairment***Abrupt discontinuation***Depression***AV block, bradycardia, cardiogenic shock, heart failure, pulmonary edema, sick sinus syndrome, ventricular dysfunction, Wolff-Parkinson-White syndrome***Cerebrovascular disease***Hyperthyroidism, thyroid disease, thyrotoxicosis***Diabetes mellitus, hyperglycemia***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Peripheral vascular disease, Raynaud's phenomenon, vasospastic angina***Pheochromocytoma***Hepatic disease***Psoriasis***Myasthenia gravis***Hypotension, surgery***Electrolyte imbalance, hypercalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis***Hypovolemia, orthostatic hypotension, sympathectomy, syncope***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Hypercholesterolemia, hypertriglyceridemia***Preeclampsia, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['68099'],famciclovir,***For the treatment of herpes zoster (shingles) infection.***For the treatment of herpes simplex virus infection including recurrent herpes genitalis and herpes labialis.***For acute treatment of recurrent episodes of herpes genitalis.***For treatment of a first episode� of herpes genitalis.***For acute treatment of recurrent episodes of herpes labialis in immunocompetent patients or orolabial herpes in HIV-infected patients.***For herpes genitalis prophylaxis.***For the adjunctive treatment of Bell's palsy� in combination with steroids.***For the treatment of varicella (chickenpox) infection� in HIV-infected patients.,"***Acyclovir hypersensitivity, famciclovir hypersensitivity, ganciclovir hypersensitivity, penciclovir hypersensitivity, valacyclovir hypersensitivity, valganciclovir hypersensitivity***Dialysis, geriatric, renal failure, renal impairment***Children, infants, neonates***Herpes infection, varicella***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['34369'],prednicarbate,"***For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as alopecia areata, atopic dermatitis, contact dermatitis, exfoliative dermatitis, Rhus dermatitis due to plants like poison ivy, seborrheic dermatitis (facial and juxtaposed skin surface areas), discoid lupus erythematosus (facial and juxtaposed skin surface areas), eczema, granuloma annulare, keloids (reduction of associated itching), cutaneous lichen planus, lichen simplex chronicus, lichen striatus, polymorphous light eruption, pompholyx (dyshidrosis), necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, nodular prurigo, anogenital or senilis pruritus, psoriasis (facial and juxtaposed skin surface areas), sarcoidosis, or xerosis (inflammatory phase). <br />        NOTE: Acute exudative inflammation, as occurs with poison ivy, may be best treated with the cream formulation, which is drying. Dry, scaly dermatoses, as occur with eczema or psoriasis, may be best treated with the ointment formulation.<br />NOTE: Occlusive dressings may be required for chronic or severe cases of lichen simplex chronicus, psoriasis, eczema, atopic dermatitis, or chronic hand eczema. More potent topical corticosteroids and/or occlusive dressings may be necessary for the treatment of discoid lupus erythematosus, lichen planus, granuloma annulare, psoriatic plaques, and psoriasis of the palms, soles, elbows, or knees. This procedure should be done only as directed by a physician","***Corticosteroid hypersensitivity***Cushing's syndrome, diabetes mellitus, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Pregnancy***Breast-feeding***Fungal infection, herpes infection, infection, measles, varicella, viral infection***Acne rosacea, acne vulgaris, ocular exposure, ophthalmic administration, perioral dermatitis, vaginal administration***Geriatric, skin atrophy***Children, growth inhibition, increased intracranial pressure, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1251'],azacitidine,"***For the treatment of myelodysplastic syndrome (MDS). <br />  NOTE: Azacitidine has been designated an orphan drug for this indication.<br /***For the treatment of MDS subtypes of refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.***For the treatment of patients with acute myelogenous leukemia (AML)� who are ineligible for or have disease that is refractory to intensive chemotherapy.***For the treatment of chronic myelogenous leukemia (CML)� in accelerated phase or blast crisis in combination with mitoxantrone.","***Mannitol hypersensitivity***Hepatic disease, hepatotoxicity, hypoalbuminemia***Bone marrow suppression, neutropenia, thrombocytopenia***Geriatric, renal failure, renal impairment***Tumor lysis syndrome (TLS)***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,meclizine hydrochloride,***For the treatment of nausea/vomiting and dizziness associated with motion sickness.***For control of vertigo associated with vestibular system diseases.,"***Bladder obstruction, prostatic hypertrophy, urinary retention***Closed-angle glaucoma, contact lenses***GI obstruction, ileus***Asthma, bronchitis, emphysema***Driving or operating machinery***Pregnancy***Breast-feeding***Children, infants, neonates***Anticholinergic medications, geriatric***Renal failure, renal impairment***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['596'],alprazolam,"***For the treatment of  transient symptoms of anxiety, anxiety associated with depression, or generalized anxiety disorder (GAD).***For the treatment of panic disorder with or without agoraphobia.***For the treatment of anxiety and mood-symptoms associated with premenstrual syndrome (PMS)� or premenstrual dysphoric disorder (PMDD)� that are unresponsive to non-pharmacologic therapy.","***Benzodiazepine hypersensitivity***Abrupt discontinuation, benzodiazepine dependence, seizure disorder, seizures, status epilepticus, substance abuse***Anxiety***Bipolar disorder, depression, mania, psychosis, suicidal ideation***Chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, pulmonary disease, respiratory depression, sleep apnea***CNS depression, coma, driving or operating machinery, ethanol intoxication, shock***Closed-angle glaucoma***Myasthenia gravis***Parkinson's disease***Porphyria***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease, obesity***Renal failure, renal impairment***Dementia, geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4278'],famotidine,"***For self-medication of pyrosis (heartburn), acid dyspepsia (acid indigestion), or sour stomach, either for prophylaxis or for symptomatic relief.***For maximum strength prevention or relief of symptoms.***For the treatment of gastroesophageal reflux disease (GERD) or esophagitis associated with gastroesophageal reflux disease (GERD).***For the treatment of peptic ulcer disease (duodenal ulcer or gastric ulcer). <br />        NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br />     ***For acute treatment.***For maintenance therapy of duodenal ulcer after the initial treatment phase has been completed.***For Helicobacter pylori (H. pylori) eradication in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�.***For pathologic GI hypersecretory conditions such as Zollinger-Ellison syndrome, systemic mastocytosis, or multiple endocrine adenoma syndrome.***For NSAID-induced ulcer prophylaxis�.***For stress gastritis prophylaxis� in critically-ill patients.***For acid aspiration prophylaxis� prior to anesthesia.","***General Information***H2-blocker hypersensitivity***Gastric cancer, GI bleeding***Infection***Hepatic disease, QT prolongation, renal disease, renal failure, renal impairment***Children, infants, neonates***Breast-feeding***Pregnancy***Tobacco smoking***Phenylketonuria***Geriatric***Vitamin B12 deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2193'],ceftriaxone,"***For the treatment of bacteremia and sepsis.***For the treatment of lower respiratory tract infections (e.g., pneumonia, community-acquired pneumonia, pleural empyema).***For the treatment of urinary tract infection (UTI).***For the treatment of gonorrhea.***For gonococcal bacterial conjunctivitis�.***For disseminated (e.g., bacteremia, arthritis, peritonitis) gonococcal infection� including scalp infection/abscess� in neonates.***For gonococcal meningitis�.***For gonococcal endocarditis�.***For ophthalmia neonatorum� caused by <em>N. gonorrhoeae</em>.***For the treatment of acute proctitis.***For the treatment of acute bacterial otitis media.***For the treatment of skin and skin structure infections, including diabetic foot ulcer, surgical incision site infections, animal bite wounds, and necrotizing infections.***For the treatment of diabetic foot ulcer.***For the treatment of surgical incision site infections.***For the treatment of animal bite wounds.***For the treatment of necrotizing infections of the skin, fascia, and muscle.***For the treatment intraabdominal infections, including perforated appendicitis and biliary tract infections such as cholecystitis.***For surgical infection prophylaxis.***For the treatment of pelvic inflammatory disease (PID).***For the treatment of bone and joint infections (i.e., osteomyelitis, prosthetic joint infections).***For the treatment of infective endocarditis�.***For bacterial endocarditis prophylaxis�.***For the treatment of bacterial meningitis or brain abscess�.***For the treatment of chancroid� due to <em>Haemophilus ducreyi</em>.***For the treatment of epididymitis�.***For gonorrhea prophylaxis�.***For neonates� whose mothers have untreated gonococcal infection.***For victims of sexual assault�.***For the treatment of disseminated Lyme disease� (i.e., neuroborreliosis, carditis, recurrent/persistent arthritis). <br />  NOTE: Ceftriaxone is not recommended for treatment of patients with early Lyme disease in the absence of neurologic involvement, advanced atrioventricular heart block, or persistent/recurrent arthritis.<br /***For meningococcal infection prophylaxis� and bacterial colonization eradication�. <br />  NOTE: The Centers for Disease Control (CDC) recommends antimicrobial chemoprophylaxis for close contacts of a person with invasive meningococcal disease. Close contacts include: household contacts, child-care center contacts, and anyone directly exposed to patient's oral secretions (e.g., kissing, mouth-to-mouth resuscitation, airway management [e.g., endotracheal tube management]) in the 7 days before symptom onset, and travelers who had direct contact with respiratory secretions from an index-patient or for anyone seated directly next to an index-patient on a prolonged flight (i.e., 8 hours or longer).<br /***For the empiric treatment of enteric infections�, including acute gastroenteritis� and infectious diarrhea� in HIV-infected patients.***For the treatment of salmonellosis� in HIV-infected patients.***For the treatment of severe typhoid fever� due to multidrug-resistant or quinolone-resistant <em>Salmonella typhii</em>.***For the treatment of syphilis�, including neurosyphilis�. <br />        NOTE: A Jarisch-Herxheimer reaction may occur within the first 24 hours of therapy.<br />NOTE: While the CDC recommends non-penicillin alternatives for the treatment of syphilis in HIV-infected patients, their efficacy has not been evaluated and they should only be used with close clinical and serologic monitoring***For primary, secondary, or early latent syphilis� (caused by <em>Treponema pallidum</em>) in nonpregnant, penicillin-allergic patients.***For neurosyphilis� in nonpregnant, penicillin-allergic patients.***For the treatment of congenital syphilis�.***For the treatment of severe leptospirosis� due to <em>Leptospira </em>sp.�.***For the treatment of acute bacterial sinusitis�.***For the treatment of severe infection requiring hospitalization.***For the treatment of mild to moderate infection in patients unable to tolerate oral antibiotics.***For bacterial infection prophylaxis� in patients with cirrhosis and GI bleeding.","***General Information***Antimicrobial resistance, viral infection***Cephalosporin hypersensitivity, penicillin hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Coagulopathy, hepatic disease, vitamin K deficiency***Intramuscular injections***Pregnancy***Breast-feeding***Jaundice, neonates, premature neonates***Coadministration of calcium-containing IV's***Gallbladder disease***Renal failure, urinary tract obstruction***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['34369'],prednicarbate,"***For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as alopecia areata, atopic dermatitis, contact dermatitis, exfoliative dermatitis, Rhus dermatitis due to plants like poison ivy, seborrheic dermatitis (facial and juxtaposed skin surface areas), discoid lupus erythematosus (facial and juxtaposed skin surface areas), eczema, granuloma annulare, keloids (reduction of associated itching), cutaneous lichen planus, lichen simplex chronicus, lichen striatus, polymorphous light eruption, pompholyx (dyshidrosis), necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, nodular prurigo, anogenital or senilis pruritus, psoriasis (facial and juxtaposed skin surface areas), sarcoidosis, or xerosis (inflammatory phase). <br />        NOTE: Acute exudative inflammation, as occurs with poison ivy, may be best treated with the cream formulation, which is drying. Dry, scaly dermatoses, as occur with eczema or psoriasis, may be best treated with the ointment formulation.<br />NOTE: Occlusive dressings may be required for chronic or severe cases of lichen simplex chronicus, psoriasis, eczema, atopic dermatitis, or chronic hand eczema. More potent topical corticosteroids and/or occlusive dressings may be necessary for the treatment of discoid lupus erythematosus, lichen planus, granuloma annulare, psoriatic plaques, and psoriasis of the palms, soles, elbows, or knees. This procedure should be done only as directed by a physician","***Corticosteroid hypersensitivity***Cushing's syndrome, diabetes mellitus, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Pregnancy***Breast-feeding***Fungal infection, herpes infection, infection, measles, varicella, viral infection***Acne rosacea, acne vulgaris, ocular exposure, ophthalmic administration, perioral dermatitis, vaginal administration***Geriatric, skin atrophy***Children, growth inhibition, increased intracranial pressure, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"chlordiazepoxide hydrochloride/clidinium bromide,""","***General Information***Benzodiazepine hypersensitivity***Bladder obstruction, prostatic hypertrophy, urinary retention***Closed-angle glaucoma***CNS depression, driving or operating machinery, ethanol ingestion***Abrupt discontinuation, alcoholism, benzodiazepine dependence, substance abuse***Diarrhea, esophagitis, gastroesophageal reflux disease (GERD), GI obstruction, hiatal hernia, ileus, toxic megacolon, ulcerative colitis***Depression, suicidal ideation***Dementia, Parkinson's disease***Chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, pulmonary disease, respiratory depression, sleep apnea***Hepatic disease***Renal failure, renal impairment***Autonomic neuropathy, myasthenia gravis***Cardiac arrhythmias, coronary artery disease, heart failure, hyperthyroidism, tachycardia***Porphyria***Ambient temperature increase***Anticholinergic medications, geriatric***Labor, obstetric delivery, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['61805'],nitisinone,***For the treatment of hereditary tyrosinemia type I. <br />        NOTE: Nitisinone has been designated an orphan drug by the FDA for this indication.<br />     ,"***Ocular disease, tyrosinemia***Hepatic disease, neoplastic disease, porphyria***Leukopenia, thrombocytopenia***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,nicardipine hydrochloride,"***For the treatment of chronic stable angina.***For the treatment of hypertension.***For chronic hypertension.***For short-term treatment of hypertension when oral therapy is not feasible or desirable; or for the treatment of hypertensive urgency� or hypertensive emergency�, except in the setting of acute heart failure.***For postoperative hypertension�, in the absence of supraventricular tachycardia or a recent myocardial infarction.***For the treatment of proteinuria� associated with diabetic nephropathy�.","***Dihydropyridine hypersensitivity***Acute myocardial infarction, bradycardia, cardiogenic shock, heart failure, ventricular dysfunction***Hypotension***Aortic stenosis***Intracranial bleeding, stroke***Renal failure, renal impairment***Hepatic disease***Neonates, pregnancy***Breast-feeding***Children, infants***Gastroesophageal reflux disease (GERD), hiatal hernia***Pheochromocytoma***Angina***Extravasation***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,carteolol hydrochloride,***For the treatment of chronic open-angle glaucoma and ocular hypertension either alone or in combination with other intraocular pressure lowering agents.,"***General Information***AV block, bradycardia, cardiogenic shock, heart failure, hypotension, pulmonary edema, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Cerebrovascular disease***Abrupt discontinuation, hyperthyroidism, thyrotoxicosis***Diabetes mellitus, hypoglycemia***Surgery***Pregnancy***Breast-feeding***Children, infants, neonates***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Depression***Psoriasis***Myasthenia gravis***Driving or operating machinery***Geriatric, peripheral vascular disease, Raynaud's phenomenon***Pheochromocytoma***Renal disease, renal failure, renal impairment***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2002'],carbamazepine,"***For the management of generalized tonic-clonic seizures, or for partial seizures, either simple or complex-partial seizures. <br />        NOTE: Periodic monitoring of serum carbamazepine concentrations is recommended.<br />     ***For the symptomatic treatment of neuropathic pain.***For the treatment of acute mania and mixed episodes associated with bipolar disorder (bipolar I disorder).***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD).***For the treatment of persistent singultus (hiccups)�.***For long-term prophylaxis of short-lasting short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT)�.","***General Information***Asian patients, serious rash***Depression, psychosis, suicidal ideation***Atonic seizures, myoclonic seizures, petit mal (absence) seizures***Abrupt discontinuation***Barbiturate hypersensitivity, carbamazepine hypersensitivity, fever, hydantoin hypersensitivity, jaundice, tricyclic antidepressant hypersensitivity***Agranulocytosis, aplastic anemia, bone marrow suppression, hematological disease, leukopenia, neutropenia, thrombocytopenia***Porphyria***Hepatic disease***AV block, bundle-branch block, cardiac arrhythmias, cardiac disease, coronary artery disease***Hyponatremia***Alcoholism***Driving or operating machinery***Renal disease, renal failure, renal impairment***Geriatric***Glaucoma, increased intraocular pressure***Pregnancy***Neonates***Breast-feeding***Sunlight (UV) exposure***MAOI therapy***Hypercholesterolemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amiloride hydrochloride,"***For the adjunctive treatment of heart failure (peripheral edema), hypertension, or hypokalemia. <br />        NOTE: Amiloride rarely should be used alone due to its weak diuretic and antihypertensive effects and its associated risk of hyperkalemia (10% when used as a single agent). Amiloride is indicated as adjunctive treatment with thiazide or loop diuretics to treat heart failure or hypertension, when it is clinically important to prevent hypokalemia or when persistent hypokalemia has been documented.<br />     ***For the treatment of ascites� (e.g., due to hepatic cirrhosis) alone or in combination with furosemide.***Formoterol; Mometasone","***Anuria, diabetes mellitus, diabetic nephropathy, hyperkalemia, renal disease, renal failure, renal impairment***Hyponatremia***Hepatic disease***Acid/base imbalance, metabolic acidosis, respiratory acidosis***Pregnancy***Breast-feeding***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7417'],nifedipine,"***For the treatment of ischemic heart disease including variant angina (Prinzmetal's angina) and chronic stable angina pectoris.***For the treatment of hypertension.***For acute hypertensive episodes including hypertensive urgency and hypertensive emergency in pediatric patients�. <br />          NOTE: Per the FDA and manufacturers, immediate-release nifedipine dosage forms should not be used to treat hypertension and should only be used to treat patients with chronic stable angina or vasospastic angina. The immediate-release nifedipine formulation has been associated with serious side effects (see Precautions and Adverse Reactions) when used to treat adult patients with hypertension, hypertensive urgency, hypertensive emergency, or coexisting myocardial infarction. Although the use of immediate-release nifedipine for the treatment of acute hypertensive episodes is still relatively common practice in pediatric patients, considerable controversy exists and caution should be used.<br />       ***For migraine prophylaxis�.***For the treatment of proteinuria� associated with diabetic nephropathy�.***For the treatment of persistent singultus (hiccups)�.***For the inhibition of uterine contractions in premature labor�. <br />        NOTE: Clinical practice guidelines recommend the use of a first line tocolytic (i.e., beta agonist, calcium channel blocker, or NSAID) for short-term use (up to 48 hours) to allow for administration of antenatal corticosteroids to enhance fetal lung maturation, magnesium sulfate for fetal neuroprotection, or transport to a tertiary facility, if indicated. There is no evidence that tocolytic therapy alone has any favorable effect on neonatal outcomes. Maintenance therapy with tocolytics is ineffective for preventing preterm birth and improving neonatal outcomes and is not recommended.<br />     ***For the treatment of achalasia�.***For the treatment of high altitude pulmonary edema associated with altitude sickness�.***For altitude sickness prophylaxis<strong>","***General Information***Dihydropyridine hypersensitivity***Pregnancy***Breast-feeding***Acute myocardial infarction, bradycardia, cardiogenic shock, coronary artery disease, heart failure, hypotension, ventricular dysfunction***Geriatric***Aortic stenosis***Colostomy, constipation, diabetes mellitus, diverticulitis, esophageal stricture, gastric cancer, gastroesophageal reflux disease (GERD), GI obstruction, hiatal hernia, hypothyroidism, ileus, inflammatory bowel disease, obesity***Children, infants***Hepatic disease***Lactase deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['7407', '31765']",nicotine,"***For use as an adjunct to psychosocial interventions for tobacco cessation (smoking cessation), including the treatment of nicotine withdrawal.***For the treatment of Tourette's syndrome� as an adjunct to haloperidol.***For ulcerative colitis�.***For the treatment of active ulcerative colitis�.***For secondary prophylaxis of ulcerative colitis (i.e., ulcerative colitis prophylaxis�).","***General Information***Soya lecithin hypersensitivity, tobacco smoking***Acute bronchospasm, asthma***Angina, cardiac arrhythmias, diabetes mellitus, hypertension, hyperthyroidism, myocardial infarction, pheochromocytoma, sodium restriction, thyroid disease, thyrotoxicosis***Nasal polyps***Geriatric***Hepatic disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Peptic ulcer disease***Children, infants, neonates***Dental disease***Esophagitis, gastroesophageal reflux disease (GERD), hiatal hernia***Eczema***Magnetic resonance imaging (MRI)***Depression***Seizure disorder, seizures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1894'],calcitriol,"***For the treatment of hypocalcemia and secondary hyperparathyroidism and resultant metabolic bone disease (renal osteodystrophy) in patients with chronic kidney disease (CKD).***For initial dosing and dosage titration in adult predialysis patients with Stage 3 or 4 CKD or pediatric predialysis patients with Stage 2 to 4 CKD. <br />          NOTE: Serum calcium, phosphorus, alkaline phosphatase, and creatinine concentrations should be determined initially, monthly for 6 months, then periodically. Serum iPTH should be monitored initially and then every 3 to 4 months. During dosage titration, calcium concentrations should be monitored at least twice weekly.<br />NOTE: Calcitriol is indicated when serum 25-(OH)-vitamin D is more than 30 ng/mL and plasma iPTH concentrations are more than 70 pg/mL (Stage 3 in adults; Stage 2 to 3 in pediatric patients) or more than 110 pg/mL (Stage 4); serum calcium concentrations should be less than 9.5 mg/dL (adults) or 10 mg/dL (pediatric patients) and serum phosphorous concentrations should be should be less than 4.6 mg/dL for adults and at age appropriate levels for pediatric patients.***For initial dosing and dosage titration in patients with Stage 5 CKD on dialysis (FDA-approved labeling).***For initial dosing and dosage titration  in patients with Stage 5 CKD on dialysis (National Kidney Foundation Guidelines)�. <br />          NOTE: Serum phosphorous concentrations should be less than 5.5 mg/dL (adults and adolescents) or less than 6.5 mg/dL (infants and children) and the calcium-phosphorous product should be less than 55 (adults and adolescents) or less than 65 (infants and children). Serum calcium concentrations should be less than 9.5 mg/dL (adults) or 10 mg/dL (pediatric patients) in patients with a serum iPTH of 1000 pg/mL or less. In patients with a serum iPTH more than 1000 pg/mL, the serum calcium concentration should be less than 10 mg/dL (adults) or 10.5 mg/dL (pediatric patients). <br />       ***For the treatment of patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism and pseudohypoparathyroidism manifesting as hypocalcemia.***For the treatment of mild to moderate plaque psoriasis. <br />        NOTE: According to the American Academy of Dermatology (AAD), combining calcitriol with a topical corticosteroid is more effective than either treatment alone. In addition, fewer adverse events were reported with combination therapy in most clinical studies.<br />     ***For the management of hypocalcemia associated with vitamin D deficiency�. <br />  NOTE: For hypocalcemia associated with chronic kidney disease, see hyperparathyroidism indication.<br /***For the treatment of vitamin D-dependent rickets�.***For the treatment of familial hypophosphatemia�.***For the treatment of postmenopausal osteoporosis�.***For osteoporosis prophylaxis� in recipients of chronic corticosteroid therapy.***For the treatment of osteopetrosis�.","***General Information***Hypercalcemia, hypervitaminosis D, occlusive dressing, renal failure***Accidental exposure, ocular exposure***Hyperphosphatemia***Arteriosclerosis, cardiac disease***Geriatric***Dehydration***Sarcoidosis***Sunlight (UV) exposure***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5492'],hydrocortisone,"***For the treatment of primary adrenocortical insufficiency (e.g., Addison's Disease, congenital adrenal hyperplasia or CAH) or secondary adrenocortical insufficiency.***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing minor surgery or with a minor illness (e.g., inguinal hernia repair, colonoscopy, mild febrile illness, gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing moderate surgery or with a moderate illness (e.g., open cholecystectomy, hemicolectomy, significant febrile illness, pneumonia, severe gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing major surgery, or with other acute stressors (e.g., major cardiothoracic surgery, Whipple procedure, liver resection, pancreatitis, acute systemic infection, shock).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency and a critical illness (e.g., shock).***For the treatment of acute adrenocortical insufficiency.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency with other acute stressors (e.g., febrile illness with a temperature more than 38.5 degrees Celsius, gastroenteritis with dehydration, major trauma):.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency undergoing surgery accompanied by general anesthesia.***For use in nonspecific proctitis, postirradiation (factitial) proctitis, cryptitis, or for other non-specific inflammatory conditions of the anorectum.***For the treatment of inflammatory bowel disease (Crohn's disease or ulcerative colitis).***For adjunctive treatment of Crohn's disease or ulcerative colitis using oral or parenteral therapy.***For adjunctive rectal treatment of chronic ulcerative colitis, particularly if disease limited to the distal portion of the rectum.***For the relief of inflammation, pruritus ani, and swelling associated with hemorrhoids.***For the treatment of allergic disorders including anaphylaxis, anaphylactic shock, or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, transfusion-related reactions, serum sickness, severe perennial or seasonal allergic rhinitis, or urticaria.***For the non-emergent treatment of hypersensitivity or allergic conditions.***For the urgent treatment of severe conditions such as anaphylaxis, angioedema, acute noninfectious laryngeal edema, or urticarial transfusion-related reactions.***For the treatment of corticosteroid-responsive dermatologic disorders (e.g., alopecia areata, atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis including Rhus dermatitis due to poison ivy, poison oak, poison sumac, discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pompholyx (dyshidrosis), pruritus, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, xerosis).***For mild-to-moderate corticosteroid responsive dermatoses.***For mild to moderate atopic dermatitis.***For the systemic treatment of severe inflammatory dermatoses, like severe exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, or psoriasis unresponsive to topical treatment.***For adjunctive therapy in the treatment of rheumatic disorders including acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of non-rheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the short-term treatment of hypercalcemia associated with neoplastic disease.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the management of nephrotic syndrome to induce diuresis or decrease proteinuria.***For the treatment of neurologic or myocardial involvement associated with trichinosis.***For the treatment of nonsuppurative thyroiditis.***For rheumatic and related disorders such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, symptomatic sarcoidosis, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive hematologic disorders, like immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia, and congenital hypoplastic anemia; OR for the palliative treatment of neoplastic disease in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), or multiple myeloma�.***For the treatment of respiratory inflammatory conditions including bronchial asthma, aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), Loeffler's syndrome, or noncardiogenic pulmonary edema�.***For the treatment of septic shock� and/or hypotension� in patients whose blood pressure is poorly responsive to adequate fluid resuscitation and vasopressor therapy.***For the prevention of chronic lung disease (CLD)� in mechanically ventilated patients.***For the treatment of refractory neonatal hypoglycemia�.***For the treatment of corticosteroid-responsive ophthalmic disorders, including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.","***Abrupt discontinuation, Cushing's syndrome, skin abrasion***Growth inhibition, increased intracranial pressure***Immunosuppression***Fungal infection, infection***Acne rosacea, acne vulgaris, herpes infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Heart failure, hypertension***Osteoporosis***Diabetes mellitus***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hypothyroidism, psychosis, renal disease, seizure disorder***Myasthenia gravis***Coagulopathy, hemophilia, thromboembolic disease***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Neonates, premature neonates***Benzyl alcohol hypersensitivity, corticosteroid hypersensitivity***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Skin atrophy***Geriatric***Epidural administration, intrathecal administration***Pheochromocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['25120', '1546428']",flunisolide,***For the maintenance treatment of asthma as bronchospasm prophylaxis.***For relief of the nasal symptoms of seasonal or perennial allergic rhinitis.,"***General Information***Acute bronchospasm, status asthmaticus***Adrenal insufficiency, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, surgery***Children, growth inhibition, increased intracranial pressure, infants, neonates***Fungal infection, herpes infection, infection, trauma, tuberculosis***Cataracts, glaucoma, increased intraocular pressure***Osteoporosis***Pregnancy***Breast-feeding***Geriatric***Corticosteroid hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clorazepate dipotassium,***For the treatment of acute alcohol withdrawal.***For the treatment of anxiety disorders or for the short-term relief of symptoms of anxiety.***For use as an alternative agent for the treatment of partial seizures.,"***General Information***Benzodiazepine hypersensitivity***Depression, suicidal ideation***Psychosis***Bipolar disorder, mania***Myasthenia gravis, neuromuscular disease, Parkinson's disease***Chronic obstructive pulmonary disease (COPD), CNS depression, coadministration with other CNS depressants, pulmonary disease, respiratory depression, respiratory insufficiency, sleep apnea***Abrupt discontinuation, benzodiazepine dependence, seizure disorder, seizures, status epilepticus, substance abuse***Closed-angle glaucoma***Porphyria***Neonates, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease***Renal failure, renal impairment***Dementia, geriatric***Children, infants***Alcoholism, driving or operating machinery, ethanol ingestion, ethanol intoxication",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,lincomycin hydrochloride,"***For the treatment of serious or severe infections (e.g., bacteremia) due to susceptible strains of streptococci, pneumococci, and staphylococci. <br />        NOTE: Use lincomycin only for serious infections in patients with penicillin allergy where other less toxic therapy is inappropriate.<br />NOTE: Do not use lincomycin for meningitis***For subconjunctival injection during ocular surgery.","***Asthma, atopy, clindamycin hypersensitivity, lincomycin hypersensitivity***Viral infection***Fungal infection***Colitis, diarrhea, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Benzyl alcohol hypersensitivity, infants, neonates***Renal disease, renal failure, renal impairment***Hepatic disease***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['60223', '153184']",adapalene,***For the treatment of acne vulgaris.,"***Pregnancy***Breast-feeding***Eczema, skin abrasion, sunburn, sunlight (UV) exposure***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['190548'],tipranavir,***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents in patients with evidence of HIV replication despite ongoing antiretroviral therapy who are either treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.***Formoterol; Mometasone,"***General Information***Hepatic decompensation, hepatic disease, hepatitis, hepatitis B and HIV coinfection, hepatitis C and HIV coinfection, hepatotoxicity, jaundice***Sulfonamide hypersensitivity***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, pancreatitis***Diabetes mellitus***Bleeding, hemophilia***Human immunodeficiency virus (HIV) infection resistance***Children, infants, neonates***Pregnancy***Breast-feeding***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Alcoholism, anticoagulant therapy, coagulopathy, head trauma, hypertension, intracranial bleeding, surgery***Serious rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,polyethylene glycol 3350/potassium chloride/sodium bicarbonate/sodium chloride/sodium sulfate,"***For use as a bowel evacuant to clean the colon prior to colonoscopy or barium enema X-ray examination (bowel preparation). <br />        NOTE: Patients should be well hydrated before, during, and after the colon preparation. The first bowel movement should occur approximately 1 hour after the start of solution administration.<br />     ***For dosing in adults and/or adolescents.***For dosing in children and older infants.***For the treatment of chronic constipation�. <br />        NOTE: This product should be used for 2 weeks or less or as directed by the prescriber.<br />     ","***General Information***Abdominal pain, acute abdomen, appendicitis, colitis, dehydration, GI obstruction, GI perforation, ileus, inflammatory bowel disease, toxic megacolon, ulcerative colitis, vomiting***Electrolyte imbalance, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, seizure disorder, seizures***Children, infants, neonates***Pregnancy***Breast-feeding***Coma, dementia, dysphagia, esophageal stricture, gag reflex depression***Angina, cardiac arrhythmias, cardiomyopathy, heart failure, myocardial infarction, QT prolongation***Renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10753'],tretinoin,"***For the treatment of acne vulgaris.***For adjunctive treatment of photoaging including palliation of fine facial wrinkles, facial mottled hyperpigmentation (i.e., 'liver spots'), and facial skin roughness.***For the treatment of acute promyelocytic leukemia (APL). <br />        NOTE: Retinoic acid-APL (RA-APL) syndrome characterized by fever, dyspnea, acute respiratory distress, weight gain, radiographic pulmonary infiltrates, pleural and pericardial effusions, edema, and hepatic, renal, and multi-organ failure requires prompt treatment with high-dose steroids (e.g., dexamethasone 10 mg IV every 12 hours for 3 days or until the resolution of symptoms). RA-APL syndrome may occur with or without leukocytosis.<br />     ***For remission induction treatment in patients with APL who are refractory to or who have relapsed from anthracycline chemotherapy or who have a contraindication to anthracycline-based therapy.***For maintenance therapy following induction and consolidation therapy�.***For remission induction and consolidation treatment in patients with newly diagnosed, low-risk APL in combination with arsenic trioxide�.***For remission induction treatment in patients with newly diagnosed APL, in combination with idarubicin�.***For consolidation treatment following tretinoin and idarubicin induction therapy in patients with newly diagnosed APL, in combination with idarubicin-containing chemotherapy�.***For the treatment of melasma�.***For the treatment of diseases of keratinization� (e.g., actinic keratosis�, ichthyosis�, keloids�, keratosis follicularis�); acne rosacea�; skin hyperpigmentation�.***For the treatment of AIDS-related Kaposi's sarcoma�.***Formoterol; Mometasone","***Requires a specialized care setting, requires an experienced clinician, respiratory insufficiency***Retinoid hypersensitivity***Paraben hypersensitivity***Fish hypersensitivity***Acute promyelocytic leukemia differentiation syndrome***Leukocytosis***Skin photosensitivity disorder, sunburn, sunlight (UV) exposure***Eczema***Hepatic disease***Contraception requirements, pregnancy, pregnancy testing, reproductive risk***Breast-feeding***Children, infants, neonates***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia***Accidental exposure, ocular exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8183'],phenytoin,"***For the treatment of status epilepticus.***For the treatment of tonic-clonic seizures or partial seizures.***For maintenance dosing to treat tonic-clonic or complex partial seizures.***For non-emergent treatment to increase phenytoin serum concentrations in a patient currently receiving phenytoin, but who has subtherapeutic serum concentrations; or to initiate phenytoin therapy for seizures in non-emergent situations.***For seizure prophylaxis due to specific neurologic conditions, including neurosurgery, head trauma� or traumatic brain injury�, or subarachnoid hemorrhage�.***For seizure prophylaxis following traumatic brain injury� or head trauma� or for seizure prophylaxis or treatment during neurosurgery.***For the treatment of serious cardiac arrhythmias secondary to digoxin toxicity�.***For seizure prophylaxis� during antenatal care in pregnant females with eclampsia� or severe preeclampsia�.","***Barbiturate hypersensitivity, carbamazepine hypersensitivity, hydantoin hypersensitivity, succinimide hypersensitivity***Asian patients, serious rash***Depression, suicidal ideation***Abrupt discontinuation***Hypoglycemia, hyponatremia, petit mal (absence) seizures***Hepatic disease, hepatotoxicity, hypoalbuminemia, jaundice***Agranulocytosis, bone marrow suppression, hematological disease, porphyria***Hodgkin's disease, lymphoma***Adams-Stokes syndrome, AV block, bradycardia, bundle-branch block, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypotension, infusion-related reactions, intravenous administration***Intramuscular administration***Alcoholism, ethanol ingestion, ethanol intoxication***Driving or operating machinery, encephalopathy, psychosis***Renal disease, renal failure, renal impairment***Diabetes mellitus***Hypothyroidism, thyroid disease***Bone fractures, osteomalacia, osteoporosis***Myasthenia gravis***Dental disease***Extravasation***Geriatric***Neonates, obstetric delivery, pregnancy, vitamin K deficiency***Breast-feeding***Contraception requirements, reproductive risk***Radiation therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amiloride hydrochloride,"***For the adjunctive treatment of heart failure (peripheral edema), hypertension, or hypokalemia. <br />        NOTE: Amiloride rarely should be used alone due to its weak diuretic and antihypertensive effects and its associated risk of hyperkalemia (10% when used as a single agent). Amiloride is indicated as adjunctive treatment with thiazide or loop diuretics to treat heart failure or hypertension, when it is clinically important to prevent hypokalemia or when persistent hypokalemia has been documented.<br />     ***For the treatment of ascites� (e.g., due to hepatic cirrhosis) alone or in combination with furosemide.***Formoterol; Mometasone","***Anuria, diabetes mellitus, diabetic nephropathy, hyperkalemia, renal disease, renal failure, renal impairment***Hyponatremia***Hepatic disease***Acid/base imbalance, metabolic acidosis, respiratory acidosis***Pregnancy***Breast-feeding***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['32624'],oxcarbazepine,"***For the treatment of partial seizures.***For monotherapy treatment of partial seizures with or without secondary generalization.***For adjunct treatment of partial seizures with or without secondary generalization. <br />  NOTE: Under adjunctive therapy (with and without enzyme-inducing antiepileptic drugs), clearance decreases when age increases such that children aged 2 to younger than 4 years may require up to twice the oxcarbazepine dose per body weight compared to adults and children aged 4�12 years may require a 50% higher oxcarbazepine dose per body weight compared to adults.<br /***For conversion of patients from carbamazepine to oxcarbazepine.***For the treatment of trigeminal neuralgia�.***For the treatment of mania� associated with bipolar disorder�.***For the treatment of mania� associated with bipolar disorder� in adults.","***Abrupt discontinuation***Asian patients, carbamazepine hypersensitivity, serious rash***Depression, suicidal ideation***Hyponatremia***Renal failure, renal impairment***Pregnancy***Breast-feeding***Driving or operating machinery, ethanol intoxication***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bromocriptine mesylate,"***For the treatment of Parkinson's disease.***For the treatment of acromegaly.***For the treatment of prolactin-secreting pituitary adenoma or disorders associated with hyperprolactinemia including amenorrhea with or without galactorrhea, male hypogonadism, or female infertility.***For use as an adjunct to diet and exercise in the treatment of type 2 diabetes mellitus.***For the treatment of mastalgia� associated with premenstrual syndrome (PMS)�.***For the maintenance treatment of alcohol dependence�.***For the treatment of symptoms associated with cocaine withdrawal�.***For the treatment of symptoms associated with neuroleptic malignant syndrome�.","***General Information***Ergot alkaloid hypersensitivity***Abrupt discontinuation***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, coronary artery disease, hypertension, peripheral vascular disease***Hypotension, orthostatic hypotension***Bipolar disorder, dementia, depression, driving or operating machinery, schizophrenia***Hepatic disease***Surgery***Pulmonary fibrosis, retroperitoneal fibrosis***GI bleeding, peptic ulcer disease***Geriatric***Basilar/hemiplegic migraine***Renal disease, renal impairment***Diabetic ketoacidosis, type 1 diabetes mellitus***Eclampsia, preeclampsia, pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clonidine hydrochloride,"***For the treatment of hypertension.***For the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients as monotherapy or as adjunctive therapy to a psychostimulant. <br />        NOTE: Clonidine is not considered a first-line agent for children with ADHD due to the potential cardiac effects and the availability of safer and more effective agents, such as some stimulants. Reports of sudden death and hypotension in children receiving oral clonidine in combination with other therapies for ADHD have been published, but causality has not been established.  Children and infants may be more sensitive to the effects of clonidine. However, not all ADHD clinical trials evaluating clonidine have reported adverse cardiac effects. The American Heart Association has recommended that children and adolescents receiving clonidine be monitored for changes in blood pressure at treatment initiation, periodically during treatment, and when tapering the drug, even when clonidine is used for psychotropic indications.<br />     ***For the treatment of ADHD in children with tic disorders�.***For the treatment of severe pain.***For the treatment of hypertensive urgency� or hypertensive emergency�.***For the treatment of opiate agonist withdrawal�.***For the treatment of neonatal abstinence syndrome�.***For pheochromocytoma diagnosis�.***For the symptomatic treatment of diabetic neuropathy�.***For the treatment of diabetic diarrhea�, diarrhea� related to opiate withdrawal, or refractory diarrhea� in cancer patients. <br />        NOTE: Clonidine has some antisecretory activity by modulating (decreasing) small intestinal transit; however, data are relatively limited and the agent is often used for refractory diarrheal cases.<br />     ***For the treatment of alcohol withdrawal�.***For use as an adjunct to psychosocial interventions in the management of tobacco cessation� (smoking cessation�).***For the treatment of hot flashes� due to menopause�.***For the treatment of hypertension and the subsequent decline in renal function associated with scleroderma renal crisis (SRC)�.***For minimization of nephrotoxicity in patients receiving cyclosporine (i.e., cyclosporine nephrotoxicity prophylaxis�) and low-dose methotrexate for allogeneic bone marrow transplant.***For use in peripheral nerve block� including brachial plexus�, intercostal� and peribulbar� blocks in combination with local anesthetics.***For the treatment of Tourette's syndrome�.***For the treatment of aggressive behavior and hyperactivity/inattentiveness in patients with autistic disorder�.***For growth hormone deficiency diagnosis�.***For the treatment of hot flashes� due to prostate cancer� and associated induced androgen deficiency� (andropause�"") in men who have had surgical or medication induced castration.""","***General Information***Abrupt discontinuation, vomiting***AV block, bradycardia, cerebrovascular disease, dehydration, heart failure, hypotension, myocardial infarction, orthostatic hypotension, syncope***Labor, obstetric delivery, pregnancy***Females***Breast-feeding***Children, infants, neonates***Depression***Driving or operating machinery***Sick sinus syndrome***Raynaud's phenomenon, thromboangiitis obliterans (Buerger's disease)***Diabetes mellitus***Renal disease, renal failure, renal impairment***Anticoagulant therapy, coagulopathy, infection***Cardiac disease***Intrathecal administration***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Polyarteritis nodosa, scleroderma, systemic lupus erythematosus (SLE)***Skin abrasion***Surgery***Pheochromocytoma***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6904'],methyltestosterone,"***For androgen replacement therapy, related to cryptorchidism.***For the treatment of delayed puberty in males.***For palliative treatment of breast cancer in women.***For androgen replacement therapy, including symptoms consistent with andropause�, erectile dysfunction (ED)�, or hypogonadism. <br />        NOTE: In the management of erectile dysfunction (ED), methyltestosterone therapy may increase libido and may or may not be effective at improving erectile function in hypogonadal men. Testosterone therapy, however, is not indicated for the treatment of erectile dysfunction in the patient with a normal serum testosterone concentration.<br />     ","***Breast cancer, geriatric, hypercalcemia, prostate cancer, prostatic hypertrophy***Cardiac disease, coronary artery disease, heart failure, hepatic disease, myocardial infarction, renal disease***Pregnancy***Breast-feeding***Diabetes mellitus***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bupivacaine hydrochloride); (bupivacaine hydrochloride/epinephrine,"***For local anesthesia or regional anesthesia. <br />        NOTE: Doses listed below are those considered necessary to produce a successful block and should be regarded as guidelines for use in adults. Individual variations in onset and duration may occur.<br />     ***For caudal anesthesia.***For infiltration anesthesia including dental anesthesia.***For epidural anesthesia (other than caudal block).***For peripheral nerve block.***For sympathetic nerve block.***For ophthalmic anesthesia (i.e., retrobulbar nerve block).***For spinal anesthesia. <br />        NOTE: The following doses are guidelines only. Lower doses may be required in elderly or debilitated patients<br />     ***For anesthesia in lower extremity and perineal procedures.","***General Information***Intraarterial administration, intrathecal administration, intravenous administration***Head and neck anesthesia***Ocular surgery***AV block, cardiac disease, cardiogenic shock, dehydration, hemorrhagic shock, hypotension, hypovolemia, myasthenia gravis, shock***Anticoagulant therapy, coagulopathy, epidural anesthesia, hypertension, infection, neurological disease, sepsis, thrombocytopenia***Bleeding, cardiac arrhythmias, children, geriatric, headache, infants, neonates, spinal anesthesia***Amide local anesthetic hypersensitivity, paraben hypersensitivity***Heart failure, hepatic disease***Eclampsia, fetal distress, fetal prematurity, labor, obstetric delivery, paracervical nerve block, pregnancy, pudendal nerve block***Breast-feeding***Continuous intraarticular infusion administration***Requires a specialized care setting, requires an experienced clinician***Malignant hyperthermia***Electrolyte imbalance, seizure disorder, seizures***Renal disease, renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dopamine hydrochloride/dextrose,"***For short-term treatment of severe, refractory, chronic congestive heart failure.***For the treatment of decreased cardiac output, blood pressure (hypotension), and/or urinary output associated with septic shock, cardiogenic shock, surgery, or acute myocardial failure; and for the treatment of hypotension that may occur after return of spontaneous circulation during cardiopulmonary resuscitation� following cardiac arrest�.***For the treatment of symptomatic bradycardia� unresponsive to atropine and/or external pacing. <br />        NOTE: ACLS guidelines recommend that dopamine may be used in patients with symptomatic bradycardia after atropine fails or when treatment with atropine is inappropriate (Class IIb, Evidence Level B recommendation) or while waiting for successful transcutaneous or transvenous pacing.<br />     ***Formoterol***Formoterol; Mometasone","***Cardiac arrhythmias, pheochromocytoma, ventricular fibrillation, ventricular tachycardia***Hypovolemia***Asthma, corn hypersensitivity, sulfite hypersensitivity***Acute myocardial infarction, angina, cardiac disease, coronary artery disease, diabetes mellitus, occlusive vascular disease, peripheral vascular disease, Raynaud's phenomenon, thromboangiitis obliterans (Buerger's disease)***Extravasation***Abrupt discontinuation***Geriatric***Pregnancy***Breast-feeding***Neonates***Hypoxemia, metabolic acidosis, respiratory acidosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,estramustine phosphate sodium,"***For the treatment of metastatic prostate cancer.***For the treatment of hormone-refractory, metastatic prostate cancer in combination with docetaxel�.***For the palliative treatment of metastatic and/or progressive prostate cancer.***Formoterol; Mometasone","***General Information***Cardiac disease, cerebrovascular disease, coronary artery disease, hypertension, myocardial infarction, stroke, thromboembolic disease, thrombophlebitis***Heart failure, hypercalcemia, hypocalcemia, migraine, peripheral edema, renal failure, renal impairment, seizure disorder***Herpes infection, varicella, viral infection***Diabetes mellitus***Hepatic disease, jaundice***Male-mediated teratogenicity, pregnancy***Breast-feeding***Children***Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['11516'],doxercalciferol,"***For the treatment of secondary hyperparathyroidism and resultant bone disease (renal osteodystrophy�).***For initial dosing and dosage titration in pre-dialysis patients with Stage 3 or Stage 4 chronic kidney disease (CrCl 15 to 59 mL/min/1.73m2).***For initial dosing and dosage titration in predialysis patients with Stage 3 or 4 chronic kidney disease (National Kidney Foundation guidelines). <br />  NOTE: Doxercalciferol is indicated when serum 25-(OH)-vitamin D are greater than 30 ng/mL and plasma iPTH concentrations are greater than 70 pg/mL (Stage 3) or greater than 110 pg/mL (Stage 4); serum calcium concentrations should be less than 9.5 mg/dL and serum phosphorous concentrations should be less than 4.6 mg/dL.<br /***For patients with Stage 5 chronic kidney disease on dialysis.***For initial dosing and dosage adjustments for patients with Stage 5 chronic kidney disease on dialysis (National Kidney Foundation Guidelines). <br />          NOTE: Serum phosphorous concentrations should be less than 5.5 mg/dL and the Calcium-Phosphorous product should be less than 55. Serum calcium concentrations should be less than 9.5 mg/dL in patients with a serum iPTH less than 1000 pg/mL. In patients with a serum iPTH greater than 1000 pg/mL, the serum calcium concentration should be less than 10 mg/dL.<br />       ",***General Information***Hypercalcemia***Children***Hypervitaminosis D***Hepatic disease***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/ethynodiol diacetate,"***For routine contraception.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding)�, hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['18631'],azithromycin,"***For the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis in patients with COPD caused by susceptible strains of <em>Haemophilus influenza</em>, <em>Moraxella catarrhalis</em>, or <em>Streptococcus pneumoniae</em>.***For the treatment of acute otitis media. <br />        NOTE: Various dosing regimens are FDA-approved. Because macrolides, including azithromycin, have limited efficacy against both H. influenzae and S. pneumoniae, these agents are not included in the preferred or alternative options recommended by the American Academy of Pediatrics (AAP) in the treatment guidelines for acute otitis media.<br />     ***For the treatment of bacterial conjunctivitis caused by susceptible strains of <em>CDC coryneform group G, H. influenzae, S. aureus, S. mitis group, and S. pneumoniae</em>.***For the treatment of community-acquired pneumonia (CAP).***For the treatment of uncomplicated skin and skin structure infections caused by <em>S. aureus, S. pyogenes</em> or <em>S. agalactiae</em>.***For the treatment of pelvic inflammatory disease (PID).***For the treatment of gonorrhea.***For the treatment of uncomplicated gonorrhea of the cervix, urethra, rectum, and pharynx.***For the treatment of disseminated (e.g., bacteremia, arthritis) gonococcal infection�, including meningitis� and endocarditis�.***For the treatment of gonococcal conjunctivitis�.***For the treatment of chancroid due to <em>Haemophilus ducreyi</em>.***For the treatment of Mycobacterium avium complex infection (MAC).***For Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients.***For primary Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients.***For secondary Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients with disseminated disease, after treatment of the acute illness.***For the treatment of acute bacterial sinusitis. <br />        NOTE: Due to the high rate of resistance among S. pneumoniae isolates, macrolides are not recommended as empiric therapy. Amoxicillin/clavulanate is recommended as the first-line empiric therapy.<br />     ***For the treatment of non-gonococcal urethiritis (NGU) and chlamydia infection, including infant pneumonia�. <br />        NOTE: For ophthalmia neonatorum caused by C. trachomatis, see ophthalmia neonatorum indication.<br />     ***For the treatment of non-gonococcal urethritis (NGU) and other urogenital infections (e.g., cervicitis, urethritis, proctitis).***For the treatment of pneumonia caused by <em>Chlamydia trachomatis</em> in neonates and infants�.***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis (primary rheumatic fever prophylaxis�) and tonsillitis. <br />        NOTE: For secondary prophylaxis of rheumatic fever, the American Heart Association (AHA) recommends prophylaxis for 10 years or until age 40 (whichever is longer) for patients who have experienced rheumatic fever with carditis and have residual heart disease (persistent valvular disease). For patients who have experienced rheumatic fever with carditis, but have no residual heart disease, the AHA recommends prophylaxis for 10 years or until age 21 (whichever is longer). For patients who have experienced rheumatic fever without carditis, the AHA recommends prophylaxis for 5 years or until age 21 (whichever is longer).<br />     ***For the treatment of primary, secondary, or early latent syphilis� (caused by <em>Treponema pallidum</em>) in nonpregnant, penicillin-allergic patients. <br />        NOTE: A Jarisch-Herxheimer reaction may occur within the first 24 hours of therapy.<br />NOTE: While the HIV guidelines recommend non-penicillin alternatives for the treatment of syphilis in HIV-infected patients, their efficacy has not been evaluated and should only be used with close clinical and serologic monitoring***For the treatment of chronic prostatitis� due to <em>Ureaplasma urealyticum</em>.***For the treatment of Legionnaire's disease�.***For the treatment of shigellosis� diarrhea.***For the treatment of shigellosis� diarrhea in non-immunocompromised patients.***For the treatment of shigellosis� in HIV-infected patients.***For the treatment of mild-to-moderate campylobacteriosis� in HIV-infected patients.***For the treatment of toxoplasmosis�, including toxoplasmic encephalitis�, in HIV-positive patients.***For the treatment of early Lyme disease�.***For the treatment of early Lyme disease� in adults.***For the treatment of early Lyme disease� in children and adolescents.***For the treatment of dental infection� or dentoalveolar infection�, including periodontitis�, acute dental abscess (apical)�, and dental abscess (periapical)�.***For adult chronic periodontitis� after scaling and root planing.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage in patients with beta-lactam allergy.***For bacterial endocarditis prophylaxis�.***For the treatment of babesiosis� in combination with atovaquone.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For use in improving pulmonary function in cystic fibrosis� patients chronically infected with <em>Pseudomonas aeruginosa</em>.***For the treatment of mild scrub typhus� due to Orientia tsutsugamushi� (formerly Rickettsia tsutsugamushi�).***For the treatment of pertussis (whooping cough)� caused by <em>Bordetella pertussis</em> or for postexposure pertussis prophylaxis�. <br />  NOTE: For postexposure prophylaxis, administer to close contacts within 3 weeks of exposure, especially in high-risk patients (e.g., pregnant women in third trimester, infants younger than 12 months). Symptomatic contacts (coughing) should be treated as if they have pertussis.<br /***For the treatment of cholera�.***For the treatment of uncomplicated typhoid fever�.***For the treatment of bartonellosis� (<em>Bartonella bacilliformis)</em> and other <em>Bartonella </em>sp.� infections in HIV-infected patients.***For the treatment of angiomatosis infections�, peliosis hepatis�, bacteremia�, and osteomyelitis� caused by <em>Bartonella </em>sp.�.***For long term suppression� of infections caused by <em>Bartonella </em>sp.� in HIV-infected patients with relapse or reinfection and with CD4 count less than 200 cells/mm3.***For the treatment of ophthalmia neonatorum� due to <em>C. trachomatis</em>.***For the treatment of lymphogranuloma venereum� caused by <em>C. trachomatis</em>.***For chlamydial infection prophylaxis� and gonorrhea prophylaxis� in victims of sexual assault.***For the treatment of moderate or severe traveler's diarrhea�.***Formoterol***Formoterol; Mometasone","***General Information***Viral infection***Macrolide hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis***Hepatic disease, hepatitis, jaundice***Renal failure, renal impairment***Colitis, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Geriatric***Pregnancy***Breast-feeding***Infants, neonates***Sunlight (UV) exposure***Sodium restriction***Contact lenses***Myasthenia gravis***Sexually transmitted disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,trimipramine maleate,***For the treatment of major depression.,"***Carbamazepine hypersensitivity, tricyclic antidepressant hypersensitivity***MAOI therapy***Acute myocardial infarction, bradycardia, cardiac arrhythmias, cardiac disease, congenital heart disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation***Children, suicidal ideation***Bipolar disorder, mania, schizophrenia***Alcoholism, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Electroconvulsive therapy (ECT), seizure disorder, seizures***Hepatic disease***Surgery***Anticholinergic medications, ileus, prostatic hypertrophy, urinary retention***Closed-angle glaucoma, increased intraocular pressure***Contact lenses***Agranulocytosis, leukopenia***Hyperthyroidism, hypothyroidism***Diabetes mellitus, pheochromocytoma***Radiographic contrast administration***Sunlight (UV) exposure***Abrupt discontinuation***Geriatric***Neonates, pregnancy***Breast-feeding***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fenoldopam mesylate,"***For the in-hospital, short-term (up to 48 hours in adult patients and up to 4 hours in pediatric patients) treatment of severe hypertension (e.g., hypertensive urgency or hypertensive emergency) when rapid, but quickly reversible, emergency reduction in blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function:.***For the management of postoperative hypertension�.","***Bleeding, cerebrovascular disease, hypotension, increased intracranial pressure, intracranial bleeding, stroke***Angina, cardiac disease, coronary artery disease, heart failure, hepatic disease, tachycardia***Cardiac arrhythmias, hypokalemia***Glaucoma, increased intraocular pressure***Geriatric***Pregnancy***Breast-feeding***Children, infants***Sulfite hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hypromellose,***For the temporary relief of xerophthalmia and minor ocular irritation.,"***Contact lenses***Corneal abrasion, ocular infection, ocular trauma, visual disturbance***Pregnancy***Children, infants, neonates***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albumin (human),"***For the treatment of shock due to hypovolemia. <br />        NOTE: Dosage should be based on patient response as indicated by blood pressure, degree of pulmonary congestion, and hematocrit.<br />     ***For adjunctive treatment of severe burns.***For the treatment of nephrosis in nephrotic syndrome.***For treatment of hypoproteinemia.***For adjunctive use with exchange transfusion in the treatment of hyperbilirubinemia and erythroblastosis fetalis.","***Albumin hypersensitivity***Anemia, heart failure, hypertension***Renal disease***Hypernatremia***Burns***Viral infection***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,rho(D) immune globulin (human),"***For Rh isoimmunization prophylaxis in Rh<sub>0</sub> [D]-negative patient and to ensure subsequent erythroblastosis fetalis prophylaxis in females with present and future pregnancies. <br />        NOTE: Never administer Rh0 [D] immune globulin to the neonate; administer to the mother only.<br />NOTE: The woman must not be sensitized to the Rh0 [D] antigen. The immune globulin is used to prevent the formation of anti-Rh0 [D] antibody.<br />NOTE: Rh0 [D] immune globulin prophylaxis for all obstetric indications is not indicated if either the father or the fetus is known to be Rh0 [D] negative. If the Rh status of the father and fetus are unknown, assume the fetus to be Rh0 [D] positive, and administer Rh0 [D] immune globulin to the mother.<br />NOTE: Passively acquired anti-Rh0 [D] may be detected in maternal or neonatal blood if antibody screening tests are performed after Rh0 [D] immune globulin administration. The presence of passively acquired anti-Rh0 [D] does not preclude further antepartum or postpartum prophylaxis with Rh0 [D] immune globulin. A woman who had a large fetomaternal hemorrhage late in pregnancy or after delivery may test Rh positive even though she is really Rh negative. Administer Rh0 [D] immune globulin if there is any doubt about the mother's Rh type. A screening test to detect fetal red blood cells may be helpful***For the suppression of Rh isoimmunization in Rh<sub>0</sub> [D]-negative patients who are exposed to Rh<sub>0</sub> [D]-positive red blood cells or Rh<sub>0</sub> [D]-positive blood products secondary to blood transfusion. <br />          NOTE: One prefilled syringe of HyperRHO S/D Full-Dose, of Rhophylac, or of RhoGAM has at least 1500 international units of Rh0 [D] antibody and will suppress the immunizing potential of 15 ml of Rh0 [D] positive packed red blood cells or the equivalent of 30 ml of whole blood. One 300 mcg vial of WinRho SDF has at least 1500 international units of Rh0 [D] antibody and will suppress the immunizing potential of 17 ml of Rh0 [D] positive packed red blood cells.<br />NOTE: The amount of incompatible blood transfusion should be determined by an approved assay such as the modified Kleihauer-Betke acid elution stain technique.<br />NOTE: Rh immunization can occur after exposure to less than 1 ml of Rh-positive red blood cells. <br />NOTE: Monitor patients by clinical and laboratory methods because of the risk for a hemolytic reaction.<br /***For the treatment of immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP) in non-splenectomized, Rh0 [D] antigen-positive patients. <br />        NOTE: Alternative treatments should be used in patients with hemoglobin concentrations less than 8 g/dl due to the risk of increasing the severity of anemia.<br />     ","***Anemia, hemolysis, hemolytic anemia, renal impairment, requires a specialized care setting***IgA deficiency***Anticoagulant therapy, coagulopathy, hemophilia, intramuscular administration, intravenous administration, thrombocytopenia, vitamin K deficiency***Agammaglobulinemia, hypogammaglobulinemia***Pregnancy***Children, infants, neonates***Breast-feeding***Diabetes mellitus***Geriatric, hepatitis, infection, leukemia, lymphoma, systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,doxylamine succinate,"***For the short-term treatment of insomnia (less than 2 weeks).***For the treatment of symptoms associated with allergic rhinitis, including rhinorrhea, sneezing, itching of the nose or throat, or itchy/watery eyes.","***Driving or operating machinery***Asthma, chronic obstructive pulmonary disease (COPD)***Bladder obstruction, cardiac disease, GI obstruction, ileus, peptic ulcer disease, prostatic hypertrophy, pyloric stenosis, urinary retention***Closed-angle glaucoma, contact lenses***Hepatic disease***Children, infants, neonates***Pregnancy***Breast-feeding***Anticholinergic medications, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10865'],ketorolac tromethamine,"***For the reduction of postoperative ocular inflammation and ocular pain following cataract ocular surgery or corneal refractive surgery .***For the reduction of postoperative ocular inflammation and ocular pain following cataract surgery.***For the reduction of ocular pain and burning/stinging following corneal refractive surgery.***For the treatment of ocular pruritus due seasonal allergic conjunctivitis.***For the short-term treatment of moderate pain or moderately severe pain that requires analgesia at the opioid level, including bone pain�, dental pain�, arthralgia�, and myalgia�.***For the short-term treatment of moderately severe pain.***For the short-term treatment of moderate pain.***For the treatment of acute, severe headache�, including migraine�.***Formoterol; Mometasone","***Limit duration of use***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, serious hypersensitivity reactions or anaphylaxis, urticaria***Bleeding, surgery***Alcoholism, chemotherapy, Crohn's disease, GI bleeding, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease, hypoalbuminemia, jaundice***Dehydration, diabetes mellitus, edema, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery bypass graft surgery (CABG), coronary artery disease, heart failure, hypertension, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Anemia, bone marrow suppression, hematological disease, immunosuppression, intracranial bleeding, neutropenia, thrombocytopenia***Keratitis, ocular disease, ocular surgery***Contact lenses***Epidural administration, intrathecal administration***Children, infants, neonates***Caesarean section, labor, obstetric delivery, pregnancy***Breast-feeding***Ocular exposure***Geriatric***Lactase deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['31805'],nilutamide,***For the treatment of metastatic prostate cancer in combination with orchiectomy.,"***Hepatic disease, hepatitis***Asian patients, pneumonitis, respiratory insufficiency***Visual disturbance***Alcoholism***Children***Breast-feeding***Females, pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10171'],silver sulfadiazine,***For the prevention and treatment of burn wound infection due to susceptible organisms in patients with second- and third-degree burns.,"***Sulfonamide hypersensitivity***Hepatic disease***Renal disease, renal impairment***Hematological disease, leukopenia, thrombocytopenia***Intramuscular injections***G6PD deficiency***Porphyria***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,phenytoin sodium,"***For the treatment of status epilepticus.***For the treatment of tonic-clonic seizures or partial seizures.***For maintenance dosing to treat tonic-clonic or complex partial seizures.***For non-emergent treatment to increase phenytoin serum concentrations in a patient currently receiving phenytoin, but who has subtherapeutic serum concentrations; or to initiate phenytoin therapy for seizures in non-emergent situations.***For seizure prophylaxis due to specific neurologic conditions, including neurosurgery, head trauma� or traumatic brain injury�, or subarachnoid hemorrhage�.***For seizure prophylaxis following traumatic brain injury� or head trauma� or for seizure prophylaxis or treatment during neurosurgery.***For the treatment of serious cardiac arrhythmias secondary to digoxin toxicity�.***For seizure prophylaxis� during antenatal care in pregnant females with eclampsia� or severe preeclampsia�.","***Barbiturate hypersensitivity, carbamazepine hypersensitivity, hydantoin hypersensitivity, succinimide hypersensitivity***Asian patients, serious rash***Depression, suicidal ideation***Abrupt discontinuation***Hypoglycemia, hyponatremia, petit mal (absence) seizures***Hepatic disease, hepatotoxicity, hypoalbuminemia, jaundice***Agranulocytosis, bone marrow suppression, hematological disease, porphyria***Hodgkin's disease, lymphoma***Adams-Stokes syndrome, AV block, bradycardia, bundle-branch block, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypotension, infusion-related reactions, intravenous administration***Intramuscular administration***Alcoholism, ethanol ingestion, ethanol intoxication***Driving or operating machinery, encephalopathy, psychosis***Renal disease, renal failure, renal impairment***Diabetes mellitus***Hypothyroidism, thyroid disease***Bone fractures, osteomalacia, osteoporosis***Myasthenia gravis***Dental disease***Extravasation***Geriatric***Neonates, obstetric delivery, pregnancy, vitamin K deficiency***Breast-feeding***Contraception requirements, reproductive risk***Radiation therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clemastine fumarate,"***For the treatment of symptoms associated with the common cold or allergic rhinitis including sneezing, rhinorrhea, itching of the nose or throat, and itchy, watery eyes (ocular pruritus).***For the relief of mild uncomplicated allergic skin manifestations (e.g., pruritus) of urticaria and angioedema.","***Asthma, chronic obstructive pulmonary disease (COPD)***Children, infants, neonates***Pregnancy***Breast-feeding***Closed-angle glaucoma, contact lenses***Bladder obstruction, GI obstruction, ileus, prostatic hypertrophy, urinary retention***Hepatic disease***Cardiac disease***Driving or operating machinery***Anticholinergic medications, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dexamethasone sodium phosphate,"***For the treatment of adrenocortical function abnormalities, such as adrenocortical insufficiency, congenital adrenal hyperplasia, chronic primary (Addison's disease) or secondary adrenocortical insufficiency, or adrenogenital syndrome.***For hypothalamic-pituitary-adrenal (HPA) suppression diagnosis (e.g., dexamethasone suppression tests).***For use as a test for Cushing's syndrome.***For use as a test to distinguish Cushing's syndrome secondary to pituitary ACTH excess from Cushing's syndrome secondary to other causes.***For the treatment of allergic conditions, such as acute anaphylaxis, anaphylactoid reactions, anaphylactic shock, angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, or serum sickness reactions.***For acute anaphylaxis or anaphylactoid reactions.***For anaphylactic shock.***For the systemic treatment of other allergic disorders including angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, or serum sickness.***For the treatment of cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.***For treatment of cerebral edema in pediatric patients.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of kidney transplant rejection in conjunction with other immunosuppressants or for the treatment of acute graft-versus-host disease (GVHD).***For the reduction of edema and inflammation associated with selected cases of otitis externa.***For the treatment of pruritus and inflammatory effects of corticosteroid-responsive dermatologic disorders, including dermatitis, alopecia areata, atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis (including Rhus dermatitis due to poison ivy, poison oak, poison sumac), discoid lupus erythematosus, eczema, exfoliative dermatitis, granuloma annulare, keloids, lichen planus, lichen simplex chronicus or neurodermatitis, necrobiosis lipoidica diabeticorum, pemphigus, polymorphous light eruption, plaque psoriasis, cutaneous T-cell lymphoma (CTCL) or mycosis fungoides, severe seborrheic dermatitis, urticaria, and severe erythema multiforme or Stevens-Johnson syndrome.***For systemic treatment of inflammatory and allergic dermatoses (e.g., severe dermatitis, psoriasis, or exfoliative dermatitis, erythema multiforme, or Stevens-Johnson syndrome).***For intralesional or soft-tissue treatment of specific corticosteroid-responsive skin or soft-tissue lesions.***For adjunctive therapy in the treatment of rheumatic disorders including acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, synovitis of osteoarthritis, and for psoriatic arthritis; or for the treatment of acute episodes or exacerbation of nonrheumatic inflammatory conditions including acute and subacute bursitis, epicondylitis, acute non-specific tenosynovitis, and cystic tumors of an aponeurosis tendon (ganglia).***For the treatment of hematologic disorders such as secondary thrombocytopenia in adults, autoimmune hemolytic anemia, erythroblastopenia, congenital hypoplastic anemia, and thrombocytopenia associated with immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of acute asthma� exacerbation.***For the treatment of hypercalcemia related to sarcoidosis or cancer, or for the treatment of nonsuppurative thyroiditis, or for severe cases of myasthenia gravis not controlled by antimyasthenic agents alone.***For the treatment of hypercalcemia related to cancer or for the treatment of nonsuppurative thyroiditis in pediatric patients.***For the treatment of nephrotic syndrome to induce diuresis or decrease proteinuria.***For the treatment of Hodgkin lymphoma.***For the treatment of non-Hodgkin's lymphoma (NHL).***For the palliative treatment of NHL.***For the treatment of relapsed or refractory, aggressive NHL in transplant eligible patients, in combination with gemcitabine and cisplatin (and rituximab for CD20-positive disease)�.***For the treatment of relapsed or refractory diffuse large B-cell lymphoma in transplant eligible patients, in combination with cisplatin and cytarabine (DHAP regimen) and ofatumumab�.***For the treatment of acute lymphocytic leukemia (ALL).***For the treatment of multiple myeloma.***For the treatment of multiple myeloma in patients who have received at least 1 prior therapy, in combination with lenalidomide.***For the treatment of patients with newly diagnosed multiple myeloma, in combination with lenalidomide.***For newly diagnosed multiple myeloma as induction therapy prior to autologous stem-cell transplantation, in combination with doxorubicin and vincristine�.***For newly diagnosed multiple myeloma, in combination with thalidomide.***For newly diagnosed multiple myeloma as induction therapy prior to autologous stem-cell transplantation, in combination with bortezomib�.***For newly diagnosed multiple myeloma as induction therapy prior to autologous stem-cell transplantation, in combination with bortezomib and thalidomide�.***For the treatment of multiple myeloma in patients who have received at least 2 prior therapies (including bortezomib and an immunomodulatory agent), in combination with panobinostat and bortezomib.***For the treatment of relapsed multiple myeloma in patients who have received 1 to 3 prior lines of therapy, in combination with carfilzomib and lenalidomide.***For the treatment multiple myeloma in patients who have received at least 1 prior therapy, in combination with daratumumab and bortezomib.***For the treatment of multiple myeloma in patients who have received at least 1 prior therapy, in combination with daratumumab and lenalidomide.***For the treatment of newly diagnosed multiple myeloma, in combination with bortezomib and lenalidomide�.***For the treatment of multiple myeloma in patients who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor, in combination with pomalidomide and daratumumab.***For the treatment of acute exacerbations of multiple sclerosis.***For the treatment of inflammatory bowel disease during critical periods of ulcerative colitis and regional enteritis (Crohn's disease).***For the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment inflammation of the globe, such as allergic conjunctivitis, eyelid acne rosacea, superficial punctate keratitis, herpes zoster ocular infection associated keratitis, iritis, cyclitis, vernal keratoconjunctivitis, selected infective viral conjunctivitis or postoperative ocular inflammation when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal abrasion, corneal ulcer, or corneal injury from chemical or thermal burns, or penetration of foreign bodies; systemic treatment may be indicated for uveitis, sympathetic ophthalmia, and ocular inflammatory conditions unresponsive to topical corticosteroids.***For the treatment of non-infectious uveitis affecting the posterior segment of the eye in adults.***For the treatment of diabetic macular edema.***For the treatment of macular edema following retinal vein occlusion, including branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).***For the prevention of extubation failure in pediatric patients at increased risk for laryngeal edema (i.e., laryngeal edema prophylaxis�).***For use as an adjunct in the management of extradural malignant spinal cord compression� (MSCC�) associated with metastatic disease.***For the adjunctive treatment of bacterial meningitis� (non-tuberculous).***For the treatment of chemotherapy-induced nausea/vomiting� (CINV�) and for chemotherapy-induced nausea/vomiting prophylaxis�.***For the treatment of respiratory conditions including aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), Loeffler's syndrome, or noncardiogenic pulmonary edema�.***For the treatment of acute respiratory distress syndrome (ARDS)�.***For the treatment of laryngotracheobronchitis (croup)�.***For hyaline membrane disease prophylaxis�, for the purpose of fetal lung maturation to prophylax against anticipated neonatal respiratory distress syndrome (RDS)� in premature infants.***For the prevention of chronic lung disease (CLD)� in mechanically ventilated neonates.***For therapy in selected cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis�, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, symptomatic sarcoidosis, vasculitis�, or Wegener's granulomatosis�; also for the treatment of neurologic or myocardial involvement associated with trichinosis.***For the treatment of acute altitude sickness�, including the treatment of high altitude cerebral edema.***For altitude sickness prophylaxis<strong>***For the adjunctive treatment of infertility� in combination with clomiphene therapy.***For the treatment of post-operative nausea/vomiting (PONV)�.***For post-operative nausea/vomiting (PONV) prophylaxis�.***For the treatment of bronchiolitis�.***For the treatment of Waldenstrom macroglobulinemia�.***For the treatment of newly diagnosed Waldenstrom macroglobulinemia, in combination with rituximab and cyclophosphamide�.***For the treatment of newly diagnosed Waldenstrom macroglobulinemia, in combination with bortezomib and rituximab�.***For the treatment of amyloidosis�.***For the treatment of systemic amyloid light-chain amyloidosis, in combination with lenalidomide and cyclophosphamide�.***For the treatment of systemic amyloid light-chain amyloidosis, in combination with lenalidomide and melphalan�.","***Epidural administration***Abrupt discontinuation, corneal abrasion, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, growth inhibition, increased intracranial pressure***Immunosuppression***Surgery***Acne rosacea, acne vulgaris, fungal infection, herpes infection, herpes simplex keratitis (dendritic keratitis), infection, measles, ocular infection, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Myocardial infarction***Heart failure, hypertension***Osteoporosis***Diabetes mellitus***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hypothyroidism, psychosis, renal disease, seizure disorder***Myasthenia gravis***Coagulopathy, thromboembolic disease***Cataracts, glaucoma, increased intraocular pressure, myopia, ocular exposure, open-angle glaucoma, rupture of posterior ocular lens capsule, visual disturbance***Pregnancy***Neonates, premature neonates***Breast-feeding***Vaccination***Asthma, benzyl alcohol hypersensitivity, sulfite hypersensitivity***Corticosteroid hypersensitivity***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,meclofenamate sodium,"***For the treatment of dysmenorrhea.***For the treatment of mild pain and moderate pain.***For the treatment of rheumatoid arthritis or osteoarthritis. <br />        NOTE: Several weeks of treatment may be needed for optimal effect.<br />     ***For the treatment of headache�, including migraine�.***For headache.***For migraine.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, intracranial bleeding, neutropenia, surgery, thrombocytopenia***Anemia***Hepatic disease, hypoalbuminemia, jaundice***Dehydration, diabetes mellitus, hypovolemia, renal failure, renal impairment, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, hypertension, myocardial infarction, peripheral vascular disease, renal disease, stroke, tachycardia, thromboembolism***Edema, heart failure***Coronary artery bypass graft surgery (CABG)***Intramuscular injections***Children, infants, neonates***Labor, obstetric delivery, pregnancy***Breast-feeding***Females***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6064'],isotretinoin,"***For the treatment of severe recalcitrant cystic acne vulgaris (nodular acne).***For the treatment of keratinization disorders including keratosis follicularis�, lamellar ichthyosis�, and pityriasis rubra pilaris�.***For the treatment of juvenile chronic myelogenous leukemia (CML)�.***For the treatment of newly diagnosed, high-risk neuroblastoma� following autologous bone marrow transplantation.***For the treatment of recurrent cervical cancer, in combination with interferon alfa�.***For the adjuvant treatment of advanced squamous cell head and neck cancer�, in combination with interferon alfa and vitamin E.***For the adjuvant treatment of aggressive squamous cell skin carcinoma�, in combination with interferon alfa.***Formoterol; Mometasone","***Paraben hypersensitivity, retinoid hypersensitivity***Pregnancy, reproductive risk***Blood donation***Breast-feeding***Anorexia nervosa, children, corticosteroid therapy, hyperostosis, infants, neonates, osteomalacia, osteoporosis***Alcoholism, diabetes mellitus, hepatic disease, hepatitis, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, obesity, pancreatitis***Inflammatory bowel disease***Depression, psychosis, suicidal ideation***Contact lenses, driving or operating machinery, papilledema, visual disturbance***Hearing impairment***Sunlight (UV) exposure***Agranulocytosis, leukopenia, neutropenia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['72937'],tolcapone,***For use as adjunctive treatment to levodopa and carbidopa for the treatment of signs and symptoms of idiopathic Parkinson's disease. <br />        NOTE: Tolcapone therapy should not be initiated if the patient exhibits clinical evidence of liver disease or 2 separate liver enzyme values greater than the upper limit of normal. Tolcapone should be discontinued if liver enzymes exceed 2 times the upper limit of normal or if clinical signs and symptoms suggest hepatic dysfunction. Patients must provide written and informed consent prior to beginning therapy with tolcapone.<br />     ,"***General Information***Abrupt discontinuation, dyskinesia, rhabdomyolysis***Hepatic disease, hepatotoxicity***Orthostatic hypotension, syncope***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Impulse control symptoms***Hematuria***Behavioral changes, psychosis***Diarrhea***Renal impairment***Melanoma***Pregnancy***Abrupt discontinuation***Breast-feeding***Geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,salicylic acid,"***For the treatment of verruca vulgaris, verruca plantaris, and hyperkeratotic lesions (e.g., corns and calluses).***For the treatment of ichthyosis (i.e., vulgaris, sex-linked and lamellar), keratosis (i.e., palmaris, plantaris, and pilaris) and pityriasis rubra pilaris.***For the treatment of psoriasis.***For the treatment of psoriasis involving the body.***For the treatment of scalp psoriasis.***For the treatment of seborrheic dermatitis.***For the treatment of acne vulgaris.","***Salicylate hypersensitivity***Diabetes mellitus, peripheral vascular disease***Children, hepatic disease, renal impairment***Influenza, varicella***Accidental exposure, ocular exposure***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,maprotiline hydrochloride,***For the treatment of depression.***Formoterol***Formoterol; Mometasone,"***Tricyclic antidepressant hypersensitivity***Bipolar disorder, mania***Children, suicidal ideation***MAOI therapy***Electroconvulsive therapy (ECT), seizure disorder, seizures***Acute myocardial infarction, AV block, bradycardia, bundle-branch block, cardiac arrhythmias, cardiac disease, coronary artery disease, females, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Prostatic hypertrophy, urinary retention***Closed-angle glaucoma, contact lenses, increased intraocular pressure***Agranulocytosis, neutropenia***Hypothyroidism***Hepatic disease, poor metabolizers***Driving or operating machinery, ethanol ingestion***Surgery***Radiographic contrast administration***Sunlight (UV) exposure***Abrupt discontinuation***Anticholinergic medications, geriatric***Neonates, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,testosterone cypionate,***For the treatment of delayed puberty in males.***For palliative treatment of breast cancer that is inoperable in women.***For the treatment of postpubertal cryptorchidism�.***For the treatment of microphallus�.***For the treatment of anemia� in patients with chronic renal failure.***For female-to-male gender change (trans-sexualism�).***For the treatment of lichen sclerosus�.***For the treatment of AIDS-associated wasting syndrome�.,"***Benzoic acid hypersensitivity, benzyl alcohol hypersensitivity, polyoxyethylated castor oil hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis, soya lecithin hypersensitivity***Magnetic resonance imaging (MRI)***Intramuscular administration, intravenous administration***Breast cancer, geriatric, prostate cancer, prostatic hypertrophy***Cardiac disease, coronary artery disease, heart failure, hepatic disease, myocardial infarction, renal disease, stroke***Obesity, pulmonary disease***Polycythemia***Accidental exposure, females***Contraception requirements, labor, obstetric delivery, pregnancy, reproductive risk***Breast-feeding***Diabetes mellitus***Hypercalcemia***Pulmonary oil microembolism***Nasal polyps, nasal septal perforation, nasal surgery, nasal trauma, rhinorrhea, Sjogren's syndrome***Children, infants, neonates***Substance abuse***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['8782', '196459']",propofol,"***For general anesthesia induction.***For cardiac anesthesia.***For neurosurgical anesthesia.***For general anesthesia maintenance.***For cardiac anesthesia.***For neurosurgical anesthesia.***For intensive care sedation induction and sedation maintenance of mechanically ventilated patients.***For monitored anesthesia care sedation.***For initiation of monitored anesthesia care sedation.***For maintenance of monitored anesthesia care sedation.***For the treatment of refractory status epilepticus�.***For the treatment of refractory migraine�. <br />        NOTE: Due to the anesthetic doses required, propofol should only be administered by an anesthetic care team.<br />     ***For post-operative nausea/vomiting (PONV) prophylaxis�. <br />        NOTE: The antiemetic effect of propofol is greatest during the infusion with an increased risk of nausea and vomiting after drug administration cessation.<br />NOTE: Prevention of nausea and vomiting appears to be associated with a plasma propofol concentration between 280 and 530 ng/mL***For the treatment of agitation� associated with alcohol withdrawal.***For procedural sedation�.","***General Information***Asthma, benzyl alcohol hypersensitivity, egg hypersensitivity, soya lecithin hypersensitivity, sulfite hypersensitivity***Extravasation***Sepsis***Cardiac disease, dehydration, heart failure, hypotension, hypovolemia, obesity, pulmonary disease***Hyperlipidemia, hyperlipoproteinemia, pancreatitis***Geriatric***Cerebrovascular disease, electroconvulsive therapy (ECT), increased intracranial pressure, seizure disorder, seizures***Brain tumor, children, head trauma, infants, neonates, stroke***Labor, obstetric delivery, pregnancy***Breast-feeding***Abrupt discontinuation***Burns, diarrhea***Driving or operating machinery***Renal disease, renal failure, renal impairment***Requires a specialized care setting, requires an experienced clinician***Substance abuse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['26237'],granisetron,"***For chemotherapy-induced nausea/vomiting (CINV) and chemotherapy-induced nausea/vomiting prophylaxis.***For chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days.***For acute and delayed chemotherapy induced nausea/vomiting (CINV) prophylaxis associated with moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide chemotherapy regimens, in combination with other antiemetics.***For chemotherapy-induced nausea/vomiting (CINV) prophylaxis, including for high-dose cisplatin.***For chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving highly emetogenic chemotherapy (HEC), in combination with fosaprepitant and dexamethasone�.***For radiation-induced nausea/vomiting prophylaxis.***For the treatment of post-operative nausea/vomiting (PONV)�.***For post-operative nausea/vomiting (PONV) prophylaxis�.***Formoterol***Formoterol; Mometasone","***Dolasetron hypersensitivity, granisetron hypersensitivity, ondansetron hypersensitivity, palonosetron hypersensitivity***Benzyl alcohol hypersensitivity, neonates***Constipation, GI obstruction, ileus, surgery***Sunlight (UV) exposure***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Bipolar disorder, depression, pain***Heating pad***Anticoagulant therapy, bleeding***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,doxazosin mesylate,***For treatment of hypertension.***For the treatment of benign prostatic hyperplasia (BPH).***For treatment of BPH in combination with finasteride.,"***General Information***Hypotension, orthostatic hypotension, syncope***Hepatic disease***Pregnancy***Breast-feeding***Ocular surgery***Priapism***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/levonorgestrel,"***For routine contraception.***For extended continuous routine contraception.***For use as postcoital contraception within 72 hours of unprotected intercourse, or known or suspected contraceptive failure, in females who have no known contraindications to oral contraceptives, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clindamycin phosphate,"***For the treatment of serious infections such as bacteremia.***For the treatment of lower respiratory tract infections (e.g., pleural empyema, anaerobic pneumonia, aspiration pneumonia, community-acquired pneumonia, and lung abscess) due to susceptible organisms<strong>***For the treatment of intraabdominal infections, including intraabdominal abscess and peritonitis.***For the treatment of peritonitis in patients receiving peritoneal dialysis.***For the treatment of skin and skin structure infections, including impetigo, ecthyma, cellulitis, erysipelas, infectious neonatal pustulosis, bite wounds, and complicated skin and skin structure infections such as necrotizing infections, gas gangrene, and diabetic foot ulcer.***For the treatment of impetigo or ecthyma.***For the treatment of necrotizing infections of the skin, fascia, and muscle (i.e. gas gangrene).***For the treatment of animal bite wounds.***For the treatment of diabetic foot ulcer.***For the treatment of gynecologic infections, including endometritis and pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of acute pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of bacterial vaginosis.***For the treatment of acne vulgaris.***For the treatment of bone and joint infections, including osteomyelitis and septic/infectious arthritis, or an orthopedic device-related infection�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated prosthetic joint infections�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated spinal implant infections�.***For the treatment of of uncomplicated acute otitis media�.***For the treatment of acute bacterial sinusitis�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis� in combination with conventional treatment (e.g., scaling and root planing) as well as acute dental abscess (apical)� and/or dental abscess (periapical)�.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage in patients with beta-lactam allergy.***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis� (rheumatic fever prophylaxis�) and for bacterial colonization eradication� in chronic carriers of group A beta-hemolytic <em>Streptococci</em> (GAS)�.***For the treatment of chronic pharyngeal carriers of group A streptococci (i.e., bacterial colonization eradication�).***For surgical infection prophylaxis�.***For bacterial endocarditis prophylaxis�.***For the treatment of anthrax�.***For the treatment of cutaneous anthrax infection.***For the treatment of systemic anthrax infection.***For anthrax prophylaxis� after exposure to Bacillus anthracis (postexposure prophylaxis, PEP).***For the treatment of toxoplasmosis�, including toxoplasmic encephalitis�.***For secondary toxoplasmosis prophylaxis� in HIV-infected patients intolerant of sulfa drugs.***For the treatment of Pneumocystis pneumonia (PCP)� in HIV-infected patients.***For the treatment of malaria� due <em>Plasmodium falciparum</em>.***For the treatment of babesiosis�.***For perinatal Group B streptococcal bacterial infection prophylaxis� in patients allergic to penicillin and cephalosporins.***Formoterol; Mometasone","***Asthma, atopy, clindamycin hypersensitivity, lincomycin hypersensitivity, serious rash, tartrazine dye hypersensitivity***Fungal infection***Diarrhea, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Neonates***Hepatic disease***Pregnancy***Breast-feeding***Ocular exposure***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7417'],nifedipine,"***For the treatment of ischemic heart disease including variant angina (Prinzmetal's angina) and chronic stable angina pectoris.***For the treatment of hypertension.***For acute hypertensive episodes including hypertensive urgency and hypertensive emergency in pediatric patients�. <br />          NOTE: Per the FDA and manufacturers, immediate-release nifedipine dosage forms should not be used to treat hypertension and should only be used to treat patients with chronic stable angina or vasospastic angina. The immediate-release nifedipine formulation has been associated with serious side effects (see Precautions and Adverse Reactions) when used to treat adult patients with hypertension, hypertensive urgency, hypertensive emergency, or coexisting myocardial infarction. Although the use of immediate-release nifedipine for the treatment of acute hypertensive episodes is still relatively common practice in pediatric patients, considerable controversy exists and caution should be used.<br />       ***For migraine prophylaxis�.***For the treatment of proteinuria� associated with diabetic nephropathy�.***For the treatment of persistent singultus (hiccups)�.***For the inhibition of uterine contractions in premature labor�. <br />        NOTE: Clinical practice guidelines recommend the use of a first line tocolytic (i.e., beta agonist, calcium channel blocker, or NSAID) for short-term use (up to 48 hours) to allow for administration of antenatal corticosteroids to enhance fetal lung maturation, magnesium sulfate for fetal neuroprotection, or transport to a tertiary facility, if indicated. There is no evidence that tocolytic therapy alone has any favorable effect on neonatal outcomes. Maintenance therapy with tocolytics is ineffective for preventing preterm birth and improving neonatal outcomes and is not recommended.<br />     ***For the treatment of achalasia�.***For the treatment of high altitude pulmonary edema associated with altitude sickness�.***For altitude sickness prophylaxis<strong>","***General Information***Dihydropyridine hypersensitivity***Pregnancy***Breast-feeding***Acute myocardial infarction, bradycardia, cardiogenic shock, coronary artery disease, heart failure, hypotension, ventricular dysfunction***Geriatric***Aortic stenosis***Colostomy, constipation, diabetes mellitus, diverticulitis, esophageal stricture, gastric cancer, gastroesophageal reflux disease (GERD), GI obstruction, hiatal hernia, hypothyroidism, ileus, inflammatory bowel disease, obesity***Children, infants***Hepatic disease***Lactase deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hyoscyamine sulfate/methenamine/methylene blue/sodium phosphate monobasic,"***For the relief of discomfort associated with lower urinary tract infection (UTI) or diagnostic procedures by producing urinary acidification, reducing bacteriuria, and reducing spasmodic activity.***Formaldehyde hypersensitivit***Formoterol; Mometasone","***General Information***Formaldehyde hypersensitivity***Bladder obstruction, cardiac arrhythmias, coronary artery disease, geriatric, GI obstruction, glaucoma, heart failure, ileus, mitral stenosis, myasthenia gravis, prostatic hypertrophy, urinary retention, urinary tract obstruction***Anuria, dehydration, hepatic disease, oliguria, renal failure, renal impairment***Children, infants, neonates***Eclampsia, pregnancy***Breast-feeding***Edema, hypernatremia, hyperphosphatemia, hypertension, sodium restriction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ipratropium bromide,"***For the treatment of acute bronchospasm� (e.g., asthma exacerbation).***For the symptomatic relief of rhinorrhea associated with seasonal allergic rhinitis or nonallergic rhinitis (e.g., common cold).***For the maintenance treatment and prevention of bronchospasm (e.g., bronchospasm prophylaxis) associated with asthma and chronic obstructive pulmonary disease (COPD) (e.g., emphysema or chronic bronchitis).***For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), such as emphysema or chronic bronchitis.***For the maintenance treatment of bronchospasm associated with asthma� in pediatric patients.***For adjunctive exercise-induced bronchospasm prophylaxis�.","***General Information***Acute bronchospasm, bromide hypersensitivity, paradoxical bronchospasm***Closed-angle glaucoma, contact lenses, ocular exposure, ophthalmic administration***Bladder obstruction, prostatic hypertrophy, urinary retention***Cardiac arrhythmias***Driving or operating machinery***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,codeine phosphate/guaifenesin,"***For the temporary relief of nonproductive cough due to minor throat and bronchial irritation as may occur with the common cold, acute bronchitis, or inhaled irritants. <br />        NOTE: Many liquid formulations contain 3% to 5% alcohol.<br />     ","***General Information***Asthma, bronchitis, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, emphysema, fever, headache, respiratory depression, tobacco smoking***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Hepatic disease***Renal failure, renal impairment***Driving or operating machinery***Abrupt discontinuation***Opiate agonist hypersensitivity***Cardiac arrhythmias, cardiac disease, heart failure, hypovolemia, orthostatic hypotension***Adenoidectomy, children, infants, neonates, neuromuscular disease, obesity, pulmonary disease, respiratory infection, sleep apnea, tonsillectomy***Bladder obstruction, prostatic hypertrophy, urethral stricture, urinary retention***Constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Breast-feeding***Substance abuse***Head trauma, increased intracranial pressure***Surgery***Geriatric***Asian patients, Black patients, Caucasian patients, Hispanic patients***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clemastine fumarate,"***For the treatment of symptoms associated with the common cold or allergic rhinitis including sneezing, rhinorrhea, itching of the nose or throat, and itchy, watery eyes (ocular pruritus).***For the relief of mild uncomplicated allergic skin manifestations (e.g., pruritus) of urticaria and angioedema.","***Asthma, chronic obstructive pulmonary disease (COPD)***Children, infants, neonates***Pregnancy***Breast-feeding***Closed-angle glaucoma, contact lenses***Bladder obstruction, GI obstruction, ileus, prostatic hypertrophy, urinary retention***Hepatic disease***Cardiac disease***Driving or operating machinery***Anticholinergic medications, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,doxycycline calcium); (doxycycline hyclate); (doxycycline monohydrate,"***For the treatment of skin and skin structure infections, including cellulitis, due to <em>Staphylococcus aureus</em>. <br />        NOTE: Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infection.<br />     ***For the treatment of bacterial urinary tract infection (UTI).***For the treatment of upper respiratory tract infections (e.g., sinusitis).***For the treatment of lower respiratory tract infections (e.g., pneumonia, community-acquired pneumonia).***For the treatment of severe acne vulgaris as adjunctive therapy.***For the treatment of acne rosacea.***For the treatment of cholera.***For the treatment of brucellosis.***For the treatment of Rickettsial infections (e.g., Rickettsial pox, Rocky Mountain spotted fever, scrub typhus) including endemic murine typhus.***For the treatment of relapsing fever due to <em>Borrelia recurrentis</em>.***For the treatment of syphilis. <br />        NOTE: A Jarisch-Herxheimer reaction may occur within the first 24 hours of therapy.<br />NOTE: While clinical practice guidelines recommend non-penicillin alternatives for the treatment of syphilis in HIV-infected patients, their efficacy has not been evaluated and should only be used with close clinical and serologic monitoring***For primary, secondary, or early latent syphilis (caused by <em>Treponema pallidum</em>) in nonpregnant, penicillin-allergic patients.***For late latent syphilis in nonpregnant, penicillin-allergic patients.***For the treatment of psittacosis.***For the treatment of non-gonococcal urethritis (NGU) and chlamydia infection, including trachoma and inclusion bacterial conjunctivitis.***For the treatment of lymphogranuloma venereum caused by <em>Chlamydia trachomatis</em>.***For the treatment of granuloma inguinale (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of epididymitis and epididymo-orchitis.***For malaria prophylaxis in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains.***For the treatment of anthrax infection due to exposure to <em>Bacillus anthracis</em>.***For the treatment of cutaneous anthrax infection.***For the treatment of systemic anthrax infection.***For anthrax prophylaxis after exposure to <em>Bacillus anthracis</em> (postexposure prophylaxis, PEP).***For the treatment of plague infection due to exposure to <em>Yersinia pestis</em>.***For the treatment of plague infection in an individual patient or in a contained casualty setting.***For the treatment of plague infection in a mass casualty setting.***For the initial treatment of tularemia infection due to exposure to <em>Francisella tularensis </em>.***For the initial treatment of tularemia infection in individual patient or in a contained casualty setting. <br />          NOTE: Streptomycin is the drug of choice to treat tularemia in most patients; gentamicin is the preferred agent in pregnant women.<br />       ***For the initial treatment of tularemia infection in a mass casualty setting. <br />          NOTE: It is recommended that pregnant women be treated with ciprofloxacin as a first-line agent; doxycycline is a preferred treatment choice if ciprofloxacin is contraindicated.<br />       ***For the treatment of intestinal amebiasis as an adjunct to amebicides.***For the treatment of infections caused by sensitive organisms including actinomycosis (<em>Actinomyces israelii</em>), yaws (<em>Treponema pertenue</em>), necrotizing ulcerative gingivitis (Fusospirochetosis or Vincent's infection), and listeriosis (<em>Listeria monocytogenes</em>).***For the treatment of Q fever.***For the treatment of chancroid (<em>Haemophilus ducreyi</em>) infections.***For the treatment of bartonellosis (<em>Bartonella bacilliformis</em>) infections, including <em>Bartonella</em> endocarditis.***For the treatment of <em>Bartonella</em> sp. infections (bartonellosis) in HIV-infected patients.***For long term suppression� of infections caused by <em>Bartonella</em> sp. in HIV-infected patients with relapse or reinfection with CD4 count less than 200 cells/mm3.***For the treatment of enterocolitis�, biliary tract infections�, and intraabdominal infections�.***For the treatment of uncomplicated gonorrhea (e.g., cervicitis, urethritis, pharyngitis, proctitis�).***For the treatment of acute proctitis�.***For chlamydial infection prophylaxis� in victims of sexual assault.***For the treatment of chronic prostatitis� due to <em>Ureaplasma urealyticum</em>.***For the treatment of Lyme disease�, including erythema migrans�, Lyme arthritis�, Lyme carditis�, and Lyme meningitis�.***For early Lyme disease� (erythema migrans�).***For Lyme arthritis�.***For Lyme carditis�.***For early neurologic Lyme disease (i.e., Lyme meningitis� or cranial nerve palsy).***For Lyme disease prophylaxis�.***For the treatment of Legionnaire's disease� caused by <em>Legionella pneumophila</em>.***For the management of pleural effusion� as an alternative to injectable tetracycline or other agents.***For the treatment of malaria� due to <em>P. falciparum</em> or <em>P. vivax</em>.***For the treatment of pelvic inflammatory disease (PID)� and tubo-ovarian abscess�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis in combination with conventional treatment (e.g., scaling and root planing).***For aggressive juvenile periodontitis�.***For chronic adult periodontitis for a gain in clinical attachment, reduction in probing depth, and reduction in bleeding on probing.***For plague prophylaxis� following exposure to <em>Yersinia pestis</em>.***For tularemia prophylaxis� following exposure to <em>Francisella tularensis</em>.***For the treatment of Bancroft's filariasis� (elephantiasis) caused by <em>Wuchereria bancrofti</em>�.***For the treatment of melioidosis� due to <em>Burkholderia pseudomallei</em>.***For use as an adjunct in the treatment of <em>Burkholderia pseudomallei</em> bacteremia�.***For use as an adjunct in the treatment of localized melioidosis�.***For the treatment of leptospirosis� due to <em>Leptospira</em> sp.�.***For mild leptospirosis�.***For severe leptospirosis�.***For surgical infection prophylaxis� for gynecologic procedures.***For surgical infection prophylaxis� for hysterosalpingogram or chromotubation.***For surgical infection prophylaxis� for induced abortion/dilation and evacuation.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated bone and joint infections�, including osteomyelitis�, or orthopedic device-related infection�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated osteomyelitis�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated prosthetic device infections�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated spinal implant infections�.","***Tetracyclines hypersensitivity***Hepatic disease***Sunlight (UV) exposure***Asthma, sulfite hypersensitivity***Achlorhydria***Pregnancy***Breast-feeding***Children, infants, neonates***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Dental disease, periodontal disease***Chemotherapy, diabetes mellitus, human immunodeficiency virus (HIV) infection, immunosuppression***Antimicrobial resistance, fungal infection, viral infection***Increased intracranial pressure, obesity***Sexually transmitted disease***Geriatric***Serious rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['83171', '1546007']",cidofovir,"***For the treatment of cytomegalovirus (CMV) retinitis in HIV-infected patients.***For secondary cytomegalovirus (CMV) retinitis prophylaxis (chronic maintenance therapy) in HIV-infected patients after treatment of the acute CMV infection. <br />  NOTE: For patients who experience progression of CMV retinitis while receiving maintenance therapy, re-induction treatment with the same drug used for maintenance followed by reinstitution of maintenance therapy is recommended.<br />NOTE: The CDC does not recommend primary prophylaxis in HIV-infected patients, as end-organ disease is best prevented by using antiretroviral therapy to maintain CD4 counts greater than 100 cells/mm3***For the treatment of adenovirus infection� in patients following bone marrow or peripheral stem cell transplantation.***For the treatment of infections due to human papillomavirus (HPV) infection�.***For the treatment of condylomata acuminata� (genital warts).***For the treatment of laryngeal papillomatosis�.***For the treatment of molluscum contagiosum�.***For the treatment of acyclovir-resistant mucocutaneous herpes simplex virus infection�, including herpes genitalis�, in HIV-infected patients.***For the second-line treatment of serious adverse reactions related to vaccinia immunization [i.e., vaccinia necrosum (progressive vaccinia)�, generalized vaccinia�, or eczema vaccinatum� and some ocular vaccinia infections�]; or for inadvertent vaccinia inoculation with the vaccinia virus�. <br />        NOTE: Vaccinia immune globulin, VIG is the preferred treatment (see VIG monograph). Cidofovir is only available via the CDC under an investigational new drug (IND) protocol and by special request to the CDC Drug and Immunobiologics Service (404�639�3670). Cidofovir efficacy for this indication is not proven. Cidofovir is only used in vaccinia cases that fail to respond to VIG, as additional therapy in a patient severely ill (near death), or in the case that VIG supplies are exhausted.<br />NOTE: Therapy requires pre- and post infusion IV hydration and probenecid therapy given in accordance with the treatment IND","***General Information***Probenecid hypersensitivity, sulfonamide hypersensitivity***Foscarnet therapy, nephrotoxicity, proteinuria, renal disease, renal failure, renal impairment***Neutropenia***Dehydration, diarrhea***Diabetes mellitus, ocular exposure***Pregnancy***Infertility, male-mediated teratogenicity***Breast-feeding***Children, females, new primary malignancy***Geriatric***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5032'],guaifenesin,"***For the treatment of cough associated with colds and minor upper respiratory tract infections and for loosening phlegm and thin bronchial secretions to aid in clearing bronchial passages and making coughs more productive.***For the treatment of cervical factor infertility�, including cervical mucus thickening induced by clomiphene treatment.","***General Information***Asthma, bronchitis, emphysema, heart failure, tobacco smoking***Fever***Children, infants***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,levocarnitine,***For the treatment carnitine deficiency.***For the treatment of primary systemic carnitine deficiency or for acute and chronic treatment of patients with an inborn error of metabolism that results in secondary carnitine deficiency. <br />          NOTE: Levocarnitine is designated an an orphan drug by the FDA for this indication.<br />       ***For the treatment of carnitine deficiency in neonates receiving total parenteral nutrition�.***For the prevention and treatment of carnitine deficiency in patients with end stage renal impairment who are undergoing dialysis. <br />        NOTE: Levocarnitine is designated an an orphan drug by the FDA for this indication.<br />     ***For the treatment of Alzheimer's disease�.***For the prevention of left ventricular dilation after anterior acute myocardial infarction�.***For the treatment of type 2 diabetes mellitus�.***For the treatment of various cardiomyopathy� states.***For the treatment of adult patients with heart failure� attributable to dilated cardiomyopathy�.***For the treatment of childhood cardiomyopathy�. <br />          NOTE: Levocarnitine is designated an an orphan drug for this indication.<br />       ***For the treatment of hyperlipoproteinemia�.***For the improvement of ergogenesis� in healthy adults.***For the treatment of male infertility� due to poor sperm quality.***For the treatment and prevention of valproate-induced hepatotoxicity� due to secondary carnitine deficiency in children. <br />        NOTE: Levocarnitine is designated an an orphan drug by the FDA for this indication.<br />     ,"***Diarrhea***Pregnancy***Seizure disorder***Cardiac disease, dialysis, hypertension, ventricular arrhythmias***Peripheral neuropathy***Renal failure, renal impairment***Hepatic disease***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,verapamil hydrochloride,"***For the treatment of ischemic heart disease including variant angina (Prinzmetal's angina), unstable angina, and chronic stable angina.***For rapid conversion of narrow-complex paroxysmal supraventricular tachycardia (PSVT) (including those associated with accessory bypass tracts such as Wolff-Parkinson-White or Lown-Ganong-Levine) to sinus rhythm.***For paroxysmal supraventricular tachycardia (PSVT) prophylaxis due to re-entry.***For the treatment of atrial flutter or atrial fibrillation.***For the acute, temporary ventricular rate control in cases of atrial flutter or atrial fibrillation except when associated with Wolff-Parkinson-White or Lown-Ganong-Levine syndrome.***For ventricular rate control in patients with chronic atrial flutter and/or atrial fibrillation in combination with digoxin.***For ventricular rate control in patients with chronic atrial flutter or atrial fibrillation.***For the treatment of hypertension.***For migraine prophylaxis�.***For the treatment of acute mania�.***For the treatment of intermittent claudication� due to peripheral vascular disease (PVD)�.***For the relief of ongoing ischemia after acute myocardial infarction� in the absence of congestive heart failure, left ventricular dysfunction, or AV block, when beta-blockers are ineffective or contraindicated.","***General Information***Acute myocardial infarction, bradycardia, cardiogenic shock, heart failure, ventricular dysfunction***Lown-Ganong-Levine syndrome, ventricular tachycardia, Wolff-Parkinson-White syndrome***Hypotension***AV block, sick sinus syndrome***Hepatic disease, renal disease, renal failure, renal impairment***Cardiomyopathy***Aortic stenosis***Myasthenia gravis, neuromuscular disease***Constipation, fecal impaction, gastroesophageal reflux disease (GERD), GI obstruction, hiatal hernia, ileus***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,zolpidem tartrate,"***For the treatment of insomnia.***For the short-term treatment of insomnia characterized by difficulty with sleep initiation.***For insomnia characterized by difficulties with sleep onset and/or sleep maintenance.***For middle-of-the night awakening that is followed by difficulty returning to sleep.***For increasing awareness and responsiveness in patients with disorders of consciousness due to traumatic brain injury� (TBI�) or nontraumatic brain injury� (e.g., head trauma� or hypoxia, respectively).","***Angioedema***Depression, suicidal ideation***Behavioral changes, CNS depression, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion, females***Abrupt discontinuation, alcoholism, substance abuse***Encephalopathy, hepatic disease***Chronic obstructive pulmonary disease (COPD), myasthenia gravis, pulmonary disease, respiratory depression, sleep apnea***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['49247'],dofetilide,"***For use in the conversion of atrial fibrillation/atrial flutter to normal sinus rhythm; or, for maintenance therapy of patients with highly symptomatic atrial fibrillation/atrial flutter of 1 week or more duration. <br />  NOTE: Patients with atrial fibrillation (AF) should be anticoagulated according to usual medical practice prior to electrical or pharmacological cardioversion. Anticoagulant therapy may be continued after cardioversion according to medical guidelines for the treatment of patients with AF.<br />NOTE: Dofetilide is not effective in patients with paroxysmal atrial fibrillation***For maintenance therapy of atrial fibrillation/atrial flutter after hospital discharge.***Formoterol***Formoterol; Mometasone","***General Information***Requires a specialized care setting, requires an experienced clinician***Alcoholism, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Dialysis, renal disease, renal failure, renal impairment***Hepatic disease***AV block, bradycardia, sick sinus syndrome***Pregnancy***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,naltrexone hydrochloride,***For the maintenance treatment of alcohol dependence.***For relapse prevention following opioid detoxification in patients with opiate agonist dependence.***For the opiate agonist withdrawal induction� during detoxification. <br />        NOTE: Rapid and ultrarapid opiate detoxification should only be done in a controlled setting under the supervision of a physician experienced in the management of opiate withdrawal. Severe withdrawal symptoms and death have been reported in patients undergoing ultrarapid opiate detoxification.<br />     ***For rapid opiate detoxification�.***For ultrarapid opiate detoxification�.***For the treatment of pruritus�.***For uremic pruritus�.***For use as an adjunct to psychosocial interventions for tobacco cessation� (smoking cessation�).,"***General Information***Hepatic disease, hepatitis***Depression, suicidal ideation***Acute opioid withdrawal***Surgery***Respiratory depression***Potential for overdose or poisoning***Renal impairment***Pregnancy***Breast-feeding***Children, infants, neonates***Driving or operating machinery***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Females, intravenous administration, obesity, subcutaneous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3478'],dinoprostone,"***For evacuation of the uterine contents in the cases of missed abortion or intrauterine fetal death, second trimester pregnancy termination, or benign hydatidiform mole.***For cervical ripening induction in women at or near term with a medical or obstetrical need for labor induction.","***Incomplete abortion, labor, pregnancy, pregnancy testing***Angioedema, requires a specialized care setting, requires an experienced clinician, risk of serious hypersensitivity reactions or anaphylaxis***Amniotic fluid embolism***Disseminated intravascular coagulation (DIC), fibrinolysis***Anemia, asthma, cardiac disease, diabetes mellitus, glaucoma, hepatic disease, hypertension, hypotension, increased intraocular pressure, jaundice, pulmonary disease, renal disease, seizure disorder***Caesarean section, cephalopelvic disproportion, fetal distress, multiparity, premature rupture of membranes (PROM), surgery, uterine atony***Bleeding, cervicitis, herpes infection, infection, placenta previa, vaginal bleeding, vaginitis***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['42736'],dexrazoxane,***For anthracycline-induced cardiomyopathy prophylaxis. <br />        NOTE: Dexrazoxane has been designated an orphan drug by the FDA for the prevention of cardiomyopathy associated with doxorubicin administration.<br />     ***For patients receiving epirubicin chemotherapy�.***For the treatment of extravasation resulting from IV anthracycline chemotherapy.,"***Renal impairment***Bone marrow suppression***Hepatic disease***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10633'],tolazamide,"***For adjunctive therapy in the treatment of type 2 diabetes mellitus, where hyperglycemia cannot be controlled by diet and exercise alone. <br />  NOTE: Some patients with type 2 diabetes being treated with insulin can be switched successfully to tolazamide therapy. For patients being treated with &lt; 20 units of insulin per day, a starting dose of 100 mg PO of tolazamide once daily may be tried. For patients being treated with &gt; 40 units of insulin per day, the manufacturer recommends that the daily insulin dose be decreased 50% and tolazamide be initiated at a dose of 250 mg PO per day.<br /","***General Information***Sulfonylurea hypersensitivity***Sulfonamide hypersensitivity***Fever, infection, surgery, trauma***Diabetic ketoacidosis, thyroid disease, type 1 diabetes mellitus***Hepatic disease, renal disease, renal failure, renal impairment***Neonates, obstetric delivery, pregnancy***Breast-feeding***Children***Geriatric***G6PD deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5492'],hydrocortisone,"***For the treatment of primary adrenocortical insufficiency (e.g., Addison's Disease, congenital adrenal hyperplasia or CAH) or secondary adrenocortical insufficiency.***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing minor surgery or with a minor illness (e.g., inguinal hernia repair, colonoscopy, mild febrile illness, gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing moderate surgery or with a moderate illness (e.g., open cholecystectomy, hemicolectomy, significant febrile illness, pneumonia, severe gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing major surgery, or with other acute stressors (e.g., major cardiothoracic surgery, Whipple procedure, liver resection, pancreatitis, acute systemic infection, shock).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency and a critical illness (e.g., shock).***For the treatment of acute adrenocortical insufficiency.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency with other acute stressors (e.g., febrile illness with a temperature more than 38.5 degrees Celsius, gastroenteritis with dehydration, major trauma):.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency undergoing surgery accompanied by general anesthesia.***For use in nonspecific proctitis, postirradiation (factitial) proctitis, cryptitis, or for other non-specific inflammatory conditions of the anorectum.***For the treatment of inflammatory bowel disease (Crohn's disease or ulcerative colitis).***For adjunctive treatment of Crohn's disease or ulcerative colitis using oral or parenteral therapy.***For adjunctive rectal treatment of chronic ulcerative colitis, particularly if disease limited to the distal portion of the rectum.***For the relief of inflammation, pruritus ani, and swelling associated with hemorrhoids.***For the treatment of allergic disorders including anaphylaxis, anaphylactic shock, or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, transfusion-related reactions, serum sickness, severe perennial or seasonal allergic rhinitis, or urticaria.***For the non-emergent treatment of hypersensitivity or allergic conditions.***For the urgent treatment of severe conditions such as anaphylaxis, angioedema, acute noninfectious laryngeal edema, or urticarial transfusion-related reactions.***For the treatment of corticosteroid-responsive dermatologic disorders (e.g., alopecia areata, atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis including Rhus dermatitis due to poison ivy, poison oak, poison sumac, discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pompholyx (dyshidrosis), pruritus, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, xerosis).***For mild-to-moderate corticosteroid responsive dermatoses.***For mild to moderate atopic dermatitis.***For the systemic treatment of severe inflammatory dermatoses, like severe exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, or psoriasis unresponsive to topical treatment.***For adjunctive therapy in the treatment of rheumatic disorders including acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of non-rheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the short-term treatment of hypercalcemia associated with neoplastic disease.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the management of nephrotic syndrome to induce diuresis or decrease proteinuria.***For the treatment of neurologic or myocardial involvement associated with trichinosis.***For the treatment of nonsuppurative thyroiditis.***For rheumatic and related disorders such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, symptomatic sarcoidosis, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive hematologic disorders, like immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia, and congenital hypoplastic anemia; OR for the palliative treatment of neoplastic disease in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), or multiple myeloma�.***For the treatment of respiratory inflammatory conditions including bronchial asthma, aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), Loeffler's syndrome, or noncardiogenic pulmonary edema�.***For the treatment of septic shock� and/or hypotension� in patients whose blood pressure is poorly responsive to adequate fluid resuscitation and vasopressor therapy.***For the prevention of chronic lung disease (CLD)� in mechanically ventilated patients.***For the treatment of refractory neonatal hypoglycemia�.***For the treatment of corticosteroid-responsive ophthalmic disorders, including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.","***Abrupt discontinuation, Cushing's syndrome, skin abrasion***Growth inhibition, increased intracranial pressure***Immunosuppression***Fungal infection, infection***Acne rosacea, acne vulgaris, herpes infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Heart failure, hypertension***Osteoporosis***Diabetes mellitus***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hypothyroidism, psychosis, renal disease, seizure disorder***Myasthenia gravis***Coagulopathy, hemophilia, thromboembolic disease***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Neonates, premature neonates***Benzyl alcohol hypersensitivity, corticosteroid hypersensitivity***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Skin atrophy***Geriatric***Epidural administration, intrathecal administration***Pheochromocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hyoscyamine sulfate/methenamine/methylene blue/phenyl salicylate/sodium phosphate monobasic,"***For the treatment of symptoms of irritative voiding including for the relief of local urinary symptoms such as inflammation, hypermotility, and mild pain, which accompany lower urinary tract infection (UTI); also for the relief of urinary tract symptoms caused by diagnostic procedures.***Formoterol; Mometasone","***General Information***Salicylate hypersensitivity***Cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, mitral stenosis***GI obstruction***Glaucoma***Myasthenia gravis***Prostatic hypertrophy, urinary retention, urinary tract obstruction***Dehydration, renal disease, renal failure, renal impairment***Hepatic disease***MAOI therapy***Children, infants, neonates***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4821'],glipizide,***For the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.,"***General Information***Sulfonylurea hypersensitivity***Sulfonamide hypersensitivity***Diabetic ketoacidosis, type 1 diabetes mellitus***Burns, fever, infection, surgery, trauma***Adrenal insufficiency, diarrhea, GI obstruction, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypothyroidism, ileus, malnutrition, pituitary insufficiency, vomiting***Hepatic disease, porphyria, renal failure, renal impairment***G6PD deficiency, hemolytic anemia***Geriatric***Neonates, obstetric delivery, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,midazolam hydrochloride,"***For procedural sedation and amnesia induction.***For sedation and amnesia induction before short diagnostic procedures or endoscopy.***For preoperative sedation induction, amnesia induction, and to control preoperative anxiety.***For general anesthesia induction and general anesthesia maintenance. <br />        NOTE: Midazolam should be administered as an inducing agent only by those trained in anesthesia.<br />     ***For sedation maintenance in mechanically-ventilated patients�, to alleviate agitation� and/or anxiety.***For the treatment of status epilepticus� refractory to standard therapy.***For the treatment of alcohol withdrawal�, including symptomatic treatment of delirium tremens�.","***General Information***Benzodiazepine hypersensitivity, benzyl alcohol hypersensitivity, epidural administration, extravasation, intraarterial administration, intrathecal administration***Intravenous administration, requires a specialized care setting, requires an experienced clinician, respiratory depression, respiratory insufficiency***Children, hypotension, in utero exposure, infants, neonates, premature neonates, seizures***Abrupt discontinuation***Dementia, geriatric***Driving or operating machinery, ethanol ingestion, ethanol intoxication***Apnea, chronic obstructive pulmonary disease (COPD), CNS depression, coadministration with other CNS depressants, congenital heart disease, dental work, pulmonary disease, sleep apnea, status asthmaticus***Neuromuscular disease, Parkinson's disease, psychosis***Bipolar disorder, mania***Cardiac disease, dehydration, electrolyte imbalance, hypovolemia, shock***Hepatic disease, hepatic encephalopathy, obesity, renal failure, renal impairment***Closed-angle glaucoma***Labor, obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083']['31994'],estradiol/norgestimate,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae) in women with an intact uterus.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['594680'],docosanol,***For the treatment of herpes labialis due to either herpes simplex virus 1 or herpes simplex virus 2.***For the treatment of Kaposi's sarcoma�.,***Ophthalmic administration***Pregnancy***Immunosuppression***Breast-feeding***Children,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,nortriptyline hydrochloride,***For the treatment of major depression . <br /***For the treatment of social phobia (social anxiety disorder)� or panic disorder�.***For migraine prophylaxis�.***For the treatment of premenstrual dysphoric disorder (PMDD)�.***For the treatment of nocturnal enuresis�.***For the treatment of postherpetic neuralgia�.***For the treatment of painful diabetic neuropathy�.***For use as an adjunct to psychosocial interventions in the management of tobacco cessation� (smoking cessation�).,"***Carbamazepine hypersensitivity, tricyclic antidepressant hypersensitivity***MAOI therapy***Acute myocardial infarction, bradycardia, Brugada syndrome, cardiac arrhythmias, cardiac disease, congenital heart disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, orthostatic hypotension, QT prolongation***Children, suicidal ideation***Bipolar disorder, mania, schizophrenia***Alcoholism, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Electroconvulsive therapy (ECT), seizure disorder, seizures***Hepatic disease***Surgery***Anticholinergic medications, ileus, prostatic hypertrophy, urinary retention***Closed-angle glaucoma, increased intraocular pressure***Contact lenses***Agranulocytosis, leukopenia***Hyperthyroidism, hypothyroidism***Diabetes mellitus, pheochromocytoma***Radiographic contrast administration***Sunlight (UV) exposure***Abrupt discontinuation***Geriatric***Pregnancy***Breast-feeding***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6922'],metronidazole,"***For the treatment of trichomoniasis.***For the treatment of bacterial vaginosis (e.g., <em>Gardnerella vaginalis</em>, <em>Mycoplasma hominis</em>�, and anaerobic bacteria such as <em>Prevotella sp.</em> and <em>Mobiluncus</em> sp.).***For the treatment of pelvic inflammatory disease (PID) in combination with other antibiotics.***For the treatment of amebiasis.***For intestinal disease (acute amebic dysentery) due to <em>Entamoeba histolytica</em>.***For hepatic abscess due to <em>Entamoeba histolytica</em>.***For amebiasis due to <em>Entamoeba polecki</em>�.***For the treatment of serious anaerobic infections (e.g., skin and skin structure infections [e.g. diabetic foot ulcer], CNS infection including meningitis and brain abscess, bone and joint infections, endocarditis, bacteremia, and gynecologic infections [e.g. endometritis, endomyometritis]).***For the treatment of acne rosacea.***For the treatment of serious anaerobic intraabdominal infections, including intraabdominal abscess, peritonitis, perforated appendicitis, necrotizing enterocolitis, and biliary tract infections such as cholangitis and cholecystitis.***For the treatment of perforated appendicitis� in pediatric patients.***For the treatment of serious anaerobic lower respiratory tract infections, including pleural empyema, pneumonia, and lung abscess.***For bacterial vaginosis prophylaxis� or trichomoniasis prophylaxis� in victims of sexual assault.***For the treatment of recurrent and persistent non-gonococcal urethritis (NGU)�.***For the treatment of dental infection�, including dentoalveolar infection� and periodontitis�.***For adolescent periodontitis� or adult chronic periodontitis� after scaling and root planing.***For adolescent aggressive periodontitis� or adult refractory chronic periodontitis� in combination with amoxicillin after scaling and root planing.***For adult refractory chronic periodontitis� in combination with ciprofloxacin after scaling and root planing in �-lactam allergic patients.***For the treatment of guinea worm disease� (dracunculiasis�).***For surgical infection prophylaxis, including bowel preparation� in patients undergoing colorectal surgery.***For bowel preparation� in patients undergoing colorectal surgery.***For the treatment of antibiotic-associated pseudomembranous colitis� due to <em>Clostridium difficile</em>.***For the treatment of antibiotic-associated pseudomembranous colitis� due to <em>Clostridium difficile </em>in adults.***For the treatment of antibiotic-associated pseudomembranous colitis� due to <em>Clostridium difficile i</em>n pediatric patients.***For the treatment of Crohn's disease� associated with colonic and/or perianal involvement.***For Helicobacter pylori (H. pylori) eradication� in the treatment of patients with duodenal ulcer� disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />  NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.  The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: Metronidazole-resistant strains of H. pylori are prevalent in the US (approximately 25%), and primarily occur in patients previously treated with metronidazole. Therapy with at least two antimicrobials is necessary to limit the development of metronidazole resistance. Patients who have persistence of H. pylori following therapy may have metronidazole-resistant H. pylori infection.<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Prevpac monograph).  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60% to 90% of patients.***For the treatment of pruritus� secondary to cholestasis.***For the treatment of giardiasis�.","***Hematological disease***Dialysis, renal failure, renal impairment***Bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***New primary malignancy***Pregnancy***Breast-feeding***Alcoholism, ethanol ingestion, ethanol intoxication***Fungal infection***Crohn's disease***Ocular exposure***Geriatric***Sexually transmitted disease***Hepatic disease, hepatic encephalopathy***Cockayne syndrome***Corticosteroid therapy, edema, sodium restriction***Laboratory test interference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"100 mg, 200 mg) (amiodarone hydrochloride","***For the treatment of life-threatening recurrent ventricular fibrillation or hemodynamically unstable (symptomatic) sustained ventricular tachycardia, including post-myocardial infarction (MI) patients. <br />        NOTE: See resuscitation indication for ECC/AHA dosage and administration guidelines for ventricular fibrillation or pulseless ventricular tachycardia.<br />NOTE: Amiodarone is FDA-approved for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy***For the treatment of ventricular arrhythmias during cardiopulmonary resuscitation� (CPR).***For cardiac arrest associated with ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) unresponsive to CPR.***For hemodynamically stable ventricular tachycardia (monomorphic or polymorphic) or wide-complex tachycardia of unknown origin during CPR (perfusing ventricular arrhythmias).***For the treatment of atrial fibrillation�, atrial flutter�, or paroxysmal supraventricular tachycardia (PSVT)�.***For primary atrial fibrillation prophylaxis� in patients receiving cardiac surgery�. <br />        NOTE: Amiodarone is listed as an alternative treatment option to other frontline treatment strategies (e.g., beta-blockers) for the prevention of atrial fibrillation after coronary artery bypass graft (CABG) surgery. <br />     ***For the prevention of sudden cardiac death in patients with heart failure�.***Formoterol***Formoterol; Mometasone","***Iodine hypersensitivity***Cardiogenic shock, heart failure, hypotension, hypovolemia, ventricular dysfunction***Alcoholism, arrhythmia exacerbation, AV block, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, hypertension, hypocalcemia, long QT syndrome, malnutrition, mortality, myocardial infarction, QT prolongation, requires an experienced clinician***Amiodarone-induced lung toxicity, chronic obstructive pulmonary disease (COPD), pneumonitis, pulmonary disease, pulmonary fibrosis, respiratory distress syndrome, respiratory insufficiency, surgery***Amiodarone-induced liver toxicity, hepatic disease, hepatitis, hepatotoxicity***Diarrhea, electrolyte imbalance, hypokalemia, hypomagnesemia***Goiter, hyperthyroidism, hypothyroidism, thyroid disease, thyrotoxicosis***Cataracts, Fabry disease, optic neuritis, visual disturbance***Geriatric***Neurological disease, peripheral neuropathy***Sunlight (UV) exposure***Halothane anesthesia***Benzyl alcohol hypersensitivity, children, infants, neonates***Pregnancy***Breast-feeding***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,edrophonium chloride,"***For myasthenia gravis diagnosis.***For the assessment of cholinesterase inhibitor therapy in patients with myasthenia gravis.***For use to differentiate a myasthenic crisis from a cholinergic crisis (e.g., myasthenic crisis diagnosis).***For use in nondepolarizing neuromuscular blockade reversal. <br />        NOTE: Neostigmine plus atropine is usually the preferred treatment.<br />     ***For the treatment of paroxysmal supraventricular tachycardia (PSVT)� or diagnosis of supraventricular arrhythmias�.","***GI obstruction, ileus, urinary tract obstruction***AV block, bradycardia, cardiac arrhythmias, cardiac disease, hypotension***Cholinesterase inhibitor toxicity***Asthma***Peptic ulcer disease***Hyperthyroidism***Sulfite hypersensitivity***Labor, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7417'],nifedipine,"***For the treatment of ischemic heart disease including variant angina (Prinzmetal's angina) and chronic stable angina pectoris.***For the treatment of hypertension.***For acute hypertensive episodes including hypertensive urgency and hypertensive emergency in pediatric patients�. <br />          NOTE: Per the FDA and manufacturers, immediate-release nifedipine dosage forms should not be used to treat hypertension and should only be used to treat patients with chronic stable angina or vasospastic angina. The immediate-release nifedipine formulation has been associated with serious side effects (see Precautions and Adverse Reactions) when used to treat adult patients with hypertension, hypertensive urgency, hypertensive emergency, or coexisting myocardial infarction. Although the use of immediate-release nifedipine for the treatment of acute hypertensive episodes is still relatively common practice in pediatric patients, considerable controversy exists and caution should be used.<br />       ***For migraine prophylaxis�.***For the treatment of proteinuria� associated with diabetic nephropathy�.***For the treatment of persistent singultus (hiccups)�.***For the inhibition of uterine contractions in premature labor�. <br />        NOTE: Clinical practice guidelines recommend the use of a first line tocolytic (i.e., beta agonist, calcium channel blocker, or NSAID) for short-term use (up to 48 hours) to allow for administration of antenatal corticosteroids to enhance fetal lung maturation, magnesium sulfate for fetal neuroprotection, or transport to a tertiary facility, if indicated. There is no evidence that tocolytic therapy alone has any favorable effect on neonatal outcomes. Maintenance therapy with tocolytics is ineffective for preventing preterm birth and improving neonatal outcomes and is not recommended.<br />     ***For the treatment of achalasia�.***For the treatment of high altitude pulmonary edema associated with altitude sickness�.***For altitude sickness prophylaxis<strong>","***General Information***Dihydropyridine hypersensitivity***Pregnancy***Breast-feeding***Acute myocardial infarction, bradycardia, cardiogenic shock, coronary artery disease, heart failure, hypotension, ventricular dysfunction***Geriatric***Aortic stenosis***Colostomy, constipation, diabetes mellitus, diverticulitis, esophageal stricture, gastric cancer, gastroesophageal reflux disease (GERD), GI obstruction, hiatal hernia, hypothyroidism, ileus, inflammatory bowel disease, obesity***Children, infants***Hepatic disease***Lactase deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7804'],aspirin/oxycodone,"***For the treatment of moderate pain to moderately-severe pain including the relief of dental pain� (e.g., toothache), headache�, migraine�, back pain�, bone pain�, arthralgia� and myalgia�. <br />        NOTE: Adjust dose based on patient response and pain severity. Opioid tolerance may necessitate higher oxycodone dosages, but do not exceed the maximum daily aspirin dosage.<br />NOTE: 4.8355 mg oxycodone HCl is equivalent to 4.3346 mg of oxycodone as the free base","***General Information***NSAID hypersensitivity, opiate agonist hypersensitivity, salicylate hypersensitivity***Acute bronchospasm, asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, nasal polyps, pulmonary disease, respiratory depression, urticaria***Anemia, constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Bone marrow suppression, coagulopathy, hemophilia, intramuscular injections, surgery, thrombocytopenia***Immunosuppression, infection***Children, influenza, varicella, viral infection***G6PD deficiency***Abrupt discontinuation***Potential for overdose or poisoning, substance abuse***Head trauma, increased intracranial pressure***Geriatric***Cardiac arrhythmias, cardiac disease, hypovolemia***Hepatic disease, hypoprothrombinemia, vitamin K deficiency***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, systemic lupus erythematosus (SLE), urethral stricture, urinary retention***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Driving or operating machinery***Adrenal insufficiency, hypothyroidism, myxedema***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['30009'],miglitol,"***For the treatment of type 2 diabetes mellitus and type 1 diabetes mellitus�.***For type 2 diabetes mellitus in patients not controlled by diet alone; may be used as monotherapy or in combination with a sulfonylurea, metformin�, or insulin�. <br />          NOTE: If miglitol is used in combination with sulfonylureas or insulin, miglitol will cause a further lowering of blood sugar that may lead to hypoglycemia. Adjustments of the sulfonylurea or insulin may be necessary.<br />       ***For adjunctive treatment of type 1 diabetes mellitus� in patients on insulin.***Formoterol; Mometasone","***General Information***Diabetic ketoacidosis, type 1 diabetes mellitus***Hypoglycemia***GI disease, GI obstruction, hiatal hernia, ileus, inflammatory bowel disease***Diarrhea, vomiting***Renal failure, renal impairment***Pregnancy***Breast-feeding***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4135'],ethosuximide,***For the treatment of generalized absence seizures.,"***Succinimide hypersensitivity***Depression, suicidal ideation***Abrupt discontinuation***Hepatic disease, hepatitis, jaundice***Porphyria***Renal disease***Agranulocytosis, bone marrow suppression, fever, hematological disease, infection***Avoid ethanol ingestion, driving or operating machinery***Children, infants, neonates***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4821'],glipizide,***For the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.,"***General Information***Sulfonylurea hypersensitivity***Sulfonamide hypersensitivity***Diabetic ketoacidosis, type 1 diabetes mellitus***Burns, fever, infection, surgery, trauma***Adrenal insufficiency, diarrhea, GI obstruction, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypothyroidism, ileus, malnutrition, pituitary insufficiency, vomiting***Hepatic disease, porphyria, renal failure, renal impairment***G6PD deficiency, hemolytic anemia***Geriatric***Neonates, obstetric delivery, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,medroxyprogesterone acetate,"***For the treatment of secondary amenorrhea.***For the treatment of dysfunctional uterine bleeding due to hormonal imbalance, in the absence of organic pathology such as fibroids or uterine cancer.***For routine contraception.***For the treatment of endometriosis-associated pain.***For the treatment of inoperable, recurrent, and metastatic endometrial cancer or renal cell cancer.***For the prevention of endometrial hyperplasia associated with estrogen replacement therapy in postmenopausal women with an intact uterus.***For the treatment of hypoventilation due to obesity-hypoventilation syndrome� (Pickwickian syndrome�).***For the treatment of hot flashes� due to menopause�.***For use to reduce the rate of decline in bone mineral density and to control biochemical indices of mild primary hyperparathyroidism� in postmenopausal women.***For the management of paraphilia� (atypical or extreme compulsive sexual behaviors�) in men.***For the treatment of hot flashes� due to prostate cancer� and associated induced androgen deficiency� (andropause�"") in men who have had surgical or medication induced castration.""","***History of angioedema***Intravenous administration***Breast cancer, cervical cancer, endometrial cancer, endometrial hyperplasia, new primary malignancy, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Diabetes mellitus***Cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, visual disturbance***Hyperlipidemia***Ectopic pregnancy, infertility, pregnancy***Incomplete abortion, menstrual irregularity***Cholestasis, hepatic disease, jaundice***Breast-feeding***Asthma, renal disease***Depression, migraine, seizure disorder***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, sexually transmitted disease***Dementia, geriatric***Hypocalcemia, porphyria, systemic lupus erythematosus (SLE)***Alcoholism, anorexia nervosa, corticosteroid therapy, osteopenia, osteoporosis***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1202']['2409'],atenolol/chlorthalidone,"***For the treatment of hypertension in patients who do not respond to monotherapy. <br />  NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br /***Formoterol***Formoterol; Mometasone","***Beta-blocker hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, renal disease, renal failure, renal impairment***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***Abrupt discontinuation***Depression***AV block, bradycardia, cardiogenic shock, heart failure, pulmonary edema, sick sinus syndrome, ventricular dysfunction***Cerebrovascular disease***Hyperthyroidism, thyroid disease, thyrotoxicosis***Diabetes mellitus, hyperglycemia***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Peripheral vascular disease, pheochromocytoma, Raynaud's phenomenon, vasospastic angina***Hepatic disease***Psoriasis***Myasthenia gravis***Surgery***Electrolyte imbalance, hypercalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Hypercholesterolemia, hypertriglyceridemia***Labor, obstetric delivery, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,homatropine methylbromide/hydrocodone bitartrate,***For cough suppression.,"***Constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Biliary tract disease***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, ethanol ingestion, pulmonary disease, respiratory depression, respiratory insufficiency***Abrupt discontinuation***Alcoholism, substance abuse***Head trauma, increased intracranial pressure***Angina, cardiac arrhythmias, cardiac disease, heart failure, hypotension, hypovolemia***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, urethral stricture, urinary retention***Labor, obstetric delivery, pregnancy***Breast-feeding***Seizure disorder, seizures***Dementia, geriatric***Children, infants, neonates***Driving or operating machinery***Opiate agonist hypersensitivity***Adrenal insufficiency, hypothyroidism***Closed-angle glaucoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mesna,***For prophylaxis of ifosfamide-induced or cyclophosphamide-induced� hemorrhagic cystitis. <br />        NOTE: Mesna has been designated an orphan drug by the FDA for this indication.<br />     ,"***General Information***Hematuria***Benzyl alcohol hypersensitivity, infants, neonates***Autoimmune disease, polyarteritis nodosa, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Pregnancy***Breast-feeding***Laboratory test interference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['1256', '202559']",azathioprine,"***For kidney transplant rejection prophylaxis. <br />        NOTE: Complete blood counts including platelet counts are advised weekly during the first month of treatment, twice monthly for the second and third months of treatment, then monthly; more frequent monitoring may be necessary if the dose is altered or other therapy changes occur. Prompt reduction in dosage or temporary withdrawal of the drug may be necessary if there is a rapid fall in or persistently low leukocyte count or if other evidence of bone marrow depression exists. Early drug discontinuation is advisable for patients with abnormal CBC results that do not respond to dose reduction.<br />     ***For the treatment of active rheumatoid arthritis (RA) to reduce signs and symptoms. <br />        NOTE: Consider alternative therapies for patients who have low or absent thiopurine S-methyltransferase (TPMT) activity (see Contraindications). Dosage reduction is recommended in patients with reduced TPMT activity.<br />NOTE: Aspirin, nonsteroidal anti-inflammatory drugs, and/or low dose glucocorticoids may be continued during treatment with azathioprine. Use of azathioprine with disease modifying antirheumatic drugs cannot be recommended; combined use has not been studied.<br />NOTE: Patients with rheumatoid arthritis previously treated with alkylating agents such as cyclophosphamide, chlorambucil, or melphalan may have a prohibitive risk of neoplasia if treated with azathioprine***For the treatment of serious manifestations of Behcet's syndrome�.***For the treatment of refractory Crohn's disease�.***For the treatment of steroid-resistant or steroid-dependent ulcerative colitis�.***For the treatment of lupus nephritis�.***For the treatment of systemic lupus erythematosus (SLE)�.***For the treatment of dermatomyositis� or polymyositis�.***For the treatment of Wegener's granulomatosis�.***For the treatment of immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP)�.***For the treatment of myasthenia gravis� in patients who are poorly controlled with cholinesterase inhibitor therapy.***For remission maintenance of autoimmune hepatitis�.***For the treatment of idiopathic pulmonary fibrosis�.***For the treatment of atopic dermatitis�.***For the treatment of psoriasis�. <br />        NOTE: Azathioprine should generally be reserved for psoriatic patients who have failed multiple other therapies due to the potential for severe adverse effects.<br />     ***Formoterol; Mometasone","***General Information***Black patients, Caucasian patients, thiopurine methyltransferase (TPMT) deficiency***Bone marrow suppression***Intramuscular injections***Hepatic disease***Inflammatory bowel disease, lymphoma, new primary malignancy, requires an experienced clinician, rheumatoid arthritis, sunlight (UV) exposure***Renal disease, renal impairment***Pregnancy***Breast-feeding***Children, vaccination***Immunosuppression, infection, progressive multifocal leukoencephalopathy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,betamethasone dipropionate/calcipotriene,"***For the treatment of psoriasis vulgaris (i.e., plaque psoriasis). <br />        NOTE: The safety and efficacy of betamethasone; calcipotriene has not been determined in patients with erythrodermic, exfoliative, or pustular psoriasis.<br />     ***For the treatment of plaque psoriasis of the body.***For the treatment of plaque psoriasis of the scalp.","***Corticosteroid hypersensitivity***Hypercalcemia, hypercalciuria, hypervitaminosis D, nephrolithiasis***Cushing's syndrome***Diabetes mellitus***Peripheral vascular disease***Occlusive dressing, skin abrasion***Fungal infection, herpes infection, infection, viral infection***Geriatric***Skin atrophy***Osteoporosis***Sunlight (UV) exposure***Accidental exposure, ocular exposure***Children, infants, neonates***Pregnancy***Breast-feeding***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4450'],fluconazole,"***For the treatment of fungal meningitis.***For the treatment of CNS blastomycosis� or blastomycosis meningitis�.***For the treatment of cryptococcal meningitis.***For the treatment of CNS infections�, including meningitis�, caused by <em>Candida</em> sp.�.***For the treatment of meningitis caused by <em>Coccidioides </em>sp.� in HIV-infected patients.***For the treatment of disseminated, systemic, or invasive candidemia and candidiasis. <br />        NOTE: For CNS infections, see meningitis.<br />     ***For the treatment of chronic disseminated (hepatosplenic) candidiasis�.***For the treatment of disseminated cutaneous neonatal candidiasis�.***For the treatment of peritonitis or intraabdominal infections caused by <em>Candida</em> sp..***For the treatment of pneumonia caused by <em>Candida</em> sp..***For the treatment of osteomyelitis� and infectious arthritis� caused by <em>Candida</em> sp..***For the treatment of <em>Candida </em>infection of the cardiovascular system, including endocarditis�, pericarditis�, myocarditis�, suppurative thrombophlebitis�, and infected pacemaker�, implantable cardiac defibrillator (ICD)�, or ventricular assist devices (VAD)�.***For the treatment of endophthalmitis� caused by <em>Candida</em> sp..***For the treatment of urinary tract infection (UTI), including symptomatic cystitis and pyelonephritis, caused by Candida species (e.g., candiduria).***For the treatment of mucocutaneous candidiasis.***For the treatment of esophageal candidiasis.***For the treatment of oropharyngeal candidiasis (thrush).***For the treatment of vulvovaginal candidiasis (VVC).***For the treatment of nonmeningeal, pulmonary or extrapulmonary cryptococcosis.***For the treatment of nonmeningeal, extrapulmonary cryptococcosis and diffuse pulmonary disease.***For the treatment of nonmeningeal cryptococcosis with mild-to-moderate symptoms and focal pulmonary infiltrates.***For candidiasis prophylaxis in high-risk patients.***For candidiasis prophylaxis in patients hospitalized in the intensive care unit (ICU)�.***For candidiasis prophylaxis in solid-organ transplant recipients�.***For primary prophylaxis of candidiasis in bone marrow transplant (BMT) patients, including stem cell transplant recipients, and other high risk cancer patients�.***For secondary oropharyngeal candidiasis prophylaxis� in HIV-infected patients.***For secondary esophageal candidiasis prophylaxis� in HIV-infected patients.***For vulvovaginal candidiasis prophylaxis� in patients with recurrent infection.***For the treatment of coccidioidomycosis�.***For the treatment of mild (focal pneumonia or positive coccidioidal serologic test alone) coccidioidomycosis� in HIV-infected patients.***For treatment of severe, nonmeningeal (diffuse pulmonary or severely ill patients with extrathoracic disseminated disease) coccidioidomycosis� in HIV-infected patients during the acute phase.***For primary coccidioidomycosis prophylaxis� in HIV-infected patients.***For the treatment of disseminated histoplasmosis� in HIV-infected patients. <br />        NOTE: For CNS infections, see meningitis.<br />     ***For secondary histoplasmosis prophylaxis� in HIV-infected patients, after treatment of the acute infection.***For primary penicilliosis prophylaxis� in HIV-infected patients.***For suppressive therapy for bacterial vaginosis�.***For surgical infection prophylaxis� in patients undergoing transplantation.***Formoterol; Mometasone","***Cardiac disease, electrolyte imbalance, QT prolongation, torsade de pointes***Hepatic disease***Renal failure, renal impairment***Pregnancy***Breast-feeding***Azole antifungals hypersensitivity***Neonates***Geriatric***Driving or operating machinery***Serious rash***Contraception requirements, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['598'],alprostadil,"***For the treatment of neonates with congenital heart defects to maintain the patency of the ductus arteriosus (ductus arteriosus maintenance) until palliative or corrective surgery can be performed.***For the treatment of erectile dysfunction (ED). <br />        NOTE: Per ED guidelines, second-line treatment options for ED treatment include intracavernous injection and intra-urethral therapy. Intracavernous injection therapy is the most effective nonsurgical treatment for ED, with predictable and sustained response. However, it is invasive and caries notable side-effects including priapism and penile fibrosis. Careful dose selection, proper patient education, and continued monitoring by a prescribing physician is warranted for successful non-oral treatment of ED. Follow-up visits for ED patients, regardless of therapy, are necessary to determine whether therapy continues to be effective and whether cardiovascular health has significantly changed.<br />     ***For erectile dysfunction due to vasculogenic, psychogenic, or mixed causes or following post-radical prostatectomy�.***For erectile dysfunction due to neurogenic origin.***For the treatment of ED in combination with other vasoactive agents (i.e., papaverine, phentolamine)�.","***General Information***Benzyl alcohol hypersensitivity, children, infants, neonates***Apnea, premature neonates, requires a specialized care setting, respiratory depression***GI obstruction***Respiratory distress syndrome***Cardiac disease, driving or operating machinery, hypotension, syncope***Anticoagulant therapy, bleeding, coagulopathy***Balanitis, hypospadia, penile implants, penile structural abnormality, Peyronie's disease, urethral stricture, urethritis***Leukemia, multiple myeloma, polycythemia, priapism, sickle cell disease, thrombocytosis***Geriatric, renal impairment***Contraception requirements, females, labor, pregnancy, sexually transmitted disease***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,terbutaline sulfate,"***For the treatment of acute bronchospasm or for bronchospasm prophylaxis in patients with asthma or reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis or emphysema.***For the inhibition of uterine contraction in premature labor�. <br />        NOTE: In February 2011, the FDA warned the public that injectable terbutaline should not be used in pregnant women for prevention or prolonged treatment (beyond 48�72 hours) of preterm labor due to the potential for serious maternal cardiovascular events and death. Furthermore, oral terbutaline should not be used either to treat preterm labor or prevent recurrent preterm labor. The labels of both injectable and oral formulations of terbutaline will carry stronger warnings, including boxed warnings and contraindications against this use.<br />NOTE: American College of Obstetrics and Gynecology recommends that a tocolytic agent be chosen based on maternal condition and side effects, as a clear-first line drug cannot be recommended. The overall rate of preterm delivery is not reduced by tocolysis, neither acute nor maintenance treatment. Tocolytics typically prolong pregnancy by approximately 2�7 days, which allows for transfer of the patient to a hospital with appropriate facilities and administration of antenatal corticosteroids to enhance fetal lung maturation***For continued suppression of uterine contractions after successful inhibition of acute premature labor� (i.e., maintenance therapy).","***Acute bronchospasm, paradoxical bronchospasm***Deterioration of asthma***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, tachycardia***Hyperthyroidism, thyrotoxicosis***Seizure disorder, seizures***Pheochromocytoma***Diabetes mellitus, diabetic ketoacidosis***Caesarean section, labor, obstetric delivery, pregnancy***Premature labor***Breast-feeding***MAOI therapy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/levonorgestrel,"***For routine contraception.***For extended continuous routine contraception.***For use as postcoital contraception within 72 hours of unprotected intercourse, or known or suspected contraceptive failure, in females who have no known contraindications to oral contraceptives, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,anthrax vaccine adsorbed,***For anthrax prophylaxis.***For pre-exposure prophylaxis against <em>Bacillus anthracis</em> in patients at high exposure risk.***For postexposure prophylaxis of disease after suspected or confirmed <em>Bacillus</em> <em>anthracis </em>exposure in combination with antibacterial drugs.,"***General Information***Anticoagulant therapy, coagulopathy, hemophilia, intramuscular injections, intravenous administration, subcutaneous administration, thrombocytopenia, vitamin K deficiency***Fever, infection***Acquired immunodeficiency syndrome (AIDS), chemotherapy, corticosteroid therapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, leukemia, lymphoma, radiation therapy***Pregnancy***Breast-feeding***Guillain-Barre syndrome***Latex hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluphenazine hydrochloride,"***For the treatment of schizophrenia.***For the treatment of acute agitated behavior (e.g., acute psychosis) when rapid control of acute symptoms is desired or for use when the oral route is not feasible.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.","***Benzyl alcohol hypersensitivity, paraben hypersensitivity, phenothiazine hypersensitivity, sesame oil hypersensitivity, tartrazine dye hypersensitivity***Agranulocytosis, bone marrow suppression, fever, hematological disease, infection, leukopenia, neutropenia***Intravenous administration***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion, head trauma***Dental work, surgery***Intracranial mass, seizure disorder, seizures***Tardive dyskinesia***Anticholinergic medications, closed-angle glaucoma, ileus, prostatic hypertrophy, urinary retention***Alcoholism, angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, pulmonary disease, QT prolongation, thyroid disease***Children, infants, neonates, Reye's syndrome***Encephalopathy, hepatic disease, jaundice***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Sunlight (UV) exposure***Accidental exposure***Abrupt discontinuation***Renal failure***Ocular disease***Chemotherapy, GI obstruction, vomiting***Tobacco smoking***Labor, obstetric delivery, pregnancy, pregnancy testing***Breast-feeding***Breast cancer, hyperprolactinemia, infertility***Radiographic contrast administration***Suicidal ideation***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,doxazosin mesylate,***For treatment of hypertension.***For the treatment of benign prostatic hyperplasia (BPH).***For treatment of BPH in combination with finasteride.,"***General Information***Hypotension, orthostatic hypotension, syncope***Hepatic disease***Pregnancy***Breast-feeding***Ocular surgery***Priapism***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2582', '202862']",clindamycin,"***For the treatment of serious infections such as bacteremia.***For the treatment of lower respiratory tract infections (e.g., pleural empyema, anaerobic pneumonia, aspiration pneumonia, community-acquired pneumonia, and lung abscess) due to susceptible organisms<strong>***For the treatment of intraabdominal infections, including intraabdominal abscess and peritonitis.***For the treatment of peritonitis in patients receiving peritoneal dialysis.***For the treatment of skin and skin structure infections, including impetigo, ecthyma, cellulitis, erysipelas, infectious neonatal pustulosis, bite wounds, and complicated skin and skin structure infections such as necrotizing infections, gas gangrene, and diabetic foot ulcer.***For the treatment of impetigo or ecthyma.***For the treatment of necrotizing infections of the skin, fascia, and muscle (i.e. gas gangrene).***For the treatment of animal bite wounds.***For the treatment of diabetic foot ulcer.***For the treatment of gynecologic infections, including endometritis and pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of acute pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of bacterial vaginosis.***For the treatment of acne vulgaris.***For the treatment of bone and joint infections, including osteomyelitis and septic/infectious arthritis, or an orthopedic device-related infection�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated prosthetic joint infections�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated spinal implant infections�.***For the treatment of of uncomplicated acute otitis media�.***For the treatment of acute bacterial sinusitis�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis� in combination with conventional treatment (e.g., scaling and root planing) as well as acute dental abscess (apical)� and/or dental abscess (periapical)�.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage in patients with beta-lactam allergy.***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis� (rheumatic fever prophylaxis�) and for bacterial colonization eradication� in chronic carriers of group A beta-hemolytic <em>Streptococci</em> (GAS)�.***For the treatment of chronic pharyngeal carriers of group A streptococci (i.e., bacterial colonization eradication�).***For surgical infection prophylaxis�.***For bacterial endocarditis prophylaxis�.***For the treatment of anthrax�.***For the treatment of cutaneous anthrax infection.***For the treatment of systemic anthrax infection.***For anthrax prophylaxis� after exposure to Bacillus anthracis (postexposure prophylaxis, PEP).***For the treatment of toxoplasmosis�, including toxoplasmic encephalitis�.***For secondary toxoplasmosis prophylaxis� in HIV-infected patients intolerant of sulfa drugs.***For the treatment of Pneumocystis pneumonia (PCP)� in HIV-infected patients.***For the treatment of malaria� due <em>Plasmodium falciparum</em>.***For the treatment of babesiosis�.***For perinatal Group B streptococcal bacterial infection prophylaxis� in patients allergic to penicillin and cephalosporins.***Formoterol; Mometasone","***Asthma, atopy, clindamycin hypersensitivity, lincomycin hypersensitivity, serious rash, tartrazine dye hypersensitivity***Fungal infection***Diarrhea, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Neonates***Hepatic disease***Pregnancy***Breast-feeding***Ocular exposure***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,enalapril maleate/hydrochlorothiazide,"***For the treatment of hypertension. <br />        NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, Black patients, hereditary angioedema***Dialysis, hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Hepatic disease***Aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hyponatremia, hypotension, hypovolemia***Orthostatic hypotension, sympathectomy, syncope***Surgery***Gout, hyperuricemia***Hypercalcemia, hypomagnesemia***Electrolyte imbalance, hyperkalemia, hypokalemia***Anuria, autoimmune disease, bone marrow suppression, collagen-vascular disease, immunosuppression, renal artery stenosis, renal disease, renal failure, renal impairment, scleroderma, systemic lupus erythematosus (SLE)***Diabetes mellitus, hyperglycemia***Pregnancy***Breast-feeding***Children***Pancreatitis***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,imipramine hydrochloride,***For the treatment of major depression.***For the temporary adjunctive treatment of functional enuresis in pediatric patients.***For the treatment of painful diabetic neuropathy�.***For the treatment of social phobia (social anxiety disorder)� and panic disorder�.***For the treatment of stress and urge urinary incontinence� (non-neurogenic overactive bladder (OAB)�).***For the adjunct treatment of bulimia nervosa�.***For the treatment of attention-deficit hyperactivity disorder (ADHD)�.,"***Carbamazepine hypersensitivity, tricyclic antidepressant hypersensitivity***MAOI therapy***Acute myocardial infarction, bradycardia, cardiac arrhythmias, cardiac disease, congenital heart disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation***Children, suicidal ideation***Bipolar disorder, mania, schizophrenia***Alcoholism, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Electroconvulsive therapy (ECT), seizure disorder, seizures***Hepatic disease***Surgery***Anticholinergic medications, ileus, prostatic hypertrophy, urinary retention***Closed-angle glaucoma, increased intraocular pressure***Contact lenses***Agranulocytosis, leukopenia***Hyperthyroidism, hypothyroidism, thyroid disease***Diabetes mellitus, pheochromocytoma***Radiographic contrast administration***Sunlight (UV) exposure***Abrupt discontinuation***Geriatric***Neonates, pregnancy***Breast-feeding***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydrocortisone acetate/neomycin sulfate/polymyxin B sulfate,"***For the treatment of superficial bacterial infections of the external auditory canal (i.e., otitis externa) caused by susceptible organisms, and for the treatment of infections of mastoidectomy and fenestration caused by susceptible organisms.***For the treatment of corticosteroid-responsive inflammatory ocular conditions and where bacterial ophthalmic infection or a risk of bacterial ophthalmic infection exists (e.g., inflammation of palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in bacterial conjunctivitis is accepted to obtain a decrease in edema and inflammation; also in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign objects).***For the treatment of corticosteroid-responsive dermatitis with secondary infection.","***General Information***Aminoglycoside hypersensitivity, neomycin hypersensitivity***Fungal infection, herpes infection, tuberculosis, varicella, viral infection***Renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Ocular exposure***Otitis media, tympanic membrane perforation***Hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing***Pregnancy***Asthma, sulfite hypersensitivity***Breast-feeding***Glaucoma, surgery***Contact lenses***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ipratropium bromide,"***For the treatment of acute bronchospasm� (e.g., asthma exacerbation).***For the symptomatic relief of rhinorrhea associated with seasonal allergic rhinitis or nonallergic rhinitis (e.g., common cold).***For the maintenance treatment and prevention of bronchospasm (e.g., bronchospasm prophylaxis) associated with asthma and chronic obstructive pulmonary disease (COPD) (e.g., emphysema or chronic bronchitis).***For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), such as emphysema or chronic bronchitis.***For the maintenance treatment of bronchospasm associated with asthma� in pediatric patients.***For adjunctive exercise-induced bronchospasm prophylaxis�.","***General Information***Acute bronchospasm, bromide hypersensitivity, paradoxical bronchospasm***Closed-angle glaucoma, contact lenses, ocular exposure, ophthalmic administration***Bladder obstruction, prostatic hypertrophy, urinary retention***Cardiac arrhythmias***Driving or operating machinery***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,nitrofurantoin macrocrystals/nitrofurantoin monohydrate,***For the treatment of uncomplicated urinary tract infection (UTI) including acute cystitis.***For long-term suppressive therapy for urinary tract infection (UTI) prophylaxis in patients predisposed to urinary tract infection.,"***General Information***Viral infection***Anuria, oliguria, renal disease, renal impairment***Anemia, G6PD deficiency, hemolytic anemia***Children, infants, neonates***Labor, obstetric delivery, pregnancy***Breast-feeding***Diabetes mellitus, electrolyte imbalance, optic neuritis, peripheral neuropathy, vitamin B12 deficiency***Hepatic disease, jaundice***Pulmonary disease***Geriatric***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7824'],oxytocin,"***For labor augmentation in patients with a medical necessity for labor induction, at or near to term, when delivery is in the best interests of the mother and the fetus.***For reduction and control of postpartum bleeding and to produce uterine contractions during the third stage of labor.***For the adjunctive treatment of inevitable or incomplete abortion.***For the evaluation of fetal distress� using an oxytocin-induced contraction stress test (aka, oxytocin challenge test or CST)�.","***Pregnancy***Breast-feeding***Abnormal fetal position, cephalopelvic disproportion, cervical cancer, elective induction of labor, fetal distress, fetal prematurity, herpes infection, multiparity, placenta previa, surgery, uterine prolapse, vasa previa***Eclampsia, uterine atony",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,benazepril hydrochloride/hydrochlorothiazide,***For the treatment of hypertension.***Formoterol***Formoterol; Mometasone,"***General Information***Penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, asthma, atopy, Black patients, hereditary angioedema, history of angioedema***Dialysis, hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Cerebrovascular disease, coronary artery disease, heart failure, hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***Hepatic disease***Electrolyte imbalance, hyperkalemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia***Anuria, autoimmune disease, bone marrow suppression, collagen-vascular disease, immunosuppression, renal artery stenosis, renal disease, renal failure, renal impairment, scleroderma, systemic lupus erythematosus (SLE)***Gout, hyperuricemia***Diabetes mellitus, hyperglycemia***Pancreatitis***Surgery***Pregnancy***Breast-feeding***Sunlight (UV) exposure***Geriatric***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clindamycin hydrochloride,"***For the treatment of serious infections such as bacteremia.***For the treatment of lower respiratory tract infections (e.g., pleural empyema, anaerobic pneumonia, aspiration pneumonia, community-acquired pneumonia, and lung abscess) due to susceptible organisms<strong>***For the treatment of intraabdominal infections, including intraabdominal abscess and peritonitis.***For the treatment of peritonitis in patients receiving peritoneal dialysis.***For the treatment of skin and skin structure infections, including impetigo, ecthyma, cellulitis, erysipelas, infectious neonatal pustulosis, bite wounds, and complicated skin and skin structure infections such as necrotizing infections, gas gangrene, and diabetic foot ulcer.***For the treatment of impetigo or ecthyma.***For the treatment of necrotizing infections of the skin, fascia, and muscle (i.e. gas gangrene).***For the treatment of animal bite wounds.***For the treatment of diabetic foot ulcer.***For the treatment of gynecologic infections, including endometritis and pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of acute pelvic inflammatory disease (PID), with or without associated tubo-ovarian abscess.***For the treatment of bacterial vaginosis.***For the treatment of acne vulgaris.***For the treatment of bone and joint infections, including osteomyelitis and septic/infectious arthritis, or an orthopedic device-related infection�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated prosthetic joint infections�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus</em>-associated spinal implant infections�.***For the treatment of of uncomplicated acute otitis media�.***For the treatment of acute bacterial sinusitis�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis� in combination with conventional treatment (e.g., scaling and root planing) as well as acute dental abscess (apical)� and/or dental abscess (periapical)�.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage in patients with beta-lactam allergy.***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis� (rheumatic fever prophylaxis�) and for bacterial colonization eradication� in chronic carriers of group A beta-hemolytic <em>Streptococci</em> (GAS)�.***For the treatment of chronic pharyngeal carriers of group A streptococci (i.e., bacterial colonization eradication�).***For surgical infection prophylaxis�.***For bacterial endocarditis prophylaxis�.***For the treatment of anthrax�.***For the treatment of cutaneous anthrax infection.***For the treatment of systemic anthrax infection.***For anthrax prophylaxis� after exposure to Bacillus anthracis (postexposure prophylaxis, PEP).***For the treatment of toxoplasmosis�, including toxoplasmic encephalitis�.***For secondary toxoplasmosis prophylaxis� in HIV-infected patients intolerant of sulfa drugs.***For the treatment of Pneumocystis pneumonia (PCP)� in HIV-infected patients.***For the treatment of malaria� due <em>Plasmodium falciparum</em>.***For the treatment of babesiosis�.***For perinatal Group B streptococcal bacterial infection prophylaxis� in patients allergic to penicillin and cephalosporins.***Formoterol; Mometasone","***Asthma, atopy, clindamycin hypersensitivity, lincomycin hypersensitivity, serious rash, tartrazine dye hypersensitivity***Fungal infection***Diarrhea, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Neonates***Hepatic disease***Pregnancy***Breast-feeding***Ocular exposure***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4821']['6809'],glipizide/metformin hydrochloride,***For the treatment of type 2 diabetes mellitus uncontrolled by diet and exercise alone.***For use as initial antidiabetic therapy in previously untreated patients.***For use when initial treatment with either glipizide or metformin alone do not result in adequate glycemic control.***For patients already on a combination of sulfonylurea-metformin who desire to switch to the combination tablet.,"***Sulfonylurea hypersensitivity***Sulfonamide hypersensitivity***Diabetic ketoacidosis, type 1 diabetes mellitus***Acidemia, hypoxemia, lactic acidosis, metabolic acidosis***Diarrhea, vomiting***Renal disease, renal failure, renal impairment***Acute heart failure, acute myocardial infarction, cardiac disease, cardiogenic shock, heart failure***Alcoholism, ethanol ingestion, ethanol intoxication, hepatic disease***Radiographic contrast administration***Burns, dehydration, fever, infection, sepsis, surgery, trauma***Adrenal insufficiency, gastroparesis, GI obstruction, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypothyroidism, ileus, malnutrition, pituitary insufficiency***Geriatric***G6PD deficiency, hemolytic anemia, pernicious anemia***Neonates, obstetric delivery, polycystic ovary syndrome, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ampicillin sodium/sulbactam sodium,"***For the treatment of skin and skin structure infections (e.g., cellulitis, diabetic foot ulcer).***For the treatment of moderate to severe bone and joint infections� (e.g., osteomyelitis�, infectious arthritis�) caused by susceptible organisms.***For the treatment of skin and skin structure infections caused by an animal or human bite.***For the treatment of moderate to severe gynecologic infections caused by susceptible organisms.***For the treatment of pelvic inflammatory disease (PID)�.***For the treatment of moderate to severe intraabdominal infections caused by susceptible organisms.***For the treatment of pneumonia�, including community-acquired pneumonia� (CAP) and pleural empyema�.***For the treatment of acute epiglottitis�.***For surgical infection prophylaxis�.***For the treatment of infective endocarditis�.***For the treatment of acute bacterial sinusitis�.***For the treatment of moderate to severe urinary tract infection (UTI)� (e.g., pyelonephritis�).","***General Information***Dialysis, renal failure, renal impairment***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, eczema, penicillin hypersensitivity, serious rash, urticaria***Mononucleosis***Diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Cholestasis, hepatic disease, hepatitis, jaundice***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sodium polystyrene sulfonate,"***For the treatment of hyperkalemia. <br />        NOTE: The dosage must be individualized, depending on the daily assessment of total body potassium.<br />     ","***General Information***Binding to other oral medications***Burns***Children, GI bleeding, GI obstruction, infants, neonates, premature neonates***Colitis, constipation, fecal impaction, hypovolemia, inflammatory bowel disease, renal failure, surgery***Edema, heart failure, hypernatremia, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, sodium restriction***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7623'],ofloxacin,"***For the treatment of urinary tract infection (UTI), including uncomplicated (cystitis) or complicated infections.***For the treatment of gonorrhea and chlamydia infection including cervicitis or urethritis as well as non-gonococcal urethritis.***For acute, uncomplicated gonococcal urethritis or cervicitis caused by <em>N. gonorrhoeae</em>.***For non-gonococcal urethritis (NGU) or cervicitis caused by <em>C. trachomatis</em>.***For the treatment of mixed infection cervicitis or urethritis caused by <em>C. trachomatis</em> and <em>N. gonorrhoeae</em>.***For the treatment of pelvic inflammatory disease (PID).***For the treatment of bacterial prostatitis due to <em>E. coli</em>.***For the treatment of otitis media.***For acute otitis media in children with tympanostomy tubes due to <em>H. influenzae</em> (beta-lactamase negative), <em>H. influenzae</em> (beta-lactamase positive), <em>M. catarrhalis</em>, <em>P. aeruginosa</em>, <em>S. aureus</em>, or <em>S. pneumoniae</em>.***For chronic suppurative otitis media in adults and adolescents with perforated tympanic membranes due to <em>P. mirabilis</em>, <em>P. aeruginosa</em>, or <em>S. aureus</em>.***For the treatment of otitis externa due to <em>E. coli</em>, <em>P. aeruginosa,</em> and <em>S. aureus</em>.***For the treatment of lower respiratory tract infections (e.g. acute exacerbations of chronic bronchitis, community-acquired pneumonia) due to susceptible organisms.***For the treatment of skin and skin structure infections due to susceptible organisms.***For the treatment of acute epididymitis�.***For the treatment of meningococcal carriers (i.e., for meningococcal infection prophylaxis�).***For the treatment of moderate or severe traveler's diarrhea�.***For the treatment of plague� infection due to exposure to <em>Yersinia pestis</em>�.***For an individual patient� or in a contained casualty setting�. <br />          NOTE: Streptomycin is the drug of choice to treat plague in most patients; gentamicin is the preferred agent in pregnant women.<br />       ***For a mass casualty setting�. <br />          NOTE: Doxycycline is the treatment of choice for plague in the mass casualty setting.<br />       ***For plague prophylaxis� following exposure to <em>Yersinia pestis</em>�. <br />        NOTE: Doxycycline is the treatment of choice for plague prophylaxis.<br />     ***For the treatment of typhoid fever� caused by <em>Salmonella typhi</em>.***For uncomplicated typhoid fever�.***For severe typhoid fever�.***For the treatment of tuberculosis infection� in patients with multi-drug resistant<em> Myocbacterium tuberculosis</em>. <br />  NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., at least 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, IDSA, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. Directly observed therapy (DOT) should be used for all regimens administered 1, 2, 3, or 5 times per week. The initial treatment regimen should include 4 drugs unless the likelihood of INH or rifampin resistance is low (i.e., less than 4%), in which case an initial regimen of INH, rifampin, and pyrazinamide may be considered. HIV-infected patients should always receive induction therapy with 4 drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate.   For multidrug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, the CDC recommends treatment for 18�24 months after culture conversion in patients with bacteriologic confirmation and for at least 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months in MDR-TB.<br /***Formoterol***Formoterol; Mometasone","***General Information***Viral infection***Quinolone hypersensitivity***Corticosteroid therapy, organ transplant, tendinitis, tendinopathy, tendon pain, tendon rupture***Acute myocardial infarction, alcoholism, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, thyroid disease, torsade de pointes***Cerebrovascular disease, neurotoxicity, peripheral neuropathy, seizure disorder***Myasthenia gravis***Renal failure, renal impairment***Dehydration***Hepatic disease, hepatitis, hepatotoxicity, jaundice***Diabetes mellitus***Sunlight (UV) exposure***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Geriatric***Pregnancy***Breast-feeding***Sexually transmitted disease***Children, infants, neonates***Contact lenses***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,metformin hydrochloride,"***For treatment of type 2 diabetes mellitus.***For monotherapy or for use in combination with an insulin secretogue (e.g., sulfonylurea) or insulin.***For conversion to metformin monotherapy from other antidiabetic agents.***For the adjunct treatment of patients with hyperinsulinemia secondary to polycystic ovary syndrome� (PCOS), including the treatment of infertility� in these patients.***For the delay of clinical puberty and early menarche in females with precocious puberty�.***For the prolongation of pubertal growth� and to prevent the delay of early menarche in low birth weight females with early-normal onset of puberty.***For the treatment of gestational diabetes� in patients not controlled by diet-therapy alone.","***General Information***Diabetic ketoacidosis, type 1 diabetes mellitus***Acidemia, hypoxemia, lactic acidosis, metabolic acidosis***Diarrhea, vomiting***Renal disease, renal failure, renal impairment***Acute heart failure, acute myocardial infarction, cardiac disease, cardiogenic shock, heart failure***Alcoholism, ethanol ingestion, ethanol intoxication, hepatic disease***Radiographic contrast administration***Burns, dehydration, fever, infection, sepsis, surgery, trauma***Adrenal insufficiency, gastroparesis, GI obstruction, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypothyroidism, ileus, malnutrition, pituitary insufficiency***Pernicious anemia***Geriatric***Polycystic ovary syndrome, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,morphine sulfate,"***For the relief of acute and chronic moderate pain or severe pain. <br />        NOTE: There is substantial interpatient variability in the relative potency of different opioid drugs and products. FDA-approved labeling defines adult opioid-tolerant patients as those who take the following per day for a minimum of 1 week: oral morphine 60 mg or more; oral oxycodone 30 mg or more; oral hydromorphone 8 mg or more; oral oxymorphone 25 mg or more; 60 mg oral hydrocodone or more; transdermal fentanyl 25 mcg or more per hour; or another opioid at an equivalent dose. <br />     ***For acute moderate to severe pain related to major orthopedic surgery of the lower extremity.***For acute moderate to severe pain related to lower abdominal or pelvic surgery.***For acute moderate to severe pain related to cesarean section after delivery and clamping of the umbilical cord.***For the management of chronic severe pain in patients who require daily, around-the-clock, long-term opioid treatment. <br />  NOTE: Reserve extended-release morphine for when alternative options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would otherwise provide inadequate pain management. Discontinue all other around-the-clock opioids upon initiation.  <br />NOTE: Do not use the following morphine products in opioid-naive patients: 60 mg, 90 mg, or 120 mg biphasic-release capsules (Avinza); 100 mg, 130 mg, 150 mg, or 200 mg extended-release capsules (Kadian); 100 mg or 200 mg controlled-release tablets (MS Contin); 100 mg extended-release tablets (Morphabond). In this population, use could result in fatal respiratory depression. Use of a single dose of more than 60 mg, or a total daily dose more than 120 mg, should be limited to opioid-tolerant patients.   <br />NOTE: There is substantial interpatient variability in the relative potency of different opioid drugs and products. FDA-approved labeling defines adult opioid-tolerant patients as those who take the following per day for a minimum of 1 week: oral morphine 60 mg or more; oral oxycodone 30 mg or more; oral hydromorphone 8 mg or more; oral oxymorphone 25 mg or more; oral hydrocodone 60 mg or more; transdermal fentanyl 25 mcg or more per hour; or another opioid at an equivalent dose.***For the treatment of diarrhea.***For the treatment of noninfectious diarrhea. <br />  WARNING: Proper product selection is critical. Deodorized opium tincture 10 mg/mL solution is 25 times more concentrated than camphorated opium tincture 0.4 mg/mL solution. Serious patient harm may occur with incorrect product selection.<br /***For control of diarrhea� secondary to AIDS-associated enteropathy.***For the management of dyspnea�.***For the adjuvant treatment of acute pulmonary edema�.***For acute myocardial infarction� or unstable angina� and to provide potentially beneficial cardiovascular effects.***For procedural sedation� before short diagnostic procedures or endoscopy. <br />        NOTE: Morphine should be administered as an inducing agent only by those trained in anesthesia.<br />     ***For sedation during rapid-sequence intubation�.***For the treatment of painful diabetic neuropathy�.","***Opiate agonist hypersensitivity***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, coma, cor pulmonale, emphysema, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Ethanol ingestion, ethanol intoxication***Anticoagulant therapy, coagulopathy, infection, intramuscular administration, intrathecal administration, intravenous administration, requires a specialized care setting, requires an experienced clinician, subcutaneous administration***Accidental exposure, opioid-naive patients, potential for overdose or poisoning***Abrupt discontinuation***Acute abdomen, constipation, diarrhea, GI bleeding, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Biliary tract disease***Arteriosclerosis, brain tumor, CNS depression, head trauma, increased intracranial pressure, seizure disorder, seizures, status epilepticus, strychnine toxicity***Angina, atrial fibrillation, atrial flutter, cardiac arrhythmias, cardiac disease, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal impairment, urethral stricture, urinary retention***Children, infants, neonates***Geriatric***Driving or operating machinery***MAOI therapy***Adrenal insufficiency, hypothyroidism, myxedema***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/norethindrone acetate,"***For routine contraception.***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae) in women with an intact uterus.***For osteoporosis prophylaxis due to menopause (natural or surgical) in women with an intact uterus.***For the treatment of moderate acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche, and who desire contraception.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Atrial fibrillation, cardiac disease, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, hypertension, myocardial infarction, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Surgery***Pregnancy***Breast-feeding, obstetric delivery***Gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Contact lenses, glaucoma, headache, migraine, visual disturbance***Asthma, renal disease, seizure disorder***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Cervical cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Systemic lupus erythematosus (SLE)***Diabetes mellitus***Obesity***Hypertriglyceridemia, pancreatitis***Hypothyroidism, thyroid disease***Depression***Hypocalcemia, hypoparathyroidism***Chloasma***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, sexually transmitted disease***Dementia, geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,anti-thymocyte globulin (rabbit),"***For the treatment of acute kidney transplant rejection.***For kidney transplant rejection prophylaxis.***For the treatment of patients with moderate to severe aplastic anemia who are not candidates for hematopoietic stem cell transplantation. <br />  NOTE: The usefulness of Atgam has not been demonstrated in patients who are suitable candidates for bone marrow transplantation or in patients with aplastic anemia secondary to neoplastic disease, storage disease, myelofibrosis, Fanconi's syndrome, or in patients known to have been exposed to myelotoxic agents or radiation.<br />NOTE: Patients may need prophylactic platelet transfusions to maintain platelets at clinically acceptable concentrations***For the treatment of heart transplant rejection�.***For heart transplant rejection prophylaxis�.***For stem cell transplant preparation� prior to allogeneic stem hematopoietic stem cell transplantation (SCT).***For the treatment of myelodysplastic syndrome (MDS)�. <br />        NOTE: Rabbit ATG (Thymoglobulin) has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of acute graft-versus-host disease (GVHD)� and graft-versus-host disease (GVHD) prophylaxis�.***Formoterol; Mometasone","***General Information***Fungal infection, herpes infection, infection, lymphoma, neoplastic disease, requires an experienced clinician, varicella, viral infection***Acute bronchospasm, equine protein hypersensitivity, hypotension, leporine protein hypersensitivity, serious hypersensitivity reactions or anaphylaxis***Leukopenia, thrombocytopenia***Vaccination***Pregnancy***Breast-feeding***Contraception requirements, reproductive risk***Thromboembolic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diclofenac sodium,"***For the treatment of osteoarthritis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the treatment of rheumatoid arthritis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the treatment of ankylosing spondylitis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the acute treatment of migraine with or without aura. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />NOTE: Diclofenac is not indicated for migraine prophylaxis***For the treatment of mild pain or moderate pain. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For primary dysmenorrhea or for mild or moderate pain associated with nonrheumatic inflammatory conditions, bone pain�, arthralgia�, myalgia�, and vascular or migraine headache�. <br />          NOTE: Voltaren XR is not indicated for the management of acute painful conditions.<br />       ***For the treatment of acute mild or moderate pain.***For the topical treatment of acute mild pain or moderate pain due to minor strains, sprains, and contusions. <br />          NOTE: Carefully consider the potential benefits and risks of the diclofenac patch. If the patch will be used, use the lowest effective dose for the shortest possible duration.<br />       ***For the treatment of postoperative ocular inflammation following cataract extraction.***For the reduction of photophobia and ocular pain following corneal refractive surgery.***For the treatment of moderate to severe pain alone or in combination with opioid analgesics.***For the treatment of actinic keratosis.***For the prevention of heterotopic ossification�.***Formoterol; Mometasone","***Acute bronchospasm, asthma, bovine protein hypersensitivity, gelatin hypersensitivity, nasal polyps, NSAID hypersensitivity, polysorbate 80 hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Contact lenses, ocular surgery, rheumatoid arthritis***Anemia***Dental disease, dental work***Hepatic disease, jaundice, porphyria***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, renal impairment, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Labor, pregnancy***Breast-feeding***Burns, eczema, exfoliative dermatitis, heating pad, occlusive dressing, ocular exposure, skin abrasion***Benzyl alcohol hypersensitivity, sunlight (UV) exposure***Coronary artery bypass graft surgery (CABG)***Accidental exposure***Phenylketonuria***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluphenazine hydrochloride,"***For the treatment of schizophrenia.***For the treatment of acute agitated behavior (e.g., acute psychosis) when rapid control of acute symptoms is desired or for use when the oral route is not feasible.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.","***Benzyl alcohol hypersensitivity, paraben hypersensitivity, phenothiazine hypersensitivity, sesame oil hypersensitivity, tartrazine dye hypersensitivity***Agranulocytosis, bone marrow suppression, fever, hematological disease, infection, leukopenia, neutropenia***Intravenous administration***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion, head trauma***Dental work, surgery***Intracranial mass, seizure disorder, seizures***Tardive dyskinesia***Anticholinergic medications, closed-angle glaucoma, ileus, prostatic hypertrophy, urinary retention***Alcoholism, angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, pulmonary disease, QT prolongation, thyroid disease***Children, infants, neonates, Reye's syndrome***Encephalopathy, hepatic disease, jaundice***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Sunlight (UV) exposure***Accidental exposure***Abrupt discontinuation***Renal failure***Ocular disease***Chemotherapy, GI obstruction, vomiting***Tobacco smoking***Labor, obstetric delivery, pregnancy, pregnancy testing***Breast-feeding***Breast cancer, hyperprolactinemia, infertility***Radiographic contrast administration***Suicidal ideation***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,lidocaine hydrochloride/dextrose,"***For the treatment of perfusing ventricular arrhythmias including ventricular fibrillation (VF) and ventricular tachycardia (VT) that may result during acute myocardial infarction or cardiac manipulation (e.g., cardiac surgery). <br />  NOTE: See resuscitation indication for dosage guidelines for VF or pulseless VT.<br />NOTE: Although not considered a drug of choice for ventricular arrhythmias, lidocaine may be used as an alternative antiarrhythmic in patients with preserved ventricular function and stable monomorphic VT. Lidocaine may also be used to treat polymorphic VT in patients with a normal QT interval (when electrolyte imbalance and ischemia are treated). If pulseless cardiac arrest associated with VF or VT, see separate dosage guidelines for the treatment ventricular arrhythmias during CPR.<br />NOTE: Lidocaine may be used to treat patients with polymorphic VT associated with QT prolongation (e.g., torsade de pointes).<br />NOTE: Monitor blood pressure and the electrocardiogram (ECG) during intravenous lidocaine administration***For topical anesthesia of skin and mucous membranes or stomatitis.***For prevention of dental pain� and for topical anesthesia of mucous membranes.***For laryngoscopy.***For nonurgent painful procedures including IV cannulation, venipuncture, lumbar puncture, or arterial puncture.***For the treatment of stage 1 thru 4 pressure ulcers, venous stasis ulcers, ulcerations of mixed vascular etiologies, diabetic skin ulcers, first and second degree burns, and post surgical incisions, cuts, and abrasions.***For endotracheal intubation.***For neonatal circumcision�.***For bronchoscopy.***For the treatment of pain associated with postherpetic neuralgia.***For ophthalmic anesthesia.***For local anesthesia including peripheral nerve block anesthesia. <br />        NOTE: In adults, the dosages for local anesthesia reported are general guidelines only. The actual dose depends on a variety of factors such as depth of anesthesia, extent of surgical procedure, degree of muscle relaxation required, duration of anesthesia and the patients' physical condition. See Lidocaine; epinephrine monograph for information concerning combination dosing.<br />     ***For dental anesthesia including mandibular nerve block and maxillary infiltration.***For infiltration anesthesia.***For intravenous regional anesthesia.***For pudendal nerve block.***For paravertebral block.***For intercostal nerve block.***For brachial plexus block.***For paracervical block.***For sympathetic nerve block.***For cervical stellate ganglion block.***For lumbar sympathetic block.***For epidural anesthesia. <br />        NOTE: The dose is determined by the number of dermatomes to anesthetized (2 to 3 mL/dermatome). The suggested concentrations and volumes serve as a guide, other volumes and concentrations may be used provided the maximum dose is not exceeded.<br />     ***For lumbar anesthesia.***For lumbar analgesia for severe pain.***For thoracic.***For caudal anesthesia.***For obstetric anesthesia.***For surgical anesthesia.***For spinal anesthesia.***For obstetrical low spinal or saddle block anesthesia.***For intraabdominal anesthesia.***For the treatment of ventricular arrhythmias during cardiopulmonary resuscitation� (CPR).***For the attenuation of increased intracranial pressure� during rapid-sequence intubation� or endotracheal tube suctioning�.***For the treatment of severe singultus (hiccups)�.***For the treatment of headache�.***For the treatment of acute headache� associated with migraine�.***For the treatment of cluster headache�.***For the symptomatic treatment of corticosteroid-dependent asthma�. <br />        NOTE: Initial bronchoconstriction can occur. In addition, lidocaine toxicity can result in tremors, hallucinations, seizures, and cardiac arrest. Caution is advised until long-term safety and efficacy can be established.<br />     ***For short-term prophylaxis of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing� (SUNCT).***For the treatment of painful diabetic neuropathy� in adults.","***General Information***Amide local anesthetic hypersensitivity, epidural anesthesia***Collagen-vascular disease***G6PD deficiency***Geriatric, heart failure, hepatic disease***Hypotension, pregnancy***Breast-feeding***Adams-Stokes syndrome, atrial fibrillation, atrial flutter, AV block, bradycardia, cardiogenic shock, hemorrhagic shock, hypovolemia, shock, Wolff-Parkinson-White syndrome***Renal disease, renal failure, renal impairment***Burns, eczema, heating pad, occlusive dressing, skin abrasion***Cataracts, ocular exposure, ocular trauma***Accidental exposure***Intraarterial administration, intrathecal administration, intravenous administration***Head and neck anesthesia***Ocular surgery***Anticoagulant therapy, bleeding, coagulopathy, infection, neurological disease, requires a specialized care setting, requires an experienced clinician, sepsis, spinal anesthesia, thrombocytopenia***Fetal distress, labor, obstetric delivery, pudendal nerve block***Continuous intraarticular infusion administration***Fetal prematurity, paracervical nerve block***Malignant hyperthermia***Children, infants, neonates, teething pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['24812'],felbamate,***For the treatment of partial seizures with or without generalization in adults. <br />        NOTE: Felbamate has not been systematically studied as initial monotherapy.<br />     ***For the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.,"***Carbamate hypersensitivity***Agranulocytosis, aplastic anemia, bone marrow suppression, hematological disease, leukopenia, neutropenia, thrombocytopenia***Hepatic disease, hepatitis, hepatotoxicity, jaundice***Renal failure, renal impairment***Depression, suicidal ideation***Pregnancy***Breast-feeding***Children, infants***Abrupt discontinuation***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sevelamer carbonate,***For the management of hyperphosphatemia in patients with stage 5 chronic kidney disease (CKD) on dialysis.,"***General Information***Constipation, dysphagia, fecal impaction, GI obstruction, GI perforation, ileus, surgery***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cytarabine liposome,***For the treatment of carcinomatous meningitis. <br />        NOTE: Cytarabine liposomal has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of lymphomatous meningitis.,"***General Information***Infection***Arachnoiditis***Peripheral neuropathy, radiation therapy***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['7407', '31765']",nicotine,"***For use as an adjunct to psychosocial interventions for tobacco cessation (smoking cessation), including the treatment of nicotine withdrawal.***For the treatment of Tourette's syndrome� as an adjunct to haloperidol.***For ulcerative colitis�.***For the treatment of active ulcerative colitis�.***For secondary prophylaxis of ulcerative colitis (i.e., ulcerative colitis prophylaxis�).","***General Information***Soya lecithin hypersensitivity, tobacco smoking***Acute bronchospasm, asthma***Angina, cardiac arrhythmias, diabetes mellitus, hypertension, hyperthyroidism, myocardial infarction, pheochromocytoma, sodium restriction, thyroid disease, thyrotoxicosis***Nasal polyps***Geriatric***Hepatic disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Peptic ulcer disease***Children, infants, neonates***Dental disease***Esophagitis, gastroesophageal reflux disease (GERD), hiatal hernia***Eczema***Magnetic resonance imaging (MRI)***Depression***Seizure disorder, seizures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['9524'],sulfasalazine,"***For the treatment of mild to moderate ulcerative colitis; as adjunctive therapy in the treatment of severe ulcerative colitis; and to prolong the remission period between acute attacks of ulcerative colitis.***For the treatment of rheumatoid arthritis in patients who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs.***For the treatment of juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA) that has responded poorly to salicylates or other nonsteroidal anti-inflammatory drugs (NSAIDs).***For the treatment of Crohn's disease�, particularly patients with colonic involvement.","***General Information***5-aminosalicylates hypersensitivity, carbonic anhydrase inhibitor hypersensitivity, salicylate hypersensitivity, sulfonamide hypersensitivity, sulfonylurea hypersensitivity, thiazide diuretic hypersensitivity***Folate deficiency megaloblastic anemia, G6PD deficiency, hematological disease***Hepatic disease, jaundice***Porphyria***Dehydration, hypovolemia, renal failure, renal impairment, urinary tract obstruction***Asthma***Pregnancy***Breast-feeding, infants, neonates***Infertility***Children***GI obstruction***Sunlight (UV) exposure***Immunosuppression, infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ipratropium bromide,"***For the treatment of acute bronchospasm� (e.g., asthma exacerbation).***For the symptomatic relief of rhinorrhea associated with seasonal allergic rhinitis or nonallergic rhinitis (e.g., common cold).***For the maintenance treatment and prevention of bronchospasm (e.g., bronchospasm prophylaxis) associated with asthma and chronic obstructive pulmonary disease (COPD) (e.g., emphysema or chronic bronchitis).***For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), such as emphysema or chronic bronchitis.***For the maintenance treatment of bronchospasm associated with asthma� in pediatric patients.***For adjunctive exercise-induced bronchospasm prophylaxis�.","***General Information***Acute bronchospasm, bromide hypersensitivity, paradoxical bronchospasm***Closed-angle glaucoma, contact lenses, ocular exposure, ophthalmic administration***Bladder obstruction, prostatic hypertrophy, urinary retention***Cardiac arrhythmias***Driving or operating machinery***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6851'],methotrexate,"***For the treatment of acute lymphocytic leukemia (ALL).***For the treatment of non-Hodgkin's lymphoma (NHL), including Burkitt's lymphoma.***For cutaneous T-cell lymphoma (CTCL), (a.k.a. mycosis fungoides).***For the treatment of epidermoid head and neck cancer.***For the treatment of lung cancer, especially squamous cell or small cell lung cancer (SCLC).***For the treatment or prophylaxis of leukemic meningitis. <br />        NOTE: The cerebrospinal fluid volume is dependent on age and not on body surface area. The CSF is at 40% of the adult volume at birth and reaches the adult volume within several years. Intrathecal methotrexate administration at a dose of 12 mg/m2 (maximum 15 mg) has been reported to result in low CSF methotrexate concentrations and reduced efficacy in pediatric patients and high concentrations and neurotoxicity in adult patients. Therefore, the dosing of intrathecal methotrexate should be based on the age not the body surface area.<br />     ***For the treatment of osteogenic sarcoma. <br />        NOTE: Methotrexate has been designated by the FDA as an orphan drug for the treatment of osteogenic sarcoma.<br />     ***For the treatment of gestational trophoblastic disease including choriocarcinoma and hydatidiform mole.***For gestational choriocarcinoma, chorioadenoma destruens, and hydatidiform mole.***For high-risk gestational trophoblastic disease in combination with leucovorin, etoposide, actinomycin D, cyclophosphamide, and vincristine (EMA-CO regimen).***For high-risk gestational trophoblastic disease in combination with leucovorin, etoposide, actinomycin D, and cisplatin (EMA-EP regimen).***For the treatment of rheumatoid arthritis (RA). <br />        NOTE: Aspirin, NSAIDs, and/or low-dose corticosteroids may be continued with methotrexate, although the possibility of increased toxicity with concomitant use of NSAIDs, including salicylates has not been fully explored.<br />NOTE: Consider a switch from oral administration to either intramuscular or subcutaneous administration for patients who have poor compliance, inadequate effectiveness, or gastrointestinal side effects***For the treatment of severe, active RA in patients who have had insufficient response to or are intolerant of an adequate trial of first-line therapy including full-dose NSAIDs. <br />  NOTE: Do not use the methotrexate for subcutaneous use formulation (Otrexup) in patients who require oral, IV, IM, intra-arterial, or intrathecal administration; weekly doses less than 10 mg or greater than 25 mg; or high-dose methotrexate regimens.<br /***For the treatment of active polyarticular juvenile idiopathic arthritis. <br />        NOTE: Aspirin, nonsteroidal anti-inflammatory agents (NSAIDs), and/or low-dose corticosteroids may be continued with methotrexate, although there is a risk of increased toxicity with concomitant use of NSAIDs, including salicylates. Steroids may be slowly tapered in patients who respond to methotrexate therapy. <br />     ***For the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. <br />        NOTE: Ensure that a psoriasis flare is not due to an undiagnosed concomitant disease affecting immune responses.<br />     ***For the treatment of bladder cancer�.***For the adjuvant treatment of early breast cancer, in combination with 5-fluorouracil and cyclophosphamide (CMF)�.***For the treatment of desmoid tumor� or aggressive fibromatosis not amenable to surgery or radiotherapy, in combination with vinblastine.***For the treatment of asthma�.***For the treatment of active Crohn's disease� or ulcerative colitis�.***For the treatment of ectopic pregnancy�.***For pregnancy termination� prior to the 63rd day of pregnancy in combination with intravaginal misoprostol.***For the treatment of psoriatic arthritis�.***For the treatment of pruritus� secondary to cholestasis and/or primary biliary cirrhosis�.***For the treatment of systemic lupus erythematosus (SLE)� including polymyositis� or dermatomyositis�.***For the treatment of sarcoidosis�.***For the treatment of carcinomatous meningitis�.***For the treatment of locally advanced or metastatic penile cancer� in combination with cisplatin and bleomycin.","***Exfoliative dermatitis, serious rash***Geriatric***Intrauterine fetal death, pregnancy***Breast-feeding***Anemia, bone marrow suppression, herpes infection, immunosuppression, infection, neutropenia, requires an experienced clinician, thrombocytopenia, varicella, viral infection***Acquired immunodeficiency syndrome (AIDS)***Diabetes mellitus, hypoalbuminemia, pulmonary disease, pulmonary fibrosis, pulmonary toxicity***Alcoholism, hepatic disease, hepatitis, hepatotoxicity, hyperlipidemia, obesity***Benzyl alcohol hypersensitivity, ensure correct formulation selection, intrathecal administration, neonates***Ascites, pleural effusion***Dehydration, nephrotoxicity, renal disease, renal failure, renal impairment***Hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, tumor lysis syndrome (TLS)***Diarrhea, GI bleeding, GI disease, GI perforation, peptic ulcer disease, stomatitis, ulcerative colitis, vomiting***Radiation therapy, sunburn, sunlight (UV) exposure***Vaccination***New primary malignancy***Contraception requirements, infertility, menstrual irregularity, pregnancy testing, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sodium phenylbutyrate,"***For use as an adjunctive therapy to dietary protein restriction and amino acid supplementation in the chronic management of patients with neonatal-onset, or late-onset with history of hyperammonemic encephalopathy, urea cycle disorders ornithine transcarbamoylase (OTC) deficiency, carbamoyl phosphate synthetase (CPS) deficiency, or argininosuccinic acid syntherase (AAS) deficiency.***Formoterol; Mometasone","***General Information***Edema, heart failure, sodium restriction***Renal disease, renal failure, renal impairment***Hepatic disease***Corticosteroid therapy***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,olopatadine hydrochloride,"***For the treatment of the signs and symptoms of allergic conjunctivitis, including ocular pruritus.***For the treatment of symptoms associated with seasonal allergic rhinitis such as rhinorrhea, sneezing, and nasal pruritus.","***Contact lenses***Geriatric***Driving or operating machinery***Children, infants, neonates***Nasal septal perforation, nasal trauma***Depression***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['36108'],salsalate,"***For treatment of rheumatoid arthritis, osteoarthritis, or related rheumatic disorder.","***Angina, cardiac disease, cerebrovascular disease, dehydration, edema, heart failure, hypertension, hypovolemia, myocardial infarction, peripheral vascular disease, renal disease, renal failure, renal impairment, stroke, systemic lupus erythematosus (SLE), thromboembolism***Coronary artery bypass graft surgery (CABG)***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity***Alcoholism, anemia, anticoagulant therapy, corticosteroid therapy, esophagitis, gastritis, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking***Coagulopathy, G6PD deficiency, hemophilia, hepatic disease, hypoprothrombinemia, jaundice, thrombolytic therapy, thrombotic thrombocytopenic purpura (TTP), vitamin K deficiency***Bone marrow suppression, immunosuppression, infection, neutropenia***Geriatric***Ascites***Acid/base imbalance, metabolic acidosis, metabolic alkalosis, respiratory acidosis, respiratory alkalosis***Gout, hyperuricemia***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, influenza, Reye's syndrome, varicella, viral infection***Hypothyroidism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amiloride hydrochloride/hydrochlorothiazide,"***For the treatment of hypertension, peripheral edema, or edema associated with heart failure in patients who develop hypokalemia when thiazides (or other kaliuretic diuretics) are used alone, or in patients with significant risks for hypokalemia (e.g., digitalized, cardiac arrhythmias). <br />        NOTE: The dosage must be determined by individual titration of the separate components, amiloride and hydrochlorothiazide (HCTZ). This combination product is not indicated for initial therapy except in individuals in whom the development of hypokalemia cannot be risked.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Diabetes mellitus, diabetic nephropathy***Anuria, electrolyte imbalance, geriatric, hypercalcemia, hyperkalemia, hyponatremia, hypovolemia, renal disease, renal failure, renal impairment***Hypotension, orthostatic hypotension, sympathectomy, syncope***Acid/base imbalance, metabolic acidosis, respiratory acidosis***Hepatic disease, hepatic encephalopathy, jaundice, neonates***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Pancreatitis***Preeclampsia, pregnancy***Breast-feeding***Children***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluphenazine hydrochloride,"***For the treatment of schizophrenia.***For the treatment of acute agitated behavior (e.g., acute psychosis) when rapid control of acute symptoms is desired or for use when the oral route is not feasible.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.","***Benzyl alcohol hypersensitivity, paraben hypersensitivity, phenothiazine hypersensitivity, sesame oil hypersensitivity, tartrazine dye hypersensitivity***Agranulocytosis, bone marrow suppression, fever, hematological disease, infection, leukopenia, neutropenia***Intravenous administration***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion, head trauma***Dental work, surgery***Intracranial mass, seizure disorder, seizures***Tardive dyskinesia***Anticholinergic medications, closed-angle glaucoma, ileus, prostatic hypertrophy, urinary retention***Alcoholism, angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, pulmonary disease, QT prolongation, thyroid disease***Children, infants, neonates, Reye's syndrome***Encephalopathy, hepatic disease, jaundice***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Sunlight (UV) exposure***Accidental exposure***Abrupt discontinuation***Renal failure***Ocular disease***Chemotherapy, GI obstruction, vomiting***Tobacco smoking***Labor, obstetric delivery, pregnancy, pregnancy testing***Breast-feeding***Breast cancer, hyperprolactinemia, infertility***Radiographic contrast administration***Suicidal ideation***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['3264']['10627', '220333']",dexamethasone/tobramycin,"***For the treatment of corticosteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ophthalmic infection or a risk of bacterial infection exists, including bacterial conjunctivitis, chronic anterior uveitis, and corneal injury (corneal abrasion) from chemical, radiation or thermal burns, or penetration of foreign bodies.","***General Information***Aminoglycoside hypersensitivity, corticosteroid hypersensitivity***Contact lenses***Fungal infection, mycobacterial infection, ocular infection, varicella, viral infection***Diabetes mellitus, increased intraocular pressure, myopia, open-angle glaucoma***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,interferon beta-1a,***For the treatment of remitting-relapsing forms of multiple sclerosis (MS) to slow physical disability and to decrease the frequency of clinical exacerbations. <br />        NOTE: Interferon beta-1a (Avonex) has been designated as an orphan drug by the FDA for this indication.<br />NOTE: Safety and efficacy have not been established in patients with chronic progressive multiple sclerosis***For the treatment of chronic hepatitis C infection� in treatment naive patients. <br />        NOTE: Interferon beta-1a has been designated as an orphan drug by the FDA for this indication.<br />     ,"***Albumin hypersensitivity, hamster protein hypersensitivity***Latex hypersensitivity***Subcutaneous administration***Angina, cardiac arrhythmias, cardiac disease, heart failure, myocardial infarction***Bone marrow suppression***Alcoholism, hepatic disease, jaundice***Pregnancy***Breast-feeding***Children***Depression, psychosis, suicidal ideation***Seizure disorder***Autoimmune disease, thyroid disease***Hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10432'],thalidomide,"***For the treatment of erythema nodosum leprosum (ENL). <br />NOTE: The FDA has designated thalidomide as an orphan drug for the treatment of erythema nodosum leprosum.<br /***For the treatment of multiple myeloma. <br />NOTE: The FDA has designated thalidomide as an orphan drug for the treatment of multiple myeloma.<br /***For newly diagnosed multiple myeloma, in combination with dexamethasone.***For newly diagnosed multiple myeloma, in combination with Total Therapy 2 regimen�.***For relapsed or refractory multiple myeloma, in combination with dexamethasone�. <br />          NOTE: Thalidomide has been designated an orphan drug by the FDA for this indication.<br />       ***For newly diagnosed multiple myeloma in elderly or transplant ineligible patients, in combination with melphalan and prednisone�.***For newly diagnosed multiple myeloma as induction therapy prior to autologous stem-cell transplantation, in combination with bortezomib and dexamethasone�.***For the treatment of AIDS-associated wasting syndrome� and cancer cachexia�. <br />        NOTE: Thalidomide has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of recurrent aphthous ulcer� and stomatitis� in severely immunocompromised patients. <br />        NOTE: Thalidomide has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of chronic graft-versus-host-disease (GVHD)� in combination with steroids and either cyclosporine or tacrolimus. <br />        NOTE: Thalidomide has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of AIDS-related Kaposi's sarcoma�. <br />        NOTE: Thalidomide has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of primary malignant glioma� (including astrocytoma�). <br />        NOTE: Thalidomide has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of recurrent primary malignant glioma�, including astrocytoma� as a single-agent.***For the treatment of primary malignant glioma, including astrocytoma in combination with chemotherapy or radiation therapy�.***For the treatment of myelodysplastic syndrome (MDS)�.***For the treatment of discoid lupus erythematosus�, subacute cutaneous lupus erythematosus�, chronic cutaneous lupus erythematosus�, and the cutaneous manifestations of systemic lupus erythematosus (SLE)�.***For the treatment of Behcet's syndrome�.***For the treatment of prurigo�, specifically, prurigo nodularis�.***For the treatment of Crohn's disease�. <br />        NOTE: Thalidomide has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of peripheral T-cell lymphoma (PTCL)�.***For the first-line treatment of PTCL in combination with gemcitabine, cisplatin, and prednisone�.","***Exfoliative dermatitis, thalidomide hypersensitivity***Myocardial infarction, stroke, thromboembolism***Peripheral neuropathy***Bleeding, GI bleeding, neutropenia, thrombocytopenia***Driving or operating machinery***Orthostatic hypotension***Human immunodeficiency virus (HIV) infection***Seizure disorder, seizures***Treatment outside of a clinical trial***Accidental exposure***Children, infants, neonates***Blood donation***Intrauterine fetal death, pregnancy***Contraception requirements, dysfunctional uterine bleeding, infertility, male-mediated teratogenicity, menstrual irregularity, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],desogestrel/ethinyl estradiol,"***For routine contraception.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�,  abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Edema, hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"regular, human insulin (rDNA origin)","***For the treatment of type 1 diabetes mellitus or for type 2 diabetes mellitus inadequately managed by diet, exercise, and oral hypoglycemics.***For the treatment of gestational diabetes or for the treatment of patients with pre-existing diabetes mellitus (Type 1 or type 2) who are now pregnant.***For pregnant patients with gestational-onset diabetes not controlled by diet-therapy alone.***For pregnant patients with preexisting diabetes prior to pregnancy.***For the treatment of diabetic ketoacidosis (DKA).***For the treatment of hyperosmolar hyperglycemic state (HHS) in patients with type 2 diabetes mellitus.***For the treatment of neonatal diabetes mellitus�.***For nutritional supplementation� to maintain normoglycemia in very low birthweight infants with persistent glucose intolerance, including those neonates on parenteral nutrition with persistent glucose intolerance.***For the treatment of hyperkalemia�.***Formoterol; Mometasone","***Diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Hepatic disease, renal failure, renal impairment***Intramuscular administration, intravenous administration***Continuous subcutaneous insulin infusion (CSII) administration***Hypoglycemia***Hypokalemia***Cresol hypersensitivity***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Children, infants***Tobacco smoking***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['214817'],sacrosidase,"***For oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID).","***General Information***Asthma, glycerin hypersensitivity, papain hypersensitivity, yeast hypersensitivity***Diabetes mellitus***Infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['10438', '91178']",theophylline,"***For treatment of reversible airways obstruction (i.e., for bronchospasm prophylaxis) associated with asthma or chronic obstructive pulmonary disease (COPD) (e.g., emphysema or chronic bronchitis). <br />        NOTE: Calculate initial mg/kg dose based on ideal body weight as theophylline distributes poorly into body fat. <br />     ***For adjunct treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases (e.g., COPD) along with inhaled beta-2 selective agonists and systemic corticosteroids.***For maintenance therapy of asthma or COPD using oral dosage.***For the treatment of acute exacerbations� of reversible airways obstruction (including status asthmaticus) in patients who are not responding to first-line therapies. <br />        NOTE: Although reference texts continue to list this indication, several studies have failed to demonstrate a benefit of theophylline in the management of acute bronchospasm. The FDA no longer includes acute bronchospasm as an approved indication. Most clinicians do not feel theophylline is warranted in the treatment of acute bronchospasm unless the patient is not responding to other treatments. The National Asthma Education and Prevention Program does not recommend theophylline for acute exacerbations because it appears to provide no additional benefit to optimal inhaled beta-2-agonist therapy and may increase risk of adverse effects.<br />     ***For the treatment of neonatal apnea of prematurity when non-pharmacologic therapies are ineffective. <br />        NOTE: Caffeine is the preferred agent for this indication (see Caffeine monograph); theophylline is used as an alternative.<br />     ***For the treatment of sleep apnea� in patients with chronic heart failure-induced systolic dysfunction.***Formoterol***Formoterol; Mometasone","***General Information***Cardiac arrhythmias, cardiac disease, cor pulmonale, coronary artery disease, heart failure, myocardial infarction***Hypothyroidism, pulmonary edema, sepsis, shock***Cystic fibrosis, hyperthyroidism***Acidemia***Cholestasis, hepatic disease, hepatitis, infants, neonates, renal impairment***Tobacco smoking***Fever, hypoxemia***Gastritis, gastroesophageal reflux disease (GERD), hiatal hernia, peptic ulcer disease***Prostatic hypertrophy***Pregnancy***Breast-feeding***Corn hypersensitivity***Seizure disorder***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['84857'],anastrozole,"***For the treatment of breast cancer. <br />        NOTE: The American Society of Clinical Oncology recommends that all postmenopausal women with hormone receptor-positive early breast cancer receive adjuvant aromatase inhibitor therapy. Options include 5 years of an aromatase inhibitor or sequential therapy with 2�3 years or 5 years of tamoxifen followed by 2�3 years or 5 years of an aromatase inhibitor. The optimal duration of therapy and regimen is not known.�<br />     ***For adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.***For adjuvant treatment of estrogen receptor-positive early breast cancer in postmenopausal women who have received 2�3 years of tamoxifen therapy to complete a total of 5 consecutive years of adjuvant hormonal therapy�.***For the first-line treatment of hormone receptor positive or hormone receptor status unknown, locally advanced or metastatic breast cancer in postmenopausal women.***For the treatment of HER2-positive, hormone receptor-positive metastatic breast cancer in combination with trastuzumab�.***For the first-line treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women, in combination with fulvestrant�.***For the treatment of uterine leiomyomata�.***For the treatment of endometriosis� refractory to other medical or surgical treatments.",***General Information***Hepatic disease***Osteoporosis***Cardiac disease***Children***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,propranolol hydrochloride,"***For the treatment of chronic stable angina.***For heart rate control in patients with atrial fibrillation and/or atrial flutter.***For the treatment of paroxysmal supraventricular tachycardia (PSVT) or for paroxysmal supraventricular tachycardia (PSVT) prophylaxis.***For the treatment of an evolving acute myocardial infarction. <br />  NOTE: For ST-elevation myocardial infarction, oral beta-blocker therapy should be initiated in the first 24 hours for patients who do not have signs of cardiac failure, evidence of low output, increased risk for cardiogenic shock, or other contraindications for beta-blocker therapy.<br /***For reduction of cardiovascular mortality in stable patients who have sustained a myocardial infarction.***For the treatment of hypertension.***For the treatment of idiopathic hypertrophic subaortic stenosis (IHSS).***For management of pheochromocytoma, including preoperative control of tachycardia before surgery, in conjunction with an alpha-blocker.***For migraine prophylaxis.***For migraine prophylaxis in pediatric patients�.***For migraine prophylaxis in adults.***For the management of tremor.***For the management of essential tremor.***For the management of lithium-induced tremor�.***For the management of essential tremor in pediatric patients.***For the treatment of a proliferating infantile hemangioma requiring systemic therapy. <br />  To reduce the risk of hypoglycemia, administer propranolol immediately after or concurrently with a feeding. Avoid fasting; if inevitable, hold medication or support with a product such as Pedialyte or glucose-containing IV fluids.  Vital signs and cardiorespiratory exam or ECG should be obtained at baseline. Obtain blood pressure and heart rate measurements at 1 and 2 hours after the initial dose and any significant dose increase (e.g., more than 0.5 mg/kg/day).  Experts have recommended propranolol therapy continue until full involution of the lesion has occurred or the patient is at least 1 year of age; recurrences have been reported with early discontinuation. At the end of therapy, gradually taper propranolol over 2 to 4 weeks.      If hemangiomas recur, treatment may reinitiated.<br /***For the treatment of unstable angina�.***For the treatment of anxiety� or panic attacks�.***For the short-term symptomatic management of thyrotoxicosis� and thyroid storm�.***For the short-term symptomatic management of thyrotoxicosis� and thyroid storm� in pediatric patients.***For the short term management of thyrotoxicosis� or thyroid storm in adults�.***For the treatment of hypertension and the subsequent decline in renal function associated with scleroderma renal crisis (SRC)�.***For the treatment of portal hypertension� and/or variceal bleeding prophylaxis� in patients with esophageal varices�.***For the prevention of first variceal bleed (primary variceal bleeding prophylaxis).***For prevention of recurrence of variceal bleed (secondary variceal bleeding prophylaxis).***For the treatment of chronic agitation� or aggressive behavior.***For the prevention and management of hypercyanotic episodes associated with tetralogy of Fallot (i.e., tetralogy spells�).***For the attenuation of hypermetabolism in patients with severe burns�.***For the attenuation of hypermetabolism in adult patients with severe burns.***For the attenuation of hypermetabolism in pediatric patients with severe burns.***For the treatment of heart failure� (ischemic origin or cardiomyopathy�) usually in conjunction with digoxin, diuretics, or ACE inhibitor therapy in children and infants.***For the maintenance of sinus rhythm in patients with supraventricular arrhythmias�, including Wolff-Parkinson-White (WPW) syndrome� and junctional ectopic tachycardia� (JET).***Formoterol; Mometasone","***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***Acute heart failure, AV block, bradycardia, cardiogenic shock, hypotension, pheochromocytoma, pulmonary edema, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Wolff-Parkinson-White syndrome***Cerebrovascular disease, PHACE syndrome, stroke***Diabetes mellitus, hypoglycemia***Hepatic disease***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Beta-blocker hypersensitivity***Raynaud's phenomenon***Myasthenia gravis, myopathy***Depression***Driving or operating machinery***Renal failure, renal impairment***Psoriasis***Surgery***Children, infants, neonates, premature neonates***Obstetric delivery, pregnancy***Breast-feeding***Geriatric***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3255'],desoximetasone,"***For the relief of moderate-to-severe inflammatory manifestations, including pruritus, of corticosteroid responsive dermatoses including alopecia areata, atopic dermatitis, contact dermatitis, dermatitis, <em>Rhus</em> <em>dermatitis</em> due to plants like poison ivy, discoid lupus erythematosus, eczema, exfoliative dermatitis, granuloma annulare, keloids, lichen planus, lichen simplex, lichen striatus, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, and xerosis. <br />        NOTE: Systemic therapy or intralesional injection of corticosteroids may be necessary for some conditions based on the type and severity of the disorder or inadequate response to topical therapy.<br />     ","***General Information***Cataracts, glaucoma, ocular exposure, ophthalmic administration***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Geriatric, skin atrophy***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, tuberculosis, varicella, viral infection***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,doxorubicin hydrochloride,"***For the treatment of acute lymphocytic leukemia (ALL).***For the treatment of acute myelogenous leukemia (AML).***For the treatment of bladder cancer.***For the treatment of rapidly recurrent (stage Ta or T1) or in situ transitional cell bladder cancer.***For the neoadjuvant treatment of bladder cancer.***For the treatment of metastatic transitional cell bladder cancer.***For the first-line treatment of advanced or metastatic bladder cancer in combination with vinblastine, cisplatin, and methotrexate.***For the treatment of breast cancer.***For the treatment of metastatic breast cancer.***For the treatment of metastatic gastric cancer.***For the treatment of Hodgkin lymphoma.***For the treatment of Hodgkin lymphoma as part of the Stanford V regimen.***For the treatment of Hodgkin lymphoma as part of the BEACOPP regimen.***For the treatment of Hodgkin lymphoma as part of the ABVD or MOPP/ABV regimens.***For the treatment of previously untreated advanced classical Hodgkin lymphoma, in combination with brentuximab vedotin, vinblastine, and dacarbazine. <br />  NOTE: Brentuximab vedotin is FDA approved in combination with chemotherapy (e.g., doxorubicin, vinblastine, and dacarbazine) for the treatment of previously untreated stage III or IV classical Hodgkin lymphoma.<br /***For the treatment of metastatic ovarian cancer.***For the treatment of small cell lung cancer (SCLC).***For the treatment of newly-diagnosed SCLC in combination with cyclophosphamide and vincristine.***For the treatment of newly-diagnosed SCLC in combination with cyclophosphamide and etoposide.***For the treatment of non-Hodgkin's lymphoma (NHL).***For the treatment of geriatric patients with NHL in combination with cyclophosphamide, vincristine, and prednisone.***For the treatment of follicular NHL, in combination with rituximab, cyclophosphamide, vincristine, and prednisone (R-CHOP).***For the first-line treatment of diffuse large B-cell, CD20-positive NHL, in combination with rituximab, cyclophosphamide, vincristine, and prednisone (R-CHOP).***For the treatment of metastatic osteogenic sarcoma.***For the treatment of metastatic Ewing's sarcoma.***For the treatment of soft-tissue sarcoma.***For the treatment of metastatic soft-tissue sarcoma.***For the first-line treatment of unresectable or metastatic soft-tissue sarcoma in combination with dacarbazine, ifosfamide, and mesna.***For the treatment of metastatic neuroblastoma.***For the treatment of intermediate-risk neuroblastoma in combination with etoposide, cyclophosphamide, and carboplatin.***For the treatment of metastatic thyroid cancer.***For the treatment of metastatic Wilms' tumor.***For the treatment of advanced or recurrent endometrial cancer� in combination with cisplatin and paclitaxel.***For induction therapy prior to autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma�, in combination with vincristine and dexamethasone.***For the treatment of advanced stage hepatocellular cancer� in combination with cisplatin.***For the treatment of thymoma�.***For the treatment of unresectable, advanced thymoma in combination with cyclophosphamide and cisplatin�.***For the treatment of unresectable, advanced thymoma in combination with cisplatin, cyclophosphamide, and vincristine�.***For the treatment of AIDS-related Kaposi's sarcoma� in combination with bleomycin and vincristine.***For the first-line treatment of rhabdomyosarcoma� in combination with vincristine, dactinomycin, and ifosfamide.***For the treatment of metastatic liver lesions from malignant melanoma�.***For the treatment of biliary tract cancer� (unresectable intrahepatic cholangiocarcinoma) in combination with cisplatin, mitomycin, ethiodol, and polyvinyl alcohol.***Formoterol; Mometasone","***Anthracycline hypersensitivity***Hepatic disease***Cardiomyopathy, cardiotoxicity, heart failure, maximum cumulative lifetime dose, myocardial infarction, myocarditis, pericarditis***Bone marrow suppression, infection, leukopenia, neutropenia, thrombocytopenia***Extravasation, tissue necrosis***New primary malignancy***Radiation therapy***Tumor lysis syndrome (TLS)***Females***Children, growth inhibition, infants***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,methylprednisolone sodium succinate,"***For the treatment of status asthmaticus.***For the treatment of asthma.***For a moderate to severe asthma exacerbation in the emergency department or the hospital.***For an acute asthma exacerbation on an outpatient basis.***For long-term prevention of symptoms in severe persistent asthma.***For the treatment of the acute respiratory distress syndrome (ARDS).***For the management of symptomatic sarcoidosis.***For the treatment of inflammatory bowel disease during critical periods of ulcerative colitis and regional enteritis (Crohn's disease).***For the treatment of allergic disorders including anaphylaxis or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, serum sickness, severe perennial or seasonal allergic rhinitis, or urticaria.***For non-emergent treatment of hypersensitivity or allergic conditions.***For the urgent treatment of severe conditions like anaphylaxis, angioedema, or urticarial transfusion-related reactions.***For the treatment of corticosteroid-responsive dermatologic disorders (e.g., alopecia areata, atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis including Rhus dermatitis due to poison ivy, poison oak, poison sumac, discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex, mycosis fungoides, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pruritus, psoriasis, seborrheic dermatitis, or xerosis).***For mild-moderate corticosteroid responsive dermatoses.***For severe inflammatory dermatoses, like exfoliative dermatitis, erythema multiforme or Stevens-Johnson syndrome, or psoriasis not responding to topical therapy.***For the treatment of acute exacerbations of multiple sclerosis.***For the treatment of myasthenia gravis in patients who are poorly controlled with cholinesterase inhibitor therapy.***For the treatment of hypercalcemia associated with certain types of cancer.***For the treatment of non-neoplastic hematologic disorders including immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), and congenital hypoplastic anemia.***For the treatment of adrenocortical function abnormalities, such as adrenocortical insufficiency, congenital adrenal hyperplasia (CAH), chronic primary (Addison's disease) or secondary adrenocortical insufficiency, or adrenogenital syndrome.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of nonsuppurative thyroiditis.***For the treatment of acute kidney transplant rejection.***For the treatment of respiratory conditions including airway-obstructing hemangioma� in infants, aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), Loeffler's syndrome, or noncardiogenic pulmonary edema�.***For chronic oral management of non-asthmatic respiratory conditions.***For parenteral management of non-asthmatic respiratory conditions when oral dosing not feasible or severity or compromised airway warrants.***For chronic maintenance therapy for idiopathic pulmonary fibrosis�.***For the treatment of laryngotracheobronchitis (croup)�.***For the treatment of acute spinal cord injury�.***For adjunctive therapy in the treatment of rheumatic disorders including acute gouty arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, psoriatic arthritis, or rheumatoid arthritis, or for the treatment of acute episodes or exacerbation of nonrheumatic inflammatory conditions including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the treatment of selected cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, vasculitis�, or Wegener's granulomatosis�.***For routine treatment.***For life-threatening manifestations including diffuse proliferative glomerulonephritis (i.e., lupus nephritis�), cerebritis, or hemolytic disease.***For the palliative management of leukemia and lymphoma in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), or multiple myeloma�.***For the treatment of Pneumocystis pneumonia (PCP)� in HIV patients as adjunctive therapy.***For the treatment of Severe Acute Respiratory Syndrome (SARS)�.***For the treatment of acute interstitial nephritis (AIN)�.***For the treatment of acute graft-versus-host disease (GVHD)�.***For the treatment of heart transplant rejection�.***For the systemic treatment of ophthalmic disorders including allergic conjunctivitis, allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.***For the treatment of IVIG-refractory Kawasaki disease�.","***General Information***Epidural administration, intramuscular administration, intrathecal administration, intravenous administration***Fungal infection, infection, measles, mycobacterial infection, sepsis, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Heart failure, hypertension***Cataracts, glaucoma, increased intraocular pressure, visual disturbance***Diabetes mellitus, herpes infection, osteoporosis, psychosis, renal disease, seizure disorder***Myasthenia gravis***Diverticulitis, GI disease, hepatic disease, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Coagulopathy, idiopathic thrombocytopenic purpura (ITP), thromboembolic disease***Pregnancy***Breast-feeding***Children, growth inhibition, increased intracranial pressure, infants***Cushing's syndrome***Abrupt discontinuation, hypothalamic-pituitary-adrenal (HPA) suppression***Neonates, premature neonates***Corticosteroid hypersensitivity***Hyperthyroidism, hypothyroidism, thyroid disease***Geriatric***Immunosuppression***Vaccination***Head trauma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,saquinavir mesylate,***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents.***Formoterol***Formoterol; Mometasone,"***General Information***Human immunodeficiency virus (HIV) infection resistance***Hepatic disease, hepatitis, hepatitis B and HIV coinfection***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, pancreatitis***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia***Hemophilia***Pregnancy***Breast-feeding***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Alcoholism, AV block, bradycardia, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydrocortisone sodium succinate,"***For the treatment of primary adrenocortical insufficiency (e.g., Addison's Disease, congenital adrenal hyperplasia or CAH) or secondary adrenocortical insufficiency.***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing minor surgery or with a minor illness (e.g., inguinal hernia repair, colonoscopy, mild febrile illness, gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing moderate surgery or with a moderate illness (e.g., open cholecystectomy, hemicolectomy, significant febrile illness, pneumonia, severe gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing major surgery, or with other acute stressors (e.g., major cardiothoracic surgery, Whipple procedure, liver resection, pancreatitis, acute systemic infection, shock).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency and a critical illness (e.g., shock).***For the treatment of acute adrenocortical insufficiency.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency with other acute stressors (e.g., febrile illness with a temperature more than 38.5 degrees Celsius, gastroenteritis with dehydration, major trauma):.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency undergoing surgery accompanied by general anesthesia.***For use in nonspecific proctitis, postirradiation (factitial) proctitis, cryptitis, or for other non-specific inflammatory conditions of the anorectum.***For the treatment of inflammatory bowel disease (Crohn's disease or ulcerative colitis).***For adjunctive treatment of Crohn's disease or ulcerative colitis using oral or parenteral therapy.***For adjunctive rectal treatment of chronic ulcerative colitis, particularly if disease limited to the distal portion of the rectum.***For the relief of inflammation, pruritus ani, and swelling associated with hemorrhoids.***For the treatment of allergic disorders including anaphylaxis, anaphylactic shock, or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, transfusion-related reactions, serum sickness, severe perennial or seasonal allergic rhinitis, or urticaria.***For the non-emergent treatment of hypersensitivity or allergic conditions.***For the urgent treatment of severe conditions such as anaphylaxis, angioedema, acute noninfectious laryngeal edema, or urticarial transfusion-related reactions.***For the treatment of corticosteroid-responsive dermatologic disorders (e.g., alopecia areata, atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis including Rhus dermatitis due to poison ivy, poison oak, poison sumac, discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pompholyx (dyshidrosis), pruritus, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, xerosis).***For mild-to-moderate corticosteroid responsive dermatoses.***For mild to moderate atopic dermatitis.***For the systemic treatment of severe inflammatory dermatoses, like severe exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, or psoriasis unresponsive to topical treatment.***For adjunctive therapy in the treatment of rheumatic disorders including acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of non-rheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the short-term treatment of hypercalcemia associated with neoplastic disease.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the management of nephrotic syndrome to induce diuresis or decrease proteinuria.***For the treatment of neurologic or myocardial involvement associated with trichinosis.***For the treatment of nonsuppurative thyroiditis.***For rheumatic and related disorders such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, symptomatic sarcoidosis, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive hematologic disorders, like immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia, and congenital hypoplastic anemia; OR for the palliative treatment of neoplastic disease in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), or multiple myeloma�.***For the treatment of respiratory inflammatory conditions including bronchial asthma, aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), Loeffler's syndrome, or noncardiogenic pulmonary edema�.***For the treatment of septic shock� and/or hypotension� in patients whose blood pressure is poorly responsive to adequate fluid resuscitation and vasopressor therapy.***For the prevention of chronic lung disease (CLD)� in mechanically ventilated patients.***For the treatment of refractory neonatal hypoglycemia�.***For the treatment of corticosteroid-responsive ophthalmic disorders, including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.","***Abrupt discontinuation, Cushing's syndrome, skin abrasion***Growth inhibition, increased intracranial pressure***Immunosuppression***Fungal infection, infection***Acne rosacea, acne vulgaris, herpes infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Heart failure, hypertension***Osteoporosis***Diabetes mellitus***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hypothyroidism, psychosis, renal disease, seizure disorder***Myasthenia gravis***Coagulopathy, hemophilia, thromboembolic disease***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Neonates, premature neonates***Benzyl alcohol hypersensitivity, corticosteroid hypersensitivity***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Skin atrophy***Geriatric***Epidural administration, intrathecal administration***Pheochromocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albumin (human),"***For the treatment of shock due to hypovolemia. <br />        NOTE: Dosage should be based on patient response as indicated by blood pressure, degree of pulmonary congestion, and hematocrit.<br />     ***For adjunctive treatment of severe burns.***For the treatment of nephrosis in nephrotic syndrome.***For treatment of hypoproteinemia.***For adjunctive use with exchange transfusion in the treatment of hyperbilirubinemia and erythroblastosis fetalis.","***Albumin hypersensitivity***Anemia, heart failure, hypertension***Renal disease***Hypernatremia***Burns***Viral infection***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2191', '1545984']",ceftazidime,"***For the treatment of intraabdominal infections, including peritonitis.***For peritonitis in patients undergoing peritoneal dialysis.***For the treatment of bone and joint infections, including osteomyelitis.***For the treatment of lower respiratory tract infections, including pneumonia such as community-acquired pneumonia (CAP) and nosocomial pneumonia.***For the treatment of urinary tract infection (UTI).***For the treatment of very severe life-threatening infections, such as bacteremia and sepsis.***For the treatment of gynecologic infections, including endometritis and pelvic cellulitis.***For the treatment of central nervous system infections, including meningitis.***For the treatment of skin and skin structure infections, including diabetic foot ulcer.***For the management of pulmonary infections in patients with cystic fibrosis.***For the empiric treatment of febrile neutropenia�.***For the treatment of melioidosis� due to <em>Burkholderia pseudomallei</em>.***For the treatment of infective endocarditis�.","***General Information***Cephalosporin hypersensitivity, penicillin hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Coagulopathy, vitamin K deficiency***Renal failure, renal impairment***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/norethindrone,"***For routine contraception.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***For gastrointestinal bleeding prophylaxis� related to arteriovenous malformations, radiation-induced rectal telangiectases, hereditary telangiectases, and gastric antral vascular ectasia in patients who have severe recurrent blood loss and frequent need for transfusion despite other medical therapies, and who have no contraindications to oral contraceptives.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Ectopic pregnancy, pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,betamethasone valerate,"***For the treatment of acute graft-versus-host disease (GVHD).***For the treatment of nonsuppurative thyroiditis.***For the treatment of acute exacerbations of multiple sclerosis.***For the management of symptomatic sarcoidosis or for the treatment of hypercalcemia associated with cancer or sarcoidosis.***For the treatment of allergic disorders including anaphylaxis or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema (or for laryngeal edema prophylaxis), drug hypersensitivity reactions, serum sickness, severe perennial or seasonal allergic rhinitis, severe urticaria, or for the treatment of urticarial transfusion reactions. <br />        NOTE: Betamethasone should be administered IM or IV initially in the treatment of anaphylaxis or anaphylactoid reactions, angioedema, and acute noninfectious laryngeal edema or to prevent impending risk of laryngeal edema.<br />     ***For the treatment of urticarial transfusion reactions.***For the treatment of immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of hematologic disorders including secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), and congenital hypoplastic anemia.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of inflammatory bowel disease including Crohn's disease (regional gastroenteritis) and ulcerative colitis.***For the induction of diuresis or remission of proteinuria in the nephrotic syndrome.***For the treatment of nasal polyps.***For the treatment of severe cases of myasthenia gravis not controlled by antimyasthenic agents alone.***For adjunctive therapy in the treatment of rheumatic disorders e.g., acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), osteoarthritis, polychondritis�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of nonrheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the treatment of moderate-to-severe inflammation and pruritus due to corticosteroid-responsive dermatologic disorders such as alopecia areata, cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis, generalized exfoliative dermatitis, nummular dermatitis, seborrheic dermatitis, eczema, granuloma annulare, keloids, lichen planus, lichen simplex chronicus, lichen striatus, subacute cutaneous and discoid lupus erythematosus, pretibial myxedema, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, psoriasis, <em>Rhus dermatitis</em> (due to poison ivy, poison oak, or poison sumac), sarcoidosis, Stevens-Johnson syndrome, sunburn, or urticaria. <br />        NOTE: Systemic corticosteroids may be necessary for some conditions based on the type and severity of the disorder (e.g., Stevens-Johnson syndrome) or inadequate response to topical therapy; intralesional injections may also be appropriate for select conditions.<br />     ***For the treatment of plaque psoriasis.***For the treatment of seborrheic dermatitis.***For hyaline membrane disease prophylaxis�, for the purpose of fetal lung maturation to prophylax against anticipated neonatal respiratory distress syndrome (RDS)� in premature infants.***For palliative management of leukemia and lymphoma in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), or for the treatment of multiple myeloma�.***For maintenance therapy in selected cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis�, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, conjunctivitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For the treatment of respiratory inflammatory conditions including airway-obstructing hemangioma� in infants, aspiration pneumonitis, berylliosis, bronchial asthma, chronic obstructive pulmonary disease (COPD), laryngotracheobronchitis (croup), Loeffler's syndrome, or non-cardiogenic pulmonary edema�, or for bronchospasm prophylaxis. <br />        NOTE: Betamethasone should be administered parenterally initially in the treatment of severe manifestations of these diseases, particularly where airway obstruction is present.<br />     ","***Abrupt discontinuation, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, growth inhibition, increased intracranial pressure, infants, neonates***Immunosuppression***Acne rosacea, acne vulgaris, fungal infection, herpes infection, infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Edema, heart failure, hypertension***Osteoporosis***Diabetes mellitus***Crohn's disease, diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hyperthyroidism, hypothyroidism, psychosis, renal disease, seizure disorder, thyroid disease***Myasthenia gravis***Idiopathic thrombocytopenic purpura (ITP), thromboembolic disease***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Epidural administration, intravenous administration***Corticosteroid hypersensitivity***Head trauma***Skin atrophy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['341018'],anidulafungin,"***For the treatment of candidemia and invasive candidiasis.***For the treatment of chronic disseminated (hepatosplenic) candidiasis�.***For the treatment of esophageal candidiasis.***For the treatment of intraabdominal infections (i.e., peritonitis, intraabdominal abscess) caused by <em>Candida</em> sp..***For the treatment of oropharyngeal candidiasis (thrush)�.***For the treatment of cardiovascular system infections, including endocarditis�, suppurative thrombophlebitis�, and infected pacemaker�, implantable cardiac defibrillator (ICD)�, or ventricular assist devices (VAD)�, caused by <em>Candida</em> sp..***For the treatment of respiratory infections (i.e., pneumonia�) caused by <em>Candida</em> sp..***For the treatment of bone and joint infections�, including osteomyelitis� and infectious arthritis�, caused by <em>Candida</em> sp..***For candidiasis prophylaxis� in high-risk patients.","***General Information***Hepatic disease***Pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1886'],aspirin/caffeine/dihydrocodeine bitartrate,"***For the treatment of moderate pain to severe pain (i.e. headache, myalgia, back pain, bone pain, dental pain, dysmenorrhea, or arthralgia).***Formoterol***Formoterol; Mometasone","***General Information***Acute bronchospasm, angioedema, asthma, nasal polyps, NSAID hypersensitivity, opiate agonist hypersensitivity, salicylate hypersensitivity, urticaria***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, depression, heart failure, hypertension, hypotension, mental status changes, suicidal ideation***Acid/base imbalance, metabolic acidosis, metabolic alkalosis, respiratory acidosis, respiratory alkalosis***Constipation, diabetes mellitus, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Bladder obstruction, oliguria, prostatic hypertrophy, urethral stricture, urinary retention, urinary tract obstruction***Adrenal insufficiency, hypothyroidism, myxedema***Renal disease, renal failure, renal impairment, systemic lupus erythematosus (SLE)***Agranulocytosis, anemia, anticoagulant therapy, coagulopathy, hemophilia, hypoprothrombinemia, thrombocytopenia, thrombolytic therapy, thrombotic thrombocytopenic purpura (TTP), vitamin K deficiency, von Willebrand's disease***Bone marrow suppression, immunosuppression, neutropenia***Hepatic disease, hepatitis***Alcoholism, bleeding, esophagitis, gastritis, GI bleeding, peptic ulcer disease, surgery, tobacco smoking***G6PD deficiency***Coma, head trauma, increased intracranial pressure, intracranial mass, shock***CNS depression, driving or operating machinery, ethanol intoxication, opioid-naive patients***Seizure disorder, seizures***Chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, respiratory depression, respiratory infection, sleep apnea, status asthmaticus***Adenoidectomy, children, infants, influenza, neonates, neuromuscular disease, pulmonary disease, tonsillectomy, varicella, viral infection***Neonatal opioid withdrawal syndrome, pregnancy***Labor, obstetric delivery***Breast-feeding***Abrupt discontinuation, substance abuse***Gout, hyperuricemia***Biliary cirrhosis, biliary obstruction, biliary tract disease, pancreatitis***Intramuscular injections***Ascites, dehydration, hypovolemia***Asian patients, Black patients, Caucasian patients, Hispanic patients***Geriatric***MAOI therapy***Accidental exposure, potential for overdose or poisoning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,gadoxetate disodium,***For use with magnetic resonance imaging (MRI) to detect and characterize liver lesions in patients with known or suspected focal hepatic disease.,"***Magnetic resonance imaging (MRI)***Extravasation***Sickle cell disease***Asthma, atopy, radiopaque contrast media hypersensitivity***Pregnancy***Breast-feeding***Diabetes mellitus, dialysis, geriatric, hypertension, nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy), renal disease, renal failure, renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['3521', '203015']",dipyridamole,"***For arterial thromboembolism prophylaxis.***For use in coronary artery disease diagnosis (i.e., dipyridamole-stress echocardiography).***For secondary prophylaxis of transient ischemic attack (TIA)� in combination with aspirin.***For the treatment of dilated cardiomyopathy�.***For the treatment of proteinuria� associated with membranous glomerulonephritis.***For myocardial infarction prophylaxis� in patients who have sustained a prior myocardial infarction (MI).","***Hypotension, orthostatic hypotension, syncope***Angina***Asthma***Labor, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease***Geriatric***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['40138'],iloprost,"***For the treatment of pulmonary hypertension (pulmonary arterial hypertension WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. <br />  NOTE: Studies establishing effectiveness were comprised predominately of patients with NYHA Functional Class III�IV symptoms and etiologies of idiopathic or heritable pulmonary arterial hypertension (PAH) (65%) or PAH associated with connective tissue diseases (23%).<br />NOTE: Inhaled iloprost should be administered via an approved pulmonary drug delivery device (e.g., I-neb AAD system). This system is designed to deliver the exact amount of prescribed inhaled iloprost.<br />NOTE: In a randomized, double-blind, placebo-controlled study (the STEP trial), 34 patients treated with bosentan 125 mg twice daily for at least 16 weeks tolerated the addition of inhaled iloprost. In this study, iloprost was dosed up to 5 mcg administered 6 to 9 times per day during waking hours. The mean daily inhaled iloprost dose was 27 mcg and the mean number of inhalations per day was 5.6","***Pulmonary edema***Hepatic disease***Renal failure, renal impairment***Driving or operating machinery, hypotension, syncope***Geriatric***Asthma, chronic obstructive pulmonary disease (COPD), respiratory infection***Pregnancy***Breast-feeding***Children***Ocular exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8588'],penicillin G potassium,"***For the treatment of serious infections caused by susceptible organisms, including pleural empyema and bacteremia.***For the treatment of serious meningococcal infections.***For the treatment of bacteremia due to <em>Pasteurella multocida</em>.***For the treatment of gram-negative bacilliary infections.***For the treatment of serious streptococcal infections.***For the treatment of serious staphylococcal infections.***For the treatment of infections due to <em>Clostridium </em>sp., including botulism (adjunctive to antitoxin), gas gangrene, and tetanus (adjunctive therapy).***For the treatment of inhalation anthrax infection caused by susceptible strains of <em>Bacillus anthracis</em>. <br />        NOTE: In the setting where high concentrations of B. anthracis organisms are present, the treatment of infections with a penicillin-type drug alone is a concern due to the risk of a beta-lactamase induction event, which would significantly increase the MIC.<br />     ***For endocarditis or pericarditis.***For the treatment of endocarditis due to penicillin-susceptible viridans streptococci and <em>Streptococcus bovis</em> (MIC of 0.1 mcg/mL or less).***For the treatment of endocarditis due to strains of viridans streptococci and <em>Streptococcus bovis</em> relatively resistant to penicillin G (MIC greater than 0.12 mcg/mL and less than 0.5 mcg/mL).***For the treatment of endocarditis due to viridans streptococci with a MIC of 0.5 mcg/mL or greater or due to enterococci.***For the treatment of staphylococcal endocarditis.***For the treatment of endocarditis due to <em>Erysipelothrix insidiosa</em>.***For the treatment of gonococcal endocarditis.***For the treatment of meningococcal endocarditis.***For the treatment of meningitis.***For the treatment of streptococcal meningitis.***For the treatment of meningococcal meningitis.***For the treatment of staphylococcal meningitis.***For the treatment of <em>Listeria</em> meningitis.***For the treatment of gonococcal meningitis.***For the treatment of meningitis due to <em>Pasteurella multocida</em>.***For the treatment of disseminated gonorrhea, including infectious arthritis, due to <em>Neisseria gonorrhoeae</em> when the infecting strain has been tested and found to be susceptible to penicillin. <br />        NOTE: For meningitis infections, see meningitis dosing. For endocarditis infections, see endocarditis dosing.<br />     ***For the treatment of listeriosis.***For the treatment of diphtheria and for the elimination of the diphtheria carrier state.***For the treatment of rat-bite fever or Haverhill fever due to <em>Spirillum minus</em> or <em>Streptobacillus moniliformis</em>.***For the treatment of actinomycosis.***For the treatment of fusospirochetosis or Vincent's infection, including necrotizing ulcerative gingivitis, oropharynx infections, lower respiratory tract infections, and genital infections caused by <em>Fusobacterium</em> sp..***For the treatment of pneumonia, including community-acquired pneumonia.***For the treatment of disseminated Lyme disease� (i.e., neuroborreliosis, carditis, recurrent/persistent arthritis). <br />  NOTE: Penicillin G is recommended as an alternative to ceftriaxone for the treatment of early Lyme disease with acute neurological disease, for the initial treatment of hospitalized patients with Lyme carditis, and for late manifestations of Lyme disease.<br /***For the treatment of leptospirosis� due to <em>Leptospira </em>sp..***For the treatment of syphilis, including congenital syphilis and neurosyphilis or syphilitic eye disease� (e.g., uveitis�, neuroretinitis�, or optic neuritis�). <br />        NOTE: If follow-up/compliance unsure, desensitize patient and treat with penicillin.<br />NOTE: Pregnant women with syphilis in any stage who report with penicillin allergy should be desensitized and treated with penicillin***For neurosyphilis or syphilitic eye disease� (e.g., uveitis�, neuroretinitis�, or optic neuritis�).***For congenital syphilis. <br />          NOTE: Current CDC guidelines should be consulted to determine the appropriate course of treatment in neonates born to mothers with syphilis. Therapy is based on physical examination, serum quantitative nontreponemal serologic titer, and whether or not the mother was treated properly before delivery. <br />       ***For perinatal Group B streptococcal bacterial infection prophylaxis�.***For the treatment of serious streptococcal or staphylococcal infections, including necrotizing skin and skin structure infections� and erysipelas�.","***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Infants, neonates, renal failure, renal impairment***Electrolyte imbalance***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8183'],phenytoin,"***For the treatment of status epilepticus.***For the treatment of tonic-clonic seizures or partial seizures.***For maintenance dosing to treat tonic-clonic or complex partial seizures.***For non-emergent treatment to increase phenytoin serum concentrations in a patient currently receiving phenytoin, but who has subtherapeutic serum concentrations; or to initiate phenytoin therapy for seizures in non-emergent situations.***For seizure prophylaxis due to specific neurologic conditions, including neurosurgery, head trauma� or traumatic brain injury�, or subarachnoid hemorrhage�.***For seizure prophylaxis following traumatic brain injury� or head trauma� or for seizure prophylaxis or treatment during neurosurgery.***For the treatment of serious cardiac arrhythmias secondary to digoxin toxicity�.***For seizure prophylaxis� during antenatal care in pregnant females with eclampsia� or severe preeclampsia�.","***Barbiturate hypersensitivity, carbamazepine hypersensitivity, hydantoin hypersensitivity, succinimide hypersensitivity***Asian patients, serious rash***Depression, suicidal ideation***Abrupt discontinuation***Hypoglycemia, hyponatremia, petit mal (absence) seizures***Hepatic disease, hepatotoxicity, hypoalbuminemia, jaundice***Agranulocytosis, bone marrow suppression, hematological disease, porphyria***Hodgkin's disease, lymphoma***Adams-Stokes syndrome, AV block, bradycardia, bundle-branch block, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypotension, infusion-related reactions, intravenous administration***Intramuscular administration***Alcoholism, ethanol ingestion, ethanol intoxication***Driving or operating machinery, encephalopathy, psychosis***Renal disease, renal failure, renal impairment***Diabetes mellitus***Hypothyroidism, thyroid disease***Bone fractures, osteomalacia, osteoporosis***Myasthenia gravis***Dental disease***Extravasation***Geriatric***Neonates, obstetric delivery, pregnancy, vitamin K deficiency***Breast-feeding***Contraception requirements, reproductive risk***Radiation therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cetrorelix acetate,***For inhibiting premature leuteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation and subsequent in vitro fertilization (IVF) or other assisted reproductive technology (ART) for the treatment of infertility. <br />        NOTE: Withhold HCG administration if the ovaries are abnormally enlarged to reduce the chance of inducing ovarian hyperstimulation syndrome (OHSS).<br />     ***For the treatment of endometriosis�.***For the treatment of benign prostatic hyperplasia (BPH)�.,"***Atopy, mannitol hypersensitivity***Ovarian failure***Pregnancy***Breast-feeding***Ovarian cyst, polycystic ovary syndrome***Ethanol intoxication, tobacco smoking***Obesity***Hepatic disease, renal failure, renal impairment***Geriatric***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sodium benzoate/sodium phenylacelate,***For the adjunctive treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.***For patients with carbamyl phosphate synthetase or ornithine transcarbamylase deficiency.***For patients with argininosuccinate lyase or argininosuccinate synthetase deficiency.***Formoterol; Mometasone,"***Extravasation, intraarterial administration, intramuscular administration***Edema, heart failure, hypernatremia, hypertension, renal failure, renal impairment, sodium restriction***Hypokalemia***Hepatic disease***Seizures***Diabetes mellitus***Labor, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2626'],clozapine,***For the treatment of refractory schizophrenia that has failed to respond adequately to appropriate courses of standard antipsychotic agents; also to reduce the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder.***For the treatment of bipolar disorder�.***Formoterol***Formoterol; Mometasone,"***General Information***Agranulocytosis, bone marrow suppression, chemotherapy, fever, infection, leukemia, leukopenia, neutropenia***Seizure disorder, seizures***CNS depression, coadministration with other CNS depressants, coma***Neurological disease, Parkinson's disease, tardive dyskinesia***Anticholinergic medications, closed-angle glaucoma, constipation, fecal impaction, GI obstruction, ileus, prostatic hypertrophy, urinary retention***Driving or operating machinery***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, myocarditis, orthostatic hypotension, QT prolongation, syncope, tachycardia, thyroid disease, torsade de pointes, ventricular arrhythmias***Pulmonary disease, thromboembolic disease***Dialysis, renal disease, renal failure***Hepatic disease, hepatitis, hepatotoxicity, jaundice, poor metabolizers***Dementia, geriatric, stroke***Neonates, pregnancy, pregnancy testing***Breast-feeding***Surgery***Children, infants***Diabetes mellitus, diabetic ketoacidosis, hypercholesterolemia, hyperglycemia, hyperlipidemia, hyperosmolar hyperglycemic state (HHS), hypertriglyceridemia, obesity***Abrupt discontinuation***Tobacco smoking***Phenylketonuria***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Dysphagia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['298869'],eplerenone,"***For the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents.***For the reduction of cardiovascular mortality in stable patients with left ventricular systolic dysfunction (ejection fraction of 40% or less) and clinical evidence of congestive heart failure after an acute myocardial infarction.","***Diabetes mellitus, hyperkalemia, proteinuria, renal disease, renal failure, renal impairment***Hepatic disease***Driving or operating machinery***Children, infants, neonates***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bacitracin zinc/polymyxin B sulfate,"***For the treatment of superficial ophthalmic infection caused by susceptible bacteria (e.g., bacterial conjunctivitis, keratitis, keratoconjunctivitis, blepharitis, and blepharoconjunctivitis).***For the prevention of skin and skin structure infections, including wound management of skin abrasion and minor burn wound infection.","***General Information***Polymyxin hypersensitivity***Fungal infection, herpes infection, mycobacterial infection, tuberculosis, varicella, viral infection***Renal failure, renal impairment***Geriatric***Children, infants, neonates***Diarrhea, pseudomembranous colitis***Contact lenses***Ophthalmic administration***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['25037'],cefdinir,***For the treatment of acute bacterial otitis media.***For the treatment of acute exacerbations of chronic bronchitis.***For the treatment of acute maxillary sinusitis.***For the treatment of community-acquired pneumonia.***For the treatment of pharyngitis or tonsillitis.***For the treatment of uncomplicated skin and skin structure infections.***For the treatment of urinary tract infection (UTI)�.,"***General Information***Antimicrobial resistance, viral infection***Cephalosporin hypersensitivity, penicillin hypersensitivity***Dialysis, renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Coagulopathy, vitamin K deficiency***Diabetes mellitus***Infants, neonates***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,balsalazide disodium,***For the treatment of mildly to moderately active ulcerative colitis.,"***5-aminosalicylates hypersensitivity, salicylate hypersensitivity***Ulcerative colitis***Pregnancy***Breast-feeding***Children, infants, neonates***Pyloric stenosis***Renal disease, renal impairment***Hepatic disease***Geriatric***Sodium restriction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2623', '202859']",clotrimazole,"***For the treatment of candidiasis, specifically mucocutaneous candidiasis (i.e., oropharyngeal candidiasis (thrush), vulvovaginal candidiasis).***For the treatment of oropharyngeal candidiasis (thrush).***For the treatment of vulvovaginal candidiasis (VVC).***For candidiasis prophylaxis to reduce the incidence of oropharyngeal candidiasis in immunocompromised patients undergoing chemotherapy or radiotherapy in the treatment of leukemia or solid tumors, or in allograft transplant patients who are receiving corticosteroid therapy.***For the treatment of tinea corporis, tinea cruris, and tinea pedis.***For the treatment of fungal otitis externa�.","***Onychomycosis***Pregnancy***Breast-feeding***Contraceptive devices, menstruation***Azole antifungals hypersensitivity***Abdominal pain, diabetes mellitus, fever, human immunodeficiency virus (HIV) infection, immunosuppression, vaginal discharge***Children, infants, neonates***Ocular exposure, ophthalmic administration***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,colesevelam hydrochloride,"***For the treatment of primary hypercholesterolemia.***For use as adjunctive therapy to diet and exercise for the reduction of elevated LDL cholesterol in patients with primary hypercholesterolemia (Fredrickson Type IIa hyperlipoproteinemia) as monotherapy or in combination with an HMG-CoA reductase inhibitor.***For use as monotherapy or in combination with an HMG-CoA reductase inhibitor to reduce LDL cholesterol (LDL-C) in pediatric patients with heterozygous familial hypercholesterolemia (FH). <br />          NOTE: Colesevelam is indicated for patients with FH who have LDL-C greater than or equal to 190 mg/dL or LDL-C greater than or equal to 160 mg/dL after an adequate trial of diet therapy and have a positive family history of premature cardiovascular disease or 2 or more other CVD risk factors.<br />       ***For use as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. <br />        NOTE: Colesevelam has been studied in combination with other antidiabetic agents; however, use with dipeptidyl peptidase 4 inhibitors has not been studied.<br />     ","***Diabetes mellitus***Biliary obstruction, cholelithiasis***Constipation, dysphagia, gastroparesis, GI obstruction, hemorrhoids, ileus, surgery***Coagulopathy, vitamin K deficiency***Hypertriglyceridemia, pancreatitis***Phenylketonuria***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,prednisolone acetate,"***For primary (Addison's disease) or secondary adrenocortical insufficiency or for the treatment of congenital adrenal hyperplasia.***For the treatment of nonsuppurative thyroiditis.***For the management of symptomatic sarcoidosis.***For the treatment of corticosteroid-responsive dermatitis and dermatologic disorders such as atopic dermatitis or eczema, bullous dermatitis herpetiformis, contact dermatitis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe psoriasis, severe seborrheic dermatitis, or severe erythema multiforme or Stevens-Johnson syndrome.***For the treatment of corticosteroid-responsive respiratory disorders including aspiration pneumonitis, berylliosis, Loeffler's syndrome, or idiopathic pulmonary fibrosis.***For the treatment of asthma.***For a moderate to severe asthma exacerbation in the emergency department or the hospital.***For an acute asthma exacerbation on an outpatient basis.***For long-term prevention of symptoms in severe persistent asthma.***For the treatment of inflammatory bowel disease including critical periods of ulcerative colitis or regional enteritis (Crohn's disease).***For the treatment of hematologic disorders with thrombocytopenia including immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), or secondary thrombocytopenia.***For the treatment of acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), or congenital hypoplastic anemia.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of kidney transplant rejection or for kidney transplant rejection prophylaxis in conjunction with other immunosuppressants.***For the treatment of acute exacerbations of multiple sclerosis.***For the treatment of nephrotic syndrome.***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis, allergic marginal corneal ulcer, anterior segment inflammation, bacterial conjunctivitis, chorioretinitis, choroiditis, cyclitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus) with appropriate antiviral therapy, iritis, non-specific keratitis or superficial punctate keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, vernal keratoconjunctivitis, or for corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies.***For topical ophthalmic treatment of corticosteroid-responsive eye disorders.***For systemic treatment of corticosteroid-responsive eye disorders unresponsive to topical ophthalmic treatment or for conditions usually requiring systemic treatment, such as sympathetic ophthalmia or optic neuritis.***For adjunctive therapy in the treatment of rheumatic disorders including ankylosing spondylitis, gout with gouty arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, psoriatic arthritis, or rheumatoid arthritis; ALSO for the treatment of acute episodes or exacerbation of nonrheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the treatment of selected cases of collagen disorders and mixed connective tissue disease�, such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, polyarteritis nodosa, relapsing polychondritis, polymyalgia rheumatica, certain cases of vasculitis, or Wegener's granulomatosis�.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.***For the treatment of mild to moderate laryngotracheobronchitis (croup)�.***For palliative management of leukemia and lymphoma in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), or multiple myeloma�; also may be used as an adjunct in managing hypercalcemia of malignancy.***For the treatment of acute interstitial nephritis (AIN)�.***For the treatment of Severe Acute Respiratory Syndrome (SARS)�.***For the management of heart transplant rejection prophylaxis�.***For the treatment of Bell's palsy�.***For the treatment of exacerbations of chronic obstructive pulmonary disease (COPD)�.***For the treatment of Kawasaki disease�.","***General Information***Corticosteroid hypersensitivity***Intravenous administration***Infection, surgery***Fungal infection***Herpes infection, measles, tuberculosis, varicella, viral infection***Myocardial infarction***Heart failure, hypertension***Cataracts, glaucoma, visual disturbance***Diverticulitis, GI disease, hepatic disease, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Diabetes mellitus, hyperthyroidism, hypothyroidism, osteoporosis, psychosis, renal disease, seizure disorder, thyroid disease***Myasthenia gravis***Coagulopathy, thromboembolic disease***Pregnancy***Breast-feeding***Children, growth inhibition, increased intracranial pressure, infants***Abrupt discontinuation, hypothalamic-pituitary-adrenal (HPA) suppression***Sulfite hypersensitivity***Tartrazine dye hypersensitivity***Benzyl alcohol hypersensitivity, neonates, premature neonates***Cushing's syndrome***Vaccination***Corneal abrasion, increased intraocular pressure, myopia, open-angle glaucoma***Geriatric***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,candesartan cilexetil/hydrochlorothiazide,"***For the treatment of hypertension in patients who do not respond to monotherapy. <br />        NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.�<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, heart failure, hypotension, renal artery stenosis, renal disease, renal impairment***Hepatic disease***Hypovolemia, orthostatic hypotension, sympathectomy, syncope***ACE-inhibitor induced angioedema, angioedema***Surgery***Pregnancy***Breast-feeding***Children***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia, hyponatremia***Diabetes mellitus, hyperglycemia***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,tetanus immune globulin (human),"***For the treatment of tetanus.***For postexposure tetanus prophylaxis in patients whose immunization is incomplete or uncertain. <br />        NOTE: Tetanus immune globulin should be given to all patients for all wounds other than clean, minor wounds if the immune status is uncertain or the last known tetanus toxoid immunization was &gt; 5 years prior to the traumatic event.<br />NOTE: Further doses of Td, DT, or DTP are needed to complete primary immunization (see Diphtheria Toxoid; Tetanus Toxoid Adsorbed, DT, Td or Diphtheria/Tetanus Toxoids; Pertussis Vaccine, DTP monographs)","***General Information***Intravenous administration***IgA deficiency***Infection***Coagulopathy, hemophilia, thrombocytopenia***Pregnancy***Breast-feeding***Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6387']['8686'],lidocaine/prilocaine,***For use as local anesthesia to provide topical anesthesia.***For the treatment of premature ejaculation�.,"***Amide local anesthetic hypersensitivity***Intravenous administration***Ocular exposure***Tympanic membrane perforation***Burns, eczema, occlusive dressing, skin abrasion***Children, G6PD deficiency, infants, methemoglobinemia, neonates, premature neonates***Cardiac disease, geriatric, hepatic disease, hepatic encephalopathy, hepatitis***Labor, obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10180']['10829'],sulfamethoxazole/trimethoprim,"***For the treatment of urinary tract infection (UTI), including pyelonephritis and cystitis.***For the treatment of Pneumocystis pneumonia (PCP).***For Pneumocystis pneumonia (PCP) prophylaxis in individuals who are immunosuppressed and considered to be at an increased risk.***For primary PCP prophylaxis in HIV-infected patients.***For secondary PCP prophylaxis in HIV-infected patients.***For primary PCP prophylaxis in immunocompromised patients with primary immunodeficiency disease (especially severe combined immunodeficiency disease), lymphoreticular malignancies (especially acute lymphatic leukemia and human T-cell lymphotropic virus-associated leukemia or lymphoma), organ transplantation (especially lung or heart-lung), and solid tumors, particularly brain tumors.***For primary PCP prophylaxis in recipients of bone marrow allografts.***For the treatment of otitis media due to susceptible strains of <em>Haemophilus influenzae</em> or <em>Streptococcus pneumoniae</em>.***For otitis media with otorrhea due to community-acquired methicillin-resistant <em>Staphylococcus aureus</em>�.***For the treatment of acute exacerbations of chronic bronchitis.***For the treatment of gastroenteritis, infectious diarrhea, and gastrointestinal infections.***For the treatment of cholera� caused by <em>Vibrio cholerae</em>.***For the treatment of cyclosporiasis� due to <em>Cyclospora cayetanensis</em>.***For the treatment of shigellosis.***For the treatment of isosporiasis� in HIV-positive patients.***For chronic maintenance therapy (secondary prophylaxis) of isosporiasis� in HIV-positive patients.***For the treatment of salmonellosis� in HIV-infected patients.***For the treatment of traveler's diarrhea due to enterotoxigenic <em>E. coli</em>.***For urinary tract infection (UTI) prophylaxis�.***For bacterial infection prophylaxis� in HIV-infected children and infants.***For secondary prophylaxis� in HIV-infected children and infants with > 2 invasive bacterial infections in a 1-year period.***For primary prophylaxis� to reduce opportunistic infection in HIV-infected children (regardless of CD4 count).***For toxoplasmosis prophylaxis�, specifically prevention of toxoplasmic encephalitis (TE) due to <em>Toxoplasma gondii</em>.***For primary prophylaxis� in HIV-infected patients.***For chronic maintenance therapy� (secondary prophylaxis�) after acute toxoplasmosis infection.***For the treatment of Legionnaire's disease� caused by <em>Legionella pneumophila</em>.***For the treatment of actinomycotic mycetoma�.***For actinomycotic mycetoma� caused by <em>Actinomadura pelletierii</em>, <em>Actinomadura madurae</em>, <em>Streptomyces somaliensis</em>.***For actinomycotic mycetoma� caused by <em>Nocardia brasiliensis</em>, <em>Nocardia asteroides</em>, or <em>Nocardia otitidiscaviarum</em>.***For the treatment of nocardiosis� caused by <em>Nocardia</em> sp..***For the treatment of pertussis (whooping cough)� caused by <em>Bordetella pertussis</em> or for postexposure pertussis prophylaxis�. <br />        NOTE: For postexposure prophylaxis, administer to close contacts within 3 weeks of exposure, especially in high-risk patients (e.g., women in 3rd trimester, infants).<br />     ***For the treatment of bacteremia� and catheter-associated infections�.***For prevention of bacteremia� (i.e., bacteremia prophylaxis�) or spontaneous bacterial peritonitis� (i.e., peritonitis prophylaxis�) in patients with cirrhosis and ascites.***For the treatment of typhoid fever� due to <em>Salmonella typhi</em>.***For acute infections.***For chronic carriers.***For the treatment of <em>Staphylococcus aureus</em> infections�, including endocarditis�.***For the treatment of methicillin-resistant <em>Staphylococcus aureus </em>(MRSA)<em>�</em> skin and skin structure infections�, including cellulitis�.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of therapy-resistant pediculosis� capitis (head lice infestation) due to <em>Pediculus capitis�</em>.***For the treatment of melioidosis� and for postexposure prophylaxis.***For sulfonamide desensitization� in patients requiring sulfamethoxazole; trimethoprim therapy.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated bone and joint infections�, including osteomyelitis� and septic/infectious arthritis�, or an orthopedic device-related infection�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated osteomyelitis�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated septic arthritis�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated prosthetic joint infections�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated spinal implant infections�.***For surgical infection prophylaxis�.***For the treatment of CNS infections�, including meningitis�, brain abscess�, subdural empyema�, spinal epidural abscess�, and septic thrombosis of the cavernous or dural venous sinus�.***Formoterol***Formoterol; Mometasone","***General Information***Carbonic anhydrase inhibitor hypersensitivity, sulfite hypersensitivity, sulfonamide hypersensitivity, sulfonylurea hypersensitivity, thiazide diuretic hypersensitivity, trimethoprim hypersensitivity***Agranulocytosis, bone marrow suppression, folate deficiency, folate deficiency megaloblastic anemia, G6PD deficiency, hemolysis, thrombocytopenia***Hyperkalemia, hyponatremia, renal disease, renal failure, renal impairment***Hepatic disease***Porphyria***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Hypothyroidism***Acquired immunodeficiency syndrome (AIDS)***Infants, neonates***Pregnancy***Breast-feeding***Antimicrobial resistance, viral infection***Hypoglycemia, malnutrition***Sunlight (UV) exposure***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, myocardial infarction, QT prolongation, thyroid disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,nicardipine hydrochloride,"***For the treatment of chronic stable angina.***For the treatment of hypertension.***For chronic hypertension.***For short-term treatment of hypertension when oral therapy is not feasible or desirable; or for the treatment of hypertensive urgency� or hypertensive emergency�, except in the setting of acute heart failure.***For postoperative hypertension�, in the absence of supraventricular tachycardia or a recent myocardial infarction.***For the treatment of proteinuria� associated with diabetic nephropathy�.","***Dihydropyridine hypersensitivity***Acute myocardial infarction, bradycardia, cardiogenic shock, heart failure, ventricular dysfunction***Hypotension***Aortic stenosis***Intracranial bleeding, stroke***Renal failure, renal impairment***Hepatic disease***Neonates, pregnancy***Breast-feeding***Children, infants***Gastroesophageal reflux disease (GERD), hiatal hernia***Pheochromocytoma***Angina***Extravasation***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2396'],chlorothiazide,"***For the treatment of hypertension.***For use as an adjunctive agent to treat peripheral edema associated with congestive heart failure, hepatic cirrhosis (ascites), corticosteroid therapy, or estrogen therapy; or to treat edema associated with renal dysfunction including nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.***For the treatment of idiopathic hypercalciuria� in children.***Formoterol***Formoterol; Mometasone","***General Information***Sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, renal disease, renal failure, renal impairment***Hepatic disease***Acid/base imbalance, electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia, hyponatremia***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***Diabetes mellitus, hyperglycemia***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Extravasation, intramuscular administration, subcutaneous administration***Sunlight (UV) exposure***Preeclampsia, pregnancy***Breast-feeding***Children, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,immune globulin infusion (human),"***For hepatitis A prophylaxis.***For postexposure prophylaxis.***For patients traveling to regions that have high or intermediate hepatitis A endemicity.***For measles prophylaxis to prevent or modify measles in an unvaccinated patient who has not previously had measles and who was exposed within the past 6 days. <br />  NOTE: For most persons 12 months and older who are exposed to measles, use of MMR or measles vaccine within 72 hours of exposure is preferred to using immune globulin (except pregnant women and others for whom the vaccine is contraindicated). Any person exposed to measles who lacks evidence of measles immunity and to whom immune globulin (IG) is administered should subsequently receive MMR vaccine but not earlier than 6 months after IMIG administration or 8 months after IGIV administration (provided the vaccine is not contraindicated).<br /***For varicella (chickenpox) infection prophylaxis.***For rubella prophylaxis in exposed, susceptible pregnant women who will not consider a therapeutic abortion. <br />        NOTE: The routine use of IMIG for rubella prophylaxis in early pregnancy is of dubious value and cannot be justified.<br />     ***For immunoglobulin deficiency. <br />  NOTE: Immune globulin may prevent serious infection in patients with immunoglobulin deficiencies if circulating IgG concentrations of approximately 200 mg/100 mL plasma are maintained.<br /","***Intravenous administration***Pregnancy***Breast-feeding***Agammaglobulinemia, hypogammaglobulinemia, IgA deficiency***Viral infection***Anticoagulant therapy, bleeding, coagulopathy, hemophilia, thrombocytopenia***Vaccination***Children***Coronary artery disease, geriatric, heart failure, hypertriglyceridemia, hyponatremia, obesity, thromboembolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,calcitonin-salmon,"***For the treatment of moderate to severe symptomatic Paget's disease.***For the treatment of hypercalcemia.***For the treatment of postmenopausal osteoporosis in combination with adequate calcium intake in women who are more than 5 years past menopause and in whom estrogens cannot be used. <br />        NOTE: North American Menopause Society notes that due to lower efficacy as compared to other pharmacotherapies for osteoporosis, calcitonin use in postmenopausal women should be reserved for those patients who can not or will not take one of the other available osteoporosis therapies.<br />     ***For osteoporosis prophylaxis�.***For the management of bone pain� due to osteoporosis, bone metastases�, or vertebral crush fractures.***For the management of neuropathic pain�, including diabetic neuropathy�, and phantom limb pain�.***For the treatment of reflex sympathetic dystrophy�.","***Acute bronchospasm, fish hypersensitivity, hypotension***Pregnancy***Breast-feeding***Hypocalcemia***Nasal trauma***Geriatric***Children***New primary malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4491'],fluorometholone,"***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis, ocular burns or trauma due to corneal injury resulting from chemical, thermal or penetration trauma, giant papillary conjunctivitis (GPC), keratitis, postoperative ocular inflammation, vernal keratoconjunctivitis, and chronic anterior uveitis. <br />  NOTE: The benefit of diminution of edema and inflammation from the use of ocular corticosteroids and the inherent risk of infection in certain conditions must be considered. Duration of treatment may vary with type of lesion and therapeutic response. Renewal of prescriptions beyond 20 mL of suspension or 8 grams of ointment should be made by a physician after re-examination with the aid of magnification. Care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of therapy should be carried out by gradually decreasing the frequency of applications.<br /","***General Information***Herpes infection, herpes simplex keratitis (dendritic keratitis), varicella, viral infection***Fungal infection, mycobacterial infection***Contact lenses***Glaucoma***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,heparin sodium,"***For the treatment of deep venous thrombosis (DVT) or pulmonary embolism; for the treatment of arterial thromboembolism including cerebral thromboembolism; or for the treatment of mural thrombosis.***For thrombosis prophylaxis.***For thrombosis prophylaxis, including arterial thromboembolism prophylaxis, during extracorporeal circulation in patients undergoing open heart or other cardiovascular surgery.***For coronary artery thrombosis prophylaxis during percutaneous coronary intervention (PCI) in patients not receiving abciximab therapy.***For deep venous thrombosis (DVT) prophylaxis.***For mural thrombosis prophylaxis in patients with an acute transmural anterior myocardial infarction.***For arterial thromboembolism prophylaxis in patients with prosthetic heart valves.***For thrombosis prophylaxis and/or for pulmonary embolism prophylaxis in patients at increased risk after sustaining an acute MI (e.g., Q-wave infarction, severe LV dysfunction, CHF, history of systemic or pulmonary embolism, 2D echo evidence of mural thrombus, or atrial fibrillation).***For thrombosis prophylaxis, including arterial thromboembolism prophylaxis, during hemodialysis.***For coronary artery thrombosis prophylaxis during percutaneous coronary intervention (PCI) in patients receiving abciximab concomitantly.***For deep venous thrombosis (DVT) prophylaxis in pregnant females.***For intravascular catheter occlusion prophylaxis. <br />        NOTE: The amount of heparin solution in each single dose is sufficient to prevent clotting within the lumen of the indwelling catheter for up to 24 hours. If the catheter is used for withdrawal of repeated blood samples for laboratory tests and the presence of heparin is likely to interfere with the test, the in situ heparin flush should be cleared from the catheter by aspirating and discarding a volume of solution equivalent to that of the indwelling catheter before the desired blood sample is drawn. If the drug to be administered is incompatible with heparin, the entire catheter or lumen should be flushed with sterile water or normal saline before and after the medication is administered. Following the second flush, the heparin flush solution may be reinstilled into the set.<br />     ***For the prevention of pregnancy loss and/or thrombosis in patients with antiphospholipid antibody syndrome (APLA).***For the treatment of disseminated intravascular coagulation (DIC).***For the treatment of unstable angina. <br />        NOTE: In 2009, the USP adopted new reference standards and manufacturing controls for heparin that result in a 10% reduction in the potency. This change in heparin potency may have clinical significance in situations that require dosage adjustments and more frequent monitoring, especially when aggressive anticoagulation is needed, including pediatric patients undergoing extracorporeal membrane oxygenation, adults and children undergoing cardiopulmonary bypass, and the treatment or prevention of life-threatening thromboses. Healthcare providers should exercise clinical judgement when deciding what dose to administer and continue to individualize heparin dosing. Higher doses may be required to achieve and maintain the desired anticoagulant effect in some patients.<br />     ***For the treatment of an evolving acute myocardial infarction (AMI) (i.e., coronary artery thrombosis�) in patients who have received thrombolytic therapy with alteplase (tPA), reteplase (r-PA), or tenecteplase (TNK-tPA).. <br />        NOTE: In 2009, the USP adopted new reference standards and manufacturing controls for heparin that result in a 10% reduction in the potency. This change in heparin potency may have clinical significance in situations that require dosage adjustments and more frequent monitoring, especially when aggressive anticoagulation is needed, including pediatric patients undergoing extracorporeal membrane oxygenation, adults and children undergoing cardiopulmonary bypass, and the treatment or prevention of life-threatening thromboses. Healthcare providers should exercise clinical judgement when deciding what dose to administer and continue to individualize heparin dosing. Higher doses may be required to achieve and maintain the desired anticoagulant effect in some patients.<br />     ***For patients receiving streptokinase or anistreplase (APSAC) concurrently.***Formoterol; Mometasone","***General Information***Asthma, benzyl alcohol hypersensitivity, corn hypersensitivity, heparin hypersensitivity, porcine protein hypersensitivity, sulfite hypersensitivity***Heparin-induced thrombocytopenia (HIT), thrombocytopenia***Aneurysm, bleeding, coagulopathy, diverticulitis, endocarditis, head trauma, hemophilia, hypertension, hypotension, inflammatory bowel disease, lumbar puncture, menstruation, peptic ulcer disease, spinal anesthesia, surgery, vaginal bleeding***Intracranial bleeding***Fever, infection, myocardial infarction, neoplastic disease, thrombophlebitis***Disseminated intravascular coagulation (DIC), hepatic disease, renal disease***Infants, neonates, premature neonates***Geriatric***Intramuscular administration, intramuscular injections***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amlodipine besylate/benazepril hydrochloride,"***For the treatment of hypertension in patients who do not respond to monotherapy. <br />        NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br />     ","***Dihydropyridine hypersensitivity***Aortic stenosis, bradycardia, cardiogenic shock, cardiomyopathy, heart failure, ventricular dysfunction***ACE-inhibitor induced angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, Black patients, history of angioedema***Dialysis, hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Acute myocardial infarction, cerebrovascular disease, coronary artery disease, hyponatremia, hypotension, hypovolemia***Autoimmune disease, bone marrow suppression, collagen-vascular disease, immunosuppression, renal artery stenosis, renal disease, renal failure, renal impairment, scleroderma, systemic lupus erythematosus (SLE)***Geriatric, hepatic disease***Surgery***Hyperkalemia***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,histrelin acetate,"***For the palliative treatment of advanced prostate cancer.***For the treatment of central precocious puberty (CPP) in children. <br />        NOTE: Prior to initiating treatment with histrelin, the diagnosis of CPP should be confirmed by measuring blood concentrations of total sex steroids, luteinizing hormone, and follicle stimulating hormone following stimulation with a GnRH analog; bone age versus chronological age should be assessed. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain to rule out an intracranial tumor, pelvic/testicular/adrenal ultrasound to rule out steroid secreting tumors, and measurement of human chorionic gonadotropin concentrations (to rule out a chorionic gonadotropin secreting tumor) and adrenal steroids (to exclude congential adrenal hyperplasia).<br />     ","***General Information***Gonadotropin-Releasing Hormone (GnRH) analogs hypersensitivity***Bladder obstruction, renal impairment, spinal cord compression, urinary tract obstruction***Females, pregnancy***Breast-feeding***Pituitary insufficiency***Children, infants, neonates***Osteoporosis***Cardiac disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, stroke, tobacco smoking***Diabetes mellitus, hyperglycemia***Depression, suicidal ideation***Seizure disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],estradiol,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For systemic treatment of the vasomotor symptoms (hot flashes) and genitourinary symptoms of menopause.***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For estrogen replacement for premenopausal women with primary ovarian failure or female hypogonadism.***For the palliative treatment of advanced inoperable prostate cancer.***For the palliative treatment of breast cancer that is inoperable and progressive in selected men and postmenopausal women.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates***Intravenous administration***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,aminocaproic acid,"***For the treatment of hemorrhage caused by hyperfibrinolysis; and for surgical bleeding prophylaxis� or treatment.***For the reduction of surgical bleeding associated with cardiopulmonary bypass as monotherapy or in combination with desmopressin (DDAVP)�.***For dental bleeding� in patients with hemophilia A.***For prevention of dental bleeding� following dental surgery.***For treatment of dental bleeding� following dental extraction.***For control of acute gingival bleeding� unrelated to dental extraction.***For the prevention of rebleeding due to fibrinolysis in patients who have sustained a recent subarachnoid hemorrhage� (SAH).***For the treatment of hemorrhagic cystitis� induced by cyclophosphamide therapy, radiation therapy, or interstitial cystitis.***For the prevention of secondary ocular hemorrhage in patients with traumatic hyphema�. <br />        NOTE: Topical aminocaproic acid has been designated an orphan drug by the FDA for this indication.<br />     ***For angioedema prophylaxis� in patients with hereditary angioedema.","***Disseminated intravascular coagulation (DIC)***Hemophilia***Cardiac disease, hypovolemia***Renal impairment***Hematuria***Paraben hypersensitivity***Benzyl alcohol hypersensitivity***Children, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['321952'],pimecrolimus,"***For short-term and intermittent long-term treatment of mild to moderate atopic dermatitis in non-immunocompromised patients who are unresponsive or intolerant of other therapies or as an alternative to conventional therapies in at-risk patients. <br />  NOTE: Topical pimecrolimus is a second line agent to treat atopic dermatitis in patients unresponsive to or intolerant of other first line agents; long-term safety has not been established.<br /***For the treatment of vulvar lichen sclerosus.***For the treatment of intertriginous psoriasis�. <br />        NOTE: According to the American Academy of Dermatology (AAD), topical pimecrolimus is not generally effective for the treatment of chronic plaque psoriasis.<br />     ","***Occlusive dressing***Herpes infection, varicella, viral infection***Sunlight (UV) exposure***Children, infants, neonates***Immunosuppression, lymphoma, mononucleosis, new primary malignancy, skin cancer***Ichthyosis***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['115264', '115265']",ibandronate,"***For the treatment of osteoporosis.***For corticosteroid-induced osteoporosis� in men and women.***For osteoporosis prophylaxis. <br />        NOTE: All postmenopausal women should receive drug therapy for osteoporosis if they have any of the following: a previous osteoporotic vertebral or hip fracture; a bone mineral density indicative of osteoporosis (i.e., a T-score equal to or worse than �2.5) at the lumbar spine, femoral neck, or total hip region; or a T-score of �1 to �2.5 plus a FRAX calculator based 10-year risk of &gt;= 20% for a major osteoporotic fracture of the spine, hip, shoulder, or wrist, or a 10-year risk of &gt;= 3% for a hip fracture ; the FRAX calculator or Fracture Risk Assessment Tool, developed by WHO, is available for download or online calculation via the World Wide Web.<br />     ***For the treatment of Paget's disease�.***For the treatment of bone metastases� in patients with prostate cancer.***For the treatment of hypercalcemia� of malignancy.","***General Information***Intraarterial administration***Achalasia, dysphagia, esophageal stricture, esophagitis, gastritis, gastroesophageal reflux disease (GERD), GI disease, GI perforation, hiatal hernia, inability to stand or sit upright***Diabetes mellitus, hypertension, multiple myeloma, renal failure, renal impairment***Hypocalcemia, vitamin D deficiency***Children, infants, neonates***Geriatric***Hypoparathyroidism***Pregnancy***Breast-feeding***Anemia, chemotherapy, coagulopathy, corticosteroid therapy, dental disease, dental work, infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,levalbuterol hydrochloride,"***For the treatment of acute bronchospasm and bronchospasm prophylaxis associated with asthma.***For bronchospasm associated with asthma in pediatric patients.***For bronchospasm associated with asthma in adults.***For the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis.***For the adjunctive emergency acute treatment of hyperkalemia� until hemodialysis is available. <br />        NOTE: Beta-agonists can be effective treatments for hyperkalemia via beta-adrenergic induction of potassium (K+) uptake. However, they are a temporary adjunctive measure.<br />     ***For exercise-induced bronchospasm prophylaxis�.","***General Information***Albuterol hypersensitivity, angioedema, levalbuterol hypersensitivity***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, tachycardia***Renal failure, renal impairment***Hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***Diabetes mellitus***Deterioration of asthma, paradoxical bronchospasm***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***MAOI therapy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amitriptyline hydrochloride/perphenazine,***For the treatment of depression in patients with moderate to severe anxiety and/or agitation.***For the treatment of schizophrenia in patients who have associated depressive symptoms.,"***General Information***Carbamazepine hypersensitivity, phenothiazine hypersensitivity, tricyclic antidepressant hypersensitivity***Acute myocardial infarction, angina, AV block, bundle-branch block, cardiac arrhythmias, cardiac disease, hypovolemia, orthostatic hypotension, pulmonary disease, QT prolongation***Encephalopathy, hepatic disease, jaundice***Abrupt discontinuation, vomiting***Bipolar disorder, mania***Children, infection, Reye's syndrome, suicidal ideation***MAOI therapy***Alcoholism, CNS depression, coma, driving or operating machinery, ethanol intoxication, head trauma***Dental work, surgery***Tardive dyskinesia***Hyperthyroidism, hypothyroidism***Anticholinergic medications, chemotherapy, constipation, gastroesophageal reflux disease (GERD), GI disease, GI obstruction, ileus, prostatic hypertrophy, urinary retention***Contact lenses***Ocular disease***Intracranial mass, seizure disorder, seizures***Parkinson's disease***Asthma***Agranulocytosis, bone marrow suppression, fever, hematological disease, leukopenia, neutropenia***Sunlight (UV) exposure***Diabetes mellitus***Radiographic contrast administration***Labor, neonates, obstetric delivery, pregnancy, pregnancy testing***Breast-feeding***Tobacco smoking***Breast cancer, hyperprolactinemia, infertility***Renal failure***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Dementia, geriatric, stroke***Closed-angle glaucoma, increased intraocular pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,prednisolone sodium phosphate,"***For primary (Addison's disease) or secondary adrenocortical insufficiency or for the treatment of congenital adrenal hyperplasia.***For the treatment of nonsuppurative thyroiditis.***For the management of symptomatic sarcoidosis.***For the treatment of corticosteroid-responsive dermatitis and dermatologic disorders such as atopic dermatitis or eczema, bullous dermatitis herpetiformis, contact dermatitis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe psoriasis, severe seborrheic dermatitis, or severe erythema multiforme or Stevens-Johnson syndrome.***For the treatment of corticosteroid-responsive respiratory disorders including aspiration pneumonitis, berylliosis, Loeffler's syndrome, or idiopathic pulmonary fibrosis.***For the treatment of asthma.***For a moderate to severe asthma exacerbation in the emergency department or the hospital.***For an acute asthma exacerbation on an outpatient basis.***For long-term prevention of symptoms in severe persistent asthma.***For the treatment of inflammatory bowel disease including critical periods of ulcerative colitis or regional enteritis (Crohn's disease).***For the treatment of hematologic disorders with thrombocytopenia including immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), or secondary thrombocytopenia.***For the treatment of acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), or congenital hypoplastic anemia.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of kidney transplant rejection or for kidney transplant rejection prophylaxis in conjunction with other immunosuppressants.***For the treatment of acute exacerbations of multiple sclerosis.***For the treatment of nephrotic syndrome.***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis, allergic marginal corneal ulcer, anterior segment inflammation, bacterial conjunctivitis, chorioretinitis, choroiditis, cyclitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus) with appropriate antiviral therapy, iritis, non-specific keratitis or superficial punctate keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, vernal keratoconjunctivitis, or for corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies.***For topical ophthalmic treatment of corticosteroid-responsive eye disorders.***For systemic treatment of corticosteroid-responsive eye disorders unresponsive to topical ophthalmic treatment or for conditions usually requiring systemic treatment, such as sympathetic ophthalmia or optic neuritis.***For adjunctive therapy in the treatment of rheumatic disorders including ankylosing spondylitis, gout with gouty arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, psoriatic arthritis, or rheumatoid arthritis; ALSO for the treatment of acute episodes or exacerbation of nonrheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the treatment of selected cases of collagen disorders and mixed connective tissue disease�, such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, polyarteritis nodosa, relapsing polychondritis, polymyalgia rheumatica, certain cases of vasculitis, or Wegener's granulomatosis�.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.***For the treatment of mild to moderate laryngotracheobronchitis (croup)�.***For palliative management of leukemia and lymphoma in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), or multiple myeloma�; also may be used as an adjunct in managing hypercalcemia of malignancy.***For the treatment of acute interstitial nephritis (AIN)�.***For the treatment of Severe Acute Respiratory Syndrome (SARS)�.***For the management of heart transplant rejection prophylaxis�.***For the treatment of Bell's palsy�.***For the treatment of exacerbations of chronic obstructive pulmonary disease (COPD)�.***For the treatment of Kawasaki disease�.","***General Information***Corticosteroid hypersensitivity***Intravenous administration***Infection, surgery***Fungal infection***Herpes infection, measles, tuberculosis, varicella, viral infection***Myocardial infarction***Heart failure, hypertension***Cataracts, glaucoma, visual disturbance***Diverticulitis, GI disease, hepatic disease, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Diabetes mellitus, hyperthyroidism, hypothyroidism, osteoporosis, psychosis, renal disease, seizure disorder, thyroid disease***Myasthenia gravis***Coagulopathy, thromboembolic disease***Pregnancy***Breast-feeding***Children, growth inhibition, increased intracranial pressure, infants***Abrupt discontinuation, hypothalamic-pituitary-adrenal (HPA) suppression***Sulfite hypersensitivity***Tartrazine dye hypersensitivity***Benzyl alcohol hypersensitivity, neonates, premature neonates***Cushing's syndrome***Vaccination***Corneal abrasion, increased intraocular pressure, myopia, open-angle glaucoma***Geriatric***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],estradiol,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For systemic treatment of the vasomotor symptoms (hot flashes) and genitourinary symptoms of menopause.***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For estrogen replacement for premenopausal women with primary ovarian failure or female hypogonadism.***For the palliative treatment of advanced inoperable prostate cancer.***For the palliative treatment of breast cancer that is inoperable and progressive in selected men and postmenopausal women.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates***Intravenous administration***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5487'],hydrochlorothiazide,"***For the treatment of hypertension.***For use as an adjunctive agent to treat peripheral edema associated with congestive heart failure, hepatic cirrhosis (ascites), corticosteroid therapy, or estrogen therapy; or to treat edema associated with renal dysfunction� including nephrotic syndrome, acute glomerulonephritis, and chronic renal failure�.***For the treatment of nephrogenic or central diabetes insipidus�.***For the prevention of nephrolithiasis� (calcium-containing renal calculus�) due to hypercalciuria�.***For the treatment of symptoms of bloating and weight gain associated with premenstrual syndrome (PMS)�.***Formoterol***Formoterol; Mometasone","***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Hepatic disease***Diabetes mellitus, hyperglycemia***Anuria, hypovolemia, renal disease, renal failure, renal impairment***Hypotension, orthostatic hypotension, sympathectomy, syncope***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Electrolyte imbalance, hypercalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis***Sunlight (UV) exposure***Jaundice, neonates***Preeclampsia, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,coagulation factor IX (human),"***For the management of hemophilia B (congenital factor IX deficiency or Christmas disease). <br />        NOTE: Many Factor IX products have been designated orphan drugs by the FDA for this indication.<br />NOTE: Guidelines for the treatment of acute bleeding and prevention of bleeding during surgery vary. For all indications, the dose of factor IX should be individualized, taking into consideration the seriousness of the bleed or procedure, the clinical status of the patient, and the baseline factor IX activity concentration***For routine bleeding prophylaxis.***For the control of hemorrhage including surgical bleeding and hemarthrosis.","***General Information***Factor IX inhibitors***Hamster protein hypersensitivity, murine protein hypersensitivity***Hepatitis, infection***Disseminated intravascular coagulation (DIC), fibrinolysis, hepatic disease, neonates, surgery, thromboembolic disease***Pregnancy***Breast-feeding***Human immunodeficiency virus (HIV) infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['723', '1297882']['21212']",amoxicillin/clarithromycin/lansoprazole,"***For Helicobacter pylori (H. pylori) eradication in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />        NOTE: The American College of Gastroenterology (ACG) recommends 10�14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10�14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of &gt;900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14-days (odds ratio: 0.62, 95% CI: 0.45�0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.   The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: In populations where H. pylori infection is common (&gt;= 10%), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy.  <br />NOTE: Clarithromycin resistance rates for H. pylori strains in the US are 13%. In patients who fail Prevpac therapy, consider susceptibility testing; if resistance to clarithromycin is demonstrated, a non-clarithromycin containing regimen is recommended.<br />NOTE: Bismuth preparations, some antimicrobials, and some PPIs suppress H. pylori. Ingestion of these substances within 4 weeks prior to performing urease or breath-tests for H. pylori detection may lead to false negative results. In the 4 weeks prior to performing the test, the patient must avoid the use of Prevpac and other agents known to suppress H. pylori.<br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60�90% of patients.***Formoterol; Mometasone","***General Information***Macrolide hypersensitivity***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, eczema, penicillin hypersensitivity, urticaria***Proton pump inhibitors (PPIs) hypersensitivity***Colitis, diarrhea, GI bleeding, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Gastric cancer***Hepatic disease, hepatitis, jaundice***Renal failure, renal impairment***Leukemia, mononucleosis, viral infection***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, mortality, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes, ventricular arrhythmias***Bone fractures, osteoporosis***Myasthenia gravis***Pregnancy***Breast-feeding***Geriatric***Children, infants***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diltiazem hydrochloride,"***For the treatment of hypertension.***For the treatment of chronic stable angina.***For the treatment of variant angina (Prinzmetal's angina).***For the treatment of paroxysmal supraventricular tachycardia (PSVT) or control of ventricular rate in atrial flutter or atrial fibrillation.***For the short-term treatment of rapid ventricular rate secondary to atrial arrhythmias� in adolescents, children, and infants.***For long-term control of ventricular rate in atrial flutter� or atrial fibrillation�.***For the relief of ongoing ischemia in patients with unstable angina� or after acute non-ST-segment elevation myocardial infarction� in the absence of congestive heart failure, pulmonary congestion, left ventricular dysfunction, or AV block, when beta-blockers are ineffective or contraindicated.***For the treatment of idiopathic dilated cardiomyopathy�.***For migraine prophylaxis�.***For the treatment of proteinuria� associated with diabetic nephropathy�.","***Acute myocardial infarction, bradycardia, cardiogenic shock, heart failure, ventricular dysfunction***Hypotension***AV block***Sick sinus syndrome***Lown-Ganong-Levine syndrome, ventricular tachycardia, Wolff-Parkinson-White syndrome***Hepatic disease***Aortic stenosis***Gastroesophageal reflux disease (GERD), hiatal hernia***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ibuprofen lysine,"***For treatment of a clinically significant patent ductus arteriosus (PDA) in premature infants when usual medical management such as fluid restriction, diuretics, and respiratory support is ineffective. <br />        NOTE: Administration as a prophylactic is not recommended as a PDA may spontaneously close after birth.<br />NOTE: Although the clinical trial was conducted among infants with an asymptomatic PDA, reserve treatment for infants with a clinically significant PDA, as the long-term consequences of treatment have not been evaluated","***Infants, neonates***Anemia, bleeding, coagulopathy, GI bleeding, intracranial bleeding, surgery, thrombocytopenia***Aortic coarctation, congenital heart disease, heart failure, hypertension, hypotension***Infection***Extravasation, intramuscular administration, subcutaneous administration***Anuria, electrolyte imbalance, oliguria, renal failure, renal impairment***GI perforation, necrotizing enterocolitis***Jaundice***Hepatic disease***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['32675'],oxybutynin,"***For the treatment of an overactive bladder (OAB) with symptoms of urinary frequency, urinary urgency, or urinary incontinence due to involuntary detrusor muscle contractions (includes neurogenic bladder).","***Angioedema***Prostatic hypertrophy, urinary retention, urinary tract obstruction***Closed-angle glaucoma, contact lenses***Esophageal stricture, gastroesophageal reflux disease (GERD), gastroparesis, GI obstruction, hiatal hernia, ileus, pyloric stenosis, toxic megacolon, ulcerative colitis***Autonomic neuropathy, myasthenia gravis***Dementia***Parkinson's disease***Hepatic disease***Anticholinergic medications, driving or operating machinery, ethanol ingestion***Ambient temperature increase***Accidental exposure, tobacco smoking***Pregnancy***Breast-feeding***Geriatric***Infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,triamcinolone acetonide,"***For bronchospasm prophylaxis or maintenance therapy in patients who require chronic treatment with corticosteroids for control of bronchial asthma.***For the treatment of severe or incapacitating allergic conditions such as asthma that are intractable to adequate trials of conventional treatment.***For the treatment of symptoms of seasonal and perennial allergic rhinitis.***For the treatment of severe or incapacitating allergic conditions that are intractable to adequate trials of conventional treatment.***For the treatment of ocular inflammation (i.e., sympathetic ophthalmia and ocular inflammatory conditions unresponsive to topical corticosteroids), temporal arteritis, and uveitis.***For visualization during ocular surgery (i.e., vitrectomy).***For the treatment of acute rheumatic carditis, berylliosis, temporal arteritis�, or systemic lupus erythematosus (SLE). <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses (e.g., alopecia areata, atopic dermatitis, contact dermatitis including <em>Rhus dermatitis</em> due to poison ivy, poison oak, poison sumac, subacute cutaneous or discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex chronicus, mycosis fungoides, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, psoriasis, sarcoidosis, seborrheic dermatitis, sunburn, or xerosis). <br />        NOTE: Occlusive dressings may be necessary for chronic or severe cases of psoriasis or other recalcitrant conditions.<br />     ***For the treatment of ulcerative or inflammatory oral lesions including aphthous ulcer, desquamative gingivitis�, and oral lichen planus�.***For the treatment of severe or incapacitating allergic conditions such as atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions, bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome) that are intractable to adequate trials of conventional treatment and for the treatment of idiopathic eosinophilic pneumonias.***For the treatment of symptomatic sarcoidosis.***For the treatment of primary (Addison's disease) or secondary adrenocortical insufficiency. <br />        NOTE: Hydrocortisone and cortisone are the preferred agents for these conditions.<br />     ***For the treatment of congenital adrenal hyperplasia.***For the treatment of hypercalcemia associated with cancer.***For the treatment of nonsuppurative thyroiditis.***For the treatment of a critical period of regional enteritis and ulcerative colitis.***For the treatment of autoimmune hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, or selected cases of secondary thrombocytopenia.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of acute exacerbations of multiple sclerosis. <br />        NOTE: Corticosteroids are effective in speeding the resolution of acute exacerbations, but they do not affect the ultimate outcome or natural history of the disease.<br />     ***For the treatment of cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.***For the treatment of proteinuria or to induce diuresis in idiopathic nephrotic syndrome or lupus erythematosus.***For the treatment of an acute episode or exacerbation of ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA) as adjunctive therapy for short-term administration.***For the treatment of dermatomyositis or polymyositis.***For the relief of inflammation and for immunosuppression associated with a variety of disorders, like Hodgkin lymphoma. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the palliative treatment of leukemias and lymphomas.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of diabetic macular edema�.***For the relief of inflammation associated with synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; gout with acute gouty arthritis; epicondylitis; acute non-specific tenosynovitis; polychondritis�; posttraumatic osteoarthritis. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of osteoarthritis pain of the knee. <br />  NOTE: Zilretta is not interchangeable with other formulations of triamcinolone acetonide.<br /","***Epidural administration, intramuscular administration, intrathecal administration, intravenous administration, subcutaneous administration***Acute bronchospasm, status asthmaticus***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hyperthyroidism, hypothalamic-pituitary-adrenal (HPA) suppression, hypothyroidism, increased intracranial pressure, occlusive dressing, skin abrasion***Head trauma***Growth inhibition, osteoporosis***Surgery***Fungal infection, infection, viral infection***Tuberculosis***Immunosuppression***Herpes infection, measles, varicella***Glaucoma***Acne rosacea, acne vulgaris***Peripheral vascular disease***Nasal septal perforation, nasal surgery, nasal trauma***Myocardial infarction***Heart failure, hypertension***Diabetes mellitus***Skin atrophy***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Myasthenia gravis***Psychosis, seizure disorder***Coagulopathy, hemophilia, thromboembolic disease***Cataracts, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Vaccination***Breast-feeding***Tartrazine dye hypersensitivity***Neonates, premature neonates***Idiopathic thrombocytopenic purpura (ITP)***Corticosteroid hypersensitivity***Geriatric***Renal disease, renal impairment***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['190376'],linezolid,"***For the treatment of pneumonia, including community-acquired pneumonia and nosocomial pneumonia.***For the treatment of nosocomial pneumonia due to <em>S. aureus</em> (MSSA or MRSA) or <em>S. pneumoniae</em> (including multi-drug resistant strains, MDRSP).***For the treatment of community-acquired pneumonia (CAP) infections due to <em>S. pneumoniae</em> (including MDRSP) or <em>S. aureus</em> (MSSA or MRSA�), including cases with concurrent bacteremia.***For the treatment of skin and skin structure infections, including cellulitis and diabetic foot ulcer, due to susceptible organisms.***For complicated skin and skin structure infections including diabetic foot infections (e.g., diabetic foot ulcer) without concomitant bone involvement and infections caused by <em>Staphylococcus aureus</em> (MSSA or MRSA), <em>S. pyogenes</em>, or <em>S. agalactiae</em>.***For uncomplicated skin and skin structure infections due to <em>Staphylococcus aureus </em>(MSSA, MRSA�) or <em>S. pyogenes</em>.***For the treatment of sepsis� or bacteremia due to vancomycin-resistant enterococci (VRE) or methicillin-resistant Staphylococcus aureus (MRSA)�.***For the treatment of infections due to vancomycin-resistant enterococci (VRE) (i.e., <em>E. faecium</em>; <em>E. faecalis</em>), including those infections with concurrent bacteremia or sepsis�.***For the treatment of persistent <em>Staphylococcus aureus</em> (MRSA) bacteremia� with vancomycin failure and sepsis�.***For the treatment of neonatal methicillin-resistant <em>Staphylococcus aureus </em>(MRSA) sepsis�.***For the treatment of MRSA-associated bone and joint infections�, including osteomyelitis� and septic/infectious arthritis�, or an orthopedic device-related infection�.***For the treatment of osteomyelitis�.***For the treatment of septic arthritis�.***For the treatment of prosthetic joint infections�.***For the treatment of spinal implant infections�.***For the treatment of central nervous system infections�, including meningitis�, ventriculitis�, brain abscess�, subdural empyema�, spinal epidural abscess�, and septic thrombosis of the cavernous or dural venous sinus�.***For the treatment of febrile neutropenia�.***For the treatment of systemic anthrax� infection.***Formoterol***Formoterol; Mometasone","***Phenylketonuria***Anemia, bleeding, bone marrow suppression, chemotherapy, coagulopathy, infection, leukopenia, renal disease, thrombocytopenia***Hypertension, hyperthyroidism, pheochromocytoma, thyrotoxicosis***Alcoholism, MAOI therapy, spinal anesthesia, surgery***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Optic neuritis***Children, infants, neonates, premature neonates***Pregnancy***Infertility***Breast-feeding***Seizure disorder, seizures***Radiographic contrast administration***Diabetes mellitus, hypoglycemia***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,trifluoperazine hydrochloride,***For the treatment of schizophrenia.***For the short-term treatment of non-psychotic generalized anxiety disorder (GAD).***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.,"***Phenothiazine hypersensitivity, sulfite hypersensitivity***Agranulocytosis, bone marrow suppression, fever, hematological disease, infection, leukopenia, neutropenia***Intravenous administration***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion, head trauma***Dental work, surgery***Intracranial mass, seizure disorder, seizures***Tardive dyskinesia***Anticholinergic medications, closed-angle glaucoma, ileus, prostatic hypertrophy, urinary retention***Alcoholism, angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, pulmonary disease, QT prolongation, thyroid disease***Children, Reye's syndrome***Encephalopathy, hepatic disease, jaundice***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Sunlight (UV) exposure***Accidental exposure***Abrupt discontinuation***Renal failure***Ocular disease***Chemotherapy, GI obstruction, vomiting***Tobacco smoking***Labor, neonates, obstetric delivery, pregnancy, pregnancy testing***Breast-feeding***Breast cancer, hyperprolactinemia, infertility***Radiographic contrast administration***Suicidal ideation***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['7454', '235559']",nitrofurantoin,***For the treatment of uncomplicated urinary tract infection (UTI) including acute cystitis.***For long-term suppressive therapy for urinary tract infection (UTI) prophylaxis in patients predisposed to urinary tract infection.,"***General Information***Viral infection***Anuria, oliguria, renal disease, renal impairment***Anemia, G6PD deficiency, hemolytic anemia***Children, infants, neonates***Labor, obstetric delivery, pregnancy***Breast-feeding***Diabetes mellitus, electrolyte imbalance, optic neuritis, peripheral neuropathy, vitamin B12 deficiency***Hepatic disease, jaundice***Pulmonary disease***Geriatric***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3322'],diazepam,"***For the treatment of anxiety disorders or for the short-term relief of the symptoms of anxiety.***For the treatment of acute alcohol withdrawal.***For the treatment of muscle spasm due to local pathology such as muscle or joint inflammation or trauma; athetosis; stiff-man syndrome; tetanus; or spasticity due to upper motor neuron diseases such as cerebral palsy.***For the treatment of status epilepticus or for treatment of drug-induced seizures. <br />        NOTE: Many clinicians now prefer IV lorazepam over IV diazepam for the acute treatment of seizures.<br />     ***For adjunctive treatment of seizures other than status epilepticus in selected, refractory patients with partial seizures or generalized tonic-clonic seizures who require intermittent use of diazepam to control bouts of increased seizure activity.***For amnesia induction or for preprocedure sedation induction.***For the treatment of benzodiazepine withdrawal�.***For febrile seizure prophylaxis�.***For the treatment of agitation� in intensive care unit patients.***For the treatment of acute chloroquine overdose� in combination with epinephrine.***For the treatment of insomnia�.","***Benzodiazepine hypersensitivity***Extravasation, intraarterial administration***Bipolar disorder, depression, mania, psychosis, suicidal ideation***Abrupt discontinuation, substance abuse***Seizure disorder, seizures, status epilepticus***CNS depression, coma, driving or operating machinery, ethanol intoxication, shock***Children, infants, neonates***Closed-angle glaucoma***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, pulmonary disease, respiratory depression, respiratory insufficiency, sleep apnea***Labor, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease, hepatitis, jaundice***Neutropenia***Renal failure, renal impairment***Myasthenia gravis, neuromuscular disease, Parkinson's disease***Dementia, geriatric***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethacrynate sodium); (ethacrynic acid,"***For the treatment of peripheral edema, including idiopathic edema, lymphedema, or edema secondary to ascites, heart failure, or nephrotic syndrome.***For the treatment of acute pulmonary edema.***For the acute treatment of hypercalcemia� associated with neoplastic disease in combination with intravenous saline.***For the treatment of hypertension�.***Formoterol; Mometasone","***General Information***Acid/base imbalance, dehydration, electrolyte imbalance, hypocalcemia, hypochloremia, hypokalemia, hypomagnesemia, metabolic alkalosis***Hepatic disease, hepatic encephalopathy***Diarrhea***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***Diabetes mellitus, hyperglycemia***Anuria, renal disease, renal failure, renal impairment***Systemic lupus erythematosus (SLE)***Gout, hyperuricemia***Acute myocardial infarction***Heart failure, hyperaldosteronism, ventricular arrhythmias***Pancreatitis***Children, infants, neonates***Pregnancy***Breast-feeding***Geriatric***Hearing impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['233603', '977863']",clevidipine,"***For treatment of hypertension, perioperative hypertension, hypertensive urgency, and hypertensive emergency when oral therapy is not feasible or desirable. <br />        NOTE: Patients who receive prolonged infusions of clevidipine and are not transitioned to other antihypertensive therapies should be monitored for rebound hypertension for a minimum of 8 hours following discontinuation of clevidipine infusion.<br />     ","***General Information***Egg hypersensitivity, soya lecithin hypersensitivity***Hyperlipidemia, pancreatitis***Aortic stenosis***Heart failure***Hypertension***Pheochromocytoma***Geriatric***Children, infants, neonates***Labor, obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"japanese encephalitis vaccine, inactivated, adsorbed",***For Japanese encephalitis prophylaxis.,"***General Information***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Immunosuppression***Pregnancy***Infants, neonates***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,antithrombin III (human),***For the treatment of deep venous thrombosis (DVT) or pulmonary embolism (PE) in patients with a deficiency in antithrombin III.***For deep venous thrombosis (DVT) prophylaxis or pulmonary embolism prophylaxis in patients with a hereditary deficiency in antithrombin III who are undergoing surgical or obstetrical procedures.***For the treatment of patients with disseminated intravascular coagulation (DIC)� associated with sepsis or trauma.,"***Viral infection***Goat milk protein hypersensitivity***Labor, obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/levonorgestrel,"***For routine contraception.***For extended continuous routine contraception.***For use as postcoital contraception within 72 hours of unprotected intercourse, or known or suspected contraceptive failure, in females who have no known contraindications to oral contraceptives, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,crotalidae polyvalent immune fab (ovine),"***For the management of North American crotalid  snake bite (rattlesnakes, copperheads, and cottonmouths/water moccasins).","***Latex hypersensitivity, papain hypersensitivity***Ovine protein hypersensitivity***Coagulopathy, diarrhea, fever, heart failure, hepatic disease, hyperthyroidism, malnutrition, neoplastic disease, vitamin K deficiency***Children, infants, thimerosal hypersensitivity***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['266604'],metyrosine,"***For the short-term management of patients with pheochromocytoma who are awaiting surgery, or for long-term management of malignant pheochromocytoma when surgery is contraindicated.","***Parkinson's disease***Driving or operating machinery***Hepatic disease, renal disease***Dehydration***Surgery***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Timoptic in O,"***For the treatment of hypertension.***For reduction of cardiovascular mortality and to reduce the risk of reinfarction (i.e., myocardial infarction prophylaxis) after an acute myocardial infarction in patients who are clinically stable.***For migraine prophylaxis.***For the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.***For the management of chronic stable angina�.***For the treatment of essential tremor�.","***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***AV block, bradycardia, cardiogenic shock, heart failure, hypotension, pheochromocytoma, pulmonary edema, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Cerebrovascular disease***Diabetes mellitus***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Surgery***Hepatic disease***Geriatric, peripheral vascular disease***Dialysis, renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Raynaud's phenomenon***Depression***Psoriasis***Myasthenia gravis***Contact lenses***Children, infants, neonates***Beta-blocker hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,calcitonin-salmon,"***For the treatment of moderate to severe symptomatic Paget's disease.***For the treatment of hypercalcemia.***For the treatment of postmenopausal osteoporosis in combination with adequate calcium intake in women who are more than 5 years past menopause and in whom estrogens cannot be used. <br />        NOTE: North American Menopause Society notes that due to lower efficacy as compared to other pharmacotherapies for osteoporosis, calcitonin use in postmenopausal women should be reserved for those patients who can not or will not take one of the other available osteoporosis therapies.<br />     ***For osteoporosis prophylaxis�.***For the management of bone pain� due to osteoporosis, bone metastases�, or vertebral crush fractures.***For the management of neuropathic pain�, including diabetic neuropathy�, and phantom limb pain�.***For the treatment of reflex sympathetic dystrophy�.","***Acute bronchospasm, fish hypersensitivity, hypotension***Pregnancy***Breast-feeding***Hypocalcemia***Nasal trauma***Geriatric***Children***New primary malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,oxymorphone hydrochloride,"***For moderate pain or severe pain.***For acute moderate to severe pain.***For acute moderate to severe pain during labor.***For the management of chronic severe pain in patients who require daily, around-the-clock, long-term opioid treatment. <br />  NOTE: Extended-release oxymorphone should be reserved for patients in whom alternative treatment options (e.g., nonopioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would otherwise provide inadequate pain management. Discontinue all other around-the-clock opioid drugs upon initiation of oxymorphone extended-release tablets.<br />NOTE: The use of initial doses higher than 5 mg PO every 12 hours should be reserved for opioid-tolerant patients. Opioid-tolerant patients are defined as those taking, for a minimum of 1 week, 60 mg or more oral morphine daily, 30 mg or more oral oxycodone daily, 8 mg or more oral hydromorphone daily, 25 mg or more oral oxymorphone daily, 25 mcg or more transdermal fentanyl per hour, or an equivalent dose of another opioid***For the relief of anxiety in patients with dyspnea associated with pulmonary edema secondary to acute left ventricular dysfunction.","***Lactase deficiency, opiate agonist hypersensitivity, paraben hypersensitivity***Accidental exposure, alcoholism, CNS depression, depression, ethanol ingestion, potential for overdose or poisoning, requires an experienced clinician, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, pulmonary edema, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Abrupt discontinuation***Acute abdomen, constipation, diarrhea, dysphagia, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Biliary tract disease, pancreatitis***Angina, cardiac arrhythmias, cardiac disease, dehydration, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock***Coma, head trauma, increased intracranial pressure, intracranial mass, seizure disorder, seizures***Hepatic disease***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, urinary retention***Infants, neonates***Geriatric***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Adrenal insufficiency, hypothyroidism, myxedema***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['9344'],ribavirin,"***For the treatment of respiratory syncytial virus (RSV) infection.***For the treatment of chronic hepatitis C infection in patients with compensated liver disease. <br />        NOTE: Ribavirin monotherapy is not effective for hepatitis C infection. <br />NOTE: Therapy should be discontinued in patients who develop hepatic decompensation during treatment***For the treatment of chronic hepatitis C infection in combination with interferon alfa-2b alone. <br />          NOTE: Consider response prognostic factors, HCV genotype, viral load, and disease progression evidence such as hepatic inflammation and fibrosis when deciding to treat a pediatric patient. Weigh treatment benefits against potential safety risks identified in clinical trials.<br />       ***For the treatment of chronic hepatitis C infection in combination with a peginterferon alfa product alone. <br />          NOTE: Guidelines recommend the use of a peginterferon product plus ribavirin as part of a combination regimen depending on patient factors and genotype. <br />       ***For the treatment of chronic hepatitis C infection genotype 1 in combination with a nucleotide analog NS5B polymerase inhibitor or NS3/4A protease inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infections in patients with hepatocellular carcinoma awaiting liver transplant as well as patients with decompensated cirrhosis who may or may not be candidates for liver transplantation�.***For the treatment of  recurrent hepatitis C infection in patients after liver transplantation�.***For the treatment of chronic hepatitis C infection genotype 2 in combination with a nucleotide analog NS5B polymerase inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infection genotype 3 in combination with a nucleotide analog NS5B polymerase inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infection genotype 4 in combination with a nucleotide analog NS5B polymerase inhibitor or NS3/4A protease inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infection genotypes 5 or 6 in combination with a nucleotide analog NS5B polymerase inhibitor and/or a peginterferon alfa product�.***For the treatment of viral hemorrhagic fever (VHF)�, including hemorrhagic fever with renal syndrome (HFRS)� secondary to Hantaan virus infection�. <br />        NOTE: Ribavirin has been designated an orphan drug by the FDA for hemorrhagic fever with renal syndrome (HFRS).<br />     ***For Lassa fever prophylaxis�.***For the treatment of adenovirus infection�, including pneumonitis�, hepatitis�, hemorrhagic cystitis�, and nephritis�.***For the treatment of viral encephalitis�.***For subacute measles encephalitis� (SME).***For subacute sclerosing panencephalitis� (SSPE) caused by the measles virus�.***For encephalitis� caused by the Nipah virus�.***For encephalitis� caused by the West Nile virus�.***For the treatment of West Nile virus infection�, including meningitis� and encephalitis�. <br />  NOTE: Other than supportive care, there is no established treatment for West Nile virus infection. The use of ribavirin is suggested by in vitro data only.<br /***For the treatment of Severe Acute Respiratory Syndrome (SARS)�.***For the treatment of Crimean-Congo virus hemorrhagic fever (CCVHF)� or Lassa fever infection�. <br />        NOTE: The use of ribavirin for hemorrhagic fever with renal syndrome (HFRS) secondary to Crimean-Congo virus is supported by in vitro data.<br />***For Crimean-Congo virus hemorrhagic fever (CCVHF) prophylaxis�.","***General Information***Requires an experienced clinician, respiratory depression, respiratory insufficiency***Contact lenses, ocular exposure***Contraception requirements, male-mediated teratogenicity, pregnancy, pregnancy testing, reproductive risk***Infertility***Breast-feeding***Anemia, angina, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, heart failure, hemolytic anemia, myocardial infarction***Infection***Hemoglobinopathy, sickle cell disease, thalassemia***Geriatric***Hepatic disease, hepatitis, hepatitis C and HIV coinfection, influenza, organ transplant, ribavirin monotherapy, viral infection***Children, growth inhibition, infants, neonates***Pancreatitis***Dialysis, renal failure, renal impairment***Thyroid disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,olmesartan medoxomil,***For the treatment of hypertension.,"***Hypotension, hypovolemia***Heart failure, renal artery stenosis***Hyperkalemia***Hepatic disease***ACE-inhibitor induced angioedema, angioedema***Black patients***Pregnancy***Breast-feeding***Infants, neonates***Surgery***Diabetes mellitus***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydrocortisone acetate/pramoxine hydrochloride,"***For the temporary relief of skin inflammation, pain, and pruritus associated with corticosteroid-responsive dermatitis, including psoriasis, anorectal inflammation, pain, pruritus, and swelling associated with hemorrhoids, proctitis, cryptitis, anal fissures, postoperative pain, and pruritus ani.***For the adjunctive treatment of chronic ulcerative colitis� when disease is limited to the distal portion of the rectum (e.g., proctosigmoiditis).","***Fungal infection, herpes infection, infection, peripheral vascular disease, tuberculosis, viral infection***Hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, infants, neonates***Geriatric, skin atrophy***Diabetes mellitus***Cataracts, glaucoma, ocular exposure, ophthalmic administration***Pregnancy***Breast-feeding***Hepatic disease***Fistula, GI obstruction, GI perforation, peritonitis, ulcerative colitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,somatropin (rDNA origin),"***For the treatment of growth hormone deficiency, growth failure, or short stature.***For replacement therapy in adults with growth hormone deficiency (GHD) for either childhood onset (secondary to congenital, genetic, acquired, or idiopathic causes) or adult onset (endogenous or associated with multiple hormone deficiencies, i.e., hypopituitarism, as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma).***For the long-term treatment of growth failure in children who have growth hormone deficiency due to inadequate growth hormone secretion.***For growth failure due to Prader-Willi syndrome.***For the long-term treatment of growth failure in children born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 to 4.***For growth failure associated with chronic renal failure up to the time of transplantation.***For short stature associated with Turner's syndrome.***For short stature in children with SHOX (short stature homeobox-containing gene) deficiency.***For short stature in children with Noonan Syndrome.***For idiopathic short stature.***For the treatment of HIV-associated failure to thrive in children, AIDS-associated wasting syndrome, or cachexia.***For the treatment of HIV-associated adipose redistribution syndrome (HARS)�.***For the treatment of short bowel syndrome in patients receiving specialized nutrition support as directed by a health care professional.***Formoterol; Mometasone","***General Information***Cresol hypersensitivity, glycerin hypersensitivity, history of angioedema, risk of serious hypersensitivity reactions or anaphylaxis***Epiphyseal closure***Children, renal impairment, renal osteodystrophy***Benzyl alcohol hypersensitivity, neonates***Chemotherapy, neoplastic disease, new primary malignancy, radiation therapy***Respiratory insufficiency, surgery, trauma***Obesity***Respiratory infection, sleep apnea***Diabetes mellitus, diabetic retinopathy***Scoliosis***Adrenal insufficiency, hypothyroidism***Increased intracranial pressure***Pregnancy***Breast-feeding***Otitis media***Geriatric***Females***Pancreatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed,"***For simultaneous diphtheria prophylaxis, tetanus prophylaxis, and pertussis prophylaxis.***For prophylaxis against diphtheria and tetanus for patients with large, contaminated wounds who also need the pertussis component.","***Children, infants, neonates, premature neonates***Intraarterial administration, intravenous administration, subcutaneous administration***Guillain-Barre syndrome***Latex hypersensitivity***Coma, encephalopathy, neurological disease, seizure disorder, seizures***Fever, shock***Anticoagulant therapy, bleeding, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Infection***Immunosuppression***Pregnancy***Breast-feeding***Syncope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,methylphenidate hydrochloride,***For the treatment of attention-deficit hyperactivity disorder (ADHD).***For once-daily product dosing.***For the treatment of narcolepsy.***For the treatment of major depression� or post-stroke depression refractory to other therapies. <br />        NOTE: The use of stimulants for the treatment of depressive disorders is usually limited to treatment-refractory cases or when standard medical therapies are not tolerated. Stimulants may aggravate coexisting anxiety or agitation in depressed patients.<br />     ,"***General Information***Hereditary fructose intolerance***Anxiety, bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Tics, Tourette's syndrome***Glaucoma, visual disturbance***Abrupt discontinuation, alcoholism, substance abuse***Hypertension***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular arrhythmias, ventricular dysfunction***Cerebrovascular disease, stroke***Children, growth inhibition***Hyperthyroidism***Seizure disorder, seizures***Neonates, pregnancy***Breast-feeding***Driving or operating machinery***Surgery***Radiographic contrast administration***Dysphagia, esophageal stricture, GI obstruction, ileus***Hepatic disease***Geriatric***MAOI therapy***Peripheral vascular disease, Raynaud's phenomenon***Chemical leukoderma, skin hypopigmentation, vitiligo***Phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,chlorothiazide sodium,"***For the treatment of hypertension.***For use as an adjunctive agent to treat peripheral edema associated with congestive heart failure, hepatic cirrhosis (ascites), corticosteroid therapy, or estrogen therapy; or to treat edema associated with renal dysfunction including nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.***For the treatment of idiopathic hypercalciuria� in children.***Formoterol***Formoterol; Mometasone","***General Information***Sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, renal disease, renal failure, renal impairment***Hepatic disease***Acid/base imbalance, electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia, hyponatremia***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***Diabetes mellitus, hyperglycemia***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Extravasation, intramuscular administration, subcutaneous administration***Sunlight (UV) exposure***Preeclampsia, pregnancy***Breast-feeding***Children, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['253337'],bevacizumab,"***For the treatment of metastatic colorectal cancer. <br />        NOTE: Bevacizumab is not indicated for adjuvant treatment of colon cancer.<br />NOTE: Bevacizumab should be permanently discontinued in patients who develop gastrointestinal perforation, fistula formation involving an internal organ, wound dehiscence and wound healing complications requiring medical intervention, serious bleeding, a severe arterial thromboembolic event, nephrotic syndrome, reversible posterior leukoencephalopathy syndrome (RPLS), hypertensive encephalopathy, or hypertensive crisis. Temporary suspension of therapy is recommended at least 4 weeks before elective surgery and in patients with evidence of moderate to severe proteinuria (pending further evaluation), in patients with severe infusion reactions, and in patients with severe hypertension that is not controlled with medical management***For the first-line treatment of metastatic colorectal cancer in combination with capecitabine and oxaliplatin�.***For the first-line or second-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL plus bevacizumab).***For the second-line treatment of metastatic colorectal cancer in patients who progressed on a first-line bevacizumab-containing regimen, in combination with fluoropyrimidine and irinotecan- or fluoropyrimidine and oxaliplatin-based chemotherapy.***For the treatment of advanced colorectal cancer, in combination with leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX4 plus bevacizumab).***For the treatment of metastatic colorectal cancer, in combination with irinotecan, leucovorin, and 5-fluorouracil (5-FU), (FOLFIRI plus bevacizumab).***For the treatment of metastatic colorectal cancer in combination with leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (mFOLFOX6 with bevacizumab).***For the first-line treatment of unresectable, locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel. <br />        NOTE: Bevacizumab should be permanently discontinued in patients who develop gastrointestinal perforation, fistula formation involving an internal organ, wound dehiscence and wound healing complications requiring medical intervention, serious bleeding, a severe arterial thromboembolic event, nephrotic syndrome, reversible posterior leukoencephalopathy syndrome (RPLS), hypertensive encephalopathy, or hypertensive crisis. Temporary suspension of therapy is recommended at least 4 weeks before elective surgery and in patients with evidence of moderate to severe proteinuria (pending further evaluation), in patients with severe infusion reactions, and in patients with severe hypertension that is not controlled with medical management.<br />     ***For the treatment of metastatic renal cell cancer. <br />        NOTE: Bevacizumab should be permanently discontinued in patients who develop gastrointestinal perforation, fistula formation involving an internal organ, wound dehiscence and wound healing complications requiring medical intervention, serious bleeding, a severe arterial thromboembolic event, nephrotic syndrome, reversible posterior leukoencephalopathy syndrome (RPLS), hypertensive encephalopathy, or hypertensive crisis. Temporary suspension of therapy is recommended at least 4 weeks before elective surgery and in patients with evidence of moderate to severe proteinuria (pending further evaluation), in patients with severe infusion reactions, and in patients with severe hypertension that is not controlled with medical management.<br />     ***For the treatment of metastatic renal cell carcinoma in combination with interferon alfa.***For the treatment of glioblastoma multiforme. <br />        NOTE: The FDA has designated bevacizumab as an orphan drug for the treatment of malignant gliomas.<br />     ***For the treatment of recurrent or relapsed glioblastoma in combination with irinotecan�.***For the first-line treatment of glioblastoma multiforme, in combination with temozolomide and radiation therapy�.***For the treatment of recurrent glioblastoma.***For the treatment of ovarian cancer.***For the adjuvant treatment of newly diagnosed ovarian cancer, in combination with carboplatin and paclitaxel�.***For use as a single-agent in the treatment of recurrent or relapsed ovarian cancer�.***For the treatment of recurrent, platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with gemcitabine and carboplatin.***For the treatment of recurrent, platinum-resistant, epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have received no more than 2 prior chemotherapy regimens, in combination with paclitaxel.***For the treatment of recurrent, platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with carboplatin and paclitaxel.***For the treatment of recurrent, platinum-resistant, epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have received no more than 2 prior chemotherapy regimens, in combination with pegylated liposomal doxorubicin.***For the treatment of recurrent, platinum-resistant, epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have received no more than 2 prior chemotherapy regimens, in combination with topotecan.***For the treatment of cervical cancer.***For the treatment of persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin.***For the treatment of persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and topotecan.***For the treatment of metastatic breast cancer�. <br />        NOTE: Bevacizumab should be permanently discontinued in patients who develop gastrointestinal perforation, wound dehiscence requiring medical intervention, serious bleeding, a severe thromboembolic event, nephrotic syndrome, or hypertensive crisis. Temporary suspension of therapy is recommended in patients with evidence of moderate to severe proteinuria (pending further evaluation) and in patients with severe hypertension that is not controlled with medical management.<br />     ***For patients who have not previously received chemotherapy for metastatic HER2-negative breast cancer, in combination with paclitaxel�. <br />          NOTE: In February 2008, the FDA granted accelerated approval to bevacizumab for the treatment of previously untreated metastatic HER2-negative breast cancer in combination with paclitaxel. In December 2010, the FDA's Center for Drug Evaluation and Research (CDER), the agency which granted the accelerated approval, recommended removal of the breast cancer indication for bevacizumab. This recommendation came after reviewing the results of 4 clinical studies of bevacizumab in combination with various chemotherapy agents (e.g., an anthracycline, docetaxel, capecitabine, or paclitaxel) in women with breast cancer and determining that the data indicate that bevacizumab does not prolong overall survival in breast cancer patients or provide a sufficient benefit in slowing disease progression to outweigh the significant risk to patients. Genentech, the manufacturer of Avastin (bevacizumab), disagreed with this assessment and was granted a public hearing on CDER's withdrawal proposal, which took place in June 2011. A final decision to remove the breast cancer indication from the bevacizumab label was rendered by the FDA Commissioner in November 2011.<br />       ***For patients who have not previously received chemotherapy for metastatic or locally recurrent HER2-negative breast cancer, in combination with docetaxel�.***For relapsed/refractory metastatic breast cancer in combination with capecitabine�.***For the first-line treatment of HER2-positive locally recurrent or metastatic breast cancer in combination with trastuzumab and docetaxel�.***For the treatment of neovascular (wet) age-related macular degeneration� (AMD).***For the treatment of diabetic macular edema�.***For the treatment of proliferative diabetic retinopathy�.***For the treatment of previously untreated, advanced, unresectable malignant pleural mesothelioma�, in combination with cisplatin and pemetrexed�:.***Formoterol; Mometasone","***Infusion-related reactions***Dental work, impaired wound healing, surgery***Fistula, GI obstruction, GI perforation, radiation therapy***Bleeding, GI bleeding, intracranial bleeding, vaginal bleeding***Hypertension, hypertensive crisis***Angina, diabetes mellitus, geriatric, myocardial infarction, stroke, thromboembolic disease***Heart failure***Proteinuria, renal impairment***Children, infants, neonates***Pregnancy***Contraception requirements, infertility, ovarian failure, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pilocarpine hydrochloride,"***For the treatment of increased intraocular pressure (IOP) in patients with glaucoma or ocular hypertension or for the prevention of increased IOP associated with laser surgery.***For the treatment of open-angle glaucoma or ocular hypertension.***For treatment of acute angle-closure glaucoma. <br />          NOTE: Prior to treatment with pilocarpine ophthalmic solution, secretory suppressants and hyperosmotic agents may be needed to lower intraocular pressure below 50 mmHg and relieve iris ischemia.<br />       ***For the prevention of increased intraocular pressure associated with laser surgery.***For miosis induction.***For the treatment of xerostomia and/or xerophthalmia�.***For xerostomia due to salivary gland hypofunction secondary to radiotherapy for cancer of the head and neck.***For xerostomia and/or xerophthalmia� in patients with Sjogren's syndrome.","***General Information***Retinal detachment***Closed-angle glaucoma***Iritis***Contact lenses***Asthma, bronchitis, chronic obstructive pulmonary disease (COPD), sulfite hypersensitivity***Pregnancy***Breast-feeding***Biliary tract disease, cholelithiasis***Hepatic disease***Cardiac disease***Nephrolithiasis***Psychosis***Driving or operating machinery***Children, infants, neonates, uveitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,benzoyl peroxide/clindamycin,"***For the treatment of acne vulgaris. <br />        NOTE: There are reports of an increase of P. acnes resistance to clindamycin in the treatment of acne. In patients with P. acnes resistant to clindamycin, the clindamycin component may provide no additional benefit beyond benzoyl peroxide alone.<br />     ***For the treatment of moderate to severe acne rosacea�.","***General Information***Benzoic acid hypersensitivity, clindamycin hypersensitivity, lincomycin hypersensitivity***Eczema, ocular exposure, skin abrasion, skin disease, sunburn, sunlight (UV) exposure***Children, infants, neonates***Colitis, Crohn's disease, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1998'],captopril,***For the treatment of hypertension.***For the treatment of hypertension associated with systemic lupus erythematosus (SLE)�.***For the treatment of heart failure.***For the treatment of proteinuria associated with diabetic nephropathy.***For the treatment of hypertensive urgency� or hypertensive emergency�.***For the treatment of hypertension and the subsequent decline in renal function associated with scleroderma renal crisis (SRC)�.***For the treatment of acute myocardial infarction� or postmyocardial infarction.,"***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, Black patients, hereditary angioedema***Diabetes mellitus, hyperkalemia, renal artery stenosis, renal disease, renal failure, renal impairment***Autoimmune disease, bone marrow suppression, collagen-vascular disease, immunosuppression, scleroderma, systemic lupus erythematosus (SLE)***Aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hyponatremia, hypotension, hypovolemia***Dialysis, hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Jaundice***Neonates, pregnancy***Breast-feeding***Infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2626'],clozapine,***For the treatment of refractory schizophrenia that has failed to respond adequately to appropriate courses of standard antipsychotic agents; also to reduce the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder.***For the treatment of bipolar disorder�.***Formoterol***Formoterol; Mometasone,"***General Information***Agranulocytosis, bone marrow suppression, chemotherapy, fever, infection, leukemia, leukopenia, neutropenia***Seizure disorder, seizures***CNS depression, coadministration with other CNS depressants, coma***Neurological disease, Parkinson's disease, tardive dyskinesia***Anticholinergic medications, closed-angle glaucoma, constipation, fecal impaction, GI obstruction, ileus, prostatic hypertrophy, urinary retention***Driving or operating machinery***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, myocarditis, orthostatic hypotension, QT prolongation, syncope, tachycardia, thyroid disease, torsade de pointes, ventricular arrhythmias***Pulmonary disease, thromboembolic disease***Dialysis, renal disease, renal failure***Hepatic disease, hepatitis, hepatotoxicity, jaundice, poor metabolizers***Dementia, geriatric, stroke***Neonates, pregnancy, pregnancy testing***Breast-feeding***Surgery***Children, infants***Diabetes mellitus, diabetic ketoacidosis, hypercholesterolemia, hyperglycemia, hyperlipidemia, hyperosmolar hyperglycemic state (HHS), hypertriglyceridemia, obesity***Abrupt discontinuation***Tobacco smoking***Phenylketonuria***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Dysphagia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,carboxymethylcellulose sodium/hypromellose,***For the temporary relief of xerophthalmia and minor ocular irritation.,"***Contact lenses***Corneal abrasion, ocular infection, ocular trauma, visual disturbance***Pregnancy***Children, infants, neonates***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluvastatin sodium,"***For the treatment of hypercholesterolemia, hyperlipoproteinemia, and/or hypertriglyceridemia, as an adjunct to dietary control, for the purpose of reducing the risk of cardiovascular events (e.g., myocardial infarction prophylaxis, stroke prophylaxis).","***General Information***Alcoholism, cholestasis, hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Electrolyte imbalance, endocrine disease, females, hypotension, hypothyroidism, infection, myopathy, organ transplant, renal disease, renal failure, renal impairment, rhabdomyolysis, seizure disorder, surgery, trauma***Diabetes mellitus***Geriatric***Contraception requirements, pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sulfacetamide sodium,"***For the treatment of conjunctivitis, corneal ulcer and other superficial ophthalmic infections caused by susceptible organisms, and as adjunctive treatment in systemic sulfonamide therapy of chlamydial conjunctivitis including trachoma and inclusion conjunctivitis.***For the topical treatment of scaling dermatoses, such as seborrheic dermatitis, and seborrhea sicca.***For the treatment of secondary bacterial skin and skin structure infections due to organisms susceptible to sulfonamides.***For the treatment of acne vulgaris.","***Ocular surgery, ocular trauma***Fungal infection, viral infection***Carbonic anhydrase inhibitor hypersensitivity, sulfonamide hypersensitivity, sulfonylurea hypersensitivity, thiazide diuretic hypersensitivity***Children, infants, neonates***Breast-feeding***Pregnancy***Sunlight (UV) exposure***Renal disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['19831']['25255'],budesonide/formoterol fumarate dihydrate,"***For the maintenance treatment of asthma.***For the maintenance treatment and to reduce exacerbations of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.","***General Information***Corticosteroid hypersensitivity***Acute bronchospasm, asthma-related death, respiratory insufficiency, status asthmaticus***Corticosteroid therapy***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, tachycardia***Diabetes mellitus***Hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***MAOI therapy***Cataracts, glaucoma, increased intraocular pressure***Hypothalamic-pituitary-adrenal (HPA) suppression***Fungal infection, herpes infection, infection, measles, tuberculosis, varicella, viral infection***Osteoporosis***Geriatric***Children, growth inhibition, increased intracranial pressure, infants, neonates***Labor***Pregnancy***Breast-feeding***Paradoxical bronchospasm",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,immune globulin (human),"***For hepatitis A prophylaxis.***For postexposure prophylaxis.***For patients traveling to regions that have high or intermediate hepatitis A endemicity.***For measles prophylaxis to prevent or modify measles in an unvaccinated patient who has not previously had measles and who was exposed within the past 6 days. <br />  NOTE: For most persons 12 months and older who are exposed to measles, use of MMR or measles vaccine within 72 hours of exposure is preferred to using immune globulin (except pregnant women and others for whom the vaccine is contraindicated). Any person exposed to measles who lacks evidence of measles immunity and to whom immune globulin (IG) is administered should subsequently receive MMR vaccine but not earlier than 6 months after IMIG administration or 8 months after IGIV administration (provided the vaccine is not contraindicated).<br /***For varicella (chickenpox) infection prophylaxis.***For rubella prophylaxis in exposed, susceptible pregnant women who will not consider a therapeutic abortion. <br />        NOTE: The routine use of IMIG for rubella prophylaxis in early pregnancy is of dubious value and cannot be justified.<br />     ***For immunoglobulin deficiency. <br />  NOTE: Immune globulin may prevent serious infection in patients with immunoglobulin deficiencies if circulating IgG concentrations of approximately 200 mg/100 mL plasma are maintained.<br /","***Intravenous administration***Pregnancy***Breast-feeding***Agammaglobulinemia, hypogammaglobulinemia, IgA deficiency***Viral infection***Anticoagulant therapy, bleeding, coagulopathy, hemophilia, thrombocytopenia***Vaccination***Children***Coronary artery disease, geriatric, heart failure, hypertriglyceridemia, hyponatremia, obesity, thromboembolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10510'],thiothixene,***For the treatment of schizophrenia.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.,"***General Information***Thyroid disease***Hypocalcemia***Cardiac disease, hypotension, orthostatic hypotension, syncope***Neonates, pregnancy, pregnancy testing***Breast-feeding***Brain tumor, Reye's syndrome***Hepatic disease***Children, infants***Agranulocytosis, hematological disease, leukopenia, neutropenia***Seizure disorder***Glaucoma***Prostatic hypertrophy, urinary retention***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Breast cancer***Tobacco smoking***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Tardive dyskinesia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,olopatadine hydrochloride,"***For the treatment of the signs and symptoms of allergic conjunctivitis, including ocular pruritus.***For the treatment of symptoms associated with seasonal allergic rhinitis such as rhinorrhea, sneezing, and nasal pruritus.","***Contact lenses***Geriatric***Driving or operating machinery***Children, infants, neonates***Nasal septal perforation, nasal trauma***Depression***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['11645'],deferiprone,"***For the treatment of transfusional iron overload due to thalassemia syndromes when current chelation treatment is inadequate. <br />        NOTE: Safety and efficacy have not been established for the treatment of transfusional iron overload in patients with other chronic anemias.<br />NOTE: Clinical trials have not established an improvement in disease-related symptoms, functioning, or increased survival","***General Information***Agranulocytosis, infection, neutropenia***Pregnancy***Breast-feeding***Geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,potassium acid phosphate,***For the treatment of hypophosphatemia.***For phosphate serum concentration below 0.5 mg/dL.***For phosphate serum concentration between 0.5�1 mg/dL.***For nutritional supplementation.***For prevention of hypophosphatemia in patients receiving total parenteral nutrition (TPN).***For urinary acidification and to augment the efficacy of methenamine therapy in treating urinary tract infections.***Formoterol; Mometasone,"***Urinary tract infection (UTI)***Preeclampsia, pregnancy***Breast-feeding***Geriatric***Hyperkalemia, hypernatremia, hyperphosphatemia, hypocalcemia, sodium restriction***Heart failure, hypertension, peripheral edema, pulmonary edema***Muscle cramps, rhabdomyolysis***Adrenal insufficiency, dehydration, hypoparathyroidism, pancreatitis, renal disease, renal failure, renal impairment***Osteomalacia***Burns",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clobetasol propionate,"***For the treatment of moderate-to-severe inflammatory manifestations, including pruritus, of corticosteroid-responsive dermatologic disorders such as alopecia areata, atopic dermatitis, contact dermatitis, generalized exfoliative dermatitis, Rhus dermatitis due to plants like poison ivy, seborrheic dermatitis, eczema (including severe hyperkeratotic eczema, severe nummular eczema, and severe eczematous conditions of the hands or feet), granuloma annulare, keloids, cutaneous lichen planus, lichen simplex chronicus, lichen striatus, subacute cutaneous and discoid lupus erythematosus, pretibial myxedema, necrobiosis lipoidica diabeticorum, pemphigoid, pemphigus, pityriasis rosea, sarcoidosis, sunburn, or urticaria. <br />        NOTE: Acute exudative inflammation, as occurs with poison ivy, may be best treated with a non-emollient cream or gel formulation, which are drying. Dry, scaly dermatoses may be best treated with emollient creams or ointments. Lower potency corticosteroids should be used on the face and intertriginous areas.<br />NOTE: Systemic therapy or intralesional injection of corticosteroids may be necessary for some conditions based on the type and severity of the disorder or inadequate response to topical therapy***For the treatment of plaque-type psoriasis.***For the alternative treatment of recalcitrant oral vesiculoerosive disease� including oral lichen planus�, mucous membrane pemphigus�, aphthous ulcer� and chronic oral erythema multiforme�.***For the treatment of vulvar lichen sclerosus�.***For the alternative treatment of vision-threatening periocular capillary hemangioma� in infancy and early childhood.","***Corticosteroid hypersensitivity***Cushing's syndrome, hepatic disease, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Diabetes mellitus***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Fungal infection, herpes infection, infection, measles, peripheral vascular disease, varicella, viral infection***Acne rosacea, acne vulgaris, cataracts, glaucoma, ocular exposure, ophthalmic administration, perioral dermatitis***Geriatric, skin atrophy***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,azelastine hydrochloride,"***For the treatment of symptoms associated with allergic rhinitis.***For the treatment of symptoms associated with seasonal allergic rhinitis such as rhinorrhea, sneezing, and nasal pruritus.***For the treatment of symptoms associated with perennial allergic rhinitis.***For the treatment of symptoms associated with vasomotor rhinitis such as nasal congestion, rhinorrhea, postnasal drip, and sneezing.***For the treatment of ocular pruritus associated with allergic conjunctivitis.",***General Information***Driving or operating machinery***Contact lenses***Breast-feeding***Pregnancy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,oxybutynin chloride,"***For the treatment of an overactive bladder (OAB) with symptoms of urinary frequency, urinary urgency, or urinary incontinence due to involuntary detrusor muscle contractions (includes neurogenic bladder).","***Angioedema***Prostatic hypertrophy, urinary retention, urinary tract obstruction***Closed-angle glaucoma, contact lenses***Esophageal stricture, gastroesophageal reflux disease (GERD), gastroparesis, GI obstruction, hiatal hernia, ileus, pyloric stenosis, toxic megacolon, ulcerative colitis***Autonomic neuropathy, myasthenia gravis***Dementia***Parkinson's disease***Hepatic disease***Anticholinergic medications, driving or operating machinery, ethanol ingestion***Ambient temperature increase***Accidental exposure, tobacco smoking***Pregnancy***Breast-feeding***Geriatric***Infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,solifenacin succinate,"***For the treatment of an overactive bladder (OAB) with symptoms of urinary frequency, urinary urgency, or urge-related urinary incontinence.","***Angioedema***Prostatic hypertrophy, renal failure, renal impairment, urinary retention, urinary tract obstruction***Closed-angle glaucoma, contact lenses, glaucoma***Gastroesophageal reflux disease (GERD), gastroparesis, GI obstruction, ileus, pyloric stenosis, toxic megacolon, ulcerative colitis***Hepatic disease***Anticholinergic medications***Driving or operating machinery***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Autonomic neuropathy, myasthenia gravis***Pregnancy***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,taliglucerase alfa,***For replacement therapy of glucosylceramidase in confirmed (type 1) Gaucher disease:. <br />        NOTE: Taliglucerase alfa is designated as an orphan drug by the FDA for this indication.<br />     ,"***Infusion-related reactions***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6470'],lorazepam,"***For the short-term management of anxiety.***For the short-term treatment of insomnia due to anxiety or transient situational stress.***For procedural sedation or preoperative sedation induction.***For operative amnesia induction in adult patients.***For preoperative sedation induction and/or relief of preoperative anxiety in adult patients.***For amnesia induction� and anxiety relief in pediatric patients.***For the treatment of status epilepticus. <br />        NOTE: The intramuscular route is not preferred for the treatment of status epilepticus because therapeutic concentrations may not be achieved as quickly compared to using the intravenous route. However, if an intravenous port is not available, the intramuscular route may be useful.<br />     ***For sedation maintenance� in mechanically-ventilated patients, to alleviate agitation� and/or anxiety.***For the treatment of alcohol withdrawal�.***For acute alcohol-related seizure prophylaxis�.***For the treatment and prevention of the symptoms of alcohol withdrawal�.***For chemotherapy-induced nausea/vomiting prophylaxis� as an adjunct to antiemetics.","***Benzodiazepine hypersensitivity, benzyl alcohol hypersensitivity***Bipolar disorder, depression, mania, psychosis, suicidal ideation***Status epilepticus***Intraarterial administration***Alcoholism, chronic obstructive pulmonary disease (COPD), CNS depression, coadministration with other CNS depressants, congenital heart disease, ethanol intoxication, pulmonary disease, pulmonary hypertension, respiratory depression, respiratory insufficiency, sleep apnea, status asthmaticus***Driving or operating machinery***Closed-angle glaucoma***Hepatic disease, hepatic encephalopathy, renal failure, renal impairment***Abrupt discontinuation, benzodiazepine dependence, seizure disorder, substance abuse***Neuromuscular disease, Parkinson's disease***GI disease***Dementia, geriatric***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates, premature neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1895'],acamprosate calcium,***For the maintenance treatment of alcohol dependence.***For use in combination with naltrexone�.,"***Sulfite hypersensitivity***Ethanol intoxication***Renal failure, renal impairment***Depression, suicidal ideation***Pregnancy***Breast-feeding***Geriatric***Children, infants, neonates***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,butorphanol tartrate,"***For treatment of moderate pain to severe pain including abdominal, orthopedic, migraine, headache, or postoperative pain when use of an opioid analgesic is appropriate.***For the treatment of obstetric pain during early labor in mothers with fetuses of at least 37 weeks gestation and without signs of fetal distress (not to be used for pain during delivery).***For preanesthesia and adjunctive use in general anesthesia induction and general anesthesia maintenance. <br />        NOTE: A 2 mg IM/IV dose of butorphanol is approximately equivalent in sedative effect to 10 mg of morphine or 80 mg of meperidine.�<br /> <br />NOTE: Butorphanol may not provide adequate intraoperative analgesia in every patient or under all conditions. If blood pressure or heart rate continue to rise, consider adding a potent volatile liquid inhalation anesthetic or another intravenous medication.***For the treatment of pruritus�.***For the treatment of opioid-induced pruritus� unresponsive to antihistamines.***For the treatment of intractable pruritus� associated with inflammatory skin or systemic diseases.","***General Information***Constipation, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Alcoholism, depression, substance abuse***Abrupt discontinuation***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, pulmonary disease, respiratory depression, respiratory insufficiency***Head trauma, increased intracranial pressure, intracranial mass***Acute myocardial infarction, angina, cardiac disease, heart failure, ventricular dysfunction***Hepatic disease, renal failure, renal impairment***Geriatric***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Opiate agonist hypersensitivity***Driving or operating machinery***Adrenal insufficiency, hypothyroidism, myxedema***Accidental exposure, potential for overdose or poisoning",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['37925'],orlistat,"***For the treatment of obesity (including weight loss and weight maintenance) in conjunction with a reduced-calorie diet and appropriate exercise. <br />  NOTE: Orlistat is indicated for obese patients with a BMI &gt;= 30 kg/m2 or a BMI &gt;= 27 kg/m2 in the presence of other risk factors (e.g., hypertension, diabetes mellitus, or dyslipidemia). The BMI is calculated by dividing weight in kilograms by height in meters squared. Conversion factors for calculation; weight in pounds (lbs.) divided by 2.2 = kilogram weight (kg); height in inches x 0.0254 = height in meters (m).<br />NOTE: Because orlistat may reduce the absorption of fat-soluble vitamins A, D, E, K, and beta-carotene, it is recommended patients take a daily multivitamin containing these vitamins at least 2 hours before or after orlistat","***General Information***Cholelithiasis, cholestasis, gallbladder disease***Hepatic disease, hepatitis, hepatotoxicity***Malabsorption syndrome***Anorexia nervosa, bulimia nervosa, malnutrition***Hypothyroidism***Nephrolithiasis***Seizure disorder***Human immunodeficiency virus (HIV) infection***Organ transplant***Diabetes mellitus***Anticoagulant therapy***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1292'],baclofen,"***For the treatment of spasticity, muscle spasm (not due to rheumatic conditions), myoclonus, and muscle rigidity in multiple sclerosis and spinal cord injury or diseases. <br />        NOTE: The efficacy of oral baclofen has not been established in stroke, cerebral palsy, and Parkinson's disease, and, therefore, is not recommended by the manufacturer for use in these disease states.<br />     ***For severe spasticity due to multiple sclerosis, cerebral palsy, spinal cord injury, or traumatic brain injury; or in patients unresponsive to oral baclofen therapy or those who experience intolerable side effects at effective oral doses. <br />          NOTE: Intrathecal baclofen has been designated an orphan drug by the FDA for this indication.<br />       ***For the treatment of persistent singultus (hiccups)�.***For the treatment of trigeminal neuralgia�.***For the treatment of central vestibular nystagmus�.***For prevention of stuttering priapism� (i.e., recurrent priapism).***For the adjunct treatment of symptomatic gastroesophageal reflux disease (GERD)� in refractory patients.","***General Information***Abrupt discontinuation***Intrathecal administration***Cerebral palsy, head trauma, intracranial bleeding, stroke***Geriatric***Bipolar disorder, depression, psychosis, schizophrenia***Diabetes mellitus***Seizure disorder, seizures***Dialysis, renal failure, renal impairment***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Children, infants***Epidural administration, intramuscular administration, intravenous administration, subcutaneous administration***Anticoagulant therapy, coagulopathy, infection, thrombocytopenia***Dental disease***Pregnancy***Breast-feeding***Phenylketonuria***Ovarian cyst",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1399'],benzocaine,"***For mild pain to provide topical anesthesia or local anesthesia. <br />        NOTE: For oral or dental uses, see dental anesthesia.<br />     ***For pain and pruritus associated with minor skin abrasion, burns, sunburn, insect bites or stings, or minor skin irritations.***For self-medication of rectal pain, especially soreness and/or pruritus associated with hemorrhoids and anorectal inflammation (temporary relief only).***For anesthesia of unbroken skin.***For oral mucosal anesthesia to control pain and/or suppress the pharyngeal and tracheal gag reflex; or for local anesthesia of accessible mucous membranes before examination, endoscopy or instrumentation; and to facilitate passage of fiberoptic gastroscopes, laryngoscopes, proctoscopes, and sigmoidoscopes.***For topical anesthesia in the external auditory canal to relieve ear pain related to acute otitis media and otitis externa.***For dental anesthesia or temporary relief of dental pain or oral pain.***For self-medication of pain associated with aphthous ulcer (i.e., canker sore), dental pain associated with toothache, or minor irritations of the mouth and gums (for temporary relief only).***For self-medication of pain and discomfort of irritations caused by dentures or orthodontic appliances (for temporary relief only).***For self-medication of dental pain due to teething (for temporary relief only).","***General Information***Burns, eczema, occlusive dressing, skin abrasion***Ear discharge, infection, tympanic membrane perforation***Ester local anesthetic hypersensitivity, para-aminobenzoic acid, PABA hypersensitivity, paraben hypersensitivity, tartrazine dye hypersensitivity***Pregnancy***Breast-feeding***Asthma, cardiac disease, chronic obstructive pulmonary disease (COPD), diabetes mellitus, G6PD deficiency, geriatric, Graves' disease, hepatic disease, hyperthyroidism, methemoglobin reductase deficiency, methemoglobinemia, shock, tobacco smoking***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2551'],ciprofloxacin,"***For the treatment of urinary tract infection (UTI), including acute uncomplicated cystitis and pyelonephritis.***For the treatment of acute, uncomplicated UTI (acute cystitis).***For the treatment of mild to moderate UTIs and for the treatment of severe and/or complicated UTIs, including pyelonephritis.***For the treatment of lower respiratory tract infections, including bronchitis, community-acquired pneumonia (CAP), and nosocomial pneumonia. <br />        NOTE: Ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. <br />     ***For the treatment of nosocomial, ventialator-associated pneumonia (VAP) or hospital-acquired pneumonia (HAP).***For the treatment of community-acquired pneumonia (CAP).***For the treatment of acute exacerbations of chronic bronchitis.***For the treatment of skin and skin structure infections, including diabetic foot ulcer, surgical incision site infections, animal bite wounds, and necrotizing infections.***For the treatment of diabetic foot ulcer.***For the treatment of surgical incision site infections.***For the treatment of animal bite wounds.***For the treatment of necrotizing infections of the skin, fascia, and muscle.***For the treatment of enteric infections, including acute gastroenteritis and infectious diarrhea.***For the treatment of uncomplicated gonorrhea (e.g., cervicitis and urethritis).***For the treatment of mild to moderate acute sinusitis.***For the treatment of prostatitis caused by susceptible organisms.***For acute prostatitis�.***For chronic bacterial prostatitis.***For the treatment of complicated intraabdominal infections in combination with metronidazole.***For empiric treatment of patients with febrile neutropenia as part of combination therapy.***For febrile neutropenia in adults.***For febrile neutropenia in pediatric patients�.***For the treatment of bacterial conjunctivitis.***For the treatment of ophthalmic infection associated with corneal ulcer.***For anthrax prophylaxis after exposure to Bacillus anthracis (postexposure prophylaxis, PEP).***For the treatment of plague infection.***For treatment in a contained casualty setting.***For treatment in a mass casualty setting.***For plague prophylaxis following exposure to <em>Yersinia pestis</em>.***For the treatment of acute otitis externa due to susceptible isolates of <em>Pseudomonas aeruginosa</em> or <em>Staphylococcus aureus</em>.***For the treatment of bone and joint infections (i.e., osteomyelitis, prosthetic joint infections, infectious arthritis).***For the treatment of bilateral otitis media with effusion in pediatric patients undergoing tympanostomy tube placement.***For the treatment of typhoid fever due to <em>Salmonella typhi</em>.***For the treatment of shigellosis.***For the treatment of campylobacteriosis.***For the treatment of acute systemic brucellosis� caused by <em>Brucella melitensis</em>.***For the treatment of chancroid� due to <em>Haemophilus ducreyi</em>.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of <em>Neisseria meningitidis</em>� nasal carrier state (i.e., for meningococcal infection prophylaxis�).***For the treatment of dental infection�, including dentoalveolar infection� and periodontitis�.***For adult chronic periodontitis� after scaling and root planing.***For adult refractory chronic periodontitis� in combination with metronidazole after scaling and root planing in beta-lactam allergic patients.***For the treatment of anthrax�.***For the treatment of cutaneous anthrax.***For the treatment of systemic anthrax infection.***For the treatment of cholera�.***For the treatment of tularemia� infection or for postexposure tularemia prophylaxis�.***For an individual patient� or in a contained casualty setting�. <br />          NOTE: Streptomycin is the drug of choice to treat tularemia in most patients; gentamicin is the preferred agent in pregnant women.<br />       ***For a mass casualty setting� and for tularemia prophylaxis� after exposure to <em>Francisella tularensis</em>. <br />          NOTE: Doxycycline is the treatment of choice for tularemia in the most patients. Ciprofloxacin is the drug of choice for pregnant women; if ciprofloxacin is contraindicated, doxycycline should be used.<br />       ***For use as maintenance treatment of melioidosis� due to <em>Burkholderia pseudomallei�</em>.***For surgical infection prophylaxis�.***For the treatment of acute pulmonary exacerbations in cystic fibrosis� (CF) patients.***For bacterial infection prophylaxis� in patients with cirrhosis and GI bleeding.***For the treatment of CAPD-associated peritonitis�.***For the treatment of exit-site� and tunnel infections� in CAPD patients.***For the treatment of infective endocarditis�.***For the treatment of Mycobacterium avium complex infection� (MAC) in HIV-infected patients.***For the treatment of salmonellosis�.***For the treatment of moderate or severe traveler's diarrhea�.***For the treatment of isosporiasis� (<em>Isospora belli</em>) in HIV-infected patients.***For the treatment of sepsis�.","***Viral infection***Quinolone hypersensitivity***Corticosteroid therapy, organ transplant, tendinitis, tendinopathy, tendon pain, tendon rupture***Alcoholism, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Cerebrovascular disease, neurotoxicity, peripheral neuropathy, seizure disorder***Myasthenia gravis***Diabetes mellitus***Dialysis, renal disease, renal failure, renal impairment***Dehydration***Hepatic disease, hepatitis, hepatotoxicity, jaundice***Sunlight (UV) exposure***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Sexually transmitted disease***Geriatric***Children, infants, neonates***Contact lenses***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['9344'],ribavirin,"***For the treatment of respiratory syncytial virus (RSV) infection.***For the treatment of chronic hepatitis C infection in patients with compensated liver disease. <br />        NOTE: Ribavirin monotherapy is not effective for hepatitis C infection. <br />NOTE: Therapy should be discontinued in patients who develop hepatic decompensation during treatment***For the treatment of chronic hepatitis C infection in combination with interferon alfa-2b alone. <br />          NOTE: Consider response prognostic factors, HCV genotype, viral load, and disease progression evidence such as hepatic inflammation and fibrosis when deciding to treat a pediatric patient. Weigh treatment benefits against potential safety risks identified in clinical trials.<br />       ***For the treatment of chronic hepatitis C infection in combination with a peginterferon alfa product alone. <br />          NOTE: Guidelines recommend the use of a peginterferon product plus ribavirin as part of a combination regimen depending on patient factors and genotype. <br />       ***For the treatment of chronic hepatitis C infection genotype 1 in combination with a nucleotide analog NS5B polymerase inhibitor or NS3/4A protease inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infections in patients with hepatocellular carcinoma awaiting liver transplant as well as patients with decompensated cirrhosis who may or may not be candidates for liver transplantation�.***For the treatment of  recurrent hepatitis C infection in patients after liver transplantation�.***For the treatment of chronic hepatitis C infection genotype 2 in combination with a nucleotide analog NS5B polymerase inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infection genotype 3 in combination with a nucleotide analog NS5B polymerase inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infection genotype 4 in combination with a nucleotide analog NS5B polymerase inhibitor or NS3/4A protease inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infection genotypes 5 or 6 in combination with a nucleotide analog NS5B polymerase inhibitor and/or a peginterferon alfa product�.***For the treatment of viral hemorrhagic fever (VHF)�, including hemorrhagic fever with renal syndrome (HFRS)� secondary to Hantaan virus infection�. <br />        NOTE: Ribavirin has been designated an orphan drug by the FDA for hemorrhagic fever with renal syndrome (HFRS).<br />     ***For Lassa fever prophylaxis�.***For the treatment of adenovirus infection�, including pneumonitis�, hepatitis�, hemorrhagic cystitis�, and nephritis�.***For the treatment of viral encephalitis�.***For subacute measles encephalitis� (SME).***For subacute sclerosing panencephalitis� (SSPE) caused by the measles virus�.***For encephalitis� caused by the Nipah virus�.***For encephalitis� caused by the West Nile virus�.***For the treatment of West Nile virus infection�, including meningitis� and encephalitis�. <br />  NOTE: Other than supportive care, there is no established treatment for West Nile virus infection. The use of ribavirin is suggested by in vitro data only.<br /***For the treatment of Severe Acute Respiratory Syndrome (SARS)�.***For the treatment of Crimean-Congo virus hemorrhagic fever (CCVHF)� or Lassa fever infection�. <br />        NOTE: The use of ribavirin for hemorrhagic fever with renal syndrome (HFRS) secondary to Crimean-Congo virus is supported by in vitro data.<br />***For Crimean-Congo virus hemorrhagic fever (CCVHF) prophylaxis�.","***General Information***Requires an experienced clinician, respiratory depression, respiratory insufficiency***Contact lenses, ocular exposure***Contraception requirements, male-mediated teratogenicity, pregnancy, pregnancy testing, reproductive risk***Infertility***Breast-feeding***Anemia, angina, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, heart failure, hemolytic anemia, myocardial infarction***Infection***Hemoglobinopathy, sickle cell disease, thalassemia***Geriatric***Hepatic disease, hepatitis, hepatitis C and HIV coinfection, influenza, organ transplant, ribavirin monotherapy, viral infection***Children, growth inhibition, infants, neonates***Pancreatitis***Dialysis, renal failure, renal impairment***Thyroid disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2409'],chlorthalidone,***For the treatment of edema.***For the treatment of hypertension.***Formoterol***Formoterol; Mometasone,"***General Information***Sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Electrolyte imbalance, hepatic disease, hypercalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, hypotension, metabolic alkalosis***Anuria, hypovolemia, renal disease, renal failure, renal impairment***Orthostatic hypotension, sympathectomy, syncope***Geriatric***Diabetes mellitus, hyperglycemia***Gout, hyperuricemia***Pancreatitis***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Preeclampsia, pregnancy***Breast-feeding***Neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['19666'],nesiritide,"***For the treatment of acutely decompensated congestive heart failure, in patients who have dyspnea at rest or with minimal activity.  <br />","***E. coli protein hypersensitivity***Aortic stenosis, atrial fibrillation, atrial flutter, cardiac arrhythmias, cardiac disease, cardiogenic shock, cardiomyopathy, cerebrovascular disease, constrictive pericarditis, coronary artery disease, hypotension, hypovolemia, idiopathic hypertrophic subaortic stenosis, mitral stenosis, orthostatic hypotension, pericardial effusion, respiratory depression, valvular heart disease, ventricular arrhythmias***Renal disease, renal failure, renal impairment***Geriatric***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,thyroid,"***For the treatment of hypothyroidism of any etiology, and for the treatment or prevention of various types of euthyroid (non-toxic) goiter.***Formoterol; Mometasone","***Porcine protein hypersensitivity***Thyrotoxicosis***Adrenal insufficiency***Hypopituitarism***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, coronary artery disease, hypertension, surgery***Obesity treatment***Diabetes mellitus***Osteoporosis***Geriatric***Pregnancy***Breast-feeding***Infertility***Neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydroxychloroquine sulfate,"***For the treatment of malaria and for malaria prophylaxis due to susceptible strains of <em>P. falciparum, P. vivax, P. malariae, P. ovale, </em>and <em>P. knowlesi�</em>.***For the treatment of malaria.***For malaria prophylaxis in areas where chloroquine-resistant <em>P. falciparum</em> has not been reported.***For the treatment of systemic lupus erythematosus (SLE).***For the treatment of rheumatoid arthritis.***For use in combination with methotrexate� for rheumatoid arthritis.***For use in combination with methotrexate and sulfasalazine� for rheumatoid arthritis.***For use in combination with sulfasalazine� for rheumatoid arthritis.***For the suppression of polymorphous light eruption�.***For the treatment of lupus nephritis�.***Formoterol***Formoterol; Mometasone","***General Information***Asian patients, ocular disease, visual disturbance***Porphyria, psoriasis***Alcoholism, hepatic disease***GI disease***G6PD deficiency***Myopathy, neurological disease***Accidental exposure, children, infants, neonates***Pregnancy***Breast-feeding***Diabetes mellitus, hypoglycemia***Bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Renal disease***Hematological disease***Seizure disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['5021', '91077']",griseofulvin,"***For the treatment of tinea corporis, tinea cruris, tinea capitis, tinea barbae, caused by susceptible strains of Trichophyton sp., Microsporum sp., or Epidermophyton sp..***For the treatment of tinea pedis or tinea unguium (onychomycosis).","***Hepatic disease***Carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Porphyria***Pregnancy***Breast-feeding***Serious rash***New primary malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,doxycycline hyclate,"***For the treatment of skin and skin structure infections, including cellulitis, due to <em>Staphylococcus aureus</em>. <br />        NOTE: Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infection.<br />     ***For the treatment of bacterial urinary tract infection (UTI).***For the treatment of upper respiratory tract infections (e.g., sinusitis).***For the treatment of lower respiratory tract infections (e.g., pneumonia, community-acquired pneumonia).***For the treatment of severe acne vulgaris as adjunctive therapy.***For the treatment of acne rosacea.***For the treatment of cholera.***For the treatment of brucellosis.***For the treatment of Rickettsial infections (e.g., Rickettsial pox, Rocky Mountain spotted fever, scrub typhus) including endemic murine typhus.***For the treatment of relapsing fever due to <em>Borrelia recurrentis</em>.***For the treatment of syphilis. <br />        NOTE: A Jarisch-Herxheimer reaction may occur within the first 24 hours of therapy.<br />NOTE: While clinical practice guidelines recommend non-penicillin alternatives for the treatment of syphilis in HIV-infected patients, their efficacy has not been evaluated and should only be used with close clinical and serologic monitoring***For primary, secondary, or early latent syphilis (caused by <em>Treponema pallidum</em>) in nonpregnant, penicillin-allergic patients.***For late latent syphilis in nonpregnant, penicillin-allergic patients.***For the treatment of psittacosis.***For the treatment of non-gonococcal urethritis (NGU) and chlamydia infection, including trachoma and inclusion bacterial conjunctivitis.***For the treatment of lymphogranuloma venereum caused by <em>Chlamydia trachomatis</em>.***For the treatment of granuloma inguinale (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of epididymitis and epididymo-orchitis.***For malaria prophylaxis in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains.***For the treatment of anthrax infection due to exposure to <em>Bacillus anthracis</em>.***For the treatment of cutaneous anthrax infection.***For the treatment of systemic anthrax infection.***For anthrax prophylaxis after exposure to <em>Bacillus anthracis</em> (postexposure prophylaxis, PEP).***For the treatment of plague infection due to exposure to <em>Yersinia pestis</em>.***For the treatment of plague infection in an individual patient or in a contained casualty setting.***For the treatment of plague infection in a mass casualty setting.***For the initial treatment of tularemia infection due to exposure to <em>Francisella tularensis </em>.***For the initial treatment of tularemia infection in individual patient or in a contained casualty setting. <br />          NOTE: Streptomycin is the drug of choice to treat tularemia in most patients; gentamicin is the preferred agent in pregnant women.<br />       ***For the initial treatment of tularemia infection in a mass casualty setting. <br />          NOTE: It is recommended that pregnant women be treated with ciprofloxacin as a first-line agent; doxycycline is a preferred treatment choice if ciprofloxacin is contraindicated.<br />       ***For the treatment of intestinal amebiasis as an adjunct to amebicides.***For the treatment of infections caused by sensitive organisms including actinomycosis (<em>Actinomyces israelii</em>), yaws (<em>Treponema pertenue</em>), necrotizing ulcerative gingivitis (Fusospirochetosis or Vincent's infection), and listeriosis (<em>Listeria monocytogenes</em>).***For the treatment of Q fever.***For the treatment of chancroid (<em>Haemophilus ducreyi</em>) infections.***For the treatment of bartonellosis (<em>Bartonella bacilliformis</em>) infections, including <em>Bartonella</em> endocarditis.***For the treatment of <em>Bartonella</em> sp. infections (bartonellosis) in HIV-infected patients.***For long term suppression� of infections caused by <em>Bartonella</em> sp. in HIV-infected patients with relapse or reinfection with CD4 count less than 200 cells/mm3.***For the treatment of enterocolitis�, biliary tract infections�, and intraabdominal infections�.***For the treatment of uncomplicated gonorrhea (e.g., cervicitis, urethritis, pharyngitis, proctitis�).***For the treatment of acute proctitis�.***For chlamydial infection prophylaxis� in victims of sexual assault.***For the treatment of chronic prostatitis� due to <em>Ureaplasma urealyticum</em>.***For the treatment of Lyme disease�, including erythema migrans�, Lyme arthritis�, Lyme carditis�, and Lyme meningitis�.***For early Lyme disease� (erythema migrans�).***For Lyme arthritis�.***For Lyme carditis�.***For early neurologic Lyme disease (i.e., Lyme meningitis� or cranial nerve palsy).***For Lyme disease prophylaxis�.***For the treatment of Legionnaire's disease� caused by <em>Legionella pneumophila</em>.***For the management of pleural effusion� as an alternative to injectable tetracycline or other agents.***For the treatment of malaria� due to <em>P. falciparum</em> or <em>P. vivax</em>.***For the treatment of pelvic inflammatory disease (PID)� and tubo-ovarian abscess�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis in combination with conventional treatment (e.g., scaling and root planing).***For aggressive juvenile periodontitis�.***For chronic adult periodontitis for a gain in clinical attachment, reduction in probing depth, and reduction in bleeding on probing.***For plague prophylaxis� following exposure to <em>Yersinia pestis</em>.***For tularemia prophylaxis� following exposure to <em>Francisella tularensis</em>.***For the treatment of Bancroft's filariasis� (elephantiasis) caused by <em>Wuchereria bancrofti</em>�.***For the treatment of melioidosis� due to <em>Burkholderia pseudomallei</em>.***For use as an adjunct in the treatment of <em>Burkholderia pseudomallei</em> bacteremia�.***For use as an adjunct in the treatment of localized melioidosis�.***For the treatment of leptospirosis� due to <em>Leptospira</em> sp.�.***For mild leptospirosis�.***For severe leptospirosis�.***For surgical infection prophylaxis� for gynecologic procedures.***For surgical infection prophylaxis� for hysterosalpingogram or chromotubation.***For surgical infection prophylaxis� for induced abortion/dilation and evacuation.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated bone and joint infections�, including osteomyelitis�, or orthopedic device-related infection�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated osteomyelitis�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated prosthetic device infections�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated spinal implant infections�.","***Tetracyclines hypersensitivity***Hepatic disease***Sunlight (UV) exposure***Asthma, sulfite hypersensitivity***Achlorhydria***Pregnancy***Breast-feeding***Children, infants, neonates***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Dental disease, periodontal disease***Chemotherapy, diabetes mellitus, human immunodeficiency virus (HIV) infection, immunosuppression***Antimicrobial resistance, fungal infection, viral infection***Increased intracranial pressure, obesity***Sexually transmitted disease***Geriatric***Serious rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['723', '1297882']",amoxicillin,"***For the treatment of upper respiratory tract infections (e.g., pharyngitis, tonsillitis).***For the treatment of tonsillitis and/or pharyngitis (rheumatic fever prophylaxis) secondary to <em>Streptococcus pyogenes</em>.***For the treatment of acute otitis media. <br />  NOTE: The American Academy of Pediatrics (AAP) does not recommend doses less than 80 mg/kg/day PO for the treatment of otitis media. Patients failing to respond within 48 to 72 hours should be re-evaluated by a healthcare provider. Amoxicillin; clavulanate is the preferred therapy for children who have received amoxicillin within the past 30 days or who have purulent conjunctivitis or a history of recurrent acute otitis media unresponsive to amoxicillin.<br /***For the treatment of skin and skin structure infections (e.g., cellulitis).***For mild to moderate infections caused by highly susceptible organisms.***For severe infections or infections caused by less susceptible organisms.***For the treatment of lower respiratory tract infections (e.g., pneumonia, community-acquired pneumonia, bronchitis).***For the treatment of urinary tract infection (UTI) including cystitis.***For mild to moderate infections caused by highly susceptible organisms.***For severe infections or infections caused by less susceptible organisms.***For the treatment of Lyme disease�.***For patients with erythema migrans�.***For early-stage Lyme disease�. <br />          NOTE: Used as an alternative to tetracycline or penicillin V in children &lt; 9 years of age or as an alternative to tetracycline in pregnant or lactating women.<br />       ***For Lyme arthritis�.***For the treatment of pregnant women with chlamydia infection� including cervicitis� and urethritis�.***For the treatment of dental infection�, including dentoalveolar infection�.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage.***For adolescent aggressive periodontitis� or adult refractory chronic periodontitis� in combination with metronidazole after scaling and root planing.***For bacterial endocarditis prophylaxis�.***For the treatment of typhoid fever� due to <em>Salmonella typhii</em>.***For Helicobacter pylori (H. pylori) eradication� in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />  NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.  The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: Resistance rates of H. pylori to metronidazole in the US are 25%; whereas amoxicillin resistance is rare.  Resistance rates for H. pylori to clarithromycin in the US are 13%.<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Prevpac monograph)  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60% to 90% of patients.***For treatment of cutaneous anthrax� infection due to exposure to <em>Bacillus anthracis</em> or as oral follow-up therapy for severe anthrax.***For anthrax prophylaxis� after exposure to <em>Bacillus anthracis</em>.","***General Information***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, eczema, penicillin hypersensitivity, urticaria***Dialysis, renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Children, infants, neonates, premature neonates***Geriatric***Pregnancy***Breast-feeding***Phenylketonuria***Mononucleosis***Sexually transmitted disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6064'],isotretinoin,"***For the treatment of severe recalcitrant cystic acne vulgaris (nodular acne).***For the treatment of keratinization disorders including keratosis follicularis�, lamellar ichthyosis�, and pityriasis rubra pilaris�.***For the treatment of juvenile chronic myelogenous leukemia (CML)�.***For the treatment of newly diagnosed, high-risk neuroblastoma� following autologous bone marrow transplantation.***For the treatment of recurrent cervical cancer, in combination with interferon alfa�.***For the adjuvant treatment of advanced squamous cell head and neck cancer�, in combination with interferon alfa and vitamin E.***For the adjuvant treatment of aggressive squamous cell skin carcinoma�, in combination with interferon alfa.***Formoterol; Mometasone","***Paraben hypersensitivity, retinoid hypersensitivity***Pregnancy, reproductive risk***Blood donation***Breast-feeding***Anorexia nervosa, children, corticosteroid therapy, hyperostosis, infants, neonates, osteomalacia, osteoporosis***Alcoholism, diabetes mellitus, hepatic disease, hepatitis, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, obesity, pancreatitis***Inflammatory bowel disease***Depression, psychosis, suicidal ideation***Contact lenses, driving or operating machinery, papilledema, visual disturbance***Hearing impairment***Sunlight (UV) exposure***Agranulocytosis, leukopenia, neutropenia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,gadobenate dimeglumine,"***For use as a contrast enhancement in magnetic resonance imaging (MRI) to visualize areas of the brain, spine, and associated tissues with disruption of the blood brain barrier or abnormal vascularity.***For use as a contrast enhancement in magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.","***General Information***Magnetic resonance imaging (MRI)***Asthma, atopy, radiopaque contrast media hypersensitivity***Diabetes mellitus, dialysis, geriatric, hypertension, nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy), renal disease, renal failure, renal impairment***Extravasation***Sickle cell disease***Cardiac arrhythmias, QT prolongation***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1291'],bacitracin,"***For the prevention of skin and skin structure infections after a minor compromise in skin integrity such as minor burns or skin abrasion.***For superficial ophthalmic infection of the conjunctiva and/or cornea caused by susceptible organisms, including the following infections - blepharitis, blepharoconjunctivitis, bacterial conjunctivitis, keratitis, and keratoconjunctivitis.***For the treatment of pneumonia or pleural empyema caused by susceptible Staphylococci. <br />  Due to the potential for nephrotoxicity, restrict bacitracin intramuscular therapy to infants with susceptible staphylococcal pneumonia infections and pleural empyema. Intramuscular bacitracin should only be used where adequate laboratory facilities are available and when constant supervision of the patient is possible.<br /***For the treatment and eradication of enteric vancomycin-resistant enterococci (VRE)� in the stool.","***General Information***Neomycin hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Nephrotoxicity, oliguria, renal failure, renal impairment***Pregnancy***Breast-feeding***Myasthenia gravis, neuromuscular disease, pulmonary disease, surgery***Ocular exposure***Fungal infection***Contact lenses***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1312397'],regorafenib,"***For the treatment of metastatic colorectal cancer in patients who have previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF therapy; and an anti-EGFR therapy if RAS wild type.***For the treatment of locally advanced, unresectable or metastatic gastrointestinal stromal tumors (GIST) in patients who have previously received imatinib and sunitinib.***For the treatment of hepatocellular cancer in patients who have<strong>","***Hepatotoxicity***Bleeding, GI bleeding***Skin disease***Hypertension***Acute myocardial infarction, cardiac disease***Fistula, GI perforation***Surgery, wound dehiscence***Asian patients***Pregnancy***Contraception requirements, infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4018'],ergocalciferol,"***For nutritional supplementation of vitamin D based on recommended dietary reference intakes. <br />  NOTE: Patients with increased risk for deficiency of vitamin D (e.g., cystic fibrosis and other conditions causing chronic fat malabsorption, patients with chronic kidney disease, patients with HIV, or patients taking certain enzyme-inducing medications, etc.) may require higher supplemental doses than those recommended for healthy individuals to maintain normal vitamin D status.   In such persons, 25(OH)D concentrations can be used to guide adequate dietary supplementation.<br /***For the treatment of vitamin D deficiency. <br />  NOTE: In adults, vitamin D deficiency is defined as 25(OH)D concentrations &lt; 50 nmol/L (&lt; 20 ng/mL) and vitamin D insufficiency as 25(OH)D concentrations of 50�80 nmol/L (20�32 ng/mL). However, consensus has not been reached as to what serum concentration determines vitamin D insufficiency in pediatric patients ; a concentration of &lt;= 37.5 nmol/L (&lt;= 15 ng/mL) has been considered indicative of deficiency in most children, although, some studies suggest deficiency may occur at concentrations similar to those defined for adults.<br />NOTE: Patients with vitamin D deficiency due to GI or liver diseases (e.g., cystic fibrosis, cholestatic liver disease, celiac disease, gastric or small bowel resection, etc.) or concomitant medications (e.g., anti-convulsants, corticosteroids, rifampin, etc.) may require higher doses and/or different treatment strategies.***For the treatment of nutritional rickets.***For the treatment of Hereditary 1,25-Dihydroxyvitamin D Resistant Rickets (HVDRR), also known as hereditary vitamin D resistant rickets type 2.***For the treatment of hypoparathyroidism with calcium supplementation.***For the treatment of familial hypocholesterolemia (eg., abetalipoproteinemia, hypobetalipoproteinemia, and chylomicron retention disease, CRD).***For the treatment and prevention of osteoporosis� in conjunction with calcium supplementation.***For the prevention and treatment of glucocorticoid-induced osteoporosis�. <br />          NOTE: The American College of Rheumatology recommends supplementation of vitamin D and calcium in all patients receiving corticosteroid therapy, especially if treatment duration will exceed 3 months.<br />       ***For the prevention of premenstrual syndrome (PMS)�.***For the treatment of secondary hyperparathyroidism and resultant bone disease (renal osteodystrophy�).","***Children, hypercalcemia, hypervitaminosis D, infants, neonates, premature neonates, tartrazine dye hypersensitivity***Renal disease, renal failure***Biliary tract disease, Crohn's disease, cystic fibrosis, fat malabsorption, gallbladder disease, hepatic disease, malabsorption syndrome***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['21107'],cilostazol,"***For the treatment of claudication associated with peripheral vascular disease (PVD); including the treatment of peripheral arterial disease in patients with diabetic neuropathy�, and for the treatment of chronic arterial occlusion due to arteriosclerosis obliterans� or thromboangiitis obliterans� (Buerger's disease�).***For thromboembolism prophylaxis in recipients of a coronary artery stent� following percutaneous coronary intervention (PCI)�, to prevent acute coronary thrombosis (i.e., abrupt closure) and the need for revascularization.","***Bleeding, GI bleeding, intracranial bleeding, peptic ulcer disease, retinal bleeding, retroperitoneal bleeding, surgery, thrombocytopenia, trauma***Driving or operating machinery, hypertension, hypotension***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, myocardial infarction, tachycardia, valvular heart disease, ventricular tachycardia***Pregnancy***Breast-feeding***Children***Renal failure, renal impairment***Hepatic disease***Tobacco smoking***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,lidocaine hydrochloride); (lidocaine hydrochloride/epinephrine,"***For the treatment of perfusing ventricular arrhythmias including ventricular fibrillation (VF) and ventricular tachycardia (VT) that may result during acute myocardial infarction or cardiac manipulation (e.g., cardiac surgery). <br />  NOTE: See resuscitation indication for dosage guidelines for VF or pulseless VT.<br />NOTE: Although not considered a drug of choice for ventricular arrhythmias, lidocaine may be used as an alternative antiarrhythmic in patients with preserved ventricular function and stable monomorphic VT. Lidocaine may also be used to treat polymorphic VT in patients with a normal QT interval (when electrolyte imbalance and ischemia are treated). If pulseless cardiac arrest associated with VF or VT, see separate dosage guidelines for the treatment ventricular arrhythmias during CPR.<br />NOTE: Lidocaine may be used to treat patients with polymorphic VT associated with QT prolongation (e.g., torsade de pointes).<br />NOTE: Monitor blood pressure and the electrocardiogram (ECG) during intravenous lidocaine administration***For topical anesthesia of skin and mucous membranes or stomatitis.***For prevention of dental pain� and for topical anesthesia of mucous membranes.***For laryngoscopy.***For nonurgent painful procedures including IV cannulation, venipuncture, lumbar puncture, or arterial puncture.***For the treatment of stage 1 thru 4 pressure ulcers, venous stasis ulcers, ulcerations of mixed vascular etiologies, diabetic skin ulcers, first and second degree burns, and post surgical incisions, cuts, and abrasions.***For endotracheal intubation.***For neonatal circumcision�.***For bronchoscopy.***For the treatment of pain associated with postherpetic neuralgia.***For ophthalmic anesthesia.***For local anesthesia including peripheral nerve block anesthesia. <br />        NOTE: In adults, the dosages for local anesthesia reported are general guidelines only. The actual dose depends on a variety of factors such as depth of anesthesia, extent of surgical procedure, degree of muscle relaxation required, duration of anesthesia and the patients' physical condition. See Lidocaine; epinephrine monograph for information concerning combination dosing.<br />     ***For dental anesthesia including mandibular nerve block and maxillary infiltration.***For infiltration anesthesia.***For intravenous regional anesthesia.***For pudendal nerve block.***For paravertebral block.***For intercostal nerve block.***For brachial plexus block.***For paracervical block.***For sympathetic nerve block.***For cervical stellate ganglion block.***For lumbar sympathetic block.***For epidural anesthesia. <br />        NOTE: The dose is determined by the number of dermatomes to anesthetized (2 to 3 mL/dermatome). The suggested concentrations and volumes serve as a guide, other volumes and concentrations may be used provided the maximum dose is not exceeded.<br />     ***For lumbar anesthesia.***For lumbar analgesia for severe pain.***For thoracic.***For caudal anesthesia.***For obstetric anesthesia.***For surgical anesthesia.***For spinal anesthesia.***For obstetrical low spinal or saddle block anesthesia.***For intraabdominal anesthesia.***For the treatment of ventricular arrhythmias during cardiopulmonary resuscitation� (CPR).***For the attenuation of increased intracranial pressure� during rapid-sequence intubation� or endotracheal tube suctioning�.***For the treatment of severe singultus (hiccups)�.***For the treatment of headache�.***For the treatment of acute headache� associated with migraine�.***For the treatment of cluster headache�.***For the symptomatic treatment of corticosteroid-dependent asthma�. <br />        NOTE: Initial bronchoconstriction can occur. In addition, lidocaine toxicity can result in tremors, hallucinations, seizures, and cardiac arrest. Caution is advised until long-term safety and efficacy can be established.<br />     ***For short-term prophylaxis of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing� (SUNCT).***For the treatment of painful diabetic neuropathy� in adults.","***General Information***Amide local anesthetic hypersensitivity, epidural anesthesia***Collagen-vascular disease***G6PD deficiency***Geriatric, heart failure, hepatic disease***Hypotension, pregnancy***Breast-feeding***Adams-Stokes syndrome, atrial fibrillation, atrial flutter, AV block, bradycardia, cardiogenic shock, hemorrhagic shock, hypovolemia, shock, Wolff-Parkinson-White syndrome***Renal disease, renal failure, renal impairment***Burns, eczema, heating pad, occlusive dressing, skin abrasion***Cataracts, ocular exposure, ocular trauma***Accidental exposure***Intraarterial administration, intrathecal administration, intravenous administration***Head and neck anesthesia***Ocular surgery***Anticoagulant therapy, bleeding, coagulopathy, infection, neurological disease, requires a specialized care setting, requires an experienced clinician, sepsis, spinal anesthesia, thrombocytopenia***Fetal distress, labor, obstetric delivery, pudendal nerve block***Continuous intraarticular infusion administration***Fetal prematurity, paracervical nerve block***Malignant hyperthermia***Children, infants, neonates, teething pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['83947'],tazarotene,"***For the treatment of stable plaque psoriasis. <br />  NOTE: According to the American Academy of Dermatology (AAD), tazarotene is best used in combination with a topical corticosteroid for the treatment of psoriasis. Combination therapy may produce a synergistic effect, increase duration of treatment benefit and length of remission, and potentially decrease steroid-induced atrophy.<br /***For the topical treatment of acne vulgaris.***For adjunctive treatment of fine facial wrinkles and facial mottled hyperpigmentation (i.e., 'liver spots') and hypopigmentation associated with photoaging.","***General Information***Pregnancy***Breast-feeding***Children, infants, neonates***Eczema***Retinoid hypersensitivity***Benzyl alcohol hypersensitivity***Skin cancer, skin photosensitivity disorder, sunburn, sunlight (UV) exposure***Accidental exposure, occlusive dressing, ocular exposure***Contraception requirements, females, pregnancy testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,valproate sodium,"***For the monotherapy or adjunct treatment of simple absence seizures, complex absence seizures, or complex partial seizures, and adjunctively for other seizure types that include absence or partial complex seizures (e.g., tonic-clonic seizures, myoclonic seizures).***For the treatment of acute mania associated with bipolar disorder, with or without psychotic features.***For migraine prophylaxis.***For the treatment of refractory status epilepticus�. <br />  NOTE: Valproate has been used for emergency treatment of seizures where other agents have failed, or, when other medications are not readily available or when phenytoin is contraindicated.<br /***For the treatment of persistent singultus (hiccups)�.***For the treatment of severe behavioral disturbances, such as agitation�.***For severe behavioral disturbances� (e.g., aggression, agitation�, explosive temper) occurring with attention-deficit hyperactivity disorder (ADHD)�.***For the symptomatic treatment of acquired pendular nystagmus�.***For the treatment of painful diabetic neuropathy�.","***General Information***Encephalopathy***Serious rash***Mitochondrial disease***Carnitine deficiency, hepatic disease, hepatotoxicity, hypoalbuminemia, organic brain syndrome***Pancreatitis***Children, infants, neonates***Depression, suicidal ideation***Bleeding, coagulopathy, surgery, thrombocytopenia***Renal failure, renal impairment***Human immunodeficiency virus (HIV) infection***Driving or operating machinery, ethanol ingestion***Colostomy, diarrhea, ileostomy***Head trauma***Abrupt discontinuation***Contraception requirements, pregnancy, reproductive risk***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1307298'],enzalutamide,***For the treatment of metastatic castration-resistant prostate cancer.,"***Brain tumor, head trauma, seizures, stroke***Encephalopathy***Females, pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,somatropin (rDNA origin),"***For the treatment of growth hormone deficiency, growth failure, or short stature.***For replacement therapy in adults with growth hormone deficiency (GHD) for either childhood onset (secondary to congenital, genetic, acquired, or idiopathic causes) or adult onset (endogenous or associated with multiple hormone deficiencies, i.e., hypopituitarism, as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma).***For the long-term treatment of growth failure in children who have growth hormone deficiency due to inadequate growth hormone secretion.***For growth failure due to Prader-Willi syndrome.***For the long-term treatment of growth failure in children born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 to 4.***For growth failure associated with chronic renal failure up to the time of transplantation.***For short stature associated with Turner's syndrome.***For short stature in children with SHOX (short stature homeobox-containing gene) deficiency.***For short stature in children with Noonan Syndrome.***For idiopathic short stature.***For the treatment of HIV-associated failure to thrive in children, AIDS-associated wasting syndrome, or cachexia.***For the treatment of HIV-associated adipose redistribution syndrome (HARS)�.***For the treatment of short bowel syndrome in patients receiving specialized nutrition support as directed by a health care professional.***Formoterol; Mometasone","***General Information***Cresol hypersensitivity, glycerin hypersensitivity, history of angioedema, risk of serious hypersensitivity reactions or anaphylaxis***Epiphyseal closure***Children, renal impairment, renal osteodystrophy***Benzyl alcohol hypersensitivity, neonates***Chemotherapy, neoplastic disease, new primary malignancy, radiation therapy***Respiratory insufficiency, surgery, trauma***Obesity***Respiratory infection, sleep apnea***Diabetes mellitus, diabetic retinopathy***Scoliosis***Adrenal insufficiency, hypothyroidism***Increased intracranial pressure***Pregnancy***Breast-feeding***Otitis media***Geriatric***Females***Pancreatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cyclobenzaprine hydrochloride,***For the relief of muscle spasm associated with acute painful musculoskeletal conditions unrelated to central nervous system disease.***For the treatment of fibromyalgia�.***Formoterol***Formoterol; Mometasone,"***Tricyclic antidepressant hypersensitivity***Hyperthyroidism***Depression, MAOI therapy***Seizure disorder, seizures***Alcoholism, driving or operating machinery***Acute myocardial infarction, AV block, bradycardia, bundle-branch block, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Closed-angle glaucoma, contact lenses, ileus, prostatic hypertrophy, urinary retention***Hepatic disease***Cerebral palsy, children, infants, neonates***Pregnancy***Breast-feeding***Radiographic contrast administration***Sunlight (UV) exposure***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albumin (human),"***For the treatment of shock due to hypovolemia. <br />        NOTE: Dosage should be based on patient response as indicated by blood pressure, degree of pulmonary congestion, and hematocrit.<br />     ***For adjunctive treatment of severe burns.***For the treatment of nephrosis in nephrotic syndrome.***For treatment of hypoproteinemia.***For adjunctive use with exchange transfusion in the treatment of hyperbilirubinemia and erythroblastosis fetalis.","***Albumin hypersensitivity***Anemia, heart failure, hypertension***Renal disease***Hypernatremia***Burns***Viral infection***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['29046', '1546022']",lisinopril,***For the treatment of hypertension.***For the treatment of heart failure.***For the treatment of persistent albuminuria� in patients with diabetic nephropathy� or in at-risk hypertensive patients�.***For migraine prophylaxis�.***For the treatment of proteinuria� in pediatric patients with IgA nephropathy�.,"***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, Black patients, hereditary angioedema***Diabetes mellitus, hyperkalemia, renal artery stenosis, renal disease, renal failure, renal impairment***Autoimmune disease, bone marrow suppression, collagen-vascular disease, immunosuppression, scleroderma, systemic lupus erythematosus (SLE)***Dialysis, hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Acute myocardial infarction, aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hyponatremia, hypotension, hypovolemia***Surgery***Jaundice***Neonates, pregnancy***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,antihemophilic factor (human),"***For the prevention and control of hemorrhage in patients with hemophilia A (classical hemophilia). <br />        NOTE: Humate, Kogenate, and ReFacto have been designated by the FDA as orphan drugs for the prophylaxis and management of hemorrhage or hemarthrosis in patients with hemophilia A.<br /> <br />NOTE: Guidelines for the treatment of acute bleeding and prevention of bleeding during surgery vary. For all indications, the dose of antihemophilic factor should be individualized taking into consideration the seriousness of the bleed or procedure, the clinical status of the patient, and the factor VIII activity concentration***For minor bleeding including early muscle bleed, early hemarthrosis, and oral bleeds.***For moderate bleeding including advanced muscle bleed, extensive hemarthrosis, hematoma, and mild head trauma.***For life- or limb-threatening bleeding including surgical bleeding, gastrointestinal bleeding, neck, tongue or pharyngeal hematoma with potential for airway compromise, intracranial, intraabdominal, or intrathoracic bleeding, or fractures.***For bleeding in patients with hemophilia A and factor VIII inhibitor titers less than 10 Bethesda Units and with low anamnestic responses.***For the perioperative management of surgical bleeding (surgical bleeding prophylaxis) in patients with hemophilia A.***For routine bleeding prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A.***For the management of hemorrhage or hemarthrosis in patients with von Willebrand's disease (vWD). <br />        NOTE: Humate-P has been designated by the FDA as orphan drugs for this indication.<br />     ***For major hemorrhage in patients with mild vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma or traumatic hemorrhage).***For minor hemorrhage in patients with moderate to severe vWD type I, type II, and type III (e.g., epistaxis, oral bleeding, or menorrhagia).***For major hemorrhage in patients with moderate to severe vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For major hemorrhage in patients with vWD type II and III (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For surgical bleeding prophylaxis during major or minor procedures in patients with vWD in whom desmopressin is either ineffective or contraindicated. <br />          NOTE: Alphanate and Humate-P have been designated by the FDA as orphan drugs for this indication.<br />       ","***General Information***Pregnancy***Breast-feeding***Thromboembolic disease***Hepatitis, infection, viral infection***Anemia***Bovine protein hypersensitivity, hamster protein hypersensitivity, latex hypersensitivity, mannitol hypersensitivity, murine protein hypersensitivity, polysorbate 80 hypersensitivity***Porcine protein hypersensitivity***Human immunodeficiency virus (HIV) infection***Cardiac disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,somatropin (rDNA origin),"***For the treatment of growth hormone deficiency, growth failure, or short stature.***For replacement therapy in adults with growth hormone deficiency (GHD) for either childhood onset (secondary to congenital, genetic, acquired, or idiopathic causes) or adult onset (endogenous or associated with multiple hormone deficiencies, i.e., hypopituitarism, as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma).***For the long-term treatment of growth failure in children who have growth hormone deficiency due to inadequate growth hormone secretion.***For growth failure due to Prader-Willi syndrome.***For the long-term treatment of growth failure in children born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 to 4.***For growth failure associated with chronic renal failure up to the time of transplantation.***For short stature associated with Turner's syndrome.***For short stature in children with SHOX (short stature homeobox-containing gene) deficiency.***For short stature in children with Noonan Syndrome.***For idiopathic short stature.***For the treatment of HIV-associated failure to thrive in children, AIDS-associated wasting syndrome, or cachexia.***For the treatment of HIV-associated adipose redistribution syndrome (HARS)�.***For the treatment of short bowel syndrome in patients receiving specialized nutrition support as directed by a health care professional.***Formoterol; Mometasone","***General Information***Cresol hypersensitivity, glycerin hypersensitivity, history of angioedema, risk of serious hypersensitivity reactions or anaphylaxis***Epiphyseal closure***Children, renal impairment, renal osteodystrophy***Benzyl alcohol hypersensitivity, neonates***Chemotherapy, neoplastic disease, new primary malignancy, radiation therapy***Respiratory insufficiency, surgery, trauma***Obesity***Respiratory infection, sleep apnea***Diabetes mellitus, diabetic retinopathy***Scoliosis***Adrenal insufficiency, hypothyroidism***Increased intracranial pressure***Pregnancy***Breast-feeding***Otitis media***Geriatric***Females***Pancreatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['161'],acetaminophen,"***For the treatment of fever. <br />        NOTE: Acetaminophen should not be used for self-medication of marked fever (greater than 39.5 degrees C or 103.1 degrees F), fever persisting longer than 3 days, or recurrent fever, unless directed by a physician.<br />     ***For the treatment of mild pain or for the temporary relief of headache, myalgia, back pain, musculoskeletal pain, dental pain (e.g., toothache), dysmenorrhea, arthralgia, or minor aches and pains associated with the common cold or flu. <br />        NOTE: Acetaminophen should not be used for self-medication of pain for longer than 10 days in adults or 5 days in children.<br />     ***For the treatment of moderate pain to severe pain with adjunctive opioid analgesics.***For minor osteoarthritis pain.***For the treatment of headache pain due to acute migraine�.","***Acetaminophen hypersensitivity***Alcoholism, ethanol intoxication, hepatic disease, hepatitis, hepatotoxicity, hypovolemia, malnutrition, potential for overdose or poisoning***Renal disease, renal failure, renal impairment***G6PD deficiency***Bone marrow suppression, immunosuppression, infection, neutropenia***Tobacco smoking***Children, infants, neonates***Pregnancy***Breast-feeding***Phenylketonuria***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,metformin hydrochloride,"***For treatment of type 2 diabetes mellitus.***For monotherapy or for use in combination with an insulin secretogue (e.g., sulfonylurea) or insulin.***For conversion to metformin monotherapy from other antidiabetic agents.***For the adjunct treatment of patients with hyperinsulinemia secondary to polycystic ovary syndrome� (PCOS), including the treatment of infertility� in these patients.***For the delay of clinical puberty and early menarche in females with precocious puberty�.***For the prolongation of pubertal growth� and to prevent the delay of early menarche in low birth weight females with early-normal onset of puberty.***For the treatment of gestational diabetes� in patients not controlled by diet-therapy alone.","***General Information***Diabetic ketoacidosis, type 1 diabetes mellitus***Acidemia, hypoxemia, lactic acidosis, metabolic acidosis***Diarrhea, vomiting***Renal disease, renal failure, renal impairment***Acute heart failure, acute myocardial infarction, cardiac disease, cardiogenic shock, heart failure***Alcoholism, ethanol ingestion, ethanol intoxication, hepatic disease***Radiographic contrast administration***Burns, dehydration, fever, infection, sepsis, surgery, trauma***Adrenal insufficiency, gastroparesis, GI obstruction, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypothyroidism, ileus, malnutrition, pituitary insufficiency***Pernicious anemia***Geriatric***Polycystic ovary syndrome, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['17128'],lansoprazole,"***For the short-term treatment of frequent dyspepsia or pyrosis (heartburn) that occurs 2 or more times per week.***For the treatment of non-erosive gastroesophageal reflux disease (GERD).***For the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.***For Helicobacter pylori (H. pylori) eradication in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), stomach ulcers�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />        NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.  The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Prevpac monograph).  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60% to 90% of patients.***For the treatment of active duodenal ulcer. <br />  NOTE: For dosing in patients with ulcers due to H. pylori, see �H. pylori eradication� indication.<br /***For the treatment of active benign gastric ulcer. <br />        NOTE: For dosing in patients with ulcers due to H. pylori, see �H. pylori eradication� indication.<br />     ***For the treatment of erosive esophagitis (erosive GERD).***For NSAID-induced ulcer prophylaxis or healing.***For stress gastritis prophylaxis� in critically-ill patients.***For the treatment of proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) in the differential diagnosis of eosinophilic esophagitis (EoE)�.","***General Information***Proton pump inhibitors (PPIs) hypersensitivity***Vitamin B12 deficiency***Hepatic disease***Diarrhea, pseudomembranous colitis***Gastric cancer***Bone fractures, geriatric, osteoporosis***Hypomagnesemia, long QT syndrome***Rebound acid hypersecretion***Pregnancy***Breast-feeding***Phenylketonuria***Infants, neonates***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,chlorpheniramine maleate/phenylephrine hydrochloride,"***For relief of upper respiratory symptoms such as nasal congestion, rhinorrhea, and sneezing associated with allergic rhinitis, vasomotor rhinitis, the common cold, or sinusitis.***Formoterol***Formoterol; Mometasone","***General Information***Driving or operating machinery***Asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease, status asthmaticus***Hepatic disease***Renal disease, renal failure, renal impairment***Acute myocardial infarction, angina, atrial fibrillation, atrial flutter, AV block, bradycardia, bundle-branch block, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, heart failure, hypertension, myocardial infarction, tachycardia, ventricular fibrillation, ventricular tachycardia***Aneurysm, arteriosclerosis, cerebrovascular disease, intracranial bleeding, organic brain syndrome, stroke***Children, infants, neonates***Labor, obstetric delivery, pregnancy***Breast-feeding***Bladder obstruction, prostatic hypertrophy, urinary retention***Geriatric***Constipation, GI disease, GI obstruction, ileus, peptic ulcer disease, pyloric stenosis, ulcerative colitis***Closed-angle glaucoma, contact lenses, increased intraocular pressure***Diabetes mellitus, hyperthyroidism, peripheral vascular disease, thyrotoxicosis***MAOI therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8698'],probenecid,"***For the treatment of hyperuricemia associated with chronic gout or secondary to other causes.***For use as an adjuvant to antibiotic therapy to increase and/or prolong antibiotic serum concentrations by delaying renal clearance of the antibiotic.***For cidofovir toxicity prophylaxis� (i.e., drug-induced nephrotoxicity) in patients receiving cidofovir.","***Probenecid hypersensitivity, sulfonamide hypersensitivity***Bone marrow suppression, hematological disease***Geriatric, renal failure, renal impairment***Nephrolithiasis, radiation therapy, tumor lysis syndrome (TLS)***Peptic ulcer disease***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['299081'],spinosad,"***For the treatment of pediculosis capitis (head lice infestation) due to <em>Pediculus capitis</em>. <br />        NOTE: For proper treatment of pediculosis, nits (eggs) should be removed with a nit comb. Also, all personal headgear, scarfs, coats, and bed linen should be disinfected by machine washing in hot water and drying using the hot cycle of a dryer for at least 20 minutes. Personal articles that cannot be washed may be dry-cleaned, sealed in a plastic bag for 4 weeks, or sprayed with a product specifically designed for this purpose. Personal combs and brushes may be disinfected by soaking in hot water (above 130 degrees F) for 5�10 minutes.<br />     ","***General Information***Infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,almotriptan malate,"***For the acute treatment of migraine attacks in patients with a history of migraine with or without aura . <br />  NOTE: Use almotriptan only when a clear diagnosis of migraine is established. If a patient does not respond to almotriptan for the first migraine attack, the diagnosis of migraine should be re-evaluated prior to subsequent use of the drug. Almotriptan is not indicated for migraine prophylaxis or for the treatment of hemiplegic or basilar migraines or cluster headaches.<br /***For the acute treatment of migraine headache pain in patients with a history of migraine attacks with or without aura usually lasting 4 hours or more (when untreated).","***General Information***Sulfonamide hypersensitivity***Angina, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, hypercholesterolemia, myocardial infarction, obesity, tobacco smoking, vasospastic angina, Wolff-Parkinson-White syndrome***Hypertension***Cerebrovascular disease, intracranial bleeding, stroke***Basilar/hemiplegic migraine***Geriatric***Hepatic disease***Renal disease, renal failure, renal impairment***Colitis, peripheral vascular disease, Raynaud's phenomenon***Driving or operating machinery***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7646'],omeprazole/sodium bicarbonate,***For the treatment of active duodenal ulcer.***For the short-term treatment of active benign gastric ulcer.***For the treatment of gastroesophageal reflux disease (GERD).***For symptomatic treatment of non-erosive GERD.***For nocturnal acid breakthrough�.***For the treatment of erosive esophagitis (erosive GERD).***For stress gastritis prophylaxis in critically ill patients.***For the treatment of frequent pyrosis (heartburn).***For the treatment of proton pump inhibitor�responsive esophageal eosinophilia (PPI-REE) in the differential diagnosis of eosinophilic esophagitis (EoE)�.,"***General Information***Proton pump inhibitors (PPIs) hypersensitivity***Bartter's syndrome, corticosteroid therapy, Cushing's syndrome, hyperaldosteronism, hypocalcemia, hypokalemia, metabolic alkalosis, respiratory alkalosis***Cardiac disease, heart failure, hypernatremia, hypertension, peripheral edema, pulmonary edema, renal disease, renal failure, renal impairment, sodium restriction***Hepatic disease***Asian patients***Gastric cancer***Vitamin B12 deficiency***Children, infants, neonates***Pregnancy***Breast-feeding***Diarrhea, pseudomembranous colitis***Bone fractures, geriatric, osteoporosis***Hypomagnesemia, long QT syndrome***Rebound acid hypersecretion***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['21090'],ciclopirox,"***For the topical treatment of mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to <em>Trichophyton rubrum </em>in immunocompetent patients. <br />        NOTE: Ciclopirox should be used in conjunction with a comprehensive management program for onychomycosis which includes removal of the unattached, infected nails (as frequently as monthly) by a health care professional and weekly trimming of the nails by the patient.<br />     ***For the topical treatment of seborrheic dermatitis of the scalp.***For the topical treatment of tinea corporis, tinea cruris, or tinea pedis (<em>Epidermophyton floccosum</em>; <em>Microsporum canis</em>; <em>Trichophyton mentagrophytes</em>; <em>Trichophyton rubrum</em>); tinea versicolor (<em>Malassezia furfur</em>); or cutaneous candidiasis due to <em>Candida albicans</em>.","***Skin abrasion***Ocular exposure***Onychomycosis***Corticosteroid therapy, human immunodeficiency virus (HIV) infection, immunosuppression, organ transplant, seizure disorder***Diabetes mellitus, peripheral vascular disease***Geriatric***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,follitropin alfa,"***For the treatment of infertility in females. <br />        NOTE: Prior to the treatment, women should have a complete gynecologic and endocrinologic evaluation. The possibility of pregnancy should be ruled out and the fertility status of the male partner should be evaluated. <br />NOTE: During FSH treatment and during a 2 week post-treatment period, patients should be examined at least every other day for signs of excessive ovarian stimulation. Ovarian hyperstimulation syndrome (OHSS) usually occurs after discontinuation of FSH and reaches its maximum at about 7 to 10 days post-ovulation.***For the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure.***For the development of multiple follicles in the ovulatory female patient participating in an Assisted Reproductive Technology (ART) program.***For the induction of pregnancy in the ovulatory female patient undergoing controlled ovarian stimulation as part of an In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) cycle. <br />          NOTE: Women should have a diagnosis of the cause of infertility.<br />       ***For the treatment of infertility in males (for the stimulation of spermatogenesis in males with primary or secondary hypogonadotropic hypogonadism and resultant oligospermia). <br />  NOTE: Pretreatment with hCG is required prior to combination treatment with r-FSH. Various hCG dosages have been advocated; continue hCG for a period sufficient to achieve normal serum testosterone concentrations. Such pretreatment may require 3 to 6 months.<br />NOTE: Complete a medical and endocrinologic evaluation before starting follitropin beta or follitropin alfa. Exclude primary testicular failure and confirm hypogonadotropic hypogonadism. Lastly, evaluate the fertility status of the female partner.<br />NOTE: Serum testosterone concentrations and semen analysis are used for clinical monitoring of spermatogenesis","***General Information***Neomycin hypersensitivity, streptomycin hypersensitivity***Children***Driving or operating machinery***Asthma***Adrenal insufficiency, pituitary adenoma, thyroid disease***Ethanol intoxication, tobacco smoking***Testicular failure***Ovarian failure***Endometriosis, uterine leiomyomata, vaginal bleeding***Geriatric***Breast cancer, ovarian cancer, ovarian cyst, uterine cancer***Ascites, polycystic ovary syndrome***Ectopic pregnancy, pregnancy***Breast-feeding***Myocardial infarction, obesity, stroke, thromboembolic disease, thrombophlebitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5640'],ibuprofen,"***For the treatment of rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA).***For the treatment of dysmenorrhea.***For the treatment of severe pain in hospitalized patients.***For the treatment of mild pain to moderate pain.***For the treatment of mild to moderate pain in hospitalized patients.***For self-treatment of minor aches and pains due to the common cold, toothache, muscular aches or backache (musculoskeletal pain), and the minor pains of arthritis.***For the treatment of fever.***For the treatment of headache.***For self-treatment of headache.***For the treatment of pain due to acute migraine.***For the treatment of osteoarthritis; ankylosing spondylitis�; acute gouty arthritis�; or psoriatic arthritis�.***For patients with cystic fibrosis� to slow the rate of decline in lung function.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, Crohn's disease, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery bypass graft surgery (CABG), coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Geriatric***Labor, obstetric delivery, pregnancy***Infertility, reproductive risk***Breast-feeding***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2101'],carisoprodol,"***For treatment of musculoskeletal pain associated with acute, painful musculoskeletal conditions.","***Porphyria***Carbamate hypersensitivity***Asian patients, hepatic disease***Renal disease, renal failure, renal impairment***CNS depression, driving or operating machinery***Seizure disorder***Abrupt discontinuation, substance abuse***Geriatric***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['612865'],tocilizumab,"***For the treatment of moderately- to severely-active rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying antirheumatic drugs.***For the treatment of active polyarticular juvenile idiopathic arthritis . <br />  NOTE: Tocilizumab has been designated an orphan drug by the FDA for this indication.<br /***For the treatment of active systemic juvenile idiopathic arthritis.***For the treatment of temporal arteritis, also known as giant cell arteritis (GCA).***For the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS).***For the treatment of systemic scleroderma (systemic sclerosis)�. <br />        NOTE: Tocilizumab has been designated an orphan drug by the FDA for this indication. �<br />     ","***General Information***Diabetes mellitus, fungal infection, human immunodeficiency virus (HIV) infection, immunosuppression, infection, influenza, sepsis, surgery, tuberculosis***Neutropenia, thrombocytopenia***Hepatic disease, hepatitis***Multiple sclerosis, neurological disease***Corticosteroid therapy, diverticulitis, GI perforation***Neoplastic disease***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia***Vaccination***Geriatric***Children***Infants, labor, neonates, obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1307404'],linaclotide,***For the treatment of chronic idiopathic constipation (CIC).***For the treatment of irritable bowel syndrome with constipation (IBS-C).,"***Abdominal pain, cholelithiasis, Crohn's disease, diverticulitis, fecal impaction, gastric cancer, GI disease, GI obstruction, inflammatory bowel disease***Diarrhea***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,benztropine mesylate,***For the treatment of Parkinsonism or Parkinson's disease.***For idiopathic parkinsonism or Parkinson's disease.***For the treatment of tremor in patients with Parkinson's disease:.***For the treatment of postencephalitic Parkinsonism.***For the treatment of drug-induced extrapyramidal symptoms.***For the treatment of chronic sialorrhea� (chronic drooling) in developmentally-disabled patients.,"***General Information***Closed-angle glaucoma***Bladder obstruction, prostatic hypertrophy, urinary retention***Cardiac disease, tachycardia***Behavioral changes, dementia, driving or operating machinery, psychosis***Tardive dyskinesia***Autonomic neuropathy, myasthenia gravis***Anticholinergic medications, geriatric***Alcoholism, ambient temperature increase, hyperthermia***Pregnancy***Breast-feeding***Children, infants, neonates***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6470'],lorazepam,"***For the short-term management of anxiety.***For the short-term treatment of insomnia due to anxiety or transient situational stress.***For procedural sedation or preoperative sedation induction.***For operative amnesia induction in adult patients.***For preoperative sedation induction and/or relief of preoperative anxiety in adult patients.***For amnesia induction� and anxiety relief in pediatric patients.***For the treatment of status epilepticus. <br />        NOTE: The intramuscular route is not preferred for the treatment of status epilepticus because therapeutic concentrations may not be achieved as quickly compared to using the intravenous route. However, if an intravenous port is not available, the intramuscular route may be useful.<br />     ***For sedation maintenance� in mechanically-ventilated patients, to alleviate agitation� and/or anxiety.***For the treatment of alcohol withdrawal�.***For acute alcohol-related seizure prophylaxis�.***For the treatment and prevention of the symptoms of alcohol withdrawal�.***For chemotherapy-induced nausea/vomiting prophylaxis� as an adjunct to antiemetics.","***Benzodiazepine hypersensitivity, benzyl alcohol hypersensitivity***Bipolar disorder, depression, mania, psychosis, suicidal ideation***Status epilepticus***Intraarterial administration***Alcoholism, chronic obstructive pulmonary disease (COPD), CNS depression, coadministration with other CNS depressants, congenital heart disease, ethanol intoxication, pulmonary disease, pulmonary hypertension, respiratory depression, respiratory insufficiency, sleep apnea, status asthmaticus***Driving or operating machinery***Closed-angle glaucoma***Hepatic disease, hepatic encephalopathy, renal failure, renal impairment***Abrupt discontinuation, benzodiazepine dependence, seizure disorder, substance abuse***Neuromuscular disease, Parkinson's disease***GI disease***Dementia, geriatric***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates, premature neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6135'],ketoconazole,"***For the treatment of chromomycosis in patients who have failed or who are intolerant to other therapies. <br />  NOTE: Due to the potential for serious adverse events (i.e., fatal hepatotoxicity, adrenal insufficiency, harmful drug interactions), oral ketoconazole should only be used to treat serious fungal infections when no other antifungal therapies are available. <br /***For the treatment of blastomycosis, coccidioidomycosis, histoplasmosis, and paracoccidioidomycosis in patients who have failed or who are intolerant to other therapies. <br />  NOTE: Due to the potential for serious adverse events (i.e., fatal hepatotoxicity, adrenal insufficiency, harmful drug interactions), oral ketoconazole should only be used to treat serious fungal infections when no other antifungal therapies are available. <br /***For treatment of mucocutaneous candidiasis.***For the treatment of dandruff, to control flaking, scaling, or itching.***For the treatment of seborrheic dermatitis.***For the treatment of tinea corporis or tinea cruris.***For the treatment of tinea pedis.***For the treatment of tinea versicolor.***For the treatment of advanced prostate cancer�.***Formoterol***Formoterol; Mometasone","***Achlorhydria, human immunodeficiency virus (HIV) infection, hypochlorhydria***Ethanol ingestion, hepatic disease, hepatitis, hepatotoxicity***Bradycardia, cardiac arrhythmias, diabetes mellitus, females, heart failure, hypocalcemia, hypokalemia, hypomagnesemia, ketoconazole coadministration with other drugs, long QT syndrome, QT prolongation, torsade de pointes, ventricular arrhythmias***Adrenal insufficiency, surgery***Azole antifungals hypersensitivity***Pregnancy***Breast-feeding***Ocular exposure***Tobacco smoking***Driving or operating machinery***Geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluocinolone acetonide,"***For the treatment of mild to moderate inflammatory manifestations of corticosteroid-responsive dermatitis such as alopecia areata, atopic dermatitis, contact dermatitis, exfoliative dermatitis, Rhus dermatitis due to plants like poison ivy, or seborrheic dermatitis (facial and intertriginous areas), discoid lupus erythematosus (facial and intertriginous areas), eczema, granuloma annulare, intertrigo, cutaneous lichen planus, lichen simplex chronicus, polymorphous light eruption, pompholyx (dyshidrosis), nodular prurigo, anogenital or senilis pruritus, psoriasis (facial and intertriginous areas), or xerosis (inflammatory phase).***For atopic dermatitis.***For psoriasis of the scalp.***For seborrheic dermatitis of the scalp.***For the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.***For the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.***For the treatment of chronic eczematous otitis externa.","***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Ocular exposure, ophthalmic administration***Children, growth inhibition, increased intracranial pressure, infants, neonates***Fungal infection, herpes infection, herpes simplex keratitis (dendritic keratitis), infection, measles, ocular infection, varicella, viral infection***Acne rosacea, acne vulgaris, perioral dermatitis***Diabetes mellitus***Geriatric, skin atrophy***Pregnancy***Breast-feeding***Peanut hypersensitivity***Corticosteroid hypersensitivity***Glaucoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['430'],albendazole,"***For the treatment of hydatid cyst disease.***For the treatment of cysticercosis or neurocysticercosis (larval form of <em>T. solium</em>). <br />  NOTE: Patients should receive steroid and anticonvulsant therapy as required. Oral or intravenous corticosteroids should be considered to prevent cerebral hypertensive episodes during the first week of treatment.<br /***For the treatment of ascariasis�, enterobiasis (pinworm infection)�, hookworm infection�, or trichuriasis�.***For the treatment of capillariasis�.***For the secondary treatment of cutaneous larva migrans�.***For the secondary treatment of giardiasis�.***For the treatment of microsporidiosis� and for secondary microsporidiosis prophylaxis�. <br />  NOTE: According to the HIV treatment guidelines, initiating antiretroviral therapy (ART) before severe immunosuppression develops is key to preventing chronic microsporidiosis, as infection most commonly occurs in patients with CD4 counts &lt; 100 cells/mm3. Other preventative measures for patients with CD4 counts &lt; 200 cells/mm3 include: avoid untreated water sources; avoid consuming undercooked meat or seafood; limit exposure to animals known to be infected with microsporidia.<br />NOTE: All patients infected with microsporidiosis should be offered ART as part of the initial treatment***For the treatment of microsporidiosis� including <em>Encephalitozoon intestinalis</em><em>�</em> infection.***For the treatment or secondary prophylaxis of disseminated (non-ocular) and gastrointestinal infections associated with microsporidiosis� (not including <em>Enterocytozoon bieneusi</em> or <em>Vittaforma corneae</em>) in HIV-infected patients.***For the treatment or secondary prophylaxis of disseminated (non-ocular) infections associated with microsporidiosis� and attributed to <em>Trachipleistophora</em> or <em>Anncaliia</em> in HIV-infected patients.***For treatment or secondary prophylaxis of ocular infections due to microsporidiosis� caused by microsporidia other than <em>V. corneae</em> in HIV-infected patients.***For the treatment of strongyloidiasis� or taeniasis� (tapeworm infection�).***For the treatment of trichinosis�.***For the treatment of trichostrongyliasis�.","***General Information***Biliary obstruction, biliary tract disease, hepatic disease, hepatitis***Driving or operating machinery***Retinal cysticercosis***Agranulocytosis, anemia, bone marrow suppression, chemotherapy, leukopenia, neutropenia***Increased intracranial pressure, seizures***Children, infants, neonates***Pregnancy***Contraception requirements, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,oxybutynin chloride,"***For the treatment of an overactive bladder (OAB) with symptoms of urinary frequency, urinary urgency, or urinary incontinence due to involuntary detrusor muscle contractions (includes neurogenic bladder).","***Angioedema***Prostatic hypertrophy, urinary retention, urinary tract obstruction***Closed-angle glaucoma, contact lenses***Esophageal stricture, gastroesophageal reflux disease (GERD), gastroparesis, GI obstruction, hiatal hernia, ileus, pyloric stenosis, toxic megacolon, ulcerative colitis***Autonomic neuropathy, myasthenia gravis***Dementia***Parkinson's disease***Hepatic disease***Anticholinergic medications, driving or operating machinery, ethanol ingestion***Ambient temperature increase***Accidental exposure, tobacco smoking***Pregnancy***Breast-feeding***Geriatric***Infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,arsenic trioxide,"***For the treatment of acute promyelocytic leukemia (APL). <br />        NOTE: The FDA has designated arsenic trioxide as an orphan drug for the treatment of APL.<br />     ***For consolidation treatment in patients with newly diagnosed APL following remission induction with tretinoin (all-trans retinoic acid) plus anthracyline-based chemotherapy�.***For induction and consolidation therapy in patients with APL who are refractory to or who have relapsed from retinoid and anthracycline therapy.***For induction and consolidation therapy in patients with newly-diagnosed, low-risk APL, in combination with tretinoin (all-trans retinoic acid).***Formoterol***Formoterol; Mometasone","***Alcoholism, AV block, cardiac arrhythmias, cardiac disease, diabetes mellitus, electrolyte imbalance, females, heart failure, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, thyroid disease, torsade de pointes, ventricular arrhythmias***Differentiation syndrome, leukocytosis***Renal failure, renal impairment***Hepatic disease***Hyperglycemia***Disseminated intravascular coagulation (DIC), neutropenia, thrombocytopenia***New primary malignancy***Geriatric***Children, infants, neonates***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6064'],isotretinoin,"***For the treatment of severe recalcitrant cystic acne vulgaris (nodular acne).***For the treatment of keratinization disorders including keratosis follicularis�, lamellar ichthyosis�, and pityriasis rubra pilaris�.***For the treatment of juvenile chronic myelogenous leukemia (CML)�.***For the treatment of newly diagnosed, high-risk neuroblastoma� following autologous bone marrow transplantation.***For the treatment of recurrent cervical cancer, in combination with interferon alfa�.***For the adjuvant treatment of advanced squamous cell head and neck cancer�, in combination with interferon alfa and vitamin E.***For the adjuvant treatment of aggressive squamous cell skin carcinoma�, in combination with interferon alfa.***Formoterol; Mometasone","***Paraben hypersensitivity, retinoid hypersensitivity***Pregnancy, reproductive risk***Blood donation***Breast-feeding***Anorexia nervosa, children, corticosteroid therapy, hyperostosis, infants, neonates, osteomalacia, osteoporosis***Alcoholism, diabetes mellitus, hepatic disease, hepatitis, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, obesity, pancreatitis***Inflammatory bowel disease***Depression, psychosis, suicidal ideation***Contact lenses, driving or operating machinery, papilledema, visual disturbance***Hearing impairment***Sunlight (UV) exposure***Agranulocytosis, leukopenia, neutropenia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,rho(D) immune globulin intravenous (human),"***For Rh isoimmunization prophylaxis in Rh<sub>0</sub> [D]-negative patient and to ensure subsequent erythroblastosis fetalis prophylaxis in females with present and future pregnancies. <br />        NOTE: Never administer Rh0 [D] immune globulin to the neonate; administer to the mother only.<br />NOTE: The woman must not be sensitized to the Rh0 [D] antigen. The immune globulin is used to prevent the formation of anti-Rh0 [D] antibody.<br />NOTE: Rh0 [D] immune globulin prophylaxis for all obstetric indications is not indicated if either the father or the fetus is known to be Rh0 [D] negative. If the Rh status of the father and fetus are unknown, assume the fetus to be Rh0 [D] positive, and administer Rh0 [D] immune globulin to the mother.<br />NOTE: Passively acquired anti-Rh0 [D] may be detected in maternal or neonatal blood if antibody screening tests are performed after Rh0 [D] immune globulin administration. The presence of passively acquired anti-Rh0 [D] does not preclude further antepartum or postpartum prophylaxis with Rh0 [D] immune globulin. A woman who had a large fetomaternal hemorrhage late in pregnancy or after delivery may test Rh positive even though she is really Rh negative. Administer Rh0 [D] immune globulin if there is any doubt about the mother's Rh type. A screening test to detect fetal red blood cells may be helpful***For the suppression of Rh isoimmunization in Rh<sub>0</sub> [D]-negative patients who are exposed to Rh<sub>0</sub> [D]-positive red blood cells or Rh<sub>0</sub> [D]-positive blood products secondary to blood transfusion. <br />          NOTE: One prefilled syringe of HyperRHO S/D Full-Dose, of Rhophylac, or of RhoGAM has at least 1500 international units of Rh0 [D] antibody and will suppress the immunizing potential of 15 ml of Rh0 [D] positive packed red blood cells or the equivalent of 30 ml of whole blood. One 300 mcg vial of WinRho SDF has at least 1500 international units of Rh0 [D] antibody and will suppress the immunizing potential of 17 ml of Rh0 [D] positive packed red blood cells.<br />NOTE: The amount of incompatible blood transfusion should be determined by an approved assay such as the modified Kleihauer-Betke acid elution stain technique.<br />NOTE: Rh immunization can occur after exposure to less than 1 ml of Rh-positive red blood cells. <br />NOTE: Monitor patients by clinical and laboratory methods because of the risk for a hemolytic reaction.<br /***For the treatment of immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP) in non-splenectomized, Rh0 [D] antigen-positive patients. <br />        NOTE: Alternative treatments should be used in patients with hemoglobin concentrations less than 8 g/dl due to the risk of increasing the severity of anemia.<br />     ","***Anemia, hemolysis, hemolytic anemia, renal impairment, requires a specialized care setting***IgA deficiency***Anticoagulant therapy, coagulopathy, hemophilia, intramuscular administration, intravenous administration, thrombocytopenia, vitamin K deficiency***Agammaglobulinemia, hypogammaglobulinemia***Pregnancy***Children, infants, neonates***Breast-feeding***Diabetes mellitus***Geriatric, hepatitis, infection, leukemia, lymphoma, systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['384455'],tigecycline,"***For the treatment of complicated skin and skin structure infections caused by susceptible organisms when alternative treatment options are not suitable. <br />        NOTE: Not indicated for the treatment of diabetic foot infections. During a clinical trial, use of the drug for this indication did not achieve non-inferiority.<br />     ***For the treatment of complicated intraabdominal infections caused by susceptible organisms when alternative treatment options are not suitable.***For the treatment of community-acquired pneumonia caused by penicillin-susceptible organisms when alternative treatment options are not suitable. <br />        NOTE: Not indicated for the treatment of hospital-acquired or ventilator-associated pneumonia. Use of the drug for these indications has resulted in greater mortality and decreased efficacy.<br />     ***For the treatment of febrile neutropenia�.","***General Information***Tetracyclines hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Hepatic disease***Pregnancy***Breast-feeding***Children, infants, neonates***GI perforation***Mortality, respiratory infection***Geriatric***Pancreatitis***Diabetes mellitus, laboratory test interference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['72435'],anakinra,"***For reducing the signs and symptoms and slowing the progression of structural damage of moderately to severely active rheumatoid arthritis in patients who have failed 1 or more disease modifying antirheumatic drugs (DMARDs). <br />  NOTE: Anakinra may be given alone or in combination with other DMARDs except for other tumor necrosis factor inhibitors.<br /***For the treatment of cryopyrin-associated periodic syndromes (CAPS), specifically Neonatal-Onset Multisystem Inflammatory Disease (NOMID).","***E. coli protein hypersensitivity, intramuscular administration, intravenous administration, latex hypersensitivity***Asthma, bone marrow suppression, geriatric, immunosuppression, infection, neoplastic disease, tuberculosis***Vaccination***Pregnancy***Breast-feeding***Renal disease, renal failure, renal impairment***Infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,methylphenidate hydrochloride,***For the treatment of attention-deficit hyperactivity disorder (ADHD).***For once-daily product dosing.***For the treatment of narcolepsy.***For the treatment of major depression� or post-stroke depression refractory to other therapies. <br />        NOTE: The use of stimulants for the treatment of depressive disorders is usually limited to treatment-refractory cases or when standard medical therapies are not tolerated. Stimulants may aggravate coexisting anxiety or agitation in depressed patients.<br />     ,"***General Information***Hereditary fructose intolerance***Anxiety, bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Tics, Tourette's syndrome***Glaucoma, visual disturbance***Abrupt discontinuation, alcoholism, substance abuse***Hypertension***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular arrhythmias, ventricular dysfunction***Cerebrovascular disease, stroke***Children, growth inhibition***Hyperthyroidism***Seizure disorder, seizures***Neonates, pregnancy***Breast-feeding***Driving or operating machinery***Surgery***Radiographic contrast administration***Dysphagia, esophageal stricture, GI obstruction, ileus***Hepatic disease***Geriatric***MAOI therapy***Peripheral vascular disease, Raynaud's phenomenon***Chemical leukoderma, skin hypopigmentation, vitiligo***Phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mesalamine,***For the treatment of active ulcerative proctitis.***For the treatment of ulcerative colitis or Crohn's disease�.***For induction of remission of mild to moderate active ulcerative colitis or Crohn's disease�.***For maintenance of remission of ulcerative colitis.,"***General Information***5-aminosalicylates hypersensitivity, salicylate hypersensitivity***Renal disease, renal failure, renal impairment***Hepatitis, myocarditis, pericarditis, pneumonitis***Geriatric***Pregnancy***Breast-feeding***GI obstruction, pyloric stenosis***Sulfite hypersensitivity***Hepatic disease***Children, infants, neonates***Phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2409'],chlorthalidone,***For the treatment of edema.***For the treatment of hypertension.***Formoterol***Formoterol; Mometasone,"***General Information***Sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Electrolyte imbalance, hepatic disease, hypercalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, hypotension, metabolic alkalosis***Anuria, hypovolemia, renal disease, renal failure, renal impairment***Orthostatic hypotension, sympathectomy, syncope***Geriatric***Diabetes mellitus, hyperglycemia***Gout, hyperuricemia***Pancreatitis***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Preeclampsia, pregnancy***Breast-feeding***Neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,metoprolol succinate,"***For the treatment of angina pectoris.***For chronic stable angina.***For unstable angina�.***For the treatment of heart failure, including idiopathic dilated cardiomyopathy.***For the treatment of heart failure in pediatric patients� (ischemic origin or cardiomyopathy) usually in conjunction with digoxin, diuretics, or ACE inhibitor therapy.***For the treatment of hypertension, either alone or in combination with other antihypertensive agents.***For the treatment of an evolving acute myocardial infarction, STEMI and for reduction of cardiovascular mortality in stable patients who have sustained a definite or suspected acute myocardial infarction.***For heart rate control in patients with atrial fibrillation� or atrial flutter� without accessory pathway.***For heart rate control in an acute setting�.***For heart rate control in a non-acute setting and chronic maintenance therapy� (metoprolol tartrate).***For heart rate control in a non-acute setting and chronic maintenance therapy� (metoprolol succinate).***For the treatment of tremor�.***For the treatment of essential tremor�.***For the treatment of lithium-induced tremor�.***For migraine prophylaxis�.","***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***Acute heart failure, AV block, bradycardia, cardiogenic shock, hypotension, pulmonary edema, sick sinus syndrome, ventricular dysfunction***Cerebrovascular disease***Diabetes mellitus***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Surgery***Hepatic disease***Pregnancy***Breast-feeding***Peripheral vascular disease, Raynaud's phenomenon, vasospastic angina***Pheochromocytoma***Depression***Psoriasis***Myasthenia gravis***Geriatric***Beta-blocker hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['4603', '202991']",furosemide,***For the treatment of peripheral edema or edema associated with heart failure or nephrotic syndrome.***For the management of pulmonary edema or prevention of adverse hemodynamic effects associated with blood product transfusions�.***For the adjunctive treatment of acute pulmonary edema.***For the prevention of adverse hemodynamic effects and/or pulmonary edema associated with blood product transfusions�.***For adjunctive treatment of edema in patients with acute or chronic renal failure (renal impairment).***For the treatment of hypertension.***For adjunctive treatment of hypertensive urgency� or hypertensive emergency�.***For the acute treatment of hypercalcemia� associated with neoplastic disease in combination with intravenous saline.***For the treatment of ascites� in combination with spironolactone or amiloride.***Formoterol; Mometasone,"***Sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Acid/base imbalance, electrolyte imbalance, hypocalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis***Diabetes mellitus, hyperglycemia***Diarrhea, heart failure, ventricular arrhythmias***Acute myocardial infarction***Anuria, hypovolemia, renal disease, renal failure, renal impairment***Hypotension, orthostatic hypotension, sympathectomy, syncope***Systemic lupus erythematosus (SLE)***Gout, hyperuricemia***Hearing impairment***Pancreatitis***Preeclampsia, pregnancy***Breast-feeding***Children, infants, neonates, premature neonates***Ascites, hepatic disease, hepatic encephalopathy***Prostatic hypertrophy, urethral stricture, urinary retention***Thyroid disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,histrelin acetate,"***For the palliative treatment of advanced prostate cancer.***For the treatment of central precocious puberty (CPP) in children. <br />        NOTE: Prior to initiating treatment with histrelin, the diagnosis of CPP should be confirmed by measuring blood concentrations of total sex steroids, luteinizing hormone, and follicle stimulating hormone following stimulation with a GnRH analog; bone age versus chronological age should be assessed. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain to rule out an intracranial tumor, pelvic/testicular/adrenal ultrasound to rule out steroid secreting tumors, and measurement of human chorionic gonadotropin concentrations (to rule out a chorionic gonadotropin secreting tumor) and adrenal steroids (to exclude congential adrenal hyperplasia).<br />     ","***General Information***Gonadotropin-Releasing Hormone (GnRH) analogs hypersensitivity***Bladder obstruction, renal impairment, spinal cord compression, urinary tract obstruction***Females, pregnancy***Breast-feeding***Pituitary insufficiency***Children, infants, neonates***Osteoporosis***Cardiac disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, stroke, tobacco smoking***Diabetes mellitus, hyperglycemia***Depression, suicidal ideation***Seizure disorder",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,quetiapine fumarate,"***For the treatment of major depression.***For the adjunctive treatment of major depression in patients who have had an inadequate response to antidepressants alone.***For the treatment of major depressive disorder as monotherapy�.***For the treatment of bipolar disorder, including mania and bipolar depression.***For the acute treatment of mania and for maintenance therapy following stabilization.***For the treatment of bipolar depression during depressive episodes of bipolar I or bipolar II disorder.***For the treatment of rapid-cycling� bipolar disorder.***For the treatment of schizophrenia.***For the adjunct treatment of refractory obsessive-compulsive disorder (OCD)�.***For the treatment of neurocognitive symptoms (e.g., impulsivity, executive functioning) associated with borderline personality disorder�.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.***For the treatment of neuropsychiatric symptoms associated with dementia with Lewy bodies� that are unresponsive to other medications and non-medication treatments.***Formoterol***Formoterol; Mometasone","***General Information***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, thyroid disease***Agranulocytosis, hematological disease, leukopenia, neutropenia***Cataracts***Hypothyroidism***Tardive dyskinesia***Dysphagia***Neurological disease, Parkinson's disease***Brain tumor, seizure disorder***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Hepatic disease***Breast cancer***Diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, obesity***Neonates, pregnancy, pregnancy testing***Breast-feeding***Abrupt discontinuation, children, suicidal ideation***Dementia, geriatric, stroke***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,esomeprazole sodium,"***For the treatment of symptomatic, non-erosive gastroesophageal reflux disease (GERD).***For the treatment of pathological hypersecretion associated with Zollinger-Ellison syndrome.***For the treatment of short-term treatment of frequent dyspepsia or pyrosis (heartburn) that occurs >= 2 times per week.***For NSAID-induced ulcer prophylaxis or healing (gastric).***For the treatment of diagnostically confirmed erosive esophagitis due to GERD.***For upper GI rebleeding prophylaxis after therapeutic endoscopy.***For Helicobacter pylori (H. pylori) eradication in combination with antimicrobial agents for the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />        NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.  The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: If the patient has an active peptic ulcer at the time therapy is initiated, additional weeks of esomeprazole may be needed to achieve ulcer healing (see therapy duration recommended for healing of gastric ulcer or duodenal ulcer).<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy.  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long-term tumor regression is observed in 60% to 90% of patients. <br />***For the treatment of proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) in the differential diagnosis of eosinophilic esophagitis (EoE)�.","***General Information***Proton pump inhibitors (PPIs) hypersensitivity***Hepatic disease***Diarrhea, pseudomembranous colitis***Gastric cancer***Vitamin B12 deficiency***Bone fractures, geriatric, osteoporosis***Hypomagnesemia, long QT syndrome***Rebound acid hypersecretion***Pregnancy***Breast-feeding***Children, infants, neonates***Abdominal pain, dysphagia, GI bleeding, vomiting***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine","***For meningococcal infection prophylaxis due to <em>Neisseria meningitidis</em> serogroups A, C, Y, and W-135. <br />  NOTE: The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of all persons 11�18 years of age, preferably with 1 dose at age 11 or 12 years and a booster dose at 16 years.<br /","***General Information***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Fever, infection***Agammaglobulinemia, chemotherapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Pregnancy***Breast-feeding***Geriatric***Guillain-Barre syndrome***Infants, neonates, premature neonates***Syncope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,betamethasone dipropionate/clotrimazole,"***For the treatment of tinea corporis, tinea cruris, and tinea pedis infections caused by Epidermophyton floccosum, Trichophyton mentagrophytes, or Trichophyton rubrum). <br />        NOTE: The efficacy for the treatment of infections caused by zoophilic dermatophytes (e.g., Microsporum canis�) has not been established. Several cases of treatment failure have been reported with betamethasone; clotrimazole cream.<br />     ***For the secondary treatment of topical candidiasis� with inflammation due to susceptible strains of <em>Candida sp</em>.� including <em>Candida albicans</em>�.","***General Information***Pregnancy***Breast-feeding***Peripheral vascular disease, skin abrasion***Azole antifungals hypersensitivity***Children, growth inhibition, increased intracranial pressure, infants, neonates***Geriatric, skin atrophy***Ocular exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4053'],erythromycin,"***For the treatment of acne vulgaris.***For mild to moderately severe lower respiratory tract infections (e.g., pneumonia, bronchitis) caused by susceptible organisms.***For the treatment of Legionnaire's disease (caused by <em>Legionella pneumophila</em>).***For the treatment of mild to moderately severe upper respiratory tract infections (e.g., pharyngitis, tonsillitis), including group A beta-hemolytic streptococcal (GAS) pharyngitis (primary rheumatic fever prophylaxis).***For upper respiratory tract infections and GAS pharyngitis (primary rheumatic fever prophylaxis).***For prevention of recurrent attacks of rheumatic fever (i.e., secondary rheumatic fever prophylaxis).***For the treatment of listeriosis.***For the treatment of chlamydia infection and non-gonococcal urethritis.***For the treatment of non-gonococcal urethritis (NGU) or chlamydial infections including urogenital infections (urethritis, cervicitis, proctitis) and infant pneumonia.***For the treatment of chlamydial conjunctivitis or ophthalmia neonatorum caused by <em>Chlamydia trachomatis</em>.***For the treatment of lymphogranuloma venereum� caused by <em>Chlamydia trachomatis</em>.***For the prevention of ophthalmia neonatorum (i.e., ophthalmia neonatorum prophylaxis) due to <em>Neisseria gonorrhoeae</em><em> </em>or<em> Chlamydia trachomatis</em>.***For the treatment of pneumonia caused by <em>Chlamydia trachomatis</em> in neonates and infants.***For the adjunctive treatment of diphtheria to prevent establishment of carrier state and for <em>Corynebacterium diphtheriae</em> bacterial colonization eradication.***For the treatment of close contacts of patients with diphtheria (i.e., diphtheria prophylaxis�).***For the treatment of acute pelvic inflammatory disease (PID).***For acute pelvic inflammatory disease (PID) caused by <em>Neisseria gonorrhoeae</em>.***For the treatment of pertussis (whooping cough) caused by <em>Bordetella pertussis</em> or for postexposure pertussis prophylaxis. <br />  NOTE: For postexposure prophylaxis, administer to close contacts within 3 weeks of exposure, especially in high-risk patients (e.g., women in third trimester, infants &lt; 12 months).<br /***For the treatment of primary syphilis (caused by <em>Treponema pallidum</em>) in penicillin-allergic, nonpregnant patients.***For bowel preparation in combination with neomycin in patients undergoing colorectal surgery.***For the treatment of superficial ophthalmic infection involving the conjunctiva and/or cornea.***For the treatment of chancroid� due to <em>Haemophilus ducreyi</em>.***For the treatment of disseminated gonorrhea�. <br />  NOTE: Erythromycin is not recommended in adults, adolescents, or children 8 years and older or in patients weighing 45 kg or more due to resistance of N. gonorrheae against erythromycin in the United States. Single-dose azithromycin in combination with ceftriaxone is the preferred therapy in these populations. <br /***For the facilitation of gastric emptying in patients with delayed gastrointestinal motility  (e.g., gastroparesis�).***For the treatment of idiopathic or postsurgical gastroparesis� or diabetic gastroparesis�.***For the facilitation of gastric emptying� in patients with feeding intolerance�.***For the treatment of early Lyme disease�.***For the treatment of skin and skin structure infections including impetigo and burn wound infection�.***For the treatment of erythrasma (caused by <em>Corynebacterium minutissimum</em>).***For the treatment of tetanus� (caused by <em>Clostridium tetani</em>) when penicillin or tetracycline is contraindicated or not tolerated.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of cholera�.***For the treatment of bartonellosis� (<em>Bartonella bacilliformis)</em> and other <em>Bartonella sp.</em>� infections in HIV-infected patients.***For the treatment of angiomatosis infections�, peliosis hepatis�, bacteremia�, and osteomyelitis� caused by <em>Bartonella sp.</em>�.***For long term suppression� of infections caused by <em>Bartonella sp.</em>� in HIV-infected patients with relapse or reinfections with < 200 CD4 cells/mm3.***For pneumococcal prophylaxis� in penicillin-allergic patients with sickle cell disease�.***For the treatment of infantile acne�.***For the oral treatment of infantile acne.***For the topical treatment of infantile acne.***Formoterol***Formoterol; Mometasone","***General Information***Viral infection***Macrolide hypersensitivity***Hepatic disease***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Hearing impairment***Benzyl alcohol hypersensitivity, neonates***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Seizure disorder***Myasthenia gravis***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3446'],succimer,***For the treatment of lead toxicity secondary to serum lead concentrations > 45 mcg/dl. <br />        NOTE: Succimer is not indicated for the prophylaxis of lead toxicity in a lead-containing environment. The use of succimer should always be accompanied by an identification and removal of the source of lead exposure. Identification of the lead source and its abatement are critical to a successful therapy outcome.<br />     ,"***General Information***Neutropenia***Dehydration, dialysis, hypovolemia, renal failure, renal impairment***Hepatic disease***Pregnancy***Breast-feeding***Infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,quinapril hydrochloride,***For the treatment of hypertension.***For the treatment of heart failure.,"***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, Black patients, hereditary angioedema***Geriatric***Autoimmune disease, bone marrow suppression, collagen-vascular disease, immunosuppression, renal artery stenosis, renal disease, renal failure, renal impairment, scleroderma, systemic lupus erythematosus (SLE)***Hepatic disease***Hyperkalemia***Dialysis, hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hyponatremia, hypotension, hypovolemia***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['61381'],olanzapine,"***For the treatment of schizophrenia.***For use  in combination with fluoxetine for treatment-resistant depression.***For the treatment of bipolar disorder (bipolar I disorder), including mania or mixed episodes.***For the treatment of acute agitation associated with schizophrenia or bipolar mania.***For the adjunct treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in combination with fluoxetine.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.***Formoterol***Formoterol; Mometasone","***Risk of serious hypersensitivity reactions or anaphylaxis, serious rash***Agranulocytosis, hematological disease, leukopenia, neutropenia***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion, post-injection delirium/sedation syndrome***Seizure disorder, seizures***Suicidal ideation***Tardive dyskinesia***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, thyroid disease***Hepatic disease***Anticholinergic medications, closed-angle glaucoma, ileus, prostatic hypertrophy, urinary retention***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, obesity***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia***Dysphagia***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Breast cancer, hyperprolactinemia, infertility***Neonates, pregnancy, pregnancy testing***Breast-feeding***Tobacco smoking***Asian patients***Abrupt discontinuation***Children, infants***Phenylketonuria***Intravenous administration, subcutaneous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,influenza vaccine,***For annual seasonal influenza prophylaxis.,"***General Information***Intravenous administration, subcutaneous administration***Fever, respiratory infection***Egg hypersensitivity, kanamycin hypersensitivity, latex hypersensitivity, neomycin hypersensitivity***Guillain-Barre syndrome***Geriatric***Children, infants***Pregnancy***Breast-feeding***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Acquired immunodeficiency syndrome (AIDS), agammaglobulinemia, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Syncope",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['28889']['8896'],loratadine/pseudoephedrine sulfate,"***For the temporary relief of symptoms due to seasonal allergic rhinitis or the common cold, including sneezing, rhinorrhea, itching of the nose or throat, nasal congestion, and itchy, watery eyes.***Formoterol***Formoterol; Mometasone","***MAOI therapy***Hepatic disease***Driving or operating machinery***Renal disease, renal failure, renal impairment***Dysphagia, GI obstruction***Closed-angle glaucoma, diabetes mellitus, hyperthyroidism, prostatic hypertrophy, urinary retention***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, heart failure, hypertension, tachycardia***Children, infants***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,metoprolol tartrate,"***For the treatment of angina pectoris.***For chronic stable angina.***For unstable angina�.***For the treatment of heart failure, including idiopathic dilated cardiomyopathy.***For the treatment of heart failure in pediatric patients� (ischemic origin or cardiomyopathy) usually in conjunction with digoxin, diuretics, or ACE inhibitor therapy.***For the treatment of hypertension, either alone or in combination with other antihypertensive agents.***For the treatment of an evolving acute myocardial infarction, STEMI and for reduction of cardiovascular mortality in stable patients who have sustained a definite or suspected acute myocardial infarction.***For heart rate control in patients with atrial fibrillation� or atrial flutter� without accessory pathway.***For heart rate control in an acute setting�.***For heart rate control in a non-acute setting and chronic maintenance therapy� (metoprolol tartrate).***For heart rate control in a non-acute setting and chronic maintenance therapy� (metoprolol succinate).***For the treatment of tremor�.***For the treatment of essential tremor�.***For the treatment of lithium-induced tremor�.***For migraine prophylaxis�.","***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***Acute heart failure, AV block, bradycardia, cardiogenic shock, hypotension, pulmonary edema, sick sinus syndrome, ventricular dysfunction***Cerebrovascular disease***Diabetes mellitus***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Surgery***Hepatic disease***Pregnancy***Breast-feeding***Peripheral vascular disease, Raynaud's phenomenon, vasospastic angina***Pheochromocytoma***Depression***Psoriasis***Myasthenia gravis***Geriatric***Beta-blocker hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/norgestrel,"***For routine contraception.***For use as postcoital contraception� within 72 hours of unprotected intercourse, or known or suspected contraceptive failure, in females who have no known contraindications to oral contraceptives, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,terbinafine hydrochloride,"***For the treatment of tinea pedis.***For the treatment of tinea cruris or tinea corporis.***For the treatment of tinea capitis.***For the treatment of tinea versicolor due to <em>Malassezia furfur</em>.***For the treatment of onychomycosis.***For the routine treatment of onychomycosis (tinea unguium).***For the treatment of onychomycosis due to <em>Candida parapsilosis�</em>.***For the treatment of refractory bronchopulmonary aspergillosis� due to various <em>Aspergillus</em> sp.�, including <em>Aspergillus fumigatus�</em>, in non-immunocompromised patients.","***General Information***Onychomycosis***Human immunodeficiency virus (HIV) infection, immunosuppression, neutropenia***Pregnancy***Breast-feeding***Anxiety, children, depression, insomnia, suicidal ideation***Hepatic disease, hepatitis, jaundice***Renal failure, renal impairment***Serious rash***Hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['83947'],tazarotene,"***For the treatment of stable plaque psoriasis. <br />  NOTE: According to the American Academy of Dermatology (AAD), tazarotene is best used in combination with a topical corticosteroid for the treatment of psoriasis. Combination therapy may produce a synergistic effect, increase duration of treatment benefit and length of remission, and potentially decrease steroid-induced atrophy.<br /***For the topical treatment of acne vulgaris.***For adjunctive treatment of fine facial wrinkles and facial mottled hyperpigmentation (i.e., 'liver spots') and hypopigmentation associated with photoaging.","***General Information***Pregnancy***Breast-feeding***Children, infants, neonates***Eczema***Retinoid hypersensitivity***Benzyl alcohol hypersensitivity***Skin cancer, skin photosensitivity disorder, sunburn, sunlight (UV) exposure***Accidental exposure, occlusive dressing, ocular exposure***Contraception requirements, females, pregnancy testing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,benzyl alcohol,***For the topical treatment of pediculosis capitis (head lice infestation) due to <em>Pediculus capitis</em>.,"***Benzyl alcohol hypersensitivity, ocular exposure***Geriatric***Infants, neonates, premature neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,deferoxamine mesylate,"***For the treatment iron toxicity.***For adjunctive therapy in acute iron toxicity. <br />          NOTE: The most reliable indication for deferoxamine discontinuation is resolution of the signs and symptoms of iron toxicity. In addition, serum iron concentrations should no longer be elevated, usually &lt; 100 mcg/dL. However, it may be difficult to assess accurate iron concentrations in the presence of deferoxamine as they may be falsely low.  In those patients that develop a vin-rose colored urine after the initiation of deferoxamine treatment, the urine should return to a normal color before the drug is discontinued. However, not all patients exhibit a change in urine color, or the urine may be dark and concentrated before deferoxamine initiation secondary to dehydration. If the urine does not change color with deferoxamine treatment, absence of color should not be used to determine length of therapy. <br />       ***For the treatment of chronic iron overload secondary to transfusional iron overload (e.g., in patients with chronic anemias requiring multiple RBC transfusions such as thalassemia and sickle cell anemia). <br />          NOTE: Deferoxamine is not approved for chronic iron overload in patients with primary hemochromatosis; phlebotomy is the treatment of choice for this condition.<br />NOTE: In general, the subcutaneous route of administration appears to be preferred for chronic iron overload.***For the treatment of aluminum toxicity�.","***Intravenous administration, shock***Hemochromatosis***Anuria, renal disease, renal failure***Pyelonephritis***Infection***Geriatric, hearing impairment, ocular disease, visual disturbance***Driving or operating machinery***Heart failure***Children, growth inhibition, infants***Radiographic contrast administration***Pregnancy***Breast-feeding***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,flurazepam hydrochloride,"***For the short-term treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.***For the short-term treatment of anxiety�.","***General Information***Benzodiazepine hypersensitivity***Bipolar disorder, depression, mania, myasthenia gravis, Parkinson's disease, psychosis, suicidal ideation***Pain***Alcoholism, driving or operating machinery, ethanol ingestion, ethanol intoxication***Asthma, bronchitis, chronic obstructive pulmonary disease (COPD), CNS depression, coadministration with other CNS depressants, coma, pulmonary disease, respiratory depression, shock, sleep apnea***Abrupt discontinuation, benzodiazepine dependence, seizure disorder, seizures, status epilepticus, substance abuse***Closed-angle glaucoma***Porphyria***Neonates, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease***Renal failure, renal impairment***Dementia, geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,vincristine sulfate liposome,***For the treatment of Philadelphia chromosome-negative acute lymphocytic leukemia (ALL) in second or greater relapse or that has progressed after 2 or more anti-leukemia therapies. <br />  NOTE: Vincristine sulfate liposome (Marqibo) has a different dosage than vincristine sulfate; verify drug name and dose prior to administration.<br />NOTE: FDA approval of vincristine sulfate liposome was based on response rate***Formoterol; Mometasone,"***General Information***Intrathecal administration***Neurological disease, peripheral neuropathy***Hepatic disease***Vaccination***Anemia, neutropenia, thrombocytopenia***Tumor lysis syndrome (TLS)***Constipation, GI obstruction, ileus***Ensure correct formulation selection***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10323'],sterile talc,"***For the treatment of recurrent malignant pleural effusion in symptomatic patients. <br />  NOTE: Talc, magnesium silicate is not an antineoplastic agent and should not be used for potentially curable malignancies in which systemic therapy would be more appropriate.<br />NOTE: Administer talc, magnesium silicate after adequate drainage of the effusion. Pleurodesis success is related to complete drainage of pleural fluid and full reexpansion of the lung, both of which promote symphysis of the pleural surfaces.","***General Information***Children, infants, neonates***Pregnancy***Breast-feeding***Intravenous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,Isordil Oral Tit,***For the prevention or treatment of angina pectoris due to coronary artery disease.***For long-term prevention of angina pectoris.***For the prevention of effort-induced or stress-induced angina.***For the treatment of acute episodes of angina.***For the treatment of congestive heart failure� due to systolic dysfunction.***For the treatment of diffuse esophageal spasm� without gastroesophageal reflux.***For the treatment of achalasia�.,"***General Information***Hypotension, hypovolemia, orthostatic hypotension, syncope***Geriatric***Cardiomyopathy, myocardial infarction***Head trauma, increased intracranial pressure, intracranial bleeding***Nitrate hypersensitivity***Closed-angle glaucoma***Anemia***Hepatic disease***GI disease***Abrupt discontinuation***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['28889'],loratadine,"***For the relief of symptoms associated with seasonal or perennial allergic rhinitis, and for management of chronic idiopathic urticaria or other histamine-mediated allergic symptoms (e.g., hives, pruritus).***For adjunctive exercise-induced bronchospasm prophylaxis� in patients with allergies.","***General Information***Asthma***Phenylketonuria***Driving or operating machinery***Hepatic disease***Renal failure, renal impairment***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['81864'],alitretinoin,***For the treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. <br />        NOTE: Alitretinoin has been designated an orphan drug by the FDA for this indication.<br />     ,"***Pregnancy***Breast-feeding***Children, geriatric***Sunlight (UV) exposure***Occlusive dressing",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1895'],fenoprofen calcium,"***For the treatment of rheumatoid arthritis.***For the treatment of osteoarthritis or ankylosing spondylitis�.***For migraine prophylaxis�.***For the treatment of arthralgia, myalgia, mild pain to moderate pain associated with nonrheumatic inflammatory conditions, bone pain�, dental pain�, or migraine� or other vascular headache�.***For the treatment of acute gouty arthritis�.***For the management of fever�.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease, jaundice***Diabetes mellitus, edema, heart failure, hypertension, renal disease, renal failure, renal impairment, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Intramuscular injections***Dental disease, dental work***Labor, obstetric delivery, pregnancy***Breast-feeding***Coronary artery bypass graft surgery (CABG)***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['7539', '8701']",penicillin G benzathine/penicillin G procaine,"***For the treatment of moderately severe to severe upper respiratory tract infections, scarlet fever, erysipelas, skin and skin structure infections, and soft-tissue infections due to susceptible streptococci. <br />  NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia.<br /***For the treatment of moderately severe pneumonia and otitis media due to susceptible pneumococci. <br />        NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage.<br />     ","***Viral infection***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Syphilis***Intravenous administration***Ester local anesthetic hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Renal disease, renal impairment***Pregnancy***Breast-feeding***Infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,chorionic gonadotropin,"***For the treatment of male infants and children with prepubertal cryptorchidism not caused by anatomical obstruction. <br />        NOTE: HCG appears to be more effective at inducing testicular descent in those infants and children with palpable testes in the high scrotal, prescrotal, or inguinal regions. Intra-abdominal testes are especially refractory to HCG treatment. While hormonal therapy is traditionally instituted after the age of 4 years, there are several studies that include male children of younger ages, and there is some evidence that treatment prior to age 2 years may be beneficial in terms of long-term outcomes. Consult specialized references for the most current recommendations.<br />     ***For the treatment of select cases of hypogonadotropic hypogonadism.***For the routine treatment of hypogonadotropic hypogonadism in adult and adolescent males.***For the stimulation of spermatogenesis in males with primary or secondary hypogonadotropic hypogonadism and resultant oligospermia. <br />          NOTE: Pretreatment with human chorionic gonadotropin (HCG) is required prior to combination treatment with menotropins or follitropin. Various dosage regimens have been advocated.<br />       ***For adjunctive treatment of anovulation in females with infertility not due to primary ovarian failure, including in women undergoing assisted reproductive technology (ART). <br />        NOTE: HCG must be withheld if there is an excessive ovarian response, as evidenced by abnormally enlarged ovaries, multiple follicular development, or excessive estradiol production. Consult specialized references.<br />     ***For induction of ovulation in females treated with clomiphene who have an appropriate follicular response but a failure to ovulate.***For induction of ovulation following treatment with menotropins or follitropin in females with infertility.***For luteal phase support� of infertile female patients with hypogonadotropic hypogonadism after they have completed a typical ovulation induction protocol with FSH/LH (menotropins).***For induction of final oocyte maturation in preparation for oocyte harvest in females undergoing IVF or other ART procedures following follitropin treatment.***For the treatment of Kaposi's sarcoma�.","***Hamster protein hypersensitivity***Benzyl alcohol hypersensitivity, neonates***Children, precocious puberty***Asthma, cardiac disease, migraine, renal disease, seizure disorder, thromboembolic disease, thrombophlebitis***Dysfunctional uterine bleeding, endometrial cancer, endometriosis, neoplastic disease, ovarian cancer, prostate cancer, uterine leiomyomata***Adrenal insufficiency, ovarian failure, pituitary adenoma, thyroid disease***Ascites, ovarian cyst, polycystic ovary syndrome***Geriatric***Pregnancy***Breast-feeding***Obesity***Ethanol intoxication, tobacco smoking***Hepatic disease, renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5492']['7299'],hydrocortisone/neomycin sulfate/polymyxin B sulfate,"***For the treatment of superficial bacterial infections of the external auditory canal (i.e., otitis externa) caused by susceptible organisms, and for the treatment of infections of mastoidectomy and fenestration caused by susceptible organisms.***For the treatment of corticosteroid-responsive inflammatory ocular conditions and where bacterial ophthalmic infection or a risk of bacterial ophthalmic infection exists (e.g., inflammation of palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in bacterial conjunctivitis is accepted to obtain a decrease in edema and inflammation; also in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign objects).***For the treatment of corticosteroid-responsive dermatitis with secondary infection.","***General Information***Aminoglycoside hypersensitivity, neomycin hypersensitivity***Fungal infection, herpes infection, tuberculosis, varicella, viral infection***Renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Ocular exposure***Otitis media, tympanic membrane perforation***Hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing***Pregnancy***Asthma, sulfite hypersensitivity***Breast-feeding***Glaucoma, surgery***Contact lenses***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6932'],miconazole,"***For the topical treatment of tinea pedis and tinea corporis.***For the treatment of tinea cruris.***For the treatment of tinea versicolor.***For the treatment of cutaneous candidiasis (including diaper dermatitis� complicated by candidiasis) or mucocutaneous candidiasis (i.e., oropharyngeal candidiasis (thrush), vulvovaginal candidiasis).***For the treatment of diaper dermatitis� complicated by candidiasis.***For the treatment of uncomplicated vulvovaginal candidiasis (VVC). <br />          NOTE: Vaginal miconazole products are often packaged with additional miconazole cream for Candida-associated external vulvar symptoms (e.g., itching, irritation); the vulvar cream may be used topically to the affected area twice daily for up to 7 days, regardless of the intravaginal regimen utilized.<br />NOTE: Pregnant women are not recommended to self-diagnose vaginal candidiasis or use OTC forms of miconazole unless specifically recommended to do so by their health care prescriber***For the treatment of recurrent or severe vulvovaginal candidiasis (VVC).***For the treatment of cutaneous candidiasis.***For the local treatment of oropharyngeal candidiasis (thrush).","***Onychomycosis***Pregnancy***Breast-feeding***Contraceptive devices, menstruation***Abdominal pain, bone marrow suppression, diabetes mellitus, females, fever, human immunodeficiency virus (HIV) infection, immunosuppression, vaginal discharge***Children, infants, neonates***Azole antifungals hypersensitivity, milk protein hypersensitivity***Hepatic disease***Tobacco smoking***Accidental exposure, ocular exposure, ophthalmic administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ampicillin trihydrate,"***For the treatment of meningitis due to susceptible organisms. <br />        NOTE: The Infectious Diseases Society of America (IDSA) recommends ampicillin as an option for the definitive treatment of Streptococcus pneumoniae with penicillin MICs &lt; 0.1 mcg/ml, Neisseria meningitides with MICs &lt; 0.1 mcg/ml, Beta-lactamase negative Haemophilus influenzae, ampicillin susceptible Enterococcus sp. (plus gentamicin), Listeria monocytogenes, and Streptococcus agalactiae. They also recommend ampicillin as empiric therapy in patients &lt; 1 month of age (with cefotaxime or an aminoglycoside) or &gt; 50 years old (with vancomycin and a 3rd generation cephalosporin).<br />     ***For the treatment of infective endocarditis.***For the treatment of severe infections, including bacteremia.***For the treatment of upper respiratory tract infections and lower respiratory tract infections, including community-acquired pneumonia. <br />        NOTE: The manufacturer suggests that higher doses may be used for severe infections. For example, see Dosage for septicemia, meningitis, and endocarditis for higher dosage recommendations.<br />     ***For the treatment of skin and skin structure infections (e.g. cellulitis). <br />        NOTE: The manufacturer suggests that higher doses may be used for severe infections. For example, see Dosage for septicemia, meningitis, and endocarditis for higher dosage recommendations.<br />     ***For the treatment of genitourinary tract infections, including urinary tract infection (UTI) (e.g. cystitis and pyelonephritis). <br />        NOTE: The manufacturer suggests that higher doses may be used for severe infections. For example, see Dosage for septicemia, meningitis, and endocarditis for higher dosage recommendations.<br />     ***For the treatment of gastrointestinal infections (e.g. enterocolitis, gastroenteritis), including those due to <em>Salmonella typhii </em>(typhoid fever), other <em>Salmonella </em>sp<em>.</em> (salmonellosis), <em>Shigella </em>sp<em>.</em> (dysentery/shigellosis). <br />        NOTE: The manufacturer suggests that higher doses may be used for severe infections. For example, see Dosage for septicemia, meningitis, and endocarditis for higher dosage recommendations.<br />     ***For management of <em>Salmonella typhii</em> chronic carrier patients�.***For the treatment of leptospirosis�.***For bacterial endocarditis prophylaxis�.***For perinatal Group B streptococcal bacterial infection prophylaxis�.***For surgical infection prophylaxis� in patients undergoing liver transplantation.***For the treatment of systemic anthrax� infection.","***General Information***Dialysis, renal disease, renal failure, renal impairment***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, eczema, penicillin hypersensitivity, serious rash, urticaria***Mononucleosis***Antimicrobial resistance***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Sexually transmitted disease***Infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/norethindrone,"***For routine contraception.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***For gastrointestinal bleeding prophylaxis� related to arteriovenous malformations, radiation-induced rectal telangiectases, hereditary telangiectases, and gastric antral vascular ectasia in patients who have severe recurrent blood loss and frequent need for transfusion despite other medical therapies, and who have no contraindications to oral contraceptives.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Ectopic pregnancy, pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],desogestrel/ethinyl estradiol,"***For routine contraception.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�,  abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Edema, hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hyoscyamine sulfate,"***For intraoperative use to reverse drug-induced bradycardia in adults.***For the relaxation of the upper gastrointestinal tract and colon prior to radiographic examination. <br />        NOTE: More effective agents are available for this indication.<br />     ***For cholinesterase inhibitor-induced muscarinic effects prophylaxis when anticholinesterase agents (i.e., neostigmine, physostigmine, pyridostigmine) are used to reverse the neuromuscular blockade produced by curariform agents.***For aspiration prophylaxis� prior to anesthesia to reduce excessive salivary and respiratory tract secretions .***For the treatment of organophosphate insecticide toxicity�.","***Anticholinergic medications***Pulmonary disease***Bladder obstruction, hepatic disease, prostatic hypertrophy, renal disease, renal impairment, urinary tract obstruction***Autonomic neuropathy, myasthenia gravis***Glaucoma***Psychosis***Bleeding, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hyperthyroidism, mitral stenosis, tachycardia***Ambient temperature increase, contact lenses, driving or operating machinery, fever***Dysentery, gastroenteritis, GI obstruction, ileus, pseudomembranous colitis, toxic megacolon, ulcerative colitis***Esophagitis, gastroesophageal reflux disease (GERD), hiatal hernia***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2002'],carbamazepine,"***For the management of generalized tonic-clonic seizures, or for partial seizures, either simple or complex-partial seizures. <br />        NOTE: Periodic monitoring of serum carbamazepine concentrations is recommended.<br />     ***For the symptomatic treatment of neuropathic pain.***For the treatment of acute mania and mixed episodes associated with bipolar disorder (bipolar I disorder).***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD).***For the treatment of persistent singultus (hiccups)�.***For long-term prophylaxis of short-lasting short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT)�.","***General Information***Asian patients, serious rash***Depression, psychosis, suicidal ideation***Atonic seizures, myoclonic seizures, petit mal (absence) seizures***Abrupt discontinuation***Barbiturate hypersensitivity, carbamazepine hypersensitivity, fever, hydantoin hypersensitivity, jaundice, tricyclic antidepressant hypersensitivity***Agranulocytosis, aplastic anemia, bone marrow suppression, hematological disease, leukopenia, neutropenia, thrombocytopenia***Porphyria***Hepatic disease***AV block, bundle-branch block, cardiac arrhythmias, cardiac disease, coronary artery disease***Hyponatremia***Alcoholism***Driving or operating machinery***Renal disease, renal failure, renal impairment***Geriatric***Glaucoma, increased intraocular pressure***Pregnancy***Neonates***Breast-feeding***Sunlight (UV) exposure***MAOI therapy***Hypercholesterolemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['28889'],loratadine,"***For the relief of symptoms associated with seasonal or perennial allergic rhinitis, and for management of chronic idiopathic urticaria or other histamine-mediated allergic symptoms (e.g., hives, pruritus).***For adjunctive exercise-induced bronchospasm prophylaxis� in patients with allergies.","***General Information***Asthma***Phenylketonuria***Driving or operating machinery***Hepatic disease***Renal failure, renal impairment***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7417'],nifedipine,"***For the treatment of ischemic heart disease including variant angina (Prinzmetal's angina) and chronic stable angina pectoris.***For the treatment of hypertension.***For acute hypertensive episodes including hypertensive urgency and hypertensive emergency in pediatric patients�. <br />          NOTE: Per the FDA and manufacturers, immediate-release nifedipine dosage forms should not be used to treat hypertension and should only be used to treat patients with chronic stable angina or vasospastic angina. The immediate-release nifedipine formulation has been associated with serious side effects (see Precautions and Adverse Reactions) when used to treat adult patients with hypertension, hypertensive urgency, hypertensive emergency, or coexisting myocardial infarction. Although the use of immediate-release nifedipine for the treatment of acute hypertensive episodes is still relatively common practice in pediatric patients, considerable controversy exists and caution should be used.<br />       ***For migraine prophylaxis�.***For the treatment of proteinuria� associated with diabetic nephropathy�.***For the treatment of persistent singultus (hiccups)�.***For the inhibition of uterine contractions in premature labor�. <br />        NOTE: Clinical practice guidelines recommend the use of a first line tocolytic (i.e., beta agonist, calcium channel blocker, or NSAID) for short-term use (up to 48 hours) to allow for administration of antenatal corticosteroids to enhance fetal lung maturation, magnesium sulfate for fetal neuroprotection, or transport to a tertiary facility, if indicated. There is no evidence that tocolytic therapy alone has any favorable effect on neonatal outcomes. Maintenance therapy with tocolytics is ineffective for preventing preterm birth and improving neonatal outcomes and is not recommended.<br />     ***For the treatment of achalasia�.***For the treatment of high altitude pulmonary edema associated with altitude sickness�.***For altitude sickness prophylaxis<strong>","***General Information***Dihydropyridine hypersensitivity***Pregnancy***Breast-feeding***Acute myocardial infarction, bradycardia, cardiogenic shock, coronary artery disease, heart failure, hypotension, ventricular dysfunction***Geriatric***Aortic stenosis***Colostomy, constipation, diabetes mellitus, diverticulitis, esophageal stricture, gastric cancer, gastroesophageal reflux disease (GERD), GI obstruction, hiatal hernia, hypothyroidism, ileus, inflammatory bowel disease, obesity***Children, infants***Hepatic disease***Lactase deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydrocortisone acetate/pramoxine hydrochloride,"***For the temporary relief of skin inflammation, pain, and pruritus associated with corticosteroid-responsive dermatitis, including psoriasis, anorectal inflammation, pain, pruritus, and swelling associated with hemorrhoids, proctitis, cryptitis, anal fissures, postoperative pain, and pruritus ani.***For the adjunctive treatment of chronic ulcerative colitis� when disease is limited to the distal portion of the rectum (e.g., proctosigmoiditis).","***Fungal infection, herpes infection, infection, peripheral vascular disease, tuberculosis, viral infection***Hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, infants, neonates***Geriatric, skin atrophy***Diabetes mellitus***Cataracts, glaucoma, ocular exposure, ophthalmic administration***Pregnancy***Breast-feeding***Hepatic disease***Fistula, GI obstruction, GI perforation, peritonitis, ulcerative colitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,micafungin sodium,"***For the treatment of candidemia and invasive candidiasis.***For the treatment of chronic disseminated (hepatosplenic) candidiasis�.***For the treatment of esophageal candidiasis.***For the treatment of intraabdominal infections (i.e., peritonitis, intraabdominal abscess).***For the treatment of intraabdominal candidiasis.***For the treatment of <em>Aspergillus </em>peritonitis�.***For candidiasis prophylaxis in high-risk patients.***For candidiasis prophylaxis in hematopoietic stem cell transplant recipients.***For candidiasis prophylaxis in high-risk intensive care unit patients�.***For the treatment of invasive aspergillosis� in patients who are refractory to or intolerant of other antifungal therapies.***For the treatment of oropharyngeal candidiasis (thrush)�.***For the treatment of cardiovascular system infections, including endocarditis�, suppurative thrombophlebitis�, and infected pacemaker�, implantable cardiac defibrillator (ICD)�, or ventricular assist devices (VAD)�.***For the treatment of <em>Candida</em> cardiovascular system infections�.***For the treatment of <em>Aspergillus</em> cardiovascular system infections�.***For the treatment of respiratory infections� (i.e., pneumonia�).***For the treatment of <em>Candida</em> pneumonia.***For the treatment of <em>Aspergillus</em> pneumonia.***For the treatment of bone and joint infections�, including osteomyelitis� and infectious arthritis�.***For the treatment of <em>Candida</em> osteomyelitis or infectious arthritis.***For the treatment of <em>Aspergillus</em> osteomyelitis or infectious arthritis.***For aspergillosis prophylaxis� in high-risk patients.***For the empiric treatment of febrile neutropenia�.","***General Information***Cholestasis, hepatic disease, hepatitis, jaundice***Renal disease, renal failure, renal impairment***Infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6069'],ivermectin,"***For the treatment of onchocerciasis due to <em>Onchocerca volvulus</em> infection.***For the treatment of strongyloidiasis due to <em>Strongyloides stercoralis</em> infection.***For the treatment of pediculosis including pediculosis capitis, pediculosis corporis�, and pediculosis pubis�.***For the treatment of inflammatory lesions of acne rosacea.***For the treatment of scabies� infections, including crusted (Norwegian) scabies�.***For the treatment of scabies�.***For the treatment of crusted scabies� (i.e., Norwegian scabies�) infection, superinfected scabies, or resistant scabies.***For the treatment of Bancroft's filariasis� caused by <em>Wuchereria bancrofti</em>�.***For the secondary treatment of cutaneous larva currens� or cutaneous larva migrans�.","***General Information***Asthma***Hepatic disease***Geriatric***Human immunodeficiency virus (HIV) infection, immunosuppression***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5093'],haloperidol,"***For the treatment of schizophrenia.***For the treatment of severe behavioral problems associated with oppositional defiant disorder or other disruptive behavioral disorders, or for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients who show excessive motor activity with accompanying conduct disorders.***For the treatment of tics and vocal utterances associated with Tourette's syndrome.***For the treatment of acute psychosis in acutely agitated schizophrenic patients with moderately severe to very severe symptoms.***For the treatment of acute mania�.***For the treatment of irritability associated with autistic disorder�.***For use as a second-line agent for rescue treatment of chemotherapy-induced nausea/vomiting�.***For the treatment of agitation� or delirium�.***For agitation� or delirium� in adult patients with no underlying psychiatric illness.***For the treatment of delirium� in the pediatric intensive care unit (PICU).***For the treatment of persistent singultus (hiccups)�.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.","***General Information***Alcoholism, angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, intravenous administration, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, thyroid disease, torsade de pointes***Agranulocytosis, hematological disease, leukopenia, neutropenia***CNS depression, coma***Tardive dyskinesia***Neurological disease, Parkinson's disease***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Seizure disorder, seizures***Dysphagia***Pulmonary disease***Hepatic disease, jaundice***Closed-angle glaucoma, increased intraocular pressure, visual disturbance***Prostatic hypertrophy, urinary retention***Dementia, geriatric, stroke***Thyrotoxicosis***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Tobacco smoking***Abrupt discontinuation***Breast cancer, hyperprolactinemia, infertility***Neonates, pregnancy, pregnancy testing***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8588'],amoxicillin/clavulanate potassium,"***For the treatment of acute otitis media (AOM). <br />  NOTE: Amoxicillin; clavulanic acid is the preferred initial therapy for children who have received amoxicillin within the past 30 days, who have concurrent conjunctivitis, or those for whom coverage of beta-lactamase-positive H. influenzae and M. catarrhalis is desired.<br /***For the treatment of sinusitis . <br />  NOTE: Amoxicillin; clavulanic acid is recommended by the Infectious Diseases Society of America (IDSA) as the first-line initial empiric therapy in adults and children with acute bacterial rhinosinusitis. The American Academy of Pediatrics (AAP) recommends amoxicillin; clavulanic as initial therapy for all patients presenting with moderate to severe illness, all children younger than 2 years, children attending daycare, and those who have been recently treated with antibiotics.<br /***For the treatment of lower respiratory tract infections (e.g., pneumonia and community-acquired pneumonia).***For the treatment of skin and skin structure infections, including impetigo.***For the treatment of urinary tract infection (UTI), including cystitis.***For the treatment of dental infection�, including dentoalveolar infection�, periodontitis�, and pericoronitis�.***For adolescent aggressive periodontitis� or adult refractory chronic periodontitis� after scaling and root planing.***For pericoronitis�.***For the treatment of actinomycotic mycetoma� caused by susceptible strains of <em>Nocardia brasiliensis</em>.***For use as oral maintenance therapy in the treatment of melioidosis� due to <em>Burkholderia pseudomallei�</em>.***For the empiric treatment of febrile neutropenia� in low risk patients.","***General Information***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, eczema, penicillin hypersensitivity, urticaria***Geriatric***Dialysis, renal disease, renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Children, infants, neonates***Labor, obstetric delivery, pregnancy***Breast-feeding***Phenylketonuria***Mononucleosis***Cholestasis, hepatic disease, jaundice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2409']['2599'],chlorthalidone/clonidine hydrochloride,"***For the treatment of hypertension. <br />        NOTE: Clonidine; chlorthalidone fixed combination therapy is not indicated for initial antihypertensive therapy. The initial dose must be titrated to the individual patient. If the fixed combination represents the individual dosages required for the patient, its use may be more convenient in patient management.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Asthma, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, hypovolemia, renal disease, renal failure, renal impairment***Hepatic disease***Hypochloremia, hypokalemia, hyponatremia, metabolic alkalosis, vomiting***Abrupt discontinuation***Bradycardia, cerebrovascular disease, myocardial infarction***Gout, hyperuricemia***Diabetes mellitus, hyperglycemia***Systemic lupus erythematosus (SLE)***Surgery***Driving or operating machinery***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1302966'],carfilzomib,"***For the treatment of multiple myeloma. <br />        NOTE: The FDA has designated carfilzomib as an orphan drug for for the treatment of multiple myeloma.<br />Dose carfilzomib at a maximum body surface area (BSA) of 2.2 m2 in patients with a BSA greater than 2.2 m2; dose adjustment is not necessary for patients with a weight change of 20% or less***For the treatment of patients with relapsed or refractory multiple myeloma who have received 1 or more lines of therapy.***For the treatment of relapsed or refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy, in combination with lenalidomide and dexamethasone.***For the treatment of relapsed or refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy, in combination with dexamethasone.","***Angina, cardiac arrest, cardiac arrhythmias, cardiomyopathy, edema, heart failure, myocardial infarction, pulmonary edema***Infusion-related reactions***Tumor lysis syndrome (TLS)***Neutropenia, thrombocytopenia***Hepatic disease, hepatotoxicity***Bleeding, GI bleeding, intracranial bleeding, pulmonary bleeding***Hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP)***Renal failure, renal impairment***Pneumonitis, pulmonary disease, respiratory distress syndrome***Hypertension***Pulmonary hypertension***Thromboembolic disease***Encephalopathy***Children, infants, neonates***Geriatric***Pregnancy***Contraception requirements, male-mediated teratogenicity, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5032']['8896'],guaifenesin/pseudoephedrine hydrochloride,"***For the treatment of cough and nasal congestion, including relief of eustachian tube congestion, associated with the common cold, sinusitis, or other upper respiratory conditions.***Formoterol***Formoterol; Mometasone","***General Information***MAOI therapy***Asthma, bronchitis, emphysema, tobacco smoking***Fever***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, heart failure, hypertension, myocardial infarction, tachycardia***Closed-angle glaucoma, diabetes mellitus, hyperthyroidism, peripheral vascular disease, prostatic hypertrophy, urinary retention***Renal failure, renal impairment***Children, infants***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,somatropin (rDNA origin),"***For the treatment of growth hormone deficiency, growth failure, or short stature.***For replacement therapy in adults with growth hormone deficiency (GHD) for either childhood onset (secondary to congenital, genetic, acquired, or idiopathic causes) or adult onset (endogenous or associated with multiple hormone deficiencies, i.e., hypopituitarism, as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma).***For the long-term treatment of growth failure in children who have growth hormone deficiency due to inadequate growth hormone secretion.***For growth failure due to Prader-Willi syndrome.***For the long-term treatment of growth failure in children born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 to 4.***For growth failure associated with chronic renal failure up to the time of transplantation.***For short stature associated with Turner's syndrome.***For short stature in children with SHOX (short stature homeobox-containing gene) deficiency.***For short stature in children with Noonan Syndrome.***For idiopathic short stature.***For the treatment of HIV-associated failure to thrive in children, AIDS-associated wasting syndrome, or cachexia.***For the treatment of HIV-associated adipose redistribution syndrome (HARS)�.***For the treatment of short bowel syndrome in patients receiving specialized nutrition support as directed by a health care professional.***Formoterol; Mometasone","***General Information***Cresol hypersensitivity, glycerin hypersensitivity, history of angioedema, risk of serious hypersensitivity reactions or anaphylaxis***Epiphyseal closure***Children, renal impairment, renal osteodystrophy***Benzyl alcohol hypersensitivity, neonates***Chemotherapy, neoplastic disease, new primary malignancy, radiation therapy***Respiratory insufficiency, surgery, trauma***Obesity***Respiratory infection, sleep apnea***Diabetes mellitus, diabetic retinopathy***Scoliosis***Adrenal insufficiency, hypothyroidism***Increased intracranial pressure***Pregnancy***Breast-feeding***Otitis media***Geriatric***Females***Pancreatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10767'],triazolam,***For the short-term treatment of insomnia.,"***Benzodiazepine hypersensitivity***Bipolar disorder, depression, mania, psychosis, suicidal ideation***Abrupt discontinuation, benzodiazepine dependence, seizure disorder, seizures, status epilepticus, substance abuse***Anxiety***Asthma, bronchitis, chronic obstructive pulmonary disease (COPD), CNS depression, coadministration with other CNS depressants, coma, pulmonary disease, respiratory depression, shock, sleep apnea***Driving or operating machinery, ethanol intoxication***Myasthenia gravis***Porphyria***Closed-angle glaucoma***Neonates, obstetric delivery, pregnancy***Breast-feeding***Hepatic disease***Renal failure, renal impairment***Parkinson's disease***Dementia, geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,isosorbide dinitrate,***For the prevention or treatment of angina pectoris due to coronary artery disease.***For long-term prevention of angina pectoris.***For the prevention of effort-induced or stress-induced angina.***For the treatment of acute episodes of angina.***For the treatment of congestive heart failure� due to systolic dysfunction.***For the treatment of diffuse esophageal spasm� without gastroesophageal reflux.***For the treatment of achalasia�.,"***General Information***Hypotension, hypovolemia, orthostatic hypotension, syncope***Geriatric***Cardiomyopathy, myocardial infarction***Head trauma, increased intracranial pressure, intracranial bleeding***Nitrate hypersensitivity***Closed-angle glaucoma***Anemia***Hepatic disease***GI disease***Abrupt discontinuation***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,primaquine phosphate,***For the  radical cure (prevention of relapse) of malaria due to the eradication of chronic liver stages of <em>P. ovale</em>� or<em> P. vivax</em>.***For malaria prophylaxis�.***For presumptive antirelapse malaria prophylaxis� of either <em>P. falciparum</em> or <em>P. vivax</em> malaria.***For primary malaria prophylaxis�.***For the treatment of Pneumocystis pneumonia (PCP)� in HIV-infected patients.,"***General Information***Rheumatoid arthritis, systemic lupus erythematosus (SLE)***Bone marrow suppression, G6PD deficiency, hematological disease, hemolytic anemia, methemoglobin reductase deficiency***Iodoquinol hypersensitivity, primaquine hypersensitivity***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, geriatric, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Pregnancy***Breast-feeding***Contraception requirements, male-mediated teratogenicity, pregnancy testing, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['60819'],bivalirudin,***For use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).***For use during percutaneous coronary intervention (PCI) in patients with or at risk of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS).***For use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).***For use during percutaneous coronary intervention (PCI) in patients receiving provisional use of a glycoprotein IIb/IIIa inhibitor.***For use as an adjunct to streptokinase in the treatment of acute myocardial infarction� associated with ST-segment elevation (STEMI). <br />        NOTE: The ACCP antithrombotic guidelines recommend against routine use of bivalirudin for patients receiving streptokinase for STEMI. Bivalirudin is recommended as an alternative antithrombotic for adjunctive use with streptokinase for the treatment of STEMI in patients with known or suspected heparin-induced thrombocytopenia (HIT).<br />     ***For deep venous thrombosis (DVT) prophylaxis� in patients undergoing orthopedic surgery.,"***General Information***Aneurysm, bleeding, coagulopathy, diverticulitis, endocarditis, geriatric, GI bleeding, hemophilia, hepatic disease, hypertension, inflammatory bowel disease, intracranial bleeding, lumbar puncture, menstruation, peptic ulcer disease, renal disease, retroperitoneal bleeding, spinal anesthesia, stroke, surgery, trauma, vitamin K deficiency***Renal failure, renal impairment***Intramuscular administration, intramuscular injections***Heparin-induced thrombocytopenia (HIT)***Obstetric delivery, pregnancy***Breast-feeding***Children***Myocardial infarction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['642274'],retapamulin,***For the treatment of impetigo due to susceptible organisms like <em>Staphylococcus aureus</em> (MSSA) or <em>Streptococcus pyogenes</em> (group A beta-hemolytic streptococci).,"***Ophthalmic administration, vaginal administration***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,selegiline hydrochloride,***For the treatment of Parkinson's disease or parkinsonism in combination with levodopa or levodopa/carbidopa.***For the treatment of major depression.,"***General Information***MAOI therapy***Alcoholism, ethanol ingestion, hypertension, hypertensive crisis***Pheochromocytoma***Children, suicidal ideation***Bipolar disorder, mania***Behavioral changes, psychosis, schizophrenia***Impulse control symptoms***Hypotension, orthostatic hypotension***Hepatic disease***Renal failure, renal impairment***Melanoma***Driving or operating machinery***Abrupt discontinuation***Pregnancy***Breast-feeding***Geriatric***Phenylketonuria***Ambient temperature increase, heating pad, sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,onabotulinumtoxinA,"***For the treatment of blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders.***For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.***For the treatment of strabismus. <br />  NOTE: Injection should be carried out only with electromyographic guidance. The toxin must be suitably diluted, and the volume injected should be between 0.05�0.15 mL per muscle, dependent on the extent of strabismus. Use the lower doses for small deviations and the larger doses only for large deviations. Initial doses typically create paralysis of injected muscles beginning 1�2 days after injection and increasing in intensity during the first week. The paralysis lasts for 2�6 weeks and gradually resolves over a similar time period. Overcorrections lasting longer than 6 months rarely occur. About 50% of patients will require subsequent doses because of inadequate paralytic response to the initial dose, because of mechanical factors such as large deviations or restrictions, or because of the lack of binocular motor fusion to stabilize the alignment.<br /***For vertical muscles, and for horizontal strabismus of less than 20 prism diopters.***For horizontal strabismus of 20 prism diopters to 50 prism diopters.***For persistent VI nerve palsy of 1 month or longer duration.***For subsequent dosing for residual or recurrent strabismus.***For temporary improvement in the appearance of facial wrinkles.***For temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugators and/or procerus muscle activity.***For temporary improvement in the appearance of other wrinkles such as melolabial folds� and other hyperkinetic facial lines�.***For temporary improvement in the appearance of moderate to severe lateral canthal lines associated with orbicularis oculi activity (crow's feet).***For the treatment of moderate to severe forehead lines associated with frontalis muscle activity.***For the treatment of spasticity.***For the chronic management of focal spasticity� in pediatric patients with cerebral palsy with concurrent equinus gait (tiptoeing).***For the treatment of severe primary axillary hyperhidrosis (excessive underarm sweating). <br />        NOTE: Safety and efficacy for the treatment of hyperhidrosis in other body areas have not ben established. Use for palmar hyperhidrosis may lead to weakness of hand muscles and use for facial hyperhidrosis may lead to blepharoptosis.<br />NOTE: Evaluate patients for potential causes of secondary hyperhidrosis (e.g. hyperthyroidism) prior to initiating therapy***For migraine prophylaxis in adult patients with chronic migraine.***For the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (e.g., as occurs with neurogenic bladder in spinal cord injury, multiple sclerosis) in patients with an inadequate response or intolerance to an anticholinergic medication.***For second line treatment of neurogenic bladder� in children.***For the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency in adults intolerant to or with inadequate response from anticholinergic medications.***For the treatment of achalasia�.***For the treatment of sialorrhea� (excessive drooling).***For sialorrhea� associated with Parkinson's disease�.***For sialorrhea� associated with amyotrophic lateral sclerosis (ALS)�.***For sialorrhea� associated with cerebral palsy� .","***General Information***Intravenous administration, requires an experienced clinician***Cerebral palsy, children, distant spread of toxin effects, infants, neonates***Infection, urinary tract infection (UTI)***Hyperthyroidism, thyroid disease***Albumin hypersensitivity, viral infection***Dysphagia***Pregnancy***Breast-feeding***Geriatric***Ocular disease, visual disturbance***Amyotrophic lateral sclerosis (ALS), autonomic neuropathy, myasthenia gravis, myopathy, neuromuscular disease***Cardiac disease***Respiratory insufficiency***Driving or operating machinery***Surgery***Anticoagulant therapy***Urinary retention",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['161']['7804'],acetaminophen/oxycodone,"***For the treatment of moderate pain to moderately-severe pain.***For the treatment of acute pain severe enough to require opioid treatment and for which alternative treatment options (e.g., non-opioid analgesics) are inadequate.","***General Information***Acetaminophen hypersensitivity, opiate agonist hypersensitivity, sulfite hypersensitivity***Acute abdomen, constipation, dysphagia, esophageal stricture, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Accidental exposure, asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Abrupt discontinuation***Substance abuse***CNS depression, head trauma, increased intracranial pressure, intracranial mass, psychosis***Cardiac arrhythmias, cardiac disease, hypotension, hypovolemia, orthostatic hypotension***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, renal impairment, urethral stricture, urinary retention***Alcoholism, hepatic disease, hepatitis, hepatotoxicity, potential for overdose or poisoning***Geriatric***Children, infants, neonates***G6PD deficiency***Bone marrow suppression, immunosuppression, infection***Driving or operating machinery***Biliary tract disease, pancreatitis***Adrenal insufficiency, hypothyroidism, myxedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diclofenac sodium,"***For the treatment of osteoarthritis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the treatment of rheumatoid arthritis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the treatment of ankylosing spondylitis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the acute treatment of migraine with or without aura. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />NOTE: Diclofenac is not indicated for migraine prophylaxis***For the treatment of mild pain or moderate pain. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For primary dysmenorrhea or for mild or moderate pain associated with nonrheumatic inflammatory conditions, bone pain�, arthralgia�, myalgia�, and vascular or migraine headache�. <br />          NOTE: Voltaren XR is not indicated for the management of acute painful conditions.<br />       ***For the treatment of acute mild or moderate pain.***For the topical treatment of acute mild pain or moderate pain due to minor strains, sprains, and contusions. <br />          NOTE: Carefully consider the potential benefits and risks of the diclofenac patch. If the patch will be used, use the lowest effective dose for the shortest possible duration.<br />       ***For the treatment of postoperative ocular inflammation following cataract extraction.***For the reduction of photophobia and ocular pain following corneal refractive surgery.***For the treatment of moderate to severe pain alone or in combination with opioid analgesics.***For the treatment of actinic keratosis.***For the prevention of heterotopic ossification�.***Formoterol; Mometasone","***Acute bronchospasm, asthma, bovine protein hypersensitivity, gelatin hypersensitivity, nasal polyps, NSAID hypersensitivity, polysorbate 80 hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Contact lenses, ocular surgery, rheumatoid arthritis***Anemia***Dental disease, dental work***Hepatic disease, jaundice, porphyria***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, renal impairment, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Labor, pregnancy***Breast-feeding***Burns, eczema, exfoliative dermatitis, heating pad, occlusive dressing, ocular exposure, skin abrasion***Benzyl alcohol hypersensitivity, sunlight (UV) exposure***Coronary artery bypass graft surgery (CABG)***Accidental exposure***Phenylketonuria***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,butenafine hydrochloride,"***For the topical treatment of tinea corporis, tinea cruris, and tinea versicolor due to susceptible organisms such as <em>Epidermophyton floccosum</em>, <em>Trichophyton mentagrophytes</em>, <em>Trichophyton rubrum</em>, <em>Trichophyton tonsurans, or Malassezia furfur</em>.***For the topical treatment of interdigital tinea pedis due to susceptible organisms such as <em>Epidermophyton floccosum</em>, <em>Trichophyton mentagrophytes</em>, <em>Trichophyton rubrum</em>, <em>Trichophyton tonsurans, or Malassezia furfur</em>.","***General Information***Ocular exposure, ophthalmic administration, vaginal administration***Onychomycosis***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,selegiline hydrochloride,***For the treatment of Parkinson's disease or parkinsonism in combination with levodopa or levodopa/carbidopa.***For the treatment of major depression.,"***General Information***MAOI therapy***Alcoholism, ethanol ingestion, hypertension, hypertensive crisis***Pheochromocytoma***Children, suicidal ideation***Bipolar disorder, mania***Behavioral changes, psychosis, schizophrenia***Impulse control symptoms***Hypotension, orthostatic hypotension***Hepatic disease***Renal failure, renal impairment***Melanoma***Driving or operating machinery***Abrupt discontinuation***Pregnancy***Breast-feeding***Geriatric***Phenylketonuria***Ambient temperature increase, heating pad, sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,memantine hydrochloride,***For the treatment of symptoms of moderate to severe Alzheimer's disease.***For the treatment of symptoms of mild to moderate vascular dementia�.***For the symptomatic treatment of acquired pendular nystagmus�.,"***General Information***Renal disease, renal failure, renal impairment, urinary tract infection (UTI)***Hepatic disease***Pregnancy***Breast-feeding***Children, infants***Geriatric***Seizure disorder, seizures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albuterol/ipratropium bromide,"***For the second-line treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis or emphysema.***For use in the acute management of patients with asthma�.","***General Information***Albuterol hypersensitivity, levalbuterol hypersensitivity, paradoxical bronchospasm***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation***Anticholinergic medications, bladder obstruction, prostatic hypertrophy, urinary retention***Geriatric***Diabetes mellitus, hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***Closed-angle glaucoma, contact lenses, ophthalmic administration***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants***Hepatic disease, renal disease, renal failure, renal impairment***MAOI therapy***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bendamustine hydrochloride,"***For the treatment of chronic lymphocytic leukemia (CLL). <br />  NOTE: The FDA has designated bendamustine as an orphan drug for the treatment of CLL.<br /***For the treatment of CLL, as a single agent.***For the treatment of relapsed or refractory CLL, in combination with idelalisib and rituximab�.***For the treatment of non-Hodgkin's lymphoma (NHL).***For the treatment of indolent B-cell NHL that progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.***For the treatment of previously untreated indolent NHL (including follicular lymphoma), in combination with rituximab�.***For the treatment of previously treated indolent NHL (including follicular lymphoma), in combination with rituximab�.***For the treatment of follicular lymphoma in patients who relapsed after or are refractory to a rituximab-containing regimen, in combination with obinutuzumab followed by obinutuzumab monotherapy�. <br />  Obinutuzumab is FDA approved in combination with bendamustine for this indication.<br /***For the treatment of mantle cell lymphoma (MCL)�.***For the treatment of previously untreated MCL, in combination with rituximab�.***For the treatment of previously treated MCL, in combination with rituximab�.***For the treatment of relapsed or refractory acute lymphocytic leukemia (ALL)�.***For the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL)�.","***Risk of serious hypersensitivity reactions or anaphylaxis***Renal impairment***Hepatic disease, hepatotoxicity***Children, infants, neonates***Infusion-related reactions***Tumor lysis syndrome (TLS)***Extravasation***Hepatitis, herpes infection, infection, mycobacterial infection, sepsis, tuberculosis, viral infection***Anemia, bone marrow suppression, neutropenia, thrombocytopenia***Serious rash***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['25037'],cefdinir,***For the treatment of acute bacterial otitis media.***For the treatment of acute exacerbations of chronic bronchitis.***For the treatment of acute maxillary sinusitis.***For the treatment of community-acquired pneumonia.***For the treatment of pharyngitis or tonsillitis.***For the treatment of uncomplicated skin and skin structure infections.***For the treatment of urinary tract infection (UTI)�.,"***General Information***Antimicrobial resistance, viral infection***Cephalosporin hypersensitivity, penicillin hypersensitivity***Dialysis, renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Coagulopathy, vitamin K deficiency***Diabetes mellitus***Infants, neonates***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['722'],amoxapine,***For the treatment of major depression.,"***Carbamazepine hypersensitivity, tricyclic antidepressant hypersensitivity***Abrupt discontinuation***Bipolar disorder, schizophrenia***Children, suicidal ideation***MAOI therapy***Alcoholism, driving or operating machinery***Acute myocardial infarction, cardiac arrhythmias, cardiac disease, tachycardia***Anticholinergic medications, gastroesophageal reflux disease (GERD), GI disease, ileus, prostatic hypertrophy, urinary retention***Closed-angle glaucoma, increased intraocular pressure***Seizure disorder, seizures***Parkinson's disease***Asthma, respiratory depression***Surgery***Agranulocytosis, hematological disease, thrombocytopenia***Hepatic disease***Sunlight (UV) exposure***Hyperthyroidism, hypothyroidism***Diabetes mellitus***Radiographic contrast administration***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['473837'],telavancin,***For the treatment of complicated skin and skin structure infections caused by susceptible gram-positive bacteria.***For the treatment of hospital-acquired and ventilator-associated nosocomial pneumonia caused by <em>Staphylococcus aureus</em> when alternative treatments are not appropriate.***For the treatment of persistent <em>Staphylococcus aureus</em> (MRSA) bacteremia� and vancomycin failure�.***Formoterol***Formoterol; Mometasone,"***General Information***Diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Antimicrobial resistance***Diabetes mellitus, hypertension, mortality, nephrotoxicity, renal disease, renal failure, renal impairment***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, ventricular dysfunction***Infusion-related reactions, intramuscular administration, subcutaneous administration***Vancomycin hypersensitivity***Children, infants, neonates***Pregnancy***Breast-feeding***Contraception requirements, pregnancy testing, reproductive risk***Anticoagulant therapy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4337'],fentanyl,"***For the control of moderate pain or severe pain.***For intraoperative or procedural management of severe pain, for use only in a monitored anesthesia care setting in the hospital.***For control of postoperative pain in the recovery room.***For the management of chronic severe pain in opioid-tolerant patients who require daily, around-the-clock, long-term opioid treatment.***For the management of severe breakthrough cancer pain in opioid-tolerant patients.***For short-term management of acute postoperative pain in the hospital setting using a fentanyl iontophoretic transdermal system (ITS) for patient-controlled analgesia.***For adjuvant management of general anesthesia maintenance and intraoperative pain control.***For minor surgical procedures and for use in the immediate postoperative period.***For major surgery, providing analgesia and some relief from the stress response. <br />          NOTE: Respiratory depression at this dosage level requires artificial ventilation.<br />       ***For open heart surgery and other complicated procedures where surgery is prolonged and the stress response would be detrimental to the patient's well-being.***For general anesthesia induction when attenuation of the responses to surgical stress is especially important such as during major surgery like open heart surgery or complicated neurological or orthopedic procedures.***For analgesia and/or sedation maintenance� in mechanically-ventilated intensive care patients.***For sedation and analgesia prior to rapid-sequence intubation (RSI)�.***For the management of dyspnea� in patients with end-stage cancer or lung disease.***For procedural sedation� of non-intubated patients during diagnostic, surgical, or other procedures.","***General Information***Dental work, headache, migraine, opioid-naive patients, surgery***Constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Accidental exposure***MAOI therapy***Potential for overdose or poisoning, requires a specialized care setting, requires an experienced clinician***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, urethral stricture, urinary retention***Brain tumor, CNS depression, head trauma, increased intracranial pressure, seizure disorder, seizures***Angina, bradycardia, cardiac arrhythmias, cardiac disease, heart failure, hypotension, orthostatic hypotension, shock***Children, infants, neonates, premature neonates***Labor, neonatal opioid withdrawal syndrome, pregnancy***Breast-feeding***Females***Geriatric***Biliary tract disease, pancreatitis***Abrupt discontinuation***Driving or operating machinery***Anticoagulant therapy, coagulopathy, epidural administration, infection, intrathecal administration, thrombocytopenia***Opiate agonist hypersensitivity***Ambient temperature increase, fever, heating pad, skin abrasion, sunlight (UV) exposure***Ocular exposure***Dental disease, diabetes mellitus, stomatitis***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Adrenal insufficiency, hypothyroidism, myxedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['27340'],desflurane,***For general anesthesia induction.***For general anesthesia maintenance.,"***Halogenated anesthetics hypersensitivity***Malignant hyperthermia***Asthma, children, infants, neonates, respiratory infection***Coronary artery disease***Hepatic disease, hepatitis***Hyperkalemia, neuromuscular disease***Increased intracranial pressure, intracranial mass***Accidental exposure, labor, obstetric delivery, pregnancy***Breast-feeding***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, diabetes mellitus, females, geriatric, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['28889'],loratadine,"***For the relief of symptoms associated with seasonal or perennial allergic rhinitis, and for management of chronic idiopathic urticaria or other histamine-mediated allergic symptoms (e.g., hives, pruritus).***For adjunctive exercise-induced bronchospasm prophylaxis� in patients with allergies.","***General Information***Asthma***Phenylketonuria***Driving or operating machinery***Hepatic disease***Renal failure, renal impairment***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluoxetine hydrochloride,***For the treatment of major depression.***For the treatment of depression with a daily dosage formulation.***For the once-weekly maintenance treatment of depression.***For acute treatment of treatment-resistant depression in combination with olanzapine.***For acute  treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in combination with olanzapine.***For the treatment of obsessive-compulsive disorder (OCD).***For the treatment of panic disorder with or without agoraphobia.***For the treatment of bulimia nervosa.***For the treatment of premenstrual dysphoric disorder (PMDD).***For the treatment of generalized anxiety disorder (GAD)�.***For the treatment of social phobia (social anxiety disorder)�.***For the treatment of posttraumatic stress disorder (PTSD)�.***For the treatment of anorexia nervosa�.***For the treatment of obesity�.***For the treatment of borderline personality disorder�.***For the treatment of autistic disorder�.***For the treatment of separation anxiety disorder�.***For the treatment of fibromyalgia�.***For the treatment of neurogenic orthostatic hypotension�.***For the treatment of premature ejaculation�.***For the treatment of hot flashes� in women with breast cancer experiencing symptoms of menopause�.***For migraine prophylaxis�.***For the treatment of selective mutism� in children who have failed an adequate trial of psychotherapy.***Formoterol***Formoterol; Mometasone,"***General Information***Abrupt discontinuation***Electroconvulsive therapy (ECT), seizure disorder***Children, growth inhibition, suicidal ideation***MAOI therapy***Bipolar disorder, mania***Hepatic disease***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diarrhea, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, poor metabolizers, QT prolongation, thyroid disease, ventricular arrhythmias***Dehydration, hyponatremia, hypovolemia***Anticoagulant therapy, bleeding, thrombolytic therapy***Closed-angle glaucoma, increased intraocular pressure***Driving or operating machinery, ethanol ingestion***Diabetes mellitus***Akathisia***Anorexia nervosa***Bone fractures, osteoporosis***Neonates, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mefenamic acid,***For the treatment of dysmenorrhea.***For the treatment of mild pain and moderate pain.***For the treatment of migraine�.***For migraine prophylaxis�.***Formoterol; Mometasone,"***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, intracranial bleeding, neutropenia, surgery, thrombocytopenia***Anemia***Hepatic disease, hypoalbuminemia, jaundice***Dehydration, diabetes mellitus, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hypertension, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Coronary artery bypass graft surgery (CABG)***Intramuscular injections***Children, infants, neonates***Labor, obstetric delivery, pregnancy***Breast-feeding***Lactase deficiency***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['274964'],ciclesonide,"***For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis.***For seasonal allergic rhinitis.***For perennial allergic rhinitis.***For the maintenance treatment of asthma as prophylactic therapy.***For patients previously receiving bronchodilators alone.***For patients previously receiving inhaled corticosteroids.***For patients previously receiving oral corticosteroids. <br />          NOTE: The manufacturer recommends that prednisone should be reduced no faster than 2.5 mg/day weekly, beginning after at least 1 week of therapy with ciclesonide. Patients should be carefully monitored for signs of asthma instability, including monitoring of serial objective measures of airflow, and for signs of adrenal insufficiency during steroid taper and following discontinuation of oral corticosteroid therapy.<br />       ***For the maintenance treatment of asthma in children�.***For exercise-induced bronchospasm prophylaxis�.","***Corticosteroid hypersensitivity***Acute bronchospasm, status asthmaticus***Adrenal insufficiency, hypothalamic-pituitary-adrenal (HPA) suppression***Fungal infection, herpes infection, infection, tuberculosis, viral infection***Vaccination***Measles, varicella***Children, growth inhibition, increased intracranial pressure***Infants, neonates, pregnancy***Breast-feeding***Cushing's syndrome***Nasal septal perforation, nasal surgery, nasal trauma***Osteoporosis***Geriatric***Cataracts, glaucoma, increased intraocular pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1300786'],mirabegron,"***For the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.","***Hypertension***Bladder obstruction, urinary tract obstruction***Dialysis, renal failure, renal impairment***Hepatic disease***Pregnancy***Breast-feeding***Children, infants, neonates***MAOI therapy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7597'],nystatin,"***For the treatment of cutaneous candidiasis (including adjunctive treatment for candidal diaper dermatitis), mucocutaneous candidiasis (i.e., oropharyngeal candidiasis (thrush), vulvovaginal candidiasis), and intestinal candidiasis (with or without coexisting vulvovaginal candidiasis).***For the treatment of oropharyngeal candidiasis (thrush).***For the treatment of cutaneous candidiasis or mucocutaneous candidiasis, or for adjunctive treatment for candidal diaper dermatitis.***For the treatment of vulvovaginal candidiasis (VVC).***For the treatment of intestinal candidiasis (with or without coexisting vulvovaginal candidiasis).",***Paraben hypersensitivity***Pregnancy***Breast-feeding***Diabetes mellitus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,azelastine hydrochloride/fluticasone propionate,***For the treatment of symptoms associated with seasonal allergic rhinitis in patients who require treatment with azelastine and fluticasone.,"***Driving or operating machinery***Nasal septal perforation, nasal surgery, nasal trauma***Cataracts, glaucoma, increased intraocular pressure, ocular exposure, ophthalmic administration***Immunosuppression, infection, tuberculosis, varicella, viral infection***Hypothalamic-pituitary-adrenal (HPA) suppression***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Corticosteroid hypersensitivity***Osteoporosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,memantine hydrochloride,***For the treatment of symptoms of moderate to severe Alzheimer's disease.***For the treatment of symptoms of mild to moderate vascular dementia�.***For the symptomatic treatment of acquired pendular nystagmus�.,"***General Information***Renal disease, renal failure, renal impairment, urinary tract infection (UTI)***Hepatic disease***Pregnancy***Breast-feeding***Children, infants***Geriatric***Seizure disorder, seizures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pyrantel pamoate,***For the treatment of enterobiasis (pinworm infection).***For the treatment of ascariasis�.***For the treatment of uncinariasis� (hookworm infection).***For the treatment of trichostrongyliasis�.,***Hepatic disease***Phenylketonuria***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,alendronate sodium,"***For the treatment of osteoporosis.***For osteoporosis prophylaxis in postmenopausal women.***For the treatment of Paget's disease in symptomatic patients or patients with alkaline phosphatase levels at least twice the upper limit of normal, or those at risk from complications..***For the treatment of malignant hypercalcemia�.","***General Information***Achalasia, dysphagia, esophageal stricture, esophagitis, gastritis, gastroesophageal reflux disease (GERD), GI disease, GI perforation, hiatal hernia, inability to stand or sit upright***Geriatric***Hypocalcemia, vitamin D deficiency***Renal failure, renal impairment***Children, infants, neonates***Pregnancy***Breast-feeding***Phosphonate hypersensitivity***Sunlight (UV) exposure***Anemia, chemotherapy, coagulopathy, corticosteroid therapy, dental disease, dental work, infection***Cardiac disease, heart failure, hypertension, sodium restriction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,oseltamivir phosphate,"***For the treatment of acute influenza A virus infection or influenza B virus infection.***For seasonal influenza prophylaxis.***For the treatment of novel influenza A viruses associated with severe human disease�, including avian influenza A virus infection�.***For prophylaxis of novel influenza A viruses associated with severe human disease�, including avian influenza prophylaxis�.","***General Information***Infection, viral infection***Immunosuppression, vaccination***Asthma, bronchitis, cardiac disease, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Renal failure, renal impairment***Hepatic disease***Psychosis***Children, infants, neonates, Reye's syndrome***Hereditary fructose intolerance***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,immune globulin intravenous (human),"***For hepatitis A prophylaxis.***For postexposure prophylaxis.***For patients traveling to regions that have high or intermediate hepatitis A endemicity.***For measles prophylaxis to prevent or modify measles in an unvaccinated patient who has not previously had measles and who was exposed within the past 6 days. <br />  NOTE: For most persons 12 months and older who are exposed to measles, use of MMR or measles vaccine within 72 hours of exposure is preferred to using immune globulin (except pregnant women and others for whom the vaccine is contraindicated). Any person exposed to measles who lacks evidence of measles immunity and to whom immune globulin (IG) is administered should subsequently receive MMR vaccine but not earlier than 6 months after IMIG administration or 8 months after IGIV administration (provided the vaccine is not contraindicated).<br /***For varicella (chickenpox) infection prophylaxis.***For rubella prophylaxis in exposed, susceptible pregnant women who will not consider a therapeutic abortion. <br />        NOTE: The routine use of IMIG for rubella prophylaxis in early pregnancy is of dubious value and cannot be justified.<br />     ***For immunoglobulin deficiency. <br />  NOTE: Immune globulin may prevent serious infection in patients with immunoglobulin deficiencies if circulating IgG concentrations of approximately 200 mg/100 mL plasma are maintained.<br /","***Intravenous administration***Pregnancy***Breast-feeding***Agammaglobulinemia, hypogammaglobulinemia, IgA deficiency***Viral infection***Anticoagulant therapy, bleeding, coagulopathy, hemophilia, thrombocytopenia***Vaccination***Children***Coronary artery disease, geriatric, heart failure, hypertriglyceridemia, hyponatremia, obesity, thromboembolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2447'],cholestyramine,"***For treatment of hypercholesterolemia, especially elevated LDL cholesterol (type IIa and IIb hyperlipoproteinemia), and for pruritus associated with biliary stasis.***For the treatment of diarrhea�.***For the adjunctive treatment of diarrhea� associated with excess fecal bile acids.***For control of diarrhea� secondary to AIDS-associated enteropathy.","***Biliary cirrhosis, biliary obstruction, cholelithiasis***Hypertriglyceridemia***Constipation, dysphagia, GI obstruction, hemorrhoids, ileus***Coagulopathy***Phenylketonuria***Hypothyroidism***Renal disease***Pregnancy***Breast-feeding***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,candesartan cilexetil,***For the treatment of hypertension.***For the treatment of heart failure.***For migraine prophylaxis�.,"***Hypotension, hypovolemia***Heart failure, renal artery stenosis, renal disease, renal failure, renal impairment***Children, infants***Hepatic disease***Hyperkalemia***ACE-inhibitor induced angioedema, angioedema***Black patients***Pregnancy***Breast-feeding***Surgery***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,levalbuterol tartrate,"***For the treatment of acute bronchospasm and bronchospasm prophylaxis associated with asthma.***For bronchospasm associated with asthma in pediatric patients.***For bronchospasm associated with asthma in adults.***For the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis.***For the adjunctive emergency acute treatment of hyperkalemia� until hemodialysis is available. <br />        NOTE: Beta-agonists can be effective treatments for hyperkalemia via beta-adrenergic induction of potassium (K+) uptake. However, they are a temporary adjunctive measure.<br />     ***For exercise-induced bronchospasm prophylaxis�.","***General Information***Albuterol hypersensitivity, angioedema, levalbuterol hypersensitivity***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, tachycardia***Renal failure, renal impairment***Hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***Diabetes mellitus***Deterioration of asthma, paradoxical bronchospasm***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***MAOI therapy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,antihemophilic factor (recombinant),"***For the prevention and control of hemorrhage in patients with hemophilia A (classical hemophilia). <br />        NOTE: Humate, Kogenate, and ReFacto have been designated by the FDA as orphan drugs for the prophylaxis and management of hemorrhage or hemarthrosis in patients with hemophilia A.<br /> <br />NOTE: Guidelines for the treatment of acute bleeding and prevention of bleeding during surgery vary. For all indications, the dose of antihemophilic factor should be individualized taking into consideration the seriousness of the bleed or procedure, the clinical status of the patient, and the factor VIII activity concentration***For minor bleeding including early muscle bleed, early hemarthrosis, and oral bleeds.***For moderate bleeding including advanced muscle bleed, extensive hemarthrosis, hematoma, and mild head trauma.***For life- or limb-threatening bleeding including surgical bleeding, gastrointestinal bleeding, neck, tongue or pharyngeal hematoma with potential for airway compromise, intracranial, intraabdominal, or intrathoracic bleeding, or fractures.***For bleeding in patients with hemophilia A and factor VIII inhibitor titers less than 10 Bethesda Units and with low anamnestic responses.***For the perioperative management of surgical bleeding (surgical bleeding prophylaxis) in patients with hemophilia A.***For routine bleeding prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A.***For the management of hemorrhage or hemarthrosis in patients with von Willebrand's disease (vWD). <br />        NOTE: Humate-P has been designated by the FDA as orphan drugs for this indication.<br />     ***For major hemorrhage in patients with mild vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma or traumatic hemorrhage).***For minor hemorrhage in patients with moderate to severe vWD type I, type II, and type III (e.g., epistaxis, oral bleeding, or menorrhagia).***For major hemorrhage in patients with moderate to severe vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For major hemorrhage in patients with vWD type II and III (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For surgical bleeding prophylaxis during major or minor procedures in patients with vWD in whom desmopressin is either ineffective or contraindicated. <br />          NOTE: Alphanate and Humate-P have been designated by the FDA as orphan drugs for this indication.<br />       ","***General Information***Pregnancy***Breast-feeding***Thromboembolic disease***Hepatitis, infection, viral infection***Anemia***Bovine protein hypersensitivity, hamster protein hypersensitivity, latex hypersensitivity, mannitol hypersensitivity, murine protein hypersensitivity, polysorbate 80 hypersensitivity***Porcine protein hypersensitivity***Human immunodeficiency virus (HIV) infection***Cardiac disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,frovatriptan succinate,***For the treatment of acute migraine headache attacks with or without aura.***For menstrual migraine prophylaxis�.,"***General Information***Acute myocardial infarction, angina, arteriosclerosis, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, hypercholesterolemia, myocardial infarction, obesity, tobacco smoking, vasospastic angina, Wolff-Parkinson-White syndrome***Hypertension***Colitis, peripheral vascular disease, Raynaud's phenomenon***Cerebrovascular disease, intracranial bleeding, stroke***Basilar/hemiplegic migraine***Hepatic disease***Visual disturbance***Pregnancy***Breast-feeding***Children, infants, neonates***Driving or operating machinery***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['161'],acetaminophen,"***For the treatment of fever. <br />        NOTE: Acetaminophen should not be used for self-medication of marked fever (greater than 39.5 degrees C or 103.1 degrees F), fever persisting longer than 3 days, or recurrent fever, unless directed by a physician.<br />     ***For the treatment of mild pain or for the temporary relief of headache, myalgia, back pain, musculoskeletal pain, dental pain (e.g., toothache), dysmenorrhea, arthralgia, or minor aches and pains associated with the common cold or flu. <br />        NOTE: Acetaminophen should not be used for self-medication of pain for longer than 10 days in adults or 5 days in children.<br />     ***For the treatment of moderate pain to severe pain with adjunctive opioid analgesics.***For minor osteoarthritis pain.***For the treatment of headache pain due to acute migraine�.","***Acetaminophen hypersensitivity***Alcoholism, ethanol intoxication, hepatic disease, hepatitis, hepatotoxicity, hypovolemia, malnutrition, potential for overdose or poisoning***Renal disease, renal failure, renal impairment***G6PD deficiency***Bone marrow suppression, immunosuppression, infection, neutropenia***Tobacco smoking***Children, infants, neonates***Pregnancy***Breast-feeding***Phenylketonuria***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pentobarbital sodium,"***For procedural sedation or for use as a preanesthetic medication.***For use as an alternative agent in the treatment of status epilepticus or for acute control of tonic-clonic seizures from meningitis, tetanus or chorea, ethanol withdrawal, eclampsia, or poisons.***For the short-term treatment of insomnia.***For the reduction of increased intracranial pressure (ICP)� in patients with traumatic brain injury (i.e., head trauma)�.***For sedation maintenance� and to alleviate agitation� and anxiety� in patients refractory to standard therapy who are mechanically-ventilated.","***Agranulocytosis, barbiturate hypersensitivity, carbamazepine hypersensitivity, hydantoin hypersensitivity***Pain***Cardiac disease, chronic obstructive pulmonary disease (COPD), heart failure, hypertension, hypotension, intraarterial administration, intravenous administration, pulmonary disease, respiratory depression, shock, sleep apnea, subcutaneous administration***Abrupt discontinuation, substance abuse***Alcoholism, CNS depression, driving or operating machinery, ethanol ingestion, mental status changes***Geriatric***Hepatic disease, hepatic encephalopathy***Renal impairment***Porphyria***Osteomalacia, osteoporosis***Children, infants, neonates, premature neonates***Breast-feeding***Labor, obstetric delivery, pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['17767']['5487'],amlodipine/hydrochlorothiazide/olmesartan medoxomil,"***For the treatment of hypertension. <br />        NOTE: Amlodipine; hydrochlorothiazide, HCTZ; olmesartan is not indicated for the initial treatment of hypertension.<br />NOTE: Combination may be used in patients already receiving amlodipine, hydrochlorothiazide, and olmesartan who desire to switch to the combination tablet or in patients not adequately controlled on maximally tolerated, labeled, or usual doses of any 2 of the following drug classes: angiotensin receptor blockers, calcium channel blockers, and diuretics.<br />NOTE: Assure that volume and/or sodium depletion is corrected prior to administration***Formoterol***Formoterol; Mometasone","***General Information***Pregnancy***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, heart failure, renal artery stenosis, renal disease, renal failure, renal impairment***Aortic stenosis, hypotension, hypovolemia, orthostatic hypotension***Angina, coronary artery disease***Hepatic disease***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia, hyponatremia***Diabetes mellitus, hyperglycemia***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***ACE-inhibitor induced angioedema, angioedema***Gastroesophageal reflux disease (GERD), hiatal hernia***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1895'],mupirocin calcium,"***For the treatment of impetigo and other skin and skin structure infections due to susceptible strains of <em>Staphylococcus aureus</em> or <em>Streptococcus pyogenes</em>.***For the treatment of impetigo.***For the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area).***For nasal bacterial colonization eradication of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) to reduce the risk of infection among high-risk patients during institutional outbreaks of infections with this pathogen.***For the treatment of mild methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated infectious neonatal pustulosis�.***For the treatment of infected eczema� due to susceptible strains of <em>Staphylococcus</em> sp. or <em>Streptococcus</em> sp..***For the treatment of folliculitis� due to susceptible strains of <em>Staphylococcus</em> sp. or <em>Streptococcus</em> sp..***For the prevention of postoperative nosocomial <em>Staphylococcus aureus</em> infections� (i.e., bacterial infection prophylaxis�).","***General Information***Burns, renal impairment***Children, infants, neonates***Ocular exposure, ophthalmic administration***Pregnancy***Breast-feeding***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5640'],ibuprofen,"***For the treatment of rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA).***For the treatment of dysmenorrhea.***For the treatment of severe pain in hospitalized patients.***For the treatment of mild pain to moderate pain.***For the treatment of mild to moderate pain in hospitalized patients.***For self-treatment of minor aches and pains due to the common cold, toothache, muscular aches or backache (musculoskeletal pain), and the minor pains of arthritis.***For the treatment of fever.***For the treatment of headache.***For self-treatment of headache.***For the treatment of pain due to acute migraine.***For the treatment of osteoarthritis; ankylosing spondylitis�; acute gouty arthritis�; or psoriatic arthritis�.***For patients with cystic fibrosis� to slow the rate of decline in lung function.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, Crohn's disease, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery bypass graft surgery (CABG), coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Geriatric***Labor, obstetric delivery, pregnancy***Infertility, reproductive risk***Breast-feeding***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,morphine sulfate,"***For the relief of acute and chronic moderate pain or severe pain. <br />        NOTE: There is substantial interpatient variability in the relative potency of different opioid drugs and products. FDA-approved labeling defines adult opioid-tolerant patients as those who take the following per day for a minimum of 1 week: oral morphine 60 mg or more; oral oxycodone 30 mg or more; oral hydromorphone 8 mg or more; oral oxymorphone 25 mg or more; 60 mg oral hydrocodone or more; transdermal fentanyl 25 mcg or more per hour; or another opioid at an equivalent dose. <br />     ***For acute moderate to severe pain related to major orthopedic surgery of the lower extremity.***For acute moderate to severe pain related to lower abdominal or pelvic surgery.***For acute moderate to severe pain related to cesarean section after delivery and clamping of the umbilical cord.***For the management of chronic severe pain in patients who require daily, around-the-clock, long-term opioid treatment. <br />  NOTE: Reserve extended-release morphine for when alternative options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would otherwise provide inadequate pain management. Discontinue all other around-the-clock opioids upon initiation.  <br />NOTE: Do not use the following morphine products in opioid-naive patients: 60 mg, 90 mg, or 120 mg biphasic-release capsules (Avinza); 100 mg, 130 mg, 150 mg, or 200 mg extended-release capsules (Kadian); 100 mg or 200 mg controlled-release tablets (MS Contin); 100 mg extended-release tablets (Morphabond). In this population, use could result in fatal respiratory depression. Use of a single dose of more than 60 mg, or a total daily dose more than 120 mg, should be limited to opioid-tolerant patients.   <br />NOTE: There is substantial interpatient variability in the relative potency of different opioid drugs and products. FDA-approved labeling defines adult opioid-tolerant patients as those who take the following per day for a minimum of 1 week: oral morphine 60 mg or more; oral oxycodone 30 mg or more; oral hydromorphone 8 mg or more; oral oxymorphone 25 mg or more; oral hydrocodone 60 mg or more; transdermal fentanyl 25 mcg or more per hour; or another opioid at an equivalent dose.***For the treatment of diarrhea.***For the treatment of noninfectious diarrhea. <br />  WARNING: Proper product selection is critical. Deodorized opium tincture 10 mg/mL solution is 25 times more concentrated than camphorated opium tincture 0.4 mg/mL solution. Serious patient harm may occur with incorrect product selection.<br /***For control of diarrhea� secondary to AIDS-associated enteropathy.***For the management of dyspnea�.***For the adjuvant treatment of acute pulmonary edema�.***For acute myocardial infarction� or unstable angina� and to provide potentially beneficial cardiovascular effects.***For procedural sedation� before short diagnostic procedures or endoscopy. <br />        NOTE: Morphine should be administered as an inducing agent only by those trained in anesthesia.<br />     ***For sedation during rapid-sequence intubation�.***For the treatment of painful diabetic neuropathy�.","***Opiate agonist hypersensitivity***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, coma, cor pulmonale, emphysema, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Ethanol ingestion, ethanol intoxication***Anticoagulant therapy, coagulopathy, infection, intramuscular administration, intrathecal administration, intravenous administration, requires a specialized care setting, requires an experienced clinician, subcutaneous administration***Accidental exposure, opioid-naive patients, potential for overdose or poisoning***Abrupt discontinuation***Acute abdomen, constipation, diarrhea, GI bleeding, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Biliary tract disease***Arteriosclerosis, brain tumor, CNS depression, head trauma, increased intracranial pressure, seizure disorder, seizures, status epilepticus, strychnine toxicity***Angina, atrial fibrillation, atrial flutter, cardiac arrhythmias, cardiac disease, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal impairment, urethral stricture, urinary retention***Children, infants, neonates***Geriatric***Driving or operating machinery***MAOI therapy***Adrenal insufficiency, hypothyroidism, myxedema***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['28889'],loratadine,"***For the relief of symptoms associated with seasonal or perennial allergic rhinitis, and for management of chronic idiopathic urticaria or other histamine-mediated allergic symptoms (e.g., hives, pruritus).***For adjunctive exercise-induced bronchospasm prophylaxis� in patients with allergies.","***General Information***Asthma***Phenylketonuria***Driving or operating machinery***Hepatic disease***Renal failure, renal impairment***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/norethindrone,"***For routine contraception.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***For gastrointestinal bleeding prophylaxis� related to arteriovenous malformations, radiation-induced rectal telangiectases, hereditary telangiectases, and gastric antral vascular ectasia in patients who have severe recurrent blood loss and frequent need for transfusion despite other medical therapies, and who have no contraindications to oral contraceptives.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Ectopic pregnancy, pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['39998'],zonisamide,***For use as adjunctive therapy in the treatment of partial seizures.,"***Abrupt discontinuation***Sulfonamide hypersensitivity***Depression, suicidal ideation***Hepatic disease***Chronic obstructive pulmonary disease (COPD), diarrhea, emphysema, metabolic acidosis, pulmonary disease, status asthmaticus, status epilepticus, surgery***Labor, pregnancy***Breast-feeding***Ambient temperature increase, anticholinergic medications, children, dehydration, hypovolemia, infants, neonates***Nephrolithiasis, renal disease, renal failure, renal impairment***Driving or operating machinery***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['134404'],urofollitropin,"***For the treatment of infertility in females. <br />        NOTE: During urofollitropin treatment and during a 2-week post-treatment period, females should be examined at least every other day for signs of excessive ovarian stimulation. Ovarian hyperstimulation syndrome (OHSS) usually occurs after discontinuation of urofollitropin and reaches its maximum at about 7�10 days post-ovulation.<br />     ***For the development of multiple follicles in the ovulatory female patient participating in an Assisted Reproductive Technology (ART) program.***For the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure.***For the treatment of infertility in males (for the stimulation of spermatogenesis in males with primary or secondary hypogonadotropic hypogonadism and resultant oligospermia). <br />        NOTE: Fertinex brand of urofollitropin is designated an orphan drug by the FDA for this indication.<br />NOTE: Pretreatment with hCG is required prior to combination treatment with urofollitropin. Various hCG dosages have been advocated; continue hCG for a period sufficient to achieve normal serum testosterone levels. Such pretreatment may require 3�6 months (see HCG monograph)","***General Information***Children***Driving or operating machinery***Asthma***Adrenal insufficiency, pituitary adenoma, thyroid disease***Infertility, testicular failure***Ovarian failure***Dysfunctional uterine bleeding, endometriosis, uterine leiomyomata, vaginal bleeding***Geriatric***Ovarian cyst***Ascites, polycystic ovary syndrome***Pregnancy***Breast-feeding***Obesity, thromboembolic disease, thrombophlebitis***Ethanol intoxication, tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,codeine sulfate,"***For the treatment of mild pain to moderate pain such as arthralgia�, back pain�, bone pain�, dental pain�, headache�, migraine�, myalgia�, and surgical pain�.***For the treatment of cough�.***For the treatment of diarrhea�.***For control of diarrhea� secondary to AIDS-associated enteropathy.","***Acute abdomen, constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Biliary tract disease***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, status asthmaticus***Abrupt discontinuation***Alcoholism, substance abuse***Head trauma, increased intracranial pressure***Angina, cardiac arrhythmias, cardiac disease, heart failure, hypotension, hypovolemia***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, urethral stricture, urinary retention***Hepatic disease, jaundice***Adenoidectomy, children, infants, neonates, neuromuscular disease, respiratory infection, sleep apnea, tonsillectomy***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Seizure disorder, seizures***Geriatric***Driving or operating machinery***Opiate agonist hypersensitivity, sulfite hypersensitivity***Adrenal insufficiency, hypothyroidism, myxedema***Asian patients, Black patients, Caucasian patients, Hispanic patients***MAOI therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5487'],hydrochlorothiazide,"***For the treatment of hypertension.***For use as an adjunctive agent to treat peripheral edema associated with congestive heart failure, hepatic cirrhosis (ascites), corticosteroid therapy, or estrogen therapy; or to treat edema associated with renal dysfunction� including nephrotic syndrome, acute glomerulonephritis, and chronic renal failure�.***For the treatment of nephrogenic or central diabetes insipidus�.***For the prevention of nephrolithiasis� (calcium-containing renal calculus�) due to hypercalciuria�.***For the treatment of symptoms of bloating and weight gain associated with premenstrual syndrome (PMS)�.***Formoterol***Formoterol; Mometasone","***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Hepatic disease***Diabetes mellitus, hyperglycemia***Anuria, hypovolemia, renal disease, renal failure, renal impairment***Hypotension, orthostatic hypotension, sympathectomy, syncope***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Electrolyte imbalance, hypercalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis***Sunlight (UV) exposure***Jaundice, neonates***Preeclampsia, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,timolol maleate,"***For the treatment of hypertension.***For reduction of cardiovascular mortality and to reduce the risk of reinfarction (i.e., myocardial infarction prophylaxis) after an acute myocardial infarction in patients who are clinically stable.***For migraine prophylaxis.***For the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.***For the management of chronic stable angina�.***For the treatment of essential tremor�.","***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***AV block, bradycardia, cardiogenic shock, heart failure, hypotension, pheochromocytoma, pulmonary edema, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Cerebrovascular disease***Diabetes mellitus***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Surgery***Hepatic disease***Geriatric, peripheral vascular disease***Dialysis, renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Raynaud's phenomenon***Depression***Psoriasis***Myasthenia gravis***Contact lenses***Children, infants, neonates***Beta-blocker hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['228476', '1546025']",gatifloxacin,***For the treatment of bacterial conjunctivitis.***For ophthalmic surgical infection prophylaxis�.,***General Information***Fungal infection***Quinolone hypersensitivity***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pantoprazole sodium,"***For the treatment of erosive esophagitis (erosive GERD).***For the treatment of pathological hypersecretion associated with Zollinger-Ellison syndrome or other hypersecretory syndromes.***For the short-term treatment of frequent dyspepsia� or pyrosis (heartburn)� that occurs >= 2 times per week.***For the treatment of non-erosive gastroesophageal reflux disease (GERD)�.***For the healing of duodenal ulcer�. <br />  NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br /***For the healing of gastric ulcer�. <br />  NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br /***For Helicobacter pylori (H. pylori) eradication� in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />  NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.   The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Prevpac monograph).  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long-term tumor regression is observed in 60% to 90% of patients.***For NSAID-induced ulcer prophylaxis�.***For stress gastritis prophylaxis� in critically-ill patients:.***For the treatment of proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) in the differential diagnosis of eosinophilic esophagitis (EoE)�.***For upper GI rebleeding prophylaxis after therapeutic endoscopy�.","***General Information***Proton pump inhibitors (PPIs) hypersensitivity***Hepatic disease***Gastric cancer, new primary malignancy***Diarrhea, pseudomembranous colitis***Vitamin B12 deficiency***Zinc deficiency***Bone fractures, geriatric, osteoporosis***Hypomagnesemia, long QT syndrome***Rebound acid hypersecretion***Pregnancy***Breast-feeding***Infants, neonates***Laboratory test interference***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,timolol maleate,"***For the treatment of hypertension.***For reduction of cardiovascular mortality and to reduce the risk of reinfarction (i.e., myocardial infarction prophylaxis) after an acute myocardial infarction in patients who are clinically stable.***For migraine prophylaxis.***For the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.***For the management of chronic stable angina�.***For the treatment of essential tremor�.","***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***AV block, bradycardia, cardiogenic shock, heart failure, hypotension, pheochromocytoma, pulmonary edema, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Cerebrovascular disease***Diabetes mellitus***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Driving or operating machinery***Surgery***Hepatic disease***Geriatric, peripheral vascular disease***Dialysis, renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Raynaud's phenomenon***Depression***Psoriasis***Myasthenia gravis***Contact lenses***Children, infants, neonates***Beta-blocker hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,carboxymethylcellulose sodium,***For the temporary relief of xerophthalmia and minor ocular irritation.,"***Contact lenses***Corneal abrasion, ocular infection, ocular trauma, visual disturbance***Pregnancy***Children, infants, neonates***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albumin (human),"***For the treatment of shock due to hypovolemia. <br />        NOTE: Dosage should be based on patient response as indicated by blood pressure, degree of pulmonary congestion, and hematocrit.<br />     ***For adjunctive treatment of severe burns.***For the treatment of nephrosis in nephrotic syndrome.***For treatment of hypoproteinemia.***For adjunctive use with exchange transfusion in the treatment of hyperbilirubinemia and erythroblastosis fetalis.","***Albumin hypersensitivity***Anemia, heart failure, hypertension***Renal disease***Hypernatremia***Burns***Viral infection***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['53654'],nevirapine,"***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents. <br />  NOTE: Although the FDA-approved labeling recommends reinitiation of lead-in dosing for patients who have interrupted therapy for more than 7 days, the HIV guidelines recommend that children who interrupt therapy for 14 days or less should be restarted on full-dose nevirapine. If dosing is interrupted for more than 14 days, dosing should be restarted with the lead-in dosing for 14 days, followed by full-dose escalation. <br /***For perinatal human immunodeficiency virus (HIV) prophylaxis� in neonates at high risk for HIV acquisition. <br />        NOTE: All HIV exposed infants should receive post-partum prophylaxis initiated as close to the time of birth as possible, preferably within 6 to 12 hours of delivery. Combination antiretroviral regimens are recommended for infants at high risk. Neonates at high risk for perinatal HIV transmission include those born to HIV-infected mothers: who have not received antepartum or intrapartum antiretroviral treatment, who have received only intrapartum antiretroviral treatment, who have suboptimal viral suppression near delivery, who have unknown HIV status, or who have known ARV drug-resistant virus.<br />","***General Information***Hepatic disease, hepatitis, hepatitis B and HIV coinfection, hepatotoxicity***Nevirapine hypersensitivity, serious rash***Pregnancy***Breast-feeding***Females***Black patients, Hispanic patients, human immunodeficiency virus (HIV) infection resistance***Dialysis***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Children, infants, neonates***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['29561', '1546029']",meropenem,"***For the treatment of intraabdominal infections, including complicated appendicitis and peritonitis.***For the treatment of bacterial meningitis.***For the treatment of complicated skin and skin structure infections.***For the empiric treatment of febrile neutropenia�.***For the treatment of febrile neutropenia in adults.***For the treatment of febrile neutropenia in pediatric patients.***For the treatment of serious gram-negative infection� (e.g. sepsis�, bacteremia�).***For the treatment of systemic anthrax� infection.***For the treatment of pneumonia�, including community-acquired pneumonia� (CAP) and nosocomial pneumonia�.","***General Information***Carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Head trauma, neurological disease, seizure disorder, seizures***Renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Driving or operating machinery***Geriatric***Heart failure, sodium restriction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,bismuth subcitrate potassium/metronidazole/tetracycline hydrochloride,"***For Helicobacter pylori (H. pylori) eradication in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />  NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole; the same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report. Quadruple-therapy regimens (e.g., Pylera with standard dose PPI or ranitidine) are a preferred second-line therapy and may be considered as an acceptable alternate first-line therapy; however, quadruple-therapy regimens may reduce patient compliance. <br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy.  <br />NOTE: Patients with persistence of H. pylori following quadruple therapy should be re-treated with a regimen which does not contain metronidazole. Metronidazole-resistant strains are prevalent in the US (approximately 25%).<br />NOTE: Bismuth preparations, some antimicrobials, and some PPIs suppress H. pylori. Ingestion of these substances within 4 weeks prior to performing urease or breath-tests for H. pylori detection may lead to false negative results. In the 4 weeks prior to performing the test, the patient must avoid the use of Pylera and other agents known to suppress H. pylori.<br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60% to 90% of patients.","***General Information***Tetracyclines hypersensitivity***Renal disease, renal failure, renal impairment***Children, infants, neonates***Fungal infection***Neurological disease, peripheral neuropathy, seizure disorder, seizures***Alcoholism, ethanol intoxication***Bone marrow suppression, hematological disease, leukopenia, neutropenia***Anticoagulant therapy***Colitis, Crohn's disease, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Sunlight (UV) exposure***Surgery***Pregnancy***Breast-feeding***New primary malignancy***Hepatic disease***Cockayne syndrome",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/levonorgestrel,"***For routine contraception.***For extended continuous routine contraception.***For use as postcoital contraception within 72 hours of unprotected intercourse, or known or suspected contraceptive failure, in females who have no known contraindications to oral contraceptives, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,thiamine hydrochloride,"***For nutritional supplementation.***For the recommended dietary allowance (RDA) of thiamine for nutritional supplementation in healthy individuals.***For the treatment of beriberi. <br />        NOTE: If beriberi occurs in a breast-fed infant, both the lactating mother and the infant should receive treatment for thiamine deficiency.<br />     ***For the treatment of Wernicke/Korsakoff syndrome. <br />        NOTE: Intravenous glucose loading may aggravate the symptoms of Wernicke's encephalopathy in some thiamine-deficient patients. Thiamine should be administered prior to glucose.<br />     ***For the treatment of metabolic disorders including necrotizing encephalomyelopathy, maple syrup urine disease (MSUD), and lactic acidosis associated with pyruvate carboxylase deficiency.",***Encephalopathy***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6472'],lovastatin,"***For the treatment of primary hypercholesterolemia, specifically hyperlipoproteinemia types IIa or IIb, in patients unresponsive to dietary control.***For slowing the progression of coronary atherosclerosis.***For myocardial infarction prophylaxis (primary prevention).***For slowing the progression of atherosclerosis in patients with carotid artery disease (i.e., stroke prophylaxis�).","***General Information***Alcoholism, cholestasis, hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Electrolyte imbalance, endocrine disease, females, hypotension, hypothyroidism, infection, myopathy, renal disease, renal failure, renal impairment, rhabdomyolysis, seizure disorder, surgery, trauma***Diabetes mellitus***Geriatric***Contraception requirements, pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],estradiol,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For systemic treatment of the vasomotor symptoms (hot flashes) and genitourinary symptoms of menopause.***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For estrogen replacement for premenopausal women with primary ovarian failure or female hypogonadism.***For the palliative treatment of advanced inoperable prostate cancer.***For the palliative treatment of breast cancer that is inoperable and progressive in selected men and postmenopausal women.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates***Intravenous administration***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,nicardipine hydrochloride,"***For the treatment of chronic stable angina.***For the treatment of hypertension.***For chronic hypertension.***For short-term treatment of hypertension when oral therapy is not feasible or desirable; or for the treatment of hypertensive urgency� or hypertensive emergency�, except in the setting of acute heart failure.***For postoperative hypertension�, in the absence of supraventricular tachycardia or a recent myocardial infarction.***For the treatment of proteinuria� associated with diabetic nephropathy�.","***Dihydropyridine hypersensitivity***Acute myocardial infarction, bradycardia, cardiogenic shock, heart failure, ventricular dysfunction***Hypotension***Aortic stenosis***Intracranial bleeding, stroke***Renal failure, renal impairment***Hepatic disease***Neonates, pregnancy***Breast-feeding***Children, infants***Gastroesophageal reflux disease (GERD), hiatal hernia***Pheochromocytoma***Angina***Extravasation***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['30125'],modafinil,"***For the treatment of narcolepsy to improve wakefulness in patients with excessive sleepiness.***For the treatment of shift work sleep disorder to improve wakefulness in patients with excessive sleepiness.***For the treatment of obstructive sleep apnea to improve wakefulness in patients with excessive sleepiness.***For the treatment of fatigue� associated with various medical conditions.***For fatigue� associated with multiple sclerosis.***For fatigue� or excessive daytime sleepiness associated with Parkinson's disease�.***For the adjunct treatment of symptoms (e.g., fatigue�, sleepiness) associated with major depression�.***For the treatment of attention-deficit hyperactivity disorder (ADHD)� in adults.","***Angioedema, serious rash***Driving or operating machinery***Bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Acute myocardial infarction, angina, cardiac disease, heart failure, hypertension, myocardial infarction, valvular heart disease***Hepatic disease***Pregnancy***Contraceptive devices***Breast-feeding***Ethanol ingestion, substance abuse***Geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5640'],ibuprofen,"***For the treatment of rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA).***For the treatment of dysmenorrhea.***For the treatment of severe pain in hospitalized patients.***For the treatment of mild pain to moderate pain.***For the treatment of mild to moderate pain in hospitalized patients.***For self-treatment of minor aches and pains due to the common cold, toothache, muscular aches or backache (musculoskeletal pain), and the minor pains of arthritis.***For the treatment of fever.***For the treatment of headache.***For self-treatment of headache.***For the treatment of pain due to acute migraine.***For the treatment of osteoarthritis; ankylosing spondylitis�; acute gouty arthritis�; or psoriatic arthritis�.***For patients with cystic fibrosis� to slow the rate of decline in lung function.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, Crohn's disease, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery bypass graft surgery (CABG), coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Geriatric***Labor, obstetric delivery, pregnancy***Infertility, reproductive risk***Breast-feeding***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,phentermine hydrochloride,"***For the short-term treatment of obesity, used as an adjunct to behavior modifications including dietary modification and appropriate exercise.***Formoterol***Formoterol; Mometasone","***General Information***Angina, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypertension, pulmonary hypertension, stroke, valvular heart disease***Hyperthyroidism, thyroid disease***MAOI therapy***Anxiety, insomnia, mania, psychosis, schizophrenia***Driving or operating machinery, ethanol ingestion***Diabetes mellitus***Anorexia nervosa, substance abuse***Abrupt discontinuation***Closed-angle glaucoma***Geriatric, renal failure, renal impairment***Pregnancy***Breast-feeding***Children, infants***Surgery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['2623', '202859']",clotrimazole,"***For the treatment of candidiasis, specifically mucocutaneous candidiasis (i.e., oropharyngeal candidiasis (thrush), vulvovaginal candidiasis).***For the treatment of oropharyngeal candidiasis (thrush).***For the treatment of vulvovaginal candidiasis (VVC).***For candidiasis prophylaxis to reduce the incidence of oropharyngeal candidiasis in immunocompromised patients undergoing chemotherapy or radiotherapy in the treatment of leukemia or solid tumors, or in allograft transplant patients who are receiving corticosteroid therapy.***For the treatment of tinea corporis, tinea cruris, and tinea pedis.***For the treatment of fungal otitis externa�.","***Onychomycosis***Pregnancy***Breast-feeding***Contraceptive devices, menstruation***Azole antifungals hypersensitivity***Abdominal pain, diabetes mellitus, fever, human immunodeficiency virus (HIV) infection, immunosuppression, vaginal discharge***Children, infants, neonates***Ocular exposure, ophthalmic administration***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4815'],glyburide,***For the treatment of type 2 diabetes mellitus to improve glucose control as an adjunct to diet and exercise.***For the treatment of gestational diabetes� that is not controlled by diet-therapy alone.,"***General Information***Sulfonamide hypersensitivity***Sulfonylurea hypersensitivity***Diabetic ketoacidosis, infection, surgery, trauma, type 1 diabetes mellitus***Thyroid disease***Neonates, obstetric delivery, pregnancy***Breast-feeding***Children***Hepatic disease, renal failure, renal impairment***G6PD deficiency***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4500'],flurandrenolide,"***For the treatment of mild to moderate pruritus and inflammatory manifestations of corticosteroid-responsive dermatitis such as alopecia areata, atopic dermatitis, contact dermatitis, exfoliative dermatitis, Rhus dermatitis due to plants like poison ivy, or seborrheic dermatitis, discoid lupus erythematosus, eczema, granuloma annulare, intertrigo, cutaneous lichen planus, lichen simplex chronicus, polymorphous light eruption, pompholyx (dyshidrosis), nodular prurigo, anogenital or senilis pruritus, psoriasis, or xerosis (inflammatory phase). <br />        NOTE: Occlusive dressings may be required for chronic or severe cases of lichen simplex chronicus, psoriasis, eczema, atopic dermatitis, or chronic hand eczema. More potent topical corticosteroids and/or occlusive dressings may be necessary for the treatment of discoid lupus erythematosus, lichen planus, granuloma annulare, psoriatic plaques, and psoriasis of the palms, soles, elbows, or knees.<br />     ","***General Information***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Diabetes mellitus***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Fungal infection, herpes infection, infection, measles, peripheral vascular disease, tuberculosis, varicella, viral infection***Acne rosacea, acne vulgaris, ocular exposure, ophthalmic administration, perioral dermatitis***Geriatric, skin atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10156'],sucralfate,"***For the treatment of duodenal ulcer not related to NSAID use.***For active disease.***For maintenance therapy of duodenal ulcer.***For the treatment of gastric ulcer� not related to NSAID use or for treatment of esophagitis� associated with gastroesophageal reflux disease (GERD)�.***For NSAID-induced ulcer prophylaxis�.***For stress gastritis prophylaxis�.***For the palliative treatment of aphthous ulcer�, or for the palliative treatment of stomatitis� due to chemotherapy or radiation therapy.***For the alternative treatment of proctitis� due to ulcerative colitis or radiation injury.","***General Information***Dialysis, renal failure, renal impairment***Diabetes mellitus***Dysphagia, gag reflex depression***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding***Intravenous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,oxymorphone hydrochloride,"***For moderate pain or severe pain.***For acute moderate to severe pain.***For acute moderate to severe pain during labor.***For the management of chronic severe pain in patients who require daily, around-the-clock, long-term opioid treatment. <br />  NOTE: Extended-release oxymorphone should be reserved for patients in whom alternative treatment options (e.g., nonopioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would otherwise provide inadequate pain management. Discontinue all other around-the-clock opioid drugs upon initiation of oxymorphone extended-release tablets.<br />NOTE: The use of initial doses higher than 5 mg PO every 12 hours should be reserved for opioid-tolerant patients. Opioid-tolerant patients are defined as those taking, for a minimum of 1 week, 60 mg or more oral morphine daily, 30 mg or more oral oxycodone daily, 8 mg or more oral hydromorphone daily, 25 mg or more oral oxymorphone daily, 25 mcg or more transdermal fentanyl per hour, or an equivalent dose of another opioid***For the relief of anxiety in patients with dyspnea associated with pulmonary edema secondary to acute left ventricular dysfunction.","***Lactase deficiency, opiate agonist hypersensitivity, paraben hypersensitivity***Accidental exposure, alcoholism, CNS depression, depression, ethanol ingestion, potential for overdose or poisoning, requires an experienced clinician, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, pulmonary edema, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Abrupt discontinuation***Acute abdomen, constipation, diarrhea, dysphagia, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Biliary tract disease, pancreatitis***Angina, cardiac arrhythmias, cardiac disease, dehydration, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock***Coma, head trauma, increased intracranial pressure, intracranial mass, seizure disorder, seizures***Hepatic disease***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, urinary retention***Infants, neonates***Geriatric***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Adrenal insufficiency, hypothyroidism, myxedema***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['7880', '235379']",pancrelipase,"***For the management of exocrine pancreatic insufficiency, such as in patients with cystic fibrosis, chronic pancreatitis, or other conditions.***For the management of exocrine pancreatic insufficiency due to pancreatectomy.***For enteral feeding tube occlusion�.","***Porcine protein hypersensitivity***Viral infection***Dysphagia, esophageal stricture***Gout, hyperuricemia, renal impairment***Fibrosing colonopathy, GI obstruction, inflammatory bowel disease, surgery***Pregnancy***Breast-feeding***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8704'],prochlorperazine,"***For treatment of nausea/vomiting.***For preoperative nausea control.***For the management of the manifestations of psychotic disorders such as schizophrenia.***For the short-term treatment of non-psychotic anxiety.***For the treatment of intractable, severe migraine� unresponsive to other therapies, or prior to administration of intravenous dihydroergotamine (DHE) to offset DHE-induced nausea.","***Phenothiazine hypersensitivity***Agranulocytosis, neutropenia***Tardive dyskinesia***Neurological disease, Parkinson's disease***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion***Hypotension, orthostatic hypotension***Alcoholism, angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, pulmonary disease, QT prolongation, thyroid disease***Hepatic disease, jaundice***Radiographic contrast administration, seizure disorder***Glaucoma, prostatic hypertrophy, urinary retention***GI obstruction, ileus***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Breast cancer, hyperprolactinemia, infertility***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Children, infants, Reye's syndrome, surgery***Dementia, geriatric, stroke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['135775'],zolmitriptan,***For the acute treatment of migraine with or without aura. <br />        NOTE: Zolmitriptan is not indicated for hemiplegic or basilar migraine.<br />     ***For menstrual migraine prophylaxis�.,"***General Information***Acute myocardial infarction, angina, arteriosclerosis, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, hypercholesterolemia, myocardial infarction, obesity, tobacco smoking, vasospastic angina, Wolff-Parkinson-White syndrome***Hypertension***Cerebrovascular disease, intracranial bleeding, stroke***Colitis, peripheral vascular disease, Raynaud's phenomenon***Phenylketonuria***Basilar/hemiplegic migraine***Geriatric***Renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***GI disease***Driving or operating machinery***MAOI therapy***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6472'],lovastatin,"***For the treatment of primary hypercholesterolemia, specifically hyperlipoproteinemia types IIa or IIb, in patients unresponsive to dietary control.***For slowing the progression of coronary atherosclerosis.***For myocardial infarction prophylaxis (primary prevention).***For slowing the progression of atherosclerosis in patients with carotid artery disease (i.e., stroke prophylaxis�).","***General Information***Alcoholism, cholestasis, hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Electrolyte imbalance, endocrine disease, females, hypotension, hypothyroidism, infection, myopathy, renal disease, renal failure, renal impairment, rhabdomyolysis, seizure disorder, surgery, trauma***Diabetes mellitus***Geriatric***Contraception requirements, pregnancy***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,terbinafine hydrochloride,"***For the treatment of tinea pedis.***For the treatment of tinea cruris or tinea corporis.***For the treatment of tinea capitis.***For the treatment of tinea versicolor due to <em>Malassezia furfur</em>.***For the treatment of onychomycosis.***For the routine treatment of onychomycosis (tinea unguium).***For the treatment of onychomycosis due to <em>Candida parapsilosis�</em>.***For the treatment of refractory bronchopulmonary aspergillosis� due to various <em>Aspergillus</em> sp.�, including <em>Aspergillus fumigatus�</em>, in non-immunocompromised patients.","***General Information***Onychomycosis***Human immunodeficiency virus (HIV) infection, immunosuppression, neutropenia***Pregnancy***Breast-feeding***Anxiety, children, depression, insomnia, suicidal ideation***Hepatic disease, hepatitis, jaundice***Renal failure, renal impairment***Serious rash***Hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['9796'],simethicone,"***For the symptomatic relief of flatulence (gas), functional gastric bloating, and postoperative gas pains.***For enhancing the delineation of upper abdominal anatomy in conjunction with ultrasound imaging.***For the treatment of functional dyspepsia�.***For use prior to gastroscopy to enhance visualization and prior to gastrointestinal radiography� to reduce gas shadows.","***General Information***Breast-feeding***Pregnancy***Phenylketonuria***Hypercalcemia, hypercalciuria***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['274964'],ciclesonide,"***For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis.***For seasonal allergic rhinitis.***For perennial allergic rhinitis.***For the maintenance treatment of asthma as prophylactic therapy.***For patients previously receiving bronchodilators alone.***For patients previously receiving inhaled corticosteroids.***For patients previously receiving oral corticosteroids. <br />          NOTE: The manufacturer recommends that prednisone should be reduced no faster than 2.5 mg/day weekly, beginning after at least 1 week of therapy with ciclesonide. Patients should be carefully monitored for signs of asthma instability, including monitoring of serial objective measures of airflow, and for signs of adrenal insufficiency during steroid taper and following discontinuation of oral corticosteroid therapy.<br />       ***For the maintenance treatment of asthma in children�.***For exercise-induced bronchospasm prophylaxis�.","***Corticosteroid hypersensitivity***Acute bronchospasm, status asthmaticus***Adrenal insufficiency, hypothalamic-pituitary-adrenal (HPA) suppression***Fungal infection, herpes infection, infection, tuberculosis, viral infection***Vaccination***Measles, varicella***Children, growth inhibition, increased intracranial pressure***Infants, neonates, pregnancy***Breast-feeding***Cushing's syndrome***Nasal septal perforation, nasal surgery, nasal trauma***Osteoporosis***Geriatric***Cataracts, glaucoma, increased intraocular pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1895'],rosuvastatin calcium,"***For the treatment of hypercholesterolemia, hyperlipoproteinemia, and/or hypertriglyceridemia as an adjunct to dietary control.***For slowing the progression of atherosclerosis (e.g., carotid, coronary).***For reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglyceride concentrations, and to increase HDL-cholesterol in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson types IIa or IIb); or to treat Fredrickson Type IV (hypertriglyceridemia, increased VLDL); or to treat primary dysbetalipoproteinemia (Type III hyperlipoproteinemia).***For the reduction of total cholesterol, LDL-cholesterol, nonHDL-cholesterol, and apolipoprotein B concentrations in patients with homozygous familial hypercholesterolemia (HoFH).***For the reduction of total cholesterol, LDL-cholesterol, and apolipoprotein B concentrations in pediatric patients with heterozygous familial hypercholesterolemia (HeFH). <br />          NOTE: Rosuvastatin is indicated for patients with HeFH who, after an adequate trial of diet therapy, have LDL-C higher than 190 mg/dL or LDL-C higher than 160 mg/dL and have a positive family history of premature cardiovascular disease or two or more other CVD risk factors.<br />       ***For primary prevention of cardiovascular disease including myocardial infarction prophylaxis and stroke prophylaxis, and to reduce the risk of arterial revascularization procedures in patients without evidence of coronary heart disease but who have risk factors for cardiovascular disease. <br />  NOTE: Increased risk of cardiovascular disease is based on age (50 years and older in men and 60 years and older in women), elevated C-reactive protein concentrations (&gt;= 2mg/L), and the presence of at least one additional cardiovascular disease risk factor (e.g.,hypertension, low HDL-C concentrations, smoking, or family history of premature coronary heart disease).<br /","***General Information***Alcoholism, hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Electrolyte imbalance, endocrine disease, females, hypotension, hypothyroidism, infection, myopathy, organ transplant, renal disease, renal failure, renal impairment, rhabdomyolysis, seizure disorder, surgery, trauma***Asian patients***Diabetes mellitus***Pregnancy***Contraception requirements, reproductive risk***Breast-feeding***Geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['61381'],olanzapine,"***For the treatment of schizophrenia.***For use  in combination with fluoxetine for treatment-resistant depression.***For the treatment of bipolar disorder (bipolar I disorder), including mania or mixed episodes.***For the treatment of acute agitation associated with schizophrenia or bipolar mania.***For the adjunct treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in combination with fluoxetine.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.***Formoterol***Formoterol; Mometasone","***Risk of serious hypersensitivity reactions or anaphylaxis, serious rash***Agranulocytosis, hematological disease, leukopenia, neutropenia***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion, post-injection delirium/sedation syndrome***Seizure disorder, seizures***Suicidal ideation***Tardive dyskinesia***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, thyroid disease***Hepatic disease***Anticholinergic medications, closed-angle glaucoma, ileus, prostatic hypertrophy, urinary retention***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, obesity***Diabetes mellitus, diabetic ketoacidosis, hyperglycemia***Dysphagia***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Breast cancer, hyperprolactinemia, infertility***Neonates, pregnancy, pregnancy testing***Breast-feeding***Tobacco smoking***Asian patients***Abrupt discontinuation***Children, infants***Phenylketonuria***Intravenous administration, subcutaneous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8588'],diclofenac potassium,"***For the treatment of osteoarthritis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the treatment of rheumatoid arthritis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the treatment of ankylosing spondylitis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the acute treatment of migraine with or without aura. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />NOTE: Diclofenac is not indicated for migraine prophylaxis***For the treatment of mild pain or moderate pain. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For primary dysmenorrhea or for mild or moderate pain associated with nonrheumatic inflammatory conditions, bone pain�, arthralgia�, myalgia�, and vascular or migraine headache�. <br />          NOTE: Voltaren XR is not indicated for the management of acute painful conditions.<br />       ***For the treatment of acute mild or moderate pain.***For the topical treatment of acute mild pain or moderate pain due to minor strains, sprains, and contusions. <br />          NOTE: Carefully consider the potential benefits and risks of the diclofenac patch. If the patch will be used, use the lowest effective dose for the shortest possible duration.<br />       ***For the treatment of postoperative ocular inflammation following cataract extraction.***For the reduction of photophobia and ocular pain following corneal refractive surgery.***For the treatment of moderate to severe pain alone or in combination with opioid analgesics.***For the treatment of actinic keratosis.***For the prevention of heterotopic ossification�.***Formoterol; Mometasone","***Acute bronchospasm, asthma, bovine protein hypersensitivity, gelatin hypersensitivity, nasal polyps, NSAID hypersensitivity, polysorbate 80 hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Contact lenses, ocular surgery, rheumatoid arthritis***Anemia***Dental disease, dental work***Hepatic disease, jaundice, porphyria***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, renal impairment, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Labor, pregnancy***Breast-feeding***Burns, eczema, exfoliative dermatitis, heating pad, occlusive dressing, ocular exposure, skin abrasion***Benzyl alcohol hypersensitivity, sunlight (UV) exposure***Coronary artery bypass graft surgery (CABG)***Accidental exposure***Phenylketonuria***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amantadine hydrochloride,"***For the treatment of idiopathic parkinsonism or Parkinson's disease.***For the treatment of dyskinesia associated with Parkinson's disease in patients receiving levodopa-based therapy, with or without concomitant dopaminergic medications.***For the treatment of drug-induced extrapyramidal symptoms (EPS).***For the treatment of uncomplicated influenza A virus infection.***For seasonal influenza prophylaxis for infections due to influenza A virus.***For the treatment of chorea associated with Huntington's Disease (Huntington's Chorea)�.***For the treatment of multiple-sclerosis associated fatigue�.***For the treatment of neuroleptic malignant syndrome�.","***General Information***Amantadine hypersensitivity, rimantadine hypersensitivity***Dialysis, renal failure, renal impairment***Heart failure, orthostatic hypotension, peripheral edema, syncope***Seizure disorder***Depression, psychosis, schizophrenia, substance abuse, suicidal ideation***Impulse control symptoms***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion, narcolepsy, sleep apnea***Hepatic disease***Eczema***Closed-angle glaucoma***Melanoma***Abrupt discontinuation***Pregnancy***Infertility***Breast-feeding***Anticholinergic medications, geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,erythromycin ethylsuccinate,"***For the treatment of acne vulgaris.***For mild to moderately severe lower respiratory tract infections (e.g., pneumonia, bronchitis) caused by susceptible organisms.***For the treatment of Legionnaire's disease (caused by <em>Legionella pneumophila</em>).***For the treatment of mild to moderately severe upper respiratory tract infections (e.g., pharyngitis, tonsillitis), including group A beta-hemolytic streptococcal (GAS) pharyngitis (primary rheumatic fever prophylaxis).***For upper respiratory tract infections and GAS pharyngitis (primary rheumatic fever prophylaxis).***For prevention of recurrent attacks of rheumatic fever (i.e., secondary rheumatic fever prophylaxis).***For the treatment of listeriosis.***For the treatment of chlamydia infection and non-gonococcal urethritis.***For the treatment of non-gonococcal urethritis (NGU) or chlamydial infections including urogenital infections (urethritis, cervicitis, proctitis) and infant pneumonia.***For the treatment of chlamydial conjunctivitis or ophthalmia neonatorum caused by <em>Chlamydia trachomatis</em>.***For the treatment of lymphogranuloma venereum� caused by <em>Chlamydia trachomatis</em>.***For the prevention of ophthalmia neonatorum (i.e., ophthalmia neonatorum prophylaxis) due to <em>Neisseria gonorrhoeae</em><em> </em>or<em> Chlamydia trachomatis</em>.***For the treatment of pneumonia caused by <em>Chlamydia trachomatis</em> in neonates and infants.***For the adjunctive treatment of diphtheria to prevent establishment of carrier state and for <em>Corynebacterium diphtheriae</em> bacterial colonization eradication.***For the treatment of close contacts of patients with diphtheria (i.e., diphtheria prophylaxis�).***For the treatment of acute pelvic inflammatory disease (PID).***For acute pelvic inflammatory disease (PID) caused by <em>Neisseria gonorrhoeae</em>.***For the treatment of pertussis (whooping cough) caused by <em>Bordetella pertussis</em> or for postexposure pertussis prophylaxis. <br />  NOTE: For postexposure prophylaxis, administer to close contacts within 3 weeks of exposure, especially in high-risk patients (e.g., women in third trimester, infants &lt; 12 months).<br /***For the treatment of primary syphilis (caused by <em>Treponema pallidum</em>) in penicillin-allergic, nonpregnant patients.***For bowel preparation in combination with neomycin in patients undergoing colorectal surgery.***For the treatment of superficial ophthalmic infection involving the conjunctiva and/or cornea.***For the treatment of chancroid� due to <em>Haemophilus ducreyi</em>.***For the treatment of disseminated gonorrhea�. <br />  NOTE: Erythromycin is not recommended in adults, adolescents, or children 8 years and older or in patients weighing 45 kg or more due to resistance of N. gonorrheae against erythromycin in the United States. Single-dose azithromycin in combination with ceftriaxone is the preferred therapy in these populations. <br /***For the facilitation of gastric emptying in patients with delayed gastrointestinal motility  (e.g., gastroparesis�).***For the treatment of idiopathic or postsurgical gastroparesis� or diabetic gastroparesis�.***For the facilitation of gastric emptying� in patients with feeding intolerance�.***For the treatment of early Lyme disease�.***For the treatment of skin and skin structure infections including impetigo and burn wound infection�.***For the treatment of erythrasma (caused by <em>Corynebacterium minutissimum</em>).***For the treatment of tetanus� (caused by <em>Clostridium tetani</em>) when penicillin or tetracycline is contraindicated or not tolerated.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of cholera�.***For the treatment of bartonellosis� (<em>Bartonella bacilliformis)</em> and other <em>Bartonella sp.</em>� infections in HIV-infected patients.***For the treatment of angiomatosis infections�, peliosis hepatis�, bacteremia�, and osteomyelitis� caused by <em>Bartonella sp.</em>�.***For long term suppression� of infections caused by <em>Bartonella sp.</em>� in HIV-infected patients with relapse or reinfections with < 200 CD4 cells/mm3.***For pneumococcal prophylaxis� in penicillin-allergic patients with sickle cell disease�.***For the treatment of infantile acne�.***For the oral treatment of infantile acne.***For the topical treatment of infantile acne.***Formoterol***Formoterol; Mometasone","***General Information***Viral infection***Macrolide hypersensitivity***Hepatic disease***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Hearing impairment***Benzyl alcohol hypersensitivity, neonates***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Seizure disorder***Myasthenia gravis***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4493']['61381'],fluoxetine/olanzapine,***For acute and maintenance treatment of treatment-resistant depression.***For the acute treatment of bipolar depression associated with Bipolar I Disorder.***Formoterol***Formoterol; Mometasone,"***General Information***MAOI therapy***Bradycardia, cardiac arrhythmias, cardiac disease, cerebrovascular disease, electrolyte imbalance, heart failure, hypokalemia, hypomagnesemia, hypovolemia, myocardial infarction, orthostatic hypotension, poor metabolizers, QT prolongation, syncope, tachycardia, ventricular arrhythmias***Neurological disease, Parkinson's disease***Dysphagia***Diabetes mellitus, obesity***Anticoagulant therapy, bleeding, thrombolytic therapy***Hyponatremia***Hepatic disease, hepatitis, jaundice***Tardive dyskinesia***Abrupt discontinuation***Electroconvulsive therapy (ECT), seizure disorder, seizures***Renal disease, renal failure, renal impairment***Anorexia nervosa***Anticholinergic medications, ileus, prostatic hypertrophy, urinary retention***Mania***Children, suicidal ideation***Agranulocytosis, fever, hematological disease, leukopenia, neutropenia***Neonates, pregnancy, pregnancy testing***Breast-feeding***Breast cancer, hyperprolactinemia, infertility***CNS depression, coma, driving or operating machinery, ethanol ingestion***Dementia, geriatric, stroke***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Surgery***Tobacco smoking***Bone fractures, osteoporosis***Closed-angle glaucoma, increased intraocular pressure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['43611'],latanoprost,***For use as a first-line agent for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.,"***Closed-angle glaucoma***Aphakia***Sunlight (UV) exposure***Iritis, uveitis***Contact lenses***Corneal abrasion, keratitis, ocular infection, ocular surgery, ocular trauma***Pregnancy***Breast-feeding***Children***Hepatic disease, renal disease, renal failure, renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,haemophilus b conjugate vaccine (tetanus toxoid conjugate),***For Haemophilus influenzae type b prophylaxis.,"***Intravenous administration***Latex hypersensitivity***Infants, neonates, premature neonates***Pregnancy***Breast-feeding***Agammaglobulinemia, corticosteroid therapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, leukemia, lymphoma, neoplastic disease, severe combined immunodeficiency (SCID)***Guillain-Barre syndrome***Fever, infection***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Native American patients",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hyoscyamine sulfate/methenamine/methylene blue/phenyl salicylate/sodium phosphate monobasic,"***For the treatment of symptoms of irritative voiding including for the relief of local urinary symptoms such as inflammation, hypermotility, and mild pain, which accompany lower urinary tract infection (UTI); also for the relief of urinary tract symptoms caused by diagnostic procedures.***Formoterol; Mometasone","***General Information***Salicylate hypersensitivity***Cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, mitral stenosis***GI obstruction***Glaucoma***Myasthenia gravis***Prostatic hypertrophy, urinary retention, urinary tract obstruction***Dehydration, renal disease, renal failure, renal impairment***Hepatic disease***MAOI therapy***Children, infants, neonates***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,beclomethasone dipropionate,***For the maintenance treatment of asthma as prophylactic therapy.***For relief of seasonal or perennial allergic rhinitis.***For relief of vasomotor rhinitis (nonallergic rhinitis).***For the prevention of recurrence of nasal polyps after surgical removal.***For the maintenance treatment of chronic obstructive pulmonary disease (COPD)� such as chronic bronchitis� or emphysema�.***For exercise-induced bronchospasm prophylaxis�.,"***General Information***Acute bronchospasm, status asthmaticus***Paradoxical bronchospasm***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, surgery***Fungal infection, herpes infection, infection, measles, tuberculosis, varicella, viral infection***Malnutrition, osteoporosis, tobacco smoking***Nasal septal perforation, nasal surgery, nasal trauma***Infants, neonates, pregnancy***Breast-feeding***Children, growth inhibition, increased intracranial pressure***Diabetes mellitus, hyperglycemia***Cataracts, glaucoma, increased intraocular pressure, ocular exposure, visual disturbance***Corticosteroid hypersensitivity***Depression, psychosis, suicidal ideation***Hepatic disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['34132'],pegaspargase,***For first line therapy of acute lymphocytic leukemia (ALL) in combination with other chemotherapeutic agents and for ALL treatment in combination with other chemotherapy agents in patients who have developed hypersensitivity reactions to native forms of L-asparaginase. <br />        NOTE: Pegaspargase has been designated an orphan drug by the FDA for this indication.<br />     ***Formoterol; Mometasone,"***General Information***Acute bronchospasm, E. coli protein hypersensitivity, hypotension, urticaria***Pancreatitis***Bleeding***Thromboembolic disease***Hyperglycemia***Coagulopathy***Hepatotoxicity***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['6923', '203002']",metyrapone,***For hypothalamic-pituitary-adrenal (HPA) suppression diagnosis.***For the treatment of Cushing's syndrome�.***Formoterol; Mometasone,"***General Information***Adrenal insufficiency***Hyperthyroidism, hypothyroidism***Driving or operating machinery***Geriatric***Pregnancy***Breast-feeding***Corticosteroid therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['161']['7804'],acetaminophen/oxycodone,"***For the treatment of moderate pain to moderately-severe pain.***For the treatment of acute pain severe enough to require opioid treatment and for which alternative treatment options (e.g., non-opioid analgesics) are inadequate.","***General Information***Acetaminophen hypersensitivity, opiate agonist hypersensitivity, sulfite hypersensitivity***Acute abdomen, constipation, dysphagia, esophageal stricture, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Accidental exposure, asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Abrupt discontinuation***Substance abuse***CNS depression, head trauma, increased intracranial pressure, intracranial mass, psychosis***Cardiac arrhythmias, cardiac disease, hypotension, hypovolemia, orthostatic hypotension***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, renal impairment, urethral stricture, urinary retention***Alcoholism, hepatic disease, hepatitis, hepatotoxicity, potential for overdose or poisoning***Geriatric***Children, infants, neonates***G6PD deficiency***Bone marrow suppression, immunosuppression, infection***Driving or operating machinery***Biliary tract disease, pancreatitis***Adrenal insufficiency, hypothyroidism, myxedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,megestrol acetate,"***For the treatment of anorexia, cachexia, or unexplained weight loss in patients with acquired immunodeficiency syndrome (AIDS).***For the palliative treatment of advanced, inoperable, recurrent metastatic breast cancer.***For the palliative treatment of advanced, inoperable, recurrent metastatic endometrial cancer.***For the treatment of advanced hormone-refractory prostate cancer�.***For the for the treatment of metastatic renal cell cancer�.***For the treatment of endometriosis�-associated pain�.***For the treatment of hot flashes� in women with a history of breast cancer or in men with prostate cancer who have undergone androgen-deprivation therapy.","***General Information***Dysfunctional uterine bleeding, females, vaginal bleeding***Breast cancer, neoplastic disease***Adrenal insufficiency, Cushing's syndrome, diabetes mellitus, hyperglycemia, hypotension, hypothalamic-pituitary-adrenal (HPA) suppression, infection, surgery, vomiting***Thromboembolic disease, thrombophlebitis***Hepatic disease***Pregnancy***Breast-feeding***Children***Renal failure, renal impairment***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/ferrous fumarate/norethindrone acetate,"***For routine contraception.***For the treatment of moderate acne vulgaris related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Pregnancy***Gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Diabetes mellitus***Hyperlipidemia, hyperlipoproteinemia, hypertriglyceridemia, pancreatitis***Systemic lupus erythematosus (SLE)***Surgery***Asthma, headache, hypertension, migraine, seizure disorder***Depression***Contact lenses, glaucoma, visual disturbance***Breast cancer***Hypercalcemia, hypocalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Obesity***Chloasma***Angioedema, hereditary angioedema***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ciprofloxacin hydrochloride,"***For the treatment of urinary tract infection (UTI), including acute uncomplicated cystitis and pyelonephritis.***For the treatment of acute, uncomplicated UTI (acute cystitis).***For the treatment of mild to moderate UTIs and for the treatment of severe and/or complicated UTIs, including pyelonephritis.***For the treatment of lower respiratory tract infections, including bronchitis, community-acquired pneumonia (CAP), and nosocomial pneumonia. <br />        NOTE: Ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. <br />     ***For the treatment of nosocomial, ventialator-associated pneumonia (VAP) or hospital-acquired pneumonia (HAP).***For the treatment of community-acquired pneumonia (CAP).***For the treatment of acute exacerbations of chronic bronchitis.***For the treatment of skin and skin structure infections, including diabetic foot ulcer, surgical incision site infections, animal bite wounds, and necrotizing infections.***For the treatment of diabetic foot ulcer.***For the treatment of surgical incision site infections.***For the treatment of animal bite wounds.***For the treatment of necrotizing infections of the skin, fascia, and muscle.***For the treatment of enteric infections, including acute gastroenteritis and infectious diarrhea.***For the treatment of uncomplicated gonorrhea (e.g., cervicitis and urethritis).***For the treatment of mild to moderate acute sinusitis.***For the treatment of prostatitis caused by susceptible organisms.***For acute prostatitis�.***For chronic bacterial prostatitis.***For the treatment of complicated intraabdominal infections in combination with metronidazole.***For empiric treatment of patients with febrile neutropenia as part of combination therapy.***For febrile neutropenia in adults.***For febrile neutropenia in pediatric patients�.***For the treatment of bacterial conjunctivitis.***For the treatment of ophthalmic infection associated with corneal ulcer.***For anthrax prophylaxis after exposure to Bacillus anthracis (postexposure prophylaxis, PEP).***For the treatment of plague infection.***For treatment in a contained casualty setting.***For treatment in a mass casualty setting.***For plague prophylaxis following exposure to <em>Yersinia pestis</em>.***For the treatment of acute otitis externa due to susceptible isolates of <em>Pseudomonas aeruginosa</em> or <em>Staphylococcus aureus</em>.***For the treatment of bone and joint infections (i.e., osteomyelitis, prosthetic joint infections, infectious arthritis).***For the treatment of bilateral otitis media with effusion in pediatric patients undergoing tympanostomy tube placement.***For the treatment of typhoid fever due to <em>Salmonella typhi</em>.***For the treatment of shigellosis.***For the treatment of campylobacteriosis.***For the treatment of acute systemic brucellosis� caused by <em>Brucella melitensis</em>.***For the treatment of chancroid� due to <em>Haemophilus ducreyi</em>.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of <em>Neisseria meningitidis</em>� nasal carrier state (i.e., for meningococcal infection prophylaxis�).***For the treatment of dental infection�, including dentoalveolar infection� and periodontitis�.***For adult chronic periodontitis� after scaling and root planing.***For adult refractory chronic periodontitis� in combination with metronidazole after scaling and root planing in beta-lactam allergic patients.***For the treatment of anthrax�.***For the treatment of cutaneous anthrax.***For the treatment of systemic anthrax infection.***For the treatment of cholera�.***For the treatment of tularemia� infection or for postexposure tularemia prophylaxis�.***For an individual patient� or in a contained casualty setting�. <br />          NOTE: Streptomycin is the drug of choice to treat tularemia in most patients; gentamicin is the preferred agent in pregnant women.<br />       ***For a mass casualty setting� and for tularemia prophylaxis� after exposure to <em>Francisella tularensis</em>. <br />          NOTE: Doxycycline is the treatment of choice for tularemia in the most patients. Ciprofloxacin is the drug of choice for pregnant women; if ciprofloxacin is contraindicated, doxycycline should be used.<br />       ***For use as maintenance treatment of melioidosis� due to <em>Burkholderia pseudomallei�</em>.***For surgical infection prophylaxis�.***For the treatment of acute pulmonary exacerbations in cystic fibrosis� (CF) patients.***For bacterial infection prophylaxis� in patients with cirrhosis and GI bleeding.***For the treatment of CAPD-associated peritonitis�.***For the treatment of exit-site� and tunnel infections� in CAPD patients.***For the treatment of infective endocarditis�.***For the treatment of Mycobacterium avium complex infection� (MAC) in HIV-infected patients.***For the treatment of salmonellosis�.***For the treatment of moderate or severe traveler's diarrhea�.***For the treatment of isosporiasis� (<em>Isospora belli</em>) in HIV-infected patients.***For the treatment of sepsis�.","***Viral infection***Quinolone hypersensitivity***Corticosteroid therapy, organ transplant, tendinitis, tendinopathy, tendon pain, tendon rupture***Alcoholism, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Cerebrovascular disease, neurotoxicity, peripheral neuropathy, seizure disorder***Myasthenia gravis***Diabetes mellitus***Dialysis, renal disease, renal failure, renal impairment***Dehydration***Hepatic disease, hepatitis, hepatotoxicity, jaundice***Sunlight (UV) exposure***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Sexually transmitted disease***Geriatric***Children, infants, neonates***Contact lenses***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pilocarpine hydrochloride,"***For the treatment of increased intraocular pressure (IOP) in patients with glaucoma or ocular hypertension or for the prevention of increased IOP associated with laser surgery.***For the treatment of open-angle glaucoma or ocular hypertension.***For treatment of acute angle-closure glaucoma. <br />          NOTE: Prior to treatment with pilocarpine ophthalmic solution, secretory suppressants and hyperosmotic agents may be needed to lower intraocular pressure below 50 mmHg and relieve iris ischemia.<br />       ***For the prevention of increased intraocular pressure associated with laser surgery.***For miosis induction.***For the treatment of xerostomia and/or xerophthalmia�.***For xerostomia due to salivary gland hypofunction secondary to radiotherapy for cancer of the head and neck.***For xerostomia and/or xerophthalmia� in patients with Sjogren's syndrome.","***General Information***Retinal detachment***Closed-angle glaucoma***Iritis***Contact lenses***Asthma, bronchitis, chronic obstructive pulmonary disease (COPD), sulfite hypersensitivity***Pregnancy***Breast-feeding***Biliary tract disease, cholelithiasis***Hepatic disease***Cardiac disease***Nephrolithiasis***Psychosis***Driving or operating machinery***Children, infants, neonates, uveitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ketamine hydrochloride,"***For general anesthesia induction. <br />        NOTE: As with other general anesthetic agents, the individual response to ketamine is somewhat varied depending on the dose, administration route, and patient age; dosage recommendations cannot be absolutely fixed. Titrate the ketamine dose according to the patient's requirements.<br />NOTE: Ketamine hydrochloride injection is indicated as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. Ketamine hydrochloride injection is best suited for short procedures but it can be used, with additional doses, for longer procedures.<br />NOTE: Ketamine is clinically compatible with the commonly used general and local anesthetic agents when an adequate respiratory exchange is maintained. The regimen of a reduced dose of ketamine supplemented with diazepam can be used to produce balanced anesthesia by combination with other agents such as nitrous oxide and oxygen***For general anesthesia maintenance. <br />  NOTE: As with other general anesthetic agents, the individual response to ketamine is somewhat varied depending on the dose, administration route, and patient age; dosage recommendations cannot be absolutely fixed. Titrate the ketamine dose according to the patient's requirements. Adjust the maintenance dose according to the patient's anesthetic needs and whether an additional anesthetic agent is employed.<br />NOTE: Purposeless and tonic-clonic movements of extremities may occur during the course of anesthesia. These movements do not imply a light plane and are not indicative of the need for additional doses of the anesthetic***For procedural sedation� during minor procedures.***For the treatment of acute respiratory failure� associated with refractory acute bronchospasm� due to respiratory syncytial virus (RSV) infection�, pneumonia�, or status asthmaticus� in patients who are mechanically ventilated. <br />        NOTE: Adjunctive treatment of a moderately severe asthma exacerbations with ketamine did not cause significant clinical improvement in either adults (bolus of 0.1 mg/kg and infusion of 0.5 mg/kg/hour for 3 hours) or children (bolus of 0.2 mg/kg and infusion of 0.5 mg/kg/hour for 2 hours) who were treated in the emergency department and were not intubated. <br />     ***For the treatment of refractory severe pain�.***For use in treatment-resistant depression� in adult patients.","***General Information***Angina, cardiac disease, coronary artery disease, dehydration, glaucoma, head trauma, heart failure, hypertension, hypovolemia, increased intracranial pressure, increased intraocular pressure, intracranial bleeding, intracranial mass, myocardial infarction, ocular surgery, ocular trauma, stroke***Driving or operating machinery, females***Alcoholism, ethanol intoxication***Intravenous administration***Pain***Psychosis, schizophrenia***Substance abuse***Thyrotoxicosis***Head and neck anesthesia***Vomiting***Labor, obstetric delivery, pregnancy***Breast-feeding***Geriatric***Children, infants, neonates***Porphyria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4492'],fluorouracil,"***For the treatment of colorectal cancer. <br />        NOTE: Dosage should be based upon body surface area using actual body weight unless patient is obese or has significant fluid retention. In these cases the dose should be based upon the ideal weight or dry weight.<br />NOTE: Fluorouracil has been given in a large number of different dosages and schedules. The correct dose of fluorouracil will vary from protocol to protocol. Clinicians should consult the appropriate references to verify the dose***For the adjuvant treatment of colon cancer in combination with leucovorin (Roswell Park)�.***For adjuvant treatment of high-risk stage II or stage III rectal cancer in combination with radiation therapy.***For the treatment of metastatic colorectal cancer in combination with irinotecan and leucovorin, with or without bevacizumab (FOLFIRI with or without bevacizumab)�. <br />          NOTE: Both bevacizumab and irinotecan are FDA approved for the treatment of metastatic colorectal cancer in combination with leucovorin and 5-FU.<br />NOTE: Outside of a clinical trial, irinotecan should only be given in combination with weekly 5-FU/leucovorin bolus regimens or continuous infusion 5-FU/leucovorin as listed below. Use of irinotecan in combination with 5-FU/leucovorin regimens administered for 4 to 5 consecutive days every 4 weeks are not recommended due to an increased risk of toxicity, including death; use of these regimens should be limited to controlled clinical trials***For the treatment of advanced colorectal cancer in combination with leucovorin (LV) and oxaliplatin with or without bevacizumab (FOLFOX4 with or without bevacizumab)�. <br />          NOTE: Bevacizumab is FDA approved for the treatment of metastatic colorectal cancer in combination with 5-FU based chemotherapy and oxaliplatin is FDA approved for advanced colorectal cancer in combination with infusional 5-FU and leucovorin.<br />       ***For the treatment of metastatic colorectal cancer in combination with leucovorin, irinotecan, and bevacizumab (IFL plus bevacizumab)�. <br />          NOTE: Bevacizumab is FDA approved for the treatment of metastatic colorectal cancer, in combination with leucovorin, 5-FU, and irinotecan (IFL)<br />       ***For the adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor, in combination with leucovorin and oxaliplatin (FOLFOX4)�. <br />          NOTE: Oxaliplatin is FDA approved for the adjuvant treatment of colorectal cancer in combination with 5-FU and leucovorin.<br />       ***For the treatment of metastatic colorectal cancer in combination with leucovorin and oxaliplatin, with or without bevacizumab (mFOLFOX6 with or without bevacizumab)�. <br />          NOTE: Bevacizumab is FDA approved for the treatment of metastatic colorectal cancer in combination with 5-FU based chemotherapy and oxaliplatin is FDA approved for advanced colorectal cancer in combination with infusional 5-FU and leucovorin.<br />       ***For the adjuvant treatment of colon cancer in combination with leucovorin (Mayo Clinic)�.***For the adjuvant treatment of colorectal cancer, in combination with leucovorin and oxaliplatin (mFOLFOX6)�. <br />          NOTE: Oxaliplatin is FDA approved for the adjuvant treatment of colorectal cancer in combination with 5-FU and leucovorin.<br />       ***For the adjuvant treatment of colorectal cancer, in combination with leucovorin and oxaliplatin (FLOX)�. <br />          NOTE: Oxaliplatin is FDA approved for the adjuvant treatment of colorectal cancer in combination with 5-FU and leucovorin.<br />       ***For the first line treatment of metastatic colorectal cancer in combination with leucovorin, oxaliplatin, and panitumumab in patients with wild-type KRAS (exon 2 in codons 12 or 13) (FOLFOX4 plus panitumumab)�. <br />          NOTE: Panitumumab is FDA approved for the treatment of metastatic colorectal cancer in combination with FOLFOX chemotherapy, and oxaliplatin is FDA approved for advanced colorectal cancer in combination with infusional 5-FU and leucovorin.<br />       ***For the first line treatment of metastatic colorectal cancer in combination with leucovorin, oxaliplatin, and panitumumab in patients with wild-type KRAS (exon 2 in codons 12 or 13) (mFOLFOX6 plus panitumumab)�. <br />          NOTE: Panitumumab is FDA approved for the treatment of metastatic colorectal cancer in combination with FOLFOX chemotherapy, and oxaliplatin is FDA approved for advanced colorectal cancer in combination with infusional 5-FU and leucovorin.<br />       ***For the first-line treatment of KRAS wild-type, EGFR-expressing metastatic colorectal cancer in combination with leucovorin and irinotecan, in combination with cetuximab (FOLFIRI plus cetuximab)�. <br />          NOTE: Cetuximab is FDA approved for the treatment of�KRAS wild-type, EGRF-expressing metastatic colorectal cancer in combination with FOLFIRI.<br />       ***For the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC), in combination with cetuximab, leucovorin, and oxaliplatin (mFOLFOX6 plus cetuximab)�. <br />          NOTE: Response rates to cetuximab do not correlate with either the percentage of EGFR-positive cells or the intensity of EGFR expression.<br />       ***For the first line treatment of advanced colorectal cancer in combination with irinotecan and oxaliplatin-based chemotherapy (FOLFOXIRI)�.***For the treatment of gastric cancer. <br />        NOTE: Dosage should be based upon body surface area using actual body weight unless patient is obese or has significant fluid retention. In these cases the dose should be based upon the ideal weight or dry weight.<br />     ***For the treatment of<strong>***For the perioperative treatment of gastric cancer in combination with epirubicin and cisplatin�.***For the treatment of breast cancer. <br />        NOTE: Dosage should be based upon body surface area using actual body weight unless patient is obese or has significant fluid retention. In these cases the dose should be based upon the ideal weight or dry weight.<br />     ***For the treatment of breast cancer in patients with evidence of axillary node involvement following resection of the primary tumor in combination with cyclophosphamide and epirubicin.***For the neoadjuvant treatment of HER2-positive breast cancer with fluorouracil and cyclophosphamide (FEC regimen) in sequence, and in combination, with paclitaxel and trastuzumab�.***For the treatment of metastatic breast cancer in combination with epirubicin and cyclophosphamide.***For the adjuvant treatment of early breast cancer, in combination with methotrexate and cyclophosphamide (CMF)�.***For the treatment of actinic keratosis (solar keratosis).***For the treatment of superficial basal cell carcinoma.***For the treatment of anal cancer�.***For the treatment of anal cancer in combination with mitomycin and radiation therapy.***For the treatment of anal cancer in combination with cisplatin and radiation therapy.***For the treatment of pancreatic cancer�. <br />        NOTE: Dosage should be based upon body surface area using actual body weight unless patient is obese or has significant fluid retention. In these cases the dose should be based upon the ideal weight or dry weight.<br />     ***For the treatment of pancreatic cancer in combination with other chemotherapy agents.***For the second-line treatment of gemcitabine-refractory advanced pancreatic cancer in combination with oxaliplatin�.***For the first-line treatment of metastatic pancreatic cancer� in combination with oxaliplatin, leucovorin, and irinotecan (FOLFIRINOX).***For the treatment of head and neck cancer�. <br />        NOTE: Dosage should be based upon body surface area using actual body weight unless patient is obese or has significant fluid retention. In these cases the dose should be based upon the ideal weight or dry weight.<br />     ***For the treatment of advanced or recurrent head and neck cancer in combination with cisplatin�.***For the treatment of advanced nasopharyngeal head and neck cancer in combination with cisplatin and radiotherapy�.***For induction treatment of inoperable locally advanced squamous cell head and neck cancer in combination with docetaxel and cisplatin�. <br />          NOTE: Docetaxel is FDA-approved for this indication.<br />       ***For induction treatment of locally advanced squamous cell head and neck cancer in combination with docetaxel and cisplatin for unresectable disease, low surgical cure, or organ preservation�. <br />  NOTE: Docetaxel is FDA-approved for this indication.<br />NOTE: Survival was significantly improved among patients who got the 3 drugs (see Dosage below) as compared with receipt of only cisplatin 100 mg/m2 IV on day 1 and 5- fluorouracil 1000 mg/m2/day by continuous IV infusion for 5 days. Specifically, the relative risk of death was 30% lower. Also, the median overall survival was 70.6 months as compared with 30.1 months for patients receiving only cisplatin and 5-fluorouracil. Three to 8 weeks after the start of the last cycle, all patients in both treatment arms who did not have progressive disease got carboplatin (AUC 1.5 weekly for 7 doses) and radiation therapy (2 Gy per day, 5 days per week for 7 weeks) followed by surgery, if appropriate***For the treatment of advanced-stage squamous cell carcinoma of the head and neck in combination with carboplatin and radiation therapy�.***For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in combination with carboplatin�.***For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck cancer in combination with carboplatin and cetuximab�.***For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck cancer in combination with cisplatin and cetuximab�.","***General Information***Bleeding, bone marrow suppression, infection, leukopenia, radiation therapy, thrombocytopenia***Diarrhea, GI bleeding, malnutrition, stomatitis, vomiting***Dihydropyrimidine dehydrogenase (DPD) deficiency, renal impairment***Biliary tract disease, hepatic disease, jaundice***Accidental exposure, ocular exposure***Occlusive dressing, skin abrasion***Sunlight (UV) exposure***Pregnancy***Breast-feeding***Intrathecal administration***Vaccination***Dental disease, dental work***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['119771'],doripenem,"***For the treatment of complicated intraabdominal infections.***For the treatment of complicated urinary tract infection (UTI), including pyelonephritis, and in patients with concurrent bacteremia.***For the treatment of sepsis�.","***Viral infection***Carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Seizure disorder, stroke***Renal disease, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Children***Geriatric***Administration via nebulizer, respiratory infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,immune globulin intravenous (human),"***For hepatitis A prophylaxis.***For postexposure prophylaxis.***For patients traveling to regions that have high or intermediate hepatitis A endemicity.***For measles prophylaxis to prevent or modify measles in an unvaccinated patient who has not previously had measles and who was exposed within the past 6 days. <br />  NOTE: For most persons 12 months and older who are exposed to measles, use of MMR or measles vaccine within 72 hours of exposure is preferred to using immune globulin (except pregnant women and others for whom the vaccine is contraindicated). Any person exposed to measles who lacks evidence of measles immunity and to whom immune globulin (IG) is administered should subsequently receive MMR vaccine but not earlier than 6 months after IMIG administration or 8 months after IGIV administration (provided the vaccine is not contraindicated).<br /***For varicella (chickenpox) infection prophylaxis.***For rubella prophylaxis in exposed, susceptible pregnant women who will not consider a therapeutic abortion. <br />        NOTE: The routine use of IMIG for rubella prophylaxis in early pregnancy is of dubious value and cannot be justified.<br />     ***For immunoglobulin deficiency. <br />  NOTE: Immune globulin may prevent serious infection in patients with immunoglobulin deficiencies if circulating IgG concentrations of approximately 200 mg/100 mL plasma are maintained.<br /","***Intravenous administration***Pregnancy***Breast-feeding***Agammaglobulinemia, hypogammaglobulinemia, IgA deficiency***Viral infection***Anticoagulant therapy, bleeding, coagulopathy, hemophilia, thrombocytopenia***Vaccination***Children***Coronary artery disease, geriatric, heart failure, hypertriglyceridemia, hyponatremia, obesity, thromboembolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8588'],amoxicillin/clavulanate potassium,"***For the treatment of acute otitis media (AOM). <br />  NOTE: Amoxicillin; clavulanic acid is the preferred initial therapy for children who have received amoxicillin within the past 30 days, who have concurrent conjunctivitis, or those for whom coverage of beta-lactamase-positive H. influenzae and M. catarrhalis is desired.<br /***For the treatment of sinusitis . <br />  NOTE: Amoxicillin; clavulanic acid is recommended by the Infectious Diseases Society of America (IDSA) as the first-line initial empiric therapy in adults and children with acute bacterial rhinosinusitis. The American Academy of Pediatrics (AAP) recommends amoxicillin; clavulanic as initial therapy for all patients presenting with moderate to severe illness, all children younger than 2 years, children attending daycare, and those who have been recently treated with antibiotics.<br /***For the treatment of lower respiratory tract infections (e.g., pneumonia and community-acquired pneumonia).***For the treatment of skin and skin structure infections, including impetigo.***For the treatment of urinary tract infection (UTI), including cystitis.***For the treatment of dental infection�, including dentoalveolar infection�, periodontitis�, and pericoronitis�.***For adolescent aggressive periodontitis� or adult refractory chronic periodontitis� after scaling and root planing.***For pericoronitis�.***For the treatment of actinomycotic mycetoma� caused by susceptible strains of <em>Nocardia brasiliensis</em>.***For use as oral maintenance therapy in the treatment of melioidosis� due to <em>Burkholderia pseudomallei�</em>.***For the empiric treatment of febrile neutropenia� in low risk patients.","***General Information***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, eczema, penicillin hypersensitivity, urticaria***Geriatric***Dialysis, renal disease, renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Children, infants, neonates***Labor, obstetric delivery, pregnancy***Breast-feeding***Phenylketonuria***Mononucleosis***Cholestasis, hepatic disease, jaundice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hepatitis B immune globulin (human),"***For post-exposure hepatitis B prophylaxis.***For prevention of hepatitis B infection recurrence after liver transplantation in HBsAg-positive liver transplant patients. <br />  NOTE: In March 2008, HepaGam B received orphan drug exclusive approval from the FDA for this indication, which provides HepaGam B seven years of market exclusivity.<br />NOTE: HBIG is most effective in patients with absent or low levels of HBV replication at the time of transplantation.<br />NOTE: Use of HBIG with antiviral therapy after transplantation has not been evaluated.<br />NOTE: Patients with surgical bleeding, patients with abdominal fluid drainage &gt; 500 mL, or patients undergoing plasmapheresis are particularly susceptible to extreme loss of circulated antiHBs","***Maltose hypersensitivity***Intravenous administration***IgA deficiency***Coagulopathy, hemophilia, thrombocytopenia***Pregnancy***Breast-feeding***Vaccination***Hyperglycemia***Viral infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['19860'],aspirin/butalbital/caffeine,"***For the treatment of occasional tension headache, occasional migraine� or co-existing migraine� and tension-type headaches.***Formoterol***Formoterol; Mometasone","***General Information***Acute bronchospasm, angioedema, asthma, barbiturate hypersensitivity, carbamazepine hypersensitivity, hydantoin hypersensitivity, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, tartrazine dye hypersensitivity, urticaria***Porphyria***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, depression, hypertension, hypotension, mental status changes, suicidal ideation***Acid/base imbalance, chronic obstructive pulmonary disease (COPD), metabolic acidosis, metabolic alkalosis, pulmonary disease, respiratory acidosis, respiratory alkalosis, respiratory depression, sleep apnea, status asthmaticus***Diabetes mellitus, hypothyroidism, prostatic hypertrophy, renal disease, renal failure, renal impairment, systemic lupus erythematosus (SLE), thyroid disease, urethral stricture***Anticoagulant therapy, thrombolytic therapy***Agranulocytosis, anemia, coagulopathy, hematological disease, hemophilia, hypoprothrombinemia, thrombocytopenia, thrombotic thrombocytopenic purpura (TTP), vitamin K deficiency, von Willebrand's disease***Bone marrow suppression, immunosuppression, infection, neutropenia, pain***Hepatic disease, hepatic encephalopathy, hepatitis***Alcoholism, bleeding, esophagitis, gastritis, GI bleeding, peptic ulcer disease, surgery, tobacco smoking***G6PD deficiency, hemolytic anemia***CNS depression, driving or operating machinery, ethanol intoxication, head trauma***Breast-feeding***Children, Reye's syndrome***Labor, obstetric delivery, pregnancy***Abrupt discontinuation, seizure disorder, seizures, status epilepticus, substance abuse***Osteomalacia, osteoporosis***Gout***Ascites, dehydration, heart failure, hypovolemia, pulmonary edema***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5487']['321064'],hydrochlorothiazide/olmesartan medoxomil,"***For the treatment of hypertension in patients who do not respond to monotherapy. <br />        NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, heart failure, renal artery stenosis, renal disease, renal failure, renal impairment***Hepatic disease***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***ACE-inhibitor induced angioedema, angioedema***Surgery***Pregnancy***Breast-feeding***Children***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia, hyponatremia***Diabetes mellitus, hyperglycemia***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['161']['5489', '221107']",acetaminophen/hydrocodone bitartrate,***For the treatment of moderate pain to moderately severe pain. <br />  NOTE: FDA-approved dosages vary depending on product. Do not exceed a total daily dose of 4 grams of acetaminophen from ALL sources. <br /,"***General Information***Acetaminophen hypersensitivity, opiate agonist hypersensitivity***Acute abdomen, biliary tract disease, constipation, GI disease, GI obstruction, ileus, inflammatory bowel disease, pancreatitis, ulcerative colitis***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, coma, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Abrupt discontinuation***Alcoholism, ethanol ingestion, ethanol intoxication, hepatic disease, hepatitis, hepatotoxicity, malnutrition***Depression, substance abuse***CNS depression, head trauma, increased intracranial pressure, intracranial mass, psychosis***Angina, cardiac arrhythmias, cardiac disease, dehydration, hypotension, hypovolemia, orthostatic hypotension, shock***Bladder obstruction, oliguria, prostatic hypertrophy, renal impairment, urethral stricture, urinary retention***Geriatric***Children, infants, neonates***G6PD deficiency***Bone marrow suppression, immunosuppression, infection, neutropenia***Driving or operating machinery***Adrenal insufficiency, hypothyroidism, myxedema***Accidental exposure, potential for overdose or poisoning***Seizure disorder, seizures***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cysteamine bitartrate,***For the treatment of cystinosis. <br />        NOTE: The FDA has granted cysteamine orphan drug status for this indication.<br />     ***For the systemic treatment of nephropathic cystinosis.***For the treatment of corneal cystine crystal accumulation in patients with cystinosis.,"***General Information***Penicillamine hypersensitivity***Increased intracranial pressure, papilledema***Driving or operating machinery***Anemia, leukopenia***Seizures***Hepatic disease***GI disease***Pregnancy***Breast-feeding***Contact lenses***Infants, neonates***Ethanol ingestion",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,epirubicin hydrochloride,"***For the treatment of breast cancer. <br />        NOTE: Epirubicin in combination with other agents is approved by the FDA for the adjuvant treatment of breast cancer with axillary node tumor involvement after resection of primary breast cancer.<br />NOTE: Consideration should be given to the administration of a lower starting dose (75�90 mg/m2) for heavily pretreated patients, patients with pre-existing bone marrow suppression, or the presence of infiltrative neoplastic disease***For the treatment of patients with breast cancer with evidence of axillary node involvement following resection of the primary tumor in combination with cyclophosphamide and fluorouracil.***For the adjuvant treatment of breast cancer in combination with cyclophosphamide.***For the neoadjuvant treatment of HER2-positive breast cancer with fluorouracil and cyclophosphamide (FEC regimen) in sequence, and in combination, with paclitaxel and trastuzumab�.***For the treatment of metastatic breast cancer�.***For the treatment of metastatic breast cancer in combination with cyclophosphamide�.***For the treatment of metastatic breast cancer in combination with cyclophosphamide and fluorouracil�.***For the treatment soft-tissue sarcoma�, in combination with ifosfamide.***For the treatment of relapsed or refractory multiple myeloma�, in combination with other chemotherapy agents.***For the first-line treatment of advanced ovarian cancer� in combination with carboplatin and paclitaxel.***For the treatment of gastric cancer�.***For the treatment of advanced gastric cancer in combination with capecitabine and cisplatin or oxaliplatin�.***For the adjuvant treatment of gastric cancer in combination with cisplatin and 5-fluorouracil given sequentially with chemoradiation therapy�.***For the perioperative treatment of gastric cancer in combination with cisplatin and 5-fluorouracil�.***For the treatment of hepatocellular cancer�.***For the treatment of hepatocellular cancer ineligible for surgical or locoregional therapy in combination with etoposide�.***For the locoregional treatment of inoperable hepatocellular cancer�.***For prophylaxis of primary or recurrent stage Ta or T1 transitional-cell bladder cancer� following transurethral resection.***For peripheral blood stem cell (PBSC) mobilization� in multiple myeloma, in combination with ifosfamide, and etoposide, and filgrastim.***Formoterol***Formoterol; Mometasone","***Anthracycline hypersensitivity***Bone marrow suppression, herpes infection, infection, neutropenia, thrombocytopenia, varicella, viral infection***Radiation therapy***Dental disease, dental work***Extravasation, intramuscular administration, subcutaneous administration***Intramuscular injections***Geriatric***Hepatic disease, jaundice***Renal failure, renal impairment***Infertility, male-mediated teratogenicity, pregnancy***Breast-feeding***New primary malignancy***Hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, tumor lysis syndrome (TLS)***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cardiomyopathy, cardiotoxicity, coronary artery disease, diabetes mellitus, heart failure, hypertension, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, maximum cumulative lifetime dose, myocardial infarction, QT prolongation, thyroid disease***Accidental exposure, ocular exposure***Vaccination***Requires an experienced clinician***Children, infants, neonates***Females",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8727'],progesterone,"***For the treatment of amenorrhea.***For the prevention of endometrial hyperplasia associated with conjugated estrogen replacement therapy in postmenopausal women who have an intact uterus.***For the treatment of dysfunctional uterine bleeding secondary to hormonal imbalance.***For the treatment of infertility or for the prevention of early pregnancy failure� (e.g., miscarriage) in women with corpus luteum insufficiency�. <br />        NOTE: The optimal dose and route of progesterone administration has not been determined. Vaginal progesterone is often used preferentially over the intramuscular formulation secondary to comparable efficacy and decreased side effects (e.g., pain at the injection site, sterile abscess formation).<br />     ***For the treatment of symptoms associated with premenstrual syndrome (PMS)�.***For preterm delivery prophylaxis�.","***Breast cancer, cervical cancer, endometrial cancer, endometrial hyperplasia, new primary malignancy, ovarian cancer, uterine cancer, vaginal cancer***Hepatic disease***Benzyl alcohol hypersensitivity, intravenous administration, pulmonary oil microembolism, sesame oil hypersensitivity***Infertility***Ectopic pregnancy, incomplete abortion, pregnancy***Breast-feeding***Children, infants, neonates***Cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, visual disturbance***Diabetes mellitus, hyperlipidemia***Asthma, cardiac disease, renal disease***Depression, migraine, seizure disorder***Infection, inflammation***Peanut hypersensitivity***Driving or operating machinery***Dementia, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sapropterin dihydrochloride,***For the treatment of hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU) in conjunction with a phenylalanine (Phe)-restricted diet. <br />        NOTE: Sapropterin is designated by the FDA as an orphan drug for this indication.<br />     ,"***General Information***Fever, infection***Anorexia nervosa, bulimia nervosa***GI disease***Renal impairment***Hepatic disease***Children, infants, neonates***Breast-feeding***Pregnancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/levonorgestrel,"***For routine contraception.***For extended continuous routine contraception.***For use as postcoital contraception within 72 hours of unprotected intercourse, or known or suspected contraceptive failure, in females who have no known contraindications to oral contraceptives, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albuterol,"***For the treatment of acute bronchospasm (e.g., asthma) and bronchospasm prophylaxis.***For bronchospasm associated reversible obstructive airway disease (i.e., asthma).***For exercise-induced bronchospasm prophylaxis.***For the adjunctive emergency acute treatment of hyperkalemia�.***For the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD)� including chronic bronchitis� and emphysema�.","***General Information***Albuterol hypersensitivity, levalbuterol hypersensitivity, milk protein hypersensitivity***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, tachycardia, thyroid disease***Geriatric***Hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyrotoxicosis***Diabetes mellitus, diabetic ketoacidosis***Deterioration of asthma, paradoxical bronchospasm***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Renal impairment***MAOI therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,valganciclovir hydrochloride,"***For cytomegalovirus (CMV) disease prophylaxis in patients at high risk for CMV disease. <br />        NOTE: The FDA-approved labeling recommends that adults and adolescents older than 16 years should receive the oral tablet and not the oral solution. For pediatric patients, if the calculated dose is within 10% of the available tablet strength (450 mg), the oral tablet may be administered.<br />     ***For prophylaxis of CMV disease in kidney transplant patients.***For prophylaxis of CMV disease in heart transplant patients.***For prophylaxis of CMV disease in kidney-pancreas transplant patients.***For primary prophylaxis of CMV disease in patients with HIV-infection�.***For secondary cytomegalovirus (CMV) prophylaxis (maintenance therapy) after induction therapy in patients with HIV, including cytomegalovirus (CMV) retinitis prophylaxis and for maintenance therapy of CMV gastrointestinal disease� with relapse or neurological disease�. <br />        NOTE: For adults and adolescents, chronic maintenance therapy is indicated for retinitis. Chronic maintenance therapy is not routinely recommended for gastrointestinal disease, pneumonitis, or CNS disease unless there is concurrent retinitis or relapses have occurred. For infants and children, chronic maintenance therapy is indicated for retinitis, disseminated, CNS, or GI disease with relapse.<br />     ***For treatment of cytomegalovirus (CMV) infection in HIV-infected patients including cytomegalovirus (CMV) retinitis and cytomegalovirus (CMV)-associated gastrointestinal disease�, including esophagitis� and colitis�. <br />        NOTE: Valganciclovir tablets cannot be substituted for ganciclovir tablets on a one-to-one basis.<br />     ***For the treatment of CNS dysfunction or encephalitis� caused by human herpesvirus 6 (HHV-6) infection�.***For the treatment of diseases associated with human herpesvirus 8 (HHV-8) infection� in HIV-infected patients, including multicentric Castleman disease� (MCD).***For multicentric Castleman disease� (MCD).***For primary effusion lymphoma� (PEL).***For the treatment of congenital cytomegalovirus (CMV) disease�.","***General Information***Acyclovir hypersensitivity, famciclovir hypersensitivity, ganciclovir hypersensitivity, penciclovir hypersensitivity, valacyclovir hypersensitivity, valganciclovir hypersensitivity***Anemia, aplastic anemia, bone marrow suppression, neutropenia, radiation therapy, thrombocytopenia***Dehydration, dialysis, geriatric, renal failure, renal impairment***Accidental exposure, new primary malignancy, ocular exposure***Antimicrobial resistance***Children, infants, neonates***Pregnancy***Breast-feeding***Contraception requirements, infertility, male-mediated teratogenicity, pregnancy testing, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,lidocaine hydrochloride,"***For the treatment of perfusing ventricular arrhythmias including ventricular fibrillation (VF) and ventricular tachycardia (VT) that may result during acute myocardial infarction or cardiac manipulation (e.g., cardiac surgery). <br />  NOTE: See resuscitation indication for dosage guidelines for VF or pulseless VT.<br />NOTE: Although not considered a drug of choice for ventricular arrhythmias, lidocaine may be used as an alternative antiarrhythmic in patients with preserved ventricular function and stable monomorphic VT. Lidocaine may also be used to treat polymorphic VT in patients with a normal QT interval (when electrolyte imbalance and ischemia are treated). If pulseless cardiac arrest associated with VF or VT, see separate dosage guidelines for the treatment ventricular arrhythmias during CPR.<br />NOTE: Lidocaine may be used to treat patients with polymorphic VT associated with QT prolongation (e.g., torsade de pointes).<br />NOTE: Monitor blood pressure and the electrocardiogram (ECG) during intravenous lidocaine administration***For topical anesthesia of skin and mucous membranes or stomatitis.***For prevention of dental pain� and for topical anesthesia of mucous membranes.***For laryngoscopy.***For nonurgent painful procedures including IV cannulation, venipuncture, lumbar puncture, or arterial puncture.***For the treatment of stage 1 thru 4 pressure ulcers, venous stasis ulcers, ulcerations of mixed vascular etiologies, diabetic skin ulcers, first and second degree burns, and post surgical incisions, cuts, and abrasions.***For endotracheal intubation.***For neonatal circumcision�.***For bronchoscopy.***For the treatment of pain associated with postherpetic neuralgia.***For ophthalmic anesthesia.***For local anesthesia including peripheral nerve block anesthesia. <br />        NOTE: In adults, the dosages for local anesthesia reported are general guidelines only. The actual dose depends on a variety of factors such as depth of anesthesia, extent of surgical procedure, degree of muscle relaxation required, duration of anesthesia and the patients' physical condition. See Lidocaine; epinephrine monograph for information concerning combination dosing.<br />     ***For dental anesthesia including mandibular nerve block and maxillary infiltration.***For infiltration anesthesia.***For intravenous regional anesthesia.***For pudendal nerve block.***For paravertebral block.***For intercostal nerve block.***For brachial plexus block.***For paracervical block.***For sympathetic nerve block.***For cervical stellate ganglion block.***For lumbar sympathetic block.***For epidural anesthesia. <br />        NOTE: The dose is determined by the number of dermatomes to anesthetized (2 to 3 mL/dermatome). The suggested concentrations and volumes serve as a guide, other volumes and concentrations may be used provided the maximum dose is not exceeded.<br />     ***For lumbar anesthesia.***For lumbar analgesia for severe pain.***For thoracic.***For caudal anesthesia.***For obstetric anesthesia.***For surgical anesthesia.***For spinal anesthesia.***For obstetrical low spinal or saddle block anesthesia.***For intraabdominal anesthesia.***For the treatment of ventricular arrhythmias during cardiopulmonary resuscitation� (CPR).***For the attenuation of increased intracranial pressure� during rapid-sequence intubation� or endotracheal tube suctioning�.***For the treatment of severe singultus (hiccups)�.***For the treatment of headache�.***For the treatment of acute headache� associated with migraine�.***For the treatment of cluster headache�.***For the symptomatic treatment of corticosteroid-dependent asthma�. <br />        NOTE: Initial bronchoconstriction can occur. In addition, lidocaine toxicity can result in tremors, hallucinations, seizures, and cardiac arrest. Caution is advised until long-term safety and efficacy can be established.<br />     ***For short-term prophylaxis of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing� (SUNCT).***For the treatment of painful diabetic neuropathy� in adults.","***General Information***Amide local anesthetic hypersensitivity, epidural anesthesia***Collagen-vascular disease***G6PD deficiency***Geriatric, heart failure, hepatic disease***Hypotension, pregnancy***Breast-feeding***Adams-Stokes syndrome, atrial fibrillation, atrial flutter, AV block, bradycardia, cardiogenic shock, hemorrhagic shock, hypovolemia, shock, Wolff-Parkinson-White syndrome***Renal disease, renal failure, renal impairment***Burns, eczema, heating pad, occlusive dressing, skin abrasion***Cataracts, ocular exposure, ocular trauma***Accidental exposure***Intraarterial administration, intrathecal administration, intravenous administration***Head and neck anesthesia***Ocular surgery***Anticoagulant therapy, bleeding, coagulopathy, infection, neurological disease, requires a specialized care setting, requires an experienced clinician, sepsis, spinal anesthesia, thrombocytopenia***Fetal distress, labor, obstetric delivery, pudendal nerve block***Continuous intraarticular infusion administration***Fetal prematurity, paracervical nerve block***Malignant hyperthermia***Children, infants, neonates, teething pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,thioridazine hydrochloride,***For the treatment of schizophrenia in patients who fail to respond adequately to treatment with other antipsychotics.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.,"***Phenothiazine hypersensitivity***Agranulocytosis, bone marrow suppression, fever, hematological disease, infection, leukopenia, neutropenia***CNS depression, coadministration with other CNS depressants, coma, driving or operating machinery, ethanol ingestion, head trauma***Dental work, surgery***Intracranial mass, seizure disorder, seizures***Tardive dyskinesia***Anticholinergic medications, closed-angle glaucoma, ileus, prostatic hypertrophy, urinary retention***Alcoholism, angina, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, thyroid disease, torsade de pointes***Pulmonary disease***Children, infants, neonates, Reye's syndrome***Encephalopathy, hepatic disease, jaundice***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Sunlight (UV) exposure***Accidental exposure***Abrupt discontinuation***Renal failure***Ocular disease***Chemotherapy, GI obstruction, vomiting***Tobacco smoking***Labor, obstetric delivery, pregnancy, pregnancy testing***Breast-feeding***Breast cancer, hyperprolactinemia, infertility***Radiographic contrast administration***Suicidal ideation***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4278']['5640'],famotidine/ibuprofen,***For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and for NSAID-induced ulcer prophylaxis. <br />  NOTE: Carefully consider the potential benefits and risks of ibuprofen; famotidine and other treatment options.<br /***Formoterol; Mometasone,"***General Information***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***H2-blocker hypersensitivity***Anemia, bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, Crohn's disease, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Labor, obstetric delivery, pregnancy***Breast-feeding***Hypertension***Dehydration, diabetes mellitus, edema, heart failure, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery bypass graft surgery (CABG), coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Seizure disorder, seizures***Hepatic disease***Geriatric***Systemic lupus erythematosus (SLE)***Vitamin B12 deficiency***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['19959']['8896'],acrivastine/pseudoephedrine hydrochloride,***For the treatment of seasonal allergic rhinitis and accompanying nasal congestion.***Formoterol***Formoterol; Mometasone,"***General Information***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, closed-angle glaucoma, coronary artery disease, diabetes mellitus, GI obstruction, heart failure, hypertension, hyperthyroidism, increased intraocular pressure, MAOI therapy, peptic ulcer disease, prostatic hypertrophy, tachycardia, urinary retention***Driving or operating machinery***Renal failure, renal impairment***Children, infants, neonates***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4491'],fluorometholone,"***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis, ocular burns or trauma due to corneal injury resulting from chemical, thermal or penetration trauma, giant papillary conjunctivitis (GPC), keratitis, postoperative ocular inflammation, vernal keratoconjunctivitis, and chronic anterior uveitis. <br />  NOTE: The benefit of diminution of edema and inflammation from the use of ocular corticosteroids and the inherent risk of infection in certain conditions must be considered. Duration of treatment may vary with type of lesion and therapeutic response. Renewal of prescriptions beyond 20 mL of suspension or 8 grams of ointment should be made by a physician after re-examination with the aid of magnification. Care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of therapy should be carried out by gradually decreasing the frequency of applications.<br /","***General Information***Herpes infection, herpes simplex keratitis (dendritic keratitis), varicella, viral infection***Fungal infection, mycobacterial infection***Contact lenses***Glaucoma***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1895'],mupirocin calcium,"***For the treatment of impetigo and other skin and skin structure infections due to susceptible strains of <em>Staphylococcus aureus</em> or <em>Streptococcus pyogenes</em>.***For the treatment of impetigo.***For the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area).***For nasal bacterial colonization eradication of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) to reduce the risk of infection among high-risk patients during institutional outbreaks of infections with this pathogen.***For the treatment of mild methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated infectious neonatal pustulosis�.***For the treatment of infected eczema� due to susceptible strains of <em>Staphylococcus</em> sp. or <em>Streptococcus</em> sp..***For the treatment of folliculitis� due to susceptible strains of <em>Staphylococcus</em> sp. or <em>Streptococcus</em> sp..***For the prevention of postoperative nosocomial <em>Staphylococcus aureus</em> infections� (i.e., bacterial infection prophylaxis�).","***General Information***Burns, renal impairment***Children, infants, neonates***Ocular exposure, ophthalmic administration***Pregnancy***Breast-feeding***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5487']['73494'],hydrochlorothiazide/telmisartan,"***For the treatment of hypertension in patients who do not respond to monotherapy. <br />        NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, heart failure, renal artery stenosis, renal disease, renal failure, renal impairment***Hepatic disease***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***ACE-inhibitor induced angioedema, angioedema***Surgery***Pregnancy***Breast-feeding***Children***Electrolyte imbalance, hypercalcemia, hyperkalemia, hypokalemia, hypomagnesemia, hyponatremia***Diabetes mellitus, hyperglycemia***Pancreatitis***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['25480'],gabapentin,"***For the adjunctive treatment of partial seizures with or without secondary generalized tonic-clonic seizures.***For neuropathic pain associated with postherpetic neuralgia (PHN).***For the treatment of moderate to severe primary restless legs syndrome (RLS). <br />        NOTE: Gabapentin enacarbil is not recommended for patients who are required to sleep during the day and remain awake at night.<br />NOTE: immediate-release and extended-release gabapentin formulations are not interchangeable; also, Gralise is not interchangeable with Horizant due to differing chemical forms and pharmacokinetic properties***For the treatment of amyotrophic lateral sclerosis (ALS)�. <br />        NOTE: Gabapentin has been granted orphan drug status by the FDA for this indication.<br />     ***For the treatment of tremor�.***For the treatment of orthostatic tremor�.***For the treatment of essential tremor�.***For the treatment of nystagmus�.***For the treatment of acquired pendular nystagmus�.***For the treatment of congenital nystagmus�.***For the treatment of paroxysmal symptoms and spasticity� due to multiple sclerosis�.***For the treatment of hot flashes� due to menopause� or in women who have been treated for breast cancer.***For reducing hot flashes� associated with natural menopause�.***For reducing hot flashes� in women with breast cancer.***For the treatment of pruritus�.***For the treatment of uremic pruritus� in hemodialysis patients.***For the treatment of brachioradial pruritus�.***For the treatment of fibromyalgia�.***For the treatment of singultus (hiccups)�.***For the treatment of dysautonomia� following severe traumatic brain injury.***For long-term prophylaxis of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT)�.***For the treatment of painful diabetic neuropathy�.","***General Information***Depression, suicidal ideation***Dialysis, renal failure, renal impairment***Driving or operating machinery***Pregnancy***Breast-feeding***Children, infants, neonates***Seizure disorder, seizures***Abrupt discontinuation***Geriatric***Substance abuse***Angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,erythromycin ethylsuccinate,"***For the treatment of acne vulgaris.***For mild to moderately severe lower respiratory tract infections (e.g., pneumonia, bronchitis) caused by susceptible organisms.***For the treatment of Legionnaire's disease (caused by <em>Legionella pneumophila</em>).***For the treatment of mild to moderately severe upper respiratory tract infections (e.g., pharyngitis, tonsillitis), including group A beta-hemolytic streptococcal (GAS) pharyngitis (primary rheumatic fever prophylaxis).***For upper respiratory tract infections and GAS pharyngitis (primary rheumatic fever prophylaxis).***For prevention of recurrent attacks of rheumatic fever (i.e., secondary rheumatic fever prophylaxis).***For the treatment of listeriosis.***For the treatment of chlamydia infection and non-gonococcal urethritis.***For the treatment of non-gonococcal urethritis (NGU) or chlamydial infections including urogenital infections (urethritis, cervicitis, proctitis) and infant pneumonia.***For the treatment of chlamydial conjunctivitis or ophthalmia neonatorum caused by <em>Chlamydia trachomatis</em>.***For the treatment of lymphogranuloma venereum� caused by <em>Chlamydia trachomatis</em>.***For the prevention of ophthalmia neonatorum (i.e., ophthalmia neonatorum prophylaxis) due to <em>Neisseria gonorrhoeae</em><em> </em>or<em> Chlamydia trachomatis</em>.***For the treatment of pneumonia caused by <em>Chlamydia trachomatis</em> in neonates and infants.***For the adjunctive treatment of diphtheria to prevent establishment of carrier state and for <em>Corynebacterium diphtheriae</em> bacterial colonization eradication.***For the treatment of close contacts of patients with diphtheria (i.e., diphtheria prophylaxis�).***For the treatment of acute pelvic inflammatory disease (PID).***For acute pelvic inflammatory disease (PID) caused by <em>Neisseria gonorrhoeae</em>.***For the treatment of pertussis (whooping cough) caused by <em>Bordetella pertussis</em> or for postexposure pertussis prophylaxis. <br />  NOTE: For postexposure prophylaxis, administer to close contacts within 3 weeks of exposure, especially in high-risk patients (e.g., women in third trimester, infants &lt; 12 months).<br /***For the treatment of primary syphilis (caused by <em>Treponema pallidum</em>) in penicillin-allergic, nonpregnant patients.***For bowel preparation in combination with neomycin in patients undergoing colorectal surgery.***For the treatment of superficial ophthalmic infection involving the conjunctiva and/or cornea.***For the treatment of chancroid� due to <em>Haemophilus ducreyi</em>.***For the treatment of disseminated gonorrhea�. <br />  NOTE: Erythromycin is not recommended in adults, adolescents, or children 8 years and older or in patients weighing 45 kg or more due to resistance of N. gonorrheae against erythromycin in the United States. Single-dose azithromycin in combination with ceftriaxone is the preferred therapy in these populations. <br /***For the facilitation of gastric emptying in patients with delayed gastrointestinal motility  (e.g., gastroparesis�).***For the treatment of idiopathic or postsurgical gastroparesis� or diabetic gastroparesis�.***For the facilitation of gastric emptying� in patients with feeding intolerance�.***For the treatment of early Lyme disease�.***For the treatment of skin and skin structure infections including impetigo and burn wound infection�.***For the treatment of erythrasma (caused by <em>Corynebacterium minutissimum</em>).***For the treatment of tetanus� (caused by <em>Clostridium tetani</em>) when penicillin or tetracycline is contraindicated or not tolerated.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of cholera�.***For the treatment of bartonellosis� (<em>Bartonella bacilliformis)</em> and other <em>Bartonella sp.</em>� infections in HIV-infected patients.***For the treatment of angiomatosis infections�, peliosis hepatis�, bacteremia�, and osteomyelitis� caused by <em>Bartonella sp.</em>�.***For long term suppression� of infections caused by <em>Bartonella sp.</em>� in HIV-infected patients with relapse or reinfections with < 200 CD4 cells/mm3.***For pneumococcal prophylaxis� in penicillin-allergic patients with sickle cell disease�.***For the treatment of infantile acne�.***For the oral treatment of infantile acne.***For the topical treatment of infantile acne.***Formoterol***Formoterol; Mometasone","***General Information***Viral infection***Macrolide hypersensitivity***Hepatic disease***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Hearing impairment***Benzyl alcohol hypersensitivity, neonates***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Seizure disorder***Myasthenia gravis***Sexually transmitted disease***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dorzolamide hydrochloride/timolol maleate,***For the treatment of glaucoma or ocular hypertension in patients who are insufficiently responsive to beta-blockers.,"***General Information***AV block, bradycardia, cardiac disease, cardiogenic shock, coronary artery disease, heart failure, hypotension, peripheral vascular disease, Raynaud's phenomenon, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Cerebrovascular disease***Renal disease, renal failure, renal impairment***Carbonic anhydrase inhibitor hypersensitivity, sulfonamide hypersensitivity***Contact lenses***Corneal abrasion, ocular infection***Hepatic disease***Pregnancy***Breast-feeding***Children, infants, neonates***Hyperthyroidism, thyrotoxicosis***Diabetes mellitus, hypoglycemia***Surgery***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,naproxen); (naproxen sodium,"***For the treatment of mild to moderately severe musculoskeletal inflammation including osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis.***For self-medication of minor pain of arthritis. <br />          NOTE: Self-medication should not exceed 10 days unless otherwise directed by health care professional.<br />       ***For the treatment of juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA).***For the treatment of acute gouty arthritis. <br />        NOTE: Enteric-coated/delayed-release naproxen (e.g., EC-Naprosyn) is not recommended for the treatment of acute gout attacks because of the absorption delay as compared to other naproxen formulations.<br />     ***For self-medication of fever. <br />        NOTE: Advise patients to seek medical help if fever worsens or persists beyond 3 days.<br />     ***For the treatment of mild pain to moderate pain, including dysmenorrhea, acute tendinitis and bursitis, headache, bone pain�, dental pain, arthralgia, and myalgia. <br />        NOTE: Enteric-coated/delayed-release naproxen (e.g., EC-Naprosyn) is not recommended for the initial treatment of pain because the absorption is delayed as compared to other naproxen formulations.<br />NOTE: Naproxen sodium formulations (e.g., Anaprox) may be preferred to naproxen products (e.g., Naprosyn) when fast-onset pain relief is needed (see Pharmacokinetics)***For self-medication. <br />          NOTE: Self-medication should not exceed 10 days unless otherwise directed.<br />       ***For the treatment of acute, severe headache or migraine�. <br />          NOTE: Naproxen sodium is preferred over naproxen due to a faster onset of action.<br />       ***For chronic migraine prophylaxis�.***For the prevention of heterotopic ossification�.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease, jaundice***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hypertension, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Dehydration, diabetes mellitus, edema, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Intramuscular injections***Dental disease, dental work***Children, infants, neonates***Coronary artery bypass graft surgery (CABG)***Geriatric***Labor, obstetric delivery, pregnancy***Breast-feeding***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,milnacipran hydrochloride,***For the treatment of fibromyalgia.***For the treatment of depression�.,"***General Information***Closed-angle glaucoma, increased intraocular pressure***MAOI therapy***Driving or operating machinery***Abrupt discontinuation***Renal disease, renal failure, renal impairment***Alcoholism, hepatic disease, jaundice***Cardiac disease, hypertension***Cardiac arrhythmias***Seizure disorder, seizures***Dehydration, hyponatremia, hypovolemia***Prostatic hypertrophy, urinary retention, urinary tract obstruction***Eclampsia, neonates, obstetric delivery, pregnancy***Breast-feeding***Children, suicidal ideation***Bipolar disorder, mania***Anticoagulant therapy, bleeding, thrombolytic therapy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['35302'],sirolimus,"***For kidney transplant rejection prophylaxis. <br />  NOTE: Rapamune oral solution 2 mg has been demonstrated to be clinically equivalent to 2 mg Rapamune oral tablets and hence, are interchangeable on a mg-to-mg basis. However, it is not known if higher doses of Rapamune oral solution are clinically equivalent to higher doses of tablets on a mg-to-mg basis.<br />NOTE: According to guidelines, initial calcineurin inhibitor-free therapy (e.g., use of a mammalian target of rapamycin inhibitor (m-TOR) like sirolimus with mycophenolate and steroids) is not sufficient to effectively prevent acute rejection. The safety and efficacy of de novo use of sirolimus without cyclosporine are not established in renal transplant patients. In a multi-center clinical study, de novo renal transplant patients were treated with sirolimus or cyclosporine in combination with mycophenolate (MMF), steroids, and an IL-2 receptor antagonist; patients treated with sirolimus had a significantly higher acute rejection rate and a numerically higher death rate compared to patients treated with cyclosporine. Patients treated with sirolimus versus cyclosporine did not experience improved renal function.<br />NOTE: Guidelines state that a mammalian target of rapamycin inhibitor (m-TOR) like sirolimus can safely replace a calcineurin inhibitor beyond the early post-transplant period, but conversion is not advisable for patients with proteinuria higher than 800 mg/day. Further, follow a cautious and individual approach for patients with a CrCl less than 30 mL/minute. The safety and efficacy of conversion from calcineurin inhibitors to sirolimus in the maintenance renal transplant population have not been established. In a study to evaluate the safety and efficacy of conversion from calcineurin inhibitors to sirolimus (initial target concentrations of 12 to 20 ng/mL, chromatographic assay), enrollment was stopped for patients with a baseline glomerular filtration rate less than 40 mL/min because of a higher rate of serious adverse events including pneumonia, acute rejection, graft loss, and death in this sirolimus treatment arm. Among patients with a baseline glomerular filtration rate of more than 40 mL/min, no benefit in regard to an improvement in renal function and a greater incidence of proteinuria were noted among patients who were switched to sirolimus. Also, a 5-fold increase in the reports of tuberculosis was noted among patients who were switched to sirolimus***For the treatment of lymphangioleiomyomatosis.***For the management of heart transplant rejection prophylaxis�.","***General Information***Immunosuppression, infection, lymphoma, new primary malignancy, requires a specialized care setting, requires an experienced clinician, sunlight (UV) exposure***Cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia***Soya lecithin hypersensitivity***Accidental exposure, ocular exposure***Hepatic disease***Black patients, dialysis, proteinuria, renal failure, renal impairment***Pregnancy***Breast-feeding***Children, infants, neonates***Vaccination***Surgery, wound dehiscence***Liver transplant, lung transplant***Diabetes mellitus***Contraception requirements, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['640062', '1546015']",regadenoson,***For use in radionuclide myocardial perfusion imaging for coronary artery disease diagnosis in patients unable to undergo adequate exercise stress.***Formoterol***Formoterol; Mometasone,"***Angina, autonomic neuropathy, cardiac arrest, cardiac disease, geriatric, hypotension, hypovolemia, myocardial infarction, pericardial effusion, pericarditis, pulmonary edema, respiratory arrest, valvular heart disease, ventricular fibrillation***Alcoholism, AV block, bradycardia, cardiac arrhythmias, coronary artery disease, diabetes mellitus, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, QT prolongation, sick sinus syndrome, thyroid disease***Asthma, chronic obstructive pulmonary disease (COPD), pulmonary disease***Pregnancy***Breast-feeding***Seizures",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6860'],methyclothiazide,"***For the treatment of hypertension.***For the treatment of edema, or diabetes insipidus� (central or nephrogenic).***Formoterol***Formoterol; Mometasone","***Sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, hypovolemia, renal disease, renal failure, renal impairment***Acid/base imbalance, electrolyte imbalance, geriatric, hypercalcemia, hyperkalemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis***Hypotension, orthostatic hypotension, sympathectomy, syncope***Diabetes mellitus, hyperglycemia***Hepatic disease***Gout, hyperuricemia***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Pancreatitis***Pregnancy***Children***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,factor IX complex,"***For the management of hemophilia B (congenital factor IX deficiency or Christmas disease) to prevent and control hemorrhage including surgical bleeding and hemarthrosis. <br />        NOTE: Guidelines for the treatment of acute bleeding and prevention of bleeding during surgery vary. For all indications, the dose of factor IX should be individualized, taking into consideration the seriousness of the bleed or procedure, the clinical status of the patient, and the baseline factor IX activity concentration.<br />","***General Information***Heparin hypersensitivity***Coronary artery disease, hepatic disease, neonates, surgery***Heparin-induced thrombocytopenia (HIT)***Pregnancy***Breast-feeding***Factor IX inhibitors***Hepatitis, infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['60223', '153184']",adapalene/benzoyl peroxide,***For the treatment of acne vulgaris.,"***Accidental exposure, eczema, skin abrasion, sunburn***Pregnancy***Breast-feeding***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ziprasidone hydrochloride); (ziprasidone mesylate,"***For the treatment of schizophrenia.***For the treatment of bipolar disorder (bipolar I disorder), including monotherapy treatment of mania or mixed episodes and as an adjunct to lithium or valproate in maintenance therapy.***For the treatment of acute agitation associated with schizophrenia or other psychiatric illness� associated with acute agitation.***For the treatment of Tourette's syndrome�.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.","***General Information***Serious rash***Agranulocytosis, leukopenia, neutropenia***Acute myocardial infarction, alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, thyroid disease, torsade de pointes***Renal failure, renal impairment***Tardive dyskinesia***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise***Hepatic disease***CNS depression, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Dysphagia***Diabetes mellitus, hyperglycemia, obesity***Seizure disorder, seizures***Suicidal ideation***Neurological disease, Parkinson's disease***Dementia, geriatric, stroke***Sunlight (UV) exposure***Breast cancer, hyperprolactinemia, infertility***Neonates, pregnancy, pregnancy testing***Breast-feeding***Children, infants***Abrupt discontinuation***Priapism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,desmopressin acetate,"***For the management of patients with central diabetes insipidus (neurohypophyseal diabetes insipidus) including polydipsia and polyuria which occurs following head surgery or trauma.***For the treatment of primary nocturnal enuresis.***For the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.***For the management of spontaneous bleeding or trauma-induced hemorrhage (e.g., hemarthrosis, intramuscular hematomas, or mucosal bleeding, uremic bleeding�) or for bleeding prophylaxis (e.g., surgical bleeding) in selected patients.***Formoterol; Mometasone","***General Information***Renal disease, renal failure, renal impairment***Children, cystic fibrosis, diarrhea, electrolyte imbalance, fever, hyponatremia, infection, vomiting***Angina, cardiac disease, coronary artery disease, heart failure, hypertension, increased intracranial pressure, thromboembolic disease, urinary retention***Von Willebrand's disease***Nasal surgery, nasal trauma***Geriatric***Pregnancy***Breast-feeding***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,epinastine hydrochloride,***For the prevention of ocular pruritus associated with allergic conjunctivitis.,***General Information***Contact lenses***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8410'],alteplase,"***For the treatment of acute myocardial infarction with ST-elevation (STEMI) due to coronary artery thrombosis. <br />        NOTE: A dose of 150 mg of alteplase is no longer recommended due to an increased incidence of intracranial bleeding.<br />NOTE: Randomized controlled trials have demonstrated beneficial outcomes when fibrinolytic therapy is administered as early as possible after onset of STEMI symptoms (e.g., prehospital fibrinolysis or within 30 minutes of hospital arrival). When indicated for patients with acute myocardial infarction and ST-elevation (STEMI), fibrinolytic therapy may be administered within 12 hours following the onset of symptoms.  It is reasonable to administer fibrinolytic therapy within 24 hours of the onset of STEMI symptoms in patients who have continuing ischemic symptoms and ST elevation greater than 0.1 mV in at least 2 contiguous precordial leads or at least 2 adjacent limb leads.<br />NOTE: See heparin monograph for suggested dosing regimens during thrombolysis for acute myocardial infarction***For the intracoronary treatment of acute coronary artery thrombosis (i.e., abrupt closure) in the setting of percutaneous coronary intervention (PCI)�, in combination with repeat balloon dilation. <br />          NOTE: The relative efficacy of alteplase compared with other treatment strategies has not been systematically evaluated.<br />       ***For the treatment of acute pulmonary embolism.***For the treatment of acute ischemic stroke.***For acute ischemic stroke in pediatric patients�.***For reestablishing patency of an occluded IV catheter.***For the treatment of deep venous thrombosis (DVT)� using local administration of thrombolytics including catheter-directed thrombolysis (CDT) and intra-clot administration. <br />  NOTE: Clinical practice guidelines recommend anticoagulant therapy alone over catheter-directed thrombolysis (CDT) in patients with acute proximal DVT; however, guidelines do state that patients who are most likely to benefit from CDT are those with iliofemoral DVT, symptoms for less than 14 days, good functional status, life expectancy of more than 1 year, and a low risk of bleeding.<br /***For the treatment of peripheral arterial thromboembolism�.***For intravascular catheter occlusion prophylaxis�.***For the management of pleural effusion� or pleural empyema�.","***General Information***Hypertension***Aneurysm, anticoagulant therapy, arteriovenous malformation, bleeding, brain tumor, coagulopathy, coronary artery bypass graft surgery (CABG), diabetic retinopathy, endocarditis, GI bleeding, head trauma, intracranial bleeding, intracranial mass, organ biopsy, peptic ulcer disease, pericarditis, seizures, stroke, surgery, thrombocytopenia, trauma, venipuncture***Hepatic disease, renal disease, renal failure***Intramuscular injections***Infection, thrombophlebitis***Geriatric***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Atrial fibrillation, mitral stenosis, thrombosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['161']['19860'],acetaminophen/butalbital/caffeine,"***For the treatment of the symptom complex of tension headache, occasional migraine� and co-existing migraine� and tension-type headaches. <br />  NOTE: Extended and repeated use of acetaminophen; butalbital; caffeine is not recommended because of the potential for physical dependence. According to published guidelines for the acute management of migraine, the use of butalbital-containing analgesics should be limited and carefully monitored due to concerns of overuse, medication-overuse headache, and withdrawal.<br /***Formoterol***Formoterol; Mometasone","***General Information***Acetaminophen hypersensitivity, agranulocytosis, barbiturate hypersensitivity, carbamazepine hypersensitivity, exfoliative dermatitis, hydantoin hypersensitivity***Porphyria***Cardiac disease, depression, mental status changes, suicidal ideation***Diabetes mellitus, hepatic disease, hepatic encephalopathy, hepatitis, inflammatory bowel disease, peptic ulcer disease, renal disease, renal failure, renal impairment, thyroid disease***Chronic obstructive pulmonary disease (COPD), pulmonary disease, respiratory depression, sleep apnea, status asthmaticus***Alcoholism, CNS depression, driving or operating machinery, ethanol intoxication, head trauma***Anemia, G6PD deficiency***Infants, labor, neonates, pregnancy***Breast-feeding***Children***Bone marrow suppression, immunosuppression, infection, pain***Abrupt discontinuation, seizure disorder, seizures, status epilepticus, substance abuse***Anticoagulant therapy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['9344'],ribavirin,"***For the treatment of respiratory syncytial virus (RSV) infection.***For the treatment of chronic hepatitis C infection in patients with compensated liver disease. <br />        NOTE: Ribavirin monotherapy is not effective for hepatitis C infection. <br />NOTE: Therapy should be discontinued in patients who develop hepatic decompensation during treatment***For the treatment of chronic hepatitis C infection in combination with interferon alfa-2b alone. <br />          NOTE: Consider response prognostic factors, HCV genotype, viral load, and disease progression evidence such as hepatic inflammation and fibrosis when deciding to treat a pediatric patient. Weigh treatment benefits against potential safety risks identified in clinical trials.<br />       ***For the treatment of chronic hepatitis C infection in combination with a peginterferon alfa product alone. <br />          NOTE: Guidelines recommend the use of a peginterferon product plus ribavirin as part of a combination regimen depending on patient factors and genotype. <br />       ***For the treatment of chronic hepatitis C infection genotype 1 in combination with a nucleotide analog NS5B polymerase inhibitor or NS3/4A protease inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infections in patients with hepatocellular carcinoma awaiting liver transplant as well as patients with decompensated cirrhosis who may or may not be candidates for liver transplantation�.***For the treatment of  recurrent hepatitis C infection in patients after liver transplantation�.***For the treatment of chronic hepatitis C infection genotype 2 in combination with a nucleotide analog NS5B polymerase inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infection genotype 3 in combination with a nucleotide analog NS5B polymerase inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infection genotype 4 in combination with a nucleotide analog NS5B polymerase inhibitor or NS3/4A protease inhibitor with or without a peginterferon alfa product�.***For the treatment of chronic hepatitis C infection genotypes 5 or 6 in combination with a nucleotide analog NS5B polymerase inhibitor and/or a peginterferon alfa product�.***For the treatment of viral hemorrhagic fever (VHF)�, including hemorrhagic fever with renal syndrome (HFRS)� secondary to Hantaan virus infection�. <br />        NOTE: Ribavirin has been designated an orphan drug by the FDA for hemorrhagic fever with renal syndrome (HFRS).<br />     ***For Lassa fever prophylaxis�.***For the treatment of adenovirus infection�, including pneumonitis�, hepatitis�, hemorrhagic cystitis�, and nephritis�.***For the treatment of viral encephalitis�.***For subacute measles encephalitis� (SME).***For subacute sclerosing panencephalitis� (SSPE) caused by the measles virus�.***For encephalitis� caused by the Nipah virus�.***For encephalitis� caused by the West Nile virus�.***For the treatment of West Nile virus infection�, including meningitis� and encephalitis�. <br />  NOTE: Other than supportive care, there is no established treatment for West Nile virus infection. The use of ribavirin is suggested by in vitro data only.<br /***For the treatment of Severe Acute Respiratory Syndrome (SARS)�.***For the treatment of Crimean-Congo virus hemorrhagic fever (CCVHF)� or Lassa fever infection�. <br />        NOTE: The use of ribavirin for hemorrhagic fever with renal syndrome (HFRS) secondary to Crimean-Congo virus is supported by in vitro data.<br />***For Crimean-Congo virus hemorrhagic fever (CCVHF) prophylaxis�.","***General Information***Requires an experienced clinician, respiratory depression, respiratory insufficiency***Contact lenses, ocular exposure***Contraception requirements, male-mediated teratogenicity, pregnancy, pregnancy testing, reproductive risk***Infertility***Breast-feeding***Anemia, angina, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, heart failure, hemolytic anemia, myocardial infarction***Infection***Hemoglobinopathy, sickle cell disease, thalassemia***Geriatric***Hepatic disease, hepatitis, hepatitis C and HIV coinfection, influenza, organ transplant, ribavirin monotherapy, viral infection***Children, growth inhibition, infants, neonates***Pancreatitis***Dialysis, renal failure, renal impairment***Thyroid disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,amiodarone hydrochloride,"***For the treatment of life-threatening recurrent ventricular fibrillation or hemodynamically unstable (symptomatic) sustained ventricular tachycardia, including post-myocardial infarction (MI) patients. <br />        NOTE: See resuscitation indication for ECC/AHA dosage and administration guidelines for ventricular fibrillation or pulseless ventricular tachycardia.<br />NOTE: Amiodarone is FDA-approved for the treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy***For the treatment of ventricular arrhythmias during cardiopulmonary resuscitation� (CPR).***For cardiac arrest associated with ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) unresponsive to CPR.***For hemodynamically stable ventricular tachycardia (monomorphic or polymorphic) or wide-complex tachycardia of unknown origin during CPR (perfusing ventricular arrhythmias).***For the treatment of atrial fibrillation�, atrial flutter�, or paroxysmal supraventricular tachycardia (PSVT)�.***For primary atrial fibrillation prophylaxis� in patients receiving cardiac surgery�. <br />        NOTE: Amiodarone is listed as an alternative treatment option to other frontline treatment strategies (e.g., beta-blockers) for the prevention of atrial fibrillation after coronary artery bypass graft (CABG) surgery. <br />     ***For the prevention of sudden cardiac death in patients with heart failure�.***Formoterol***Formoterol; Mometasone","***Iodine hypersensitivity***Cardiogenic shock, heart failure, hypotension, hypovolemia, ventricular dysfunction***Alcoholism, arrhythmia exacerbation, AV block, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, hypertension, hypocalcemia, long QT syndrome, malnutrition, mortality, myocardial infarction, QT prolongation, requires an experienced clinician***Amiodarone-induced lung toxicity, chronic obstructive pulmonary disease (COPD), pneumonitis, pulmonary disease, pulmonary fibrosis, respiratory distress syndrome, respiratory insufficiency, surgery***Amiodarone-induced liver toxicity, hepatic disease, hepatitis, hepatotoxicity***Diarrhea, electrolyte imbalance, hypokalemia, hypomagnesemia***Goiter, hyperthyroidism, hypothyroidism, thyroid disease, thyrotoxicosis***Cataracts, Fabry disease, optic neuritis, visual disturbance***Geriatric***Neurological disease, peripheral neuropathy***Sunlight (UV) exposure***Halothane anesthesia***Benzyl alcohol hypersensitivity, children, infants, neonates***Pregnancy***Breast-feeding***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['233272'],bexarotene,"***For the treatment cutaneous T-cell lymphoma (CTCL), including mycosis fungoides. <br />  NOTE: Bexarotene has been designated an orphan drug by the FDA for this indication.<br /***For the treatment of cutaneous manifestations of CTCL in patients who are refractory to at least 1 prior systemic therapy.***For the treatment of cutaneous lesions of stage IA or IB CTCL in patients who have refractory or persistent disease after other therapies or who have not tolerated other therapies.***For the treatment of advanced non-small cell lung cancer (NSCLC)�.***For the treatment of AIDS-related Kaposi's sarcoma�.***For the treatment of metastatic breast cancer�.***For the treatment of severe plaque psoriasis�.","***Retinoid hypersensitivity***Diabetes mellitus***Alcoholism, biliary tract disease, pancreatitis***Cholestasis, hepatic disease, hepatotoxicity***Hypothyroidism, thyroid disease***Leukopenia, neutropenia***Cataracts***Sunlight (UV) exposure***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia***Pregnancy***Contraception requirements, male-mediated teratogenicity, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,immune globulin injection (human),"***For hepatitis A prophylaxis.***For postexposure prophylaxis.***For patients traveling to regions that have high or intermediate hepatitis A endemicity.***For measles prophylaxis to prevent or modify measles in an unvaccinated patient who has not previously had measles and who was exposed within the past 6 days. <br />  NOTE: For most persons 12 months and older who are exposed to measles, use of MMR or measles vaccine within 72 hours of exposure is preferred to using immune globulin (except pregnant women and others for whom the vaccine is contraindicated). Any person exposed to measles who lacks evidence of measles immunity and to whom immune globulin (IG) is administered should subsequently receive MMR vaccine but not earlier than 6 months after IMIG administration or 8 months after IGIV administration (provided the vaccine is not contraindicated).<br /***For varicella (chickenpox) infection prophylaxis.***For rubella prophylaxis in exposed, susceptible pregnant women who will not consider a therapeutic abortion. <br />        NOTE: The routine use of IMIG for rubella prophylaxis in early pregnancy is of dubious value and cannot be justified.<br />     ***For immunoglobulin deficiency. <br />  NOTE: Immune globulin may prevent serious infection in patients with immunoglobulin deficiencies if circulating IgG concentrations of approximately 200 mg/100 mL plasma are maintained.<br /","***Intravenous administration***Pregnancy***Breast-feeding***Agammaglobulinemia, hypogammaglobulinemia, IgA deficiency***Viral infection***Anticoagulant therapy, bleeding, coagulopathy, hemophilia, thrombocytopenia***Vaccination***Children***Coronary artery disease, geriatric, heart failure, hypertriglyceridemia, hyponatremia, obesity, thromboembolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydrocortisone acetate/pramoxine hydrochloride,"***For the temporary relief of skin inflammation, pain, and pruritus associated with corticosteroid-responsive dermatitis, including psoriasis, anorectal inflammation, pain, pruritus, and swelling associated with hemorrhoids, proctitis, cryptitis, anal fissures, postoperative pain, and pruritus ani.***For the adjunctive treatment of chronic ulcerative colitis� when disease is limited to the distal portion of the rectum (e.g., proctosigmoiditis).","***Fungal infection, herpes infection, infection, peripheral vascular disease, tuberculosis, viral infection***Hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, infants, neonates***Geriatric, skin atrophy***Diabetes mellitus***Cataracts, glaucoma, ocular exposure, ophthalmic administration***Pregnancy***Breast-feeding***Hepatic disease***Fistula, GI obstruction, GI perforation, peritonitis, ulcerative colitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,zolpidem tartrate,"***For the treatment of insomnia.***For the short-term treatment of insomnia characterized by difficulty with sleep initiation.***For insomnia characterized by difficulties with sleep onset and/or sleep maintenance.***For middle-of-the night awakening that is followed by difficulty returning to sleep.***For increasing awareness and responsiveness in patients with disorders of consciousness due to traumatic brain injury� (TBI�) or nontraumatic brain injury� (e.g., head trauma� or hypoxia, respectively).","***Angioedema***Depression, suicidal ideation***Behavioral changes, CNS depression, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion, females***Abrupt discontinuation, alcoholism, substance abuse***Encephalopathy, hepatic disease***Chronic obstructive pulmonary disease (COPD), myasthenia gravis, pulmonary disease, respiratory depression, sleep apnea***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***Children, infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,calcitonin-salmon (rDNA origin),"***For the treatment of moderate to severe symptomatic Paget's disease.***For the treatment of hypercalcemia.***For the treatment of postmenopausal osteoporosis in combination with adequate calcium intake in women who are more than 5 years past menopause and in whom estrogens cannot be used. <br />        NOTE: North American Menopause Society notes that due to lower efficacy as compared to other pharmacotherapies for osteoporosis, calcitonin use in postmenopausal women should be reserved for those patients who can not or will not take one of the other available osteoporosis therapies.<br />     ***For osteoporosis prophylaxis�.***For the management of bone pain� due to osteoporosis, bone metastases�, or vertebral crush fractures.***For the management of neuropathic pain�, including diabetic neuropathy�, and phantom limb pain�.***For the treatment of reflex sympathetic dystrophy�.","***Acute bronchospasm, fish hypersensitivity, hypotension***Pregnancy***Breast-feeding***Hypocalcemia***Nasal trauma***Geriatric***Children***New primary malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1306284']['1306286'],cobicistat/elvitegravir/emtricitabine/tenofovir disoproxil fumarate,"***For the treatment of human immunodeficiency virus (HIV) infection in antiretroviral-naive and certain treatment-experienced patients. <br />        NOTE: Use in treatment-experienced patients is limited to those who have been virologically-suppressed (i.e., HIV RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months, have no history of treatment failure, and who are without known substitutions associated with resistance to any of the individual components. For patients meeting these criteria, cobicistat; elvitegravir, emtricitabine; tenofovir disoproxil fumarate may replace the current antiretroviral therapy.<br />NOTE: Cobicistat; elvitegravir, emtricitabine; tenofovir disoproxil fumarate is not indicated for the treatment of chronic hepatitis B virus (HBV) infection, and the safety and efficacy of treatment have not been established in patients co-infected with HBV and HIV***For human immunodeficiency virus (HIV) prophylaxis� after occupational exposure to HIV.***Formoterol; Mometasone","***General Information***Hepatitis B and HIV coinfection, hepatitis B exacerbation***Alcoholism, females, hepatotoxicity or lactic acidosis, obesity***Bone fractures, hypophosphatemia, renal disease, renal failure, renal impairment***Osteomalacia, osteoporosis***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Hepatic disease***Children, infants, neonates***Pregnancy***Breast-feeding***Human immunodeficiency virus (HIV) infection resistance***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,quetiapine fumarate,"***For the treatment of major depression.***For the adjunctive treatment of major depression in patients who have had an inadequate response to antidepressants alone.***For the treatment of major depressive disorder as monotherapy�.***For the treatment of bipolar disorder, including mania and bipolar depression.***For the acute treatment of mania and for maintenance therapy following stabilization.***For the treatment of bipolar depression during depressive episodes of bipolar I or bipolar II disorder.***For the treatment of rapid-cycling� bipolar disorder.***For the treatment of schizophrenia.***For the adjunct treatment of refractory obsessive-compulsive disorder (OCD)�.***For the treatment of neurocognitive symptoms (e.g., impulsivity, executive functioning) associated with borderline personality disorder�.***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD)�.***For the treatment of neuropsychiatric symptoms associated with dementia with Lewy bodies� that are unresponsive to other medications and non-medication treatments.***Formoterol***Formoterol; Mometasone","***General Information***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, hypovolemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, thyroid disease***Agranulocytosis, hematological disease, leukopenia, neutropenia***Cataracts***Hypothyroidism***Tardive dyskinesia***Dysphagia***Neurological disease, Parkinson's disease***Brain tumor, seizure disorder***Coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Hepatic disease***Breast cancer***Diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, obesity***Neonates, pregnancy, pregnancy testing***Breast-feeding***Abrupt discontinuation, children, suicidal ideation***Dementia, geriatric, stroke***Ambient temperature increase, dehydration, hyperthermia, hypothermia, strenuous exercise",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['338036'],pegfilgrastim,"***For chemotherapy-induced neutropenia prophylaxis, to decrease the incidence of febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia. <br />        NOTE: Pegfilgrastim is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.<br />     ***For the treatment of acute radiation exposure, to increase survival, in patients who receive myelosuppressive doses of radiation. <br />  NOTE: The On-body injector is not recommended for use in patients with acute radiation exposure.<br /","***E. coli protein hypersensitivity***Radiation therapy***Respiratory distress syndrome***Sickle cell disease***Hematuria, proteinuria***Leukemia***Leukocytosis***Pregnancy***Breast-feeding***Latex hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,loperamide hydrochloride,"***For the treatment of diarrhea, including nonspecific diarrhea, AIDS-associated diarrhea�, traveler's diarrhea, chronic diarrhea, diarrhea predominant irritable bowel syndrome�, ileostomy-associated diarrhea, and late-onset irinotecan-induced diarrhea�.***For acute nonspecific diarrhea including AIDS-associated diarrhea� with no identifiable infectious cause.***For self medication (OTC use) for acute nonspecific diarrhea, including traveler's diarrhea.***For chronic diarrhea.***For management of diarrhea predominant irritable bowel syndrome�.***For ileostomy-associated diarrhea.***For management of late-onset irinotecan-induced diarrhea�.***Formoterol***Formoterol; Mometasone","***General Information***Cardiac arrest, QT prolongation, substance abuse, syncope, torsade de pointes, ventricular tachycardia***Dysentery, fever, gastroenteritis, GI bleeding, infection, pseudomembranous colitis***Abdominal pain, constipation, GI obstruction, GI perforation, ileus, toxic megacolon, ulcerative colitis, vomiting***Hepatic disease***Renal impairment***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2599'],clonidine,"***For the treatment of hypertension.***For the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients as monotherapy or as adjunctive therapy to a psychostimulant. <br />        NOTE: Clonidine is not considered a first-line agent for children with ADHD due to the potential cardiac effects and the availability of safer and more effective agents, such as some stimulants. Reports of sudden death and hypotension in children receiving oral clonidine in combination with other therapies for ADHD have been published, but causality has not been established.  Children and infants may be more sensitive to the effects of clonidine. However, not all ADHD clinical trials evaluating clonidine have reported adverse cardiac effects. The American Heart Association has recommended that children and adolescents receiving clonidine be monitored for changes in blood pressure at treatment initiation, periodically during treatment, and when tapering the drug, even when clonidine is used for psychotropic indications.<br />     ***For the treatment of ADHD in children with tic disorders�.***For the treatment of severe pain.***For the treatment of hypertensive urgency� or hypertensive emergency�.***For the treatment of opiate agonist withdrawal�.***For the treatment of neonatal abstinence syndrome�.***For pheochromocytoma diagnosis�.***For the symptomatic treatment of diabetic neuropathy�.***For the treatment of diabetic diarrhea�, diarrhea� related to opiate withdrawal, or refractory diarrhea� in cancer patients. <br />        NOTE: Clonidine has some antisecretory activity by modulating (decreasing) small intestinal transit; however, data are relatively limited and the agent is often used for refractory diarrheal cases.<br />     ***For the treatment of alcohol withdrawal�.***For use as an adjunct to psychosocial interventions in the management of tobacco cessation� (smoking cessation�).***For the treatment of hot flashes� due to menopause�.***For the treatment of hypertension and the subsequent decline in renal function associated with scleroderma renal crisis (SRC)�.***For minimization of nephrotoxicity in patients receiving cyclosporine (i.e., cyclosporine nephrotoxicity prophylaxis�) and low-dose methotrexate for allogeneic bone marrow transplant.***For use in peripheral nerve block� including brachial plexus�, intercostal� and peribulbar� blocks in combination with local anesthetics.***For the treatment of Tourette's syndrome�.***For the treatment of aggressive behavior and hyperactivity/inattentiveness in patients with autistic disorder�.***For growth hormone deficiency diagnosis�.***For the treatment of hot flashes� due to prostate cancer� and associated induced androgen deficiency� (andropause�"") in men who have had surgical or medication induced castration.""","***General Information***Abrupt discontinuation, vomiting***AV block, bradycardia, cerebrovascular disease, dehydration, heart failure, hypotension, myocardial infarction, orthostatic hypotension, syncope***Labor, obstetric delivery, pregnancy***Females***Breast-feeding***Children, infants, neonates***Depression***Driving or operating machinery***Sick sinus syndrome***Raynaud's phenomenon, thromboangiitis obliterans (Buerger's disease)***Diabetes mellitus***Renal disease, renal failure, renal impairment***Anticoagulant therapy, coagulopathy, infection***Cardiac disease***Intrathecal administration***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Polyarteritis nodosa, scleroderma, systemic lupus erythematosus (SLE)***Skin abrasion***Surgery***Pheochromocytoma***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5032']['8896'],guaifenesin/pseudoephedrine hydrochloride,"***For the treatment of cough and nasal congestion, including relief of eustachian tube congestion, associated with the common cold, sinusitis, or other upper respiratory conditions.***Formoterol***Formoterol; Mometasone","***General Information***MAOI therapy***Asthma, bronchitis, emphysema, tobacco smoking***Fever***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, heart failure, hypertension, myocardial infarction, tachycardia***Closed-angle glaucoma, diabetes mellitus, hyperthyroidism, peripheral vascular disease, prostatic hypertrophy, urinary retention***Renal failure, renal impairment***Children, infants***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,prednisolone acetate/sulfacetamide sodium,"***For steroid-responsive inflammatory ocular inflammation conditions (e.g., uveitis, bacterial conjunctivitis, corneal abrasion) for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. <br />        NOTE: Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies.<br />     ","***General Information***Fungal infection, herpes simplex keratitis (dendritic keratitis), mycobacterial infection, varicella, viral infection***Corticosteroid hypersensitivity, sulfonamide hypersensitivity, thimerosal hypersensitivity***Black patients, cataracts, glaucoma, increased intraocular pressure, ocular infection, ocular surgery, uveitis, visual disturbance***Abrupt discontinuation, corticosteroid withdrawal***Contact lenses***Intramuscular administration, intravenous administration***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,antihemophilic factor (recombinant),"***For the prevention and control of hemorrhage in patients with hemophilia A (classical hemophilia). <br />        NOTE: Humate, Kogenate, and ReFacto have been designated by the FDA as orphan drugs for the prophylaxis and management of hemorrhage or hemarthrosis in patients with hemophilia A.<br /> <br />NOTE: Guidelines for the treatment of acute bleeding and prevention of bleeding during surgery vary. For all indications, the dose of antihemophilic factor should be individualized taking into consideration the seriousness of the bleed or procedure, the clinical status of the patient, and the factor VIII activity concentration***For minor bleeding including early muscle bleed, early hemarthrosis, and oral bleeds.***For moderate bleeding including advanced muscle bleed, extensive hemarthrosis, hematoma, and mild head trauma.***For life- or limb-threatening bleeding including surgical bleeding, gastrointestinal bleeding, neck, tongue or pharyngeal hematoma with potential for airway compromise, intracranial, intraabdominal, or intrathoracic bleeding, or fractures.***For bleeding in patients with hemophilia A and factor VIII inhibitor titers less than 10 Bethesda Units and with low anamnestic responses.***For the perioperative management of surgical bleeding (surgical bleeding prophylaxis) in patients with hemophilia A.***For routine bleeding prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A.***For the management of hemorrhage or hemarthrosis in patients with von Willebrand's disease (vWD). <br />        NOTE: Humate-P has been designated by the FDA as orphan drugs for this indication.<br />     ***For major hemorrhage in patients with mild vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma or traumatic hemorrhage).***For minor hemorrhage in patients with moderate to severe vWD type I, type II, and type III (e.g., epistaxis, oral bleeding, or menorrhagia).***For major hemorrhage in patients with moderate to severe vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For major hemorrhage in patients with vWD type II and III (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For surgical bleeding prophylaxis during major or minor procedures in patients with vWD in whom desmopressin is either ineffective or contraindicated. <br />          NOTE: Alphanate and Humate-P have been designated by the FDA as orphan drugs for this indication.<br />       ","***General Information***Pregnancy***Breast-feeding***Thromboembolic disease***Hepatitis, infection, viral infection***Anemia***Bovine protein hypersensitivity, hamster protein hypersensitivity, latex hypersensitivity, mannitol hypersensitivity, murine protein hypersensitivity, polysorbate 80 hypersensitivity***Porcine protein hypersensitivity***Human immunodeficiency virus (HIV) infection***Cardiac disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pyrantel pamoate,***For the treatment of enterobiasis (pinworm infection).***For the treatment of ascariasis�.***For the treatment of uncinariasis� (hookworm infection).***For the treatment of trichostrongyliasis�.,***Hepatic disease***Phenylketonuria***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"10 mg, 25 mg, 50 mg, 75 mg, 100 mg) (doxepin hydrochloride","***For the treatment of major depression and/or anxiety, including psychotic depressive disorders with associated anxiety.***For the topical treatment of eczematous dermatitis (atopic dermatitis, eczema, or lichen simplex chronicus).***For migraine prophylaxis�.","***Carbamazepine hypersensitivity, tricyclic antidepressant hypersensitivity***MAOI therapy***Acute myocardial infarction, cardiac arrhythmias, cardiac disease, congenital heart disease, heart failure, myocardial infarction, orthostatic hypotension, QT prolongation***Children, suicidal ideation***Bipolar disorder, mania, schizophrenia***Alcoholism, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Electroconvulsive therapy (ECT), seizure disorder, seizures***Hepatic disease***Surgery***Anticholinergic medications, ileus, prostatic hypertrophy, urinary retention***Closed-angle glaucoma, increased intraocular pressure***Contact lenses***Agranulocytosis, leukopenia***Hyperthyroidism, hypothyroidism, thyroid disease***Diabetes mellitus, pheochromocytoma***Sleep apnea***Radiographic contrast administration***Sunlight (UV) exposure***Occlusive dressing***Abrupt discontinuation***Geriatric***Pregnancy***Breast-feeding***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,atropine sulfate/hyoscyamine sulfate/phenobarbital/scopolamine hydrobromide,"***For the adjunctive treatment of irritable bowel syndrome� (irritable colon, spastic colon, mucous colitis), acute enterocolitis�, or duodenal ulcer�.","***Barbiturate hypersensitivity, carbamazepine hypersensitivity, hydantoin hypersensitivity, lactase deficiency***Abrupt discontinuation, substance abuse***Driving or operating machinery, ethanol intoxication***Depression, mental status changes, suicidal ideation***Geriatric***Acute myocardial infarction, bleeding, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypertension, hyperthyroidism, mitral stenosis, tachycardia, thyrotoxicosis***Asthma, chronic obstructive pulmonary disease (COPD), pulmonary disease, respiratory depression, respiratory infection***Autonomic neuropathy, bladder obstruction, prostatic hypertrophy, renal failure, renal impairment, urinary retention, urinary tract obstruction***Hepatic disease***Anticoagulant therapy, porphyria***Myasthenia gravis***Achalasia, colostomy, diarrhea, esophagitis, gastroesophageal reflux disease (GERD), GI obstruction, hiatal hernia, ileostomy, ileus, peptic ulcer disease, pseudomembranous colitis, pyloric stenosis, toxic megacolon, ulcerative colitis***Closed-angle glaucoma, contact lenses, glaucoma, synechia***Ambient temperature increase, dehydration, fever, strenuous exercise***Children, infants, neonates***Pregnancy***Breast-feeding***Dental disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7005'],mitoxantrone,"***For the treatment of acute myelogenous leukemia (AML). <br />        NOTE: Mitoxantrone has been designated an orphan drug by the FDA for this indication.<br />NOTE: If used, consolidation therapy is recommended to be withheld until full hematologic recovery occurs***For the treatment of refractory acute myelogenous leukemia in combination with etoposide and cytarabine�.***For the treatment of relapsed or refractory acute myelogenous leukemia in combination with cladribine, cytarabine, and filgrastim�.***For the treatment of acute myelogenous leukemia in combination with cytarabine.***For the palliative treatment of severe pain related to advanced hormone-refractory prostate cancer in combination with corticosteroids. <br />        NOTE: Mitoxantrone has been designated an orphan drug by the FDA for this indication.<br />     ***For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis to reduce neurologic disability and/or frequency of clinical relapses. <br />  NOTE: Mitoxantrone is not indicated in the treatment of primary progressive multiple sclerosis.<br />NOTE: Mitoxantrone has been designated an orphan drug by the FDA for this indication.<br />NOTE: Patients with LVEF less than 50%, a clinically significant reduction in LVEF during mitoxantrone therapy, neutrophil count less than 1500/mm3, or a cumulative lifetime dose of 140 mg/m2 should not be treated with mitoxantrone. Further, in July 2008, the FDA issued a MedWatch alerting clinicians to the possibility of decreased LVEF and frank congestive heart failure in patients who had received a cumulative lifetime mitoxantrone dose less than 100 mg/m2. LVEF should be evaluated before initiating treatment with mitoxantrone, prior to administration of each dose, and at yearly intervals after completion of treatment***For the treatment of relapsed or refractory acute lymphocytic leukemia (ALL)� in combination with ifosfamide and etoposide.***For the treatment of malignant pleural effusion�.***For the treatment of previously treated metastatic breast cancer�.***For autologous stem cell transplant preparation� in patients with relapsed/refractory lymphoma, in combination with melphalan.***For the treatment of metastatic hepatocellular cancer� in combination with 5-fluorouracil and cisplatin.***For the treatment of chronic lymphocytic leukemia (CLL)�, in combination with cladribine and cyclophosphamide.***For the treatment of non-Hodgkin's lymphoma (NHL)�.***For the treatment of relapsed or refractory NHL in combination with rituximab, ifosfamide, and etoposide�.***For the treatment of intermediate or high-grade NHL in combination with cyclophosphamide, vincristine, and prednisone�.***For the treatment of previously untreated follicular NHL in combination with fludarabine and rituximab�.***Formoterol; Mometasone","***Cardiac disease, cardiotoxicity, heart failure, maximum cumulative lifetime dose, radiation therapy, ventricular dysfunction***New primary malignancy***Bone marrow suppression, coagulopathy, fungal infection, herpes infection, neutropenia, requires an experienced clinician, thrombocytopenia, varicella, viral infection***Dental disease, dental work***Intraarterial administration, intrathecal administration***Intramuscular injections***Extravasation, intramuscular administration, subcutaneous administration***Hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, tumor lysis syndrome (TLS)***Hepatic disease, jaundice***Pregnancy***Breast-feeding***Accidental exposure, ocular exposure***Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['59839'],penciclovir,***For the treatment of recurrent herpes labialis or herpes facialis.,"***Acyclovir hypersensitivity, famciclovir hypersensitivity, ganciclovir hypersensitivity, penciclovir hypersensitivity, valacyclovir hypersensitivity, valganciclovir hypersensitivity***Ophthalmic administration***Immunosuppression***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,lidocaine hydrochloride,"***For the treatment of perfusing ventricular arrhythmias including ventricular fibrillation (VF) and ventricular tachycardia (VT) that may result during acute myocardial infarction or cardiac manipulation (e.g., cardiac surgery). <br />  NOTE: See resuscitation indication for dosage guidelines for VF or pulseless VT.<br />NOTE: Although not considered a drug of choice for ventricular arrhythmias, lidocaine may be used as an alternative antiarrhythmic in patients with preserved ventricular function and stable monomorphic VT. Lidocaine may also be used to treat polymorphic VT in patients with a normal QT interval (when electrolyte imbalance and ischemia are treated). If pulseless cardiac arrest associated with VF or VT, see separate dosage guidelines for the treatment ventricular arrhythmias during CPR.<br />NOTE: Lidocaine may be used to treat patients with polymorphic VT associated with QT prolongation (e.g., torsade de pointes).<br />NOTE: Monitor blood pressure and the electrocardiogram (ECG) during intravenous lidocaine administration***For topical anesthesia of skin and mucous membranes or stomatitis.***For prevention of dental pain� and for topical anesthesia of mucous membranes.***For laryngoscopy.***For nonurgent painful procedures including IV cannulation, venipuncture, lumbar puncture, or arterial puncture.***For the treatment of stage 1 thru 4 pressure ulcers, venous stasis ulcers, ulcerations of mixed vascular etiologies, diabetic skin ulcers, first and second degree burns, and post surgical incisions, cuts, and abrasions.***For endotracheal intubation.***For neonatal circumcision�.***For bronchoscopy.***For the treatment of pain associated with postherpetic neuralgia.***For ophthalmic anesthesia.***For local anesthesia including peripheral nerve block anesthesia. <br />        NOTE: In adults, the dosages for local anesthesia reported are general guidelines only. The actual dose depends on a variety of factors such as depth of anesthesia, extent of surgical procedure, degree of muscle relaxation required, duration of anesthesia and the patients' physical condition. See Lidocaine; epinephrine monograph for information concerning combination dosing.<br />     ***For dental anesthesia including mandibular nerve block and maxillary infiltration.***For infiltration anesthesia.***For intravenous regional anesthesia.***For pudendal nerve block.***For paravertebral block.***For intercostal nerve block.***For brachial plexus block.***For paracervical block.***For sympathetic nerve block.***For cervical stellate ganglion block.***For lumbar sympathetic block.***For epidural anesthesia. <br />        NOTE: The dose is determined by the number of dermatomes to anesthetized (2 to 3 mL/dermatome). The suggested concentrations and volumes serve as a guide, other volumes and concentrations may be used provided the maximum dose is not exceeded.<br />     ***For lumbar anesthesia.***For lumbar analgesia for severe pain.***For thoracic.***For caudal anesthesia.***For obstetric anesthesia.***For surgical anesthesia.***For spinal anesthesia.***For obstetrical low spinal or saddle block anesthesia.***For intraabdominal anesthesia.***For the treatment of ventricular arrhythmias during cardiopulmonary resuscitation� (CPR).***For the attenuation of increased intracranial pressure� during rapid-sequence intubation� or endotracheal tube suctioning�.***For the treatment of severe singultus (hiccups)�.***For the treatment of headache�.***For the treatment of acute headache� associated with migraine�.***For the treatment of cluster headache�.***For the symptomatic treatment of corticosteroid-dependent asthma�. <br />        NOTE: Initial bronchoconstriction can occur. In addition, lidocaine toxicity can result in tremors, hallucinations, seizures, and cardiac arrest. Caution is advised until long-term safety and efficacy can be established.<br />     ***For short-term prophylaxis of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing� (SUNCT).***For the treatment of painful diabetic neuropathy� in adults.","***General Information***Amide local anesthetic hypersensitivity, epidural anesthesia***Collagen-vascular disease***G6PD deficiency***Geriatric, heart failure, hepatic disease***Hypotension, pregnancy***Breast-feeding***Adams-Stokes syndrome, atrial fibrillation, atrial flutter, AV block, bradycardia, cardiogenic shock, hemorrhagic shock, hypovolemia, shock, Wolff-Parkinson-White syndrome***Renal disease, renal failure, renal impairment***Burns, eczema, heating pad, occlusive dressing, skin abrasion***Cataracts, ocular exposure, ocular trauma***Accidental exposure***Intraarterial administration, intrathecal administration, intravenous administration***Head and neck anesthesia***Ocular surgery***Anticoagulant therapy, bleeding, coagulopathy, infection, neurological disease, requires a specialized care setting, requires an experienced clinician, sepsis, spinal anesthesia, thrombocytopenia***Fetal distress, labor, obstetric delivery, pudendal nerve block***Continuous intraarticular infusion administration***Fetal prematurity, paracervical nerve block***Malignant hyperthermia***Children, infants, neonates, teething pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dexamethasone sodium phosphate,"***For the treatment of adrenocortical function abnormalities, such as adrenocortical insufficiency, congenital adrenal hyperplasia, chronic primary (Addison's disease) or secondary adrenocortical insufficiency, or adrenogenital syndrome.***For hypothalamic-pituitary-adrenal (HPA) suppression diagnosis (e.g., dexamethasone suppression tests).***For use as a test for Cushing's syndrome.***For use as a test to distinguish Cushing's syndrome secondary to pituitary ACTH excess from Cushing's syndrome secondary to other causes.***For the treatment of allergic conditions, such as acute anaphylaxis, anaphylactoid reactions, anaphylactic shock, angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, or serum sickness reactions.***For acute anaphylaxis or anaphylactoid reactions.***For anaphylactic shock.***For the systemic treatment of other allergic disorders including angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, or serum sickness.***For the treatment of cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.***For treatment of cerebral edema in pediatric patients.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of kidney transplant rejection in conjunction with other immunosuppressants or for the treatment of acute graft-versus-host disease (GVHD).***For the reduction of edema and inflammation associated with selected cases of otitis externa.***For the treatment of pruritus and inflammatory effects of corticosteroid-responsive dermatologic disorders, including dermatitis, alopecia areata, atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis (including Rhus dermatitis due to poison ivy, poison oak, poison sumac), discoid lupus erythematosus, eczema, exfoliative dermatitis, granuloma annulare, keloids, lichen planus, lichen simplex chronicus or neurodermatitis, necrobiosis lipoidica diabeticorum, pemphigus, polymorphous light eruption, plaque psoriasis, cutaneous T-cell lymphoma (CTCL) or mycosis fungoides, severe seborrheic dermatitis, urticaria, and severe erythema multiforme or Stevens-Johnson syndrome.***For systemic treatment of inflammatory and allergic dermatoses (e.g., severe dermatitis, psoriasis, or exfoliative dermatitis, erythema multiforme, or Stevens-Johnson syndrome).***For intralesional or soft-tissue treatment of specific corticosteroid-responsive skin or soft-tissue lesions.***For adjunctive therapy in the treatment of rheumatic disorders including acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, synovitis of osteoarthritis, and for psoriatic arthritis; or for the treatment of acute episodes or exacerbation of nonrheumatic inflammatory conditions including acute and subacute bursitis, epicondylitis, acute non-specific tenosynovitis, and cystic tumors of an aponeurosis tendon (ganglia).***For the treatment of hematologic disorders such as secondary thrombocytopenia in adults, autoimmune hemolytic anemia, erythroblastopenia, congenital hypoplastic anemia, and thrombocytopenia associated with immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of acute asthma� exacerbation.***For the treatment of hypercalcemia related to sarcoidosis or cancer, or for the treatment of nonsuppurative thyroiditis, or for severe cases of myasthenia gravis not controlled by antimyasthenic agents alone.***For the treatment of hypercalcemia related to cancer or for the treatment of nonsuppurative thyroiditis in pediatric patients.***For the treatment of nephrotic syndrome to induce diuresis or decrease proteinuria.***For the treatment of Hodgkin lymphoma.***For the treatment of non-Hodgkin's lymphoma (NHL).***For the palliative treatment of NHL.***For the treatment of relapsed or refractory, aggressive NHL in transplant eligible patients, in combination with gemcitabine and cisplatin (and rituximab for CD20-positive disease)�.***For the treatment of relapsed or refractory diffuse large B-cell lymphoma in transplant eligible patients, in combination with cisplatin and cytarabine (DHAP regimen) and ofatumumab�.***For the treatment of acute lymphocytic leukemia (ALL).***For the treatment of multiple myeloma.***For the treatment of multiple myeloma in patients who have received at least 1 prior therapy, in combination with lenalidomide.***For the treatment of patients with newly diagnosed multiple myeloma, in combination with lenalidomide.***For newly diagnosed multiple myeloma as induction therapy prior to autologous stem-cell transplantation, in combination with doxorubicin and vincristine�.***For newly diagnosed multiple myeloma, in combination with thalidomide.***For newly diagnosed multiple myeloma as induction therapy prior to autologous stem-cell transplantation, in combination with bortezomib�.***For newly diagnosed multiple myeloma as induction therapy prior to autologous stem-cell transplantation, in combination with bortezomib and thalidomide�.***For the treatment of multiple myeloma in patients who have received at least 2 prior therapies (including bortezomib and an immunomodulatory agent), in combination with panobinostat and bortezomib.***For the treatment of relapsed multiple myeloma in patients who have received 1 to 3 prior lines of therapy, in combination with carfilzomib and lenalidomide.***For the treatment multiple myeloma in patients who have received at least 1 prior therapy, in combination with daratumumab and bortezomib.***For the treatment of multiple myeloma in patients who have received at least 1 prior therapy, in combination with daratumumab and lenalidomide.***For the treatment of newly diagnosed multiple myeloma, in combination with bortezomib and lenalidomide�.***For the treatment of multiple myeloma in patients who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor, in combination with pomalidomide and daratumumab.***For the treatment of acute exacerbations of multiple sclerosis.***For the treatment of inflammatory bowel disease during critical periods of ulcerative colitis and regional enteritis (Crohn's disease).***For the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment inflammation of the globe, such as allergic conjunctivitis, eyelid acne rosacea, superficial punctate keratitis, herpes zoster ocular infection associated keratitis, iritis, cyclitis, vernal keratoconjunctivitis, selected infective viral conjunctivitis or postoperative ocular inflammation when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal abrasion, corneal ulcer, or corneal injury from chemical or thermal burns, or penetration of foreign bodies; systemic treatment may be indicated for uveitis, sympathetic ophthalmia, and ocular inflammatory conditions unresponsive to topical corticosteroids.***For the treatment of non-infectious uveitis affecting the posterior segment of the eye in adults.***For the treatment of diabetic macular edema.***For the treatment of macular edema following retinal vein occlusion, including branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).***For the prevention of extubation failure in pediatric patients at increased risk for laryngeal edema (i.e., laryngeal edema prophylaxis�).***For use as an adjunct in the management of extradural malignant spinal cord compression� (MSCC�) associated with metastatic disease.***For the adjunctive treatment of bacterial meningitis� (non-tuberculous).***For the treatment of chemotherapy-induced nausea/vomiting� (CINV�) and for chemotherapy-induced nausea/vomiting prophylaxis�.***For the treatment of respiratory conditions including aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), Loeffler's syndrome, or noncardiogenic pulmonary edema�.***For the treatment of acute respiratory distress syndrome (ARDS)�.***For the treatment of laryngotracheobronchitis (croup)�.***For hyaline membrane disease prophylaxis�, for the purpose of fetal lung maturation to prophylax against anticipated neonatal respiratory distress syndrome (RDS)� in premature infants.***For the prevention of chronic lung disease (CLD)� in mechanically ventilated neonates.***For therapy in selected cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis�, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, symptomatic sarcoidosis, vasculitis�, or Wegener's granulomatosis�; also for the treatment of neurologic or myocardial involvement associated with trichinosis.***For the treatment of acute altitude sickness�, including the treatment of high altitude cerebral edema.***For altitude sickness prophylaxis<strong>***For the adjunctive treatment of infertility� in combination with clomiphene therapy.***For the treatment of post-operative nausea/vomiting (PONV)�.***For post-operative nausea/vomiting (PONV) prophylaxis�.***For the treatment of bronchiolitis�.***For the treatment of Waldenstrom macroglobulinemia�.***For the treatment of newly diagnosed Waldenstrom macroglobulinemia, in combination with rituximab and cyclophosphamide�.***For the treatment of newly diagnosed Waldenstrom macroglobulinemia, in combination with bortezomib and rituximab�.***For the treatment of amyloidosis�.***For the treatment of systemic amyloid light-chain amyloidosis, in combination with lenalidomide and cyclophosphamide�.***For the treatment of systemic amyloid light-chain amyloidosis, in combination with lenalidomide and melphalan�.","***Epidural administration***Abrupt discontinuation, corneal abrasion, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, growth inhibition, increased intracranial pressure***Immunosuppression***Surgery***Acne rosacea, acne vulgaris, fungal infection, herpes infection, herpes simplex keratitis (dendritic keratitis), infection, measles, ocular infection, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Myocardial infarction***Heart failure, hypertension***Osteoporosis***Diabetes mellitus***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hypothyroidism, psychosis, renal disease, seizure disorder***Myasthenia gravis***Coagulopathy, thromboembolic disease***Cataracts, glaucoma, increased intraocular pressure, myopia, ocular exposure, open-angle glaucoma, rupture of posterior ocular lens capsule, visual disturbance***Pregnancy***Neonates, premature neonates***Breast-feeding***Vaccination***Asthma, benzyl alcohol hypersensitivity, sulfite hypersensitivity***Corticosteroid hypersensitivity***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['26225'],ondansetron,***For chemotherapy-induced nausea/vomiting prophylaxis (CINV prophylaxis) and radiation-induced nausea/vomiting prophylaxis (RINV prophylaxis).***For post-operative nausea/vomiting (PONV) prophylaxis.***For the treatment of post-operative nausea/vomiting (PONV)�.***For hyperemesis gravidarum� (severe pregnancy-induced nausea/vomiting) unresponsive to other antiemetics.***For the short-term treatment of nausea/vomiting associated with acute gastroenteritis�.***For the treatment of pruritus� secondary to cholestasis.***For the maintenance treatment of alcohol dependence�.***For the treatment of cyclic vomiting syndrome�.***Formoterol***Formoterol; Mometasone,"***General Information***Hepatic disease, hepatitis***Dolasetron hypersensitivity, granisetron hypersensitivity, ondansetron hypersensitivity, palonosetron hypersensitivity***Phenylketonuria***GI obstruction, ileus***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Children***Infants, neonates***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['161'],acetaminophen,"***For the treatment of fever. <br />        NOTE: Acetaminophen should not be used for self-medication of marked fever (greater than 39.5 degrees C or 103.1 degrees F), fever persisting longer than 3 days, or recurrent fever, unless directed by a physician.<br />     ***For the treatment of mild pain or for the temporary relief of headache, myalgia, back pain, musculoskeletal pain, dental pain (e.g., toothache), dysmenorrhea, arthralgia, or minor aches and pains associated with the common cold or flu. <br />        NOTE: Acetaminophen should not be used for self-medication of pain for longer than 10 days in adults or 5 days in children.<br />     ***For the treatment of moderate pain to severe pain with adjunctive opioid analgesics.***For minor osteoarthritis pain.***For the treatment of headache pain due to acute migraine�.","***Acetaminophen hypersensitivity***Alcoholism, ethanol intoxication, hepatic disease, hepatitis, hepatotoxicity, hypovolemia, malnutrition, potential for overdose or poisoning***Renal disease, renal failure, renal impairment***G6PD deficiency***Bone marrow suppression, immunosuppression, infection, neutropenia***Tobacco smoking***Children, infants, neonates***Pregnancy***Breast-feeding***Phenylketonuria***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],estradiol/norethindrone acetate,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For osteoporosis prophylaxis due to menopause (natural or surgical) in women with an intact uterus.***For the treatment of female hypogonadism or primary ovarian failure in premenopausal females with an intact uterus.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['263034'],panitumumab,"***For the treatment of wild-type RAS (both KRAS and NRAS) metastatic colorectal cancer. ***For the first-line treatment of wild-type RAS (both KRAS and NRAS) metastatic colorectal cancer in combination with FOLFOX4.***For the monotherapy treatment of wild-type RAS (both KRAS and NRAS) metastatic colorectal cancer that has progressed during or after fluoropyrimidine-, oxaliplatin-, and irinotecan-containing regimens.***For the first-line treatment of wild-type RAS (both KRAS and NRAS) metastatic colorectal cancer in combination with mFOLFOX6.","***KRAS mutations***Hamster protein hypersensitivity***Acute bronchospasm, fever, hypotension, infusion-related reactions***Infection, sepsis, serious rash, skin disease, sunlight (UV) exposure***Pneumonitis, pulmonary disease, pulmonary fibrosis***Electrolyte imbalance, hypocalcemia, hypokalemia, hypomagnesemia***Keratitis, ocular disease***Geriatric***Pregnancy***Contraception requirements, infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['3640', '1545992']",doxycycline,"***For the treatment of skin and skin structure infections, including cellulitis, due to <em>Staphylococcus aureus</em>. <br />        NOTE: Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infection.<br />     ***For the treatment of bacterial urinary tract infection (UTI).***For the treatment of upper respiratory tract infections (e.g., sinusitis).***For the treatment of lower respiratory tract infections (e.g., pneumonia, community-acquired pneumonia).***For the treatment of severe acne vulgaris as adjunctive therapy.***For the treatment of acne rosacea.***For the treatment of cholera.***For the treatment of brucellosis.***For the treatment of Rickettsial infections (e.g., Rickettsial pox, Rocky Mountain spotted fever, scrub typhus) including endemic murine typhus.***For the treatment of relapsing fever due to <em>Borrelia recurrentis</em>.***For the treatment of syphilis. <br />        NOTE: A Jarisch-Herxheimer reaction may occur within the first 24 hours of therapy.<br />NOTE: While clinical practice guidelines recommend non-penicillin alternatives for the treatment of syphilis in HIV-infected patients, their efficacy has not been evaluated and should only be used with close clinical and serologic monitoring***For primary, secondary, or early latent syphilis (caused by <em>Treponema pallidum</em>) in nonpregnant, penicillin-allergic patients.***For late latent syphilis in nonpregnant, penicillin-allergic patients.***For the treatment of psittacosis.***For the treatment of non-gonococcal urethritis (NGU) and chlamydia infection, including trachoma and inclusion bacterial conjunctivitis.***For the treatment of lymphogranuloma venereum caused by <em>Chlamydia trachomatis</em>.***For the treatment of granuloma inguinale (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of epididymitis and epididymo-orchitis.***For malaria prophylaxis in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains.***For the treatment of anthrax infection due to exposure to <em>Bacillus anthracis</em>.***For the treatment of cutaneous anthrax infection.***For the treatment of systemic anthrax infection.***For anthrax prophylaxis after exposure to <em>Bacillus anthracis</em> (postexposure prophylaxis, PEP).***For the treatment of plague infection due to exposure to <em>Yersinia pestis</em>.***For the treatment of plague infection in an individual patient or in a contained casualty setting.***For the treatment of plague infection in a mass casualty setting.***For the initial treatment of tularemia infection due to exposure to <em>Francisella tularensis </em>.***For the initial treatment of tularemia infection in individual patient or in a contained casualty setting. <br />          NOTE: Streptomycin is the drug of choice to treat tularemia in most patients; gentamicin is the preferred agent in pregnant women.<br />       ***For the initial treatment of tularemia infection in a mass casualty setting. <br />          NOTE: It is recommended that pregnant women be treated with ciprofloxacin as a first-line agent; doxycycline is a preferred treatment choice if ciprofloxacin is contraindicated.<br />       ***For the treatment of intestinal amebiasis as an adjunct to amebicides.***For the treatment of infections caused by sensitive organisms including actinomycosis (<em>Actinomyces israelii</em>), yaws (<em>Treponema pertenue</em>), necrotizing ulcerative gingivitis (Fusospirochetosis or Vincent's infection), and listeriosis (<em>Listeria monocytogenes</em>).***For the treatment of Q fever.***For the treatment of chancroid (<em>Haemophilus ducreyi</em>) infections.***For the treatment of bartonellosis (<em>Bartonella bacilliformis</em>) infections, including <em>Bartonella</em> endocarditis.***For the treatment of <em>Bartonella</em> sp. infections (bartonellosis) in HIV-infected patients.***For long term suppression� of infections caused by <em>Bartonella</em> sp. in HIV-infected patients with relapse or reinfection with CD4 count less than 200 cells/mm3.***For the treatment of enterocolitis�, biliary tract infections�, and intraabdominal infections�.***For the treatment of uncomplicated gonorrhea (e.g., cervicitis, urethritis, pharyngitis, proctitis�).***For the treatment of acute proctitis�.***For chlamydial infection prophylaxis� in victims of sexual assault.***For the treatment of chronic prostatitis� due to <em>Ureaplasma urealyticum</em>.***For the treatment of Lyme disease�, including erythema migrans�, Lyme arthritis�, Lyme carditis�, and Lyme meningitis�.***For early Lyme disease� (erythema migrans�).***For Lyme arthritis�.***For Lyme carditis�.***For early neurologic Lyme disease (i.e., Lyme meningitis� or cranial nerve palsy).***For Lyme disease prophylaxis�.***For the treatment of Legionnaire's disease� caused by <em>Legionella pneumophila</em>.***For the management of pleural effusion� as an alternative to injectable tetracycline or other agents.***For the treatment of malaria� due to <em>P. falciparum</em> or <em>P. vivax</em>.***For the treatment of pelvic inflammatory disease (PID)� and tubo-ovarian abscess�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis in combination with conventional treatment (e.g., scaling and root planing).***For aggressive juvenile periodontitis�.***For chronic adult periodontitis for a gain in clinical attachment, reduction in probing depth, and reduction in bleeding on probing.***For plague prophylaxis� following exposure to <em>Yersinia pestis</em>.***For tularemia prophylaxis� following exposure to <em>Francisella tularensis</em>.***For the treatment of Bancroft's filariasis� (elephantiasis) caused by <em>Wuchereria bancrofti</em>�.***For the treatment of melioidosis� due to <em>Burkholderia pseudomallei</em>.***For use as an adjunct in the treatment of <em>Burkholderia pseudomallei</em> bacteremia�.***For use as an adjunct in the treatment of localized melioidosis�.***For the treatment of leptospirosis� due to <em>Leptospira</em> sp.�.***For mild leptospirosis�.***For severe leptospirosis�.***For surgical infection prophylaxis� for gynecologic procedures.***For surgical infection prophylaxis� for hysterosalpingogram or chromotubation.***For surgical infection prophylaxis� for induced abortion/dilation and evacuation.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated bone and joint infections�, including osteomyelitis�, or orthopedic device-related infection�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated osteomyelitis�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated prosthetic device infections�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated spinal implant infections�.","***Tetracyclines hypersensitivity***Hepatic disease***Sunlight (UV) exposure***Asthma, sulfite hypersensitivity***Achlorhydria***Pregnancy***Breast-feeding***Children, infants, neonates***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Dental disease, periodontal disease***Chemotherapy, diabetes mellitus, human immunodeficiency virus (HIV) infection, immunosuppression***Antimicrobial resistance, fungal infection, viral infection***Increased intracranial pressure, obesity***Sexually transmitted disease***Geriatric***Serious rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hypromellose,***For the temporary relief of xerophthalmia and minor ocular irritation.,"***Contact lenses***Corneal abrasion, ocular infection, ocular trauma, visual disturbance***Pregnancy***Children, infants, neonates***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['595060'],ranibizumab,***For the treatment of neovascular (wet) age-related macular degeneration (AMD).***For the treatment of diabetic macular edema and diabetic retinopathy.***For the treatment of macular edema following retinal vein occlusion.***For the treatment of myopic choroidal neovascularization (CNV).,"***General Information***Ocular infection***Ocular surgery***Glaucoma, increased intraocular pressure***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,echothiophate iodide,"***For the treatment of chronic open-angle glaucoma; subacute or chronic angle-closure glaucoma following iridectomy or where surgery is refused or contraindicated; or non-uveitic secondary glaucoma, especially following cataract surgery.***For the diagnosis and treatment of strabismus of the accommodative estropia type.***For diagnosis.***For the treatment of accommodative strabismus.","***General Information***Closed-angle glaucoma***Aphakia, retinal detachment***Iritis, uveitis***Acute myocardial infarction, bradycardia, cardiac disease, hypotension***Asthma***Contact lenses, corneal abrasion***Ocular surgery***GI obstruction, Parkinson's disease, peptic ulcer disease, seizure disorder, urinary tract obstruction***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['358263'],tadalafil,"***For the treatment of erectile dysfunction (ED), including ED patients with diabetes mellitus or following radical prostatectomy.***For use as needed for ED.***For use once daily for ED without regard to timing of sexual activity.***For the concurrent treatment of erectile dysfunction and benign prostatic hypertrophy.***For improvement in exercise ability in patients with WHO Group I pulmonary hypertension.***For the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).***For the concurrent treatment of benign prostatic hyperplasia and erectile dysfunction.***For the treatment of sexual dysfunction� in males receiving antidepressant therapy.***For altitude sickness prophylaxis<strong>","***General Information***Nitrate/nitrite therapy***Dialysis, renal failure, renal impairment***Hepatic disease***Angina, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypertension, hypotension, hypovolemia, myocardial infarction, stroke***Leukemia, multiple myeloma, penile structural abnormality, polycythemia, priapism, sickle cell disease***Human immunodeficiency virus (HIV) infection***Non-arteritic anterior ischemic optic neuropathy, retinitis pigmentosa, visual disturbance***Geriatric***Prostate cancer***Gastroesophageal reflux disease (GERD), hiatal hernia, peptic ulcer disease***Pregnancy***Breast-feeding***Hematological disease***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diltiazem hydrochloride,"***For the treatment of hypertension.***For the treatment of chronic stable angina.***For the treatment of variant angina (Prinzmetal's angina).***For the treatment of paroxysmal supraventricular tachycardia (PSVT) or control of ventricular rate in atrial flutter or atrial fibrillation.***For the short-term treatment of rapid ventricular rate secondary to atrial arrhythmias� in adolescents, children, and infants.***For long-term control of ventricular rate in atrial flutter� or atrial fibrillation�.***For the relief of ongoing ischemia in patients with unstable angina� or after acute non-ST-segment elevation myocardial infarction� in the absence of congestive heart failure, pulmonary congestion, left ventricular dysfunction, or AV block, when beta-blockers are ineffective or contraindicated.***For the treatment of idiopathic dilated cardiomyopathy�.***For migraine prophylaxis�.***For the treatment of proteinuria� associated with diabetic nephropathy�.","***Acute myocardial infarction, bradycardia, cardiogenic shock, heart failure, ventricular dysfunction***Hypotension***AV block***Sick sinus syndrome***Lown-Ganong-Levine syndrome, ventricular tachycardia, Wolff-Parkinson-White syndrome***Hepatic disease***Aortic stenosis***Gastroesophageal reflux disease (GERD), hiatal hernia***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,propranolol hydrochloride,"***For the treatment of chronic stable angina.***For heart rate control in patients with atrial fibrillation and/or atrial flutter.***For the treatment of paroxysmal supraventricular tachycardia (PSVT) or for paroxysmal supraventricular tachycardia (PSVT) prophylaxis.***For the treatment of an evolving acute myocardial infarction. <br />  NOTE: For ST-elevation myocardial infarction, oral beta-blocker therapy should be initiated in the first 24 hours for patients who do not have signs of cardiac failure, evidence of low output, increased risk for cardiogenic shock, or other contraindications for beta-blocker therapy.<br /***For reduction of cardiovascular mortality in stable patients who have sustained a myocardial infarction.***For the treatment of hypertension.***For the treatment of idiopathic hypertrophic subaortic stenosis (IHSS).***For management of pheochromocytoma, including preoperative control of tachycardia before surgery, in conjunction with an alpha-blocker.***For migraine prophylaxis.***For migraine prophylaxis in pediatric patients�.***For migraine prophylaxis in adults.***For the management of tremor.***For the management of essential tremor.***For the management of lithium-induced tremor�.***For the management of essential tremor in pediatric patients.***For the treatment of a proliferating infantile hemangioma requiring systemic therapy. <br />  To reduce the risk of hypoglycemia, administer propranolol immediately after or concurrently with a feeding. Avoid fasting; if inevitable, hold medication or support with a product such as Pedialyte or glucose-containing IV fluids.  Vital signs and cardiorespiratory exam or ECG should be obtained at baseline. Obtain blood pressure and heart rate measurements at 1 and 2 hours after the initial dose and any significant dose increase (e.g., more than 0.5 mg/kg/day).  Experts have recommended propranolol therapy continue until full involution of the lesion has occurred or the patient is at least 1 year of age; recurrences have been reported with early discontinuation. At the end of therapy, gradually taper propranolol over 2 to 4 weeks.      If hemangiomas recur, treatment may reinitiated.<br /***For the treatment of unstable angina�.***For the treatment of anxiety� or panic attacks�.***For the short-term symptomatic management of thyrotoxicosis� and thyroid storm�.***For the short-term symptomatic management of thyrotoxicosis� and thyroid storm� in pediatric patients.***For the short term management of thyrotoxicosis� or thyroid storm in adults�.***For the treatment of hypertension and the subsequent decline in renal function associated with scleroderma renal crisis (SRC)�.***For the treatment of portal hypertension� and/or variceal bleeding prophylaxis� in patients with esophageal varices�.***For the prevention of first variceal bleed (primary variceal bleeding prophylaxis).***For prevention of recurrence of variceal bleed (secondary variceal bleeding prophylaxis).***For the treatment of chronic agitation� or aggressive behavior.***For the prevention and management of hypercyanotic episodes associated with tetralogy of Fallot (i.e., tetralogy spells�).***For the attenuation of hypermetabolism in patients with severe burns�.***For the attenuation of hypermetabolism in adult patients with severe burns.***For the attenuation of hypermetabolism in pediatric patients with severe burns.***For the treatment of heart failure� (ischemic origin or cardiomyopathy�) usually in conjunction with digoxin, diuretics, or ACE inhibitor therapy in children and infants.***For the maintenance of sinus rhythm in patients with supraventricular arrhythmias�, including Wolff-Parkinson-White (WPW) syndrome� and junctional ectopic tachycardia� (JET).***Formoterol; Mometasone","***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***Acute heart failure, AV block, bradycardia, cardiogenic shock, hypotension, pheochromocytoma, pulmonary edema, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Wolff-Parkinson-White syndrome***Cerebrovascular disease, PHACE syndrome, stroke***Diabetes mellitus, hypoglycemia***Hepatic disease***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Beta-blocker hypersensitivity***Raynaud's phenomenon***Myasthenia gravis, myopathy***Depression***Driving or operating machinery***Renal failure, renal impairment***Psoriasis***Surgery***Children, infants, neonates, premature neonates***Obstetric delivery, pregnancy***Breast-feeding***Geriatric***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,alpha1-proteinase inhibitor (human),***For chronic augmentation and maintenance therapy in adults with emphysema due to alpha-1 proteinase inhibitor (A1PI) deficiency.,"***General Information***IgA deficiency***Viral infection***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['6876', '1545996']",methyldopa,***For the treatment of hypertension.***For the treatment of hypertensive emergency or hypertensive urgency.,"***General Information***Autoimmune disease, hemolytic anemia***Hepatic disease, hepatitis***MAOI therapy***Pheochromocytoma***Dialysis, renal failure, renal impairment***Cardiac disease, cerebrovascular disease***Depression, mental status changes, Parkinson's disease***Sulfite hypersensitivity***Geriatric***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,cyproheptadine hydrochloride,"***For treatment of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and foods, amelioration of allergic reactions to blood or plasma, cold urticaria, mild/uncomplicated allergic skin manifestations of urticaria and angioedema (e.g. pruritus), dermatographism, and for adjunctive treatment to epinephrine and other standard measures for anaphylaxis or anaphylactoid reactions after the acute manifestations have been controlled.***For the adjunct treatment of anorexia� nervosa or non-psychogenic anorexia� for stimulation of appetite. <br />        NOTE: Exclude organic causes of weight loss before treatment begins.<br />     ***For the treatment of male or female anorgasmy� secondary to antidepressant therapy.***For the treatment of Cushing's syndrome� secondary to pituitary disorders.***For the treatment of spasticity� associated with spinal cord injury.***For migraine prophylaxis�.","***MAOI therapy***Asthma, chronic obstructive pulmonary disease (COPD)***Children, infants, neonates***Pregnancy***Breast-feeding***Bladder obstruction, GI obstruction, ileus, peptic ulcer disease, prostatic hypertrophy, urinary retention***Closed-angle glaucoma, contact lenses***Hepatic disease***Cardiac disease***Driving or operating machinery***Anticholinergic medications, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['33199'],permethrin,"***For the treatment of pediculosis. <br />  NOTE: For proper treatment of pediculosis, nits (eggs) should be removed with a nit comb. Also, all personal headgear, scarfs, coats, and bed linen should be disinfected by machine washing in hot water and drying using the hot cycle of a dryer for at least 20 minutes. Personal articles that cannot be washed may be dry-cleaned, sealed in a plastic bag for 4 weeks, or sprayed with a product specifically designed for this purpose. Personal combs and brushes may be disinfected by soaking in hot water (above 130 degrees F) for 5 to 10 minutes.<br /***For the treatment of pediculosis capitis (head lice infestation) due to <em>Pediculus capitis</em>.***For the treatment of pediculosis pubis�.***For pediculosis prophylaxis. <br />        NOTE: Prophylaxis is only recommended for individuals exposed to head lice epidemics in which at least 20% of the population at an institution are infested and for immediate household members of the infested individuals.<br />     ***For the treatment scabies infection, including crusted (Norwegian) scabies�.***For the treatment of crusted (Norwegian) scabies�.","***General Information***Ocular exposure***Infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydrocortisone acetate/pramoxine hydrochloride,"***For the temporary relief of skin inflammation, pain, and pruritus associated with corticosteroid-responsive dermatitis, including psoriasis, anorectal inflammation, pain, pruritus, and swelling associated with hemorrhoids, proctitis, cryptitis, anal fissures, postoperative pain, and pruritus ani.***For the adjunctive treatment of chronic ulcerative colitis� when disease is limited to the distal portion of the rectum (e.g., proctosigmoiditis).","***Fungal infection, herpes infection, infection, peripheral vascular disease, tuberculosis, viral infection***Hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, infants, neonates***Geriatric, skin atrophy***Diabetes mellitus***Cataracts, glaucoma, ocular exposure, ophthalmic administration***Pregnancy***Breast-feeding***Hepatic disease***Fistula, GI obstruction, GI perforation, peritonitis, ulcerative colitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,desipramine hydrochloride,"***For the treatment of major depression.***For the treatment of social phobia (social anxiety disorder)� and panic disorder�.***For the treatment of bulimia nervosa�, as an adjunct to cognitive behavioral therapy.***For the treatment of pain due to postherpetic neuralgia�.***For the treatment of painful diabetic neuropathy�.***For the treatment of attention-deficit hyperactivity disorder (ADHD)�.","***Carbamazepine hypersensitivity, tricyclic antidepressant hypersensitivity***MAOI therapy***Acute myocardial infarction, bradycardia, cardiac arrhythmias, cardiac disease, congenital heart disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation***Children, suicidal ideation***Bipolar disorder, mania, schizophrenia***Alcoholism, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Electroconvulsive therapy (ECT), seizure disorder, seizures***Hepatic disease***Surgery***Anticholinergic medications, ileus, prostatic hypertrophy, urinary retention***Closed-angle glaucoma, increased intraocular pressure***Contact lenses***Agranulocytosis, leukopenia***Hyperthyroidism, hypothyroidism, thyroid disease***Diabetes mellitus, pheochromocytoma***Radiographic contrast administration***Sunlight (UV) exposure***Abrupt discontinuation***Geriatric***Neonates, pregnancy***Breast-feeding***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,lorcaserin hydrochloride,***For the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity.,"***Heart failure, valvular heart disease***AV block, bradycardia, bundle-branch block, sick sinus syndrome***Pulmonary hypertension***Hyperprolactinemia***Anemia, hematological disease, leukopenia, neutropenia***Leukemia, multiple myeloma, Peyronie's disease, sickle cell disease***Diabetes mellitus, hypoglycemia***Depression, suicidal ideation***Driving or operating machinery***Dialysis, renal failure, renal impairment***Hepatic disease***MAOI therapy***Geriatric***Labor, obstetric delivery, pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],estradiol,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For systemic treatment of the vasomotor symptoms (hot flashes) and genitourinary symptoms of menopause.***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For estrogen replacement for premenopausal women with primary ovarian failure or female hypogonadism.***For the palliative treatment of advanced inoperable prostate cancer.***For the palliative treatment of breast cancer that is inoperable and progressive in selected men and postmenopausal women.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates***Intravenous administration***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ketotifen fumarate,"***For the temporary prevention of ocular pruritus due to allergic conjunctivitis.***For the treatment of allergic conditions including allergic rhinitis�, atopic dermatitis�, and acute or chronic urticaria�.","***Children, infants, neonates***Contact lenses***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1244607'],tafluprost,***For the reduction of increased intraocular pressure in patients with open-angle glaucoma or ocular hypertension..,"***Inflammation, iritis, uveitis***Aphakia***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5933'],povidone iodine,***For the prevention of infection in minor burns and skin abrasion (cuts and scraps).***For surgical infection prophylaxis.***For use as an antiseptic prior to surgery.***For use as an antiseptic hand scrub prior to surgery.,"***Iodine hypersensitivity***Thyroid disease***Ocular exposure***Burns, renal impairment***Children, infants***Caesarean section, labor, neonates, obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,enalapril maleate/hydrochlorothiazide,"***For the treatment of hypertension. <br />        NOTE: Individualize the dosage by titration of the separate components. If the optimal dose corresponds to the ratio contained in the combination formulation, this product can be used for convenient dosing.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, Black patients, hereditary angioedema***Dialysis, hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Hepatic disease***Aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hyponatremia, hypotension, hypovolemia***Orthostatic hypotension, sympathectomy, syncope***Surgery***Gout, hyperuricemia***Hypercalcemia, hypomagnesemia***Electrolyte imbalance, hyperkalemia, hypokalemia***Anuria, autoimmune disease, bone marrow suppression, collagen-vascular disease, immunosuppression, renal artery stenosis, renal disease, renal failure, renal impairment, scleroderma, systemic lupus erythematosus (SLE)***Diabetes mellitus, hyperglycemia***Pregnancy***Breast-feeding***Children***Pancreatitis***Sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5657'],ifosfamide,"***For use as a third line chemotherapeutic agent in the treatment of germ cell testicular cancer. <br />        NOTE: Ifosfamide has been designated an orphan drug by the FDA for the treatment of testicular cancer.<br />     ***For the treatment of non-Hodgkin's lymphoma (NHL)�.***For the treatment of relapsed or refractory NHL in combination with carboplatin and etoposide�.***For the treatment of relapsed or refractory CD20-positive diffuse large B-cell non-Hodgkin's lymphoma in combination with rituximab, carboplatin, and etoposide�.***For the treatment soft-tissue sarcoma�. <br />        NOTE: Ifosfamide has been designated an orphan drug by the FDA for the treatment of soft-tissue sarcoma.<br />     ***For the first-line treatment of unresectable or metastatic soft-tissue sarcoma� in combination with dacarbazine, doxorubicin, and mesna.***For the treatment of unresectable or metastatic osteogenic sarcoma�, in combination with mesna, dacarbazine, and doxorubicin. <br />        Ifosfamide has been designated an orphan drug by the FDA for the treatment of osteogenic sarcomas<br />     ***For the treatment of Ewing's sarcoma�.***For the treatment of recurrent or refractory Ewing's sarcoma as a high-dose single-agent�.***For the treatment of newly diagnosed Ewing's sarcoma in combination with vincristine, doxorubicin, and etoposide (VIDE) followed by ifosfamide, vincristine, and dactinomycin (VAI)�.***For the treatment of newly diagnosed Ewing's sarcoma family tumors, in combination with etoposide, alternating with vincristine, doxorubicin, and cyclophoshpamide�.***For the treatment of newly diagnosed unresectable or metastatic Ewing's sarcoma in combination with doxorubicin and dacarbazine�.***For the treatment of recurrent or refractory Ewing's sarcoma in combination with carboplatin and etoposide�.***For the treatment of newly diagnosed Ewing's sarcoma in combination with carboplatin and etoposide, followed by cyclophosphamide, doxorubicin, and vincristine�.***For the treatment of rhabdomyosarcoma�.***For the treatment of rhabdomyosarcoma as part of the MAID regimen.***For the first-line treatment of rhabdomyosarcoma in children and adolescents in combination with vincristine, dactinomycin, and doxorubicin�.***For the treatment of refractory desmoid tumor� and fibromatosis�.***For the treatment of bladder cancer�.***For the treatment of previously treated bladder cancer�.***For the treatment of recurrent metastatic bladder cancer in combination with gemcitabine�.***For the treatment of advanced or metastatic bladder cancer in combination with cisplatin and a taxane�.***For the treatment of unresectable, advanced thymoma�, in combination with cisplatin and etoposide.***For the first-line treatment of unresectable, advanced thymic carcinoma�, in combination with cisplatin and etoposide.***For the treatment of poor-risk relapsed Wilms' tumor� in combination with carboplatin and etoposide.***For stem cell transplant preparation�.***For stem cell mobilization in combination with carboplatin and etoposide, in transplant eligible patients with non-Hodgkin's lymphoma�.***For the treatment of relapsed or refractory acute lymphocytic leukemia (ALL)� in combination with carboplatin, etoposide, and rituximab.***For the neoadjuvant treatment of locally advanced or metastatic penile cancer� in combination with paclitaxel and cisplatin.***Formoterol; Mometasone","***Bone marrow suppression, herpes infection, infection, radiation therapy, varicella***Dental disease, dental work***Intramuscular injections***Dehydration, hematuria, hemorrhagic cystitis, hepatic disease, nephrotoxicity***Children, renal failure, renal impairment***Pregnancy***Breast-feeding***Coma, neurotoxicity***Accidental exposure, ocular exposure***Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,immune globulin intravenous (human),"***For hepatitis A prophylaxis.***For postexposure prophylaxis.***For patients traveling to regions that have high or intermediate hepatitis A endemicity.***For measles prophylaxis to prevent or modify measles in an unvaccinated patient who has not previously had measles and who was exposed within the past 6 days. <br />  NOTE: For most persons 12 months and older who are exposed to measles, use of MMR or measles vaccine within 72 hours of exposure is preferred to using immune globulin (except pregnant women and others for whom the vaccine is contraindicated). Any person exposed to measles who lacks evidence of measles immunity and to whom immune globulin (IG) is administered should subsequently receive MMR vaccine but not earlier than 6 months after IMIG administration or 8 months after IGIV administration (provided the vaccine is not contraindicated).<br /***For varicella (chickenpox) infection prophylaxis.***For rubella prophylaxis in exposed, susceptible pregnant women who will not consider a therapeutic abortion. <br />        NOTE: The routine use of IMIG for rubella prophylaxis in early pregnancy is of dubious value and cannot be justified.<br />     ***For immunoglobulin deficiency. <br />  NOTE: Immune globulin may prevent serious infection in patients with immunoglobulin deficiencies if circulating IgG concentrations of approximately 200 mg/100 mL plasma are maintained.<br /","***Intravenous administration***Pregnancy***Breast-feeding***Agammaglobulinemia, hypogammaglobulinemia, IgA deficiency***Viral infection***Anticoagulant therapy, bleeding, coagulopathy, hemophilia, thrombocytopenia***Vaccination***Children***Coronary artery disease, geriatric, heart failure, hypertriglyceridemia, hyponatremia, obesity, thromboembolism",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1596450']['8638'],gentamicin/prednisolone acetate,"***For steroid-responsive inflammatory ocular inflammation conditions (e.g., uveitis, bacterial conjunctivitis, corneal abrasion) for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular/ophthalmic infection exists. <br />        NOTE: Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies.<br />     ","***General Information***Aminoglycoside hypersensitivity, corticosteroid hypersensitivity***Keratitis***Fungal infection, herpes simplex keratitis (dendritic keratitis), mycobacterial infection, varicella, viral infection***Cataracts, glaucoma, increased intraocular pressure, ocular surgery***Intravenous administration***Abrupt discontinuation, corticosteroid withdrawal***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,mechlorethamine hydrochloride,"***For the treatment of chronic lymphocytic leukemia (CLL).***For the treatment of chronic myelogenous leukemia (CML).***For the treatment of Hodgkin lymphoma.***For the treatment of Hodgkin lymphoma as part of the Stanford V regimen.***For the treatment of lung cancer.***For intracavitary administration for neoplastic effusions including pericardial effusion, pleural effusion, and peritoneal effusion.***For the treatment of polycythemia vera (PCV).***For the treatment of cutaneous T-cell lymphoma (CTCL), including mycosis fungoides.***For the palliative treatment of mycosis fungoides.***For the treatment of of stage IA and IB mycosis fungoides in patients who have received prior skin directed therapy.","***General Information***Anemia, bleeding, bone marrow suppression, herpes infection, immunosuppression, infection, leukopenia, neutropenia, radiation therapy, requires an experienced clinician, thrombocytopenia, varicella, viral infection***Dental disease, dental work***Extravasation***Accidental exposure, ocular exposure***Hyperuricemia, tumor lysis syndrome (TLS)***Inflammation, skin disease***Suppurative inflammation***Vaccination***New primary malignancy***Children, infants, neonates***Pregnancy***Infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ibandronate sodium,"***For the treatment of osteoporosis.***For corticosteroid-induced osteoporosis� in men and women.***For osteoporosis prophylaxis. <br />        NOTE: All postmenopausal women should receive drug therapy for osteoporosis if they have any of the following: a previous osteoporotic vertebral or hip fracture; a bone mineral density indicative of osteoporosis (i.e., a T-score equal to or worse than �2.5) at the lumbar spine, femoral neck, or total hip region; or a T-score of �1 to �2.5 plus a FRAX calculator based 10-year risk of &gt;= 20% for a major osteoporotic fracture of the spine, hip, shoulder, or wrist, or a 10-year risk of &gt;= 3% for a hip fracture ; the FRAX calculator or Fracture Risk Assessment Tool, developed by WHO, is available for download or online calculation via the World Wide Web.<br />     ***For the treatment of Paget's disease�.***For the treatment of bone metastases� in patients with prostate cancer.***For the treatment of hypercalcemia� of malignancy.","***General Information***Intraarterial administration***Achalasia, dysphagia, esophageal stricture, esophagitis, gastritis, gastroesophageal reflux disease (GERD), GI disease, GI perforation, hiatal hernia, inability to stand or sit upright***Diabetes mellitus, hypertension, multiple myeloma, renal failure, renal impairment***Hypocalcemia, vitamin D deficiency***Children, infants, neonates***Geriatric***Hypoparathyroidism***Pregnancy***Breast-feeding***Anemia, chemotherapy, coagulopathy, corticosteroid therapy, dental disease, dental work, infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['194000'],capecitabine,"***For the treatment of metastatic breast cancer.***For the treatment of metastatic breast cancer that is resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen, or resistant to paclitaxel and for whom further anthracycline therapy is not indicated (e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalent), as monotherapy. <br />          NOTE: Resistance is defined as progressive disease while on treatment regardless of an initial response or relapse within 6 months of treatment completion with an anthracycline-containing adjuvant regimen.<br />       ***For the treatment of metastatic breast cancer after failure of prior anthracycline-containing chemotherapy, in combination with docetaxel.***For the treatment of patients with advanced or metastatic breast cancer whose tumor overexpresses the HER2 protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab, in combination with lapatinib�. <br />  NOTE: Lapatinib is FDA-approved in combination with capecitabine for this indication. Patients should exhibit disease progression on trastuzumab prior to initiating combination therapy with lapatinib and capecitabine. In a randomized, open-label study of HER2-positive metastatic breast cancer patients (n = 540), median progression free survival (PFS) and overall survival (OS) for lapatinib plus capecitabine was less than for patients treated with trastuzumab plus capecitabine (PFS: 6.6 months vs. 8 months, HR 1.3, 95% CI, 1.04 to 1.64; OS: HR 1.34, 95% CI, 0.95 to 1.92). In another randomized, open-label study of women with HER2-positive metastatic breast cancer, first-line treatment with lapatinib plus taxane-based chemotherapy also had a shorter median PFS compared with trastuzumab plus taxane-based chemotherapy (9 months vs. 11.3 months; HR 1.37; 95% CI, 1.13 to 1.65)<br /***For the treatment of metastatic or locally advanced breast cancer that is resistant to treatment with an anthracycline and a taxane, or that is taxane resistant and for whom further anthracycline therapy is contraindicated in combination with ixabepilone�. <br />  NOTE: Ixabepilone is FDA approved in combination with capecitabine for this indication. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting.<br /***For the treatment of colorectal cancer.***For the adjuvant treatment of Dukes' C colorectal cancer as monotherapy, in patients who have a complete resection of the primary tumor when fluoropyrimidine therapy alone is preferred.***For the first-line treatment of metastatic colorectal cancer as monotherapy, when fluoropyrimidine therapy alone is preferred.***For the first- and second-line treatment of advanced colorectal cancer in combination with oxaliplatin (XELOX or CapeOX)�.***For the first line treatment of metastatic colorectal cancer in combination with oxaliplatin and bevacizumab (XELOX or CapeOx, with or without bevacizumab)�.***For the adjuvant treatment of stage III (Dukes C) colon cancer in combination with oxaliplatin (XELOX or CapeOX)�.***For the treatment of unresectable advanced or metastatic biliary tract cancer�.***For the treatment of inoperable, recurrent, platinum- and taxane-resistant ovarian cancer�.***For the treatment of gastric cancer�.***For the treatment of advanced gastric cancer in combination with cisplatin�.***For the treatment of advanced gastric cancer in combination with epirubicin and cisplatin or oxaliplatin�.***For the treatment of previously untreated patients with metastatic gastric or gastroesophageal junction adenocarcinoma in combination with cisplatin and trastuzumab�.***For the adjuvant treatment of stage II through IIIB gastric cancer� in combination with oxaliplatin.***For the adjuvant treatment of pancreatic cancer (ductal adenocarcinoma), in combination with gemcitabine�.","***Dehydration, diarrhea***Nausea/vomiting, renal failure, renal impairment***Dihydropyrimidine dehydrogenase (DPD) deficiency***Bone marrow suppression, chemotherapy, fungal infection, herpes infection, infection, radiation therapy, varicella, viral infection***Anticoagulant therapy***Angina, cardiac arrhythmias, cardiac disease, coronary artery disease***Hepatic disease, jaundice***Geriatric***Skin disease***Pregnancy***Contraception requirements, infertility, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['72962', '1299922']",docetaxel,"***For the treatment of breast cancer.***For locally advanced or metastatic breast cancer after failure of previous chemotherapy.***For the treatment of metastatic breast cancer after failure of prior anthracycline-containing chemotherapy in combination with capecitabine�. <br />          NOTE: Capecitabine is FDA approved for use in combination with docetaxel for the treatment of metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.<br />       ***For adjuvant treatment of operable node-positive breast cancer in combination with cyclophosphamide and doxorubicin.***For adjuvant treatment of operable stage I to III invasive breast cancer in combination with cyclophosphamide�.***For adjuvant treatment of operable node-positive or high-risk node-negative (tumor greater than 2 cm) breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy�.***For adjuvant treatment of HER2 overexpressing, node-positive or node negative (ER/PR negative or with one high-risk feature) breast cancer, in combination with trastuzumab and carboplatin (TCH regimen)�. <br />          NOTE: Trastuzumab is FDA approved for the adjuvant treatment of HER2 overexpressing, node-positive or node negative (ER/PR negative or with one high-risk feature) breast cancer, in combination with docetaxel and carboplatin.<br />       ***For adjuvant treatment of node-positive breast cancer in sequence with fluorouracil, epirubicin, and cyclophosphamide (FEC-D regimen)�.***For first-line treatment of metastatic breast cancer�.***For HER2-positive metastatic breast cancer in combination with trastuzumab�. <br />          NOTE: Trastuzumab is FDA approved for use in combination with docetaxel for the treatment of metastatic HER-2 positive breast cancer<br />       ***For patients who have not previously received chemotherapy for metastatic or inoperable locally recurrent HER2-negative breast cancer, in combination with bevacizumab�.***For first-line treatment of HER2-positive metastatic breast cancer in combination with pertuzumab and trastuzumab�. <br />          NOTE: Pertuzumab is FDA approved in combination with trastuzumab and docetaxel for the first-line treatment of HER2-positive metastatic breast cancer.<br />       ***For the treatment of non-small cell lung cancer (NSCLC).***For advanced or metastatic non-small cell lung cancer (NSCLC) after the failure of prior platinum containing chemotherapy.***For first-line treatment of unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with cisplatin in patients who have not received prior chemotherapy.***For first-line treatment of unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with carboplatin�.***For first-line treatment of unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with gemcitabine�.***For the treatment of metastatic prostate cancer.***For the treatment of hormone-refractory, metastatic prostate cancer in combination with prednisone.***For the treatment of hormone-refractory, metastatic prostate cancer in combination with estramustine�.***For the first-line treatment of metastatic, hormone-sensitive prostate cancer in selected patients, in combination with androgen-deprivation therapy�.***For the treatment of gastric cancer.***For advanced gastric cancer, including adenocarcinoma of the gastroesophageal junction, in combination with cisplatin and 5-fluorouracil in patients who have not received prior chemotherapy for advanced disease.***For the treatment of advanced gastric cancer as a single agent�.***For the treatment of head and neck cancer.***For induction treatment of locally advanced inoperable squamous cell head and neck cancer in combination with cisplatin and 5-fluorouracil (5-FU).***For induction treatment of locally advanced (unresectable disease, low surgical cure, or organ preservation) squamous cell head and neck cancer in combination with cisplatin and 5-fluorouracil (5-FU). <br />          NOTE: Survival was significantly improved among patients who got the 3 drugs (see Dosage below) as compared with receipt of only cisplatin 100 mg/m2 IV on day 1 and 5- fluorouracil 1000 mg/m2/day by continuous IV infusion for 5 days. Specifically, the relative risk of death was 30% lower. Also, the median overall survival was 70.6 months as compared with 30.1 months for patients receiving only cisplatin and 5-fluorouracil. Three to 8 weeks after the start of the last cycle, all patients in both treatment arms who did not have progressive disease got carboplatin (AUC 1.5 weekly for 7 doses) and radiation therapy (2 Gy per day, 5 days per week for 7 weeks) followed by surgery, if appropriate.<br />       ***For the treatment of ovarian cancer�.***For refractory advanced ovarian cancer�.***For the first-line adjuvant treatment of Stage Ic through IV ovarian cancer and peritoneal cancers in combination with carboplatin�.***For the treatment of metastatic malignant melanoma�.","***Bone marrow suppression, herpes infection, infection, neutropenia, radiation therapy, thrombocytopenia, varicella, viral infection***Biliary tract disease, hepatic disease, jaundice***Acute bronchospasm, hypotension, polysorbate 80 hypersensitivity, serious hypersensitivity reactions or anaphylaxis, taxane hypersensitivity***Dental disease, dental work***Ascites, cardiac tamponade, edema, fluid retention, peripheral edema, pleural effusion***Accidental exposure, ocular exposure***Children, infants, neonates***Geriatric***Vaccination***Intramuscular injections***Ocular disease***Driving or operating machinery, ethanol ingestion, ethanol intoxication***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2002'],carbamazepine,"***For the management of generalized tonic-clonic seizures, or for partial seizures, either simple or complex-partial seizures. <br />        NOTE: Periodic monitoring of serum carbamazepine concentrations is recommended.<br />     ***For the symptomatic treatment of neuropathic pain.***For the treatment of acute mania and mixed episodes associated with bipolar disorder (bipolar I disorder).***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD).***For the treatment of persistent singultus (hiccups)�.***For long-term prophylaxis of short-lasting short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT)�.","***General Information***Asian patients, serious rash***Depression, psychosis, suicidal ideation***Atonic seizures, myoclonic seizures, petit mal (absence) seizures***Abrupt discontinuation***Barbiturate hypersensitivity, carbamazepine hypersensitivity, fever, hydantoin hypersensitivity, jaundice, tricyclic antidepressant hypersensitivity***Agranulocytosis, aplastic anemia, bone marrow suppression, hematological disease, leukopenia, neutropenia, thrombocytopenia***Porphyria***Hepatic disease***AV block, bundle-branch block, cardiac arrhythmias, cardiac disease, coronary artery disease***Hyponatremia***Alcoholism***Driving or operating machinery***Renal disease, renal failure, renal impairment***Geriatric***Glaucoma, increased intraocular pressure***Pregnancy***Neonates***Breast-feeding***Sunlight (UV) exposure***MAOI therapy***Hypercholesterolemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,antihemophilic factor (human),"***For the prevention and control of hemorrhage in patients with hemophilia A (classical hemophilia). <br />        NOTE: Humate, Kogenate, and ReFacto have been designated by the FDA as orphan drugs for the prophylaxis and management of hemorrhage or hemarthrosis in patients with hemophilia A.<br /> <br />NOTE: Guidelines for the treatment of acute bleeding and prevention of bleeding during surgery vary. For all indications, the dose of antihemophilic factor should be individualized taking into consideration the seriousness of the bleed or procedure, the clinical status of the patient, and the factor VIII activity concentration***For minor bleeding including early muscle bleed, early hemarthrosis, and oral bleeds.***For moderate bleeding including advanced muscle bleed, extensive hemarthrosis, hematoma, and mild head trauma.***For life- or limb-threatening bleeding including surgical bleeding, gastrointestinal bleeding, neck, tongue or pharyngeal hematoma with potential for airway compromise, intracranial, intraabdominal, or intrathoracic bleeding, or fractures.***For bleeding in patients with hemophilia A and factor VIII inhibitor titers less than 10 Bethesda Units and with low anamnestic responses.***For the perioperative management of surgical bleeding (surgical bleeding prophylaxis) in patients with hemophilia A.***For routine bleeding prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A.***For the management of hemorrhage or hemarthrosis in patients with von Willebrand's disease (vWD). <br />        NOTE: Humate-P has been designated by the FDA as orphan drugs for this indication.<br />     ***For major hemorrhage in patients with mild vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma or traumatic hemorrhage).***For minor hemorrhage in patients with moderate to severe vWD type I, type II, and type III (e.g., epistaxis, oral bleeding, or menorrhagia).***For major hemorrhage in patients with moderate to severe vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For major hemorrhage in patients with vWD type II and III (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For surgical bleeding prophylaxis during major or minor procedures in patients with vWD in whom desmopressin is either ineffective or contraindicated. <br />          NOTE: Alphanate and Humate-P have been designated by the FDA as orphan drugs for this indication.<br />       ","***General Information***Pregnancy***Breast-feeding***Thromboembolic disease***Hepatitis, infection, viral infection***Anemia***Bovine protein hypersensitivity, hamster protein hypersensitivity, latex hypersensitivity, mannitol hypersensitivity, murine protein hypersensitivity, polysorbate 80 hypersensitivity***Porcine protein hypersensitivity***Human immunodeficiency virus (HIV) infection***Cardiac disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['1100699', '1100703']['6809']",linagliptin/metformin hydrochloride,***For the treatment of type 2 diabetes mellitus in combination with diet and exercise when treatment with both linagliptin and metformin is appropriate.***Formoterol; Mometasone,"***Exfoliative dermatitis, history of angioedema, serious rash***Diabetic ketoacidosis, type 1 diabetes mellitus***Acidemia, hypoxemia, lactic acidosis, metabolic acidosis***Acute heart failure, acute myocardial infarction, cardiac disease, cardiogenic shock, heart failure***Renal disease, renal failure, renal impairment***Alcoholism, ethanol ingestion, ethanol intoxication, hepatic disease***Radiographic contrast administration***Burns, dehydration, fever, infection, sepsis, surgery, trauma***Pernicious anemia***Pancreatitis***Adrenal insufficiency, diarrhea, gastroparesis, GI obstruction, hypercortisolism, hyperglycemia, hyperthyroidism, hypoglycemia, hypothyroidism, ileus, malnutrition, pituitary insufficiency, vomiting***Arthralgia***Geriatric***Polycystic ovary syndrome, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['276237'],emtricitabine,"***For the treatment of human immunodeficiency virus (HIV) infection in combination with other antiretroviral agents. <br />        NOTE: Antiretroviral drug resistance testing is recommended prior to initiation of therapy in antiretroviral treatment naive patients and prior to changing therapy for treatment failure. <br />NOTE: The following abbreviation is used: nucleoside reverse transcriptase inhibitor (NRTI)***For human immunodeficiency virus (HIV) prophylaxis�.***For human immunodeficiency virus (HIV) prophylaxis� after occupational exposure.***For human immunodeficiency virus (HIV) prophylaxis� after nonoccupational exposure, including sexual assault. <br />          NOTE: Higher risk exposures for which prophylaxis is recommended include exposure of vagina, rectum, eye, mouth, or other mucous membrane, nonintact skin, or percutaneous contact with blood, semen, vaginal secretions, rectal secretions, breast milk, or any body fluid that is visibly contaminated with blood when the source is known to be HIV-positive. Exposures to a source patient with unknown HIV status should be assessed on a case-by-case basis.<br />       ***For the treatment of chronic hepatitis B infection� in HIV-positive patients. <br />        NOTE: Emtricitabine is not indicated for the treatment of chronic hepatitis B virus (HBV) infection, and safety and efficacy of treatment have not been established in patients co-infected with HBV and HIV.<br />     ","***General Information***Human immunodeficiency virus (HIV) infection resistance***Hepatitis B and HIV coinfection, hepatitis B exacerbation***Children, infants, neonates***Geriatric***Alcoholism, females, hepatic disease, hepatotoxicity or lactic acidosis, obesity***Pregnancy***Breast-feeding***Renal failure, renal impairment***Autoimmune disease, Graves' disease, Guillain-Barre syndrome, immune reconstitution syndrome***Hepatitis C and HIV coinfection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6922'],metronidazole,"***For the treatment of trichomoniasis.***For the treatment of bacterial vaginosis (e.g., <em>Gardnerella vaginalis</em>, <em>Mycoplasma hominis</em>�, and anaerobic bacteria such as <em>Prevotella sp.</em> and <em>Mobiluncus</em> sp.).***For the treatment of pelvic inflammatory disease (PID) in combination with other antibiotics.***For the treatment of amebiasis.***For intestinal disease (acute amebic dysentery) due to <em>Entamoeba histolytica</em>.***For hepatic abscess due to <em>Entamoeba histolytica</em>.***For amebiasis due to <em>Entamoeba polecki</em>�.***For the treatment of serious anaerobic infections (e.g., skin and skin structure infections [e.g. diabetic foot ulcer], CNS infection including meningitis and brain abscess, bone and joint infections, endocarditis, bacteremia, and gynecologic infections [e.g. endometritis, endomyometritis]).***For the treatment of acne rosacea.***For the treatment of serious anaerobic intraabdominal infections, including intraabdominal abscess, peritonitis, perforated appendicitis, necrotizing enterocolitis, and biliary tract infections such as cholangitis and cholecystitis.***For the treatment of perforated appendicitis� in pediatric patients.***For the treatment of serious anaerobic lower respiratory tract infections, including pleural empyema, pneumonia, and lung abscess.***For bacterial vaginosis prophylaxis� or trichomoniasis prophylaxis� in victims of sexual assault.***For the treatment of recurrent and persistent non-gonococcal urethritis (NGU)�.***For the treatment of dental infection�, including dentoalveolar infection� and periodontitis�.***For adolescent periodontitis� or adult chronic periodontitis� after scaling and root planing.***For adolescent aggressive periodontitis� or adult refractory chronic periodontitis� in combination with amoxicillin after scaling and root planing.***For adult refractory chronic periodontitis� in combination with ciprofloxacin after scaling and root planing in �-lactam allergic patients.***For the treatment of guinea worm disease� (dracunculiasis�).***For surgical infection prophylaxis, including bowel preparation� in patients undergoing colorectal surgery.***For bowel preparation� in patients undergoing colorectal surgery.***For the treatment of antibiotic-associated pseudomembranous colitis� due to <em>Clostridium difficile</em>.***For the treatment of antibiotic-associated pseudomembranous colitis� due to <em>Clostridium difficile </em>in adults.***For the treatment of antibiotic-associated pseudomembranous colitis� due to <em>Clostridium difficile i</em>n pediatric patients.***For the treatment of Crohn's disease� associated with colonic and/or perianal involvement.***For Helicobacter pylori (H. pylori) eradication� in the treatment of patients with duodenal ulcer� disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />  NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.  The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: Metronidazole-resistant strains of H. pylori are prevalent in the US (approximately 25%), and primarily occur in patients previously treated with metronidazole. Therapy with at least two antimicrobials is necessary to limit the development of metronidazole resistance. Patients who have persistence of H. pylori following therapy may have metronidazole-resistant H. pylori infection.<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Prevpac monograph).  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60% to 90% of patients.***For the treatment of pruritus� secondary to cholestasis.***For the treatment of giardiasis�.","***Hematological disease***Dialysis, renal failure, renal impairment***Bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***New primary malignancy***Pregnancy***Breast-feeding***Alcoholism, ethanol ingestion, ethanol intoxication***Fungal infection***Crohn's disease***Ocular exposure***Geriatric***Sexually transmitted disease***Hepatic disease, hepatic encephalopathy***Cockayne syndrome***Corticosteroid therapy, edema, sodium restriction***Laboratory test interference",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5781'],indomethacin,"***For the treatment of mild pain, moderate pain, or severe pain, such as arthralgia, myalgia, bursitis, or tendinitis.***For the treatment of mild to moderate acute pain.***For the treatment of moderate to severe pain.***For treatment of acute gouty arthritis. <br />        NOTE: Sustained-release capsules should not be used for this condition.<br />     ***For treatment of a hemodynamically significant patent ductus arteriosus (PDA) in premature infants.***For treatment of moderate to severe rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA)�, osteoarthritis, or ankylosing spondylitis. <br />        NOTE: If minor adverse effects develop as the dosage is increased, rapidly reduce the dose to a tolerated dose and closely observe the patient. If severe adverse reactions occur, stop indomethacin.<br />     ***For treatment of idiopathic or viral pericarditis�. <br />        NOTE: Use of NSAIDs are contraindicated in pericarditis after myocardial infarction; NSAIDs retard myocardial scar formation and the incidence of rupture may increase.<br />     ***For treatment of headache�.***For prophylaxis of chronic cluster headache�.***For the prevention of heterotopic ossification�.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Aortic coarctation, bleeding, congenital heart disease, infection, intracranial bleeding, necrotizing enterocolitis, neonates***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, hemorrhoids, peptic ulcer disease, tobacco smoking, ulcerative colitis***Bone marrow suppression, coagulopathy, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Visual disturbance***Hepatic disease, jaundice***Dental disease, dental work***Dehydration, hyperkalemia, renal disease, renal failure, renal impairment***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hypertension, myocardial infarction, peripheral vascular disease, stroke, thromboembolism***Coronary artery bypass graft surgery (CABG)***Depression, driving or operating machinery, headache, Parkinson's disease, seizure disorder***Labor, pregnancy***Breast-feeding***Geriatric***Children, infants***Intramuscular injections",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,collagenase clostridium histolyticum,"***For the treatment of severe partial- or full-thickness burns. <br />  NOTE: Removal of necrotic tissue by mechanical debridement should be considered during the initial and subsequent assessments.<br />NOTE: Collagenase should only be used on wounds that have necrotic material. Antibiotic administration is paramount for infected wounds.<br />NOTE: Collagenase should be discontinued as soon as the wound bed is devoid of necrotic tissue and has more than 90% granulation tissue***For the treatment of decubitus ulcer, diabetic foot ulcer, or varicose ulcer that requires debridement. <br />  NOTE: Removal of necrotic tissue by mechanical debridement should be considered during the initial and subsequent assessments.<br />NOTE: Collagenase should only be used on wounds that have necrotic material. Stage 1 ulcers are not appropriate candidates. Antibiotic administration is paramount for infected wounds.<br />NOTE: Collagenase should be discontinued as soon as the wound bed is devoid of necrotic tissue and has more than 90% granulation tissue***For the treatment of Dupuytren's contracture with a palpable cord.***For the treatment of Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.","***General Information***Bone marrow suppression, hyperglycemia, immunosuppression, infection, malnutrition***Arteriosclerosis, diabetes mellitus, peripheral vascular disease***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Children***Pregnancy***Breast-feeding***Corporal rupture***Requires an experienced clinician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,icosapent ethyl,***For use as an adjunct to diet to reduce triglycerides in adults with severe hypertriglyceridemia (triglyceride blood concentrations 500 mg/dL or more).,"***Fish hypersensitivity***Anticoagulant therapy, bleeding, thrombolytic therapy***Pregnancy***Breast-feeding***Children, infants, neonates***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,guanidine hydrochloride,***For the reduction of the symptoms of muscle weakness and easy fatigability associated with Eaton-Lambert syndrome.,"***General Information***Anemia, bone marrow suppression, leukopenia, thrombocytopenia***Renal impairment***Hepatic disease***Pregnancy***Breast-feeding***Children, infants, neonates***GI disease, peptic ulcer disease, psychosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4500'],flurandrenolide,"***For the treatment of mild to moderate pruritus and inflammatory manifestations of corticosteroid-responsive dermatitis such as alopecia areata, atopic dermatitis, contact dermatitis, exfoliative dermatitis, Rhus dermatitis due to plants like poison ivy, or seborrheic dermatitis, discoid lupus erythematosus, eczema, granuloma annulare, intertrigo, cutaneous lichen planus, lichen simplex chronicus, polymorphous light eruption, pompholyx (dyshidrosis), nodular prurigo, anogenital or senilis pruritus, psoriasis, or xerosis (inflammatory phase). <br />        NOTE: Occlusive dressings may be required for chronic or severe cases of lichen simplex chronicus, psoriasis, eczema, atopic dermatitis, or chronic hand eczema. More potent topical corticosteroids and/or occlusive dressings may be necessary for the treatment of discoid lupus erythematosus, lichen planus, granuloma annulare, psoriatic plaques, and psoriasis of the palms, soles, elbows, or knees.<br />     ","***General Information***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Diabetes mellitus***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Fungal infection, herpes infection, infection, measles, peripheral vascular disease, tuberculosis, varicella, viral infection***Acne rosacea, acne vulgaris, ocular exposure, ophthalmic administration, perioral dermatitis***Geriatric, skin atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ziv-aflibercept,"***For the treatment of metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen, in combination with 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI).","***Bleeding, GI bleeding, intracranial bleeding***GI perforation***Dental work, surgery, wound dehiscence***Encephalopathy***Hypertension***Proteinuria***Infection, neutropenia***Geriatric***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8588'],amoxicillin/clavulanate potassium,"***For the treatment of acute otitis media (AOM). <br />  NOTE: Amoxicillin; clavulanic acid is the preferred initial therapy for children who have received amoxicillin within the past 30 days, who have concurrent conjunctivitis, or those for whom coverage of beta-lactamase-positive H. influenzae and M. catarrhalis is desired.<br /***For the treatment of sinusitis . <br />  NOTE: Amoxicillin; clavulanic acid is recommended by the Infectious Diseases Society of America (IDSA) as the first-line initial empiric therapy in adults and children with acute bacterial rhinosinusitis. The American Academy of Pediatrics (AAP) recommends amoxicillin; clavulanic as initial therapy for all patients presenting with moderate to severe illness, all children younger than 2 years, children attending daycare, and those who have been recently treated with antibiotics.<br /***For the treatment of lower respiratory tract infections (e.g., pneumonia and community-acquired pneumonia).***For the treatment of skin and skin structure infections, including impetigo.***For the treatment of urinary tract infection (UTI), including cystitis.***For the treatment of dental infection�, including dentoalveolar infection�, periodontitis�, and pericoronitis�.***For adolescent aggressive periodontitis� or adult refractory chronic periodontitis� after scaling and root planing.***For pericoronitis�.***For the treatment of actinomycotic mycetoma� caused by susceptible strains of <em>Nocardia brasiliensis</em>.***For use as oral maintenance therapy in the treatment of melioidosis� due to <em>Burkholderia pseudomallei�</em>.***For the empiric treatment of febrile neutropenia� in low risk patients.","***General Information***Asthma, carbapenem hypersensitivity, cephalosporin hypersensitivity, eczema, penicillin hypersensitivity, urticaria***Geriatric***Dialysis, renal disease, renal failure, renal impairment***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Children, infants, neonates***Labor, obstetric delivery, pregnancy***Breast-feeding***Phenylketonuria***Mononucleosis***Cholestasis, hepatic disease, jaundice",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6387'],lidocaine,"***For the treatment of perfusing ventricular arrhythmias including ventricular fibrillation (VF) and ventricular tachycardia (VT) that may result during acute myocardial infarction or cardiac manipulation (e.g., cardiac surgery). <br />  NOTE: See resuscitation indication for dosage guidelines for VF or pulseless VT.<br />NOTE: Although not considered a drug of choice for ventricular arrhythmias, lidocaine may be used as an alternative antiarrhythmic in patients with preserved ventricular function and stable monomorphic VT. Lidocaine may also be used to treat polymorphic VT in patients with a normal QT interval (when electrolyte imbalance and ischemia are treated). If pulseless cardiac arrest associated with VF or VT, see separate dosage guidelines for the treatment ventricular arrhythmias during CPR.<br />NOTE: Lidocaine may be used to treat patients with polymorphic VT associated with QT prolongation (e.g., torsade de pointes).<br />NOTE: Monitor blood pressure and the electrocardiogram (ECG) during intravenous lidocaine administration***For topical anesthesia of skin and mucous membranes or stomatitis.***For prevention of dental pain� and for topical anesthesia of mucous membranes.***For laryngoscopy.***For nonurgent painful procedures including IV cannulation, venipuncture, lumbar puncture, or arterial puncture.***For the treatment of stage 1 thru 4 pressure ulcers, venous stasis ulcers, ulcerations of mixed vascular etiologies, diabetic skin ulcers, first and second degree burns, and post surgical incisions, cuts, and abrasions.***For endotracheal intubation.***For neonatal circumcision�.***For bronchoscopy.***For the treatment of pain associated with postherpetic neuralgia.***For ophthalmic anesthesia.***For local anesthesia including peripheral nerve block anesthesia. <br />        NOTE: In adults, the dosages for local anesthesia reported are general guidelines only. The actual dose depends on a variety of factors such as depth of anesthesia, extent of surgical procedure, degree of muscle relaxation required, duration of anesthesia and the patients' physical condition. See Lidocaine; epinephrine monograph for information concerning combination dosing.<br />     ***For dental anesthesia including mandibular nerve block and maxillary infiltration.***For infiltration anesthesia.***For intravenous regional anesthesia.***For pudendal nerve block.***For paravertebral block.***For intercostal nerve block.***For brachial plexus block.***For paracervical block.***For sympathetic nerve block.***For cervical stellate ganglion block.***For lumbar sympathetic block.***For epidural anesthesia. <br />        NOTE: The dose is determined by the number of dermatomes to anesthetized (2 to 3 mL/dermatome). The suggested concentrations and volumes serve as a guide, other volumes and concentrations may be used provided the maximum dose is not exceeded.<br />     ***For lumbar anesthesia.***For lumbar analgesia for severe pain.***For thoracic.***For caudal anesthesia.***For obstetric anesthesia.***For surgical anesthesia.***For spinal anesthesia.***For obstetrical low spinal or saddle block anesthesia.***For intraabdominal anesthesia.***For the treatment of ventricular arrhythmias during cardiopulmonary resuscitation� (CPR).***For the attenuation of increased intracranial pressure� during rapid-sequence intubation� or endotracheal tube suctioning�.***For the treatment of severe singultus (hiccups)�.***For the treatment of headache�.***For the treatment of acute headache� associated with migraine�.***For the treatment of cluster headache�.***For the symptomatic treatment of corticosteroid-dependent asthma�. <br />        NOTE: Initial bronchoconstriction can occur. In addition, lidocaine toxicity can result in tremors, hallucinations, seizures, and cardiac arrest. Caution is advised until long-term safety and efficacy can be established.<br />     ***For short-term prophylaxis of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing� (SUNCT).***For the treatment of painful diabetic neuropathy� in adults.","***General Information***Amide local anesthetic hypersensitivity, epidural anesthesia***Collagen-vascular disease***G6PD deficiency***Geriatric, heart failure, hepatic disease***Hypotension, pregnancy***Breast-feeding***Adams-Stokes syndrome, atrial fibrillation, atrial flutter, AV block, bradycardia, cardiogenic shock, hemorrhagic shock, hypovolemia, shock, Wolff-Parkinson-White syndrome***Renal disease, renal failure, renal impairment***Burns, eczema, heating pad, occlusive dressing, skin abrasion***Cataracts, ocular exposure, ocular trauma***Accidental exposure***Intraarterial administration, intrathecal administration, intravenous administration***Head and neck anesthesia***Ocular surgery***Anticoagulant therapy, bleeding, coagulopathy, infection, neurological disease, requires a specialized care setting, requires an experienced clinician, sepsis, spinal anesthesia, thrombocytopenia***Fetal distress, labor, obstetric delivery, pudendal nerve block***Continuous intraarticular infusion administration***Fetal prematurity, paracervical nerve block***Malignant hyperthermia***Children, infants, neonates, teething pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['19831'],budesonide,"***For the management of nasal symptoms associated with perennial vasomotor rhinitis.***For the management of nasal symptoms associated with allergic rhinitis.***For maintenance treatment of asthma as prophylactic therapy (bronchospasm prophylaxis). <br />        NOTE: Budesonide is not indicated for the treatment of acute bronchospasm.<br />     ***For mild to moderate Crohn's disease involving the ileum and/or ascending colon.***For active disease in patients not previously receiving oral prednisolone.***For active disease in patients previously receiving oral prednisolone.***For maintenance of clinical remission for up to 3 months. <br />  NOTE: A Crohn�s Disease Activity Index (CDAI) less than 150 after 8 weeks of treatment for active disease is recommended before maintenance treatment is initiated.<br /***For the induction of remission in patients with active, mild to moderate ulcerative colitis.***For the treatment of laryngotracheobronchitis (croup)�.***For the treatment of collagenous colitis� (a form of microscopic colitis).***For exercise-induced bronchospasm prophylaxis�.","***General Information***Acute bronchospasm, milk protein hypersensitivity, status asthmaticus***Fungal infection, herpes infection, immunosuppression, infection, ocular infection, tuberculosis, viral infection***Measles, varicella***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Abrupt discontinuation, adrenal insufficiency, corticosteroid withdrawal, hypothalamic-pituitary-adrenal (HPA) suppression***Gastroenteritis, surgery, trauma***Cushing's syndrome, hypercortisolism***Nasal septal perforation, nasal surgery, nasal trauma***Malnutrition, osteoporosis, tobacco smoking***Edema, heart failure, hypertension***Diabetes mellitus, hyperglycemia, hyperthyroidism, hypothyroidism, psychosis, renal disease, seizure disorder, thyroid disease***Diverticulitis, GI disease, GI perforation, hepatic disease, peptic ulcer disease***Cataracts, glaucoma, increased intraocular pressure, visual disturbance***Myasthenia gravis***Corticosteroid hypersensitivity***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['5021', '91077']",griseofulvin,"***For the treatment of tinea corporis, tinea cruris, tinea capitis, tinea barbae, caused by susceptible strains of Trichophyton sp., Microsporum sp., or Epidermophyton sp..***For the treatment of tinea pedis or tinea unguium (onychomycosis).","***Hepatic disease***Carbapenem hypersensitivity, cephalosporin hypersensitivity, penicillin hypersensitivity***Systemic lupus erythematosus (SLE)***Sunlight (UV) exposure***Porphyria***Pregnancy***Breast-feeding***Serious rash***New primary malignancy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albumin (human),"***For the treatment of shock due to hypovolemia. <br />        NOTE: Dosage should be based on patient response as indicated by blood pressure, degree of pulmonary congestion, and hematocrit.<br />     ***For adjunctive treatment of severe burns.***For the treatment of nephrosis in nephrotic syndrome.***For treatment of hypoproteinemia.***For adjunctive use with exchange transfusion in the treatment of hyperbilirubinemia and erythroblastosis fetalis.","***Albumin hypersensitivity***Anemia, heart failure, hypertension***Renal disease***Hypernatremia***Burns***Viral infection***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6574'],esomeprazole magnesium,"***For the treatment of symptomatic, non-erosive gastroesophageal reflux disease (GERD).***For the treatment of pathological hypersecretion associated with Zollinger-Ellison syndrome.***For the treatment of short-term treatment of frequent dyspepsia or pyrosis (heartburn) that occurs >= 2 times per week.***For NSAID-induced ulcer prophylaxis or healing (gastric).***For the treatment of diagnostically confirmed erosive esophagitis due to GERD.***For upper GI rebleeding prophylaxis after therapeutic endoscopy.***For Helicobacter pylori (H. pylori) eradication in combination with antimicrobial agents for the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />        NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.  The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: If the patient has an active peptic ulcer at the time therapy is initiated, additional weeks of esomeprazole may be needed to achieve ulcer healing (see therapy duration recommended for healing of gastric ulcer or duodenal ulcer).<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy.  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long-term tumor regression is observed in 60% to 90% of patients. <br />***For the treatment of proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) in the differential diagnosis of eosinophilic esophagitis (EoE)�.","***General Information***Proton pump inhibitors (PPIs) hypersensitivity***Hepatic disease***Diarrhea, pseudomembranous colitis***Gastric cancer***Vitamin B12 deficiency***Bone fractures, geriatric, osteoporosis***Hypomagnesemia, long QT syndrome***Rebound acid hypersecretion***Pregnancy***Breast-feeding***Children, infants, neonates***Abdominal pain, dysphagia, GI bleeding, vomiting***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,teriparatide (rDNA origin),***For the treatment of osteoporosis.***For treatment of osteoporosis in postmenopausal women or in men with primary or hypogonadal osteoporosis.***For glucocorticoid-induced osteoporosis in men or women at high risk of fracture.***For the treatment of hypoparathyroidism�.,"***Hypercalcemia, new primary malignancy, osteogenic sarcoma, radiation therapy***Pregnancy***Breast-feeding***Hyperparathyroidism***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pantoprazole sodium,"***For the treatment of erosive esophagitis (erosive GERD).***For the treatment of pathological hypersecretion associated with Zollinger-Ellison syndrome or other hypersecretory syndromes.***For the short-term treatment of frequent dyspepsia� or pyrosis (heartburn)� that occurs >= 2 times per week.***For the treatment of non-erosive gastroesophageal reflux disease (GERD)�.***For the healing of duodenal ulcer�. <br />  NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br /***For the healing of gastric ulcer�. <br />  NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br /***For Helicobacter pylori (H. pylori) eradication� in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />  NOTE: The American College of Gastroenterology (ACG) recommends 10 to 14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole. Although 10 to 14 days is recommended, ACG also indicates that giving therapy for 2 weeks may be preferred; a meta-analysis of more than 900 patients found that, as compared to a 7-day regimen, the rate of H. pylori eradication was significantly higher in patients taking triple therapy for 14 days (odds ratio 0.62, 95% CI 0.45 to 0.84). Although not significant, there was a trend towards improved eradication rates with 10 days of therapy vs. 7 days of therapy.   The same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.<br />NOTE: In populations where H. pylori infection is common (10% or more), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Prevpac monograph).  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long-term tumor regression is observed in 60% to 90% of patients.***For NSAID-induced ulcer prophylaxis�.***For stress gastritis prophylaxis� in critically-ill patients:.***For the treatment of proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) in the differential diagnosis of eosinophilic esophagitis (EoE)�.***For upper GI rebleeding prophylaxis after therapeutic endoscopy�.","***General Information***Proton pump inhibitors (PPIs) hypersensitivity***Hepatic disease***Gastric cancer, new primary malignancy***Diarrhea, pseudomembranous colitis***Vitamin B12 deficiency***Zinc deficiency***Bone fractures, geriatric, osteoporosis***Hypomagnesemia, long QT syndrome***Rebound acid hypersecretion***Pregnancy***Breast-feeding***Infants, neonates***Laboratory test interference***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['358263'],tadalafil,"***For the treatment of erectile dysfunction (ED), including ED patients with diabetes mellitus or following radical prostatectomy.***For use as needed for ED.***For use once daily for ED without regard to timing of sexual activity.***For the concurrent treatment of erectile dysfunction and benign prostatic hypertrophy.***For improvement in exercise ability in patients with WHO Group I pulmonary hypertension.***For the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).***For the concurrent treatment of benign prostatic hyperplasia and erectile dysfunction.***For the treatment of sexual dysfunction� in males receiving antidepressant therapy.***For altitude sickness prophylaxis<strong>","***General Information***Nitrate/nitrite therapy***Dialysis, renal failure, renal impairment***Hepatic disease***Angina, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypertension, hypotension, hypovolemia, myocardial infarction, stroke***Leukemia, multiple myeloma, penile structural abnormality, polycythemia, priapism, sickle cell disease***Human immunodeficiency virus (HIV) infection***Non-arteritic anterior ischemic optic neuropathy, retinitis pigmentosa, visual disturbance***Geriatric***Prostate cancer***Gastroesophageal reflux disease (GERD), hiatal hernia, peptic ulcer disease***Pregnancy***Breast-feeding***Hematological disease***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,estradiol valerate,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For systemic treatment of the vasomotor symptoms (hot flashes) and genitourinary symptoms of menopause.***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For estrogen replacement for premenopausal women with primary ovarian failure or female hypogonadism.***For the palliative treatment of advanced inoperable prostate cancer.***For the palliative treatment of breast cancer that is inoperable and progressive in selected men and postmenopausal women.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates***Intravenous administration***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5296'],altretamine,***For the palliative treatment of recurrent or persistent ovarian cancer as a single agent following first-line combination chemotherapy. <br />        NOTE: Altretamine has been designated an orphan drug by the FDA for this indication.<br />     ***Formoterol; Mometasone,"***Bone marrow suppression, herpes infection, infection, neutropenia, radiation therapy, requires an experienced clinician, thrombocytopenia, varicella, viral infection***MAOI therapy***Intramuscular injections***Dental disease, dental work***Neurotoxicity***Pregnancy***Breast-feeding***Children***Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,propranolol hydrochloride,"***For the treatment of chronic stable angina.***For heart rate control in patients with atrial fibrillation and/or atrial flutter.***For the treatment of paroxysmal supraventricular tachycardia (PSVT) or for paroxysmal supraventricular tachycardia (PSVT) prophylaxis.***For the treatment of an evolving acute myocardial infarction. <br />  NOTE: For ST-elevation myocardial infarction, oral beta-blocker therapy should be initiated in the first 24 hours for patients who do not have signs of cardiac failure, evidence of low output, increased risk for cardiogenic shock, or other contraindications for beta-blocker therapy.<br /***For reduction of cardiovascular mortality in stable patients who have sustained a myocardial infarction.***For the treatment of hypertension.***For the treatment of idiopathic hypertrophic subaortic stenosis (IHSS).***For management of pheochromocytoma, including preoperative control of tachycardia before surgery, in conjunction with an alpha-blocker.***For migraine prophylaxis.***For migraine prophylaxis in pediatric patients�.***For migraine prophylaxis in adults.***For the management of tremor.***For the management of essential tremor.***For the management of lithium-induced tremor�.***For the management of essential tremor in pediatric patients.***For the treatment of a proliferating infantile hemangioma requiring systemic therapy. <br />  To reduce the risk of hypoglycemia, administer propranolol immediately after or concurrently with a feeding. Avoid fasting; if inevitable, hold medication or support with a product such as Pedialyte or glucose-containing IV fluids.  Vital signs and cardiorespiratory exam or ECG should be obtained at baseline. Obtain blood pressure and heart rate measurements at 1 and 2 hours after the initial dose and any significant dose increase (e.g., more than 0.5 mg/kg/day).  Experts have recommended propranolol therapy continue until full involution of the lesion has occurred or the patient is at least 1 year of age; recurrences have been reported with early discontinuation. At the end of therapy, gradually taper propranolol over 2 to 4 weeks.      If hemangiomas recur, treatment may reinitiated.<br /***For the treatment of unstable angina�.***For the treatment of anxiety� or panic attacks�.***For the short-term symptomatic management of thyrotoxicosis� and thyroid storm�.***For the short-term symptomatic management of thyrotoxicosis� and thyroid storm� in pediatric patients.***For the short term management of thyrotoxicosis� or thyroid storm in adults�.***For the treatment of hypertension and the subsequent decline in renal function associated with scleroderma renal crisis (SRC)�.***For the treatment of portal hypertension� and/or variceal bleeding prophylaxis� in patients with esophageal varices�.***For the prevention of first variceal bleed (primary variceal bleeding prophylaxis).***For prevention of recurrence of variceal bleed (secondary variceal bleeding prophylaxis).***For the treatment of chronic agitation� or aggressive behavior.***For the prevention and management of hypercyanotic episodes associated with tetralogy of Fallot (i.e., tetralogy spells�).***For the attenuation of hypermetabolism in patients with severe burns�.***For the attenuation of hypermetabolism in adult patients with severe burns.***For the attenuation of hypermetabolism in pediatric patients with severe burns.***For the treatment of heart failure� (ischemic origin or cardiomyopathy�) usually in conjunction with digoxin, diuretics, or ACE inhibitor therapy in children and infants.***For the maintenance of sinus rhythm in patients with supraventricular arrhythmias�, including Wolff-Parkinson-White (WPW) syndrome� and junctional ectopic tachycardia� (JET).***Formoterol; Mometasone","***Abrupt discontinuation***Hyperthyroidism, thyroid disease, thyrotoxicosis***Acute heart failure, AV block, bradycardia, cardiogenic shock, hypotension, pheochromocytoma, pulmonary edema, sick sinus syndrome, vasospastic angina, ventricular dysfunction***Wolff-Parkinson-White syndrome***Cerebrovascular disease, PHACE syndrome, stroke***Diabetes mellitus, hypoglycemia***Hepatic disease***Acute bronchospasm, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary disease***Beta-blocker hypersensitivity***Raynaud's phenomenon***Myasthenia gravis, myopathy***Depression***Driving or operating machinery***Renal failure, renal impairment***Psoriasis***Surgery***Children, infants, neonates, premature neonates***Obstetric delivery, pregnancy***Breast-feeding***Geriatric***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['135775'],zolmitriptan,***For the acute treatment of migraine with or without aura. <br />        NOTE: Zolmitriptan is not indicated for hemiplegic or basilar migraine.<br />     ***For menstrual migraine prophylaxis�.,"***General Information***Acute myocardial infarction, angina, arteriosclerosis, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, hypercholesterolemia, myocardial infarction, obesity, tobacco smoking, vasospastic angina, Wolff-Parkinson-White syndrome***Hypertension***Cerebrovascular disease, intracranial bleeding, stroke***Colitis, peripheral vascular disease, Raynaud's phenomenon***Phenylketonuria***Basilar/hemiplegic migraine***Geriatric***Renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***GI disease***Driving or operating machinery***MAOI therapy***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,vilazodone hydrochloride,***For the treatment of major depression.,"***Abrupt discontinuation***Bipolar disorder, mania***Hepatic disease***Electroconvulsive therapy (ECT), seizure disorder, seizures***Anticoagulant therapy, bleeding, thrombolytic therapy***Dehydration, hyponatremia, hypovolemia***Substance abuse***Avoid ethanol ingestion, driving or operating machinery***Children, suicidal ideation***Labor, neonates, obstetric delivery, pregnancy***Breast-feeding***MAOI therapy***Closed-angle glaucoma, increased intraocular pressure***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/norgestrel,"***For routine contraception.***For use as postcoital contraception� within 72 hours of unprotected intercourse, or known or suspected contraceptive failure, in females who have no known contraindications to oral contraceptives, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,typhoid vaccine live oral Ty21a,"***For primary immunization against typhoid disease cause by <em>Salmonella typhi</em> (typhoid prophylaxis) in persons at risk of infection. <br />  NOTE: Routine vaccination against typhoid disease is not recommended in the US.<br />NOTE: Vaccination against typhoid disease is recommended for: travelers to areas where the risk of exposure to typhoid exists, persons with intimate exposure (i.e., continued household contact) to a documented typhoid carrier, and microbiology laboratory employees with frequent exposure to Salmonella typhi. <br />NOTE: The vaccine is not effective in preventing infections caused by Salmonella paratyphi A or B, non-Salmonella typhi species of Salmonella enterica serovar Typhi, or other bacteria that cause enteric disease","***Yeast hypersensitivity***Intravenous administration, subcutaneous administration***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Agammaglobulinemia, corticosteroid therapy, human immunodeficiency virus (HIV) infection, hypogammaglobulinemia, immunosuppression, leukemia, lymphoma, neoplastic disease, radiation therapy, severe combined immunodeficiency (SCID)***Diarrhea, fever, vomiting***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6901'],methylphenidate,***For the treatment of attention-deficit hyperactivity disorder (ADHD).***For once-daily product dosing.***For the treatment of narcolepsy.***For the treatment of major depression� or post-stroke depression refractory to other therapies. <br />        NOTE: The use of stimulants for the treatment of depressive disorders is usually limited to treatment-refractory cases or when standard medical therapies are not tolerated. Stimulants may aggravate coexisting anxiety or agitation in depressed patients.<br />     ,"***General Information***Hereditary fructose intolerance***Anxiety, bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Tics, Tourette's syndrome***Glaucoma, visual disturbance***Abrupt discontinuation, alcoholism, substance abuse***Hypertension***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular arrhythmias, ventricular dysfunction***Cerebrovascular disease, stroke***Children, growth inhibition***Hyperthyroidism***Seizure disorder, seizures***Neonates, pregnancy***Breast-feeding***Driving or operating machinery***Surgery***Radiographic contrast administration***Dysphagia, esophageal stricture, GI obstruction, ileus***Hepatic disease***Geriatric***MAOI therapy***Peripheral vascular disease, Raynaud's phenomenon***Chemical leukoderma, skin hypopigmentation, vitiligo***Phenylketonuria",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,lidocaine hydrochloride,"***For the treatment of perfusing ventricular arrhythmias including ventricular fibrillation (VF) and ventricular tachycardia (VT) that may result during acute myocardial infarction or cardiac manipulation (e.g., cardiac surgery). <br />  NOTE: See resuscitation indication for dosage guidelines for VF or pulseless VT.<br />NOTE: Although not considered a drug of choice for ventricular arrhythmias, lidocaine may be used as an alternative antiarrhythmic in patients with preserved ventricular function and stable monomorphic VT. Lidocaine may also be used to treat polymorphic VT in patients with a normal QT interval (when electrolyte imbalance and ischemia are treated). If pulseless cardiac arrest associated with VF or VT, see separate dosage guidelines for the treatment ventricular arrhythmias during CPR.<br />NOTE: Lidocaine may be used to treat patients with polymorphic VT associated with QT prolongation (e.g., torsade de pointes).<br />NOTE: Monitor blood pressure and the electrocardiogram (ECG) during intravenous lidocaine administration***For topical anesthesia of skin and mucous membranes or stomatitis.***For prevention of dental pain� and for topical anesthesia of mucous membranes.***For laryngoscopy.***For nonurgent painful procedures including IV cannulation, venipuncture, lumbar puncture, or arterial puncture.***For the treatment of stage 1 thru 4 pressure ulcers, venous stasis ulcers, ulcerations of mixed vascular etiologies, diabetic skin ulcers, first and second degree burns, and post surgical incisions, cuts, and abrasions.***For endotracheal intubation.***For neonatal circumcision�.***For bronchoscopy.***For the treatment of pain associated with postherpetic neuralgia.***For ophthalmic anesthesia.***For local anesthesia including peripheral nerve block anesthesia. <br />        NOTE: In adults, the dosages for local anesthesia reported are general guidelines only. The actual dose depends on a variety of factors such as depth of anesthesia, extent of surgical procedure, degree of muscle relaxation required, duration of anesthesia and the patients' physical condition. See Lidocaine; epinephrine monograph for information concerning combination dosing.<br />     ***For dental anesthesia including mandibular nerve block and maxillary infiltration.***For infiltration anesthesia.***For intravenous regional anesthesia.***For pudendal nerve block.***For paravertebral block.***For intercostal nerve block.***For brachial plexus block.***For paracervical block.***For sympathetic nerve block.***For cervical stellate ganglion block.***For lumbar sympathetic block.***For epidural anesthesia. <br />        NOTE: The dose is determined by the number of dermatomes to anesthetized (2 to 3 mL/dermatome). The suggested concentrations and volumes serve as a guide, other volumes and concentrations may be used provided the maximum dose is not exceeded.<br />     ***For lumbar anesthesia.***For lumbar analgesia for severe pain.***For thoracic.***For caudal anesthesia.***For obstetric anesthesia.***For surgical anesthesia.***For spinal anesthesia.***For obstetrical low spinal or saddle block anesthesia.***For intraabdominal anesthesia.***For the treatment of ventricular arrhythmias during cardiopulmonary resuscitation� (CPR).***For the attenuation of increased intracranial pressure� during rapid-sequence intubation� or endotracheal tube suctioning�.***For the treatment of severe singultus (hiccups)�.***For the treatment of headache�.***For the treatment of acute headache� associated with migraine�.***For the treatment of cluster headache�.***For the symptomatic treatment of corticosteroid-dependent asthma�. <br />        NOTE: Initial bronchoconstriction can occur. In addition, lidocaine toxicity can result in tremors, hallucinations, seizures, and cardiac arrest. Caution is advised until long-term safety and efficacy can be established.<br />     ***For short-term prophylaxis of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing� (SUNCT).***For the treatment of painful diabetic neuropathy� in adults.","***General Information***Amide local anesthetic hypersensitivity, epidural anesthesia***Collagen-vascular disease***G6PD deficiency***Geriatric, heart failure, hepatic disease***Hypotension, pregnancy***Breast-feeding***Adams-Stokes syndrome, atrial fibrillation, atrial flutter, AV block, bradycardia, cardiogenic shock, hemorrhagic shock, hypovolemia, shock, Wolff-Parkinson-White syndrome***Renal disease, renal failure, renal impairment***Burns, eczema, heating pad, occlusive dressing, skin abrasion***Cataracts, ocular exposure, ocular trauma***Accidental exposure***Intraarterial administration, intrathecal administration, intravenous administration***Head and neck anesthesia***Ocular surgery***Anticoagulant therapy, bleeding, coagulopathy, infection, neurological disease, requires a specialized care setting, requires an experienced clinician, sepsis, spinal anesthesia, thrombocytopenia***Fetal distress, labor, obstetric delivery, pudendal nerve block***Continuous intraarticular infusion administration***Fetal prematurity, paracervical nerve block***Malignant hyperthermia***Children, infants, neonates, teething pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,terbinafine hydrochloride,"***For the treatment of tinea pedis.***For the treatment of tinea cruris or tinea corporis.***For the treatment of tinea capitis.***For the treatment of tinea versicolor due to <em>Malassezia furfur</em>.***For the treatment of onychomycosis.***For the routine treatment of onychomycosis (tinea unguium).***For the treatment of onychomycosis due to <em>Candida parapsilosis�</em>.***For the treatment of refractory bronchopulmonary aspergillosis� due to various <em>Aspergillus</em> sp.�, including <em>Aspergillus fumigatus�</em>, in non-immunocompromised patients.","***General Information***Onychomycosis***Human immunodeficiency virus (HIV) infection, immunosuppression, neutropenia***Pregnancy***Breast-feeding***Anxiety, children, depression, insomnia, suicidal ideation***Hepatic disease, hepatitis, jaundice***Renal failure, renal impairment***Serious rash***Hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3100'],dactinomycin,"***For the treatment of gestational trophoblastic disease including choriocarcinoma and hydatidiform mole.***For neoplastic trophoblastic disease such as choriocarcinoma and hydatidiform mole.***For high-risk gestational trophoblastic disease in combination with methotrexate, leucovorin, etoposide, cyclophosphamide, and vincristine (EMA-CO regimen).***For high-risk gestational trophoblastic disease in combination with methotrexate, leucovorin, etoposide, and cisplatin (EMA-EP regimen).***For the treatment of germ cell cancer including metastatic nonseminomatous (germ cell) testicular cancer.***For the treatment of Wilms' tumor or Ewing's sarcoma.***For the treatment of malignant melanoma.***For the treatment of malignant melanoma as a single-agent or in combination with other chemotherapy�.***For the treatment of rhabdomyosarcoma.***For the treatment of childhood rhabdomyosarcoma.***For the first-line treatment of rhabdomyosarcoma in children and adolescents in combination with vincristine, ifosfamide, and doxorubicin.***For the treatment of osteogenic sarcoma�.***For the treatment of Kaposi's sarcoma�.***Formoterol; Mometasone","***General Information***New primary malignancy***Bone marrow suppression, herpes infection, infection, requires an experienced clinician, varicella, viral infection***Radiation therapy***Dental disease, dental work***Extravasation***Intramuscular injections***Accidental exposure, ocular exposure***Hepatic disease***Hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, tumor lysis syndrome (TLS)***Geriatric***Renal failure, renal impairment***Children, infants***Pregnancy***Vaccination***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['28889'],loratadine,"***For the relief of symptoms associated with seasonal or perennial allergic rhinitis, and for management of chronic idiopathic urticaria or other histamine-mediated allergic symptoms (e.g., hives, pruritus).***For adjunctive exercise-induced bronchospasm prophylaxis� in patients with allergies.","***General Information***Asthma***Phenylketonuria***Driving or operating machinery***Hepatic disease***Renal failure, renal impairment***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluoxetine hydrochloride,***For the treatment of major depression.***For the treatment of depression with a daily dosage formulation.***For the once-weekly maintenance treatment of depression.***For acute treatment of treatment-resistant depression in combination with olanzapine.***For acute  treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in combination with olanzapine.***For the treatment of obsessive-compulsive disorder (OCD).***For the treatment of panic disorder with or without agoraphobia.***For the treatment of bulimia nervosa.***For the treatment of premenstrual dysphoric disorder (PMDD).***For the treatment of generalized anxiety disorder (GAD)�.***For the treatment of social phobia (social anxiety disorder)�.***For the treatment of posttraumatic stress disorder (PTSD)�.***For the treatment of anorexia nervosa�.***For the treatment of obesity�.***For the treatment of borderline personality disorder�.***For the treatment of autistic disorder�.***For the treatment of separation anxiety disorder�.***For the treatment of fibromyalgia�.***For the treatment of neurogenic orthostatic hypotension�.***For the treatment of premature ejaculation�.***For the treatment of hot flashes� in women with breast cancer experiencing symptoms of menopause�.***For migraine prophylaxis�.***For the treatment of selective mutism� in children who have failed an adequate trial of psychotherapy.***Formoterol***Formoterol; Mometasone,"***General Information***Abrupt discontinuation***Electroconvulsive therapy (ECT), seizure disorder***Children, growth inhibition, suicidal ideation***MAOI therapy***Bipolar disorder, mania***Hepatic disease***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diarrhea, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, poor metabolizers, QT prolongation, thyroid disease, ventricular arrhythmias***Dehydration, hyponatremia, hypovolemia***Anticoagulant therapy, bleeding, thrombolytic therapy***Closed-angle glaucoma, increased intraocular pressure***Driving or operating machinery, ethanol ingestion***Diabetes mellitus***Akathisia***Anorexia nervosa***Bone fractures, osteoporosis***Neonates, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['17767']['321064'],amlodipine/olmesartan medoxomil,"***For the treatment of hypertension, either alone or in combination with other antihypertensive agents.***For initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals.***For patients already receiving amlodipine and olmesartan who desire to switch to the combination tablet or patients not adequately controlled on amlodipine or olmesartan alone.","***General Information***Dihydropyridine hypersensitivity***Aortic stenosis, bradycardia, cardiogenic shock, coronary artery disease, heart failure, hypotension, hypovolemia***Hepatic disease***Renal artery stenosis, renal impairment***Hyperkalemia***ACE-inhibitor induced angioedema, angioedema***Black patients***Surgery***Gastroesophageal reflux disease (GERD), hiatal hernia***Geriatric***Pregnancy***Children***Breast-feeding***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5764'],indapamide,***For treatment of edema of congestive heart failure.***For the treatment of hypertension.***Formoterol; Mometasone,"***Sulfonamide hypersensitivity***Thyroid disease***Electrolyte imbalance, hypercalcemia, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis, parathyroid disease***Hypotension, hypovolemia, orthostatic hypotension, sympathectomy, syncope***Hepatic disease***Diabetes mellitus, hyperglycemia***Anuria, gout, hyperuricemia, renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Children***Sunlight (UV) exposure***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dextromethorphan hydrobromide/guaifenesin,"***For the temporary relief of cough, especially non-productive cough, due to minor throat and bronchial irritation such as may occur with the common cold.","***General Information***Asthma, bronchitis, emphysema, fever, headache, tobacco smoking, vomiting***Hepatic disease***Driving or operating machinery***Children, infants***Pregnancy***Breast-feeding***MAOI therapy***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],estradiol,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For systemic treatment of the vasomotor symptoms (hot flashes) and genitourinary symptoms of menopause.***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For estrogen replacement for premenopausal women with primary ovarian failure or female hypogonadism.***For the palliative treatment of advanced inoperable prostate cancer.***For the palliative treatment of breast cancer that is inoperable and progressive in selected men and postmenopausal women.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates***Intravenous administration***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['392509'],laronidase,***For the treatment of the Hurler and Hurler-Scheie forms of mucopolysaccharidosis I (MPS I) and for treatment of the Scheie form of MPS I (moderate to severe symptoms only). <br />  NOTE: Laronidase has been designated as an orphan drug for this indication by the FDA.<br /,"***Infusion-related reactions, laronidase hypersensitivity, pulmonary disease, serious hypersensitivity reactions or anaphylaxis***Pregnancy***Breast-feeding***Infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['616739'],rotigotine,***For the treatment of the signs and symptoms of idiopathic Parkinson's disease.***For the treatment of Restless Legs Syndrome (RLS).,"***Asthma, sulfite hypersensitivity***Driving or operating machinery, ethanol ingestion***Behavioral changes, impulse control symptoms, psychosis, schizophrenia***Cardiac disease, hypertension, orthostatic hypotension, syncope***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Ambient temperature increase, heating pad, sunlight (UV) exposure***Abrupt discontinuation***Heart failure, peripheral edema, renal impairment***Tardive dyskinesia***Melanoma***Pregnancy***Breast-feeding***Geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albuterol sulfate,"***For the treatment of acute bronchospasm (e.g., asthma) and bronchospasm prophylaxis.***For bronchospasm associated reversible obstructive airway disease (i.e., asthma).***For exercise-induced bronchospasm prophylaxis.***For the adjunctive emergency acute treatment of hyperkalemia�.***For the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD)� including chronic bronchitis� and emphysema�.","***General Information***Albuterol hypersensitivity, levalbuterol hypersensitivity, milk protein hypersensitivity***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hepatic disease, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, malnutrition, myocardial infarction, QT prolongation, tachycardia, thyroid disease***Geriatric***Hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyrotoxicosis***Diabetes mellitus, diabetic ketoacidosis***Deterioration of asthma, paradoxical bronchospasm***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Renal impairment***MAOI therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5175'],hemin,"***For the treatment of recurrent attacks of acute intermittent porphyria related to the menstrual cycle or other patients� with acute intermittent porphyria, porphyria variegata�, or hereditary coproporphyria�. <br />  NOTE: Clinical benefits from hemin depend on prompt administration. Control of pain, hypertension, tachycardia, abnormal mental status, and mild to progressive neurologic signs may be achieved in patients with acute intermittent porphyria, porphyria variegata, or hereditary coproporphyria. Attacks of porphyria may progress to a point where irreversible neuronal damage has occurred. Hemin therapy is intended to prevent an attack from reaching the critical stage of neuronal degeneration; it does not repair neuronal damage.<br />NOTE: Recommended dosage guidelines should be strictly followed","***General Information***Intramuscular administration, subcutaneous administration***Infection, requires an experienced clinician, viral infection***Anticoagulant therapy***Pregnancy***Breast-feeding***Latex hypersensitivity***Preeclampsia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['282357'],fulvestrant,"***For the treatment of breast cancer.***For the treatment of hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression following endocrine therapy, as monotherapy.***For the first-line treatment of hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women, in combination with anastrozole�.***For the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer after disease progression following endocrine-based therapy, in combination with palbociclib.***For the treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer in postmenopausal women who have not previously been treated with endocrine therapy, as monotherapy.***For the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy, in combination with abemaciclib.","***Intravenous administration, neurologic events, peripheral neuropathy***Hepatic disease***Anticoagulant therapy, coagulopathy, thrombocytopenia***Laboratory test interference***Children, infants, neonates***Pregnancy***Contraception requirements, infertility, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,guanfacine hydrochloride,"***For the treatment of hypertension.***For the treatment of attention-deficit hyperactivity disorder (ADHD), as monotherapy or as adjunctive therapy to a psychostimulant.","***General Information***Acute myocardial infarction, AV block, bradycardia, cardiac disease, cerebrovascular disease, coronary artery disease, dehydration, hypotension, orthostatic hypotension, syncope***Hepatic disease, renal disease, renal failure, renal impairment***Abrupt discontinuation***Geriatric***Depression***Driving or operating machinery, ethanol ingestion***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['1307619', '1307625', '1314319']",bosutinib,"***For the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). <br />        NOTE: The FDA has designated bosutinib as an orphan drug for the treatment of CML.<br />     ***For the treatment of newly diagnosed chronic phase Ph+ CML.***For the treatment of chronic phase, accelerated phase, or blast phase Ph+ CML with resistance or intolerance to prior therapy.","***General Information***Abdominal pain, diarrhea, nausea/vomiting***Anemia, neutropenia, thrombocytopenia***Hepatic disease, hepatotoxicity***Pericardial effusion, peripheral edema, pleural effusion, pulmonary edema***Nephrotoxicity, renal disease, renal failure, renal impairment***Contraception requirements, infertility, pregnancy testing, reproductive risk***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7417'],nifedipine,"***For the treatment of ischemic heart disease including variant angina (Prinzmetal's angina) and chronic stable angina pectoris.***For the treatment of hypertension.***For acute hypertensive episodes including hypertensive urgency and hypertensive emergency in pediatric patients�. <br />          NOTE: Per the FDA and manufacturers, immediate-release nifedipine dosage forms should not be used to treat hypertension and should only be used to treat patients with chronic stable angina or vasospastic angina. The immediate-release nifedipine formulation has been associated with serious side effects (see Precautions and Adverse Reactions) when used to treat adult patients with hypertension, hypertensive urgency, hypertensive emergency, or coexisting myocardial infarction. Although the use of immediate-release nifedipine for the treatment of acute hypertensive episodes is still relatively common practice in pediatric patients, considerable controversy exists and caution should be used.<br />       ***For migraine prophylaxis�.***For the treatment of proteinuria� associated with diabetic nephropathy�.***For the treatment of persistent singultus (hiccups)�.***For the inhibition of uterine contractions in premature labor�. <br />        NOTE: Clinical practice guidelines recommend the use of a first line tocolytic (i.e., beta agonist, calcium channel blocker, or NSAID) for short-term use (up to 48 hours) to allow for administration of antenatal corticosteroids to enhance fetal lung maturation, magnesium sulfate for fetal neuroprotection, or transport to a tertiary facility, if indicated. There is no evidence that tocolytic therapy alone has any favorable effect on neonatal outcomes. Maintenance therapy with tocolytics is ineffective for preventing preterm birth and improving neonatal outcomes and is not recommended.<br />     ***For the treatment of achalasia�.***For the treatment of high altitude pulmonary edema associated with altitude sickness�.***For altitude sickness prophylaxis<strong>","***General Information***Dihydropyridine hypersensitivity***Pregnancy***Breast-feeding***Acute myocardial infarction, bradycardia, cardiogenic shock, coronary artery disease, heart failure, hypotension, ventricular dysfunction***Geriatric***Aortic stenosis***Colostomy, constipation, diabetes mellitus, diverticulitis, esophageal stricture, gastric cancer, gastroesophageal reflux disease (GERD), GI obstruction, hiatal hernia, hypothyroidism, ileus, inflammatory bowel disease, obesity***Children, infants***Hepatic disease***Lactase deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1895'],amlodipine besylate/atorvastatin calcium,"***For the treatment of hypertension or coronary artery disease including angina (chronic stable angina or variant angina) in patients with coexisting hyperlipoproteinemia (hypercholesterolemia, type IV hypertriglyceridemia, or type III hyperlipoproteinemia) and/or patients at risk for complications of coronary artery disease (stroke prophylaxis, myocardial infarction prophylaxis). <br />        NOTE: The combination product (Caduet) is indicated in patients for whom treatment with both amlodipine and atorvastatin are appropriate (see separate monographs for more specific information regarding indications for each component).<br />     ","***Dihydropyridine hypersensitivity***Alcoholism, cholestasis, hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Hypotension***Electrolyte imbalance, endocrine disease, infection, myopathy, organ transplant, renal disease, renal failure, renal impairment, rhabdomyolysis, seizure disorder, surgery, trauma***Bradycardia, cardiogenic shock, heart failure, ventricular dysfunction***Aortic stenosis***Acute myocardial infarction, coronary artery disease***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric***Gastroesophageal reflux disease (GERD), hiatal hernia***Hypertension, stroke***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hyoscyamine sulfate/methenamine/methylene blue/monobasic sodium phosphate,"***For the relief of discomfort associated with lower urinary tract infection (UTI) or diagnostic procedures by producing urinary acidification, reducing bacteriuria, and reducing spasmodic activity.***Formaldehyde hypersensitivit***Formoterol; Mometasone","***General Information***Formaldehyde hypersensitivity***Bladder obstruction, cardiac arrhythmias, coronary artery disease, geriatric, GI obstruction, glaucoma, heart failure, ileus, mitral stenosis, myasthenia gravis, prostatic hypertrophy, urinary retention, urinary tract obstruction***Anuria, dehydration, hepatic disease, oliguria, renal failure, renal impairment***Children, infants, neonates***Eclampsia, pregnancy***Breast-feeding***Edema, hypernatremia, hyperphosphatemia, hypertension, sodium restriction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['259280'],tenecteplase,"***For the treatment of acute myocardial infarction with ST-elevation (STEMI) due to coronary artery thrombosis. <br />        NOTE: Standard management of myocardial infarction should be implemented concomitantly with tenecteplase treatment. <br />NOTE: Randomized controlled trials have demonstrated beneficial outcomes when fibrinolytic therapy is administered as early as possible after onset of STEMI symptoms (e.g., prehospital fibrinolysis or within 30 minutes of hospital arrival). When indicated for patients with acute myocardial infarction and ST-elevation (STEMI), fibrinolytic therapy may be administered within 12 hours following the onset of symptoms.  It is reasonable to administer fibrinolytic therapy within 24 hours of the onset of STEMI symptoms in patients who have continuing ischemic symptoms and ST elevation greater than 0.1 mV in at least 2 contiguous precordial leads or at least 2 adjacent limb leads.<br />NOTE: During pre-marketing trials, the safety and efficacy of tenecteplase was primarily studied in AMI patients receiving aspirin and heparin. In the primary efficacy and safety trial, ASSENT 2, the use of glycoprotein IIb/IIIa inhibitors was discouraged for the first 24 hours following randomization. Tenecteplase has also been used to treat myocardial infarction in combination with enoxaparin as an alternative to unfractionated heparin.  ***For re-establishing patency of an occluded IV catheter<strong>","***General Information***Cardiac arrhythmias, hypertension***Aneurysm, arteriovenous malformation, bleeding, brain tumor, coagulopathy, diabetic retinopathy, endocarditis, head trauma, hepatic disease, intracranial mass, organ biopsy, peptic ulcer disease, pericarditis, renal disease, renal failure, spinal anesthesia, stroke, surgery, venipuncture***Geriatric***Intramuscular injections***Infection, thrombophlebitis***Anticoagulant therapy***Atrial fibrillation, mitral stenosis***Labor, obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,rimabotulinumtoxinB,"***For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.***For the treatment of sialorrhea� (excessive drooling) associated with neurological disorders (e.g., Parkinson's disease).","***General Information***Dysphagia***Amyotrophic lateral sclerosis (ALS), autonomic neuropathy, myasthenia gravis, myopathy, neuromuscular disease***Infection, inflammation***Albumin hypersensitivity***Cerebral palsy, children, distant spread of toxin effects***Geriatric***Pregnancy***Breast-feeding***Viral infection***Respiratory insufficiency***Driving or operating machinery***Surgery***Requires an experienced clinician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['641465'],armodafinil,***For the treatment of narcolepsy to improve wakefulness in patients with excessive sleepiness.***For the treatment of shift work sleep disorder to improve wakefulness in patients with excessive sleepiness.***For the treatment of obstructive sleep apnea (OSA) to improve wakefulness in patients with excessive sleepiness.,"***General Information***Angioedema, serious rash***Bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Neurological disease***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, heart failure, hypertension, myocardial infarction, valvular heart disease, ventricular dysfunction***Contraception requirements, pregnancy***Breast-feeding***Abrupt discontinuation, alcoholism, substance abuse***Geriatric***Hepatic disease, hepatitis***Renal disease, renal failure, renal impairment***Children, infants, neonates***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,phenytoin sodium,"***For the treatment of status epilepticus.***For the treatment of tonic-clonic seizures or partial seizures.***For maintenance dosing to treat tonic-clonic or complex partial seizures.***For non-emergent treatment to increase phenytoin serum concentrations in a patient currently receiving phenytoin, but who has subtherapeutic serum concentrations; or to initiate phenytoin therapy for seizures in non-emergent situations.***For seizure prophylaxis due to specific neurologic conditions, including neurosurgery, head trauma� or traumatic brain injury�, or subarachnoid hemorrhage�.***For seizure prophylaxis following traumatic brain injury� or head trauma� or for seizure prophylaxis or treatment during neurosurgery.***For the treatment of serious cardiac arrhythmias secondary to digoxin toxicity�.***For seizure prophylaxis� during antenatal care in pregnant females with eclampsia� or severe preeclampsia�.","***Barbiturate hypersensitivity, carbamazepine hypersensitivity, hydantoin hypersensitivity, succinimide hypersensitivity***Asian patients, serious rash***Depression, suicidal ideation***Abrupt discontinuation***Hypoglycemia, hyponatremia, petit mal (absence) seizures***Hepatic disease, hepatotoxicity, hypoalbuminemia, jaundice***Agranulocytosis, bone marrow suppression, hematological disease, porphyria***Hodgkin's disease, lymphoma***Adams-Stokes syndrome, AV block, bradycardia, bundle-branch block, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypotension, infusion-related reactions, intravenous administration***Intramuscular administration***Alcoholism, ethanol ingestion, ethanol intoxication***Driving or operating machinery, encephalopathy, psychosis***Renal disease, renal failure, renal impairment***Diabetes mellitus***Hypothyroidism, thyroid disease***Bone fractures, osteomalacia, osteoporosis***Myasthenia gravis***Dental disease***Extravasation***Geriatric***Neonates, obstetric delivery, pregnancy, vitamin K deficiency***Breast-feeding***Contraception requirements, reproductive risk***Radiation therapy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5640'],ibuprofen,"***For the treatment of rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA).***For the treatment of dysmenorrhea.***For the treatment of severe pain in hospitalized patients.***For the treatment of mild pain to moderate pain.***For the treatment of mild to moderate pain in hospitalized patients.***For self-treatment of minor aches and pains due to the common cold, toothache, muscular aches or backache (musculoskeletal pain), and the minor pains of arthritis.***For the treatment of fever.***For the treatment of headache.***For self-treatment of headache.***For the treatment of pain due to acute migraine.***For the treatment of osteoarthritis; ankylosing spondylitis�; acute gouty arthritis�; or psoriatic arthritis�.***For patients with cystic fibrosis� to slow the rate of decline in lung function.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, Crohn's disease, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery bypass graft surgery (CABG), coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Geriatric***Labor, obstetric delivery, pregnancy***Infertility, reproductive risk***Breast-feeding***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine","***For simultaneous diphtheria prophylaxis, tetanus prophylaxis, pertussis prophylaxis, Haemophilus influenzae type b prophylaxis, and poliovirus prophylaxis.","***General Information***Children, geriatric, infants, neonates, premature neonates***Intraarterial administration, intravenous administration, subcutaneous administration***Guillain-Barre syndrome***Albumin hypersensitivity, neomycin hypersensitivity, polymyxin hypersensitivity, polysorbate 80 hypersensitivity***Encephalopathy, fever, neurological disease, seizure disorder, seizures***Shock***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency***Immunosuppression***Pregnancy***Breast-feeding***Infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,dextroamphetamine sulfate,"***For the treatment of attention-deficit hyperactivity disorder (ADHD). <br />        NOTE: Dosage should be individualized; use lowest effective dose after stabilization. Lack of response to one stimulant does not predict a response to other stimulants. ADHD is a chronic condition that will require ongoing management and monitoring. Sixty to eighty percent of children will continue to need treatment in adulthood. The effect of behavioral therapy is controversial; however, combined drug and behavioral therapy has been shown to be more effective than behavioral therapy alone. In many cases, drug treatment alone showed a consistent dose-sensitive effect in improving core ADHD symptoms. Treatment strategies must be individualized for patients based on psychosocial and comorbid factors. Stimulants have been shown to be effective first-line agents in the treatment of ADHD.   <br />NOTE: Avoid late evening doses to help prevent insomnia. Reduce dose if anorexia or insomnia occur***For the treatment of narcolepsy.***For the short-term treatment (i.e., 3 to 6 weeks) of exogenous obesity� in adults.***For the treatment of hypothalamic obesity� after craniopharyngioma surgical resection.***Formoterol***Formoterol; Mometasone","***General Information***Alcoholism, substance abuse***Bipolar disorder, depression, mania, psychosis, schizophrenia, suicidal ideation***Hypertension, tachycardia***Acute myocardial infarction, aortic stenosis, arteriosclerosis, cardiac arrhythmias, cardiac disease, cardiomyopathy, congenital heart disease, coronary artery disease, heart failure, myocardial infarction, prosthetic heart valves, valvular heart disease, ventricular arrhythmias, ventricular dysfunction***Cerebrovascular disease, stroke***Glaucoma, visual disturbance***Hyperthyroidism, thyrotoxicosis***Neonates, pregnancy***Breast-feeding***Tics, Tourette's syndrome***Driving or operating machinery***Seizure disorder, seizures***Surgery***Radiographic contrast administration***Abrupt discontinuation***Hypercortisolism***Geriatric***Hepatic disease, renal impairment***Children, growth inhibition, infants***MAOI therapy***Peripheral vascular disease, Raynaud's phenomenon***Anorexia nervosa, bulimia nervosa, obesity treatment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,terbinafine hydrochloride,"***For the treatment of tinea pedis.***For the treatment of tinea cruris or tinea corporis.***For the treatment of tinea capitis.***For the treatment of tinea versicolor due to <em>Malassezia furfur</em>.***For the treatment of onychomycosis.***For the routine treatment of onychomycosis (tinea unguium).***For the treatment of onychomycosis due to <em>Candida parapsilosis�</em>.***For the treatment of refractory bronchopulmonary aspergillosis� due to various <em>Aspergillus</em> sp.�, including <em>Aspergillus fumigatus�</em>, in non-immunocompromised patients.","***General Information***Onychomycosis***Human immunodeficiency virus (HIV) infection, immunosuppression, neutropenia***Pregnancy***Breast-feeding***Anxiety, children, depression, insomnia, suicidal ideation***Hepatic disease, hepatitis, jaundice***Renal failure, renal impairment***Serious rash***Hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fibrin sealant,***For skin graft management by promoting adherence of autologous skin grafts to surgically prepared wound beds from burns.***For use as an adjunct to hemostasis in patients undergoing surgery when control of surgical bleeding by standard surgical techniques is ineffective or impractical.***For use as an adjunct to standard surgical techniques for colonic anastomotic leak prophylaxis after the reversal of temporary colostomies.,"***General Information***Intraarterial administration, intravenous administration***Aprotinin hypersensitivity***Bleeding***Infection***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['47858'],methsuximide,***For the treatment of generalized absence seizures.,"***Succinimide hypersensitivity***Depression, suicidal ideation***Abrupt discontinuation***Bone marrow suppression, fever, hematological disease, infection***Driving or operating machinery***Psychosis, schizophrenia***Porphyria***Hepatic disease, hepatitis, jaundice***Renal disease, renal impairment***Systemic lupus erythematosus (SLE)***Pregnancy***Breast-feeding***Infants***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2541'],cimetidine,"***For the treatment of gastroesophageal reflux disease (GERD) or esophagitis associated with gastroesophageal reflux disease (GERD).***For the self-medication of pyrosis (heartburn), acid dyspepsia (acid indigestion), or sour stomach.***For the treatment of peptic ulcer disease (duodenal ulcer or gastric ulcer). <br />        NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br />     ***For acute treatment.***For maintenance therapy of refractory duodenal ulcer or gastric ulcer in patients with peptic ulcer disease.***For Helicobacter pylori (H. pylori) eradication in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�. <br />        NOTE: The American College of Gastroenterology (ACG) recommends 10�14 days of a triple-drug regimen containing a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole; the same combination for 14 days continues to be recommended as first line therapy in the 2006 global updates from the Maastricht III Consensus Report.�<br />NOTE: Famotidine is not effective as a single agent for the eradication of H. pylori. Quadruple regimens that include an H2-blocker as an anti-secretory agent are FDA-approved, but are associated with lower compliance and efficacy rates than other recommended regimens.  An H2-blocker should not be substituted for a PPI in any current H. pylori treatment regimen unless the patient cannot tolerate a PPI.�<br />NOTE: In populations where H. pylori infection is common (&gt;= 10%), patients presenting with non-ulcer dyspepsia should be tested for H. pylori; those found to be H. pylori positive should be started on combination eradication therapy (also see Helidac monograph).  <br />NOTE: A large body of data exist to support the importance of H. pylori eradication as the first line treatment of gastric MALT lymphoma. Following H. pylori eradication, long term tumor regression is observed in 60�90% of patients.***For the treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome, systemic mastocytosis, and multiple endocrine adenoma syndrome.***For the treatment of upper GI bleeding or acute gastritis.***For stress gastritis prophylaxis in critically-ill patients.***For acid aspiration prophylaxis� prior to intubation or anesthesia.***For NSAID-induced ulcer prophylaxis�.***For the treatment of acute, severe urticaria� or angioedema� associated with systemic symptoms in combination with an H1-blocker.***For the prevention of urticaria and other histamine-mediated reactions to specific types of chemotherapy� (e.g., paclitaxel).***Formoterol; Mometasone","***General Information***Benzyl alcohol hypersensitivity, H2-blocker hypersensitivity***Intravenous administration***Gastric cancer***Infection***Hepatic disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Neonates***Tobacco smoking***Immunosuppression***Geriatric***Vitamin B12 deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,risedronate sodium,"***For the treatment of Paget's disease (osteitis deformans) to induce remission in patients who have serum alkaline phosphatase concentrations at least twice the upper limit of normal, or are symptomatic, or are at risk for future complications of their disease.***For the treatment of osteoporosis.***For osteoporosis prophylaxis.***For the treatment of osteolytic bone metastases� in patients with multiple myeloma.","***General Information***Asthma, phosphonate hypersensitivity***Hyperparathyroidism, hypocalcemia, vitamin D deficiency***Achalasia, dysphagia, esophageal stricture, esophagitis, gastritis, gastroesophageal reflux disease (GERD), GI disease, hiatal hernia, inability to stand or sit upright***Children***Pregnancy***Breast-feeding***Renal failure, renal impairment***Geriatric***Anemia, chemotherapy, coagulopathy, corticosteroid therapy, dental disease, dental work, infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,theophylline anhydrous,"***For treatment of reversible airways obstruction (i.e., for bronchospasm prophylaxis) associated with asthma or chronic obstructive pulmonary disease (COPD) (e.g., emphysema or chronic bronchitis). <br />        NOTE: Calculate initial mg/kg dose based on ideal body weight as theophylline distributes poorly into body fat. <br />     ***For adjunct treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases (e.g., COPD) along with inhaled beta-2 selective agonists and systemic corticosteroids.***For maintenance therapy of asthma or COPD using oral dosage.***For the treatment of acute exacerbations� of reversible airways obstruction (including status asthmaticus) in patients who are not responding to first-line therapies. <br />        NOTE: Although reference texts continue to list this indication, several studies have failed to demonstrate a benefit of theophylline in the management of acute bronchospasm. The FDA no longer includes acute bronchospasm as an approved indication. Most clinicians do not feel theophylline is warranted in the treatment of acute bronchospasm unless the patient is not responding to other treatments. The National Asthma Education and Prevention Program does not recommend theophylline for acute exacerbations because it appears to provide no additional benefit to optimal inhaled beta-2-agonist therapy and may increase risk of adverse effects.<br />     ***For the treatment of neonatal apnea of prematurity when non-pharmacologic therapies are ineffective. <br />        NOTE: Caffeine is the preferred agent for this indication (see Caffeine monograph); theophylline is used as an alternative.<br />     ***For the treatment of sleep apnea� in patients with chronic heart failure-induced systolic dysfunction.***Formoterol***Formoterol; Mometasone","***General Information***Cardiac arrhythmias, cardiac disease, cor pulmonale, coronary artery disease, heart failure, myocardial infarction***Hypothyroidism, pulmonary edema, sepsis, shock***Cystic fibrosis, hyperthyroidism***Acidemia***Cholestasis, hepatic disease, hepatitis, infants, neonates, renal impairment***Tobacco smoking***Fever, hypoxemia***Gastritis, gastroesophageal reflux disease (GERD), hiatal hernia, peptic ulcer disease***Prostatic hypertrophy***Pregnancy***Breast-feeding***Corn hypersensitivity***Seizure disorder***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8640'],prednisone,"***For maintenance therapy (i.e., replacement therapy) of primary (Addison's disease) or secondary adrenocortical insufficiency.***For the treatment of congenital adrenal hyperplasia.***For kidney transplant rejection prophylaxis.***For the treatment of chronic graft-versus-host disease (GVHD).***For palliative management of acute lymphocytic leukemia (ALL).***For the treatment of chronic lymphocytic leukemia (CLL).***For the first-line treatment of CLL, in combination with cladribine�.***For the first-line treatment of CLL, in combination with chlorambucil�.***For the palliative treatment of CLL.***For the short-term treatment of hypercalcemia secondary to neoplastic disease.***For the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis.***For short-term treatment of acute exacerbations of Crohn's disease.***For short-term treatment of acute exacerbations of ulcerative colitis.***For the treatment of rheumatic conditions such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, acute and subacute bursitis, acute non-specific tenosynovitis, acute gouty arthritis and gout, osteoarthritis, or epicondylitis.***For the treatment of systemic autoimmune conditions such as acquired hemolytic anemia, congenital hypoplastic anemia, mycosis fungoides, pemphigus, symptomatic sarcoidosis, or nonsuppurative thyroiditis.***For the treatment of asthma.***For a moderate to severe asthma exacerbation in the emergency department or the hospital.***For an acute asthma exacerbation on an outpatient basis in selected patients.***For long-term prevention of symptoms in severe persistent asthma.***For the treatment of thrombocytopenia or idiopathic thrombocytopenic purpura (ITP).***For autoimmune thrombocytopenia associated with SLE.***For the treatment of acute, severe urticaria or the treatment of late-phase angioedema, such as ACE-inhibitor induced angioedema once acute symptoms are controlled.***For the treatment of myasthenia gravis in patients who are poorly controlled with cholinesterase inhibitor therapy.***For the treatment of nephrotic syndrome or to treat lupus nephritis.***For the treatment of lupus nephritis.***For the treatment of severe erythema multiforme or Stevens-Johnson syndrome.***For the treatment of the acute respiratory distress syndrome (ARDS).***For the treatment of Hodgkin lymphoma in combination with antineoplastic agents.***For the treatment of corticosteroid-responsive dermatitis and dermatologic disorders such as atopic dermatitis or eczema, bullous dermatitis herpetiformis, contact dermatitis, exfoliative dermatitis, or severe seborrheic dermatitis.***For the treatment of Loeffler's syndrome, berylliosis, erythroblastopenia, or trichinosis.***For the treatment of pulmonary fibrosis due to known underlying causative conditions or for idiopathic pulmonary fibrosis�.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of multiple myeloma�.***For the palliative treatment of multiple myeloma in combination with melphalan�.***For newly diagnosed multiple myeloma in geriatric adults or transplant ineligible patients, in combination with melphalan and thalidomide�.***For previously untreated multiple myeloma, in combination with melphalan and bortezomib�.***For the treatment of previously untreated multiple myeloma in patients ineligible for autologous stem-cell transplantation, in combination with daratumumab, bortezomib, and melphalan�.***For the treatment of serious manifestations of Behcet's syndrome�.***For the symptomatic treatment of Duchenne muscular dystrophy�.***For the adjunctive treatment of carpal tunnel syndrome�.***For the treatment of selected cases of collagen disorders and mixed connective tissue disease�, such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, polyarteritis nodosa, relapsing polychondritis, polymyalgia rheumatica, certain cases of vasculitis, or Wegener's granulomatosis�.***For additional guidance for systemic lupus erythematosus (SLE) in adults.***For systemic dermatomyositis (polymyositis) when dosed in combination with azathioprine.***For treatment using usual labeled dosage.***For the treatment of autoimmune hepatitis�.***For the treatment of primary amyloidosis� not associated with familial Mediterranean fever.***For the treatment of idiopathic or viral pericarditis�.***For the treatment of acute interstitial nephritis (AIN)�.***For the systemic treatment of ophthalmic inflammatory conditions such as endophthalmitis�, optic neuritis, allergic conjunctivitis, keratitis, allergic corneal ulcer, iritis, chorioretinitis, anterior segment inflammation, uveitis, choroiditis, or sympathetic ophthalmia.***For use as an adjunct in the management of extradural malignant spinal cord compression� (MSCC�) associated with metastatic disease.***For the treatment of Bell's palsy�.***For the adjunct treatment of West syndrome (infantile spasms�).***For the adjunct treatment of refractory seizures�, including absence seizures�, myoclonic seizures�, Lennox-Gastaut syndrome�, and other intractable seizure disorders�.***For the treatment of heart transplant rejection�.***For the management of heart transplant rejection prophylaxis�.***For adjunct therapy in patients with Mycobacterium avium complex infection� (MAC) experiencing moderate to severe immune reconstitution inflammatory syndrome (IRIS).***For adjunctive treatment in selected cases of pneumonia� or pneumonitis.***For the treatment of Pneumocystis pneumonia (PCP)� in HIV patients as adjunctive therapy.***For aspiration pneumonitis.***For adjunct therapy in patients with chorioretinitis associated with congenital toxoplasmosis�.***For the treatment of exacerbations of chronic obstructive pulmonary disease (COPD)�.***For the treatment of peripheral T-cell lymphoma (PTCL)�.***For the first-line treatment of PTCL in combination with gemcitabine, cisplatin, and thalidomide�.***For the treatment of Kawasaki disease�.","***General Information***Infection, surgery***Fungal infection***Herpes infection, measles, tuberculosis, varicella, viral infection***Myocardial infarction***Heart failure, hypertension***Cataracts, glaucoma, visual disturbance***Diverticulitis, GI disease, hepatic disease, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Diabetes mellitus, hypothyroidism, osteoporosis, psychosis, renal disease, seizure disorder***Myasthenia gravis***Coagulopathy, thromboembolic disease***Pregnancy***Breast-feeding***Vaccination***Growth inhibition, increased intracranial pressure, neonates***Cushing's syndrome***Abrupt discontinuation, hypothalamic-pituitary-adrenal (HPA) suppression***Corticosteroid hypersensitivity***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,glycopyrrolate,"***For use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; reduce gastric acid production and acidity (aspiration prophylaxis); and to block vagal inhibitory reflexes during intubation and induction of anesthesia.***For the treatment of sialorrhea.***For severe chronic sialorrhea (chronic drooling) associated with neurologic conditions such as cerebral palsy in pediatric patients.***For clozapine-induced sialorrhea� in adults.***For the treatment of cardiac arrhythmias (e.g., bradycardia) that occur intraoperatively and are drug-induced or are associated with visceral traction stimulation of vagal reflexes.***For cholinesterase inhibitor-induced muscarinic effects prophylaxis when anticholinesterase agents (i.e., neostigmine, physostigmine, pyridostigmine) are used to reverse neuromuscular blockade produced by curariform agents.***For the treatment of peptic or duodenal ulcer. <br />        NOTE: Due to the potential for side effects, as well as the availability of more effective alternatives, glycopyrrolate is rarely used for this indication.<br />     ***For the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis or emphysema.***For the treatment of irritable bowel syndrome� and/or diarrhea�.","***Benzyl alcohol hypersensitivity, milk protein hypersensitivity***Latex hypersensitivity***Ambient temperature increase***Closed-angle glaucoma, ocular exposure***Prostatic hypertrophy, urinary retention, urinary tract obstruction***Autonomic neuropathy, myasthenia gravis***Achalasia, biliary-GI fistula, constipation, diarrhea, esophagitis, gastroesophageal reflux disease (GERD), GI bleeding, GI obstruction, hemorrhagic shock, hiatal hernia, ileus, pyloric stenosis, toxic megacolon, ulcerative colitis***Hepatic disease, renal failure, renal impairment***Cardiac arrhythmias, coronary artery disease, heart failure, hypertension, hyperthyroidism, tachycardia, ventricular tachycardia***Pregnancy***Breast-feeding***Children, Down's syndrome, infants, neonates***Driving or operating machinery***Acute bronchospasm***Paradoxical bronchospasm***Anticholinergic medications, dementia, geriatric***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1828'],busulfan,***For the palliative treatment of chronic myelogenous leukemia (CML).***For stem cell transplant preparation. <br />        NOTE: The FDA has designated busulfan as an orphan drug as preparative therapy in the treatment of malignancies with bone marrow transplantation.<br />     ,"***Bleeding, bone marrow suppression, infection, leukopenia, neutropenia, radiation therapy, thrombocytopenia***Hepatic disease, hepatotoxicity, sinusoidal obstruction syndrome (SOS), veno-occlusive disease (VOD)***Head trauma, seizures***New primary malignancy***Hyperuricemia, tumor lysis syndrome (TLS)***Children, infants, neonates***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ciprofloxacin hydrochloride,"***For the treatment of urinary tract infection (UTI), including acute uncomplicated cystitis and pyelonephritis.***For the treatment of acute, uncomplicated UTI (acute cystitis).***For the treatment of mild to moderate UTIs and for the treatment of severe and/or complicated UTIs, including pyelonephritis.***For the treatment of lower respiratory tract infections, including bronchitis, community-acquired pneumonia (CAP), and nosocomial pneumonia. <br />        NOTE: Ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. <br />     ***For the treatment of nosocomial, ventialator-associated pneumonia (VAP) or hospital-acquired pneumonia (HAP).***For the treatment of community-acquired pneumonia (CAP).***For the treatment of acute exacerbations of chronic bronchitis.***For the treatment of skin and skin structure infections, including diabetic foot ulcer, surgical incision site infections, animal bite wounds, and necrotizing infections.***For the treatment of diabetic foot ulcer.***For the treatment of surgical incision site infections.***For the treatment of animal bite wounds.***For the treatment of necrotizing infections of the skin, fascia, and muscle.***For the treatment of enteric infections, including acute gastroenteritis and infectious diarrhea.***For the treatment of uncomplicated gonorrhea (e.g., cervicitis and urethritis).***For the treatment of mild to moderate acute sinusitis.***For the treatment of prostatitis caused by susceptible organisms.***For acute prostatitis�.***For chronic bacterial prostatitis.***For the treatment of complicated intraabdominal infections in combination with metronidazole.***For empiric treatment of patients with febrile neutropenia as part of combination therapy.***For febrile neutropenia in adults.***For febrile neutropenia in pediatric patients�.***For the treatment of bacterial conjunctivitis.***For the treatment of ophthalmic infection associated with corneal ulcer.***For anthrax prophylaxis after exposure to Bacillus anthracis (postexposure prophylaxis, PEP).***For the treatment of plague infection.***For treatment in a contained casualty setting.***For treatment in a mass casualty setting.***For plague prophylaxis following exposure to <em>Yersinia pestis</em>.***For the treatment of acute otitis externa due to susceptible isolates of <em>Pseudomonas aeruginosa</em> or <em>Staphylococcus aureus</em>.***For the treatment of bone and joint infections (i.e., osteomyelitis, prosthetic joint infections, infectious arthritis).***For the treatment of bilateral otitis media with effusion in pediatric patients undergoing tympanostomy tube placement.***For the treatment of typhoid fever due to <em>Salmonella typhi</em>.***For the treatment of shigellosis.***For the treatment of campylobacteriosis.***For the treatment of acute systemic brucellosis� caused by <em>Brucella melitensis</em>.***For the treatment of chancroid� due to <em>Haemophilus ducreyi</em>.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of <em>Neisseria meningitidis</em>� nasal carrier state (i.e., for meningococcal infection prophylaxis�).***For the treatment of dental infection�, including dentoalveolar infection� and periodontitis�.***For adult chronic periodontitis� after scaling and root planing.***For adult refractory chronic periodontitis� in combination with metronidazole after scaling and root planing in beta-lactam allergic patients.***For the treatment of anthrax�.***For the treatment of cutaneous anthrax.***For the treatment of systemic anthrax infection.***For the treatment of cholera�.***For the treatment of tularemia� infection or for postexposure tularemia prophylaxis�.***For an individual patient� or in a contained casualty setting�. <br />          NOTE: Streptomycin is the drug of choice to treat tularemia in most patients; gentamicin is the preferred agent in pregnant women.<br />       ***For a mass casualty setting� and for tularemia prophylaxis� after exposure to <em>Francisella tularensis</em>. <br />          NOTE: Doxycycline is the treatment of choice for tularemia in the most patients. Ciprofloxacin is the drug of choice for pregnant women; if ciprofloxacin is contraindicated, doxycycline should be used.<br />       ***For use as maintenance treatment of melioidosis� due to <em>Burkholderia pseudomallei�</em>.***For surgical infection prophylaxis�.***For the treatment of acute pulmonary exacerbations in cystic fibrosis� (CF) patients.***For bacterial infection prophylaxis� in patients with cirrhosis and GI bleeding.***For the treatment of CAPD-associated peritonitis�.***For the treatment of exit-site� and tunnel infections� in CAPD patients.***For the treatment of infective endocarditis�.***For the treatment of Mycobacterium avium complex infection� (MAC) in HIV-infected patients.***For the treatment of salmonellosis�.***For the treatment of moderate or severe traveler's diarrhea�.***For the treatment of isosporiasis� (<em>Isospora belli</em>) in HIV-infected patients.***For the treatment of sepsis�.","***Viral infection***Quinolone hypersensitivity***Corticosteroid therapy, organ transplant, tendinitis, tendinopathy, tendon pain, tendon rupture***Alcoholism, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Cerebrovascular disease, neurotoxicity, peripheral neuropathy, seizure disorder***Myasthenia gravis***Diabetes mellitus***Dialysis, renal disease, renal failure, renal impairment***Dehydration***Hepatic disease, hepatitis, hepatotoxicity, jaundice***Sunlight (UV) exposure***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding***Sexually transmitted disease***Geriatric***Children, infants, neonates***Contact lenses***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],desogestrel/ethinyl estradiol,"***For routine contraception.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�,  abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Edema, hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8588'],diclofenac potassium,"***For the treatment of osteoarthritis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the treatment of rheumatoid arthritis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the treatment of ankylosing spondylitis. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For the acute treatment of migraine with or without aura. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />NOTE: Diclofenac is not indicated for migraine prophylaxis***For the treatment of mild pain or moderate pain. <br />        NOTE: Different oral formulations of diclofenac are not bioequivalent even if of equivalent milligram strength.<br />     ***For primary dysmenorrhea or for mild or moderate pain associated with nonrheumatic inflammatory conditions, bone pain�, arthralgia�, myalgia�, and vascular or migraine headache�. <br />          NOTE: Voltaren XR is not indicated for the management of acute painful conditions.<br />       ***For the treatment of acute mild or moderate pain.***For the topical treatment of acute mild pain or moderate pain due to minor strains, sprains, and contusions. <br />          NOTE: Carefully consider the potential benefits and risks of the diclofenac patch. If the patch will be used, use the lowest effective dose for the shortest possible duration.<br />       ***For the treatment of postoperative ocular inflammation following cataract extraction.***For the reduction of photophobia and ocular pain following corneal refractive surgery.***For the treatment of moderate to severe pain alone or in combination with opioid analgesics.***For the treatment of actinic keratosis.***For the prevention of heterotopic ossification�.***Formoterol; Mometasone","***Acute bronchospasm, asthma, bovine protein hypersensitivity, gelatin hypersensitivity, nasal polyps, NSAID hypersensitivity, polysorbate 80 hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Contact lenses, ocular surgery, rheumatoid arthritis***Anemia***Dental disease, dental work***Hepatic disease, jaundice, porphyria***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, renal impairment, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Labor, pregnancy***Breast-feeding***Burns, eczema, exfoliative dermatitis, heating pad, occlusive dressing, ocular exposure, skin abrasion***Benzyl alcohol hypersensitivity, sunlight (UV) exposure***Coronary artery bypass graft surgery (CABG)***Accidental exposure***Phenylketonuria***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,calcipotriene,"***For the treatment of plaque psoriasis. <br />        NOTE: According to the American Academy of Dermatology (AAD), combining calcipotriene with a topical corticosteroid is more effective than either treatment alone. In addition, fewer adverse events were reported with combination therapy in most clinical studies.<br />     ***For the treatment of chronic, moderate scalp psoriasis.","***General Information***Hypercalcemia, hypercalciuria, hypervitaminosis D, nephrolithiasis, occlusive dressing***Accidental exposure, ocular exposure***Children, infants, neonates***Sunlight (UV) exposure***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['7880', '235379']",pancrelipase,"***For the management of exocrine pancreatic insufficiency, such as in patients with cystic fibrosis, chronic pancreatitis, or other conditions.***For the management of exocrine pancreatic insufficiency due to pancreatectomy.***For enteral feeding tube occlusion�.","***Porcine protein hypersensitivity***Viral infection***Dysphagia, esophageal stricture***Gout, hyperuricemia, renal impairment***Fibrosing colonopathy, GI obstruction, inflammatory bowel disease, surgery***Pregnancy***Breast-feeding***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,ethinyl estradiol/levonorgestrel,"***For routine contraception.***For extended continuous routine contraception.***For use as postcoital contraception within 72 hours of unprotected intercourse, or known or suspected contraceptive failure, in females who have no known contraindications to oral contraceptives, have achieved menarche, and are not known or suspected to be pregnant.***For the treatment of severe acne vulgaris� related to sebum overproduction in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.***For the treatment or adjuvant treatment of amenorrhea�, abnormal uterine bleeding� (dysfunctional uterine bleeding�), hirsutism�, hypermenorrhea�, or polycystic ovary syndrome� related to hypoestrogenic or hyperandrogenic conditions in females who have no known contraindications to oral contraceptives, desire contraception, have achieved menarche, and have been evaluated for causes of the condition.***For the treatment of endometriosis� to induce endometrial involution to a 'resting' phase and reduce the size and growth of endometrial tissue in females with no contraindications to hormonal contraceptives, have achieved menarche and who desire contraception.***Formoterol; Mometasone","***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Pregnancy***Cholestasis, gallbladder disease, hepatic disease, hepatitis, hepatocellular cancer, jaundice, porphyria***Breast-feeding, obstetric delivery***Obesity***Diabetes mellitus***Hyperlipidemia, hypertriglyceridemia***Atrial fibrillation, cerebrovascular disease, coronary artery disease, coronary thrombosis, endocarditis, hypercholesterolemia, myocardial infarction, protein C deficiency, protein S deficiency, renal disease, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, valvular heart disease***Systemic lupus erythematosus (SLE)***Surgery***Hypertension***Headache, migraine***Depression***Contact lenses, glaucoma, visual disturbance***Children***Breast cancer***Hypercalcemia***Cervical cancer***Endometrial cancer, ovarian cancer, uterine cancer, vaginal bleeding, vaginal cancer***Hypothyroidism, thyroid disease***Chloasma***Angioedema, hereditary angioedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,triamcinolone acetonide,"***For bronchospasm prophylaxis or maintenance therapy in patients who require chronic treatment with corticosteroids for control of bronchial asthma.***For the treatment of severe or incapacitating allergic conditions such as asthma that are intractable to adequate trials of conventional treatment.***For the treatment of symptoms of seasonal and perennial allergic rhinitis.***For the treatment of severe or incapacitating allergic conditions that are intractable to adequate trials of conventional treatment.***For the treatment of ocular inflammation (i.e., sympathetic ophthalmia and ocular inflammatory conditions unresponsive to topical corticosteroids), temporal arteritis, and uveitis.***For visualization during ocular surgery (i.e., vitrectomy).***For the treatment of acute rheumatic carditis, berylliosis, temporal arteritis�, or systemic lupus erythematosus (SLE). <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of pruritus and topical inflammation associated with moderate to severe corticosteroid-responsive dermatoses (e.g., alopecia areata, atopic dermatitis, contact dermatitis including <em>Rhus dermatitis</em> due to poison ivy, poison oak, poison sumac, subacute cutaneous or discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex chronicus, mycosis fungoides, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, psoriasis, sarcoidosis, seborrheic dermatitis, sunburn, or xerosis). <br />        NOTE: Occlusive dressings may be necessary for chronic or severe cases of psoriasis or other recalcitrant conditions.<br />     ***For the treatment of ulcerative or inflammatory oral lesions including aphthous ulcer, desquamative gingivitis�, and oral lichen planus�.***For the treatment of severe or incapacitating allergic conditions such as atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions, bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome) that are intractable to adequate trials of conventional treatment and for the treatment of idiopathic eosinophilic pneumonias.***For the treatment of symptomatic sarcoidosis.***For the treatment of primary (Addison's disease) or secondary adrenocortical insufficiency. <br />        NOTE: Hydrocortisone and cortisone are the preferred agents for these conditions.<br />     ***For the treatment of congenital adrenal hyperplasia.***For the treatment of hypercalcemia associated with cancer.***For the treatment of nonsuppurative thyroiditis.***For the treatment of a critical period of regional enteritis and ulcerative colitis.***For the treatment of autoimmune hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, or selected cases of secondary thrombocytopenia.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of acute exacerbations of multiple sclerosis. <br />        NOTE: Corticosteroids are effective in speeding the resolution of acute exacerbations, but they do not affect the ultimate outcome or natural history of the disease.<br />     ***For the treatment of cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.***For the treatment of proteinuria or to induce diuresis in idiopathic nephrotic syndrome or lupus erythematosus.***For the treatment of an acute episode or exacerbation of ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA) as adjunctive therapy for short-term administration.***For the treatment of dermatomyositis or polymyositis.***For the relief of inflammation and for immunosuppression associated with a variety of disorders, like Hodgkin lymphoma. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the palliative treatment of leukemias and lymphomas.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of diabetic macular edema�.***For the relief of inflammation associated with synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; gout with acute gouty arthritis; epicondylitis; acute non-specific tenosynovitis; polychondritis�; posttraumatic osteoarthritis. <br />        NOTE: For many conditions, the dosing of corticosteroids is highly variable; the following general dosing recommendations apply.<br />     ***For the treatment of osteoarthritis pain of the knee. <br />  NOTE: Zilretta is not interchangeable with other formulations of triamcinolone acetonide.<br /","***Epidural administration, intramuscular administration, intrathecal administration, intravenous administration, subcutaneous administration***Acute bronchospasm, status asthmaticus***Abrupt discontinuation, adrenal insufficiency, Cushing's syndrome, hyperthyroidism, hypothalamic-pituitary-adrenal (HPA) suppression, hypothyroidism, increased intracranial pressure, occlusive dressing, skin abrasion***Head trauma***Growth inhibition, osteoporosis***Surgery***Fungal infection, infection, viral infection***Tuberculosis***Immunosuppression***Herpes infection, measles, varicella***Glaucoma***Acne rosacea, acne vulgaris***Peripheral vascular disease***Nasal septal perforation, nasal surgery, nasal trauma***Myocardial infarction***Heart failure, hypertension***Diabetes mellitus***Skin atrophy***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Myasthenia gravis***Psychosis, seizure disorder***Coagulopathy, hemophilia, thromboembolic disease***Cataracts, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Pregnancy***Vaccination***Breast-feeding***Tartrazine dye hypersensitivity***Neonates, premature neonates***Idiopathic thrombocytopenic purpura (ITP)***Corticosteroid hypersensitivity***Geriatric***Renal disease, renal impairment***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['591781'],eculizumab,"***For the reduction of hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH).***For the treatment of patients with atypical hemolytic-uremic syndrome (aHUS) to prevent complement-mediated thrombotic microangiopathy. <br />        NOTE: The approval of eculizumab in patients with aHUS is based on the results of 3 clinical studies. In all 3 studies, recipients of eculizumab experienced a reduction in complement-mediated thrombotic microangiopathy (TMA) as indicated by an increase in mean platelet counts from baseline. In study 1, the mean platelet count at baseline of 109 +/- 32 x 109/L increased to 210 +/- 68 x 109/L by treatment week 26. The change in mean platelet count in study 2 was 229 +/- 78 x 109/L at baseline to 233 +/- 69 x 109/L at week 26. Finally, in study 3 the mean platelet count increased from 171 +/- 83 x 109/L at baseline to 254 +/- 79 x 109/L by week 26.<br />NOTE: A duration of therapy is not defined; following discontinuation, monitor patients for at least 12 weeks to detect signs and symptoms of TMA complications. Clinical signs and symptoms of TMA complications include changes in mental status, seizures, angina, dyspnea, and thrombosis. Laboratory parameters indicating TMA complications include repeated measurements of any of the following: decreased platelet count by &gt;= 25% compared to baseline or peak levels during eculizumab therapy; increase in serum creatinine by &gt;= 25% compared to baseline or nadir during eculizumab therapy; or increase in serum LDH by &gt;= 25% over baseline or nadir during eculizumab therapy. If TMA complications are detected after discontinuation, consider initiating plasma exchange or plasmapheresis, infusing fresh frozen plasma, restarting eculizumab therapy, or beginning appropriate organ-specific supportive care***For the treatment of anti-acetylcholine antibody positive generalized myasthenia gravis .","***Fungal infection, immunosuppression, infection, meningococcal infection, neutropenia, streptococcal infection***Infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4491'],fluorometholone,"***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis, ocular burns or trauma due to corneal injury resulting from chemical, thermal or penetration trauma, giant papillary conjunctivitis (GPC), keratitis, postoperative ocular inflammation, vernal keratoconjunctivitis, and chronic anterior uveitis. <br />  NOTE: The benefit of diminution of edema and inflammation from the use of ocular corticosteroids and the inherent risk of infection in certain conditions must be considered. Duration of treatment may vary with type of lesion and therapeutic response. Renewal of prescriptions beyond 20 mL of suspension or 8 grams of ointment should be made by a physician after re-examination with the aid of magnification. Care should be taken not to discontinue therapy prematurely. In chronic conditions, withdrawal of therapy should be carried out by gradually decreasing the frequency of applications.<br /","***General Information***Herpes infection, herpes simplex keratitis (dendritic keratitis), varicella, viral infection***Fungal infection, mycobacterial infection***Contact lenses***Glaucoma***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hypromellose,***For the temporary relief of xerophthalmia and minor ocular irritation.,"***Contact lenses***Corneal abrasion, ocular infection, ocular trauma, visual disturbance***Pregnancy***Children, infants, neonates***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,anti-inhibitor coagulant complex,"***For the control and prevention of bleeding episodes (i.e., hemorrhage, hemarthrosis), perioperative management (surgical bleeding), and routine bleeding prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or hemophilia B with inhibitors or patients with acquired inhibitors to other factors including patients with factor VII deficiency� or von Willebrand's disease�. <br />  NOTE: 1 unit of activity is defined as the amount of FEIBA that shortens the aPTT of high titer factor VIII inhibitor reference plasma to 50% of the blank value.<br />NOTE: FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to factor VIII or factor IX***For treatment of joint hemorrhage.***For treatment of mucous membrane bleeding.***For the treatment of soft tissue hemorrhage.***For the treatment of severe hemorrhage (CNS bleeding).***For preoperative management of surgical bleeding.***For postoperative management of surgical bleeding.***For routine prophylaxis.***For rivaroxaban reversal�.***For dabigatran reversal�.","***General Information***Disseminated intravascular coagulation (DIC), myocardial infarction, thromboembolism***Viral infection***Thrombocytopenia***Pregnancy***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1291301'],avanafil,***For the treatment of erectile dysfunction (ED).,"***General Information***Nitrate/nitrite therapy***Dialysis, hepatic disease, renal disease, renal failure, renal impairment***Non-arteritic anterior ischemic optic neuropathy, retinitis pigmentosa, visual disturbance***Human immunodeficiency virus (HIV) infection***Geriatric***Hearing impairment, tinnitus***Angina, aortic stenosis, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypertension, hypotension, idiopathic hypertrophic subaortic stenosis, myocardial infarction, stroke***Leukemia, multiple myeloma, penile structural abnormality, Peyronie's disease, polycythemia, priapism, sickle cell disease***Coagulopathy, peptic ulcer disease***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,diethylpropion hydrochloride,***For the treatment of obesity as a short-term adjunct in a regimen of caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m<sup>2</sup> or greater and who have not responded to a weight-reducing regimen of diet and exercise alone.***Formoterol***Formoterol; Mometasone,"***Anorexia nervosa***Arteriosclerosis, cardiac arrhythmias, hypertension, pulmonary hypertension, valvular heart disease***Glaucoma***MAOI therapy***Hyperthyroidism, thyroid disease***Abrupt discontinuation, substance abuse***Mania, psychosis***Children, infants, neonates***Seizure disorder***Pregnancy***Breast-feeding***Surgery***Geriatric, renal failure, renal impairment",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albumin (human),"***For the treatment of shock due to hypovolemia. <br />        NOTE: Dosage should be based on patient response as indicated by blood pressure, degree of pulmonary congestion, and hematocrit.<br />     ***For adjunctive treatment of severe burns.***For the treatment of nephrosis in nephrotic syndrome.***For treatment of hypoproteinemia.***For adjunctive use with exchange transfusion in the treatment of hyperbilirubinemia and erythroblastosis fetalis.","***Albumin hypersensitivity***Anemia, heart failure, hypertension***Renal disease***Hypernatremia***Burns***Viral infection***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['42635'],iron dextran,***For the treatment of iron-deficiency anemia in patients in whom oral iron administration is unsatisfactory or impossible.***For nutritional supplementation� and to prevent iron deficiency in patients receiving long-term total parenteral nutrition.,"***Iron dextran hypersensitivity, serious hypersensitivity reactions or anaphylaxis***Ankylosing spondylitis, asthma, atopy, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Cardiac disease, hypotension, intravenous administration***Anemia, hemochromatosis, hemoglobinopathy, hemosiderosis***Dialysis, renal disease, renal failure***Hepatic disease***Infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pyrantel pamoate,***For the treatment of enterobiasis (pinworm infection).***For the treatment of ascariasis�.***For the treatment of uncinariasis� (hookworm infection).***For the treatment of trichostrongyliasis�.,***Hepatic disease***Phenylketonuria***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,meningococcal groups C and Y and haemophilus b tetanus toxoid conjugate vaccine,***For simultaneous meningococcal infection prophylaxis due to Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b prophylaxis.,"***General Information***Guillain-Barre syndrome***Immunosuppression***Premature neonates***Pregnancy***Breast-feeding***Syncope, visual disturbance***Anticoagulant therapy, coagulopathy, hemophilia, thrombocytopenia, vitamin K deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clonidine hydrochloride,"***For the treatment of hypertension.***For the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients as monotherapy or as adjunctive therapy to a psychostimulant. <br />        NOTE: Clonidine is not considered a first-line agent for children with ADHD due to the potential cardiac effects and the availability of safer and more effective agents, such as some stimulants. Reports of sudden death and hypotension in children receiving oral clonidine in combination with other therapies for ADHD have been published, but causality has not been established.  Children and infants may be more sensitive to the effects of clonidine. However, not all ADHD clinical trials evaluating clonidine have reported adverse cardiac effects. The American Heart Association has recommended that children and adolescents receiving clonidine be monitored for changes in blood pressure at treatment initiation, periodically during treatment, and when tapering the drug, even when clonidine is used for psychotropic indications.<br />     ***For the treatment of ADHD in children with tic disorders�.***For the treatment of severe pain.***For the treatment of hypertensive urgency� or hypertensive emergency�.***For the treatment of opiate agonist withdrawal�.***For the treatment of neonatal abstinence syndrome�.***For pheochromocytoma diagnosis�.***For the symptomatic treatment of diabetic neuropathy�.***For the treatment of diabetic diarrhea�, diarrhea� related to opiate withdrawal, or refractory diarrhea� in cancer patients. <br />        NOTE: Clonidine has some antisecretory activity by modulating (decreasing) small intestinal transit; however, data are relatively limited and the agent is often used for refractory diarrheal cases.<br />     ***For the treatment of alcohol withdrawal�.***For use as an adjunct to psychosocial interventions in the management of tobacco cessation� (smoking cessation�).***For the treatment of hot flashes� due to menopause�.***For the treatment of hypertension and the subsequent decline in renal function associated with scleroderma renal crisis (SRC)�.***For minimization of nephrotoxicity in patients receiving cyclosporine (i.e., cyclosporine nephrotoxicity prophylaxis�) and low-dose methotrexate for allogeneic bone marrow transplant.***For use in peripheral nerve block� including brachial plexus�, intercostal� and peribulbar� blocks in combination with local anesthetics.***For the treatment of Tourette's syndrome�.***For the treatment of aggressive behavior and hyperactivity/inattentiveness in patients with autistic disorder�.***For growth hormone deficiency diagnosis�.***For the treatment of hot flashes� due to prostate cancer� and associated induced androgen deficiency� (andropause�"") in men who have had surgical or medication induced castration.""","***General Information***Abrupt discontinuation, vomiting***AV block, bradycardia, cerebrovascular disease, dehydration, heart failure, hypotension, myocardial infarction, orthostatic hypotension, syncope***Labor, obstetric delivery, pregnancy***Females***Breast-feeding***Children, infants, neonates***Depression***Driving or operating machinery***Sick sinus syndrome***Raynaud's phenomenon, thromboangiitis obliterans (Buerger's disease)***Diabetes mellitus***Renal disease, renal failure, renal impairment***Anticoagulant therapy, coagulopathy, infection***Cardiac disease***Intrathecal administration***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Polyarteritis nodosa, scleroderma, systemic lupus erythematosus (SLE)***Skin abrasion***Surgery***Pheochromocytoma***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albuterol sulfate/ipratropium bromide,"***For the second-line treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis or emphysema.***For use in the acute management of patients with asthma�.","***General Information***Albuterol hypersensitivity, levalbuterol hypersensitivity, paradoxical bronchospasm***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation***Anticholinergic medications, bladder obstruction, prostatic hypertrophy, urinary retention***Geriatric***Diabetes mellitus, hyperthyroidism, pheochromocytoma, seizure disorder, seizures, thyroid disease, thyrotoxicosis***Closed-angle glaucoma, contact lenses, ophthalmic administration***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants***Hepatic disease, renal disease, renal failure, renal impairment***MAOI therapy***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fesoterodine fumarate,"***For the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urinary urgency, and urinary frequency.","***General Information***Prostatic hypertrophy, urinary retention, urinary tract obstruction***Constipation, gastroesophageal reflux disease (GERD), gastroparesis, GI obstruction, ileus, pyloric stenosis, toxic megacolon, ulcerative colitis***Closed-angle glaucoma, contact lenses***Driving or operating machinery, ethanol ingestion***Hepatic disease***Renal failure, renal impairment***Autonomic neuropathy, myasthenia gravis***Ambient temperature increase***Geriatric***Children, infants***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1291'],bacitracin,"***For the prevention of skin and skin structure infections after a minor compromise in skin integrity such as minor burns or skin abrasion.***For superficial ophthalmic infection of the conjunctiva and/or cornea caused by susceptible organisms, including the following infections - blepharitis, blepharoconjunctivitis, bacterial conjunctivitis, keratitis, and keratoconjunctivitis.***For the treatment of pneumonia or pleural empyema caused by susceptible Staphylococci. <br />  Due to the potential for nephrotoxicity, restrict bacitracin intramuscular therapy to infants with susceptible staphylococcal pneumonia infections and pleural empyema. Intramuscular bacitracin should only be used where adequate laboratory facilities are available and when constant supervision of the patient is possible.<br /***For the treatment and eradication of enteric vancomycin-resistant enterococci (VRE)� in the stool.","***General Information***Neomycin hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Nephrotoxicity, oliguria, renal failure, renal impairment***Pregnancy***Breast-feeding***Myasthenia gravis, neuromuscular disease, pulmonary disease, surgery***Ocular exposure***Fungal infection***Contact lenses***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,olsalazine sodium,***For the maintenance of remission in ulcerative colitis patients intolerant of sulfasalazine.,"***5-aminosalicylates hypersensitivity, salicylate hypersensitivity***Colitis, inflammatory bowel disease***Renal disease, renal failure, renal impairment***Geriatric***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8727'],progesterone,"***For the treatment of amenorrhea.***For the prevention of endometrial hyperplasia associated with conjugated estrogen replacement therapy in postmenopausal women who have an intact uterus.***For the treatment of dysfunctional uterine bleeding secondary to hormonal imbalance.***For the treatment of infertility or for the prevention of early pregnancy failure� (e.g., miscarriage) in women with corpus luteum insufficiency�. <br />        NOTE: The optimal dose and route of progesterone administration has not been determined. Vaginal progesterone is often used preferentially over the intramuscular formulation secondary to comparable efficacy and decreased side effects (e.g., pain at the injection site, sterile abscess formation).<br />     ***For the treatment of symptoms associated with premenstrual syndrome (PMS)�.***For preterm delivery prophylaxis�.","***Breast cancer, cervical cancer, endometrial cancer, endometrial hyperplasia, new primary malignancy, ovarian cancer, uterine cancer, vaginal cancer***Hepatic disease***Benzyl alcohol hypersensitivity, intravenous administration, pulmonary oil microembolism, sesame oil hypersensitivity***Infertility***Ectopic pregnancy, incomplete abortion, pregnancy***Breast-feeding***Children, infants, neonates***Cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking, visual disturbance***Diabetes mellitus, hyperlipidemia***Asthma, cardiac disease, renal disease***Depression, migraine, seizure disorder***Infection, inflammation***Peanut hypersensitivity***Driving or operating machinery***Dementia, geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,estropipate,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For treatment of  premenopausal females with estrogen deficiency due to hypogonadism or primary ovarian failure.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,nortriptyline hydrochloride,***For the treatment of major depression . <br /***For the treatment of social phobia (social anxiety disorder)� or panic disorder�.***For migraine prophylaxis�.***For the treatment of premenstrual dysphoric disorder (PMDD)�.***For the treatment of nocturnal enuresis�.***For the treatment of postherpetic neuralgia�.***For the treatment of painful diabetic neuropathy�.***For use as an adjunct to psychosocial interventions in the management of tobacco cessation� (smoking cessation�).,"***Carbamazepine hypersensitivity, tricyclic antidepressant hypersensitivity***MAOI therapy***Acute myocardial infarction, bradycardia, Brugada syndrome, cardiac arrhythmias, cardiac disease, congenital heart disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, orthostatic hypotension, QT prolongation***Children, suicidal ideation***Bipolar disorder, mania, schizophrenia***Alcoholism, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Electroconvulsive therapy (ECT), seizure disorder, seizures***Hepatic disease***Surgery***Anticholinergic medications, ileus, prostatic hypertrophy, urinary retention***Closed-angle glaucoma, increased intraocular pressure***Contact lenses***Agranulocytosis, leukopenia***Hyperthyroidism, hypothyroidism***Diabetes mellitus, pheochromocytoma***Radiographic contrast administration***Sunlight (UV) exposure***Abrupt discontinuation***Geriatric***Pregnancy***Breast-feeding***Tobacco smoking",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['6038'],isoniazid/rifampin,***For the treatment of pulmonary tuberculosis infection in patients already receiving the individual drug components in an established fixed dosage.***Formoterol; Mometasone,"***General Information***Alcoholism, Black patients, females, geriatric, hepatic disease, hepatitis, hepatotoxicity, Hispanic patients, jaundice***Rifamycin hypersensitivity***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection***Contact lenses***Renal failure, renal impairment***Diabetes mellitus, peripheral neuropathy***MAOI therapy***Visual disturbance***Children, infants, neonates***Pregnancy***Breast-feeding***Gout, hyperuricemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,raloxifene hydrochloride,***For the treatment of osteoporosis or for osteoporosis prophylaxis in postmenopausal women.***For invasive breast cancer prophylaxis in postmenopausal women with osteoporosis or in postmenopausal women who are at high risk for developing the disease. <br />   �<br /***For the treatment of uterine leiomyomata� in postmenopausal women.,"***General Information***Heart failure, neoplastic disease, surgery, thromboembolic disease, thromboembolism, thrombophlebitis***Atrial fibrillation, cardiac disease, cerebrovascular disease, coronary artery disease, hypertension, mortality, stroke, tobacco smoking***Hepatic disease***Renal failure, renal impairment***Vaginal bleeding***Breast cancer***Hypertriglyceridemia***Pregnancy***Breast-feeding***Infertility, reproductive risk***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['42372'],mupirocin,"***For the treatment of impetigo and other skin and skin structure infections due to susceptible strains of <em>Staphylococcus aureus</em> or <em>Streptococcus pyogenes</em>.***For the treatment of impetigo.***For the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area).***For nasal bacterial colonization eradication of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) to reduce the risk of infection among high-risk patients during institutional outbreaks of infections with this pathogen.***For the treatment of mild methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated infectious neonatal pustulosis�.***For the treatment of infected eczema� due to susceptible strains of <em>Staphylococcus</em> sp. or <em>Streptococcus</em> sp..***For the treatment of folliculitis� due to susceptible strains of <em>Staphylococcus</em> sp. or <em>Streptococcus</em> sp..***For the prevention of postoperative nosocomial <em>Staphylococcus aureus</em> infections� (i.e., bacterial infection prophylaxis�).","***General Information***Burns, renal impairment***Children, infants, neonates***Ocular exposure, ophthalmic administration***Pregnancy***Breast-feeding***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,apomorphine hydrochloride,"***For use as acute, intermittent treatment  of 'off' episodes ('end-of-dose wearing off' and unpredictable 'on/off' episodes) associated with advanced Parkinson's disease.***For use in the differential diagnosis of idiopathic parkinsonism� and as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes� to determine whether a patient will respond or is still responsive to levodopa therapy. <br />        NOTE: To reduce the incidence of adverse effects (emesis) from apomorphine injection, one study suggests the following: domperidone 20 mg PO three times per day for 2�3 days prior to the administration of apomorphine and domperidone 20 mg PO three times per day during the day of apomorphine administration beginning 30�60 minutes prior to the apomorphine dose. Domperidone is not available in the United States; data are not available on the use of trimethobenzamide for this indication.<br /> <br />NOTE: The dose of SC apomorphine should be expressed in ml to avoid prescription dosing errors***Formoterol***Formoterol; Mometasone","***General Information***Benzyl alcohol hypersensitivity, hypotension, opiate agonist hypersensitivity, sulfite hypersensitivity, vomiting***Intravenous administration***Depression, psychosis, schizophrenia, suicidal ideation***Asthma, CNS depression, coma, driving or operating machinery, emphysema, gag reflex depression, respiratory depression, seizure disorder, seizures***Alcoholism, angina, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, cerebrovascular disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, orthostatic hypotension, QT prolongation, shock, syncope, thyroid disease***Hepatic disease***Renal disease, renal failure, renal impairment***Impulse control symptoms, substance abuse***Abrupt discontinuation***Pregnancy***Breast-feeding***Geriatric***Children, infants***Melanoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,estradiol acetate,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For systemic treatment of the vasomotor symptoms (hot flashes) and genitourinary symptoms of menopause.***For the treatment of isolated vaginal and/or urogenital symptoms of menopause.***For osteoporosis prophylaxis in women due to menopause (either natural or surgical).***For estrogen replacement for premenopausal women with primary ovarian failure or female hypogonadism.***For the palliative treatment of advanced inoperable prostate cancer.***For the palliative treatment of breast cancer that is inoperable and progressive in selected men and postmenopausal women.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants, neonates***Intravenous administration***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,methenamine hippurate,"***For prophylactic or suppressive treatment of frequently recurring urinary tract infection (UTI), specifically cystitis, when long term therapy is considered necessary (i.e., neurogenic bladder).","***Viral infection***Dehydration, renal disease, renal failure, renal impairment***Hepatic disease***Tartrazine dye hypersensitivity***Gout***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,doxycycline monohydrate,"***For the treatment of skin and skin structure infections, including cellulitis, due to <em>Staphylococcus aureus</em>. <br />        NOTE: Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infection.<br />     ***For the treatment of bacterial urinary tract infection (UTI).***For the treatment of upper respiratory tract infections (e.g., sinusitis).***For the treatment of lower respiratory tract infections (e.g., pneumonia, community-acquired pneumonia).***For the treatment of severe acne vulgaris as adjunctive therapy.***For the treatment of acne rosacea.***For the treatment of cholera.***For the treatment of brucellosis.***For the treatment of Rickettsial infections (e.g., Rickettsial pox, Rocky Mountain spotted fever, scrub typhus) including endemic murine typhus.***For the treatment of relapsing fever due to <em>Borrelia recurrentis</em>.***For the treatment of syphilis. <br />        NOTE: A Jarisch-Herxheimer reaction may occur within the first 24 hours of therapy.<br />NOTE: While clinical practice guidelines recommend non-penicillin alternatives for the treatment of syphilis in HIV-infected patients, their efficacy has not been evaluated and should only be used with close clinical and serologic monitoring***For primary, secondary, or early latent syphilis (caused by <em>Treponema pallidum</em>) in nonpregnant, penicillin-allergic patients.***For late latent syphilis in nonpregnant, penicillin-allergic patients.***For the treatment of psittacosis.***For the treatment of non-gonococcal urethritis (NGU) and chlamydia infection, including trachoma and inclusion bacterial conjunctivitis.***For the treatment of lymphogranuloma venereum caused by <em>Chlamydia trachomatis</em>.***For the treatment of granuloma inguinale (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For the treatment of epididymitis and epididymo-orchitis.***For malaria prophylaxis in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains.***For the treatment of anthrax infection due to exposure to <em>Bacillus anthracis</em>.***For the treatment of cutaneous anthrax infection.***For the treatment of systemic anthrax infection.***For anthrax prophylaxis after exposure to <em>Bacillus anthracis</em> (postexposure prophylaxis, PEP).***For the treatment of plague infection due to exposure to <em>Yersinia pestis</em>.***For the treatment of plague infection in an individual patient or in a contained casualty setting.***For the treatment of plague infection in a mass casualty setting.***For the initial treatment of tularemia infection due to exposure to <em>Francisella tularensis </em>.***For the initial treatment of tularemia infection in individual patient or in a contained casualty setting. <br />          NOTE: Streptomycin is the drug of choice to treat tularemia in most patients; gentamicin is the preferred agent in pregnant women.<br />       ***For the initial treatment of tularemia infection in a mass casualty setting. <br />          NOTE: It is recommended that pregnant women be treated with ciprofloxacin as a first-line agent; doxycycline is a preferred treatment choice if ciprofloxacin is contraindicated.<br />       ***For the treatment of intestinal amebiasis as an adjunct to amebicides.***For the treatment of infections caused by sensitive organisms including actinomycosis (<em>Actinomyces israelii</em>), yaws (<em>Treponema pertenue</em>), necrotizing ulcerative gingivitis (Fusospirochetosis or Vincent's infection), and listeriosis (<em>Listeria monocytogenes</em>).***For the treatment of Q fever.***For the treatment of chancroid (<em>Haemophilus ducreyi</em>) infections.***For the treatment of bartonellosis (<em>Bartonella bacilliformis</em>) infections, including <em>Bartonella</em> endocarditis.***For the treatment of <em>Bartonella</em> sp. infections (bartonellosis) in HIV-infected patients.***For long term suppression� of infections caused by <em>Bartonella</em> sp. in HIV-infected patients with relapse or reinfection with CD4 count less than 200 cells/mm3.***For the treatment of enterocolitis�, biliary tract infections�, and intraabdominal infections�.***For the treatment of uncomplicated gonorrhea (e.g., cervicitis, urethritis, pharyngitis, proctitis�).***For the treatment of acute proctitis�.***For chlamydial infection prophylaxis� in victims of sexual assault.***For the treatment of chronic prostatitis� due to <em>Ureaplasma urealyticum</em>.***For the treatment of Lyme disease�, including erythema migrans�, Lyme arthritis�, Lyme carditis�, and Lyme meningitis�.***For early Lyme disease� (erythema migrans�).***For Lyme arthritis�.***For Lyme carditis�.***For early neurologic Lyme disease (i.e., Lyme meningitis� or cranial nerve palsy).***For Lyme disease prophylaxis�.***For the treatment of Legionnaire's disease� caused by <em>Legionella pneumophila</em>.***For the management of pleural effusion� as an alternative to injectable tetracycline or other agents.***For the treatment of malaria� due to <em>P. falciparum</em> or <em>P. vivax</em>.***For the treatment of pelvic inflammatory disease (PID)� and tubo-ovarian abscess�.***For the treatment of acute dental infection�, dentoalveolar infection�, or endodontic infection� including periodontitis in combination with conventional treatment (e.g., scaling and root planing).***For aggressive juvenile periodontitis�.***For chronic adult periodontitis for a gain in clinical attachment, reduction in probing depth, and reduction in bleeding on probing.***For plague prophylaxis� following exposure to <em>Yersinia pestis</em>.***For tularemia prophylaxis� following exposure to <em>Francisella tularensis</em>.***For the treatment of Bancroft's filariasis� (elephantiasis) caused by <em>Wuchereria bancrofti</em>�.***For the treatment of melioidosis� due to <em>Burkholderia pseudomallei</em>.***For use as an adjunct in the treatment of <em>Burkholderia pseudomallei</em> bacteremia�.***For use as an adjunct in the treatment of localized melioidosis�.***For the treatment of leptospirosis� due to <em>Leptospira</em> sp.�.***For mild leptospirosis�.***For severe leptospirosis�.***For surgical infection prophylaxis� for gynecologic procedures.***For surgical infection prophylaxis� for hysterosalpingogram or chromotubation.***For surgical infection prophylaxis� for induced abortion/dilation and evacuation.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated bone and joint infections�, including osteomyelitis�, or orthopedic device-related infection�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated osteomyelitis�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated prosthetic device infections�.***For the management of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA)-associated spinal implant infections�.","***Tetracyclines hypersensitivity***Hepatic disease***Sunlight (UV) exposure***Asthma, sulfite hypersensitivity***Achlorhydria***Pregnancy***Breast-feeding***Children, infants, neonates***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Dental disease, periodontal disease***Chemotherapy, diabetes mellitus, human immunodeficiency virus (HIV) infection, immunosuppression***Antimicrobial resistance, fungal infection, viral infection***Increased intracranial pressure, obesity***Sexually transmitted disease***Geriatric***Serious rash",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1399'],benzocaine,"***For mild pain to provide topical anesthesia or local anesthesia. <br />        NOTE: For oral or dental uses, see dental anesthesia.<br />     ***For pain and pruritus associated with minor skin abrasion, burns, sunburn, insect bites or stings, or minor skin irritations.***For self-medication of rectal pain, especially soreness and/or pruritus associated with hemorrhoids and anorectal inflammation (temporary relief only).***For anesthesia of unbroken skin.***For oral mucosal anesthesia to control pain and/or suppress the pharyngeal and tracheal gag reflex; or for local anesthesia of accessible mucous membranes before examination, endoscopy or instrumentation; and to facilitate passage of fiberoptic gastroscopes, laryngoscopes, proctoscopes, and sigmoidoscopes.***For topical anesthesia in the external auditory canal to relieve ear pain related to acute otitis media and otitis externa.***For dental anesthesia or temporary relief of dental pain or oral pain.***For self-medication of pain associated with aphthous ulcer (i.e., canker sore), dental pain associated with toothache, or minor irritations of the mouth and gums (for temporary relief only).***For self-medication of pain and discomfort of irritations caused by dentures or orthodontic appliances (for temporary relief only).***For self-medication of dental pain due to teething (for temporary relief only).","***General Information***Burns, eczema, occlusive dressing, skin abrasion***Ear discharge, infection, tympanic membrane perforation***Ester local anesthetic hypersensitivity, para-aminobenzoic acid, PABA hypersensitivity, paraben hypersensitivity, tartrazine dye hypersensitivity***Pregnancy***Breast-feeding***Asthma, cardiac disease, chronic obstructive pulmonary disease (COPD), diabetes mellitus, G6PD deficiency, geriatric, Graves' disease, hepatic disease, hyperthyroidism, methemoglobin reductase deficiency, methemoglobinemia, shock, tobacco smoking***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pentosan polysulfate sodium,***For the relief of bladder pain or discomfort associated with interstitial cystitis.,"***General Information***Aneurysm, bleeding, coagulopathy, diverticulitis, hemophilia, inflammatory bowel disease, peptic ulcer disease***Anticoagulant therapy***Thrombocytopenia***Obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates***Hepatic disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['11248'],cyanocobalamin,"***For nutritional supplementation.***For the recommended dietary allowance (RDA) of cyanocobalamin in healthy individuals. <br />          NOTE: Adequate intakes (AI) and RDAs are established and updated via the IOM Food and Nutrition Board.<br />       ***For the treatment of vitamin B12 deficiency or for the treatment of vitamin B12 deficiency megaloblastic anemia or macrocytic anemia thought to be due to vitamin B12 deficiency.***For the treatment of pernicious anemia. <br />        NOTE: Patients with pernicious anemia are 3 times more likely to develop carcinoma of the stomach than the general population, necessitating an appropriate work-up.<br />     ***For the treatment of pernicious anemia in patients who are in hematologic remission with no nervous system involvement . <br />          NOTE: A decline in serum concentrations of B12 after one month of therapy may indicate that the dose needs to be adjusted. Patients should be seen one month after each dosage adjustment. Continued low serum concentrations may indicate that the patient is not a candidate for this mode of administration.<br />       ***For vitamin B12 deficiency diagnosis (Schilling test).***For the treatment of methylmalonic aciduria�.","***General Information***Hereditary optic nerve atrophy (Leber's disease)***Benzyl alcohol hypersensitivity, neonates***Polycythemia vera***Anemia, iron-deficiency anemia***Bone marrow suppression, infection, renal failure, uremia***Respiratory infection, rhinorrhea***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,colistimethate sodium,"***For the treatment of serious systemic gram-negative infection due to susceptible organisms, including multi-drug resistant organisms. <br />  NOTE: To avoid errors in dosing and administration, colistimethate sodium or colistin should only be prescribed and administered in terms of colistin base activity.<br />NOTE: There are approximately 12",500 International Units per mg of colistimethate sodium. Parenteral vials contain colistimethate sodium equivalent to 150 mg colistin base activity (based on microbiological standardization) per vial (approximately 400 mg or 5 million International Units of colistimethate sodium)***For the treatment of meningitis or ventriculitis due to susceptible organisms. <br />  NOTE: To avoid errors in dosing and administration,colistimethate sodium or colistin should only be prescribed and administered in terms of colistin base activity.<br />NOTE: There are approximately 12,500 International Units per mg of colistimethate sodium. Parenteral vials contain colistimethate sodium equivalent to 150 mg colistin base activity (based on microbiological standardization) per vial (approximately 400 mg or 5 million International Units of colistimethate sodium)***For the management of pulmonary infections in patients with cystic fibrosis. <br />        NOTE: To avoid errors in dosing and administration,colistimethate sodium or colistin should only be prescribed and administered in terms of colistin base activity.<br />NOTE: There are approximately 12,500 International Units per mg of colistimethate sodium. Parenteral vials contain colistimethate sodium equivalent to 150 mg colistin base activity (based on microbiological standardization) per vial (approximately 400 mg or 5 million International Units of colistimethate sodium).<br />NOTE: Bronchodilators and oxygen can be given if bronchoconstriction occurs with the administration of colistimethate sodium inhalation***For the treatment of nosocomial pneumonia,including ventilator-associated pneumonia. <br />        NOTE: To avoid errors in dosing and administration,colistimethate sodium or colistin should only be prescribed and administered in terms of colistin base activity.<br />NOTE: There are approximately 12,"500 International Units per mg of colistimethate sodium. Parenteral vials contain colistimethate sodium equivalent to 150 mg colistin base activity (based on microbiological standardization) per vial (approximately 400 mg or 5 million International Units of colistimethate sodium).<br />NOTE: Bronchodilators and oxygen can be given if bronchoconstriction occurs with the administration of colistimethate sodium inhalation""","***General Information***Polymyxin hypersensitivity***Renal disease, renal failure, renal impairment***Driving or operating machinery, myasthenia gravis, neurological disease, neuromuscular disease***Asthma, chronic obstructive pulmonary disease (COPD), pulmonary disease***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,
['114477'],levetiracetam,***For the adjunctive treatment of partial seizures. <br />        NOTE: Treatment may be initiated with IV or PO therapy.<br />     ***For the adjunctive treatment of myoclonic seizures in those with juvenile myoclonic epilepsy.***For the adjunctive treatment of primary generalized tonic-clonic seizures in those with idiopathic generalized epilepsy.***For the first-line treatment of convulsive status epilepticus�.***For seizure prophylaxis�.***For seizure prophylaxis� after traumatic brain injury.***Formoterol; Mometasone,"***General Information***Abrupt discontinuation***Dialysis, renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Driving or operating machinery***Depression, suicidal ideation***Psychosis, schizophrenia***Geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10865'],fosfomycin tromethamine,"***For the treatment of uncomplicated urinary tract infection (UTI), including cystitis.","***Breast-feeding***Children, infants, neonates***Pregnancy***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4278'],famotidine,"***For self-medication of pyrosis (heartburn), acid dyspepsia (acid indigestion), or sour stomach, either for prophylaxis or for symptomatic relief.***For maximum strength prevention or relief of symptoms.***For the treatment of gastroesophageal reflux disease (GERD) or esophagitis associated with gastroesophageal reflux disease (GERD).***For the treatment of peptic ulcer disease (duodenal ulcer or gastric ulcer). <br />        NOTE: For dosing in patients with gastric or duodenal ulcers due to H. pylori, see �H. pylori eradication� indication.<br />     ***For acute treatment.***For maintenance therapy of duodenal ulcer after the initial treatment phase has been completed.***For Helicobacter pylori (H. pylori) eradication in the treatment of patients with duodenal ulcer disease (active or a history of duodenal ulcer), gastric ulcer�, dyspepsia�, or gastric mucosa associated lymphoid tissue (MALT) lymphoma�.***For pathologic GI hypersecretory conditions such as Zollinger-Ellison syndrome, systemic mastocytosis, or multiple endocrine adenoma syndrome.***For NSAID-induced ulcer prophylaxis�.***For stress gastritis prophylaxis� in critically-ill patients.***For acid aspiration prophylaxis� prior to anesthesia.","***General Information***H2-blocker hypersensitivity***Gastric cancer, GI bleeding***Infection***Hepatic disease, QT prolongation, renal disease, renal failure, renal impairment***Children, infants, neonates***Breast-feeding***Pregnancy***Tobacco smoking***Phenylketonuria***Geriatric***Vitamin B12 deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,insulin lispro protamine (rDNA origin)/insulin lispro (rDNA origin),"***For the treatment of type 1 diabetes mellitus or for type 2 diabetes mellitus inadequately managed by diet, exercise, and oral hypoglycemics. <br />        NOTE: A consensus algorithm issued by the ADA and the European Association for the Study of Diabetes lists basal or intermediate-acting insulin as a second line or third line agent in patients with type 2 diabetes not controlled on oral drugs; metformin is the initial recommended therapy in all type 2 diabetics without contraindications. Once insulin is added, therapy can be intensified (e.g., addition of prandial insulin) to achieve optimal glycemic control. In patients that are receiving a sulfonylurea, the sulfonylurea should be discontinued when insulin therapy is initiated.<br />     ***Formoterol; Mometasone","***General Information***Diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting***Hepatic disease, renal failure, renal impairment***Coma, continuous subcutaneous insulin infusion (CSII) administration, diabetic ketoacidosis, hyperosmolar hyperglycemic state (HHS), intravenous administration***Hypoglycemia***Hypokalemia***Cresol hypersensitivity***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants***Tobacco smoking***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['42316', '235991']",tacrolimus,"***For liver transplant rejection prophylaxis.***For kidney transplant rejection prophylaxis. <br />        NOTE: Do not administer concomitantly with cyclosporine. Additionally, use with sirolimus is not recommended in kidney transplant recipients. <br />NOTE: According to renal transplant guidelines, tacrolimus is the suggested first-line calcineurin inhibitor (CNI) to be used for initial maintenance immunosuppression with an antiproliferative agent such as mycophenolate plus or minus corticosteroids. The CNI is suggested to be started before or at the time of transplantation rather than delayed until graft function onset. Further, the CNI is suggested to be continued rather than withdrawn during long-term maintenance therapy.***For conversion from tacrolimus immediate-release products in combination with other immunosuppresants. <br />          NOTE: Tacrolimus immediate-release capsules (administered twice daily), extended-release capsules (Astagraf XL; administered once daily,) and extended-release tablets (Envarsus XR; administered once daily) are not interchangeable or substitutable. <br />       ***For the management of heart transplant rejection prophylaxis. <br />        NOTE: Tacrolimus is recommended to be used in conjunction with azathioprine or mycophenolate mofetil. Adjunct therapy with adrenal corticosteroids is recommended early post transplant.<br />     ***For the treatment of atopic dermatitis.***For short-term or intermittent long-term treatment of moderate-to-severe atopic dermatitis. <br />          NOTE: Topical tacrolimus is a second line agent to treat atopic dermatitis in patients unresponsive to or intolerant of other first line agents; long-term safety has not been established.<br />NOTE: If no improvement occurs after 6 weeks of treatment or if exacerbation of atopic dermatitis occurs, treatment should be stopped and other therapeutic options considered***For the maintenance of disease stabilization� in patients with moderate-to-severe atopic dermatitis. <br />  NOTE: Precautions apply to the chronic use of topical tacrolimus in children and adolescents; FDA-approved labeling warns against continuous long-term use of topical calcineurin inhibitors in any age group.<br /***For the treatment of acute liver transplant rejection�.***For the treatment of acute kidney transplant rejection�.***For pancreas transplant rejection prophylaxis�.***For the management of pancreas/kidney or solitary pancreas transplant rejection prophylaxis� and refractory kidney and/or pancreas transplant rejection�.***For islet transplantation rejection prophylaxis�.***For the management of heart transplant rejection�.***For the rescue treatment for lung transplant rejection� or the management of lung transplant rejection prophylaxis�.***For the management of small bowel transplant rejection prophylaxis�.***For the treatment of graft-versus-host disease (GVHD)� in combination with other immunosuppressants. <br />        NOTE: Tacrolimus has been designated an orphan drug by the FDA for this indication.<br />     ***For graft-versus-host disease (GVHD) prophylaxis�.***For the treatment of chronic allergic contact dermatitis�.***For the treatment of psoriasis�.***For the treatment of severe, recalcitrant, plaque-type psoriasis�.***For the treatment of facial or intertriginous psoriasis. <br />          NOTE: According to the American Academy of Dermatology (AAD), topical tacrolimus is not generally effective for the treatment of chronic plaque psoriasis.<br />       ***For the treatment of severe, refractory uveitis�.***For the treatment of steroid- and cyclosporine-resistant nephrotic syndrome�.***For the induction of remission of moderately to severely active ulcerative colitis� in patients with either steroid-dependent or steroid-resistant disease. <br />        NOTE: Most patients used medications containing 5-aminosalicylic acid or steroids.<br />     ***For the treatment of vulvar lichen sclerosus�.***For the treatment of lupus nephritis�.***Formoterol***Formoterol; Mometasone","***General Information***Fungal infection, herpes infection, infection, requires a specialized care setting, requires an experienced clinician, varicella, viral infection***Immunosuppression, lymphoma, mononucleosis, new primary malignancy, skin cancer***Liver transplant***Children, infants, neonates***Oliguria, renal disease, renal failure, renal impairment***Hepatic disease***Hyperkalemia, hypertension***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, cardiomyopathy, coronary artery disease, females, geriatric, heart failure, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Seizure disorder, seizures***Black patients, diabetes mellitus, hyperglycemia***Intravenous administration, polyoxyethylated castor oil hypersensitivity***Pregnancy***Breast-feeding***Vaccination***Sunlight (UV) exposure***Occlusive dressing, ocular exposure***Exfoliative dermatitis, ichthyosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['25483'],gadoteridol,***For use with magnetic resonance imaging (MRI) to enhance visualization of lesions with abnormal vascularity within the central nervous system (CNS) or extracranial/extraspinal tissues of the head and neck.***For visualization of lesions within the CNS.***For visualization of lesions in extracranial/extraspinal tissues of the head and neck.,"***Diabetes mellitus, geriatric, hypertension, nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy), renal disease, renal failure, renal impairment***Magnetic resonance imaging (MRI)***Asthma, atopy, radiopaque contrast media hypersensitivity***Sickle cell disease***Hemolytic anemia***Seizure disorder***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['337525'],erlotinib,"***For the treatment of metastatic non-small cell lung cancer (NSCLC) in patients whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. <br />        NOTE: If EGFR exon 19 deletions or exon 21 (L858R) substitution mutations are not detected in a plasma specimen, test tumor tissue if available. Information on FDA-approved tests for the detection of EGFR mutations in NSCLC is available at: http://www.fda.gov/CompanionDiagnostics.<br />     ***For the first-line treatment of locally advanced, unresectable or metastatic pancreatic cancer in combination with gemcitabine.***For the treatment of recurrent or metastatic squamous cell head and neck cancer�.","***Chronic lung disease (CLD), pneumonitis, pulmonary disease***Biliary obstruction, hepatic disease, hepatotoxicity***Keratitis, ocular disease***Corticosteroid therapy, diverticulitis, GI perforation, peptic ulcer disease***Tobacco smoking***Dehydration, renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Contraception requirements, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,levothyroxine sodium,"***For the treatment of primary hypothyroidism with or without goiter due to diminished or absent thyroid function caused by functional deficiency, primary atrophy, partial or complete absence of the thyroid gland, or from the effects of surgery, radiation, or an antithyroid agent, and for the treatment of secondary (pituitary) or tertiary (hypothalamic) hypothyroidism.***For the treatment of myxedema coma.***For thyroid stimulating hormone (TSH) suppression in thyroid nodules, euthyroid goiters, and well-differentiated thyroid cancer.***Formoterol; Mometasone","***General Information***Adrenal insufficiency***Hypopituitarism***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, coronary artery disease, hypertension, myocardial infarction***Diabetes mellitus***Obesity treatment***Infertility***Osteoporosis***Pregnancy***Breast-feeding***Dysphagia***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3478'],dinoprostone,"***For evacuation of the uterine contents in the cases of missed abortion or intrauterine fetal death, second trimester pregnancy termination, or benign hydatidiform mole.***For cervical ripening induction in women at or near term with a medical or obstetrical need for labor induction.","***Incomplete abortion, labor, pregnancy, pregnancy testing***Angioedema, requires a specialized care setting, requires an experienced clinician, risk of serious hypersensitivity reactions or anaphylaxis***Amniotic fluid embolism***Disseminated intravascular coagulation (DIC), fibrinolysis***Anemia, asthma, cardiac disease, diabetes mellitus, glaucoma, hepatic disease, hypertension, hypotension, increased intraocular pressure, jaundice, pulmonary disease, renal disease, seizure disorder***Caesarean section, cephalopelvic disproportion, fetal distress, multiparity, premature rupture of membranes (PROM), surgery, uterine atony***Bleeding, cervicitis, herpes infection, infection, placenta previa, vaginal bleeding, vaginitis***Breast-feeding***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,prednisolone acetate,"***For primary (Addison's disease) or secondary adrenocortical insufficiency or for the treatment of congenital adrenal hyperplasia.***For the treatment of nonsuppurative thyroiditis.***For the management of symptomatic sarcoidosis.***For the treatment of corticosteroid-responsive dermatitis and dermatologic disorders such as atopic dermatitis or eczema, bullous dermatitis herpetiformis, contact dermatitis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe psoriasis, severe seborrheic dermatitis, or severe erythema multiforme or Stevens-Johnson syndrome.***For the treatment of corticosteroid-responsive respiratory disorders including aspiration pneumonitis, berylliosis, Loeffler's syndrome, or idiopathic pulmonary fibrosis.***For the treatment of asthma.***For a moderate to severe asthma exacerbation in the emergency department or the hospital.***For an acute asthma exacerbation on an outpatient basis.***For long-term prevention of symptoms in severe persistent asthma.***For the treatment of inflammatory bowel disease including critical periods of ulcerative colitis or regional enteritis (Crohn's disease).***For the treatment of hematologic disorders with thrombocytopenia including immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), or secondary thrombocytopenia.***For the treatment of acquired (autoimmune) hemolytic anemia, erythroblastopenia (RBC anemia), or congenital hypoplastic anemia.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of trichinosis with neurologic or myocardial involvement.***For the treatment of kidney transplant rejection or for kidney transplant rejection prophylaxis in conjunction with other immunosuppressants.***For the treatment of acute exacerbations of multiple sclerosis.***For the treatment of nephrotic syndrome.***For the treatment of corticosteroid-responsive ophthalmic disorders including allergic conjunctivitis, allergic marginal corneal ulcer, anterior segment inflammation, bacterial conjunctivitis, chorioretinitis, choroiditis, cyclitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus) with appropriate antiviral therapy, iritis, non-specific keratitis or superficial punctate keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, vernal keratoconjunctivitis, or for corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies.***For topical ophthalmic treatment of corticosteroid-responsive eye disorders.***For systemic treatment of corticosteroid-responsive eye disorders unresponsive to topical ophthalmic treatment or for conditions usually requiring systemic treatment, such as sympathetic ophthalmia or optic neuritis.***For adjunctive therapy in the treatment of rheumatic disorders including ankylosing spondylitis, gout with gouty arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, psoriatic arthritis, or rheumatoid arthritis; ALSO for the treatment of acute episodes or exacerbation of nonrheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the treatment of selected cases of collagen disorders and mixed connective tissue disease�, such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, polyarteritis nodosa, relapsing polychondritis, polymyalgia rheumatica, certain cases of vasculitis, or Wegener's granulomatosis�.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.***For the treatment of mild to moderate laryngotracheobronchitis (croup)�.***For palliative management of leukemia and lymphoma in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), or multiple myeloma�; also may be used as an adjunct in managing hypercalcemia of malignancy.***For the treatment of acute interstitial nephritis (AIN)�.***For the treatment of Severe Acute Respiratory Syndrome (SARS)�.***For the management of heart transplant rejection prophylaxis�.***For the treatment of Bell's palsy�.***For the treatment of exacerbations of chronic obstructive pulmonary disease (COPD)�.***For the treatment of Kawasaki disease�.","***General Information***Corticosteroid hypersensitivity***Intravenous administration***Infection, surgery***Fungal infection***Herpes infection, measles, tuberculosis, varicella, viral infection***Myocardial infarction***Heart failure, hypertension***Cataracts, glaucoma, visual disturbance***Diverticulitis, GI disease, hepatic disease, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Diabetes mellitus, hyperthyroidism, hypothyroidism, osteoporosis, psychosis, renal disease, seizure disorder, thyroid disease***Myasthenia gravis***Coagulopathy, thromboembolic disease***Pregnancy***Breast-feeding***Children, growth inhibition, increased intracranial pressure, infants***Abrupt discontinuation, hypothalamic-pituitary-adrenal (HPA) suppression***Sulfite hypersensitivity***Tartrazine dye hypersensitivity***Benzyl alcohol hypersensitivity, neonates, premature neonates***Cushing's syndrome***Vaccination***Corneal abrasion, increased intraocular pressure, myopia, open-angle glaucoma***Geriatric***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['68442', '1433764', '1605064']",filgrastim,"***For the treatment of neutropenia.***For the treatment of HIV-induced� or drug therapy-induced� neutropenia (e.g., ganciclovir-induced neutropenia� or zidovudine-induced neutropenia�) in patients with HIV disease to decrease the risk of bacterial infections.***For the treatment of severe chronic congenital neutropenia. <br />  NOTE: Filgrastim has been designated an orphan drug by the FDA for this indication.<br /***For the treatment of  severe chronic cyclic neutropenia. <br />  NOTE: Filgrastim has been designated an orphan drug by the FDA for this indication.<br /***For the treatment of severe chronic idiopathic neutropenia. <br />  NOTE: Filgrastim has been designated an orphan drug by the FDA for this indication.<br /***For chemotherapy-induced neutropenia prophylaxis, to decrease the incidence of febrile neutropenia, in patients receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia.***For peripheral blood stem cell (PBSC) mobilization prior to and during leukapheresis in cancer patients undergoing an autologous PBSC collection and therapy. <br />  Filgrastim has been designated an orphan drug by the FDA for this indication.<br /***For the treatment of acute radiation exposure, to increase survival, in patients who receive myelosuppressive doses of radiation. <br />  Filgrastim has been designated an orphan drug by the FDA for this indication.<br /***For the treatment of aplastic anemia�.","***E. coli protein hypersensitivity***Radiation therapy***Respiratory distress syndrome***Sickle cell disease***Leukocytosis, thrombocytopenia***Leukemia***Latex hypersensitivity***Vasculitis***Pulmonary bleeding***Obstetric delivery***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,atropine sulfate/hyoscyamine sulfate/phenobarbital/scopolamine hydrobromide,"***For the adjunctive treatment of irritable bowel syndrome� (irritable colon, spastic colon, mucous colitis), acute enterocolitis�, or duodenal ulcer�.","***Barbiturate hypersensitivity, carbamazepine hypersensitivity, hydantoin hypersensitivity, lactase deficiency***Abrupt discontinuation, substance abuse***Driving or operating machinery, ethanol intoxication***Depression, mental status changes, suicidal ideation***Geriatric***Acute myocardial infarction, bleeding, cardiac arrhythmias, cardiac disease, coronary artery disease, heart failure, hypertension, hyperthyroidism, mitral stenosis, tachycardia, thyrotoxicosis***Asthma, chronic obstructive pulmonary disease (COPD), pulmonary disease, respiratory depression, respiratory infection***Autonomic neuropathy, bladder obstruction, prostatic hypertrophy, renal failure, renal impairment, urinary retention, urinary tract obstruction***Hepatic disease***Anticoagulant therapy, porphyria***Myasthenia gravis***Achalasia, colostomy, diarrhea, esophagitis, gastroesophageal reflux disease (GERD), GI obstruction, hiatal hernia, ileostomy, ileus, peptic ulcer disease, pseudomembranous colitis, pyloric stenosis, toxic megacolon, ulcerative colitis***Closed-angle glaucoma, contact lenses, glaucoma, synechia***Ambient temperature increase, dehydration, fever, strenuous exercise***Children, infants, neonates***Pregnancy***Breast-feeding***Dental disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,trimethobenzamide hydrochloride,"***For the control of nausea/vomiting of a known etiology (e.g., post-operative or gastroenteritis).","***Renal failure, renal impairment***Children, ester local anesthetic hypersensitivity, infants, intravenous administration, neonates, premature neonates***Agranulocytosis, bone marrow suppression, fever, jaundice***Pregnancy***Breast-feeding***Dehydration, electrolyte imbalance, encephalopathy, gastroenteritis, Reye's syndrome, viral infection***Geriatric***Appendicitis***Driving or operating machinery, ethanol intoxication***Hepatic disease, hepatotoxicity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,moxifloxacin hydrochloride,"***For the treatment of acute bacterial exacerbation of chronic bronchitis.***For the treatment of acute bacterial sinusitis.***For the treatment of mild to moderate community-acquired pneumonia (CAP).***For the treatment of skin and skin structure infections.***For uncomplicated skin and skin structure infections due to <em>Staphylococcus aureus</em> (MSSA) and <em>Streptococcus pyogenes</em>.***For complicated skin and skin structure infections due to <em>Enterobacter cloacae</em>, <em>Escherichia coli</em>, <em>Klebsiella pneumoniae</em>, or <em>Staphylococcus aureus</em> (MSSA).***For the treatment of complicated intraabdominal infections including polymicrobial infections such as abscesses.***For the treatment of bacterial conjunctivitis (including chlamydial conjunctivitis) due to susceptible organisms.***For the treatment of plague, including pneumonic and septicemic plague, and plague prophylaxis due to susceptible isolates.***For the treatment of tuberculosis infection� caused by <em>Mycobacterium tuberculosis�</em> in combination with other antituberculosis agents as a second line agent. <br />        NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., &gt;= 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, IDSA, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. Directly observed therapy (DOT) should be used for all regimens administered 1, 2, 3, or 5 times per week. The initial treatment regimen should include four drugs unless the likelihood of INH or rifampin resistance is low (i.e., &lt; 4%), in which case an initial regimen of INH, rifampin, and pyrazinamide may be considered. HIV-infected patients should always receive induction therapy with four drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate.   For multi-drug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, the CDC recommends treatment for 18�24 months after culture conversion in patients with bacteriologic confirmation and for &gt;= 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months in MDR-TB.<br />     ***For the treatment of Mycobacterium avium complex infection� (MAC) in HIV-infected patients.***For the treatment of anthrax�.***For the treatment of systemic anthrax infection.***For the treatment of cutaneous anthrax infection.***For the treatment of bacterial gastroenteritis� and infectious diarrhea�.***For salmonellosis� in HIV-infected patients.***For shigellosis� in HIV-infected patients.***For the treatment of campylobacteriosis� in HIV-infected patients.***For surgical infection prophylaxis�.***For ophthalmic surgical prophylaxis�.***For the treatment of recurrent or persistent non-gonococcal urethritis (NGU)�.***For the treatment of pelvic inflammatory disease (PID)�.***For anthrax prophylaxis� after exposure to <em>Bacillus anthracis</em> (postexposure prophylaxis, PEP).***Formoterol***Formoterol; Mometasone","***Viral infection***Quinolone hypersensitivity***Corticosteroid therapy, organ transplant, tendinitis, tendinopathy, tendon pain, tendon rupture***Alcoholism, atrial fibrillation, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease, torsade de pointes***Cerebrovascular disease, neurotoxicity, peripheral neuropathy, seizure disorder***Myasthenia gravis***Hepatic disease, hepatitis, hepatotoxicity, jaundice***Diabetes mellitus***Sunlight (UV) exposure***Colitis, diarrhea, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Geriatric***Pregnancy***Breast-feeding***Sexually transmitted disease***Children, infants, neonates***Sodium restriction***Contact lenses***Driving or operating machinery",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4083'],estradiol/norethindrone acetate,"***For treatment of moderate to severe vasomotor symptoms (hot flashes) of menopause and/or related genitourinary symptoms including atrophic vaginitis, vulvar atrophy (kraurosis vulvae), whether menopause is natural or surgical (e.g., due to oophorectomy).***For osteoporosis prophylaxis due to menopause (natural or surgical) in women with an intact uterus.***For the treatment of female hypogonadism or primary ovarian failure in premenopausal females with an intact uterus.***Formoterol; Mometasone","***Angioedema, hereditary angioedema***Breast cancer, hypercalcemia, new primary malignancy***Ovarian cancer***Endometrial cancer, endometrial hyperplasia, vaginal bleeding***Cervical cancer, endometriosis, uterine cancer, uterine leiomyomata, vaginal cancer***Cardiac disease, cerebrovascular disease, coronary artery disease, hypercholesterolemia, hypertension, myocardial infarction, obesity, protein C deficiency, protein S deficiency, stroke, thromboembolic disease, thromboembolism, thrombophlebitis, tobacco smoking***Surgery***Pregnancy***Breast-feeding***Gallbladder disease, hepatic disease, hepatocellular cancer, jaundice, porphyria***Systemic lupus erythematosus (SLE)***Hypertriglyceridemia, pancreatitis***Contact lenses, migraine, visual disturbance***Diabetes mellitus***Hypothyroidism, thyroid disease***Asthma, renal disease, seizure disorder***Depression***Hypocalcemia, hypoparathyroidism***Dementia, geriatric***Children, infants",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10753'],tretinoin,"***For the treatment of acne vulgaris.***For adjunctive treatment of photoaging including palliation of fine facial wrinkles, facial mottled hyperpigmentation (i.e., 'liver spots'), and facial skin roughness.***For the treatment of acute promyelocytic leukemia (APL). <br />        NOTE: Retinoic acid-APL (RA-APL) syndrome characterized by fever, dyspnea, acute respiratory distress, weight gain, radiographic pulmonary infiltrates, pleural and pericardial effusions, edema, and hepatic, renal, and multi-organ failure requires prompt treatment with high-dose steroids (e.g., dexamethasone 10 mg IV every 12 hours for 3 days or until the resolution of symptoms). RA-APL syndrome may occur with or without leukocytosis.<br />     ***For remission induction treatment in patients with APL who are refractory to or who have relapsed from anthracycline chemotherapy or who have a contraindication to anthracycline-based therapy.***For maintenance therapy following induction and consolidation therapy�.***For remission induction and consolidation treatment in patients with newly diagnosed, low-risk APL in combination with arsenic trioxide�.***For remission induction treatment in patients with newly diagnosed APL, in combination with idarubicin�.***For consolidation treatment following tretinoin and idarubicin induction therapy in patients with newly diagnosed APL, in combination with idarubicin-containing chemotherapy�.***For the treatment of melasma�.***For the treatment of diseases of keratinization� (e.g., actinic keratosis�, ichthyosis�, keloids�, keratosis follicularis�); acne rosacea�; skin hyperpigmentation�.***For the treatment of AIDS-related Kaposi's sarcoma�.***Formoterol; Mometasone","***Requires a specialized care setting, requires an experienced clinician, respiratory insufficiency***Retinoid hypersensitivity***Paraben hypersensitivity***Fish hypersensitivity***Acute promyelocytic leukemia differentiation syndrome***Leukocytosis***Skin photosensitivity disorder, sunburn, sunlight (UV) exposure***Eczema***Hepatic disease***Contraception requirements, pregnancy, pregnancy testing, reproductive risk***Breast-feeding***Children, infants, neonates***Hypercholesterolemia, hyperlipidemia, hypertriglyceridemia***Accidental exposure, ocular exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,desmopressin acetate,"***For the management of patients with central diabetes insipidus (neurohypophyseal diabetes insipidus) including polydipsia and polyuria which occurs following head surgery or trauma.***For the treatment of primary nocturnal enuresis.***For the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.***For the management of spontaneous bleeding or trauma-induced hemorrhage (e.g., hemarthrosis, intramuscular hematomas, or mucosal bleeding, uremic bleeding�) or for bleeding prophylaxis (e.g., surgical bleeding) in selected patients.***Formoterol; Mometasone","***General Information***Renal disease, renal failure, renal impairment***Children, cystic fibrosis, diarrhea, electrolyte imbalance, fever, hyponatremia, infection, vomiting***Angina, cardiac disease, coronary artery disease, heart failure, hypertension, increased intracranial pressure, thromboembolic disease, urinary retention***Von Willebrand's disease***Nasal surgery, nasal trauma***Geriatric***Pregnancy***Breast-feeding***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1298944'],pertuzumab,"***For the treatment of HER2-positive breast cancer. <br />        NOTE: Patients should be selected based on the presence of HER2 protein overexpression or HER2 gene amplification in tumor specimens. Information on FDA-approved tests for the detection of HER2 protein overexpression and HER2 gene amplification is available at http://www.fda.gov/CompanionDiagnostics.<br />     ***For the treatment of HER2-positive metastatic breast cancer in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease, in combination with trastuzumab and docetaxel.***For the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory, or early stage breast cancer (greater than 2 cm diameter or node positive) in combination with other chemotherapy regimens.***For the adjuvant treatment of early breast cancer<strong>","***Cardiac arrhythmias, cardiac disease, heart failure, hypertension, myocardial infarction, radiation therapy, ventricular dysfunction***Infusion-related reactions***Intrauterine fetal death, pregnancy***Contraception requirements, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['37801'],terbinafine,"***For the treatment of tinea pedis.***For the treatment of tinea cruris or tinea corporis.***For the treatment of tinea capitis.***For the treatment of tinea versicolor due to <em>Malassezia furfur</em>.***For the treatment of onychomycosis.***For the routine treatment of onychomycosis (tinea unguium).***For the treatment of onychomycosis due to <em>Candida parapsilosis�</em>.***For the treatment of refractory bronchopulmonary aspergillosis� due to various <em>Aspergillus</em> sp.�, including <em>Aspergillus fumigatus�</em>, in non-immunocompromised patients.","***General Information***Onychomycosis***Human immunodeficiency virus (HIV) infection, immunosuppression, neutropenia***Pregnancy***Breast-feeding***Anxiety, children, depression, insomnia, suicidal ideation***Hepatic disease, hepatitis, jaundice***Renal failure, renal impairment***Serious rash***Hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (TTP)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,enalapril maleate,***For the treatment of hypertension.***For the treatment of heart failure.***For the treatment of proteinuria� in pediatric patients.***For the treatment of hypertensive emergency� or hypertensive urgency�.***For the treatment of asymptomatic left ventricular dysfunction including postmyocardial infarction� patients.***For the treatment of persistent albuminuria� in patients with diabetic nephropathy� or in at-risk hypertensive patients�.,"***ACE-inhibitor induced angioedema, angioedema, Angiotensin-converting enzyme inhibitors (ACE inhibitors) hypersensitivity, Black patients, hereditary angioedema***Hyperkalemia, renal artery stenosis, renal disease, renal failure, renal impairment***Autoimmune disease, bone marrow suppression, collagen-vascular disease, immunosuppression, scleroderma, systemic lupus erythematosus (SLE)***Aortic stenosis, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hyponatremia, hypotension, hypovolemia***Dialysis, hymenoptera venom (insect sting) allergy desensitization, low-density lipoprotein apheresis***Hepatic disease, jaundice***Surgery***Geriatric***Neonates, pregnancy***Breast-feeding***Infants, premature neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,"dibasic sodium phosphate anhydrous/monobasic potassium phosphate/monobasic sodium phosphate monohydrate,"",""",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10156'],sucralfate,"***For the treatment of duodenal ulcer not related to NSAID use.***For active disease.***For maintenance therapy of duodenal ulcer.***For the treatment of gastric ulcer� not related to NSAID use or for treatment of esophagitis� associated with gastroesophageal reflux disease (GERD)�.***For NSAID-induced ulcer prophylaxis�.***For stress gastritis prophylaxis�.***For the palliative treatment of aphthous ulcer�, or for the palliative treatment of stomatitis� due to chemotherapy or radiation therapy.***For the alternative treatment of proctitis� due to ulcerative colitis or radiation injury.","***General Information***Dialysis, renal failure, renal impairment***Diabetes mellitus***Dysphagia, gag reflex depression***Geriatric***Children, infants, neonates***Pregnancy***Breast-feeding***Intravenous administration",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3008'],cyclosporine,"***For kidney transplant rejection prophylaxis.***For kidney transplant rejection prophylaxis in combination with sirolimus and corticosteroids in patients who are considered low to moderate immunologic risk.***For kidney transplant rejection prophylaxis in combination with sirolimus and corticosteroids in patients who are considered high immunologic risk. <br />          NOTE: Black transplant recipients, repeat renal transplant recipients who lost a previous allograft for immunologic reason, or patients with high-panel reactive antibodies (PRA; peak PRA level greater than 80%) are considered high immunologic risk.<br />NOTE: The protocol-specified target Cmin range for cyclosporine was 200 to 300 ng/mL up to week 2, 150 to 200 ng/mL for weeks 2 to 26, and 100 to 150 ng/mL for weeks 26 to 52, and for sirolimus was 10 to 15 ng/mL***For the treatment of severe, plaque-type psoriasis in immunocompetent patients who failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated.***For the treatment of severe rheumatoid arthritis (RA) in patients unresponsive to conventional therapy, alone or in combination with methotrexate when the disease has not adequately responded to methotrexate.***For early rheumatoid arthritis (RA).***For the treatment of xerophthalmia by increasing tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.***For the treatment of heart transplant rejection prophylaxis, liver transplant rejection prophylaxis, and the treatment of acute and chronic graft-versus-host disease (GVHD)� and graft-versus-host disease (GVHD) prophylaxis�. <br />        NOTE: In general, children may undergo the same dosing regimen as adults but often require and tolerate higher doses.<br />NOTE: In the prevention of organ transplant rejection, cyclosporine is intended to be used in combination with corticosteroid therapy***For the treatment of severe atopic dermatitis�.***For the treatment of severe aplastic anemia�.***For the treatment of chronic immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP)�.***For the treatment of myasthenia gravis� in patients who are poorly controlled with cholinesterase inhibitor therapy.***For the treatment of psoriatic arthritis�.***For the treatment of lupus nephritis� in patients with systemic lupus erythematosus (SLE) unresponsive to conventional therapy, or for the treatment of children with idiopathic nephrotic syndrome�.","***General Information***Fungal infection, herpes infection, immunosuppression, infection, requires a specialized care setting, requires an experienced clinician, varicella, viral infection***Herpes simplex keratitis (dendritic keratitis), ocular infection***Lymphoma, new primary malignancy, radiation therapy, skin cancer, sunlight (UV) exposure***Nephrotoxicity, renal disease, renal failure, renal impairment***Hyperkalemia, hypertension***Electrolyte imbalance***Polyoxyethylated castor oil hypersensitivity***Children, infants***Pregnancy***Breast-feeding***Geriatric***Alcoholism, biliary tract disease, hepatic disease, jaundice***Gout, hyperuricemia***Encephalopathy, hypomagnesemia***Vaccination***Contact lenses",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5640'],ibuprofen,"***For the treatment of rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA).***For the treatment of dysmenorrhea.***For the treatment of severe pain in hospitalized patients.***For the treatment of mild pain to moderate pain.***For the treatment of mild to moderate pain in hospitalized patients.***For self-treatment of minor aches and pains due to the common cold, toothache, muscular aches or backache (musculoskeletal pain), and the minor pains of arthritis.***For the treatment of fever.***For the treatment of headache.***For self-treatment of headache.***For the treatment of pain due to acute migraine.***For the treatment of osteoarthritis; ankylosing spondylitis�; acute gouty arthritis�; or psoriatic arthritis�.***For patients with cystic fibrosis� to slow the rate of decline in lung function.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, Crohn's disease, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery bypass graft surgery (CABG), coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Geriatric***Labor, obstetric delivery, pregnancy***Infertility, reproductive risk***Breast-feeding***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,alglucosidase alfa,***For the treatment of acid alpha-glucosidase deficiency (Pompe disease). <br />        NOTE: Alglucosidase alfa was designated as an orphan drug for the treatment of Pompe disease in 1997.<br />NOTE: Initiation of alglucosidase alfa therapy in the earliest stages of the disease process is associated with the most clinical benefit***For the treatment of infantile-onset acid alpha-glucosidase deficiency (Pompe disease).***For the treatment of late-onset (non-infantile) acid alpha-glucosidase deficiency (Pompe disease) .,"***General Information***Alglucosidase alfa hypersensitivity, infusion-related reactions, serious hypersensitivity reactions or anaphylaxis***Cardiac disease, cardiomyopathy, heart failure, respiratory insufficiency, sepsis, surgery***Pregnancy***Breast-feeding***Geriatric***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,aclidinium bromide,"***For the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.","***General Information***Acute bronchospasm, angioedema, milk protein hypersensitivity***Closed-angle glaucoma, contact lenses, ocular exposure, ophthalmic administration***Anticholinergic medications, bladder obstruction, prostatic hypertrophy***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1596450']['8638'],gentamicin/prednisolone acetate,"***For steroid-responsive inflammatory ocular inflammation conditions (e.g., uveitis, bacterial conjunctivitis, corneal abrasion) for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular/ophthalmic infection exists. <br />        NOTE: Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies.<br />     ","***General Information***Aminoglycoside hypersensitivity, corticosteroid hypersensitivity***Keratitis***Fungal infection, herpes simplex keratitis (dendritic keratitis), mycobacterial infection, varicella, viral infection***Cataracts, glaucoma, increased intraocular pressure, ocular surgery***Intravenous administration***Abrupt discontinuation, corticosteroid withdrawal***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['407990'],cinacalcet,"***For the treatment of hypercalcemia in patients with parathyroid carcinoma.***For the treatment of hyperparathyroidism.***For patients with secondary hyperparathyroidism and chronic kidney disease undergoing dialysis (CKD Stage 5).***For patients with secondary hyperparathyroidism and chronic kidney disease not undergoing dialysis (e.g., CKD stage 3 and 4)�.***For severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.","***Hypocalcemia***Seizure disorder***Long QT syndrome***Hepatic disease***Esophagitis, gastritis, peptic ulcer disease, vomiting***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,antihemophilic factor/von Willebrand factor complex (human),"***For the prevention and control of hemorrhage in patients with hemophilia A (classical hemophilia). <br />        NOTE: Humate, Kogenate, and ReFacto have been designated by the FDA as orphan drugs for the prophylaxis and management of hemorrhage or hemarthrosis in patients with hemophilia A.<br /> <br />NOTE: Guidelines for the treatment of acute bleeding and prevention of bleeding during surgery vary. For all indications, the dose of antihemophilic factor should be individualized taking into consideration the seriousness of the bleed or procedure, the clinical status of the patient, and the factor VIII activity concentration***For minor bleeding including early muscle bleed, early hemarthrosis, and oral bleeds.***For moderate bleeding including advanced muscle bleed, extensive hemarthrosis, hematoma, and mild head trauma.***For life- or limb-threatening bleeding including surgical bleeding, gastrointestinal bleeding, neck, tongue or pharyngeal hematoma with potential for airway compromise, intracranial, intraabdominal, or intrathoracic bleeding, or fractures.***For bleeding in patients with hemophilia A and factor VIII inhibitor titers less than 10 Bethesda Units and with low anamnestic responses.***For the perioperative management of surgical bleeding (surgical bleeding prophylaxis) in patients with hemophilia A.***For routine bleeding prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A.***For the management of hemorrhage or hemarthrosis in patients with von Willebrand's disease (vWD). <br />        NOTE: Humate-P has been designated by the FDA as orphan drugs for this indication.<br />     ***For major hemorrhage in patients with mild vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma or traumatic hemorrhage).***For minor hemorrhage in patients with moderate to severe vWD type I, type II, and type III (e.g., epistaxis, oral bleeding, or menorrhagia).***For major hemorrhage in patients with moderate to severe vWD type I (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For major hemorrhage in patients with vWD type II and III (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, or traumatic hemorrhage).***For surgical bleeding prophylaxis during major or minor procedures in patients with vWD in whom desmopressin is either ineffective or contraindicated. <br />          NOTE: Alphanate and Humate-P have been designated by the FDA as orphan drugs for this indication.<br />       ","***General Information***Pregnancy***Breast-feeding***Thromboembolic disease***Hepatitis, infection, viral infection***Anemia***Bovine protein hypersensitivity, hamster protein hypersensitivity, latex hypersensitivity, mannitol hypersensitivity, murine protein hypersensitivity, polysorbate 80 hypersensitivity***Porcine protein hypersensitivity***Human immunodeficiency virus (HIV) infection***Cardiac disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albumin (human),"***For the treatment of shock due to hypovolemia. <br />        NOTE: Dosage should be based on patient response as indicated by blood pressure, degree of pulmonary congestion, and hematocrit.<br />     ***For adjunctive treatment of severe burns.***For the treatment of nephrosis in nephrotic syndrome.***For treatment of hypoproteinemia.***For adjunctive use with exchange transfusion in the treatment of hyperbilirubinemia and erythroblastosis fetalis.","***Albumin hypersensitivity***Anemia, heart failure, hypertension***Renal disease***Hypernatremia***Burns***Viral infection***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,anhydrous citric acid/magnesium oxide/sodium picosulfate,***For use as a bowel evacuant to clean the colon prior to colonoscopy (bowel preparation).,"***Renal failure, renal impairment***Colitis, gag reflex depression, gastroparesis, GI obstruction, GI perforation, ileus, inflammatory bowel disease, pyloric stenosis, toxic megacolon, ulcerative colitis***Seizure disorder, seizures***Dehydration, electrolyte imbalance, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, orthostatic hypotension, vomiting***Angina, cardiac arrhythmias, cardiomyopathy, heart failure, myocardial infarction, QT prolongation***Geriatric***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,glycopyrrolate,"***For use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; reduce gastric acid production and acidity (aspiration prophylaxis); and to block vagal inhibitory reflexes during intubation and induction of anesthesia.***For the treatment of sialorrhea.***For severe chronic sialorrhea (chronic drooling) associated with neurologic conditions such as cerebral palsy in pediatric patients.***For clozapine-induced sialorrhea� in adults.***For the treatment of cardiac arrhythmias (e.g., bradycardia) that occur intraoperatively and are drug-induced or are associated with visceral traction stimulation of vagal reflexes.***For cholinesterase inhibitor-induced muscarinic effects prophylaxis when anticholinesterase agents (i.e., neostigmine, physostigmine, pyridostigmine) are used to reverse neuromuscular blockade produced by curariform agents.***For the treatment of peptic or duodenal ulcer. <br />        NOTE: Due to the potential for side effects, as well as the availability of more effective alternatives, glycopyrrolate is rarely used for this indication.<br />     ***For the maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis or emphysema.***For the treatment of irritable bowel syndrome� and/or diarrhea�.","***Benzyl alcohol hypersensitivity, milk protein hypersensitivity***Latex hypersensitivity***Ambient temperature increase***Closed-angle glaucoma, ocular exposure***Prostatic hypertrophy, urinary retention, urinary tract obstruction***Autonomic neuropathy, myasthenia gravis***Achalasia, biliary-GI fistula, constipation, diarrhea, esophagitis, gastroesophageal reflux disease (GERD), GI bleeding, GI obstruction, hemorrhagic shock, hiatal hernia, ileus, pyloric stenosis, toxic megacolon, ulcerative colitis***Hepatic disease, renal failure, renal impairment***Cardiac arrhythmias, coronary artery disease, heart failure, hypertension, hyperthyroidism, tachycardia, ventricular tachycardia***Pregnancy***Breast-feeding***Children, Down's syndrome, infants, neonates***Driving or operating machinery***Acute bronchospasm***Paradoxical bronchospasm***Anticholinergic medications, dementia, geriatric***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,vardenafil hydrochloride,***For the treatment of erectile dysfunction (ED) including ED associated with diabetes or after radical prostatectomy.,"***General Information***Nitrate/nitrite therapy***Hepatic disease, renal disease, renal failure, renal impairment***Geriatric***Alcoholism, angina, aortic stenosis, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, hypotension, idiopathic hypertrophic subaortic stenosis, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, stroke, thyroid disease***Leukemia, multiple myeloma, penile structural abnormality, polycythemia, priapism, sickle cell disease***Human immunodeficiency virus (HIV) infection***Non-arteritic anterior ischemic optic neuropathy, retinitis pigmentosa, visual disturbance***Pregnancy***Breast-feeding***Children, infants, neonates***Gastroesophageal reflux disease (GERD), hiatal hernia***Coagulopathy, peptic ulcer disease***Hearing impairment, tinnitus***Phenylketonuria***Hereditary fructose intolerance",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['3264'],dexamethasone,"***For the treatment of adrenocortical function abnormalities, such as adrenocortical insufficiency, congenital adrenal hyperplasia, chronic primary (Addison's disease) or secondary adrenocortical insufficiency, or adrenogenital syndrome.***For hypothalamic-pituitary-adrenal (HPA) suppression diagnosis (e.g., dexamethasone suppression tests).***For use as a test for Cushing's syndrome.***For use as a test to distinguish Cushing's syndrome secondary to pituitary ACTH excess from Cushing's syndrome secondary to other causes.***For the treatment of allergic conditions, such as acute anaphylaxis, anaphylactoid reactions, anaphylactic shock, angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, or serum sickness reactions.***For acute anaphylaxis or anaphylactoid reactions.***For anaphylactic shock.***For the systemic treatment of other allergic disorders including angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, or serum sickness.***For the treatment of cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury.***For treatment of cerebral edema in pediatric patients.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of kidney transplant rejection in conjunction with other immunosuppressants or for the treatment of acute graft-versus-host disease (GVHD).***For the reduction of edema and inflammation associated with selected cases of otitis externa.***For the treatment of pruritus and inflammatory effects of corticosteroid-responsive dermatologic disorders, including dermatitis, alopecia areata, atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis (including Rhus dermatitis due to poison ivy, poison oak, poison sumac), discoid lupus erythematosus, eczema, exfoliative dermatitis, granuloma annulare, keloids, lichen planus, lichen simplex chronicus or neurodermatitis, necrobiosis lipoidica diabeticorum, pemphigus, polymorphous light eruption, plaque psoriasis, cutaneous T-cell lymphoma (CTCL) or mycosis fungoides, severe seborrheic dermatitis, urticaria, and severe erythema multiforme or Stevens-Johnson syndrome.***For systemic treatment of inflammatory and allergic dermatoses (e.g., severe dermatitis, psoriasis, or exfoliative dermatitis, erythema multiforme, or Stevens-Johnson syndrome).***For intralesional or soft-tissue treatment of specific corticosteroid-responsive skin or soft-tissue lesions.***For adjunctive therapy in the treatment of rheumatic disorders including acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, synovitis of osteoarthritis, and for psoriatic arthritis; or for the treatment of acute episodes or exacerbation of nonrheumatic inflammatory conditions including acute and subacute bursitis, epicondylitis, acute non-specific tenosynovitis, and cystic tumors of an aponeurosis tendon (ganglia).***For the treatment of hematologic disorders such as secondary thrombocytopenia in adults, autoimmune hemolytic anemia, erythroblastopenia, congenital hypoplastic anemia, and thrombocytopenia associated with immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP).***For the treatment of acute asthma� exacerbation.***For the treatment of hypercalcemia related to sarcoidosis or cancer, or for the treatment of nonsuppurative thyroiditis, or for severe cases of myasthenia gravis not controlled by antimyasthenic agents alone.***For the treatment of hypercalcemia related to cancer or for the treatment of nonsuppurative thyroiditis in pediatric patients.***For the treatment of nephrotic syndrome to induce diuresis or decrease proteinuria.***For the treatment of Hodgkin lymphoma.***For the treatment of non-Hodgkin's lymphoma (NHL).***For the palliative treatment of NHL.***For the treatment of relapsed or refractory, aggressive NHL in transplant eligible patients, in combination with gemcitabine and cisplatin (and rituximab for CD20-positive disease)�.***For the treatment of relapsed or refractory diffuse large B-cell lymphoma in transplant eligible patients, in combination with cisplatin and cytarabine (DHAP regimen) and ofatumumab�.***For the treatment of acute lymphocytic leukemia (ALL).***For the treatment of multiple myeloma.***For the treatment of multiple myeloma in patients who have received at least 1 prior therapy, in combination with lenalidomide.***For the treatment of patients with newly diagnosed multiple myeloma, in combination with lenalidomide.***For newly diagnosed multiple myeloma as induction therapy prior to autologous stem-cell transplantation, in combination with doxorubicin and vincristine�.***For newly diagnosed multiple myeloma, in combination with thalidomide.***For newly diagnosed multiple myeloma as induction therapy prior to autologous stem-cell transplantation, in combination with bortezomib�.***For newly diagnosed multiple myeloma as induction therapy prior to autologous stem-cell transplantation, in combination with bortezomib and thalidomide�.***For the treatment of multiple myeloma in patients who have received at least 2 prior therapies (including bortezomib and an immunomodulatory agent), in combination with panobinostat and bortezomib.***For the treatment of relapsed multiple myeloma in patients who have received 1 to 3 prior lines of therapy, in combination with carfilzomib and lenalidomide.***For the treatment multiple myeloma in patients who have received at least 1 prior therapy, in combination with daratumumab and bortezomib.***For the treatment of multiple myeloma in patients who have received at least 1 prior therapy, in combination with daratumumab and lenalidomide.***For the treatment of newly diagnosed multiple myeloma, in combination with bortezomib and lenalidomide�.***For the treatment of multiple myeloma in patients who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor, in combination with pomalidomide and daratumumab.***For the treatment of acute exacerbations of multiple sclerosis.***For the treatment of inflammatory bowel disease during critical periods of ulcerative colitis and regional enteritis (Crohn's disease).***For the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment inflammation of the globe, such as allergic conjunctivitis, eyelid acne rosacea, superficial punctate keratitis, herpes zoster ocular infection associated keratitis, iritis, cyclitis, vernal keratoconjunctivitis, selected infective viral conjunctivitis or postoperative ocular inflammation when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal abrasion, corneal ulcer, or corneal injury from chemical or thermal burns, or penetration of foreign bodies; systemic treatment may be indicated for uveitis, sympathetic ophthalmia, and ocular inflammatory conditions unresponsive to topical corticosteroids.***For the treatment of non-infectious uveitis affecting the posterior segment of the eye in adults.***For the treatment of diabetic macular edema.***For the treatment of macular edema following retinal vein occlusion, including branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).***For the prevention of extubation failure in pediatric patients at increased risk for laryngeal edema (i.e., laryngeal edema prophylaxis�).***For use as an adjunct in the management of extradural malignant spinal cord compression� (MSCC�) associated with metastatic disease.***For the adjunctive treatment of bacterial meningitis� (non-tuberculous).***For the treatment of chemotherapy-induced nausea/vomiting� (CINV�) and for chemotherapy-induced nausea/vomiting prophylaxis�.***For the treatment of respiratory conditions including aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), Loeffler's syndrome, or noncardiogenic pulmonary edema�.***For the treatment of acute respiratory distress syndrome (ARDS)�.***For the treatment of laryngotracheobronchitis (croup)�.***For hyaline membrane disease prophylaxis�, for the purpose of fetal lung maturation to prophylax against anticipated neonatal respiratory distress syndrome (RDS)� in premature infants.***For the prevention of chronic lung disease (CLD)� in mechanically ventilated neonates.***For therapy in selected cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis�, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, symptomatic sarcoidosis, vasculitis�, or Wegener's granulomatosis�; also for the treatment of neurologic or myocardial involvement associated with trichinosis.***For the treatment of acute altitude sickness�, including the treatment of high altitude cerebral edema.***For altitude sickness prophylaxis<strong>***For the adjunctive treatment of infertility� in combination with clomiphene therapy.***For the treatment of post-operative nausea/vomiting (PONV)�.***For post-operative nausea/vomiting (PONV) prophylaxis�.***For the treatment of bronchiolitis�.***For the treatment of Waldenstrom macroglobulinemia�.***For the treatment of newly diagnosed Waldenstrom macroglobulinemia, in combination with rituximab and cyclophosphamide�.***For the treatment of newly diagnosed Waldenstrom macroglobulinemia, in combination with bortezomib and rituximab�.***For the treatment of amyloidosis�.***For the treatment of systemic amyloid light-chain amyloidosis, in combination with lenalidomide and cyclophosphamide�.***For the treatment of systemic amyloid light-chain amyloidosis, in combination with lenalidomide and melphalan�.","***Epidural administration***Abrupt discontinuation, corneal abrasion, Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Children, growth inhibition, increased intracranial pressure***Immunosuppression***Surgery***Acne rosacea, acne vulgaris, fungal infection, herpes infection, herpes simplex keratitis (dendritic keratitis), infection, measles, ocular infection, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Myocardial infarction***Heart failure, hypertension***Osteoporosis***Diabetes mellitus***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hypothyroidism, psychosis, renal disease, seizure disorder***Myasthenia gravis***Coagulopathy, thromboembolic disease***Cataracts, glaucoma, increased intraocular pressure, myopia, ocular exposure, open-angle glaucoma, rupture of posterior ocular lens capsule, visual disturbance***Pregnancy***Neonates, premature neonates***Breast-feeding***Vaccination***Asthma, benzyl alcohol hypersensitivity, sulfite hypersensitivity***Corticosteroid hypersensitivity***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['10865'],ketorolac tromethamine,"***For the reduction of postoperative ocular inflammation and ocular pain following cataract ocular surgery or corneal refractive surgery .***For the reduction of postoperative ocular inflammation and ocular pain following cataract surgery.***For the reduction of ocular pain and burning/stinging following corneal refractive surgery.***For the treatment of ocular pruritus due seasonal allergic conjunctivitis.***For the short-term treatment of moderate pain or moderately severe pain that requires analgesia at the opioid level, including bone pain�, dental pain�, arthralgia�, and myalgia�.***For the short-term treatment of moderately severe pain.***For the short-term treatment of moderate pain.***For the treatment of acute, severe headache�, including migraine�.***Formoterol; Mometasone","***Limit duration of use***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, serious hypersensitivity reactions or anaphylaxis, urticaria***Bleeding, surgery***Alcoholism, chemotherapy, Crohn's disease, GI bleeding, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease, hypoalbuminemia, jaundice***Dehydration, diabetes mellitus, edema, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis, systemic lupus erythematosus (SLE)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery bypass graft surgery (CABG), coronary artery disease, heart failure, hypertension, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Anemia, bone marrow suppression, hematological disease, immunosuppression, intracranial bleeding, neutropenia, thrombocytopenia***Keratitis, ocular disease, ocular surgery***Contact lenses***Epidural administration, intrathecal administration***Children, infants, neonates***Caesarean section, labor, obstetric delivery, pregnancy***Breast-feeding***Ocular exposure***Geriatric***Lactase deficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,escitalopram oxalate,"***For the treatment of major depression.***For the treatment of generalized anxiety disorder (GAD), as well as other anxiety disorders such as panic disorder� or social phobia (social anxiety disorder)�.***For the treatment of generalized anxiety disorder (GAD).***For the treatment of panic disorder� (panic attacks) with or without agoraphobia.***For the treatment of social phobia (social anxiety disorder)�.***For the treatment of irritability associated with autistic disorder�.","***Citalopram hypersensitivity, escitalopram hypersensitivity***Abrupt discontinuation***Bipolar disorder, mania***Children, growth inhibition, suicidal ideation***MAOI therapy***Electroconvulsive therapy (ECT), seizure disorder, seizures***Dehydration, hyponatremia, hypovolemia***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Hepatic disease***Renal failure, renal impairment***Anticoagulant therapy, bleeding, thrombolytic therapy***Bone fractures, osteoporosis***Closed-angle glaucoma, increased intraocular pressure***Akathisia***Anorexia nervosa***Driving or operating machinery, ethanol ingestion***Neonates, pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4500'],flurandrenolide,"***For the treatment of mild to moderate pruritus and inflammatory manifestations of corticosteroid-responsive dermatitis such as alopecia areata, atopic dermatitis, contact dermatitis, exfoliative dermatitis, Rhus dermatitis due to plants like poison ivy, or seborrheic dermatitis, discoid lupus erythematosus, eczema, granuloma annulare, intertrigo, cutaneous lichen planus, lichen simplex chronicus, polymorphous light eruption, pompholyx (dyshidrosis), nodular prurigo, anogenital or senilis pruritus, psoriasis, or xerosis (inflammatory phase). <br />        NOTE: Occlusive dressings may be required for chronic or severe cases of lichen simplex chronicus, psoriasis, eczema, atopic dermatitis, or chronic hand eczema. More potent topical corticosteroids and/or occlusive dressings may be necessary for the treatment of discoid lupus erythematosus, lichen planus, granuloma annulare, psoriatic plaques, and psoriasis of the palms, soles, elbows, or knees.<br />     ","***General Information***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Diabetes mellitus***Children, growth inhibition, increased intracranial pressure, infants, neonates***Pregnancy***Breast-feeding***Fungal infection, herpes infection, infection, measles, peripheral vascular disease, tuberculosis, varicella, viral infection***Acne rosacea, acne vulgaris, ocular exposure, ophthalmic administration, perioral dermatitis***Geriatric, skin atrophy",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,morphine sulfate,"***For the relief of acute and chronic moderate pain or severe pain. <br />        NOTE: There is substantial interpatient variability in the relative potency of different opioid drugs and products. FDA-approved labeling defines adult opioid-tolerant patients as those who take the following per day for a minimum of 1 week: oral morphine 60 mg or more; oral oxycodone 30 mg or more; oral hydromorphone 8 mg or more; oral oxymorphone 25 mg or more; 60 mg oral hydrocodone or more; transdermal fentanyl 25 mcg or more per hour; or another opioid at an equivalent dose. <br />     ***For acute moderate to severe pain related to major orthopedic surgery of the lower extremity.***For acute moderate to severe pain related to lower abdominal or pelvic surgery.***For acute moderate to severe pain related to cesarean section after delivery and clamping of the umbilical cord.***For the management of chronic severe pain in patients who require daily, around-the-clock, long-term opioid treatment. <br />  NOTE: Reserve extended-release morphine for when alternative options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would otherwise provide inadequate pain management. Discontinue all other around-the-clock opioids upon initiation.  <br />NOTE: Do not use the following morphine products in opioid-naive patients: 60 mg, 90 mg, or 120 mg biphasic-release capsules (Avinza); 100 mg, 130 mg, 150 mg, or 200 mg extended-release capsules (Kadian); 100 mg or 200 mg controlled-release tablets (MS Contin); 100 mg extended-release tablets (Morphabond). In this population, use could result in fatal respiratory depression. Use of a single dose of more than 60 mg, or a total daily dose more than 120 mg, should be limited to opioid-tolerant patients.   <br />NOTE: There is substantial interpatient variability in the relative potency of different opioid drugs and products. FDA-approved labeling defines adult opioid-tolerant patients as those who take the following per day for a minimum of 1 week: oral morphine 60 mg or more; oral oxycodone 30 mg or more; oral hydromorphone 8 mg or more; oral oxymorphone 25 mg or more; oral hydrocodone 60 mg or more; transdermal fentanyl 25 mcg or more per hour; or another opioid at an equivalent dose.***For the treatment of diarrhea.***For the treatment of noninfectious diarrhea. <br />  WARNING: Proper product selection is critical. Deodorized opium tincture 10 mg/mL solution is 25 times more concentrated than camphorated opium tincture 0.4 mg/mL solution. Serious patient harm may occur with incorrect product selection.<br /***For control of diarrhea� secondary to AIDS-associated enteropathy.***For the management of dyspnea�.***For the adjuvant treatment of acute pulmonary edema�.***For acute myocardial infarction� or unstable angina� and to provide potentially beneficial cardiovascular effects.***For procedural sedation� before short diagnostic procedures or endoscopy. <br />        NOTE: Morphine should be administered as an inducing agent only by those trained in anesthesia.<br />     ***For sedation during rapid-sequence intubation�.***For the treatment of painful diabetic neuropathy�.","***Opiate agonist hypersensitivity***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, coma, cor pulmonale, emphysema, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Ethanol ingestion, ethanol intoxication***Anticoagulant therapy, coagulopathy, infection, intramuscular administration, intrathecal administration, intravenous administration, requires a specialized care setting, requires an experienced clinician, subcutaneous administration***Accidental exposure, opioid-naive patients, potential for overdose or poisoning***Abrupt discontinuation***Acute abdomen, constipation, diarrhea, GI bleeding, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Biliary tract disease***Arteriosclerosis, brain tumor, CNS depression, head trauma, increased intracranial pressure, seizure disorder, seizures, status epilepticus, strychnine toxicity***Angina, atrial fibrillation, atrial flutter, cardiac arrhythmias, cardiac disease, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal impairment, urethral stricture, urinary retention***Children, infants, neonates***Geriatric***Driving or operating machinery***MAOI therapy***Adrenal insufficiency, hypothyroidism, myxedema***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,fluocinolone acetonide,"***For the treatment of mild to moderate inflammatory manifestations of corticosteroid-responsive dermatitis such as alopecia areata, atopic dermatitis, contact dermatitis, exfoliative dermatitis, Rhus dermatitis due to plants like poison ivy, or seborrheic dermatitis (facial and intertriginous areas), discoid lupus erythematosus (facial and intertriginous areas), eczema, granuloma annulare, intertrigo, cutaneous lichen planus, lichen simplex chronicus, polymorphous light eruption, pompholyx (dyshidrosis), nodular prurigo, anogenital or senilis pruritus, psoriasis (facial and intertriginous areas), or xerosis (inflammatory phase).***For atopic dermatitis.***For psoriasis of the scalp.***For seborrheic dermatitis of the scalp.***For the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.***For the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.***For the treatment of chronic eczematous otitis externa.","***Cushing's syndrome, hypothalamic-pituitary-adrenal (HPA) suppression, occlusive dressing, skin abrasion***Ocular exposure, ophthalmic administration***Children, growth inhibition, increased intracranial pressure, infants, neonates***Fungal infection, herpes infection, herpes simplex keratitis (dendritic keratitis), infection, measles, ocular infection, varicella, viral infection***Acne rosacea, acne vulgaris, perioral dermatitis***Diabetes mellitus***Geriatric, skin atrophy***Pregnancy***Breast-feeding***Peanut hypersensitivity***Corticosteroid hypersensitivity***Glaucoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['44151'],clofarabine,"***For the treatment of acute lymphocytic leukemia (ALL).***For the treatment of relapsed or refractory ALL after at least 2 prior regimens.***For the treatment of relapsed or refractory ALL, in combination with etoposide and cyclophosphamide�.***Formoterol; Mometasone","***Anemia, bone marrow suppression, fungal infection, herpes infection, infection, neutropenia, sepsis, thrombocytopenia, viral infection***Bleeding, GI bleeding, intracranial bleeding, pulmonary bleeding***Hypotension***Capillary leak syndrome, pericardial effusion, pleural effusion, pulmonary edema, tachycardia***Hyperuricemia, tumor lysis syndrome (TLS)***Colitis***Hepatic disease, hepatitis, jaundice***Hematuria, renal disease, renal failure, renal impairment***Serious rash***Pregnancy***Contraception requirements, infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,conivaptan hydrochloride,"***For the treatment of hospitalized patients with euvolemic hyponatremia (e.g., syndrome of inappropriate secretion of antidiuretic hormone (SIADH), hypothyroidism, adrenal insufficiency, pulmonary disorders) or hypervolemic hyponatremia (e.g., cirrhosis, nephrotic syndrome). <br />  NOTE: Conivaptan is not indicated for the treatment of heart failure and has not been shown to be effective for the treatment of the signs and symptoms of heart failure.<br />NOTE: Conivaptan should be administered only in settings where serum sodium concentrations, volume status, and blood pressure can be closely monitored.<br />NOTE: It has not been established that utilizing conivaptan to raise serum sodium concentrations provides a symptomatic benefit to patients***For the treatment of increased intracranial pressure�.***Formoterol; Mometasone","***General Information***Corn hypersensitivity***Heart failure, hyponatremia***Hypotension, hypovolemia***Alcoholism, malnutrition***Anuria, renal disease, renal failure, renal impairment***Hepatic disease***Geriatric***Pregnancy***Breast-feeding***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['5487']['6876', '1545996']",hydrochlorothiazide/methyldopa,"***For the treatment of hypertension. <br />        NOTE: Hydrochlorothiazide; methyldopa (Aldoril) is not indicated for the initial treatment of hypertension. Once the patient has been successfully titrated on each individual agent and the optimal dose corresponds to a ratio contained in the combination formulation, this product may be used for convenient dosing.<br />     ***Formoterol***Formoterol; Mometasone","***General Information***Cardiac disease, cerebrovascular disease, hypotension, initial treatment***Autoimmune disease, hemolytic anemia, systemic lupus erythematosus (SLE)***Hepatic disease, hepatitis, jaundice***Asthma, penicillin hypersensitivity, sulfonamide hypersensitivity, thiazide diuretic hypersensitivity***Anuria, dialysis, hypovolemia, renal disease, renal failure, renal impairment***MAOI therapy***Diabetes mellitus***Orthostatic hypotension, sympathectomy***Pancreatitis***Gout, hyperuricemia***Acid/base imbalance, diarrhea, electrolyte imbalance, hyperaldosteronism, hypercalcemia, hyperparathyroidism, hypochloremia, hypokalemia, hypomagnesemia, hyponatremia, metabolic alkalosis, vomiting***Sunlight (UV) exposure***Pheochromocytoma***Driving or operating machinery, mental status changes***Depression***Parkinson's disease***Geriatric***Preeclampsia, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7804'],aspirin/oxycodone,"***For the treatment of moderate pain to moderately-severe pain including the relief of dental pain� (e.g., toothache), headache�, migraine�, back pain�, bone pain�, arthralgia� and myalgia�. <br />        NOTE: Adjust dose based on patient response and pain severity. Opioid tolerance may necessitate higher oxycodone dosages, but do not exceed the maximum daily aspirin dosage.<br />NOTE: 4.8355 mg oxycodone HCl is equivalent to 4.3346 mg of oxycodone as the free base","***General Information***NSAID hypersensitivity, opiate agonist hypersensitivity, salicylate hypersensitivity***Acute bronchospasm, asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, nasal polyps, pulmonary disease, respiratory depression, urticaria***Anemia, constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Bone marrow suppression, coagulopathy, hemophilia, intramuscular injections, surgery, thrombocytopenia***Immunosuppression, infection***Children, influenza, varicella, viral infection***G6PD deficiency***Abrupt discontinuation***Potential for overdose or poisoning, substance abuse***Head trauma, increased intracranial pressure***Geriatric***Cardiac arrhythmias, cardiac disease, hypovolemia***Hepatic disease, hypoprothrombinemia, vitamin K deficiency***Bladder obstruction, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, systemic lupus erythematosus (SLE), urethral stricture, urinary retention***Labor, neonatal opioid withdrawal syndrome, obstetric delivery, pregnancy***Breast-feeding***Driving or operating machinery***Adrenal insufficiency, hypothyroidism, myxedema***Accidental exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['2002'],carbamazepine,"***For the management of generalized tonic-clonic seizures, or for partial seizures, either simple or complex-partial seizures. <br />        NOTE: Periodic monitoring of serum carbamazepine concentrations is recommended.<br />     ***For the symptomatic treatment of neuropathic pain.***For the treatment of acute mania and mixed episodes associated with bipolar disorder (bipolar I disorder).***For the treatment of severe behavioral or psychological symptoms of dementia� (BPSD).***For the treatment of persistent singultus (hiccups)�.***For long-term prophylaxis of short-lasting short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT)�.","***General Information***Asian patients, serious rash***Depression, psychosis, suicidal ideation***Atonic seizures, myoclonic seizures, petit mal (absence) seizures***Abrupt discontinuation***Barbiturate hypersensitivity, carbamazepine hypersensitivity, fever, hydantoin hypersensitivity, jaundice, tricyclic antidepressant hypersensitivity***Agranulocytosis, aplastic anemia, bone marrow suppression, hematological disease, leukopenia, neutropenia, thrombocytopenia***Porphyria***Hepatic disease***AV block, bundle-branch block, cardiac arrhythmias, cardiac disease, coronary artery disease***Hyponatremia***Alcoholism***Driving or operating machinery***Renal disease, renal failure, renal impairment***Geriatric***Glaucoma, increased intraocular pressure***Pregnancy***Neonates***Breast-feeding***Sunlight (UV) exposure***MAOI therapy***Hypercholesterolemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,alendronate sodium,"***For the treatment of osteoporosis.***For osteoporosis prophylaxis in postmenopausal women.***For the treatment of Paget's disease in symptomatic patients or patients with alkaline phosphatase levels at least twice the upper limit of normal, or those at risk from complications..***For the treatment of malignant hypercalcemia�.","***General Information***Achalasia, dysphagia, esophageal stricture, esophagitis, gastritis, gastroesophageal reflux disease (GERD), GI disease, GI perforation, hiatal hernia, inability to stand or sit upright***Geriatric***Hypocalcemia, vitamin D deficiency***Renal failure, renal impairment***Children, infants, neonates***Pregnancy***Breast-feeding***Phosphonate hypersensitivity***Sunlight (UV) exposure***Anemia, chemotherapy, coagulopathy, corticosteroid therapy, dental disease, dental work, infection***Cardiac disease, heart failure, hypertension, sodium restriction",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8640'],prednisone,"***For maintenance therapy (i.e., replacement therapy) of primary (Addison's disease) or secondary adrenocortical insufficiency.***For the treatment of congenital adrenal hyperplasia.***For kidney transplant rejection prophylaxis.***For the treatment of chronic graft-versus-host disease (GVHD).***For palliative management of acute lymphocytic leukemia (ALL).***For the treatment of chronic lymphocytic leukemia (CLL).***For the first-line treatment of CLL, in combination with cladribine�.***For the first-line treatment of CLL, in combination with chlorambucil�.***For the palliative treatment of CLL.***For the short-term treatment of hypercalcemia secondary to neoplastic disease.***For the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis.***For short-term treatment of acute exacerbations of Crohn's disease.***For short-term treatment of acute exacerbations of ulcerative colitis.***For the treatment of rheumatic conditions such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, acute and subacute bursitis, acute non-specific tenosynovitis, acute gouty arthritis and gout, osteoarthritis, or epicondylitis.***For the treatment of systemic autoimmune conditions such as acquired hemolytic anemia, congenital hypoplastic anemia, mycosis fungoides, pemphigus, symptomatic sarcoidosis, or nonsuppurative thyroiditis.***For the treatment of asthma.***For a moderate to severe asthma exacerbation in the emergency department or the hospital.***For an acute asthma exacerbation on an outpatient basis in selected patients.***For long-term prevention of symptoms in severe persistent asthma.***For the treatment of thrombocytopenia or idiopathic thrombocytopenic purpura (ITP).***For autoimmune thrombocytopenia associated with SLE.***For the treatment of acute, severe urticaria or the treatment of late-phase angioedema, such as ACE-inhibitor induced angioedema once acute symptoms are controlled.***For the treatment of myasthenia gravis in patients who are poorly controlled with cholinesterase inhibitor therapy.***For the treatment of nephrotic syndrome or to treat lupus nephritis.***For the treatment of lupus nephritis.***For the treatment of severe erythema multiforme or Stevens-Johnson syndrome.***For the treatment of the acute respiratory distress syndrome (ARDS).***For the treatment of Hodgkin lymphoma in combination with antineoplastic agents.***For the treatment of corticosteroid-responsive dermatitis and dermatologic disorders such as atopic dermatitis or eczema, bullous dermatitis herpetiformis, contact dermatitis, exfoliative dermatitis, or severe seborrheic dermatitis.***For the treatment of Loeffler's syndrome, berylliosis, erythroblastopenia, or trichinosis.***For the treatment of pulmonary fibrosis due to known underlying causative conditions or for idiopathic pulmonary fibrosis�.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the treatment of multiple myeloma�.***For the palliative treatment of multiple myeloma in combination with melphalan�.***For newly diagnosed multiple myeloma in geriatric adults or transplant ineligible patients, in combination with melphalan and thalidomide�.***For previously untreated multiple myeloma, in combination with melphalan and bortezomib�.***For the treatment of previously untreated multiple myeloma in patients ineligible for autologous stem-cell transplantation, in combination with daratumumab, bortezomib, and melphalan�.***For the treatment of serious manifestations of Behcet's syndrome�.***For the symptomatic treatment of Duchenne muscular dystrophy�.***For the adjunctive treatment of carpal tunnel syndrome�.***For the treatment of selected cases of collagen disorders and mixed connective tissue disease�, such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, polyarteritis nodosa, relapsing polychondritis, polymyalgia rheumatica, certain cases of vasculitis, or Wegener's granulomatosis�.***For additional guidance for systemic lupus erythematosus (SLE) in adults.***For systemic dermatomyositis (polymyositis) when dosed in combination with azathioprine.***For treatment using usual labeled dosage.***For the treatment of autoimmune hepatitis�.***For the treatment of primary amyloidosis� not associated with familial Mediterranean fever.***For the treatment of idiopathic or viral pericarditis�.***For the treatment of acute interstitial nephritis (AIN)�.***For the systemic treatment of ophthalmic inflammatory conditions such as endophthalmitis�, optic neuritis, allergic conjunctivitis, keratitis, allergic corneal ulcer, iritis, chorioretinitis, anterior segment inflammation, uveitis, choroiditis, or sympathetic ophthalmia.***For use as an adjunct in the management of extradural malignant spinal cord compression� (MSCC�) associated with metastatic disease.***For the treatment of Bell's palsy�.***For the adjunct treatment of West syndrome (infantile spasms�).***For the adjunct treatment of refractory seizures�, including absence seizures�, myoclonic seizures�, Lennox-Gastaut syndrome�, and other intractable seizure disorders�.***For the treatment of heart transplant rejection�.***For the management of heart transplant rejection prophylaxis�.***For adjunct therapy in patients with Mycobacterium avium complex infection� (MAC) experiencing moderate to severe immune reconstitution inflammatory syndrome (IRIS).***For adjunctive treatment in selected cases of pneumonia� or pneumonitis.***For the treatment of Pneumocystis pneumonia (PCP)� in HIV patients as adjunctive therapy.***For aspiration pneumonitis.***For adjunct therapy in patients with chorioretinitis associated with congenital toxoplasmosis�.***For the treatment of exacerbations of chronic obstructive pulmonary disease (COPD)�.***For the treatment of peripheral T-cell lymphoma (PTCL)�.***For the first-line treatment of PTCL in combination with gemcitabine, cisplatin, and thalidomide�.***For the treatment of Kawasaki disease�.","***General Information***Infection, surgery***Fungal infection***Herpes infection, measles, tuberculosis, varicella, viral infection***Myocardial infarction***Heart failure, hypertension***Cataracts, glaucoma, visual disturbance***Diverticulitis, GI disease, hepatic disease, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Diabetes mellitus, hypothyroidism, osteoporosis, psychosis, renal disease, seizure disorder***Myasthenia gravis***Coagulopathy, thromboembolic disease***Pregnancy***Breast-feeding***Vaccination***Growth inhibition, increased intracranial pressure, neonates***Cushing's syndrome***Abrupt discontinuation, hypothalamic-pituitary-adrenal (HPA) suppression***Corticosteroid hypersensitivity***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['18631'],azithromycin,"***For the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis in patients with COPD caused by susceptible strains of <em>Haemophilus influenza</em>, <em>Moraxella catarrhalis</em>, or <em>Streptococcus pneumoniae</em>.***For the treatment of acute otitis media. <br />        NOTE: Various dosing regimens are FDA-approved. Because macrolides, including azithromycin, have limited efficacy against both H. influenzae and S. pneumoniae, these agents are not included in the preferred or alternative options recommended by the American Academy of Pediatrics (AAP) in the treatment guidelines for acute otitis media.<br />     ***For the treatment of bacterial conjunctivitis caused by susceptible strains of <em>CDC coryneform group G, H. influenzae, S. aureus, S. mitis group, and S. pneumoniae</em>.***For the treatment of community-acquired pneumonia (CAP).***For the treatment of uncomplicated skin and skin structure infections caused by <em>S. aureus, S. pyogenes</em> or <em>S. agalactiae</em>.***For the treatment of pelvic inflammatory disease (PID).***For the treatment of gonorrhea.***For the treatment of uncomplicated gonorrhea of the cervix, urethra, rectum, and pharynx.***For the treatment of disseminated (e.g., bacteremia, arthritis) gonococcal infection�, including meningitis� and endocarditis�.***For the treatment of gonococcal conjunctivitis�.***For the treatment of chancroid due to <em>Haemophilus ducreyi</em>.***For the treatment of Mycobacterium avium complex infection (MAC).***For Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients.***For primary Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients.***For secondary Mycobacterium avium complex (MAC) prophylaxis in HIV-infected patients with disseminated disease, after treatment of the acute illness.***For the treatment of acute bacterial sinusitis. <br />        NOTE: Due to the high rate of resistance among S. pneumoniae isolates, macrolides are not recommended as empiric therapy. Amoxicillin/clavulanate is recommended as the first-line empiric therapy.<br />     ***For the treatment of non-gonococcal urethiritis (NGU) and chlamydia infection, including infant pneumonia�. <br />        NOTE: For ophthalmia neonatorum caused by C. trachomatis, see ophthalmia neonatorum indication.<br />     ***For the treatment of non-gonococcal urethritis (NGU) and other urogenital infections (e.g., cervicitis, urethritis, proctitis).***For the treatment of pneumonia caused by <em>Chlamydia trachomatis</em> in neonates and infants�.***For the treatment of group A beta-hemolytic streptococcal (GAS) pharyngitis (primary rheumatic fever prophylaxis�) and tonsillitis. <br />        NOTE: For secondary prophylaxis of rheumatic fever, the American Heart Association (AHA) recommends prophylaxis for 10 years or until age 40 (whichever is longer) for patients who have experienced rheumatic fever with carditis and have residual heart disease (persistent valvular disease). For patients who have experienced rheumatic fever with carditis, but have no residual heart disease, the AHA recommends prophylaxis for 10 years or until age 21 (whichever is longer). For patients who have experienced rheumatic fever without carditis, the AHA recommends prophylaxis for 5 years or until age 21 (whichever is longer).<br />     ***For the treatment of primary, secondary, or early latent syphilis� (caused by <em>Treponema pallidum</em>) in nonpregnant, penicillin-allergic patients. <br />        NOTE: A Jarisch-Herxheimer reaction may occur within the first 24 hours of therapy.<br />NOTE: While the HIV guidelines recommend non-penicillin alternatives for the treatment of syphilis in HIV-infected patients, their efficacy has not been evaluated and should only be used with close clinical and serologic monitoring***For the treatment of chronic prostatitis� due to <em>Ureaplasma urealyticum</em>.***For the treatment of Legionnaire's disease�.***For the treatment of shigellosis� diarrhea.***For the treatment of shigellosis� diarrhea in non-immunocompromised patients.***For the treatment of shigellosis� in HIV-infected patients.***For the treatment of mild-to-moderate campylobacteriosis� in HIV-infected patients.***For the treatment of toxoplasmosis�, including toxoplasmic encephalitis�, in HIV-positive patients.***For the treatment of early Lyme disease�.***For the treatment of early Lyme disease� in adults.***For the treatment of early Lyme disease� in children and adolescents.***For the treatment of dental infection� or dentoalveolar infection�, including periodontitis�, acute dental abscess (apical)�, and dental abscess (periapical)�.***For adult chronic periodontitis� after scaling and root planing.***For acute dental abscess (apical)� and/or dental abscess (periapical)� in combination with surgical incision and drainage in patients with beta-lactam allergy.***For bacterial endocarditis prophylaxis�.***For the treatment of babesiosis� in combination with atovaquone.***For the treatment of granuloma inguinale� (Donovanosis) caused by <em>Klebsiella granulomatis</em>.***For use in improving pulmonary function in cystic fibrosis� patients chronically infected with <em>Pseudomonas aeruginosa</em>.***For the treatment of mild scrub typhus� due to Orientia tsutsugamushi� (formerly Rickettsia tsutsugamushi�).***For the treatment of pertussis (whooping cough)� caused by <em>Bordetella pertussis</em> or for postexposure pertussis prophylaxis�. <br />  NOTE: For postexposure prophylaxis, administer to close contacts within 3 weeks of exposure, especially in high-risk patients (e.g., pregnant women in third trimester, infants younger than 12 months). Symptomatic contacts (coughing) should be treated as if they have pertussis.<br /***For the treatment of cholera�.***For the treatment of uncomplicated typhoid fever�.***For the treatment of bartonellosis� (<em>Bartonella bacilliformis)</em> and other <em>Bartonella </em>sp.� infections in HIV-infected patients.***For the treatment of angiomatosis infections�, peliosis hepatis�, bacteremia�, and osteomyelitis� caused by <em>Bartonella </em>sp.�.***For long term suppression� of infections caused by <em>Bartonella </em>sp.� in HIV-infected patients with relapse or reinfection and with CD4 count less than 200 cells/mm3.***For the treatment of ophthalmia neonatorum� due to <em>C. trachomatis</em>.***For the treatment of lymphogranuloma venereum� caused by <em>C. trachomatis</em>.***For chlamydial infection prophylaxis� and gonorrhea prophylaxis� in victims of sexual assault.***For the treatment of moderate or severe traveler's diarrhea�.***Formoterol***Formoterol; Mometasone","***General Information***Viral infection***Macrolide hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis***Hepatic disease, hepatitis, jaundice***Renal failure, renal impairment***Colitis, GI disease, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease***Geriatric***Pregnancy***Breast-feeding***Infants, neonates***Sunlight (UV) exposure***Sodium restriction***Contact lenses***Myasthenia gravis***Sexually transmitted disease",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4337'],fentanyl,"***For the control of moderate pain or severe pain.***For intraoperative or procedural management of severe pain, for use only in a monitored anesthesia care setting in the hospital.***For control of postoperative pain in the recovery room.***For the management of chronic severe pain in opioid-tolerant patients who require daily, around-the-clock, long-term opioid treatment.***For the management of severe breakthrough cancer pain in opioid-tolerant patients.***For short-term management of acute postoperative pain in the hospital setting using a fentanyl iontophoretic transdermal system (ITS) for patient-controlled analgesia.***For adjuvant management of general anesthesia maintenance and intraoperative pain control.***For minor surgical procedures and for use in the immediate postoperative period.***For major surgery, providing analgesia and some relief from the stress response. <br />          NOTE: Respiratory depression at this dosage level requires artificial ventilation.<br />       ***For open heart surgery and other complicated procedures where surgery is prolonged and the stress response would be detrimental to the patient's well-being.***For general anesthesia induction when attenuation of the responses to surgical stress is especially important such as during major surgery like open heart surgery or complicated neurological or orthopedic procedures.***For analgesia and/or sedation maintenance� in mechanically-ventilated intensive care patients.***For sedation and analgesia prior to rapid-sequence intubation (RSI)�.***For the management of dyspnea� in patients with end-stage cancer or lung disease.***For procedural sedation� of non-intubated patients during diagnostic, surgical, or other procedures.","***General Information***Dental work, headache, migraine, opioid-naive patients, surgery***Constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, ulcerative colitis***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Accidental exposure***MAOI therapy***Potential for overdose or poisoning, requires a specialized care setting, requires an experienced clinician***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal failure, renal impairment, urethral stricture, urinary retention***Brain tumor, CNS depression, head trauma, increased intracranial pressure, seizure disorder, seizures***Angina, bradycardia, cardiac arrhythmias, cardiac disease, heart failure, hypotension, orthostatic hypotension, shock***Children, infants, neonates, premature neonates***Labor, neonatal opioid withdrawal syndrome, pregnancy***Breast-feeding***Females***Geriatric***Biliary tract disease, pancreatitis***Abrupt discontinuation***Driving or operating machinery***Anticoagulant therapy, coagulopathy, epidural administration, infection, intrathecal administration, thrombocytopenia***Opiate agonist hypersensitivity***Ambient temperature increase, fever, heating pad, skin abrasion, sunlight (UV) exposure***Ocular exposure***Dental disease, diabetes mellitus, stomatitis***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Adrenal insufficiency, hypothyroidism, myxedema",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,lidocaine hydrochloride,"***For the treatment of perfusing ventricular arrhythmias including ventricular fibrillation (VF) and ventricular tachycardia (VT) that may result during acute myocardial infarction or cardiac manipulation (e.g., cardiac surgery). <br />  NOTE: See resuscitation indication for dosage guidelines for VF or pulseless VT.<br />NOTE: Although not considered a drug of choice for ventricular arrhythmias, lidocaine may be used as an alternative antiarrhythmic in patients with preserved ventricular function and stable monomorphic VT. Lidocaine may also be used to treat polymorphic VT in patients with a normal QT interval (when electrolyte imbalance and ischemia are treated). If pulseless cardiac arrest associated with VF or VT, see separate dosage guidelines for the treatment ventricular arrhythmias during CPR.<br />NOTE: Lidocaine may be used to treat patients with polymorphic VT associated with QT prolongation (e.g., torsade de pointes).<br />NOTE: Monitor blood pressure and the electrocardiogram (ECG) during intravenous lidocaine administration***For topical anesthesia of skin and mucous membranes or stomatitis.***For prevention of dental pain� and for topical anesthesia of mucous membranes.***For laryngoscopy.***For nonurgent painful procedures including IV cannulation, venipuncture, lumbar puncture, or arterial puncture.***For the treatment of stage 1 thru 4 pressure ulcers, venous stasis ulcers, ulcerations of mixed vascular etiologies, diabetic skin ulcers, first and second degree burns, and post surgical incisions, cuts, and abrasions.***For endotracheal intubation.***For neonatal circumcision�.***For bronchoscopy.***For the treatment of pain associated with postherpetic neuralgia.***For ophthalmic anesthesia.***For local anesthesia including peripheral nerve block anesthesia. <br />        NOTE: In adults, the dosages for local anesthesia reported are general guidelines only. The actual dose depends on a variety of factors such as depth of anesthesia, extent of surgical procedure, degree of muscle relaxation required, duration of anesthesia and the patients' physical condition. See Lidocaine; epinephrine monograph for information concerning combination dosing.<br />     ***For dental anesthesia including mandibular nerve block and maxillary infiltration.***For infiltration anesthesia.***For intravenous regional anesthesia.***For pudendal nerve block.***For paravertebral block.***For intercostal nerve block.***For brachial plexus block.***For paracervical block.***For sympathetic nerve block.***For cervical stellate ganglion block.***For lumbar sympathetic block.***For epidural anesthesia. <br />        NOTE: The dose is determined by the number of dermatomes to anesthetized (2 to 3 mL/dermatome). The suggested concentrations and volumes serve as a guide, other volumes and concentrations may be used provided the maximum dose is not exceeded.<br />     ***For lumbar anesthesia.***For lumbar analgesia for severe pain.***For thoracic.***For caudal anesthesia.***For obstetric anesthesia.***For surgical anesthesia.***For spinal anesthesia.***For obstetrical low spinal or saddle block anesthesia.***For intraabdominal anesthesia.***For the treatment of ventricular arrhythmias during cardiopulmonary resuscitation� (CPR).***For the attenuation of increased intracranial pressure� during rapid-sequence intubation� or endotracheal tube suctioning�.***For the treatment of severe singultus (hiccups)�.***For the treatment of headache�.***For the treatment of acute headache� associated with migraine�.***For the treatment of cluster headache�.***For the symptomatic treatment of corticosteroid-dependent asthma�. <br />        NOTE: Initial bronchoconstriction can occur. In addition, lidocaine toxicity can result in tremors, hallucinations, seizures, and cardiac arrest. Caution is advised until long-term safety and efficacy can be established.<br />     ***For short-term prophylaxis of short-lasting unilateral neuralgiform headache with conjunctival injection and tearing� (SUNCT).***For the treatment of painful diabetic neuropathy� in adults.","***General Information***Amide local anesthetic hypersensitivity, epidural anesthesia***Collagen-vascular disease***G6PD deficiency***Geriatric, heart failure, hepatic disease***Hypotension, pregnancy***Breast-feeding***Adams-Stokes syndrome, atrial fibrillation, atrial flutter, AV block, bradycardia, cardiogenic shock, hemorrhagic shock, hypovolemia, shock, Wolff-Parkinson-White syndrome***Renal disease, renal failure, renal impairment***Burns, eczema, heating pad, occlusive dressing, skin abrasion***Cataracts, ocular exposure, ocular trauma***Accidental exposure***Intraarterial administration, intrathecal administration, intravenous administration***Head and neck anesthesia***Ocular surgery***Anticoagulant therapy, bleeding, coagulopathy, infection, neurological disease, requires a specialized care setting, requires an experienced clinician, sepsis, spinal anesthesia, thrombocytopenia***Fetal distress, labor, obstetric delivery, pudendal nerve block***Continuous intraarticular infusion administration***Fetal prematurity, paracervical nerve block***Malignant hyperthermia***Children, infants, neonates, teething pain",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8628'],praziquantel,***For the treatment of cysticercosis� or neurocysticercosis� (larval form of <em>Taenia solium</em>�).***For the treatment of taeniasis� (tapeworm infection�).***For adjunctive treatment of hydatid cyst disease� in combination with albendazole. <br />        NOTE: Praziquantel is not effective as monotherapy for hydatid cyst disease.<br />     ,"***General Information***Retinal cysticercosis, seizure disorder***Hepatic disease***AV block, bradycardia, cardiac arrhythmias, ventricular fibrillation***Driving or operating machinery***Pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,prednisolone acetate/sulfacetamide sodium,"***For steroid-responsive inflammatory ocular inflammation conditions (e.g., uveitis, bacterial conjunctivitis, corneal abrasion) for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. <br />        NOTE: Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies.<br />     ","***General Information***Fungal infection, herpes simplex keratitis (dendritic keratitis), mycobacterial infection, varicella, viral infection***Corticosteroid hypersensitivity, sulfonamide hypersensitivity, thimerosal hypersensitivity***Black patients, cataracts, glaucoma, increased intraocular pressure, ocular infection, ocular surgery, uveitis, visual disturbance***Abrupt discontinuation, corticosteroid withdrawal***Contact lenses***Intramuscular administration, intravenous administration***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,adefovir dipivoxil,"***For the treatment of chronic hepatitis B infection. <br />  NOTE: In order to reduce the risk of resistance in patients with lamivudine-resistant hepatitis B virus, the manufacturer recommends using adefovir plus lamivudine.<br />NOTE: In order to reduce the risk of resistance in all patients receiving adefovir monotherapy, the manufacturer recommends that hepatitis B treatment therapy with adefovir be potentially modified if serum hepatitis B virus DNA remains &gt; 1000 copies/ml with continued treatment","***Hepatitis B exacerbation***Dialysis, nephrotoxicity, renal disease, renal failure, renal impairment***Hepatitis B and HIV coinfection, human immunodeficiency virus (HIV) infection, human immunodeficiency virus (HIV) infection resistance***Females, hepatic disease, Hepatotoxicity or Lactic Acidosis, obesity***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric***Liver transplant",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,hydromorphone hydrochloride,"***For the relief of moderate pain or severe pain.***For the relief of acute and chronic moderate pain or severe pain.***For the management of chronic severe pain in opioid-tolerant patients who require daily, around-the-clock, long-term opioid treatment. <br />          NOTE: Extended-release hydromorphone should be reserved for patients in whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would otherwise provide inadequate pain management. Discontinue all other around-the-clock opioid drugs upon initiation of hydromorphone extended-release tablets.<br />NOTE: Opioid-tolerant patients are defined as those taking, for a minimum of 1 week, &gt;= 60 mg oral morphine daily, &gt;= 30 mg oral oxycodone daily, &gt;= 8 mg oral hydromorphone daily, &gt;= 25 mg oral oxymorphone daily, &gt;= 25 mcg transdermal fentanyl per hour, or an equivalent dose of another opioid","***Acute abdomen, constipation, diarrhea, GI disease, GI obstruction, ileus, inflammatory bowel disease, surgery, ulcerative colitis***Alcoholism, depression, substance abuse***Asthma, chronic obstructive pulmonary disease (COPD), coadministration with other CNS depressants, cor pulmonale, emphysema, hypoxemia, obesity, pulmonary disease, respiratory depression, respiratory insufficiency, scoliosis, sleep apnea, status asthmaticus***Opioid-naive patients***Abrupt discontinuation***Coma, head trauma, increased intracranial pressure, intracranial mass, seizure disorder, seizures***Angina, cardiac arrhythmias, cardiac disease, heart failure, hypotension, hypovolemia, orthostatic hypotension, shock***Bladder obstruction, hepatic disease, oliguria, prostatic hypertrophy, renal disease, renal impairment, urethral stricture, urinary retention***Geriatric***Children, infants, neonates***Biliary tract disease, gallbladder disease, pancreatitis***Neonatal opioid withdrawal syndrome, pregnancy***Labor, obstetric delivery***Breast-feeding***Driving or operating machinery***Epidural administration***Opiate agonist hypersensitivity***Lactase deficiency, latex hypersensitivity, paraben hypersensitivity, sulfite hypersensitivity***Adrenal insufficiency, hypothyroidism, myxedema***Intravenous administration***Accidental exposure, ethanol ingestion, ethanol intoxication, potential for overdose or poisoning, requires an experienced clinician",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8011'],pentostatin,"***For the treatment of untreated and alpha-interferon-refractory hairy-cell leukemia (HCL) (patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms). <br />  NOTE: Pentostatin was designated an orphan drug by the FDA for this indication (9/10/87, expired).<br />NOTE: To assess treatment response, periodic monitoring of the peripheral blood for hairy cells and bone marrow aspirates and biopsies may be required at 2 to 3 month intervals***For the treatment of chronic lymphocytic leukemia (CLL)�, in combination with cyclophosphamide and rituximab. <br />        NOTE: Pentostatin was designated an orphan drug by the FDA for this indication<br />     ***For stem cell transplant preparation� prior to allogeneic stem cell transplantation, in combination with extracorporeal photopheresis and reduced dose total body irradiation.***For the treatment of graft-versus-host disease (GVHD)�.***For the treatment of corticosteroid-refractory acute graft-versus-host disease (GVHD)�.***For the treatment of corticosteroid-refractory chronic graft-versus-host disease (GVHD)�.***For graft-versus-host disease (GVHD) prophylaxis�.***For the treatment of advanced cutaneous T-cell lymphoma (CTCL)�, including mycosis fungoides� and Sezary syndrome�. <br />  NOTE: Pentostatin has been designated an orphan drug by the FDA for the treatment of cutaneous T cell lymphoma and peripheral T cell lymphoma.<br /***Formoterol; Mometasone","***Hepatotoxicity, nephrotoxicity, neurotoxicity, pulmonary edema, pulmonary toxicity, requires an experienced clinician***Use with fludarabine***Mannitol hypersensitivity***Anemia, bone marrow suppression, fungal infection, herpes infection, infection, neutropenia, radiation therapy, thrombocytopenia, varicella, viral infection***Dental disease, dental work***Intramuscular injections***Hepatic disease***Dehydration, renal failure, renal impairment***Hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia, tumor lysis syndrome (TLS)***Pregnancy***Breast-feeding***Infertility***Seizures***Accidental exposure, ocular exposure***Children***Vaccination",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['12574'],gemcitabine,"***For the treatment of non-small cell lung cancer (NSCLC).***For first-line treatment of inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) NSCLC in combination with cisplatin.***For first-line treatment of inoperable, locally advanced or metastatic NSCLC in combination with carboplatin�.***For the treatment of advanced or metastatic NSCLC (stage IIIB or IV) in combination with paclitaxel�.***For first-line treatment of unresectable, locally advanced or metastatic NSCLC in combination with docetaxel�.***For the treatment of previously untreated advanced NSCLC in combination with topotecan�.***For the second-line treatment of advanced NSCLC in combination with topotecan�.***For the treatment of pancreatic cancer.***For first-line treatment of locally advanced (nonresectable Stage II or III) or metastatic (Stage IV) pancreatic cancer, or as second-line treatment in patients who were previously treated with 5-fluorouracil (5-FU).***For first-line treatment of locally advanced, unresectable or metastatic pancreatic cancer in combination with erlotinib�. <br />          NOTE: Erlotinib is FDA-approved for the first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer in combination with gemcitabine.<br />       ***For adjuvant treatment of pancreatic cancer as monotherapy�.***For first-line treatment of unresectable locally advanced or metastatic pancreatic cancer in combination with oxaliplatin�.***For the first-line treatment of metastatic pancreatic cancer in combination with nab-paclitaxel�. <br />          NOTE: Nab-paclitaxel is FDA approved in combination with gemcitabine for the first-line treatment of metastatic pancreatic cancer.<br />       ***For the adjuvant treatment of pancreatic ductal adenocarcinoma, in combination with capecitabine�.***For the treatment of metastatic breast cancer.***For the treatment of metastatic breast cancer as a single agent�.***For the treatment of ovarian cancer.***For recurrent advanced ovarian cancer as a single agent�.***For the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of a platinum-based therapy in combination with carboplatin.***For the treatment of biliary tract cancer�.***For the treatment of advanced or metastatic biliary tract cancer� in combination with cisplatin.***For the first-line treatment of locally advanced or metastatic transitional-cell bladder cancer�, in combination with cisplatin.***For the treatment of malignant mesothelioma�.***For the treatment of malignant pleural mesothelioma in combination with cisplatin or carboplatin�.***For the treatment of relapsed malignant mesothelioma as a single-agent�.***For the treatment of advanced cutaneous T-cell lymphoma (CTCL)�, including mycosis fungoides� and Sezary syndrome�.***For the treatment of non-Hodgkin's lymphoma (NHL)�.***For the treatment of relapsed or refractory, aggressive NHL in transplant eligible patients, in combination with dexamethasone and cisplatin (and rituximab for CD20-positive disease)�.***For the treatment of peripheral T-cell lymphoma (PTCL)�.***For the first-line treatment of PTCL in combination with cisplatin, prednisone, and thalidomide�.","***Bone marrow suppression, chemotherapy, herpes infection, infection, neutropenia, thrombocytopenia, varicella, viral infection***Radiation therapy***Alcoholism, hepatic disease, hepatitis, hepatotoxicity***Infusion-related reactions***Pneumonitis, pulmonary disease, pulmonary edema, pulmonary fibrosis***Capillary leak syndrome***Hemolytic-uremic syndrome, renal failure, renal impairment***Encephalopathy***Children***Females, geriatric***Pregnancy***Infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,somatropin (rDNA origin),"***For the treatment of growth hormone deficiency, growth failure, or short stature.***For replacement therapy in adults with growth hormone deficiency (GHD) for either childhood onset (secondary to congenital, genetic, acquired, or idiopathic causes) or adult onset (endogenous or associated with multiple hormone deficiencies, i.e., hypopituitarism, as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma).***For the long-term treatment of growth failure in children who have growth hormone deficiency due to inadequate growth hormone secretion.***For growth failure due to Prader-Willi syndrome.***For the long-term treatment of growth failure in children born small for gestational age (SGA) who fail to manifest catch-up growth by age 2 to 4.***For growth failure associated with chronic renal failure up to the time of transplantation.***For short stature associated with Turner's syndrome.***For short stature in children with SHOX (short stature homeobox-containing gene) deficiency.***For short stature in children with Noonan Syndrome.***For idiopathic short stature.***For the treatment of HIV-associated failure to thrive in children, AIDS-associated wasting syndrome, or cachexia.***For the treatment of HIV-associated adipose redistribution syndrome (HARS)�.***For the treatment of short bowel syndrome in patients receiving specialized nutrition support as directed by a health care professional.***Formoterol; Mometasone","***General Information***Cresol hypersensitivity, glycerin hypersensitivity, history of angioedema, risk of serious hypersensitivity reactions or anaphylaxis***Epiphyseal closure***Children, renal impairment, renal osteodystrophy***Benzyl alcohol hypersensitivity, neonates***Chemotherapy, neoplastic disease, new primary malignancy, radiation therapy***Respiratory insufficiency, surgery, trauma***Obesity***Respiratory infection, sleep apnea***Diabetes mellitus, diabetic retinopathy***Scoliosis***Adrenal insufficiency, hypothyroidism***Increased intracranial pressure***Pregnancy***Breast-feeding***Otitis media***Geriatric***Females***Pancreatitis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,menotropins,"***For the stimulation of spermatogenesis in males with primary or secondary hypogonadotropic hypogonadism and resultant oligospermia. <br />  NOTE: Pretreatment with human chorionic gonadotropin (HCG) is required prior to combination with menotropins. Various HCG dosages have been used; continue for a period sufficient to achieve normal serum testosterone. HCG pretreatment may require 3 to 6 months (see HCG monograph).<br /***For the treatment of infertility in females. <br />  NOTE: During any protocol for ovulation induction, menotropins must be discontinued and hCG must not be given if the ovaries are abnormally enlarged, more than 3 follicles of 15 mm size are present, an ovarian cyst is present, or the serum estradiol exceeds 2000 pg/mL. Consult specialized references for specific fertility protocols.<br /***For the treatment of anovulation in females with infertility not due to primary ovarian failure including those who have received GnRH agonist or antagonist pituitary suppression, or in those women with hypogonadotropic hypogonadism.***For the induction of follicle development in women who have received GnRH agonist or antagonist pituitary suppression and who are enrolled in protocols for in vitro fertilization (IVF) or other assisted reproductive technology (ART).","***General Information***Children***Adrenal insufficiency, ovarian failure, pituitary adenoma, thyroid disease***Dysfunctional uterine bleeding, endometriosis, neoplastic disease, uterine leiomyomata***Ovarian cyst***Ascites, polycystic ovary syndrome***Pregnancy***Breast-feeding***Obesity, thromboembolic disease, thrombophlebitis***Geriatric***Ethanol intoxication, tobacco smoking***Testicular failure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['84959'],imiglucerase,"***For enzyme replacement therapy in patients with confirmed Gaucher disease type 1 (GD1) who have at least one of the following conditions: anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly. <br />        NOTE: The needed dosage should be calculated for the patient, then the appropriate number of vials needed to administer that dose should be reconstituted on the day of administration.<br />NOTE: To avoid drug wastage, the manufacturer states that small dosage adjustments may be made occasionally to the calculated dosage in order to fully utilize a reconstituted vial. Thus, the dosage of each infusion may be increased or decreased to fully utilize each vial as long as the monthly administered dosage remains substantially unaltered",***General Information***Pulmonary hypertension***Gelatin hypersensitivity***Pregnancy***Breast-feeding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,clonidine hydrochloride,"***For the treatment of hypertension.***For the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients as monotherapy or as adjunctive therapy to a psychostimulant. <br />        NOTE: Clonidine is not considered a first-line agent for children with ADHD due to the potential cardiac effects and the availability of safer and more effective agents, such as some stimulants. Reports of sudden death and hypotension in children receiving oral clonidine in combination with other therapies for ADHD have been published, but causality has not been established.  Children and infants may be more sensitive to the effects of clonidine. However, not all ADHD clinical trials evaluating clonidine have reported adverse cardiac effects. The American Heart Association has recommended that children and adolescents receiving clonidine be monitored for changes in blood pressure at treatment initiation, periodically during treatment, and when tapering the drug, even when clonidine is used for psychotropic indications.<br />     ***For the treatment of ADHD in children with tic disorders�.***For the treatment of severe pain.***For the treatment of hypertensive urgency� or hypertensive emergency�.***For the treatment of opiate agonist withdrawal�.***For the treatment of neonatal abstinence syndrome�.***For pheochromocytoma diagnosis�.***For the symptomatic treatment of diabetic neuropathy�.***For the treatment of diabetic diarrhea�, diarrhea� related to opiate withdrawal, or refractory diarrhea� in cancer patients. <br />        NOTE: Clonidine has some antisecretory activity by modulating (decreasing) small intestinal transit; however, data are relatively limited and the agent is often used for refractory diarrheal cases.<br />     ***For the treatment of alcohol withdrawal�.***For use as an adjunct to psychosocial interventions in the management of tobacco cessation� (smoking cessation�).***For the treatment of hot flashes� due to menopause�.***For the treatment of hypertension and the subsequent decline in renal function associated with scleroderma renal crisis (SRC)�.***For minimization of nephrotoxicity in patients receiving cyclosporine (i.e., cyclosporine nephrotoxicity prophylaxis�) and low-dose methotrexate for allogeneic bone marrow transplant.***For use in peripheral nerve block� including brachial plexus�, intercostal� and peribulbar� blocks in combination with local anesthetics.***For the treatment of Tourette's syndrome�.***For the treatment of aggressive behavior and hyperactivity/inattentiveness in patients with autistic disorder�.***For growth hormone deficiency diagnosis�.***For the treatment of hot flashes� due to prostate cancer� and associated induced androgen deficiency� (andropause�"") in men who have had surgical or medication induced castration.""","***General Information***Abrupt discontinuation, vomiting***AV block, bradycardia, cerebrovascular disease, dehydration, heart failure, hypotension, myocardial infarction, orthostatic hypotension, syncope***Labor, obstetric delivery, pregnancy***Females***Breast-feeding***Children, infants, neonates***Depression***Driving or operating machinery***Sick sinus syndrome***Raynaud's phenomenon, thromboangiitis obliterans (Buerger's disease)***Diabetes mellitus***Renal disease, renal failure, renal impairment***Anticoagulant therapy, coagulopathy, infection***Cardiac disease***Intrathecal administration***Defibrillation (cardioversion), magnetic resonance imaging (MRI)***Polyarteritis nodosa, scleroderma, systemic lupus erythematosus (SLE)***Skin abrasion***Surgery***Pheochromocytoma***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pemetrexed disodium,"***For the treatment of malignant pleural mesothelioma.***For the treatment of unresectable malignant pleural mesothelioma, in combination with cisplatin.***For the treatment of previously untreated, advanced, unresectable malignant pleural mesothelioma, in combination with cisplatin and bevacizumab�.***For the treatment of previously untreated, advanced, unresectable malignant pleural mesothelioma, in combination with carboplatin�.***For the treatment of nonsquamous non-small cell lung cancer (NSCLC). <br />  NOTE: Pemetrexed is not indicated for the treatment of patients with squamous cell NSCLC.<br /***For the treatment of recurrent, metastatic, non-squamous NSCLC, after prior chemotherapy, as monotherapy.***For first-line treatment of locally advanced or metastatic, non-squamous, NSCLC, in combination with cisplatin.***For maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC, whose disease has not progressed after 4 cycles of first-line platinum-based chemotherapy, as monotherapy.***For the first line treatment of stage IIIB or IV non-small cell lung cancer (NSCLC), in combination with carboplatin�.***For the treatment of advanced unresectable squamous cell head and neck cancer�.***For the second line treatment of metastatic transitional-cell bladder cancer�.***For the treatment of metastatic breast cancer�.***For the first-line treatment of unresectable, locally advanced or metastatic pancreatic cancer, in combination with gemcitabine�.***For the treatment of gastric cancer�.","***General Information***Renal impairment***Bone marrow suppression, neutropenia, thrombocytopenia***Pneumonitis, pulmonary disease***Radiation therapy***Geriatric***Children, infants, neonates***Pregnancy***Contraception requirements, infertility, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['114970'],zafirlukast,"***For the chronic treatment and prevention of the symptoms of asthma, either as monotherapy or as add-on therapy in patients whose persistent mild-moderate asthma is inadequately controlled with inhaled corticosteroids. <br />        NOTE: Zafirlukast is not a 'rescue' medication; it should not be used for the treatment of an acute asthmatic attack or acute bronchospasm. However, zafirlukast may be continued during the treatment of an acute asthmatic event.<br />     ***For the treatment of allergic rhinitis�.***For exercise-induced bronchospasm prophylaxis�.","***General Information***Acute bronchospasm, status asthmaticus***Pregnancy***Breast-feeding***Females, hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Geriatric***Corticosteroid withdrawal, vasculitis***Depression, suicidal ideation***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"['8152', '221138']['38404']",phentermine/topiramate,***For the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity.***Formoterol***Formoterol; Mometasone,"***General Information***MAOI therapy***Cardiac arrhythmias, cardiac disease, heart failure, myocardial infarction, stroke***Hyperthyroidism, thyroid disease***Dialysis, renal failure, renal impairment***Glaucoma, increased intraocular pressure***Ambient temperature increase, anticholinergic medications***Anxiety, depression, insomnia, suicidal ideation***Driving or operating machinery, ethanol ingestion***Nephrolithiasis***Chronic obstructive pulmonary disease (COPD), diarrhea, emphysema, hypokalemia, metabolic acidosis, status asthmaticus, status epilepticus, surgery***Hepatic disease***Diabetes mellitus***Hypotension***Geriatric***Anorexia nervosa, substance abuse***Abrupt discontinuation***Labor, obstetric delivery, pregnancy***Breast-feeding***Children, infants, neonates",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,acyclovir,"***For the treatment of neonatal herpes simplex virus infection.***For the treatment of viral encephalitis.***For herpes simplex encephalitis.***For varicella-zoster encephalitis�.***For encephalitis due to B virus (cercopithecine herpesvirus) infection� as an alternative to valacyclovir.***For the treatment of herpes labialis (i.e., cold sores) or herpes fibrilis caused by herpes simplex virus.***For the treatment of recurrent herpes labialis in immunocompetent adults.***For the treatment of varicella (chickenpox) infection.***For the treatment of varicella (chickenpox) infection in immunocompetent patients.***For the treatment of for varicella (chickenpox) infection in immunocompromised patients.***For the treatment of herpes zoster (shingles) infection. <br />        NOTE: For CNS infections, see encephalitis.<br />     ***For the treatment of herpes zoster (shingles) infection in bone marrow and organ transplant patients, patients receiving chemotherapy, and other immunocompromised patients.***For the treatment of herpes zoster (shingles) infection in immunocompetent patients.***For the treatment of herpes genitalis caused by herpes simplex virus.***For the treatment of initial herpes genitalis infection.***For the treatment of recurrent herpes genitalis.***For chronic suppression therapy of recurrent herpes genitalis (i.e., herpes genitalis prophylaxis).***For the treatment of complicated herpes simplex virus infection (e.g., disseminated disease�, pneumonitis�, infection in immunocompromised hosts, and infections requiring hospitalization). <br />        NOTE: For congenital herpes, see neonatal herpes simplex virus infection; for CNS disease, see encephalitis.<br />     ***For neonatal herpes simplex virus infection prophylaxis� (i.e., suppressive therapy) in neonates with any neonatal herpes simplex disease classification.***For chronic suppression of recurrent herpes labialis� (i.e., herpes labialis prophylaxis�).***For herpes simplex infection prophylaxis� in immunocompromised hosts.***For primary herpes simplex infection prophylaxis in HSV-seropositive recipients of a bone marrow transplant�.***For primary herpes simplex infection prophylaxis in immunocompromised hosts who are HSV-seropositive patients�.***For primary varicella (chickenpox) infection prophylaxis� in HIV-infected patients with significant exposure to chickenpox or shingles for patients who have no history of either condition or, if available, negative antibody to varicella-zoster virus (VZV).***For cytomegalovirus (CMV) disease prophylaxis�.***For prevention of CMV disease� in immunocompromised patients.***For prevention of CMV disease� in CMV-seropositive patients receiving bone marrow transplantation.***For CMV disease prophylaxis� in adults receiving renal transplantation.***For the treatment of hairy leukoplakia� in HIV-positive adults.***For the adjunctive treatment of Bell's palsy�in combination with steroids.***For secondary herpes simplex ocular infection prophylaxis�.***For the treatment of acute herpes zoster ocular infection� (herpes zoster ophthalmicus�) in immunocompetent patients.***For the treatment of acute retinal necrosis (ARN)� due to varicella-zoster virus in HIV-infected patients.","***Acyclovir hypersensitivity, famciclovir hypersensitivity, ganciclovir hypersensitivity, milk protein hypersensitivity, penciclovir hypersensitivity, valacyclovir hypersensitivity, valganciclovir hypersensitivity***Dehydration, renal failure, renal impairment***Neurological disease, seizure disorder***Geriatric***Pregnancy***Breast-feeding***Children, infants, neonates***Ophthalmic administration***Extravasation, intramuscular administration, subcutaneous administration***Obesity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['161'],acetaminophen,"***For the treatment of fever. <br />        NOTE: Acetaminophen should not be used for self-medication of marked fever (greater than 39.5 degrees C or 103.1 degrees F), fever persisting longer than 3 days, or recurrent fever, unless directed by a physician.<br />     ***For the treatment of mild pain or for the temporary relief of headache, myalgia, back pain, musculoskeletal pain, dental pain (e.g., toothache), dysmenorrhea, arthralgia, or minor aches and pains associated with the common cold or flu. <br />        NOTE: Acetaminophen should not be used for self-medication of pain for longer than 10 days in adults or 5 days in children.<br />     ***For the treatment of moderate pain to severe pain with adjunctive opioid analgesics.***For minor osteoarthritis pain.***For the treatment of headache pain due to acute migraine�.","***Acetaminophen hypersensitivity***Alcoholism, ethanol intoxication, hepatic disease, hepatitis, hepatotoxicity, hypovolemia, malnutrition, potential for overdose or poisoning***Renal disease, renal failure, renal impairment***G6PD deficiency***Bone marrow suppression, immunosuppression, infection, neutropenia***Tobacco smoking***Children, infants, neonates***Pregnancy***Breast-feeding***Phenylketonuria***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,pramipexole dihydrochloride,***For the treatment of moderate to severe primary Restless Legs Syndrome (RLS).***For the treatment of the signs and symptoms of idiopathic Parkinson's disease.,"***Cardiac disease, orthostatic hypotension***Geriatric***Driving or operating machinery***Renal disease, renal failure, renal impairment***Pregnancy***Breast-feeding***Children***Melanoma***Impulse control symptoms***Abrupt discontinuation***Psychosis, schizophrenia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['8134'],phenobarbital,"***For the treatment of status epilepticus. <br />        NOTE: The full antiepileptic effect of phenobarbital is not immediate. IV benzodiazepines, (e.g., lorazepam or diazepam) should be given initially.<br />     ***For the maintenance treatment of all types of seizures, including but not limited to partial seizures, myoclonic seizures, tonic-clonic seizures, or neonatal seizures not responding to other anticonvulsants.***For the short-term treatment of insomnia.***For procedural sedation and relief of preoperative anxiety.***For sedation maintenance, to relieve anxiety, tension, and apprehension.***For the treatment of hyperbilirubinemia�.***For the treatment of hyperbilirubinemia due to chronic cholestasis.***For the treatment of hyperbilirubinemia in neonates.***For the treatment of hyperbilirubinemia due to type II Crigler-Najjar syndrome.***For neonatal abstinence syndrome�.","***Agranulocytosis, barbiturate hypersensitivity, carbamazepine hypersensitivity, exfoliative dermatitis, hydantoin hypersensitivity***Pain***Depression, suicidal ideation***Cardiac disease, heart failure, hypertension, hypotension, intraarterial administration, intravenous administration, shock, subcutaneous administration***Chronic obstructive pulmonary disease (COPD), pulmonary disease, respiratory depression, sleep apnea***Abrupt discontinuation, seizure disorder, seizures, status epilepticus, substance abuse***Alcoholism, CNS depression, driving or operating machinery, ethanol ingestion, mental status changes***Geriatric***Hepatic disease, hepatic encephalopathy***Anuria, dialysis, renal failure, renal impairment***Porphyria***Anticoagulant therapy***Osteomalacia, osteoporosis***Children, infants, neonates, premature neonates***Labor, obstetric delivery, pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,tiagabine hydrochloride,"***For the adjunctive treatment of partial seizures. <br />        NOTE: Dosage adjustment of tiagabine should be considered whenever a change in patient's enzyme-inducing status occurs as a result of the addition, discontinuation, or dose change of the enzyme-inducing agent. The systemic exposure after a tiagabine dose of 32 mg/day in an induced population is expected to be comparable to the systemic exposure after a dose of 12 mg/day in a NON-induced population. Similarly, the systemic exposure after a dose of 56 mg/day in an induced population is expected to be comparable to the systemic exposure after a dose of 22 mg/day in a NON-induced population.<br />     ","***Bipolar disorder, children, infants, mania, neonates, seizures, status epilepticus***Depression, suicidal ideation***Abrupt discontinuation***Hepatic disease***Driving or operating machinery***Pregnancy***Breast-feeding***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,sodium polystyrene sulfonate,"***For the treatment of hyperkalemia. <br />        NOTE: The dosage must be individualized, depending on the daily assessment of total body potassium.<br />     ","***General Information***Binding to other oral medications***Burns***Children, GI bleeding, GI obstruction, infants, neonates, premature neonates***Colitis, constipation, fecal impaction, hypovolemia, inflammatory bowel disease, renal failure, surgery***Edema, heart failure, hypernatremia, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, sodium restriction***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['461016'],eszopiclone,***For the treatment of insomnia.,"***Angioedema***Depression, suicidal ideation***Behavioral changes, CNS depression, coadministration with other CNS depressants, driving or operating machinery, ethanol ingestion***Chronic obstructive pulmonary disease (COPD), respiratory depression, sleep apnea***Hepatic disease***Pregnancy***Breast-feeding***Children, infants, neonates***Geriatric***Abrupt discontinuation, alcoholism, substance abuse",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['75207'],bosentan,"***For the treatment of pulmonary hypertension (pulmonary arterial hypertension WHO Group 1). <br />  NOTE: Studies establishing effectiveness in adult patients were comprised predominately of patients with NYHA Functional Class II to IV symptoms and etiologies of idiopathic or heritable pulmonary arterial hypertension (PAH) (60%), PAH associated with connective tissue diseases (21%) and PAH associated with congenital heart disease with left-to-right shunts (18%).<br /***For the treatment of persistent pulmonary hypertension of the newborn (PPHN)�.","***General Information***Hepatic disease, hepatitis, hepatotoxicity, jaundice***Edema, heart failure, peripheral edema, pulmonary edema, veno-occlusive disease (VOD), ventricular dysfunction***Anemia***Geriatric***Phenylketonuria***Pregnancy***Breast-feeding***Contraception requirements, infertility, pregnancy testing, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,albumin (human),"***For the treatment of shock due to hypovolemia. <br />        NOTE: Dosage should be based on patient response as indicated by blood pressure, degree of pulmonary congestion, and hematocrit.<br />     ***For adjunctive treatment of severe burns.***For the treatment of nephrosis in nephrotic syndrome.***For treatment of hypoproteinemia.***For adjunctive use with exchange transfusion in the treatment of hyperbilirubinemia and erythroblastosis fetalis.","***Albumin hypersensitivity***Anemia, heart failure, hypertension***Renal disease***Hypernatremia***Burns***Viral infection***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['214555'],etanercept,"***For reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA).***For the reduction in signs and symptoms of moderately to severely active polyarticular course juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA) in patients who have had an inadequate response to 1 or more disease-modifying antirheumatic drugs. <br />  NOTE: Etanercept has been designated an orphan drug by the FDA for this indication.<br /***For the treatment of chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.***For the treatment of signs and symptoms of active psoriatic arthritis, to improve physical function, and to prevent the progression of structural damage.***For the treatment of the signs and symptoms of spondylitis, such as active ankylosing spondylitis in adults or for the treatment of juvenile spondyloarthropathy� (JSpA) in pediatric patients.","***Hepatitis***Bone marrow suppression, corticosteroid therapy, diabetes mellitus, fungal infection, geriatric, hematological disease, immunosuppression, infection, mycobacterial infection, sepsis, tuberculosis, viral infection***Vasculitis***Lymphoma, new primary malignancy***Heart failure***Vaccination, varicella***Multiple sclerosis, neurological disease, seizure disorder, seizures***Autoimmune disease***Neonates, pregnancy***Breast-feeding***Children, infants***Latex hypersensitivity",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['59078'],metaxalone,"***For the treatment of musculoskeletal pain associated with acute, painful musculoskeletal conditions, as an adjunct to rest, physical therapy, and other measures.","***Hepatic disease, renal disease, renal failure, renal impairment***Anemia, hemolytic anemia***Driving or operating machinery***Geriatric***Pregnancy***Breast-feeding***Hyperglycemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,liothyronine sodium,"***For the treatment of hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (pediatrics and adults of all ages), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism.***For the treatment of mild hypothyroidism.***For the treatment of cretinism (congenital hypothyroidism).***For the treatment of myxedema.***For the treatment of myxedema coma.***For the treatment or prevention of euthyroid (non-toxic) goiter of various types, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter; thyroid hormones act as pituitary thyroid-stimulating hormone (TSH) suppressants in these conditions.***For thyroid suppression testing (T-3 suppression test) as an aid for hyperthyroidism diagnosis in patients with signs of mild hyperthyroidism in whom baseline laboratory tests appear normal, or to demonstrate thyroid gland autonomy in patients with Graves' ophthalmopathy.***For augmentation of antidepressant therapy in the treatment of refractory depression�.***For use as triiodothyronine replacement therapy for organ preservation� of heart transplantation donors prior to procurement.***Formoterol; Mometasone","***General Information***Intramuscular administration, subcutaneous administration***Thyrotoxicosis***Adrenal insufficiency***Hypopituitarism***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, coronary artery disease, hypertension, surgery***Geriatric***Renal failure, renal impairment***Diabetes mellitus***Obesity treatment***Hyponatremia, hypothermia, myxedema, water intoxication***Children, infants, neonates***Pregnancy***Breast-feeding***Infertility***Osteoporosis",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,capreomycin sulfate,"***For the treatment of pulmonary tuberculosis infection in patients infected with susceptible strains of <em>Mycobacterium tuberculosis </em>when use of primary agents (isoniazid, rifampin, ethambutol, aminosalicylic acid, and streptomycin) is not possible due to resistance and/or intolerance. <br />  NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., at least 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, IDSA, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. The initial treatment regimen should include 4 drugs unless the likelihood of INH or rifampin resistance is low (i.e., less than 4%), in which case an initial regimen of INH, rifampin, and pyrazinamide may be considered. HIV positive patients should always receive induction therapy with 4 drugs by DOT. Alter the regimen as appropriate when drug susceptibility results are available.   For multi-drug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, CDC recommends treatment for 18 to 24 months after culture conversion in patients with bacteriologic confirmation and for at least 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months.<br /","***General Information***Dehydration, nephrotoxicity, renal impairment***Hearing impairment, ototoxicity, tinnitus***Neuromuscular disease, respiratory depression, respiratory insufficiency, surgery***Colitis, diarrhea, inflammatory bowel disease, pseudomembranous colitis, ulcerative colitis***Geriatric***Hepatic disease, jaundice***Children, infants, neonates***Pregnancy***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['136198'],darifenacin,"***For the treatment of an overactive bladder (OAB) with symptoms of urinary frequency, urinary urgency, or urge-related urinary incontinence.","***General Information***Prostatic hypertrophy, renal disease, urinary retention, urinary tract obstruction***Anticholinergic medications, constipation, gastroesophageal reflux disease (GERD), gastroparesis, GI obstruction, ileus, pyloric stenosis, toxic megacolon, ulcerative colitis***Closed-angle glaucoma, contact lenses***Driving or operating machinery***Autonomic neuropathy, hepatic disease, myasthenia gravis***Pregnancy***Breast-feeding***Children***Geriatric",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['83008'],bicalutamide,"***For the treatment of stage D-2 metastatic prostate cancer in combination with a luteinizing hormone-releasing hormone (LHRH) analog.***For prevention of stuttering priapism� (i.e., recurrent priapism).","***Contraception requirements, females, infertility, male-mediated teratogenicity, pregnancy, reproductive risk***Breast-feeding***Hepatic disease, hepatitis, jaundice***Children***Diabetes mellitus",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['4127'],ethionamide,"***For the treatment of active tuberculosis infection in patients as second line therapy. <br />  NOTE: During the conversion from sugar-coated to film-coated tablets, monitor patients carefully, and retitrate the dosage. The same total daily dosage may be tolerated, but if gastrointestinal intolerance occurs, downward dosage adjustment may be necessary.<br />NOTE: Administer with pyridoxine.<br />NOTE: Currently, there is no data to support intermittent administration of ethionamide.<br />NOTE: The American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA), and and the Centers for Disease Control and Prevention (CDC) recommend short-course regimens (e.g., at least 6 months) for uncomplicated pulmonary tuberculosis and most cases of extrapulmonary tuberculosis in adults. According to the ATS, IDSA, CDC, and American Academy of Pediatrics (AAP), short-course regimens are also suitable in children. The initial regimen for the treatment of tuberculosis should include four drugs unless the likelihood of INH or rifampin resistance is low (i.e., &lt; 4%), in which case an initial regimen of INH, rifampin, and pyrazinamide may be considered. HIV-infected patients should always receive induction therapy with four drugs by DOT. When drug susceptibility results are available, the regimen should be altered as appropriate. �When drug susceptibility results are available, the regimen should be altered as appropriate.   For multi-drug resistant tuberculosis (MDR-TB), drug therapy choice should be based on specific resistance patterns. For pediatrics, the CDC recommends treatment for 18�24 months after culture conversion in patients with bacteriologic confirmation and for at least 12 months in patients who are culture-negative. The World Health Organization (WHO) recommends at least 8 months of an intensive phase of treatment with a total treatment duration of 20 months in MDR-TB***For the treatment of tuberculosis when isoniazid cannot be used or for strains of <em>Mycobacterium tuberculosis</em> resistant to isoniazid.","***General Information***Hepatic disease, hepatitis***Alcoholism***Depression***Hypothyroidism, thyroid disease***Diabetes mellitus***Children, infants, neonates***Pregnancy***Breast-feeding***Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5640'],ibuprofen,"***For the treatment of rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA).***For the treatment of dysmenorrhea.***For the treatment of severe pain in hospitalized patients.***For the treatment of mild pain to moderate pain.***For the treatment of mild to moderate pain in hospitalized patients.***For self-treatment of minor aches and pains due to the common cold, toothache, muscular aches or backache (musculoskeletal pain), and the minor pains of arthritis.***For the treatment of fever.***For the treatment of headache.***For self-treatment of headache.***For the treatment of pain due to acute migraine.***For the treatment of osteoarthritis; ankylosing spondylitis�; acute gouty arthritis�; or psoriatic arthritis�.***For patients with cystic fibrosis� to slow the rate of decline in lung function.***Formoterol; Mometasone","***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, salicylate hypersensitivity, urticaria***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, Crohn's disease, GI bleeding, GI disease, GI perforation, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease***Dehydration, diabetes mellitus, edema, heart failure, hypertension, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery bypass graft surgery (CABG), coronary artery disease, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, neutropenia, surgery, thrombocytopenia***Anemia***Geriatric***Labor, obstetric delivery, pregnancy***Infertility, reproductive risk***Breast-feeding***Systemic lupus erythematosus (SLE)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,norethindrone,***For the treatment of secondary amenorrhea or dysfunctional uterine bleeding due to hormonal imbalance in the absence of organic pathology such as submucous fibroids or uterine cancer.***For routine contraception. <br />        NOTE: Ortho-Micronor and NOR-QD are not considered bioequivalent and are not substitutable for each other.<br />NOTE: These products have not been studied for and are not indicated for use in emergency contraception***For the treatment of endometriosis.***For the prevention of endometrial changes associated with estrogen replacement therapy in postmenopausal women.,"***General Information***Human immunodeficiency virus (HIV) infection***Hepatic disease***Incomplete abortion, vaginal bleeding***Breast cancer***Ectopic pregnancy, pregnancy***Breast-feeding***Diabetes mellitus***Hyperlipidemia***Cerebrovascular disease, myocardial infarction, stroke, thromboembolic disease, thrombophlebitis, tobacco smoking***Asthma, renal disease***Depression, migraine, seizure disorder***Ovarian cyst***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,selegiline hydrochloride,***For the treatment of Parkinson's disease or parkinsonism in combination with levodopa or levodopa/carbidopa.***For the treatment of major depression.,"***General Information***MAOI therapy***Alcoholism, ethanol ingestion, hypertension, hypertensive crisis***Pheochromocytoma***Children, suicidal ideation***Bipolar disorder, mania***Behavioral changes, psychosis, schizophrenia***Impulse control symptoms***Hypotension, orthostatic hypotension***Hepatic disease***Renal failure, renal impairment***Melanoma***Driving or operating machinery***Abrupt discontinuation***Pregnancy***Breast-feeding***Geriatric***Phenylketonuria***Ambient temperature increase, heating pad, sunlight (UV) exposure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,esomeprazole magnesium/naproxen,"***For the treatment of osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis in patients at risk of developing NSAID-associated gastric ulcers.***For the treatment of juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA) in patients at risk of developing NSAID-associated gastric ulcers.***Formoterol; Mometasone","***General Information***Acute bronchospasm, asthma, nasal polyps, NSAID hypersensitivity, proton pump inhibitors (PPIs) hypersensitivity, salicylate hypersensitivity, urticaria***Bleeding***Bone marrow suppression, coagulopathy, hematological disease, hemophilia, immunosuppression, infection, neutropenia, surgery, thrombocytopenia***Coronary artery bypass graft surgery (CABG)***Acute myocardial infarction, angina, cardiac arrhythmias, cardiac disease, cardiomyopathy, cerebrovascular disease, coronary artery disease, heart failure, hypertension, myocardial infarction, peripheral vascular disease, stroke, tachycardia, thromboembolism***Alcoholism, anticoagulant therapy, chemotherapy, corticosteroid therapy, Crohn's disease, GI bleeding, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, tobacco smoking, ulcerative colitis***Hepatic disease, jaundice***Dehydration, diabetes mellitus, edema, hyponatremia, hypovolemia, renal disease, renal failure, renal impairment, rheumatoid arthritis***Anemia***Intramuscular injections***Dental disease, dental work***Children***Gastric cancer***Osteoporosis***Labor, obstetric delivery, pregnancy***Breast-feeding***Geriatric***Asian patients, Caucasian patients***Driving or operating machinery***Hypomagnesemia, long QT syndrome***Diarrhea, pseudomembranous colitis***Vitamin B12 deficiency***Rebound acid hypersecretion***Systemic lupus erythematosus (SLE)***Infertility, reproductive risk",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['5492'],hydrocortisone,"***For the treatment of primary adrenocortical insufficiency (e.g., Addison's Disease, congenital adrenal hyperplasia or CAH) or secondary adrenocortical insufficiency.***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing minor surgery or with a minor illness (e.g., inguinal hernia repair, colonoscopy, mild febrile illness, gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing moderate surgery or with a moderate illness (e.g., open cholecystectomy, hemicolectomy, significant febrile illness, pneumonia, severe gastroenteritis).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency undergoing major surgery, or with other acute stressors (e.g., major cardiothoracic surgery, Whipple procedure, liver resection, pancreatitis, acute systemic infection, shock).***For adrenal crisis prophylaxis in adult patients with known or suspected adrenal insufficiency and a critical illness (e.g., shock).***For the treatment of acute adrenocortical insufficiency.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency with other acute stressors (e.g., febrile illness with a temperature more than 38.5 degrees Celsius, gastroenteritis with dehydration, major trauma):.***For adrenal crisis prophylaxis in pediatric patients with known or suspected adrenal insufficiency undergoing surgery accompanied by general anesthesia.***For use in nonspecific proctitis, postirradiation (factitial) proctitis, cryptitis, or for other non-specific inflammatory conditions of the anorectum.***For the treatment of inflammatory bowel disease (Crohn's disease or ulcerative colitis).***For adjunctive treatment of Crohn's disease or ulcerative colitis using oral or parenteral therapy.***For adjunctive rectal treatment of chronic ulcerative colitis, particularly if disease limited to the distal portion of the rectum.***For the relief of inflammation, pruritus ani, and swelling associated with hemorrhoids.***For the treatment of allergic disorders including anaphylaxis, anaphylactic shock, or anaphylactoid reactions, angioedema, acute noninfectious laryngeal edema, drug hypersensitivity reactions, transfusion-related reactions, serum sickness, severe perennial or seasonal allergic rhinitis, or urticaria.***For the non-emergent treatment of hypersensitivity or allergic conditions.***For the urgent treatment of severe conditions such as anaphylaxis, angioedema, acute noninfectious laryngeal edema, or urticarial transfusion-related reactions.***For the treatment of corticosteroid-responsive dermatologic disorders (e.g., alopecia areata, atopic dermatitis, bullous dermatitis herpetiformis, contact dermatitis including Rhus dermatitis due to poison ivy, poison oak, poison sumac, discoid lupus erythematosus, eczema, exfoliative dermatitis, insect bites or stings, granuloma annulare, keloids, lichen striatus, lichen planus, lichen simplex, necrobiosis lipoidica diabeticorum, pemphigus, pityriasis rosea, polymorphous light eruption, pompholyx (dyshidrosis), pruritus, psoriasis, sarcoidosis, seborrheic dermatitis, urticaria, xerosis).***For mild-to-moderate corticosteroid responsive dermatoses.***For mild to moderate atopic dermatitis.***For the systemic treatment of severe inflammatory dermatoses, like severe exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, or psoriasis unresponsive to topical treatment.***For adjunctive therapy in the treatment of rheumatic disorders including acute gouty arthritis, ankylosing spondylitis, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis, pseudogout�, or psoriatic arthritis.***For the treatment of acute episodes or exacerbation of non-rheumatic inflammation including acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis.***For the short-term treatment of hypercalcemia associated with neoplastic disease.***For the treatment of complicated or disseminated pulmonary tuberculosis infection (i.e., tuberculous meningitis and pericarditis) as adjunctive therapy in combination with antituberculous therapy.***For the management of nephrotic syndrome to induce diuresis or decrease proteinuria.***For the treatment of neurologic or myocardial involvement associated with trichinosis.***For the treatment of nonsuppurative thyroiditis.***For rheumatic and related disorders such as acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE), temporal arteritis, Churg-Strauss syndrome�, mixed connective tissue disease�, polyarteritis nodosa�, relapsing polychondritis�, polymyalgia rheumatica�, symptomatic sarcoidosis, vasculitis�, or Wegener's granulomatosis�.***For the treatment of corticosteroid-responsive hematologic disorders, like immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, erythroblastopenia, and congenital hypoplastic anemia; OR for the palliative treatment of neoplastic disease in adults and acute leukemias of childhood including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin's lymphoma (NHL), cutaneous T-cell lymphoma (CTCL) (aka mycosis fungoides), or multiple myeloma�.***For the treatment of respiratory inflammatory conditions including bronchial asthma, aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), Loeffler's syndrome, or noncardiogenic pulmonary edema�.***For the treatment of septic shock� and/or hypotension� in patients whose blood pressure is poorly responsive to adequate fluid resuscitation and vasopressor therapy.***For the prevention of chronic lung disease (CLD)� in mechanically ventilated patients.***For the treatment of refractory neonatal hypoglycemia�.***For the treatment of corticosteroid-responsive ophthalmic disorders, including allergic conjunctivitis (not controlled topically), allergic marginal corneal ulcer, anterior segment inflammation, chorioretinitis, endophthalmitis�, Graves' ophthalmopathy, herpes zoster ocular infection (herpes zoster ophthalmicus), iritis, keratitis, postoperative ocular inflammation, optic neuritis, diffuse posterior uveitis, or vernal keratoconjunctivitis.***For adjunctive therapy in the treatment of carpal tunnel syndrome�.","***Abrupt discontinuation, Cushing's syndrome, skin abrasion***Growth inhibition, increased intracranial pressure***Immunosuppression***Fungal infection, infection***Acne rosacea, acne vulgaris, herpes infection, measles, perioral dermatitis, peripheral vascular disease, tuberculosis, varicella, viral infection***Surgery***Myocardial infarction***Heart failure, hypertension***Osteoporosis***Diabetes mellitus***Diverticulitis, GI disease, GI perforation, inflammatory bowel disease, peptic ulcer disease, ulcerative colitis***Hepatic disease, hypothyroidism, psychosis, renal disease, seizure disorder***Myasthenia gravis***Coagulopathy, hemophilia, thromboembolic disease***Pregnancy***Breast-feeding***Vaccination***Asthma, sulfite hypersensitivity***Neonates, premature neonates***Benzyl alcohol hypersensitivity, corticosteroid hypersensitivity***Cataracts, glaucoma, ocular exposure, ocular infection, ophthalmic administration, visual disturbance***Skin atrophy***Geriatric***Epidural administration, intrathecal administration***Pheochromocytoma",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['7779'],oxandrolone,"***For the treatment of cachexia, and as adjunct therapy to promote weight gain and protein anabolism after weight loss following extensive surgery, chronic infections, severe trauma, or prolonged administration of corticosteroids, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight. <br />        NOTE: Adequate caloric and protein consumption is required.<br />     ***For the treatment of AIDS-associated wasting syndrome� and associated muscle weakness.***For the treatment of growth failure�.","***Pregnancy***Breast-feeding***Diabetes mellitus***Children***Breast cancer, prostate cancer, prostatic hypertrophy***Hypercalcemia***Arteriosclerosis, cardiac disease, coronary artery disease, heart failure, hypercholesterolemia, myocardial infarction, peripheral edema***Cholestasis, hepatic disease, hepatocellular cancer, jaundice, peliosis hepatis***Renal disease***Geriatric***Polycythemia",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,testosterone enanthate,***For the treatment of delayed puberty in males.***For palliative treatment of breast cancer that is inoperable in women.***For the treatment of postpubertal cryptorchidism�.***For the treatment of microphallus�.***For the treatment of anemia� in patients with chronic renal failure.***For female-to-male gender change (trans-sexualism�).***For the treatment of lichen sclerosus�.***For the treatment of AIDS-associated wasting syndrome�.,"***Benzoic acid hypersensitivity, benzyl alcohol hypersensitivity, polyoxyethylated castor oil hypersensitivity, risk of serious hypersensitivity reactions or anaphylaxis, soya lecithin hypersensitivity***Magnetic resonance imaging (MRI)***Intramuscular administration, intravenous administration***Breast cancer, geriatric, prostate cancer, prostatic hypertrophy***Cardiac disease, coronary artery disease, heart failure, hepatic disease, myocardial infarction, renal disease, stroke***Obesity, pulmonary disease***Polycythemia***Accidental exposure, females***Contraception requirements, labor, obstetric delivery, pregnancy, reproductive risk***Breast-feeding***Diabetes mellitus***Hypercalcemia***Pulmonary oil microembolism***Nasal polyps, nasal septal perforation, nasal surgery, nasal trauma, rhinorrhea, Sjogren's syndrome***Children, infants, neonates***Substance abuse***Infertility",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,vinorelbine tartrate,"***For the treatment of non-small cell lung cancer (NSCLC).***For the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with every-4-week cisplatin.***For adjuvant treatment of resected non-small cell lung cancer (NSCLC) in combination with cisplatin�.***For the first-line treatment of advanced non-small cell lung cancer (NSCLC) in combination with cisplatin and cetuximab�.***For the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with every-6-week cisplatin.***For the treatment of metastatic breast cancer�.***For the treatment of HER2-positive metastatic breast cancer in combination with trastuzumab�.***For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy�.***For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus�.***For the treatment of recurrent ovarian cancer�.***For the treatment of recurrent or metastatic squamous cell head and neck cancer�.***For the treatment of desmoid tumor� or aggressive fibromatosis, in combination with methotrexate.***For the treatment of relapsed or refractory Hodgkin lymphoma�, in combination with other chemotherapy agents.","***Anemia, bleeding, bone marrow suppression, infection, neutropenia, thrombocytopenia***Radiation therapy***Extravasation***Intramuscular administration, intrathecal administration, subcutaneous administration***Biliary tract disease, hepatic disease, jaundice***Neurological disease***Acute bronchospasm, asthma, chronic obstructive pulmonary disease (COPD), pneumonitis, pulmonary disease***Autonomic neuropathy, constipation, GI obstruction, GI perforation, ileus***Children, infants, neonates***Pregnancy***Contraception requirements, infertility, male-mediated teratogenicity, pregnancy testing, reproductive risk***Breast-feeding",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1895'],atorvastatin calcium,"***For the treatment of hypercholesterolemia, hyperlipoproteinemia, and/or hypertriglyceridemia, as an adjunct to dietary control, for the purpose of reducing the risk of cardiovascular events (e.g., myocardial infarction prophylaxis, stroke prophylaxis).***For slowing the progression of atherosclerosis� (e.g., carotid, coronary, femoral).***For cerebral vasospasm prophylaxis� after aneurysmal subarachnoid hemorrhage.***For the treatment of chronic heart failure�.***For graft coronary artery disease prevention after heart transplantation�.","***General Information***Alcoholism, cholestasis, hepatic disease, hepatic encephalopathy, hepatitis, jaundice***Electrolyte imbalance, endocrine disease, females, hypotension, hypothyroidism, infection, myopathy, organ transplant, renal failure, renal impairment, rhabdomyolysis, seizure disorder, sepsis, surgery, trauma***Diabetes mellitus***Contraception requirements, pregnancy***Breast-feeding***Children, infants***Geriatric***Stroke",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
['1310520'],teriflunomide,***For the treatment of relapsing forms of multiple sclerosis.,"***Risk of serious hypersensitivity reactions or anaphylaxis, serious rash***Alcoholism, hepatic disease, hepatitis, hepatotoxicity, jaundice***Agranulocytosis, bone marrow suppression, chemotherapy, immunosuppression, infection, thrombocytopenia, tuberculosis***Vaccination***Eosinophilic pneumonia, pneumonitis, pulmonary disease, pulmonary fibrosis, sarcoidosis***Hypertension***Diabetes mellitus, geriatric, peripheral neuropathy***Intrauterine fetal death, pregnancy***Contraception requirements, male-mediated teratogenicity, pregnancy testing, reproductive risk***Breast-feeding***Children",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,